<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="0" size="10" family="Times" color="#231f20"/>
	<fontspec id="1" size="10" family="Times" color="#231f20"/>
	<fontspec id="2" size="11" family="Times" color="#231f20"/>
	<fontspec id="3" size="8" family="Times" color="#ce171e"/>
	<fontspec id="4" size="8" family="Times" color="#231f20"/>
	<fontspec id="5" size="8" family="Times" color="#ce171e"/>
	<fontspec id="6" size="13" family="Times" color="#ed1b24"/>
	<fontspec id="7" size="13" family="Times" color="#231f20"/>
	<fontspec id="8" size="25" family="Times" color="#ce171e"/>
	<fontspec id="9" size="29" family="Times" color="#231f20"/>
	<fontspec id="10" size="17" family="Times" color="#231f20"/>
	<fontspec id="11" size="34" family="Times" color="#c4161c"/>
	<fontspec id="12" size="8" family="Times" color="#231f20"/>
	<fontspec id="13" size="10" family="Times" color="#000000"/>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e272</text>
<text top="671" left="623" width="56" height="12" font="3"><b>Key Words:</b></text>
<text top="671" left="679" width="125" height="12" font="4">  AHA Scientific Statements </text>
<text top="684" left="623" width="7" height="13" font="5">◼</text>
<text top="685" left="631" width="119" height="12" font="4"> acute coronary syndrome </text>
<text top="684" left="749" width="7" height="13" font="5">◼</text>
<text top="685" left="756" width="3" height="12" font="4"> </text>
<text top="698" left="623" width="129" height="12" font="4">ambulatory ECG monitoring </text>
<text top="698" left="752" width="7" height="13" font="5">◼</text>
<text top="698" left="759" width="3" height="12" font="4"> </text>
<text top="712" left="623" width="128" height="12" font="4">antiarrhythmic drug therapy </text>
<text top="711" left="752" width="7" height="13" font="5">◼</text>
<text top="712" left="759" width="3" height="12" font="4"> </text>
<text top="725" left="623" width="148" height="12" font="4">arrhythmogenic cardiomyopathy </text>
<text top="725" left="771" width="7" height="13" font="5">◼</text>
<text top="725" left="779" width="3" height="12" font="4"> </text>
<text top="739" left="623" width="38" height="12" font="4">athletes </text>
<text top="738" left="661" width="7" height="13" font="5">◼</text>
<text top="739" left="668" width="117" height="12" font="4"> cardiac electrophysiology </text>
<text top="752" left="623" width="7" height="13" font="5">◼</text>
<text top="752" left="631" width="155" height="12" font="4"> cardiac resynchronization therapy </text>
<text top="752" left="786" width="7" height="13" font="5">◼</text>
<text top="752" left="793" width="3" height="12" font="4"> </text>
<text top="766" left="623" width="74" height="12" font="4">cardiomyopathy </text>
<text top="765" left="698" width="7" height="13" font="5">◼</text>
<text top="766" left="705" width="82" height="12" font="4"> catheter ablation </text>
<text top="779" left="623" width="7" height="13" font="5">◼</text>
<text top="779" left="631" width="114" height="12" font="4"> congenital heart disease </text>
<text top="779" left="744" width="7" height="13" font="5">◼</text>
<text top="779" left="752" width="18" height="12" font="4"> CT </text>
<text top="793" left="623" width="39" height="12" font="4">imaging </text>
<text top="792" left="662" width="7" height="13" font="5">◼</text>
<text top="793" left="670" width="26" height="12" font="4"> ECG </text>
<text top="792" left="695" width="7" height="13" font="5">◼</text>
<text top="793" left="703" width="86" height="12" font="4"> echocardiography </text>
<text top="792" left="788" width="7" height="13" font="5">◼</text>
<text top="793" left="795" width="3" height="12" font="4"> </text>
<text top="806" left="623" width="123" height="12" font="4">electrophysiological testing </text>
<text top="806" left="747" width="7" height="13" font="5">◼</text>
<text top="806" left="754" width="39" height="12" font="4"> genetic </text>
<text top="820" left="623" width="55" height="12" font="4">arrhythmias </text>
<text top="819" left="679" width="7" height="13" font="5">◼</text>
<text top="820" left="686" width="51" height="12" font="4"> guidelines </text>
<text top="819" left="737" width="7" height="13" font="5">◼</text>
<text top="820" left="744" width="60" height="12" font="4"> heart failure </text>
<text top="833" left="623" width="7" height="13" font="5">◼</text>
<text top="833" left="631" width="42" height="12" font="4"> imaging </text>
<text top="833" left="673" width="7" height="13" font="5">◼</text>
<text top="833" left="680" width="114" height="12" font="4"> implantable cardioverter-</text>
<text top="847" left="623" width="54" height="12" font="4">defibrillator </text>
<text top="846" left="678" width="7" height="13" font="5">◼</text>
<text top="847" left="685" width="117" height="12" font="4"> implantable and external </text>
<text top="860" left="623" width="91" height="12" font="4">cardioverter devices </text>
<text top="860" left="714" width="7" height="13" font="5">◼</text>
<text top="860" left="721" width="56" height="12" font="4"> medication-</text>
<text top="874" left="623" width="94" height="12" font="4">induced arrhythmias </text>
<text top="873" left="717" width="7" height="13" font="5">◼</text>
<text top="874" left="724" width="60" height="12" font="4"> MR imaging </text>
<text top="887" left="623" width="7" height="13" font="5">◼</text>
<text top="887" left="631" width="99" height="12" font="4"> myocardial infarction </text>
<text top="887" left="730" width="7" height="13" font="5">◼</text>
<text top="887" left="737" width="52" height="12" font="4"> premature </text>
<text top="901" left="623" width="76" height="12" font="4">ventricular beats </text>
<text top="900" left="700" width="7" height="13" font="5">◼</text>
<text top="901" left="707" width="62" height="12" font="4"> resuscitation </text>
<text top="900" left="769" width="7" height="13" font="5">◼</text>
<text top="901" left="776" width="3" height="12" font="4"> </text>
<text top="914" left="623" width="51" height="12" font="4">sarcoidosis </text>
<text top="914" left="674" width="7" height="13" font="5">◼</text>
<text top="914" left="681" width="106" height="12" font="4"> specific pathology (eg, </text>
<text top="928" left="623" width="170" height="12" font="4">congenital heart disease, myocarditis, </text>
<text top="941" left="623" width="59" height="12" font="4">renal failure) </text>
<text top="941" left="682" width="7" height="13" font="5">◼</text>
<text top="941" left="689" width="102" height="12" font="4"> stable coronary artery </text>
<text top="955" left="623" width="35" height="12" font="4">disease </text>
<text top="954" left="658" width="7" height="13" font="5">◼</text>
<text top="955" left="666" width="101" height="12" font="4"> sudden cardiac arrest </text>
<text top="954" left="766" width="7" height="13" font="5">◼</text>
<text top="955" left="773" width="3" height="12" font="4"> </text>
<text top="968" left="623" width="98" height="12" font="4">sudden cardiac death </text>
<text top="968" left="722" width="7" height="13" font="5">◼</text>
<text top="968" left="729" width="57" height="12" font="4"> torsades de </text>
<text top="982" left="623" width="36" height="12" font="4">pointes </text>
<text top="981" left="659" width="7" height="13" font="5">◼</text>
<text top="982" left="666" width="100" height="12" font="4"> ventricular fibrillation </text>
<text top="981" left="766" width="7" height="13" font="5">◼</text>
<text top="982" left="774" width="3" height="12" font="4"> </text>
<text top="995" left="623" width="100" height="12" font="4">ventricular tachycardia</text>
<text top="363" left="74" width="229" height="18" font="6"><b>WRITING COMMITTEE MEMBERS</b></text>
<text top="381" left="74" width="373" height="18" font="7"><b>Sana M. Al-Khatib, MD, MHS, FACC, FAHA, FHRS, Chair</b></text>
<text top="399" left="74" width="395" height="18" font="7"><b>William G. Stevenson, MD, FACC, FAHA, FHRS, Vice Chair*</b></text>
<text top="417" left="74" width="224" height="18" font="7"><b>Michael J. Ackerman, MD, PhD*†</b></text>
<text top="435" left="74" width="184" height="18" font="7"><b>William J. Bryant, JD, LLM†</b></text>
<text top="453" left="74" width="240" height="18" font="7"><b>David J. Callans, MD, FACC, FHRS*‡</b></text>
<text top="471" left="74" width="278" height="18" font="7"><b>Anne B. Curtis, MD, FACC, FAHA, FHRS*†</b></text>
<text top="489" left="74" width="232" height="18" font="7"><b>Barbara J. Deal, MD, FACC, FAHA†</b></text>
<text top="507" left="74" width="225" height="18" font="7"><b>Timm Dickfeld, MD, PhD, FHRS*†</b></text>
<text top="525" left="74" width="279" height="18" font="7"><b>Michael E. Field, MD, FACC, FAHA, FHRS†</b></text>
<text top="543" left="74" width="312" height="18" font="7"><b>Gregg C. Fonarow, MD, FACC, FAHA, FHFSA*§</b></text>
<text top="561" left="74" width="187" height="18" font="7"><b>Anne M. Gillis, MD, FHRS*†</b></text>
<text top="579" left="74" width="294" height="18" font="7"><b>Christopher B. Granger, MD, FACC, FAHA*†</b></text>
<text top="597" left="74" width="261" height="18" font="7"><b>Stephen C. Hammill, MD, FACC, FHRS‡</b></text>
<text top="615" left="74" width="231" height="18" font="7"><b>Mark A. Hlatky, MD, FACC, FAHA†</b></text>
<text top="633" left="74" width="260" height="18" font="7"><b>José A. Joglar, MD, FACC, FAHA, FHRS‖</b></text>
<text top="651" left="74" width="118" height="18" font="7"><b>G. Neal Kay, MD†</b></text>
<text top="669" left="74" width="202" height="18" font="7"><b>Daniel D. Matlock, MD, MPH†</b></text>
<text top="687" left="74" width="215" height="18" font="7"><b>Robert J. Myerburg, MD, FACC†</b></text>
<text top="705" left="74" width="276" height="18" font="7"><b>Richard L. Page, MD, FACC, FAHA, FHRS‡</b></text>
<text top="1019" left="623" width="160" height="12" font="4">© 2017 by the American College of </text>
<text top="1033" left="623" width="167" height="12" font="4">Cardiology Foundation, the American </text>
<text top="1046" left="623" width="166" height="12" font="4">Heart Association, Inc., and the Heart </text>
<text top="1060" left="623" width="69" height="12" font="4">Rhythm Society.</text>
<text top="137" left="74" width="276" height="32" font="8"><b>AHA/ACC/HRS GUIDELINE</b></text>
<text top="186" left="74" width="711" height="37" font="9"><b>2017 AHA/ACC/HRS Guideline for Management </b></text>
<text top="220" left="74" width="682" height="37" font="9"><b>of Patients With Ventricular Arrhythmias and </b></text>
<text top="255" left="74" width="595" height="37" font="9"><b>the Prevention of Sudden Cardiac Death</b></text>
<text top="299" left="74" width="704" height="23" font="10"><b>A Report of the American College of Cardiology/American Heart Association </b></text>
<text top="322" left="74" width="651" height="23" font="10"><b>Task Force on Clinical Practice Guidelines and the Heart Rhythm Society</b></text>
<text top="48" left="74" width="163" height="43" font="11">Circulation</text>
<text top="952" left="74" width="522" height="12" font="4">*Writing committee members are required to recuse themselves from voting on sections to which their specific rela-</text>
<text top="966" left="74" width="522" height="12" font="4">tionships with industry may apply; see Appendix 1 for detailed information. †ACC/AHA Representative. ‡HRS Rep-</text>
<text top="979" left="74" width="525" height="12" font="4">resentative. §ACC/AHA Task Force on Performance Measures Liaison/HFSA Representative. ‖ACC/AHA Task Force on </text>
<text top="993" left="74" width="155" height="12" font="4">Clinical Practice Guidelines Liaison.</text>
<text top="1084" left="623" width="176" height="12" font="4">https://www.ahajournals.org/journal/circ</text>
<text top="426" left="623" width="163" height="14" font="0">ACC/AHA Task Force Members,  </text>
<text top="441" left="623" width="72" height="14" font="0">see page e354</text>
<text top="1016" left="74" width="500" height="12" font="4">The American Heart Association requests that this document be cited as follows: Al-Khatib SM, Stevenson WG, </text>
<text top="1030" left="74" width="514" height="12" font="4">Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, </text>
<text top="1043" left="74" width="512" height="12" font="4">Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for </text>
<text top="1057" left="74" width="510" height="12" font="4">management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the </text>
<text top="1070" left="74" width="511" height="12" font="4">American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines </text>
<text top="1084" left="74" width="471" height="12" font="4">and the Heart Rhythm Society. <i>Circulation</i>. 2018;138:e272–e391. doi: 10.1161/CIR.0000000000000549.</text>
<text top="372" left="623" width="145" height="14" font="1"><i>Developed in Collaboration  </i></text>
<text top="387" left="623" width="159" height="14" font="1"><i>With the Heart Failure Society  </i></text>
<text top="402" left="623" width="56" height="14" font="1"><i>of America</i></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="14" size="14" family="Times" color="#ffffff"/>
	<fontspec id="15" size="17" family="Times" color="#ce171e"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e273</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="86" left="74" width="190" height="23" font="15"><b>TABLE OF CONTENTS</b></text>
<text top="115" left="74" width="351" height="16" font="2">Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e274</text>
<text top="132" left="74" width="351" height="16" font="2">1. Introduction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e275</text>
<text top="148" left="91" width="335" height="16" font="2">1.1.  Methodology and Evidence Review  . . . . . . . . . e275</text>
<text top="165" left="91" width="335" height="16" font="2">1.2.  Organization of the Writing Committee. . . . . . e276</text>
<text top="182" left="91" width="335" height="16" font="2">1.3.  Document Review and Approval  . . . . . . . . . . . e276</text>
<text top="198" left="91" width="335" height="16" font="2">1.4.  Scope of the Guideline  . . . . . . . . . . . . . . . . . . e277</text>
<text top="215" left="91" width="335" height="16" font="2">1.5. Abbreviations  . . . . . . . . . . . . . . . . . . . . . . . . . e279</text>
<text top="232" left="74" width="351" height="16" font="2">2. Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e279</text>
<text top="248" left="91" width="335" height="16" font="2">2.1.  General Concepts  . . . . . . . . . . . . . . . . . . . . . . e279</text>
<text top="265" left="121" width="237" height="16" font="2">2.1.1. Premature Ventricular Complexes  </text>
<text top="282" left="160" width="266" height="16" font="2">and Nonsustained VT  . . . . . . . . . . . . . . e279</text>
<text top="298" left="121" width="305" height="16" font="2">2.1.2. VT and VF During ACS  . . . . . . . . . . . . . e281</text>
<text top="315" left="121" width="251" height="16" font="2">2.1.3. Sustained VT and VF Not Associated </text>
<text top="332" left="160" width="266" height="16" font="2">With ACS  . . . . . . . . . . . . . . . . . . . . . . . e281</text>
<text top="348" left="91" width="335" height="16" font="2">2.2.  Sudden Cardiac Death. . . . . . . . . . . . . . . . . . . e281</text>
<text top="365" left="121" width="305" height="16" font="2">2.2.1. Incidence of SCD. . . . . . . . . . . . . . . . . . e281</text>
<text top="382" left="121" width="199" height="16" font="2">2.2.2. Population Subgroups and  </text>
<text top="398" left="160" width="266" height="16" font="2">Risk Prediction. . . . . . . . . . . . . . . . . . . . e282</text>
<text top="415" left="74" width="351" height="16" font="2">3. Mechanisms of VA. . . . . . . . . . . . . . . . . . . . . . . . . . e283</text>
<text top="432" left="91" width="335" height="16" font="2">3.1.  Cellular Mechanisms and Substrates  . . . . . . . . e283</text>
<text top="448" left="91" width="335" height="16" font="2">3.2. Automaticity  . . . . . . . . . . . . . . . . . . . . . . . . . . e283</text>
<text top="465" left="91" width="335" height="16" font="2">3.3.  Triggered Activity. . . . . . . . . . . . . . . . . . . . . . . e283</text>
<text top="481" left="91" width="335" height="16" font="2">3.4. Reentry  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . e284</text>
<text top="498" left="74" width="306" height="16" font="2">4. General Evaluation of Patients With Documented  </text>
<text top="515" left="91" width="335" height="16" font="2">or Suspected VA  . . . . . . . . . . . . . . . . . . . . . . . . . . . e284</text>
<text top="531" left="91" width="335" height="16" font="2">4.1.  History and Physical Examination . . . . . . . . . . . e284</text>
<text top="548" left="91" width="335" height="16" font="2">4.2.  Noninvasive Evaluation  . . . . . . . . . . . . . . . . . . e286</text>
<text top="565" left="121" width="305" height="16" font="2">4.2.1. 12-lead ECG and Exercise Testing  . . . . . e286</text>
<text top="581" left="121" width="305" height="16" font="2">4.2.2. Ambulatory Electrocardiography . . . . . .  e286</text>
<text top="598" left="121" width="305" height="16" font="2">4.2.3. Implanted Cardiac Monitors  . . . . . . . . . e287</text>
<text top="615" left="121" width="305" height="16" font="2">4.2.4. Noninvasive Cardiac Imaging. . . . . . . . . e287</text>
<text top="631" left="121" width="305" height="16" font="2">4.2.5. Biomarkers  . . . . . . . . . . . . . . . . . . . . . . e288</text>
<text top="648" left="121" width="180" height="16" font="2">4.2.6. Genetic Considerations  </text>
<text top="665" left="160" width="266" height="16" font="2">in Arrhythmia Syndromes  . . . . . . . . . . . e288</text>
<text top="681" left="91" width="335" height="16" font="2">4.3.  Invasive Testing  . . . . . . . . . . . . . . . . . . . . . . . . e289</text>
<text top="698" left="121" width="235" height="16" font="2">4.3.1. Invasive Cardiac Imaging: Cardiac </text>
<text top="715" left="160" width="266" height="16" font="2">Catheterization or CT Angiography . . . . e289</text>
<text top="731" left="121" width="305" height="16" font="2">4.3.2. Electrophysiological Study for VA  . . . . . e289</text>
<text top="748" left="74" width="351" height="16" font="2">5. Therapies for Treatment or Prevention of VA  . . . . . . e290</text>
<text top="765" left="91" width="335" height="16" font="2">5.1.  Medication Therapy. . . . . . . . . . . . . . . . . . . . . e290</text>
<text top="781" left="121" width="211" height="16" font="2">5.1.1. Medications With Prominent  </text>
<text top="798" left="160" width="266" height="16" font="2">Sodium Channel Blockade. . . . . . . . . . . e290</text>
<text top="815" left="121" width="305" height="16" font="2">5.1.2. Beta Blockers  . . . . . . . . . . . . . . . . . . . . e293</text>
<text top="831" left="121" width="305" height="16" font="2">5.1.3. Amiodarone and Sotalol  . . . . . . . . . . . . e293</text>
<text top="848" left="121" width="305" height="16" font="2">5.1.4. Calcium Channel Blockers . . . . . . . . . . . e294</text>
<text top="865" left="121" width="227" height="16" font="2">5.1.5. Nonantiarrhythmic Medications  </text>
<text top="881" left="160" width="266" height="16" font="2">and Therapies . . . . . . . . . . . . . . . . . . . . e294</text>
<text top="898" left="91" width="335" height="16" font="2">5.2.  Preventing SCD With HF Medications  . . . . . . . e295</text>
<text top="915" left="91" width="335" height="16" font="2">5.3.  Defibrillators for Treatment of VA and SCD  . . . e295</text>
<text top="931" left="91" width="335" height="16" font="2">5.4.  Catheter Ablation  . . . . . . . . . . . . . . . . . . . . . . e295</text>
<text top="948" left="121" width="305" height="16" font="2">5.4.1. General Considerations . . . . . . . . . . . . . e295</text>
<text top="965" left="121" width="232" height="16" font="2">5.4.2. VA in Patients With No Apparent </text>
<text top="981" left="160" width="266" height="16" font="2">Structural Heart Disease  . . . . . . . . . . . . e296</text>
<text top="998" left="121" width="305" height="16" font="2">5.4.3. Scar-Related VT . . . . . . . . . . . . . . . . . . . e296</text>
<text top="1015" left="91" width="275" height="16" font="2">5.5.  Surgery and Revascularization Procedures  </text>
<text top="1031" left="121" width="305" height="16" font="2">in Patients With Ischemic Heart Disease . . . . . . e296</text>
<text top="1048" left="121" width="305" height="16" font="2">5.5.1. Surgery for Arrhythmia Management  . . e297</text>
<text top="1065" left="91" width="335" height="16" font="2">5.6.  Autonomic Modulation . . . . . . . . . . . . . . . . . . e297</text>
<text top="1081" left="74" width="351" height="16" font="2">6. Acute Management of Specific VA  . . . . . . . . . . . . . e297</text>
<text top="88" left="460" width="272" height="16" font="2">7. Ongoing Management of VA and SCD Risk  </text>
<text top="104" left="476" width="327" height="16" font="2">Related to Specific Disease States  . . . . . . . . . . . . . e301</text>
<text top="121" left="478" width="325" height="16" font="2">7.1.  Ischemic Heart Disease  . . . . . . . . . . . . . . . . . e301</text>
<text top="137" left="508" width="214" height="16" font="2">7.1.1. Secondary Prevention of SCD  </text>
<text top="154" left="547" width="186" height="16" font="2">in Patients With Ischemic Heart  </text>
<text top="171" left="547" width="257" height="16" font="2">Disease . . . . . . . . . . . . . . . . . . . . . . . . e301</text>
<text top="187" left="508" width="261" height="16" font="2">7.1.2. Primary Prevention of SCD in Patients  </text>
<text top="204" left="547" width="257" height="16" font="2">With Ischemic Heart Disease . . . . . . . . e304</text>
<text top="220" left="508" width="194" height="16" font="2">7.1.3. Treatment and Prevention  </text>
<text top="237" left="547" width="194" height="16" font="2">of Recurrent VA in Patients With  </text>
<text top="253" left="547" width="257" height="16" font="2">Ischemic Heart Disease  . . . . . . . . . . . . e306</text>
<text top="270" left="478" width="325" height="16" font="2">7.2.  Nonischemic Cardiomyopathy . . . . . . . . . . . . e308</text>
<text top="286" left="508" width="214" height="16" font="2">7.2.1. Secondary Prevention of SCD  </text>
<text top="303" left="547" width="257" height="16" font="2">in Patients With NICM  . . . . . . . . . . . . e308</text>
<text top="320" left="508" width="198" height="16" font="2">7.2.2. Primary Prevention of SCD  </text>
<text top="336" left="547" width="257" height="16" font="2">in Patients With NICM  . . . . . . . . . . . . e309</text>
<text top="353" left="508" width="199" height="16" font="2">7.2.3. Treatment of Recurrent VA  </text>
<text top="369" left="547" width="257" height="16" font="2">in Patients With NICM  . . . . . . . . . . . . e310</text>
<text top="386" left="478" width="164" height="16" font="2">7.3.  Arrhythmogenic Right  </text>
<text top="402" left="508" width="296" height="16" font="2">Ventricular Cardiomyopathy  . . . . . . . . . . . . . e312</text>
<text top="419" left="478" width="325" height="16" font="2">7.4.  Hypertrophic Cardiomyopathy. . . . . . . . . . . . e315</text>
<text top="435" left="478" width="325" height="16" font="2">7.5. Myocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . e318</text>
<text top="452" left="478" width="325" height="16" font="2">7.6.  Cardiac Sarcoidosis . . . . . . . . . . . . . . . . . . . .  e318</text>
<text top="469" left="508" width="296" height="16" font="2">7.6.1. Other Infiltrative Cardiomyopathies. . . e320</text>
<text top="485" left="478" width="325" height="16" font="2">7.7.  Heart Failure . . . . . . . . . . . . . . . . . . . . . . . . . e321</text>
<text top="502" left="508" width="296" height="16" font="2">7.7.1. HF With Reduced Ejection Fraction . . .  e321</text>
<text top="518" left="508" width="206" height="16" font="2">7.7.2. HF With Preserved Ejection  </text>
<text top="535" left="547" width="257" height="16" font="2">Fraction  . . . . . . . . . . . . . . . . . . . . . . . e321</text>
<text top="551" left="508" width="296" height="16" font="2">7.7.3. Left Ventricular Assist Device. . . . . . . . e322</text>
<text top="568" left="508" width="296" height="16" font="2">7.7.4.  ICD Use After Heart Transplantation. . . . e322</text>
<text top="584" left="478" width="325" height="16" font="2">7.8.  Neuromuscular Disorders. . . . . . . . . . . . . . . . e322</text>
<text top="601" left="478" width="325" height="16" font="2">7.9.  Cardiac Channelopathies  . . . . . . . . . . . . . . . e324</text>
<text top="617" left="508" width="229" height="16" font="2">7.9.1. Specific Cardiac Channelopathy  </text>
<text top="634" left="547" width="257" height="16" font="2">Syndromes  . . . . . . . . . . . . . . . . . . . . . e325</text>
<text top="651" left="460" width="343" height="16" font="2">8. VA in the Structurally Normal Heart . . . . . . . . . . . . e334</text>
<text top="667" left="478" width="234" height="16" font="2">8.1.  Outflow Tract and Atrioventricular  </text>
<text top="684" left="508" width="296" height="16" font="2">Annular VA . . . . . . . . . . . . . . . . . . . . . . . . . . e335</text>
<text top="700" left="478" width="325" height="16" font="2">8.2.  Papillary Muscle VA . . . . . . . . . . . . . . . . . . . . e335</text>
<text top="717" left="478" width="196" height="16" font="2">8.3.  Interfascicular Reentrant VT  </text>
<text top="733" left="508" width="296" height="16" font="2">(Belhassen Tachycardia)   . . . . . . . . . . . . . . . . e335</text>
<text top="750" left="478" width="325" height="16" font="2">8.4.  Idiopathic Polymorphic VT/VF  . . . . . . . . . . . . e336</text>
<text top="766" left="460" width="343" height="16" font="2">9. PVC-Induced Cardiomyopathy . . . . . . . . . . . . . . . . e337</text>
<text top="783" left="452" width="351" height="16" font="2">10.  VA and SCD Related to Specific Populations  . . . . . e338</text>
<text top="800" left="476" width="327" height="16" font="2">10.1. Athletes. . . . . . . . . . . . . . . . . . . . . . . . . . . . e338</text>
<text top="816" left="476" width="327" height="16" font="2">10.2. Pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . e338</text>
<text top="833" left="476" width="327" height="16" font="2">10.3.  Older Patients With Comorbidities. . . . . . . . e339</text>
<text top="849" left="476" width="327" height="16" font="2">10.4.  Chronic Kidney Disease . . . . . . . . . . . . . . . . e340</text>
<text top="866" left="476" width="327" height="16" font="2">10.5.  Valvular Heart Disease . . . . . . . . . . . . . . . . . e340</text>
<text top="882" left="476" width="250" height="16" font="2">10.6.  Sex-Related Differences in the Risk  </text>
<text top="899" left="514" width="289" height="16" font="2">of SCD  . . . . . . . . . . . . . . . . . . . . . . . . . . . . e340</text>
<text top="915" left="476" width="327" height="16" font="2">10.7.  Medication-Induced Arrhythmias . . . . . . . . . e341</text>
<text top="932" left="476" width="327" height="16" font="2">10.8.  Adult Congenital Heart Disease . . . . . . . . . . e342</text>
<text top="948" left="452" width="351" height="16" font="2">11.  Defibrillators Other than Transvenous ICDs  . . . . . . e347</text>
<text top="965" left="476" width="197" height="16" font="2">11.1.  Subcutaneous Implantable  </text>
<text top="982" left="514" width="289" height="16" font="2">Cardioverter-Defibrillator . . . . . . . . . . . . . . . e347</text>
<text top="998" left="476" width="327" height="16" font="2">11.2.  Wearable Cardioverter-Defibrillator  . . . . . . . e348</text>
<text top="1015" left="476" width="327" height="16" font="2">11.3.  Automated External Defibrillator . . . . . . . . .  e349</text>
<text top="1031" left="452" width="351" height="16" font="2">12.  Special Considerations for Catheter Ablation. . . . . e349</text>
<text top="1048" left="452" width="351" height="16" font="2">13.  Postmortem Evaluation of SCD  . . . . . . . . . . . . . . . e350</text>
<text top="1064" left="452" width="351" height="16" font="2">14.  Terminal Care  . . . . . . . . . . . . . . . . . . . . . . . . . . . . e351</text>
<text top="1081" left="452" width="351" height="16" font="2">15.  Shared Decision-Making  . . . . . . . . . . . . . . . . . . . . e351</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="16" size="14" family="Times" color="#ffffff"/>
	<fontspec id="17" size="13" family="Times" color="#231f20"/>
	<fontspec id="18" size="16" family="Times" color="#ce171e"/>
	<fontspec id="19" size="6" family="Times" color="#231f20"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e274</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="16" font="2">16.  Cost and Value Considerations  . . . . . . . . . . . . . . . e352</text>
<text top="104" left="74" width="351" height="16" font="2">17.  Quality of Life  . . . . . . . . . . . . . . . . . . . . . . . . . . . . e353</text>
<text top="121" left="74" width="351" height="16" font="2">18.  Evidence Gaps and Future Research Needs  . . . . . . e354</text>
<text top="137" left="74" width="282" height="16" font="2">Appendix 1:  Author Relationships With Industry  </text>
<text top="154" left="148" width="277" height="16" font="2">and Other Entities (Relevant)  . . . . . . . . . .  e387</text>
<text top="171" left="74" width="293" height="16" font="2">Appendix 2:  Reviewer Relationships With Industry  </text>
<text top="187" left="148" width="277" height="16" font="2">and Other Entities (Comprehensive)  . . . . .  e389</text>
<text top="234" left="74" width="99" height="23" font="15"><b>PREAMBLE</b></text>
<text top="262" left="74" width="357" height="17" font="17">Since 1980, the American College of Cardiology (ACC) </text>
<text top="280" left="74" width="357" height="17" font="17">and American Heart Association (AHA) have translated </text>
<text top="298" left="74" width="358" height="17" font="17">scientific evidence into clinical practice guidelines with </text>
<text top="316" left="74" width="363" height="17" font="17">recommendations to improve cardiovascular health. </text>
<text top="335" left="74" width="351" height="17" font="17">These guidelines, which are based on systematic meth-</text>
<text top="353" left="74" width="351" height="17" font="17">ods to evaluate and classify evidence, provide a corner-</text>
<text top="371" left="74" width="356" height="17" font="17">stone for quality cardiovascular care. The ACC and AHA </text>
<text top="389" left="74" width="357" height="17" font="17">sponsor the development and publication of guidelines </text>
<text top="407" left="74" width="351" height="17" font="17">without commercial support, and members of each or-</text>
<text top="425" left="74" width="355" height="17" font="17">ganization volunteer their time to the writing and review </text>
<text top="443" left="74" width="351" height="17" font="17">efforts. Guidelines are official policy of the ACC and AHA.</text>
<text top="489" left="74" width="112" height="21" font="18"><b>Intended Use</b></text>
<text top="516" left="74" width="351" height="17" font="17">Practice guidelines provide recommendations applica-</text>
<text top="535" left="74" width="351" height="17" font="17">ble to patients with or at risk of developing cardiovas-</text>
<text top="553" left="74" width="357" height="17" font="17">cular disease. The focus is on medical practice in the </text>
<text top="571" left="74" width="351" height="17" font="17">United States, but guidelines developed in collabora-</text>
<text top="589" left="74" width="354" height="17" font="17">tion with other organizations may have a global impact. </text>
<text top="607" left="74" width="356" height="17" font="17">Although guidelines may be used to inform regulatory </text>
<text top="625" left="74" width="357" height="17" font="17">or payer decisions, their intent is to improve patients’ </text>
<text top="643" left="74" width="351" height="17" font="17">quality of care and align with patients’ interests. Guide-</text>
<text top="661" left="74" width="360" height="17" font="17">lines are intended to define practices meeting the </text>
<text top="679" left="74" width="357" height="17" font="17">needs of patients in most, but not all, circumstances </text>
<text top="697" left="74" width="263" height="17" font="17">and should not replace clinical judgment.</text>
<text top="743" left="74" width="200" height="21" font="18"><b>Clinical Implementation</b></text>
<text top="771" left="74" width="356" height="17" font="17">Guideline-recommended management is effective only </text>
<text top="789" left="74" width="358" height="17" font="17">when followed by healthcare providers and patients. </text>
<text top="807" left="74" width="357" height="17" font="17">Adherence to recommendations can be enhanced by </text>
<text top="825" left="74" width="351" height="17" font="17">shared decision-making between healthcare provid-</text>
<text top="843" left="74" width="356" height="17" font="17">ers and patients, with patient engagement in selecting </text>
<text top="861" left="74" width="357" height="17" font="17">interventions based on individual values, preferences, </text>
<text top="879" left="74" width="287" height="17" font="17">and associated conditions and comorbidities.</text>
<text top="925" left="74" width="282" height="21" font="18"><b>Methodology and Modernization</b></text>
<text top="952" left="74" width="354" height="17" font="17">The ACC/AHA Task Force on Clinical Practice Guidelines </text>
<text top="970" left="74" width="351" height="17" font="17">(Task Force) continuously reviews, updates, and modi-</text>
<text top="989" left="74" width="357" height="17" font="17">fies guideline methodology on the basis of published </text>
<text top="1007" left="74" width="356" height="17" font="17">standards from organizations including the Institute of </text>
<text top="1025" left="74" width="58" height="17" font="17">Medicine</text>
<text top="1025" left="133" width="27" height="10" font="19">P-1,P-2</text>
<text top="1025" left="159" width="270" height="17" font="17"> and on the basis of internal reevaluation. </text>
<text top="1043" left="74" width="355" height="17" font="17">Similarly, the presentation and delivery of guidelines are </text>
<text top="1061" left="74" width="351" height="17" font="17">reevaluated and modified on the basis of evolving tech-</text>
<text top="1079" left="74" width="351" height="17" font="17">nologies and other factors to facilitate optimal dissemi-</text>
<text top="88" left="452" width="355" height="17" font="17">nation of information at the point of care to healthcare </text>
<text top="106" left="452" width="86" height="17" font="17">professionals.</text>
<text top="124" left="470" width="337" height="17" font="17">Toward this goal, this guideline heralds the introduction </text>
<text top="142" left="452" width="351" height="17" font="17">of an evolved format of presenting guideline recommenda-</text>
<text top="160" left="452" width="356" height="17" font="17">tions and associated text called the “modular knowledge </text>
<text top="178" left="452" width="355" height="17" font="17">chunk format.” Each modular “chunk” includes a table of </text>
<text top="196" left="452" width="351" height="17" font="17">related recommendations, a brief synopsis, recommenda-</text>
<text top="214" left="452" width="357" height="17" font="17">tion-specific supportive text and, when appropriate, flow </text>
<text top="232" left="452" width="359" height="17" font="17">diagrams or additional tables. References are provided </text>
<text top="250" left="452" width="356" height="17" font="17">within the modular chunk itself to facilitate quick review. </text>
<text top="268" left="452" width="351" height="17" font="17">This format also will facilitate seamless updating of guide-</text>
<text top="286" left="452" width="356" height="17" font="17">lines with focused updates as new evidence is published, </text>
<text top="304" left="452" width="355" height="17" font="17">and content tagging for rapid electronic retrieval of related </text>
<text top="322" left="452" width="351" height="17" font="17">recommendations on a topic of interest. This evolved for-</text>
<text top="340" left="452" width="351" height="17" font="17">mat was instituted when this guideline was near comple-</text>
<text top="358" left="452" width="351" height="17" font="17">tion; therefore, the current document represents a transi-</text>
<text top="376" left="452" width="355" height="17" font="17">tional formatting that best suits the text as written. Future </text>
<text top="394" left="452" width="358" height="17" font="17">guidelines will fully implement this format, including </text>
<text top="412" left="452" width="351" height="17" font="17">provisions for limiting the amount of text in a guideline.</text>
<text top="430" left="470" width="333" height="17" font="17">Recognizing the importance of cost–value consider-</text>
<text top="448" left="452" width="351" height="17" font="17">ations in certain guidelines, when appropriate and fea-</text>
<text top="466" left="452" width="354" height="17" font="17">sible, an analysis of the value of a medication, device, or </text>
<text top="484" left="452" width="355" height="17" font="17">intervention may be performed in accordance with the </text>
<text top="502" left="452" width="156" height="17" font="17">ACC/AHA methodology.</text>
<text top="503" left="608" width="12" height="10" font="19">P-3</text>
<text top="520" left="470" width="340" height="17" font="17">To ensure that guideline recommendations remain </text>
<text top="538" left="452" width="357" height="17" font="17">current, new data are reviewed on an ongoing basis, </text>
<text top="556" left="452" width="351" height="17" font="17">with full guideline revisions commissioned in approxi-</text>
<text top="574" left="452" width="359" height="17" font="17">mately 6-year cycles. Publication of new, potentially </text>
<text top="592" left="452" width="356" height="17" font="17">practice-changing study results that are relevant to an </text>
<text top="610" left="452" width="358" height="17" font="17">existing or new medication, device, or management </text>
<text top="628" left="452" width="358" height="17" font="17">strategy will prompt evaluation by the Task Force, in </text>
<text top="646" left="452" width="351" height="17" font="17">consultation with the relevant guideline writing com-</text>
<text top="664" left="452" width="355" height="17" font="17">mittee, to determine whether a focused update should </text>
<text top="682" left="452" width="351" height="17" font="17">be commissioned. For additional information and poli-</text>
<text top="700" left="452" width="358" height="17" font="17">cies regarding guideline development, we encourage </text>
<text top="718" left="452" width="351" height="17" font="17">readers to consult the ACC/AHA guideline methodol-</text>
<text top="737" left="452" width="75" height="17" font="17">ogy manual</text>
<text top="737" left="527" width="12" height="10" font="19">P-4</text>
<text top="736" left="539" width="208" height="17" font="17"> and other methodology articles.</text>
<text top="737" left="748" width="29" height="10" font="19">P-5–P-8</text>
<text top="780" left="452" width="351" height="21" font="18"><b>Selection of Writing Committee Members</b></text>
<text top="807" left="452" width="355" height="17" font="17">The Task Force strives to avoid bias by selecting experts </text>
<text top="825" left="452" width="351" height="17" font="17">from a broad array of backgrounds. Writing commit-</text>
<text top="843" left="452" width="358" height="17" font="17">tee members represent different geographic regions, </text>
<text top="861" left="452" width="355" height="17" font="17">sexes, ethnicities, races, intellectual perspectives/biases, </text>
<text top="879" left="452" width="355" height="17" font="17">and scopes of clinical practice. The Task Force may also </text>
<text top="897" left="452" width="351" height="17" font="17">invite organizations and professional societies with re-</text>
<text top="915" left="452" width="356" height="17" font="17">lated interests and expertise to participate as partners, </text>
<text top="933" left="452" width="174" height="17" font="17">collaborators, or endorsers.</text>
<text top="977" left="452" width="330" height="21" font="18"><b>Relationships With Industry and Other </b></text>
<text top="998" left="452" width="63" height="21" font="18"><b>Entities</b></text>
<text top="1025" left="452" width="357" height="17" font="17">The ACC and AHA have rigorous policies and methods </text>
<text top="1043" left="452" width="359" height="17" font="17">to ensure that guidelines are developed without bias </text>
<text top="1061" left="452" width="357" height="17" font="17">or improper influence. The complete relationships with  </text>
<text top="1079" left="452" width="357" height="17" font="17">industry and other entities (RWI) policy can be found  </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="20" size="13" family="Times" color="#3c4ba7"/>
	<fontspec id="21" size="13" family="Times" color="#231f20"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e275</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="38" height="17" font="20"><a href="">online</a></text>
<text top="88" left="112" width="318" height="17" font="17">. Appendix 1 of the current document lists writing </text>
<text top="106" left="74" width="357" height="17" font="17">committee members’ relevant RWI. For the purposes of </text>
<text top="124" left="74" width="351" height="17" font="17">full transparency, writing committee members’ compre-</text>
<text top="142" left="74" width="257" height="17" font="17">hensive disclosur<a href="">e information is available </a></text>
<text top="142" left="331" width="38" height="17" font="20"><a href="">online</a></text>
<text top="142" left="369" width="60" height="17" font="17">, as is the </text>
<text top="160" left="74" width="345" height="17" font="20"><a href="">comprehensive disclosure information for the Task Force</a></text>
<text top="160" left="419" width="4" height="17" font="17">.</text>
<text top="203" left="74" width="331" height="21" font="18"><b>Evidence Review and Evidence Review </b></text>
<text top="224" left="74" width="101" height="21" font="18"><b>Committees</b></text>
<text top="251" left="74" width="351" height="17" font="17">When developing recommendations, the writing com-</text>
<text top="269" left="74" width="360" height="17" font="17">mittee uses evidence-based methodologies that are </text>
<text top="287" left="74" width="166" height="17" font="17">based on all available data.</text>
<text top="288" left="241" width="28" height="10" font="19">P-4–P-7</text>
<text top="287" left="269" width="159" height="17" font="17"> Literature searches focus </text>
<text top="305" left="74" width="356" height="17" font="17">on randomized controlled trials (RCTs) but also include </text>
<text top="323" left="74" width="357" height="17" font="17">registries, nonrandomized comparative and descriptive </text>
<text top="341" left="74" width="357" height="17" font="17">studies, case series, cohort studies, systematic reviews, </text>
<text top="359" left="74" width="313" height="17" font="17">and expert opinion. Only key references are cited.</text>
<text top="377" left="92" width="339" height="17" font="17">An independent evidence review committee (ERC) is </text>
<text top="395" left="74" width="357" height="17" font="17">commissioned when there are ≥1 questions deemed of </text>
<text top="413" left="74" width="357" height="17" font="17">utmost clinical importance that merit formal systematic </text>
<text top="431" left="74" width="359" height="17" font="17">review. This systematic review will strive to determine </text>
<text top="449" left="74" width="351" height="17" font="17">which patients are most likely to benefit from a test, med-</text>
<text top="467" left="74" width="354" height="17" font="17">ication, device, or treatment strategy and to what degree. </text>
<text top="485" left="74" width="355" height="17" font="17">Criteria for commissioning an ERC and formal systematic </text>
<text top="503" left="74" width="356" height="17" font="17">review include: a) the absence of a current authoritative </text>
<text top="521" left="74" width="351" height="17" font="17">systematic review; b) the feasibility of defining the ben-</text>
<text top="539" left="74" width="356" height="17" font="17">efit and risk in a time frame consistent with the writing </text>
<text top="557" left="74" width="356" height="17" font="17">of a guideline; c) the relevance to a substantial number </text>
<text top="575" left="74" width="357" height="17" font="17">of patients; and d) the likelihood that the findings can </text>
<text top="593" left="74" width="360" height="17" font="17">be translated into actionable recommendations. ERC </text>
<text top="611" left="74" width="357" height="17" font="17">members may include methodologists, epidemiologists, </text>
<text top="629" left="74" width="355" height="17" font="17">healthcare providers, and biostatisticians. When a formal </text>
<text top="647" left="74" width="351" height="17" font="17">systematic review has been commissioned, the recom-</text>
<text top="665" left="74" width="356" height="17" font="17">mendations developed by the writing committee on the </text>
<text top="683" left="74" width="296" height="17" font="17">basis of the systematic review are marked with“</text>
<text top="684" left="370" width="9" height="10" font="19">SR</text>
<text top="683" left="379" width="12" height="17" font="17">.”</text>
<text top="726" left="74" width="318" height="21" font="18"><b>Guideline-Directed Management and </b></text>
<text top="747" left="74" width="69" height="21" font="18"><b>Therapy</b></text>
<text top="775" left="74" width="355" height="17" font="17">The term <i>guideline-directed management and therapy</i> </text>
<text top="793" left="74" width="351" height="17" font="17">(GDMT) encompasses clinical evaluation, diagnostic test-</text>
<text top="811" left="74" width="354" height="17" font="17">ing, and pharmacological and procedural treatments. For </text>
<text top="829" left="74" width="351" height="17" font="17">these and all recommended medication treatment regi-</text>
<text top="847" left="74" width="351" height="17" font="17">mens, the reader should confirm the dosage by review-</text>
<text top="865" left="74" width="357" height="17" font="17">ing product insert material and evaluate the treatment </text>
<text top="883" left="74" width="351" height="17" font="17">regimen for contraindications and interactions. The rec-</text>
<text top="901" left="74" width="356" height="17" font="17">ommendations are limited to medications, devices, and </text>
<text top="919" left="74" width="351" height="17" font="17">treatments approved for clinical use in the United States.</text>
<text top="962" left="74" width="314" height="21" font="18"><b>Class of Recommendation and Level  </b></text>
<text top="983" left="74" width="98" height="21" font="18"><b>of Evidence</b></text>
<text top="1010" left="74" width="361" height="17" font="17">The Class of Recommendation (COR) indicates the </text>
<text top="1028" left="74" width="351" height="17" font="17">strength of the recommendation, encompassing the esti-</text>
<text top="1046" left="74" width="355" height="17" font="17">mated magnitude and certainty of benefit in proportion </text>
<text top="1064" left="74" width="356" height="17" font="17">to risk. The Level of Evidence (LOE) rates the quality of </text>
<text top="1082" left="74" width="356" height="17" font="17">scientific evidence that supports the intervention on the </text>
<text top="88" left="452" width="355" height="17" font="17">basis of the type, quantity, and consistency of data from </text>
<text top="106" left="452" width="253" height="17" font="17">clinical trials and other sources (Table 1).</text>
<text top="106" left="705" width="41" height="10" font="19">P-4,P-6,P-8</text>
<text top="124" left="584" width="219" height="18" font="21"><i>Glenn N. Levine, MD, FACC, FAHA</i></text>
<text top="142" left="508" width="300" height="18" font="21"><i>Chair, ACC/AHA Task Force on Clinical Practice </i></text>
<text top="160" left="737" width="67" height="18" font="21"><i>Guidelines</i></text>
<text top="208" left="452" width="165" height="23" font="15"><b>1. INTRODUCTION</b></text>
<text top="237" left="452" width="334" height="21" font="18"><b>1.1. Methodology and Evidence Review</b></text>
<text top="264" left="452" width="351" height="17" font="17">The recommendations listed in this clinical practice guide-</text>
<text top="282" left="452" width="358" height="17" font="17">line are, whenever possible, evidence-based. An initial </text>
<text top="301" left="452" width="351" height="17" font="17">extensive evidence review, which included literature de-</text>
<text top="319" left="452" width="356" height="17" font="17">rived from research involving human subjects, published </text>
<text top="337" left="452" width="357" height="17" font="17">in English, and indexed in MEDLINE (through PubMed), </text>
<text top="355" left="452" width="351" height="17" font="17">EMBASE, the Cochrane Library, the Agency for Health-</text>
<text top="373" left="452" width="351" height="17" font="17">care Research and Quality, and other selected databas-</text>
<text top="392" left="452" width="357" height="17" font="17">es relevant to this guideline, was conducted from April </text>
<text top="410" left="452" width="358" height="17" font="17">2016 to September 2016. Key search words included, </text>
<text top="428" left="452" width="357" height="17" font="17">but were not limited, to the following: sudden cardiac </text>
<text top="446" left="452" width="351" height="17" font="17">death, ventricular tachycardia, ventricular fibrillation, pre-</text>
<text top="464" left="452" width="351" height="17" font="17">mature ventricular contractions, implantable cardioverter-</text>
<text top="482" left="452" width="351" height="17" font="17">defibrillator, subcutaneous implantable cardioverter-defi-</text>
<text top="501" left="452" width="356" height="17" font="17">brillator, wearable cardioverter-defibrillator, and catheter </text>
<text top="519" left="452" width="358" height="17" font="17">ablation. Additional relevant studies published  through </text>
<text top="537" left="452" width="356" height="17" font="17">March 2017, during the guideline writing process, were </text>
<text top="555" left="452" width="356" height="17" font="17">also considered by the writing committee, and added to </text>
<text top="573" left="452" width="355" height="17" font="17">the evidence tables when appropriate. The final evidence </text>
<text top="592" left="452" width="167" height="17" font="17">tables are included in <a href="">the </a></text>
<text top="592" left="619" width="155" height="17" font="20"><a href="">Online Data Supplement</a></text>
<text top="592" left="774" width="35" height="17" font="17"><a href=""> and</a> </text>
<text top="610" left="452" width="356" height="17" font="17">summarize the evidence used by the writing committee </text>
<text top="628" left="452" width="356" height="17" font="17">to formulate recommendations. Additionally, the writing </text>
<text top="646" left="452" width="359" height="17" font="17">committee reviewed documents related to ventricular </text>
<text top="664" left="452" width="351" height="17" font="17">arrhythmias (VA) and sudden cardiac death (SCD) previ-</text>
<text top="682" left="452" width="355" height="17" font="17">ously published by the ACC, AHA, and the Heart Rhythm </text>
<text top="701" left="452" width="355" height="17" font="17">Society (HRS). References selected and published in this </text>
<text top="719" left="452" width="318" height="17" font="17">document are representative and not all-inclusive.</text>
<text top="737" left="470" width="339" height="17" font="17">As noted in the Preamble, an independent ERC was </text>
<text top="755" left="452" width="355" height="17" font="17">commissioned to perform a formal systematic review of 2 </text>
<text top="773" left="452" width="356" height="17" font="17">important clinical questions for which clear literature and </text>
<text top="792" left="452" width="355" height="17" font="17">prior guideline consensus were felt to be lacking or limited </text>
<text top="810" left="452" width="355" height="17" font="17">(Table 2). The results of the ERC review were considered by </text>
<text top="828" left="452" width="351" height="17" font="17">the writing committee for incorporation into this guide-</text>
<text top="846" left="452" width="360" height="17" font="17">line. Concurrent with this process, writing committee </text>
<text top="864" left="452" width="356" height="17" font="17">members evaluated other published data relevant to the </text>
<text top="882" left="452" width="351" height="17" font="17">guideline. The findings of the ERC and the writing com-</text>
<text top="901" left="452" width="356" height="17" font="17">mittee members were formally presented and discussed, </text>
<text top="919" left="452" width="359" height="17" font="17">then guideline recommendations were developed. The </text>
<text top="937" left="452" width="351" height="17" font="17">“Systematic Review for the 2017 AHA/ACC/HRS Guide-</text>
<text top="955" left="452" width="351" height="17" font="17">line for Management of Patients With Ventricular Ar-</text>
<text top="973" left="452" width="356" height="17" font="17">rhythmias and the Prevention of Sudden Cardiac Death” </text>
<text top="991" left="452" width="282" height="17" font="17">is published in conjunction with this guideline.</text>
<text top="992" left="734" width="23" height="10" font="19">S1.4-1</text>
<text top="1009" left="470" width="333" height="17" font="17">The ACC and AHA have acknowledged the impor-</text>
<text top="1028" left="452" width="351" height="17" font="17">tance of value in health care and have called for even-</text>
<text top="1046" left="452" width="355" height="17" font="17">tual development of a Level of Value for clinical practice </text>
<text top="1064" left="452" width="119" height="17" font="17">recommendations.</text>
<text top="1065" left="571" width="24" height="10" font="19">S1.4-2</text>
<text top="1064" left="595" width="211" height="17" font="17"> Available cost-effectiveness data </text>
<text top="1082" left="452" width="356" height="17" font="17">were determined to be sufficient to support 2 specific </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="22" size="8" family="Times" color="#231f20"/>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e276</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="864" left="74" width="356" height="17" font="17">recommendations in this guideline (see Sections 7.1.1 </text>
<text top="882" left="74" width="357" height="17" font="17">and 7.1.2). As a result, a Level of Value was assigned </text>
<text top="900" left="74" width="351" height="17" font="17">to those 2 recommendations on the basis of the “ACC/</text>
<text top="919" left="74" width="351" height="17" font="17">AHA Statement on Cost/Value Methodology in Clini-</text>
<text top="937" left="74" width="355" height="17" font="17">cal Practice Guidelines and Performance Measures,” as </text>
<text top="955" left="74" width="110" height="17" font="17">shown in Table 3.</text>
<text top="955" left="184" width="24" height="10" font="19">S1.4-2</text>
<text top="955" left="209" width="220" height="17" font="17"> Available quality of life (QoL) data </text>
<text top="973" left="74" width="351" height="17" font="17">were deemed to be insufficient to support specific rec-</text>
<text top="991" left="74" width="205" height="17" font="17">ommendations in this guideline.</text>
<text top="1034" left="74" width="350" height="21" font="18"><b>1.2. Organization of the Writing Committee</b></text>
<text top="1062" left="74" width="351" height="17" font="17">The writing committee consisted of cardiac electro-</text>
<text top="1080" left="74" width="356" height="17" font="17">physiologists (including those specialized in pediatrics), </text>
<text top="864" left="452" width="361" height="17" font="17">general adult and pediatric cardiologists (including </text>
<text top="882" left="452" width="359" height="17" font="17">those specialized in critical care and acute coronary </text>
<text top="900" left="452" width="355" height="17" font="17">syndromes [ACS], genetic cardiology, heart failure, and </text>
<text top="919" left="452" width="351" height="17" font="17">cost-effectiveness analyses), a geriatrician with exper-</text>
<text top="937" left="452" width="357" height="17" font="17">tise in terminal care and shared decision-making, and </text>
<text top="955" left="452" width="355" height="17" font="17">a lay representative, in addition to representatives from </text>
<text top="973" left="452" width="357" height="17" font="17">the ACC, AHA, HRS, and the Heart Failure Society of </text>
<text top="991" left="452" width="103" height="17" font="17">America (HFSA).</text>
<text top="1034" left="452" width="309" height="21" font="18"><b>1.3. Document Review and Approval</b></text>
<text top="1062" left="452" width="359" height="17" font="17">This document was reviewed by 2 official reviewers </text>
<text top="1080" left="452" width="351" height="17" font="17">nominated by the ACC, AHA, and HRS; 1 official lay re-</text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 1.</b></text>
<text top="88" left="112" width="694" height="12" font="22"><b>  Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient </b></text>
<text top="102" left="74" width="145" height="12" font="22"><b>Care* (Updated August 2015)</b></text>
<text top="828" left="83" width="3" height="12" font="4"> </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="23" size="4" family="Times" color="#231f20"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e277</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="315" left="74" width="351" height="17" font="17">viewer nominated by the AHA; 1 organizational review-</text>
<text top="333" left="74" width="357" height="17" font="17">er nominated by the HFSA; and 28 individual content </text>
<text top="351" left="74" width="356" height="17" font="17">reviewers. Reviewers’ RWI information was distributed </text>
<text top="369" left="74" width="351" height="17" font="17">to the writing committee and is published in this docu-</text>
<text top="387" left="74" width="123" height="17" font="17">ment (Appendix 2).</text>
<text top="405" left="92" width="338" height="17" font="17">This document was approved for publication by the </text>
<text top="423" left="74" width="356" height="17" font="17">governing bodies of the ACC, the AHA, and the HRS; </text>
<text top="441" left="74" width="174" height="17" font="17">and endorsed by the HFSA.</text>
<text top="485" left="74" width="227" height="21" font="18"><b>1.4. Scope of the Guideline</b></text>
<text top="512" left="74" width="351" height="17" font="17">The purpose of this AHA/ACC/HRS document is to pro-</text>
<text top="530" left="74" width="356" height="17" font="17">vide a contemporary guideline for the management of </text>
<text top="548" left="74" width="354" height="17" font="17">adults who have VA or who are at risk for SCD, including </text>
<text top="566" left="74" width="356" height="17" font="17">diseases and syndromes associated with a risk of SCD </text>
<text top="584" left="74" width="351" height="17" font="17">from VA. This guideline supersedes the “ACC/AHA/</text>
<text top="602" left="74" width="355" height="17" font="17">ESC 2006 Guidelines for Management of Patients With </text>
<text top="620" left="74" width="356" height="17" font="17">Ventricular Arrhythmias and the Prevention of Sudden </text>
<text top="638" left="74" width="103" height="17" font="17">Cardiac Death.”</text>
<text top="638" left="177" width="24" height="10" font="19">S1.4-4</text>
<text top="638" left="201" width="228" height="17" font="17"> It also supersedes some sections of </text>
<text top="656" left="74" width="356" height="17" font="17">the “ACC/AHA/HRS 2008 Guidelines for Device-Based </text>
<text top="674" left="74" width="278" height="17" font="17">Therapy of Cardiac Rhythm Abnormalities,”</text>
<text top="674" left="352" width="24" height="10" font="19">S1.4-5</text>
<text top="674" left="376" width="49" height="17" font="17"> specifi-</text>
<text top="692" left="74" width="357" height="17" font="17">cally those sections on indications for the implantable </text>
<text top="710" left="74" width="355" height="17" font="17">cardioverter-defibrillator (ICD); and, it updates the SCD </text>
<text top="728" left="74" width="356" height="17" font="17">prevention recommendations in the “2011 ACCF/AHA </text>
<text top="88" left="452" width="351" height="17" font="17">Guideline for the Diagnosis and Treatment of Hyper-</text>
<text top="106" left="452" width="166" height="17" font="17">trophic Cardiomyopathy.”</text>
<text top="106" left="619" width="24" height="10" font="19">S1.4-6</text>
<text top="106" left="643" width="165" height="17" font="17"> Some recommendations </text>
<text top="124" left="452" width="351" height="17" font="17">from the earlier guidelines have been updated as war-</text>
<text top="142" left="452" width="357" height="17" font="17">ranted by new evidence or a better understanding of </text>
<text top="160" left="452" width="351" height="17" font="17">existing evidence, and irrelevant or overlapping recom-</text>
<text top="178" left="452" width="245" height="17" font="17">mendations were deleted or modified.</text>
<text top="196" left="470" width="338" height="17" font="17">In the current guideline, sudden cardiac arrest (SCA) </text>
<text top="214" left="452" width="355" height="17" font="17">is defined as the “sudden cessation of cardiac activity so </text>
<text top="232" left="452" width="357" height="17" font="17">that the victim becomes unresponsive, with no normal </text>
<text top="250" left="452" width="248" height="17" font="17">breathing and no signs of circulation.”</text>
<text top="251" left="700" width="24" height="10" font="19">S1.4-7</text>
<text top="250" left="724" width="85" height="17" font="17"> If corrective </text>
<text top="268" left="452" width="355" height="17" font="17">measures are not taken rapidly, this condition progresses </text>
<text top="286" left="452" width="355" height="17" font="17">to SCD. Cardiac arrest is used to signify an event that can </text>
<text top="304" left="452" width="359" height="17" font="17">be reversed, usually by cardiopulmonary resuscitation </text>
<text top="322" left="452" width="355" height="17" font="17">(CPR), administration of medications and/or defibrillation </text>
<text top="340" left="452" width="357" height="17" font="17">or cardioversion. SCA and SCD can result from causes </text>
<text top="358" left="452" width="351" height="17" font="17">other than VA, such as bradyarrhythmias, electrome-</text>
<text top="376" left="452" width="357" height="17" font="17">chanical dissociation, pulmonary embolism, intracranial </text>
<text top="394" left="452" width="357" height="17" font="17">hemorrhage, and aortic dissection; however, the scope </text>
<text top="412" left="452" width="351" height="17" font="17">of this document includes only SCA and SCD due to VA.</text>
<text top="430" left="470" width="339" height="17" font="17">This guideline includes indications for ICDs for the </text>
<text top="448" left="452" width="358" height="17" font="17">treatment of VA and prevention of SCD, but it does </text>
<text top="466" left="452" width="355" height="17" font="17">not delve into details on individual device selection and </text>
<text top="485" left="452" width="351" height="17" font="17">programming, including considerations relevant to car-</text>
<text top="503" left="452" width="351" height="17" font="17">diac resynchronization therapy (CRT), bradycardia pac-</text>
<text top="521" left="452" width="359" height="17" font="17">ing, and hemodynamic monitoring. These important </text>
<text top="539" left="452" width="356" height="17" font="17">aspects of ICD management have been covered in an </text>
<text top="557" left="452" width="216" height="17" font="17">HRS expert consensus statement.</text>
<text top="557" left="668" width="24" height="10" font="19">S1.4-8</text>
<text top="557" left="692" width="116" height="17" font="17"> An AHA science </text>
<text top="575" left="452" width="351" height="17" font="17">advisory discusses the use of wearable cardioverter-</text>
<text top="593" left="452" width="83" height="17" font="17">defibrillators.</text>
<text top="593" left="536" width="24" height="10" font="19">S1.4-9</text>
<text top="593" left="560" width="249" height="17" font="17"> The findings of that document were </text>
<text top="611" left="452" width="360" height="17" font="17">reviewed; however, recommendations on this topic </text>
<text top="629" left="452" width="356" height="17" font="17">were developed independently of that document. This </text>
<text top="647" left="452" width="357" height="17" font="17">guideline includes indications for catheter ablation of </text>
<text top="665" left="452" width="355" height="17" font="17">VA, but does not provide recommendations on specific </text>
<text top="683" left="452" width="351" height="17" font="17">techniques or ablation technologies, which were be-</text>
<text top="701" left="452" width="215" height="17" font="17">yond the scope of this document.</text>
<text top="719" left="470" width="333" height="17" font="17">Recommendations for interventional therapies, in-</text>
<text top="737" left="452" width="355" height="17" font="17">cluding ablation and the implantation of devices, apply </text>
<text top="755" left="452" width="351" height="17" font="17">only if these therapies can be implemented by quali-</text>
<text top="773" left="452" width="351" height="17" font="17">fied clinicians, such that outcomes consistent with pub-</text>
<text top="791" left="452" width="351" height="17" font="17">lished literature are a reasonable expectation. The writ-</text>
<text top="809" left="452" width="356" height="17" font="17">ing committee agreed that a high degree of expertise </text>
<text top="827" left="452" width="356" height="17" font="17">was particularly important for performance of catheter </text>
<text top="845" left="452" width="356" height="17" font="17">ablation of VA, and this point is further emphasized in </text>
<text top="863" left="452" width="351" height="17" font="17">relevant sections. In addition, all recommendations re-</text>
<text top="881" left="452" width="354" height="17" font="17">lated to ICDs require that meaningful survival of &gt;1 year </text>
<text top="899" left="452" width="357" height="17" font="17">is expected; meaningful survival means that a patient </text>
<text top="918" left="452" width="336" height="17" font="17">has a reasonable quality of life and functional status.</text>
<text top="936" left="470" width="333" height="17" font="17">Although this document is aimed at the adult popu-</text>
<text top="954" left="452" width="351" height="17" font="17">lation (≥18 years of age) and offers no specific recom-</text>
<text top="972" left="452" width="351" height="17" font="17">mendations for pediatric patients, some of the litera-</text>
<text top="990" left="452" width="355" height="17" font="17">ture on pediatric patients was examined. In some cases, </text>
<text top="1008" left="452" width="355" height="17" font="17">the data from pediatric patients beyond infancy helped </text>
<text top="1026" left="452" width="153" height="17" font="17">to inform this guideline.</text>
<text top="1044" left="470" width="339" height="17" font="17">The writing committee recognized the importance of </text>
<text top="1062" left="452" width="359" height="17" font="17">shared decision-making and patient-centered care and, </text>
<text top="1080" left="452" width="351" height="17" font="17">when possible, it endeavored to formulate recommenda-</text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 2.</b></text>
<text top="88" left="112" width="250" height="12" font="22"><b>  Systematic Review Questions on SCD Prevention</b></text>
<text top="112" left="85" width="48" height="12" font="22"><b>Question </b></text>
<text top="126" left="85" width="40" height="12" font="22"><b>Number</b></text>
<text top="126" left="231" width="45" height="12" font="22"><b>Question</b></text>
<text top="112" left="377" width="39" height="12" font="22"><b>Section </b></text>
<text top="126" left="375" width="40" height="12" font="22"><b>Number</b></text>
<text top="147" left="85" width="6" height="12" font="4">1</text>
<text top="147" left="150" width="184" height="12" font="4">For asymptomatic patients with Brugada </text>
<text top="160" left="150" width="210" height="12" font="4">syndrome, what is the association between an </text>
<text top="174" left="150" width="209" height="12" font="4">abnormal programmed ventricular stimulation </text>
<text top="187" left="150" width="167" height="12" font="4">study and SCD and other arrhythmia </text>
<text top="201" left="150" width="50" height="12" font="4">endpoints?</text>
<text top="147" left="379" width="32" height="12" font="4">7.9.1.3</text>
<text top="222" left="85" width="6" height="12" font="4">2</text>
<text top="222" left="150" width="194" height="12" font="4">What is the impact of ICD implantation for </text>
<text top="235" left="150" width="182" height="12" font="4">primary prevention in older patients and </text>
<text top="249" left="150" width="175" height="12" font="4">patients with significant comorbidities?</text>
<text top="222" left="385" width="20" height="12" font="4">10.3</text>
<text top="272" left="86" width="310" height="12" font="4">ICD indicates implantable cardioverter-defibrillator; and SCD, sudden </text>
<text top="286" left="74" width="63" height="12" font="4">cardiac death.</text>
<text top="763" left="74" width="37" height="12" font="3"><b>Table 3.</b></text>
<text top="763" left="112" width="305" height="12" font="22"><b>  Proposed Integration of Level of Value Into Clinical Practice </b></text>
<text top="776" left="74" width="147" height="12" font="22"><b>Guideline Recommendations*</b></text>
<text top="800" left="85" width="69" height="12" font="22"><b>Level of Value</b></text>
<text top="821" left="85" width="316" height="12" font="4">High value: Better outcomes at lower cost or ICER &lt;$50 000 per QALY </text>
<text top="835" left="85" width="30" height="12" font="4">gained</text>
<text top="856" left="85" width="267" height="12" font="4">Intermediate value: $50 000 to &lt;$150 000 per QALY gained</text>
<text top="877" left="85" width="177" height="12" font="4">Low value: ≥$150 000 per QALY gained</text>
<text top="898" left="85" width="304" height="12" font="4">Uncertain value: Value examined but data are insufficient to draw a </text>
<text top="911" left="85" width="328" height="12" font="4">conclusion because of no studies, low-quality studies, conflicting studies, </text>
<text top="925" left="85" width="189" height="12" font="4">or prior studies that are no longer relevant</text>
<text top="945" left="85" width="263" height="12" font="4">Not assessed: Value not assessed by the writing committee</text>
<text top="966" left="85" width="257" height="12" font="4">Proposed abbreviations for each value recommendation:  </text>
<text top="980" left="85" width="336" height="12" font="12"><i>Level of Value: H to indicate high value; I, intermediate value; L, low value; </i></text>
<text top="993" left="85" width="209" height="12" font="12"><i>U, uncertain value; and NA, value not assessed</i></text>
<text top="1016" left="86" width="328" height="12" font="4">*Dollar amounts used in this table are based on US GDP data from 2012 </text>
<text top="1030" left="74" width="313" height="12" font="4">and were obtained from WHO-CHOICE Cost-Effectiveness Thresholds.</text>
<text top="1030" left="388" width="17" height="7" font="23">S1.4-3</text>
<text top="1043" left="86" width="338" height="12" font="4">GDP indicates gross domestic product; ICER, incremental cost-effectiveness </text>
<text top="1057" left="74" width="327" height="12" font="4">ratio; QALY, quality-adjusted life-years; and WHO-CHOICE, World Health </text>
<text top="1070" left="74" width="353" height="12" font="4">Organization Choosing Interventions that are Cost-Effective. Reproduced from </text>
<text top="1084" left="74" width="71" height="12" font="4">Anderson, et al.</text>
<text top="1084" left="146" width="17" height="7" font="23">S1.4-2</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e278</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="354" height="17" font="17">tions relevant to these important concepts. The importance </text>
<text top="106" left="74" width="356" height="17" font="17">of a shared decision-making process in which the patient, </text>
<text top="124" left="74" width="351" height="17" font="17">family, and clinicians discuss risks and benefits of diag-</text>
<text top="142" left="74" width="355" height="17" font="17">nostic and treatment options and consider the patients’ </text>
<text top="160" left="74" width="335" height="17" font="17">personal preferences is emphasized (see Section 15).</text>
<text top="178" left="92" width="338" height="17" font="17">In developing this guideline, the writing committee </text>
<text top="196" left="74" width="358" height="17" font="17">reviewed previously published guidelines and related </text>
<text top="214" left="74" width="358" height="17" font="17">statements.  Table  4 contains a list of guidelines and </text>
<text top="232" left="74" width="355" height="17" font="17">statements deemed pertinent to this writing effort and </text>
<text top="250" left="74" width="355" height="17" font="17">is intended for use as a resource, obviating repetition of </text>
<text top="268" left="74" width="234" height="17" font="17">existing guideline recommendations.</text>
<text top="286" left="92" width="341" height="17" font="17">During final production review of the guidelines, </text>
<text top="304" left="74" width="355" height="17" font="17">several recommendations were refined to better reflect </text>
<text top="88" left="452" width="357" height="17" font="17">the data and current recommended medical practice. </text>
<text top="106" left="452" width="355" height="17" font="17">These refinements were reviewed and approved by the </text>
<text top="124" left="452" width="355" height="17" font="17">writing committee, the Task Force, and ACC, AHA, and </text>
<text top="142" left="452" width="354" height="17" font="17">HRS organizational leadership. These recommendations </text>
<text top="160" left="452" width="36" height="17" font="17">were:</text>
<text top="178" left="467" width="240" height="17" font="17">•  Section 7.1.1., recommendation 1</text>
<text top="196" left="467" width="240" height="17" font="17">•  Section 7.1.3., recommendation 2</text>
<text top="214" left="467" width="240" height="17" font="17">•  Section 7.2.1., recommendation 1</text>
<text top="232" left="467" width="252" height="17" font="17">•  Section 7.9.1.4., recommendation 2</text>
<text top="250" left="467" width="236" height="17" font="17">•  Section 10.8., recommendation 6</text>
<text top="268" left="470" width="333" height="17" font="17">Readers should refer to these sections for the up-</text>
<text top="286" left="452" width="69" height="17" font="17">dated text.</text>
<text top="354" left="74" width="37" height="12" font="3"><b>Table 4.</b></text>
<text top="354" left="112" width="199" height="12" font="22"><b>  Associated Guidelines and Statements</b></text>
<text top="378" left="85" width="22" height="12" font="22"><b>Title</b></text>
<text top="378" left="534" width="65" height="12" font="22"><b>Organization</b></text>
<text top="378" left="660" width="138" height="12" font="22"><b>Publication Year (Reference)</b></text>
<text top="399" left="85" width="47" height="12" font="4">Guidelines</text>
<text top="420" left="85" width="48" height="12" font="4"> Syncope</text>
<text top="420" left="533" width="66" height="12" font="4">ACC/AHA/HRS</text>
<text top="420" left="707" width="23" height="12" font="4">2017</text>
<text top="420" left="730" width="21" height="7" font="23">S1.4–10</text>
<text top="440" left="85" width="66" height="12" font="4">  Heart failure</text>
<text top="440" left="541" width="50" height="12" font="4">ACCF/AHA</text>
<text top="440" left="672" width="23" height="12" font="4">2017</text>
<text top="441" left="695" width="21" height="7" font="23">S1.4–11</text>
<text top="440" left="717" width="29" height="12" font="4"> 2016,</text>
<text top="441" left="746" width="21" height="7" font="23">S1.4–12</text>
<text top="440" left="767" width="23" height="12" font="4"> and </text>
<text top="454" left="707" width="23" height="12" font="4">2013</text>
<text top="454" left="730" width="21" height="7" font="23">S1.4–13</text>
<text top="475" left="85" width="107" height="12" font="4">  Valvular heart disease</text>
<text top="475" left="544" width="45" height="12" font="4">AHA/ACC</text>
<text top="475" left="673" width="23" height="12" font="4">2017</text>
<text top="475" left="697" width="21" height="7" font="23">S1.4–14</text>
<text top="475" left="718" width="46" height="12" font="4"> and 2014</text>
<text top="475" left="764" width="21" height="7" font="23">S1.4–15</text>
<text top="495" left="85" width="136" height="12" font="4">  Supraventricular tachycardia</text>
<text top="495" left="533" width="66" height="12" font="4">ACC/AHA/HRS</text>
<text top="495" left="707" width="23" height="12" font="4">2015</text>
<text top="496" left="730" width="21" height="7" font="23">S1.4–16</text>
<text top="516" left="85" width="312" height="12" font="4">  Ventricular arrhythmias and the prevention of sudden cardiac death</text>
<text top="516" left="557" width="18" height="12" font="4">ESC</text>
<text top="516" left="707" width="23" height="12" font="4">2015</text>
<text top="517" left="730" width="21" height="7" font="23">S1.4–17</text>
<text top="537" left="85" width="368" height="12" font="4">  Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care</text>
<text top="537" left="556" width="21" height="12" font="4">AHA</text>
<text top="537" left="707" width="23" height="12" font="4">2015</text>
<text top="538" left="730" width="21" height="7" font="23">S1.4–18</text>
<text top="558" left="85" width="82" height="12" font="4">  Atrial fibrillation</text>
<text top="558" left="533" width="66" height="12" font="4">AHA/ACC/HRS</text>
<text top="558" left="707" width="23" height="12" font="4">2014</text>
<text top="558" left="730" width="21" height="7" font="23">S1.4–19</text>
<text top="579" left="85" width="207" height="12" font="4">  Non–ST-elevation acute coronary syndromes</text>
<text top="579" left="544" width="45" height="12" font="4">AHA/ACC</text>
<text top="579" left="707" width="23" height="12" font="4">2014</text>
<text top="579" left="730" width="21" height="7" font="23">S1.4–20</text>
<text top="599" left="85" width="158" height="12" font="4">  Assessment of cardiovascular risk</text>
<text top="599" left="544" width="45" height="12" font="4">ACC/AHA</text>
<text top="599" left="707" width="23" height="12" font="4">2013</text>
<text top="600" left="730" width="21" height="7" font="23">S1.4–21</text>
<text top="620" left="85" width="160" height="12" font="4">  ST-elevation myocardial infarction</text>
<text top="620" left="541" width="50" height="12" font="4">ACCF/AHA</text>
<text top="620" left="707" width="23" height="12" font="4">2013</text>
<text top="621" left="730" width="21" height="7" font="23">S1.4–22</text>
<text top="641" left="85" width="353" height="12" font="4">  Acute myocardial infarction in patients presenting with ST-segment elevation</text>
<text top="641" left="557" width="18" height="12" font="4">ESC</text>
<text top="641" left="707" width="23" height="12" font="4">2012</text>
<text top="641" left="730" width="21" height="7" font="23">S1.4–23</text>
<text top="662" left="85" width="261" height="12" font="4">  Device-based therapies for cardiac rhythm abnormalities</text>
<text top="662" left="531" width="71" height="12" font="4">ACCF/AHA/HRS</text>
<text top="662" left="707" width="23" height="12" font="4">2012</text>
<text top="662" left="730" width="21" height="7" font="23">S1.4–24</text>
<text top="682" left="85" width="173" height="12" font="4">  Coronary artery bypass graft surgery</text>
<text top="682" left="541" width="50" height="12" font="4">ACCF/AHA</text>
<text top="682" left="707" width="23" height="12" font="4">2011</text>
<text top="683" left="730" width="21" height="7" font="23">S1.4–25</text>
<text top="703" left="85" width="143" height="12" font="4">  Hypertrophic cardiomyopathy</text>
<text top="703" left="541" width="50" height="12" font="4">ACCF/AHA</text>
<text top="703" left="709" width="23" height="12" font="4">2011</text>
<text top="704" left="732" width="18" height="7" font="23">S1.4–6</text>
<text top="724" left="85" width="169" height="12" font="4">  Percutaneous coronary intervention</text>
<text top="724" left="529" width="74" height="12" font="4">ACCF/AHA/SCAI</text>
<text top="724" left="707" width="23" height="12" font="4">2011</text>
<text top="725" left="730" width="21" height="7" font="23">S1.4–26</text>
<text top="745" left="85" width="369" height="12" font="4">   Secondary prevention and risk reduction therapy for patients with coronary and </text>
<text top="758" left="95" width="165" height="12" font="4">other atherosclerotic vascular disease</text>
<text top="745" left="541" width="50" height="12" font="4">AHA/ACCF</text>
<text top="745" left="707" width="23" height="12" font="4">2011</text>
<text top="745" left="730" width="21" height="7" font="23">S1.4–27</text>
<text top="779" left="85" width="93" height="12" font="4">Scientific Statements</text>
<text top="800" left="85" width="337" height="12" font="4">   Wearable cardioverter-defibrillator therapy for the prevention of sudden  </text>
<text top="813" left="95" width="60" height="12" font="4">cardiac death</text>
<text top="800" left="556" width="21" height="12" font="4">AHA</text>
<text top="800" left="709" width="23" height="12" font="4">2016</text>
<text top="800" left="732" width="18" height="7" font="23">S1.4–9</text>
<text top="834" left="85" width="329" height="12" font="4">   Optimal implantable cardioverter defibrillator programming and testing</text>
<text top="834" left="504" width="124" height="12" font="4">HRS/EHRA/APHRS/SOLAECE</text>
<text top="834" left="709" width="23" height="12" font="4">2016</text>
<text top="835" left="732" width="18" height="7" font="23">S1.4–8</text>
<text top="855" left="85" width="356" height="12" font="4">   Treatment of cardiac arrest: current status and future directions: strategies to </text>
<text top="868" left="95" width="134" height="12" font="4">improve cardiac arrest survival</text>
<text top="855" left="556" width="19" height="12" font="4">IOM</text>
<text top="855" left="707" width="23" height="12" font="4">2015</text>
<text top="855" left="730" width="21" height="7" font="23">S1.4–28</text>
<text top="889" left="85" width="357" height="12" font="4">   Eligibility and disqualification recommendations for competitive athletes with </text>
<text top="903" left="95" width="126" height="12" font="4">cardiovascular abnormalities</text>
<text top="889" left="544" width="45" height="12" font="4">ACC/AHA</text>
<text top="889" left="707" width="23" height="12" font="4">2015</text>
<text top="890" left="730" width="21" height="7" font="23">S1.4–29</text>
<text top="923" left="85" width="114" height="12" font="4">  Ventricular arrhythmias</text>
<text top="923" left="526" width="79" height="12" font="4">EHRA/HRS/APHRS</text>
<text top="923" left="707" width="23" height="12" font="4">2014</text>
<text top="924" left="730" width="21" height="7" font="23">S1.4–30</text>
<text top="944" left="85" width="212" height="12" font="4">  Arrhythmias in adult congenital heart disease</text>
<text top="944" left="541" width="50" height="12" font="4">PACES/HRS</text>
<text top="944" left="707" width="23" height="12" font="4">2014</text>
<text top="945" left="730" width="21" height="7" font="23">S1.4–31</text>
<text top="965" left="85" width="373" height="12" font="4">   Implantable cardioverter-defibrillator therapy in patients who are not included or </text>
<text top="978" left="95" width="159" height="12" font="4">not well represented in clinical trials</text>
<text top="965" left="533" width="66" height="12" font="4">HRS/ACC/AHA</text>
<text top="965" left="707" width="23" height="12" font="4">2014</text>
<text top="965" left="730" width="21" height="7" font="23">S1.4–32</text>
<text top="999" left="85" width="95" height="12" font="4">  Cardiac sarcoidosis</text>
<text top="999" left="557" width="18" height="12" font="4">HRS</text>
<text top="999" left="707" width="23" height="12" font="4">2014</text>
<text top="1000" left="730" width="21" height="7" font="23">S1.4–33</text>
<text top="1020" left="85" width="189" height="12" font="4">  Inherited primary arrhythmia syndromes</text>
<text top="1020" left="526" width="79" height="12" font="4">HRS/EHRA/APHRS</text>
<text top="1020" left="707" width="23" height="12" font="4">2013</text>
<text top="1021" left="730" width="21" height="7" font="23">S1.4–34</text>
<text top="1043" left="86" width="719" height="12" font="4">ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; APHRS, Asia Pacific Heart </text>
<text top="1057" left="74" width="715" height="12" font="4">Rhythm Society; EHRA, European Heart Rhythm Association; ESC, European Society of Cardiology; HRS, Heart Rhythm Society; PACES, Pediatric and Congenital </text>
<text top="1070" left="74" width="720" height="12" font="4">Electrophysiology Society; SCAI, Society for Cardiovascular Angiography and Interventions; and, SOLAECE, Sociedad Latinoamericana de Estimulacion Cardiaca y </text>
<text top="1084" left="74" width="73" height="12" font="4">Electrofisiologia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="24" size="13" family="Times" color="#ce171e"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e279</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="154" height="21" font="18"><b>1.5. Abbreviations</b></text>
<text top="121" left="85" width="65" height="12" font="22"><b>Abbreviation</b></text>
<text top="121" left="250" width="81" height="12" font="22"><b>Meaning/Phrase</b></text>
<text top="142" left="85" width="19" height="12" font="4">ACS</text>
<text top="142" left="167" width="117" height="12" font="4">acute coronary syndromes</text>
<text top="162" left="85" width="19" height="12" font="4">AED</text>
<text top="162" left="167" width="142" height="12" font="4">automated external defibrillator</text>
<text top="183" left="85" width="19" height="12" font="4">AMI</text>
<text top="183" left="167" width="121" height="12" font="4">acute myocardial infarction</text>
<text top="204" left="85" width="18" height="12" font="4">BNP</text>
<text top="204" left="167" width="114" height="12" font="4">B-type natriuretic peptide</text>
<text top="225" left="85" width="27" height="12" font="4">CABG</text>
<text top="225" left="167" width="125" height="12" font="4">coronary artery bypass graft</text>
<text top="246" left="85" width="20" height="12" font="4">CKD</text>
<text top="246" left="167" width="100" height="12" font="4">chronic kidney disease</text>
<text top="266" left="85" width="18" height="12" font="4">CPR</text>
<text top="266" left="167" width="134" height="12" font="4">cardiopulmonary resuscitation</text>
<text top="287" left="85" width="18" height="12" font="4">CRT</text>
<text top="287" left="167" width="149" height="12" font="4">cardiac resynchronization therapy</text>
<text top="308" left="85" width="12" height="12" font="4">CT</text>
<text top="308" left="167" width="103" height="12" font="4">computed tomography</text>
<text top="329" left="85" width="20" height="12" font="4">ECG</text>
<text top="329" left="167" width="81" height="12" font="4">electrocardiogram</text>
<text top="349" left="85" width="18" height="12" font="4">ERC</text>
<text top="349" left="167" width="122" height="12" font="4">evidence review committee</text>
<text top="370" left="85" width="23" height="12" font="4">ESRD</text>
<text top="370" left="167" width="104" height="12" font="4">end-stage renal disease</text>
<text top="391" left="85" width="29" height="12" font="4">GDMT</text>
<text top="391" left="167" width="199" height="12" font="4">guideline-directed management and therapy</text>
<text top="412" left="85" width="23" height="12" font="4">HCM</text>
<text top="412" left="167" width="131" height="12" font="4">hypertrophic cardiomyopathy</text>
<text top="433" left="85" width="12" height="12" font="4">HF</text>
<text top="433" left="167" width="54" height="12" font="4">heart failure</text>
<text top="453" left="85" width="27" height="12" font="4">HF<i>p</i>EF</text>
<text top="453" left="167" width="198" height="12" font="4">heart failure with preserved ejection fraction</text>
<text top="474" left="85" width="25" height="12" font="4">HF<i>r</i>EF</text>
<text top="474" left="167" width="191" height="12" font="4">heart failure with reduced ejection fraction</text>
<text top="495" left="85" width="16" height="12" font="4">ICD</text>
<text top="495" left="167" width="163" height="12" font="4">implantable cardioverter-defibrillator</text>
<text top="516" left="85" width="10" height="12" font="4">LV</text>
<text top="516" left="167" width="64" height="12" font="4">left ventricular</text>
<text top="537" left="85" width="24" height="12" font="4">LVAD</text>
<text top="537" left="167" width="121" height="12" font="4">left ventricular assist device</text>
<text top="557" left="85" width="20" height="12" font="4">LVEF</text>
<text top="557" left="167" width="139" height="12" font="4">left ventricular ejection fraction</text>
<text top="578" left="85" width="12" height="12" font="4">MI</text>
<text top="578" left="167" width="94" height="12" font="4">myocardial infarction</text>
<text top="599" left="85" width="26" height="12" font="4">NICM</text>
<text top="599" left="167" width="130" height="12" font="4">nonischemic cardiomyopathy</text>
<text top="620" left="85" width="24" height="12" font="4">NSVT</text>
<text top="620" left="167" width="163" height="12" font="4">nonsustained ventricular tachycardia</text>
<text top="640" left="85" width="16" height="12" font="4">PET</text>
<text top="640" left="167" width="136" height="12" font="4">positron emission tomography</text>
<text top="661" left="85" width="15" height="12" font="4">PCI</text>
<text top="661" left="167" width="159" height="12" font="4">percutaneous coronary intervention</text>
<text top="682" left="85" width="19" height="12" font="4">PVC</text>
<text top="682" left="167" width="136" height="12" font="4">premature ventricular complex</text>
<text top="703" left="85" width="18" height="12" font="4">QoL</text>
<text top="703" left="167" width="58" height="12" font="4">quality of life</text>
<text top="724" left="85" width="18" height="12" font="4">RCT</text>
<text top="724" left="167" width="121" height="12" font="4">randomized controlled trial</text>
<text top="744" left="85" width="12" height="12" font="4">RV</text>
<text top="744" left="167" width="71" height="12" font="4">right ventricular</text>
<text top="765" left="85" width="25" height="12" font="4">RVOT</text>
<text top="765" left="167" width="132" height="12" font="4">right ventricular outflow tract</text>
<text top="786" left="85" width="19" height="12" font="4">SCA</text>
<text top="786" left="167" width="95" height="12" font="4">sudden cardiac arrest</text>
<text top="807" left="85" width="19" height="12" font="4">SCD</text>
<text top="807" left="167" width="95" height="12" font="4">sudden cardiac death</text>
<text top="827" left="85" width="17" height="12" font="4">SVT</text>
<text top="827" left="167" width="125" height="12" font="4">supraventricular tachycardia</text>
<text top="848" left="85" width="17" height="12" font="4">TOF</text>
<text top="848" left="167" width="79" height="12" font="4">tetralogy of Fallot</text>
<text top="869" left="85" width="13" height="12" font="4">VA</text>
<text top="869" left="167" width="98" height="12" font="4">ventricular arrhythmia</text>
<text top="890" left="85" width="12" height="12" font="4">VT</text>
<text top="890" left="167" width="100" height="12" font="4">ventricular tachycardia</text>
<text top="934" left="74" width="165" height="23" font="15"><b>2. EPIDEMIOLOGY</b></text>
<text top="963" left="74" width="183" height="21" font="18"><b>2.1. General Concepts</b></text>
<text top="990" left="74" width="359" height="17" font="17">VA include a spectrum that ranges from premature </text>
<text top="1008" left="74" width="355" height="17" font="17">ventricular complex (PVC) to ventricular fibrillation (VF), </text>
<text top="1026" left="74" width="355" height="17" font="17">with a clinical presentation that ranges from a total lack </text>
<text top="1044" left="74" width="355" height="17" font="17">of symptoms to cardiac arrest. Most life-threatening VA </text>
<text top="1062" left="74" width="356" height="17" font="17">are associated with ischemic heart disease, particularly </text>
<text top="1080" left="74" width="109" height="17" font="17">in older patients.</text>
<text top="1081" left="183" width="32" height="10" font="19">S2.2.2-1</text>
<text top="1080" left="215" width="215" height="17" font="17"> The risks of VA and SCD vary in </text>
<text top="88" left="452" width="358" height="17" font="17">specific populations with different underlying cardiac </text>
<text top="106" left="452" width="355" height="17" font="17">conditions, and with specific family history and genetic </text>
<text top="124" left="452" width="357" height="17" font="17">variants, and this variation has important implications </text>
<text top="142" left="452" width="230" height="17" font="17">for studying and applying therapies.</text>
<text top="170" left="452" width="312" height="18" font="24"><i><b>2.1.1. Premature Ventricular Complexes and </b></i></text>
<text top="188" left="452" width="119" height="18" font="24"><i><b>Nonsustained VT</b></i></text>
<text top="207" left="452" width="359" height="17" font="17">PVCs are common and increase in frequency with </text>
<text top="225" left="452" width="356" height="17" font="17">age. Although PVCs were found in a healthy military </text>
<text top="243" left="452" width="357" height="17" font="17">population in only 0.6% of those  &lt;20 years of age </text>
<text top="261" left="452" width="242" height="17" font="17">and 2.7% of those &gt;50 years of age</text>
<text top="262" left="695" width="32" height="10" font="19">S2.2.2-5</text>
<text top="261" left="727" width="81" height="17" font="17"> on 12-lead </text>
<text top="279" left="452" width="357" height="17" font="17">ECGs, longer term monitoring shows PVCs in about </text>
<text top="297" left="452" width="319" height="17" font="17">50% of all people with or without heart disease.</text>
<text top="298" left="771" width="32" height="10" font="19">S2.2.2-6</text>
<text top="297" left="803" width="4" height="17" font="17"> </text>
<text top="316" left="452" width="358" height="17" font="17">The presence of PVCs on 2 minutes of monitoring </text>
<text top="334" left="452" width="357" height="17" font="17">of middle-aged patients in the ARIC (Atherosclerosis </text>
<text top="352" left="452" width="351" height="17" font="17">Risk In Communities) study was associated with in-</text>
<text top="370" left="452" width="355" height="17" font="17">creased risk of both ischemic heart disease events and </text>
<text top="388" left="452" width="359" height="17" font="17">mortality, with or without prevalent ischemic heart </text>
<text top="407" left="452" width="51" height="17" font="17">disease.</text>
<text top="407" left="503" width="67" height="10" font="19">S2.2.2-7,S2.2.2-8</text>
<text top="407" left="571" width="237" height="17" font="17"> In the general population, frequent </text>
<text top="425" left="452" width="357" height="17" font="17">PVCs, which are defined as the presence of at least </text>
<text top="443" left="452" width="357" height="17" font="17">1 PVC on a 12-lead ECG or &gt;30 PVCs per hour, are </text>
<text top="461" left="452" width="351" height="17" font="17">associated with increased cardiovascular risk and in-</text>
<text top="479" left="452" width="115" height="17" font="17">creased mortality.</text>
<text top="480" left="568" width="32" height="10" font="19">S2.2.2-9</text>
<text top="479" left="600" width="203" height="17" font="17"> In a study from Taiwan of pa-</text>
<text top="498" left="452" width="355" height="17" font="17">tients without sustained VT or structural heart disease </text>
<text top="516" left="452" width="351" height="17" font="17">who had 24-hour Holter monitoring for clinical evalu-</text>
<text top="534" left="452" width="355" height="17" font="17">ation, multifocal PVCs were associated with increased </text>
<text top="552" left="452" width="360" height="17" font="17">risk of death and nonfatal cardiovascular adverse </text>
<text top="570" left="452" width="68" height="17" font="17">outcomes.</text>
<text top="571" left="520" width="37" height="10" font="19">S2.2.2-10</text>
<text top="570" left="558" width="249" height="17" font="17"> In the same population, nonsustained </text>
<text top="589" left="452" width="351" height="17" font="17">ventricular tachycardia (NSVT) was independently as-</text>
<text top="607" left="452" width="351" height="17" font="17">sociated with increased risk of death and other cardio-</text>
<text top="625" left="452" width="291" height="17" font="17">vascular adverse outcomes, including stroke.</text>
<text top="626" left="743" width="37" height="10" font="19">S2.2.2-11</text>
<text top="625" left="780" width="27" height="17" font="17"> An </text>
<text top="643" left="452" width="356" height="17" font="17">association of PVCs with increased risk of stroke was </text>
<text top="661" left="452" width="217" height="17" font="17">also seen in the ARIC population.</text>
<text top="662" left="670" width="32" height="10" font="19">S2.2.2-8</text>
<text top="680" left="470" width="337" height="17" font="17">Because some studies have shown an association of </text>
<text top="698" left="452" width="357" height="17" font="17">PVCs with adverse outcomes, the detection of PVCs, </text>
<text top="716" left="452" width="351" height="17" font="17">particularly if multifocal and frequent, is generally con-</text>
<text top="734" left="452" width="353" height="17" font="17">sidered a risk factor for adverse cardiovascular outcomes, </text>
<text top="752" left="452" width="354" height="17" font="17">and such patients are generally evaluated to ensure they </text>
<text top="771" left="452" width="356" height="17" font="17">do not have underlying conditions (eg, ischemic heart </text>
<text top="789" left="452" width="357" height="17" font="17">disease, left ventricular [LV] dysfunction) that warrant </text>
<text top="807" left="452" width="351" height="17" font="17">further treatment to reduce risk. PVC and NSVT in pa-</text>
<text top="825" left="452" width="354" height="17" font="17">tients with cardiovascular disease are common and have </text>
<text top="843" left="452" width="259" height="17" font="17">been associated with adverse outcomes.</text>
<text top="844" left="712" width="75" height="10" font="19">S2.2.2-12,S2.2.2-13</text>
<text top="843" left="787" width="21" height="17" font="17"> In </text>
<text top="862" left="452" width="351" height="17" font="17">CAST (Cardiac Arrhythmia Suppression Trials), treat-</text>
<text top="880" left="452" width="357" height="17" font="17">ment of patients with post-myocardial infarction (MI) </text>
<text top="898" left="452" width="358" height="17" font="17">who took antiarrhythmic medications (eg, flecainide, </text>
<text top="916" left="452" width="351" height="17" font="17">encainide, moricizine) increased the risk of death de-</text>
<text top="934" left="452" width="153" height="17" font="17">spite suppression of VA.</text>
<text top="935" left="605" width="75" height="10" font="19">S2.2.2-14,S2.2.2-15</text>
<text top="934" left="681" width="127" height="17" font="17"> Treatment of PVCs </text>
<text top="952" left="452" width="357" height="17" font="17">with antiarrhythmic medications has not been shown </text>
<text top="971" left="452" width="359" height="17" font="17">to reduce mortality and, in the post-MI population, </text>
<text top="989" left="452" width="351" height="17" font="17">treatment with class I sodium channel–blocking medi-</text>
<text top="1007" left="452" width="357" height="17" font="17">cations (eg, quinidine, flecainide) increases the risk of </text>
<text top="1025" left="452" width="41" height="17" font="17">death.</text>
<text top="1026" left="493" width="75" height="10" font="19">S2.2.2-15,S2.2.2-16</text>
<text top="1025" left="568" width="239" height="17" font="17"> Likewise, in patients with a reduced </text>
<text top="1043" left="452" width="355" height="17" font="17">LVEF class I, sodium channel–blocking medications and </text>
<text top="1062" left="452" width="240" height="17" font="17">d-sotalol increase the  risk of death.</text>
<text top="1062" left="692" width="75" height="10" font="19">S2.2.2-16,S2.2.2-17</text>
<text top="1062" left="768" width="43" height="17" font="17"> Beta </text>
<text top="1080" left="452" width="351" height="17" font="17">blockers, nondihydropyridines calcium channel block-</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e280</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 5.</b></text>
<text top="88" left="112" width="322" height="12" font="22"><b>  Table of Definitions of Commonly Used Terms in this Document</b></text>
<text top="112" left="85" width="24" height="12" font="22"><b>Term</b></text>
<text top="112" left="454" width="122" height="12" font="22"><b>Definition or Description</b></text>
<text top="133" left="85" width="101" height="12" font="4">Ventricular tachycardia</text>
<text top="134" left="186" width="22" height="7" font="23">S2.2.2-2</text>
<text top="134" left="232" width="562" height="12" font="4">Cardiac arrhythmia of ≥3 consecutive complexes originating in the ventricles at a rate &gt;100 bpm (cycle length: &lt;600 ms). Types of VT:</text>
<text top="151" left="232" width="407" height="12" font="4">  Sustained: VT &gt;30 s or requiring termination due to hemodynamic compromise in &lt;30 s.</text>
<text top="168" left="232" width="141" height="12" font="4"> Nonsustained/unsustained: </text>
<text top="167" left="366" width="166" height="13" font="4">≥3 beats, terminating spontaneously.</text>
<text top="185" left="232" width="300" height="12" font="4">  Monomorphic: Stable single QRS morphology from beat to beat.</text>
<text top="201" left="232" width="338" height="12" font="4">  Polymorphic: Changing or multiform QRS morphology from beat to beat.</text>
<text top="218" left="232" width="567" height="12" font="4">   Bidirectional: VT with a beat-to-beat alternation in the QRS frontal plane axis, often seen in the setting of digitalis toxicity or </text>
<text top="232" left="242" width="154" height="12" font="4">catecholaminergic polymorphic VT</text>
<text top="252" left="473" width="78" height="12" font="4">Monomorphic VT</text>
<text top="315" left="478" width="69" height="12" font="4">Polymorphic VT</text>
<text top="413" left="478" width="69" height="12" font="4">Bidirectional VT</text>
<text top="475" left="85" width="88" height="12" font="4">Torsades de pointes</text>
<text top="476" left="172" width="22" height="7" font="23">S2.2.2-2</text>
<text top="475" left="232" width="550" height="12" font="4">Torsades de pointes is polymorphic VT that occurs in the setting of a long QT interval and is characterized by a waxing and </text>
<text top="489" left="232" width="544" height="12" font="4">waning QRS amplitude. It often has a long-short initiating sequence with a long coupling interval to the first VT beat and </text>
<text top="502" left="232" width="562" height="12" font="4">may present with salvos of NSVT. The twisting of the points, although characteristic, may not always be seen, especially if the </text>
<text top="516" left="232" width="545" height="12" font="4">episode is nonsustained or if only a limited number of leads are available. Torsades de pointes can result from bradycardia </text>
<text top="529" left="232" width="431" height="12" font="4">including high-grade AV block that leads to a long-short sequence initiating torsades de pointes.</text>
<text top="622" left="85" width="78" height="12" font="4">Ventricular flutter</text>
<text top="622" left="163" width="22" height="7" font="23">S2.2.2-2</text>
<text top="622" left="232" width="554" height="12" font="4">A regular VA ≈300 bpm (cycle length: 200 ms) with a sinusoidal, monomorphic appearance; no isoelectric interval between </text>
<text top="636" left="232" width="119" height="12" font="4">successive QRS complexes.</text>
<text top="725" left="85" width="96" height="12" font="4">Ventricular fibrillation</text>
<text top="726" left="181" width="22" height="7" font="23">S2.2.2-2</text>
<text top="725" left="232" width="570" height="12" font="4">Rapid, grossly irregular electrical activity with marked variability in electrocardiographic waveform, ventricular rate usually &gt;300 </text>
<text top="739" left="232" width="131" height="12" font="4">bpm (cycle length: &lt;200 ms).</text>
<text top="824" left="85" width="96" height="12" font="4">Sudden cardiac arrest</text>
<text top="824" left="181" width="22" height="7" font="23">S2.2.2-2</text>
<text top="824" left="232" width="541" height="12" font="4">SCA is the sudden cessation of cardiac activity such that the victim becomes unresponsive, with either persisting gasping </text>
<text top="837" left="232" width="561" height="12" font="4">respirations or absence of any respiratory movements, and no signs of circulation as manifest by the absence of a perceptible </text>
<text top="851" left="232" width="555" height="12" font="4">pulse. An arrest is presumed to be of cardiac etiology unless it is known or likely to have been caused by trauma, drowning, </text>
<text top="864" left="232" width="408" height="12" font="4">respiratory failure or asphyxia, electrocution, drug overdose, or any other noncardiac cause.</text>
<text top="884" left="85" width="97" height="12" font="4">Sudden cardiac death</text>
<text top="885" left="182" width="22" height="7" font="23">S2.2.2-2</text>
<text top="884" left="232" width="567" height="12" font="4">Sudden and unexpected death occurring within an hour of the onset of symptoms, or occurring in patients found dead within </text>
<text top="898" left="232" width="462" height="12" font="4">24 h of being asymptomatic and presumably due to a cardiac arrhythmia or hemodynamic catastrophe.</text>
<text top="918" left="85" width="54" height="12" font="4">VT/VF storm</text>
<text top="918" left="139" width="23" height="7" font="23">S2.2.2–3</text>
<text top="918" left="232" width="568" height="12" font="4">VT/VF storm (electrical storm or arrhythmic storm) refers to a state of cardiac electrical instability that is defined by ≥3 episodes </text>
<text top="931" left="232" width="301" height="12" font="4">of sustained VT, VF, or appropriate shocks from an ICD within 24 h.</text>
<text top="951" left="85" width="103" height="12" font="4">Primary prevention ICD</text>
<text top="952" left="188" width="22" height="7" font="23">S2.2.2-2</text>
<text top="951" left="232" width="540" height="12" font="4">ICD placement with the intention of preventing SCD in a patient who has not had sustained VT or SCA but who is at an </text>
<text top="965" left="232" width="137" height="12" font="4">increased risk for these events.</text>
<text top="985" left="85" width="110" height="12" font="4">Secondary prevention ICD</text>
<text top="985" left="195" width="21" height="7" font="23">S2.2.2-2</text>
<text top="985" left="232" width="370" height="12" font="4">ICD placement in a patient with prior SCA, sustained VT, or syncope caused by VA.</text>
<text top="1005" left="85" width="110" height="12" font="4">Structural heart disease*</text>
<text top="1005" left="232" width="513" height="12" font="4">This term encompasses IHD, all types of cardiomyopathy, valvular heart disease, and adult congenital heart disease.</text>
<text top="1024" left="85" width="102" height="12" font="4">Cardiac channelopathy</text>
<text top="1025" left="187" width="23" height="7" font="23">S2.2.2–4</text>
<text top="1024" left="232" width="528" height="12" font="4">Arrhythmogenic disease due to a genetic abnormality that results in dysfunction of a cardiac ion channel (eg, long QT </text>
<text top="1038" left="232" width="209" height="12" font="4">syndrome, catecholaminergic polymorphic VT).</text>
<text top="1061" left="86" width="526" height="12" font="4">*The definition of this term may differ across publications. Refer to the entry for the definition used in this document.</text>
<text top="1074" left="86" width="706" height="12" font="4">AV indicates atrioventricular; ICD, implantable cardioverter-defibrillator; IHD, ischemic heart disease; NSVT, nonsustained ventricular tachycardia; SCA, sudden </text>
<text top="1088" left="74" width="569" height="12" font="4">cardiac arrest; SCD, sudden cardiac death; VA, ventricular arrhythmia; VF, ventricular fibrillation; and VT, ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e281</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="357" height="17" font="17">ers, and some antiarrhythmic medications may relieve </text>
<text top="106" left="74" width="165" height="17" font="17">symptoms of palpitations.</text>
<text top="106" left="239" width="36" height="10" font="19">S2.2.2-18</text>
<text top="124" left="92" width="333" height="17" font="17">PVCs that occur during an exercise test are associ-</text>
<text top="142" left="74" width="207" height="17" font="17">ated with a higher risk of death.</text>
<text top="143" left="282" width="36" height="10" font="19">S2.2.2-19</text>
<text top="142" left="318" width="112" height="17" font="17"> In 1 study, PVCs </text>
<text top="160" left="74" width="357" height="17" font="17">that occur during recovery are a stronger predictor of </text>
<text top="179" left="74" width="315" height="17" font="17">death than PVCs occurring only during exercise.</text>
<text top="179" left="389" width="36" height="10" font="19">S2.2.2-20</text>
<text top="179" left="425" width="4" height="17" font="17"> </text>
<text top="197" left="74" width="358" height="17" font="17">However, PVCs are common in trained athletes who </text>
<text top="215" left="74" width="355" height="17" font="17">have palpitations, in whom there does not appear to be </text>
<text top="233" left="74" width="351" height="17" font="17">increased risk of death based on studies of small num-</text>
<text top="251" left="74" width="351" height="17" font="17">bers of athletes, at least in those without other cardio-</text>
<text top="270" left="74" width="146" height="17" font="17">vascular abnormalities.</text>
<text top="270" left="220" width="75" height="10" font="19">S2.2.2-21,S2.2.2-22</text>
<text top="270" left="295" width="135" height="17" font="17"> Complex PVCs may </text>
<text top="288" left="74" width="357" height="17" font="17">not represent a benign finding in endurance athletes. </text>
<text top="306" left="74" width="351" height="17" font="17">An electrophysiological study may be needed to as-</text>
<text top="324" left="74" width="222" height="17" font="17">sess patients’ arrhythmogenic risk.</text>
<text top="325" left="296" width="36" height="10" font="19">S2.2.2-22</text>
<text top="324" left="333" width="98" height="17" font="17"> Very frequent </text>
<text top="342" left="74" width="355" height="17" font="17">PVCs, &gt;10 000 to 20 000 a day, can be associated with </text>
<text top="361" left="74" width="351" height="17" font="17">depressed LV function in some patients that is revers-</text>
<text top="379" left="74" width="357" height="17" font="17">ible with control of the PVCs, and has been referred </text>
<text top="397" left="74" width="240" height="17" font="17">to as PVC-induced cardiomyopathy.</text>
<text top="398" left="315" width="75" height="10" font="19">S2.2.2-23,S2.2.2-24</text>
<text top="397" left="390" width="44" height="17" font="17"> (See </text>
<text top="415" left="74" width="357" height="17" font="17">also Section 8.5. PVC-Induced Cardiomyopathy.) Very </text>
<text top="433" left="74" width="351" height="17" font="17">rarely, idiopathic PVCs from the outflow tract may trig-</text>
<text top="451" left="74" width="357" height="17" font="17">ger malignant VA in patients without structural heart </text>
<text top="470" left="74" width="50" height="17" font="17">disease.</text>
<text top="470" left="124" width="75" height="10" font="19">S2.2.2-25,S2.2.2-26</text>
<text top="497" left="74" width="198" height="18" font="24"><i><b>2.1.2. VT and VF During ACS</b></i></text>
<text top="516" left="74" width="360" height="17" font="17">Approximately half of patients with out-of-hospital </text>
<text top="534" left="74" width="359" height="17" font="17">cardiac arrest with the first rhythm identified as VF </text>
<text top="552" left="74" width="357" height="17" font="17">and who survive to hospital admission have evidence </text>
<text top="570" left="74" width="122" height="17" font="17">of acute MI (AMI).</text>
<text top="571" left="196" width="36" height="10" font="19">S2.2.2-27</text>
<text top="570" left="232" width="199" height="17" font="17"> Of all out-of-hospital cardiac </text>
<text top="589" left="74" width="351" height="17" font="17">arrests, &gt;50% will have significant coronary artery le-</text>
<text top="607" left="74" width="239" height="17" font="17">sions on acute coronary angiography.</text>
<text top="607" left="313" width="36" height="10" font="19">S2.2.2-27</text>
<text top="607" left="350" width="80" height="17" font="17"> Of patients </text>
<text top="625" left="74" width="351" height="17" font="17">hospitalized with AMI, 5% to 10% have VF or sus-</text>
<text top="643" left="74" width="357" height="17" font="17">tained VT prior to hospital presentation, and another </text>
<text top="661" left="74" width="356" height="17" font="17">5% will have VF or sustained VT after hospital arrival, </text>
<text top="680" left="74" width="355" height="17" font="17">most within 48 hours of admission. A study of patients </text>
<text top="698" left="74" width="360" height="17" font="17">with non–ST-elevation ACS who underwent cardiac </text>
<text top="716" left="74" width="357" height="17" font="17">catheterization within 48 hours found VT/VF in 7.6% </text>
<text top="734" left="74" width="356" height="17" font="17">of patients, with 60% of those events within 48 hours </text>
<text top="752" left="74" width="87" height="17" font="17">of admission.</text>
<text top="753" left="161" width="36" height="10" font="19">S2.2.2-28</text>
<text top="752" left="197" width="234" height="17" font="17"> Accelerated idioventricular rhythm </text>
<text top="771" left="74" width="359" height="17" font="17">is a common arrhythmia in patients with acute MI, </text>
<text top="789" left="74" width="351" height="17" font="17">including patients with ST-segment elevation MI un-</text>
<text top="807" left="74" width="358" height="17" font="17">dergoing primary percutaneous coronary intervention </text>
<text top="825" left="74" width="355" height="17" font="17">(PCI). Accelerated idioventricular rhythm is more closely </text>
<text top="843" left="74" width="357" height="17" font="17">related to the extent of infarction than to reperfusion </text>
<text top="862" left="74" width="34" height="17" font="17">itself.</text>
<text top="862" left="108" width="36" height="10" font="19">S2.2.2-29</text>
<text top="880" left="92" width="337" height="17" font="17">Sustained VA that occurs in the setting of an ACS is </text>
<text top="898" left="74" width="356" height="17" font="17">more often polymorphic VT or VF than monomorphic </text>
<text top="916" left="74" width="351" height="17" font="17">VT. Risk factors for VT/VF include prior history of hy-</text>
<text top="934" left="74" width="351" height="17" font="17">pertension, prior MI, ST-segment changes at presenta-</text>
<text top="952" left="74" width="314" height="17" font="17">tion, and chronic obstructive pulmonary disease.</text>
<text top="953" left="388" width="37" height="10" font="19">S2.2.2-30</text>
<text top="952" left="425" width="4" height="17" font="17"> </text>
<text top="971" left="74" width="351" height="17" font="17">A nationwide Danish study found that 11.6% of pa-</text>
<text top="989" left="74" width="357" height="17" font="17">tients with ST-segment elevation MI who underwent </text>
<text top="1007" left="74" width="351" height="17" font="17">PCI had VF prior to the PCI, and that VF was associ-</text>
<text top="1025" left="74" width="357" height="17" font="17">ated with alcohol consumption, preinfarction angina, </text>
<text top="1043" left="74" width="351" height="17" font="17">anterior infarct location, and complete coronary occlu-</text>
<text top="1062" left="74" width="282" height="17" font="17">sion at the time of coronary angiography.</text>
<text top="1062" left="356" width="37" height="10" font="19">S2.2.2-31</text>
<text top="1062" left="393" width="39" height="17" font="17"> In a </text>
<text top="1080" left="74" width="357" height="17" font="17">select group of patients undergoing primary PCI in a </text>
<text top="88" left="452" width="356" height="17" font="17">clinical trial, 5.7% developed sustained VT or VF, with </text>
<text top="106" left="452" width="357" height="17" font="17">two thirds of these events occurring prior to the end </text>
<text top="124" left="452" width="355" height="17" font="17">of the catheterization, and 90% within 48 hours from </text>
<text top="142" left="452" width="351" height="17" font="17">the procedure. VT or VF after primary PCI was associ-</text>
<text top="160" left="452" width="354" height="17" font="17">ated with lower blood pressure, higher heart rate, poor </text>
<text top="178" left="452" width="351" height="17" font="17">coronary flow at the end of the procedure, and incom-</text>
<text top="197" left="452" width="204" height="17" font="17">plete resolution of ST elevation.</text>
<text top="197" left="656" width="37" height="10" font="19">S2.2.2-32</text>
<text top="197" left="693" width="114" height="17" font="17"> Importantly, and </text>
<text top="215" left="452" width="355" height="17" font="17">in contrast to some earlier studies, VT or VF at any time </text>
<text top="233" left="452" width="355" height="17" font="17">was associated with a substantially higher risk of death </text>
<text top="251" left="452" width="351" height="17" font="17">within 90 days. Late VT or VF (after 48 hours of hos-</text>
<text top="269" left="452" width="355" height="17" font="17">pital presentation) was associated with a higher risk of </text>
<text top="288" left="452" width="356" height="17" font="17">death than early VT or VF (within 48 hours of hospital </text>
<text top="306" left="452" width="89" height="17" font="17">presentation).</text>
<text top="307" left="541" width="37" height="10" font="19">S2.2.2-33</text>
<text top="336" left="452" width="304" height="18" font="24"><i><b>2.1.3. Sustained VT and VF Not Associated  </b></i></text>
<text top="354" left="452" width="67" height="18" font="24"><i><b>With ACS</b></i></text>
<text top="372" left="452" width="351" height="17" font="17">Patients with structural heart disease are at an in-</text>
<text top="391" left="452" width="355" height="17" font="17">creased risk for sustained VT and VF. Sustained VT that </text>
<text top="409" left="452" width="357" height="17" font="17">is not associated with an ACS is often monomorphic </text>
<text top="427" left="452" width="357" height="17" font="17">as it is usually due to scar-related reentry, but it may </text>
<text top="445" left="452" width="116" height="17" font="17">degenerate to VF.</text>
<text top="446" left="569" width="37" height="10" font="19">S2.2.2-34</text>
<text top="445" left="605" width="203" height="17" font="17"> The risk and predictors of VT </text>
<text top="463" left="452" width="355" height="17" font="17">in patients with structural heart disease depend on the </text>
<text top="482" left="452" width="355" height="17" font="17">type, severity, and duration of structural heart disease, </text>
<text top="500" left="452" width="351" height="17" font="17">increasing with the severity of ventricular dysfunc-</text>
<text top="518" left="452" width="351" height="17" font="17">tion and the presence of symptomatic HF. Monomor-</text>
<text top="536" left="452" width="358" height="17" font="17">phic VT occurring in the absence of structural heart </text>
<text top="554" left="452" width="357" height="17" font="17">disease is commonly referred to as idiopathic VT and </text>
<text top="572" left="452" width="351" height="17" font="17">is often due to an automatic focus in a characteris-</text>
<text top="591" left="452" width="357" height="17" font="17">tic location, giving rise to typical electrocardiographic </text>
<text top="609" left="452" width="356" height="17" font="17">appearances. Polymorphic VT and VF occurring in the </text>
<text top="627" left="452" width="357" height="17" font="17">absence of structural heart disease are  rare and may </text>
<text top="645" left="452" width="235" height="17" font="17">be due to a cardiac channelopathy,</text>
<text top="646" left="687" width="76" height="10" font="19">S2.2.2-35,S2.2.2-36</text>
<text top="645" left="764" width="40" height="17" font="17"> med-</text>
<text top="663" left="452" width="230" height="17" font="17">ication-induced long QT syndrome,</text>
<text top="664" left="682" width="37" height="10" font="19">S2.2.2-36</text>
<text top="663" left="719" width="90" height="17" font="17"> or they may </text>
<text top="682" left="452" width="88" height="17" font="17">be idiopathic.</text>
<text top="682" left="540" width="76" height="10" font="19">S2.2.2-37,S2.2.2-38</text>
<text top="725" left="452" width="222" height="21" font="18"><b>2.2. Sudden Cardiac Death</b></text>
<text top="752" left="452" width="159" height="18" font="24"><i><b>2.2.1. Incidence of SCD</b></i></text>
<text top="771" left="452" width="362" height="17" font="17">SCA and its most common consequence, SCD, </text>
<text top="771" left="803" width="4" height="17" font="17"> </text>
<text top="789" left="452" width="351" height="17" font="17">constitute major public health problems, account-</text>
<text top="807" left="452" width="362" height="17" font="17">ing for approximately 50% of all cardiovascular </text>
<text top="825" left="452" width="48" height="17" font="17">deaths,</text>
<text top="826" left="501" width="73" height="10" font="19">S2.2.2-1,S2.2.2-39</text>
<text top="825" left="573" width="230" height="17" font="17"> with at least 25% being first symp-</text>
<text top="843" left="452" width="155" height="17" font="17">tomatic cardiac events.</text>
<text top="844" left="607" width="113" height="10" font="19">S2.2.2-1,S2.2.2-40,S2.2.2-41</text>
<text top="843" left="720" width="89" height="17" font="17"> In addition, </text>
<text top="862" left="452" width="355" height="17" font="17">analyses of the magnitude of SCD are limited, in part </text>
<text top="880" left="452" width="357" height="17" font="17">because of the broad range of estimates of the risk </text>
<text top="898" left="452" width="313" height="17" font="17">based on different epidemiological methods.</text>
<text top="899" left="766" width="38" height="10" font="19">S2.2.2-42</text>
<text top="898" left="803" width="4" height="17" font="17"> </text>
<text top="916" left="452" width="357" height="17" font="17">During the past 20 to 30 years, SCD accounted for </text>
<text top="934" left="452" width="358" height="17" font="17">approximately 230 000 to 350 000 deaths per year </text>
<text top="953" left="452" width="358" height="17" font="17">in the United States, with a range of  &lt;170 000 to </text>
<text top="971" left="452" width="359" height="17" font="17">&gt;450 000, depending on epidemiological methods, </text>
<text top="989" left="452" width="242" height="17" font="17">data sources, and inclusion criteria.</text>
<text top="990" left="695" width="78" height="10" font="19">S2.2.2-41,S2.2.2-43</text>
<text top="989" left="773" width="37" height="17" font="17"> The </text>
<text top="1007" left="452" width="351" height="17" font="17">lowest of these extremes came from national extrapo-</text>
<text top="1025" left="452" width="357" height="17" font="17">lation of data from specific local programs, while the </text>
<text top="1043" left="452" width="359" height="17" font="17">highest rates included noncardiac causes of sudden </text>
<text top="1062" left="452" width="361" height="17" font="17">death such as pulmonary embolism or intracranial </text>
<text top="1080" left="452" width="357" height="17" font="17">bleeding. The mid-range numbers were largely based </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="25" size="4" family="Times" color="#231f20"/>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e282</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="484" left="74" width="351" height="17" font="17">on death certificate studies that required a code inclu-</text>
<text top="502" left="74" width="191" height="17" font="17">sive of ischemic heart disease.</text>
<text top="520" left="92" width="339" height="17" font="17">The 2017 update of cardiovascular statistics from </text>
<text top="538" left="74" width="351" height="17" font="17">the AHA estimated the total annual burden of out-</text>
<text top="556" left="74" width="257" height="17" font="17">of-hospital cardiac arrest at 356 500.</text>
<text top="557" left="331" width="37" height="10" font="19">S2.2.2-44</text>
<text top="556" left="368" width="57" height="17" font="17"> An ad-</text>
<text top="574" left="74" width="97" height="17" font="17">ditional 209 </text>
<text top="574" left="162" width="275" height="17" font="17">000 in-hospital cardiac arrests occur </text>
<text top="592" left="74" width="57" height="17" font="17">annually.</text>
<text top="593" left="132" width="37" height="10" font="19">S2.2.2-45</text>
<text top="592" left="169" width="267" height="17" font="17"> Among the out-of-hospital cardiac </text>
<text top="610" left="74" width="359" height="17" font="17">arrest group, approximately 357 000 events trigger </text>
<text top="628" left="74" width="358" height="17" font="17">emergency rescue response, with 97% occurring in </text>
<text top="646" left="74" width="157" height="17" font="17">adults &gt;18 years of age.</text>
<text top="664" left="92" width="333" height="17" font="17">The survival statistics for out-of-hospital cardiac ar-</text>
<text top="682" left="74" width="360" height="17" font="17">rest remain disappointing, with an estimated 10% </text>
<text top="700" left="74" width="136" height="17" font="17">overall survival rate.</text>
<text top="701" left="210" width="36" height="10" font="19">S2.2.2-44</text>
<text top="700" left="246" width="188" height="17" font="17"> Among the subgroup of </text>
<text top="718" left="74" width="355" height="17" font="17">70% of out-of-hospital cardiac arrests that occur in the </text>
<text top="736" left="74" width="356" height="17" font="17">home, survival is 6%. The best reported outcomes are </text>
<text top="754" left="74" width="351" height="17" font="17">from locations with highly developed and publicly vis-</text>
<text top="772" left="74" width="351" height="17" font="17">ible emergency rescue response, along with the com-</text>
<text top="484" left="452" width="356" height="17" font="17">bination of public location of cardiac arrest, bystander </text>
<text top="503" left="452" width="351" height="17" font="17">witnesses willing to provide CPR, first responders arriv-</text>
<text top="522" left="452" width="351" height="17" font="17">ing quickly, shockable rhythm at initial contact, avail-</text>
<text top="541" left="452" width="356" height="17" font="17">ability of automated external defibrillators (AEDs), and </text>
<text top="561" left="452" width="361" height="17" font="17">possibly a benefit from telecommunication-directed </text>
<text top="580" left="452" width="30" height="17" font="17">CPR.</text>
<text top="581" left="482" width="75" height="10" font="19">S2.2.2-46,S2.2.2-47</text>
<text top="580" left="558" width="246" height="17" font="17"> Survival to hospital discharge after in-</text>
<text top="599" left="452" width="299" height="17" font="17">hospital cardiac arrests is estimated to be 24%.</text>
<text top="600" left="751" width="36" height="10" font="19">S2.2.2-48</text>
<text top="599" left="788" width="19" height="17" font="17"> In </text>
<text top="618" left="452" width="355" height="17" font="17">all settings, survival statistics appear to be better when </text>
<text top="638" left="452" width="360" height="17" font="17">rhythms recorded by responders are shockable (VF, </text>
<text top="657" left="452" width="351" height="17" font="17">pulseless VT), compared with pulseless electrical activ-</text>
<text top="676" left="452" width="91" height="17" font="17">ity or asystole.</text>
<text top="677" left="544" width="36" height="10" font="19">S2.2.2-49</text>
<text top="676" left="580" width="228" height="17" font="17"> Although the apparent increase in </text>
<text top="695" left="452" width="356" height="17" font="17">the incidence of pulseless electrical activity or asystole </text>
<text top="715" left="452" width="357" height="17" font="17">could be due to the later arrival of medical care, the </text>
<text top="734" left="452" width="355" height="17" font="17">decrease in the incidence of shockable rhythm has also </text>
<text top="753" left="452" width="356" height="17" font="17">been attributed, in part, to improvements in diagnosis </text>
<text top="772" left="452" width="265" height="17" font="17">and treatment of structural heart disease.</text>
<text top="773" left="717" width="36" height="10" font="19">S2.2.2-40</text>
<text top="425" left="74" width="53" height="12" font="3"><b>Figure 1A. </b></text>
<text top="425" left="127" width="155" height="12" font="22"><b>SCD incidence and total events.</b></text>
<text top="425" left="282" width="22" height="7" font="25"><b>S2.2.2-1</b></text>
<text top="425" left="305" width="3" height="12" font="4"> </text>
<text top="438" left="74" width="276" height="12" font="4">EF indicates ejection fraction; and SCD, sudden cardiac death.</text>
<text top="1070" left="74" width="52" height="12" font="3"><b>Figure 1B. </b></text>
<text top="1070" left="126" width="120" height="12" font="22"><b>SCD and clinical subsets.</b></text>
<text top="1071" left="246" width="22" height="7" font="25"><b>S2.2.2-1</b></text>
<text top="1070" left="269" width="6" height="12" font="22"><b>  </b></text>
<text top="1084" left="74" width="163" height="12" font="4">SCD indicates sudden cardiac death.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e283</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="337" height="18" font="24"><i><b>2.2.2. Population Subgroups and Risk Prediction</b></i></text>
<text top="106" left="74" width="351" height="17" font="17">Risk prediction for SCA and SCD is complex. Risk analy-</text>
<text top="124" left="74" width="356" height="17" font="17">sis is divided into 2 general categories: population risk </text>
<text top="143" left="74" width="276" height="17" font="17">prediction and individual risk prediction.</text>
<text top="143" left="350" width="75" height="10" font="19">S2.2.2-41,S2.2.2-50</text>
<text top="143" left="425" width="4" height="17" font="17"> </text>
<text top="161" left="74" width="357" height="17" font="17">Conventional epidemiological markers provide insight </text>
<text top="179" left="74" width="355" height="17" font="17">into probabilities for the development of ischemic heart </text>
<text top="198" left="74" width="351" height="17" font="17">disease within a general class of subjects, but ade-</text>
<text top="216" left="74" width="351" height="17" font="17">quately tested and validated profiles for SCA risk strati-</text>
<text top="235" left="74" width="355" height="17" font="17">fication of individuals in the general population do not </text>
<text top="253" left="74" width="357" height="17" font="17">presently exist. The challenge of defining SCA risk in </text>
<text top="271" left="74" width="351" height="17" font="17">individuals derives from a population model character-</text>
<text top="290" left="74" width="354" height="17" font="17">ized by large numbers of events diluted into a very large </text>
<text top="308" left="74" width="356" height="17" font="17">denominator (Figure 1). The overall population can be </text>
<text top="326" left="74" width="359" height="17" font="17">subgrouped into  categories based on integration of </text>
<text top="345" left="74" width="356" height="17" font="17">age, presence and extent of disease, and identification </text>
<text top="363" left="74" width="351" height="17" font="17">of small, high-risk subgroups within the large denomi-</text>
<text top="382" left="74" width="163" height="17" font="17">nator general population.</text>
<text top="400" left="92" width="338" height="17" font="17">Increasing age is a strong predictor of risk for SCA, </text>
<text top="418" left="74" width="356" height="17" font="17">but it is not linear. Risk in the general population, over </text>
<text top="437" left="74" width="355" height="17" font="17">time, beginning at 35 years of age has been estimated </text>
<text top="455" left="74" width="357" height="17" font="17">at 1 per 1000 population per year, increasing from a </text>
<text top="473" left="74" width="357" height="17" font="17">risk &lt;1000 at the younger end of that spectrum to a </text>
<text top="492" left="74" width="169" height="17" font="17">higher risk in the elderly.</text>
<text top="493" left="243" width="36" height="10" font="19">S2.2.2-41</text>
<text top="492" left="280" width="153" height="17" font="17"> However, an analysis </text>
<text top="510" left="74" width="357" height="17" font="17">of lifetime risk of SCD, derived from the Framingham </text>
<text top="529" left="74" width="355" height="17" font="17">data, suggested that the incidence of SCD decreases in </text>
<text top="547" left="74" width="315" height="17" font="17">later years, especially in people &gt;75 years of age.</text>
<text top="548" left="389" width="36" height="10" font="19">S2.2.2-51</text>
<text top="547" left="425" width="4" height="17" font="17"> </text>
<text top="565" left="74" width="358" height="17" font="17">The data also suggested that SCD is uniformly more </text>
<text top="584" left="74" width="358" height="17" font="17">common in men than in women at all age groups. </text>
<text top="602" left="74" width="359" height="17" font="17">In contrast, the population of children, adolescents, </text>
<text top="620" left="74" width="357" height="17" font="17">and young adults has an overall annual risk of 1 per </text>
<text top="639" left="74" width="357" height="17" font="17">100 000, and there is somewhat a higher risk of SCD </text>
<text top="657" left="74" width="256" height="17" font="17">at the younger end of that age range.</text>
<text top="658" left="330" width="36" height="10" font="19">S2.2.2-41</text>
<text top="657" left="366" width="59" height="17" font="17"> An age-</text>
<text top="676" left="74" width="356" height="17" font="17">associated transition range, from the mid-20s to 35 to </text>
<text top="694" left="74" width="356" height="17" font="17">40 years of age, is characterized by a steep increase in </text>
<text top="712" left="74" width="351" height="17" font="17">risk from that of the adolescent group to the middle-</text>
<text top="731" left="74" width="351" height="17" font="17">aged group, corresponding to the emergence of isch-</text>
<text top="749" left="74" width="122" height="17" font="17">emic heart disease.</text>
<text top="767" left="92" width="337" height="17" font="17">Although ischemic heart disease remains the most </text>
<text top="786" left="74" width="357" height="17" font="17">common underlying substrate associated with SCD, </text>
<text top="804" left="74" width="357" height="17" font="17">the incidence of ischemic heart disease-related SCD </text>
<text top="823" left="74" width="178" height="17" font="17">appears to be decreasing,</text>
<text top="823" left="252" width="38" height="10" font="19">S2.2.2-52</text>
<text top="823" left="290" width="142" height="17" font="17"> with various forms </text>
<text top="841" left="74" width="351" height="17" font="17">of cardiomyopathy associated with myocardial fibro-</text>
<text top="859" left="74" width="230" height="17" font="17">sis and LV hypertrophy increasing.</text>
<text top="860" left="305" width="38" height="10" font="19">S2.2.2-53</text>
<text top="859" left="342" width="89" height="17" font="17"> In addition, </text>
<text top="878" left="74" width="356" height="17" font="17">a trend over time has suggested that out-of-hospital </text>
<text top="896" left="74" width="358" height="17" font="17">cardiac arrest patients who are admitted alive to a </text>
<text top="914" left="74" width="357" height="17" font="17">hospital are becoming more likely to have high-risk </text>
<text top="933" left="74" width="313" height="17" font="17">clinical profiles, as opposed to manifest disease.</text>
<text top="934" left="388" width="38" height="10" font="19">S2.2.2-54</text>
<text top="933" left="425" width="4" height="17" font="17"> </text>
<text top="951" left="74" width="357" height="17" font="17">The younger population—children, adolescents, and </text>
<text top="970" left="74" width="359" height="17" font="17">young adults—is affected by a series of disorders </text>
<text top="988" left="74" width="359" height="17" font="17">that manifest earlier in life, including the genetic </text>
<text top="1006" left="74" width="362" height="17" font="17">structural disorders and cardiac channelopathies, </text>
<text top="1025" left="74" width="356" height="17" font="17">myocarditis, congenital heart disease, and other rare </text>
<text top="1043" left="74" width="63" height="17" font="17">disorders.</text>
<text top="1044" left="138" width="38" height="10" font="19">S2.2.2-43</text>
<text top="1043" left="176" width="254" height="17" font="17"> During the transition range, from the </text>
<text top="1061" left="74" width="351" height="17" font="17">mid-20s to the mid-30s, causes of SCA and SCD in-</text>
<text top="1080" left="74" width="351" height="17" font="17">clude a lower proportion of inherited diseases and in-</text>
<text top="88" left="452" width="356" height="17" font="17">creasing proportion of ischemic heart disease (&gt;40% </text>
<text top="106" left="452" width="61" height="17" font="17">of cases).</text>
<text top="106" left="514" width="38" height="10" font="19">S2.2.2-43</text>
<text top="124" left="470" width="336" height="17" font="17">Despite the small progress that has been made in risk </text>
<text top="142" left="452" width="357" height="17" font="17">prediction of SCA and SCD, the greatest challenge is </text>
<text top="160" left="452" width="351" height="17" font="17">to identify the relatively small, high-risk subgroups con-</text>
<text top="178" left="452" width="357" height="17" font="17">cealed within the large general population who have </text>
<text top="197" left="452" width="355" height="17" font="17">no identified disease but are at risk of SCA as their first </text>
<text top="215" left="452" width="152" height="17" font="17">cardiac event (Figure 1).</text>
<text top="215" left="604" width="36" height="10" font="19">S2.2.2-50</text>
<text top="263" left="452" width="212" height="23" font="15"><b>3. MECHANISMS OF VA</b></text>
<text top="291" left="452" width="339" height="21" font="18"><b>3.1. Cellular Mechanisms and Substrates</b></text>
<text top="319" left="452" width="351" height="17" font="17">Mechanisms of VA include enhanced normal au-</text>
<text top="337" left="452" width="351" height="17" font="17">tomaticity, abnormal automaticity, triggered activ-</text>
<text top="355" left="452" width="357" height="17" font="17">ity induced by early or late afterdepolarizations, and </text>
<text top="373" left="452" width="49" height="17" font="17">reentry.</text>
<text top="374" left="501" width="54" height="10" font="19">S3.4-1–S3.4-3</text>
<text top="373" left="555" width="254" height="17" font="17"> Reentry requires a trigger to initiate </text>
<text top="391" left="452" width="351" height="17" font="17">the arrhythmia and a substrate to sustain it. The trig-</text>
<text top="410" left="452" width="355" height="17" font="17">ger may be a PVC, which may be due to automaticity. </text>
<text top="428" left="452" width="355" height="17" font="17">The substrate may be structural remodeling secondary </text>
<text top="446" left="452" width="357" height="17" font="17">to an underlying disease process, and often includes </text>
<text top="464" left="452" width="357" height="17" font="17">a scar secondary to a prior MI or surgical repair, or </text>
<text top="482" left="452" width="358" height="17" font="17">patchy fibrosis in the setting of cardiomyopathy or </text>
<text top="500" left="452" width="358" height="17" font="17">hypertrophy. Changes in ion channel or transporter </text>
<text top="519" left="452" width="358" height="17" font="17">function and/or expression and cell to cell coupling </text>
<text top="537" left="452" width="356" height="17" font="17">secondary to the underlying pathology may alter the </text>
<text top="555" left="452" width="351" height="17" font="17">initiation or propagation of the cardiac action poten-</text>
<text top="573" left="452" width="357" height="17" font="17">tial. The electrophysiological substrate is dynamically </text>
<text top="591" left="452" width="359" height="17" font="17">influenced by a variety of factors including cardiac </text>
<text top="609" left="452" width="351" height="17" font="17">metabolism, electrolytes, signaling pathways and au-</text>
<text top="628" left="452" width="357" height="17" font="17">tonomic effects. Enhanced automaticity or abnormal </text>
<text top="646" left="452" width="357" height="17" font="17">automaticity causing VA may arise from subordinate </text>
<text top="664" left="452" width="351" height="17" font="17">pacemaker cells in the His-Purkinje system or ventricu-</text>
<text top="682" left="452" width="105" height="17" font="17">lar myocardium.</text>
<text top="726" left="452" width="145" height="21" font="18"><b>3.2. Automaticity</b></text>
<text top="753" left="452" width="351" height="17" font="17">Normal automaticity results from phase 4 spontane-</text>
<text top="771" left="452" width="351" height="17" font="17">ous depolarization of the transmembrane action po-</text>
<text top="789" left="452" width="351" height="17" font="17">tential arising from a normal resting potential, reach-</text>
<text top="807" left="452" width="300" height="17" font="17">ing threshold and initiating an action potential.</text>
<text top="808" left="752" width="51" height="10" font="19">S3.4-1,S3.4-3</text>
<text top="807" left="803" width="4" height="17" font="17"> </text>
<text top="826" left="452" width="143" height="17" font="17">An initiating current (I</text>
<text top="836" left="595" width="3" height="10" font="19">f</text>
<text top="826" left="598" width="211" height="17" font="17">) is responsible for spontaneous </text>
<text top="844" left="452" width="357" height="17" font="17">phase 4 depolarization in the sinus node. The rate is </text>
<text top="862" left="452" width="351" height="17" font="17">determined by the integration of the maximum dia-</text>
<text top="880" left="452" width="357" height="17" font="17">stolic potential at the end of repolarization, the slope </text>
<text top="898" left="452" width="355" height="17" font="17">of phase 4 depolarization, and the threshold potential. </text>
<text top="916" left="452" width="351" height="17" font="17">In contrast, abnormal automaticity arises from a par-</text>
<text top="935" left="452" width="358" height="17" font="17">tially depolarized membrane potential that is usually </text>
<text top="953" left="452" width="357" height="17" font="17">close to the activation potential  for calcium channels </text>
<text top="971" left="452" width="140" height="17" font="17">in the cell membrane.</text>
<text top="972" left="592" width="51" height="10" font="19">S3.4-1,S3.4-3</text>
<text top="971" left="643" width="165" height="17" font="17"> In the acute phase of an </text>
<text top="989" left="452" width="356" height="17" font="17">MI or during transient ischemia, increased extracellular </text>
<text top="1007" left="452" width="357" height="17" font="17">potassium causes partial depolarization of the resting </text>
<text top="1025" left="452" width="357" height="17" font="17">membrane potential creating injury currents between </text>
<text top="1044" left="452" width="356" height="17" font="17">the infarcted/ischemic tissue and healthy myocardium. </text>
<text top="1062" left="452" width="356" height="17" font="17">These injury currents may initiate spontaneous activity. </text>
<text top="1080" left="452" width="356" height="17" font="17">In ischemia, abnormal automaticity may occur in both </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="26" size="8" family="Times" color="#ffffff"/>
	<fontspec id="27" size="8" family="Times" color="#171849"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e284</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="356" height="17" font="17">ventricular myocytes and Purkinje fibers, and may also </text>
<text top="106" left="74" width="357" height="17" font="17">enhance normal automaticity in Purkinje fibers in the </text>
<text top="124" left="74" width="93" height="17" font="17">ischemic zone.</text>
<text top="167" left="74" width="185" height="21" font="18"><b>3.3. Triggered Activity</b></text>
<text top="194" left="74" width="355" height="17" font="17">Early afterdepolarizations occur during late phase 2 or </text>
<text top="213" left="74" width="247" height="17" font="17">early phase 3 of the action potential,</text>
<text top="213" left="321" width="54" height="10" font="19">S3.4-3–S3.4-5</text>
<text top="213" left="376" width="55" height="17" font="17"> usually </text>
<text top="231" left="74" width="356" height="17" font="17">in the setting of action potential prolongation due to </text>
<text top="249" left="74" width="351" height="17" font="17">an increase in inward currents (the late sodium cur-</text>
<text top="267" left="74" width="351" height="17" font="17">rent, the inward calcium current or the sodium cal-</text>
<text top="285" left="74" width="357" height="17" font="17">cium exchange current) or a decrease in repolarizing </text>
<text top="303" left="74" width="361" height="17" font="17">potassium currents. Under these conditions, early </text>
<text top="321" left="74" width="351" height="17" font="17">afterdepolarizations may be initiated when reacti-</text>
<text top="339" left="74" width="358" height="17" font="17">vation of the inward L-type calcium channel occurs </text>
<text top="357" left="74" width="351" height="17" font="17">before the membrane has returned to a more nega-</text>
<text top="376" left="74" width="357" height="17" font="17">tive potential than that required for calcium channel </text>
<text top="394" left="74" width="359" height="17" font="17">reactivation. Spontaneous calcium release from the </text>
<text top="412" left="74" width="358" height="17" font="17">sarcoplasmic reticulum may also result in activation </text>
<text top="430" left="74" width="358" height="17" font="17">of a depolarizing sodium/calcium exchange current. </text>
<text top="448" left="74" width="356" height="17" font="17">Early afterdepolarizations are the trigger for torsades </text>
<text top="466" left="74" width="356" height="17" font="17">de pointes VT associated with QT prolongation either </text>
<text top="484" left="74" width="357" height="17" font="17">induced by medications or other acquired factors or </text>
<text top="502" left="74" width="355" height="17" font="17">due to mutations of ion channels causing the long QT </text>
<text top="520" left="74" width="356" height="17" font="17">syndrome. In these cases, it is possible that the early </text>
<text top="538" left="74" width="358" height="17" font="17">afterdepolarization/triggered activity sequence is the </text>
<text top="557" left="74" width="294" height="17" font="17">trigger that culminates in polymorphic VT/VF.</text>
<text top="575" left="92" width="340" height="17" font="17">Delayed afterdepolarizations occur after complete </text>
<text top="593" left="74" width="351" height="17" font="17">membrane repolarization and develop under condi-</text>
<text top="611" left="74" width="351" height="17" font="17">tions of intracellular calcium overload. Factors con-</text>
<text top="629" left="74" width="356" height="17" font="17">tributing to elevated intracellular calcium load include </text>
<text top="647" left="74" width="363" height="17" font="17">tachycardia, catecholamines, hypokalemia, digoxin </text>
<text top="665" left="74" width="240" height="17" font="17">toxicity, cardiac hypertrophy, and HF.</text>
<text top="666" left="314" width="52" height="10" font="19">S3.4-6,S3.4-7</text>
<text top="665" left="366" width="65" height="17" font="17"> Elevated </text>
<text top="683" left="74" width="355" height="17" font="17">sarcoplasmic calcium content or increased sensitivity of </text>
<text top="701" left="74" width="351" height="17" font="17">the ryanodine receptor can initiate spontaneous calci-</text>
<text top="719" left="74" width="356" height="17" font="17">um release, which activates a transient inward current </text>
<text top="738" left="74" width="354" height="17" font="17">driven predominantly by the sodium–calcium exchange </text>
<text top="756" left="74" width="356" height="17" font="17">current. If the membrane depolarization is sufficiently </text>
<text top="774" left="74" width="356" height="17" font="17">large, the inward sodium current is activated resulting </text>
<text top="792" left="74" width="351" height="17" font="17">in a triggered action potential. Delayed afterdepolar-</text>
<text top="810" left="74" width="357" height="17" font="17">izations are the underlying mechanism for VT in the </text>
<text top="828" left="74" width="351" height="17" font="17">setting of digoxin toxicity, catecholaminergic polymor-</text>
<text top="846" left="74" width="351" height="17" font="17">phic VT, and idiopathic outflow tract VA. Delayed af-</text>
<text top="864" left="74" width="351" height="17" font="17">terdepolarizations are also considered to be an impor-</text>
<text top="882" left="74" width="357" height="17" font="17">tant trigger of VA in the setting of HF. Purkinje cells </text>
<text top="901" left="74" width="351" height="17" font="17">are more susceptible to spontaneous sarcoplasmic re-</text>
<text top="919" left="74" width="351" height="17" font="17">ticulum calcium release than ventricular myocytes sug-</text>
<text top="937" left="74" width="358" height="17" font="17">gesting that delayed afterdepolarizations may be an </text>
<text top="955" left="74" width="357" height="17" font="17">important mechanism for some Purkinje fiber-related </text>
<text top="973" left="74" width="23" height="17" font="17">VA.</text>
<text top="974" left="97" width="79" height="10" font="19">S3.4-3,S3.4-8,S3.4-9</text>
<text top="1016" left="74" width="101" height="21" font="18"><b>3.4. Reentry</b></text>
<text top="1044" left="74" width="365" height="17" font="17">Reentry is the underlying mechanism for most </text>
<text top="1044" left="425" width="4" height="17" font="17"> </text>
<text top="1062" left="74" width="361" height="17" font="17">sustained VA in the presence of structural heart </text>
<text top="1080" left="74" width="51" height="17" font="17">disease.</text>
<text top="1081" left="125" width="121" height="10" font="19">S3.4-1–S3.4-3,S3.4-10–S3.4-12</text>
<text top="1080" left="246" width="184" height="17" font="17"> Reentry may occur around </text>
<text top="88" left="452" width="357" height="17" font="17">a fixed anatomical obstacle, such as scar after an MI </text>
<text top="106" left="452" width="357" height="17" font="17">or surgically repaired congenital heart disease. In this </text>
<text top="124" left="452" width="351" height="17" font="17">setting, an excitable gap separates the excitation wave-</text>
<text top="142" left="452" width="358" height="17" font="17">front from its tail of refractoriness. The existence of </text>
<text top="161" left="452" width="355" height="17" font="17">structural reentrant substrates provide the rationale for </text>
<text top="179" left="452" width="195" height="17" font="17">VT ablation in scar-related VTs.</text>
<text top="180" left="647" width="61" height="10" font="19">S3.4-11,S3.4-12</text>
<text top="197" left="470" width="338" height="17" font="17">Functional reentry around areas of functional block </text>
<text top="215" left="452" width="355" height="17" font="17">without anatomical obstacles can also occur. Two main </text>
<text top="234" left="452" width="302" height="17" font="17">models of functional reentry have been proposed.</text>
<text top="234" left="754" width="50" height="10" font="19">S3.4-2,S3.4-3</text>
<text top="234" left="803" width="4" height="17" font="17"> </text>
<text top="252" left="452" width="357" height="17" font="17">The leading circle model has a functionally refractory </text>
<text top="270" left="452" width="355" height="17" font="17">core and no excitable gap. Spiral wave reentry is driven </text>
<text top="288" left="452" width="354" height="17" font="17">by a rotor with a curved wavefront and wavetail pivoting </text>
<text top="307" left="452" width="356" height="17" font="17">around an excitable but unexcited core. There remains </text>
<text top="325" left="452" width="351" height="17" font="17">much debate about the precise mechanism(s) of VF (ro-</text>
<text top="343" left="452" width="356" height="17" font="17">tor versus multiple wavelet reentry). Both mechanisms </text>
<text top="361" left="452" width="285" height="17" font="17">may be operational in different phases of VF.</text>
<text top="362" left="737" width="29" height="10" font="19">S3.4-10</text>
<text top="380" left="470" width="338" height="17" font="17">Phase 2 reentry may occur due to heterogeneity of </text>
<text top="398" left="452" width="361" height="17" font="17">ventricular repolarization. Electrotonic currents may </text>
<text top="416" left="452" width="351" height="17" font="17">flow from endocardial sites with longer action poten-</text>
<text top="434" left="452" width="351" height="17" font="17">tial durations to the epicardium with shorter action po-</text>
<text top="453" left="452" width="356" height="17" font="17">tential durations which can result in reexcitation when </text>
<text top="471" left="452" width="357" height="17" font="17">these sites have recovered from refractoriness. This is </text>
<text top="489" left="452" width="358" height="17" font="17">believed to be one potential mechanism of VT/VF in </text>
<text top="507" left="452" width="121" height="17" font="17">Brugada syndrome</text>
<text top="508" left="573" width="24" height="10" font="19">S3.4-3</text>
<text top="507" left="597" width="206" height="17" font="17"> and may also be operative dur-</text>
<text top="526" left="452" width="83" height="17" font="17">ing ischemia.</text>
<text top="578" left="452" width="269" height="23" font="15"><b>4. GENERAL EVALUATION OF </b></text>
<text top="601" left="452" width="293" height="23" font="15"><b>PATIENTS WITH DOCUMENTED  </b></text>
<text top="624" left="452" width="170" height="23" font="15"><b>OR SUSPECTED VA</b></text>
<text top="653" left="452" width="316" height="21" font="18"><b>4.1. History and Physical Examination</b></text>
<text top="687" left="463" width="154" height="12" font="26"><b>Recommendation for Syncope*</b></text>
<text top="704" left="463" width="285" height="12" font="26"><b>Referenced studies that support the recommendation are </b></text>
<text top="717" left="463" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="717" left="538" width="130" height="12" font="27"><a href=""><b>Online Data Supplement 1</b></a></text>
<text top="717" left="668" width="3" height="12" font="26"><b>.</b></text>
<text top="738" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="738" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="738" left="583" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="779" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="779" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="759" left="583" width="207" height="12" font="4">1.  Patients presenting with syncope for which </text>
<text top="772" left="595" width="198" height="12" font="4">VA is documented, or thought to be a likely </text>
<text top="786" left="595" width="201" height="12" font="4">cause, should be hospitalized for evaluation, </text>
<text top="799" left="595" width="138" height="12" font="4">monitoring, and management.</text>
<text top="800" left="732" width="37" height="7" font="23">S4.1-1–S4.1-4</text>
<text top="823" left="464" width="289" height="12" font="4">*This section covers practices that are well accepted, and a new </text>
<text top="836" left="452" width="306" height="12" font="4">recommendation was determined to only be warranted for syncope.</text>
<text top="870" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="897" left="452" width="355" height="17" font="17">VA can produce a wide spectrum of symptoms, and the </text>
<text top="916" left="452" width="357" height="17" font="17">severity of symptoms does not necessarily reflect the </text>
<text top="934" left="452" width="357" height="17" font="17">extent of structural heart disease or the potential risk </text>
<text top="952" left="452" width="358" height="17" font="17">of SCD. Symptoms of VA include palpitations, either </text>
<text top="970" left="452" width="351" height="17" font="17">skipped or extra beats or sustained palpitations, short-</text>
<text top="989" left="452" width="355" height="17" font="17">ness of breath, chest pain, dizziness, near syncope, and </text>
<text top="1007" left="452" width="56" height="17" font="17">syncope.</text>
<text top="1008" left="508" width="51" height="10" font="19">S4.1-5,S4.1-6</text>
<text top="1007" left="559" width="248" height="17" font="17"> Palpitations may correlate with VA but </text>
<text top="1025" left="452" width="299" height="17" font="17">are frequently reported during normal rhythm.</text>
<text top="1026" left="751" width="24" height="10" font="19">S4.1-7</text>
<text top="1025" left="775" width="33" height="17" font="17"> The </text>
<text top="1043" left="452" width="354" height="17" font="17">differential diagnosis of exercise intolerance, chest pain, </text>
<text top="1062" left="452" width="355" height="17" font="17">dyspnea, presyncope, and syncope includes VA but also </text>
<text top="1080" left="452" width="357" height="17" font="17">includes other etiologies. Nonetheless, more dramatic </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e285</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="357" left="452" width="351" height="17" font="17">symptoms, particularly in patients with known or dis-</text>
<text top="375" left="452" width="359" height="17" font="17">covered structural or electrical heart disease should </text>
<text top="394" left="452" width="358" height="17" font="17">prompt focused investigation for possible association </text>
<text top="412" left="452" width="113" height="17" font="17">with VA (Table 6).</text>
<text top="430" left="470" width="341" height="17" font="17">The elucidation of precipitating factors, such as  </text>
<text top="448" left="452" width="351" height="17" font="17">exertional or emotional stress, concurrent medica-</text>
<text top="466" left="452" width="358" height="17" font="17">tions or illness, and alleviating factors is important. </text>
<text top="484" left="452" width="359" height="17" font="17">The presence of a family history of SCD, ischemic </text>
<text top="502" left="452" width="361" height="17" font="17">heart disease, valvular heart disease, nonischemic </text>
<text top="520" left="452" width="356" height="17" font="17">cardiomyopathy (NICM), or HF raises concern for the </text>
<text top="538" left="452" width="359" height="17" font="17">presence of one of these disorders associated with </text>
<text top="556" left="452" width="351" height="17" font="17">VA. Obtaining a complete medication history is im-</text>
<text top="575" left="452" width="356" height="17" font="17">portant. Various antiarrhythmic and other medications </text>
<text top="593" left="452" width="358" height="17" font="17">can cause QT prolongation and torsades de pointes  </text>
<text top="611" left="452" width="4" height="17" font="17">(</text>
<text top="611" left="457" width="152" height="17" font="20"><a href="">www.crediblemeds.org</a></text>
<text top="611" left="608" width="4" height="17" font="17">)</text>
<text top="612" left="613" width="25" height="10" font="19">S4.1-8</text>
<text top="611" left="638" width="174" height="17" font="17">; some medications can </text>
<text top="629" left="452" width="351" height="17" font="17">also induce Brugada type I electrocardiographic pat-</text>
<text top="647" left="452" width="85" height="17" font="17">tern and VF (</text>
<text top="647" left="538" width="156" height="17" font="20"><a href="">www.brugadadrugs.org</a></text>
<text top="647" left="694" width="8" height="17" font="17">).</text>
<text top="648" left="703" width="57" height="10" font="19">S4.1-9,S4.1-10</text>
<text top="665" left="470" width="340" height="17" font="17">Patients with bigeminy and trigeminy can present </text>
<text top="683" left="452" width="355" height="17" font="17">with effective bradycardia, an apical-radial pulse deficit </text>
<text top="701" left="452" width="357" height="17" font="17">and relative hypertension with a wide pulse pressure. </text>
<text top="719" left="452" width="355" height="17" font="17">Effective bradycardia from PVCs can result in inaccurate </text>
<text top="738" left="452" width="355" height="17" font="17">estimation of the heart rate. Although premature beats </text>
<text top="756" left="452" width="351" height="17" font="17">on auscultation of the heart can be detected, the physi-</text>
<text top="774" left="452" width="356" height="17" font="17">cal examination is focused largely on finding evidence </text>
<text top="792" left="452" width="355" height="17" font="17">of structural heart disease. Carotid bruits or diminished </text>
<text top="810" left="452" width="357" height="17" font="17">peripheral pulses may be indicators of atherosclerotic </text>
<text top="828" left="452" width="356" height="17" font="17">disease associated with ischemic heart disease. Jugular </text>
<text top="846" left="452" width="355" height="17" font="17">venous distention, rales, gallops, and peripheral edema </text>
<text top="864" left="452" width="355" height="17" font="17">provide evidence of HF. Auscultation may reveal cardiac </text>
<text top="882" left="452" width="355" height="17" font="17">murmurs consistent with valvular heart disease, such as </text>
<text top="900" left="452" width="351" height="17" font="17">aortic stenosis or mitral regurgitation, and may be as-</text>
<text top="919" left="452" width="351" height="17" font="17">sociated with HF and VA. A midsystolic click may indi-</text>
<text top="937" left="452" width="356" height="17" font="17">cate mitral valve prolapse that can be associated with </text>
<text top="955" left="452" width="23" height="17" font="17">VA.</text>
<text top="956" left="475" width="63" height="10" font="19">S4.1-11–S4.1-13</text>
<text top="955" left="537" width="270" height="17" font="17"> Many VA are asymptomatic and detected </text>
<text top="973" left="452" width="356" height="17" font="17">only on an ECG or telemetry. Such cases highlight the </text>
<text top="991" left="452" width="351" height="17" font="17">need to search for evidence of underlying heart disease.</text>
<text top="1034" left="452" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="1062" left="467" width="337" height="17" font="17">1. Rapid, sustained VT may result in syncope sec-</text>
<text top="1080" left="485" width="326" height="17" font="17">ondary to marked reduction in cardiac output, </text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 6.</b></text>
<text top="88" left="112" width="309" height="12" font="22"><b>  Important Considerations in the Evaluation of Patients With </b></text>
<text top="102" left="74" width="119" height="12" font="22"><b>Known or Suspected VA</b></text>
<text top="139" left="85" width="58" height="12" font="22"><b>Component</b></text>
<text top="126" left="208" width="176" height="12" font="22"><b>Assessment and Findings Relevant  </b></text>
<text top="139" left="236" width="113" height="12" font="22"><b>for VA and/or SCD Risk</b></text>
<text top="160" left="85" width="31" height="12" font="4">History</text>
<text top="160" left="171" width="250" height="12" font="4">1.  Symptoms/events related to arrhythmia: Palpitations, </text>
<text top="174" left="183" width="214" height="12" font="4">lightheadedness, syncope, dyspnea, chest pain, </text>
<text top="187" left="183" width="59" height="12" font="4">cardiac arrest</text>
<text top="208" left="171" width="222" height="12" font="4">2.  Symptoms related to underlying heart disease: </text>
<text top="222" left="183" width="193" height="12" font="4">Dyspnea at rest or on exertion, orthopnea, </text>
<text top="235" left="183" width="223" height="12" font="4">paroxysmal nocturnal dyspnea, chest pain, edema</text>
<text top="256" left="171" width="219" height="12" font="4">3. Precipitating factors: Exercise, emotional stress</text>
<text top="277" left="171" width="242" height="12" font="4">4.  Known heart disease: Coronary, valvular (eg, mitral </text>
<text top="291" left="183" width="209" height="12" font="4">valve prolapse), congenital heart disease, other</text>
<text top="312" left="171" width="250" height="12" font="4">5.  Risk factors for heart disease: Hypertension, diabetes </text>
<text top="325" left="183" width="169" height="12" font="4">mellitus, hyperlipidemia, and smoking</text>
<text top="346" left="171" width="66" height="12" font="4">6. Medications</text>
<text top="367" left="171" width="134" height="12" font="4">  Antiarrhythmic medications</text>
<text top="388" left="171" width="193" height="12" font="4">   Other medications with potential for QT </text>
<text top="402" left="182" width="167" height="12" font="4">prolongation and torsades de pointes</text>
<text top="423" left="171" width="205" height="12" font="4">   Medications with potential to provoke or </text>
<text top="436" left="182" width="60" height="12" font="4">aggravate VA</text>
<text top="457" left="171" width="237" height="12" font="4">    Stimulants including cocaine and amphetamines</text>
<text top="478" left="171" width="200" height="12" font="4">    Supplements including anabolic steroids</text>
<text top="499" left="171" width="244" height="12" font="4">   Medication-medication interaction that could cause </text>
<text top="513" left="182" width="183" height="12" font="4">QT prolongation and torsades de pointes</text>
<text top="534" left="171" width="100" height="12" font="4">7. Past medical history</text>
<text top="555" left="171" width="79" height="12" font="4">  Thyroid disease</text>
<text top="576" left="171" width="219" height="12" font="4">   Acute kidney injury, chronic kidney disease, or </text>
<text top="589" left="182" width="109" height="12" font="4">electrolyte abnormalities</text>
<text top="610" left="171" width="121" height="12" font="4">  Stroke or embolic events</text>
<text top="631" left="171" width="68" height="12" font="4">  Lung disease</text>
<text top="652" left="171" width="239" height="12" font="4">   Epilepsy (arrhythmic syncope can be misdiagnosed </text>
<text top="666" left="182" width="51" height="12" font="4">as epilepsy)</text>
<text top="687" left="171" width="121" height="12" font="4">  Alcohol or illicit drug use</text>
<text top="708" left="171" width="225" height="12" font="4">   Use of over-the-counter medications that could </text>
<text top="721" left="182" width="211" height="12" font="4">cause QT prolongation and torsades de pointes</text>
<text top="742" left="171" width="165" height="12" font="4">  Unexplained motor vehicle crashes</text>
<text top="763" left="85" width="62" height="12" font="4">Family History</text>
<text top="763" left="171" width="251" height="12" font="4">1.  SCD, SCA, or unexplained drowning in a first-degree </text>
<text top="777" left="183" width="32" height="12" font="4">relative</text>
<text top="798" left="171" width="229" height="12" font="4">2.  SIDS or repetitive spontaneous pregnancy losses </text>
<text top="811" left="183" width="202" height="12" font="4">given their potential association with cardiac </text>
<text top="825" left="183" width="73" height="12" font="4">channelopathies</text>
<text top="846" left="171" width="71" height="12" font="4">3. Heart disease</text>
<text top="867" left="171" width="27" height="12" font="4"> IHD</text>
<text top="888" left="171" width="216" height="12" font="4">  Cardiomyopathy: Hypertrophic, dilated, ARVC</text>
<text top="909" left="171" width="121" height="12" font="4">  Congenital heart disease</text>
<text top="930" left="171" width="238" height="12" font="4">   Cardiac channelopathies: Long QT, Brugada, Short </text>
<text top="943" left="182" width="41" height="12" font="4">QT, CPVT</text>
<text top="964" left="171" width="65" height="12" font="4"> Arrhythmias</text>
<text top="985" left="171" width="188" height="12" font="4">  Conduction disorders, pacemakers/ICDs</text>
<text top="1006" left="171" width="189" height="12" font="4">4.  Neuromuscular disease associated with </text>
<text top="1020" left="183" width="79" height="12" font="4">cardiomyopathies</text>
<text top="1041" left="171" width="98" height="12" font="4">  Muscular dystrophy</text>
<text top="1062" left="171" width="47" height="12" font="4">5. Epilepsy</text>
<text top="1084" left="371" width="54" height="12" font="4">(<i>Continued</i> )</text>
<text top="146" left="463" width="55" height="12" font="4">Examination</text>
<text top="146" left="549" width="192" height="12" font="4">1. Heart rate and regularity, blood pressure</text>
<text top="167" left="549" width="118" height="12" font="4">2. Jugular venous pressure</text>
<text top="188" left="549" width="53" height="12" font="4">3. Murmurs</text>
<text top="209" left="549" width="86" height="12" font="4">4. Pulses and bruits</text>
<text top="230" left="549" width="42" height="12" font="4">5. Edema</text>
<text top="250" left="549" width="88" height="12" font="4">6. Sternotomy scars</text>
<text top="274" left="464" width="324" height="12" font="4">ARVC indicates arrhythmogenic right ventricular cardiomyopathy; CPVT, </text>
<text top="287" left="452" width="338" height="12" font="4">catecholaminergic polymorphic ventricular tachycardia; IHD, ischemic heart </text>
<text top="301" left="452" width="351" height="12" font="4">disease; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SIDS, sudden </text>
<text top="314" left="452" width="247" height="12" font="4">infant death syndrome; and VA, ventricular arrhythmia.</text>
<text top="88" left="452" width="37" height="12" font="3"><b>Table 6.</b></text>
<text top="88" left="490" width="62" height="12" font="22"><b> Continued</b></text>
<text top="126" left="463" width="58" height="12" font="22"><b>Component</b></text>
<text top="112" left="586" width="176" height="12" font="22"><b>Assessment and Findings Relevant  </b></text>
<text top="126" left="614" width="113" height="12" font="22"><b>for VA and/or SCD Risk</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e286</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="107" width="319" height="17" font="17">followed by spontaneous recovery if VT termi-</text>
<text top="106" left="107" width="326" height="17" font="17">nates, or SCA if VT persists and is not treated </text>
<text top="125" left="107" width="329" height="17" font="17">promptly. Syncope or SCA may be the first </text>
<text top="143" left="107" width="329" height="17" font="17">manifestation of structural or electrical heart </text>
<text top="162" left="107" width="51" height="17" font="17">disease,</text>
<text top="163" left="158" width="30" height="10" font="19">S4.1-14</text>
<text top="162" left="187" width="238" height="17" font="17"> and some SCA victims have preced-</text>
<text top="181" left="107" width="223" height="17" font="17">ing “sentinel” syncope episodes.</text>
<text top="181" left="330" width="30" height="10" font="19">S4.1-15</text>
<text top="181" left="359" width="73" height="17" font="17"> Syncope, </text>
<text top="199" left="107" width="322" height="17" font="17">or its forewarnings of dizziness, lightheadedness, </text>
<text top="218" left="107" width="324" height="17" font="17">or near-syncope, may constitute a risk factor for </text>
<text top="237" left="107" width="98" height="17" font="17">SCA and SCD.</text>
<text top="237" left="205" width="25" height="10" font="19">S4.1-2</text>
<text top="237" left="230" width="202" height="17" font="17"> The initial evaluation at any </text>
<text top="255" left="106" width="325" height="17" font="17">age focuses on detection or exclusion of heart </text>
<text top="274" left="106" width="324" height="17" font="17">disease. Syncope during exercise should prompt </text>
<text top="292" left="106" width="325" height="17" font="17">thorough evaluation to rule out cardiac causes. </text>
<text top="311" left="106" width="337" height="17" font="17">Cardiac evaluation with echocardiography, </text>
<text top="330" left="106" width="323" height="17" font="17">ambulatory monitoring, and exercise testing may </text>
<text top="348" left="106" width="319" height="17" font="17">be warranted depending on the clinical informa-</text>
<text top="367" left="106" width="82" height="17" font="17">tion elicited.</text>
<text top="368" left="189" width="52" height="10" font="19">S4.1-3,S4.1-4</text>
<text top="367" left="241" width="190" height="17" font="17"> Cardiac causes of syncope </text>
<text top="386" left="107" width="324" height="17" font="17">include sustained VT, high-grade atrioventricular </text>
<text top="404" left="107" width="325" height="17" font="17">block or severe sinus bradycardia or prolonged </text>
<text top="423" left="107" width="324" height="17" font="17">sinus pauses, supraventricular tachycardia (SVT), </text>
<text top="441" left="107" width="329" height="17" font="17">malfunction of pacemakers, VA from cardiac </text>
<text top="460" left="107" width="319" height="17" font="17">channelopathies or structural heart disease syn-</text>
<text top="479" left="107" width="328" height="17" font="17">dromes, such as hypertrophic cardiomyopathy </text>
<text top="497" left="107" width="234" height="17" font="17">(HCM) or congenital heart disease.</text>
<text top="498" left="341" width="84" height="10" font="19">S4.1-3,S4.1-4,S4.1-16</text>
<text top="497" left="425" width="4" height="17" font="17"> </text>
<text top="516" left="107" width="319" height="17" font="17">Cardiac channelopathies and HCM are particu-</text>
<text top="535" left="107" width="326" height="17" font="17">larly important to consider in adolescents and </text>
<text top="553" left="107" width="324" height="17" font="17">young adults. Arrhythmic causes of syncope are </text>
<text top="572" left="107" width="319" height="17" font="17">often associated with very short periods of pre-</text>
<text top="590" left="107" width="324" height="17" font="17">monitory symptoms, or palpitations, and known </text>
<text top="609" left="107" width="325" height="17" font="17">preexisting heart disease, especially a history of </text>
<text top="628" left="107" width="112" height="17" font="17">a low LVEF or HF.</text>
<text top="628" left="219" width="25" height="10" font="19">S4.1-1</text>
<text top="628" left="244" width="181" height="17" font="17"> Among nonarrhythmic car-</text>
<text top="646" left="107" width="319" height="17" font="17">diac causes, considerations should include myo-</text>
<text top="665" left="107" width="328" height="17" font="17">cardial ischemia, severe aortic stenosis, HCM, </text>
<text top="684" left="107" width="324" height="17" font="17">HF, and prosthetic valve malfunction, pulmonary </text>
<text top="702" left="107" width="282" height="17" font="17">embolism, medications, and illicit drug use.</text>
<text top="703" left="389" width="25" height="10" font="19">S4.1-3</text>
<text top="746" left="74" width="234" height="21" font="18"><b>4.2. Noninvasive Evaluation</b></text>
<text top="774" left="74" width="273" height="18" font="24"><i><b>4.2.1. 12-lead ECG and Exercise Testing</b></i></text>
<text top="802" left="85" width="272" height="12" font="26"><b>Recommendations for 12-lead ECG and Exercise Testing</b></text>
<text top="819" left="85" width="290" height="12" font="26"><b>Referenced studies that support the recommendations are </b></text>
<text top="833" left="85" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="833" left="160" width="130" height="12" font="27"><a href=""><b>Online Data Supplement 2</b></a></text>
<text top="833" left="290" width="3" height="12" font="26"><b>.</b></text>
<text top="853" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="853" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="853" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="895" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="895" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="874" left="205" width="212" height="12" font="4">1.  In patients with sustained, hemodynamically </text>
<text top="888" left="217" width="177" height="12" font="4">stable, wide complex tachycardia, a 12-</text>
<text top="901" left="217" width="177" height="12" font="4">lead ECG during tachycardia should be </text>
<text top="915" left="217" width="43" height="12" font="4">obtained.</text>
<text top="915" left="259" width="47" height="7" font="23">S4.2.1-1–S4.2.1-3</text>
<text top="970" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="970" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="936" left="205" width="197" height="12" font="4">2.  In patients with VA symptoms associated </text>
<text top="949" left="217" width="179" height="12" font="4">with exertion, suspected ischemic heart </text>
<text top="963" left="217" width="193" height="12" font="4">disease, or catecholaminergic polymorphic </text>
<text top="976" left="217" width="185" height="12" font="4">ventricular tachycardia, exercise treadmill </text>
<text top="990" left="217" width="207" height="12" font="4">testing is useful to assess for exercise-induced </text>
<text top="1003" left="217" width="16" height="12" font="4">VA.</text>
<text top="1004" left="232" width="46" height="7" font="23">S4.2.1-4,S4.2.1-5</text>
<text top="1044" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="1044" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1024" left="205" width="203" height="12" font="4">3.  In patients with suspected or documented </text>
<text top="1037" left="217" width="187" height="12" font="4">VA, a 12-lead ECG should be obtained in </text>
<text top="1051" left="217" width="191" height="12" font="4">sinus rhythm to look for evidence of heart </text>
<text top="1064" left="217" width="35" height="12" font="4">disease.</text>
<text top="1065" left="252" width="22" height="7" font="23">S4.2.1-6</text>
<text top="87" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="108" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="136" left="467" width="344" height="17" font="17">1. A 12-lead ECG during tachycardia is the first </text>
<text top="155" left="489" width="317" height="17" font="17">diagnostic test that should be done in any patient </text>
<text top="173" left="489" width="314" height="17" font="17">found to be in a stable wide QRS complex tachy-</text>
<text top="192" left="489" width="319" height="17" font="17">cardia on a monitor. VT is the diagnosis in most </text>
<text top="211" left="489" width="314" height="17" font="17">adults with wide complex tachycardia and under-</text>
<text top="229" left="489" width="196" height="17" font="17">lying structural heart disease.</text>
<text top="230" left="685" width="32" height="10" font="19">S4.2.1-3</text>
<text top="229" left="717" width="92" height="17" font="17"> Criteria that </text>
<text top="248" left="489" width="314" height="17" font="17">support a diagnosis of VT include AV dissocia-</text>
<text top="266" left="489" width="317" height="17" font="17">tion, a QRS complex &gt;0.14 s, monophasic R wave </text>
<text top="285" left="489" width="318" height="17" font="17">in aVR, specific QRS morphologies (eg, positively </text>
<text top="304" left="489" width="320" height="17" font="17">or negatively concordant QRS complexes in the </text>
<text top="322" left="489" width="319" height="17" font="17">precordial leads), the absence of an RS complex </text>
<text top="341" left="489" width="320" height="17" font="17">in all precordial leads and an RS interval &gt;100 </text>
<text top="359" left="489" width="208" height="17" font="17">ms in at least 1 precordial lead.</text>
<text top="360" left="697" width="32" height="10" font="19">S4.2.1-2</text>
<text top="360" left="729" width="79" height="17" font="17"> Exceptions </text>
<text top="378" left="489" width="324" height="17" font="17">occur, particularly in patients with advanced </text>
<text top="397" left="489" width="314" height="17" font="17">heart disease and with the use of certain anti-</text>
<text top="415" left="489" width="159" height="17" font="17">arrhythmic medications.</text>
<text top="416" left="649" width="32" height="10" font="19">S4.2.1-1</text>
<text top="415" left="681" width="129" height="17" font="17"> For patients with </text>
<text top="434" left="489" width="319" height="17" font="17">preexisting bundle branch block, comparison of </text>
<text top="453" left="489" width="320" height="17" font="17">the QRS morphology during sinus rhythm with </text>
<text top="471" left="489" width="321" height="17" font="17">that during wide complex tachycardia is often </text>
<text top="490" left="489" width="56" height="17" font="17">relevant.</text>
<text top="508" left="467" width="336" height="17" font="17">2.  For exertion-related arrhythmic symptoms, exer-</text>
<text top="527" left="489" width="321" height="17" font="17">cise in a monitored setting may reproduce the </text>
<text top="546" left="489" width="314" height="17" font="17">symptoms and/or the related arrhythmia, allow-</text>
<text top="564" left="489" width="321" height="17" font="17">ing for diagnosis. Exercise testing is particularly </text>
<text top="583" left="489" width="321" height="17" font="17">important when catecholaminergic polymorphic </text>
<text top="602" left="489" width="321" height="17" font="17">ventricular tachycardia is a possibility. However, </text>
<text top="620" left="489" width="319" height="17" font="17">exertion-related symptoms and findings may not </text>
<text top="639" left="489" width="324" height="17" font="17">be reliably reproducible with exercise testing, </text>
<text top="657" left="489" width="323" height="17" font="17">and long-term electrocardiographic monitoring </text>
<text top="676" left="489" width="322" height="17" font="17">with external or implantable recorders may be </text>
<text top="695" left="489" width="64" height="17" font="17">necessary.</text>
<text top="713" left="467" width="343" height="17" font="17">3. A 12-lead ECG may indicate the presence of </text>
<text top="732" left="489" width="323" height="17" font="17">structural heart disease such as prior MI or </text>
<text top="750" left="489" width="320" height="17" font="17">chamber enlargement that would increase the </text>
<text top="769" left="489" width="321" height="17" font="17">likelihood that a patient’s symptoms might be </text>
<text top="788" left="489" width="321" height="17" font="17">due to VA, or it may provide evidence of the </text>
<text top="806" left="489" width="322" height="17" font="17">underlying substrate for documented VA. An </text>
<text top="825" left="489" width="325" height="17" font="17">ECG may also reveal evidence of inherited </text>
<text top="844" left="489" width="314" height="17" font="17">arrhythmia disorders, such as long QT syn-</text>
<text top="862" left="489" width="318" height="17" font="17">drome, Brugada syndrome, and arrhythmogenic </text>
<text top="881" left="489" width="324" height="17" font="17">right ventricular cardiomyopathy. In patients </text>
<text top="899" left="489" width="319" height="17" font="17">with structural heart disease, QRS duration and </text>
<text top="918" left="489" width="314" height="17" font="17">the presence  of conduction abnormalities pro-</text>
<text top="937" left="489" width="198" height="17" font="17">vide prognostic information.</text>
<text top="937" left="688" width="75" height="10" font="19">S4.2.1-7–S4.2.1-14</text>
<text top="937" left="762" width="51" height="17" font="17"> Data </text>
<text top="955" left="489" width="320" height="17" font="17">on the use of microvolt T wave alternans and </text>
<text top="974" left="489" width="322" height="17" font="17">the signal averaged ECG are inconclusive, as </text>
<text top="993" left="489" width="318" height="17" font="17">such these tests are not routinely used in clinical </text>
<text top="1011" left="489" width="52" height="17" font="17">practice</text>
<text top="1012" left="541" width="80" height="10" font="19">S4.2.1-15–S4.2.1-19</text>
<text top="1011" left="621" width="190" height="17" font="17">; the one exception is the </text>
<text top="1030" left="489" width="318" height="17" font="17">potential use of signal averaged ECG in patients </text>
<text top="1048" left="489" width="314" height="17" font="17">with arrhythmogenic right ventricular cardiomy-</text>
<text top="1067" left="489" width="163" height="17" font="17">opathy (see Section 7.3).</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e287</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="272" height="18" font="24"><i><b>4.2.2. Ambulatory Electrocardiography</b></i></text>
<text top="115" left="85" width="267" height="12" font="26"><b>Recommendation for Ambulatory Electrocardiography</b></text>
<text top="132" left="85" width="285" height="12" font="26"><b>Referenced studies that support the recommendation are </b></text>
<text top="146" left="85" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="146" left="160" width="165" height="12" font="27"><a href=""><b>Online Data Supplements 3 and 4</b></a></text>
<text top="146" left="325" width="3" height="12" font="26"><b>.</b></text>
<text top="166" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="166" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="166" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="208" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="208" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="188" left="205" width="213" height="12" font="4">1.  Ambulatory electrocardiographic monitoring </text>
<text top="201" left="217" width="183" height="12" font="4">is useful to evaluate whether symptoms, </text>
<text top="215" left="217" width="170" height="12" font="4">including palpitations, presyncope, or </text>
<text top="228" left="217" width="122" height="12" font="4">syncope, are caused by VA.</text>
<text top="229" left="338" width="47" height="7" font="23">S4.2.2-1–S4.2.2-4</text>
<text top="267" left="74" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="294" left="89" width="341" height="17" font="17">1.  Ambulatory electrocardiographic monitoring is often </text>
<text top="312" left="107" width="319" height="17" font="17">used to assess the effectiveness of treatments to sup-</text>
<text top="330" left="107" width="323" height="17" font="17">press arrhythmias, but more robust data are needed </text>
<text top="348" left="107" width="328" height="17" font="17">on the clinical use of this practice. Continuous </text>
<text top="366" left="107" width="333" height="17" font="17">or  intermittent ambulatory electrocardiographic </text>
<text top="384" left="107" width="323" height="17" font="17">recording with a Holter monitor or an event recorder </text>
<text top="402" left="107" width="319" height="17" font="17">is helpful in diagnosing suspected arrhythmias, estab-</text>
<text top="420" left="107" width="324" height="17" font="17">lishing their frequency, relating them to symptoms, </text>
<text top="438" left="107" width="323" height="17" font="17">and assessing the response to therapy. Although the </text>
<text top="456" left="107" width="319" height="17" font="17">yield of these tests is relatively low, VT is occasion-</text>
<text top="474" left="107" width="106" height="17" font="17">ally documented.</text>
<text top="475" left="212" width="30" height="10" font="19">S4.2.2-4</text>
<text top="474" left="243" width="188" height="17" font="17"> A 24-hour continuous Holter </text>
<text top="492" left="106" width="326" height="17" font="17">recording is appropriate when symptoms occur at </text>
<text top="510" left="106" width="323" height="17" font="17">least once a day or when quantitation of PVCs/NSVT </text>
<text top="528" left="106" width="326" height="17" font="17">is desired to assess possible VA-related depressed </text>
<text top="546" left="106" width="325" height="17" font="17">ventricular function. For sporadic symptoms, event </text>
<text top="564" left="106" width="322" height="17" font="17">or “looping” monitors are more appropriate because </text>
<text top="582" left="106" width="323" height="17" font="17">they can be activated over extended periods of time </text>
<text top="600" left="106" width="192" height="17" font="17">and increase diagnostic yield.</text>
<text top="601" left="298" width="63" height="10" font="19">S4.2.2-2,S4.2.2-3</text>
<text top="600" left="361" width="73" height="17" font="17"> Adhesive </text>
<text top="618" left="106" width="325" height="17" font="17">patch electrocardiographic monitors can record for </text>
<text top="636" left="106" width="325" height="17" font="17">weeks and allow for continuous short-term 1-lead </text>
<text top="654" left="106" width="327" height="17" font="17">monitoring and patient  activation for symptoms. </text>
<text top="672" left="106" width="319" height="17" font="17">Studies have shown satisfactory patient compli-</text>
<text top="690" left="106" width="330" height="17" font="17">ance, and arrhythmia detection; however, with </text>
<text top="708" left="106" width="319" height="17" font="17">some monitors, detected arrhythmias  are not dis-</text>
<text top="726" left="106" width="293" height="17" font="17">covered until the patch is returned for analysis.</text>
<text top="727" left="400" width="26" height="10" font="19">S4.2.2-</text>
<text top="745" left="107" width="37" height="10" font="19">1,S4.2.2-4</text>
<text top="744" left="144" width="282" height="17" font="17"> Serial evaluations with exercise  testing and/</text>
<text top="763" left="106" width="324" height="17" font="17">or 24-hour ambulatory monitoring are also used to </text>
<text top="781" left="106" width="322" height="17" font="17">assess rhythm burden and response of VA to therapy. </text>
<text top="799" left="106" width="323" height="17" font="17">Notably, implantable monitors are covered in Section </text>
<text top="817" left="106" width="325" height="17" font="17">4.2.3. Importantly, when the suspicion of VA in a </text>
<text top="835" left="106" width="323" height="17" font="17">patient is high, outpatient ambulatory monitoring is </text>
<text top="853" left="106" width="323" height="17" font="17">inappropriate as prompt diagnosis and prevention of </text>
<text top="871" left="106" width="319" height="17" font="17">VA are warranted. It is important to accurately cor-</text>
<text top="889" left="106" width="324" height="17" font="17">relate the symptoms with the arrhythmias detected </text>
<text top="907" left="106" width="195" height="17" font="17">by ambulatory ECG monitoring.</text>
<text top="936" left="74" width="238" height="18" font="24"><i><b>4.2.3. Implanted Cardiac Monitors</b></i></text>
<text top="964" left="85" width="244" height="12" font="26"><b>Recommendation for Implanted Cardiac Monitors</b></text>
<text top="981" left="85" width="285" height="12" font="26"><b>Referenced studies that support the recommendation are </b></text>
<text top="995" left="85" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="995" left="160" width="130" height="12" font="27"><a href=""><b>Online Data Supplement 5</b></a></text>
<text top="995" left="290" width="3" height="12" font="26"><b>.</b></text>
<text top="1016" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="1016" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="1016" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="1057" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="1057" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="1037" left="205" width="173" height="12" font="4">1.  In patients with sporadic symptoms </text>
<text top="1050" left="217" width="196" height="12" font="4">(including syncope) suspected to be related </text>
<text top="1064" left="217" width="188" height="12" font="4">to VA, implanted cardiac monitors can be </text>
<text top="1077" left="217" width="30" height="12" font="4">useful.</text>
<text top="1078" left="246" width="47" height="7" font="23">S4.2.3-1–S4.2.3-4</text>
<text top="87" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="108" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="136" left="467" width="337" height="17" font="17">1. Implanted cardiac monitors provide continu-</text>
<text top="154" left="485" width="325" height="17" font="17">ous rhythm monitoring and stored recordings of </text>
<text top="172" left="485" width="319" height="17" font="17">electrograms based on patient activation or pre-</text>
<text top="191" left="485" width="319" height="17" font="17">set parameters, allowing a prolonged monitor-</text>
<text top="209" left="485" width="325" height="17" font="17">ing period of a few years. These devices require </text>
<text top="227" left="485" width="325" height="17" font="17">a minor invasive procedure with local anesthesia </text>
<text top="246" left="485" width="319" height="17" font="17">for implantation. In patients with sporadic symp-</text>
<text top="264" left="485" width="328" height="17" font="17">toms, including syncope, implantable recorders </text>
<text top="282" left="485" width="324" height="17" font="17">are useful in diagnosing serious tachyarrhythmias </text>
<text top="301" left="485" width="251" height="17" font="17">(including VA) and bradyarrhythmias.</text>
<text top="301" left="736" width="68" height="10" font="19">S4.2.3-2–S4.2.3-4</text>
<text top="301" left="803" width="4" height="17" font="17"> </text>
<text top="319" left="485" width="324" height="17" font="17">They are generally reserved for patients in whom </text>
<text top="337" left="485" width="324" height="17" font="17">other ambulatory monitoring is nonrevealing due </text>
<text top="356" left="485" width="324" height="17" font="17">to the infrequency of events. A 25% added yield </text>
<text top="374" left="485" width="319" height="17" font="17">in diagnosis has been described after an unreveal-</text>
<text top="392" left="485" width="216" height="17" font="17">ing external ambulatory monitor.</text>
<text top="393" left="700" width="32" height="10" font="19">S4.2.3-5</text>
<text top="392" left="732" width="78" height="17" font="17"> In a study </text>
<text top="411" left="485" width="319" height="17" font="17">of patients with syncope, the implantable moni-</text>
<text top="429" left="485" width="319" height="17" font="17">tor had a greater diagnostic yield than “conven-</text>
<text top="447" left="485" width="324" height="17" font="17">tional” testing with external monitoring, tilt table </text>
<text top="466" left="485" width="265" height="17" font="17">testing and electrophysiological study.</text>
<text top="466" left="750" width="32" height="10" font="19">S4.2.3-2</text>
<text top="466" left="781" width="34" height="17" font="17"> A </text>
<text top="484" left="484" width="319" height="17" font="17">systematic review in patients with syncope con-</text>
<text top="502" left="484" width="324" height="17" font="17">cluded that use of these devices provide a higher </text>
<text top="521" left="484" width="326" height="17" font="17">rate of diagnosis and a trend toward reduction </text>
<text top="539" left="484" width="325" height="17" font="17">in syncope relapse after diagnosis, as compared </text>
<text top="558" left="484" width="211" height="17" font="17">with conventional management.</text>
<text top="558" left="695" width="32" height="10" font="19">S4.2.3-3</text>
<text top="558" left="727" width="76" height="17" font="17"> A prospec-</text>
<text top="576" left="484" width="324" height="17" font="17">tive study of patients after MI, with LVEF &lt;40%, </text>
<text top="594" left="484" width="324" height="17" font="17">demonstrated NSVT (&gt;16 beats long) in 13%, VT </text>
<text top="613" left="484" width="273" height="17" font="17">(&gt;30 s) in 3% and VF in 3% of patients.</text>
<text top="613" left="757" width="32" height="10" font="19">S4.2.3-1</text>
<text top="613" left="789" width="20" height="17" font="17"> It </text>
<text top="631" left="484" width="323" height="17" font="17">is important to accurately correlate the symptoms </text>
<text top="649" left="484" width="319" height="17" font="17">with the arrhythmias detected by implanted car-</text>
<text top="668" left="484" width="91" height="17" font="17">diac monitors.</text>
<text top="698" left="452" width="246" height="18" font="24"><i><b>4.2.4. Noninvasive Cardiac Imaging</b></i></text>
<text top="726" left="463" width="254" height="12" font="26"><b>Recommendations for Noninvasive Cardiac Imaging</b></text>
<text top="743" left="463" width="290" height="12" font="26"><b>Referenced studies that support the recommendations are </b></text>
<text top="756" left="463" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="756" left="538" width="130" height="12" font="27"><a href=""><b>Online Data Supplement 6</b></a></text>
<text top="756" left="668" width="3" height="12" font="26"><b>.</b></text>
<text top="777" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="777" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="777" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="832" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="832" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="798" left="583" width="193" height="12" font="4">1.  In patients with known or suspected VA </text>
<text top="812" left="595" width="179" height="12" font="4">that may be associated with underlying </text>
<text top="825" left="595" width="182" height="12" font="4">structural heart disease or a risk of SCA, </text>
<text top="839" left="595" width="159" height="12" font="4">echocardiography is recommended </text>
<text top="852" left="595" width="173" height="12" font="4">for evaluation of cardiac structure and </text>
<text top="866" left="595" width="40" height="12" font="4">function.</text>
<text top="866" left="635" width="46" height="7" font="23">S4.2.4-1,S4.2.4-2</text>
<text top="920" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="920" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="886" left="583" width="189" height="12" font="4">2.  In patients presenting with VA who are </text>
<text top="900" left="595" width="201" height="12" font="4">suspected of having structural heart disease, </text>
<text top="913" left="595" width="204" height="12" font="4">cardiac magnetic resonance imaging (MRI) or </text>
<text top="927" left="595" width="202" height="12" font="4">computed tomography (CT) can be useful to </text>
<text top="940" left="595" width="202" height="12" font="4">detect and characterize underlying structural </text>
<text top="954" left="595" width="61" height="12" font="4">heart disease.</text>
<text top="994" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="1016" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="1043" left="467" width="345" height="17" font="17">1. Assessment of global and regional myocardial </text>
<text top="1061" left="489" width="321" height="17" font="17">function, valvular structure and function, along </text>
<text top="1080" left="489" width="327" height="17" font="17">with assessment for adult congenital heart </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e288</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="319" height="17" font="17">disease is required in patients with or at high risk </text>
<text top="106" left="111" width="314" height="17" font="17">for VA or SCD, including patients with cardiomy-</text>
<text top="124" left="111" width="314" height="17" font="17">opathy, HF, prior MI, family history of cardiomy-</text>
<text top="142" left="111" width="321" height="17" font="17">opathy or SCD, or an inherited structural heart </text>
<text top="160" left="111" width="321" height="17" font="17">disease associated with SCD. Echocardiography </text>
<text top="178" left="111" width="319" height="17" font="17">is the most readily available and commonly used </text>
<text top="196" left="111" width="127" height="17" font="17">imaging technique.</text>
<text top="197" left="238" width="66" height="10" font="19">S4.2.4-1,S4.2.4-2</text>
<text top="196" left="304" width="129" height="17" font="17"> LVEF is a strong, </text>
<text top="214" left="111" width="319" height="17" font="17">independent predictor of SCD and cardiovascular </text>
<text top="232" left="111" width="319" height="17" font="17">mortality and a determinant of eligibility for ICD </text>
<text top="250" left="111" width="283" height="17" font="17">implantation for primary prevention of SCD.</text>
<text top="251" left="394" width="32" height="10" font="19">S4.2.4-1</text>
<text top="250" left="425" width="4" height="17" font="17"> </text>
<text top="268" left="111" width="319" height="17" font="17">In SCD-HeFT (the Sudden Cardiac Death in Heart </text>
<text top="286" left="111" width="80" height="17" font="17">Failure Trial),</text>
<text top="287" left="191" width="32" height="10" font="19">S4.2.4-2</text>
<text top="286" left="222" width="208" height="17" font="17"> the benefit of the ICD was not </text>
<text top="304" left="111" width="314" height="17" font="17">dependent on the modality (ie, echocardiogra-</text>
<text top="323" left="111" width="314" height="17" font="17">phy, radionuclide angiography, or contrast angio-</text>
<text top="341" left="111" width="318" height="17" font="17">grams) by which the LVEF was assessed. In clinical </text>
<text top="359" left="111" width="148" height="17" font="17">practice, if cardiac CT</text>
<text top="359" left="259" width="32" height="10" font="19">S4.2.4-3</text>
<text top="359" left="290" width="143" height="17" font="17"> or cardiac MRI has </text>
<text top="377" left="111" width="314" height="17" font="17">been performed and provides sufficient evalua-</text>
<text top="395" left="111" width="319" height="17" font="17">tion, echocardiography may be unnecessary. This </text>
<text top="413" left="111" width="319" height="17" font="17">recommendation for imaging differs from that of </text>
<text top="431" left="111" width="283" height="17" font="17">the 2017 ACC/AHA/HRS syncope guideline</text>
<text top="432" left="394" width="32" height="10" font="19">S4.2.4-4</text>
<text top="431" left="425" width="4" height="17" font="17"> </text>
<text top="449" left="111" width="297" height="17" font="17">that applies to patients who may not have VA.</text>
<text top="467" left="89" width="336" height="17" font="17">2.  VA or SCA can be an initial manifestation of isch-</text>
<text top="485" left="111" width="320" height="17" font="17">emic heart disease, cardiomyopathic processes, or </text>
<text top="503" left="111" width="320" height="17" font="17">myocarditis. Cardiac CT and cardiac MRI allow for </text>
<text top="521" left="111" width="314" height="17" font="17">evaluation of structural heart disease and assess-</text>
<text top="539" left="111" width="317" height="17" font="17">ment of LV and RV function including quantification </text>
<text top="557" left="111" width="318" height="17" font="17">of LVEF, LV mass and volume, valvular structure and </text>
<text top="576" left="111" width="321" height="17" font="17">coronary anatomy including anomalous coronary </text>
<text top="594" left="111" width="318" height="17" font="17">origins. Cardiac MRI can be useful in the evaluation </text>
<text top="612" left="111" width="314" height="17" font="17">for myocardial scar and infiltrative processes evi-</text>
<text top="630" left="111" width="249" height="17" font="17">dent as late gadolinium enhancement.</text>
<text top="630" left="360" width="65" height="10" font="19">S4.2.4-5–S4.2.4-9</text>
<text top="630" left="425" width="4" height="17" font="17"> </text>
<text top="648" left="111" width="320" height="17" font="17">Cardiac MRI also provides high-quality assessment </text>
<text top="666" left="111" width="319" height="17" font="17">of LV and RV function, size, and degree of fibrosis </text>
<text top="684" left="111" width="321" height="17" font="17">and is particularly useful in arrhythmogenic right </text>
<text top="702" left="111" width="235" height="17" font="17">ventricular cardiomyopathy and HCM.</text>
<text top="732" left="74" width="121" height="18" font="24"><i><b>4.2.5. Biomarkers</b></i></text>
<text top="760" left="85" width="162" height="12" font="26"><b>Recommendation for Biomarkers</b></text>
<text top="777" left="85" width="285" height="12" font="26"><b>Referenced studies that support the recommendation are </b></text>
<text top="790" left="85" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="790" left="160" width="130" height="12" font="27"><a href=""><b>Online Data Supplement 7</b></a></text>
<text top="790" left="290" width="3" height="12" font="26"><b>.</b></text>
<text top="811" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="811" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="811" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="859" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="859" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="832" left="205" width="193" height="12" font="4">1.  In patients with structural heart disease, </text>
<text top="846" left="217" width="201" height="12" font="4">measurement of natriuretic peptides (BNP or </text>
<text top="859" left="217" width="202" height="12" font="4">N-terminal pro-BNP) can be useful by adding </text>
<text top="873" left="217" width="178" height="12" font="4">prognostic information to standard risk </text>
<text top="886" left="217" width="153" height="12" font="4">factors for predicting SCD or SCA.</text>
<text top="887" left="370" width="47" height="7" font="23">S4.2.5-1–S4.2.5-4</text>
<text top="926" left="74" width="346" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="953" left="89" width="337" height="17" font="17">1.  Elevated levels of natriuretic peptides—B-type natri-</text>
<text top="971" left="107" width="327" height="17" font="17">uretic peptide (BNP) or N-terminal pro-BNP—are </text>
<text top="989" left="107" width="319" height="17" font="17">associated with increased risk of SCA and appro-</text>
<text top="1008" left="107" width="323" height="17" font="17">priate ICD therapies, even after adjustment of LVEF </text>
<text top="1026" left="107" width="138" height="17" font="17">and other risk factors.</text>
<text top="1026" left="245" width="66" height="10" font="19">S4.2.5-1–S4.2.5-4</text>
<text top="1026" left="311" width="119" height="17" font="17"> These biomarkers </text>
<text top="1044" left="106" width="328" height="17" font="17">are also predictive of nonsudden cardiovascular </text>
<text top="1062" left="106" width="322" height="17" font="17">mortality and thus are not specific to SCD risk alone. </text>
<text top="1080" left="106" width="325" height="17" font="17">Natriuretic peptides have also been evaluated for </text>
<text top="88" left="484" width="255" height="17" font="17">predicting SCD in the general population.</text>
<text top="88" left="739" width="64" height="10" font="19">S4.2.5-5,S4.2.5-6</text>
<text top="88" left="803" width="4" height="17" font="17"> </text>
<text top="106" left="485" width="323" height="17" font="17">In the Nurses’ Health Study, an elevated N-terminal </text>
<text top="124" left="485" width="322" height="17" font="17">pro-BNP was an independent risk marker for SCD in </text>
<text top="142" left="485" width="178" height="17" font="17">presumably healthy women.</text>
<text top="143" left="663" width="31" height="10" font="19">S4.2.5-5</text>
<text top="142" left="694" width="114" height="17" font="17"> In an older adult </text>
<text top="160" left="484" width="328" height="17" font="17">population, higher baseline levels of N-terminal </text>
<text top="178" left="484" width="324" height="17" font="17">pro-BNP were associated with SCD over a 16-year </text>
<text top="196" left="484" width="110" height="17" font="17">follow-up period.</text>
<text top="197" left="594" width="31" height="10" font="19">S4.2.5-6</text>
<text top="196" left="625" width="184" height="17" font="17"> These biomarkers may also </text>
<text top="215" left="484" width="319" height="17" font="17">have a potential role in facilitating the identifica-</text>
<text top="233" left="484" width="324" height="17" font="17">tion of individuals at increased risk of SCD and VA </text>
<text top="251" left="484" width="325" height="17" font="17">in the general population, particularly in those at </text>
<text top="269" left="484" width="323" height="17" font="17">intermediate or high risk of ischemic heart disease, </text>
<text top="287" left="484" width="319" height="17" font="17">but further studies are needed. Use of biomark-</text>
<text top="305" left="484" width="324" height="17" font="17">ers has not been shown to be useful for selecting </text>
<text top="323" left="484" width="324" height="17" font="17">patients for ICDs. A study of 4431 patients found </text>
<text top="341" left="484" width="319" height="17" font="17">high-sensitivity troponin to be only weakly predic-</text>
<text top="360" left="484" width="79" height="17" font="17">tive of SCD.</text>
<text top="360" left="563" width="31" height="10" font="19">S4.2.5-7</text>
<text top="360" left="594" width="216" height="17" font="17"> However, there are no data on </text>
<text top="378" left="484" width="325" height="17" font="17">whether high-sensitivity troponin can improve the </text>
<text top="396" left="484" width="216" height="17" font="17">current SCD prediction algorithms.</text>
<text top="429" left="452" width="311" height="18" font="24"><i><b>4.2.6. Genetic Considerations in Arrhythmia </b></i></text>
<text top="447" left="452" width="78" height="18" font="24"><i><b>Syndromes</b></i></text>
<text top="475" left="463" width="210" height="12" font="26"><b>Recommendation for Genetic Counselling*</b></text>
<text top="496" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="496" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="496" left="583" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="537" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="537" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="517" left="583" width="198" height="12" font="4">1.  In patients and family members in whom </text>
<text top="531" left="595" width="199" height="12" font="4">genetic testing for risk stratification for SCA </text>
<text top="544" left="595" width="201" height="12" font="4">or SCD is recommended, genetic counseling </text>
<text top="558" left="595" width="55" height="12" font="4">is beneficial.</text>
<text top="582" left="464" width="295" height="12" font="4">*Please refer to section 7.9 for disease-specific recommendations.</text>
<text top="617" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="645" left="452" width="357" height="17" font="17">The diagnosis of most inherited arrhythmia syndromes </text>
<text top="663" left="452" width="360" height="17" font="17">is based on clinical features and family history. The </text>
<text top="681" left="452" width="351" height="17" font="17">availability of genetic testing for inherited arrhyth-</text>
<text top="699" left="452" width="357" height="17" font="17">mia syndromes can: 1) provide opportunity to confirm </text>
<text top="717" left="452" width="359" height="17" font="17">a suspected clinical diagnosis and sometimes provide </text>
<text top="735" left="452" width="359" height="17" font="17">prognostic information for the proband and 2) offer </text>
<text top="753" left="452" width="351" height="17" font="17">cascade screening of potentially affected family mem-</text>
<text top="772" left="452" width="358" height="17" font="17">bers when a disease-causing mutation is identified in </text>
<text top="790" left="452" width="351" height="17" font="17">the proband. The yield of genetic testing varies by dis-</text>
<text top="808" left="452" width="360" height="17" font="17">ease. The verification of pathogenicity of suspected </text>
<text top="826" left="452" width="358" height="17" font="17">mutations is an evolving field, and exome sequencing </text>
<text top="844" left="452" width="351" height="17" font="17">has identified an increasing number of variants of un-</text>
<text top="862" left="452" width="285" height="17" font="17">certain significance in the general population.</text>
<text top="863" left="737" width="66" height="10" font="19">S4.2.6-1–S4.2.6-5</text>
<text top="862" left="803" width="6" height="17" font="17">  </text>
<text top="880" left="452" width="356" height="17" font="17">Genotyping can have therapeutic implications for some </text>
<text top="898" left="452" width="351" height="17" font="17">arrhythmogenic phenotypes such as long QT syn-</text>
<text top="917" left="452" width="176" height="17" font="17">drome and Fabry’s disease,</text>
<text top="917" left="628" width="66" height="10" font="19">S4.2.6-6–S4.2.6-9</text>
<text top="917" left="694" width="109" height="17" font="17"> where a mono-</text>
<text top="935" left="452" width="351" height="17" font="17">genic pathogenic mutation has been clearly identi-</text>
<text top="953" left="452" width="357" height="17" font="17">fied, the risk to mutation positive individuals has been </text>
<text top="971" left="452" width="363" height="17" font="17">extensively studied, and effective therapy relevant </text>
<text top="989" left="452" width="359" height="17" font="17">to the mutation can be instituted. In other diseases, </text>
<text top="1007" left="452" width="351" height="17" font="17">such as Brugada syndrome, the role of a clear mono-</text>
<text top="1025" left="452" width="357" height="17" font="17">genic disease-causing mutation is less certain, and the </text>
<text top="1044" left="452" width="359" height="17" font="17">genotype does not provide therapeutic or prognostic </text>
<text top="1062" left="452" width="196" height="17" font="17">information for the proband.</text>
<text top="1062" left="648" width="109" height="10" font="19">S4.2.6-5,S4.2.6-10–S4.2.6-12</text>
<text top="1062" left="757" width="46" height="17" font="17"> In ar-</text>
<text top="1080" left="452" width="360" height="17" font="17">rhythmogenic right ventricular cardiomyopathy, some </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e289</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="17" font="17">desmosomal mutation positive individuals do not de-</text>
<text top="106" left="74" width="357" height="17" font="17">velop disease, indicating that additional mutations and </text>
<text top="124" left="74" width="359" height="17" font="17">environmental interactions likely influence the clinical  </text>
<text top="142" left="74" width="162" height="17" font="17">development of disease.</text>
<text top="142" left="236" width="76" height="10" font="19">S4.2.6-13–S4.2.6-16</text>
<text top="142" left="312" width="123" height="17" font="17"> Importantly, the </text>
<text top="160" left="74" width="351" height="17" font="17">absence of an identified disease-causing genetic muta-</text>
<text top="178" left="74" width="357" height="17" font="17">tion does not exclude the presence of disease, and as </text>
<text top="196" left="74" width="354" height="17" font="17">such, ongoing monitoring and decision-making are done </text>
<text top="214" left="74" width="351" height="17" font="17">based on the clinical phenotype. Genotyping is frequent-</text>
<text top="232" left="74" width="355" height="17" font="17">ly most useful when a pathogenic mutation is identified </text>
<text top="250" left="74" width="357" height="17" font="17">in the proband, such that screening can be applied to </text>
<text top="268" left="74" width="351" height="17" font="17">relatives who are in a preclinical phase, allowing institu-</text>
<text top="286" left="74" width="355" height="17" font="17">tion of lifestyle changes, therapy, or ongoing monitoring </text>
<text top="304" left="74" width="266" height="17" font="17">for those who are gene mutation positive.</text>
<text top="304" left="340" width="31" height="10" font="19">S4.2.6-7</text>
<text top="304" left="371" width="59" height="17" font="17"> Refer to </text>
<text top="322" left="74" width="312" height="17" font="17">Section 7.9 for disease-specific recommendations.</text>
<text top="340" left="92" width="337" height="17" font="17">In young patients (&lt;40 years of age) without structural </text>
<text top="358" left="74" width="351" height="17" font="17">heart disease who have unexplained cardiac arrest, unex-</text>
<text top="376" left="74" width="357" height="17" font="17">plained near drowning, or recurrent exertional syncope, </text>
<text top="394" left="74" width="356" height="17" font="17">genetic testing may be important to identify an inherited </text>
<text top="412" left="74" width="245" height="17" font="17">arrhythmia syndrome as a likely cause.</text>
<text top="412" left="319" width="77" height="10" font="19">S4.2.6-17–S4.2.6-23</text>
<text top="455" left="74" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="482" left="89" width="339" height="17" font="17">1.  The decision to proceed with genetic testing requires </text>
<text top="500" left="107" width="328" height="17" font="17">discussion regarding the clinical use of genetic </text>
<text top="518" left="107" width="325" height="17" font="17">information to be obtained for both the proband </text>
<text top="536" left="107" width="322" height="17" font="17">and family members, as well as consideration of the </text>
<text top="554" left="107" width="329" height="17" font="17">important psychological, financial, employment, </text>
<text top="572" left="107" width="319" height="17" font="17">disability, and life insurance implications of posi-</text>
<text top="590" left="107" width="103" height="17" font="17">tive genotyping.</text>
<text top="591" left="209" width="150" height="10" font="19">S4.2.6-17,S4.2.6-18,S4.2.6-20,S4.2.6-24</text>
<text top="590" left="359" width="72" height="17" font="17"> Balancing </text>
<text top="608" left="107" width="324" height="17" font="17">privacy of health care information for the proband </text>
<text top="626" left="107" width="323" height="17" font="17">with the “right to know” for family members, and </text>
<text top="644" left="107" width="322" height="17" font="17">the ability to provide appropriate communication of </text>
<text top="662" left="107" width="319" height="17" font="17">information to all potentially affected family mem-</text>
<text top="680" left="107" width="324" height="17" font="17">bers can be challenging on many levels, including </text>
<text top="698" left="107" width="324" height="17" font="17">family dynamics, geographic proximity, and access </text>
<text top="716" left="107" width="99" height="17" font="17">to health care.</text>
<text top="717" left="206" width="36" height="10" font="19">S4.2.6-25</text>
<text top="716" left="241" width="193" height="17" font="17"> For these reasons, genetic </text>
<text top="734" left="107" width="322" height="17" font="17">counseling generally occurs before proceeding with </text>
<text top="752" left="107" width="323" height="17" font="17">genetic testing, and, from a patient’s perspective, is </text>
<text top="770" left="107" width="319" height="17" font="17">optimally provided by genetic counselors, if avail-</text>
<text top="788" left="107" width="245" height="17" font="17">able, in collaboration with physicians.</text>
<text top="789" left="351" width="74" height="10" font="19">S4.2.6-26,S4.2.6-27</text>
<text top="788" left="425" width="4" height="17" font="17"> </text>
<text top="806" left="107" width="325" height="17" font="17">A combined approach of genetic counseling with </text>
<text top="824" left="107" width="326" height="17" font="17">medical guidance may appropriately balance the </text>
<text top="842" left="107" width="326" height="17" font="17">decision as to  whether genetic testing would be </text>
<text top="860" left="107" width="201" height="17" font="17">beneficial on an individual basis.</text>
<text top="903" left="74" width="169" height="21" font="18"><b>4.3. Invasive Testing</b></text>
<text top="930" left="74" width="281" height="18" font="24"><i><b>4.3.1. Invasive Cardiac Imaging: Cardiac </b></i></text>
<text top="948" left="74" width="247" height="18" font="24"><i><b>Catheterization or CT Angiography</b></i></text>
<text top="976" left="85" width="311" height="12" font="26"><b>Recommendation for Invasive Imaging: Cardiac Catheterization</b></text>
<text top="997" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="997" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="997" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="1045" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="1045" left="152" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="1018" left="205" width="173" height="12" font="4">1.  In patients who have recovered from </text>
<text top="1032" left="216" width="183" height="12" font="4">unexplained SCA, CT or invasive coronary </text>
<text top="1045" left="216" width="201" height="12" font="4">angiography is useful to confirm the presence </text>
<text top="1059" left="216" width="206" height="12" font="4">or absence of ischemic heart disease and guide </text>
<text top="1072" left="216" width="180" height="12" font="4">decisions for myocardial revascularization.</text>
<text top="87" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="108" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="135" left="467" width="348" height="17" font="17">1. Although randomized studies are unavailable, </text>
<text top="153" left="485" width="327" height="17" font="17">coronary angiography has an important role in </text>
<text top="171" left="485" width="319" height="17" font="17">establishing or excluding the presence of sig-</text>
<text top="189" left="485" width="330" height="17" font="17">nificant obstructive ischemic heart disease in </text>
<text top="207" left="485" width="325" height="17" font="17">patients with SCA or those with life-threatening  </text>
<text top="225" left="485" width="23" height="17" font="17">VA.</text>
<text top="226" left="508" width="70" height="10" font="19">S4.3.1-1–S4.3.1-4</text>
<text top="225" left="577" width="232" height="17" font="17"> Recurrent polymorphic VT or VF </text>
<text top="243" left="484" width="328" height="17" font="17">can be due to ongoing myocardial ischemia </text>
<text top="261" left="484" width="329" height="17" font="17">that resolves with coronary revascularization. </text>
<text top="279" left="484" width="326" height="17" font="17">Presence of ST-elevation on preresuscitation or </text>
<text top="297" left="484" width="323" height="17" font="17">early postresuscitation ECG suggests ischemia and </text>
<text top="315" left="484" width="322" height="17" font="17">potential ACS warranting urgent angiography and </text>
<text top="333" left="484" width="110" height="17" font="17">revascularization.</text>
<text top="334" left="594" width="32" height="10" font="19">S4.3.1-5</text>
<text top="333" left="626" width="182" height="17" font="17"> ST-elevation can also result </text>
<text top="351" left="485" width="322" height="17" font="17">from coronary spasm or DC shocks. The absence of </text>
<text top="369" left="485" width="324" height="17" font="17">ST-elevation after cardiac arrest does not exclude </text>
<text top="387" left="485" width="319" height="17" font="17">obstructive or thrombotic coronary lesions. A cor-</text>
<text top="405" left="485" width="319" height="17" font="17">onary angiogram may not be warranted if a non-</text>
<text top="423" left="485" width="326" height="17" font="17">ischemic cause of SCA is established. Coronary </text>
<text top="441" left="485" width="324" height="17" font="17">and CT angiography also have an important role </text>
<text top="459" left="485" width="323" height="17" font="17">excluding the presence of anomalous origin of the </text>
<text top="477" left="485" width="243" height="17" font="17">coronary arteries that may cause SCD.</text>
<text top="511" left="452" width="277" height="18" font="24"><i><b>4.3.2. Electrophysiological Study for VA</b></i></text>
<text top="539" left="463" width="241" height="12" font="26"><b>Recommendations for Electrophysiological Study</b></text>
<text top="556" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="569" left="463" width="165" height="12" font="27"><a href=""><b>Online Data Supplements 8 and 9</b></a></text>
<text top="569" left="628" width="3" height="12" font="26"><b>.</b></text>
<text top="590" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="590" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="590" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="652" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="652" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="611" left="583" width="201" height="12" font="4">1.  In patients with ischemic cardiomyopathy, </text>
<text top="625" left="595" width="203" height="12" font="4">NICM, or adult congenital heart disease who </text>
<text top="638" left="595" width="186" height="12" font="4">have syncope or other VA symptoms and </text>
<text top="652" left="595" width="193" height="12" font="4">who do not meet indications for a primary </text>
<text top="665" left="595" width="177" height="12" font="4">prevention ICD, an electrophysiological </text>
<text top="679" left="595" width="197" height="12" font="4">study can be useful for assessing the risk of </text>
<text top="692" left="595" width="58" height="12" font="4">sustained VT.</text>
<text top="693" left="653" width="47" height="7" font="23">S4.3.2-1–S4.3.2-7</text>
<text top="727" left="468" width="32" height="12" font="22"><b>III: No </b></text>
<text top="740" left="465" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="733" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="713" left="583" width="178" height="12" font="4">2.  In patients who meet criteria for ICD </text>
<text top="727" left="595" width="193" height="12" font="4">implantation, an electrophysiological study </text>
<text top="740" left="595" width="183" height="12" font="4">for the sole reason of inducing VA is not </text>
<text top="754" left="595" width="136" height="12" font="4">indicated for risk stratification.</text>
<text top="754" left="731" width="51" height="7" font="23">S4.3.2-8–S4.3.2-11</text>
<text top="801" left="468" width="32" height="12" font="22"><b>III: No </b></text>
<text top="815" left="465" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="808" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="774" left="583" width="172" height="12" font="4">3.  An electrophysiological study is not </text>
<text top="788" left="595" width="175" height="12" font="4">recommended for risk stratification for </text>
<text top="801" left="595" width="178" height="12" font="4">VA in the setting of long QT syndrome, </text>
<text top="815" left="595" width="192" height="12" font="4">catecholaminergic polymorphic ventricular </text>
<text top="828" left="595" width="183" height="12" font="4">tachycardia, short QT syndrome, or early </text>
<text top="842" left="595" width="115" height="12" font="4">repolarization syndromes.</text>
<text top="842" left="709" width="54" height="7" font="23">S4.3.2-12–S4.3.2-16</text>
<text top="885" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="912" left="452" width="351" height="17" font="17">Electrophysiological study can be used to induce sus-</text>
<text top="930" left="452" width="354" height="17" font="17">tained VA in patients with known or suspected VA. With </text>
<text top="948" left="452" width="351" height="17" font="17">the advent of the ICD and its proven benefit in the pri-</text>
<text top="966" left="452" width="355" height="17" font="17">mary and secondary prevention of SCD, there are fewer </text>
<text top="984" left="452" width="355" height="17" font="17">indications for programmed stimulation to provoke VA. </text>
<text top="1002" left="452" width="355" height="17" font="17">Patients with HF and LVEF ≤35% generally will have an </text>
<text top="1020" left="452" width="357" height="17" font="17">indication for an ICD and specific induction of VT/VF </text>
<text top="1038" left="452" width="355" height="17" font="17">before implantation is not necessary. Patients with LVEF </text>
<text top="1056" left="452" width="356" height="17" font="17">&gt;35% and unexplained syncope or near-syncope may </text>
<text top="1074" left="452" width="355" height="17" font="17">benefit from an electrophysiological study to determine </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e290</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="355" height="17" font="17">if VT/VF is the cause of symptoms and to guide further </text>
<text top="106" left="74" width="357" height="17" font="17">therapy. Induction of VT/VF is often attempted before </text>
<text top="124" left="74" width="356" height="17" font="17">catheter ablation of the arrhythmia substrate to guide </text>
<text top="142" left="74" width="351" height="17" font="17">the procedure and to determine the success of the in-</text>
<text top="160" left="74" width="351" height="17" font="17">tervention after ablation is performed. An electrophysi-</text>
<text top="178" left="74" width="354" height="17" font="17">ological study can be used to determine the mechanism </text>
<text top="196" left="74" width="357" height="17" font="17">of a wide complex tachycardia. See Sections 7.3, 7.4, </text>
<text top="214" left="74" width="356" height="17" font="17">7.6, 7.9.1.3, and 10.8 for recommendations regarding </text>
<text top="232" left="74" width="331" height="17" font="17">electrophysiological study for specific disease states.</text>
<text top="275" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="296" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="324" left="89" width="340" height="17" font="17">1.  A study of electrophysiological testing in patients </text>
<text top="342" left="111" width="321" height="17" font="17">with symptomatic NICM found inducible VT/VF </text>
<text top="360" left="111" width="320" height="17" font="17">in 28% of patients which was associated with a </text>
<text top="378" left="111" width="278" height="17" font="17">higher rate of ICD events during follow-up.</text>
<text top="379" left="389" width="36" height="10" font="19">S4.3.2-17</text>
<text top="378" left="425" width="4" height="17" font="17"> </text>
<text top="396" left="111" width="314" height="17" font="17">In a prospective cohort of 180 patients with isch-</text>
<text top="414" left="111" width="318" height="17" font="17">emic or NICM and syncope, induction of VT or VF </text>
<text top="432" left="111" width="314" height="17" font="17">at electrophysiological study correlated with car-</text>
<text top="450" left="111" width="318" height="17" font="17">diac mortality only in patients with ischemic heart </text>
<text top="468" left="111" width="319" height="17" font="17">disease. In patients with NICM, cardiac mortality </text>
<text top="486" left="111" width="320" height="17" font="17">correlated with LVEF but not with inducibility on </text>
<text top="504" left="111" width="166" height="17" font="17">electrophysiological study.</text>
<text top="505" left="277" width="36" height="10" font="19">S4.3.2-18</text>
<text top="522" left="89" width="336" height="17" font="17">2. In patients who meet criteria for ICD implanta-</text>
<text top="540" left="111" width="314" height="17" font="17">tion (ie, HF and LVEF  ≤35%), data do not sup-</text>
<text top="558" left="111" width="321" height="17" font="17">port the routine use of electrophysiological study </text>
<text top="576" left="111" width="321" height="17" font="17">solely for risk stratification, as such patients have </text>
<text top="595" left="111" width="322" height="17" font="17">been shown to derive survival benefit from the  </text>
<text top="613" left="111" width="26" height="17" font="17">ICD.</text>
<text top="613" left="137" width="68" height="10" font="19">S4.3.2-8–S4.3.2-11</text>
<text top="613" left="204" width="224" height="17" font="17"> An electrophysiological study may be </text>
<text top="631" left="111" width="321" height="17" font="17">helpful, however, in selected patients suspected to </text>
<text top="649" left="111" width="319" height="17" font="17">have preexcitation or supraventricular arrhythmias as </text>
<text top="667" left="111" width="318" height="17" font="17">the cause of symptoms or wide complex tachycardias </text>
<text top="685" left="111" width="320" height="17" font="17">that warrant definitive diagnosis and management. </text>
<text top="703" left="111" width="321" height="17" font="17">SVT leading to VT/VF or aberrantly conducted SVT </text>
<text top="721" left="111" width="320" height="17" font="17">may also be suspected in younger patients or those </text>
<text top="739" left="111" width="319" height="17" font="17">with a preserved LVEF. Induction of SVT and ablation </text>
<text top="757" left="111" width="320" height="17" font="17">may then be curative, with no need for an ICD. In </text>
<text top="775" left="111" width="320" height="17" font="17">such cases, failure to induce VT/VF after elimination </text>
<text top="793" left="111" width="263" height="17" font="17">of the substrate for SVT would be expected.</text>
<text top="811" left="89" width="340" height="17" font="17">3.  Risk stratification for channelopathies is generally </text>
<text top="829" left="111" width="274" height="17" font="17">made on the basis of symptoms, the ECG,</text>
<text top="830" left="385" width="43" height="10" font="19">S4.3.2-13, </text>
<text top="848" left="111" width="74" height="10" font="19">S4.3.2-19–S4.3.2-24</text>
<text top="847" left="185" width="166" height="17" font="17"> exercise treadmill testing,</text>
<text top="848" left="351" width="74" height="10" font="19">S4.3.2-25–S4.3.2-27</text>
<text top="847" left="425" width="4" height="17" font="17"> </text>
<text top="865" left="111" width="235" height="17" font="17">and the results of genetic testing.</text>
<text top="866" left="346" width="79" height="10" font="19">S4.3.2-28–S4.3.2-32</text>
<text top="865" left="425" width="4" height="17" font="17"> </text>
<text top="883" left="111" width="322" height="17" font="17">The electrophysiological study (ie, programmed </text>
<text top="901" left="111" width="320" height="17" font="17">ventricular stimulation) does not have prognostic </text>
<text top="919" left="111" width="319" height="17" font="17">value for risk stratification in patients with these </text>
<text top="938" left="111" width="157" height="17" font="17">cardiac channelopathies.</text>
<text top="938" left="268" width="77" height="10" font="19">S4.3.2-12–S4.3.2-15</text>
<text top="986" left="74" width="291" height="23" font="15"><b>5. THERAPIES FOR TREATMENT  </b></text>
<text top="1008" left="74" width="211" height="23" font="15"><b>OR PREVENTION OF VA</b></text>
<text top="1037" left="74" width="204" height="21" font="18"><b>5.1. Medication Therapy</b></text>
<text top="1064" left="74" width="358" height="17" font="17">With the exception of beta blockers (eg, metoprolol </text>
<text top="1082" left="74" width="356" height="17" font="17">succinate, carvedilol), there is no evidence from RCTs </text>
<text top="88" left="452" width="355" height="17" font="17">that antiarrhythmic medications for VA improve survival </text>
<text top="106" left="452" width="355" height="17" font="17">when given for the primary or secondary prevention of </text>
<text top="124" left="452" width="355" height="17" font="17">SCD. However, the use of these medications is essential </text>
<text top="142" left="452" width="357" height="17" font="17">in some patients to control arrhythmias and improve </text>
<text top="160" left="452" width="359" height="17" font="17">symptoms. Medication use for VA is discussed, and </text>
<text top="178" left="452" width="351" height="17" font="17">any recommendations are listed, in subsequent sec-</text>
<text top="197" left="452" width="351" height="17" font="17">tions. Further, medication-induced proarrhythmia is ad-</text>
<text top="215" left="452" width="152" height="17" font="17">dressed in Section 10.7.</text>
<text top="233" left="470" width="341" height="17" font="17">Antiarrhythmic medications are often categorized </text>
<text top="251" left="452" width="357" height="17" font="17">by the Vaughan Williams 4-level schema (class I: fast </text>
<text top="269" left="452" width="357" height="17" font="17">sodium channel blockers; class II: beta blockers; class </text>
<text top="287" left="452" width="357" height="17" font="17">III: repolarization potassium current blockers; class IV: </text>
<text top="306" left="452" width="312" height="17" font="17">nondihydropyridines calcium channel blockers).</text>
<text top="306" left="764" width="39" height="10" font="19">S5.1.5.2-1</text>
<text top="306" left="803" width="4" height="17" font="17"> </text>
<text top="324" left="452" width="351" height="17" font="17">This system does not address the complexities in antiar-</text>
<text top="342" left="452" width="351" height="17" font="17">rhythmic medications, since nearly every agent has mul-</text>
<text top="360" left="452" width="358" height="17" font="17">tiple effects. Table  7 shows uses, electrophysiological </text>
<text top="378" left="452" width="356" height="17" font="17">effects, pharmacological effects, and common adverse </text>
<text top="396" left="452" width="241" height="17" font="17">effects of antiarrhythmic medications.</text>
<text top="428" left="452" width="305" height="18" font="24"><i><b>5.1.1. Medications With Prominent Sodium </b></i></text>
<text top="446" left="452" width="125" height="18" font="24"><i><b>Channel Blockade</b></i></text>
<text top="464" left="452" width="351" height="17" font="17">Except in specific circumstances, sodium channel block-</text>
<text top="483" left="452" width="356" height="17" font="17">ers (Vaughn-Williams class I agents) have a limited role </text>
<text top="501" left="452" width="356" height="17" font="17">in the prevention of VT/SCD; this is based on a lack of </text>
<text top="519" left="452" width="351" height="17" font="17">survival benefit and increased mortality observed dur-</text>
<text top="537" left="452" width="351" height="17" font="17">ing chronic therapy in patients with ischemic heart dis-</text>
<text top="555" left="452" width="357" height="17" font="17">ease (see Section 10.7). Specific circumstances where </text>
<text top="573" left="452" width="351" height="17" font="17">sodium channel blockers have been used to treat VT/</text>
<text top="591" left="452" width="351" height="17" font="17">SCA include: intravenous lidocaine for patients with re-</text>
<text top="610" left="452" width="308" height="17" font="17">fractory VT/cardiac arrest (especially witnessed)</text>
<text top="610" left="760" width="39" height="10" font="19">S5.1.5.2-3</text>
<text top="610" left="799" width="8" height="17" font="17">; </text>
<text top="628" left="452" width="308" height="17" font="17">oral mexiletine for congenital long QT syndrome</text>
<text top="628" left="760" width="39" height="10" font="19">S5.1.5.2-4</text>
<text top="628" left="799" width="8" height="17" font="17">; </text>
<text top="646" left="452" width="351" height="17" font="17">quinidine for patients with Brugada syndrome; and fle-</text>
<text top="664" left="452" width="351" height="17" font="17">cainide for patients with catecholaminergic polymor-</text>
<text top="682" left="452" width="184" height="17" font="17">phic ventricular tachycardia.</text>
<text top="683" left="636" width="39" height="10" font="19">S5.1.5.2-5</text>
<text top="682" left="675" width="135" height="17" font="17"> These medications </text>
<text top="700" left="452" width="351" height="17" font="17">could also be used in ICD patients with drug- and abla-</text>
<text top="719" left="452" width="115" height="17" font="17">tion-refractory VT.</text>
<text top="737" left="470" width="339" height="17" font="17">One newer medication of potential benefit, based </text>
<text top="755" left="452" width="359" height="17" font="17">on very limited data, is ranolazine. This medication, </text>
<text top="773" left="452" width="356" height="17" font="17">developed and FDA-approved as an antianginal agent, </text>
<text top="791" left="452" width="356" height="17" font="17">provides relatively specific late sodium channel current </text>
<text top="809" left="452" width="358" height="17" font="17">blockade in addition to less potent blockade of the </text>
<text top="828" left="452" width="351" height="17" font="17">phase 3 repolarizing potassium current; that is, the rap-</text>
<text top="846" left="452" width="355" height="17" font="17">id delayed rectifier potassium current; IKr. The potential </text>
<text top="864" left="452" width="355" height="17" font="17">for clinical antiarrhythmic efficacy is supported by basic </text>
<text top="882" left="452" width="210" height="17" font="17">studies and experimental models.</text>
<text top="883" left="662" width="39" height="10" font="19">S5.1.5.2-6</text>
<text top="882" left="701" width="105" height="17" font="17"> Clinical data are </text>
<text top="900" left="452" width="355" height="17" font="17">scant. In a study of 12 patients, ranolazine reduced ICD </text>
<text top="918" left="452" width="358" height="17" font="17">shocks in otherwise medication-resistant VT/VF in 11 </text>
<text top="937" left="452" width="55" height="17" font="17">patients.</text>
<text top="937" left="507" width="39" height="10" font="19">S5.1.5.2-7</text>
<text top="937" left="546" width="261" height="17" font="17"> In MERLIN TIMI-36 (Metabolic Efficiency </text>
<text top="955" left="452" width="356" height="17" font="17">With Ranolazine for Less Ischemia in Non-ST-Elevation </text>
<text top="973" left="452" width="355" height="17" font="17">Acute Coronary Syndromes-Thrombolysis In Myocardial </text>
<text top="991" left="452" width="357" height="17" font="17">Infarction 36), ranolazine did not reduce SCD but did </text>
<text top="1009" left="452" width="356" height="17" font="17">reduce VT in the first few days after a non-ST-segment </text>
<text top="1027" left="452" width="96" height="17" font="17">elevation ACS.</text>
<text top="1028" left="548" width="39" height="10" font="19">S5.1.5.2-8</text>
<text top="1027" left="587" width="223" height="17" font="17"> In 1 RCT, high-risk ICD patients </text>
<text top="1045" left="452" width="351" height="17" font="17">with ischemic or NICM were randomly assigned to ra-</text>
<text top="1064" left="452" width="312" height="17" font="17">nolazine 1000 mg twice a day versus placebo.</text>
<text top="1064" left="764" width="39" height="10" font="19">S5.1.5.2-9</text>
<text top="1064" left="803" width="4" height="17" font="17"> </text>
<text top="1082" left="452" width="354" height="17" font="17">High risk was defined as: 1) having a primary prevention </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e291</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 7.</b></text>
<text top="88" left="112" width="445" height="12" font="22"><b>  Pharmacological Characteristics of Available Antiarrhythmic Medications for Treating VA</b></text>
<text top="112" left="85" width="78" height="12" font="22"><b>Antiarrhythmic </b></text>
<text top="126" left="85" width="93" height="12" font="22"><b>Medication (Class) </b></text>
<text top="139" left="85" width="46" height="12" font="22"><b>and Dose</b></text>
<text top="139" left="203" width="76" height="12" font="22"><b>Uses in VA/SCA</b></text>
<text top="139" left="330" width="31" height="12" font="22"><b>Target</b></text>
<text top="126" left="418" width="101" height="12" font="22"><b>Electrophysiological </b></text>
<text top="139" left="451" width="33" height="12" font="22"><b>Effects</b></text>
<text top="126" left="548" width="83" height="12" font="22"><b>Pharmacological </b></text>
<text top="139" left="553" width="71" height="12" font="22"><b>Characteristics</b></text>
<text top="139" left="665" width="123" height="12" font="22"><b>Common Adverse Effects</b></text>
<text top="160" left="85" width="48" height="12" font="4">Acebutolol</text>
<text top="177" left="85" width="106" height="12" font="4">PO 200–1200 mg daily </text>
<text top="191" left="85" width="91" height="12" font="4">or up to 600 mg bid</text>
<text top="160" left="203" width="39" height="12" font="4">VT, PVCs</text>
<text top="160" left="293" width="95" height="12" font="4">Beta 1, Mild intrinsic </text>
<text top="174" left="293" width="82" height="12" font="4">sympathomimetic </text>
<text top="187" left="293" width="31" height="12" font="4">activity</text>
<text top="160" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="177" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="191" left="414" width="42" height="12" font="4">increased</text>
<text top="160" left="535" width="85" height="12" font="4">Active metabolite t</text>
<text top="168" left="620" width="9" height="7" font="23">1/2</text>
<text top="160" left="629" width="6" height="12" font="4">: </text>
<text top="174" left="536" width="32" height="12" font="4">8–13 h</text>
<text top="191" left="536" width="102" height="12" font="4">pProlonged with renal </text>
<text top="204" left="536" width="54" height="12" font="4">impairment)</text>
<text top="221" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="238" left="536" width="92" height="12" font="4">Excr: F 60%, U 40%</text>
<text top="160" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="174" left="657" width="96" height="12" font="4">hypotension, HF, AVB</text>
<text top="191" left="657" width="115" height="12" font="4">Other: Dizziness, fatigue, </text>
<text top="204" left="657" width="117" height="12" font="4">anxiety, impotence, hyper/</text>
<text top="218" left="657" width="58" height="12" font="4">hypoesthesia</text>
<text top="259" left="85" width="71" height="12" font="4">Amiodarone (III)</text>
<text top="276" left="85" width="93" height="12" font="4">IV: 300 mg bolus for </text>
<text top="289" left="85" width="100" height="12" font="4">VF/pulseless VT arrest; </text>
<text top="303" left="85" width="109" height="12" font="4">150-mg bolus for stable </text>
<text top="316" left="85" width="90" height="12" font="4">VT; 1 mg/min x 6 h, </text>
<text top="330" left="85" width="105" height="12" font="4">then 0.5 mg/min x 18 h</text>
<text top="347" left="85" width="92" height="12" font="4">PO: 400 mg* q 8 to </text>
<text top="360" left="85" width="102" height="12" font="4">12 h for 1–2 wk, then </text>
<text top="374" left="85" width="87" height="12" font="4">300–400 mg daily; </text>
<text top="387" left="85" width="107" height="12" font="4">reduce dose to 200 mg </text>
<text top="401" left="85" width="68" height="12" font="4">daily if possible</text>
<text top="259" left="203" width="53" height="12" font="4">VT, VF, PVC,</text>
<text top="259" left="293" width="2" height="12" font="4">I</text>
<text top="266" left="295" width="7" height="7" font="23">Na</text>
<text top="259" left="302" width="8" height="12" font="4">, I</text>
<text top="266" left="310" width="7" height="7" font="23">Ca</text>
<text top="259" left="317" width="8" height="12" font="4">, I</text>
<text top="266" left="325" width="6" height="7" font="23">Kr</text>
<text top="259" left="331" width="8" height="12" font="4">, I</text>
<text top="266" left="339" width="7" height="7" font="23">K1</text>
<text top="259" left="347" width="8" height="12" font="4">, I</text>
<text top="266" left="355" width="6" height="7" font="23">Ks</text>
<text top="259" left="361" width="8" height="12" font="4">, I</text>
<text top="266" left="369" width="5" height="7" font="23">to</text>
<text top="259" left="374" width="3" height="12" font="4">,</text>
<text top="276" left="292" width="62" height="12" font="4">Beta receptor,</text>
<text top="293" left="292" width="66" height="12" font="4">Alpha receptor</text>
<text top="310" left="292" width="47" height="12" font="4">nuclear T3</text>
<text top="327" left="292" width="37" height="12" font="4">receptor</text>
<text top="259" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="276" left="414" width="68" height="12" font="4">QRS prolonged</text>
<text top="293" left="414" width="65" height="12" font="4">QTc prolonged</text>
<text top="310" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="323" left="414" width="109" height="12" font="4">increased; increased DFT</text>
<text top="259" left="535" width="3" height="12" font="4">t</text>
<text top="266" left="539" width="9" height="7" font="23">1/2</text>
<text top="259" left="548" width="49" height="12" font="4">: 26–107 d</text>
<text top="276" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="293" left="536" width="29" height="12" font="4">Excr: F</text>
<text top="259" left="657" width="101" height="12" font="4">Cardiac: Hypotension, </text>
<text top="273" left="657" width="130" height="12" font="4">bradycardia, AVB, TdP, slows </text>
<text top="286" left="657" width="125" height="12" font="4">VT below programmed ICD </text>
<text top="300" left="657" width="111" height="12" font="4">detection rate, increases </text>
<text top="313" left="657" width="101" height="12" font="4">defibrillation threshold</text>
<text top="330" left="657" width="137" height="12" font="4">Other: Corneal microdeposits, </text>
<text top="343" left="657" width="132" height="12" font="4">thyroid abnormalities, ataxia, </text>
<text top="357" left="657" width="134" height="12" font="4">nausea, emesis, constipation, </text>
<text top="370" left="657" width="95" height="12" font="4">photosensitivity, skin </text>
<text top="384" left="657" width="140" height="12" font="4">discoloration, ataxia, dizziness, </text>
<text top="397" left="657" width="139" height="12" font="4">peripheral neuropathy, tremor, </text>
<text top="411" left="657" width="137" height="12" font="4">hepatitis, cirrhosis, pulmonary </text>
<text top="424" left="657" width="102" height="12" font="4">fibrosis or pneumonitis</text>
<text top="445" left="85" width="51" height="12" font="4">Atenolol (II)</text>
<text top="462" left="85" width="88" height="12" font="4">PO: 25–100 mg qd </text>
<text top="476" left="85" width="26" height="12" font="4">or bid</text>
<text top="445" left="203" width="73" height="12" font="4">VT, PVC, ARVC, </text>
<text top="459" left="203" width="23" height="12" font="4">LQTS</text>
<text top="445" left="293" width="29" height="12" font="4">Beta 1</text>
<text top="445" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="462" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="476" left="414" width="42" height="12" font="4">increased</text>
<text top="445" left="535" width="3" height="12" font="4">t</text>
<text top="453" left="539" width="9" height="7" font="23">1/2</text>
<text top="445" left="548" width="32" height="12" font="4">: 6–7 h</text>
<text top="462" left="536" width="99" height="12" font="4">(prolonged with renal </text>
<text top="476" left="536" width="57" height="12" font="4">impairment) </text>
<text top="493" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="510" left="536" width="92" height="12" font="4">Excr: F 50%, U 40%</text>
<text top="445" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="459" left="657" width="96" height="12" font="4">hypotension, HF, AVB</text>
<text top="476" left="657" width="115" height="12" font="4">Other: Dizziness, fatigue, </text>
<text top="489" left="657" width="101" height="12" font="4">depression, impotence</text>
<text top="530" left="85" width="57" height="12" font="4">Bisoprolol (II)</text>
<text top="547" left="85" width="95" height="12" font="4">PO: 2.5–10 mg once </text>
<text top="561" left="85" width="20" height="12" font="4">daily</text>
<text top="530" left="203" width="35" height="12" font="4">VT, PVC</text>
<text top="530" left="293" width="69" height="12" font="4">Beta 1 receptor</text>
<text top="530" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="547" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="561" left="414" width="42" height="12" font="4">increased</text>
<text top="530" left="535" width="3" height="12" font="4">t</text>
<text top="538" left="539" width="9" height="7" font="23">1/2</text>
<text top="530" left="548" width="37" height="12" font="4">: 9–12 h</text>
<text top="547" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="564" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="530" left="657" width="93" height="12" font="4">Cardiac: Chest pain, </text>
<text top="544" left="657" width="79" height="12" font="4">bradycardia, AVB </text>
<text top="561" left="657" width="116" height="12" font="4">Other: Fatigue, insomnia, </text>
<text top="574" left="657" width="37" height="12" font="4">diarrhea</text>
<text top="595" left="85" width="58" height="12" font="4">Carvedilol (II)</text>
<text top="612" left="85" width="91" height="12" font="4">PO: 3.125–25 mg q </text>
<text top="626" left="85" width="20" height="12" font="4">12 h</text>
<text top="595" left="203" width="35" height="12" font="4">VT, PVC</text>
<text top="595" left="293" width="107" height="12" font="4">Beta 1 and 2 receptors, </text>
<text top="609" left="293" width="26" height="12" font="4">Alpha</text>
<text top="595" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="612" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="626" left="414" width="42" height="12" font="4">increased</text>
<text top="595" left="535" width="3" height="12" font="4">t</text>
<text top="603" left="539" width="9" height="7" font="23">1/2</text>
<text top="595" left="548" width="37" height="12" font="4">: 7–10 h</text>
<text top="612" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="629" left="536" width="29" height="12" font="4">Excr: F</text>
<text top="595" left="657" width="90" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="609" left="657" width="113" height="12" font="4">hypotension, AVB, edema, </text>
<text top="622" left="657" width="34" height="12" font="4">syncope</text>
<text top="639" left="657" width="103" height="12" font="4">Other: Hyperglycemia, </text>
<text top="653" left="657" width="119" height="12" font="4">dizziness, fatigue, diarrhea</text>
<text top="673" left="85" width="59" height="12" font="4">Diltiazem (IV)</text>
<text top="690" left="85" width="54" height="12" font="4">IV: 5–10 mg</text>
<text top="707" left="85" width="66" height="12" font="4">qd: 15–30 min</text>
<text top="724" left="85" width="100" height="12" font="4">Extended release: PO: </text>
<text top="738" left="85" width="76" height="12" font="4">120–360 mg/day</text>
<text top="673" left="203" width="62" height="12" font="4">VT specifically</text>
<text top="690" left="203" width="27" height="12" font="4">RVOT,</text>
<text top="707" left="203" width="62" height="12" font="4">idiopathic LVT</text>
<text top="673" left="293" width="2" height="12" font="4">I</text>
<text top="681" left="295" width="12" height="7" font="23">Ca-L</text>
<text top="673" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="690" left="414" width="60" height="12" font="4">PR prolonged</text>
<text top="707" left="414" width="97" height="12" font="4">AV nodal conduction </text>
<text top="721" left="414" width="32" height="12" font="4">slowed</text>
<text top="673" left="535" width="3" height="12" font="4">t</text>
<text top="681" left="539" width="9" height="7" font="23">1/2</text>
<text top="673" left="548" width="78" height="12" font="4">: Injection 2–5 h, </text>
<text top="687" left="536" width="104" height="12" font="4">immediate release 4.5–</text>
<text top="700" left="536" width="104" height="12" font="4">12 h, extended release </text>
<text top="714" left="536" width="112" height="12" font="4">12 h, and severe hepatic </text>
<text top="727" left="536" width="92" height="12" font="4">impairment 14–16 h</text>
<text top="744" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="761" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="673" left="657" width="101" height="12" font="4">Cardiac: Hypotension, </text>
<text top="687" left="657" width="134" height="12" font="4">edema, HF, AVB, bradycardia, </text>
<text top="700" left="657" width="97" height="12" font="4">exacerbation of HF<i>r</i>EF</text>
<text top="717" left="657" width="106" height="12" font="4">Other: Headache, rash, </text>
<text top="731" left="657" width="55" height="12" font="4">constipation</text>
<text top="782" left="85" width="48" height="12" font="4">Esmolol (II)</text>
<text top="799" left="85" width="93" height="12" font="4">IV: 0.5 mg/kg bolus, </text>
<text top="812" left="85" width="72" height="12" font="4">0.05 mg/kg/min</text>
<text top="782" left="203" width="12" height="12" font="4">VT</text>
<text top="782" left="293" width="69" height="12" font="4">Beta 1 receptor</text>
<text top="782" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="799" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="812" left="414" width="42" height="12" font="4">increased</text>
<text top="782" left="535" width="3" height="12" font="4">t</text>
<text top="789" left="539" width="9" height="7" font="23">1/2</text>
<text top="782" left="548" width="32" height="12" font="4">: 9 min</text>
<text top="799" left="536" width="97" height="12" font="4">Metab: RBC esterases</text>
<text top="816" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="782" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="795" left="657" width="96" height="12" font="4">hypotension, HF, AVB</text>
<text top="812" left="657" width="109" height="12" font="4">Other: Dizziness, nausea</text>
<text top="837" left="85" width="83" height="12" font="4">Flecainide (IC) PO: </text>
<text top="850" left="85" width="84" height="12" font="4">50–200 mg q 12 h</text>
<text top="837" left="203" width="52" height="12" font="4">VT, PVC (in </text>
<text top="850" left="203" width="69" height="12" font="4">the absence of </text>
<text top="864" left="203" width="71" height="12" font="4">structural heart </text>
<text top="877" left="203" width="68" height="12" font="4">disease). Has a </text>
<text top="891" left="203" width="68" height="12" font="4">role in treating </text>
<text top="904" left="203" width="61" height="12" font="4">patients with </text>
<text top="918" left="203" width="24" height="12" font="4">CPVT</text>
<text top="837" left="293" width="2" height="12" font="4">I</text>
<text top="844" left="295" width="7" height="7" font="23">Na</text>
<text top="837" left="302" width="8" height="12" font="4">, I</text>
<text top="844" left="310" width="6" height="7" font="23">Kr</text>
<text top="837" left="316" width="8" height="12" font="4">, I</text>
<text top="844" left="324" width="9" height="7" font="23">Kur</text>
<text top="837" left="414" width="60" height="12" font="4">PR prolonged</text>
<text top="854" left="414" width="73" height="12" font="4">QRS prolonged; </text>
<text top="867" left="414" width="62" height="12" font="4">increased DFT</text>
<text top="837" left="535" width="3" height="12" font="4">t</text>
<text top="844" left="539" width="9" height="7" font="23">1/2</text>
<text top="837" left="548" width="37" height="12" font="4">: 7–22 h</text>
<text top="854" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="871" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="837" left="657" width="141" height="12" font="4">Cardiac: Sinus node dysfunction, </text>
<text top="850" left="657" width="128" height="12" font="4">AVB, drug-induced Brugada </text>
<text top="864" left="657" width="138" height="12" font="4">syndrome, monomorphic VT in </text>
<text top="877" left="657" width="140" height="12" font="4">patients with a myocardial scar, </text>
<text top="891" left="657" width="97" height="12" font="4">exacerbation of HF<i>r</i>EF</text>
<text top="908" left="657" width="141" height="12" font="4">Other: Dizziness, tremor, vision </text>
<text top="921" left="657" width="132" height="12" font="4">disturbance, dyspnea, nausea</text>
<text top="942" left="85" width="59" height="12" font="4">Lidocaine (IB)</text>
<text top="959" left="85" width="104" height="12" font="4">IV: 1 mg/kg bolus, 1–3 </text>
<text top="972" left="85" width="34" height="12" font="4">mg/min</text>
<text top="989" left="85" width="97" height="12" font="4">1–1.5 mg/kg. Repeat </text>
<text top="1003" left="85" width="102" height="12" font="4">0.5–0.75 mg/kg bolus </text>
<text top="1016" left="85" width="96" height="12" font="4">every 5–10 min (max </text>
<text top="1030" left="85" width="84" height="12" font="4">cumulative dose 3 </text>
<text top="1043" left="85" width="99" height="12" font="4">mg/kg). Maintenance </text>
<text top="1057" left="85" width="105" height="12" font="4">infusion is 1–4 mg/min </text>
<text top="1070" left="85" width="90" height="12" font="4">although one could </text>
<text top="1084" left="85" width="86" height="12" font="4">start at 0.5 mg/min</text>
<text top="942" left="203" width="27" height="12" font="4">VT, VF</text>
<text top="942" left="293" width="2" height="12" font="4">I</text>
<text top="949" left="295" width="7" height="7" font="23">Na</text>
<text top="942" left="414" width="95" height="12" font="4">No marked effect on </text>
<text top="955" left="414" width="106" height="12" font="4">most intervals; QTc can </text>
<text top="969" left="414" width="68" height="12" font="4">slightly shorten</text>
<text top="942" left="535" width="30" height="12" font="4">Initial t</text>
<text top="949" left="566" width="9" height="7" font="23">1/2</text>
<text top="942" left="574" width="51" height="12" font="4"> 7–30 min; </text>
<text top="955" left="536" width="100" height="12" font="4">terminal 90–120 min. </text>
<text top="969" left="536" width="96" height="12" font="4">Prolonged in HF, liver </text>
<text top="982" left="536" width="100" height="12" font="4">disease, shock, severe </text>
<text top="996" left="536" width="102" height="12" font="4">renal disease Metab: H</text>
<text top="1013" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="942" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="955" left="657" width="132" height="12" font="4">hemodynamic collapse, AVB, </text>
<text top="969" left="657" width="50" height="12" font="4">sinus arrest</text>
<text top="986" left="657" width="122" height="12" font="4">Other: Delirium, psychosis, </text>
<text top="999" left="657" width="113" height="12" font="4">seizure, nausea, tinnitus, </text>
<text top="1013" left="657" width="108" height="12" font="4">dyspnea, bronchospasm</text>
<text top="1103" left="749" width="54" height="12" font="4">(<i>Continued</i> )</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e292</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="160" left="85" width="63" height="12" font="4">Metoprolol (II)</text>
<text top="177" left="85" width="104" height="12" font="4">IV: 5 mg q 5 min up to </text>
<text top="190" left="85" width="34" height="12" font="4">3 doses</text>
<text top="207" left="85" width="74" height="12" font="4">PO: 25–100 mg </text>
<text top="221" left="85" width="95" height="12" font="4">Extended release qd  </text>
<text top="234" left="85" width="41" height="12" font="4">or q 12 h</text>
<text top="160" left="203" width="35" height="12" font="4">VT, PVC</text>
<text top="160" left="293" width="69" height="12" font="4">Beta 1 receptor</text>
<text top="160" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="177" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="190" left="414" width="42" height="12" font="4">increased</text>
<text top="160" left="535" width="3" height="12" font="4">t</text>
<text top="168" left="539" width="9" height="7" font="23">1/2</text>
<text top="160" left="548" width="32" height="12" font="4">: 3–4 h</text>
<text top="177" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="194" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="160" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="174" left="657" width="79" height="12" font="4">hypotension, AVB</text>
<text top="190" left="657" width="115" height="12" font="4">Other: Dizziness, fatigue, </text>
<text top="204" left="657" width="133" height="12" font="4">diarrhea, depression, dyspnea</text>
<text top="256" left="85" width="63" height="12" font="4">Mexiletine (IB)</text>
<text top="272" left="85" width="106" height="12" font="4">PO: 150–300 mg q 8 h </text>
<text top="286" left="85" width="41" height="12" font="4">or q 12 h</text>
<text top="256" left="203" width="76" height="12" font="4">T, VF, PVC, has a </text>
<text top="269" left="203" width="69" height="12" font="4">role in patients </text>
<text top="283" left="203" width="46" height="12" font="4">with LQT3</text>
<text top="256" left="293" width="2" height="12" font="4">I</text>
<text top="263" left="295" width="7" height="7" font="23">Na</text>
<text top="256" left="414" width="95" height="12" font="4">No marked effect on </text>
<text top="269" left="414" width="106" height="12" font="4">most intervals; QTc can </text>
<text top="283" left="414" width="68" height="12" font="4">slightly shorten</text>
<text top="256" left="535" width="3" height="12" font="4">t</text>
<text top="263" left="539" width="9" height="7" font="23">1/2</text>
<text top="256" left="548" width="43" height="12" font="4">: 10–14 h</text>
<text top="272" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="289" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="256" left="657" width="74" height="12" font="4">Cardiac: HF, AVB</text>
<text top="272" left="657" width="128" height="12" font="4">Other: Lightheaded, tremor, </text>
<text top="286" left="657" width="129" height="12" font="4">ataxia, paresthesias, nausea, </text>
<text top="299" left="657" width="72" height="12" font="4">blood dyscrasias</text>
<text top="321" left="85" width="48" height="12" font="4">Nadolol (II)</text>
<text top="337" left="85" width="94" height="12" font="4">PO: 40–320 mg daily</text>
<text top="321" left="203" width="69" height="12" font="4">VT, PVC, LQTS, </text>
<text top="334" left="203" width="24" height="12" font="4">CPVT</text>
<text top="321" left="293" width="101" height="12" font="4">Beta 1 and 2 receptors</text>
<text top="321" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="337" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="351" left="414" width="42" height="12" font="4">increased</text>
<text top="321" left="535" width="3" height="12" font="4">t</text>
<text top="328" left="539" width="9" height="7" font="23">1/2</text>
<text top="321" left="548" width="43" height="12" font="4">: 20–24 h</text>
<text top="337" left="536" width="58" height="12" font="4">Metab: none</text>
<text top="354" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="321" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="334" left="657" width="96" height="12" font="4">hypotension, HF, AVB</text>
<text top="351" left="657" width="134" height="12" font="4">Other: Edema, dizziness, cold </text>
<text top="364" left="657" width="119" height="12" font="4">extremities, bronchospasm</text>
<text top="386" left="85" width="78" height="12" font="4">Procainamide (IA)</text>
<text top="403" left="85" width="105" height="12" font="4">IV: loading dose 10–17 </text>
<text top="416" left="85" width="92" height="12" font="4">mg/kg at 20–50 mg/</text>
<text top="430" left="85" width="17" height="12" font="4">min</text>
<text top="446" left="85" width="108" height="12" font="4">Maintenance dose: 1–4 </text>
<text top="460" left="85" width="34" height="12" font="4">mg/min</text>
<text top="477" left="85" width="93" height="12" font="4">PO (SR preparation): </text>
<text top="490" left="85" width="90" height="12" font="4">500–1250 mg q 6 h</text>
<text top="386" left="203" width="12" height="12" font="4">VT</text>
<text top="386" left="293" width="2" height="12" font="4">I</text>
<text top="393" left="295" width="7" height="7" font="23">Na</text>
<text top="386" left="302" width="8" height="12" font="4">, I</text>
<text top="393" left="310" width="6" height="7" font="23">Kr</text>
<text top="386" left="414" width="68" height="12" font="4">QRS prolonged</text>
<text top="403" left="414" width="71" height="12" font="4">QTc prolonged; </text>
<text top="416" left="414" width="62" height="12" font="4">increased DFT</text>
<text top="386" left="535" width="42" height="12" font="4">Metab: H</text>
<text top="403" left="535" width="3" height="12" font="4">t</text>
<text top="410" left="539" width="9" height="7" font="23">1/2</text>
<text top="403" left="548" width="91" height="12" font="4">: 2–5 h; NAPA 6–8 h</text>
<text top="419" left="536" width="3" height="12" font="4">t</text>
<text top="427" left="539" width="9" height="7" font="23">1/2</text>
<text top="419" left="548" width="88" height="12" font="4"> prolonged in renal </text>
<text top="433" left="536" width="104" height="12" font="4">dysfunction. Anephric: </text>
<text top="446" left="536" width="94" height="12" font="4">proc 11 h and NAPA </text>
<text top="460" left="536" width="20" height="12" font="4">42 h</text>
<text top="477" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="386" left="657" width="144" height="12" font="4">Cardiac: TdP; AVB, hypotension </text>
<text top="399" left="657" width="117" height="12" font="4">and exacerbation of HF<i>r</i>EF</text>
<text top="416" left="657" width="112" height="12" font="4">Other: Lupus symptoms, </text>
<text top="430" left="657" width="109" height="12" font="4">diarrhea, nausea, blood </text>
<text top="443" left="657" width="44" height="12" font="4">dyscrasias</text>
<text top="512" left="85" width="75" height="12" font="4">Propafenone (IC)</text>
<text top="528" left="85" width="102" height="12" font="4">PO: Immediate release </text>
<text top="542" left="85" width="84" height="12" font="4">150–300 mg q 8 h</text>
<text top="559" left="85" width="101" height="12" font="4">Extended release 225–</text>
<text top="572" left="85" width="67" height="12" font="4">425 mg q 12 h</text>
<text top="512" left="203" width="52" height="12" font="4">VT, PVC (in </text>
<text top="525" left="203" width="69" height="12" font="4">the absence of </text>
<text top="539" left="203" width="71" height="12" font="4">structural heart </text>
<text top="552" left="203" width="35" height="12" font="4">disease)</text>
<text top="512" left="293" width="2" height="12" font="4">I</text>
<text top="519" left="295" width="7" height="7" font="23">Na</text>
<text top="511" left="302" width="8" height="12" font="4">, I</text>
<text top="519" left="310" width="6" height="7" font="23">Kr</text>
<text top="511" left="316" width="8" height="12" font="4">, I</text>
<text top="519" left="324" width="9" height="7" font="23">Kur</text>
<text top="511" left="333" width="71" height="12" font="4">, Beta receptor, </text>
<text top="525" left="293" width="66" height="12" font="4">Alpha receptor</text>
<text top="511" left="414" width="60" height="12" font="4">PR prolonged</text>
<text top="528" left="414" width="73" height="12" font="4">QRS prolonged; </text>
<text top="542" left="414" width="62" height="12" font="4">increased DFT</text>
<text top="511" left="535" width="3" height="12" font="4">t</text>
<text top="519" left="539" width="9" height="7" font="23">1/2</text>
<text top="511" left="548" width="90" height="12" font="4">: 2–10 h or 10–32 h</text>
<text top="528" left="536" width="3" height="12" font="4">t</text>
<text top="536" left="539" width="9" height="7" font="23">1/2</text>
<text top="528" left="548" width="50" height="12" font="4">: extensive </text>
<text top="542" left="536" width="85" height="12" font="4">metabolizers 2–10 </text>
<text top="555" left="536" width="95" height="12" font="4">h; poor metabolizers </text>
<text top="569" left="536" width="40" height="12" font="4">10–32 h.</text>
<text top="586" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="603" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="512" left="657" width="143" height="12" font="4">Cardiac: HF, AVB, drug-induced </text>
<text top="525" left="657" width="84" height="12" font="4">Brugada syndrome</text>
<text top="542" left="657" width="115" height="12" font="4">Other: Dizziness, fatigue, </text>
<text top="555" left="657" width="135" height="12" font="4">nausea, diarrhea, xerostomia, </text>
<text top="569" left="657" width="95" height="12" font="4">tremor, blurred vision</text>
<text top="624" left="85" width="65" height="12" font="4">Propranolol (II)</text>
<text top="641" left="85" width="109" height="12" font="4">IV: 1–3 mg q 5 min to a </text>
<text top="654" left="85" width="59" height="12" font="4">total of 5 mg</text>
<text top="671" left="85" width="69" height="12" font="4">PO: Immediate </text>
<text top="685" left="85" width="91" height="12" font="4">release 10–40 mg q </text>
<text top="698" left="85" width="98" height="12" font="4">6 h; Extended release </text>
<text top="712" left="85" width="84" height="12" font="4">60–160 mg q 12 h</text>
<text top="624" left="203" width="64" height="12" font="4">VT, PVC, LQTS</text>
<text top="624" left="293" width="107" height="12" font="4">Beta 1 and 2 receptors, </text>
<text top="637" left="293" width="2" height="12" font="4">I</text>
<text top="645" left="295" width="7" height="7" font="23">Na</text>
<text top="624" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="641" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="654" left="414" width="42" height="12" font="4">increased</text>
<text top="624" left="535" width="3" height="12" font="4">t</text>
<text top="631" left="539" width="9" height="7" font="23">1/2</text>
<text top="624" left="548" width="90" height="12" font="4">: Immediate release </text>
<text top="637" left="536" width="26" height="12" font="4">3–6 h</text>
<text top="654" left="536" width="110" height="12" font="4">Extended release 8–10 h</text>
<text top="671" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="688" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="624" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="637" left="657" width="96" height="12" font="4">hypotension, HF, AVB</text>
<text top="654" left="657" width="144" height="12" font="4">Other: Sleep disorder, dizziness, </text>
<text top="668" left="657" width="126" height="12" font="4">nightmares, hyperglycemia, </text>
<text top="681" left="657" width="108" height="12" font="4">diarrhea, bronchospasm</text>
<text top="733" left="85" width="61" height="12" font="4">Quinidine (IA)</text>
<text top="750" left="85" width="72" height="12" font="4">PO: sulfate salt  </text>
<text top="763" left="85" width="99" height="12" font="4">200–600 mg q 6 h to </text>
<text top="777" left="85" width="29" height="12" font="4">q 12 h</text>
<text top="794" left="85" width="68" height="12" font="4">gluconate salt  </text>
<text top="807" left="85" width="90" height="12" font="4">324–648 mg q 8 h  </text>
<text top="821" left="85" width="41" height="12" font="4">to q 12 h</text>
<text top="838" left="85" width="97" height="12" font="4">IV: loading dose: 800 </text>
<text top="851" left="85" width="107" height="12" font="4">mg in 50 mL infused at </text>
<text top="865" left="85" width="49" height="12" font="4">50 mg/min</text>
<text top="733" left="203" width="72" height="12" font="4">T, VF, (including </text>
<text top="746" left="203" width="41" height="12" font="4">short QT </text>
<text top="760" left="203" width="49" height="12" font="4">syndrome, </text>
<text top="773" left="203" width="40" height="12" font="4">Brugada)</text>
<text top="733" left="293" width="2" height="12" font="4">I</text>
<text top="740" left="295" width="7" height="7" font="23">Na</text>
<text top="733" left="302" width="8" height="12" font="4">, I</text>
<text top="740" left="310" width="5" height="7" font="23">to</text>
<text top="733" left="316" width="8" height="12" font="4">, I</text>
<text top="740" left="324" width="6" height="7" font="23">Kr</text>
<text top="733" left="330" width="50" height="12" font="4">, M, Alpha </text>
<text top="746" left="292" width="37" height="12" font="4">receptor</text>
<text top="733" left="414" width="68" height="12" font="4">QRS prolonged</text>
<text top="750" left="414" width="71" height="12" font="4">QTc prolonged; </text>
<text top="763" left="414" width="62" height="12" font="4">increased DFT</text>
<text top="740" left="536" width="9" height="7" font="23">1/2</text>
<text top="733" left="544" width="93" height="12" font="4">: 6–8 h longer in HF, </text>
<text top="746" left="536" width="106" height="12" font="4">liver cirrhosis, and with </text>
<text top="760" left="536" width="42" height="12" font="4">older age</text>
<text top="777" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="794" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="733" left="657" width="122" height="12" font="4">Cardiac: Syncope, TdP, AVB</text>
<text top="750" left="657" width="120" height="12" font="4">Other: Dizziness, diarrhea, </text>
<text top="763" left="657" width="129" height="12" font="4">nausea, esophagitis, emesis, </text>
<text top="777" left="657" width="129" height="12" font="4">tinnitus, blurred vision, rash, </text>
<text top="790" left="657" width="114" height="12" font="4">weakness, tremor; blood </text>
<text top="804" left="657" width="44" height="12" font="4">dyscrasias</text>
<text top="886" left="85" width="72" height="12" font="4">Ranolazine (not </text>
<text top="899" left="85" width="43" height="12" font="4">classified)</text>
<text top="916" left="85" width="94" height="12" font="4">PO: 500–1000 mg q </text>
<text top="930" left="85" width="20" height="12" font="4">12 h</text>
<text top="886" left="203" width="12" height="12" font="4">VT</text>
<text top="886" left="293" width="2" height="12" font="4">I</text>
<text top="893" left="295" width="7" height="7" font="23">Na</text>
<text top="886" left="302" width="8" height="12" font="4">, I</text>
<text top="893" left="310" width="6" height="7" font="23">Kr</text>
<text top="886" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="903" left="414" width="58" height="12" font="4">Tc prolonged</text>
<text top="886" left="535" width="3" height="12" font="4">t</text>
<text top="893" left="539" width="9" height="7" font="23">1/2</text>
<text top="886" left="548" width="20" height="12" font="4">: 7 h</text>
<text top="903" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="920" left="536" width="92" height="12" font="4">Excr: U 75%, F 25%</text>
<text top="886" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="899" left="657" width="55" height="12" font="4">hypotension</text>
<text top="916" left="657" width="127" height="12" font="4">Other: Headache, dizziness, </text>
<text top="930" left="657" width="116" height="12" font="4">syncope, nausea, dyspnea</text>
<text top="951" left="85" width="46" height="12" font="4">Sotalol (III)</text>
<text top="968" left="85" width="75" height="12" font="4">IV: 75 mg q 12 h</text>
<text top="985" left="85" width="97" height="12" font="4">PO: 80–120 mg q 12 </text>
<text top="998" left="85" width="96" height="12" font="4">h, may increase dose </text>
<text top="1012" left="85" width="89" height="12" font="4">every 3 d; max 320 </text>
<text top="1025" left="85" width="23" height="12" font="4">mg/d</text>
<text top="951" left="203" width="51" height="12" font="4">VT, VF, PVC</text>
<text top="951" left="293" width="2" height="12" font="4">I</text>
<text top="958" left="295" width="6" height="7" font="23">Kr</text>
<text top="951" left="301" width="66" height="12" font="4">, Beta 1 and 2 </text>
<text top="964" left="293" width="37" height="12" font="4">receptor</text>
<text top="951" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="968" left="414" width="65" height="12" font="4">QTc prolonged</text>
<text top="985" left="414" width="107" height="12" font="4">AV nodal refractoriness </text>
<text top="998" left="414" width="95" height="12" font="4">increased; decreased </text>
<text top="1012" left="414" width="17" height="12" font="4">DFT</text>
<text top="951" left="535" width="3" height="12" font="4">t</text>
<text top="958" left="539" width="9" height="7" font="23">1/2</text>
<text top="951" left="548" width="26" height="12" font="4">: 12 h</text>
<text top="968" left="536" width="58" height="12" font="4">Metab: none</text>
<text top="985" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="951" left="657" width="97" height="12" font="4">Cardiac: Bradycardia, </text>
<text top="964" left="657" width="135" height="12" font="4">hypotension, HF, syncope, TdP</text>
<text top="981" left="657" width="115" height="12" font="4">Other: Fatigue, dizziness, </text>
<text top="995" left="657" width="141" height="12" font="4">weakness, dyspnea, bronchitis, </text>
<text top="1008" left="657" width="128" height="12" font="4">depression, nausea, diarrhea</text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 7.</b></text>
<text top="88" left="112" width="62" height="12" font="22"><b> Continued</b></text>
<text top="112" left="85" width="78" height="12" font="22"><b>Antiarrhythmic </b></text>
<text top="126" left="85" width="93" height="12" font="22"><b>Medication (Class) </b></text>
<text top="139" left="85" width="46" height="12" font="22"><b>and Dose</b></text>
<text top="139" left="203" width="76" height="12" font="22"><b>Uses in VA/SCA</b></text>
<text top="139" left="330" width="31" height="12" font="22"><b>Target</b></text>
<text top="126" left="418" width="101" height="12" font="22"><b>Electrophysiological </b></text>
<text top="139" left="451" width="33" height="12" font="22"><b>Effects</b></text>
<text top="126" left="548" width="83" height="12" font="22"><b>Pharmacological </b></text>
<text top="139" left="553" width="71" height="12" font="22"><b>Characteristics</b></text>
<text top="139" left="665" width="123" height="12" font="22"><b>Common Adverse Effects</b></text>
<text top="1046" left="749" width="54" height="12" font="4">(<i>Continued</i> )</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e293</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="402" left="74" width="357" height="17" font="17">ICD without a history of documented VT/VF and with </text>
<text top="420" left="74" width="356" height="17" font="17">one of the following conditions: BUN ≥26 mg/dL, QRS </text>
<text top="438" left="74" width="355" height="17" font="17">&gt;120 msec, atrial fibrillation, or NSVT or &gt;500 VPBs on </text>
<text top="457" left="74" width="351" height="17" font="17">24-hour Holter recording; 2) having a primary preven-</text>
<text top="475" left="74" width="351" height="17" font="17">tion ICD with a history of documented VT/VF appropri-</text>
<text top="493" left="74" width="355" height="17" font="17">ately treated with ICD therapy or untreated NSVT; or 3) </text>
<text top="511" left="74" width="357" height="17" font="17">having a secondary prevention ICD after documented </text>
<text top="529" left="74" width="355" height="17" font="17">VT/VF or cardiac arrest. Ranolazine did not significantly </text>
<text top="547" left="74" width="351" height="17" font="17">reduce the primary endpoint of VT/VF requiring appro-</text>
<text top="565" left="74" width="355" height="17" font="17">priate ICD therapy or death. In a prespecified secondary </text>
<text top="583" left="74" width="358" height="17" font="17">analysis, ranolazine was associated with a significant </text>
<text top="601" left="74" width="359" height="17" font="17">reduction in VT events treated with anti-tachycardia </text>
<text top="619" left="74" width="47" height="17" font="17">pacing.</text>
<text top="620" left="121" width="39" height="10" font="19">S5.1.5.2-9</text>
<text top="646" left="74" width="136" height="18" font="24"><i><b>5.1.2. Beta Blockers</b></i></text>
<text top="665" left="74" width="351" height="17" font="17">Because of their excellent safety profile and effec-</text>
<text top="683" left="74" width="357" height="17" font="17">tiveness in treating VA and reducing the risk of SCD,  </text>
<text top="701" left="74" width="363" height="17" font="17">beta blockers are often first-line antiarrhythmic </text>
<text top="719" left="74" width="53" height="17" font="17">therapy.</text>
<text top="720" left="127" width="93" height="10" font="19">S5.1.5.2-10,S5.1.5.2-11</text>
<text top="719" left="220" width="209" height="17" font="17"> Their antiarrhythmic efficacy is </text>
<text top="737" left="74" width="357" height="17" font="17">related to the effects of adrenergic-receptor blockade </text>
<text top="755" left="74" width="359" height="17" font="17">on sympathetically mediated triggering mechanisms, </text>
<text top="773" left="74" width="351" height="17" font="17">slowing of the sinus rate, and possibly inhibition of ex-</text>
<text top="791" left="74" width="298" height="17" font="17">cess calcium release by the ryanodine receptor.</text>
<text top="792" left="372" width="44" height="10" font="19">S5.1.5.2-12</text>
<text top="809" left="92" width="338" height="17" font="17">Beta blockers reduce all-cause mortality and SCD in </text>
<text top="827" left="74" width="259" height="17" font="17">patients with HF with reduced EF (HF<i>r</i>EF).</text>
<text top="828" left="333" width="92" height="10" font="19">S5.1.5.2-13–S5.1.5.2-15</text>
<text top="827" left="425" width="4" height="17" font="17"> </text>
<text top="845" left="74" width="351" height="17" font="17">Although beta blockers have long been proven to re-</text>
<text top="863" left="74" width="161" height="17" font="17">duce mortality after MI,</text>
<text top="864" left="235" width="44" height="10" font="19">S5.1.5.2-16</text>
<text top="863" left="279" width="154" height="17" font="17"> registry data confirm </text>
<text top="881" left="74" width="355" height="17" font="17">that early beta blocker use in patients with MI and risk </text>
<text top="899" left="74" width="358" height="17" font="17">factors for shock (&gt;70 years of age, symptoms  &lt;12 </text>
<text top="917" left="74" width="351" height="17" font="17">hours [ST-elevation MI patients], systolic blood pres-</text>
<text top="935" left="74" width="357" height="17" font="17">sure  &lt;120 mm  Hg, and heart rate &gt;110 beat/min on </text>
<text top="954" left="74" width="359" height="17" font="17">presentation) is associated with an increased risk of </text>
<text top="972" left="74" width="105" height="17" font="17">shock or death.</text>
<text top="972" left="179" width="44" height="10" font="19">S5.1.5.2-17</text>
<text top="972" left="223" width="210" height="17" font="17"> In the setting of polymorphic </text>
<text top="990" left="74" width="275" height="17" font="17">VT after MI, beta blockers reduce mortality.</text>
<text top="990" left="349" width="44" height="10" font="19">S5.1.5.2-18</text>
<text top="990" left="393" width="36" height="17" font="17"> Beta </text>
<text top="1008" left="74" width="355" height="17" font="17">blockers suppress VA in some patients with structurally </text>
<text top="1026" left="74" width="93" height="17" font="17">normal hearts.</text>
<text top="1026" left="168" width="44" height="10" font="19">S5.1.5.2-19</text>
<text top="1026" left="211" width="219" height="17" font="17"> When used in combination with </text>
<text top="1044" left="74" width="355" height="17" font="17">membrane-stabilizing antiarrhythmic medications, beta </text>
<text top="1062" left="74" width="307" height="17" font="17">blockers can enhance antiarrhythmic efficacy.</text>
<text top="1062" left="381" width="44" height="10" font="19">S5.1.5.2-20</text>
<text top="1062" left="425" width="4" height="17" font="17"> </text>
<text top="1080" left="74" width="351" height="17" font="17">Beta blockers (eg, nadolol, propranolol) are also first-</text>
<text top="402" left="452" width="355" height="17" font="17">line therapy for some cardiac channelopathies (eg, long </text>
<text top="420" left="452" width="351" height="17" font="17">QT syndrome, catecholaminergic polymorphic ventricu-</text>
<text top="438" left="452" width="101" height="17" font="17">lar tachycardia).</text>
<text top="466" left="452" width="213" height="18" font="24"><i><b>5.1.3. Amiodarone and Sotalol</b></i></text>
<text top="484" left="452" width="355" height="17" font="17">Amiodarone possesses a wide spectrum of actions that </text>
<text top="502" left="452" width="351" height="17" font="17">include blockade of beta receptors and sodium, calci-</text>
<text top="520" left="452" width="355" height="17" font="17">um and potassium currents (ie, a multichannel blocker). </text>
<text top="538" left="452" width="356" height="17" font="17">Its overall long-term effect on survival is controversial, </text>
<text top="556" left="452" width="358" height="17" font="17">with most studies showing no clear advantage over </text>
<text top="575" left="452" width="356" height="17" font="17">placebo. A few studies and a meta-analysis of several </text>
<text top="593" left="452" width="351" height="17" font="17">large studies have shown a reduction in SCD using ami-</text>
<text top="611" left="452" width="357" height="17" font="17">odarone in patients with LV dysfunction due to prior </text>
<text top="629" left="452" width="98" height="17" font="17">MI and NICM,</text>
<text top="629" left="551" width="92" height="10" font="19">S5.1.5.2-21–S5.1.5.2-23</text>
<text top="629" left="642" width="169" height="17" font="17"> but SCD-HeFT showed </text>
<text top="647" left="452" width="358" height="17" font="17">no survival benefit from amiodarone compared with </text>
<text top="665" left="452" width="54" height="17" font="17">placebo.</text>
<text top="665" left="506" width="44" height="10" font="19">S5.1.5.2-24</text>
<text top="665" left="550" width="258" height="17" font="17"> A secondary analysis of the SCD-HeFT </text>
<text top="683" left="452" width="356" height="17" font="17">showed increased risk of mortality with amiodarone in </text>
<text top="701" left="452" width="355" height="17" font="17">patients with New York Heart Association (NYHA) class </text>
<text top="719" left="452" width="85" height="17" font="17">III symptoms.</text>
<text top="720" left="537" width="44" height="10" font="19">S5.1.5.2-25</text>
<text top="719" left="581" width="222" height="17" font="17"> A systematic review of the litera-</text>
<text top="737" left="452" width="356" height="17" font="17">ture in high-risk patients (LVEF &lt;40%, with or without </text>
<text top="755" left="452" width="351" height="17" font="17">coronary disease), concluded that, for primary preven-</text>
<text top="773" left="452" width="351" height="17" font="17">tion, amiodarone, compared with no treatment or pla-</text>
<text top="791" left="452" width="356" height="17" font="17">cebo, decreased the risk of SCD (Risk ratio: 0.76; 95% </text>
<text top="809" left="452" width="356" height="17" font="17">CI: 0.66–0.88) and all-cause mortality (Risk ratio: 0.88; </text>
<text top="827" left="452" width="356" height="17" font="17">95% CI: 0.78–1.00), but the quality of the supporting </text>
<text top="845" left="452" width="144" height="17" font="17">evidence was very low.</text>
<text top="846" left="596" width="44" height="10" font="19">S5.1.5.2-26</text>
<text top="845" left="640" width="167" height="17" font="17"> For secondary prevention </text>
<text top="863" left="452" width="357" height="17" font="17">of SCD, the same systematic review identified neither </text>
<text top="881" left="452" width="231" height="17" font="17">risk nor benefit with amiodarone.</text>
<text top="882" left="684" width="44" height="10" font="19">S5.1.5.2-26</text>
<text top="881" left="727" width="84" height="17" font="17"> Compared </text>
<text top="899" left="452" width="360" height="17" font="17">with beta-blocker therapy and other antiarrhythmic </text>
<text top="917" left="452" width="355" height="17" font="17">medications (including sotalol), amiodarone appears to </text>
<text top="935" left="452" width="307" height="17" font="17">reduce the risk of SCD and all-cause mortality.</text>
<text top="936" left="759" width="44" height="10" font="19">S5.1.5.2-26</text>
<text top="935" left="803" width="4" height="17" font="17"> </text>
<text top="954" left="452" width="351" height="17" font="17">Intravenous amiodarone has a role in reducing recur-</text>
<text top="972" left="452" width="199" height="17" font="17">rent VF/VF during resuscitation.</text>
<text top="972" left="652" width="133" height="10" font="19">S5.1.5.2-3,S5.1.5.2-27–S5.1.5.2-29</text>
<text top="990" left="470" width="338" height="17" font="17">Chronic administration of amiodarone is associated </text>
<text top="1008" left="452" width="358" height="17" font="17">with complex medication interactions and a host of </text>
<text top="1026" left="452" width="357" height="17" font="17">adverse effects involving the lung, liver, thyroid, skin, </text>
<text top="1044" left="452" width="356" height="17" font="17">and nervous system. As a general rule, the longer the </text>
<text top="1062" left="452" width="351" height="17" font="17">therapy and the higher dose of amiodarone, the great-</text>
<text top="1080" left="452" width="358" height="17" font="17">er the likelihood of adverse effects that will require </text>
<text top="160" left="85" width="62" height="12" font="4">Verapamil (IV)</text>
<text top="177" left="85" width="100" height="12" font="4">IV: 2.5–5 mg q 15–30 </text>
<text top="190" left="85" width="17" height="12" font="4">min</text>
<text top="207" left="85" width="98" height="12" font="4">Sustained release PO: </text>
<text top="221" left="85" width="67" height="12" font="4">240–480 mg/d</text>
<text top="160" left="203" width="68" height="12" font="4">VT (specifically </text>
<text top="173" left="203" width="76" height="12" font="4">RVOT, verapamil-</text>
<text top="187" left="203" width="40" height="12" font="4">sensitive </text>
<text top="200" left="203" width="65" height="12" font="4">idiopathic LVT)</text>
<text top="160" left="293" width="2" height="12" font="4">I</text>
<text top="167" left="295" width="12" height="7" font="23">Ca-L</text>
<text top="160" left="414" width="78" height="12" font="4">Sinus rate slowed</text>
<text top="177" left="414" width="60" height="12" font="4">PR prolonged</text>
<text top="194" left="414" width="97" height="12" font="4">AV nodal conduction </text>
<text top="207" left="414" width="32" height="12" font="4">slowed</text>
<text top="160" left="535" width="3" height="12" font="4">t</text>
<text top="167" left="539" width="9" height="7" font="23">1/2</text>
<text top="160" left="548" width="32" height="12" font="4">: 3–7 h</text>
<text top="177" left="536" width="42" height="12" font="4">Metab: H</text>
<text top="194" left="536" width="31" height="12" font="4">Excr: U</text>
<text top="160" left="657" width="101" height="12" font="4">Cardiac: Hypotension, </text>
<text top="173" left="657" width="134" height="12" font="4">edema, HF, AVB, bradycardia, </text>
<text top="187" left="657" width="97" height="12" font="4">exacerbation of HFrEF</text>
<text top="204" left="657" width="144" height="12" font="4">Other: Headache, rash, gingival </text>
<text top="217" left="657" width="117" height="12" font="4">hyperplasia, constipation, </text>
<text top="231" left="657" width="43" height="12" font="4">dyspepsia</text>
<text top="254" left="86" width="709" height="12" font="4">*Although up to 800 mg every 8 h might be used, higher doses of amiodarone are associated with a higher risk of adverse events. Modified from Shleifer JW, </text>
<text top="268" left="74" width="22" height="12" font="4">et al.</text>
<text top="268" left="97" width="27" height="7" font="23">S5.1.5.2-2</text>
<text top="281" left="86" width="712" height="12" font="4">Alpha indicates alpha-adrenergic receptor; ARVC, arrhythmogenic right ventricular cardiomyopathy; AV, atrioventricular; AVB, atrioventricular block; Beta, beta-</text>
<text top="295" left="74" width="665" height="12" font="4">adrenergic receptor; HF, heart failure; CPVT, catecholaminergic polymorphic ventricular tachycardia; DFT, defibrillation threshold; F, feces; H, hepatic; I</text>
<text top="302" left="740" width="7" height="7" font="23">Ca</text>
<text top="295" left="747" width="36" height="12" font="4">, L-type </text>
<text top="308" left="74" width="115" height="12" font="4">calcium channel current; I</text>
<text top="316" left="189" width="7" height="7" font="23">K1</text>
<text top="308" left="196" width="168" height="12" font="4">, inward rectifier potassium channel; I</text>
<text top="316" left="364" width="15" height="7" font="23">KACh</text>
<text top="308" left="379" width="216" height="12" font="4">, muscarinic receptor-gated potassium channel; I</text>
<text top="316" left="595" width="14" height="7" font="23">KATP</text>
<text top="308" left="609" width="187" height="12" font="4">, adenosine-activated potassium channel; </text>
<text top="322" left="74" width="2" height="12" font="4">I</text>
<text top="329" left="77" width="6" height="7" font="23">Kr</text>
<text top="322" left="83" width="194" height="12" font="4">, rapid delayed rectifier potassium current; I</text>
<text top="329" left="276" width="6" height="7" font="23">Ks</text>
<text top="322" left="283" width="192" height="12" font="4">, slow delayed rectifier potassium current; I</text>
<text top="329" left="474" width="9" height="7" font="23">Kur</text>
<text top="322" left="483" width="218" height="12" font="4">, ultra-rapid delayed rectifier potassium current; I</text>
<text top="329" left="701" width="7" height="7" font="23">Na</text>
<text top="322" left="708" width="94" height="12" font="4">, fast inward sodium </text>
<text top="335" left="74" width="40" height="12" font="4">current; I</text>
<text top="343" left="114" width="5" height="7" font="23">to</text>
<text top="335" left="120" width="665" height="12" font="4">, transient outward potassium current; LQTS, long QT syndrome; LVT, left ventricular tachycardia; M, muscarinic; Metab, metabolism; NAPA, n-acetyl </text>
<text top="349" left="74" width="357" height="12" font="4">procainamide; PVC, premature ventricular complex; QTc, corrected QT interval; t</text>
<text top="356" left="432" width="9" height="7" font="23">1/2</text>
<text top="349" left="440" width="328" height="12" font="4">, half-life; RVOT, right ventricular outflow tract; T3, triiodothyronine; TdP, </text>
<text top="362" left="74" width="389" height="12" font="4">torsades de pointes; U, urine; VT, ventricular tachycardia; and VF, ventricular fibrillation.</text>
<text top="88" left="74" width="37" height="12" font="3"><b>Table 7.</b></text>
<text top="88" left="112" width="62" height="12" font="22"><b> Continued</b></text>
<text top="112" left="85" width="78" height="12" font="22"><b>Antiarrhythmic </b></text>
<text top="126" left="85" width="93" height="12" font="22"><b>Medication (Class) </b></text>
<text top="139" left="85" width="46" height="12" font="22"><b>and Dose</b></text>
<text top="139" left="203" width="76" height="12" font="22"><b>Uses in VA/SCA</b></text>
<text top="139" left="330" width="31" height="12" font="22"><b>Target</b></text>
<text top="126" left="418" width="101" height="12" font="22"><b>Electrophysiological </b></text>
<text top="139" left="451" width="33" height="12" font="22"><b>Effects</b></text>
<text top="126" left="548" width="83" height="12" font="22"><b>Pharmacological </b></text>
<text top="139" left="553" width="71" height="12" font="22"><b>Characteristics</b></text>
<text top="139" left="665" width="123" height="12" font="22"><b>Common Adverse Effects</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="28" size="13" family="Times" color="#ce171e"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e294</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="223" height="17" font="17">discontinuance of the medication.</text>
<text top="88" left="297" width="44" height="10" font="19">S5.1.5.2-26</text>
<text top="88" left="342" width="84" height="17" font="17"> For this rea-</text>
<text top="106" left="74" width="351" height="17" font="17">son, chronic treatment of young patients with amioda-</text>
<text top="124" left="74" width="355" height="17" font="17">rone should be reserved as a bridge to more definitive </text>
<text top="142" left="74" width="357" height="17" font="17">treatment options such as catheter ablation. Baseline </text>
<text top="160" left="74" width="356" height="17" font="17">evaluation of patients may include ECG, liver function </text>
<text top="178" left="74" width="351" height="17" font="17">tests, thyroid function tests, chest x-ray, and pulmo-</text>
<text top="196" left="74" width="356" height="17" font="17">nary function tests (including diffusing capacity of the </text>
<text top="214" left="74" width="358" height="17" font="17">lungs  for carbon monoxide). Monitoring for toxicity </text>
<text top="232" left="74" width="351" height="17" font="17">generally includes periodic history and physical exami-</text>
<text top="250" left="74" width="357" height="17" font="17">nation, as well as evaluation of the ECG, chest x-ray, </text>
<text top="268" left="74" width="357" height="17" font="17">and thyroid, liver, and lung function. High-resolution </text>
<text top="286" left="74" width="355" height="17" font="17">chest CT is generally reserved for suspected pulmonary </text>
<text top="304" left="74" width="48" height="17" font="17">toxicity.</text>
<text top="304" left="123" width="44" height="10" font="19">S5.1.5.2-30</text>
<text top="322" left="92" width="340" height="17" font="17">Although sotalol has some efficacy in suppressing </text>
<text top="340" left="74" width="355" height="17" font="17">VA, it has significant proarrhythmic effects and has not </text>
<text top="358" left="74" width="214" height="17" font="17">been shown to improve survival.</text>
<text top="358" left="288" width="44" height="10" font="19">S5.1.5.2-31</text>
<text top="358" left="332" width="100" height="17" font="17"> D-sotalol was </text>
<text top="376" left="74" width="359" height="17" font="17">shown in the SWORD (Survival With Oral d-Sotalol) </text>
<text top="394" left="74" width="356" height="17" font="17">trial to increase the risk of death in patients with heart </text>
<text top="412" left="74" width="44" height="17" font="17">failure.</text>
<text top="413" left="118" width="44" height="10" font="19">S5.1.5.2-32</text>
<text top="412" left="162" width="263" height="17" font="17"> Unlike amiodarone and many other an-</text>
<text top="430" left="74" width="351" height="17" font="17">tiarrhythmic agents, sotalol appears to reduce the de-</text>
<text top="448" left="74" width="135" height="17" font="17">fibrillation threshold.</text>
<text top="449" left="209" width="44" height="10" font="19">S5.1.5.2-33</text>
<text top="448" left="253" width="179" height="17" font="17"> Also, sotalol may lead to </text>
<text top="466" left="74" width="356" height="17" font="17">HF decompensation, and so its use in patients with an </text>
<text top="484" left="74" width="207" height="17" font="17">LVEF &lt;20% is generally avoided.</text>
<text top="511" left="74" width="221" height="18" font="24"><i><b>5.1.4. Calcium Channel Blockers</b></i></text>
<text top="530" left="74" width="351" height="17" font="17">For the treatment of most VA, nondihydropyridines cal-</text>
<text top="548" left="74" width="355" height="17" font="17">cium channel blockers have no role. In fact, intravenous </text>
<text top="566" left="74" width="357" height="17" font="17">verapamil given for sustained VT has been associated </text>
<text top="584" left="74" width="355" height="17" font="17">with hemodynamic collapse, especially in patients with </text>
<text top="602" left="74" width="57" height="17" font="17">prior MI.</text>
<text top="602" left="132" width="90" height="10" font="19">S5.1.5.2-34,S5.1.5.2-35</text>
<text top="602" left="221" width="204" height="17" font="17"> For patients with a structural-</text>
<text top="620" left="74" width="357" height="17" font="17">ly normal hearts, verapamil or diltiazem can suppress </text>
<text top="638" left="74" width="173" height="17" font="17">some outflow tract origin.</text>
<text top="638" left="247" width="92" height="10" font="19">S5.1.5.2-35–S5.1.5.2-39</text>
<text top="638" left="339" width="86" height="17" font="17"> Oral and in-</text>
<text top="656" left="74" width="356" height="17" font="17">travenous verapamil are effective in treating idiopathic </text>
<text top="674" left="74" width="189" height="17" font="17">interfascicular reentrant LVT.</text>
<text top="674" left="263" width="44" height="10" font="19">S5.1.5.2-38</text>
<text top="674" left="307" width="127" height="17" font="17"> Calcium channel </text>
<text top="692" left="74" width="355" height="17" font="17">bloickers should not be given to patients with VT in the </text>
<text top="710" left="74" width="95" height="17" font="17">settin of HF<i>r</i>EF.</text>
<text top="737" left="74" width="300" height="18" font="24"><i><b>5.1.5. Nonantiarrhythmic Medications and </b></i></text>
<text top="755" left="74" width="68" height="18" font="24"><i><b>Therapies</b></i></text>
<text top="776" left="74" width="126" height="18" font="28"><i>5.1.5.1. Electrolytes</i></text>
<text top="794" left="74" width="361" height="17" font="17">Administration of potassium and magnesium has </text>
<text top="812" left="74" width="357" height="17" font="17">been proposed as helpful adjuncts in the prevention </text>
<text top="830" left="74" width="44" height="17" font="17">of VA.</text>
<text top="831" left="119" width="92" height="10" font="19">S5.1.5.2-40,S5.1.5.2-41</text>
<text top="830" left="211" width="215" height="17" font="17"> Hypokalemia and hypomagne-</text>
<text top="848" left="74" width="356" height="17" font="17">semia are common consequences of diuretic therapy </text>
<text top="866" left="74" width="357" height="17" font="17">in HF, both have been associated with VA during an </text>
<text top="884" left="74" width="63" height="17" font="17">acute MI,</text>
<text top="885" left="138" width="92" height="10" font="19">S5.1.5.2-41,S5.1.5.2-42</text>
<text top="884" left="230" width="202" height="17" font="17"> and can increase the risk of </text>
<text top="902" left="74" width="355" height="17" font="17">torsades de pointes in patients on medications or with </text>
<text top="920" left="74" width="291" height="17" font="17">conditions known to prolong the QT interval.</text>
<text top="921" left="365" width="45" height="10" font="19">S5.1.5.2-43</text>
<text top="920" left="410" width="19" height="17" font="17"> In </text>
<text top="938" left="74" width="355" height="17" font="17">fact, in patients with torsades de pointes, intravenous </text>
<text top="956" left="74" width="202" height="17" font="17">magnesium is first-line therapy.</text>
<text top="957" left="276" width="45" height="10" font="19">S5.1.5.2-44</text>
<text top="956" left="321" width="108" height="17" font="17"> In patients who </text>
<text top="974" left="74" width="351" height="17" font="17">are deficient in both magnesium and potassium, mag-</text>
<text top="992" left="74" width="355" height="17" font="17">nesium should be repleted to facilitate replacement of </text>
<text top="1010" left="74" width="97" height="17" font="17">the potassium.</text>
<text top="1011" left="171" width="45" height="10" font="19">S5.1.5.2-45</text>
<text top="1010" left="216" width="214" height="17" font="17"> In the case of potassium, some </text>
<text top="1028" left="74" width="360" height="17" font="17">recommend keeping the potassium level between </text>
<text top="1028" left="425" width="4" height="17" font="17"> </text>
<text top="1046" left="74" width="362" height="17" font="17">4.5 mmol/L and 5 mmol/L to prevent VA and </text>
<text top="1046" left="425" width="4" height="17" font="17"> </text>
<text top="1064" left="74" width="32" height="17" font="17">SCD.</text>
<text top="1065" left="106" width="90" height="10" font="19">S5.1.5.2-46,S5.1.5.2-47</text>
<text top="1064" left="196" width="229" height="17" font="17"> A large observational study of pa-</text>
<text top="1082" left="74" width="357" height="17" font="17">tients with an acute MI found that the lowest rates </text>
<text top="88" left="452" width="357" height="17" font="17">of death were seen in patients with serum potassium </text>
<text top="106" left="452" width="351" height="17" font="17">concentrations between 3.5 mmol/L and  &lt;4.5 mmol/</text>
<text top="124" left="452" width="11" height="17" font="17">L.</text>
<text top="125" left="463" width="44" height="10" font="19">S5.1.5.2-48</text>
<text top="124" left="507" width="300" height="17" font="17"> Interestingly, the rates of VA did not rise unless </text>
<text top="142" left="452" width="355" height="17" font="17">the potassium was &lt;3 mmol/L or ≥5 mmol/L. Likewise, </text>
<text top="161" left="452" width="358" height="17" font="17">a large randomized, double-blind trial of intravenous </text>
<text top="179" left="452" width="359" height="17" font="17">magnesium in the post-MI period demonstrated no </text>
<text top="197" left="452" width="174" height="17" font="17">benefit in 30-day mortality.</text>
<text top="198" left="626" width="44" height="10" font="19">S5.1.5.2-40</text>
<text top="197" left="670" width="133" height="17" font="17"> It remains quite rea-</text>
<text top="215" left="452" width="356" height="17" font="17">sonable to monitor potassium and magnesium during </text>
<text top="233" left="452" width="289" height="17" font="17">aggressive diuresis and in the post-MI period.</text>
<text top="261" left="452" width="218" height="18" font="28"><i>5.1.5.2. n-3 Fatty Acids and Lipids</i></text>
<text top="280" left="452" width="363" height="17" font="17">Both n-3 poly-unsaturated fatty acids and statin </text>
<text top="298" left="452" width="358" height="17" font="17">therapies may have a role in the prevention of SCD, </text>
<text top="316" left="452" width="351" height="17" font="17">thought to be due to a stabilization of the bilipid myo-</text>
<text top="334" left="452" width="361" height="17" font="17">cyte membrane involved in maintaining electrolyte </text>
<text top="353" left="452" width="63" height="17" font="17">gradients.</text>
<text top="353" left="516" width="44" height="10" font="19">S5.1.5.2-49</text>
<text top="371" left="470" width="339" height="17" font="17">Early data were promising regarding the effects of </text>
<text top="389" left="452" width="359" height="17" font="17">n-3 polyunsaturated fatty acids on the reduction of </text>
<text top="407" left="452" width="351" height="17" font="17">cardiovascular events and SCD. In 2006, a large meta-</text>
<text top="426" left="452" width="358" height="17" font="17">analysis of 19 observational and RCTs demonstrated </text>
<text top="444" left="452" width="361" height="17" font="17">a significant association between the consumption </text>
<text top="462" left="452" width="358" height="17" font="17">of n-3 polyunsaturated fatty acids and prevention of </text>
<text top="480" left="452" width="32" height="17" font="17">SCD.</text>
<text top="481" left="484" width="44" height="10" font="19">S5.1.5.2-50</text>
<text top="480" left="528" width="279" height="17" font="17"> The randomized GISSI (Gruppo Italiano per </text>
<text top="499" left="452" width="357" height="17" font="17">lo Studio della Sopravvivenza nell'Infarto)-Prevenzione </text>
<text top="517" left="452" width="356" height="17" font="17">trial in people with recent MI, found that fish oil 1 g/d </text>
<text top="535" left="452" width="243" height="17" font="17">reduced mortality, due to fewer SCD.</text>
<text top="536" left="695" width="44" height="10" font="19">S5.1.5.2-51</text>
<text top="535" left="739" width="70" height="17" font="17"> However, </text>
<text top="553" left="452" width="359" height="17" font="17">subsequent RCTs have not replicated these benefits </text>
<text top="571" left="452" width="356" height="17" font="17">and have shown n-3 polyunsaturated fatty acids to be </text>
<text top="590" left="452" width="70" height="17" font="17">ineffective.</text>
<text top="590" left="522" width="92" height="10" font="19">S5.1.5.2-52–S5.1.5.2-56</text>
<text top="590" left="614" width="198" height="17" font="17"> Because studies showed a </text>
<text top="608" left="452" width="355" height="17" font="17">consistent lack of harm from n-3 polyunsaturated fatty </text>
<text top="626" left="452" width="351" height="17" font="17">acids, patients can be reassured of their safety. Longer-</text>
<text top="644" left="452" width="338" height="17" font="17">term data will hopefully clarify the conflicting results.</text>
<text top="663" left="470" width="333" height="17" font="17">In contrast, statin medications clearly reduce mor-</text>
<text top="681" left="452" width="357" height="17" font="17">tality and appear to reduce the risk of SCD related to </text>
<text top="699" left="452" width="144" height="17" font="17">ischemic heart disease.</text>
<text top="700" left="596" width="44" height="10" font="19">S5.1.5.2-57</text>
<text top="699" left="640" width="163" height="17" font="17"> The predominant mecha-</text>
<text top="717" left="452" width="356" height="17" font="17">nism remains uncertain. Prevention of coronary plaque </text>
<text top="736" left="452" width="356" height="17" font="17">rupture or a direct cardioprotective effect reducing VA </text>
<text top="754" left="452" width="351" height="17" font="17">has been suggested. Experimental ischemia/reperfu-</text>
<text top="772" left="452" width="358" height="17" font="17">sion models demonstrate a cardioprotective effect of </text>
<text top="790" left="452" width="355" height="17" font="17">statins, and a large observational analysis observed this </text>
<text top="809" left="452" width="119" height="17" font="17">effect in humans.</text>
<text top="809" left="572" width="138" height="10" font="19">S5.1.5.2-42,S5.1.5.2-56–S5.1.5.2-58</text>
<text top="809" left="710" width="94" height="17" font="17"> This was ex-</text>
<text top="827" left="452" width="358" height="17" font="17">plored further in HF in several secondary analyses of </text>
<text top="845" left="452" width="358" height="17" font="17">patients on statins in ICD prevention trials, including </text>
<text top="863" left="452" width="360" height="17" font="17">the MADIT-CRT (Multicenter Automatic Defibrillator </text>
<text top="882" left="452" width="357" height="17" font="17">Implantation Trial-Cardiac Resynchronization Therapy), </text>
<text top="900" left="452" width="359" height="17" font="17">SCD-HeFT, AVID (Antiarrhythmics versus Implantable </text>
<text top="918" left="452" width="89" height="17" font="17">Defibrillators),</text>
<text top="919" left="541" width="44" height="10" font="19">S5.1.5.2-59</text>
<text top="918" left="585" width="228" height="17" font="17"> and DEFINITE (DEFibrillators In </text>
<text top="936" left="452" width="359" height="17" font="17">Non-Ischemic Cardiomyopathy Treatment Evaluation) </text>
<text top="954" left="452" width="358" height="17" font="17">trials that showed less SCD risk among the patients </text>
<text top="973" left="452" width="67" height="17" font="17">on statins.</text>
<text top="973" left="519" width="138" height="10" font="19">S5.1.5.2-58,S5.1.5.2-60–S5.1.5.2-62</text>
<text top="973" left="657" width="151" height="17" font="17"> However, this general </text>
<text top="991" left="452" width="357" height="17" font="17">effect in HF was not confirmed in 2 prospective RCTs </text>
<text top="1009" left="452" width="351" height="17" font="17">of rosuvastatin in HF; the CORONA (Controlled Rosu-</text>
<text top="1027" left="452" width="351" height="17" font="17">vastatin Multinational Trial in Heart Failure) and GISSI-</text>
<text top="1046" left="452" width="357" height="17" font="17">HF (Gruppo Italiano per lo Studio della Sopravvivenza </text>
<text top="1064" left="452" width="261" height="17" font="17">nell'Insufficienza Cardiaca-Heart Failure).</text>
<text top="1065" left="713" width="90" height="10" font="19">S5.1.5.2-63,S5.1.5.2-64</text>
<text top="1064" left="803" width="4" height="17" font="17"> </text>
<text top="1082" left="452" width="351" height="17" font="17">It appears that the beneficial effects of statins are con-</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e295</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="17" font="17">fined to the population with or at risk for atheroscle-</text>
<text top="106" left="74" width="354" height="17" font="17">rotic cardiovascular disease and/or ischemia, and not HF </text>
<text top="124" left="74" width="60" height="17" font="17">generally.</text>
<text top="167" left="74" width="248" height="21" font="18"><b>5.2. Preventing SCD With HF </b></text>
<text top="189" left="74" width="105" height="21" font="18"><b>Medications</b></text>
<text top="222" left="85" width="280" height="12" font="26"><b>Recommendation for Pharmacological Prevention of SCD</b></text>
<text top="239" left="85" width="321" height="12" font="26"><b>References that support the recommendation are summarized in </b></text>
<text top="253" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 10</b></a></text>
<text top="253" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="274" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="274" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="274" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="342" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="342" left="161" width="8" height="12" font="22"><b>A</b></text>
<text top="295" left="205" width="175" height="12" font="4">1.  In patients with HF<i>r</i>EF (LVEF ≤40%), </text>
<text top="309" left="217" width="146" height="12" font="4">treatment with a beta blocker, a </text>
<text top="322" left="217" width="191" height="12" font="4">mineralocorticoid receptor antagonist and </text>
<text top="336" left="217" width="186" height="12" font="4">either an angiotensin-converting enzyme </text>
<text top="349" left="217" width="201" height="12" font="4">inhibitor, an angiotensin-receptor blocker, or </text>
<text top="363" left="217" width="203" height="12" font="4">an angiotensin receptor-neprilysin inhibitor is </text>
<text top="376" left="217" width="196" height="12" font="4">recommended to reduce SCD and all-cause </text>
<text top="390" left="217" width="42" height="12" font="4">mortality.</text>
<text top="390" left="258" width="37" height="7" font="23">S5.2-1–S5.2-8</text>
<text top="433" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="454" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="481" left="89" width="337" height="17" font="17">1. For patients with HF and depressed LV func-</text>
<text top="499" left="107" width="326" height="17" font="17">tion, appropriate medical therapy is important </text>
<text top="517" left="107" width="327" height="17" font="17">to reduce SCD. These therapies have various </text>
<text top="536" left="107" width="328" height="17" font="17">beneficial effects on arrhythmia mechanisms. </text>
<text top="554" left="107" width="322" height="17" font="17">Beta blockers reduce myocardial oxygen demand </text>
<text top="572" left="107" width="319" height="17" font="17">and electrical excitability, and counter arrhyth-</text>
<text top="590" left="107" width="331" height="17" font="17">mogenic effects of sympathetic stimulation. </text>
<text top="608" left="107" width="328" height="17" font="17">Angiotensin-converting enzyme inhibitors and </text>
<text top="626" left="107" width="326" height="17" font="17">angiotensin-receptor blockers decrease preload </text>
<text top="644" left="107" width="329" height="17" font="17">and afterload, decreasing myocardial oxygen </text>
<text top="663" left="107" width="319" height="17" font="17">demand, blocking the formation of angioten-</text>
<text top="681" left="107" width="323" height="17" font="17">sin II, and slowing the progression of ventricular </text>
<text top="699" left="107" width="319" height="17" font="17">remodeling and fibrosis. Mineralocorticoid recep-</text>
<text top="717" left="107" width="327" height="17" font="17">tor antagonists limit potassium loss, decrease </text>
<text top="735" left="107" width="325" height="17" font="17">fibrosis, and increase the myocardial uptake of </text>
<text top="753" left="107" width="105" height="17" font="17">norepinephrine.</text>
<text top="754" left="211" width="25" height="10" font="19">S5.2-7</text>
<text top="771" left="92" width="343" height="17" font="17">RCTs in patients with HF<i>r</i>EF have consistently </text>
<text top="771" left="425" width="4" height="17" font="17"> </text>
<text top="790" left="74" width="365" height="17" font="17">demonstrated that chronic therapy with beta </text>
<text top="790" left="425" width="4" height="17" font="17"> </text>
<text top="808" left="74" width="366" height="17" font="17">blockers reduces all-cause mortality, VA, and </text>
<text top="808" left="425" width="4" height="17" font="17"> </text>
<text top="826" left="74" width="32" height="17" font="17">SCD.</text>
<text top="827" left="106" width="105" height="10" font="19">S5.2-2,S5.2-4,S5.2-5,S5.2-9</text>
<text top="826" left="210" width="215" height="17" font="17"> Three beta blockers (ie, biso-</text>
<text top="844" left="74" width="351" height="17" font="17">prolol, carvedilol, sustained-release metoprolol suc-</text>
<text top="862" left="74" width="361" height="17" font="17">cinate) have been proven to reduce mortality in </text>
<text top="880" left="74" width="355" height="17" font="17">patients with current or prior symptoms of HF<i>r</i>EF </text>
<text top="898" left="74" width="351" height="17" font="17">without beta-blocker contraindications. Angiotensin-</text>
<text top="917" left="74" width="358" height="17" font="17">converting enzyme inhibition also reduces mortality </text>
<text top="935" left="74" width="66" height="17" font="17">and SCD.</text>
<text top="935" left="140" width="25" height="10" font="19">S5.2-3</text>
<text top="935" left="165" width="268" height="17" font="17"> Angiotensin-receptor blockers added </text>
<text top="953" left="74" width="358" height="17" font="17">to angiotensin-converting enzyme inhibitor showed </text>
<text top="971" left="74" width="357" height="17" font="17">additional benefit to angiotensin-converting enzyme </text>
<text top="989" left="74" width="122" height="17" font="17">inhibitors in some</text>
<text top="990" left="196" width="30" height="10" font="19">S5.2-10</text>
<text top="989" left="226" width="141" height="17" font="17"> but not other RCTs.</text>
<text top="990" left="368" width="58" height="10" font="19">S5.2-8,S5.2-11</text>
<text top="989" left="425" width="4" height="17" font="17"> </text>
<text top="1007" left="74" width="351" height="17" font="17">Therapy with the mineralocorticoid-receptor antago-</text>
<text top="1025" left="74" width="351" height="17" font="17">nists, spironolactone and eplerenone, have also dem-</text>
<text top="1044" left="74" width="357" height="17" font="17">onstrated reductions in both all-cause mortality and </text>
<text top="1062" left="74" width="32" height="17" font="17">SCD.</text>
<text top="1062" left="107" width="90" height="10" font="19">S5.2-6,S5.2-12,S5.2-13</text>
<text top="1062" left="197" width="234" height="17" font="17"> Recent studies of the angiotensin </text>
<text top="1080" left="74" width="356" height="17" font="17">receptor-neprilysin inhibitor (sacubitril/valsartan) versus </text>
<text top="88" left="452" width="355" height="17" font="17">angiotensin-converting enzyme inhibitor demonstrated </text>
<text top="106" left="452" width="261" height="17" font="17">a reduction in SCD and cardiac mortality.</text>
<text top="106" left="713" width="29" height="10" font="19">S5.2-14</text>
<text top="149" left="452" width="324" height="21" font="18"><b>5.3. Defibrillators for Treatment of VA </b></text>
<text top="170" left="452" width="71" height="21" font="18"><b>and SCD</b></text>
<text top="197" left="452" width="274" height="17" font="17">See Sections 7, 10.2, 10.3, 10.8, and 10.9.</text>
<text top="215" left="470" width="333" height="17" font="17">Defibrillation is highly effective in terminating life-</text>
<text top="233" left="452" width="359" height="17" font="17">threatening VA. This therapy can be delivered by a </text>
<text top="251" left="452" width="351" height="17" font="17">transvenous ICD, a subcutaneous implantable cardio-</text>
<text top="269" left="452" width="356" height="17" font="17">verter-defibrillator, a wearable cardioverter-defibrillator </text>
<text top="287" left="452" width="357" height="17" font="17">or an external defibrillator. These devices monitor the </text>
<text top="306" left="452" width="351" height="17" font="17">heart rhythm continuously and deliver therapy in re-</text>
<text top="324" left="452" width="359" height="17" font="17">sponse to a tachycardia that meets preprogrammed </text>
<text top="342" left="452" width="351" height="17" font="17">detection rates and arrhythmia duration. The vast ma-</text>
<text top="360" left="452" width="351" height="17" font="17">jority of transvenous ICDs are implanted in the subcla-</text>
<text top="378" left="452" width="355" height="17" font="17">vicular area under fluoroscopy guidance. subcutaneous </text>
<text top="396" left="452" width="356" height="17" font="17">implantable cardioverter-defibrillators are implanted in </text>
<text top="414" left="452" width="355" height="17" font="17">the left side of the chest over the sixth rib between the </text>
<text top="432" left="452" width="355" height="17" font="17">left midaxillary and left anterior axillary lines. ICDs with </text>
<text top="450" left="452" width="351" height="17" font="17">epicardial sensing and pacing leads are still being im-</text>
<text top="468" left="452" width="357" height="17" font="17">planted in some patients especially those with certain </text>
<text top="486" left="452" width="217" height="17" font="17">forms of congenital heart disease.</text>
<text top="504" left="470" width="340" height="17" font="17">The transvenous ICD has been in clinical use for </text>
<text top="522" left="452" width="357" height="17" font="17">&gt;3 decades, and robust data from high-quality RCTs </text>
<text top="540" left="452" width="351" height="17" font="17">support its use in various patient populations includ-</text>
<text top="558" left="452" width="358" height="17" font="17">ing survivors of cardiac arrest, patients with VT and </text>
<text top="576" left="452" width="357" height="17" font="17">structural heart disease, and patients with significant </text>
<text top="594" left="452" width="98" height="17" font="17">LV dysfunction.</text>
<text top="638" left="452" width="186" height="21" font="18"><b>5.4. Catheter Ablation</b></text>
<text top="664" left="452" width="206" height="18" font="24"><i><b>5.4.1. General Considerations</b></i></text>
<text top="683" left="452" width="356" height="17" font="17">Catheter ablation is an important treatment option for </text>
<text top="701" left="452" width="356" height="17" font="17">patients with VA when antiarrhythmic medications are </text>
<text top="719" left="452" width="355" height="17" font="17">ineffective, not tolerated, or not desired by the patient. </text>
<text top="737" left="452" width="357" height="17" font="17">Monomorphic VA usually have an origin or substrate </text>
<text top="755" left="452" width="351" height="17" font="17">that can be targeted for ablation. Ablation is an op-</text>
<text top="773" left="452" width="356" height="17" font="17">tion for selected patients with polymorphic VT/VF only </text>
<text top="791" left="452" width="355" height="17" font="17">if an initiating PVC focus or substrate can be identified. </text>
<text top="809" left="452" width="355" height="17" font="17">The ablation strategy, risks and outcomes are related to </text>
<text top="827" left="452" width="351" height="17" font="17">the mechanism and location of the VA. Most VA origi-</text>
<text top="845" left="452" width="355" height="17" font="17">nate close to the subendocardium and are approached </text>
<text top="863" left="452" width="351" height="17" font="17">through a transvenous (for the right ventricle) or trans-</text>
<text top="881" left="452" width="356" height="17" font="17">aortic/transeptal (for the left ventricle) catheterization. </text>
<text top="899" left="452" width="355" height="17" font="17">Some diseases give rise to VA from the subepicardium, </text>
<text top="917" left="452" width="356" height="17" font="17">which may be approached by epicardial mapping and </text>
<text top="935" left="452" width="351" height="17" font="17">ablation. Pericardial access is usually achieved by a per-</text>
<text top="954" left="452" width="356" height="17" font="17">cutaneous subxiphoid puncture. The catheter ablation </text>
<text top="972" left="452" width="358" height="17" font="17">procedure usually involves attempts to induce VT by </text>
<text top="990" left="452" width="351" height="17" font="17">programmed electrical stimulation to confirm the di-</text>
<text top="1008" left="452" width="357" height="17" font="17">agnosis and guide ablation. Problems limiting success </text>
<text top="1026" left="452" width="357" height="17" font="17">include inability to induce an arrhythmia for mapping </text>
<text top="1044" left="452" width="351" height="17" font="17">(common with idiopathic VA), or origin of the arrhyth-</text>
<text top="1062" left="452" width="357" height="17" font="17">mia from an inaccessible location in the myocardium </text>
<text top="1080" left="452" width="240" height="17" font="17">(common in some cardiomyopathies).</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e296</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="351" height="18" font="24"><i><b>5.4.2. VA in Patients With No Apparent Structural </b></i></text>
<text top="105" left="74" width="97" height="18" font="24"><i><b>Heart Disease</b></i></text>
<text top="124" left="74" width="90" height="17" font="17">See Section 8.</text>
<text top="142" left="92" width="333" height="17" font="17">VA that are not associated with underlying structur-</text>
<text top="160" left="74" width="355" height="17" font="17">al heart disease or a genetic arrhythmia syndrome are </text>
<text top="179" left="74" width="357" height="17" font="17">commonly referred to as idiopathic. Most idiopathic </text>
<text top="197" left="74" width="351" height="17" font="17">VA are monomorphic and based on a focal mecha-</text>
<text top="215" left="74" width="358" height="17" font="17">nism of triggered activity or abnormal automaticity; </text>
<text top="233" left="74" width="351" height="17" font="17">a few are due to reentry. For patients who are symp-</text>
<text top="251" left="74" width="360" height="17" font="17">tomatic, and in whom antiarrhythmic medications </text>
<text top="270" left="74" width="358" height="17" font="17">are ineffective, not tolerated, or not desired by the </text>
<text top="288" left="74" width="357" height="17" font="17">patient, catheter ablation is a treatment option. The </text>
<text top="306" left="74" width="351" height="17" font="17">ablation strategy is to identify the site of origin mani-</text>
<text top="324" left="74" width="358" height="17" font="17">fested by the earliest site of electrical activation, or </text>
<text top="342" left="74" width="355" height="17" font="17">when this is not practical, by pace mapping. Catheter </text>
<text top="361" left="74" width="355" height="17" font="17">ablation of idiopathic VA is usually accomplished with </text>
<text top="379" left="74" width="351" height="17" font="17">endocardial catheterization, though an epicardial ap-</text>
<text top="397" left="74" width="357" height="17" font="17">proach through the coronary venous circulation or a </text>
<text top="415" left="74" width="358" height="17" font="17">subxiphoid pericardial puncture may occasionally be </text>
<text top="433" left="74" width="358" height="17" font="17">required. Ablation failure for idiopathic VA is often </text>
<text top="451" left="74" width="358" height="17" font="17">due to inability to provoke the arrhythmia to allow </text>
<text top="470" left="74" width="351" height="17" font="17">mapping in the electrophysiological laboratory or ori-</text>
<text top="488" left="74" width="207" height="17" font="17">gin from an inaccessible region.</text>
<text top="515" left="74" width="152" height="18" font="24"><i><b>5.4.3. Scar-Related VT</b></i></text>
<text top="534" left="74" width="90" height="17" font="17">See Section 8.</text>
<text top="552" left="92" width="343" height="17" font="17">For most patients with structural heart disease, </text>
<text top="570" left="74" width="357" height="17" font="17">sustained monomorphic VT is due to reentry through </text>
<text top="589" left="74" width="357" height="17" font="17">regions of surviving myocardial fibers associated with </text>
<text top="607" left="74" width="351" height="17" font="17">areas of fibrous scar. The ablation strategy for these re-</text>
<text top="625" left="74" width="358" height="17" font="17">entry circuits is to identify and eliminate channels of </text>
<text top="643" left="74" width="351" height="17" font="17">surviving myocardium within the scar that are often as-</text>
<text top="661" left="74" width="357" height="17" font="17">sociated with slow conduction facilitating reentry. For </text>
<text top="680" left="74" width="357" height="17" font="17">most VTs that are related to prior MI, the substrate is </text>
<text top="698" left="74" width="357" height="17" font="17">on the subendocardial surface of the left ventricle. In </text>
<text top="716" left="74" width="351" height="17" font="17">NICM, the reentrant circuits are more variable in loca-</text>
<text top="734" left="74" width="351" height="17" font="17">tion, often involve the epicardial surface of either ven-</text>
<text top="752" left="74" width="351" height="17" font="17">tricle and frequently extending into the midmyocar-</text>
<text top="771" left="74" width="357" height="17" font="17">dium where ablation may be difficult to achieve from </text>
<text top="789" left="74" width="359" height="17" font="17">either surface. In tetralogy of Fallot specific reentry </text>
<text top="807" left="74" width="164" height="17" font="17">paths have been defined.</text>
<text top="808" left="238" width="32" height="10" font="19">S5.4.3-1</text>
<text top="807" left="269" width="156" height="17" font="17"> Electroanatomical map-</text>
<text top="825" left="74" width="351" height="17" font="17">ping that helps clarify the relation of electrophysiologi-</text>
<text top="843" left="74" width="351" height="17" font="17">cal abnormalities to cardiac anatomy is commonly em-</text>
<text top="862" left="74" width="356" height="17" font="17">ployed. Areas of scar can be appreciated as regions of </text>
<text top="880" left="74" width="355" height="17" font="17">relatively low electrogram voltage. For scar-related VTs, </text>
<text top="898" left="74" width="356" height="17" font="17">hemodynamic intolerance often limits mapping during </text>
<text top="916" left="74" width="354" height="17" font="17">VT. Ablation is then often guided by substrate mapping, </text>
<text top="934" left="74" width="351" height="17" font="17">in which areas of scar and potential reentry circuit sub-</text>
<text top="952" left="74" width="358" height="17" font="17">strate are delineated in electroanatomic maps based </text>
<text top="971" left="74" width="351" height="17" font="17">on electrocardiographic and pacing characteristics as-</text>
<text top="989" left="74" width="357" height="17" font="17">sessed during hemodynamically stable sinus or paced </text>
<text top="1007" left="74" width="355" height="17" font="17">rhythm. Catheter ablation of scar-related VT requires an </text>
<text top="1025" left="74" width="351" height="17" font="17">advanced level of experience by the operator, electro-</text>
<text top="1043" left="74" width="356" height="17" font="17">physiological laboratory staff, and anesthesiologists as </text>
<text top="1062" left="74" width="357" height="17" font="17">well as availability of surgical back-up and specialized </text>
<text top="1080" left="74" width="283" height="17" font="17">mapping, imaging, and ablation equipment.</text>
<text top="1081" left="357" width="66" height="10" font="19">S5.4.3-2,S5.4.3-3</text>
<text top="87" left="452" width="296" height="21" font="18"><b>5.5. Surgery and Revascularization </b></text>
<text top="108" left="452" width="313" height="21" font="18"><b>Procedures in Patients With Ischemic </b></text>
<text top="129" left="452" width="116" height="21" font="18"><b>Heart Disease</b></text>
<text top="163" left="463" width="333" height="12" font="26"><b>Recommendations for Surgery and Revascularization Procedures in </b></text>
<text top="177" left="463" width="181" height="12" font="26"><b>Patients With Ischemic Heart Disease</b></text>
<text top="194" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="207" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 11</b></a></text>
<text top="207" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="228" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="228" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="228" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="269" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="269" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="249" left="583" width="207" height="12" font="4">1.  Patients with sustained VA and survivors of </text>
<text top="263" left="595" width="198" height="12" font="4">SCA should be evaluated for ischemic heart </text>
<text top="276" left="595" width="182" height="12" font="4">disease, and should be revascularized as </text>
<text top="290" left="595" width="55" height="12" font="4">appropriate.</text>
<text top="290" left="649" width="37" height="7" font="23">S5.5-1–S5.5-4</text>
<text top="331" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="331" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="310" left="583" width="185" height="12" font="4">2.  In patients with anomalous origin of a </text>
<text top="324" left="595" width="189" height="12" font="4">coronary artery suspected to be the cause </text>
<text top="337" left="595" width="164" height="12" font="4">of SCA, repair or revascularization is </text>
<text top="351" left="595" width="67" height="12" font="4">recommended.</text>
<text top="391" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="412" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="440" left="467" width="336" height="17" font="17">1.  Myocardial ischemia is a cause of sustained poly-</text>
<text top="458" left="489" width="314" height="17" font="17">morphic VT/VF, and revascularization is an effec-</text>
<text top="476" left="489" width="323" height="17" font="17">tive treatment to prevent myocardial ischemia. </text>
<text top="495" left="489" width="314" height="17" font="17">For patients with life-threatening VA, observa-</text>
<text top="513" left="489" width="324" height="17" font="17">tional studies show that patients undergoing </text>
<text top="531" left="489" width="314" height="17" font="17">coronary artery bypass graft (CABG) had substan-</text>
<text top="550" left="489" width="322" height="17" font="17">tially better survival after accounting  for other  </text>
<text top="568" left="489" width="62" height="17" font="17">predictors.</text>
<text top="569" left="550" width="47" height="10" font="19">S5.5-1,S5.5-5</text>
<text top="568" left="598" width="206" height="17" font="17"> The risk of SCD appears compara-</text>
<text top="586" left="489" width="319" height="17" font="17">ble for patients with complex ischemic heart disease </text>
<text top="604" left="489" width="291" height="17" font="17">randomized to treatment with PCI versus CABG.</text>
<text top="605" left="779" width="24" height="10" font="19">S5.5-6</text>
<text top="604" left="803" width="4" height="17" font="17">  </text>
<text top="623" left="489" width="322" height="17" font="17">For patients with low LVEF and ischemic heart </text>
<text top="641" left="489" width="321" height="17" font="17">disease amenable to CABG, the risk of SCD is </text>
<text top="659" left="489" width="263" height="17" font="17">lower with CABG than medical therapy.</text>
<text top="660" left="752" width="51" height="10" font="19">S5.5-2,S5.5-7</text>
<text top="659" left="803" width="4" height="17" font="17"> </text>
<text top="678" left="489" width="320" height="17" font="17">Observational studies show an association between </text>
<text top="696" left="489" width="320" height="17" font="17">a lower likelihood of death with revascularization </text>
<text top="714" left="489" width="214" height="17" font="17">for survivors of SCA and CABG</text>
<text top="715" left="702" width="24" height="10" font="19">S5.5-3</text>
<text top="714" left="726" width="53" height="17" font="17"> or PCI.</text>
<text top="715" left="779" width="24" height="10" font="19">S5.5-4</text>
<text top="714" left="803" width="4" height="17" font="17"> </text>
<text top="732" left="489" width="323" height="17" font="17">Revascularization alone is usually insufficient to </text>
<text top="751" left="489" width="319" height="17" font="17">prevent recurrence of sustained monomorphic VT; </text>
<text top="769" left="489" width="314" height="17" font="17">further evaluation for inducible VT is generally con-</text>
<text top="787" left="489" width="320" height="17" font="17">sidered if ventricular function is depressed and/or </text>
<text top="806" left="489" width="92" height="17" font="17">scar is present.</text>
<text top="824" left="467" width="336" height="17" font="17">2. Anomalous aortic origin of the coronary arter-</text>
<text top="842" left="489" width="321" height="17" font="17">ies is detected in approximately 1% of patients </text>
<text top="860" left="489" width="334" height="17" font="17">undergoing routine coronary angiography, </text>
<text top="879" left="489" width="314" height="17" font="17">and  &lt;0.2% of children and adolescents under-</text>
<text top="897" left="489" width="160" height="17" font="17">going echocardiography.</text>
<text top="898" left="649" width="24" height="10" font="19">S5.5-8</text>
<text top="897" left="673" width="139" height="17" font="17"> Although ischemic </text>
<text top="915" left="489" width="320" height="17" font="17">heart disease is detected in as many as 24% to </text>
<text top="934" left="489" width="321" height="17" font="17">55% of SCD cases in young patients  &lt;35 years </text>
<text top="952" left="489" width="53" height="17" font="17">of age,</text>
<text top="953" left="542" width="55" height="10" font="19">S5.5-9,S5.5-10</text>
<text top="952" left="598" width="219" height="17" font="17"> anomalous aortic origin of </text>
<text top="970" left="489" width="322" height="17" font="17">the coronary arteries is an important cause of </text>
<text top="988" left="489" width="321" height="17" font="17">SCD in the young, reported in 10% to 17% of </text>
<text top="1007" left="489" width="254" height="17" font="17">patients included in postmortem studies.</text>
<text top="1007" left="743" width="60" height="10" font="19">S5.5-10,S5.5-11</text>
<text top="1007" left="803" width="4" height="17" font="17"> </text>
<text top="1025" left="489" width="319" height="17" font="17">Anomalous origin of the coronary arteries can be </text>
<text top="1043" left="489" width="320" height="17" font="17">identified by echocardiography, invasive coronary </text>
<text top="1062" left="489" width="321" height="17" font="17">angiography, CT angiography or cardiac MRI. In </text>
<text top="1080" left="489" width="317" height="17" font="17">patients with SCA or life-threatening VA presumed </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e297</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="321" height="17" font="17">related to ischemia caused by anomalous origin </text>
<text top="106" left="111" width="320" height="17" font="17">of a coronary artery, repair or revascularization is </text>
<text top="124" left="111" width="321" height="17" font="17">performed to alleviate ischemia and reduce the </text>
<text top="142" left="111" width="110" height="17" font="17">recurrence of VA.</text>
<text top="143" left="221" width="115" height="10" font="19">S5.5-6,S5.5-7,S5.5-12–S5.5-14</text>
<text top="172" left="74" width="305" height="18" font="24"><i><b>5.5.1. Surgery for Arrhythmia Management</b></i></text>
<text top="200" left="85" width="291" height="12" font="26"><b>Recommendation for Surgery for Arrhythmia Management</b></text>
<text top="217" left="85" width="321" height="12" font="26"><b>References that support the recommendation are summarized in </b></text>
<text top="231" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 12</b></a></text>
<text top="231" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="251" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="251" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="251" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="293" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="293" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="273" left="205" width="210" height="12" font="4">1.  In patients with monomorphic VT refractory </text>
<text top="286" left="217" width="199" height="12" font="4">to antiarrhythmic medications and attempts </text>
<text top="300" left="217" width="205" height="12" font="4">at catheter ablation, surgical ablation may be </text>
<text top="313" left="217" width="51" height="12" font="4">reasonable.</text>
<text top="314" left="268" width="47" height="7" font="23">S5.5.1-1–S5.5.1-7</text>
<text top="353" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="375" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="402" left="89" width="345" height="17" font="17">1. Cardiac surgery as a standalone procedure for </text>
<text top="420" left="107" width="326" height="17" font="17">VT is rarely performed, but has a role in some </text>
<text top="438" left="107" width="319" height="17" font="17">highly symptomatic patients, when antiarrhyth-</text>
<text top="457" left="107" width="328" height="17" font="17">mic medications and catheter ablation fails or </text>
<text top="475" left="107" width="319" height="17" font="17">are not possible, particularly if the failure of abla-</text>
<text top="493" left="107" width="324" height="17" font="17">tion is due to an arrhythmia arising from an area </text>
<text top="511" left="107" width="325" height="17" font="17">that is inaccessible to catheter ablation, such as </text>
<text top="530" left="107" width="325" height="17" font="17">deep in the myocardium, beneath epicardial fat, </text>
<text top="548" left="107" width="324" height="17" font="17">or near the coronary arteries. Surgical ablation of </text>
<text top="566" left="107" width="324" height="17" font="17">tachycardia can also be performed at the time of </text>
<text top="584" left="107" width="319" height="17" font="17">other cardiac surgical interventions, such as dur-</text>
<text top="602" left="107" width="325" height="17" font="17">ing surgical resection of large aneurysms due to </text>
<text top="621" left="107" width="319" height="17" font="17">prior MI in which the border zone is often a sub-</text>
<text top="639" left="107" width="324" height="17" font="17">strate for VT, or placement of an LV assist device  </text>
<text top="657" left="107" width="46" height="17" font="17">(LVAD).</text>
<text top="658" left="153" width="68" height="10" font="19">S5.5.1-5–S5.5.1-7</text>
<text top="657" left="220" width="209" height="17" font="17"> The procedure requires detailed </text>
<text top="675" left="107" width="327" height="17" font="17">characterization of the arrhythmia usually with </text>
<text top="694" left="107" width="329" height="17" font="17">preoperative imaging and mapping, therefore, </text>
<text top="712" left="107" width="327" height="17" font="17">surgical ablation is best undertaken at tertiary </text>
<text top="730" left="107" width="326" height="17" font="17">referral centers and with collaboration between </text>
<text top="748" left="107" width="299" height="17" font="17">experienced surgeons and electrophysiologists.</text>
<text top="778" left="74" width="193" height="18" font="24"><i><b>5.6. Autonomic Modulation</b></i></text>
<text top="806" left="85" width="226" height="12" font="26"><b>Recommendations for Autonomic Modulation</b></text>
<text top="823" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="837" left="85" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 13 and 14</b></a></text>
<text top="837" left="262" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="858" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="858" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="858" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="892" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="892" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="879" left="205" width="187" height="12" font="4">1.  In patients with symptomatic, non–life-</text>
<text top="892" left="217" width="174" height="12" font="4">threatening VA, treatment with a beta </text>
<text top="906" left="217" width="96" height="12" font="4">blocker is reasonable.</text>
<text top="906" left="313" width="17" height="7" font="23">S5.6-1</text>
<text top="960" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="960" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="927" left="205" width="184" height="12" font="4">2.  In patients with VT/VF storm in whom </text>
<text top="940" left="217" width="163" height="12" font="4">a beta blocker, other antiarrhythmic </text>
<text top="954" left="217" width="175" height="12" font="4">medications, and catheter ablation are </text>
<text top="967" left="217" width="188" height="12" font="4">ineffective, not tolerated, or not possible, </text>
<text top="981" left="217" width="180" height="12" font="4">cardiac sympathetic denervation may be </text>
<text top="994" left="217" width="50" height="12" font="4">reasonable.</text>
<text top="995" left="266" width="36" height="7" font="23">S5.6-2–S5.6-4</text>
<text top="1034" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="1062" left="74" width="351" height="17" font="17">Sympathetic activation is proarrhythmic and parasym-</text>
<text top="1080" left="74" width="356" height="17" font="17">pathetic activation is generally antiarrhythmic in VT/VF. </text>
<text top="88" left="452" width="351" height="17" font="17">Modulating the autonomic nervous system for the pur-</text>
<text top="106" left="452" width="351" height="17" font="17">pose of preventing arrhythmias is an emerging thera-</text>
<text top="124" left="452" width="357" height="17" font="17">peutic modality. For the prevention of VA, autonomic </text>
<text top="142" left="452" width="358" height="17" font="17">modulation can be done either through interruption </text>
<text top="160" left="452" width="357" height="17" font="17">of sympathetic outflow to the heart, pharmacological </text>
<text top="179" left="452" width="351" height="17" font="17">beta blockade, or through stimulation of the parasym-</text>
<text top="197" left="452" width="358" height="17" font="17">pathetic pathway (eg, vagal nerve stimulators, spinal </text>
<text top="215" left="452" width="355" height="17" font="17">cord stimulators). Although autonomic modulation has </text>
<text top="233" left="452" width="356" height="17" font="17">proven efficacy for certain conditions such as long QT </text>
<text top="251" left="452" width="351" height="17" font="17">syndrome and catecholaminergic polymorphic ventricu-</text>
<text top="270" left="452" width="355" height="17" font="17">lar tachycardia (see Section 7.9), evidence is limited for </text>
<text top="288" left="452" width="355" height="17" font="17">its applicability to the broader group of VA, but studies </text>
<text top="306" left="452" width="357" height="17" font="17">are ongoing. Currently, there are limited data on the </text>
<text top="324" left="452" width="351" height="17" font="17">role of vagal nerve stimulators and spinal cord stimula-</text>
<text top="343" left="452" width="355" height="17" font="17">tors for the prevention of VA/SCD in humans, and thus </text>
<text top="361" left="452" width="308" height="17" font="17">no formal recommendation could be supported.</text>
<text top="361" left="760" width="24" height="10" font="19">S5.6-5</text>
<text top="404" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="425" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="453" left="467" width="349" height="17" font="17">1. Many patients with non–life-threatening VA </text>
<text top="471" left="489" width="314" height="17" font="17">require only reassurance, but others have symp-</text>
<text top="489" left="489" width="325" height="17" font="17">toms that warrant therapy. A small RCT of </text>
<text top="507" left="489" width="322" height="17" font="17">patients with symptomatic VA demonstrated a </text>
<text top="526" left="489" width="323" height="17" font="17">significant reduction in the arrhythmic burden </text>
<text top="544" left="489" width="88" height="17" font="17">with atenolol.</text>
<text top="544" left="577" width="24" height="10" font="19">S5.6-1</text>
<text top="562" left="467" width="346" height="17" font="17">2. VT/VF storm causes significant morbidity and </text>
<text top="580" left="489" width="314" height="17" font="17">is associated with increased mortality. For VT/</text>
<text top="598" left="489" width="322" height="17" font="17">VF storm refractory to treatment (medications, </text>
<text top="617" left="489" width="314" height="17" font="17">catheter ablation), cardiac sympathetic denerva-</text>
<text top="635" left="489" width="314" height="17" font="17">tion has been shown in several small, observa-</text>
<text top="653" left="489" width="87" height="17" font="17">tional studies</text>
<text top="654" left="576" width="51" height="10" font="19">S5.6-3,S5.6-6</text>
<text top="653" left="627" width="80" height="17" font="17"> and 1 RCT</text>
<text top="654" left="708" width="24" height="10" font="19">S5.6-4</text>
<text top="653" left="732" width="78" height="17" font="17"> to reduce </text>
<text top="671" left="489" width="319" height="17" font="17">the arrhythmia burden. This has been shown for </text>
<text top="689" left="489" width="320" height="17" font="17">left or bilateral cardiac sympathetic denervation, </text>
<text top="708" left="489" width="320" height="17" font="17">and it has been suggested that bilateral cardiac </text>
<text top="726" left="489" width="290" height="17" font="17">sympathetic denervation may be superior.</text>
<text top="727" left="779" width="24" height="10" font="19">S5.6-3</text>
<text top="726" left="803" width="4" height="17" font="17"> </text>
<text top="744" left="489" width="314" height="17" font="17">Although data are limited, the significant morbid-</text>
<text top="762" left="489" width="314" height="17" font="17">ity and limited options in these patients make car-</text>
<text top="780" left="489" width="318" height="17" font="17">diac sympathetic denervation a reasonable option </text>
<text top="799" left="489" width="127" height="17" font="17">in selected patients.</text>
<text top="842" left="452" width="308" height="21" font="18"><b>6. Acute Management of Specific VA</b></text>
<text top="876" left="463" width="263" height="12" font="26"><b>Recommendations for Management of Cardiac Arrest</b></text>
<text top="893" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="907" left="463" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 15 and 16</b></a></text>
<text top="907" left="640" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="927" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="927" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="927" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="969" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="969" left="539" width="8" height="12" font="22"><b>A</b></text>
<text top="948" left="583" width="190" height="12" font="4">1.  CPR should be performed in patients in </text>
<text top="962" left="595" width="192" height="12" font="4">cardiac arrest according to published basic </text>
<text top="975" left="595" width="185" height="12" font="4">and advanced cardiovascular life support </text>
<text top="989" left="595" width="50" height="12" font="4">algorithms.</text>
<text top="989" left="645" width="27" height="7" font="23">S6-1–S6-3</text>
<text top="1044" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="1044" left="539" width="8" height="12" font="22"><b>A</b></text>
<text top="1010" left="583" width="205" height="12" font="4">2.  In patients with hemodynamically unstable </text>
<text top="1023" left="595" width="182" height="12" font="4">VA that persist or recur after a maximal </text>
<text top="1037" left="595" width="180" height="12" font="4">energy shock, intravenous amiodarone </text>
<text top="1050" left="595" width="174" height="12" font="4">should be administered to attempt to </text>
<text top="1064" left="595" width="168" height="12" font="4">achieve a stable rhythm after further </text>
<text top="1077" left="595" width="59" height="12" font="4">defibrillation.</text>
<text top="1078" left="654" width="40" height="7" font="23">S6-1,S6-4–S6-6</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e298</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="150" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="150" left="161" width="8" height="12" font="22"><b>A</b></text>
<text top="136" left="205" width="161" height="12" font="4">3.  Patients presenting with VA with </text>
<text top="150" left="217" width="184" height="12" font="4">hemodynamic instability should undergo </text>
<text top="163" left="217" width="124" height="12" font="4">direct current cardioversion.</text>
<text top="164" left="341" width="27" height="7" font="23">S6-1–S6-3</text>
<text top="198" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="198" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="184" left="205" width="206" height="12" font="4">4.  In patients with polymorphic VT or VF with </text>
<text top="198" left="217" width="207" height="12" font="4">ST-elevation MI, angiography with emergency </text>
<text top="211" left="217" width="154" height="12" font="4">revascularization is recommended.</text>
<text top="212" left="370" width="30" height="7" font="23">S6-7–S6-10</text>
<text top="246" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="246" left="152" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="232" left="205" width="213" height="12" font="4">5.  Patients with a wide-QRS tachycardia should </text>
<text top="245" left="217" width="192" height="12" font="4">be presumed to have VT if the diagnosis is </text>
<text top="259" left="217" width="35" height="12" font="4">unclear.</text>
<text top="300" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="300" left="161" width="8" height="12" font="22"><b>A</b></text>
<text top="280" left="205" width="203" height="12" font="4">6.  In patients with hemodynamically stable  </text>
<text top="293" left="217" width="156" height="12" font="4">VT, administration of intravenous </text>
<text top="307" left="217" width="195" height="12" font="4">procainamide can be useful to attempt to </text>
<text top="320" left="217" width="61" height="12" font="4">terminate VT.</text>
<text top="321" left="278" width="35" height="7" font="23">S6-11–S6-13</text>
<text top="368" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="368" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="341" left="205" width="174" height="12" font="4">7.  In patients with a witnessed cardiac </text>
<text top="354" left="217" width="180" height="12" font="4">arrest due to VF or polymorphic VT that </text>
<text top="368" left="217" width="188" height="12" font="4">is unresponsive to CPR, defibrillation, and </text>
<text top="381" left="217" width="191" height="12" font="4">vasopressor therapy, intravenous lidocaine </text>
<text top="395" left="217" width="78" height="12" font="4">can be beneficial.</text>
<text top="395" left="295" width="73" height="7" font="23">S6-1,S6-4,S6-5,S6-14,S6-15</text>
<text top="429" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="429" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="416" left="205" width="189" height="12" font="4">8.  In patients with polymorphic VT due to </text>
<text top="429" left="217" width="173" height="12" font="4">myocardial ischemia, intravenous beta </text>
<text top="443" left="217" width="102" height="12" font="4">blockers can be useful.</text>
<text top="443" left="319" width="32" height="7" font="23">S6-16,S6-17</text>
<text top="491" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="491" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="463" left="205" width="213" height="12" font="4">9.  In patients with a recent MI who have VT/VF </text>
<text top="477" left="217" width="198" height="12" font="4">that repeatedly recurs despite direct current </text>
<text top="490" left="217" width="206" height="12" font="4">cardioversion and antiarrhythmic medications </text>
<text top="504" left="217" width="193" height="12" font="4">(VT/VF storm), an intravenous beta blocker </text>
<text top="517" left="217" width="62" height="12" font="4">can be useful.</text>
<text top="518" left="279" width="32" height="7" font="23">S6-17,S6-18</text>
<text top="552" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="552" left="161" width="8" height="12" font="22"><b>A</b></text>
<text top="538" left="199" width="210" height="12" font="4">10.  In patients in cardiac arrest, administration </text>
<text top="552" left="217" width="195" height="12" font="4">of epinephrine (1 mg every 3 to 5 minutes) </text>
<text top="565" left="217" width="140" height="12" font="4">during CPR may be reasonable.</text>
<text top="566" left="356" width="47" height="7" font="23">S6-1,S6-19–S6-24</text>
<text top="606" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="606" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="586" left="199" width="216" height="12" font="4">11.  In patients with hemodynamically stable VT, </text>
<text top="600" left="217" width="191" height="12" font="4">administration of intravenous amiodarone </text>
<text top="613" left="217" width="194" height="12" font="4">or sotalol may be considered to attempt to </text>
<text top="627" left="217" width="59" height="12" font="4">terminate VT.</text>
<text top="627" left="276" width="63" height="7" font="23">S6-5,S6-13,S6-25,S6-26</text>
<text top="661" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="674" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="668" left="161" width="8" height="12" font="22"><b>A</b></text>
<text top="647" left="199" width="222" height="12" font="4">12.  In patients with cardiac arrest, administration </text>
<text top="661" left="217" width="190" height="12" font="4">of high-dose epinephrine (&gt;1 mg boluses) </text>
<text top="674" left="217" width="168" height="12" font="4">compared with standard doses is not </text>
<text top="688" left="217" width="46" height="12" font="4">beneficial.</text>
<text top="688" left="262" width="32" height="7" font="23">S6-19,S6-21</text>
<text top="722" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="736" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="729" left="161" width="8" height="12" font="22"><b>A</b></text>
<text top="709" left="199" width="211" height="12" font="4">13.  In patients with refractory VF not related </text>
<text top="722" left="217" width="193" height="12" font="4">to torsades de pointes, administration of </text>
<text top="736" left="217" width="191" height="12" font="4">intravenous magnesium is not beneficial.</text>
<text top="736" left="408" width="9" height="7" font="23">S6-</text>
<text top="750" left="217" width="25" height="7" font="23">27,S6-28</text>
<text top="790" left="84" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="790" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="770" left="199" width="219" height="12" font="4">14.  In patients with suspected AMI, prophylactic </text>
<text top="783" left="217" width="181" height="12" font="4">administration of lidocaine or high-dose </text>
<text top="797" left="217" width="176" height="12" font="4">amiodarone for the prevention of VT is </text>
<text top="810" left="217" width="87" height="12" font="4">potentially harmful.</text>
<text top="811" left="304" width="32" height="7" font="23">S6-16,S6-29</text>
<text top="852" left="84" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="852" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="831" left="199" width="184" height="12" font="4">15.  In patients with a wide QRS complex </text>
<text top="845" left="217" width="179" height="12" font="4">tachycardia of unknown origin, calcium </text>
<text top="858" left="217" width="163" height="12" font="4">channel blockers (eg, verapamil and </text>
<text top="872" left="217" width="150" height="12" font="4">diltiazem) are potentially harmful.</text>
<text top="872" left="367" width="32" height="7" font="23">S6-30,S6-31</text>
<text top="920" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="941" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="969" left="89" width="336" height="17" font="17">1.  The most common electrical mechanisms for car-</text>
<text top="987" left="111" width="314" height="17" font="17">diac arrest are VF and pulseless VT, but substan-</text>
<text top="1006" left="111" width="322" height="17" font="17">tial numbers of cardiac arrests begin as severe </text>
<text top="1024" left="111" width="318" height="17" font="17">bradyarrhythmias or asystole. Survival is better for </text>
<text top="1043" left="111" width="319" height="17" font="17">patients presenting with VT or VF than for those </text>
<text top="1061" left="111" width="292" height="17" font="17">with bradyarrhythmic or asystolic mechanisms.</text>
<text top="1062" left="403" width="22" height="10" font="19">S6-32</text>
<text top="1061" left="425" width="4" height="17" font="17"> </text>
<text top="1080" left="111" width="324" height="17" font="17">Rapid arrival of paramedical personnel is the </text>
<text top="88" left="489" width="314" height="17" font="17">major determinant of survival. A number of strat-</text>
<text top="106" left="489" width="318" height="17" font="17">egies for responding to unexpected cardiac arrest, </text>
<text top="124" left="489" width="318" height="17" font="17">including rapid defibrillation and initiation of CPR </text>
<text top="142" left="489" width="314" height="17" font="17">for a witnessed cardiac arrest, have improved sur-</text>
<text top="160" left="489" width="278" height="17" font="17">vival probabilities for cardiac arrest victims.</text>
<text top="160" left="767" width="36" height="10" font="19">S6-2,S6-3</text>
<text top="160" left="803" width="4" height="17" font="17"> </text>
<text top="178" left="489" width="314" height="17" font="17">Nonetheless, the absolute number and propor-</text>
<text top="196" left="489" width="322" height="17" font="17">tion of survivors remain low, except in unique </text>
<text top="214" left="489" width="322" height="17" font="17">circumstances where there is an extraordinarily </text>
<text top="232" left="489" width="320" height="17" font="17">rapid response time to victims in VF or VT such </text>
<text top="250" left="489" width="314" height="17" font="17">as in monitored intensive care units, where sur-</text>
<text top="268" left="489" width="94" height="17" font="17">vival is &gt;90%.</text>
<text top="269" left="583" width="48" height="10" font="19">S6-33–S6-36</text>
<text top="268" left="632" width="178" height="17" font="17"> Survival decreases rapidly </text>
<text top="286" left="489" width="314" height="17" font="17">after the initial 2 minutes from the onset of car-</text>
<text top="304" left="489" width="318" height="17" font="17">diac arrest, so that by 4 to 5 minutes, survival may </text>
<text top="322" left="489" width="244" height="17" font="17">be ≤25%, and by 10 minutes it is 0%.</text>
<text top="323" left="733" width="70" height="10" font="19">S6-33,S6-35,S6-36</text>
<text top="322" left="803" width="4" height="17" font="17"> </text>
<text top="340" left="489" width="319" height="17" font="17">Advanced life support activities, other than those </text>
<text top="358" left="489" width="319" height="17" font="17">directly related to cardioversion and defibrillation </text>
<text top="376" left="489" width="320" height="17" font="17">for control of tachyarrhythmias, have led to the </text>
<text top="394" left="489" width="320" height="17" font="17">generation of comprehensive protocols to guide </text>
<text top="412" left="489" width="324" height="17" font="17">responders. These AHA documents cover the </text>
<text top="430" left="489" width="314" height="17" font="17">broad expanse of clinical circumstances and con-</text>
<text top="448" left="489" width="173" height="17" font="17">siderations of mechanisms.</text>
<text top="449" left="662" width="41" height="10" font="19">S6-1,S6-37</text>
<text top="466" left="467" width="341" height="17" font="17">2.  Paramedic administration of amiodarone after at </text>
<text top="484" left="489" width="314" height="17" font="17">least 3 failed shocks and administration of epi-</text>
<text top="503" left="489" width="318" height="17" font="17">nephrine improved hospital admission rates when </text>
<text top="521" left="489" width="159" height="17" font="17">compared with placebo</text>
<text top="521" left="648" width="17" height="10" font="19">S6-6</text>
<text top="521" left="665" width="138" height="17" font="17"> or 1.5 mg/kg lido-</text>
<text top="539" left="489" width="33" height="17" font="17">caine</text>
<text top="539" left="522" width="36" height="10" font="19">S6-1,S6-4</text>
<text top="539" left="559" width="249" height="17" font="17"> in RCTs in adults with out-of-hospital </text>
<text top="557" left="489" width="318" height="17" font="17">cardiac arrest due to refractory VF or polymorphic </text>
<text top="575" left="489" width="321" height="17" font="17">VT, although survival to hospital discharge and </text>
<text top="593" left="489" width="319" height="17" font="17">survival with favorable neurologic outcome were </text>
<text top="611" left="489" width="297" height="17" font="17">not improved with amiodarone or lidocaine.</text>
<text top="611" left="786" width="17" height="10" font="19">S6-5</text>
<text top="611" left="803" width="4" height="17" font="17"> </text>
<text top="629" left="489" width="318" height="17" font="17">However, in the subset of patients with witnessed </text>
<text top="647" left="489" width="319" height="17" font="17">cardiac arrest due to initial shock-refractory VF or </text>
<text top="665" left="489" width="321" height="17" font="17">pulseless VT, survival to hospital discharge after </text>
<text top="683" left="489" width="319" height="17" font="17">amiodarone administration was higher than with </text>
<text top="701" left="489" width="54" height="17" font="17">placebo.</text>
<text top="702" left="543" width="17" height="10" font="19">S6-5</text>
<text top="701" left="560" width="246" height="17" font="17"> The administration of procainamide in </text>
<text top="719" left="489" width="314" height="17" font="17">out-of-hospital cardiac arrest due to VF or pulse-</text>
<text top="737" left="489" width="321" height="17" font="17">less VT has been associated with more shocks, </text>
<text top="755" left="489" width="314" height="17" font="17">more pharmacologic interventions, longer resus-</text>
<text top="773" left="489" width="213" height="17" font="17">citation times, and lower survival.</text>
<text top="774" left="702" width="22" height="10" font="19">S6-38</text>
<text top="791" left="467" width="344" height="17" font="17">3. VA with hemodynamic instability, including VF </text>
<text top="809" left="489" width="321" height="17" font="17">and pulseless monomorphic or polymorphic VT, </text>
<text top="827" left="489" width="320" height="17" font="17">causes loss of consciousness and leads to death </text>
<text top="845" left="489" width="314" height="17" font="17">if untreated. A short time to direct current car-</text>
<text top="863" left="489" width="314" height="17" font="17">dioversion is the major determinant of sur-</text>
<text top="881" left="489" width="321" height="17" font="17">vival, and defibrillation should be performed as </text>
<text top="899" left="489" width="319" height="17" font="17">quickly as possible. CPR is used until a perfusing </text>
<text top="917" left="489" width="314" height="17" font="17">rhythm is restored. If defibrillation is unsuccess-</text>
<text top="936" left="489" width="314" height="17" font="17">ful in returning spontaneous circulation, respond-</text>
<text top="954" left="489" width="322" height="17" font="17">ers follow advanced cardiovascular life support </text>
<text top="972" left="489" width="58" height="17" font="17">activities.</text>
<text top="972" left="547" width="38" height="10" font="19">S6-1–S6-3</text>
<text top="990" left="467" width="345" height="17" font="17">4. Quickly identifying and treating patients with </text>
<text top="1008" left="489" width="314" height="17" font="17">out-of-hospital cardiac arrest related to acute cor-</text>
<text top="1026" left="489" width="314" height="17" font="17">onary occlusion is associated with improved sur-</text>
<text top="1044" left="489" width="229" height="17" font="17">vival and better functional recovery.</text>
<text top="1044" left="718" width="22" height="10" font="19">S6-37</text>
<text top="1044" left="740" width="68" height="17" font="17"> Coronary </text>
<text top="1062" left="489" width="314" height="17" font="17">occlusion as a cause of cardiac arrest is not reli-</text>
<text top="1080" left="489" width="318" height="17" font="17">ably predicted by clinical and electrocardiographic </text>
<text top="95" left="85" width="324" height="12" font="26"><b>Recommendations for Management of Cardiac Arrest (Continued)</b></text>
<text top="116" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="116" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="116" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e299</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="55" height="17" font="17">findings,</text>
<text top="88" left="166" width="17" height="10" font="19">S6-7</text>
<text top="88" left="183" width="242" height="17" font="17"> and emergency coronary angiogra-</text>
<text top="106" left="111" width="318" height="17" font="17">phy should be considered (rather than later in the </text>
<text top="124" left="111" width="320" height="17" font="17">hospital stay or not at all) for unstable patients </text>
<text top="142" left="111" width="321" height="17" font="17">with a suspected cardiac etiology regardless of </text>
<text top="160" left="111" width="273" height="17" font="17">whether the patient is comatose or awake.</text>
<text top="160" left="384" width="41" height="10" font="19">S6-9,S6-39</text>
<text top="160" left="425" width="4" height="17" font="17"> </text>
<text top="178" left="111" width="320" height="17" font="17">In 1 observational study of patients resuscitated </text>
<text top="196" left="111" width="318" height="17" font="17">from SCA who did not have ST elevation and had </text>
<text top="214" left="111" width="314" height="17" font="17">angiography, one third were found to have a cul-</text>
<text top="232" left="111" width="319" height="17" font="17">prit lesion and coronary intervention appeared to </text>
<text top="250" left="111" width="314" height="17" font="17">be associated with a greater likelihood of favor-</text>
<text top="268" left="111" width="163" height="17" font="17">able neurologic outcome.</text>
<text top="269" left="274" width="22" height="10" font="19">S6-10</text>
<text top="286" left="89" width="339" height="17" font="17">5.  The initial management of any tachycardia should </text>
<text top="304" left="111" width="314" height="17" font="17">proceed according to published AHA advanced car-</text>
<text top="322" left="111" width="221" height="17" font="17">diovascular life support guidelines.</text>
<text top="323" left="332" width="22" height="10" font="19">S6-40</text>
<text top="322" left="353" width="76" height="17" font="17"> Immediate </text>
<text top="340" left="111" width="314" height="17" font="17">cardioversion should be performed for hemody-</text>
<text top="358" left="111" width="320" height="17" font="17">namic instability at presentation or if it develops </text>
<text top="376" left="111" width="314" height="17" font="17">subsequently. An ECG should be obtained for sta-</text>
<text top="394" left="111" width="318" height="17" font="17">ble rhythms. Wide-complex tachycardias, defined </text>
<text top="412" left="111" width="174" height="17" font="17">by a QRS duration ≥0.12 s,</text>
<text top="413" left="285" width="22" height="10" font="19">S6-37</text>
<text top="412" left="307" width="123" height="17" font="17"> can be due to VT, </text>
<text top="430" left="111" width="322" height="17" font="17">SVT with aberrancy, preexcited tachycardia, or </text>
<text top="448" left="111" width="323" height="17" font="17">a paced rhythm such as pacemaker-mediated </text>
<text top="466" left="111" width="314" height="17" font="17">tachycardia. An irregular wide-complex tachycar-</text>
<text top="485" left="111" width="319" height="17" font="17">dia may be AF with aberrancy, preexcited AF (ie, </text>
<text top="503" left="111" width="320" height="17" font="17">AF using an accessory pathway for anterograde </text>
<text top="521" left="111" width="211" height="17" font="17">conduction), atrial flutter, or VT.</text>
<text top="521" left="322" width="22" height="10" font="19">S6-37</text>
<text top="521" left="344" width="88" height="17" font="17"> A diagnosis </text>
<text top="539" left="111" width="320" height="17" font="17">should be established, and consultation with an </text>
<text top="557" left="111" width="191" height="17" font="17">arrhythmia expert considered.</text>
<text top="557" left="302" width="22" height="10" font="19">S6-37</text>
<text top="575" left="89" width="347" height="17" font="17">6. In 1 study, amiodarone was more effective </text>
<text top="593" left="111" width="321" height="17" font="17">than lidocaine in terminating incessant VT with </text>
<text top="611" left="111" width="206" height="17" font="17">improved survival at 24 hours.</text>
<text top="611" left="317" width="22" height="10" font="19">S6-26</text>
<text top="611" left="339" width="94" height="17" font="17"> For patients </text>
<text top="629" left="111" width="322" height="17" font="17">with recurrent, stable VT not in the setting of </text>
<text top="647" left="111" width="325" height="17" font="17">an AMI, intravenous procainamide has been </text>
<text top="665" left="111" width="314" height="17" font="17">shown to be superior to lidocaine for terminat-</text>
<text top="683" left="111" width="127" height="17" font="17">ing the arrhythmia.</text>
<text top="684" left="238" width="22" height="10" font="19">S6-11</text>
<text top="683" left="260" width="172" height="17" font="17"> One randomized trial of </text>
<text top="701" left="111" width="314" height="17" font="17">62 patients found procainamide superior to amio-</text>
<text top="719" left="111" width="236" height="17" font="17">darone for termination of stable VT.</text>
<text top="720" left="347" width="22" height="10" font="19">S6-13</text>
<text top="719" left="369" width="62" height="17" font="17"> Adverse </text>
<text top="737" left="111" width="314" height="17" font="17">events, including hypotension were more com-</text>
<text top="755" left="111" width="322" height="17" font="17">mon with amiodarone, but the difference was </text>
<text top="773" left="111" width="320" height="17" font="17">not statistically significant. Procainamide and its </text>
<text top="791" left="111" width="319" height="17" font="17">metabolite n-acetylprocainamide have potassium </text>
<text top="809" left="111" width="318" height="17" font="17">channel blocking properties that may prolong the </text>
<text top="827" left="111" width="314" height="17" font="17">QT interval. In patients who already have QT pro-</text>
<text top="845" left="111" width="322" height="17" font="17">longation, administration of procainamide may </text>
<text top="863" left="111" width="314" height="17" font="17">further prolong the QT interval and lead to tors-</text>
<text top="881" left="111" width="104" height="17" font="17">ades de pointes.</text>
<text top="882" left="215" width="70" height="10" font="19">S6-11,S6-12,S6-26</text>
<text top="899" left="89" width="336" height="17" font="17">7. Intravenous lidocaine is an alternative antiar-</text>
<text top="917" left="111" width="330" height="17" font="17">rhythmic medication of long-standing and </text>
<text top="936" left="111" width="330" height="17" font="17">widespread familiarity. Compared with no </text>
<text top="954" left="111" width="326" height="17" font="17">antiarrhythmic medication, lidocaine did not </text>
<text top="972" left="111" width="324" height="17" font="17">consistently increase a return of spontaneous </text>
<text top="990" left="111" width="314" height="17" font="17">circulation after defibrillation and was not asso-</text>
<text top="1008" left="111" width="321" height="17" font="17">ciated with improvement in survival to hospital  </text>
<text top="1026" left="111" width="65" height="17" font="17">discharge.</text>
<text top="1026" left="176" width="66" height="10" font="19">S6-4,S6-14,S6-41</text>
<text top="1026" left="242" width="198" height="17" font="17"> In prospective, blinded, </text>
<text top="1044" left="111" width="319" height="17" font="17">RCTs, lidocaine was less effective than amiodarone </text>
<text top="1062" left="111" width="314" height="17" font="17">in improving hospital admission rates after out-of-</text>
<text top="1080" left="111" width="318" height="17" font="17">hospital cardiac arrest due to shock-refractory VF or  </text>
<text top="88" left="489" width="321" height="17" font="17">polymorphic VT; but there were no differences </text>
<text top="106" left="489" width="319" height="17" font="17">between the 2 medications in survival to hospital  </text>
<text top="124" left="489" width="65" height="17" font="17">discharge.</text>
<text top="124" left="554" width="36" height="10" font="19">S6-4,S6-5</text>
<text top="124" left="590" width="226" height="17" font="17"> However, in the subset of </text>
<text top="142" left="489" width="314" height="17" font="17">patients with witnessed SCA due to initial shock-</text>
<text top="160" left="489" width="319" height="17" font="17">refractory VF or pulseless VT, a subgroup analysis </text>
<text top="178" left="489" width="321" height="17" font="17">showed that survival to hospital discharge with </text>
<text top="196" left="489" width="253" height="17" font="17">lidocaine was better than with placebo.</text>
<text top="197" left="742" width="41" height="10" font="19">S6-5,S6-42</text>
<text top="214" left="467" width="336" height="17" font="17">8.  In a large meta-analysis of antiarrhythmic medi-</text>
<text top="232" left="489" width="323" height="17" font="17">cations in the setting of AMI, beta blockers </text>
<text top="250" left="489" width="324" height="17" font="17">were associated  with a significant reduction </text>
<text top="268" left="489" width="80" height="17" font="17">in mortality.</text>
<text top="269" left="569" width="22" height="10" font="19">S6-16</text>
<text top="268" left="591" width="219" height="17" font="17"> Beta blockers can be effective </text>
<text top="286" left="489" width="324" height="17" font="17">in suppressing recurrent VF in patients with </text>
<text top="304" left="489" width="321" height="17" font="17">recent MI, with an associated improvement in </text>
<text top="322" left="489" width="52" height="17" font="17">survival.</text>
<text top="323" left="541" width="22" height="10" font="19">S6-17</text>
<text top="340" left="467" width="341" height="17" font="17">9.  In patients with recurrent VT/VF (VT/VF storm) in </text>
<text top="358" left="489" width="314" height="17" font="17">the setting of a recent MI that is refractory to ami-</text>
<text top="376" left="489" width="314" height="17" font="17">odarone and/or lidocaine and repeated cardiover-</text>
<text top="394" left="489" width="320" height="17" font="17">sion, administration of a beta blocker has been </text>
<text top="412" left="489" width="320" height="17" font="17">shown to improve survival at 1 week. For those </text>
<text top="430" left="489" width="319" height="17" font="17">who did not survive, mortality was mostly due to </text>
<text top="448" left="489" width="319" height="17" font="17">recurrent VF. Survival at 1 year was also better in </text>
<text top="466" left="489" width="225" height="17" font="17">those treated with a beta blocker.</text>
<text top="467" left="714" width="46" height="10" font="19">S6-17,S6-18</text>
<text top="466" left="760" width="49" height="17" font="17"> Other </text>
<text top="484" left="489" width="321" height="17" font="17">measures to reduce sympathetic tone including </text>
<text top="503" left="489" width="321" height="17" font="17">sedation and general anesthesia are also often </text>
<text top="521" left="489" width="34" height="17" font="17">used.</text>
<text top="539" left="459" width="347" height="17" font="17">10.  Epinephrine produces beneficial effects in patients </text>
<text top="557" left="489" width="323" height="17" font="17">during cardiac arrest, primarily because of its </text>
<text top="575" left="489" width="297" height="17" font="17">alpha-adrenergic (ie, vasoconstrictor) effects.</text>
<text top="575" left="786" width="17" height="10" font="19">S6-1</text>
<text top="575" left="803" width="4" height="17" font="17"> </text>
<text top="593" left="489" width="328" height="17" font="17">These alpha-adrenergic effects can increase </text>
<text top="611" left="489" width="320" height="17" font="17">coronary and cerebral perfusion pressure during </text>
<text top="629" left="489" width="319" height="17" font="17">CPR. The value and safety of the beta-adrenergic </text>
<text top="647" left="489" width="320" height="17" font="17">effects of epinephrine are controversial because </text>
<text top="665" left="489" width="321" height="17" font="17">they may increase myocardial work and reduce </text>
<text top="683" left="489" width="169" height="17" font="17">subendocardial perfusion.</text>
<text top="684" left="658" width="17" height="10" font="19">S6-1</text>
<text top="683" left="675" width="137" height="17" font="17"> One trial assessed </text>
<text top="701" left="489" width="314" height="17" font="17">short-term and longer-term outcomes when com-</text>
<text top="719" left="489" width="292" height="17" font="17">paring standard-dose epinephrine to placebo.</text>
<text top="720" left="781" width="22" height="10" font="19">S6-23</text>
<text top="719" left="803" width="4" height="17" font="17"> </text>
<text top="737" left="489" width="319" height="17" font="17">Standard-dose epinephrine was defined as 1 mg </text>
<text top="755" left="489" width="319" height="17" font="17">given intravenously or intraosseously every 3 to 5 </text>
<text top="773" left="489" width="314" height="17" font="17">minutes. For both survival to discharge and sur-</text>
<text top="791" left="489" width="318" height="17" font="17">vival to discharge with good neurologic outcome, </text>
<text top="809" left="489" width="314" height="17" font="17">there was no benefit with standard-dose epi-</text>
<text top="827" left="489" width="319" height="17" font="17">nephrine; however, the study was underpowered </text>
<text top="845" left="489" width="321" height="17" font="17">for analysis of either of these outcomes. There </text>
<text top="863" left="489" width="321" height="17" font="17">was, nevertheless, improved survival to hospital </text>
<text top="881" left="489" width="321" height="17" font="17">admission and improved return of spontaneous </text>
<text top="899" left="489" width="314" height="17" font="17">circulation with the use of standard-dose epi-</text>
<text top="918" left="489" width="314" height="17" font="17">nephrine. A number of trials have compared out-</text>
<text top="936" left="489" width="320" height="17" font="17">comes of standard-dose epinephrine with those </text>
<text top="954" left="489" width="322" height="17" font="17">of high-dose epinephrine. These trials did not </text>
<text top="972" left="489" width="314" height="17" font="17">demonstrate any benefit for high-dose epineph-</text>
<text top="990" left="489" width="322" height="17" font="17">rine over standard-dose epinephrine in relation </text>
<text top="1008" left="489" width="321" height="17" font="17">to survival to  discharge with a good neurologic </text>
<text top="1026" left="489" width="314" height="17" font="17">recovery, survival to discharge, or survival to hos-</text>
<text top="1044" left="489" width="99" height="17" font="17">pital admission.</text>
<text top="1044" left="588" width="90" height="10" font="19">S6-1,S6-19,S6-21,S6-22</text>
<text top="1062" left="459" width="349" height="17" font="17">11.  Amiodarone was more effective than lidocaine in </text>
<text top="1080" left="489" width="320" height="17" font="17">terminating incessant VT with improved survival </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e300</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="864" left="111" width="80" height="17" font="17">at 24 hours.</text>
<text top="864" left="191" width="22" height="10" font="19">S6-26</text>
<text top="864" left="213" width="212" height="17" font="17"> For patients with recurrent, sta-</text>
<text top="882" left="111" width="319" height="17" font="17">ble VT not in the setting of an AMI, intravenous </text>
<text top="900" left="111" width="320" height="17" font="17">procainamide has been shown to be superior to </text>
<text top="918" left="111" width="261" height="17" font="17">lidocaine for terminating the arrhythmia.</text>
<text top="918" left="372" width="22" height="10" font="19">S6-11</text>
<text top="918" left="394" width="36" height="17" font="17"> One </text>
<text top="936" left="111" width="320" height="17" font="17">RCT in 62 patients found procainamide superior </text>
<text top="954" left="111" width="292" height="17" font="17">to amiodarone for termination of stable VT.</text>
<text top="954" left="403" width="22" height="10" font="19">S6-13</text>
<text top="954" left="425" width="7" height="17" font="17">  </text>
<text top="972" left="111" width="326" height="17" font="17">Adverse events, including hypotension, were </text>
<text top="990" left="111" width="314" height="17" font="17">more common with amiodarone, but the differ-</text>
<text top="1008" left="111" width="318" height="17" font="17">ence was not statistically signficant. Procainamide </text>
<text top="1026" left="111" width="325" height="17" font="17">and its metabolite n-acetylprocainamide have </text>
<text top="1044" left="111" width="328" height="17" font="17">potassium channel blocking properties that </text>
<text top="1062" left="111" width="322" height="17" font="17">may prolong the QT interval. In patients who </text>
<text top="1080" left="111" width="320" height="17" font="17">already have QT prolongation, administration of  </text>
<text top="864" left="489" width="314" height="17" font="17">procainamide may further prolong the QT inter-</text>
<text top="882" left="489" width="235" height="17" font="17">val and lead to torsades de pointes.</text>
<text top="882" left="724" width="22" height="10" font="19">S6-11</text>
<text top="882" left="746" width="63" height="17" font="17"> A single </text>
<text top="900" left="489" width="314" height="17" font="17">RCT of 33 patients comparing sotalol with lido-</text>
<text top="918" left="489" width="314" height="17" font="17">caine for treating patients with hemodynami-</text>
<text top="936" left="489" width="321" height="17" font="17">cally stable VT showed that VT was terminated </text>
<text top="954" left="489" width="325" height="17" font="17">in 69% of patients using sotalol and 18% </text>
<text top="972" left="489" width="101" height="17" font="17">using lidocaine.</text>
<text top="972" left="590" width="22" height="10" font="19">S6-25</text>
<text top="972" left="612" width="197" height="17" font="17"> Intravenous sotalol has been </text>
<text top="990" left="489" width="318" height="17" font="17">approved for use in the United States. Sotalol has </text>
<text top="1008" left="489" width="320" height="17" font="17">potassium channel blocking properties that may </text>
<text top="1026" left="489" width="320" height="17" font="17">prolong the QT interval. In patients who already </text>
<text top="1044" left="489" width="320" height="17" font="17">have QT interval prolongation, administration of </text>
<text top="1062" left="489" width="320" height="17" font="17">sotalol may further prolong the QT interval and </text>
<text top="1080" left="489" width="177" height="17" font="17">lead to torsades de pointes.</text>
<text top="1080" left="666" width="22" height="10" font="19">S6-25</text>
<text top="790" left="74" width="45" height="12" font="3"><b>Figure 2. </b></text>
<text top="790" left="120" width="222" height="12" font="22"><b>Management of sustained monomorphic VT.</b> </text>
<text top="804" left="74" width="716" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Sections 7, 8.1.3, 8.2.3, and 10 for discussion. *Known history of verapamil sensitive or classical </text>
<text top="817" left="74" width="712" height="12" font="4">electrocardiographic presentation. ACLS indicates advanced cardiovascular life support; ECG, electrocardiogram; VA, ventricular arrhythmia; and VT, ventricular </text>
<text top="831" left="74" width="53" height="12" font="4">tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e301</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="81" width="350" height="17" font="17">12.  Epinephrine may increase coronary and cerebral </text>
<text top="106" left="111" width="323" height="17" font="17">perfusion pressure during CPR because of its </text>
<text top="124" left="111" width="314" height="17" font="17">vasoconstrictive effects. High doses of epineph-</text>
<text top="142" left="111" width="314" height="17" font="17">rine (0.1 to 0.2 mg/kg IV, as opposed to a stan-</text>
<text top="160" left="111" width="320" height="17" font="17">dard dose of 1 mg) have been studied in RCTs. </text>
<text top="178" left="111" width="320" height="17" font="17">In out-of-hospital cardiac arrest unresponsive to </text>
<text top="196" left="111" width="314" height="17" font="17">defibrillation, administration of high-dose epi-</text>
<text top="214" left="111" width="314" height="17" font="17">nephrine improved survival to hospital admis-</text>
<text top="232" left="111" width="321" height="17" font="17">sion, but there was no difference compared to </text>
<text top="251" left="111" width="319" height="17" font="17">standard dose epinephrine in survival to hospital </text>
<text top="269" left="111" width="65" height="17" font="17">discharge.</text>
<text top="269" left="176" width="22" height="10" font="19">S6-19</text>
<text top="269" left="198" width="232" height="17" font="17"> There was also no improvement in </text>
<text top="287" left="111" width="121" height="17" font="17">long-term survival.</text>
<text top="288" left="232" width="22" height="10" font="19">S6-21</text>
<text top="287" left="254" width="171" height="17" font="17"> Of note, the administra-</text>
<text top="305" left="111" width="319" height="17" font="17">tion of vasopressin is no longer recommended in </text>
<text top="323" left="111" width="314" height="17" font="17">the most recent advanced cardiovascular life sup-</text>
<text top="341" left="111" width="103" height="17" font="17">port algorithms.</text>
<text top="342" left="214" width="17" height="10" font="19">S6-1</text>
<text top="359" left="81" width="348" height="17" font="17">13.  Magnesium may suppress automaticity, suppress </text>
<text top="377" left="111" width="320" height="17" font="17">early and late after-depolarizations, and inhibit </text>
<text top="395" left="111" width="320" height="17" font="17">calcium flux into cardiomyocytes. It is effective </text>
<text top="414" left="111" width="321" height="17" font="17">in suppressing VA related to acquired long QT </text>
<text top="432" left="111" width="323" height="17" font="17">syndrome. However, 2 RCTs that investigated </text>
<text top="450" left="111" width="321" height="17" font="17">the use of intravenous magnesium in patients </text>
<text top="468" left="111" width="320" height="17" font="17">with cardiac arrest and refractory VF found no </text>
<text top="486" left="111" width="50" height="17" font="17">benefit.</text>
<text top="487" left="161" width="47" height="10" font="19">S6-27,S6-28</text>
<text top="486" left="208" width="217" height="17" font="17"> In a study of out-of-hospital car-</text>
<text top="504" left="111" width="317" height="17" font="17">diac arrest, administration of 2 to 4 g magnesium </text>
<text top="522" left="111" width="318" height="17" font="17">intravenously did not improve survival to hospital </text>
<text top="540" left="111" width="69" height="17" font="17">admission.</text>
<text top="541" left="180" width="22" height="10" font="19">S6-27</text>
<text top="540" left="202" width="223" height="17" font="17"> In a similar study involving inpa-</text>
<text top="558" left="111" width="319" height="17" font="17">tient cardiac arrest, magnesium did not improve </text>
<text top="577" left="111" width="323" height="17" font="17">return of spontaneous circulation, survival to </text>
<text top="595" left="111" width="292" height="17" font="17">24 hours, or survival to hospital discharge.</text>
<text top="595" left="403" width="22" height="10" font="19">S6-28</text>
<text top="595" left="425" width="4" height="17" font="17"> </text>
<text top="613" left="111" width="314" height="17" font="17">There are exceptions such as marked hypokale-</text>
<text top="631" left="111" width="320" height="17" font="17">mia or medication-induced torsades de pointes </text>
<text top="649" left="111" width="314" height="17" font="17">in which administration of intravenous magne-</text>
<text top="667" left="111" width="120" height="17" font="17">sium is warranted.</text>
<text top="685" left="81" width="358" height="17" font="17">14. Several studies have tested the hypothesis </text>
<text top="703" left="111" width="318" height="17" font="17">that prophylactic administration of antiarrhythmic </text>
<text top="721" left="111" width="314" height="17" font="17">medications could reduce the incidence of post-</text>
<text top="740" left="111" width="314" height="17" font="17">MI VA and lead to better outcomes. One meta-</text>
<text top="758" left="111" width="320" height="17" font="17">analysis assessed studies in which beta blockers, </text>
<text top="776" left="111" width="318" height="17" font="17">class I antiarrhythmic agents such as lidocaine and </text>
<text top="794" left="111" width="318" height="17" font="17">procainamide, and amiodarone were given in the </text>
<text top="812" left="111" width="320" height="17" font="17">setting of AMI. The routine use of lidocaine and </text>
<text top="830" left="111" width="314" height="17" font="17">procainamide was associated with increased mor-</text>
<text top="848" left="111" width="318" height="17" font="17">tality, whereas beta blockers were associated with </text>
<text top="866" left="111" width="237" height="17" font="17">a significantly lower mortality rate.</text>
<text top="867" left="348" width="22" height="10" font="19">S6-16</text>
<text top="866" left="370" width="63" height="17" font="17"> Limited </text>
<text top="885" left="111" width="318" height="17" font="17">data with amiodarone appeared to be promising, </text>
<text top="903" left="111" width="322" height="17" font="17">but a subsequent RCT involving 1073 patients </text>
<text top="921" left="111" width="314" height="17" font="17">found that administration of high-dose amio-</text>
<text top="939" left="111" width="319" height="17" font="17">darone led to a higher mortality rate, although a </text>
<text top="88" left="489" width="320" height="17" font="17">moderate dose of amiodarone was not superior </text>
<text top="106" left="489" width="72" height="17" font="17">to placebo.</text>
<text top="106" left="561" width="22" height="10" font="19">S6-29</text>
<text top="124" left="459" width="351" height="17" font="17">15.  With a stable, wide QRS complex tachycardia, </text>
<text top="142" left="489" width="319" height="17" font="17">differentiation between SVT with aberrancy and </text>
<text top="160" left="489" width="321" height="17" font="17">VT is often possible by review of the patient’s </text>
<text top="178" left="489" width="314" height="17" font="17">history and the 12-lead ECG during tachycar-</text>
<text top="196" left="489" width="314" height="17" font="17">dia. Patients with wide QRS complex tachycar-</text>
<text top="214" left="489" width="321" height="17" font="17">dia and known structural heart disease should </text>
<text top="232" left="489" width="319" height="17" font="17">be presumed to have VT until proven otherwise. </text>
<text top="250" left="489" width="324" height="17" font="17">Administration of a calcium channel blocker </text>
<text top="268" left="489" width="323" height="17" font="17">such as verapamil to a patient with VT may </text>
<text top="286" left="489" width="263" height="17" font="17">result in severe hypotension or syncope.</text>
<text top="287" left="752" width="22" height="10" font="19">S6-31</text>
<text top="286" left="775" width="33" height="17" font="17"> The </text>
<text top="304" left="489" width="314" height="17" font="17">exception is verapamil-sensitive VT (interfascicu-</text>
<text top="323" left="489" width="320" height="17" font="17">lar reentry) that occurs in a structurally normal </text>
<text top="341" left="489" width="320" height="17" font="17">heart; but this is often difficult to recognize on </text>
<text top="359" left="489" width="125" height="17" font="17">initial presentation.</text>
<text top="359" left="614" width="22" height="10" font="19">S6-30</text>
<text top="407" left="452" width="326" height="23" font="15"><b>7. ONGOING MANAGEMENT OF VA </b></text>
<text top="429" left="452" width="337" height="23" font="15"><b>AND SCD RISK RELATED TO SPECIFIC </b></text>
<text top="452" left="452" width="148" height="23" font="15"><b>DISEASE STATES</b></text>
<text top="480" left="452" width="227" height="21" font="18"><b>7.1. Ischemic Heart Disease</b></text>
<text top="507" left="452" width="330" height="18" font="24"><i><b>7.1.1. Secondary Prevention of SCD in Patients </b></i></text>
<text top="525" left="452" width="198" height="18" font="24"><i><b>With Ischemic Heart Disease</b></i></text>
<text top="553" left="463" width="313" height="12" font="26"><b>Recommendations for Secondary Prevention of SCD in Patients </b></text>
<text top="567" left="463" width="139" height="12" font="26"><b>With Ischemic Heart Disease</b></text>
<text top="584" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="597" left="463" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 17 and 18</b></a></text>
<text top="597" left="640" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="618" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="618" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="618" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="686" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="654" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="639" left="583" width="189" height="12" font="4">1.  In patients with ischemic heart disease, </text>
<text top="653" left="595" width="180" height="12" font="4">who either survive SCA due to VT/VF or </text>
<text top="666" left="595" width="187" height="12" font="4">experience hemodynamically unstable VT </text>
<text top="680" left="595" width="47" height="12" font="4">(LOE: B-R) </text>
<text top="680" left="642" width="47" height="7" font="23">S7.1.1-1–S7.1.1-4</text>
<text top="680" left="689" width="89" height="12" font="4"> or stable sustained </text>
<text top="693" left="595" width="69" height="12" font="4">VT (LOE: B-NR) </text>
<text top="694" left="663" width="22" height="7" font="23">S7.1.1-5</text>
<text top="693" left="686" width="98" height="12" font="4"> not due to reversible </text>
<text top="707" left="595" width="154" height="12" font="4">causes, an ICD is recommended if </text>
<text top="720" left="595" width="187" height="12" font="4">meaningful survival greater than 1 year is </text>
<text top="734" left="595" width="43" height="12" font="4">expected.</text>
<text top="712" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="788" left="470" width="88" height="12" font="22"><b>Value Statement: </b></text>
<text top="802" left="465" width="97" height="12" font="22"><b>Intermediate Value </b></text>
<text top="815" left="488" width="48" height="12" font="22"><b>(LOE: B-R)</b></text>
<text top="754" left="583" width="197" height="12" font="4">2.  A transvenous ICD provides intermediate </text>
<text top="768" left="595" width="188" height="12" font="4">value in the secondary prevention of SCD </text>
<text top="781" left="595" width="197" height="12" font="4">particularly when the patient’s risk of death </text>
<text top="795" left="595" width="183" height="12" font="4">due to a VA is deemed high and the risk </text>
<text top="808" left="595" width="175" height="12" font="4">of nonarrhythmic death (either cardiac </text>
<text top="822" left="595" width="178" height="12" font="4">or noncardiac) is deemed low based on </text>
<text top="835" left="595" width="188" height="12" font="4">the patient’s burden of comorbidities and </text>
<text top="849" left="595" width="77" height="12" font="4">functional status.</text>
<text top="849" left="672" width="22" height="7" font="23">S7.1.1-6</text>
<text top="903" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="903" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="869" left="578" width="186" height="12" font="4">3.  In patients with ischemic heart disease </text>
<text top="883" left="590" width="163" height="12" font="4">and unexplained syncope who have </text>
<text top="896" left="590" width="169" height="12" font="4">inducible sustained monomorphic VT </text>
<text top="910" left="590" width="176" height="12" font="4">on electrophysiological study, an ICD is </text>
<text top="923" left="590" width="178" height="12" font="4">recommended if meaningful survival of </text>
<text top="937" left="590" width="141" height="12" font="4">greater than 1 year is expected.</text>
<text top="937" left="731" width="22" height="7" font="23">S7.1.1-7</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e302</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="586" left="74" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="613" left="89" width="121" height="17" font="17">1. In the AVID trial,</text>
<text top="614" left="209" width="30" height="10" font="19">S7.1.1-1</text>
<text top="613" left="239" width="186" height="17" font="17"> the ICD improved overall sur-</text>
<text top="631" left="107" width="319" height="17" font="17">vival compared with antiarrhythmic medication ther-</text>
<text top="649" left="107" width="324" height="17" font="17">apy (primarily amiodarone) in patients who survived </text>
<text top="667" left="107" width="325" height="17" font="17">SCD or with hemodynamically unstable VT, with a </text>
<text top="685" left="107" width="322" height="17" font="17">2-year relative risk reduction in mortality of 27% and </text>
<text top="703" left="107" width="323" height="17" font="17">an absolute risk reduction of 7%. CIDS (Canadian </text>
<text top="721" left="107" width="207" height="17" font="17">Implantable Defibrillator Study),</text>
<text top="722" left="313" width="30" height="10" font="19">S7.1.1-2</text>
<text top="721" left="343" width="93" height="17" font="17"> which was </text>
<text top="739" left="107" width="323" height="17" font="17">stopped early after the results of the AVID trial were </text>
<text top="757" left="107" width="319" height="17" font="17">released, showed a similar, but not statistically signifi-</text>
<text top="775" left="107" width="319" height="17" font="17">cant, benefit of the ICD over antiarrhythmic medi-</text>
<text top="793" left="107" width="324" height="17" font="17">cation therapy. A subsequent meta-analysis using </text>
<text top="811" left="107" width="325" height="17" font="17">data from 3  RCTs showed a statistically significant </text>
<text top="829" left="107" width="319" height="17" font="17">reduction in both arrhythmic and all-cause mortal-</text>
<text top="847" left="107" width="226" height="17" font="17">ity with secondary prevention ICDs.</text>
<text top="848" left="332" width="32" height="10" font="19">S7.1.1-3</text>
<text top="865" left="125" width="307" height="17" font="17">In survivors of life-threatening VA that may be </text>
<text top="883" left="107" width="324" height="17" font="17">due to transient or reversible factors, such as AMI, </text>
<text top="901" left="107" width="329" height="17" font="17">proarrhythmic medication effects, or electrolyte </text>
<text top="919" left="107" width="324" height="17" font="17">disturbances, an ICD is not implanted if the cause </text>
<text top="937" left="107" width="323" height="17" font="17">may be correctable. This is a population of patients </text>
<text top="955" left="107" width="325" height="17" font="17">that still requires thorough evaluation, treatment, </text>
<text top="973" left="107" width="325" height="17" font="17">and close follow-up and, as in the AVID registry, </text>
<text top="991" left="107" width="324" height="17" font="17">mortality was still high in the population that may </text>
<text top="1009" left="107" width="288" height="17" font="17">have had a reversible cause for their arrest.</text>
<text top="1010" left="394" width="31" height="10" font="19">S7.1.1-8</text>
<text top="1009" left="425" width="4" height="17" font="17"> </text>
<text top="1027" left="107" width="325" height="17" font="17">Small increases in troponin present a challenge in </text>
<text top="1045" left="107" width="326" height="17" font="17">selecting patients for an ICD, as it often cannot </text>
<text top="1063" left="107" width="325" height="17" font="17">be determined whether troponin elevation is due </text>
<text top="1081" left="107" width="323" height="17" font="17">to ischemia from VT/VF and resuscitation, in which </text>
<text top="88" left="485" width="322" height="17" font="17">case an ICD is likely warranted, or an indication that </text>
<text top="106" left="485" width="319" height="17" font="17">ischemia caused the arrhythmia, in which case pre-</text>
<text top="124" left="485" width="319" height="17" font="17">vention of ischemia would be the therapeutic focus.</text>
<text top="142" left="503" width="310" height="17" font="17">ICDs may improve the outcomes of patients </text>
<text top="160" left="485" width="326" height="17" font="17">with hemodynamically tolerated sustained VT and </text>
<text top="178" left="485" width="144" height="17" font="17">structural heart disease</text>
<text top="178" left="628" width="30" height="10" font="19">S7.1.1-5</text>
<text top="178" left="658" width="151" height="17" font="17">; however, this has not </text>
<text top="196" left="485" width="323" height="17" font="17">proved in any RCT. VT ablation has been used as an </text>
<text top="214" left="485" width="322" height="17" font="17">alternative in selected patients with well-tolerated VT </text>
<text top="232" left="485" width="324" height="17" font="17">and appears to reduce recurrences, but the impact </text>
<text top="250" left="485" width="324" height="17" font="17">on long-term mortality is unknown; there is not yet </text>
<text top="268" left="485" width="324" height="17" font="17">sufficient evidence to recommend this approach as </text>
<text top="286" left="485" width="216" height="17" font="17">an alternative to ICD implantation.</text>
<text top="286" left="700" width="69" height="10" font="19">S7.1.1-9,S7.1.1-10</text>
<text top="304" left="463" width="341" height="17" font="17">2.  Economic outcomes of ICD implantation for second-</text>
<text top="322" left="485" width="325" height="17" font="17">ary prevention of SCD were assessed in the AVID </text>
<text top="340" left="485" width="93" height="17" font="17">and CIDS trials,</text>
<text top="340" left="577" width="73" height="10" font="19">S7.1.1-11,S7.1.1-12</text>
<text top="340" left="650" width="157" height="17" font="17"> as well as in a simulation </text>
<text top="358" left="484" width="39" height="17" font="17">model</text>
<text top="358" left="523" width="35" height="10" font="19">S7.1.1-13</text>
<text top="358" left="559" width="248" height="17" font="17"> and an observational study of Medicare </text>
<text top="376" left="484" width="81" height="17" font="17">beneficiaries.</text>
<text top="376" left="565" width="35" height="10" font="19">S7.1.1-14</text>
<text top="376" left="600" width="203" height="17" font="17"> All studies compared ICD recipi-</text>
<text top="394" left="484" width="323" height="17" font="17">ents with non-ICD recipients, and all found that ICD </text>
<text top="412" left="484" width="327" height="17" font="17">recipients had longer overall survival and higher </text>
<text top="430" left="484" width="325" height="17" font="17">lifetime costs of medical care. All studies reported </text>
<text top="448" left="484" width="336" height="17" font="17">incremental cost-effectiveness ratios between </text>
<text top="466" left="484" width="323" height="17" font="17">$64 000 and $100 000 per year of life added by an  </text>
<text top="484" left="484" width="27" height="17" font="17">ICD,</text>
<text top="484" left="511" width="75" height="10" font="19">S7.1.1-11–S7.1.1-14</text>
<text top="484" left="586" width="217" height="17" font="17"> which is in the range of intermedi-</text>
<text top="502" left="485" width="319" height="17" font="17">ate value by the benchmarks applied in the ACC/</text>
<text top="520" left="485" width="165" height="17" font="17">AHA cost/value statement.</text>
<text top="520" left="649" width="35" height="10" font="19">S7.1.1-15</text>
<text top="538" left="463" width="341" height="17" font="17">3.  VAs are an important cause of syncope or near syn-</text>
<text top="556" left="485" width="319" height="17" font="17">cope in patients with ischemic heart disease, particu-</text>
<text top="574" left="485" width="323" height="17" font="17">larly those with prior infarction. A study of 70 patients </text>
<text top="592" left="485" width="319" height="17" font="17">with unexplained syncope who underwent an elec-</text>
<text top="610" left="485" width="326" height="17" font="17">trophysiological study identified positive findings in </text>
<text top="628" left="485" width="324" height="17" font="17">37 patients; 31 with VT. During 3 years of follow-up, </text>
<text top="646" left="485" width="323" height="17" font="17">patients with a positive electrophysiological study had </text>
<text top="664" left="485" width="324" height="17" font="17">higher rates of SCD and 3-year total mortality (61% </text>
<text top="682" left="485" width="324" height="17" font="17">versus 15%, respectively) than those with a negative </text>
<text top="700" left="485" width="156" height="17" font="17">electrophysiological study.</text>
<text top="700" left="640" width="30" height="10" font="19">S7.1.1-7</text>
<text top="700" left="670" width="140" height="17" font="17"> An ICD is warranted </text>
<text top="718" left="485" width="327" height="17" font="17">for patients with syncope and inducible sustained </text>
<text top="736" left="485" width="323" height="17" font="17">monomorphic VT even if they do not otherwise meet </text>
<text top="754" left="485" width="240" height="17" font="17">criteria for primary prevention (Figure 4).</text>
<text top="776" left="452" width="202" height="18" font="28"><i>7.1.1.1. Coronary Artery Spasm</i></text>
<text top="804" left="463" width="296" height="12" font="26"><b>Recommendations for Patients With Coronary Artery Spasm</b></text>
<text top="821" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="834" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 20</b></a></text>
<text top="834" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="855" left="475" width="21" height="12" font="22"><b>COR</b></text>
<text top="855" left="536" width="19" height="12" font="22"><b>LOE</b></text>
<text top="855" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="903" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="903" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="876" left="583" width="202" height="12" font="4">1.  In patients with VA due to coronary artery </text>
<text top="889" left="595" width="194" height="12" font="4">spasm, treatment with maximally tolerated </text>
<text top="903" left="595" width="179" height="12" font="4">doses of a calcium channel blocker and </text>
<text top="917" left="595" width="190" height="12" font="4">smoking cessation are indicated to reduce </text>
<text top="930" left="595" width="120" height="12" font="4">recurrent ischemia and VA.</text>
<text top="930" left="715" width="56" height="7" font="23">S7.1.1.1-1,S7.1.1.1-2</text>
<text top="978" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="978" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="951" left="583" width="196" height="12" font="4">2.  In patients resuscitated from SCA due to </text>
<text top="964" left="595" width="181" height="12" font="4">coronary artery spasm in whom medical </text>
<text top="978" left="595" width="205" height="12" font="4">therapy is ineffective or not tolerated, an ICD </text>
<text top="991" left="595" width="206" height="12" font="4">is reasonable if meaningful survival of greater </text>
<text top="1005" left="595" width="106" height="12" font="4">than 1 year is expected.</text>
<text top="1005" left="701" width="58" height="7" font="23">S7.1.1.1-3–S7.1.1.1-6</text>
<text top="1053" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="1053" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1026" left="583" width="196" height="12" font="4">3.  In patients resuscitated from SCA due to </text>
<text top="1039" left="595" width="188" height="12" font="4">coronary artery spasm, an ICD in addition </text>
<text top="1053" left="595" width="182" height="12" font="4">to medical therapy may be reasonable if </text>
<text top="1066" left="595" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="1080" left="595" width="43" height="12" font="4">expected.</text>
<text top="1080" left="638" width="58" height="7" font="23">S7.1.1.1-3–S7.1.1.1-6</text>
<text top="457" left="74" width="45" height="12" font="3"><b>Figure 3. </b></text>
<text top="457" left="120" width="296" height="12" font="22"><b>Secondary prevention patients with ischemic heart disease.</b> </text>
<text top="470" left="74" width="323" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Sections </text>
<text top="484" left="74" width="349" height="12" font="4">4.3.1 and 7.1.1 for discussion. *Exclude reversible causes. †History consistent </text>
<text top="497" left="74" width="336" height="12" font="4">with an arrhythmic etiology for syncope. ‡ICD candidacy as determined by </text>
<text top="511" left="74" width="327" height="12" font="4">functional status, life expectancy, or patient preference. EP indicates elec-</text>
<text top="524" left="74" width="337" height="12" font="4">trophysiological; GDMT, guideline-directed management and therapy; ICD, </text>
<text top="538" left="74" width="338" height="12" font="4">implantable cardioverter-defibrillator; IHD, ischemic heart disease; LVEF, left </text>
<text top="551" left="74" width="339" height="12" font="4">ventricular ejection fraction; pts, patients; SCA, sudden cardiac arrest; SCD, </text>
<text top="565" left="74" width="241" height="12" font="4">sudden cardiac death; and VT, ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e303</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="108" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="135" left="89" width="344" height="17" font="17">1. Coronary artery spasm results from vasomotor </text>
<text top="153" left="111" width="322" height="17" font="17">dysfunction and can occur in the presence or </text>
<text top="171" left="111" width="318" height="17" font="17">absence of atherosclerotic ischemic heart disease. </text>
<text top="189" left="111" width="322" height="17" font="17">Vasospasm episodes can lead to VA, syncope, </text>
<text top="207" left="111" width="314" height="17" font="17">and SCD. Treatment includes risk factor elimina-</text>
<text top="225" left="111" width="320" height="17" font="17">tion including smoking cessation, and treatment </text>
<text top="244" left="111" width="314" height="17" font="17">with vasodilators including dihydropyridine cal-</text>
<text top="262" left="111" width="321" height="17" font="17">cium channel blockers with or without nitrates. </text>
<text top="280" left="111" width="314" height="17" font="17">A more detailed summary of treatments for coro-</text>
<text top="298" left="111" width="318" height="17" font="17">nary artery spasm can be found in other guideline </text>
<text top="316" left="111" width="75" height="17" font="17">documents.</text>
<text top="317" left="186" width="80" height="10" font="19">S7.1.1.1-7,S7.1.1.1-8</text>
<text top="334" left="89" width="340" height="17" font="17">2.  Patients with coronary artery spasm who survive an </text>
<text top="352" left="111" width="189" height="17" font="17">SCA are a high-risk population.</text>
<text top="353" left="300" width="38" height="10" font="19">S7.1.1.1-5</text>
<text top="352" left="338" width="91" height="17" font="17"> Recurrent VA, </text>
<text top="370" left="111" width="318" height="17" font="17">even life-threatening, may be prevented if coronary </text>
<text top="388" left="111" width="319" height="17" font="17">artery spasm can be effectively addressed with risk </text>
<text top="406" left="111" width="314" height="17" font="17">factor modification, smoking cessation, and ongo-</text>
<text top="424" left="111" width="314" height="17" font="17">ing treatment with nitrates and dihydropyridine cal-</text>
<text top="443" left="111" width="143" height="17" font="17">cium channel blockers.</text>
<text top="443" left="253" width="38" height="10" font="19">S7.1.1.1-9</text>
<text top="442" left="291" width="139" height="17" font="17"> However, SCA or VA </text>
<text top="461" left="111" width="319" height="17" font="17">can recur despite medical therapy or if compliance </text>
<text top="479" left="111" width="314" height="17" font="17">is poor. Whether a wearable cardioverter-defibrilla-</text>
<text top="497" left="111" width="320" height="17" font="17">tor may provide protection while medical therapy </text>
<text top="515" left="111" width="319" height="17" font="17">is being evaluated has not been assessed but is of </text>
<text top="533" left="111" width="50" height="17" font="17">interest.</text>
<text top="534" left="160" width="42" height="10" font="19">S7.1.1.1-10</text>
<text top="533" left="203" width="223" height="17" font="17"> An ICD can terminate VT/VF initi-</text>
<text top="551" left="111" width="266" height="17" font="17">ated by spasm, potentially preventing SCD.</text>
<text top="569" left="89" width="340" height="17" font="17">3.  Patients with coronary vasospasm who survive an </text>
<text top="587" left="111" width="314" height="17" font="17">SCA are a high-risk population, and some sup-</text>
<text top="605" left="111" width="318" height="17" font="17">port the use of an ICD in those patients based on </text>
<text top="623" left="111" width="314" height="17" font="17">the reported event rates from observational stud-</text>
<text top="641" left="111" width="17" height="17" font="17">ies</text>
<text top="642" left="128" width="39" height="10" font="19">S7.1.1.1-5</text>
<text top="641" left="167" width="266" height="17" font="17"> even before determining the patient’s </text>
<text top="660" left="111" width="319" height="17" font="17">response to or compliance with medical therapy. </text>
<text top="678" left="111" width="318" height="17" font="17">Recurrent SCA can occur despite medical therapy. </text>
<text top="696" left="111" width="314" height="17" font="17">Regardless of the approach, risk factor modifica-</text>
<text top="714" left="111" width="319" height="17" font="17">tion (eg, illicit drug use), smoking cessation, and </text>
<text top="732" left="111" width="320" height="17" font="17">ongoing treatment with dihydropyridine calcium </text>
<text top="750" left="111" width="314" height="17" font="17">channel blockers with or without nitrates repre-</text>
<text top="768" left="111" width="162" height="17" font="17">sent essential treatments.</text>
<text top="769" left="273" width="39" height="10" font="19">S7.1.1.1-9</text>
<text top="796" left="74" width="164" height="18" font="28"><i>7.1.1.2. Post CABG VT/VF</i></text>
<text top="814" left="74" width="355" height="17" font="17">The incidence of sustained VT or VF early after CABG is </text>
<text top="832" left="74" width="356" height="17" font="17">low, but these VAs are associated with high in-hospital </text>
<text top="850" left="74" width="59" height="17" font="17">mortality.</text>
<text top="851" left="133" width="38" height="10" font="19">S7.1.1.2-1</text>
<text top="850" left="171" width="258" height="17" font="17"> VF occurring very early (intraoperatively </text>
<text top="868" left="74" width="356" height="17" font="17">or within 24 hours postoperatively) may be due to the </text>
<text top="886" left="74" width="354" height="17" font="17">transient effects of reperfusion, electrolyte and acid base </text>
<text top="904" left="74" width="358" height="17" font="17">disturbances, and the use of inotropes. Patients who </text>
<text top="923" left="74" width="355" height="17" font="17">present with VF or polymorphic VT in the postoperative </text>
<text top="941" left="74" width="351" height="17" font="17">period more often have associated ischemia, while pa-</text>
<text top="959" left="74" width="355" height="17" font="17">tients presenting with monomorphic VT usually have an </text>
<text top="977" left="74" width="192" height="17" font="17">old infarct and ventricular scar.</text>
<text top="977" left="266" width="38" height="10" font="19">S7.1.1.2-2</text>
<text top="977" left="304" width="125" height="17" font="17"> Polymorphic VT/VF </text>
<text top="995" left="74" width="356" height="17" font="17">occurring after CABG warrants a therapeutic approach </text>
<text top="1013" left="74" width="355" height="17" font="17">targeting treatment of myocardial ischemia, including a </text>
<text top="1031" left="74" width="357" height="17" font="17">possible need for assessment of graft patency, as well </text>
<text top="1049" left="74" width="351" height="17" font="17">as identification and treatment of mechanical compli-</text>
<text top="1067" left="74" width="356" height="17" font="17">cations and acute electrolyte or acid base disturbances. </text>
<text top="1085" left="74" width="351" height="17" font="17">Risk factors for occurrence of monomorphic VT early af-</text>
<text top="88" left="452" width="351" height="17" font="17">ter CABG include prior MI, ventricular scar, LV dysfunc-</text>
<text top="107" left="452" width="351" height="17" font="17">tion, and placement of a bypass graft across a noncol-</text>
<text top="126" left="452" width="356" height="17" font="17">lateralized occluded coronary vessel to a chronic infarct </text>
<text top="145" left="452" width="35" height="17" font="17">zone.</text>
<text top="146" left="487" width="38" height="10" font="19">S7.1.1.2-3</text>
<text top="145" left="525" width="285" height="17" font="17"> Unlike polymorphic VT and VF, sustained </text>
<text top="165" left="452" width="355" height="17" font="17">monomorphic VT is typically not due to acute ischemia. </text>
<text top="184" left="452" width="357" height="17" font="17">Many of these patients have inducible sustained VT at </text>
<text top="203" left="452" width="351" height="17" font="17">electrophysiological study. Management of symptomat-</text>
<text top="223" left="452" width="351" height="17" font="17">ic VA in the early period after CABG follows the recom-</text>
<text top="242" left="452" width="356" height="17" font="17">mendations for acute and ongoing management of VT </text>
<text top="261" left="452" width="355" height="17" font="17">detailed elsewhere in this document. In patients without </text>
<text top="280" left="452" width="351" height="17" font="17">sustained VT or VF but with LV dysfunction prior to un-</text>
<text top="300" left="452" width="354" height="17" font="17">dergoing CABG, implantation of an ICD did not improve </text>
<text top="319" left="452" width="50" height="17" font="17">survival.</text>
<text top="320" left="502" width="38" height="10" font="19">S7.1.1.2-4</text>
<text top="319" left="541" width="267" height="17" font="17"> For patients with LV dysfunction who are </text>
<text top="338" left="452" width="357" height="17" font="17">undergoing revascularization, there is a possibility that </text>
<text top="358" left="452" width="351" height="17" font="17">the LV function may improve, so many advocate for re-</text>
<text top="377" left="452" width="351" height="17" font="17">assessment of the LV function 3 months after revascu-</text>
<text top="396" left="452" width="357" height="17" font="17">larization before a decision about ICD implantation is </text>
<text top="415" left="452" width="40" height="17" font="17">made.</text>
<text top="416" left="492" width="38" height="10" font="19">S7.1.1.2-5</text>
<text top="415" left="530" width="279" height="17" font="17"> For patients with a high burden of NSVT </text>
<text top="435" left="452" width="355" height="17" font="17">and reduced LVEF, an electrophysiological study may be </text>
<text top="454" left="452" width="351" height="17" font="17">helpful for risk stratification; those with inducible sus-</text>
<text top="473" left="452" width="224" height="17" font="17">tained VT may benefit from an ICD.</text>
<text top="474" left="676" width="38" height="10" font="19">S7.1.1.2-6</text>
<text top="473" left="714" width="93" height="17" font="17"> The wearable </text>
<text top="493" left="452" width="357" height="17" font="17">cardioverter-defibrillator may play a role in patients at </text>
<text top="512" left="452" width="356" height="17" font="17">risk of SCD in the early phase after revascularization to </text>
<text top="531" left="452" width="293" height="17" font="17">allow time for recovery of ventricular function.</text>
<text top="532" left="745" width="38" height="10" font="19">S7.1.1.2-7</text>
<text top="562" left="452" width="319" height="18" font="28"><i>7.1.2. Primary Prevention of SCD in Patients With </i></text>
<text top="582" left="452" width="145" height="18" font="28"><i>Ischemic Heart Disease</i></text>
<text top="611" left="463" width="327" height="12" font="26"><b>Recommendations for Primary Prevention of SCD in Patients With </b></text>
<text top="624" left="463" width="112" height="12" font="26"><b>Ischemic Heart Disease</b></text>
<text top="641" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="655" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 21</b></a></text>
<text top="655" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="675" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="675" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="675" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="737" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="737" left="539" width="8" height="12" font="22"><b>A</b></text>
<text top="696" left="583" width="196" height="12" font="4">1.  In patients with LVEF of 35% or less that </text>
<text top="710" left="595" width="183" height="12" font="4">is due to ischemic heart disease who are </text>
<text top="723" left="595" width="182" height="12" font="4">at least 40 days’ post-MI and at least 90 </text>
<text top="737" left="595" width="195" height="12" font="4">days postrevascularization, and with NYHA </text>
<text top="750" left="595" width="179" height="12" font="4">class II or III HF despite GDMT, an ICD is </text>
<text top="764" left="595" width="178" height="12" font="4">recommended if meaningful survival of </text>
<text top="777" left="595" width="141" height="12" font="4">greater than 1 year is expected.</text>
<text top="778" left="736" width="46" height="7" font="23">S7.1.2-1,S7.1.2-2</text>
<text top="846" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="846" left="539" width="8" height="12" font="22"><b>A</b></text>
<text top="798" left="583" width="206" height="12" font="4">2.  In patients with LVEF of 30% or less that is </text>
<text top="812" left="595" width="185" height="12" font="4">due to ischemic heart disease who are at </text>
<text top="825" left="595" width="193" height="12" font="4">least 40 days’ post-MI and at least 90 days </text>
<text top="839" left="595" width="200" height="12" font="4">postrevascularization, and with NYHA class I </text>
<text top="852" left="595" width="202" height="12" font="4">HF despite GDMT, an ICD is recommended if </text>
<text top="866" left="595" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="879" left="595" width="43" height="12" font="4">expected.</text>
<text top="880" left="638" width="46" height="7" font="23">S7.1.2-2,S7.1.2-3</text>
<text top="954" left="457" width="114" height="12" font="22"><b>Value Statement: High </b></text>
<text top="968" left="473" width="79" height="12" font="22"><b>Value (LOE: B-R)</b></text>
<text top="913" left="583" width="202" height="12" font="4">3.  A transvenous ICD provides high value in </text>
<text top="927" left="595" width="195" height="12" font="4">the primary prevention of SCD particularly </text>
<text top="940" left="595" width="168" height="12" font="4">when the patient’s risk of death due </text>
<text top="954" left="595" width="179" height="12" font="4">to a VA is deemed high and the risk of </text>
<text top="967" left="595" width="179" height="12" font="4">nonarrhythmic death (either cardiac or </text>
<text top="981" left="595" width="187" height="12" font="4">noncardiac) is deemed low based on the </text>
<text top="994" left="595" width="174" height="12" font="4">patient’s burden of comorbidities and </text>
<text top="1008" left="595" width="79" height="12" font="4">functional status.</text>
<text top="1008" left="674" width="23" height="7" font="23">S7.1.2-4</text>
<text top="1056" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="1056" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="1029" left="583" width="207" height="12" font="4">4.  In patients with NSVT due to prior MI, LVEF </text>
<text top="1042" left="595" width="191" height="12" font="4">of 40% or less and inducible sustained VT </text>
<text top="1056" left="595" width="190" height="12" font="4">or VF at electrophysiological study, an ICD </text>
<text top="1069" left="595" width="187" height="12" font="4">is recommended if meaningful survival of </text>
<text top="1083" left="595" width="141" height="12" font="4">greater than 1 year is expected.</text>
<text top="1083" left="736" width="22" height="7" font="23">S7.1.2-5</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e304</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="177" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="177" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="150" left="205" width="188" height="12" font="4">5.  In nonhospitalized patients with NYHA </text>
<text top="163" left="217" width="189" height="12" font="4">class IV symptoms who are candidates for </text>
<text top="177" left="217" width="203" height="12" font="4">cardiac transplantation or an LVAD, an ICD is </text>
<text top="190" left="217" width="196" height="12" font="4">reasonable if meaningful survival of greater </text>
<text top="204" left="217" width="106" height="12" font="4">than 1 year is expected.</text>
<text top="204" left="323" width="47" height="7" font="23">S7.1.2-6–S7.1.2-9</text>
<text top="252" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="265" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="259" left="152" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="225" left="205" width="187" height="12" font="4">6.  An ICD is not indicated for NYHA class </text>
<text top="238" left="217" width="186" height="12" font="4">IV patients with medication-refractory HF </text>
<text top="252" left="217" width="179" height="12" font="4">who are not also candidates for cardiac </text>
<text top="265" left="217" width="158" height="12" font="4">transplantation, an LVAD, or a CRT </text>
<text top="279" left="217" width="190" height="12" font="4">defibrillator that incorporates both pacing </text>
<text top="292" left="217" width="131" height="12" font="4">and defibrillation capabilities.</text>
<text top="332" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="353" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="381" left="89" width="342" height="17" font="17">1.  The rationale for recommending that an ICD be </text>
<text top="399" left="111" width="321" height="17" font="17">offered to patients with NYHA class II or III HF, </text>
<text top="417" left="111" width="314" height="17" font="17">in addition to LVEF  ≤35%, is based on the sur-</text>
<text top="435" left="111" width="319" height="17" font="17">vival benefit observed in SCD-HeFT and MADIT-II </text>
<text top="453" left="111" width="318" height="17" font="17">(which used LVEF cutoff of below 35% and 30%, </text>
<text top="472" left="111" width="324" height="17" font="17">respectively). Selection for implantation of an </text>
<text top="490" left="111" width="319" height="17" font="17">ICD must be individualized. Patients with serious </text>
<text top="508" left="111" width="318" height="17" font="17">comorbidities associated with a survival of &lt;1 year </text>
<text top="526" left="111" width="319" height="17" font="17">are generally not considered ICD candidates. The </text>
<text top="544" left="111" width="321" height="17" font="17">recommendation to wait at least 40 days after </text>
<text top="88" left="489" width="322" height="17" font="17">an MI before implanting a primary prevention </text>
<text top="106" left="489" width="319" height="17" font="17">ICD is based on the fact that such patients were </text>
<text top="124" left="489" width="323" height="17" font="17">excluded from MADIT-II and SCD-HeFT and 2 </text>
<text top="142" left="489" width="319" height="17" font="17">other RCTs showed no survival benefit from ICDs </text>
<text top="161" left="489" width="217" height="17" font="17">implanted early after an acute MI.</text>
<text top="161" left="706" width="75" height="10" font="19">S7.1.2-10,S7.1.2-11</text>
<text top="179" left="467" width="169" height="17" font="17">2. In the MADIT-II trial,</text>
<text top="180" left="636" width="32" height="10" font="19">S7.1.2-2</text>
<text top="179" left="668" width="146" height="17" font="17"> which randomized </text>
<text top="197" left="489" width="319" height="17" font="17">patients with LVEF ≤30% and prior MI to an ICD </text>
<text top="215" left="489" width="321" height="17" font="17">or not,  approximately one third of the patients </text>
<text top="234" left="489" width="319" height="17" font="17">had NYHA class I symptoms. A subgroup analysis </text>
<text top="252" left="489" width="320" height="17" font="17">supported benefit of the ICD on survival in this </text>
<text top="270" left="489" width="65" height="17" font="17">subgroup.</text>
<text top="271" left="554" width="32" height="10" font="19">S7.1.2-2</text>
<text top="289" left="467" width="347" height="17" font="17">3. Economic outcomes of ICD implantation for </text>
<text top="307" left="489" width="322" height="17" font="17">primary prevention of SCD were assessed in 3 </text>
<text top="325" left="489" width="98" height="17" font="17">RCTs [MADIT-I,</text>
<text top="326" left="587" width="36" height="10" font="19">S7.1.2-12</text>
<text top="325" left="623" width="68" height="17" font="17"> MADIT-II,</text>
<text top="326" left="691" width="36" height="10" font="19">S7.1.2-13</text>
<text top="325" left="727" width="77" height="17" font="17"> and SCD-</text>
<text top="343" left="489" width="31" height="17" font="17">HeFT</text>
<text top="344" left="520" width="36" height="10" font="19">S7.1.2-14</text>
<text top="343" left="556" width="162" height="17" font="17">], 1 observational study,</text>
<text top="344" left="718" width="36" height="10" font="19">S7.1.2-15</text>
<text top="343" left="754" width="57" height="17" font="17"> and 4 </text>
<text top="362" left="489" width="126" height="17" font="17">simulation models,</text>
<text top="362" left="615" width="77" height="10" font="19">S7.1.2-16–S7.1.2-19</text>
<text top="362" left="692" width="123" height="17" font="17"> which all had </text>
<text top="380" left="489" width="321" height="17" font="17">generally consistent results. All studies reported </text>
<text top="398" left="489" width="319" height="17" font="17">increased survival and life expectancy, and higher </text>
<text top="416" left="489" width="321" height="17" font="17">lifetime costs of medical care with an ICD than </text>
<text top="435" left="489" width="314" height="17" font="17">without an ICD. The incremental cost-effective-</text>
<text top="453" left="489" width="321" height="17" font="17">ness ratios were generally  &lt;$50 000 per year of </text>
<text top="471" left="489" width="320" height="17" font="17">life added by an ICD, which provides high value </text>
<text top="490" left="489" width="323" height="17" font="17">according to the benchmarks adopted for the </text>
<text top="508" left="489" width="112" height="17" font="17">current guideline.</text>
<text top="508" left="601" width="36" height="10" font="19">S7.1.2-20</text>
<text top="508" left="637" width="171" height="17" font="17"> The value provided by an </text>
<text top="526" left="489" width="321" height="17" font="17">ICD was consistently high when life expectancy </text>
<text top="544" left="489" width="261" height="17" font="17">was projected to increase by &gt;1.4 years.</text>
<text top="545" left="750" width="36" height="10" font="19">S7.1.2-18</text>
<text top="544" left="786" width="23" height="17" font="17"> In </text>
<text top="993" left="74" width="45" height="12" font="3"><b>Figure 4. </b></text>
<text top="993" left="120" width="331" height="12" font="22"><b>Primary prevention of SCD in patients with ischemic heart disease.</b> </text>
<text top="1006" left="74" width="721" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 7.1.2 for discussion. *Scenarios exist for early ICD placement in select circumstances such </text>
<text top="1020" left="74" width="729" height="12" font="4">as patients with a pacing indication or syncope †Advanced HF therapy includes CRT, cardiac transplant, and LVAD thought due to VT. These are detailed elsewhere </text>
<text top="1033" left="74" width="221" height="12" font="4">in an HRS/ACC/AHA expert consensus statement.</text>
<text top="1034" left="295" width="26" height="7" font="23">S7.1.2-24</text>
<text top="1033" left="321" width="446" height="12" font="4"> CRT indicates cardiac resynchronization therapy; EP, electrophysiological; GDMT, guideline-directed </text>
<text top="1047" left="74" width="703" height="12" font="4">management and therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MI, </text>
<text top="1060" left="74" width="713" height="12" font="4">myocardial infarction; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association; pts, patients; SCD, sudden cardiac death; VT, ventricular </text>
<text top="1074" left="74" width="259" height="12" font="4">tachycardia; and WCD, wearable cardioverter-defibrillator.</text>
<text top="95" left="85" width="327" height="12" font="26"><b>Recommendations for Primary Prevention of SCD in Patients With </b></text>
<text top="108" left="85" width="173" height="12" font="26"><b>Ischemic Heart Disease (Continued)</b></text>
<text top="129" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="129" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="129" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e305</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="319" height="17" font="17">contrast, when survival was not increased by ICD </text>
<text top="106" left="111" width="254" height="17" font="17">implantation, as in the CABG-Patch trial,</text>
<text top="106" left="365" width="36" height="10" font="19">S7.1.2-18</text>
<text top="106" left="401" width="28" height="17" font="17"> the </text>
<text top="124" left="111" width="317" height="17" font="17">ICD did not provide value, because the higher costs </text>
<text top="142" left="111" width="313" height="17" font="17">were unaccompanied by a gain in life expectancy.</text>
<text top="160" left="89" width="349" height="17" font="17">4. MUSTT (Multicenter Unsustained Tachycardia </text>
<text top="178" left="111" width="321" height="17" font="17">Trial) demonstrated that patients with prior MI, </text>
<text top="196" left="111" width="314" height="17" font="17">NSVT, and reduced LVEF with inducible VT at elec-</text>
<text top="214" left="111" width="314" height="17" font="17">trophysiological study have a higher overall mor-</text>
<text top="232" left="111" width="319" height="17" font="17">tality rate than similar patients without inducible </text>
<text top="250" left="111" width="84" height="17" font="17">sustained VT.</text>
<text top="251" left="195" width="36" height="10" font="19">S7.1.2-21</text>
<text top="250" left="231" width="199" height="17" font="17"> Patients who received an ICD </text>
<text top="268" left="111" width="320" height="17" font="17">after failing to have inducible VT suppressed by </text>
<text top="286" left="111" width="314" height="17" font="17">an antiarrhythmic medication had lower mortal-</text>
<text top="304" left="111" width="320" height="17" font="17">ity rate than those who did not receive an ICD. </text>
<text top="322" left="111" width="320" height="17" font="17">Although the entry criteria into MUSTT required </text>
<text top="340" left="111" width="320" height="17" font="17">an LVEF of  ≤40%, the average LVEF in enrolled </text>
<text top="358" left="111" width="320" height="17" font="17">patients was 30%, and ICD placement was not </text>
<text top="376" left="111" width="314" height="17" font="17">randomized but rather was selected by the treat-</text>
<text top="394" left="111" width="319" height="17" font="17">ing physician for patients with VT that could not </text>
<text top="412" left="111" width="323" height="17" font="17">be suppressed with antiarrhythmic medication </text>
<text top="430" left="111" width="321" height="17" font="17">therapy. MUSTT allowed enrollment of patients </text>
<text top="448" left="111" width="314" height="17" font="17">who were ≥4 days after an acute MI or revascu-</text>
<text top="466" left="111" width="320" height="17" font="17">larization. The ICD was of no benefit in 2 other </text>
<text top="485" left="111" width="318" height="17" font="17">RCTs that examined the efficacy of the ICD in the </text>
<text top="503" left="111" width="139" height="17" font="17">acute phase of an MI.</text>
<text top="503" left="250" width="75" height="10" font="19">S7.1.2-10,S7.1.2-11</text>
<text top="503" left="325" width="100" height="17" font="17"> In a single cen-</text>
<text top="521" left="111" width="323" height="17" font="17">ter observational study, an electrophysiological </text>
<text top="539" left="111" width="321" height="17" font="17">study was performed a median of 9  days after </text>
<text top="557" left="111" width="321" height="17" font="17">acute MI in 115 patients with LVEF  &lt;40% and </text>
<text top="575" left="111" width="320" height="17" font="17">ICDs recommended for those with inducible VT. </text>
<text top="593" left="111" width="324" height="17" font="17">Median follow-up was 12 months. Sustained </text>
<text top="611" left="111" width="321" height="17" font="17">VT was induced in 27% of patients, and 22% </text>
<text top="629" left="111" width="320" height="17" font="17">of those who received ICDs had spontanous VT </text>
<text top="647" left="111" width="319" height="17" font="17">terminated by the ICD during follow-up. None of </text>
<text top="665" left="111" width="319" height="17" font="17">the patients without inducible VT had VT or SCD </text>
<text top="683" left="111" width="112" height="17" font="17">during follow-up.</text>
<text top="684" left="223" width="36" height="10" font="19">S7.1.2-22</text>
<text top="701" left="89" width="344" height="17" font="17">5.  In a retrospective analysis of the UNOS (United </text>
<text top="719" left="111" width="318" height="17" font="17">Network for Organ Sharing) registry that extended </text>
<text top="737" left="111" width="324" height="17" font="17">from 1999 to 2014, data on 32 599 patients </text>
<text top="755" left="111" width="321" height="17" font="17">showed that during a median follow-up of 154 </text>
<text top="773" left="111" width="314" height="17" font="17">days, 3638 patients (11%) died while on the wait-</text>
<text top="791" left="111" width="317" height="17" font="17">list for cardiac transplantation (9% in the ICD group </text>
<text top="809" left="111" width="318" height="17" font="17">versus 15% in the non-ICD group; <i>P</i>&lt;0.0001). The </text>
<text top="827" left="111" width="320" height="17" font="17">presence of an ICD at listing was associated with </text>
<text top="845" left="111" width="314" height="17" font="17">an adjusted 13% relative risk reduction in mor-</text>
<text top="863" left="111" width="321" height="17" font="17">tality. In the subgroup of patients with an LVAD </text>
<text top="881" left="111" width="318" height="17" font="17">(n=9478), an ICD was associated with an adjusted </text>
<text top="899" left="111" width="264" height="17" font="17">19% relative risk reduction in mortality.</text>
<text top="900" left="375" width="31" height="10" font="19">S7.1.2-9</text>
<text top="899" left="406" width="27" height="17" font="17"> In </text>
<text top="917" left="111" width="314" height="17" font="17">another study of 380 patients listed for heart trans-</text>
<text top="936" left="111" width="320" height="17" font="17">plantation between 2005 and 2009 at 1 tertiary </text>
<text top="954" left="111" width="320" height="17" font="17">heart transplant center, 122 patients received an </text>
<text top="972" left="111" width="320" height="17" font="17">ICD before or within 3 months after being listed </text>
<text top="990" left="111" width="321" height="17" font="17">for heart transplantation. Non-ICD patients were </text>
<text top="1008" left="111" width="319" height="17" font="17">more likely to die while on the transplant list. In a </text>
<text top="1026" left="111" width="321" height="17" font="17">multivariable model, the ICD was not associated </text>
<text top="1044" left="111" width="319" height="17" font="17">with improved survival; however, that analysis was </text>
<text top="1062" left="111" width="194" height="17" font="17">limited by the small sample size.</text>
<text top="1062" left="305" width="31" height="10" font="19">S7.1.2-8</text>
<text top="1062" left="336" width="92" height="17" font="17"> Another small </text>
<text top="1080" left="111" width="319" height="17" font="17">study (n=79) conducted at 1 institution suggested </text>
<text top="88" left="489" width="320" height="17" font="17">that ICDs reduce the risk of SCD in patients with </text>
<text top="107" left="489" width="314" height="17" font="17">LVEF  ≤30% who are awaiting heart transplanta-</text>
<text top="126" left="489" width="319" height="17" font="17">tion; however, this study was limited by the small </text>
<text top="145" left="489" width="130" height="17" font="17">number of patients.</text>
<text top="146" left="618" width="31" height="10" font="19">S7.1.2-6</text>
<text top="145" left="649" width="154" height="17" font="17"> In a retrospective mul-</text>
<text top="165" left="489" width="322" height="17" font="17">ticenter study of 1089 patients listed for heart </text>
<text top="184" left="489" width="318" height="17" font="17">transplantation, 550 patients (51%) had an ICD. In </text>
<text top="203" left="489" width="320" height="17" font="17">216 patients, the ICD was for primary prevention </text>
<text top="222" left="489" width="314" height="17" font="17">of SCD and, in 334 patients, the ICD was for sec-</text>
<text top="242" left="489" width="318" height="17" font="17">ondary prevention. The remaining 539 patients did </text>
<text top="261" left="489" width="320" height="17" font="17">not receive an ICD. During a median time on the </text>
<text top="280" left="489" width="320" height="17" font="17">waiting list of 8 months, the ICD was associated </text>
<text top="299" left="489" width="314" height="17" font="17">with a reduction in all-cause mortality in the pri-</text>
<text top="319" left="489" width="318" height="17" font="17">mary and secondary prevention cohorts (estimated </text>
<text top="338" left="489" width="321" height="17" font="17">1-year: 88±3% versus 77±3% versus 67±3%;  </text>
<text top="357" left="489" width="320" height="18" font="21"><i>P</i> =0.0001). This relationship between the ICD and </text>
<text top="376" left="489" width="321" height="17" font="17">improved survival persisted even after adjusting </text>
<text top="396" left="489" width="168" height="17" font="17">for potential confounders.</text>
<text top="396" left="657" width="32" height="10" font="19">S7.1.2-7</text>
<text top="415" left="467" width="336" height="17" font="17">6. There are insufficient data from RCTs regard-</text>
<text top="434" left="489" width="320" height="17" font="17">ing the value of the ICD in patients with NYHA </text>
<text top="453" left="489" width="319" height="17" font="17">class IV HF. Ambulatory class IV patients with HF </text>
<text top="473" left="489" width="320" height="17" font="17">were included in the COMPANION (Comparison </text>
<text top="492" left="489" width="323" height="17" font="17">of Medical Therapy, Pacing, and Defibrillation </text>
<text top="511" left="489" width="321" height="17" font="17">in Heart Failure) trial, which showed an overall </text>
<text top="530" left="489" width="322" height="17" font="17">improved functional status and survival with a </text>
<text top="550" left="489" width="107" height="17" font="17">CRT defibrillator.</text>
<text top="550" left="596" width="36" height="10" font="19">S7.1.2-23</text>
<text top="550" left="633" width="176" height="17" font="17"> Unless such a patient is a </text>
<text top="569" left="489" width="318" height="17" font="17">candidate for CRT or advanced HF therapies such </text>
<text top="588" left="489" width="318" height="17" font="17">as heart transplantation or an LVAD, an ICD is not </text>
<text top="607" left="489" width="271" height="17" font="17">expected to meaningfully prolong survival.</text>
<text top="608" left="760" width="36" height="10" font="19">S7.1.2-23</text>
<text top="638" left="452" width="346" height="18" font="24"><i><b>7.1.3. Treatment and Prevention of Recurrent VA </b></i></text>
<text top="657" left="452" width="277" height="18" font="24"><i><b>in Patients With Ischemic Heart Disease</b></i></text>
<text top="687" left="463" width="327" height="12" font="26"><b>Recommendations for Treatment of Recurrent VA in Patients With </b></text>
<text top="700" left="463" width="112" height="12" font="26"><b>Ischemic Heart Disease</b></text>
<text top="717" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="731" left="463" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 22 and 23</b></a></text>
<text top="731" left="640" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="751" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="751" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="751" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="806" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="806" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="772" left="583" width="206" height="12" font="4">1.  In patients with ischemic heart disease and </text>
<text top="786" left="595" width="182" height="12" font="4">recurrent VA, with significant symptoms </text>
<text top="799" left="595" width="167" height="12" font="4">or ICD shocks despite optimal device </text>
<text top="813" left="595" width="202" height="12" font="4">programming and ongoing treatment with a </text>
<text top="826" left="595" width="200" height="12" font="4">beta blocker, amiodarone or sotalol is useful </text>
<text top="840" left="595" width="113" height="12" font="4">to suppress recurrent VA.</text>
<text top="840" left="707" width="47" height="7" font="23">S7.1.3-1–S7.1.3-3</text>
<text top="901" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="875" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="860" left="583" width="186" height="12" font="4">2.  In patients with prior MI and recurrent </text>
<text top="873" left="595" width="175" height="12" font="4">episodes of symptomatic sustained VT, </text>
<text top="887" left="595" width="181" height="12" font="4">or who present with VT storm and have </text>
<text top="900" left="595" width="171" height="12" font="4">failed or are intolerant of amiodarone </text>
<text top="914" left="595" width="47" height="12" font="4">(LOE: B-R).</text>
<text top="914" left="642" width="22" height="7" font="23">S7.1.3-4</text>
<text top="914" left="664" width="110" height="12" font="4"> or other antiarrhythmic </text>
<text top="927" left="595" width="111" height="12" font="4">medications (LOE: B-NR) </text>
<text top="928" left="705" width="47" height="7" font="23">S7.1.3-5–S7.1.3-9</text>
<text top="927" left="753" width="45" height="12" font="4">, catheter </text>
<text top="941" left="595" width="116" height="12" font="4">ablation is recommended </text>
<text top="941" left="711" width="54" height="7" font="23">S7.1.3-10–S7.1.3-12</text>
<text top="926" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="996" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="996" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="962" left="583" width="206" height="12" font="4">3.  In patients with ischemic heart disease and </text>
<text top="975" left="595" width="205" height="12" font="4">ICD shocks for sustained monomorphic VT or </text>
<text top="989" left="595" width="207" height="12" font="4">symptomatic sustained monomorphic VT that </text>
<text top="1002" left="595" width="194" height="12" font="4">is recurrent, or hemodynamically tolerated, </text>
<text top="1016" left="595" width="193" height="12" font="4">catheter ablation as first-line therapy may be </text>
<text top="1029" left="595" width="149" height="12" font="4">considered to reduce recurrent VA.</text>
<text top="1030" left="743" width="51" height="7" font="23">S7.1.3-10,S7.1.3-11</text>
<text top="1064" left="462" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="1064" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="1050" left="583" width="161" height="12" font="4">4.  In patients with prior MI, class IC </text>
<text top="1064" left="595" width="190" height="12" font="4">antiarrhythmic medications (eg, flecainide </text>
<text top="1077" left="595" width="172" height="12" font="4">and propafenone) should not be used.</text>
<text top="1078" left="767" width="26" height="7" font="23">S7.1.3-13</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e306</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="170" left="84" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="170" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="150" left="205" width="203" height="12" font="4">5.  In patients with incessant VT or VF, an ICD </text>
<text top="163" left="217" width="179" height="12" font="4">should not be implanted until sufficient </text>
<text top="177" left="217" width="180" height="12" font="4">control of the VA is achieved to prevent </text>
<text top="190" left="217" width="94" height="12" font="4">repeated ICD shocks.</text>
<text top="191" left="311" width="26" height="7" font="23">S7.1.3-14</text>
<text top="225" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="238" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="232" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="211" left="205" width="186" height="12" font="4">6.  In patients with ischemic heart disease </text>
<text top="225" left="217" width="189" height="12" font="4">and sustained monomorphic VT, coronary </text>
<text top="238" left="217" width="176" height="12" font="4">revascularization alone is an ineffective </text>
<text top="252" left="217" width="142" height="12" font="4">therapy to prevent recurrent VT.</text>
<text top="252" left="359" width="53" height="7" font="23">S7.1.3-15,S7.1.3-16</text>
<text top="292" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="313" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="340" left="89" width="344" height="17" font="17">1. The most common antiarrhythmic medications </text>
<text top="358" left="111" width="320" height="17" font="17">used for suppression of VA include amiodarone </text>
<text top="376" left="111" width="325" height="17" font="17">and sotalol, while mexiletine, quinidine, and </text>
<text top="394" left="111" width="239" height="17" font="17">ranolazine are occasionally used.</text>
<text top="394" left="350" width="75" height="10" font="19">S7.1.3-17,S7.1.3-18</text>
<text top="394" left="425" width="4" height="17" font="17"> </text>
<text top="412" left="111" width="328" height="17" font="17">Amiodarone appears to be more effective </text>
<text top="430" left="111" width="322" height="17" font="17">than sotalol and has a low rate of ventricular </text>
<text top="88" left="489" width="325" height="17" font="17">proarrhythmia, but has an increased risk of </text>
<text top="107" left="489" width="322" height="17" font="17">medication-related adverse effects that lead to </text>
<text top="126" left="489" width="322" height="17" font="17">its discontinuation in many patients within 18 </text>
<text top="145" left="489" width="288" height="17" font="17">to 24 months from initiation of therapy.</text>
<text top="145" left="777" width="27" height="10" font="19">S7.1.3-</text>
<text top="164" left="489" width="44" height="10" font="19">1,S7.1.3-19</text>
<text top="164" left="533" width="278" height="17" font="17"> Data supporting effectiveness of sotalol </text>
<text top="183" left="489" width="320" height="17" font="17">for suppression of VA are conflicting, but given </text>
<text top="202" left="489" width="323" height="17" font="17">its more favorable adverse effect profile than </text>
<text top="221" left="489" width="314" height="17" font="17">amiodarone, it may be a better first-line antiar-</text>
<text top="240" left="489" width="288" height="17" font="17">rhythmic medication in appropriate patients.</text>
<text top="240" left="777" width="27" height="10" font="19">S7.1.3-</text>
<text top="259" left="489" width="41" height="10" font="19">1–S7.1.3-3</text>
<text top="259" left="530" width="281" height="17" font="17"> However, sotalol is generally avoided in </text>
<text top="278" left="489" width="319" height="17" font="17">patients with a severely reduced LVEF &lt;20% due </text>
<text top="297" left="489" width="321" height="17" font="17">to its negative inotropic effects and the risk of </text>
<text top="316" left="489" width="314" height="17" font="17">torsades de pointes. In a double-blind placebo-</text>
<text top="335" left="489" width="318" height="17" font="17">controlled study of 674 patients with HF and ≥10 </text>
<text top="354" left="489" width="322" height="17" font="17">PVCs/h and an LVEF  ≤40% randomly assigned </text>
<text top="373" left="489" width="320" height="17" font="17">to receive amiodarone (336 patients) or placebo </text>
<text top="392" left="489" width="318" height="17" font="17">(338 patients), there was no significant difference </text>
<text top="411" left="489" width="320" height="17" font="17">in overall mortality or SCD between the 2 arms. </text>
<text top="430" left="489" width="320" height="17" font="17">There was a trend toward a reduction in overall </text>
<text top="998" left="74" width="45" height="12" font="3"><b>Figure 5. </b></text>
<text top="998" left="120" width="374" height="12" font="22"><b>Treatment of recurrent VA in patients with ischemic heart disease or NICM. </b> </text>
<text top="1011" left="74" width="715" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Sections 5.6, 6, 7.1.3, and 7.2 for discussion. *Management should start with ensuring that the </text>
<text top="1025" left="74" width="714" height="12" font="4">ICD is programmed appropriately and that potential precipitating causes, including heart failure exacerbation, are addressed. For information regarding optimal </text>
<text top="1038" left="74" width="420" height="12" font="4">ICD programming, refer to the 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement.</text>
<text top="1039" left="495" width="26" height="7" font="23">S7.1.3-26</text>
<text top="1038" left="520" width="278" height="12" font="4"> APHRS indicates Asia Pacific Heart Rhythm Society; EHRA, Eu-</text>
<text top="1052" left="74" width="723" height="12" font="4">ropean Heart Rhythm Association; HRS, Heart Rhythm Society; IHD, ischemic heart disease; ICD, implantable cardioverter-defibrillator; PVC, premature ventricular </text>
<text top="1065" left="74" width="728" height="12" font="4">complex; NICM, nonischemic cardiomyopathy; SOLAECE, Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología; VF, ventricular fibrillation; and VT, </text>
<text top="1079" left="74" width="103" height="12" font="4">ventricular tachycardia.</text>
<text top="95" left="85" width="327" height="12" font="26"><b>Recommendations for Treatment of Recurrent VA in Patients With </b></text>
<text top="108" left="85" width="173" height="12" font="26"><b>Ischemic Heart Disease (Continued)</b></text>
<text top="129" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="129" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="129" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e307</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="322" height="17" font="17">mortality among the patients with NICM who </text>
<text top="106" left="111" width="197" height="17" font="17">received amiodarone (<i>P</i> =0.07).</text>
<text top="106" left="308" width="36" height="10" font="19">S7.1.3-20</text>
<text top="124" left="89" width="336" height="17" font="17">2. Patients with prior MI may present with fre-</text>
<text top="142" left="111" width="318" height="17" font="17">quent episodes of sustained monomorphic VT or </text>
<text top="160" left="111" width="319" height="17" font="17">recurrent VF episodes that are initiated by PVCs </text>
<text top="178" left="111" width="322" height="17" font="17">arising from Purkinje Fibers in the peri-infarct </text>
<text top="196" left="111" width="321" height="17" font="17">zone. VA storms are  associated with increased </text>
<text top="214" left="111" width="61" height="17" font="17">mortality.</text>
<text top="215" left="172" width="37" height="10" font="19">S7.1.3-12</text>
<text top="214" left="209" width="229" height="17" font="17"> The arrhythmia substrate is </text>
<text top="232" left="111" width="314" height="17" font="17">usually in the subendocardium. The random-</text>
<text top="250" left="111" width="323" height="17" font="17">ized VANISH (Ventricular Tachycardia Ablation </text>
<text top="268" left="111" width="322" height="17" font="17">versus Escalated Antiarrhythmic Drug Therapy </text>
<text top="286" left="111" width="210" height="17" font="17">in Ischemic Heart Disease) trial</text>
<text top="287" left="321" width="32" height="10" font="19">S7.1.3-4</text>
<text top="286" left="353" width="79" height="17" font="17"> compared </text>
<text top="304" left="111" width="325" height="17" font="17">escalating antiarrhythmic medication therapy </text>
<text top="322" left="111" width="320" height="17" font="17">versus catheter ablation for patients with prior </text>
<text top="340" left="111" width="323" height="17" font="17">MI  and recurrent sustained monomorphic VT </text>
<text top="358" left="111" width="318" height="17" font="17">despite antiarrhythmic medications. The primary </text>
<text top="376" left="111" width="321" height="17" font="17">outcome, a composite of death, VT storm, or </text>
<text top="394" left="111" width="321" height="17" font="17">ICD shocks occurred in 59.1% in the ablation </text>
<text top="412" left="111" width="322" height="17" font="17">group and in 68.5% in the escalated-therapy </text>
<text top="430" left="111" width="324" height="17" font="17">group. There was no difference in mortality </text>
<text top="448" left="111" width="320" height="17" font="17">between the groups. Recurrent ICD shocks and </text>
<text top="466" left="111" width="320" height="17" font="17">VT storm and treatment-related adverse events </text>
<text top="485" left="111" width="319" height="17" font="17">were lower in the ablation group. In a subgroup </text>
<text top="503" left="111" width="319" height="17" font="17">analysis, patients having VT on amiodarone had </text>
<text top="521" left="111" width="321" height="17" font="17">better outcomes with ablation compared with </text>
<text top="539" left="111" width="326" height="17" font="17">increasing amiodarone or adding mexiletine </text>
<text top="557" left="111" width="314" height="17" font="17">to amiodarone. For patients receiving medica-</text>
<text top="575" left="111" width="314" height="17" font="17">tions other than amiodarone, catheter abla-</text>
<text top="593" left="111" width="321" height="17" font="17">tion did not reduce the risk of ICD shocks or </text>
<text top="611" left="111" width="314" height="17" font="17">VT storm compared with switching to amioda-</text>
<text top="629" left="111" width="314" height="17" font="17">rone. Although recurrent VT after catheter abla-</text>
<text top="647" left="111" width="282" height="17" font="17">tion is associated with increased mortality,</text>
<text top="648" left="393" width="32" height="10" font="19">S7.1.3-9</text>
<text top="647" left="425" width="4" height="17" font="17"> </text>
<text top="665" left="111" width="314" height="17" font="17">whether mortality is reduced by catheter abla-</text>
<text top="683" left="111" width="314" height="17" font="17">tion has not been established. Procedural com-</text>
<text top="701" left="111" width="317" height="17" font="17">plications occur in approximately 6% of patients, </text>
<text top="719" left="111" width="319" height="17" font="17">most of which are related to vascular access but </text>
<text top="737" left="111" width="323" height="17" font="17">stroke, tamponade, and atrioventricular block </text>
<text top="755" left="111" width="314" height="17" font="17">can occur. Procedure mortality is &lt;1% in experi-</text>
<text top="773" left="111" width="94" height="17" font="17">enced centers.</text>
<text top="774" left="206" width="67" height="10" font="19">S7.1.3-4,S7.1.3-9</text>
<text top="791" left="129" width="303" height="17" font="17">Sustained monomorphic VT often occurs as </text>
<text top="809" left="111" width="324" height="17" font="17">occasional isolated episodes in patients with </text>
<text top="827" left="111" width="322" height="17" font="17">prior MI. Several nonrandomized studies have </text>
<text top="845" left="111" width="320" height="17" font="17">shown that catheter ablation reduces recurrent </text>
<text top="863" left="111" width="120" height="17" font="17">VT or ICD shocks.</text>
<text top="864" left="231" width="102" height="10" font="19">S7.1.3-5,S7.1.3-7,S7.1.3-8</text>
<text top="863" left="333" width="92" height="17" font="17"> A meta-anal-</text>
<text top="881" left="111" width="188" height="17" font="17">ysis of 5 VT ablation studies</text>
<text top="882" left="299" width="32" height="10" font="19">S7.1.3-5</text>
<text top="881" left="332" width="99" height="17" font="17"> reported that </text>
<text top="899" left="111" width="321" height="17" font="17">VT recurred in 35% of patients after catheter </text>
<text top="917" left="111" width="319" height="17" font="17">ablation compared with 55% on antiarrhythmic </text>
<text top="936" left="111" width="320" height="17" font="17">medications. In a multicenter study of catheter </text>
<text top="954" left="111" width="53" height="17" font="17">ablation</text>
<text top="954" left="164" width="32" height="10" font="19">S7.1.3-7</text>
<text top="954" left="196" width="236" height="17" font="17"> for patients with  ≥3 episodes of </text>
<text top="972" left="111" width="320" height="17" font="17">sustained VT in the prior 6 months, 53% were </text>
<text top="990" left="111" width="320" height="17" font="17">free from recurrent VT at 6 months follow-up; </text>
<text top="1008" left="111" width="318" height="17" font="17">the median number of VT episodes was reduced </text>
<text top="1026" left="111" width="314" height="17" font="17">from 11.5 to 0. Superiority of ablation over es-</text>
<text top="1044" left="111" width="321" height="17" font="17">calating medication therapy was shown in the </text>
<text top="1062" left="111" width="319" height="17" font="17">composite endpoint of death, VT storm, or ICD </text>
<text top="1080" left="111" width="176" height="17" font="17">shocks by the VANISH trial.</text>
<text top="1081" left="288" width="32" height="10" font="19">S7.1.3-4</text>
<text top="88" left="467" width="344" height="17" font="17">3. Patients with prior MI who develop sustained </text>
<text top="106" left="489" width="319" height="17" font="17">monomorphic VT often have recurrent episodes. </text>
<text top="124" left="489" width="320" height="17" font="17">The VTACH (Ventricular Tachycardia Ablation in </text>
<text top="142" left="489" width="317" height="17" font="17">Addition to Implantable Defibrillators in Coronary </text>
<text top="160" left="489" width="131" height="17" font="17">Heart Disease) trial</text>
<text top="160" left="620" width="37" height="10" font="19">S7.1.3-11</text>
<text top="160" left="657" width="156" height="17" font="17"> randomized patients </text>
<text top="178" left="489" width="318" height="17" font="17">undergoing ICD implantation for stable sustained </text>
<text top="196" left="489" width="314" height="17" font="17">monomorphic VT, who had not failed antiarrhyth-</text>
<text top="214" left="489" width="314" height="17" font="17">mic medication therapy, to catheter ablation ver-</text>
<text top="232" left="489" width="320" height="17" font="17">sus ICD implantation alone. At 2 years, any VT </text>
<text top="250" left="489" width="320" height="17" font="17">had recurred in 53% of the ablation group and </text>
<text top="268" left="489" width="321" height="17" font="17">71% of the control group. Ablation prolonged </text>
<text top="286" left="489" width="320" height="17" font="17">the time to recurrent VT from a median of 5.9 </text>
<text top="304" left="489" width="179" height="17" font="17">months to 18.6 months.</text>
<text top="305" left="668" width="37" height="10" font="19">S7.1.3-11</text>
<text top="304" left="705" width="98" height="17" font="17"> Several non-</text>
<text top="322" left="489" width="322" height="17" font="17">randomized studies have shown that catheter </text>
<text top="340" left="489" width="320" height="17" font="17">ablation reduces the risk of recurrent VT or ICD </text>
<text top="358" left="489" width="321" height="17" font="17">shocks in patients with sustained VT related to </text>
<text top="376" left="489" width="58" height="17" font="17">prior MI.</text>
<text top="377" left="547" width="101" height="10" font="19">S7.1.3-5,S7.1.3-7,S7.1.3-8</text>
<text top="376" left="648" width="162" height="17" font="17"> In a multicenter study </text>
<text top="394" left="489" width="135" height="17" font="17">of catheter ablation</text>
<text top="395" left="624" width="32" height="10" font="19">S7.1.3-7</text>
<text top="394" left="656" width="152" height="17" font="17"> for patients with  ≥3 </text>
<text top="412" left="489" width="320" height="17" font="17">episodes of sustained VT in the prior 6 months, </text>
<text top="430" left="489" width="314" height="17" font="17">53% were free from recurrent VT at 6 months fol-</text>
<text top="448" left="489" width="319" height="17" font="17">low-up; the median number of VT episodes was </text>
<text top="466" left="489" width="319" height="17" font="17">reduced from 11.5 to 0. A meta-analysis of 5 VT </text>
<text top="485" left="489" width="104" height="17" font="17">ablation studies</text>
<text top="485" left="593" width="32" height="10" font="19">S7.1.3-5</text>
<text top="484" left="625" width="185" height="17" font="17"> reported that VT recurred </text>
<text top="503" left="489" width="314" height="17" font="17">in 35% of patients after catheter ablation com-</text>
<text top="521" left="489" width="319" height="17" font="17">pared with 55% on antiarrhythmic medications. </text>
<text top="539" left="489" width="320" height="17" font="17">Another study of 63 patients with recurrent VT </text>
<text top="557" left="489" width="314" height="17" font="17">after MI demonstrated acute success with cath-</text>
<text top="575" left="489" width="319" height="17" font="17">eter ablation in 83% of mappable VTs and 40% </text>
<text top="593" left="489" width="136" height="17" font="17">of nonmappable VTs.</text>
<text top="593" left="625" width="32" height="10" font="19">S7.1.3-8</text>
<text top="593" left="657" width="150" height="17" font="17"> Superiority of ablation </text>
<text top="611" left="489" width="321" height="17" font="17">over escalating medication therapy for patients </text>
<text top="629" left="489" width="314" height="17" font="17">with recurrent VT despite antiarrhythmic medica-</text>
<text top="647" left="489" width="253" height="17" font="17">tions was shown by the VANISH trial.</text>
<text top="648" left="742" width="32" height="10" font="19">S7.1.3-4</text>
<text top="647" left="774" width="36" height="17" font="17"> See </text>
<text top="665" left="489" width="77" height="17" font="17">Section 5.6.</text>
<text top="683" left="467" width="57" height="17" font="17">4. CAST</text>
<text top="684" left="524" width="36" height="10" font="19">S7.1.3-21</text>
<text top="683" left="560" width="243" height="17" font="17"> demonstrated higher rates of mortal-</text>
<text top="701" left="489" width="320" height="17" font="17">ity or nonfatal cardiac arrest in post-MI patients </text>
<text top="719" left="489" width="321" height="17" font="17">treated with encainide or flecainide when used </text>
<text top="737" left="489" width="179" height="17" font="17">to suppress PVCs and NSVT.</text>
<text top="738" left="668" width="36" height="10" font="19">S7.1.3-13</text>
<text top="737" left="704" width="103" height="17" font="17"> Propafenone is </text>
<text top="755" left="489" width="314" height="17" font="17">associated with increased mortality in SCA survi-</text>
<text top="773" left="489" width="320" height="17" font="17">vors compared  with beta blockers, amiodarone, </text>
<text top="791" left="489" width="81" height="17" font="17">and the ICD.</text>
<text top="792" left="570" width="36" height="10" font="19">S7.1.3-22</text>
<text top="809" left="467" width="336" height="17" font="17">5.  Implantation of an ICD prior to achieving sup-</text>
<text top="827" left="489" width="320" height="17" font="17">pression of frequent or incessant VA places the </text>
<text top="845" left="489" width="318" height="17" font="17">patient at high risk of repetitive shocks, which can </text>
<text top="863" left="489" width="314" height="17" font="17">be psychologically detrimental and has been asso-</text>
<text top="881" left="489" width="198" height="17" font="17">ciated with increased mortality.</text>
<text top="882" left="687" width="75" height="10" font="19">S7.1.3-23,S7.1.3-24</text>
<text top="899" left="467" width="344" height="17" font="17">6. Sustained monomorphic VT in the setting of </text>
<text top="917" left="489" width="321" height="17" font="17">prior MI is typically due to scar-related reentry </text>
<text top="936" left="489" width="321" height="17" font="17">and is not due to acute ischemia. Although it </text>
<text top="954" left="489" width="314" height="17" font="17">may be appropriate to recommend revascular-</text>
<text top="972" left="489" width="314" height="17" font="17">ization when another indication for revascular-</text>
<text top="990" left="489" width="320" height="17" font="17">ization exists, revascularization alone is unlikely </text>
<text top="1008" left="489" width="322" height="17" font="17">to reduce the recurrence of monomorphic VT </text>
<text top="1026" left="489" width="323" height="17" font="17">and specific therapies such as antiarrhythmic </text>
<text top="1044" left="489" width="314" height="17" font="17">medications or ablation may be needed to pre-</text>
<text top="1062" left="489" width="106" height="17" font="17">vent recurrence.</text>
<text top="1062" left="595" width="37" height="10" font="19">S7.1.3-16</text>
<text top="1062" left="632" width="171" height="17" font="17"> On the contrary, revascu-</text>
<text top="1080" left="489" width="322" height="17" font="17">larization might be beneficial in patients with </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e308</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="320" height="17" font="17">ischemic heart disease and VF, polymorphic VT, </text>
<text top="106" left="111" width="319" height="17" font="17">or exercise-induced arrhythmias associated with </text>
<text top="125" left="111" width="60" height="17" font="17">ischemia.</text>
<text top="126" left="172" width="37" height="10" font="19">S7.1.3-25</text>
<text top="166" left="74" width="287" height="21" font="18"><b>7.2. Nonischemic Cardiomyopathy</b></text>
<text top="201" left="85" width="208" height="12" font="26"><b>Recommendations for Patients With NICM</b></text>
<text top="218" left="85" width="250" height="12" font="26"><b>References that support the recommendations are </b></text>
<text top="231" left="85" width="75" height="12" font="26"><a href=""><b>summarized in </b></a></text>
<text top="231" left="160" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 24</b></a></text>
<text top="231" left="296" width="3" height="12" font="26"><b>.</b></text>
<text top="252" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="252" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="252" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="300" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="300" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="273" left="205" width="160" height="12" font="4">1.  In patients with suspected NICM </text>
<text top="286" left="217" width="123" height="12" font="4">from myocardial infiltrative </text>
<text top="300" left="217" width="145" height="12" font="4">processes, cardiac MRI with late </text>
<text top="313" left="217" width="172" height="12" font="4">gadolinium enhancement is useful for </text>
<text top="327" left="217" width="44" height="12" font="4">diagnosis.</text>
<text top="327" left="261" width="37" height="7" font="23">S7.2-1–S7.2-3</text>
<text top="368" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="368" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="348" left="205" width="163" height="12" font="4">2.  In patients with suspected NICM, </text>
<text top="361" left="217" width="150" height="12" font="4">cardiac MRI with late gadolinium </text>
<text top="375" left="217" width="142" height="12" font="4">enhancement can be useful for </text>
<text top="388" left="217" width="118" height="12" font="4">assessing risk of SCA/SCD.</text>
<text top="389" left="335" width="37" height="7" font="23">S7.2-1–S7.2-3</text>
<text top="470" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="470" left="152" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="409" left="205" width="173" height="12" font="4">3.  In patients with NICM who develop </text>
<text top="422" left="217" width="168" height="12" font="4">conduction disease or LV dysfunction </text>
<text top="436" left="217" width="163" height="12" font="4">at less than 40 years of age, or who </text>
<text top="449" left="217" width="148" height="12" font="4">have a family history of NICM or </text>
<text top="463" left="217" width="154" height="12" font="4">SCD in a first-degree relative (&lt;50 </text>
<text top="476" left="217" width="149" height="12" font="4">years of age), genetic counseling </text>
<text top="490" left="217" width="169" height="12" font="4">and genetic testing are reasonable to </text>
<text top="503" left="217" width="159" height="12" font="4">detect a heritable disease that may </text>
<text top="517" left="217" width="174" height="12" font="4">clarify prognosis and facilitate cascade </text>
<text top="530" left="217" width="96" height="12" font="4">screening of relatives.</text>
<text top="531" left="313" width="36" height="7" font="23">S7.2-4,S7.2-5</text>
<text top="571" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="593" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="621" left="89" width="343" height="17" font="17">1.  Cardiac MRI allows for evaluation of structural </text>
<text top="639" left="111" width="314" height="17" font="17">heart disease and assessment of LV and RV func-</text>
<text top="658" left="111" width="323" height="17" font="17">tion including quantification of LVEF, LV mass </text>
<text top="677" left="111" width="320" height="17" font="17">and volume, and valvular structure. Cardiac MRI </text>
<text top="695" left="111" width="314" height="17" font="17">can help in the evaluation for myocardial infil-</text>
<text top="714" left="111" width="320" height="17" font="17">trative processes and evidence of scar, indicated </text>
<text top="733" left="111" width="321" height="17" font="17">by delayed hyperenhancement, associated with </text>
<text top="752" left="111" width="23" height="17" font="17">VA.</text>
<text top="752" left="134" width="80" height="10" font="19">S7.2-1–S7.2-4,S7.2-6</text>
<text top="770" left="89" width="341" height="17" font="17">2.  The presence of delayed hyperenhancement has </text>
<text top="789" left="111" width="319" height="17" font="17">been associated with worse outcomes, including </text>
<text top="808" left="111" width="32" height="17" font="17">SCD.</text>
<text top="808" left="143" width="53" height="10" font="19">S7.2-1–S7.2-3</text>
<text top="826" left="89" width="342" height="17" font="17">3.  It is important to consider genetic etiologies for </text>
<text top="845" left="111" width="323" height="17" font="17">NICM. Goals of genetic testing for NICM are </text>
<text top="864" left="111" width="314" height="17" font="17">to identify at-risk relatives who host a disease-</text>
<text top="883" left="111" width="321" height="17" font="17">causing mutation and to help clarify prognosis. </text>
<text top="901" left="111" width="230" height="18" font="21"><i>Lamin A/C</i> and <i>NKX 2.5</i> mutations</text>
<text top="902" left="341" width="58" height="10" font="19">S7.2-7–S7.2-12</text>
<text top="901" left="399" width="32" height="17" font="17"> are </text>
<text top="920" left="111" width="321" height="17" font="17">associated with a particularly high risk of early </text>
<text top="939" left="111" width="321" height="17" font="17">conduction disease, arrhythmias, and SCD, and </text>
<text top="957" left="111" width="321" height="17" font="17">their identification often prompts consideration </text>
<text top="976" left="111" width="320" height="17" font="17">of early use of an ICD. It is unknown, however, </text>
<text top="995" left="111" width="327" height="17" font="17">whether early pharmacological treatment of </text>
<text top="1014" left="111" width="326" height="17" font="17">mutation-positive, asymptomatic subjects can </text>
<text top="1032" left="111" width="323" height="17" font="17">prevent or delay manifestation of the disease </text>
<text top="1051" left="111" width="322" height="17" font="17">or whether genetic testing ultimately improves </text>
<text top="1070" left="111" width="51" height="17" font="17">survival.</text>
<text top="87" left="452" width="330" height="18" font="24"><i><b>7.2.1. Secondary Prevention of SCD in Patients </b></i></text>
<text top="106" left="452" width="77" height="18" font="24"><i><b>With NICM</b></i></text>
<text top="134" left="463" width="313" height="12" font="26"><b>Recommendations for Secondary Prevention of SCD in Patients </b></text>
<text top="148" left="463" width="54" height="12" font="26"><b>With NICM</b></text>
<text top="161" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="175" left="463" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 25 and 26</b></a></text>
<text top="175" left="640" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="196" left="475" width="21" height="12" font="22"><b>COR</b></text>
<text top="196" left="536" width="19" height="12" font="22"><b>LOE</b></text>
<text top="196" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="257" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="232" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="217" left="583" width="217" height="12" font="4">1.  In patients with NICM who either survive SCA </text>
<text top="230" left="594" width="202" height="12" font="4">due to VT/VF or experience hemodynamically </text>
<text top="244" left="594" width="102" height="12" font="4">unstable VT (LOE: B-R) </text>
<text top="244" left="696" width="47" height="7" font="23">S7.2.1-1–S7.2.1-4</text>
<text top="244" left="743" width="44" height="12" font="4"> or stable </text>
<text top="257" left="594" width="113" height="12" font="4">sustained VT (LOE: B-NR) </text>
<text top="258" left="707" width="22" height="7" font="23">S7.2.1-5</text>
<text top="257" left="729" width="53" height="12" font="4"> not due to </text>
<text top="271" left="594" width="188" height="12" font="4">reversible causes, an ICD is recommended </text>
<text top="284" left="594" width="194" height="12" font="4">if meaningful survival greater than 1 year is </text>
<text top="298" left="594" width="43" height="12" font="4">expected.</text>
<text top="283" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="366" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="366" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="319" left="583" width="186" height="12" font="4">2.  In patients with NICM who experience </text>
<text top="332" left="595" width="160" height="12" font="4">syncope presumed to be due to VA </text>
<text top="346" left="595" width="167" height="12" font="4">and who do not meet indications for </text>
<text top="359" left="595" width="163" height="12" font="4">a primary prevention ICD, an ICD or </text>
<text top="373" left="595" width="165" height="12" font="4">an electrophysiological study for risk </text>
<text top="386" left="595" width="183" height="12" font="4">stratification for SCD can be beneficial if </text>
<text top="400" left="595" width="187" height="12" font="4">meaningful survival greater than 1 year is </text>
<text top="413" left="595" width="43" height="12" font="4">expected.</text>
<text top="414" left="638" width="51" height="7" font="23">S7.2.1-6–S7.2.1-11</text>
<text top="474" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="474" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="434" left="583" width="177" height="12" font="4">3.  In patients with NICM who survive a </text>
<text top="447" left="595" width="186" height="12" font="4">cardiac arrest, have sustained VT, or have </text>
<text top="461" left="595" width="188" height="12" font="4">symptomatic VA who are ineligible for an </text>
<text top="474" left="595" width="185" height="12" font="4">ICD (due to a limited life-expectancy and/</text>
<text top="488" left="595" width="191" height="12" font="4">or functional status or lack of access to an </text>
<text top="501" left="595" width="184" height="12" font="4">ICD), amiodarone may be considered for </text>
<text top="515" left="595" width="85" height="12" font="4">prevention of SCD.</text>
<text top="515" left="680" width="53" height="7" font="23">S7.2.1-12,S7.2.1-13</text>
<text top="555" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="577" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="605" left="467" width="342" height="17" font="17">1.  Three prospective RCTs compared the ICD with </text>
<text top="623" left="489" width="320" height="17" font="17">pharmacological therapy in patients resuscitated </text>
<text top="642" left="489" width="314" height="17" font="17">from SCA due to VT/VF or hemodynamically sig-</text>
<text top="661" left="489" width="78" height="17" font="17">nificant VT.</text>
<text top="661" left="567" width="97" height="10" font="19">S7.2.1-1,S7.2.1-2,S7.2.1-4</text>
<text top="661" left="664" width="152" height="17" font="17"> The antiarrhythmic </text>
<text top="679" left="489" width="314" height="17" font="17">medications most commonly used were amio-</text>
<text top="698" left="489" width="320" height="17" font="17">darone, a beta blocker, or both, although in the </text>
<text top="716" left="489" width="283" height="17" font="17">CASH (Cardiac Arrest Study Hamburg) trial,</text>
<text top="717" left="772" width="32" height="10" font="19">S7.2.1-4</text>
<text top="716" left="803" width="4" height="17" font="17"> </text>
<text top="735" left="489" width="314" height="17" font="17">there was also a propafenone arm that was termi-</text>
<text top="754" left="489" width="314" height="17" font="17">nated early due to increased mortality. The 3 tri-</text>
<text top="772" left="489" width="319" height="17" font="17">als enrolled 1963 patients, but only 292 (14.8%) </text>
<text top="791" left="489" width="321" height="17" font="17">had NICM. A meta-analysis in which data from </text>
<text top="809" left="489" width="314" height="17" font="17">AVID and CIDS were pooled found a nonsignifi-</text>
<text top="828" left="489" width="319" height="17" font="17">cant 31% reduction in all-cause mortality relative </text>
<text top="847" left="489" width="283" height="17" font="17">to medical therapy in patients with NICM.</text>
<text top="847" left="772" width="32" height="10" font="19">S7.2.1-3</text>
<text top="847" left="803" width="4" height="17" font="17"> </text>
<text top="865" left="489" width="322" height="17" font="17">Although this analysis was underpowered, the </text>
<text top="884" left="489" width="319" height="17" font="17">observed mortality reduction was consistent with </text>
<text top="902" left="489" width="314" height="17" font="17">the observed benefit in the entire study popula-</text>
<text top="921" left="489" width="150" height="17" font="17">tion. In the AVID trial,</text>
<text top="922" left="640" width="32" height="10" font="19">S7.2.1-1</text>
<text top="921" left="671" width="139" height="17" font="17"> patients who were </text>
<text top="940" left="489" width="319" height="17" font="17">ineligible for the RCT were included in a registry, </text>
<text top="958" left="489" width="321" height="17" font="17">and sustained VT without serious symptoms or </text>
<text top="977" left="489" width="321" height="17" font="17">hemodynamic compromise was associated with </text>
<text top="995" left="489" width="321" height="17" font="17">a mortality rate similar to that of patients with </text>
<text top="1014" left="489" width="314" height="17" font="17">unstable VT who were assigned to medical ther-</text>
<text top="1033" left="489" width="320" height="17" font="17">apy. Therefore, stable VT is likely a marker for a </text>
<text top="1051" left="489" width="318" height="17" font="17">substrate capable of producing subsequent lethal </text>
<text top="1070" left="489" width="79" height="17" font="17">arrhythmias.</text>
<text top="1070" left="568" width="32" height="10" font="19">S7.2.1-5</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e309</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="89" width="344" height="17" font="17">2. Small observational studies demonstrated high </text>
<text top="106" left="111" width="318" height="17" font="17">mortality and frequent appropriate ICD shocks in </text>
<text top="124" left="111" width="217" height="17" font="17">patients with syncope and NICM.</text>
<text top="124" left="329" width="68" height="10" font="19">S7.2.1-7–S7.2.1-9</text>
<text top="124" left="397" width="33" height="17" font="17"> The </text>
<text top="142" left="111" width="316" height="17" font="17">assumption that malignant VAs are the likely cause </text>
<text top="160" left="111" width="314" height="17" font="17">of syncope and that the ICD would be protec-</text>
<text top="178" left="111" width="319" height="17" font="17">tive has recently been challenged. In a subgroup </text>
<text top="196" left="111" width="318" height="17" font="17">analysis of SCD-HeFT that included 472 patients, </text>
<text top="214" left="111" width="319" height="17" font="17">the ICD did not reduce either recurrent syncope </text>
<text top="232" left="111" width="324" height="17" font="17">or the increased risk of mortality associated </text>
<text top="250" left="111" width="91" height="17" font="17">with syncope.</text>
<text top="251" left="202" width="37" height="10" font="19">S7.2.1-10</text>
<text top="250" left="239" width="192" height="17" font="17"> A subgroup analysis of the </text>
<text top="268" left="111" width="323" height="17" font="17">MADIT-RIT (Multicenter Automatic Defibrillator </text>
<text top="286" left="111" width="318" height="17" font="17">Implantation Trial-Reduce Inappropriate Therapy) </text>
<text top="304" left="111" width="318" height="17" font="17">trial found syncope to be arrhythmic only in 39% </text>
<text top="322" left="111" width="79" height="17" font="17">of patients.</text>
<text top="323" left="190" width="37" height="10" font="19">S7.2.1-11</text>
<text top="322" left="227" width="208" height="17" font="17"> These studies suggest that </text>
<text top="340" left="111" width="314" height="17" font="17">syncope in some HF patients may be an indica-</text>
<text top="358" left="111" width="321" height="17" font="17">tor of an end-stage cardiomyopathy associated </text>
<text top="376" left="111" width="156" height="17" font="17">with a poor prognosis.</text>
<text top="377" left="267" width="37" height="10" font="19">S7.2.1-11</text>
<text top="376" left="304" width="129" height="17" font="17"> In a substudy of </text>
<text top="394" left="111" width="318" height="17" font="17">DEFINITE, inducible sustained VT/VF was found in </text>
<text top="412" left="111" width="318" height="17" font="17">a minority of patients, but it was associated with </text>
<text top="430" left="111" width="170" height="17" font="17">appropriate ICD therapy.</text>
<text top="431" left="281" width="37" height="10" font="19">S7.2.1-14</text>
<text top="430" left="318" width="117" height="17" font="17"> Another study </text>
<text top="448" left="111" width="323" height="17" font="17">of electrophysiological testing in NICM found </text>
<text top="466" left="111" width="323" height="17" font="17">inducible VT/VF in 27.8% of patients, which </text>
<text top="484" left="111" width="259" height="17" font="17">was associated with future ICD events.</text>
<text top="485" left="371" width="37" height="10" font="19">S7.2.1-15</text>
<text top="484" left="407" width="24" height="17" font="17"> In </text>
<text top="503" left="111" width="319" height="17" font="17">a study of patients with NICM, cardiac mortality </text>
<text top="521" left="111" width="319" height="17" font="17">correlated with LVEF but not with inducibility on </text>
<text top="539" left="111" width="170" height="17" font="17">electrophysiological study.</text>
<text top="539" left="281" width="37" height="10" font="19">S7.2.1-16</text>
<text top="539" left="318" width="114" height="17" font="17"> Based on these </text>
<text top="557" left="111" width="314" height="17" font="17">data, many experts are uncomfortable withhold-</text>
<text top="575" left="111" width="314" height="17" font="17">ing an ICD from patients with NICM who expe-</text>
<text top="593" left="111" width="321" height="17" font="17">rience syncope potentially due to a VA even if </text>
<text top="611" left="111" width="318" height="17" font="17">the electrophysiological study shows no inducible </text>
<text top="629" left="111" width="84" height="17" font="17">sustained VT.</text>
<text top="647" left="89" width="336" height="17" font="17">3.  Access to ICDs may be limited by financial, medi-</text>
<text top="665" left="111" width="321" height="17" font="17">cal, or personal considerations. In addition, not </text>
<text top="683" left="111" width="314" height="17" font="17">all patients at high risk of SCD meet ICD indica-</text>
<text top="701" left="111" width="319" height="17" font="17">tions, such as those with class IV HF without CRT </text>
<text top="719" left="111" width="321" height="17" font="17">possibility or with a life expectancy  &lt;1 year. A </text>
<text top="737" left="111" width="318" height="17" font="17">meta-analysis of RCTs, which examined the use of </text>
<text top="755" left="111" width="319" height="17" font="17">amiodarone for the prevention of SCD, included </text>
<text top="773" left="111" width="314" height="17" font="17">15 studies with 8522 patients assigned to amio-</text>
<text top="791" left="111" width="186" height="17" font="17">darone or placebo/control.</text>
<text top="792" left="297" width="36" height="10" font="19">S7.2.1-12</text>
<text top="791" left="334" width="104" height="17" font="17"> Amiodarone </text>
<text top="809" left="111" width="322" height="17" font="17">reduced the risk of SCD by 29%; however, it </text>
<text top="827" left="111" width="314" height="17" font="17">did not reduce all-cause mortality and was asso-</text>
<text top="845" left="111" width="321" height="17" font="17">ciated with an increased risk of pulmonary and </text>
<text top="863" left="111" width="314" height="17" font="17">thyroid toxicity. In a subgroup analysis, the ben-</text>
<text top="881" left="111" width="321" height="17" font="17">efit of amiodarone appeared similar in patients </text>
<text top="899" left="111" width="323" height="17" font="17">with ischemic cardiomyopathy and those with </text>
<text top="917" left="111" width="41" height="17" font="17">NICM.</text>
<text top="918" left="152" width="36" height="10" font="19">S7.2.1-12</text>
<text top="917" left="188" width="200" height="17" font="17"> In a separate meta-analysis,</text>
<text top="918" left="389" width="36" height="10" font="19">S7.2.1-13</text>
<text top="917" left="425" width="4" height="17" font="17"> </text>
<text top="936" left="111" width="314" height="17" font="17">the evidence was insufficent to support amioda-</text>
<text top="954" left="111" width="319" height="17" font="17">rone’s efficacy for reduction of SCD and all-cause </text>
<text top="972" left="111" width="321" height="17" font="17">mortality in  survivors of cardiac arrest or those </text>
<text top="990" left="111" width="322" height="17" font="17">with syncope due to VA. A subgroup analysis </text>
<text top="1008" left="111" width="321" height="17" font="17">of the VALIANT (Valsartan in Acute Myocardial </text>
<text top="1026" left="111" width="314" height="17" font="17">Infarction) trial found that amiodarone was asso-</text>
<text top="1044" left="111" width="321" height="17" font="17">ciated with increased mortality in patients with </text>
<text top="1062" left="111" width="110" height="17" font="17">NYHA class III HF.</text>
<text top="1062" left="221" width="36" height="10" font="19">S7.2.1-17</text>
<text top="1062" left="257" width="168" height="17" font="17"> These data call for a care-</text>
<text top="1080" left="111" width="320" height="17" font="17">ful and nuanced approach to using amiodarone </text>
<text top="88" left="489" width="320" height="17" font="17">for the secondary prevention of SCD in patients </text>
<text top="106" left="489" width="73" height="17" font="17">with NICM.</text>
<text top="136" left="452" width="349" height="18" font="24"><i><b>7.2.2. Primary Prevention of SCD in Patients With </b></i></text>
<text top="154" left="452" width="38" height="18" font="24"><i><b>NICM</b></i></text>
<text top="182" left="463" width="327" height="12" font="26"><b>Recommendations for Primary Prevention of SCD in Patients With </b></text>
<text top="195" left="463" width="27" height="12" font="26"><b>NICM</b></text>
<text top="212" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="226" left="463" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 27 and 28</b></a></text>
<text top="226" left="640" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="247" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="247" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="247" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="295" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="295" left="539" width="8" height="12" font="22"><b>A</b></text>
<text top="268" left="583" width="207" height="12" font="4">1.  In patients with NICM, HF with NYHA class </text>
<text top="281" left="595" width="196" height="12" font="4">II–III symptoms and an LVEF of 35% or less, </text>
<text top="295" left="595" width="188" height="12" font="4">despite GDMT, an ICD is recommended if </text>
<text top="308" left="595" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="322" left="595" width="43" height="12" font="4">expected.</text>
<text top="322" left="638" width="47" height="7" font="23">S7.2.2-1–S7.2.2-6</text>
<text top="376" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="376" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="342" left="583" width="202" height="12" font="4">2.  In patients with NICM due to a <i>Lamin A/C</i> </text>
<text top="356" left="595" width="189" height="12" font="4">mutation who have 2 or more risk factors </text>
<text top="369" left="595" width="196" height="12" font="4">(NSVT, LVEF &lt;45%, nonmissense mutation, </text>
<text top="383" left="595" width="187" height="12" font="4">and male sex), an ICD can be beneficial if </text>
<text top="397" left="595" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="410" left="595" width="43" height="12" font="4">expected.</text>
<text top="410" left="638" width="51" height="7" font="23">S7.2.2-7–S7.2.2-10</text>
<text top="458" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="458" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="431" left="583" width="207" height="12" font="4">3.  In patients with NICM, HF with NYHA class </text>
<text top="444" left="595" width="182" height="12" font="4">I symptoms and an LVEF of 35% or less, </text>
<text top="458" left="595" width="198" height="12" font="4">despite GDMT, an ICD may be considered if </text>
<text top="471" left="595" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="485" left="595" width="43" height="12" font="4">expected.</text>
<text top="485" left="638" width="22" height="7" font="23">S7.2.2-5</text>
<text top="533" left="468" width="32" height="12" font="22"><b>III: No </b></text>
<text top="546" left="465" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="539" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="506" left="583" width="213" height="12" font="4">4.  In patients with medication-refractory NYHA </text>
<text top="519" left="595" width="194" height="12" font="4">class IV HF who are not also candidates for </text>
<text top="533" left="595" width="193" height="12" font="4">cardiac transplantation, an LVAD, or a CRT </text>
<text top="546" left="595" width="190" height="12" font="4">defibrillator that incorporates both pacing </text>
<text top="560" left="595" width="200" height="12" font="4">and defibrillation capabilities, an ICD should </text>
<text top="573" left="595" width="80" height="12" font="4">not be implanted.</text>
<text top="613" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="634" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="662" left="467" width="342" height="17" font="17">1.  For all patients with NICM, it is imperative that </text>
<text top="680" left="489" width="318" height="17" font="17">patients be on GDMT for HF for at least 3 months </text>
<text top="698" left="489" width="320" height="17" font="17">before a primary prevention ICD is offered. Four </text>
<text top="716" left="489" width="119" height="17" font="17">prospective RCTs</text>
<text top="717" left="608" width="134" height="10" font="19">S7.2.2-1,S7.2.2-2,S7.2.2-5,S7.2.2-6</text>
<text top="716" left="742" width="78" height="17" font="17"> initially </text>
<text top="734" left="489" width="319" height="17" font="17">evaluated ICDs for primary prevention of SCD in </text>
<text top="753" left="489" width="169" height="17" font="17">patients with NICM. Two</text>
<text top="753" left="658" width="66" height="10" font="19">S7.2.2-2,S7.2.2-6</text>
<text top="753" left="724" width="87" height="17" font="17"> were small </text>
<text top="771" left="489" width="320" height="17" font="17">studies that were terminated early due to a low </text>
<text top="789" left="489" width="151" height="17" font="17">event rate. In DEFINITE,</text>
<text top="790" left="640" width="32" height="10" font="19">S7.2.2-5</text>
<text top="789" left="672" width="137" height="17" font="17"> an ICD reduced the </text>
<text top="807" left="489" width="314" height="17" font="17">risk of SCD, with a trend toward reduced all-</text>
<text top="825" left="489" width="322" height="17" font="17">cause mortality. SCD-HeFT included 792 NICM </text>
<text top="843" left="489" width="55" height="17" font="17">patients.</text>
<text top="844" left="544" width="32" height="10" font="19">S7.2.2-1</text>
<text top="843" left="576" width="232" height="17" font="17"> Total mortality at 5 years was 27% </text>
<text top="862" left="489" width="319" height="17" font="17">in the placebo group and 21% in the ICD group </text>
<text top="880" left="489" width="314" height="17" font="17">(<i>P</i> =0.06). A pooled analysis of these studies dem-</text>
<text top="898" left="489" width="318" height="17" font="17">onstrated a significant 31% reduction in all-cause </text>
<text top="916" left="489" width="283" height="17" font="17">mortality for ICD relative to medical therapy.</text>
<text top="917" left="772" width="32" height="10" font="19">S7.2.2-4</text>
<text top="916" left="803" width="4" height="17" font="17"> </text>
<text top="934" left="489" width="319" height="17" font="17">The DANISH (Danish Study to Assess the Efficacy </text>
<text top="953" left="489" width="322" height="17" font="17">of ICDs in Patients with Non-ischemic Systolic </text>
<text top="971" left="489" width="196" height="17" font="17">Heart Failure on Mortality) trial</text>
<text top="971" left="685" width="36" height="10" font="19">S7.2.2-11</text>
<text top="971" left="722" width="81" height="17" font="17"> raised ques-</text>
<text top="989" left="489" width="319" height="17" font="17">tions about the role of primary pevention ICDs in </text>
<text top="1007" left="489" width="320" height="17" font="17">patients with NICM. This trial randomized 1116 </text>
<text top="1025" left="489" width="321" height="17" font="17">patients with NICM LVEF  &lt;35% and class II, III, </text>
<text top="1043" left="489" width="321" height="17" font="17">or IV (if CRT was planned) HF to an ICD or no </text>
<text top="1062" left="489" width="314" height="17" font="17">ICD. CRT (either ICD or pacemaker) was pres-</text>
<text top="1080" left="489" width="321" height="17" font="17">ent in 58% of patients in the ICD and medical </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e310</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="321" height="17" font="17">therapy arms. Therefore, the results of DANISH </text>
<text top="106" left="111" width="319" height="17" font="17">should not be generalized to patients with NICM </text>
<text top="124" left="111" width="323" height="17" font="17">who are ineligible for CRT. During a median </text>
<text top="143" left="111" width="321" height="17" font="17">follow-up of 5.6 years, ICD reduced SCD from </text>
<text top="161" left="111" width="321" height="17" font="17">8.4% to 4.3%, but there was no difference in </text>
<text top="179" left="111" width="124" height="17" font="17">all-cause mortality.</text>
<text top="180" left="235" width="36" height="10" font="19">S7.2.2-11</text>
<text top="179" left="271" width="163" height="17" font="17"> Several meta-analyses </text>
<text top="198" left="111" width="142" height="17" font="17">have been published.</text>
<text top="199" left="253" width="75" height="10" font="19">S7.2.2-12,S7.2.2-13</text>
<text top="198" left="328" width="104" height="17" font="17"> One provided </text>
<text top="216" left="111" width="319" height="17" font="17">data on ICDs with and without CRT and showed </text>
<text top="235" left="111" width="196" height="17" font="17">survival benefit from the ICD.</text>
<text top="235" left="307" width="36" height="10" font="19">S7.2.2-13</text>
<text top="235" left="344" width="88" height="17" font="17"> The second </text>
<text top="253" left="111" width="319" height="17" font="17">used patient level data from 2 trials and adopted </text>
<text top="271" left="111" width="314" height="17" font="17">a more robust approach to reducing heterogene-</text>
<text top="290" left="111" width="314" height="17" font="17">ity by excluding patients with CRT and those ran-</text>
<text top="308" left="111" width="321" height="17" font="17">domized to antiarrhythmic medications; a 25% </text>
<text top="326" left="111" width="321" height="17" font="17">relative risk reduction in mortality with an ICD </text>
<text top="345" left="111" width="76" height="17" font="17">was shown.</text>
<text top="346" left="187" width="36" height="10" font="19">S7.2.2-12</text>
<text top="363" left="89" width="341" height="17" font="17">2.  Laminopathies are diseases caused by mutations </text>
<text top="382" left="111" width="317" height="17" font="17">mainly in the <i>Lamin A/C</i> gene that produce various </text>
<text top="400" left="111" width="318" height="17" font="17">inherited diseases including subtypes of muscular </text>
<text top="418" left="111" width="314" height="17" font="17">dystrophy and progeria. Isolated cardiac involve-</text>
<text top="437" left="111" width="319" height="17" font="17">ment is also observed and is an important cause </text>
<text top="455" left="111" width="180" height="17" font="17">of familial cardiomyopathy.</text>
<text top="456" left="291" width="32" height="10" font="19">S7.2.2-9</text>
<text top="455" left="323" width="110" height="17" font="17"> The disease is </text>
<text top="473" left="111" width="314" height="17" font="17">highly penetrant such that all affected individu-</text>
<text top="492" left="111" width="319" height="17" font="17">als have evidence of disease by 60 years of age. </text>
<text top="510" left="111" width="314" height="17" font="17">Cardiac manifestations may include atrial fibril-</text>
<text top="529" left="111" width="320" height="17" font="17">lation, conduction disturbances, VA, and NICM. </text>
<text top="547" left="111" width="323" height="17" font="17">A number of observational studies reported a </text>
<text top="565" left="111" width="322" height="17" font="17">high risk of SCD when cardiac involvement is </text>
<text top="584" left="111" width="51" height="17" font="17">present.</text>
<text top="584" left="162" width="72" height="10" font="19">S7.2.2-7–S7.2.2-10</text>
<text top="584" left="235" width="197" height="17" font="17"> One study reported SCD as </text>
<text top="602" left="111" width="319" height="17" font="17">the most frequent mode of death (46%) in both </text>
<text top="620" left="111" width="314" height="17" font="17">the isolated cardiac and the neuromuscular phe-</text>
<text top="639" left="111" width="167" height="17" font="17">notypes of <i>Lamin</i> diseases.</text>
<text top="640" left="278" width="32" height="10" font="19">S7.2.2-9</text>
<text top="639" left="310" width="119" height="17" font="17"> In a cohort of 269 </text>
<text top="657" left="111" width="237" height="18" font="21"><i>LMNA</i> mutation positive individuals,</text>
<text top="658" left="348" width="36" height="10" font="19">S7.2.2-10</text>
<text top="657" left="385" width="47" height="17" font="17"> NSVT </text>
<text top="676" left="111" width="314" height="17" font="17">during ambulatory electrocardiographic monitor-</text>
<text top="694" left="111" width="319" height="17" font="17">ing, LVEF &lt;45% at first evaluation, male sex, and </text>
<text top="712" left="111" width="323" height="17" font="17">nonmissense mutations were independent risk </text>
<text top="731" left="111" width="319" height="17" font="17">factors for VA. Malignant VA were observed only </text>
<text top="749" left="111" width="255" height="17" font="17">in persons with ≥2 of these risk factors.</text>
<text top="750" left="366" width="36" height="10" font="19">S7.2.2-10</text>
<text top="749" left="402" width="27" height="17" font="17"> No </text>
<text top="767" left="111" width="314" height="17" font="17">studies have tested the effect of the ICD on long-</text>
<text top="786" left="111" width="85" height="17" font="17">term survival.</text>
<text top="804" left="89" width="340" height="17" font="17">3.  Patients with NICM and class I HF symptoms were </text>
<text top="823" left="111" width="244" height="17" font="17">not included in SCD-HeFT or DANISH.</text>
<text top="823" left="355" width="70" height="10" font="19">S7.2.2-1,S7.2.2-11</text>
<text top="823" left="425" width="4" height="17" font="17"> </text>
<text top="841" left="111" width="324" height="17" font="17">Although such patients were included in the </text>
<text top="859" left="111" width="318" height="17" font="17">DEFINITE trial, only 99 (21.6%) of 458 patients in </text>
<text top="878" left="111" width="201" height="17" font="17">the DEFINITE trial had class I HF.</text>
<text top="878" left="312" width="32" height="10" font="19">S7.2.2-5</text>
<text top="878" left="343" width="86" height="17" font="17"> Therefore, it </text>
<text top="896" left="111" width="319" height="17" font="17">is uncertain whether a primary prevention ICD in </text>
<text top="914" left="111" width="201" height="17" font="17">such patients improves survival.</text>
<text top="933" left="89" width="342" height="17" font="17">4.  There are insufficient data from RCTs regarding </text>
<text top="951" left="111" width="319" height="17" font="17">the value of the ICD in patients with NYHA class </text>
<text top="970" left="111" width="319" height="17" font="17">IV. Ambulatory class IV HF patients were included </text>
<text top="988" left="111" width="322" height="17" font="17">in the COMPANION trial that, overall, showed </text>
<text top="1006" left="111" width="322" height="17" font="17">improved functional status and survival with a </text>
<text top="1025" left="111" width="108" height="17" font="17">CRT defibrillator.</text>
<text top="1025" left="219" width="32" height="10" font="19">S7.2.2-3</text>
<text top="1025" left="251" width="181" height="17" font="17"> Unless such a patient is a </text>
<text top="1043" left="111" width="318" height="17" font="17">candidate for CRT or advanced HF therapies such </text>
<text top="1061" left="111" width="318" height="17" font="17">as heart transplantation or an LVAD, an ICD is not </text>
<text top="1080" left="111" width="271" height="17" font="17">expected to meaningfully prolong survival.</text>
<text top="1081" left="382" width="32" height="10" font="19">S7.2.2-3</text>
<text top="87" left="452" width="319" height="18" font="24"><i><b>7.2.3. Treatment of Recurrent VA in Patients </b></i></text>
<text top="105" left="452" width="78" height="18" font="24"><i><b>With NICM</b></i></text>
<text top="133" left="463" width="327" height="12" font="26"><b>Recommendations for Treatment of Recurrent VA in Patients With </b></text>
<text top="147" left="463" width="27" height="12" font="26"><b>NICM</b></text>
<text top="164" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="177" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 29</b></a></text>
<text top="177" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="198" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="198" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="198" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="253" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="253" left="534" width="16" height="12" font="22"><b>B-R</b></text>
<text top="219" left="583" width="188" height="12" font="4">1.  In patients with NICM and an ICD who </text>
<text top="233" left="595" width="182" height="12" font="4">experience spontaneous VA or recurrent </text>
<text top="246" left="595" width="190" height="12" font="4">appropriate shocks despite optimal device </text>
<text top="260" left="595" width="185" height="12" font="4">programming and treatment with a beta </text>
<text top="273" left="595" width="171" height="12" font="4">blocker, amiodarone or sotalol can be </text>
<text top="287" left="595" width="46" height="12" font="4">beneficial.</text>
<text top="287" left="640" width="22" height="7" font="23">S7.2.3-1</text>
<text top="341" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="341" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="308" left="583" width="184" height="12" font="4">2.  In patients with NICM and recurrent </text>
<text top="321" left="595" width="175" height="12" font="4">sustained monomorphic VT who fail  </text>
<text top="335" left="595" width="162" height="12" font="4">or are intolerant of antiarrhythmic </text>
<text top="348" left="595" width="178" height="12" font="4">medications, catheter ablation can be </text>
<text top="362" left="595" width="193" height="12" font="4">useful for reducing recurrent VT and ICD </text>
<text top="375" left="595" width="34" height="12" font="4">shocks.</text>
<text top="376" left="629" width="48" height="7" font="23">S7.2.3-2,S7.2.3-3</text>
<text top="415" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="436" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="464" left="467" width="342" height="17" font="17">1.  ICDs reduce mortality from VA, yet ICD shocks </text>
<text top="482" left="489" width="326" height="17" font="17">are painful and associated with significant </text>
<text top="500" left="489" width="323" height="17" font="17">morbidity and poor QoL. Although ICDs are </text>
<text top="518" left="489" width="314" height="17" font="17">highly programmable and provide antitachy-</text>
<text top="536" left="489" width="320" height="17" font="17">cardia pacing therapy that can terminate most </text>
<text top="554" left="489" width="314" height="17" font="17">VT episodes without the need for a shock, pre-</text>
<text top="572" left="489" width="314" height="17" font="17">vention of shocks, both appropriate and inap-</text>
<text top="590" left="489" width="324" height="17" font="17">propriate, remains an important concern. In </text>
<text top="608" left="489" width="324" height="17" font="17">the OPTIC (Optimal Pharmacological Therapy </text>
<text top="627" left="489" width="327" height="17" font="17">in Cardioverter Defibrillator Patients) study, </text>
<text top="645" left="489" width="320" height="17" font="17">412 patients with documented VT and VF who </text>
<text top="663" left="489" width="314" height="17" font="17">received an ICD within 21 days of the docu-</text>
<text top="681" left="489" width="130" height="17" font="17">mented arrhythmia</text>
<text top="682" left="619" width="32" height="10" font="19">S7.2.3-1</text>
<text top="681" left="652" width="161" height="17" font="17"> were randomized to </text>
<text top="699" left="489" width="320" height="17" font="17">amiodarone plus beta blocker, sotalol alone, or </text>
<text top="717" left="489" width="318" height="17" font="17">beta blocker alone. Over 1 year, shocks occurred </text>
<text top="735" left="489" width="326" height="17" font="17">in 38.5% assigned to beta blocker alone, </text>
<text top="754" left="489" width="319" height="17" font="17">24.3% assigned to sotalol, and 10.3% assigned </text>
<text top="772" left="489" width="321" height="17" font="17">to amiodarone plus beta blocker. The rates of </text>
<text top="790" left="489" width="318" height="17" font="17">study medication discontinuation at 1 year were </text>
<text top="808" left="489" width="320" height="17" font="17">18.2% for amiodarone, 23.5% for sotalol, and </text>
<text top="826" left="489" width="318" height="17" font="17">5.3% for beta blocker alone. Adverse pulmonary </text>
<text top="844" left="489" width="314" height="17" font="17">and thyroid events and symptomatic bradycar-</text>
<text top="862" left="489" width="314" height="17" font="17">dia were more common among patients ran-</text>
<text top="880" left="489" width="319" height="17" font="17">domized to amiodarone. Thus, amiodarone plus </text>
<text top="898" left="489" width="321" height="17" font="17">beta blocker were more effective than sotalol </text>
<text top="917" left="489" width="322" height="17" font="17">in preventing ICD shocks but at the expense </text>
<text top="935" left="489" width="321" height="17" font="17">of increased risk of medication-related adverse </text>
<text top="953" left="489" width="47" height="17" font="17">effects.</text>
<text top="954" left="537" width="32" height="10" font="19">S7.2.3-1</text>
<text top="953" left="569" width="245" height="17" font="17"> Sotalol should not be used in </text>
<text top="971" left="489" width="319" height="17" font="17">patients with an LVEF &lt;20% due to its negative </text>
<text top="989" left="489" width="110" height="17" font="17">inotropic effects.</text>
<text top="1007" left="467" width="345" height="17" font="17">2. Sustained monomorphic VT due to NICM is </text>
<text top="1025" left="489" width="319" height="17" font="17">most often due to scar-related reentry. Cardiac </text>
<text top="1044" left="489" width="320" height="17" font="17">MRI often indicates scar location, which tends </text>
<text top="1062" left="489" width="320" height="17" font="17">to be basal along the mitral annulus or in the </text>
<text top="1080" left="489" width="53" height="17" font="17">septum.</text>
<text top="1081" left="543" width="68" height="10" font="19">S7.2.3-4,S7.2.3-5</text>
<text top="1080" left="611" width="202" height="17" font="17"> The VT substrate can be </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e311</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="494" left="74" width="45" height="12" font="3"><b>Figure 6. </b></text>
<text top="494" left="120" width="327" height="12" font="22"><b>Secondary and primary prevention of SCD in patients with NICM. </b> </text>
<text top="508" left="74" width="704" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 7.2 for discussion. *ICD candidacy as determined by functional status, life expectancy </text>
<text top="522" left="74" width="706" height="12" font="4">or patient preference. 2° indicates secondary; EP, electrophysiological; GDMT, guideline-directed management and therapy; HF, heart failure; ICD, implantable </text>
<text top="535" left="74" width="721" height="12" font="4">cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NICM, nonischemic cardiomyopathy; SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA, </text>
<text top="549" left="74" width="306" height="12" font="4">ventricular arrhythmia; and WCD, wearable cardioverter-defibrillator.</text>
<text top="615" left="111" width="314" height="17" font="17">subendocardial, subepicardial, or intramyo-</text>
<text top="633" left="111" width="320" height="17" font="17">cardial, and all locations may be affected and </text>
<text top="652" left="111" width="325" height="17" font="17">require endocardial and epicardial ablation. </text>
<text top="671" left="111" width="322" height="17" font="17">In the HELP-VT (Heart Center of Leipzig VT) </text>
<text top="689" left="111" width="38" height="17" font="17">study,</text>
<text top="690" left="150" width="33" height="10" font="19">S7.2.3-2</text>
<text top="689" left="183" width="242" height="17" font="17"> successful ablation of all VT mor-</text>
<text top="708" left="111" width="321" height="17" font="17">phologies was achieved in 66.7% of patients </text>
<text top="727" left="111" width="314" height="17" font="17">with NICM, compared with the 77.4% suc-</text>
<text top="745" left="111" width="314" height="17" font="17">cess rate in ischemic cardiomyopathy. An epi-</text>
<text top="764" left="111" width="322" height="17" font="17">cardial approach to ablation was required in </text>
<text top="783" left="111" width="320" height="17" font="17">30.2% of NICM patients, compared with only </text>
<text top="801" left="111" width="319" height="17" font="17">1.2% with ischemic cardiomyopathy. Epicardial </text>
<text top="820" left="111" width="314" height="17" font="17">ablation was an independent predictor of suc-</text>
<text top="839" left="111" width="320" height="17" font="17">cessful ablation. Acute and long-term success </text>
<text top="857" left="111" width="320" height="17" font="17">of ablation is lower for NICM, compared with </text>
<text top="876" left="111" width="318" height="17" font="17">post-MI patients. The long-term survival-free of </text>
<text top="895" left="111" width="321" height="17" font="17">VT recurrence after catheter ablation appears </text>
<text top="913" left="111" width="322" height="17" font="17">to be better for patients with ischemic than </text>
<text top="932" left="111" width="281" height="17" font="17">NICM (57% versus 40.5% at 1 year).</text>
<text top="933" left="392" width="33" height="10" font="19">S7.2.3-2</text>
<text top="932" left="425" width="4" height="17" font="17"> </text>
<text top="951" left="111" width="319" height="17" font="17">Risks are similar to those observed for post-MI </text>
<text top="969" left="111" width="320" height="17" font="17">VT ablation, with additional risks of epicardial </text>
<text top="988" left="111" width="321" height="17" font="17">access and ablation when required. Although </text>
<text top="1006" left="111" width="319" height="17" font="17">any NICM can produce scar-related VT, cardiac </text>
<text top="1025" left="111" width="314" height="17" font="17">sarcoidosis (see Section 7.6) and <i>Lamin</i> muta-</text>
<text top="1044" left="111" width="319" height="17" font="17">tions are particularly associated with sustained </text>
<text top="1062" left="111" width="118" height="17" font="17">monomorphic VT.</text>
<text top="1063" left="229" width="33" height="10" font="19">S7.2.3-6</text>
<text top="614" left="452" width="325" height="21" font="18"><b>7.3. Arrhythmogenic Right Ventricular </b></text>
<text top="635" left="452" width="141" height="21" font="18"><b>Cardiomyopathy</b></text>
<text top="669" left="463" width="281" height="12" font="26"><b>Recommendations for Arrhythmogenic Right Ventricular </b></text>
<text top="682" left="463" width="82" height="12" font="26"><b>Cardiomyopathy</b></text>
<text top="699" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="713" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 30</b></a></text>
<text top="713" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="733" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="733" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="733" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="788" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="788" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="755" left="583" width="203" height="12" font="4">1.  In selected first-degree relatives of patients </text>
<text top="768" left="594" width="168" height="12" font="4">with arrhythmogenic right ventricular </text>
<text top="782" left="594" width="186" height="12" font="4">cardiomyopathy, clinical screening for the </text>
<text top="795" left="594" width="196" height="12" font="4">disease is recommended along with genetic </text>
<text top="809" left="594" width="207" height="12" font="4">counseling and genetic testing, if the proband </text>
<text top="822" left="594" width="140" height="12" font="4">has a disease causing mutation.</text>
<text top="823" left="735" width="37" height="7" font="23">S7.3-1–S7.3-4</text>
<text top="870" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="870" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="843" left="583" width="205" height="12" font="4">2.  In patients with suspected arrhythmogenic </text>
<text top="856" left="595" width="196" height="12" font="4">right ventricular cardiomyopathy and VA or </text>
<text top="870" left="595" width="194" height="12" font="4">electrocardiographic abnormalities, cardiac </text>
<text top="883" left="595" width="203" height="12" font="4">MRI is useful for establishing a diagnosis and </text>
<text top="897" left="595" width="92" height="12" font="4">for risk stratification.</text>
<text top="897" left="687" width="37" height="7" font="23">S7.3-5–S7.3-8</text>
<text top="965" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="965" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="918" left="583" width="186" height="12" font="4">3.  In patients with arrhythmogenic right </text>
<text top="931" left="595" width="161" height="12" font="4">ventricular cardiomyopathy and an </text>
<text top="945" left="595" width="195" height="12" font="4">additional marker of increased risk of SCD </text>
<text top="958" left="595" width="198" height="12" font="4">(resuscitated SCA, sustained VT, significant </text>
<text top="972" left="595" width="168" height="12" font="4">ventricular dysfunction with RVEF or </text>
<text top="985" left="595" width="183" height="12" font="4">LVEF ≤35%), an ICD is recommended if </text>
<text top="999" left="595" width="191" height="12" font="4">meaningful survival greater than 1 year is </text>
<text top="1012" left="595" width="44" height="12" font="4">expected.</text>
<text top="1013" left="639" width="41" height="7" font="23">S7.3-9–S7.3-13</text>
<text top="1047" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="1047" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1033" left="583" width="181" height="12" font="4">4.  In patients with arrhythmogenic right </text>
<text top="1046" left="595" width="193" height="12" font="4">ventricular cardiomyopathy and VA, a beta </text>
<text top="1060" left="595" width="112" height="12" font="4">blocker is recommended.</text>
<text top="1060" left="707" width="65" height="7" font="23">S7.3-11,S7.3-14,S7.3-15</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e312</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="170" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="170" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="150" left="205" width="169" height="12" font="4">5.  In patients with a clinical diagnosis </text>
<text top="163" left="217" width="159" height="12" font="4">of arrhythmogenic right ventricular </text>
<text top="177" left="217" width="206" height="12" font="4">cardiomyopathy, avoiding intensive exercise is </text>
<text top="190" left="217" width="67" height="12" font="4">recommended.</text>
<text top="191" left="284" width="88" height="7" font="23">S7.3-11,S7.3-12,S7.3-16–S7.3-21</text>
<text top="245" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="245" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="211" left="205" width="185" height="12" font="4">6.  In patients with clinically diagnosed or </text>
<text top="225" left="217" width="194" height="12" font="4">suspected arrhythmogenic right ventricular </text>
<text top="238" left="217" width="183" height="12" font="4">cardiomyopathy, genetic counseling and </text>
<text top="252" left="217" width="191" height="12" font="4">genetic testing can be useful for diagnosis </text>
<text top="265" left="217" width="167" height="12" font="4">and for gene-specific targeted family </text>
<text top="279" left="217" width="45" height="12" font="4">screening.</text>
<text top="279" left="262" width="81" height="7" font="23">S7.3-1,S7.3-4,S7.3-22–S7.3-26</text>
<text top="327" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="327" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="299" left="205" width="181" height="12" font="4">7.  In patients with arrhythmogenic right </text>
<text top="313" left="217" width="183" height="12" font="4">ventricular cardiomyopathy and syncope </text>
<text top="326" left="217" width="194" height="12" font="4">presumed due to VA, an ICD can be useful </text>
<text top="340" left="217" width="196" height="12" font="4">if meaningful survival greater than 1 year is </text>
<text top="353" left="217" width="43" height="12" font="4">expected.</text>
<text top="354" left="260" width="65" height="7" font="23">S7.3-10,S7.3-11,S7.3-13</text>
<text top="395" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="395" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="374" left="205" width="159" height="12" font="4">8.  In patients with clinical evidence </text>
<text top="388" left="217" width="159" height="12" font="4">of arrhythmogenic right ventricular </text>
<text top="401" left="217" width="196" height="12" font="4">cardiomyopathy but not VA, a beta blocker </text>
<text top="415" left="217" width="62" height="12" font="4">can be useful.</text>
<text top="415" left="279" width="43" height="7" font="23">S7.3-14,S7.3-15</text>
<text top="476" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="476" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="435" left="205" width="188" height="12" font="4">9.  In patients with arrhythmogenic right </text>
<text top="449" left="217" width="193" height="12" font="4">ventricular cardiomyopathy and recurrent </text>
<text top="462" left="217" width="199" height="12" font="4">symptomatic sustained VT in whom a beta </text>
<text top="476" left="217" width="176" height="12" font="4">blocker is ineffective or not tolerated, </text>
<text top="489" left="217" width="177" height="12" font="4">catheter ablation with availability of a </text>
<text top="503" left="217" width="198" height="12" font="4">combined endocardial/epicardial approach </text>
<text top="516" left="217" width="81" height="12" font="4">can be beneficial.</text>
<text top="517" left="298" width="45" height="7" font="23">S7.3-27–S7.3-33</text>
<text top="558" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="558" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="537" left="199" width="220" height="12" font="4">10.  In patients with suspected arrhythmogenic </text>
<text top="551" left="217" width="195" height="12" font="4">right ventricular cardiomyopathy, a signal </text>
<text top="564" left="217" width="197" height="12" font="4">averaged ECG can be useful for diagnosis </text>
<text top="578" left="217" width="101" height="12" font="4">and risk stratification.</text>
<text top="578" left="318" width="67" height="7" font="23">S7.3-14,S7.3-34,S7.3-35</text>
<text top="626" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="626" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="598" left="199" width="188" height="12" font="4">11.  In asymptomatic patients with clinical </text>
<text top="612" left="217" width="201" height="12" font="4">evidence of arrhythmogenic right ventricular </text>
<text top="625" left="217" width="181" height="12" font="4">cardiomyopathy, an electrophysiological </text>
<text top="639" left="217" width="147" height="12" font="4">study may be considered for risk </text>
<text top="652" left="217" width="58" height="12" font="4">stratification.</text>
<text top="653" left="275" width="39" height="7" font="23">S7.3-9,S7.3-36</text>
<text top="693" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="721" left="74" width="358" height="17" font="17">Arrhythmogenic right ventricular cardiomyopathy is </text>
<text top="740" left="74" width="351" height="17" font="17">an inherited cardiomyopathy that predominantly af-</text>
<text top="759" left="74" width="351" height="17" font="17">fects the right ventricle but can affect the left ven-</text>
<text top="777" left="74" width="357" height="17" font="17">tricle causing areas of myocardial replacement with </text>
<text top="796" left="74" width="356" height="17" font="17">fibrosis and adipose tissue that frequently causes VA </text>
<text top="815" left="74" width="62" height="17" font="17">and SCD.</text>
<text top="864" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="885" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="913" left="89" width="336" height="17" font="17">1. Selected first-degree relatives refers to rela-</text>
<text top="932" left="111" width="320" height="17" font="17">tives who are willing to undergo further testing </text>
<text top="951" left="111" width="322" height="17" font="17">and who could benefit from further screening </text>
<text top="970" left="111" width="322" height="17" font="17">and testing (and not the terminally ill patients </text>
<text top="988" left="111" width="321" height="17" font="17">or those who do not want to be screened and </text>
<text top="1007" left="111" width="314" height="17" font="17">tested). Arrhythmogenic right ventricular cardio-</text>
<text top="1026" left="111" width="321" height="17" font="17">myopathy is often due to a mutation involving </text>
<text top="1045" left="111" width="314" height="17" font="17">a desmosomal protein, and it usually has auto-</text>
<text top="1063" left="111" width="314" height="17" font="17">somal dominant inheritance with variable pen-</text>
<text top="1082" left="111" width="320" height="17" font="17">etrance. SCD can be the initial manifestation of </text>
<text top="88" left="489" width="318" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy. </text>
<text top="106" left="489" width="324" height="17" font="17">Clinical screening with ECG, cardiac imaging, </text>
<text top="124" left="489" width="314" height="17" font="17">and ambulatory rhythm monitoring and/or exer-</text>
<text top="142" left="489" width="320" height="17" font="17">cise testing may identify family members at risk </text>
<text top="160" left="489" width="314" height="17" font="17">for arrhythmogenic right ventricular cardiomy-</text>
<text top="178" left="489" width="314" height="17" font="17">opathy. Arrhythmogenic right ventricular cardio-</text>
<text top="196" left="489" width="321" height="17" font="17">myopathy is detected clinically in approximately </text>
<text top="214" left="489" width="263" height="17" font="17">35% to 40% of first-degree relatives,</text>
<text top="215" left="752" width="51" height="10" font="19">S7.3-3,S7.3-4</text>
<text top="214" left="803" width="4" height="17" font="17"> </text>
<text top="232" left="489" width="314" height="17" font="17">most commonly in siblings or symptomatic first-</text>
<text top="250" left="489" width="106" height="17" font="17">degree relatives.</text>
<text top="251" left="595" width="24" height="10" font="19">S7.3-4</text>
<text top="250" left="620" width="184" height="17" font="17"> When a proband is identi-</text>
<text top="268" left="489" width="322" height="17" font="17">fied with a disease-causing mutation, targeted </text>
<text top="286" left="489" width="318" height="17" font="17">genotype screening can identify mutation positive </text>
<text top="305" left="489" width="56" height="17" font="17">relatives,</text>
<text top="305" left="545" width="24" height="10" font="19">S7.3-1</text>
<text top="305" left="569" width="234" height="17" font="17"> with approximately 35% of muta-</text>
<text top="323" left="489" width="325" height="17" font="17">tion positive individuals ultimately developing </text>
<text top="341" left="489" width="203" height="17" font="17">progressive disease expression.</text>
<text top="341" left="692" width="51" height="10" font="19">S7.3-1,S7.3-4</text>
<text top="341" left="743" width="60" height="17" font="17"> In  stud-</text>
<text top="359" left="489" width="314" height="17" font="17">ies of arrhythmogenic right ventricular cardiomy-</text>
<text top="377" left="489" width="319" height="17" font="17">opathy mutation-positive individuals who do not </text>
<text top="395" left="489" width="321" height="17" font="17">initially manifest the disease, 8% to 16% have </text>
<text top="413" left="489" width="320" height="17" font="17">a major arrhythmic event over the next 7 to 39 </text>
<text top="431" left="489" width="37" height="17" font="17">years.</text>
<text top="432" left="526" width="83" height="10" font="19">S7.3-1,S7.3-4,S7.3-26</text>
<text top="431" left="608" width="199" height="17" font="17"> Early identification of affected </text>
<text top="449" left="489" width="319" height="17" font="17">or potentially affected family members can allow </text>
<text top="467" left="489" width="320" height="17" font="17">lifestyle modifications in sports participation and </text>
<text top="485" left="489" width="314" height="17" font="17">serial monitoring for development of electrocar-</text>
<text top="503" left="489" width="321" height="17" font="17">diographic abnormalities, symptoms, ventricular </text>
<text top="522" left="489" width="318" height="17" font="17">dysfunction, or arrhythmia. As genetic testing for </text>
<text top="540" left="489" width="319" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy </text>
<text top="558" left="489" width="320" height="17" font="17">has subtle complexities, the decision to proceed </text>
<text top="576" left="489" width="321" height="17" font="17">with family screening is facilitated by informed </text>
<text top="594" left="489" width="314" height="17" font="17">genetic counseling to discuss the cost of test-</text>
<text top="612" left="489" width="321" height="17" font="17">ing, the potential lack of a single gene as the </text>
<text top="630" left="489" width="318" height="17" font="17">determinant for disease expression, psychological </text>
<text top="648" left="489" width="318" height="17" font="17">implications of uncertain disease progression, and </text>
<text top="666" left="489" width="320" height="17" font="17">implications for lifestyle modification, screening, </text>
<text top="684" left="489" width="156" height="17" font="17">and potential treatment.</text>
<text top="702" left="467" width="336" height="17" font="17">2. Cardiac MRI provides high-quality assess-</text>
<text top="720" left="489" width="321" height="17" font="17">ment of ventricular function, size, regional wall </text>
<text top="738" left="489" width="323" height="17" font="17">motion abnormalities, and extent of scar and </text>
<text top="756" left="489" width="321" height="17" font="17">fibrosis (late  gadolinium enhancement) that are </text>
<text top="775" left="489" width="314" height="17" font="17">seen in 30% to 95% of patients with the clini-</text>
<text top="793" left="489" width="314" height="17" font="17">cal diagnosis of arrhythmogenic right ventricu-</text>
<text top="811" left="489" width="136" height="17" font="17">lar cardiomyopathy.</text>
<text top="812" left="625" width="114" height="10" font="19">S7.3-5,S7.3-6,S7.3-37,S7.3-38</text>
<text top="811" left="740" width="79" height="17" font="17"> Cardiac </text>
<text top="829" left="489" width="323" height="17" font="17">MRI detects biventricular involvement in 34% </text>
<text top="847" left="489" width="314" height="17" font="17">to 56% of patients, with isolated LV involve-</text>
<text top="865" left="489" width="252" height="17" font="17">ment noted in 4% to 9% of patients.</text>
<text top="866" left="741" width="63" height="10" font="19">S7.3-37–S7.3-40</text>
<text top="865" left="803" width="4" height="17" font="17"> </text>
<text top="883" left="489" width="322" height="17" font="17">Cardiac MRI should include assessment of late </text>
<text top="901" left="489" width="327" height="17" font="17">gadolinium enhancement with quantification </text>
<text top="919" left="489" width="322" height="17" font="17">of fibrosis. Application of the 2010 Task Force </text>
<text top="937" left="489" width="321" height="17" font="17">Criteria to cardiac MRI criteria for diagnosis of </text>
<text top="955" left="489" width="314" height="17" font="17">arrhythmogenic right ventricular cardiomyopa-</text>
<text top="974" left="489" width="295" height="17" font="17">thy has improved the specificity of this test.</text>
<text top="974" left="784" width="19" height="10" font="19">S7.3-</text>
<text top="992" left="489" width="32" height="10" font="19">5,S7.3-8</text>
<text top="992" left="521" width="292" height="17" font="17"> Electrocardiographic and Holter findings </text>
<text top="1010" left="489" width="320" height="17" font="17">precede detectable cardiac MRI abnormalities in </text>
<text top="1028" left="489" width="314" height="17" font="17">arrhythmogenic right ventricular cardiomyopa-</text>
<text top="1046" left="489" width="321" height="17" font="17">thy mutation-positive individuals, with only 4% </text>
<text top="1064" left="489" width="319" height="17" font="17">of patients with normal electrocardiographic and </text>
<text top="1082" left="489" width="321" height="17" font="17">Holter results having cardiac MRI abnormalities, </text>
<text top="95" left="85" width="281" height="12" font="26"><b>Recommendations for Arrhythmogenic Right Ventricular </b></text>
<text top="108" left="85" width="143" height="12" font="26"><b>Cardiomyopathy (Continued)</b></text>
<text top="129" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="129" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="129" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e313</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="317" height="17" font="17">suggesting that evaluation of cardiac structure and </text>
<text top="106" left="111" width="320" height="17" font="17">function using cardiac MRI may be unnecessary </text>
<text top="124" left="111" width="319" height="17" font="17">in mutation-positive individuals who do not have </text>
<text top="142" left="111" width="150" height="17" font="17">electrical abnormalities.</text>
<text top="142" left="261" width="24" height="10" font="19">S7.3-7</text>
<text top="142" left="285" width="144" height="17" font="17"> The presence of both </text>
<text top="160" left="111" width="314" height="17" font="17">electrocardiographic abnormalities and abnor-</text>
<text top="178" left="111" width="322" height="17" font="17">mal cardiac MRI findings may identify patients </text>
<text top="196" left="111" width="324" height="17" font="17">at an increased risk for developing sustained </text>
<text top="196" left="425" width="4" height="17" font="17"> </text>
<text top="214" left="111" width="23" height="17" font="17">VA.</text>
<text top="215" left="134" width="56" height="10" font="19">S7.3-7,S7.3-38</text>
<text top="214" left="189" width="243" height="17" font="17"> Areas of scar identified on cardiac </text>
<text top="232" left="111" width="314" height="17" font="17">MRI have correlated with the location of VT sub-</text>
<text top="250" left="111" width="323" height="17" font="17">strate identified by endocardial and epicardial </text>
<text top="268" left="111" width="61" height="17" font="17">mapping.</text>
<text top="269" left="172" width="29" height="10" font="19">S7.3-38</text>
<text top="268" left="201" width="231" height="17" font="17"> During early stages  of disease, a </text>
<text top="286" left="111" width="314" height="17" font="17">baseline cardiac MRI may provide useful informa-</text>
<text top="304" left="111" width="319" height="17" font="17">tion along with electrocardiographic and rhythm </text>
<text top="322" left="111" width="318" height="17" font="17">abnormalities to monitor disease progression over </text>
<text top="340" left="111" width="318" height="17" font="17">time. Experience and expertise in interpretation of </text>
<text top="358" left="111" width="169" height="17" font="17">cardiac MRI are important.</text>
<text top="359" left="280" width="51" height="10" font="19">S7.3-5,S7.3-8</text>
<text top="376" left="89" width="336" height="17" font="17">3. Arrhythmogenic right ventricular cardiomy-</text>
<text top="394" left="111" width="314" height="17" font="17">opathy is characterized by progressive ven-</text>
<text top="412" left="111" width="327" height="17" font="17">tricular myocyte loss with replacement by </text>
<text top="430" left="111" width="321" height="17" font="17">fatty or fibrous tissue, and is associated with </text>
<text top="448" left="111" width="324" height="17" font="17">progressive ventricular dysfunction that may </text>
<text top="466" left="111" width="327" height="17" font="17">involve both ventricles. VA, syncope, and </text>
<text top="485" left="111" width="325" height="17" font="17">SCD may occur at a relatively young age, </text>
<text top="503" left="111" width="323" height="17" font="17">particularly in the second and third decades </text>
<text top="521" left="111" width="325" height="17" font="17">of life and often occurring during physical </text>
<text top="521" left="425" width="4" height="17" font="17"> </text>
<text top="539" left="111" width="47" height="17" font="17">activity.</text>
<text top="539" left="158" width="119" height="10" font="19">S7.3-1,S7.3-16,S7.3-22,S7.3-41</text>
<text top="539" left="277" width="159" height="17" font="17"> Sustained VT is an </text>
<text top="557" left="111" width="314" height="17" font="17">important predictor of SCA and SCD or appropri-</text>
<text top="575" left="111" width="320" height="17" font="17">ate ICD shocks in patients with arrhythmogenic </text>
<text top="593" left="111" width="228" height="17" font="17">right ventricular cardiomyopathy.</text>
<text top="593" left="339" width="61" height="10" font="19">S7.3-10,S7.3-13</text>
<text top="593" left="400" width="38" height="17" font="17"> In </text>
<text top="611" left="111" width="319" height="17" font="17">patients receiving an ICD for primary prevention, </text>
<text top="629" left="111" width="320" height="17" font="17">appropriate ICD shocks are reported in 24% to </text>
<text top="647" left="111" width="110" height="17" font="17">48% of patients.</text>
<text top="648" left="221" width="119" height="10" font="19">S7.3-9,S7.3-10,S7.3-12,S7.3-13</text>
<text top="647" left="340" width="90" height="17" font="17"> As sustained </text>
<text top="665" left="111" width="314" height="17" font="17">VT in arrhythmogenic right ventricular cardiomy-</text>
<text top="683" left="111" width="319" height="17" font="17">opathy patients is monomorphic in 55% to 90% </text>
<text top="701" left="111" width="314" height="17" font="17">of episodes based on ICD interrogation or elec-</text>
<text top="719" left="111" width="153" height="17" font="17">trophysiological studies,</text>
<text top="720" left="264" width="61" height="10" font="19">S7.3-12,S7.3-36</text>
<text top="719" left="324" width="105" height="17" font="17"> antitachycardia </text>
<text top="737" left="111" width="279" height="17" font="17">pacing algorithms are used to terminate VT.</text>
<text top="755" left="89" width="336" height="17" font="17">4.  Frequent PVCs, &gt;760 to 1000 per 24 hours dur-</text>
<text top="773" left="111" width="318" height="17" font="17">ing ambulatory rhythm monitoring, correlate with </text>
<text top="791" left="111" width="98" height="17" font="17">arrhythmic risk.</text>
<text top="792" left="209" width="56" height="10" font="19">S7.3-9,S7.3-23</text>
<text top="791" left="265" width="164" height="17" font="17"> The presence of NSVT or </text>
<text top="809" left="111" width="319" height="17" font="17">sustained VT is an important predictor of adverse </text>
<text top="827" left="111" width="115" height="17" font="17">cardiac events.</text>
<text top="828" left="226" width="151" height="10" font="19">S7.3-9,S7.3-12,S7.3-13,S7.3-42,S7.3-43</text>
<text top="827" left="377" width="74" height="17" font="17"> The </text>
<text top="845" left="111" width="323" height="17" font="17">increased arrhythmia risk conferred by intense </text>
<text top="863" left="111" width="314" height="17" font="17">exercise is consistent with beta-adrenergic modu-</text>
<text top="881" left="111" width="194" height="17" font="17">lation of disease expression.</text>
<text top="882" left="305" width="92" height="10" font="19">S7.3-17,S7.3-20,S7.3-21</text>
<text top="881" left="397" width="37" height="17" font="17"> An </text>
<text top="899" left="111" width="324" height="17" font="17">observational registry reported that treatment </text>
<text top="917" left="111" width="318" height="17" font="17">with atenolol or amiodarone was associated with </text>
<text top="936" left="111" width="314" height="17" font="17">less clinically relevant VA, while sotalol was associ-</text>
<text top="954" left="111" width="285" height="17" font="17">ated with no effect or increased arrhythmia.</text>
<text top="954" left="396" width="29" height="10" font="19">S7.3-15</text>
<text top="954" left="425" width="4" height="17" font="17"> </text>
<text top="972" left="111" width="325" height="17" font="17">Ambulatory monitoring to assess VA burden </text>
<text top="990" left="111" width="320" height="17" font="17">and adequacy of beta-blocker therapy is usually </text>
<text top="1008" left="111" width="34" height="17" font="17">used.</text>
<text top="1008" left="145" width="119" height="10" font="19">S7.3-9,S7.3-14,S7.3-23,S7.3-42</text>
<text top="1026" left="89" width="346" height="17" font="17">5. Patients with arrhythmogenic right ventricular </text>
<text top="1044" left="111" width="324" height="17" font="17">cardiomyopathy have a significantly increased </text>
<text top="1062" left="111" width="190" height="17" font="17">risk of SCD during exertion.</text>
<text top="1062" left="301" width="124" height="10" font="19">S7.3-16,S7.3-17,S7.3-20,S7.3-21</text>
<text top="1062" left="425" width="4" height="17" font="17"> </text>
<text top="1080" left="111" width="318" height="17" font="17">Vigorous exercise in patients with arrhythmogenic </text>
<text top="88" left="489" width="318" height="17" font="17">right ventricular cardiomyopathy has been shown </text>
<text top="106" left="489" width="314" height="17" font="17">to impair myocardial function by echocardiogra-</text>
<text top="124" left="489" width="144" height="17" font="17">phy and cardiac MRI.</text>
<text top="124" left="633" width="29" height="10" font="19">S7.3-19</text>
<text top="124" left="662" width="149" height="17" font="17"> Participation in high </text>
<text top="142" left="489" width="321" height="17" font="17">intensity/duration or endurance physical activity </text>
<text top="160" left="489" width="324" height="17" font="17">accelerates the penetrance/disease progression </text>
<text top="178" left="489" width="324" height="17" font="17">and arrhythmic risk for arrhythmogenic right </text>
<text top="196" left="489" width="314" height="17" font="17">ventricular cardiomyopathy patients and muta-</text>
<text top="214" left="489" width="324" height="17" font="17">tion positive individuals, as well as mutation </text>
<text top="232" left="489" width="163" height="17" font="17">positive family members.</text>
<text top="233" left="652" width="94" height="10" font="19">S7.3-17,S7.3-19–S7.3-21</text>
<text top="232" left="747" width="63" height="17" font="17"> Patients </text>
<text top="250" left="489" width="314" height="17" font="17">with arrhythmogenic right ventricular cardiomy-</text>
<text top="268" left="489" width="319" height="17" font="17">opathy who participate in competitive sports are </text>
<text top="286" left="489" width="320" height="17" font="17">at increased risk for VT or SCD, compared with </text>
<text top="304" left="489" width="322" height="17" font="17">those who participate in recreational sports or </text>
<text top="322" left="489" width="83" height="17" font="17">are inactive.</text>
<text top="323" left="572" width="94" height="10" font="19">S7.3-17–S7.3-19,S7.3-21</text>
<text top="322" left="667" width="148" height="17" font="17"> Exercise influences </text>
<text top="340" left="489" width="322" height="17" font="17">disease progression in a linear manner; family </text>
<text top="358" left="489" width="322" height="17" font="17">members who limited activity to less than the </text>
<text top="376" left="489" width="314" height="17" font="17">AHA recommended minimum for activity guide-</text>
<text top="394" left="489" width="320" height="17" font="17">lines (&lt;650 metabolic equivalent hours per year </text>
<text top="412" left="489" width="321" height="17" font="17">[MET-Hr/year]) were less likely to develop VA or </text>
<text top="430" left="489" width="131" height="17" font="17">disease progression.</text>
<text top="431" left="620" width="29" height="10" font="19">S7.3-21</text>
<text top="430" left="649" width="154" height="17" font="17"> In a study of arrhyth-</text>
<text top="448" left="489" width="314" height="17" font="17">mogenic right ventricular cardiomyopathy pro-</text>
<text top="466" left="489" width="319" height="17" font="17">bands and exercise, athletes (defined as subjects </text>
<text top="484" left="489" width="319" height="17" font="17">with ≥4 h vigorous exercise/week) were found to </text>
<text top="503" left="489" width="324" height="17" font="17">have reduced biventricular function compared </text>
<text top="521" left="489" width="314" height="17" font="17">with nonathletes in arrhythmogenic right ven-</text>
<text top="539" left="489" width="314" height="17" font="17">tricular cardiomyopathy patients and in muta-</text>
<text top="557" left="489" width="195" height="17" font="17">tion-positive family members.</text>
<text top="557" left="684" width="29" height="10" font="19">S7.3-19</text>
<text top="557" left="713" width="98" height="17" font="17"> Many advise </text>
<text top="575" left="489" width="321" height="17" font="17">limiting exercise intensity and duration to  &lt;650 </text>
<text top="593" left="489" width="224" height="17" font="17">MET-Hr/year, or 12.5 MET-Hr/week.</text>
<text top="593" left="713" width="29" height="10" font="19">S7.3-21</text>
<text top="611" left="467" width="336" height="17" font="17">6. The proband with arrhythmogenic right ven-</text>
<text top="629" left="489" width="321" height="17" font="17">tricular cardiomyopathy is usually diagnosed by </text>
<text top="647" left="489" width="323" height="17" font="17">the presence of clinical symptoms along with </text>
<text top="665" left="489" width="314" height="17" font="17">the presence of arrhythmogenic right ventricu-</text>
<text top="683" left="489" width="320" height="17" font="17">lar cardiomyopathy Task Force criteria including: </text>
<text top="701" left="489" width="320" height="17" font="17">abnormalities on ECG, structural and functional </text>
<text top="719" left="489" width="324" height="17" font="17">changes of either ventricle, arrhythmias, and </text>
<text top="737" left="489" width="319" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy </text>
<text top="755" left="489" width="149" height="17" font="17">in first-degree relatives.</text>
<text top="756" left="638" width="24" height="10" font="19">S7.3-6</text>
<text top="755" left="662" width="145" height="17" font="17"> A pathogenic genetic </text>
<text top="773" left="489" width="323" height="17" font="17">mutation was added to the major Task Force </text>
<text top="791" left="489" width="107" height="17" font="17">criteria in 2010.</text>
<text top="792" left="596" width="29" height="10" font="19">S7.3-44</text>
<text top="791" left="625" width="178" height="17" font="17"> The yield of genetic test-</text>
<text top="809" left="489" width="320" height="17" font="17">ing in probands with suspected arrhythmogenic </text>
<text top="827" left="489" width="326" height="17" font="17">right ventricular cardiomyopathy is generally </text>
<text top="845" left="489" width="319" height="17" font="17">30% to 54%, and is up to 58% among patients </text>
<text top="863" left="489" width="321" height="17" font="17">with a strong family history of SCD in multiple </text>
<text top="881" left="489" width="63" height="17" font="17">members.</text>
<text top="882" left="552" width="87" height="10" font="19">S7.3-3,S7.3-25,S7.3-45</text>
<text top="881" left="640" width="171" height="17" font="17"> A negative genetic test </text>
<text top="899" left="489" width="314" height="17" font="17">for arrhythmogenic right ventricular cardiomyop-</text>
<text top="917" left="489" width="319" height="17" font="17">athy does not exclude the disease, and a positive </text>
<text top="936" left="489" width="285" height="17" font="17">genetic test currently does not guide therapy.</text>
<text top="936" left="774" width="29" height="10" font="19">S7.3-22</text>
<text top="936" left="803" width="4" height="17" font="17"> </text>
<text top="954" left="489" width="324" height="17" font="17">For the proband with a clinical diagnosis of </text>
<text top="972" left="489" width="318" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy, </text>
<text top="990" left="489" width="321" height="17" font="17">identification of pathogenic mutations provides </text>
<text top="1008" left="489" width="319" height="17" font="17">limited prognostic information relative to the risk </text>
<text top="1026" left="489" width="56" height="17" font="17">of VT/VF</text>
<text top="1026" left="545" width="61" height="10" font="19">S7.3-22,S7.3-26</text>
<text top="1026" left="605" width="151" height="17" font="17"> or development of HF.</text>
<text top="1026" left="757" width="29" height="10" font="19">S7.3-22</text>
<text top="1026" left="786" width="23" height="17" font="17"> In </text>
<text top="1044" left="489" width="314" height="17" font="17">a large multicenter study, the presence of posi-</text>
<text top="1062" left="489" width="314" height="17" font="17">tive mutations among probands was not asso-</text>
<text top="1080" left="489" width="321" height="17" font="17">ciated with a difference in mortality or cardiac </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e314</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="101" height="17" font="17">transplantation.</text>
<text top="88" left="212" width="24" height="10" font="19">S7.3-1</text>
<text top="88" left="236" width="198" height="17" font="17"> However, the identification </text>
<text top="106" left="111" width="324" height="17" font="17">of a pathogenic mutation facilitates targeted </text>
<text top="124" left="111" width="314" height="17" font="17">genetic screening for that mutation in first-</text>
<text top="142" left="111" width="319" height="17" font="17">degree relatives, that may identify approximately </text>
<text top="160" left="111" width="191" height="17" font="17">60% to 70% as gene positive,</text>
<text top="160" left="302" width="24" height="10" font="19">S7.3-1</text>
<text top="160" left="327" width="102" height="17" font="17"> highest among </text>
<text top="178" left="111" width="224" height="17" font="17">siblings, and those with symptoms.</text>
<text top="178" left="335" width="24" height="10" font="19">S7.3-4</text>
<text top="178" left="359" width="70" height="17" font="17"> Screening </text>
<text top="196" left="111" width="319" height="17" font="17">for the specific mutation can identify some gene </text>
<text top="214" left="111" width="314" height="17" font="17">positive family members prior to disease expres-</text>
<text top="232" left="111" width="314" height="17" font="17">sion, while relieving others from the need for life-</text>
<text top="250" left="111" width="260" height="17" font="17">style changes and long-term monitoring.</text>
<text top="251" left="371" width="51" height="10" font="19">S7.3-2,S7.3-3</text>
<text top="268" left="89" width="336" height="17" font="17">7.  Syncope is reported in 16% to 39% of arrhythmo-</text>
<text top="286" left="111" width="318" height="17" font="17">genic right ventricular cardiomyopathy patients at </text>
<text top="304" left="111" width="144" height="17" font="17">the time of diagnosis,</text>
<text top="305" left="255" width="156" height="10" font="19">S7.3-13,S7.3-14,S7.3-16,S7.3-41,S7.3-43</text>
<text top="304" left="410" width="21" height="17" font="17"> is  </text>
<text top="322" left="111" width="330" height="17" font="17">frequently exercise-related, and has been </text>
<text top="340" left="111" width="323" height="17" font="17">associated with high arrhythmic risk in some  </text>
<text top="358" left="111" width="48" height="17" font="17">studies.</text>
<text top="359" left="159" width="61" height="10" font="19">S7.3-10,S7.3-41</text>
<text top="358" left="220" width="205" height="17" font="17"> Among patients with arrhyth-</text>
<text top="376" left="111" width="323" height="17" font="17">mogenic right ventricular cardiomyopathy and </text>
<text top="394" left="111" width="314" height="17" font="17">implanted ICDs, syncope was an important pre-</text>
<text top="412" left="111" width="258" height="17" font="17">dictor of appropriate shocks in 1 study,</text>
<text top="413" left="369" width="29" height="10" font="19">S7.3-10</text>
<text top="412" left="398" width="33" height="17" font="17"> but </text>
<text top="430" left="111" width="141" height="17" font="17">not in other studies.</text>
<text top="431" left="252" width="119" height="10" font="19">S7.3-9,S7.3-12,S7.3-13,S7.3-43</text>
<text top="430" left="371" width="63" height="17" font="17"> Studies </text>
<text top="448" left="111" width="320" height="17" font="17">have not provided information about ventricular </text>
<text top="466" left="111" width="318" height="17" font="17">function or abnormalities on ECG in patients with </text>
<text top="484" left="111" width="314" height="17" font="17">syncope, limiting its assessment as an indepen-</text>
<text top="503" left="111" width="320" height="17" font="17">dent risk factor. Syncope may be a harbinger of </text>
<text top="521" left="111" width="319" height="17" font="17">progression of underlying disease and should be </text>
<text top="539" left="111" width="321" height="17" font="17">integrated into the decision-making process for </text>
<text top="557" left="111" width="219" height="17" font="17">ICD implantation with the patient.</text>
<text top="575" left="89" width="339" height="17" font="17">8.  Asymptomatic patients with arrhythmogenic right </text>
<text top="593" left="111" width="314" height="17" font="17">ventricular cardiomyopathy and no VA or ventric-</text>
<text top="611" left="111" width="321" height="17" font="17">ular dysfunction are generally observed without </text>
<text top="629" left="111" width="322" height="17" font="17">antiarrhythmic therapy other than beta-blocker </text>
<text top="647" left="111" width="320" height="17" font="17">therapy, with ongoing periodic reassessment for </text>
<text top="665" left="111" width="323" height="17" font="17">the development  of arrhythmias or ventricular </text>
<text top="683" left="111" width="78" height="17" font="17">dysfunction.</text>
<text top="684" left="189" width="61" height="10" font="19">S7.3-46,S7.3-47</text>
<text top="683" left="250" width="185" height="17" font="17"> Atenolol was shown to </text>
<text top="701" left="111" width="143" height="17" font="17">reduce VA in 1 study.</text>
<text top="702" left="254" width="29" height="10" font="19">S7.3-15</text>
<text top="701" left="283" width="142" height="17" font="17"> Ambulatory monitor-</text>
<text top="719" left="111" width="320" height="17" font="17">ing and/or exercise testing can be performed to </text>
<text top="737" left="111" width="263" height="17" font="17">assess adequacy of beta-blocking dosing.</text>
<text top="755" left="89" width="336" height="17" font="17">9.  Interrogation of ICDs shows that &gt;90% of sponta-</text>
<text top="773" left="111" width="314" height="17" font="17">neous sustained VTs in arrhythmogenic right ven-</text>
<text top="791" left="111" width="285" height="17" font="17">tricular cardiomyopathy are monomorphic,</text>
<text top="792" left="396" width="29" height="10" font="19">S7.3-12</text>
<text top="791" left="425" width="4" height="17" font="17"> </text>
<text top="809" left="111" width="314" height="17" font="17">while sustained monomorphic VT is induc-</text>
<text top="827" left="111" width="323" height="17" font="17">ible at electrophysiological study in 55% of </text>
<text top="845" left="111" width="57" height="17" font="17">patients.</text>
<text top="846" left="168" width="30" height="10" font="19">S7.3-36</text>
<text top="845" left="198" width="230" height="17" font="17"> VT is usually related to scar-related </text>
<text top="863" left="111" width="325" height="17" font="17">reentry, and the subepicardium usually has </text>
<text top="881" left="111" width="284" height="17" font="17">more extensive scar than the endocardium.</text>
<text top="882" left="395" width="30" height="10" font="19">S7.3-27</text>
<text top="881" left="425" width="4" height="17" font="17"> </text>
<text top="899" left="111" width="314" height="17" font="17">In experienced centers, use of epicardial map-</text>
<text top="917" left="111" width="324" height="17" font="17">ping and ablation is associated with  better </text>
<text top="917" left="425" width="4" height="17" font="17"> </text>
<text top="936" left="111" width="69" height="17" font="17">outcomes.</text>
<text top="936" left="180" width="162" height="10" font="19">S7.3-27,S7.3-28,S7.3-30,S7.3-31,S7.3-33</text>
<text top="936" left="343" width="99" height="17" font="17"> Important </text>
<text top="954" left="111" width="323" height="17" font="17">complications including pericardial tamponade, </text>
<text top="972" left="111" width="314" height="17" font="17">MI, and death occur in 2.3% to 3.3% of abla-</text>
<text top="990" left="111" width="70" height="17" font="17">tion cases,</text>
<text top="990" left="181" width="63" height="10" font="19">S7.3-27–S7.3-29</text>
<text top="990" left="244" width="189" height="17" font="17"> emphasizing the need for </text>
<text top="1008" left="111" width="319" height="17" font="17">performance in centers with specialized expertise </text>
<text top="1026" left="111" width="314" height="17" font="17">in epicardial procedures. Ablation reduces the fre-</text>
<text top="1044" left="111" width="321" height="17" font="17">quency of recurrent VT, although 27% to 55% </text>
<text top="1062" left="111" width="71" height="17" font="17">of patients</text>
<text top="1062" left="182" width="61" height="10" font="19">S7.3-27,S7.3-28</text>
<text top="1062" left="242" width="189" height="17" font="17"> have at least 1 recurrence; </text>
<text top="1080" left="111" width="318" height="17" font="17">ablation of VT in arrhythmogenic right ventricular </text>
<text top="88" left="489" width="320" height="17" font="17">cardiomyopathy patients does not eliminate the </text>
<text top="106" left="489" width="321" height="17" font="17">need for an ICD in appropriate candidates. The </text>
<text top="124" left="489" width="314" height="17" font="17">potential risk of VT recurrence due to disease pro-</text>
<text top="143" left="489" width="319" height="17" font="17">gression should be reviewed with patients when </text>
<text top="161" left="489" width="322" height="17" font="17">considering ablation. There are no randomized </text>
<text top="179" left="489" width="314" height="17" font="17">comparisons of antiarrhythmic therapy to sup-</text>
<text top="198" left="489" width="314" height="17" font="17">press recurrent VT. Beta blockers, sotalol and ami-</text>
<text top="216" left="489" width="161" height="17" font="17">odarone have been used.</text>
<text top="217" left="650" width="29" height="10" font="19">S7.3-15</text>
<text top="216" left="679" width="128" height="17" font="17"> In an observational </text>
<text top="235" left="489" width="322" height="17" font="17">series, sotalol suppressed inducible VT in 58% </text>
<text top="253" left="489" width="314" height="17" font="17">of patients with  &lt;10% of patients experienc-</text>
<text top="271" left="489" width="285" height="17" font="17">ing arrhythmia recurrence during follow-up.</text>
<text top="272" left="774" width="29" height="10" font="19">S7.3-48</text>
<text top="271" left="803" width="4" height="17" font="17"> </text>
<text top="290" left="489" width="318" height="17" font="17">Effectiveness of the different medications appears </text>
<text top="308" left="489" width="303" height="17" font="17">to be variable, and so more studies are needed.</text>
<text top="326" left="459" width="344" height="17" font="17">10.  In arrhythmogenic right ventricular cardiomyop-</text>
<text top="345" left="489" width="320" height="17" font="17">athy, areas of fibrofatty scar in the RV free wall </text>
<text top="363" left="489" width="325" height="17" font="17">create areas of delayed ventricular activation </text>
<text top="382" left="489" width="324" height="17" font="17">causing fractionated deflections following the </text>
<text top="400" left="489" width="318" height="17" font="17">QRS, known as epsilon waves on the surface ECG </text>
<text top="418" left="489" width="318" height="17" font="17">(a major criterion) and late potentials in the signal </text>
<text top="437" left="489" width="320" height="17" font="17">averaged ECG (minor criterion) in the 2010 Task </text>
<text top="455" left="489" width="323" height="17" font="17">Force Criteria for diagnosis of arrhythmogenic </text>
<text top="473" left="489" width="216" height="17" font="17">right ventricular cardiomyopathy.</text>
<text top="474" left="705" width="24" height="10" font="19">S7.3-6</text>
<text top="473" left="730" width="81" height="17" font="17"> When the </text>
<text top="492" left="489" width="320" height="17" font="17">standard ECG QRS duration is ≤110 ms, criteria </text>
<text top="510" left="489" width="319" height="17" font="17">for abnormal signal-averaged ECG include any 1 </text>
<text top="529" left="489" width="319" height="17" font="17">of the following: filtered QRS duration ≥114 ms, </text>
<text top="547" left="489" width="317" height="17" font="17">duration of the terminal QRS &lt;40 uV exceeding 37 </text>
<text top="565" left="489" width="318" height="17" font="17">ms, or a root mean square voltage in the terminal </text>
<text top="584" left="489" width="115" height="17" font="17">40 ms of ≤20 uV.</text>
<text top="584" left="604" width="24" height="10" font="19">S7.3-6</text>
<text top="584" left="628" width="175" height="17" font="17"> Abnormal findings on sig-</text>
<text top="602" left="489" width="318" height="17" font="17">nal averaged ECG correlated with disease severity </text>
<text top="620" left="489" width="98" height="17" font="17">on cardiac MRI,</text>
<text top="621" left="587" width="29" height="10" font="19">S7.3-35</text>
<text top="620" left="616" width="191" height="17" font="17"> and increased adverse events </text>
<text top="639" left="489" width="57" height="17" font="17">in males.</text>
<text top="640" left="546" width="29" height="10" font="19">S7.3-34</text>
<text top="639" left="576" width="233" height="17" font="17"> In an assessment of the diagnostic </text>
<text top="657" left="489" width="314" height="17" font="17">use of testing for arrhythmogenic right ventricu-</text>
<text top="676" left="489" width="320" height="17" font="17">lar cardiomyopathy, signal averaged ECG was of </text>
<text top="694" left="489" width="260" height="17" font="17">greater value than cardiac MRI or biopsy.</text>
<text top="695" left="749" width="29" height="10" font="19">S7.3-14</text>
<text top="712" left="459" width="344" height="17" font="17">11.  The value of an electrophysiological study is uncer-</text>
<text top="731" left="489" width="314" height="17" font="17">tain in asymptomatic arrhythmogenic right ven-</text>
<text top="749" left="489" width="322" height="17" font="17">tricular cardiomyopathy patients with preserved </text>
<text top="767" left="489" width="326" height="17" font="17">ventricular function in predicting subsequent </text>
<text top="786" left="489" width="320" height="17" font="17">risk for SCD. Studies of programmed ventricular </text>
<text top="804" left="489" width="321" height="17" font="17">stimulation in patients with definite or probable </text>
<text top="823" left="489" width="320" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy </text>
<text top="841" left="489" width="314" height="17" font="17">include most symptomatic patients, making rec-</text>
<text top="859" left="489" width="317" height="17" font="17">ommendations on asymptomatic patients difficult. </text>
<text top="878" left="489" width="318" height="17" font="17">Electrophysiological studies induce sustained VT in </text>
<text top="896" left="489" width="207" height="17" font="17">approximately 60% of patients</text>
<text top="897" left="696" width="60" height="10" font="19">S7.3-10,S7.3-36</text>
<text top="896" left="756" width="55" height="17" font="17">; many </text>
<text top="914" left="489" width="318" height="17" font="17">of whom have had prior spontaneous episodes of </text>
<text top="933" left="489" width="319" height="17" font="17">sustained VT. In patients with primary prevention </text>
<text top="951" left="489" width="314" height="17" font="17">ICDs, inducible sustained VT did not predict sub-</text>
<text top="970" left="489" width="212" height="17" font="17">sequent appropriate ICD shocks.</text>
<text top="970" left="701" width="29" height="10" font="19">S7.3-13</text>
<text top="970" left="730" width="80" height="17" font="17"> In 1 study </text>
<text top="988" left="489" width="320" height="17" font="17">including symptomatic patients, patients without </text>
<text top="1006" left="489" width="318" height="17" font="17">inducible VT were less likely to receive appropriate </text>
<text top="1025" left="489" width="74" height="17" font="17">ICD shocks.</text>
<text top="1025" left="563" width="24" height="10" font="19">S7.3-9</text>
<text top="1025" left="587" width="220" height="17" font="17"> In asymptomatic patients without </text>
<text top="1043" left="489" width="314" height="17" font="17">evidence of VA on ambulatory monitoring, a neg-</text>
<text top="1061" left="489" width="319" height="17" font="17">ative electrophysiological study may have limited </text>
<text top="1080" left="489" width="232" height="17" font="17">value in decision-making for an ICD.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e315</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="291" height="21" font="18"><b>7.4. Hypertrophic Cardiomyopathy</b></text>
<text top="120" left="85" width="135" height="12" font="26"><b>Recommendations for HCM</b></text>
<text top="137" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="151" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 31</b></a></text>
<text top="151" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="172" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="172" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="172" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="213" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="213" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="193" left="205" width="160" height="12" font="4">1.  In patients with HCM, SCD risk </text>
<text top="206" left="217" width="193" height="12" font="4">stratification should be performed at the </text>
<text top="220" left="217" width="193" height="12" font="4">time of initial evaluation and periodically </text>
<text top="233" left="217" width="48" height="12" font="4">thereafter.</text>
<text top="234" left="266" width="39" height="7" font="23">S7.4-1–S7.4-8</text>
<text top="288" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="288" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="254" left="205" width="196" height="12" font="4">2.  In patients with HCM who have survived </text>
<text top="268" left="217" width="147" height="12" font="4">an SCA due to VT or VF, or have </text>
<text top="281" left="217" width="195" height="12" font="4">spontaneous sustained VT causing syncope </text>
<text top="295" left="217" width="181" height="12" font="4">or hemodynamic compromise, an ICD is </text>
<text top="308" left="217" width="200" height="12" font="4">recommended if meaningful survival greater </text>
<text top="322" left="217" width="106" height="12" font="4">than 1 year is expected.</text>
<text top="322" left="323" width="77" height="7" font="23">S7.4-1,S7.4-6,S7.4-9,S7.4-10</text>
<text top="356" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="356" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="342" left="205" width="218" height="12" font="4">3.  In first-degree relatives of patients with HCM, </text>
<text top="356" left="217" width="178" height="12" font="4">an ECG and echocardiogram should be </text>
<text top="369" left="217" width="50" height="12" font="4">performed.</text>
<text top="370" left="267" width="44" height="7" font="23">S7.4-11–S7.4-17</text>
<text top="417" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="417" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="390" left="205" width="176" height="12" font="4">4.  In first-degree relatives of patients  </text>
<text top="404" left="217" width="172" height="12" font="4">with HCM due to a known causative </text>
<text top="417" left="217" width="158" height="12" font="4">mutation, genetic counseling and </text>
<text top="431" left="217" width="171" height="12" font="4">mutation-specific genetic testing are </text>
<text top="444" left="217" width="69" height="12" font="4">recommended.</text>
<text top="445" left="286" width="91" height="7" font="23">S7.4-13–S7.4-15,S7.4-18,S7.4-19</text>
<text top="479" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="479" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="465" left="205" width="219" height="12" font="4">5.  In patients with clinically suspected or diagnosed </text>
<text top="478" left="216" width="202" height="12" font="4">HCM, genetic counseling and genetic testing </text>
<text top="492" left="216" width="68" height="12" font="4">are reasonable.</text>
<text top="492" left="284" width="89" height="7" font="23">S7.4-13–S7.4-15,S7.4-18–S7.4-22</text>
<text top="590" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="527" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="513" left="205" width="207" height="12" font="4">6.  In patients with HCM and 1 or more of the </text>
<text top="526" left="217" width="202" height="12" font="4">following risk factors, an ICD is reasonable if </text>
<text top="540" left="217" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="553" left="217" width="43" height="12" font="4">expected:</text>
<text top="567" left="205" width="191" height="12" font="4">  a.  Maximum LV wall thickness ≥30 mm  </text>
<text top="580" left="227" width="54" height="12" font="4">(LOE: B-NR).</text>
<text top="581" left="281" width="80" height="7" font="23">S7.4-2,S7.4-3,S7.4-23,S7.4-24</text>
<text top="594" left="205" width="195" height="12" font="4">  b.  SCD in 1 or more first-degree relatives </text>
<text top="607" left="227" width="131" height="12" font="4">presumably caused by HCM  </text>
<text top="621" left="227" width="54" height="12" font="4">(LOE: C-LD).</text>
<text top="621" left="281" width="43" height="7" font="23">S7.4-25,S7.4-26</text>
<text top="634" left="205" width="182" height="12" font="4">  c.  1 or more episodes of unexplained  </text>
<text top="648" left="226" width="180" height="12" font="4">syncope within the preceding 6 months </text>
<text top="661" left="226" width="54" height="12" font="4">(LOE: C-LD).</text>
<text top="662" left="280" width="39" height="7" font="23">S7.4-8,S7.4-26</text>
<text top="584" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="647" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="729" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="703" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="688" left="205" width="213" height="12" font="4">7.  In patients with HCM who have spontaneous </text>
<text top="702" left="216" width="81" height="12" font="4">NSVT (LOE: C-LD) </text>
<text top="702" left="297" width="61" height="7" font="23">S7.4-2,S7.4-26,S7.4-27</text>
<text top="702" left="359" width="29" height="12" font="4"> or an </text>
<text top="716" left="216" width="179" height="12" font="4">abnormal blood pressure response with </text>
<text top="729" left="216" width="90" height="12" font="4">exercise (LOE: B-NR) </text>
<text top="729" left="306" width="60" height="7" font="23">S7.4-5,S7.4-28,S7.4-29</text>
<text top="729" left="366" width="48" height="12" font="4">, who also </text>
<text top="743" left="216" width="205" height="12" font="4">have additional SCD risk modifiers or high-risk </text>
<text top="756" left="216" width="193" height="12" font="4">features, an ICD is reasonable if meaningful </text>
<text top="770" left="216" width="172" height="12" font="4">survival greater than 1 year is expected.</text>
<text top="754" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="824" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="802" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="790" left="205" width="184" height="12" font="4">8.  In patients with HCM who have NSVT </text>
<text top="804" left="217" width="51" height="12" font="4">(LOE: B-NR)</text>
<text top="804" left="268" width="61" height="7" font="23">S7.4-2,S7.4-26,S7.4-27</text>
<text top="804" left="329" width="75" height="12" font="4"> or an abnormal </text>
<text top="817" left="217" width="198" height="12" font="4">blood pressure response with exercise (LOE: </text>
<text top="831" left="217" width="25" height="12" font="4">B-NR)</text>
<text top="831" left="242" width="61" height="7" font="23">S7.4-5,S7.4-28,S7.4-29</text>
<text top="831" left="303" width="96" height="12" font="4"> but do not have any </text>
<text top="844" left="217" width="183" height="12" font="4">other SCD risk modifiers, an ICD may be </text>
<text top="858" left="217" width="174" height="12" font="4">considered, but its benefit is uncertain.</text>
<text top="846" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="899" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="899" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="879" left="205" width="183" height="12" font="4">9.  In patients with HCM and a history of </text>
<text top="892" left="217" width="179" height="12" font="4">sustained VT or VF, amiodarone may be </text>
<text top="906" left="217" width="207" height="12" font="4">considered when an ICD is not feasible or not </text>
<text top="919" left="217" width="109" height="12" font="4">preferred by the patient.</text>
<text top="920" left="326" width="43" height="7" font="23">S7.4-30,S7.4-31</text>
<text top="954" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="967" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="960" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="940" left="199" width="170" height="12" font="4">10.  In patients with HCM, an invasive </text>
<text top="953" left="217" width="201" height="12" font="4">electrophysiological study with programmed </text>
<text top="967" left="217" width="167" height="12" font="4">ventricular stimulation should not be </text>
<text top="980" left="217" width="142" height="12" font="4">performed for risk stratification.</text>
<text top="981" left="359" width="43" height="7" font="23">S7.4-32,S7.4-33</text>
<text top="1008" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="1022" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="1015" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1001" left="200" width="211" height="12" font="4">11.  In patients with an identified HCM genotype </text>
<text top="1015" left="216" width="190" height="12" font="4">in the absence of SCD risk factors, an ICD </text>
<text top="1028" left="216" width="113" height="12" font="4">should not be implanted.</text>
<text top="1029" left="329" width="61" height="7" font="23">S7.4-7,S7.4-34,S7.4-35</text>
<text top="681" left="470" width="333" height="17" font="17">Refer to the ACCF/AHA HCM guideline for the defi-</text>
<text top="699" left="452" width="96" height="17" font="17">nition of HCM.</text>
<text top="699" left="548" width="29" height="10" font="19">S7.4-36</text>
<text top="742" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="763" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="790" left="467" width="340" height="17" font="17">1.  Patients with HCM have approximately a 1% risk </text>
<text top="808" left="489" width="116" height="17" font="17">of SCD per year.</text>
<text top="809" left="605" width="51" height="10" font="19">S7.4-1,S7.4-6</text>
<text top="808" left="656" width="155" height="17" font="17"> Selection of patients </text>
<text top="826" left="489" width="314" height="17" font="17">who are appropriate candidates for implanta-</text>
<text top="844" left="489" width="320" height="17" font="17">tion of an ICD can be a difficult clinical decision </text>
<text top="862" left="489" width="320" height="17" font="17">because of the individuality of each patient and </text>
<text top="880" left="489" width="319" height="17" font="17">family, variable definitions of risk factors and risk </text>
<text top="898" left="489" width="314" height="17" font="17">modifiers, sparse clinical data, the relative infre-</text>
<text top="916" left="489" width="321" height="17" font="17">quency of both HCM and  SCD in most clinical </text>
<text top="934" left="489" width="314" height="17" font="17">practices, and the potential complications of liv-</text>
<text top="952" left="489" width="319" height="17" font="17">ing with an ICD. Table 8 lists risk factors and risk </text>
<text top="970" left="489" width="321" height="17" font="17">modifiers associated with SCD in patients with </text>
<text top="988" left="489" width="319" height="17" font="17">HCM. ICD risk stratification should be performed </text>
<text top="1006" left="489" width="320" height="17" font="17">every 1 to 3 years in patients with HCM. There </text>
<text top="1024" left="489" width="319" height="17" font="17">is increasing evidence supporting the association </text>
<text top="1042" left="489" width="320" height="17" font="17">of late gadolinium enhancement on cardiac MRI </text>
<text top="1060" left="489" width="320" height="17" font="17">with the risk of sudden death and it is included </text>
<text top="1078" left="489" width="113" height="17" font="17">as a risk modifier.</text>
<text top="1079" left="602" width="63" height="10" font="19">S7.4-37–S7.4-39</text>
<text top="1078" left="665" width="143" height="17" font="17"> LV aneurysm may be </text>
<text top="88" left="452" width="37" height="12" font="3"><b>Table 8.</b></text>
<text top="88" left="490" width="294" height="12" font="22"><b>  Major Clinical Features Associated With Increased Risk of </b></text>
<text top="102" left="452" width="128" height="12" font="22"><b>SCD in Patients With HCM</b></text>
<text top="126" left="463" width="107" height="12" font="4">Established risk factors*</text>
<text top="147" left="463" width="215" height="12" font="4">  Survival from a cardiac arrest due to VT or VF </text>
<text top="148" left="678" width="56" height="7" font="23">S7.4-1,S7.4–5,S7.4–6</text>
<text top="168" left="463" width="285" height="12" font="4">   Spontaneous sustained VT causing syncope or hemodynamic </text>
<text top="181" left="473" width="58" height="12" font="4">compromise </text>
<text top="182" left="531" width="56" height="7" font="23">S7.4-1,S7.4–5,S7.4–6</text>
<text top="202" left="463" width="207" height="12" font="4">   Family history of SCD associated with HCM </text>
<text top="203" left="669" width="45" height="7" font="23">S7.4–25,S7.4–26</text>
<text top="223" left="463" width="130" height="12" font="4">   LV wall thickness ≥30 mm </text>
<text top="224" left="592" width="82" height="7" font="23">S7.4-2,S7.4-3,S7.4–23,S7.4–24</text>
<text top="244" left="463" width="165" height="12" font="4">   Unexplained syncope within 6 mo </text>
<text top="244" left="628" width="41" height="7" font="23">S7.4–8,S7.4–26</text>
<text top="265" left="463" width="79" height="12" font="4">   NSVT  ≥3 beats </text>
<text top="266" left="542" width="63" height="7" font="23">S7.4-2,S7.4–26,S7.4–27</text>
<text top="286" left="463" width="244" height="12" font="4">   Abnormal blood pressure response during exercise† </text>
<text top="286" left="707" width="64" height="7" font="23">S7.4–5,S7.4–28,S7.4–29</text>
<text top="307" left="463" width="107" height="12" font="4">Potential risk modifiers‡</text>
<text top="327" left="463" width="36" height="12" font="4">   &lt;30  y </text>
<text top="328" left="502" width="41" height="7" font="23">S7.4–5,S7.4–26</text>
<text top="348" left="463" width="207" height="12" font="4">   Delayed hyperenhancement on cardiac MRI </text>
<text top="349" left="670" width="69" height="7" font="23">S7.4–37–S7.4–39,S7.4–54</text>
<text top="369" left="463" width="87" height="12" font="4">   LVOT  obstruction </text>
<text top="369" left="553" width="36" height="7" font="23">S7.4-2,S7.4-4</text>
<text top="390" left="463" width="93" height="12" font="4">   Syncope &gt;5 y ago </text>
<text top="390" left="556" width="41" height="7" font="23">S7.4–8,S7.4–26</text>
<text top="410" left="463" width="81" height="12" font="4">High-risk subsets§</text>
<text top="431" left="463" width="67" height="12" font="4">   LV  aneurysm </text>
<text top="432" left="533" width="68" height="7" font="23">S7.4–40,S7.4–55,S7.4–56</text>
<text top="452" left="463" width="62" height="12" font="4">   LVEF  &lt;50% </text>
<text top="453" left="528" width="21" height="7" font="23">S7.4–52</text>
<text top="475" left="464" width="341" height="12" font="4">*There is general agreement in the literature that these factors independently </text>
<text top="489" left="452" width="247" height="12" font="4">convey an increased risk for SCD in patients with HCM.</text>
<text top="502" left="464" width="341" height="12" font="4">†Decrease in blood pressure of 20 mm Hg or failure to increase systolic blood </text>
<text top="516" left="452" width="163" height="12" font="4">pressure &gt;20 mm Hg during exertion.</text>
<text top="529" left="464" width="299" height="12" font="4">‡There is a lack of agreement in the literature that these modifiers </text>
<text top="543" left="452" width="345" height="12" font="4">independently convey an increased risk of SCD in patients with HCM; however, </text>
<text top="556" left="452" width="343" height="12" font="4">a risk modifier when combined with a risk factor often identifies a patient with </text>
<text top="570" left="452" width="348" height="12" font="4">HCM at increased risk for SCD beyond the risk conveyed by the risk factor alone.</text>
<text top="583" left="464" width="335" height="12" font="4">§A small subset of patients with an LVEF &lt;50% (end-stage disease) or an LV </text>
<text top="597" left="452" width="236" height="12" font="4">aneurysm warrant consideration for ICD implantation.</text>
<text top="597" left="688" width="20" height="7" font="23">S7.4-52</text>
<text top="610" left="464" width="331" height="12" font="4">HCM indicates hypertrophic cardiomyopathy; ICD, implantable cardioverter-</text>
<text top="624" left="452" width="330" height="12" font="4">defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; LVOT, </text>
<text top="637" left="452" width="345" height="12" font="4">left ventricular outflow tract; NSVT, nonsustained ventricular tachycardia; SCD, </text>
<text top="651" left="452" width="348" height="12" font="4">sudden cardiac death; VT, ventricular tachycardia; and VF, ventricular fibrillation.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e316</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="319" height="17" font="17">associated with a risk of sustained monomorphic </text>
<text top="106" left="111" width="19" height="17" font="17">VT.</text>
<text top="106" left="130" width="29" height="10" font="19">S7.4-40</text>
<text top="106" left="159" width="272" height="17" font="17"> Age is also an important consideration, </text>
<text top="124" left="111" width="318" height="17" font="17">as sudden death risk is greater in those &lt;30 years </text>
<text top="142" left="111" width="314" height="17" font="17">of age, and low in patients whose initial presenta-</text>
<text top="160" left="111" width="204" height="17" font="17">tion is after the age of 60 years,</text>
<text top="161" left="315" width="56" height="10" font="19">S7.4-5,S7.4-26</text>
<text top="160" left="371" width="4" height="17" font="17">.</text>
<text top="161" left="375" width="29" height="10" font="19">S7.4-41</text>
<text top="178" left="89" width="345" height="17" font="17">2. HCM is the most common cause of SCD in </text>
<text top="196" left="111" width="208" height="17" font="17">individuals  &lt;40 years of age.</text>
<text top="197" left="319" width="29" height="10" font="19">S7.4-26</text>
<text top="196" left="348" width="88" height="17" font="17"> Individuals </text>
<text top="214" left="111" width="330" height="17" font="17">who have survived an episode of SCD, </text>
<text top="232" left="111" width="329" height="17" font="17">VF, or sustained VT resulting in syncope </text>
<text top="232" left="425" width="4" height="17" font="17"> </text>
<text top="250" left="111" width="329" height="17" font="17">or hemodynamic compromise warrant ICD </text>
<text top="250" left="425" width="4" height="17" font="17"> </text>
<text top="268" left="111" width="85" height="17" font="17">implantation.</text>
<text top="269" left="196" width="109" height="10" font="19">S7.4-1,S7.4-6,S7.4-9,S7.4-10</text>
<text top="268" left="305" width="133" height="17" font="17"> Although there </text>
<text top="286" left="111" width="323" height="17" font="17">are no RCTs assessing the use of the ICD in </text>
<text top="304" left="111" width="322" height="17" font="17">patients with HCM who have survived SCD, 1 </text>
<text top="322" left="111" width="319" height="17" font="17">study reported that 54% of patients with an ICD </text>
<text top="340" left="111" width="314" height="17" font="17">placed for secondary prevention received appro-</text>
<text top="358" left="111" width="318" height="17" font="17">priate ICD therapy during an average follow-up of </text>
<text top="376" left="111" width="63" height="17" font="17">4.6 years.</text>
<text top="377" left="174" width="29" height="10" font="19">S7.4-10</text>
<text top="376" left="203" width="228" height="17" font="17"> Select patients with HCM may be </text>
<text top="395" left="111" width="319" height="17" font="17">candidates for implantation of the subcutaneous </text>
<text top="413" left="111" width="236" height="17" font="17">implantable cardioverter-defibrillator</text>
<text top="413" left="347" width="29" height="10" font="19">S7.4-42</text>
<text top="413" left="375" width="50" height="17" font="17">; how-</text>
<text top="431" left="111" width="318" height="17" font="17">ever, more data on this group are needed especially </text>
<text top="449" left="111" width="319" height="17" font="17">given their higher risk of T wave oversensing that </text>
<text top="467" left="111" width="311" height="17" font="17">may increase the risk of inappropriate ICD shocks.</text>
<text top="485" left="89" width="344" height="17" font="17">3. Clinical and/or genetic screening of first- and </text>
<text top="503" left="111" width="320" height="17" font="17">second-degree family members of patients with </text>
<text top="521" left="111" width="314" height="17" font="17">HCM is important to identify those with unrec-</text>
<text top="539" left="111" width="327" height="17" font="17">ognized disease. Genetic counseling should </text>
<text top="557" left="111" width="322" height="17" font="17">precede genetic testing of family members to </text>
<text top="575" left="111" width="314" height="17" font="17">enhance their understanding of the useful-</text>
<text top="593" left="111" width="189" height="17" font="17">ness and cost of testing.</text>
<text top="594" left="300" width="93" height="10" font="19">S7.4-18,S7.4-20,S7.4-43</text>
<text top="593" left="394" width="44" height="17" font="17"> On </text>
<text top="611" left="111" width="323" height="17" font="17">the basis of family history, clinical screening, </text>
<text top="629" left="111" width="314" height="17" font="17">and  pedigree analyses, the pattern of inheri-</text>
<text top="647" left="111" width="324" height="17" font="17">tance is ascertained to  identify and manage </text>
<text top="88" left="489" width="125" height="17" font="17">relatives at risk.</text>
<text top="88" left="614" width="190" height="10" font="19">S7.4-13,S7.4-14,S7.4-18,S7.4-19,S7.4-43–S7.4-45</text>
<text top="88" left="803" width="11" height="17" font="17">   </text>
<text top="106" left="489" width="321" height="17" font="17">Because familial HCM is a dominant disorder, the </text>
<text top="124" left="489" width="319" height="17" font="17">risk that an affected patient will transmit disease to </text>
<text top="142" left="489" width="317" height="17" font="17">each offspring is 50%. When a pathogenic mutation </text>
<text top="160" left="489" width="320" height="17" font="17">is identified in an index patient, the genetic status </text>
<text top="178" left="489" width="320" height="17" font="17">of each family member can be readily ascertained. </text>
<text top="196" left="489" width="314" height="17" font="17">Relatives with overt HCM will have the same patho-</text>
<text top="214" left="489" width="317" height="17" font="17">genic HCM mutation as the index patient. Pathogenic </text>
<text top="232" left="489" width="318" height="17" font="17">mutations may also be identified in other relatives </text>
<text top="250" left="489" width="314" height="17" font="17">with  unknown clinical status. These mutation-</text>
<text top="268" left="489" width="314" height="17" font="17">positive individuals should be evaluated by physi-</text>
<text top="286" left="489" width="251" height="17" font="17">cal examination, electrocardiography,</text>
<text top="287" left="741" width="63" height="10" font="19">S7.4-11,S7.4-17</text>
<text top="286" left="803" width="4" height="17" font="17"> </text>
<text top="304" left="489" width="140" height="17" font="17">and echocardiography</text>
<text top="305" left="629" width="90" height="10" font="19">S7.4-12,S7.4-16,S7.4-17</text>
<text top="304" left="720" width="89" height="17" font="17"> and, if HCM  </text>
<text top="322" left="489" width="322" height="17" font="17">is identified, these individuals should undergo </text>
<text top="340" left="489" width="314" height="17" font="17">risk stratification. Gene-positive subjects with-</text>
<text top="358" left="489" width="320" height="17" font="17">out evidence of HCM may be at risk for future </text>
<text top="376" left="489" width="319" height="17" font="17">development of HCM and benefit from ongoing </text>
<text top="395" left="489" width="116" height="17" font="17">clinical evaluation.</text>
<text top="395" left="605" width="91" height="10" font="19">S7.4-15,S7.4-46,S7.4-47</text>
<text top="395" left="697" width="112" height="17" font="17"> If the proband’s </text>
<text top="413" left="489" width="314" height="17" font="17">implicated mutation is the bona fide disease–</text>
<text top="431" left="489" width="314" height="17" font="17">causing mutation, then mutation-negative fam-</text>
<text top="449" left="489" width="319" height="17" font="17">ily members and their descendants are not at an </text>
<text top="467" left="489" width="321" height="17" font="17">increased risk for developing HCM and do not </text>
<text top="485" left="489" width="314" height="17" font="17">need further evaluation. However, such muta-</text>
<text top="503" left="489" width="325" height="17" font="17">tion-negative family members must have an </text>
<text top="521" left="489" width="314" height="17" font="17">echocardiogram to ensure genotype and pheno-</text>
<text top="539" left="489" width="118" height="17" font="17">type concordance.</text>
<text top="557" left="467" width="336" height="17" font="17">4.  In a study of 1053 unrelated patients with clini-</text>
<text top="575" left="489" width="322" height="17" font="17">cally manifest HCM, 359 patients (34%) were </text>
<text top="593" left="489" width="314" height="17" font="17">genotype positive for an HCM-associated muta-</text>
<text top="611" left="489" width="223" height="17" font="17">tion in ≥1 HCM-associated genes.</text>
<text top="612" left="712" width="29" height="10" font="19">S7.4-22</text>
<text top="611" left="742" width="68" height="17" font="17"> Whether </text>
<text top="629" left="489" width="323" height="17" font="17">the results of genetic testing in the proband </text>
<text top="647" left="489" width="319" height="17" font="17">improve outcomes is uncertain, but identification </text>
<text top="1020" left="74" width="45" height="12" font="3"><b>Figure 7. </b></text>
<text top="1020" left="120" width="203" height="12" font="22"><b>Prevention of SCD in patients with HCM.</b> </text>
<text top="1033" left="74" width="718" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 7.4 for discussion. *ICD candidacy as determined by functional status, life expectancy, or </text>
<text top="1047" left="74" width="714" height="12" font="4">patient preference. †Risk modifiers: Age &lt;30 y, late gadolinium enhancement on cardiac MRI, LVOT obstruction, LV aneurysm, syncope &gt;5 y. BP indicates blood </text>
<text top="1060" left="74" width="729" height="12" font="4">pressure; HCM, hypertrophic cardiomyopathy; Hx, history; ICD, implantable cardioverter-defibrillator; LVOT, left ventricular outflow tract; LVWT, left ventricular wall </text>
<text top="1074" left="74" width="667" height="12" font="4">thickness; MRI, magnetic resonance imaging; NSVT, nonsustained ventricular tachycardia; SCD, sudden cardiac death; and VT, ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e317</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="324" height="17" font="17">of a mutation can help inform screening of </text>
<text top="106" left="111" width="56" height="17" font="17">relatives.</text>
<text top="124" left="89" width="342" height="17" font="17">5.  Genetic counseling is important in patients with </text>
<text top="142" left="111" width="321" height="17" font="17">HCM, and genetic screening of relatives is also </text>
<text top="160" left="111" width="324" height="17" font="17">important unless there are no living first- or </text>
<text top="178" left="111" width="323" height="17" font="17">second-degree relatives. Most HCM is caused </text>
<text top="196" left="111" width="322" height="17" font="17">by an autosomal dominant mutation in genes </text>
<text top="214" left="111" width="314" height="17" font="17">that encode sarcomere proteins or sarcomere-</text>
<text top="232" left="111" width="323" height="17" font="17">associated proteins. Presence of a pathogenic </text>
<text top="250" left="111" width="324" height="17" font="17">sarcomere protein gene mutation in patients </text>
<text top="268" left="111" width="321" height="17" font="17">with HCM identifies risk of LV dysfunction and </text>
<text top="286" left="111" width="319" height="17" font="17">adverse outcome irrespective of the myofilament </text>
<text top="304" left="111" width="57" height="17" font="17">involved.</text>
<text top="305" left="168" width="157" height="10" font="19">S7.4-13–S7.4-15,S7.4-18,S7.4-19,S7.4-22</text>
<text top="304" left="325" width="100" height="17" font="17"> A single muta-</text>
<text top="322" left="111" width="320" height="17" font="17">tion in 1 of the 2 alleles (or copies) of a gene is </text>
<text top="340" left="111" width="318" height="17" font="17">sufficient to cause HCM; however, 5% of patients </text>
<text top="358" left="111" width="318" height="17" font="17">with HCM have ≥2 mutations in the same gene or </text>
<text top="376" left="111" width="318" height="17" font="17">different genes, which can be a marker for worse </text>
<text top="394" left="111" width="67" height="17" font="17">outcomes.</text>
<text top="395" left="178" width="92" height="10" font="19">S7.4-13,S7.4-34,S7.4-48</text>
<text top="394" left="270" width="164" height="17" font="17"> When genetic testing </text>
<text top="412" left="111" width="314" height="17" font="17">reveals a mutation in the index patient, ascertain-</text>
<text top="430" left="111" width="318" height="17" font="17">ment of genetic status in first- and second-degree </text>
<text top="448" left="111" width="320" height="17" font="17">relatives can be predictive of risk for developing </text>
<text top="466" left="111" width="38" height="17" font="17">HCM.</text>
<text top="467" left="149" width="61" height="10" font="19">S7.4-14,S7.4-49</text>
<text top="466" left="209" width="225" height="17" font="17"> Relatives with overt HCM will </text>
<text top="484" left="111" width="319" height="17" font="17">have the same pathogenic HCM mutation as the </text>
<text top="503" left="111" width="88" height="17" font="17">index patient.</text>
<text top="521" left="89" width="336" height="17" font="17">6. Several studies have described an indepen-</text>
<text top="539" left="111" width="328" height="17" font="17">dent relationship between hypertrophy and </text>
<text top="557" left="111" width="329" height="17" font="17">SCD when the magnitude of hypertrophy is   </text>
<text top="574" left="111" width="57" height="18" font="17">≥30 mm.</text>
<text top="575" left="168" width="112" height="10" font="19">S7.4-2,S7.4-3,S7.4-23,S7.4-24</text>
<text top="575" left="280" width="149" height="17" font="17"> Risk does not abruptly </text>
<text top="593" left="111" width="314" height="17" font="17">increase for patients with a ≥30 mm wall thick-</text>
<text top="611" left="111" width="285" height="17" font="17">ness, but it rather increases in a linear manner</text>
<text top="611" left="396" width="29" height="10" font="19">S7.4-24</text>
<text top="611" left="425" width="4" height="17" font="17"> </text>
<text top="629" left="111" width="318" height="17" font="17">and appears to carry more prognostic significance </text>
<text top="647" left="111" width="314" height="17" font="17">in younger patients. A young adult with hypertro-</text>
<text top="665" left="111" width="319" height="17" font="17">phy that approaches 30 mm may have similar or </text>
<text top="683" left="111" width="314" height="17" font="17">greater SCD risk than an older patient with maxi-</text>
<text top="701" left="111" width="189" height="17" font="17">mum wall thickness ≥30 mm.</text>
<text top="702" left="300" width="61" height="10" font="19">S7.4-23,S7.4-50</text>
<text top="719" left="129" width="301" height="17" font="17">Patients with HCM are at an increased risk for </text>
<text top="737" left="111" width="314" height="17" font="17">SCD if they have a first-degree relative who expe-</text>
<text top="755" left="111" width="319" height="17" font="17">rienced SCD presumably caused by HCM. Family </text>
<text top="773" left="111" width="321" height="17" font="17">history appears to be an independent predictor </text>
<text top="791" left="111" width="319" height="17" font="17">of SCD although the supportive studies are small </text>
<text top="809" left="111" width="117" height="17" font="17">and observational.</text>
<text top="810" left="228" width="61" height="10" font="19">S7.4-25,S7.4-26</text>
<text top="809" left="289" width="136" height="17" font="17"> Syncope can be neu-</text>
<text top="827" left="111" width="321" height="17" font="17">rally mediated or medication-related as well as </text>
<text top="845" left="111" width="314" height="17" font="17">due to VA and requires a careful evaluation be-</text>
<text top="863" left="111" width="258" height="17" font="17">fore considering it a risk factor for SCD.</text>
<text top="864" left="369" width="56" height="10" font="19">S7.4-8,S7.4-26</text>
<text top="863" left="425" width="6" height="17" font="17">  </text>
<text top="881" left="111" width="320" height="17" font="17">In an analysis, syncope that was unexplained or </text>
<text top="899" left="111" width="314" height="17" font="17">thought not to be neurally mediated was associ-</text>
<text top="917" left="111" width="320" height="17" font="17">ated with SCD risk only when it occurred within </text>
<text top="936" left="111" width="321" height="17" font="17">the past 6 months but not if the most episode </text>
<text top="954" left="111" width="184" height="17" font="17">occurred &gt;5 years previously.</text>
<text top="954" left="295" width="24" height="10" font="19">S7.4-8</text>
<text top="972" left="89" width="347" height="17" font="17">7. Although sustained VT is clearly associated </text>
<text top="990" left="111" width="322" height="17" font="17">with SCD, the data for NSVT are less robust. </text>
<text top="1008" left="111" width="314" height="17" font="17">Most studies do not support NSVT as an inde-</text>
<text top="1026" left="111" width="323" height="17" font="17">pendent risk factor for SCD in patients with  </text>
<text top="1044" left="111" width="37" height="17" font="17">HCM,</text>
<text top="1044" left="148" width="86" height="10" font="19">S7.4-2,S7.4-26,S7.4-27</text>
<text top="1044" left="233" width="199" height="17" font="17"> but the risk increases if risk </text>
<text top="1062" left="111" width="321" height="17" font="17">modifiers are present, especially in patients  &lt;30 </text>
<text top="1080" left="111" width="81" height="17" font="17">years of age.</text>
<text top="1081" left="191" width="29" height="10" font="19">S7.4-27</text>
<text top="1080" left="220" width="210" height="17" font="17"> Up to one third of patients with </text>
<text top="88" left="489" width="320" height="17" font="17">HCM have an abnormal blood pressure response </text>
<text top="106" left="489" width="318" height="17" font="17">during exercise testing (defined variably as either a </text>
<text top="124" left="489" width="319" height="17" font="17">20 mm Hg decrease in blood pressure or a failure </text>
<text top="142" left="489" width="320" height="17" font="17">to increase systolic blood pressure by at least 20 </text>
<text top="160" left="489" width="146" height="17" font="17">mm  Hg during effort).</text>
<text top="160" left="635" width="60" height="10" font="19">S7.4-28,S7.4-29</text>
<text top="160" left="694" width="116" height="17" font="17"> This finding has </text>
<text top="178" left="489" width="314" height="17" font="17">been postulated to be a risk factor for SCD; how-</text>
<text top="196" left="489" width="318" height="17" font="17">ever, it is unclear how this relates to the increase in </text>
<text top="214" left="489" width="320" height="17" font="17">dynamic LV outflow tract obstruction that occurs </text>
<text top="232" left="489" width="322" height="17" font="17">with exertion, a hemodynamic condition that is </text>
<text top="250" left="489" width="320" height="17" font="17">readily modifiable with medication or mechanical </text>
<text top="268" left="489" width="318" height="17" font="17">procedures. The significance of an abnormal blood </text>
<text top="286" left="489" width="318" height="17" font="17">pressure response with exercise predicting SCD risk </text>
<text top="304" left="489" width="314" height="17" font="17">increases in the presence of risk modifiers (Table 8).</text>
<text top="322" left="467" width="342" height="17" font="17">8.  Most studies have found that NSVT alone has a </text>
<text top="340" left="489" width="257" height="17" font="17">low positive predictive value for SCD</text>
<text top="341" left="746" width="60" height="10" font="19">S7.4-2,S7.4-26, </text>
<text top="359" left="489" width="28" height="10" font="19">S7.4-27</text>
<text top="358" left="516" width="292" height="17" font="17">; therefore, use of an ICD is more appropriate if </text>
<text top="376" left="489" width="320" height="17" font="17">risk modifiers are also present. An abnormal blood </text>
<text top="394" left="489" width="314" height="17" font="17">pressure response to exercise has also been associ-</text>
<text top="412" left="489" width="228" height="17" font="17">ated with the risk of sudden death,</text>
<text top="413" left="717" width="87" height="10" font="19">S7.4-5,S7.4-28,S7.4-29</text>
<text top="412" left="803" width="4" height="17" font="17"> </text>
<text top="430" left="489" width="319" height="17" font="17">but it is unclear how this relates to the increase in </text>
<text top="448" left="489" width="320" height="17" font="17">dynamic LV outflow tract obstruction that occurs </text>
<text top="466" left="489" width="314" height="17" font="17">with effort, which is often treatable. The signifi-</text>
<text top="485" left="489" width="322" height="17" font="17">cance of an abnormal blood pressure response </text>
<text top="503" left="489" width="323" height="17" font="17">with exercise for predicting SCD risk increases </text>
<text top="521" left="489" width="259" height="17" font="17">when risk modifiers are present (Table 8).</text>
<text top="539" left="467" width="342" height="17" font="17">9.  The ICD is recommended for the prevention of </text>
<text top="557" left="489" width="321" height="17" font="17">SCD in patients with HCM who have survived </text>
<text top="575" left="489" width="318" height="17" font="17">sustained VT or VF as antiarrhythmic medications </text>
<text top="593" left="489" width="172" height="17" font="17">have limited effectiveness.</text>
<text top="593" left="661" width="29" height="10" font="19">S7.4-31</text>
<text top="593" left="690" width="118" height="17" font="17"> Amiodarone has </text>
<text top="611" left="489" width="314" height="17" font="17">been associated with improved survival in obser-</text>
<text top="629" left="489" width="319" height="17" font="17">vational studies and is an option for patients for </text>
<text top="647" left="489" width="314" height="17" font="17">whom an ICD is not feasible due to limited expec-</text>
<text top="665" left="489" width="253" height="17" font="17">tation for survival or patient preference.</text>
<text top="666" left="742" width="61" height="10" font="19">S7.4-30,S7.4-31</text>
<text top="683" left="459" width="350" height="17" font="17">10.  Approximately one third of consecutive patients </text>
<text top="701" left="489" width="314" height="17" font="17">with HCM undergoing an electrophysiologi-</text>
<text top="719" left="489" width="322" height="17" font="17">cal study have polymorphic VT or VF induced </text>
<text top="737" left="489" width="321" height="17" font="17">by programmed ventricular stimulation, but the </text>
<text top="755" left="489" width="318" height="17" font="17">results of programmed stimulation do not predict </text>
<text top="773" left="489" width="320" height="17" font="17">SCD risk. Programmed ventricular stimulation in </text>
<text top="791" left="489" width="320" height="17" font="17">patients with HCM has low predictive value and </text>
<text top="809" left="489" width="222" height="17" font="17">a nontrivial risk of complications.</text>
<text top="810" left="711" width="92" height="10" font="19">S7.4-32,S7.4-33,S7.4-51</text>
<text top="809" left="803" width="4" height="17" font="17"> </text>
<text top="827" left="489" width="318" height="17" font="17">Electrophysiological studies can help to clarify the </text>
<text top="845" left="489" width="320" height="17" font="17">diagnosis of wide complex tachycardia or guide </text>
<text top="863" left="489" width="314" height="17" font="17">therapy for supraventricular tachycardia or bun-</text>
<text top="881" left="489" width="119" height="17" font="17">dle branch reentry.</text>
<text top="899" left="459" width="350" height="17" font="17">11.  SCD may cluster in certain families with HCM, </text>
<text top="917" left="489" width="314" height="17" font="17">and the possibility that specific sarcomere muta-</text>
<text top="936" left="489" width="314" height="17" font="17">tions may confer SCD risk has been hypothe-</text>
<text top="954" left="489" width="320" height="17" font="17">sized. However, subsequent studies of selected </text>
<text top="972" left="489" width="134" height="17" font="17">patients with HCM</text>
<text top="972" left="623" width="62" height="10" font="19">S7.4-34,S7.4-35</text>
<text top="972" left="685" width="128" height="17" font="17"> were unable to </text>
<text top="990" left="489" width="324" height="17" font="17">establish a clinically useful relation between </text>
<text top="1008" left="489" width="319" height="17" font="17">genotype and SCD risk. In some cases, the rate </text>
<text top="1026" left="489" width="319" height="17" font="17">of adverse events (and prevalence of associated </text>
<text top="1044" left="489" width="323" height="17" font="17">SCD risk factors) was lower in patients with </text>
<text top="1062" left="489" width="324" height="17" font="17">mutations initially felt to be malignant than </text>
<text top="1080" left="489" width="321" height="17" font="17">it was in those with mutations believed to be </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e318</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="49" height="17" font="17">benign.</text>
<text top="88" left="160" width="62" height="10" font="19">S7.4-34,S7.4-35</text>
<text top="88" left="222" width="207" height="17" font="17"> Data from series of unselected </text>
<text top="106" left="111" width="328" height="17" font="17">consecutive outpatients suggest that most </text>
<text top="125" left="111" width="322" height="17" font="17">mutations are novel and limited to particular </text>
<text top="143" left="111" width="54" height="17" font="17">families.</text>
<text top="144" left="165" width="62" height="10" font="19">S7.4-34,S7.4-35</text>
<text top="143" left="227" width="207" height="17" font="17"> Therefore, routine mutation </text>
<text top="161" left="111" width="318" height="17" font="17">screening would appear to be of little prognostic </text>
<text top="180" left="111" width="96" height="17" font="17">value in HCM.</text>
<text top="181" left="208" width="30" height="10" font="19">S7.4-52</text>
<text top="180" left="237" width="188" height="17" font="17"> The short-term risk of sud-</text>
<text top="198" left="111" width="318" height="17" font="17">den death in patients who are genotype positive </text>
<text top="217" left="111" width="319" height="17" font="17">but have no other manifestations of the disease </text>
<text top="235" left="111" width="122" height="17" font="17">appears to be low.</text>
<text top="236" left="233" width="30" height="10" font="19">S7.4-53</text>
<text top="235" left="263" width="167" height="17" font="17"> Therefore, an ICD is not </text>
<text top="254" left="111" width="192" height="17" font="17">indicated in these individuals.</text>
<text top="284" left="74" width="112" height="18" font="24"><i><b>7.5. Myocarditis</b></i></text>
<text top="312" left="85" width="169" height="12" font="26"><b>Recommendations for Myocarditis</b></text>
<text top="329" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="343" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 32</b></a></text>
<text top="343" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="363" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="363" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="363" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="418" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="418" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="385" left="205" width="196" height="12" font="4">1.  In patients with life-threatening VT or VF </text>
<text top="398" left="217" width="172" height="12" font="4">associated with confirmed or clinically </text>
<text top="412" left="217" width="186" height="12" font="4">suspected myocarditis, referral to centers </text>
<text top="425" left="217" width="179" height="12" font="4">with mechanical hemodynamic support </text>
<text top="439" left="217" width="188" height="12" font="4">and advanced arrhythmia management is </text>
<text top="452" left="217" width="67" height="12" font="4">recommended.</text>
<text top="453" left="284" width="17" height="7" font="23">S7.5-1</text>
<text top="507" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="507" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="473" left="205" width="203" height="12" font="4">2.  In patients with giant cell myocarditis with </text>
<text top="486" left="217" width="197" height="12" font="4">VF or hemodynamically unstable VT treated </text>
<text top="500" left="217" width="172" height="12" font="4">according to GDMT, an ICD and/or an </text>
<text top="513" left="217" width="207" height="12" font="4">antiarrhythmic medication may be considered </text>
<text top="527" left="217" width="199" height="12" font="4">if meaningful survival of greater than 1 year </text>
<text top="540" left="217" width="52" height="12" font="4">is expected.</text>
<text top="541" left="269" width="37" height="7" font="23">S7.5-2–S7.5-4</text>
<text top="581" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="602" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="630" left="89" width="343" height="17" font="17">1. Myocarditis is an inflammatory process often </text>
<text top="648" left="111" width="130" height="17" font="17">related to infection.</text>
<text top="649" left="242" width="83" height="10" font="19">S7.5-1,S7.5-5–S7.5-9</text>
<text top="648" left="325" width="104" height="17" font="17"> When patients </text>
<text top="667" left="111" width="325" height="17" font="17">are treated in centers with the availability </text>
<text top="685" left="111" width="314" height="17" font="17">of mechanical hemodynamic support proce-</text>
<text top="704" left="111" width="320" height="17" font="17">dures, cardiac catheterization, endomyocardial </text>
<text top="722" left="111" width="321" height="17" font="17">biopsy, advanced cardiac imaging procedures, </text>
<text top="741" left="111" width="325" height="17" font="17">and arrhythmia management including ICD </text>
<text top="759" left="111" width="289" height="17" font="17">implantation, outcomes appear improved.</text>
<text top="760" left="400" width="25" height="10" font="19">S7.5-1</text>
<text top="759" left="425" width="4" height="17" font="17"> </text>
<text top="778" left="111" width="319" height="17" font="17">The acute course of myocarditis varies ranging </text>
<text top="796" left="111" width="319" height="17" font="17">from an asymptomatic finding of transient ST-T </text>
<text top="815" left="111" width="322" height="17" font="17">changes noted on ECG to cardiogenic shock </text>
<text top="833" left="111" width="115" height="17" font="17">and recurrent VA.</text>
<text top="834" left="227" width="65" height="10" font="19">S7.5-10–S7.5-12</text>
<text top="833" left="292" width="136" height="17" font="17"> Acute management </text>
<text top="851" left="111" width="318" height="17" font="17">is largely supportive and can rapidly advance to </text>
<text top="870" left="111" width="197" height="17" font="17">requiring mechanical support.</text>
<text top="871" left="308" width="63" height="10" font="19">S7.5-13,S7.5-14</text>
<text top="870" left="372" width="57" height="17" font="17"> Cardiac </text>
<text top="888" left="111" width="314" height="17" font="17">arrhythmias range from conduction abnormali-</text>
<text top="907" left="111" width="249" height="17" font="17">ties to life-threatening VT and VF.</text>
<text top="908" left="360" width="65" height="10" font="19">S7.5-15–S7.5-17</text>
<text top="907" left="425" width="9" height="17" font="17">  </text>
<text top="925" left="111" width="314" height="17" font="17">Arrhythmias may require antiarrhythmic medi-</text>
<text top="944" left="111" width="209" height="17" font="17">cations and/or device therapy.</text>
<text top="944" left="321" width="30" height="10" font="19">S7.5-18</text>
<text top="944" left="351" width="82" height="17" font="17"> Giant cell  </text>
<text top="962" left="111" width="323" height="17" font="17">myocarditis is fairly uncommon, but it is of </text>
<text top="981" left="111" width="329" height="17" font="17">particular importance because it typically </text>
<text top="999" left="111" width="320" height="17" font="17">affects young individuals and is usually fatal if </text>
<text top="1018" left="111" width="69" height="17" font="17">untreated.</text>
<text top="1018" left="180" width="88" height="10" font="19">S7.5-2–S7.5-4,S7.5-19</text>
<text top="1018" left="269" width="157" height="17" font="17"> VT may require antiar-</text>
<text top="1036" left="111" width="314" height="17" font="17">rhythmic medications such as amiodarone and/</text>
<text top="1055" left="111" width="320" height="17" font="17">or an ICD that in some instances can be used </text>
<text top="1073" left="111" width="323" height="17" font="17">as a bridge to more advanced HF therapies </text>
<text top="88" left="489" width="322" height="17" font="17">such as LVAD or transplant. Myocarditis and </text>
<text top="106" left="489" width="294" height="17" font="17">SCD have been reported with HIV infection.</text>
<text top="106" left="783" width="20" height="10" font="19">S7.5-</text>
<text top="124" left="489" width="43" height="10" font="19">20,S7.5-21</text>
<text top="124" left="532" width="276" height="17" font="17"> Systemic lupus erythematous can cause </text>
<text top="142" left="489" width="239" height="17" font="17">myocarditis but only rarely VT or VF.</text>
<text top="142" left="728" width="58" height="10" font="19">S7.5-8,S7.5-22</text>
<text top="142" left="787" width="21" height="17" font="17"> In </text>
<text top="160" left="489" width="314" height="17" font="17">patients with Chagas disease, acute myocardi-</text>
<text top="178" left="489" width="320" height="17" font="17">tis is rare but more than one third of affected </text>
<text top="196" left="489" width="320" height="17" font="17">patients develop late myocardial damage with </text>
<text top="214" left="489" width="314" height="17" font="17">progressive HF. Conduction defects with pro-</text>
<text top="232" left="489" width="319" height="17" font="17">gression to complete heart block and VT or VF </text>
<text top="250" left="489" width="314" height="17" font="17">are common. Amiodarone appears to be effec-</text>
<text top="268" left="489" width="133" height="17" font="17">tive in treating VA.</text>
<text top="268" left="623" width="30" height="10" font="19">S7.5-23</text>
<text top="268" left="653" width="157" height="17" font="17"> An ICD is frequently </text>
<text top="286" left="489" width="254" height="17" font="17">used in the late phase of myocarditis,</text>
<text top="286" left="743" width="30" height="10" font="19">S7.5-24</text>
<text top="286" left="773" width="35" height="17" font="17"> and </text>
<text top="304" left="489" width="314" height="17" font="17">radiofrequency catheter ablation has been suc-</text>
<text top="322" left="489" width="320" height="17" font="17">cessfully used to control recurrent VA in some </text>
<text top="340" left="489" width="63" height="17" font="17">patietnts.</text>
<text top="340" left="552" width="30" height="10" font="19">S7.5-25</text>
<text top="358" left="467" width="349" height="17" font="17">2. Giant cell myocarditis is fairly uncommon, </text>
<text top="376" left="489" width="320" height="17" font="17">but it is of particular importance as it typically </text>
<text top="394" left="489" width="321" height="17" font="17">affects young individuals and is usually fatal if </text>
<text top="412" left="489" width="314" height="17" font="17">untreated. The diagnosis is confirmed by endo-</text>
<text top="430" left="489" width="321" height="17" font="17">myocardial biopsy. Patients may develop heart </text>
<text top="448" left="489" width="322" height="17" font="17">block, requiring a temporary or a permanent </text>
<text top="466" left="489" width="314" height="17" font="17">pacemakers. An ICD and antiarrhythmic medica-</text>
<text top="484" left="489" width="319" height="17" font="17">tions, such as amiodarone are often used in the </text>
<text top="502" left="489" width="318" height="17" font="17">acute phase to treat VT or VF and reduce the risk </text>
<text top="520" left="489" width="50" height="17" font="17">of SCD.</text>
<text top="521" left="539" width="153" height="10" font="19">S7.5-2–S7.5-4,S7.5-19,S7.5-26–S7.5-28</text>
<text top="549" left="452" width="163" height="18" font="24"><i><b>7.6. Cardiac Sarcoidosis</b></i></text>
<text top="578" left="463" width="205" height="12" font="26"><b>Recommendations for Cardiac Sarcoidosis</b></text>
<text top="594" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="608" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 33</b></a></text>
<text top="608" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="629" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="629" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="629" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="677" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="677" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="650" left="583" width="192" height="12" font="4">1.  In patients with cardiac sarcoidosis who </text>
<text top="663" left="595" width="188" height="12" font="4">have sustained VT or are survivors of SCA </text>
<text top="677" left="595" width="187" height="12" font="4">or have an LVEF of 35% or less, an ICD is </text>
<text top="690" left="595" width="181" height="12" font="4">recommended, if meaningful survival of </text>
<text top="704" left="595" width="141" height="12" font="4">greater than 1 year is expected.</text>
<text top="704" left="736" width="37" height="7" font="23">S7.6-1–S7.6-5</text>
<text top="779" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="779" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="725" left="583" width="218" height="12" font="4">2.  In patients with cardiac sarcoidosis and LVEF </text>
<text top="738" left="595" width="195" height="12" font="4">greater than 35% who have syncope and/</text>
<text top="752" left="595" width="192" height="12" font="4">or evidence of myocardial scar by cardiac </text>
<text top="765" left="595" width="179" height="12" font="4">MRI or positron emission tomographic </text>
<text top="779" left="595" width="173" height="12" font="4">(PET) scan, and/or have an indication </text>
<text top="792" left="595" width="168" height="12" font="4">for permanent pacing, implantation </text>
<text top="806" left="595" width="178" height="12" font="4">of an ICD is reasonable, provided that </text>
<text top="819" left="595" width="206" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="833" left="595" width="44" height="12" font="4">expected.</text>
<text top="833" left="640" width="42" height="7" font="23">S7.6-6–S7.6-10</text>
<text top="887" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="887" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="853" left="583" width="212" height="12" font="4">3.  In patients with cardiac sarcoidosis and LVEF </text>
<text top="867" left="595" width="207" height="12" font="4">greater than 35%, it is reasonable to perform </text>
<text top="880" left="595" width="200" height="12" font="4">an electrophysiological study and to implant </text>
<text top="894" left="595" width="203" height="12" font="4">an ICD, if sustained VA is inducible, provided </text>
<text top="907" left="595" width="189" height="12" font="4">that meaningful survival of greater than 1 </text>
<text top="921" left="595" width="74" height="12" font="4">year is expected.</text>
<text top="921" left="669" width="43" height="7" font="23">S7.6-11,S7.6-12</text>
<text top="962" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="962" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="942" left="583" width="173" height="12" font="4">4.  In patients with cardiac sarcoidosis </text>
<text top="955" left="595" width="179" height="12" font="4">who have an indication for permanent </text>
<text top="969" left="595" width="177" height="12" font="4">pacing, implantation of an ICD can be </text>
<text top="982" left="595" width="46" height="12" font="4">beneficial.</text>
<text top="983" left="641" width="21" height="7" font="23">S7.6-13</text>
<text top="1037" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="1037" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="1003" left="583" width="169" height="12" font="4">5.  In patients with cardiac sarcoidosis </text>
<text top="1016" left="595" width="160" height="12" font="4">with frequent symptomatic VA and </text>
<text top="1030" left="595" width="171" height="12" font="4">evidence of myocardial inflammation, </text>
<text top="1043" left="595" width="185" height="12" font="4">immunosuppression in combination with </text>
<text top="1057" left="595" width="190" height="12" font="4">antiarrhythmic medication therapy can be </text>
<text top="1070" left="595" width="126" height="12" font="4">useful to reduce VA burden.</text>
<text top="1071" left="720" width="44" height="7" font="23">S7.6-14–S7.6-16</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e319</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="108" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="135" left="89" width="342" height="17" font="17">1.  Sarcoidosis is a systemic granulomatous disease </text>
<text top="154" left="111" width="323" height="17" font="17">of unknown cause. Pulmonary involvement is </text>
<text top="172" left="111" width="321" height="17" font="17">most frequent but any organ can be affected. </text>
<text top="190" left="111" width="320" height="17" font="17">Cardiac involvement, diagnosed by cardiac MRI </text>
<text top="209" left="111" width="318" height="17" font="17">or positron emission tomography (PET), has been </text>
<text top="227" left="111" width="314" height="17" font="17">reported in up to 55% of patients with extra-</text>
<text top="245" left="111" width="318" height="17" font="17">cardiac disease, while isolated cardiac sarcoidosis </text>
<text top="264" left="111" width="318" height="17" font="17">was seen in most patients diagnosed with cardiac </text>
<text top="282" left="111" width="154" height="17" font="17">sarcoidosis in 1 report.</text>
<text top="283" left="265" width="29" height="10" font="19">S7.6-17</text>
<text top="282" left="294" width="131" height="17" font="17"> Cardiac manifesta-</text>
<text top="300" left="111" width="319" height="17" font="17">tions include conduction abnormalities, VA, and </text>
<text top="318" left="111" width="317" height="17" font="17">depressed ventricular function with or without HF, </text>
<text top="337" left="111" width="318" height="17" font="17">and these contribute greatly to a higher mortality </text>
<text top="355" left="111" width="319" height="17" font="17">in cardiac sarcoidosis compared with sarcoidosis </text>
<text top="373" left="111" width="196" height="17" font="17">without cardiac involvement.</text>
<text top="374" left="307" width="25" height="10" font="19">S7.6-2</text>
<text top="373" left="331" width="103" height="17" font="17"> In a 25-year </text>
<text top="392" left="111" width="322" height="17" font="17">study of 110 patients with cardiac sarcoidosis </text>
<text top="410" left="111" width="321" height="17" font="17">in Finland with HF at presentation, marked LV </text>
<text top="428" left="111" width="314" height="17" font="17">dysfunction at diagnosis (LVEF  &lt;35%), and iso-</text>
<text top="447" left="111" width="323" height="17" font="17">lated cardiac sarcoidosis predicted an adverse </text>
<text top="465" left="111" width="61" height="17" font="17">outcome.</text>
<text top="466" left="172" width="25" height="10" font="19">S7.6-1</text>
<text top="465" left="197" width="233" height="17" font="17"> VA can also occur in patients with </text>
<text top="483" left="111" width="323" height="17" font="17">relatively normal LV function, some of whom </text>
<text top="501" left="111" width="314" height="17" font="17">have RV involvement that can mimic arrhythmo-</text>
<text top="520" left="111" width="322" height="17" font="17">genic right ventricular cardiomyopathy. Several </text>
<text top="538" left="111" width="320" height="17" font="17">reports of patients with cardiac sarcoidosis and </text>
<text top="556" left="111" width="320" height="17" font="17">ICDs implanted for either primary or secondary </text>
<text top="575" left="111" width="322" height="17" font="17">prevention of SCD show a high frequency of </text>
<text top="593" left="111" width="181" height="17" font="17">appropriate ICD therapies,</text>
<text top="594" left="292" width="54" height="10" font="19">S7.6-3–S7.6-5</text>
<text top="593" left="346" width="89" height="17" font="17"> supporting </text>
<text top="88" left="489" width="318" height="17" font="17">use of ICDs for primary and secondary prevention </text>
<text top="106" left="489" width="320" height="17" font="17">of SCD according to the indications applied for </text>
<text top="124" left="489" width="314" height="17" font="17">other cardiomyopathies. The frequency of con-</text>
<text top="142" left="489" width="322" height="17" font="17">duction abnormalities often warrants a device </text>
<text top="160" left="489" width="262" height="17" font="17">that provides bradycardia pacing as well.</text>
<text top="178" left="467" width="343" height="17" font="17">2.  Patients with cardiac sarcoidosis can experience </text>
<text top="196" left="489" width="322" height="17" font="17">VA and SCD, even if the LVEF is normal, and </text>
<text top="214" left="489" width="319" height="17" font="17">approaches to identification of patients at risk of </text>
<text top="232" left="489" width="321" height="17" font="17">SCD despite preserved LV function are not well </text>
<text top="250" left="489" width="319" height="17" font="17">defined. A number of studies have evaluated the </text>
<text top="268" left="489" width="319" height="17" font="17">role of cardiac MRI for predicting VA and SCD. A </text>
<text top="286" left="489" width="89" height="17" font="17">meta-analysis,</text>
<text top="287" left="578" width="24" height="10" font="19">S7.6-6</text>
<text top="286" left="602" width="206" height="17" font="17"> which included 760 patients in </text>
<text top="304" left="489" width="314" height="17" font="17">10 studies, found that late gadolinium enhance-</text>
<text top="322" left="489" width="324" height="17" font="17">ment was associated with increased all-cause </text>
<text top="340" left="489" width="314" height="17" font="17">mortality and more VA compared with those with-</text>
<text top="358" left="489" width="319" height="17" font="17">out late gadolinium enhancement. Applicability is </text>
<text top="376" left="489" width="318" height="17" font="17">limited by the lack of precise quantification of late </text>
<text top="394" left="489" width="319" height="17" font="17">gadolinium enhancement burden that may allow </text>
<text top="412" left="489" width="314" height="17" font="17">for more nuanced risk stratification. Some stud-</text>
<text top="430" left="489" width="320" height="17" font="17">ies suggested that a threshold effect exists, with </text>
<text top="449" left="489" width="314" height="17" font="17">extensive LV and RV involvement being a particu-</text>
<text top="467" left="489" width="139" height="17" font="17">larly high-risk feature.</text>
<text top="467" left="628" width="51" height="10" font="19">S7.6-7,S7.6-8</text>
<text top="467" left="678" width="125" height="17" font="17"> However, late gad-</text>
<text top="485" left="489" width="320" height="17" font="17">olinium enhancement can be present even if the </text>
<text top="503" left="489" width="320" height="17" font="17">LVEF is &gt;50% and was associated with a risk of </text>
<text top="521" left="489" width="318" height="17" font="17">death or VT of 4.9% per year compared to 0.24% </text>
<text top="539" left="489" width="319" height="17" font="17">per year when late gadolinium enhancement was </text>
<text top="557" left="489" width="196" height="17" font="17">absent in 1 observational study.</text>
<text top="558" left="685" width="24" height="10" font="19">S7.6-7</text>
<text top="557" left="709" width="94" height="17" font="17"> PET for assess-</text>
<text top="575" left="489" width="314" height="17" font="17">ing inflammation and scar is also being increas-</text>
<text top="593" left="489" width="320" height="17" font="17">ingly used, but data are limited. In 1 report, the </text>
<text top="1020" left="74" width="45" height="12" font="3"><b>Figure 8. </b></text>
<text top="1020" left="120" width="271" height="12" font="22"><b>prevention of SCD in patients with cardiac sarcoidosis.</b> </text>
<text top="1033" left="74" width="718" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 7.6 for discussion. *ICD candidacy as determined by functional status, life expectancy, or </text>
<text top="1047" left="74" width="714" height="12" font="4">patient preference. †For recurrent sustained monomorphic VT, refer to Figure 2. CEP indicates electrophysiological; GDMT, guideline-directed management and </text>
<text top="1060" left="74" width="720" height="12" font="4">therapy; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging; PET, positron emission tomography; </text>
<text top="1074" left="74" width="514" height="12" font="4">SCA, sudden cardiac arrest; SCD, sudden cardiac death; VA, ventricular arrhythmia; and VT, ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e320</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="319" height="17" font="17">presence of inflammation and RV involvement on </text>
<text top="106" left="111" width="318" height="17" font="17">PET scanning was associated with increased risk of </text>
<text top="124" left="111" width="157" height="17" font="17">death or e g of relatives.</text>
<text top="124" left="268" width="29" height="10" font="19">S7.6-10</text>
<text top="124" left="297" width="133" height="17" font="17"> Electrophysiological </text>
<text top="142" left="111" width="319" height="17" font="17">studies in a series of 76 patients with evidence of </text>
<text top="160" left="111" width="319" height="17" font="17">cardiac sarcoid found that 11% had inducible VT. </text>
<text top="178" left="111" width="321" height="17" font="17">During a median follow-up of 5 years, 75% of </text>
<text top="196" left="111" width="318" height="17" font="17">patients with inducible VT had spontaneous VT or </text>
<text top="214" left="111" width="319" height="17" font="17">death compared with 1.5% of those who did not </text>
<text top="232" left="111" width="114" height="17" font="17">have inducible VT.</text>
<text top="233" left="225" width="29" height="10" font="19">S7.6-18</text>
<text top="250" left="89" width="342" height="17" font="17">3.  Electrophysiological study has been proposed as </text>
<text top="268" left="111" width="320" height="17" font="17">a potential  tool for risk stratification of VA and </text>
<text top="286" left="111" width="319" height="17" font="17">SCD in patients who had demonstrable evidence </text>
<text top="304" left="111" width="318" height="17" font="17">of cardiac sarcoidosis based on imaging studies or </text>
<text top="322" left="111" width="318" height="17" font="17">biopsy, but do not have documented arrhythmias </text>
<text top="340" left="111" width="314" height="17" font="17">or arrhythmic symptoms nor meet standard pri-</text>
<text top="358" left="111" width="291" height="17" font="17">mary prevention criteria for ICD implantation.</text>
<text top="376" left="129" width="296" height="17" font="17">One study evaluated 76 patients with document-</text>
<text top="394" left="111" width="321" height="17" font="17">ed cardiac sarcoidosis by PET or cardiac MRI who </text>
<text top="412" left="111" width="244" height="17" font="17">underwent electrophysiological study.</text>
<text top="413" left="355" width="28" height="10" font="19">S7.6-12</text>
<text top="412" left="383" width="54" height="17" font="17"> Eight </text>
<text top="430" left="111" width="314" height="17" font="17">(11%) were inducible for sustained VAs and re-</text>
<text top="448" left="111" width="319" height="17" font="17">ceived an ICD, while the rest did not receive an ICD </text>
<text top="466" left="111" width="321" height="17" font="17">because they were not inducible. LVEF was lower </text>
<text top="485" left="111" width="320" height="17" font="17">in patients with inducible VA (36.4 + 4.2% versus </text>
<text top="503" left="111" width="319" height="17" font="17">55.8 + 1.5%). Over a median follow-up of 5 years, </text>
<text top="521" left="111" width="319" height="17" font="17">6 of 8 patients in the group with inducible VA had </text>
<text top="539" left="111" width="319" height="17" font="17">VA or died, compared with 1 death in the negative </text>
<text top="557" left="111" width="41" height="17" font="17">group.</text>
<text top="557" left="151" width="28" height="10" font="19">S7.6-12</text>
<text top="557" left="179" width="252" height="17" font="17"> An important caveat is that it remains </text>
<text top="575" left="111" width="314" height="17" font="17">unclear if electrophysiological study is more predic-</text>
<text top="593" left="111" width="321" height="17" font="17">tive than LVEF alone, because inducibility appears </text>
<text top="611" left="111" width="319" height="17" font="17">to reversely correlate with LVEF. Furthermore, in this </text>
<text top="629" left="111" width="314" height="17" font="17">study the average LVEF of the inducible patients de-</text>
<text top="647" left="111" width="254" height="17" font="17">clined further during the followup period.</text>
<text top="648" left="365" width="28" height="10" font="19">S7.6-12</text>
<text top="665" left="89" width="340" height="17" font="17">4.  In addition to VA and LV dysfunction, conduction </text>
<text top="683" left="111" width="319" height="17" font="17">abnormalities, including heart block, can also be </text>
<text top="701" left="111" width="321" height="17" font="17">a common manifestation of cardiac sarcoidosis. </text>
<text top="719" left="111" width="318" height="17" font="17">Patients with documented VA and LV dysfunction </text>
<text top="737" left="111" width="320" height="17" font="17">are at increased risk of cardiac events including </text>
<text top="755" left="111" width="323" height="17" font="17">cardiac death. One study compared outcomes </text>
<text top="773" left="111" width="321" height="17" font="17">in 22 patients with high-degree atrioventricular </text>
<text top="791" left="111" width="314" height="17" font="17">block as the initial manifestation of cardiac sar-</text>
<text top="809" left="111" width="322" height="17" font="17">coidosis, to 31 patients who initially presented </text>
<text top="827" left="111" width="318" height="17" font="17">with VT and/or HF. After a median follow up of 34 </text>
<text top="845" left="111" width="320" height="17" font="17">months, the patients who presented with heart </text>
<text top="863" left="111" width="314" height="17" font="17">block had fewer HF hospitalization, yet fatal car-</text>
<text top="881" left="111" width="318" height="17" font="17">diac events, including sustained VAs, were similar </text>
<text top="899" left="111" width="320" height="17" font="17">to those with VT and/or HF, suggesting that the </text>
<text top="918" left="111" width="321" height="17" font="17">risk of fatal cardiac events is high regardless of </text>
<text top="936" left="111" width="200" height="17" font="17">the initial clinical presentation.</text>
<text top="936" left="311" width="29" height="10" font="19">S7.6-13</text>
<text top="936" left="340" width="91" height="17" font="17"> In the same </text>
<text top="954" left="111" width="314" height="17" font="17">study, administration of steroids led to some clini-</text>
<text top="972" left="111" width="320" height="17" font="17">cal improvement, with some patients recovering </text>
<text top="990" left="111" width="314" height="17" font="17">conduction, yet steroid effectiveness was not uni-</text>
<text top="1008" left="111" width="319" height="17" font="17">versal and did not seem to be protective against </text>
<text top="1026" left="111" width="146" height="17" font="17">adverse cardiac events.</text>
<text top="1026" left="257" width="29" height="10" font="19">S7.6-13</text>
<text top="1044" left="89" width="342" height="17" font="17">5.  Several studies have attempted to evaluate the </text>
<text top="1062" left="111" width="321" height="17" font="17">role of immunosuppression for reducing VA in </text>
<text top="1080" left="111" width="324" height="17" font="17">patients with cardiac sarcoidosis, but results </text>
<text top="88" left="489" width="158" height="17" font="17">have been inconsistent.</text>
<text top="88" left="648" width="64" height="10" font="19">S7.6-14–S7.6-16</text>
<text top="88" left="712" width="98" height="17" font="17"> Furthermore, </text>
<text top="106" left="489" width="324" height="17" font="17">a worsening of VA has been reported with </text>
<text top="124" left="489" width="314" height="17" font="17">immunosuppressive therapy (usually glucocorti-</text>
<text top="142" left="489" width="314" height="17" font="17">coids) in a number of patients, including electri-</text>
<text top="160" left="489" width="319" height="17" font="17">cal storm developing in some within 12 months </text>
<text top="179" left="489" width="135" height="17" font="17">of initiating therapy.</text>
<text top="179" left="624" width="30" height="10" font="19">S7.6-15</text>
<text top="179" left="654" width="155" height="17" font="17"> One study reported a </text>
<text top="197" left="489" width="314" height="17" font="17">decrease of arrhythmia burden with steroid ther-</text>
<text top="215" left="489" width="320" height="17" font="17">apy but only when given in the early stages of </text>
<text top="233" left="489" width="318" height="17" font="17">the disease; those with advanced LV dysfunction </text>
<text top="251" left="489" width="189" height="17" font="17">did not experience benefit.</text>
<text top="252" left="678" width="30" height="10" font="19">S7.6-16</text>
<text top="251" left="708" width="104" height="17" font="17"> A systematic </text>
<text top="270" left="489" width="319" height="17" font="17">combined treatment approach was successful in </text>
<text top="288" left="489" width="314" height="17" font="17">63% of patient in a series in which medical ther-</text>
<text top="306" left="489" width="321" height="17" font="17">apy included both steroids and antiarrhythmic </text>
<text top="324" left="489" width="314" height="17" font="17">medications, followed by radiofrequency cath-</text>
<text top="342" left="489" width="152" height="17" font="17">eter ablation if needed.</text>
<text top="343" left="641" width="30" height="10" font="19">S7.6-14</text>
<text top="342" left="671" width="136" height="17" font="17"> Immunosuppressive </text>
<text top="361" left="489" width="325" height="17" font="17">therapy may serve a dual purpose beyond </text>
<text top="379" left="489" width="314" height="17" font="17">arrhythmia effects as it may help stabilize dis-</text>
<text top="397" left="489" width="314" height="17" font="17">ease progression and prevent further deteriora-</text>
<text top="415" left="489" width="319" height="17" font="17">tion of LV function, although this has yet to be </text>
<text top="433" left="489" width="321" height="17" font="17">demonstrated in RCTs. Steroids do not appear </text>
<text top="451" left="489" width="318" height="17" font="17">to reverse advanced ventricular dysfunction once </text>
<text top="470" left="489" width="319" height="17" font="17">present, which supports the importance of early </text>
<text top="488" left="489" width="177" height="17" font="17">diagnosis and intervention.</text>
<text top="489" left="666" width="25" height="10" font="19">S7.6-1</text>
<text top="488" left="691" width="117" height="17" font="17"> PET scanning for </text>
<text top="506" left="489" width="314" height="17" font="17">assessing inflammation and scar is being increas-</text>
<text top="524" left="489" width="314" height="17" font="17">ingly used in sarcoidosis as well, but data sup-</text>
<text top="542" left="489" width="317" height="17" font="17">porting its use for guiding therapy of arrhythmias </text>
<text top="561" left="489" width="73" height="17" font="17">are limited.</text>
<text top="588" left="452" width="293" height="18" font="24"><i><b>7.6.1. Other Infiltrative Cardiomyopathies</b></i></text>
<text top="607" left="452" width="362" height="17" font="17">Infiltrative cardiomyopathies are a heterogeneous </text>
<text top="625" left="452" width="351" height="17" font="17">group of uncommon systemic diseases with associat-</text>
<text top="643" left="452" width="351" height="17" font="17">ed cardiac involvement. In some infiltrative cardiomy-</text>
<text top="661" left="452" width="355" height="17" font="17">opathies, such as Fabry’s disease, VAs are uncommon. </text>
<text top="680" left="452" width="355" height="17" font="17">Some, such as hemochromatosis, are highly treatable </text>
<text top="698" left="452" width="351" height="17" font="17">especially when diagnosed early. In all cases, treat-</text>
<text top="716" left="452" width="358" height="17" font="17">ment of the underlying condition must accompany </text>
<text top="734" left="452" width="359" height="17" font="17">management of cardiac arrhythmias. Most studies </text>
<text top="752" left="452" width="357" height="17" font="17">of infiltrative cardiomyopathies and arrhythmias are </text>
<text top="771" left="452" width="159" height="17" font="17">small and observational</text>
<text top="771" left="612" width="33" height="10" font="19">S7.6.1-1</text>
<text top="771" left="644" width="165" height="17" font="17"> but, in general, unless </text>
<text top="789" left="452" width="356" height="17" font="17">contraindications are present, VAs should be treated </text>
<text top="807" left="452" width="357" height="17" font="17">as in any other cardiomyopathy. See Section 7.6 for </text>
<text top="825" left="452" width="359" height="17" font="17">sarcoidosis. Until recently, cardiac amyloidosis was </text>
<text top="843" left="452" width="357" height="17" font="17">associated with a very poor prognosis with patients </text>
<text top="862" left="452" width="284" height="17" font="17">ultimately succumbing to progressive HF.</text>
<text top="862" left="737" width="33" height="10" font="19">S7.6.1-2</text>
<text top="862" left="769" width="42" height="17" font="17"> This </text>
<text top="880" left="452" width="360" height="17" font="17">perception is changing with advances in medical </text>
<text top="898" left="452" width="358" height="17" font="17">therapy for light-chain amyloidosis, which have led </text>
<text top="916" left="452" width="157" height="17" font="17">to improved outcomes.</text>
<text top="917" left="610" width="33" height="10" font="19">S7.6.1-3</text>
<text top="916" left="643" width="167" height="17" font="17"> Yet, decisions must be </text>
<text top="934" left="452" width="351" height="17" font="17">individualized because data remain too limited to al-</text>
<text top="952" left="452" width="355" height="17" font="17">low formal recommendations as published reports on </text>
<text top="971" left="452" width="351" height="17" font="17">ICD effectiveness in amyloidosis are small, observa-</text>
<text top="989" left="452" width="219" height="17" font="17">tional and with limited follow up.</text>
<text top="990" left="671" width="33" height="10" font="19">S7.6.1-4</text>
<text top="989" left="704" width="103" height="17" font="17"> Whether there </text>
<text top="1007" left="452" width="359" height="17" font="17">is greater benefit to ICD placement in light chain </text>
<text top="1025" left="452" width="358" height="17" font="17">amyloidosis versus transthyreitin-related amyloidosis </text>
<text top="1043" left="452" width="360" height="17" font="17">remains uncertain, because most studies included </text>
<text top="1062" left="452" width="357" height="17" font="17">mainly patients with amyloid light-chain amyloidosis </text>
<text top="1080" left="452" width="351" height="17" font="17">for which the rate of VA may be greater and prog-</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="29" size="8" family="Times" color="#ffffff"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e321</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="357" height="17" font="17">nosis is generally worse. Whether ICDs are effective </text>
<text top="106" left="74" width="355" height="17" font="17">for primary prevention of SCD is uncertain, but many </text>
<text top="124" left="74" width="351" height="17" font="17">deaths in patients with cardiac amyloidosis do not ap-</text>
<text top="142" left="74" width="223" height="17" font="17">pear to be preventable by an ICD.</text>
<text top="143" left="297" width="33" height="10" font="19">S7.6.1-2</text>
<text top="192" left="74" width="144" height="21" font="18"><b>7.7. Heart Failure</b></text>
<text top="219" left="74" width="283" height="18" font="24"><i><b>7.7.1. HF With Reduced Ejection Fraction</b></i></text>
<text top="247" left="85" width="135" height="12" font="26"><b>Recommendation for HF<i>r</i></b><b>EF</b></text>
<text top="264" left="85" width="321" height="12" font="26"><b>References that support the recommendation are summarized in </b></text>
<text top="277" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 35</b></a></text>
<text top="277" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="298" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="298" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="298" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="346" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="346" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="319" left="205" width="217" height="12" font="4">1.  In patients with HF<i>r</i>EF who are awaiting heart </text>
<text top="332" left="216" width="184" height="12" font="4">transplant and who otherwise would not </text>
<text top="346" left="216" width="185" height="12" font="4">qualify for an ICD (eg, NYHA class IV and/</text>
<text top="359" left="216" width="199" height="12" font="4">or use of inotropes) with a plan to discharge </text>
<text top="373" left="216" width="124" height="12" font="4">home, an ICD is reasonable.</text>
<text top="373" left="340" width="47" height="7" font="23">S7.7.1-1–S7.7.1-5</text>
<text top="419" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="446" left="74" width="359" height="17" font="17">Patients with HF<i>r</i>EF are at an increased risk for VA </text>
<text top="465" left="74" width="355" height="17" font="17">and SCD. The risk is increased irrespective of HF<i>r</i>EF </text>
<text top="483" left="74" width="54" height="17" font="17">etiology.</text>
<text top="483" left="128" width="32" height="10" font="19">S7.7.1-6</text>
<text top="483" left="159" width="276" height="17" font="17"> SCD makes up a greater proportion </text>
<text top="501" left="74" width="358" height="17" font="17">of deaths in patients with milder HF symptoms and </text>
<text top="519" left="74" width="359" height="17" font="17">lesser proportion in those with moderate/severe HF </text>
<text top="537" left="74" width="69" height="17" font="17">symptoms.</text>
<text top="538" left="143" width="32" height="10" font="19">S7.7.1-7</text>
<text top="537" left="175" width="256" height="17" font="17"> The reported incidence of SCD varies </text>
<text top="555" left="74" width="357" height="17" font="17">depending on the definition used and the population </text>
<text top="574" left="74" width="357" height="17" font="17">studied. Although many deaths, classified as sudden, </text>
<text top="592" left="74" width="358" height="17" font="17">are indeed due to lethal VA, others may be due to </text>
<text top="610" left="74" width="351" height="17" font="17">bradyarrhythmias, pulseless electrical activity, and sud-</text>
<text top="628" left="74" width="209" height="17" font="17">den hemodynamic deterioration.</text>
<text top="629" left="283" width="68" height="10" font="19">S7.7.1-7–S7.7.1-9</text>
<text top="646" left="92" width="333" height="17" font="17">Medical therapy with neurohormonal agents de-</text>
<text top="664" left="74" width="355" height="17" font="17">creases the risk of SCD by reducing both the incidence </text>
<text top="683" left="74" width="210" height="17" font="17">of VA and disease progression.</text>
<text top="683" left="284" width="111" height="10" font="19">S7.7.1-7,S7.7.1-10–S7.7.1-12</text>
<text top="683" left="395" width="30" height="17" font="17"> De-</text>
<text top="701" left="74" width="356" height="17" font="17">spite GDMT for HF<i>r</i>EF, some patients remain at risk for </text>
<text top="719" left="74" width="356" height="17" font="17">SCD, and an ICD may be helpful. See Sections 7.1 and </text>
<text top="737" left="74" width="355" height="17" font="17">7.2 for the indications on ICDs in patients with reduced </text>
<text top="755" left="74" width="355" height="17" font="17">LVEF. CRT, in appropriate patients, has also been shown </text>
<text top="773" left="74" width="203" height="17" font="17">to reduce the incidence of SCD.</text>
<text top="774" left="277" width="36" height="10" font="19">S7.7.1-13</text>
<text top="792" left="92" width="333" height="17" font="17">The pathophysiology of SCD in HF is complex, re-</text>
<text top="810" left="74" width="356" height="17" font="17">sulting from interactions between both functional and </text>
<text top="828" left="74" width="355" height="17" font="17">structural changes that occur in patients with HF<i>r</i>EF </text>
<text top="846" left="74" width="315" height="17" font="17">that result in increased susceptibility to SCD.</text>
<text top="847" left="389" width="36" height="10" font="19">S7.7.1-14</text>
<text top="846" left="425" width="4" height="17" font="17"> </text>
<text top="864" left="74" width="357" height="17" font="17">Although many of the risk factors are shared among </text>
<text top="882" left="74" width="355" height="17" font="17">HF<i>r</i>EF patients, the reason that SCD strikes a particular </text>
<text top="901" left="74" width="351" height="17" font="17">individual is usually unknown; however, some individu-</text>
<text top="919" left="74" width="236" height="17" font="17">als may have a genetic susceptibility.</text>
<text top="919" left="310" width="36" height="10" font="19">S7.7.1-15</text>
<text top="919" left="347" width="78" height="17" font="17"> Varying de-</text>
<text top="937" left="74" width="355" height="17" font="17">grees of myocardial fibrosis, neurohormonal activation, </text>
<text top="955" left="74" width="356" height="17" font="17">and increased wall stress alter the electrophysiological </text>
<text top="973" left="74" width="356" height="17" font="17">properties with changes in cell coupling, ionic currents </text>
<text top="991" left="74" width="355" height="17" font="17">(electrical remodeling), and calcium handling that likely </text>
<text top="1010" left="74" width="279" height="17" font="17">contribute to the development of lethal VA.</text>
<text top="1010" left="353" width="36" height="10" font="19">S7.7.1-16</text>
<text top="1010" left="389" width="36" height="17" font="17"> Con-</text>
<text top="1028" left="74" width="351" height="17" font="17">tributing factors extrinsic to the heart include electro-</text>
<text top="1046" left="74" width="356" height="17" font="17">lyte abnormalities related to volume shifts and diuretic </text>
<text top="1064" left="74" width="357" height="17" font="17">use, sympathetic activation, hemodynamic stress, and </text>
<text top="1082" left="74" width="53" height="17" font="17">hypoxia.</text>
<text top="87" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="108" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="136" left="467" width="343" height="17" font="17">1. Many patients with advanced HF listed for heart </text>
<text top="154" left="485" width="326" height="17" font="17">transplant would not otherwise qualify for ICD </text>
<text top="172" left="485" width="322" height="17" font="17">given the severity of illness including NYHA class IV </text>
<text top="191" left="485" width="324" height="17" font="17">status and/or use of inotropic infusion. Although </text>
<text top="209" left="485" width="319" height="17" font="17">no randomized data  on ICD use in this popula-</text>
<text top="227" left="485" width="329" height="17" font="17">tion exist, data from observational and large </text>
<text top="246" left="485" width="319" height="17" font="17">registry studies of patients awaiting heart trans-</text>
<text top="264" left="485" width="325" height="17" font="17">plant suggest improved survival in  patients with </text>
<text top="283" left="485" width="52" height="17" font="17">an ICD.</text>
<text top="283" left="537" width="100" height="10" font="19">S7.7.1-1,S7.7.1-4,S7.7.1-5</text>
<text top="283" left="637" width="176" height="17" font="17"> One  alternative to ICD </text>
<text top="301" left="484" width="319" height="17" font="17">in this population is the wearable  cardioverter-</text>
<text top="319" left="484" width="76" height="17" font="17">defibrillator.</text>
<text top="320" left="561" width="66" height="10" font="19">S7.7.1-2,S7.7.1-3</text>
<text top="319" left="626" width="188" height="17" font="17"> The recommendation in </text>
<text top="338" left="484" width="325" height="17" font="17">this section is relevant to those patients without </text>
<text top="356" left="484" width="326" height="17" font="17">an ICD where there is a plan to discharge the </text>
<text top="374" left="484" width="325" height="17" font="17">patient to home to await cardiac transplant and </text>
<text top="393" left="484" width="325" height="17" font="17">not, for example, to those patients who remain </text>
<text top="411" left="484" width="324" height="17" font="17">hospitalized with no intention to discharge home </text>
<text top="430" left="484" width="327" height="17" font="17">until transplant occurs. For those patients with </text>
<text top="448" left="484" width="319" height="17" font="17">an LVAD, the decision to place an ICD is gener-</text>
<text top="466" left="484" width="327" height="17" font="17">ally independent of whether they are awaiting </text>
<text top="485" left="484" width="323" height="17" font="17">heart transplant but rather the indication in those </text>
<text top="503" left="484" width="325" height="17" font="17">patients is generally based on the need to treat </text>
<text top="521" left="484" width="23" height="17" font="17">VA.</text>
<text top="522" left="507" width="36" height="10" font="19">S7.7.1-17</text>
<text top="549" left="452" width="293" height="18" font="24"><i><b>7.7.2. HF With Preserved Ejection Fraction</b></i></text>
<text top="568" left="452" width="357" height="17" font="17">Nearly half of the patients with HF have a preserved </text>
<text top="586" left="452" width="31" height="17" font="17">LVEF.</text>
<text top="587" left="484" width="32" height="10" font="19">S7.7.2-1</text>
<text top="586" left="516" width="293" height="17" font="17"> These patients tend to be older and have </text>
<text top="605" left="452" width="351" height="17" font="17">more comorbidities than patients with HF<i>r</i>EF. Howev-</text>
<text top="623" left="452" width="356" height="17" font="17">er, although the rate of SCD is lower in patients with </text>
<text top="641" left="452" width="358" height="17" font="17">HF with preserved ejection fraction (HF<i>p</i>EF) than in </text>
<text top="660" left="452" width="128" height="17" font="17">patients with HF<i>r</i>EF,</text>
<text top="660" left="580" width="32" height="10" font="19">S7.7.2-2</text>
<text top="660" left="613" width="195" height="17" font="17"> nearly a quarter of all deaths </text>
<text top="678" left="452" width="282" height="17" font="17">among patients with HF<i>p</i>EF are sudden.</text>
<text top="679" left="734" width="69" height="10" font="19">S7.7.2-3–S7.7.2-5</text>
<text top="678" left="803" width="4" height="17" font="17"> </text>
<text top="696" left="452" width="351" height="17" font="17">The challenge in preventing SCD in patients with HF-</text>
<text top="715" left="452" width="355" height="18" font="21"><i>p</i>EF is identifying which patients are at a high enough </text>
<text top="733" left="452" width="351" height="17" font="17">risk to benefit from preventive therapies. Studies ex-</text>
<text top="752" left="452" width="358" height="17" font="17">ploring noninvasive risk factors for SCD in patients </text>
<text top="770" left="452" width="359" height="17" font="17">with HF<i>p</i>EF do not identify consistent factors with </text>
<text top="788" left="452" width="284" height="17" font="17">the exception of ischemic heart disease.</text>
<text top="789" left="736" width="67" height="10" font="19">S7.7.2-2,S7.7.2-6</text>
<text top="788" left="803" width="4" height="17" font="17"> </text>
<text top="807" left="452" width="358" height="17" font="17">Consequently, there is no accepted noninvasive test </text>
<text top="825" left="452" width="356" height="17" font="17">to identify high-risk patients with HF<i>p</i>EF. Invasive risk </text>
<text top="843" left="452" width="355" height="17" font="17">stratification with an electrophysiological study shows </text>
<text top="862" left="452" width="174" height="17" font="17">promise in this population.</text>
<text top="862" left="627" width="67" height="10" font="19">S7.7.2-7,S7.7.2-8</text>
<text top="862" left="694" width="109" height="17" font="17"> This topic is cur-</text>
<text top="880" left="452" width="351" height="17" font="17">rently being studied in the PRESERVE-EF (Risk Strati-</text>
<text top="899" left="452" width="357" height="17" font="17">fication in Patients With Preserved Ejection Fraction) </text>
<text top="917" left="452" width="138" height="17" font="17"><a href="ctgov:NCT02124018">trial (NCT02124018).</a></text>
<text top="935" left="470" width="337" height="17" font="17">Whether to include a recommendation related to an </text>
<text top="954" left="452" width="357" height="17" font="17">electrophysiological study in patients with HF<i>p</i>EF and </text>
<text top="972" left="452" width="356" height="17" font="17">ischemic heart disease was carefully considered by the </text>
<text top="990" left="452" width="359" height="17" font="17">writing committee. However, evidence was deemed </text>
<text top="1009" left="452" width="356" height="17" font="17">insufficient to support a formal recommendation. Still, </text>
<text top="1027" left="452" width="356" height="17" font="17">the pros and cons of an electrophysiological study can </text>
<text top="1046" left="452" width="355" height="17" font="17">reasonably be considered in select patients with HF<i>p</i>EF </text>
<text top="1064" left="452" width="351" height="17" font="17">and ischemic heart disease who are experiencing symp-</text>
<text top="1082" left="452" width="158" height="17" font="17">toms suggestive of a VA.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e322</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="246" height="18" font="24"><i><b>7.7.3. Left Ventricular Assist Device</b></i></text>
<text top="116" left="85" width="217" height="12" font="26"><b>Recommendation for Patients With an LVAD</b></text>
<text top="133" left="85" width="321" height="12" font="26"><b>References that support the recommendation are summarized in </b></text>
<text top="146" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 36</b></a></text>
<text top="146" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="167" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="167" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="167" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="194" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="194" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="188" left="205" width="208" height="12" font="4">1.  In patients with an LVAD and sustained VA, </text>
<text top="201" left="217" width="111" height="12" font="4">an ICD can be beneficial.</text>
<text top="202" left="328" width="22" height="7" font="23">S7.7.3-1</text>
<text top="242" left="74" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="269" left="89" width="28" height="17" font="17">1. </text>
<text top="269" left="107" width="334" height="17" font="17">Patients with an LVAD have a high risk </text>
<text top="287" left="107" width="332" height="17" font="17">of VA, particularly those with a history of </text>
<text top="287" left="425" width="4" height="17" font="17"> </text>
<text top="306" left="107" width="78" height="17" font="17">arrhythmias.</text>
<text top="307" left="184" width="66" height="10" font="19">S7.7.3-2–S7.7.3-4</text>
<text top="306" left="250" width="184" height="17" font="17"> The increased risk of VA </text>
<text top="324" left="107" width="324" height="17" font="17">may be due to myocardial irritation from insertion </text>
<text top="343" left="107" width="323" height="17" font="17">of the LVAD inflow cannula, LV compression due to </text>
<text top="361" left="107" width="322" height="17" font="17">a suctioning effect from the LVAD, inotropic support </text>
<text top="379" left="107" width="319" height="17" font="17">frequently needed by some patients, and repolar-</text>
<text top="398" left="107" width="319" height="17" font="17">ization changes that can occur after LVAD place-</text>
<text top="416" left="107" width="322" height="17" font="17">ment. Although VT/VF is tolerated by some patients </text>
<text top="434" left="107" width="323" height="17" font="17">with an LVAD, others experience a decrease in flow </text>
<text top="453" left="107" width="319" height="17" font="17">as the RV is unsupported; syncope and hypoperfu-</text>
<text top="471" left="107" width="323" height="17" font="17">sion can result. Having an ICD can allow for prompt </text>
<text top="489" left="107" width="323" height="17" font="17">termination of VA before significant hemodynamic </text>
<text top="508" left="107" width="323" height="17" font="17">consequences occur. Data on ICDs in patients with </text>
<text top="526" left="107" width="319" height="17" font="17">an LVAD are from observational series. A system-</text>
<text top="544" left="107" width="323" height="17" font="17">atic review of 6 observational studies observed that </text>
<text top="563" left="107" width="325" height="17" font="17">within 7 months, 26% of patients with an LVAD </text>
<text top="581" left="107" width="61" height="17" font="17">had died.</text>
<text top="582" left="168" width="31" height="10" font="19">S7.7.3-1</text>
<text top="581" left="199" width="233" height="17" font="17"> The death rate was lower among </text>
<text top="599" left="107" width="325" height="17" font="17">patients who previously had an ICD (16% versus </text>
<text top="618" left="107" width="328" height="17" font="17">32%), suggesting a 39% relative-risk reduction </text>
<text top="636" left="107" width="288" height="17" font="17">in all-cause mortality in an adjusted analysis.</text>
<text top="637" left="394" width="31" height="10" font="19">S7.7.3-1</text>
<text top="636" left="425" width="4" height="17" font="17"> </text>
<text top="654" left="107" width="324" height="17" font="17">Patients with a history of pre-LVAD VA have nearly </text>
<text top="673" left="107" width="200" height="17" font="17">a ≥10-fold risk of post-LVAD VA.</text>
<text top="673" left="306" width="66" height="10" font="19">S7.7.3-2–S7.7.3-4</text>
<text top="673" left="372" width="56" height="17" font="17"> In many </text>
<text top="691" left="106" width="327" height="17" font="17">of the initial studies demonstrating ICD benefit, </text>
<text top="709" left="106" width="255" height="17" font="17">older pulsatile LVAD devices were in use.</text>
<text top="710" left="361" width="64" height="10" font="19">S7.7.3-2,S7.7.3-5</text>
<text top="709" left="425" width="4" height="17" font="17"> </text>
<text top="728" left="107" width="323" height="17" font="17">Studies of ICD use with the newer, continuous flow </text>
<text top="746" left="107" width="259" height="17" font="17">LVADs have inconsistently shown benefit.</text>
<text top="747" left="366" width="59" height="10" font="19">S7.7.3-1,S7.7.3-</text>
<text top="765" left="107" width="71" height="10" font="19">4,S7.7.3-6,S7.7.3-7</text>
<text top="765" left="178" width="251" height="17" font="17"> Of note, approximately 2 of 10 patients </text>
<text top="783" left="107" width="323" height="17" font="17">with an LVAD develop an LVAD related infection in </text>
<text top="801" left="107" width="81" height="17" font="17">the first year.</text>
<text top="802" left="187" width="64" height="10" font="19">S7.7.3-8,S7.7.3-9</text>
<text top="831" left="74" width="295" height="18" font="24"><i><b>7.7.4. ICD Use After Heart Transplantation</b></i></text>
<text top="860" left="85" width="284" height="12" font="26"><b>Recommendation for ICD Use After Heart Transplantation</b></text>
<text top="877" left="85" width="321" height="12" font="26"><b>References that support the recommendation are summarized in </b></text>
<text top="890" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 37</b></a></text>
<text top="890" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="911" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="911" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="911" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="952" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="952" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="932" left="205" width="216" height="12" font="4">1.  In patients with a heart transplant and severe </text>
<text top="945" left="217" width="204" height="12" font="4">allograft vasculopathy with LV dysfunction, an </text>
<text top="959" left="217" width="199" height="12" font="4">ICD may be reasonable if meaningful survival </text>
<text top="972" left="217" width="150" height="12" font="4">of greater than 1 year is expected.</text>
<text top="973" left="366" width="46" height="7" font="23">S7.7.4-1–S7.7.4-3</text>
<text top="1013" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="1034" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="1061" left="89" width="349" height="17" font="17">1. Development of disease in the transplanted </text>
<text top="1080" left="107" width="326" height="17" font="17">heart places some patients at an increased risk </text>
<text top="88" left="485" width="326" height="17" font="17">of SCD that has ranged from 10% to 35% in </text>
<text top="106" left="485" width="145" height="17" font="17">observational studies.</text>
<text top="107" left="630" width="66" height="10" font="19">S7.7.4-4,S7.7.4-5</text>
<text top="106" left="695" width="120" height="17" font="17"> Both rejection </text>
<text top="124" left="485" width="324" height="17" font="17">and a decreased LVEF are predictors of SCD. The </text>
<text top="142" left="485" width="327" height="17" font="17">mechanisms underlying SCD in patients with a </text>
<text top="160" left="485" width="319" height="17" font="17">heart transplant include damage to the conduc-</text>
<text top="179" left="485" width="319" height="17" font="17">tion system itself and VA due to coronary vas-</text>
<text top="197" left="485" width="325" height="17" font="17">culopathy or during episodes of acute rejection. </text>
<text top="215" left="485" width="327" height="17" font="17">Several small case series observing appropriate </text>
<text top="233" left="485" width="325" height="17" font="17">ICD termination of VA suggest that an ICD can </text>
<text top="251" left="485" width="330" height="17" font="17">be beneficial in selected patients, particularly </text>
<text top="270" left="485" width="319" height="17" font="17">those with severe allograft vasculopathy, unex-</text>
<text top="288" left="485" width="324" height="17" font="17">plained syncope, a history of SCA, and severe LV  </text>
<text top="306" left="485" width="78" height="17" font="17">dysfunction.</text>
<text top="307" left="563" width="68" height="10" font="19">S7.7.4-1–S7.7.4-3</text>
<text top="306" left="630" width="176" height="17" font="17"> Additionally, a patient with </text>
<text top="324" left="485" width="319" height="17" font="17">severe allograft vasculopathy who is being consid-</text>
<text top="343" left="485" width="325" height="17" font="17">ered for retransplant may be appropriate for an </text>
<text top="361" left="485" width="326" height="17" font="17">ICD as a bridging device. Secondary prevention </text>
<text top="379" left="485" width="326" height="17" font="17">indications for an ICD in patients with a heart </text>
<text top="397" left="485" width="316" height="17" font="17">transplant are identical to those in other patients.</text>
<text top="441" left="452" width="247" height="21" font="18"><b>7.8. Neuromuscular Disorders</b></text>
<text top="475" left="463" width="235" height="12" font="26"><b>Recommendations for Neuromuscular Disorders</b></text>
<text top="492" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="505" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 38</b></a></text>
<text top="505" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="526" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="526" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="526" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="574" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="574" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="547" left="583" width="199" height="12" font="4">1.  In patients with neuromuscular disorders, </text>
<text top="561" left="595" width="195" height="12" font="4">primary and secondary prevention ICDs are </text>
<text top="574" left="595" width="206" height="12" font="4">recommended for the same indications as for </text>
<text top="588" left="595" width="200" height="12" font="4">patients with NICM if meaningful survival of </text>
<text top="601" left="595" width="141" height="12" font="4">greater than 1 year is expected.</text>
<text top="602" left="736" width="36" height="7" font="23">S7.8-1,S7.8-2</text>
<text top="649" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="649" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="622" left="583" width="196" height="12" font="4">2.  In patients with Emery-Dreifuss and limb-</text>
<text top="635" left="595" width="180" height="12" font="4">girdle type IB muscular dystrophies with </text>
<text top="649" left="595" width="190" height="12" font="4">progressive cardiac involvement, an ICD is </text>
<text top="662" left="595" width="196" height="12" font="4">reasonable if meaningful survival of greater </text>
<text top="676" left="595" width="106" height="12" font="4">than 1 year is expected.</text>
<text top="676" left="701" width="37" height="7" font="23">S7.8-3–S7.8-8</text>
<text top="717" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="717" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="697" left="583" width="207" height="12" font="4">3.  In patients with muscular dystrophy, follow-</text>
<text top="710" left="595" width="195" height="12" font="4">up for development of cardiac involvement </text>
<text top="724" left="595" width="157" height="12" font="4">is reasonable, even if the patient is </text>
<text top="737" left="595" width="136" height="12" font="4">asymptomatic at presentation.</text>
<text top="738" left="730" width="40" height="7" font="23">S7.8-9–S7.8-12</text>
<text top="785" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="785" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="758" left="583" width="218" height="12" font="4">4.  In patients with myotonic dystrophy type 1 with </text>
<text top="771" left="594" width="196" height="12" font="4">an indication for a permanent pacemaker, an </text>
<text top="785" left="594" width="200" height="12" font="4">ICD may be considered to minimize the risk of </text>
<text top="798" left="594" width="197" height="12" font="4">SCA from VT if meaningful survival of greater </text>
<text top="812" left="594" width="101" height="12" font="4">than 1 year is expected.</text>
<text top="812" left="695" width="59" height="7" font="23">S7.8-9,S7.8-13,S7.8-14</text>
<text top="852" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="879" left="452" width="351" height="17" font="17">The muscular dystrophies are a group of inherited diseas-</text>
<text top="898" left="452" width="357" height="17" font="17">es affecting skeletal and cardiac muscle. Some present </text>
<text top="916" left="452" width="351" height="17" font="17">primarily as a NICM (eg, Duchenne, Becker, and limb-gir-</text>
<text top="934" left="452" width="354" height="17" font="17">dle types 2C, 2F, and 2I), while others present primarily as </text>
<text top="952" left="452" width="351" height="17" font="17">conduction system degeneration with a variable associa-</text>
<text top="971" left="452" width="355" height="17" font="17">tion with cardiomyopathy (eg, myotonic dystrophy types </text>
<text top="989" left="452" width="351" height="17" font="17">1 and 2, Emery-Dreifuss, limb-girdle type 1B; summa-</text>
<text top="1007" left="452" width="103" height="17" font="17">rized in Table 9).</text>
<text top="1008" left="555" width="29" height="10" font="19">S7.8-15</text>
<text top="1007" left="583" width="224" height="17" font="17"> Because SCD can occur either due </text>
<text top="1025" left="452" width="351" height="17" font="17">to VA or due to bradyarrhythmias from rapid and unpre-</text>
<text top="1043" left="452" width="357" height="17" font="17">dictable progression of conduction system disease, the </text>
<text top="1062" left="452" width="356" height="17" font="17">clinician is faced with the challenge of identifying those </text>
<text top="1080" left="452" width="351" height="17" font="17">patients who would benefit from prophylactic pacemak-</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e323</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="356" height="17" font="17">er or ICD implantation. There should be a high level of </text>
<text top="106" left="74" width="355" height="17" font="17">concern for those patients with muscular dystrophy who </text>
<text top="125" left="74" width="237" height="17" font="17">present with arrhythmia symptoms.</text>
<text top="125" left="311" width="29" height="10" font="19">S7.8-15</text>
<text top="125" left="339" width="95" height="17" font="17"> The current </text>
<text top="143" left="74" width="355" height="17" font="17">guideline focuses on VA and indications for implantation </text>
<text top="162" left="74" width="355" height="17" font="17">of an ICD. The indications for permanent pacemaker are </text>
<text top="180" left="74" width="289" height="17" font="17">discussed in another ACC/AHA/HRS guideline.</text>
<text top="181" left="363" width="29" height="10" font="19">S7.8-16</text>
<text top="224" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="246" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="274" left="89" width="342" height="17" font="17">1.  In general, the indications for an ICD in patients </text>
<text top="292" left="111" width="321" height="17" font="17">with muscular dystrophy should follow standard </text>
<text top="311" left="111" width="323" height="17" font="17">ICD recommendations for patients with NICM </text>
<text top="329" left="111" width="321" height="17" font="17">(see Section 7.2.1 on Secondary Prevention and </text>
<text top="348" left="111" width="320" height="17" font="17">Section 7.2.2 on Primary Prevention of SCD with </text>
<text top="367" left="111" width="314" height="17" font="17">NICM). A high index of suspicion for bundle-</text>
<text top="385" left="111" width="325" height="17" font="17">branch reentrant tachycardia is warranted in </text>
<text top="404" left="111" width="323" height="17" font="17">patients with myotonic dystrophy who exhibit </text>
<text top="422" left="111" width="314" height="17" font="17">wide QRS complex tachycardia or tachycardia-</text>
<text top="441" left="111" width="116" height="17" font="17">related symptoms.</text>
<text top="442" left="227" width="24" height="10" font="19">S7.8-2</text>
<text top="459" left="89" width="343" height="17" font="17">2.  In patients with Emery-Dreifuss and limb-girdle </text>
<text top="478" left="111" width="324" height="17" font="17">type 1B muscular dystrophies associated with </text>
<text top="497" left="111" width="322" height="18" font="21"><i>Lamin A/C</i> mutations, SCD accounts for about </text>
<text top="515" left="111" width="148" height="17" font="17">one third of all deaths.</text>
<text top="516" left="259" width="24" height="10" font="19">S7.8-4</text>
<text top="515" left="284" width="147" height="17" font="17"> Observational studies </text>
<text top="534" left="111" width="318" height="17" font="17">show a significant rate of appropriate ICD therapy </text>
<text top="552" left="111" width="318" height="17" font="17">in patients with cardiac conduction disorders who </text>
<text top="571" left="111" width="319" height="17" font="17">are gene positive for <i>Lamin A/C</i> mutation even if </text>
<text top="589" left="111" width="154" height="17" font="17">LV function is preserved.</text>
<text top="590" left="265" width="83" height="10" font="19">S7.8-3,S7.8-5,S7.8-17</text>
<text top="589" left="347" width="78" height="17" font="17"> In an obser-</text>
<text top="608" left="111" width="318" height="17" font="17">vational study in which 38% had isolated skeletal </text>
<text top="627" left="111" width="319" height="17" font="17">muscular involvement but included patients with </text>
<text top="645" left="111" width="314" height="17" font="17">conduction defects and other risk factors (includ-</text>
<text top="664" left="111" width="317" height="17" font="17">ing PR interval &gt;240 ms, left bundle-branch block, </text>
<text top="88" left="489" width="314" height="17" font="17">NSVT, or bradycardia requiring a permanent pace-</text>
<text top="106" left="489" width="314" height="17" font="17">maker) life-threatening VAs were relatively com-</text>
<text top="124" left="489" width="319" height="17" font="17">mon; with 52% of patients receiving appropriate </text>
<text top="142" left="489" width="324" height="17" font="17">ICD therapy including approximately 40% of </text>
<text top="160" left="489" width="222" height="17" font="17">those patients with an LVEF ≥45%.</text>
<text top="160" left="711" width="24" height="10" font="19">S7.8-3</text>
<text top="160" left="735" width="72" height="17" font="17"> A study of </text>
<text top="178" left="489" width="320" height="17" font="17">patients who had <i>Lamin A/C</i> mutation, in which </text>
<text top="196" left="489" width="314" height="17" font="17">approximately 21% had a skeletal muscular dys-</text>
<text top="214" left="489" width="314" height="17" font="17">trophy phenotype, SCD and appropriate ICD ther-</text>
<text top="232" left="489" width="318" height="17" font="17">apy were associated with NSVT, LVEF &lt;45%, male </text>
<text top="250" left="489" width="290" height="17" font="17">sex, and <i>Lamin A/C</i> nonmissense mutations.</text>
<text top="250" left="779" width="24" height="10" font="19">S7.8-4</text>
<text top="250" left="803" width="4" height="17" font="17"> </text>
<text top="268" left="489" width="321" height="17" font="17">These observational studies support the use of </text>
<text top="286" left="489" width="320" height="17" font="17">an ICD when a pacing indication is present and </text>
<text top="304" left="489" width="320" height="17" font="17">likely also when evidence of progressive cardiac </text>
<text top="322" left="489" width="320" height="17" font="17">involvement such as cardiac conduction defects, </text>
<text top="340" left="489" width="209" height="17" font="17">NSVT or reduced LVEF is present.</text>
<text top="340" left="698" width="24" height="10" font="19">S7.8-8</text>
<text top="358" left="507" width="303" height="17" font="17">There is a paucity of data regarding the rare </text>
<text top="376" left="489" width="318" height="17" font="17">form of x-linked recessive Emery-Dreifuss muscular </text>
<text top="394" left="489" width="320" height="17" font="17">dystrophy (related to the <i>Emerin</i> gene mutation), </text>
<text top="412" left="489" width="319" height="17" font="17">but arrhythmias may be less frequent than for the </text>
<text top="430" left="489" width="137" height="18" font="21"><i>Lamin A/C</i> mutations.</text>
<text top="430" left="626" width="29" height="10" font="19">S7.8-15</text>
<text top="448" left="467" width="344" height="17" font="17">3. Cardiac involvement can occur in a number of </text>
<text top="466" left="489" width="319" height="17" font="17">neuromuscular dystrophies (Table 9). To determine </text>
<text top="484" left="489" width="314" height="17" font="17">cardiac involvement, a 12-lead ECG and echocar-</text>
<text top="502" left="489" width="314" height="17" font="17">diogram are important for the initial clinical assess-</text>
<text top="520" left="489" width="318" height="17" font="17">ment, independent of symptom status. In general, </text>
<text top="538" left="489" width="314" height="17" font="17">the more extensive the cardiac involvement, includ-</text>
<text top="556" left="489" width="314" height="17" font="17">ing evidence of distal conduction disease, ven-</text>
<text top="574" left="489" width="323" height="17" font="17">tricular dysfunction, and atrial arrhythmias, the </text>
<text top="592" left="489" width="320" height="17" font="17">more likely a VA will occur. The initial evaluation </text>
<text top="610" left="489" width="314" height="17" font="17">for myotonic dystrophy patients includes ambula-</text>
<text top="628" left="489" width="320" height="17" font="17">tory monitoring. In asymptomatic patients, some </text>
<text top="646" left="489" width="320" height="17" font="17">experts advocate for annual follow-up during the </text>
<text top="664" left="489" width="322" height="17" font="17">concealed phase of the disease with an annual </text>
<text top="701" left="74" width="37" height="12" font="3"><b>Table 9.</b></text>
<text top="701" left="112" width="288" height="12" font="22"><b>  Neuromuscular Disorders Associated With Heart Disease</b></text>
<text top="752" left="90" width="99" height="12" font="22"><b>Muscular Dystrophy</b></text>
<text top="752" left="227" width="55" height="12" font="22"><b>Inheritance</b></text>
<text top="738" left="327" width="68" height="12" font="22"><b>Gene/Protein </b></text>
<text top="752" left="338" width="42" height="12" font="22"><b>Affected</b></text>
<text top="738" left="421" width="80" height="12" font="22"><b>Primary Cardiac </b></text>
<text top="752" left="434" width="50" height="12" font="22"><b>Pathology</b></text>
<text top="725" left="525" width="53" height="12" font="22"><b>Frequency </b></text>
<text top="738" left="525" width="52" height="12" font="22"><b>of Cardiac </b></text>
<text top="752" left="519" width="62" height="12" font="22"><b>Involvement</b></text>
<text top="752" left="598" width="80" height="12" font="22"><b>Causes of Death</b></text>
<text top="738" left="705" width="83" height="12" font="22"><b>Associated With </b></text>
<text top="752" left="707" width="75" height="12" font="22"><b>Sudden Death?</b></text>
<text top="773" left="85" width="46" height="12" font="4">Duchenne</text>
<text top="773" left="216" width="79" height="12" font="4">X-linked recessive</text>
<text top="773" left="335" width="48" height="12" font="4">Dystrophin</text>
<text top="773" left="446" width="26" height="12" font="4">NICM</text>
<text top="773" left="536" width="28" height="12" font="4">&gt;90%</text>
<text top="773" left="605" width="66" height="12" font="4">Respiratory, HF</text>
<text top="773" left="694" width="101" height="12" font="4">Yes, uncertain etiology</text>
<text top="794" left="85" width="30" height="12" font="4">Becker</text>
<text top="794" left="216" width="79" height="12" font="4">X-linked recessive</text>
<text top="794" left="335" width="48" height="12" font="4">Dystrophin</text>
<text top="794" left="446" width="26" height="12" font="4">NICM</text>
<text top="794" left="525" width="50" height="12" font="4">60%–75%</text>
<text top="794" left="606" width="63" height="12" font="4">HF, respiratory</text>
<text top="794" left="694" width="101" height="12" font="4">Yes, uncertain etiology</text>
<text top="814" left="85" width="87" height="12" font="4">Limb-girdle type 1B</text>
<text top="814" left="208" width="95" height="12" font="4">Autosomal dominant</text>
<text top="814" left="337" width="46" height="12" font="12"><i>Lamin A/C</i></text>
<text top="814" left="416" width="89" height="12" font="4">Conduction system </text>
<text top="828" left="419" width="81" height="12" font="4">disease and NICM</text>
<text top="814" left="536" width="28" height="12" font="4">&gt;90%</text>
<text top="814" left="612" width="51" height="12" font="4">Sudden, HF</text>
<text top="814" left="737" width="15" height="12" font="4">Yes</text>
<text top="849" left="85" width="102" height="12" font="4">Limb-girdle type 2C-2F</text>
<text top="849" left="210" width="90" height="12" font="4">Autosomal recessive</text>
<text top="849" left="333" width="53" height="12" font="4">Sarcoglycan</text>
<text top="849" left="446" width="26" height="12" font="4">NICM</text>
<text top="849" left="536" width="28" height="12" font="4">&lt;25%</text>
<text top="849" left="605" width="66" height="12" font="4">Respiratory, HF</text>
<text top="849" left="723" width="43" height="12" font="4">Uncertain</text>
<text top="869" left="85" width="83" height="12" font="4">Limb-girdle type 2I</text>
<text top="869" left="210" width="90" height="12" font="4">Autosomal recessive</text>
<text top="869" left="326" width="70" height="12" font="4">Fukutin-related </text>
<text top="883" left="344" width="32" height="12" font="4">protein</text>
<text top="869" left="446" width="26" height="12" font="4">NICM</text>
<text top="869" left="525" width="50" height="12" font="4">20%–80%</text>
<text top="869" left="605" width="66" height="12" font="4">Respiratory, HF</text>
<text top="869" left="723" width="43" height="12" font="4">Uncertain</text>
<text top="904" left="85" width="73" height="12" font="4">Myotonic type 1</text>
<text top="904" left="208" width="95" height="12" font="4">Autosomal dominant</text>
<text top="904" left="334" width="54" height="12" font="4">CTG repeat </text>
<text top="917" left="337" width="45" height="12" font="4">expansion</text>
<text top="904" left="416" width="89" height="12" font="4">Conduction system </text>
<text top="917" left="419" width="81" height="12" font="4">disease and NICM</text>
<text top="904" left="525" width="50" height="12" font="4">60%–80%</text>
<text top="904" left="612" width="54" height="12" font="4">Respiratory, </text>
<text top="917" left="613" width="50" height="12" font="4">sudden, HF</text>
<text top="904" left="709" width="73" height="12" font="4">30% of deaths, </text>
<text top="917" left="696" width="100" height="12" font="4">uncertain bradycardia </text>
<text top="931" left="704" width="81" height="12" font="4">versus tachycardia</text>
<text top="952" left="85" width="73" height="12" font="4">Myotonic type 2</text>
<text top="952" left="208" width="95" height="12" font="4">Autosomal dominant</text>
<text top="952" left="330" width="61" height="12" font="4">CCTG repeat </text>
<text top="965" left="337" width="45" height="12" font="4">expansion</text>
<text top="952" left="416" width="89" height="12" font="4">Conduction system </text>
<text top="965" left="443" width="32" height="12" font="4">disease</text>
<text top="952" left="525" width="50" height="12" font="4">10%–25%</text>
<text top="952" left="605" width="65" height="12" font="4">Normal causes</text>
<text top="952" left="724" width="41" height="12" font="4">Reported</text>
<text top="986" left="85" width="66" height="12" font="4">Emery-Dreifuss</text>
<text top="986" left="227" width="60" height="12" font="4">X-linked and </text>
<text top="999" left="209" width="96" height="12" font="4">autosomal dominant </text>
<text top="1013" left="229" width="51" height="12" font="4">or recessive</text>
<text top="986" left="318" width="83" height="12" font="4">Emerin, <i>Lamin A/C</i></text>
<text top="986" left="416" width="89" height="12" font="4">Conduction system </text>
<text top="999" left="419" width="81" height="12" font="4">disease and NICM</text>
<text top="986" left="536" width="28" height="12" font="4">&gt;90%</text>
<text top="986" left="612" width="51" height="12" font="4">Sudden, HF</text>
<text top="986" left="737" width="15" height="12" font="4">Yes</text>
<text top="1034" left="85" width="93" height="12" font="4">Facioscapulohumeral</text>
<text top="1034" left="208" width="95" height="12" font="4">Autosomal dominant</text>
<text top="1034" left="332" width="58" height="12" font="4">D4Z4 repeat </text>
<text top="1047" left="334" width="51" height="12" font="4">contraction</text>
<text top="1034" left="415" width="90" height="12" font="4">Possibly conduction </text>
<text top="1047" left="443" width="32" height="12" font="4">disease</text>
<text top="1034" left="528" width="44" height="12" font="4">5%–15%</text>
<text top="1034" left="604" width="71" height="12" font="4">Normal causes, </text>
<text top="1047" left="600" width="74" height="12" font="4">respiratory rarely</text>
<text top="1034" left="716" width="58" height="12" font="4">Not reported</text>
<text top="1070" left="86" width="300" height="12" font="4">HF indicates heart failure; and NICM, nonischemic cardiomyopathy.</text>
<text top="1084" left="86" width="190" height="12" font="4">Adapted with permission from Groh, et al.</text>
<text top="1084" left="276" width="21" height="7" font="23">S7.8–15</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e324</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="314" height="17" font="17">12-lead ECG to screen for development of conduc-</text>
<text top="106" left="111" width="317" height="17" font="17">tion abnormalities. However, the optimal frequency </text>
<text top="124" left="111" width="286" height="17" font="17">of electrocardiographic screening is unknown.</text>
<text top="125" left="397" width="29" height="10" font="19">S7.8-18</text>
<text top="124" left="425" width="4" height="17" font="17"> </text>
<text top="142" left="111" width="319" height="17" font="17">Once cardiac involvement is present, either on the </text>
<text top="161" left="111" width="322" height="17" font="17">basis of conduction delay, atrial arrhythmias, or </text>
<text top="179" left="111" width="314" height="17" font="17">ventricular dysfunction, a low threshold for investi-</text>
<text top="197" left="111" width="320" height="17" font="17">gating symptoms or electrocardiographic findings </text>
<text top="215" left="111" width="314" height="17" font="17">by the clinician to determine the need for pace-</text>
<text top="234" left="111" width="322" height="17" font="17">maker implantation, invasive electrophysiological </text>
<text top="252" left="111" width="248" height="17" font="17">studies, or ICD implantation is optimal.</text>
<text top="270" left="89" width="342" height="17" font="17">4.  Up to one third of deaths in myotonic dystrophy </text>
<text top="288" left="111" width="143" height="17" font="17">patients are sudden.</text>
<text top="289" left="253" width="24" height="10" font="19">S7.8-9</text>
<text top="288" left="277" width="161" height="17" font="17"> Although commonly </text>
<text top="307" left="111" width="320" height="17" font="17">attributed to conduction block and asystole, SCD </text>
<text top="325" left="111" width="319" height="17" font="17">due to VT/VF has been recognized in patients with </text>
<text top="343" left="111" width="314" height="17" font="17">functioning permanent pacemakers, and spontane-</text>
<text top="361" left="111" width="256" height="17" font="17">ous VA have been documented in some.</text>
<text top="362" left="366" width="59" height="10" font="19">S7.8-13,S7.8-19</text>
<text top="361" left="425" width="4" height="17" font="17"> </text>
<text top="380" left="111" width="314" height="17" font="17">The risk of SCD in patients with pacemakers sug-</text>
<text top="398" left="111" width="318" height="17" font="17">gests that an ICD may be preferred to a pacemaker. </text>
<text top="416" left="111" width="322" height="17" font="17">However, these patients are also at high risk of </text>
<text top="434" left="111" width="320" height="17" font="17">respiratory failure as a competing cause of death. </text>
<text top="453" left="111" width="321" height="17" font="17">Therefore, in patients with severe skeletal muscle </text>
<text top="471" left="111" width="318" height="17" font="17">involvement, a pacemaker or ICD may not improve </text>
<text top="489" left="111" width="65" height="17" font="17">outcomes.</text>
<text top="490" left="176" width="28" height="10" font="19">S7.8-15</text>
<text top="489" left="204" width="224" height="17" font="17"> A shared decision-making approach </text>
<text top="507" left="111" width="321" height="17" font="17">to selecting ICD or pacing therapy is warranted. </text>
<text top="526" left="111" width="314" height="17" font="17">Compared with myotonic type 1 patients, myo-</text>
<text top="544" left="111" width="318" height="17" font="17">tonic dystrophy type 2 patients are not well studied </text>
<text top="562" left="111" width="287" height="17" font="17">but may also benefit from the same approach.</text>
<text top="606" left="74" width="244" height="21" font="18"><b>7.9. Cardiac Channelopathies</b></text>
<text top="640" left="85" width="233" height="12" font="26"><b>Recommendations for Cardiac Channelopathies</b></text>
<text top="657" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="670" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 39</b></a></text>
<text top="670" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="691" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="691" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="691" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="753" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="753" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="712" left="205" width="194" height="12" font="4">1.  In first-degree relatives of patients who </text>
<text top="726" left="217" width="178" height="12" font="4">have a causative mutation for long QT </text>
<text top="739" left="217" width="196" height="12" font="4">syndrome, catecholaminergic polymorphic </text>
<text top="753" left="217" width="201" height="12" font="4">ventricular tachycardia, short QT syndrome, </text>
<text top="766" left="217" width="192" height="12" font="4">or Brugada syndrome, genetic counseling </text>
<text top="780" left="217" width="189" height="12" font="4">and mutation-specific genetic testing are </text>
<text top="793" left="217" width="69" height="12" font="4">recommended.</text>
<text top="794" left="286" width="38" height="7" font="23">S7.9-1–S7.9-6</text>
<text top="834" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="834" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="814" left="205" width="199" height="12" font="4">2.  In patients with a cardiac channelopathy </text>
<text top="827" left="217" width="167" height="12" font="4">and SCA, an ICD is recommended if </text>
<text top="841" left="217" width="204" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="854" left="217" width="44" height="12" font="4">expected.</text>
<text top="855" left="261" width="41" height="7" font="23">S7.9-7–S7.9-13</text>
<text top="895" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="922" left="74" width="351" height="17" font="17">Implantation of an ICD in asymptomatic low-risk pa-</text>
<text top="940" left="74" width="355" height="17" font="17">tients with a cardiac channelopathy for a positive family </text>
<text top="959" left="74" width="355" height="17" font="17">history of SCD as the sole indication is unsupported by </text>
<text top="977" left="74" width="98" height="17" font="17">published data.</text>
<text top="978" left="173" width="63" height="10" font="19">S7.9-13–S7.9-18</text>
<text top="1017" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="1039" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="1066" left="89" width="345" height="17" font="17">1. Clinical screening of first-degree relatives of </text>
<text top="1084" left="111" width="321" height="17" font="17">patients with inherited arrhythmia syndromes </text>
<text top="88" left="489" width="314" height="17" font="17">is crucial to identifying affected family mem-</text>
<text top="106" left="489" width="314" height="17" font="17">bers. Due to the increased risk of adverse car-</text>
<text top="125" left="489" width="320" height="17" font="17">diac events in genotype positive patients with </text>
<text top="143" left="489" width="314" height="17" font="17">long QT syndrome, catecholaminergic poly-</text>
<text top="161" left="489" width="321" height="17" font="17">morphic ventricular tachycardia, and Brugada </text>
<text top="180" left="489" width="318" height="17" font="17">syndrome, targeted screening for the identified </text>
<text top="198" left="489" width="318" height="17" font="17">family-specific mutation can identify individuals </text>
<text top="217" left="489" width="294" height="17" font="17">who are at risk for these adverse outcomes.</text>
<text top="217" left="783" width="20" height="10" font="19">S7.9-</text>
<text top="236" left="489" width="35" height="10" font="19">2–S7.9-5</text>
<text top="235" left="524" width="286" height="17" font="17"> Screening ECGs may be insufficient for </text>
<text top="254" left="489" width="319" height="17" font="17">diagnosis, because the resting ECG in patients </text>
<text top="272" left="489" width="318" height="17" font="17">with catecholaminergic polymorphic ventricular </text>
<text top="291" left="489" width="319" height="17" font="17">tachycardia is normal, and as many as 25% of </text>
<text top="309" left="489" width="314" height="17" font="17">genotype-positive patients with long QT syn-</text>
<text top="328" left="489" width="254" height="17" font="17">drome have QTc intervals  ≤440 ms.</text>
<text top="328" left="743" width="25" height="10" font="19">S7.9-2</text>
<text top="328" left="768" width="43" height="17" font="17"> Due </text>
<text top="346" left="489" width="320" height="17" font="17">to the increased risk of adverse cardiac events </text>
<text top="364" left="489" width="320" height="17" font="17">in young patients with long QT syndrome and </text>
<text top="383" left="489" width="334" height="17" font="17">catecholaminergic polymorphic ventricular </text>
<text top="401" left="489" width="81" height="17" font="17">tachycardia,</text>
<text top="402" left="570" width="94" height="10" font="19">S7.9-2,S7.9-19–S7.9-22</text>
<text top="401" left="664" width="158" height="17" font="17"> screening infants </text>
<text top="420" left="489" width="322" height="17" font="17">and young children is particularly important to </text>
<text top="438" left="489" width="318" height="17" font="17">guide therapy and institute preventive measures, </text>
<text top="457" left="489" width="314" height="17" font="17">including the avoidance of possible provoca-</text>
<text top="475" left="489" width="126" height="17" font="17">tive medications <a href="">(</a></text>
<text top="475" left="615" width="150" height="17" font="20"><a href="">www.crediblemeds.org</a></text>
<text top="475" left="765" width="8" height="17" font="17"><a href="">).</a></text>
<text top="476" left="774" width="30" height="10" font="19">S7.9-23</text>
<text top="475" left="803" width="4" height="17" font="17"> </text>
<text top="494" left="489" width="314" height="17" font="17">However, because up to 15% of mutations pre-</text>
<text top="512" left="489" width="314" height="17" font="17">viously associated with catecholaminergic poly-</text>
<text top="531" left="489" width="321" height="17" font="17">morphic ventricular tachycardia do not appear </text>
<text top="549" left="489" width="109" height="17" font="17">to cause disease,</text>
<text top="550" left="598" width="30" height="10" font="19">S7.9-24</text>
<text top="549" left="628" width="179" height="17" font="17"> caution is advised to avoid </text>
<text top="568" left="489" width="322" height="17" font="17">unnecessary treatment or sports restriction in </text>
<text top="586" left="489" width="314" height="17" font="17">phenotype-negative catecholaminergic polymor-</text>
<text top="604" left="489" width="323" height="17" font="17">phic ventricular tachycardia mutation positive </text>
<text top="623" left="489" width="321" height="17" font="17">individuals. Notably, some patients may prefer </text>
<text top="641" left="489" width="314" height="17" font="17">not to undergo genetic testing, so genetic coun-</text>
<text top="660" left="489" width="213" height="17" font="17">seling should focus on this issue.</text>
<text top="678" left="467" width="343" height="17" font="17">2.  Patients with cardiac channelopathies (ie, long </text>
<text top="697" left="489" width="325" height="17" font="17">QT syndrome, catecholaminergic polymorphic </text>
<text top="715" left="489" width="319" height="17" font="17">ventricular tachycardia, Brugada syndrome, early </text>
<text top="734" left="489" width="317" height="17" font="17">repolarization syndrome, and short QT syndrome) </text>
<text top="752" left="489" width="319" height="17" font="17">and prior SCA have a significantly increased risk </text>
<text top="771" left="489" width="190" height="17" font="17">of subsequent SCA or SCD.</text>
<text top="771" left="679" width="124" height="10" font="19">S7.9-7–S7.9-13,S7.9-25–S7.9-28</text>
<text top="771" left="803" width="4" height="17" font="17"> </text>
<text top="789" left="489" width="319" height="17" font="17">Implantation of an ICD reduces the risk of death </text>
<text top="807" left="489" width="139" height="17" font="17">in high-risk patients.</text>
<text top="808" left="628" width="90" height="10" font="19">S7.9-9,S7.9-29–S7.9-31</text>
<text top="807" left="718" width="93" height="17" font="17"> Appropriate </text>
<text top="826" left="489" width="320" height="17" font="17">ICD therapy for VF/fast VT is reported in 8% to  </text>
<text top="844" left="489" width="314" height="17" font="17">33% of channelopathy patients, while inappropri-</text>
<text top="863" left="489" width="320" height="17" font="17">ate shocks and device complications are reported </text>
<text top="881" left="489" width="99" height="17" font="17">in 8% to 35%.</text>
<text top="882" left="588" width="159" height="10" font="19">S7.9-10,S7.9-29,S7.9-30,S7.9-32–S7.9-36</text>
<text top="881" left="747" width="56" height="17" font="17"> To mini-</text>
<text top="900" left="489" width="314" height="17" font="17">mize inappropriate shocks, concurrent beta block-</text>
<text top="918" left="489" width="320" height="17" font="17">ers in long QT syndrome and catecholaminergic </text>
<text top="937" left="489" width="327" height="17" font="17">polymorphic ventricular tachycardia patients, </text>
<text top="955" left="489" width="323" height="17" font="17">optimal device programming, and appropriate </text>
<text top="974" left="489" width="321" height="17" font="17">lead selection are necessary. Ventricular pacing </text>
<text top="992" left="489" width="319" height="17" font="17">without ICD implantation was associated with a </text>
<text top="1011" left="489" width="320" height="17" font="17">significant risk of recurrent SCA or SCD in long </text>
<text top="1029" left="489" width="162" height="17" font="17">QT syndrome patients.</text>
<text top="1030" left="651" width="63" height="10" font="19">S7.9-37–S7.9-39</text>
<text top="1029" left="714" width="101" height="17" font="17"> In selected </text>
<text top="1047" left="489" width="320" height="17" font="17">patients with LQT1 in whom the SCA occurred </text>
<text top="1066" left="489" width="314" height="17" font="17">in the absence of beta-blocker treatment, beta-</text>
<text top="1084" left="489" width="318" height="17" font="17">blocker therapy is offered as an alternative to ICD </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="30" size="8" family="Times" color="#3c4ba7"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e325</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="318" height="17" font="17">implantation in patients who refuse to receive an </text>
<text top="106" left="111" width="28" height="17" font="17">ICD.</text>
<text top="106" left="139" width="29" height="10" font="19">S7.9-40</text>
<text top="133" left="74" width="345" height="18" font="24"><i><b>7.9.1. Specific Cardiac Channelopathy Syndromes</b></i></text>
<text top="151" left="74" width="250" height="18" font="28"><i>7.9.1.1. Congenital Long QT Syndrome</i></text>
<text top="179" left="85" width="206" height="12" font="26"><b>Recommendations for Long QT Syndrome</b></text>
<text top="196" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="209" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 40</b></a></text>
<text top="209" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="230" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="230" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="230" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="265" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="265" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="251" left="205" width="200" height="12" font="4">1.  In patients with long QT syndrome with a </text>
<text top="265" left="217" width="180" height="12" font="4">resting QTc greater than 470 ms, a beta </text>
<text top="278" left="217" width="112" height="12" font="4">blocker is recommended.</text>
<text top="279" left="329" width="58" height="7" font="23">S7.9.1.1-1–S7.9.1.1-5</text>
<text top="346" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="346" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="299" left="205" width="204" height="12" font="4">2.  In high-risk patients with symptomatic long </text>
<text top="313" left="217" width="181" height="12" font="4">QT syndrome in whom a beta blocker is </text>
<text top="326" left="217" width="191" height="12" font="4">ineffective or not tolerated, intensification </text>
<text top="340" left="217" width="176" height="12" font="4">of therapy with additional medications </text>
<text top="353" left="217" width="188" height="12" font="4">(guided by consideration of the particular </text>
<text top="367" left="217" width="161" height="12" font="4">long QT syndrome type), left cardiac </text>
<text top="380" left="217" width="186" height="12" font="4">sympathetic denervation, and/or an ICD is </text>
<text top="394" left="217" width="66" height="12" font="4">recommended.</text>
<text top="394" left="283" width="88" height="7" font="23">S7.9.1.1-2,S7.9.1.1-6–S7.9.1.1-12</text>
<text top="468" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="468" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="414" left="205" width="189" height="12" font="4">3.  In patients with long QT syndrome and </text>
<text top="428" left="217" width="185" height="12" font="4">recurrent appropriate ICD shocks despite </text>
<text top="441" left="217" width="162" height="12" font="4">maximum tolerated doses of a beta </text>
<text top="455" left="217" width="189" height="12" font="4">blocker, intensification of medical therapy </text>
<text top="468" left="217" width="177" height="12" font="4">with additional medications (guided by </text>
<text top="482" left="217" width="176" height="12" font="4">consideration of the particular long QT </text>
<text top="495" left="217" width="192" height="12" font="4">syndrome type) or left cardiac sympathetic </text>
<text top="509" left="217" width="136" height="12" font="4">denervation, is recommended.</text>
<text top="509" left="352" width="31" height="7" font="23">S7.9.1.1-6, </text>
<text top="523" left="217" width="126" height="7" font="23">S7.9.1.1-7,S7.9.1.1-10,S7.9.1.1-13–S7.9.1.1-16</text>
<text top="557" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="557" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="543" left="205" width="211" height="12" font="4">4.  In patients with clinically diagnosed long QT </text>
<text top="557" left="217" width="191" height="12" font="4">syndrome, genetic counseling and genetic </text>
<text top="570" left="217" width="117" height="12" font="4">testing are recommended.</text>
<text top="571" left="334" width="64" height="7" font="23">S7.9.1.1-17–S7.9.1.1-21</text>
<text top="632" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="632" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="591" left="205" width="173" height="12" font="4">5.  In patients with suspected long QT </text>
<text top="604" left="217" width="201" height="12" font="4">syndrome, ambulatory electrocardiographic </text>
<text top="618" left="217" width="168" height="12" font="4">monitoring, recording the ECG lying </text>
<text top="631" left="217" width="172" height="12" font="4">and immediately on standing, and/or </text>
<text top="645" left="217" width="195" height="12" font="4">exercise treadmill testing can be useful for </text>
<text top="658" left="217" width="202" height="12" font="4">establishing a diagnosis and monitoring the </text>
<text top="672" left="217" width="92" height="12" font="4">response to therapy.</text>
<text top="672" left="309" width="66" height="7" font="23">S7.9.1.1-22–S7.9.1.1-29</text>
<text top="713" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="713" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="693" left="205" width="188" height="12" font="4">6.  In asymptomatic patients with long QT </text>
<text top="706" left="217" width="189" height="12" font="4">syndrome and a resting QTc less than 470 </text>
<text top="720" left="217" width="189" height="12" font="4">ms, chronic therapy with a beta blocker is </text>
<text top="733" left="217" width="51" height="12" font="4">reasonable.</text>
<text top="734" left="268" width="92" height="7" font="23">S7.9.1.1-3,S7.9.1.1-30,S7.9.1.1-31</text>
<text top="801" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="801" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="754" left="205" width="188" height="12" font="4">7.  In asymptomatic patients with long QT </text>
<text top="767" left="217" width="185" height="12" font="4">syndrome and a resting QTc greater than </text>
<text top="781" left="217" width="174" height="12" font="4">500 ms while receiving a beta blocker, </text>
<text top="794" left="217" width="194" height="12" font="4">intensification of therapy with medications </text>
<text top="808" left="217" width="188" height="12" font="4">(guided by consideration of the particular </text>
<text top="821" left="217" width="165" height="12" font="4">long QT syndrome type), left cardiac </text>
<text top="835" left="217" width="194" height="12" font="4">sympathetic denervation or an ICD may be </text>
<text top="848" left="217" width="51" height="12" font="4">considered.</text>
<text top="849" left="268" width="121" height="7" font="23">S7.9.1.1-2,S7.9.1.1-8,S7.9.1.1-11,S7.9.1.1-30</text>
<text top="883" left="84" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="883" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="869" left="205" width="187" height="12" font="4">8.  In patients with long QT syndrome, QT-</text>
<text top="883" left="217" width="175" height="12" font="4">prolonging medications are potentially </text>
<text top="896" left="217" width="38" height="12" font="4">harmful.</text>
<text top="897" left="255" width="126" height="7" font="23">S7.9.1.1-5,S7.9.1.1-12,S7.9.1.1-32–S7.9.1.1-34</text>
<text top="936" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="957" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="984" left="89" width="342" height="17" font="17">1.  Beta blockers reduce adverse cardiac events for </text>
<text top="1002" left="111" width="322" height="17" font="17">long QT syndrome type 1 (Figure  10) (&gt;95%), </text>
<text top="1020" left="111" width="318" height="17" font="17">long QT syndrome type 2 (Figure 11) (&gt;75%), and </text>
<text top="1038" left="111" width="318" height="17" font="17">females with long QT syndrome type 3 (Figure 12) </text>
<text top="1056" left="111" width="69" height="17" font="17">by &gt;60%.</text>
<text top="1057" left="180" width="82" height="10" font="19">S7.9.1.1-1–S7.9.1.1-5</text>
<text top="1056" left="262" width="172" height="17" font="17"> There are limited data </text>
<text top="1074" left="111" width="319" height="17" font="17">regarding efficacy of beta blockers in males with </text>
<text top="88" left="489" width="183" height="17" font="17">long QT syndrome type 3</text>
<text top="88" left="672" width="131" height="10" font="19">S7.9.1.1-3,S7.9.1.1-35,S7.9.1.1-36</text>
<text top="88" left="803" width="4" height="17" font="17"> </text>
<text top="106" left="489" width="322" height="17" font="17">but, in selected patients, beta blockers can be </text>
<text top="124" left="489" width="166" height="17" font="17">protective against SCA.</text>
<text top="124" left="655" width="90" height="10" font="19">S7.9.1.1-36,S7.9.1.1-37</text>
<text top="124" left="745" width="71" height="17" font="17"> Several </text>
<text top="142" left="489" width="319" height="17" font="17">observational studies have reported effectiveness </text>
<text top="160" left="489" width="314" height="17" font="17">for risk reduction in long QT syndrome with pro-</text>
<text top="178" left="489" width="320" height="17" font="17">pranolol, atenolol, and nadolol with appropriate </text>
<text top="196" left="489" width="47" height="17" font="17">dosing,</text>
<text top="196" left="536" width="184" height="10" font="19">S7.9.1.1-26,S7.9.1.1-28,S7.9.1.1-38–S7.9.1.1-40</text>
<text top="196" left="720" width="83" height="17" font="17"> while meto-</text>
<text top="214" left="489" width="178" height="17" font="17">prolol appears less effective.</text>
<text top="214" left="667" width="44" height="10" font="19">S7.9.1.1-41</text>
<text top="214" left="711" width="96" height="17" font="17"> RCTs to assess </text>
<text top="232" left="489" width="319" height="17" font="17">comparative efficacy of specific beta blockers are </text>
<text top="250" left="489" width="318" height="17" font="17">unavailable, although many centers favor the use </text>
<text top="268" left="489" width="318" height="17" font="17">of nadolol. For long QT syndrome type 1, 1 study </text>
<text top="286" left="489" width="314" height="17" font="17">reported atenolol reduced risk of VA while nado-</text>
<text top="304" left="489" width="275" height="17" font="17">lol was not associated with risk reduction.</text>
<text top="304" left="764" width="39" height="10" font="19">S7.9.1.1-2</text>
<text top="304" left="803" width="4" height="17" font="17"> </text>
<text top="322" left="489" width="325" height="17" font="17">For long QT syndrome type 2, nadolol was </text>
<text top="340" left="489" width="234" height="17" font="17">reported to show superior efficacy.</text>
<text top="340" left="723" width="80" height="10" font="19">S7.9.1.1-1,S7.9.1.1-2</text>
<text top="340" left="803" width="4" height="17" font="17"> </text>
<text top="358" left="489" width="319" height="17" font="17">Patients receiving a beta blocker should undergo </text>
<text top="376" left="489" width="323" height="17" font="17">ongoing monitoring to assess changes in QTc </text>
<text top="394" left="489" width="320" height="17" font="17">over time, and adequacy of beta blockade with </text>
<text top="412" left="489" width="56" height="17" font="17">exertion.</text>
<text top="412" left="545" width="90" height="10" font="19">S7.9.1.1-26,S7.9.1.1-28</text>
<text top="430" left="467" width="348" height="17" font="17">2. High-risk patients with long QT syndrome </text>
<text top="448" left="489" width="323" height="17" font="17">include those with QTc &gt;500 ms, genotypes </text>
<text top="466" left="489" width="314" height="17" font="17">long QT syndrome type 2 and long QT syn-</text>
<text top="484" left="489" width="320" height="17" font="17">drome type 3, females with genotype long QT  </text>
<text top="502" left="489" width="321" height="17" font="17">syndrome type 2,  &lt;40 years of age, onset of </text>
<text top="520" left="489" width="322" height="17" font="17">symptoms at  &lt;10 years of age, and patients  </text>
<text top="538" left="489" width="332" height="17" font="17">with prior cardiac arrest or recurrent </text>
<text top="556" left="489" width="63" height="17" font="17">syncope.</text>
<text top="556" left="553" width="251" height="10" font="19">S7.9.1.1-3,S7.9.1.1-8,S7.9.1.1-11,S7.9.1.1-30,S7.9.1.1-38</text>
<text top="556" left="803" width="4" height="17" font="17"> </text>
<text top="574" left="489" width="321" height="17" font="17">Women with long QT syndrome type 2 are at </text>
<text top="592" left="489" width="318" height="17" font="17">a higher risk of postpartum cardiac arrest/ </text>
<text top="610" left="489" width="28" height="17" font="17">SCD</text>
<text top="610" left="517" width="90" height="10" font="19">S7.9.1.1-42,S7.9.1.1-43</text>
<text top="610" left="606" width="197" height="17" font="17"> and should receive prepreg-</text>
<text top="628" left="489" width="314" height="17" font="17">nancy counseling. Patients with long QT syn-</text>
<text top="646" left="489" width="321" height="17" font="17">drome and recurrent syncope while receiving a </text>
<text top="664" left="489" width="321" height="17" font="17">beta blocker have an increased risk of SCA or </text>
<text top="682" left="489" width="154" height="17" font="17">appropriate ICD shocks</text>
<text top="682" left="643" width="39" height="10" font="19">S7.9.1.1-9</text>
<text top="682" left="682" width="129" height="17" font="17"> and escalation of </text>
<text top="700" left="489" width="314" height="17" font="17">therapy is warranted to prevent SCD. Earlier stud-</text>
<text top="718" left="489" width="322" height="17" font="17">ies reported benefit of antibradycardia pacing, </text>
<text top="768" left="452" width="43" height="12" font="3"><b>Table 10.</b></text>
<text top="768" left="496" width="227" height="12" font="22"><b>  Commonly Used QT-Prolonging Medications</b></text>
<text top="769" left="723" width="64" height="7" font="25"><b>S7.9.1.1-59,S7.9.1.1-62</b></text>
<text top="792" left="529" width="203" height="12" font="22"><b>Examples of QT Prolonging Medications*</b></text>
<text top="813" left="463" width="78" height="12" font="22"><b>Antiarrhythmic </b></text>
<text top="826" left="463" width="60" height="12" font="22"><b>Medications</b></text>
<text top="813" left="584" width="65" height="12" font="22"><b>Psychotropic </b></text>
<text top="826" left="585" width="60" height="12" font="22"><b>Medications</b></text>
<text top="826" left="668" width="53" height="12" font="22"><b>Antibiotics</b></text>
<text top="826" left="751" width="33" height="12" font="22"><b>Others</b></text>
<text top="848" left="463" width="61" height="12" font="4">Disopyramide</text>
<text top="848" left="589" width="51" height="12" font="4">Haloperidol</text>
<text top="848" left="665" width="58" height="12" font="4">Erythromycin</text>
<text top="848" left="742" width="52" height="12" font="4">Methadone</text>
<text top="868" left="463" width="63" height="12" font="4">Procainamide </text>
<text top="882" left="463" width="102" height="12" font="4">(N-acetylprocainamide)</text>
<text top="868" left="581" width="67" height="12" font="4">Phenothiazines</text>
<text top="868" left="666" width="55" height="12" font="4">Pentamidine</text>
<text top="868" left="748" width="39" height="12" font="4">Probucol</text>
<text top="903" left="463" width="43" height="12" font="4">Quinidine</text>
<text top="903" left="590" width="50" height="12" font="4">Citalopram</text>
<text top="903" left="665" width="59" height="12" font="4">Azithromycin</text>
<text top="903" left="744" width="50" height="12" font="4">Droperidol </text>
<text top="923" left="463" width="43" height="12" font="4">Dofetilide</text>
<text top="923" left="598" width="33" height="12" font="4">Tricyclic</text>
<text top="923" left="666" width="55" height="12" font="4">Chloroquine</text>
<text top="923" left="738" width="58" height="12" font="4">Ondansetron</text>
<text top="944" left="463" width="59" height="12" font="4">Dronedarone</text>
<text top="944" left="580" width="69" height="12" font="4">antidepressants</text>
<text top="944" left="665" width="59" height="12" font="4">Ciprofloxacin</text>
<text top="944" left="765" width="3" height="12" font="4"> </text>
<text top="965" left="463" width="36" height="12" font="4">Ibutilide</text>
<text top="965" left="612" width="3" height="12" font="4"> </text>
<text top="965" left="668" width="52" height="12" font="4">Fluconazole</text>
<text top="965" left="765" width="3" height="12" font="4"> </text>
<text top="986" left="463" width="30" height="12" font="4">Sotalol</text>
<text top="986" left="612" width="3" height="12" font="4"> </text>
<text top="986" left="667" width="55" height="12" font="4">Levofloxacin</text>
<text top="986" left="765" width="3" height="12" font="4"> </text>
<text top="1007" left="463" width="61" height="12" font="4">Amiodarone†</text>
<text top="1007" left="612" width="3" height="12" font="4"> </text>
<text top="1007" left="666" width="57" height="12" font="4">Moxifloxacin</text>
<text top="1020" left="662" width="65" height="12" font="4">Clarithromycin</text>
<text top="1034" left="667" width="54" height="12" font="4">Itraconazole</text>
<text top="1047" left="664" width="61" height="12" font="4">Ketoconazole</text>
<text top="1007" left="765" width="3" height="12" font="4"> </text>
<text top="1070" left="464" width="178" height="12" font="4">*A more complete list is maintained at: </text>
<text top="1070" left="643" width="104" height="12" font="30"><a href="">www.crediblemeds.org</a></text>
<text top="1070" left="746" width="3" height="12" font="4">.</text>
<text top="1071" left="749" width="31" height="7" font="23">S7.9.1.1-59</text>
<text top="1084" left="464" width="213" height="12" font="4">†Amiodarone rarely causes torsades de pointes.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e326</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="509" left="111" width="319" height="17" font="17">with recurrent syncope or cardiac arrest reported </text>
<text top="527" left="111" width="199" height="17" font="17">in 7% to 24% of patients.</text>
<text top="528" left="310" width="94" height="10" font="19">S7.9.1.1-44–S7.9.1.1-47</text>
<text top="527" left="404" width="31" height="17" font="17"> In </text>
<text top="545" left="111" width="314" height="17" font="17">high-risk patients, observational studies sup-</text>
<text top="563" left="111" width="320" height="17" font="17">port effectiveness of the ICD in preventing SCD, </text>
<text top="581" left="111" width="323" height="17" font="17">with consideration of left cardiac sympathetic </text>
<text top="599" left="111" width="325" height="17" font="17">denervation to reduce the frequency of ICD </text>
<text top="617" left="111" width="47" height="17" font="17">shocks.</text>
<text top="618" left="158" width="136" height="10" font="19">S7.9.1.1-16,S7.9.1.1-48,S7.9.1.1-49</text>
<text top="617" left="294" width="131" height="17" font="17"> Left cardiac sympa-</text>
<text top="635" left="111" width="319" height="17" font="17">thetic denervation can reduce VA burden, but up </text>
<text top="653" left="111" width="320" height="17" font="17">to 27% of high-risk patients experience at least </text>
<text top="671" left="111" width="89" height="17" font="17">1 recurrence.</text>
<text top="672" left="200" width="139" height="10" font="19">S7.9.1.1-16,S7.9.1.1-48,S7.9.1.1-50</text>
<text top="671" left="339" width="94" height="17" font="17"> Left cardiac </text>
<text top="689" left="111" width="319" height="17" font="17">sympathetic denervation may be more effective </text>
<text top="707" left="111" width="320" height="17" font="17">in patients with long QT syndrome type 1 and </text>
<text top="509" left="489" width="172" height="17" font="17">long QT syndrome type 3.</text>
<text top="510" left="661" width="45" height="10" font="19">S7.9.1.1-16</text>
<text top="509" left="706" width="102" height="17" font="17"> Complications </text>
<text top="527" left="489" width="322" height="17" font="17">related to left cardiac sympathetic denervation </text>
<text top="545" left="489" width="224" height="17" font="17">occur in 8% to 20% of patients.</text>
<text top="546" left="713" width="90" height="10" font="19">S7.9.1.1-48,S7.9.1.1-51</text>
<text top="545" left="803" width="4" height="17" font="17"> </text>
<text top="563" left="489" width="319" height="17" font="17">Syncope in patients with long QT syndrome may </text>
<text top="581" left="489" width="320" height="17" font="17">occur due to vasovagal syncope, noncompliance </text>
<text top="599" left="489" width="314" height="17" font="17">with medications, or proarrhythmia from concur-</text>
<text top="617" left="489" width="114" height="17" font="17">rent medications.</text>
<text top="618" left="603" width="39" height="10" font="19">S7.9.1.1-5</text>
<text top="617" left="642" width="169" height="17" font="17"> Clinical evaluation that </text>
<text top="635" left="489" width="314" height="17" font="17">incorporates consideration of genotype, QTc inter-</text>
<text top="653" left="489" width="314" height="17" font="17">val, medication compliance, and shared decision-</text>
<text top="671" left="489" width="318" height="17" font="17">making regarding the need to change or escalate </text>
<text top="689" left="489" width="314" height="17" font="17">therapy is important. Use of additional medica-</text>
<text top="707" left="489" width="318" height="17" font="17">tions is guided by long QT syndrome type. In long </text>
<text top="409" left="74" width="45" height="12" font="3"><b>Figure 9. </b></text>
<text top="409" left="120" width="270" height="12" font="22"><b>Prevention of SCD in patients with long QT syndrome.</b> </text>
<text top="423" left="74" width="723" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 7.9.1.1 for discussion. *ICD candidacy as determined by functional status, life expectancy, </text>
<text top="436" left="74" width="725" height="12" font="4">or patient preference. †High-risk patients with LQTS include those with QTc &gt;500 ms, genotypes LQT2 and LQT3, females with genotype LQT2, &lt;40 years of age, </text>
<text top="450" left="74" width="710" height="12" font="4">onset of symptoms at &lt;10 years of age, and patients with recurrent syncope. ICD indicates implantable cardioverter-defibrillator; LQTS, long QT syndrome; VT, </text>
<text top="463" left="74" width="103" height="12" font="4">ventricular tachycardia.</text>
<text top="1084" left="74" width="51" height="12" font="3"><b>Figure 10. </b></text>
<text top="1084" left="125" width="130" height="12" font="22"><b>Long QT syndrome type 1.</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e327</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="492" left="111" width="320" height="17" font="17">QT syndrome type 3 ranolazine, mexiletine, and </text>
<text top="510" left="111" width="318" height="17" font="17">flecainide shorten the QTc and have been used to </text>
<text top="528" left="111" width="186" height="17" font="17">reduce recurrent arrhythmias.</text>
<text top="529" left="297" width="125" height="10" font="19">S7.9.1.1-6,S7.9.1.1-7,S7.9.1.1-10</text>
<text top="546" left="89" width="341" height="17" font="17">3.  Mexiletine is an additional medication that can </text>
<text top="564" left="111" width="323" height="17" font="17">be used in patients with long QT syndrome </text>
<text top="582" left="111" width="314" height="17" font="17">and recurrent ICD shocks. Left cardiac sympa-</text>
<text top="600" left="111" width="314" height="17" font="17">thetic denervation is associated with a reduc-</text>
<text top="618" left="111" width="324" height="17" font="17">tion the number of appropriate ICD shocks </text>
<text top="636" left="111" width="117" height="17" font="17">and VA burden.</text>
<text top="637" left="228" width="95" height="10" font="19">S7.9.1.1-13–S7.9.1.1-16</text>
<text top="636" left="323" width="113" height="17" font="17"> Reduction of </text>
<text top="654" left="111" width="314" height="17" font="17">the QTc to  &lt;500 ms after left cardiac sympa-</text>
<text top="672" left="111" width="324" height="17" font="17">thetic denervation has been correlated with </text>
<text top="492" left="489" width="314" height="17" font="17">reduced risk of recurrent ICD shocks and fre-</text>
<text top="510" left="489" width="147" height="17" font="17">quency of symptoms</text>
<text top="511" left="637" width="93" height="10" font="19">S7.9.1.1-16,S7.9.1.1-52</text>
<text top="510" left="730" width="83" height="17" font="17">; however, </text>
<text top="528" left="489" width="323" height="17" font="17">SCD or SCA is reported in 3% to 10% of </text>
<text top="546" left="489" width="57" height="17" font="17">patients.</text>
<text top="547" left="546" width="188" height="10" font="19">S7.9.1.1-15,S7.9.1.1-16,S7.9.1.1-48,S7.9.1.1-50</text>
<text top="546" left="734" width="76" height="17" font="17"> Although </text>
<text top="564" left="489" width="324" height="17" font="17">arrhythmia burden is often reduced, up to </text>
<text top="582" left="489" width="322" height="17" font="17">27% of high-risk patients experience at least </text>
<text top="600" left="489" width="88" height="17" font="17">1 recurrence.</text>
<text top="601" left="577" width="141" height="10" font="19">S7.9.1.1-13,S7.9.1.1-14,S7.9.1.1-48</text>
<text top="600" left="718" width="85" height="17" font="17"> Patient out-</text>
<text top="618" left="489" width="314" height="17" font="17">comes are improved if the left cardiac sym-</text>
<text top="636" left="489" width="323" height="17" font="17">pathetic denervation is performed in centers </text>
<text top="654" left="489" width="322" height="17" font="17">with surgical expertise in this procedure. Use </text>
<text top="672" left="489" width="319" height="17" font="17">of additional medications is guided by long QT </text>
<text top="456" left="74" width="51" height="12" font="3"><b>Figure 11. </b></text>
<text top="456" left="125" width="130" height="12" font="22"><b>Long QT syndrome type 2.</b></text>
<text top="1084" left="74" width="51" height="12" font="3"><b>Figure 12. </b></text>
<text top="1084" left="125" width="130" height="12" font="22"><b>Long QT syndrome type 3.</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e328</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="321" height="17" font="17">syndrome type. In long QT syndrome type 3, </text>
<text top="106" left="111" width="322" height="17" font="17">ranolazine, mexiletine, and flecainide shorten </text>
<text top="124" left="111" width="318" height="17" font="17">the QTc and have been used to reduce recurrent </text>
<text top="142" left="111" width="82" height="17" font="17">arrhythmias.</text>
<text top="142" left="193" width="131" height="10" font="19">S7.9.1.1-6,S7.9.1.1-7,S7.9.1.1-10</text>
<text top="160" left="89" width="344" height="17" font="17">4. Genetic testing for disease-causing mutations </text>
<text top="178" left="111" width="314" height="17" font="17">in long QT syndrome offers important diagnos-</text>
<text top="196" left="111" width="321" height="17" font="17">tic, prognostic, and therapeutic information in </text>
<text top="214" left="111" width="314" height="17" font="17">addition to the clinical evaluation, and a posi-</text>
<text top="232" left="111" width="319" height="17" font="17">tive test can facilitate establishing risk for family </text>
<text top="250" left="111" width="318" height="17" font="17">members. The yield of genetic testing in long QT </text>
<text top="268" left="111" width="318" height="17" font="17">syndrome phenotype-positive patients is 50% to </text>
<text top="286" left="111" width="319" height="17" font="17">86%, with the higher range present in patients </text>
<text top="304" left="111" width="319" height="17" font="17">with marked QT prolongation or positive family </text>
<text top="322" left="111" width="99" height="17" font="17">history of SCD.</text>
<text top="323" left="211" width="139" height="10" font="19">S7.9.1.1-17,S7.9.1.1-21,S7.9.1.1-53</text>
<text top="322" left="350" width="80" height="17" font="17"> A negative </text>
<text top="340" left="111" width="321" height="17" font="17">genetic test does not exclude the diagnosis of </text>
<text top="358" left="111" width="321" height="17" font="17">long QT syndrome, which relies on the clinical </text>
<text top="376" left="111" width="314" height="17" font="17">evaluation. In asymptomatic patients with oth-</text>
<text top="394" left="111" width="324" height="17" font="17">erwise unexplained prolonged QTc  ≥480 ms </text>
<text top="412" left="111" width="314" height="17" font="17">on serial ECGs, genetic testing may help con-</text>
<text top="430" left="111" width="321" height="17" font="17">firm the diagnosis and supplement prognostic </text>
<text top="448" left="111" width="324" height="17" font="17">information in addition to clinical symptoms </text>
<text top="466" left="111" width="128" height="17" font="17">and QTc duration.</text>
<text top="467" left="239" width="188" height="10" font="19">S7.9.1.1-5,S7.9.1.1-18–S7.9.1.1-20,S7.9.1.1-30, </text>
<text top="485" left="111" width="141" height="10" font="19">S7.9.1.1-35,S7.9.1.1-54–S7.9.1.1-56</text>
<text top="503" left="89" width="341" height="17" font="17">5.  In a prospective, observational study of patients </text>
<text top="521" left="111" width="319" height="17" font="17">with suspected long QT syndrome, patients with </text>
<text top="539" left="111" width="319" height="17" font="17">a history of syncope or cardiac arrest and either </text>
<text top="557" left="111" width="321" height="17" font="17">an affected first-degree relative or a borderline </text>
<text top="575" left="111" width="323" height="17" font="17">or prolonged QTc interval underwent exercise </text>
<text top="593" left="111" width="319" height="17" font="17">treadmill testing and bicycle exercise, with ECGs </text>
<text top="611" left="111" width="321" height="17" font="17">recorded before, during, and after exercise, as </text>
<text top="629" left="111" width="184" height="17" font="17">well as in different positions.</text>
<text top="630" left="296" width="44" height="10" font="19">S7.9.1.1-27</text>
<text top="629" left="340" width="85" height="17" font="17"> long QT syn-</text>
<text top="647" left="111" width="321" height="17" font="17">drome was confirmed by genetic testing in all </text>
<text top="665" left="111" width="314" height="17" font="17">affected individuals. Among patients with border-</text>
<text top="683" left="111" width="318" height="17" font="17">line-to-normal resting QTc intervals, prolongation </text>
<text top="701" left="111" width="319" height="17" font="17">of the 4-minute recovery QTc ≥445 ms had high </text>
<text top="719" left="111" width="320" height="17" font="17">sensitivity for correctly identifying patients with </text>
<text top="737" left="111" width="130" height="17" font="17">long QT syndrome.</text>
<text top="738" left="241" width="44" height="10" font="19">S7.9.1.1-27</text>
<text top="737" left="285" width="148" height="17" font="17"> A study in younger </text>
<text top="755" left="111" width="322" height="17" font="17">patients demonstrated QTc prolongation &gt;460 </text>
<text top="773" left="111" width="320" height="17" font="17">ms at 7 minutes of recovery predicted long QT </text>
<text top="791" left="111" width="321" height="17" font="17">syndrome type 1 or long QT syndrome type 2 </text>
<text top="809" left="111" width="158" height="17" font="17">patients versus controls.</text>
<text top="810" left="269" width="44" height="10" font="19">S7.9.1.1-23</text>
<text top="809" left="313" width="118" height="17" font="17"> In a study using </text>
<text top="827" left="111" width="321" height="17" font="17">burst bicycle exercise, patients with latent long </text>
<text top="845" left="111" width="319" height="17" font="17">QT syndrome had a significantly greater increase </text>
<text top="863" left="111" width="318" height="17" font="17">in QTc with exercise than either controls or those </text>
<text top="881" left="111" width="227" height="17" font="17">with QTc prolongation at baseline.</text>
<text top="882" left="338" width="44" height="10" font="19">S7.9.1.1-24</text>
<text top="881" left="383" width="48" height="17" font="17"> These </text>
<text top="899" left="111" width="321" height="17" font="17">findings can be useful in establishing whether </text>
<text top="917" left="111" width="314" height="17" font="17">long QT syndrome is present. Monitoring ade-</text>
<text top="936" left="111" width="324" height="17" font="17">quacy of beta-blocker therapy using exercise </text>
<text top="954" left="111" width="314" height="17" font="17">testing can be beneficial, particularly in school-</text>
<text top="972" left="111" width="96" height="17" font="17">aged patients.</text>
<text top="972" left="207" width="91" height="10" font="19">S7.9.1.1-26,S7.9.1.1-28</text>
<text top="972" left="298" width="128" height="17" font="17"> Beta-blocker ther-</text>
<text top="990" left="111" width="319" height="17" font="17">apy may be associated with a decrease in supine </text>
<text top="1008" left="111" width="322" height="17" font="17">and peak exercise QTc, with the exception of </text>
<text top="1026" left="111" width="321" height="17" font="17">long QT syndrome type 1 patients with C-loop </text>
<text top="1044" left="111" width="69" height="17" font="17">mutations.</text>
<text top="1044" left="180" width="44" height="10" font="19">S7.9.1.1-25</text>
<text top="1062" left="89" width="336" height="17" font="17">6. Approximately 10% to 36% of genotype-pos-</text>
<text top="1080" left="111" width="321" height="17" font="17">itive patients with long QT syndrome have QTc </text>
<text top="88" left="489" width="319" height="17" font="17">intervals ≤440 ms, most commonly patients with </text>
<text top="106" left="489" width="169" height="17" font="17">long QT syndrome type 1.</text>
<text top="107" left="658" width="90" height="10" font="19">S7.9.1.1-31,S7.9.1.1-35</text>
<text top="106" left="748" width="60" height="17" font="17"> Patients </text>
<text top="124" left="489" width="322" height="17" font="17">with long QT  syndrome and normal QTc have </text>
<text top="142" left="489" width="320" height="17" font="17">a lower risk of VA and SCD compared to those </text>
<text top="160" left="489" width="142" height="17" font="17">with prolonged QTc,</text>
<text top="161" left="631" width="44" height="10" font="19">S7.9.1.1-35</text>
<text top="160" left="674" width="139" height="17" font="17"> but still have an </text>
<text top="178" left="489" width="314" height="17" font="17">increased risk of SCA or SCD compared with gen-</text>
<text top="196" left="489" width="323" height="17" font="17">otype-negative, age- and sex-matched general </text>
<text top="214" left="489" width="55" height="17" font="17">patients.</text>
<text top="215" left="544" width="44" height="10" font="19">S7.9.1.1-31</text>
<text top="214" left="588" width="221" height="17" font="17"> Beta blockers reduce the risk of </text>
<text top="232" left="489" width="230" height="17" font="17">adverse cardiac events substantially.</text>
<text top="233" left="719" width="87" height="10" font="19">S7.9.1.1-1–S7.9.1.1-5, </text>
<text top="251" left="489" width="236" height="10" font="19">S7.9.1.1-30,S7.9.1.1-36,S7.9.1.1-38,S7.9.1.1-41,S7.9.1.1-57</text>
<text top="250" left="725" width="84" height="17" font="17"> During the </text>
<text top="268" left="489" width="320" height="17" font="17">periods of highest risk in the first 3 decades of </text>
<text top="286" left="489" width="23" height="17" font="17">life,</text>
<text top="287" left="512" width="90" height="10" font="19">S7.9.1.1-11,S7.9.1.1-18</text>
<text top="286" left="602" width="206" height="17" font="17"> treatment with a beta blocker </text>
<text top="304" left="489" width="176" height="17" font="17">may reduce risk of SCA.</text>
<text top="305" left="665" width="141" height="10" font="19">S7.9.1.1-26,S7.9.1.1-28,S7.9.1.1-36, </text>
<text top="323" left="489" width="44" height="10" font="19">S7.9.1.1-38</text>
<text top="322" left="533" width="270" height="17" font="17"> Changes in QTc occur over time, particu-</text>
<text top="341" left="489" width="314" height="17" font="17">larly during puberty and during and after preg-</text>
<text top="359" left="489" width="319" height="17" font="17">nancy, indicating the need for assessment of QTc </text>
<text top="377" left="489" width="322" height="17" font="17">on ECG annually or with medication changes, </text>
<text top="395" left="489" width="321" height="17" font="17">and assessing medication efficacy with exercise </text>
<text top="413" left="489" width="323" height="17" font="17">testing as feasible. Asymptomatic adult (male) </text>
<text top="431" left="489" width="324" height="17" font="17">long QT syndrome patients with normal QTc </text>
<text top="449" left="489" width="325" height="17" font="17">intervals may choose to decline beta-blocker </text>
<text top="467" left="489" width="51" height="17" font="17">therapy.</text>
<text top="467" left="540" width="90" height="10" font="19">S7.9.1.1-11,S7.9.1.1-34</text>
<text top="485" left="467" width="344" height="17" font="17">7. The risk of adverse cardiac events from VA is </text>
<text top="503" left="489" width="314" height="17" font="17">influenced by the patient’s resting QTc inter-</text>
<text top="521" left="489" width="314" height="17" font="17">val, age, sex, and long QT syndrome genotype/</text>
<text top="539" left="489" width="319" height="17" font="17">mutation. For asymptomatic males with long QT </text>
<text top="557" left="489" width="319" height="17" font="17">syndrome, the risk of cardiac events is highest in </text>
<text top="575" left="489" width="68" height="17" font="17">childhood,</text>
<text top="576" left="557" width="173" height="10" font="19">S7.9.1.1-2,S7.9.1.1-8,S7.9.1.1-11,S7.9.1.1-30</text>
<text top="575" left="729" width="87" height="17" font="17"> during a </text>
<text top="593" left="489" width="314" height="17" font="17">time when medication compliance is challeng-</text>
<text top="611" left="489" width="322" height="17" font="17">ing. Young women  with LQT2 and  QTc &gt;500 </text>
<text top="629" left="489" width="227" height="17" font="17">ms are at increased risk of SCA</text>
<text top="630" left="716" width="90" height="10" font="19">S7.9.1.1-2,S7.9.1.1-11, </text>
<text top="648" left="489" width="184" height="10" font="19">S7.9.1.1-18–S7.9.1.1-20,S7.9.1.1-30,S7.9.1.1-35</text>
<text top="647" left="673" width="137" height="17" font="17"> especially in the 9 </text>
<text top="665" left="489" width="320" height="17" font="17">months postpartum, and may be candidates for </text>
<text top="683" left="489" width="322" height="17" font="17">primary prevention ICD placement or use of a </text>
<text top="701" left="489" width="218" height="17" font="17">wearable cardioverter-defibrillator.</text>
<text top="702" left="707" width="44" height="10" font="19">S7.9.1.1-30</text>
<text top="719" left="467" width="340" height="17" font="17">8.  The risk of adverse events increases in patients with  </text>
<text top="737" left="489" width="320" height="17" font="17">long QT syndrome with prolongation of the QTc  </text>
<text top="755" left="489" width="60" height="17" font="17">&gt;500 ms.</text>
<text top="756" left="549" width="255" height="10" font="19">S7.9.1.1-2,S7.9.1.1-12,S7.9.1.1-26,S7.9.1.1-35,S7.9.1.1-41,S7.9.1.1-58</text>
<text top="755" left="803" width="4" height="17" font="17"> </text>
<text top="773" left="489" width="188" height="17" font="17">QT-prolonging medications (</text>
<text top="773" left="677" width="126" height="17" font="20"><a href="">www.crediblemeds.</a></text>
<text top="791" left="489" width="22" height="17" font="20"><a href="">org</a></text>
<text top="791" left="511" width="4" height="17" font="17"><a href="">)</a></text>
<text top="792" left="515" width="44" height="10" font="19">S7.9.1.1-59</text>
<text top="791" left="559" width="251" height="17" font="17"> should not be used in patients with </text>
<text top="809" left="489" width="323" height="17" font="17">long QT syndrome unless there is no suitable </text>
<text top="827" left="489" width="319" height="17" font="17">alternative; careful monitoring of the QTc during </text>
<text top="845" left="489" width="320" height="17" font="17">therapy is recommended, with consideration for </text>
<text top="863" left="489" width="314" height="17" font="17">discontinuing therapy with marked QTc prolonga-</text>
<text top="881" left="489" width="314" height="17" font="17">tion. Concurrent use of stimulant or nonstimu-</text>
<text top="899" left="489" width="325" height="17" font="17">lant attention deficit/hyperactivity medications </text>
<text top="918" left="489" width="314" height="17" font="17">was associated with an increased risk of syncope/</text>
<text top="936" left="489" width="321" height="17" font="17">cardiac arrest in long QT syndrome, particularly </text>
<text top="954" left="489" width="113" height="17" font="17">males, in 1 study,</text>
<text top="954" left="602" width="45" height="10" font="19">S7.9.1.1-34</text>
<text top="954" left="647" width="160" height="17" font="17"> but it did not appear to </text>
<text top="972" left="489" width="314" height="17" font="17">be associated with increased risk in another ret-</text>
<text top="990" left="489" width="108" height="17" font="17">rospective study.</text>
<text top="990" left="597" width="45" height="10" font="19">S7.9.1.1-60</text>
<text top="990" left="642" width="166" height="17" font="17"> Episodes of torsades de </text>
<text top="1008" left="489" width="319" height="17" font="17">pointes can be precipitated by exposure to a QT </text>
<text top="1026" left="489" width="319" height="17" font="17">prolonging medication, or hypokalemia induced </text>
<text top="1044" left="489" width="319" height="17" font="17">by diuretics or gastrointestinal illenss. Attention </text>
<text top="1062" left="489" width="314" height="17" font="17">to maintaining normal potassium and magne-</text>
<text top="1080" left="489" width="323" height="17" font="17">sium balance when medications or situations </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e329</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="321" height="17" font="17">that promote depletion are  encountered is an </text>
<text top="106" left="111" width="325" height="17" font="17">important component of management. Rare </text>
<text top="124" left="111" width="322" height="17" font="17">case reports exist of fever prolonging the QT </text>
<text top="142" left="111" width="318" height="17" font="17">interval in patients with long QT syndrome type 2; </text>
<text top="160" left="111" width="270" height="17" font="17">fever should be reduced with antipyretics</text>
<text top="161" left="381" width="44" height="10" font="19">S7.9.1.1-61</text>
<text top="160" left="425" width="4" height="17" font="17"> </text>
<text top="178" left="111" width="67" height="17" font="17">(Table 10).</text>
<text top="213" left="74" width="332" height="18" font="28"><i>7.9.1.2. Catecholaminergic Polymorphic Ventricular </i></text>
<text top="231" left="74" width="74" height="18" font="28"><i>Tachycardia</i></text>
<text top="259" left="85" width="326" height="12" font="26"><b>Recommendations for Catecholaminergic Polymorphic Ventricular </b></text>
<text top="273" left="85" width="57" height="12" font="26"><b>Tachycardia</b></text>
<text top="289" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="303" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 41</b></a></text>
<text top="303" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="324" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="324" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="324" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="358" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="358" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="345" left="205" width="168" height="12" font="4">1.  In patients with catecholaminergic </text>
<text top="358" left="217" width="195" height="12" font="4">polymorphic ventricular tachycardia, a beta </text>
<text top="372" left="217" width="112" height="12" font="4">blocker is recommended.</text>
<text top="372" left="329" width="56" height="7" font="23">S7.9.1.2-1,S7.9.1.2-2</text>
<text top="453" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="453" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="393" left="205" width="174" height="12" font="4">2.  In patients with catecholaminergic </text>
<text top="406" left="217" width="170" height="12" font="4">polymorphic ventricular tachycardia  </text>
<text top="420" left="217" width="183" height="12" font="4">and recurrent sustained VT or syncope, </text>
<text top="433" left="217" width="179" height="12" font="4">while receiving adequate or maximally </text>
<text top="447" left="217" width="156" height="12" font="4">tolerated beta blocker, treatment </text>
<text top="460" left="217" width="181" height="12" font="4">intensification with either combination </text>
<text top="474" left="217" width="175" height="12" font="4">medication therapy (eg, beta blocker, </text>
<text top="487" left="217" width="165" height="12" font="4">flecainide), left cardiac sympathetic </text>
<text top="501" left="217" width="138" height="12" font="4">denervation, and/or an ICD is </text>
<text top="514" left="217" width="69" height="12" font="4">recommended.</text>
<text top="515" left="286" width="59" height="7" font="23">S7.9.1.2-2–S7.9.1.2-6</text>
<text top="562" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="562" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="535" left="205" width="168" height="12" font="4">3.  In patients with catecholaminergic </text>
<text top="548" left="217" width="181" height="12" font="4">polymorphic ventricular tachycardia and </text>
<text top="562" left="217" width="171" height="12" font="4">with clinical VT or exertional syncope, </text>
<text top="575" left="217" width="192" height="12" font="4">genetic counseling and genetic testing are </text>
<text top="589" left="217" width="51" height="12" font="4">reasonable.</text>
<text top="589" left="268" width="27" height="7" font="23">S7.9.1.2-7</text>
<text top="632" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="653" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="680" left="89" width="336" height="17" font="17">1.  Catecholaminergic polymorphic ventricular tachy-</text>
<text top="699" left="111" width="314" height="17" font="17">cardia is characterized by exertion-related poly-</text>
<text top="717" left="111" width="318" height="17" font="17">morphic or bidirectional VT (Figure 13), associated </text>
<text top="735" left="111" width="323" height="17" font="17">with syncope and SCA. SCA/SCD is reported </text>
<text top="753" left="111" width="193" height="17" font="17">in 3% to 13% of patients.</text>
<text top="754" left="304" width="122" height="10" font="19">S7.9.1.2-1,S7.9.1.2-2,S7.9.1.2-8</text>
<text top="753" left="425" width="4" height="17" font="17"> </text>
<text top="771" left="111" width="319" height="17" font="17">Treatment with beta blockers is associated with a </text>
<text top="789" left="111" width="234" height="17" font="17">reduction in adverse cardiac events.</text>
<text top="790" left="345" width="80" height="10" font="19">S7.9.1.2-1,S7.9.1.2-2</text>
<text top="789" left="425" width="4" height="17" font="17"> </text>
<text top="807" left="111" width="323" height="17" font="17">Some experts prefer the use of nadolol over </text>
<text top="826" left="111" width="321" height="17" font="17">other types of beta blockers; direct comparison </text>
<text top="844" left="111" width="321" height="17" font="17">data among beta blockers are unavailable. Use </text>
<text top="862" left="111" width="320" height="17" font="17">of a maximally tolerated dose of a beta blocker </text>
<text top="880" left="111" width="314" height="17" font="17">is important. Small observational studies  sug-</text>
<text top="898" left="111" width="326" height="17" font="17">gest possible benefit of nondihydropyridine </text>
<text top="916" left="111" width="326" height="17" font="17">calcium channel blockers in the treatment </text>
<text top="916" left="425" width="4" height="17" font="17"> </text>
<text top="935" left="111" width="324" height="17" font="17">of catecholaminergic polymorphic ventricular </text>
<text top="935" left="425" width="4" height="17" font="17"> </text>
<text top="953" left="111" width="76" height="17" font="17">tachycardia.</text>
<text top="953" left="187" width="85" height="10" font="19">S7.9.1.2-9,S7.9.1.2-10</text>
<text top="971" left="89" width="341" height="17" font="17">2.  Flecainide in combination with a beta blocker </text>
<text top="989" left="111" width="319" height="17" font="17">can suppress ventricular ectopy by as much as </text>
<text top="1007" left="111" width="314" height="17" font="17">76% in patients with catecholaminergic poly-</text>
<text top="1025" left="111" width="318" height="17" font="17">morphic ventricular tachycardia during exercise </text>
<text top="1043" left="111" width="181" height="17" font="17">testing or clinical follow-up.</text>
<text top="1044" left="292" width="133" height="10" font="19">S7.9.1.2-2,S7.9.1.2-6,S7.9.1.2-11</text>
<text top="1044" left="425" width="4" height="17" font="17"> </text>
<text top="1062" left="111" width="322" height="17" font="17">For refractory VA, verapamil or propafenone </text>
<text top="1080" left="111" width="146" height="17" font="17">may also be effective.</text>
<text top="1081" left="258" width="138" height="10" font="19">S7.9.1.2-9,S7.9.1.2-10,S7.9.1.2-12</text>
<text top="1080" left="396" width="33" height="17" font="17"> ICD </text>
<text top="88" left="489" width="317" height="17" font="17">implantation in patients with catecholaminergic </text>
<text top="106" left="489" width="320" height="17" font="17">polymorphic ventricular tachycardia should be </text>
<text top="124" left="489" width="317" height="17" font="17">reserved for patients with prior SCA, or patients </text>
<text top="143" left="489" width="322" height="17" font="17">with refractory VAs on combination medical </text>
<text top="161" left="489" width="326" height="17" font="17">therapy. Inappropriate shocks are reported </text>
<text top="179" left="489" width="314" height="17" font="17">in 20% to 30% of catecholaminergic poly-</text>
<text top="198" left="489" width="321" height="17" font="17">morphic ventricular tachycardia patients with  </text>
<text top="216" left="489" width="35" height="17" font="17">ICDs.</text>
<text top="217" left="524" width="140" height="10" font="19">S7.9.1.2-2,S7.9.1.2-13–S7.9.1.2-16</text>
<text top="216" left="665" width="142" height="17" font="17"> ICD programming in </text>
<text top="235" left="489" width="322" height="17" font="17">patients with catecholaminergic polymorphic </text>
<text top="253" left="489" width="319" height="17" font="17">ventricular tachycardia should be optimized to </text>
<text top="271" left="489" width="314" height="17" font="17">deliver therapy for VF and to minimize inappro-</text>
<text top="290" left="489" width="320" height="17" font="17">priate shocks and the risk of potentially fatal  </text>
<text top="308" left="489" width="121" height="17" font="17">electrical storms.</text>
<text top="309" left="610" width="95" height="10" font="19">S7.9.1.2-13,S7.9.1.2-15</text>
<text top="308" left="705" width="110" height="17" font="17"> Left cardiac </text>
<text top="308" left="803" width="4" height="17" font="17"> </text>
<text top="326" left="489" width="314" height="17" font="17">sympathetic denervation for catecholaminer-</text>
<text top="345" left="489" width="323" height="17" font="17">gic polymorphic ventricular tachycardia may </text>
<text top="363" left="489" width="320" height="17" font="17">reduce the frequency of recurrent ICD shocks </text>
<text top="382" left="489" width="130" height="17" font="17">by 32% to 75%</text>
<text top="382" left="619" width="184" height="10" font="19">S7.9.1.2-3–S7.9.1.2-5,S7.9.1.2-17,S7.9.1.2-18</text>
<text top="382" left="803" width="4" height="17" font="17"> </text>
<text top="400" left="489" width="326" height="17" font="17">although recurrent syncope, SCA, or SCD </text>
<text top="418" left="489" width="322" height="17" font="17">is reported in 9% to 32% of patients, with </text>
<text top="437" left="489" width="323" height="17" font="17">other minor complications in 20% to 70% </text>
<text top="455" left="489" width="314" height="17" font="17">of patients. It is best if the left cardiac sym-</text>
<text top="473" left="489" width="322" height="17" font="17">pathetic denervation is performed in centers </text>
<text top="492" left="489" width="318" height="17" font="17">with expertise in this procedure. Intensification </text>
<text top="510" left="489" width="319" height="17" font="17">of medical therapy or left cardiac sympathetic </text>
<text top="529" left="489" width="322" height="17" font="17">denervation is important in treating patients </text>
<text top="547" left="489" width="322" height="17" font="17">who present with recurrent appropriate ICD </text>
<text top="565" left="489" width="49" height="17" font="17">shocks.</text>
<text top="566" left="538" width="46" height="10" font="19">S7.9.1.2-19</text>
<text top="584" left="467" width="343" height="17" font="17">3.  Genetic testing may be useful to confirm the </text>
<text top="602" left="489" width="327" height="17" font="17">diagnosis of catecholaminergic polymorphic </text>
<text top="620" left="489" width="327" height="17" font="17">ventricular tachycardia, which is suggested </text>
<text top="639" left="489" width="322" height="17" font="17">by the development of bidirectional VT with </text>
<text top="657" left="489" width="314" height="17" font="17">exertion or stress. Recognition of catechol-</text>
<text top="676" left="489" width="322" height="17" font="17">aminergic polymorphic ventricular tachycardia </text>
<text top="694" left="489" width="322" height="17" font="17">as the cause for exertional symptoms should </text>
<text top="712" left="489" width="314" height="17" font="17">prompt aggressive therapy to prevent the sig-</text>
<text top="731" left="489" width="314" height="17" font="17">nificant risk of SCD. Therapy for catechol-</text>
<text top="749" left="489" width="322" height="17" font="17">aminergic polymorphic ventricular tachycardia </text>
<text top="767" left="489" width="314" height="17" font="17">is not guided by genotype status, but screen-</text>
<text top="786" left="489" width="321" height="17" font="17">ing of first-degree relatives may be facilitated </text>
<text top="804" left="489" width="143" height="17" font="17">with genetic testing.</text>
<text top="805" left="632" width="45" height="10" font="19">S7.9.1.2-20</text>
<text top="804" left="677" width="126" height="17" font="17"> Ryanodine recep-</text>
<text top="823" left="489" width="325" height="17" font="17">tor mutations have been reported in 47% </text>
<text top="841" left="489" width="322" height="17" font="17">of probands, which were de novo mutations </text>
<text top="859" left="489" width="69" height="17" font="17">in &gt;70%.</text>
<text top="860" left="559" width="40" height="10" font="19">S7.9.1.2-7</text>
<text top="859" left="599" width="216" height="17" font="17"> Ryanodine genotype status </text>
<text top="878" left="489" width="325" height="17" font="17">has not correlated with disease severity or </text>
<text top="896" left="489" width="171" height="17" font="17">response to medications.</text>
<text top="897" left="660" width="40" height="10" font="19">S7.9.1.2-7</text>
<text top="896" left="700" width="111" height="17" font="17"> In very young </text>
<text top="914" left="489" width="314" height="17" font="17">patients presenting with idiopathic VF, muta-</text>
<text top="933" left="489" width="322" height="17" font="17">tions in calmodulin have been identified and </text>
<text top="951" left="489" width="219" height="17" font="17">are associated with high lethality.</text>
<text top="952" left="708" width="95" height="10" font="19">S7.9.1.2-21–S7.9.1.2-24</text>
<text top="951" left="803" width="6" height="17" font="17">  </text>
<text top="970" left="489" width="327" height="17" font="17">Studies of proposed pathogenic mutations </text>
<text top="988" left="489" width="325" height="17" font="17">in catecholaminergic polymorphic ventricular </text>
<text top="1006" left="489" width="319" height="17" font="17">tachycardia genes report up to 15% of variants </text>
<text top="1025" left="489" width="318" height="17" font="17">were present in exome databases of the general </text>
<text top="1043" left="489" width="314" height="17" font="17">population, raising questions as to the mono-</text>
<text top="1061" left="489" width="321" height="17" font="17">genic cause of catecholaminergic polymorphic </text>
<text top="1080" left="489" width="152" height="17" font="17">ventricular tachycardia.</text>
<text top="1081" left="642" width="93" height="10" font="19">S7.9.1.2-20,S7.9.1.2-25</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e330</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="505" left="74" width="176" height="18" font="28"><i>7.9.1.3. Brugada Syndrome</i></text>
<text top="537" left="85" width="206" height="12" font="26"><b>Recommendations for Brugada Syndrome</b></text>
<text top="554" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="568" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 42</b></a></text>
<text top="568" left="221" width="156" height="12" font="26"><a href=""><b> and Systematic Review Report.</b></a></text>
<text top="588" left="97" width="21" height="12" font="22"><b>COR</b></text>
<text top="588" left="158" width="19" height="12" font="22"><b>LOE</b></text>
<text top="588" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="629" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="629" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="609" left="205" width="214" height="12" font="4">1.  In asymptomatic patients with only inducible </text>
<text top="623" left="217" width="165" height="12" font="4">type 1 Brugada electrocardiographic </text>
<text top="636" left="217" width="178" height="12" font="4">pattern, observation without therapy is </text>
<text top="650" left="217" width="67" height="12" font="4">recommended.</text>
<text top="650" left="284" width="58" height="7" font="23">S7.9.1.3-1–S7.9.1.3-5</text>
<text top="718" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="718" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="671" left="205" width="176" height="12" font="4">2.  In patients with Brugada syndrome </text>
<text top="684" left="217" width="159" height="12" font="4">with spontaneous type 1 Brugada </text>
<text top="698" left="217" width="157" height="12" font="4">electrocardiographic pattern and  </text>
<text top="711" left="217" width="183" height="12" font="4">cardiac arrest, sustained VA or a recent </text>
<text top="725" left="217" width="191" height="12" font="4">history of syncope presumed due to VA,  </text>
<text top="738" left="217" width="178" height="12" font="4">an ICD is recommended if meaningful </text>
<text top="752" left="217" width="151" height="12" font="4">survival of greater than 1 year is </text>
<text top="765" left="217" width="44" height="12" font="4">expected.</text>
<text top="766" left="262" width="58" height="7" font="23">S7.9.1.3-4,S7.9.1.3-6</text>
<text top="813" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="813" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="786" left="205" width="171" height="12" font="4">3.  In patients with Brugada syndrome </text>
<text top="799" left="217" width="171" height="12" font="4">experiencing recurrent ICD shocks for </text>
<text top="813" left="217" width="189" height="12" font="4">polymorphic VT, intensification of therapy </text>
<text top="826" left="217" width="167" height="12" font="4">with quinidine or catheter ablation is </text>
<text top="840" left="217" width="67" height="12" font="4">recommended.</text>
<text top="840" left="284" width="61" height="7" font="23">S7.9.1.3-7–S7.9.1.3-11</text>
<text top="895" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="895" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="861" left="205" width="147" height="12" font="4">4.  In patients with spontaneous  </text>
<text top="874" left="217" width="168" height="12" font="4">type 1 Brugada electrocardiographic  </text>
<text top="888" left="217" width="183" height="12" font="4">pattern and symptomatic VA who either </text>
<text top="901" left="217" width="162" height="12" font="4">are not candidates for or decline an </text>
<text top="915" left="217" width="167" height="12" font="4">ICD, quinidine or catheter ablation is </text>
<text top="928" left="217" width="67" height="12" font="4">recommended.</text>
<text top="929" left="284" width="90" height="7" font="23">S7.9.1.3-7,S7.9.1.3-9–S7.9.1.3-11</text>
<text top="983" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="983" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="949" left="205" width="177" height="12" font="4">5.  In patients with suspected Brugada </text>
<text top="962" left="217" width="201" height="12" font="4">syndrome in the absence of a spontaneous </text>
<text top="976" left="217" width="170" height="12" font="4">type 1 Brugada electrocardiographic </text>
<text top="989" left="217" width="202" height="12" font="4">pattern, a pharmacological challenge using </text>
<text top="1003" left="217" width="202" height="12" font="4">a sodium channel blocker can be useful for </text>
<text top="1016" left="217" width="46" height="12" font="4">diagnosis.</text>
<text top="1017" left="263" width="66" height="7" font="23">S7.9.1.3-12–S7.9.1.3-14</text>
<text top="601" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="601" left="527" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="602" left="551" width="7" height="7" font="25"><b>SR</b></text>
<text top="554" left="583" width="157" height="12" font="4">6.  In patients with asymptomatic  </text>
<text top="567" left="595" width="183" height="12" font="4">Brugada syndrome and a spontaneous  </text>
<text top="581" left="595" width="170" height="12" font="4">type 1 Brugada electrocardiographic </text>
<text top="594" left="595" width="173" height="12" font="4">pattern, an electrophysiological study  </text>
<text top="608" left="595" width="186" height="12" font="4">with programmed ventricular stimulation </text>
<text top="621" left="595" width="166" height="12" font="4">using single and double extrastimuli  </text>
<text top="635" left="595" width="158" height="12" font="4">may be considered for further risk  </text>
<text top="648" left="595" width="54" height="12" font="4">stratification.</text>
<text top="649" left="648" width="142" height="7" font="23">S7.9.1.3-1,S7.9.1.3-6,S7.9.1.3-13,S7.9.1.3-15–S7.9.1.3-17</text>
<text top="696" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="696" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="669" left="583" width="203" height="12" font="4">7.  In patients with suspected or established </text>
<text top="682" left="595" width="185" height="12" font="4">Brugada syndrome, genetic counseling  </text>
<text top="696" left="595" width="159" height="12" font="4">and genetic testing may be useful </text>
<text top="709" left="595" width="154" height="12" font="4">to facilitate cascade screening of </text>
<text top="723" left="595" width="40" height="12" font="4">relatives.</text>
<text top="723" left="636" width="66" height="7" font="23">S7.9.1.3-18–S7.9.1.3-20</text>
<text top="746" left="464" width="138" height="12" font="4">SR indicated systematic review.</text>
<text top="783" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="811" left="452" width="351" height="17" font="17">Refer to the “Systematic Review for the 2017 ACC/</text>
<text top="830" left="452" width="356" height="17" font="17">AHA/HRS Guideline for Management of Patients With </text>
<text top="849" left="452" width="356" height="17" font="17">Ventricular Arrhythmias and the Prevention of Sudden </text>
<text top="868" left="452" width="357" height="17" font="17">Cardiac Death” for the complete systematic evidence </text>
<text top="887" left="452" width="275" height="17" font="17">review for additional data and analyses.</text>
<text top="888" left="728" width="44" height="10" font="19">S7.9.1.3-15</text>
<text top="887" left="771" width="41" height="17" font="17"> The </text>
<text top="906" left="452" width="357" height="17" font="17">results from the question “For asymptomatic patients </text>
<text top="925" left="452" width="351" height="17" font="17">with Brugada syndrome, what is the association be-</text>
<text top="944" left="452" width="351" height="17" font="17">tween an abnormal EP study and SCD and other ar-</text>
<text top="962" left="452" width="351" height="17" font="17">rhythmia endpoints? (Part 1)” and the writing commit-</text>
<text top="981" left="452" width="357" height="17" font="17">tee’s review of the totality of the literature were used </text>
<text top="1000" left="452" width="357" height="17" font="17">to frame decision-making. Recommendations that are </text>
<text top="1019" left="452" width="351" height="17" font="17">based on a body of evidence that includes the system-</text>
<text top="460" left="74" width="51" height="12" font="3"><b>Figure 13. </b></text>
<text top="460" left="125" width="450" height="12" font="22"><b>Exercise-induced polymorphic VT in catecholaminergic polymorphic ventricular tachycardia.</b></text>
<text top="512" left="463" width="267" height="12" font="26"><b>Recommendations for Brugada Syndrome (Continued)</b></text>
<text top="533" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="533" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="533" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e331</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="603" left="74" width="356" height="17" font="17">atic review conducted by the ERC are denoted by the </text>
<text top="621" left="74" width="177" height="17" font="17">superscript SR (eg, LOE: B-R</text>
<text top="622" left="251" width="9" height="10" font="19">SR</text>
<text top="621" left="260" width="8" height="17" font="17">).</text>
<text top="640" left="92" width="339" height="17" font="17">Factors identified as potential triggers of VF and SCA </text>
<text top="658" left="74" width="351" height="17" font="17">in Brugada syndrome include some psychotropic medica-</text>
<text top="677" left="74" width="355" height="17" font="17">tions, and anesthetic agents, cocaine, excessive alcohol </text>
<text top="695" left="74" width="110" height="17" font="17"><a href="">intake, and fever (</a></text>
<text top="695" left="184" width="148" height="17" font="20"><a href="">www.brugadadrugs.org</a></text>
<text top="695" left="331" width="8" height="17" font="17">).</text>
<text top="696" left="339" width="86" height="10" font="19">S7.9.1.3-21,S7.9.1.3-22</text>
<text top="695" left="425" width="5" height="17" font="17">  </text>
<text top="714" left="74" width="351" height="17" font="17">These agents should be avoided, and fever war-</text>
<text top="732" left="74" width="363" height="17" font="17">rants early and aggressive measures to reduce </text>
<text top="751" left="74" width="86" height="17" font="17">temperature.</text>
<text top="751" left="160" width="45" height="10" font="19">S7.9.1.3-23</text>
<text top="796" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="818" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="845" left="89" width="347" height="17" font="17">1. The risk of major adverse cardiac events in </text>
<text top="864" left="111" width="328" height="17" font="17">asymptomatic patients without spontaneous </text>
<text top="603" left="489" width="320" height="17" font="17">type 1 electrocardiographic changes of Brugada </text>
<text top="621" left="489" width="314" height="17" font="17">syndrome (Figure  15), or with only medica-</text>
<text top="640" left="489" width="338" height="17" font="17">tion-induced electrocardiographic changes, </text>
<text top="659" left="489" width="47" height="17" font="17">is low.</text>
<text top="659" left="536" width="82" height="10" font="19">S7.9.1.3-1–S7.9.1.3-5</text>
<text top="659" left="618" width="196" height="17" font="17"> A positive family history </text>
<text top="677" left="489" width="314" height="17" font="17">of Brugada syndrome or SCA is not a signifi-</text>
<text top="696" left="489" width="325" height="17" font="17">cant predictor of adverse events in Brugada </text>
<text top="715" left="489" width="66" height="17" font="17">syndrome.</text>
<text top="715" left="555" width="163" height="10" font="19">S7.9.1.3-1,S7.9.1.3-2,S7.9.1.3-4,S7.9.1.3-5</text>
<text top="715" left="718" width="89" height="17" font="17"> Implantation </text>
<text top="733" left="489" width="320" height="17" font="17">of an ICD in an asymptomatic patient without a </text>
<text top="752" left="489" width="318" height="17" font="17">spontaneous type 1 Brugada electrocardiographic </text>
<text top="770" left="489" width="273" height="17" font="17">has not been shown to confer any benefit.</text>
<text top="789" left="467" width="342" height="17" font="17">2.  Brugada syndrome is characterized by coved ST </text>
<text top="808" left="489" width="322" height="17" font="17">elevation in leads V1 or V2 positioned in the </text>
<text top="826" left="489" width="320" height="17" font="17">second, third, or fourth intercostal space either </text>
<text top="845" left="489" width="321" height="17" font="17">spontaneously or induced by administration of </text>
<text top="864" left="489" width="319" height="17" font="17">a sodium channel–blocking drug in the absence </text>
<text top="526" left="74" width="51" height="12" font="3"><b>Figure 14. </b></text>
<text top="526" left="125" width="273" height="12" font="22"><b>Prevention of SCD in patients with Brugada syndrome.</b> </text>
<text top="540" left="74" width="698" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 7.9.1.3 for discussion. *ICD candidacy as determined by functional status, life expec-</text>
<text top="553" left="74" width="724" height="12" font="4">tancy or patient preference. 1° indicates primary; ECG, electrocardiogram; EP, electrophysiological; ICD implantable cardioverter-defibrillator; SCD, sudden cardiac </text>
<text top="567" left="74" width="287" height="12" font="4">death; VT, ventricular tachycardia; and VF, ventricular fibrillation.</text>
<text top="1084" left="74" width="51" height="12" font="3"><b>Figure 15. </b></text>
<text top="1084" left="125" width="96" height="12" font="22"><b>Brugada syndrome.</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e332</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="200" height="17" font="17">of other causes of ST elevation</text>
<text top="88" left="311" width="44" height="10" font="19">S7.9.1.3-24</text>
<text top="88" left="355" width="70" height="17" font="17"> and nega-</text>
<text top="106" left="111" width="319" height="17" font="17">tive T waves in the right precordial leads, and is </text>
<text top="124" left="111" width="314" height="17" font="17">associated with syncope or SCA due to VF, pre-</text>
<text top="142" left="111" width="318" height="17" font="17">dominantly in young males, although it has been </text>
<text top="160" left="111" width="320" height="17" font="17">reported in all age groups. The type 1 Brugada </text>
<text top="178" left="111" width="320" height="17" font="17">ECG with coved ST elevation in right precordial </text>
<text top="196" left="111" width="325" height="17" font="17">leads may be present spontaneously, during </text>
<text top="214" left="111" width="322" height="17" font="17">fever or vagotonic states, or after medication </text>
<text top="232" left="111" width="323" height="17" font="17">challenge with sodium channel blockers. QRS </text>
<text top="250" left="111" width="322" height="17" font="17">complex fractionation is seen in a minority of </text>
<text top="268" left="111" width="320" height="17" font="17">patients. Patients with spontaneous coved type </text>
<text top="286" left="111" width="321" height="17" font="17">ST elevation and a history of syncope or prior </text>
<text top="304" left="111" width="319" height="17" font="17">SCA are at the highest risk for potentially lethal </text>
<text top="322" left="111" width="319" height="17" font="17">VA. ICD implantation has been shown to reduce </text>
<text top="340" left="111" width="320" height="17" font="17">mortality in symptomatic patients with Brugada </text>
<text top="358" left="111" width="67" height="17" font="17">syndrome.</text>
<text top="359" left="178" width="91" height="10" font="19">S7.9.1.3-25,S7.9.1.3-26</text>
<text top="376" left="89" width="349" height="17" font="17">3. Ablation of abnormal areas of epicardial </text>
<text top="394" left="111" width="314" height="17" font="17">late activation in the RV can suppress recur-</text>
<text top="412" left="111" width="325" height="17" font="17">rent VA as shown in a small  number of </text>
<text top="412" left="425" width="4" height="17" font="17"> </text>
<text top="430" left="111" width="57" height="17" font="17">patients.</text>
<text top="431" left="169" width="180" height="10" font="19">S7.9.1.3-8,S7.9.1.3-9,S7.9.1.3-11,S7.9.1.3-27</text>
<text top="430" left="349" width="90" height="17" font="17"> In these </text>
<text top="448" left="111" width="314" height="17" font="17">reports, the spontaneous type 1 Brugada pat-</text>
<text top="466" left="111" width="323" height="17" font="17">tern on ECG may be eliminated in &gt;75% of </text>
<text top="484" left="111" width="320" height="17" font="17">patients, and recurrences of VT/VF are markedly </text>
<text top="503" left="111" width="56" height="17" font="17">reduced.</text>
<text top="503" left="167" width="87" height="10" font="19">S7.9.1.3-9–S7.9.1.3-11</text>
<text top="503" left="254" width="177" height="17" font="17"> Experience and follow-up </text>
<text top="521" left="111" width="318" height="17" font="17">after ablation are limited, and an ICD for patients </text>
<text top="539" left="111" width="319" height="17" font="17">who have had syncope or SCA is recommended. </text>
<text top="557" left="111" width="324" height="17" font="17">A series of patients with Brugada syndrome </text>
<text top="575" left="111" width="321" height="17" font="17">treated with quinidine had no deaths during a </text>
<text top="593" left="111" width="318" height="17" font="17">mean follow-up of over 9 years, although adverse </text>
<text top="611" left="111" width="322" height="17" font="17">effects of quinidine were reported in 38% of </text>
<text top="629" left="111" width="320" height="17" font="17">patients, these authors felt that quinidine could </text>
<text top="647" left="111" width="320" height="17" font="17">be used as an alternative to the ICD in selected </text>
<text top="665" left="111" width="55" height="17" font="17">patients.</text>
<text top="666" left="166" width="39" height="10" font="19">S7.9.1.3-7</text>
<text top="683" left="89" width="343" height="17" font="17">4.  Observational studies show that quinidine can </text>
<text top="701" left="111" width="314" height="17" font="17">suppress VF storm in patients with Brugada syn-</text>
<text top="719" left="111" width="317" height="17" font="17">drome, and a low risk of arrhythmia was observed </text>
<text top="737" left="111" width="279" height="17" font="17">in a long-term observational study.</text>
<text top="738" left="390" width="35" height="10" font="19">7.9.1.3-7</text>
<text top="737" left="425" width="4" height="17" font="17">  </text>
<text top="755" left="111" width="321" height="17" font="17">No patient treated with quinidine experienced </text>
<text top="773" left="111" width="318" height="17" font="17">SCD. Adverse effects of quinidine occur in up to </text>
<text top="791" left="111" width="318" height="17" font="17">37% of patients. Catheter ablation targeting the </text>
<text top="809" left="111" width="320" height="17" font="17">epicardial right ventricular areas of abnormality </text>
<text top="827" left="111" width="314" height="17" font="17">has also been shown to reduce recurrent VF epi-</text>
<text top="845" left="111" width="197" height="17" font="17">sodes and normalize the ECG.</text>
<text top="846" left="308" width="80" height="10" font="19">7.9.1.3-9–7.9.1.3-11</text>
<text top="863" left="89" width="345" height="17" font="17">5. Administration of procainamide, flecainide, or </text>
<text top="881" left="111" width="322" height="17" font="17">ajmaline may be useful to provoke type 1 ST </text>
<text top="899" left="111" width="320" height="17" font="17">elevation in patients suspected to have Brugada </text>
<text top="917" left="111" width="321" height="17" font="17">syndrome as a cause of symptoms but who do </text>
<text top="936" left="111" width="321" height="17" font="17">not have a type 1 electrocardiographic pattern </text>
<text top="954" left="111" width="314" height="17" font="17">at baseline. Medication challenge should be ter-</text>
<text top="972" left="111" width="322" height="17" font="17">minated with the development of VA, marked </text>
<text top="990" left="111" width="314" height="17" font="17">QRS widening, or type 1 Brugada electrocardio-</text>
<text top="1008" left="111" width="106" height="17" font="17">graphic pattern.</text>
<text top="1008" left="217" width="90" height="10" font="19">S7.9.1.3-14,S7.9.1.3-28</text>
<text top="1008" left="307" width="126" height="17" font="17"> The use of high </text>
<text top="1026" left="111" width="320" height="17" font="17">electrocardiographic electrode positioning in the </text>
<text top="1044" left="111" width="314" height="17" font="17">second and third interspaces for electrocardio-</text>
<text top="1062" left="111" width="321" height="17" font="17">graphic recording improves detection of a type </text>
<text top="1080" left="111" width="111" height="17" font="17">1 Brugada ECG.</text>
<text top="1081" left="222" width="44" height="10" font="19">S7.9.1.3-29</text>
<text top="1080" left="266" width="168" height="17" font="17"> Asymptomatic patients </text>
<text top="88" left="489" width="320" height="17" font="17">with a family history of Brugada syndrome may </text>
<text top="106" left="489" width="319" height="17" font="17">be offered sodium channel blocker challenge for </text>
<text top="124" left="489" width="323" height="17" font="17">diagnostic evaluation, although a positive test </text>
<text top="143" left="489" width="318" height="17" font="17">does not require chronic therapy due to a low risk </text>
<text top="161" left="489" width="97" height="17" font="17">in this setting.</text>
<text top="162" left="586" width="44" height="10" font="19">S7.9.1.3-12</text>
<text top="161" left="629" width="181" height="17" font="17"> In asymptomatic patients </text>
<text top="179" left="489" width="314" height="17" font="17">with type 1 Brugada electrocardiographic find-</text>
<text top="198" left="489" width="314" height="17" font="17">ings, medication challenge does not offer addi-</text>
<text top="216" left="489" width="147" height="17" font="17">tional diagnostic value.</text>
<text top="235" left="467" width="336" height="17" font="17">6.  Polymorphic VT/VF induced by programmed stim-</text>
<text top="253" left="489" width="317" height="17" font="17">ulation has been associated with an increased risk </text>
<text top="271" left="489" width="320" height="17" font="17">of VA in some patients with spontaneous type </text>
<text top="290" left="489" width="111" height="17" font="17">1 Brugada ECG.</text>
<text top="290" left="600" width="45" height="10" font="19">S7.9.1.3-13</text>
<text top="290" left="645" width="158" height="17" font="17"> The specificity of pro-</text>
<text top="308" left="489" width="317" height="17" font="17">grammed stimulation for assessing risk decreases </text>
<text top="326" left="489" width="272" height="17" font="17">with the inclusion of triple extrastimuli.</text>
<text top="327" left="761" width="45" height="10" font="19">S7.9.1.3-6, </text>
<text top="346" left="489" width="45" height="10" font="19">S7.9.1.3-13</text>
<text top="345" left="534" width="274" height="17" font="17"> The value of programmed stimulation in </text>
<text top="363" left="489" width="322" height="17" font="17">asymptomatic patients with spontaneous type </text>
<text top="382" left="489" width="314" height="17" font="17">1 Brugada ECGs has been the subject of mul-</text>
<text top="400" left="489" width="84" height="17" font="17">tiple studies.</text>
<text top="401" left="573" width="167" height="10" font="19">S7.9.1.3-1,S7.9.1.3-2,S7.9.1.3-4,S7.9.1.3-5</text>
<text top="400" left="740" width="70" height="17" font="17"> A report </text>
<text top="418" left="489" width="320" height="17" font="17">found that the prognostic value has decreased </text>
<text top="437" left="489" width="328" height="17" font="17">over time, possibly as patients with less </text>
<text top="455" left="489" width="322" height="17" font="17">severe phenotypes have been recognized and </text>
<text top="473" left="489" width="52" height="17" font="17">studied.</text>
<text top="474" left="541" width="40" height="10" font="19">S7.9.1.3-1</text>
<text top="473" left="581" width="229" height="17" font="17"> Some experts use the results of </text>
<text top="492" left="489" width="314" height="17" font="17">programmed ventricular stimulation for inform-</text>
<text top="510" left="489" width="320" height="17" font="17">ing shared decision-making in consideration of </text>
<text top="529" left="489" width="320" height="17" font="17">the ICD. In symptomatic patients with Brugada </text>
<text top="547" left="489" width="314" height="17" font="17">syndrome, programmed ventricular stimula-</text>
<text top="565" left="489" width="319" height="17" font="17">tion for risk stratification does not add anything </text>
<text top="584" left="489" width="321" height="17" font="17">to the evaluation of the patients as an ICD is </text>
<text top="602" left="489" width="71" height="17" font="17">warranted.</text>
<text top="603" left="561" width="124" height="10" font="19">S7.9.1.3-2,S7.9.1.3-4,S7.9.1.3-6</text>
<text top="620" left="467" width="340" height="17" font="17">7.  The yield of genetic testing in phenotype positive </text>
<text top="639" left="489" width="317" height="17" font="17">patients is approximately 20% to 30% in Brugada </text>
<text top="657" left="489" width="70" height="17" font="17">syndrome.</text>
<text top="658" left="560" width="246" height="10" font="19">S7.9.1.3-4,S7.9.1.3-16,S7.9.1.3-18,S7.9.1.3-19,S7.9.1.3-30, </text>
<text top="676" left="489" width="46" height="10" font="19">S7.9.1.3-31</text>
<text top="676" left="535" width="277" height="17" font="17">  <i>SCN5A</i> variants account for  most of </text>
<text top="694" left="489" width="327" height="17" font="17">this subset of genotype positive Brugada </text>
<text top="712" left="489" width="314" height="17" font="17">syndrome. However, 2% to 10% of other-</text>
<text top="731" left="489" width="320" height="17" font="17">wise healthy  individuals host a rare variant of  </text>
<text top="749" left="489" width="49" height="18" font="21"><i>SCN5A</i>.</text>
<text top="750" left="538" width="90" height="10" font="19">S7.9.1.3-20,S7.9.1.3-31</text>
<text top="749" left="628" width="177" height="17" font="17"> A negative genetic test does </text>
<text top="767" left="489" width="319" height="17" font="17">not exclude the diagnosis of Brugada syndrome, </text>
<text top="786" left="489" width="322" height="17" font="17">which is usually based on electrocardiographic </text>
<text top="804" left="489" width="322" height="17" font="17">and clinical characteristics. Risk stratification is </text>
<text top="823" left="489" width="266" height="17" font="17">based on symptoms and clinical findings</text>
<text top="823" left="755" width="44" height="10" font="19">S7.9.1.3-32</text>
<text top="823" left="799" width="8" height="17" font="17">; </text>
<text top="841" left="489" width="322" height="17" font="17">genotype status is not  correlated with the risk </text>
<text top="859" left="489" width="137" height="17" font="17">of adverse events.</text>
<text top="860" left="626" width="177" height="10" font="19">S7.9.1.3-5,S7.9.1.3-18,S7.9.1.3-19,S7.9.1.3-33</text>
<text top="859" left="803" width="4" height="17" font="17"> </text>
<text top="878" left="489" width="322" height="17" font="17">Identification of a  pathogenetic mutation may </text>
<text top="896" left="489" width="314" height="17" font="17">help facilitate recognition of carrier status in fam-</text>
<text top="914" left="489" width="322" height="17" font="17">ily members, allowing for lifestyle  modification </text>
<text top="933" left="489" width="156" height="17" font="17">and potential treatment.</text>
<text top="951" left="467" width="341" height="17" font="17">8.  Factors identified as potential triggers of VF and </text>
<text top="970" left="489" width="314" height="17" font="17">SCA in  Brugada syndrome include some psy-</text>
<text top="988" left="489" width="324" height="17" font="17">chotropic medications, and anesthetic agents, </text>
<text top="1006" left="489" width="326" height="17" font="17">cocaine, excessive alcohol intake, and fever </text>
<text top="1025" left="489" width="4" height="17" font="17"><a href="">(</a></text>
<text top="1025" left="493" width="159" height="17" font="20"><a href="">www.brugadadrugs.org</a></text>
<text top="1025" left="653" width="9" height="17" font="17"><a href="">).</a></text>
<text top="1025" left="662" width="94" height="10" font="19">S7.9.1.3-21,S7.9.1.3-22</text>
<text top="1025" left="756" width="57" height="17" font="17"> These </text>
<text top="1043" left="489" width="323" height="17" font="17">agents should be avoided and fever warrants </text>
<text top="1061" left="489" width="314" height="17" font="17">early and aggressive measures to reduce tempera</text>
<text top="1080" left="489" width="30" height="17" font="17">ture.</text>
<text top="1081" left="519" width="44" height="10" font="19">S7.9.1.3-23</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e333</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="308" height="18" font="28"><i>7.9.1.4. Early Repolarization “J-wave” Syndrome</i></text>
<text top="116" left="85" width="264" height="12" font="26"><b>Recommendations for Early Repolarization Syndrome</b></text>
<text top="133" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="146" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 43</b></a></text>
<text top="146" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="167" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="167" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="167" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="208" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="208" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="188" left="205" width="171" height="12" font="4">1.  In asymptomatic patients with an  </text>
<text top="202" left="217" width="173" height="12" font="4">early repolarization pattern on ECG,  </text>
<text top="215" left="217" width="154" height="12" font="4">observation without treatment is </text>
<text top="229" left="217" width="69" height="12" font="4">recommended.</text>
<text top="229" left="286" width="58" height="7" font="23">S7.9.1.4-1,S7.9.1.4-2</text>
<text top="277" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="277" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="249" left="205" width="175" height="12" font="4">2.  In patients with early repolarization  </text>
<text top="263" left="217" width="167" height="12" font="4">pattern on ECG and cardiac arrest or </text>
<text top="276" left="217" width="182" height="12" font="4">sustained VA, an ICD is recommended if </text>
<text top="290" left="217" width="187" height="12" font="4">meaningful survival greater than 1 year is </text>
<text top="303" left="217" width="43" height="12" font="4">expected.</text>
<text top="304" left="260" width="56" height="7" font="23">S7.9.1.4-3,S7.9.1.4-4</text>
<text top="331" left="90" width="32" height="12" font="22"><b>III: No </b></text>
<text top="345" left="87" width="36" height="12" font="22"><b>Benefit</b></text>
<text top="338" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="324" left="205" width="172" height="12" font="4">3.  In patients with early repolarization </text>
<text top="338" left="217" width="172" height="12" font="4">pattern on ECG, genetic testing is not </text>
<text top="351" left="217" width="67" height="12" font="4">recommended.</text>
<text top="352" left="284" width="27" height="7" font="23">S7.9.1.4-5</text>
<text top="390" left="74" width="346" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="418" left="89" width="341" height="17" font="17">1.  The prevalence of an early repolarization pattern </text>
<text top="436" left="111" width="320" height="17" font="17">on ECG with J point elevation in the inferior or </text>
<text top="455" left="111" width="318" height="17" font="17">lateral leads of at least 0.1 mV has been reported </text>
<text top="474" left="111" width="197" height="17" font="17">to be as high as 5.8% in adults</text>
<text top="474" left="308" width="39" height="10" font="19">S7.9.1.4-1</text>
<text top="474" left="347" width="82" height="17" font="17"> and is more </text>
<text top="492" left="111" width="314" height="17" font="17">common in males. The early repolarization pat-</text>
<text top="511" left="111" width="320" height="17" font="17">tern was lost during 10-year follow-up in &gt;60% </text>
<text top="529" left="111" width="109" height="17" font="17">of young males.</text>
<text top="530" left="220" width="39" height="10" font="19">S7.9.1.4-2</text>
<text top="529" left="259" width="174" height="17" font="17"> Patients are determined </text>
<text top="548" left="111" width="320" height="17" font="17">to have an early repolarization syndrome when, </text>
<text top="566" left="111" width="319" height="17" font="17">in addition to having early repolarization pattern </text>
<text top="585" left="111" width="320" height="17" font="17">on an ECG, they either have symptoms such as </text>
<text top="604" left="111" width="322" height="17" font="17">syncope or present with an arrhythmia. When </text>
<text top="622" left="111" width="314" height="17" font="17">patients present with an early repolarization pat-</text>
<text top="641" left="111" width="314" height="17" font="17">tern on an ECG, it is important to rule out revers-</text>
<text top="659" left="111" width="320" height="17" font="17">ible causes such as ischemia. Patients with early </text>
<text top="678" left="111" width="314" height="17" font="17">repolarization are more susceptible to the devel-</text>
<text top="696" left="111" width="314" height="17" font="17">opment of VF during acute cardiac ischemia and/</text>
<text top="715" left="111" width="318" height="17" font="17">or in the presence of QRS abnormalities due to LV </text>
<text top="734" left="111" width="232" height="17" font="17">hypertrophy or bundle-branch block.</text>
<text top="734" left="343" width="82" height="10" font="19">S7.9.1.4-6–S7.9.1.4-8</text>
<text top="752" left="89" width="340" height="17" font="17">2.  Patients with cardiac arrest or VF in the setting of </text>
<text top="771" left="111" width="314" height="17" font="17">an electrocardiographic pattern of early repolar-</text>
<text top="789" left="111" width="314" height="17" font="17">ization are at increased risk for subsequent recur-</text>
<text top="808" left="111" width="321" height="17" font="17">rent episodes of VF, occurring in at least 40% </text>
<text top="826" left="111" width="83" height="17" font="17">of patients.</text>
<text top="827" left="194" width="122" height="10" font="19">S7.9.1.4-3,S7.9.1.4-4,S7.9.1.4-9</text>
<text top="826" left="316" width="124" height="17" font="17"> Antiarrhythmic </text>
<text top="845" left="111" width="314" height="17" font="17">medications, with the exception of quindine/</text>
<text top="863" left="111" width="314" height="17" font="17">hydroquinidine, have limited efficacy in prevent-</text>
<text top="882" left="111" width="109" height="17" font="17">ing recurrent VA.</text>
<text top="883" left="220" width="80" height="10" font="19">S7.9.1.4-3,S7.9.1.4-4</text>
<text top="901" left="89" width="343" height="17" font="17">3.  To date, genetic testing has not reliably identified </text>
<text top="919" left="111" width="278" height="17" font="17">mutations predisposing to early repolarization.</text>
<text top="920" left="388" width="37" height="10" font="19">S7.9.1.4-5</text>
<text top="950" left="74" width="179" height="18" font="28"><i>7.9.1.5. Short QT Syndrome</i></text>
<text top="978" left="85" width="208" height="12" font="26"><b>Recommendations for Short QT Syndrome</b></text>
<text top="995" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="1008" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 44</b></a></text>
<text top="1008" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="1029" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="1029" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="1029" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="1064" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="1064" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1050" left="205" width="202" height="12" font="4">1.  In asymptomatic patients with a short QTc </text>
<text top="1064" left="217" width="188" height="12" font="4">interval, observation without treatment is </text>
<text top="1077" left="217" width="67" height="12" font="4">recommended.</text>
<text top="1078" left="284" width="56" height="7" font="23">S7.9.1.5-1,S7.9.1.5-2</text>
<text top="164" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="164" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="136" left="583" width="181" height="12" font="4">2.  In patients with short QT syndrome  </text>
<text top="150" left="595" width="183" height="12" font="4">who have a cardiac arrest or sustained  </text>
<text top="163" left="595" width="145" height="12" font="4">VA, an ICD is recommended if  </text>
<text top="177" left="595" width="187" height="12" font="4">meaningful survival greater than 1 year  </text>
<text top="190" left="595" width="54" height="12" font="4">is expected.</text>
<text top="191" left="649" width="59" height="7" font="23">S7.9.1.5-3–S7.9.1.5-5</text>
<text top="225" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="225" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="211" left="583" width="192" height="12" font="4">3.  In patients with short QT syndrome and </text>
<text top="225" left="595" width="177" height="12" font="4">recurrent sustained VA, treatment with </text>
<text top="238" left="595" width="107" height="12" font="4">quinidine can be useful.</text>
<text top="239" left="701" width="85" height="7" font="23">S7.9.1.5-3,S7.9.1.5-5,S7.9.1.5-6</text>
<text top="273" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="273" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="259" left="583" width="206" height="12" font="4">4.  In patients with short QT syndrome and VT/</text>
<text top="272" left="595" width="178" height="12" font="4">VF storm, isoproterenol infusion can be </text>
<text top="286" left="595" width="41" height="12" font="4">effective.</text>
<text top="286" left="635" width="27" height="7" font="23">S7.9.1.5-7</text>
<text top="320" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="320" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="307" left="583" width="210" height="12" font="4">5.  In patients with short QT syndrome, genetic </text>
<text top="320" left="595" width="173" height="12" font="4">testing may be considered to facilitate </text>
<text top="334" left="595" width="151" height="12" font="4">screening of first-degree relatives.</text>
<text top="334" left="745" width="27" height="7" font="23">S7.9.1.5-4</text>
<text top="374" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="395" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="423" left="467" width="336" height="17" font="17">1. The prevalence of short QTc  ≤340 ms is esti-</text>
<text top="441" left="489" width="177" height="17" font="17">mated to be 5 in 10 </text>
<text top="441" left="656" width="159" height="17" font="17">000 in persons  &lt;21 </text>
<text top="459" left="489" width="330" height="17" font="17">years of age and is more common in </text>
<text top="459" left="803" width="4" height="17" font="17"> </text>
<text top="477" left="489" width="41" height="17" font="17">males.</text>
<text top="478" left="530" width="163" height="10" font="19">S7.9.1.5-1,S7.9.1.5-4,S7.9.1.5-8,S7.9.1.5-9</text>
<text top="477" left="693" width="126" height="17" font="17"> An incidental </text>
<text top="496" left="489" width="314" height="17" font="17">finding of a short QTc  ≤320 ms in an asymp-</text>
<text top="514" left="489" width="332" height="17" font="17">tomatic patient warrants monitoring and </text>
<text top="532" left="489" width="332" height="17" font="17">follow-up without prophylactic medication </text>
<text top="550" left="489" width="67" height="17" font="17">treatment.</text>
<text top="551" left="556" width="80" height="10" font="19">S7.9.1.5-1,S7.9.1.5-2</text>
<text top="569" left="467" width="345" height="17" font="17">2. Patients with cardiac arrest in the setting of </text>
<text top="587" left="489" width="319" height="17" font="17">short QT syndrome are known to be at increased </text>
<text top="605" left="489" width="232" height="17" font="17">risk for recurrent cardiac arrest.</text>
<text top="606" left="721" width="82" height="10" font="19">S7.9.1.5-3–S7.9.1.5-5</text>
<text top="605" left="803" width="4" height="17" font="17"> </text>
<text top="623" left="489" width="324" height="17" font="17">Approximately 18% of the small number of </text>
<text top="642" left="489" width="321" height="17" font="17">reported patients with short QT and implanted </text>
<text top="660" left="489" width="319" height="17" font="17">ICDs have experienced appropriate ICD therapies </text>
<text top="678" left="489" width="193" height="17" font="17">during short-term follow-up.</text>
<text top="679" left="682" width="122" height="10" font="19">S7.9.1.5-3,S7.9.1.5-5,S7.9.1.5-6</text>
<text top="678" left="803" width="4" height="17" font="17"> </text>
<text top="696" left="489" width="320" height="17" font="17">Therapy with quinidine may reduce the number </text>
<text top="715" left="489" width="92" height="17" font="17">of ICD shocks.</text>
<text top="715" left="581" width="122" height="10" font="19">S7.9.1.5-3,S7.9.1.5-5,S7.9.1.5-6</text>
<text top="733" left="467" width="350" height="17" font="17">3. Markedly shortened QTc values  ≤300 ms </text>
<text top="751" left="489" width="326" height="17" font="17">are associated with increased risk of SCD, </text>
<text top="769" left="489" width="328" height="17" font="17">especially during sleep or rest, in young </text>
<text top="788" left="489" width="329" height="17" font="17">persons, in whom the median QTc was </text>
<text top="788" left="803" width="4" height="17" font="17"> </text>
<text top="806" left="489" width="51" height="17" font="17">285 ms.</text>
<text top="807" left="540" width="79" height="10" font="19">S7.9.1.5-5,S7.9.1.5-9</text>
<text top="806" left="619" width="188" height="17" font="17"> A clinical score including QTc </text>
<text top="824" left="489" width="314" height="17" font="17">duration, clinical history of documented polymor-</text>
<text top="842" left="489" width="318" height="17" font="17">phic VT or VF, unexplained syncope, family history </text>
<text top="861" left="489" width="320" height="17" font="17">of autopsy-negative SCD or sudden infant death </text>
<text top="879" left="489" width="326" height="17" font="17">syndrome, and positive genotype results has </text>
<text top="897" left="489" width="321" height="17" font="17">been proposed to identify patients at increased  </text>
<text top="915" left="489" width="82" height="17" font="17">risk for SCD.</text>
<text top="916" left="571" width="87" height="10" font="19">S7.9.1.5-4,S7.9.1.5-10</text>
<text top="916" left="658" width="145" height="17" font="17"> Treatment with quini-</text>
<text top="934" left="489" width="321" height="17" font="17">dine results in lengthening of the QTc and, in </text>
<text top="952" left="489" width="320" height="17" font="17">selected patients, may be an alternative to ICD </text>
<text top="970" left="489" width="87" height="17" font="17">implantation.</text>
<text top="971" left="576" width="124" height="10" font="19">S7.9.1.5-3,S7.9.1.5-5,S7.9.1.5-6</text>
<text top="989" left="467" width="339" height="17" font="17">4.  In the setting of electrical storm with refractory VF </text>
<text top="1007" left="489" width="318" height="17" font="17">and short QT syndrome, infusion of isoproterenol </text>
<text top="1025" left="489" width="323" height="17" font="17">can be effective in restoring/maintaining sinus </text>
<text top="1043" left="489" width="50" height="17" font="17">rhythm.</text>
<text top="1044" left="539" width="39" height="10" font="19">S7.9.1.5-7</text>
<text top="1062" left="467" width="348" height="17" font="17">5. Pathogenic mutations in potassium channels </text>
<text top="1080" left="489" width="322" height="17" font="17">have been identified in approximately 10% to </text>
<text top="95" left="463" width="269" height="12" font="26"><b>Recommendations for Short QT Syndrome (Continued)</b></text>
<text top="116" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="116" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="116" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e334</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="314" height="17" font="17">20% of patients with short QT syndrome includ-</text>
<text top="106" left="111" width="318" height="17" font="17">ing in <i>KCNH2</i> (SQT1), <i>KCNQ1</i> (SQT2), and <i>KCNJ2</i> </text>
<text top="124" left="111" width="47" height="17" font="17">(SQT3).</text>
<text top="124" left="158" width="39" height="10" font="19">S7.9.1.5-4</text>
<text top="124" left="197" width="236" height="17" font="17"> Due to the rarity of the disease, </text>
<text top="142" left="111" width="318" height="17" font="17">genotype/phenotype correlations are unavailable, </text>
<text top="160" left="111" width="314" height="17" font="17">limiting the use of knowledge of genotype status.</text>
<text top="208" left="74" width="354" height="23" font="15"><b>8. VA IN THE STRUCTURALLY NORMAL </b></text>
<text top="230" left="74" width="61" height="23" font="15"><b>HEART</b></text>
<text top="265" left="85" width="286" height="12" font="26"><b>Recommendations for VA in the Structurally Normal Heart</b></text>
<text top="282" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="296" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 45</b></a></text>
<text top="296" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="316" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="316" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="316" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="371" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="371" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="337" left="205" width="201" height="12" font="4">1.  In patients with symptomatic PVCs in an </text>
<text top="351" left="217" width="186" height="12" font="4">otherwise normal heart, treatment with </text>
<text top="365" left="217" width="177" height="12" font="4">a beta blocker or nondihydropyradine </text>
<text top="378" left="217" width="167" height="12" font="4">calcium channel blocker is useful to </text>
<text top="392" left="217" width="197" height="12" font="4">reduce recurrent arrhythmias and improve </text>
<text top="405" left="217" width="50" height="12" font="4">symptoms.</text>
<text top="405" left="267" width="26" height="7" font="23">S8-1,S8-2</text>
<text top="473" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="473" left="156" width="16" height="12" font="22"><b>B-R</b></text>
<text top="426" left="205" width="193" height="12" font="4">2.  In patients with symptomatic VA in an </text>
<text top="439" left="217" width="191" height="12" font="4">otherwise normal heart, treatment with  </text>
<text top="453" left="217" width="203" height="12" font="4">an antiarrhythmic medication is reasonable </text>
<text top="466" left="217" width="155" height="12" font="4">to reduce recurrent symptomatic </text>
<text top="480" left="217" width="182" height="12" font="4">arrhythmias and improve symptoms if  </text>
<text top="493" left="217" width="182" height="12" font="4">beta blockers and nondihydropyradine </text>
<text top="507" left="217" width="201" height="12" font="4">calcium channel blockers are ineffective or </text>
<text top="520" left="217" width="64" height="12" font="4">not tolerated.</text>
<text top="521" left="281" width="26" height="7" font="23">S8-3,S8-4</text>
<text top="560" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="587" left="74" width="358" height="17" font="17">Most idiopathic VA are due to a focal mechanism of </text>
<text top="605" left="74" width="351" height="17" font="17">triggered activity or abnormal automaticity, some, no-</text>
<text top="623" left="74" width="358" height="17" font="17">tably interfascicular reentrant LV tachycardias, are due </text>
<text top="641" left="74" width="357" height="17" font="17">to reentry. The clinical manifestations of idiopathic VA </text>
<text top="659" left="74" width="351" height="17" font="17">are highly variable and range from benign, asymptom-</text>
<text top="677" left="74" width="355" height="17" font="17">atic PVCs to sustained VT or even VF. On initial discovery, </text>
<text top="695" left="74" width="357" height="17" font="17">an evaluation for structural heart disease is warranted </text>
<text top="713" left="74" width="351" height="17" font="17">with physical examination, an ECG, and imaging, usu-</text>
<text top="731" left="74" width="351" height="17" font="17">ally with echocardiography. In the absence of any ab-</text>
<text top="749" left="74" width="356" height="17" font="17">normality or a family history of SCD, further assessment </text>
<text top="767" left="74" width="356" height="17" font="17">and treatment are guided by symptoms. If the patient is </text>
<text top="785" left="74" width="356" height="17" font="17">asymptomatic and does not have evidence of a cardiac </text>
<text top="803" left="74" width="357" height="17" font="17">channelopathy, reassurance as to the benign nature is </text>
<text top="821" left="74" width="351" height="17" font="17">sufficient. If the arrhythmia is suspected of being suf-</text>
<text top="839" left="74" width="357" height="17" font="17">ficiently frequent to cause ventricular dysfunction over </text>
<text top="857" left="74" width="355" height="17" font="17">time, periodic follow-up with reassessment of ventricular </text>
<text top="875" left="74" width="351" height="17" font="17">function is warranted (see Section 10.8). For mild symp-</text>
<text top="893" left="74" width="355" height="17" font="17">toms, avoidance of aggravating factors such as excessive </text>
<text top="911" left="74" width="359" height="17" font="17">consumption of caffeine or sympathomimetic agents, </text>
<text top="929" left="74" width="351" height="17" font="17">may be sufficient. Therapy with a beta blocker or non-</text>
<text top="947" left="74" width="351" height="17" font="17">dihydropyradine calcium channel blocker reduces symp-</text>
<text top="965" left="74" width="351" height="17" font="17">toms for some patients. Class I antiarrhythmic medica-</text>
<text top="983" left="74" width="357" height="17" font="17">tions can be effective, but those are generally avoided </text>
<text top="1001" left="74" width="357" height="17" font="17">due to concerns for adverse effects. For patients who </text>
<text top="1019" left="74" width="355" height="17" font="17">require arrhythmia suppression for whom antiarrhythmic </text>
<text top="1037" left="74" width="356" height="17" font="17">medications are ineffective, not tolerated, or undesired, </text>
<text top="1055" left="74" width="355" height="17" font="17">catheter ablation can be a highly effective treatment (see </text>
<text top="1073" left="74" width="355" height="17" font="17">Section 9). The ablation strategy is to identify the site of </text>
<text top="88" left="452" width="351" height="17" font="17">origin manifested by the earliest site of electrical activa-</text>
<text top="106" left="452" width="356" height="17" font="17">tion or, when this is not feasible, by pace-mapping. The </text>
<text top="124" left="452" width="355" height="17" font="17">most common site of origin for idiopathic VA is from the </text>
<text top="142" left="452" width="357" height="17" font="17">right ventricular outflow tract (RVOT) or the ostium of </text>
<text top="160" left="452" width="357" height="17" font="17">the LV, which is comprised of the oval opening of the </text>
<text top="178" left="452" width="356" height="17" font="17">LV to which the aorta is attached anteriorly and the left </text>
<text top="196" left="452" width="358" height="17" font="17">atrium is attached posteriorly. The likely origin can be </text>
<text top="214" left="452" width="357" height="17" font="17">reasonably predicted from the QRS morphology of the </text>
<text top="232" left="452" width="351" height="17" font="17">VA, which provides a good indication of the type of ap-</text>
<text top="250" left="452" width="356" height="17" font="17">proach required and the likelihood of success and risks. </text>
<text top="268" left="452" width="355" height="17" font="17">Ablation failure is often related to the absence of the VA </text>
<text top="286" left="452" width="357" height="17" font="17">for mapping at the time of the procedure, or origin of </text>
<text top="304" left="452" width="356" height="17" font="17">the VA in an inaccessible region of the heart. These foci </text>
<text top="322" left="452" width="307" height="17" font="17">occasionally produce sustained monomorphic VT.</text>
<text top="322" left="759" width="38" height="10" font="19">S8-5–S8-7</text>
<text top="365" left="452" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="392" left="467" width="336" height="17" font="17">1. In a randomized, double-blinded, placebo-con-</text>
<text top="410" left="489" width="319" height="17" font="17">trolled study of 52 patients with symptomatic VA </text>
<text top="428" left="489" width="321" height="17" font="17">and a mean PVC count of 21 407±1740 beats </text>
<text top="446" left="489" width="323" height="17" font="17">per 24 hours, atenolol significantly decreased </text>
<text top="464" left="489" width="324" height="17" font="17">symptom frequency (<i>P</i> =0.03) and PVC count </text>
<text top="482" left="489" width="317" height="17" font="17">(<i>P</i> =0.001), whereas placebo had no effect on PVC </text>
<text top="500" left="489" width="297" height="17" font="17">count (<i>P</i> =0.78) or average heart rate (<i>P</i> =0.44).</text>
<text top="501" left="786" width="17" height="10" font="19">S8-8</text>
<text top="500" left="803" width="4" height="17" font="17"> </text>
<text top="518" left="489" width="314" height="17" font="17">A prospective randomized comparison of antiar-</text>
<text top="536" left="489" width="323" height="17" font="17">rhythmic medications versus catheter ablation, </text>
<text top="554" left="489" width="320" height="17" font="17">metoprolol or propafenone had modest efficacy </text>
<text top="572" left="489" width="319" height="17" font="17">to suppress RVOT VA although with a far higher </text>
<text top="590" left="489" width="264" height="17" font="17">rate of recurrence than catheter ablation.</text>
<text top="591" left="753" width="17" height="10" font="19">S8-9</text>
<text top="608" left="467" width="343" height="17" font="17">2.  In an RCT of 233 patients with  ≥30 PVCs per </text>
<text top="626" left="489" width="322" height="17" font="17">hour, d-sotalol was shown to reduce frequent </text>
<text top="644" left="489" width="323" height="17" font="17">PVCs, but only racemic dl-sotalol is presently </text>
<text top="662" left="489" width="59" height="17" font="17">available.</text>
<text top="663" left="548" width="22" height="10" font="19">S8-10</text>
<text top="662" left="570" width="233" height="17" font="17"> In a prospective randomized com-</text>
<text top="680" left="489" width="326" height="17" font="17">parison of antiarrhythmic medications versus </text>
<text top="698" left="489" width="324" height="17" font="17">catheter ablation, therapy with metoprolol or </text>
<text top="716" left="489" width="314" height="17" font="17">propafenone was shown to have modest effi-</text>
<text top="734" left="489" width="318" height="17" font="17">cacy when used to suppress RVOT PVCs although </text>
<text top="752" left="489" width="318" height="17" font="17">with a far higher rate of recurrence than catheter </text>
<text top="770" left="489" width="56" height="17" font="17">ablation.</text>
<text top="771" left="545" width="17" height="10" font="19">S8-9</text>
<text top="770" left="562" width="247" height="17" font="17"> Nondihydropyridine calcium channel </text>
<text top="788" left="489" width="183" height="17" font="17">blockers reduce arrhythmias.</text>
<text top="789" left="672" width="85" height="10" font="19">S8-1,S8-2,S8-11,S8-12</text>
<text top="831" left="452" width="332" height="21" font="18"><b>8.1. Outflow Tract and Atrioventricular </b></text>
<text top="852" left="452" width="97" height="21" font="18"><b>Annular VA</b></text>
<text top="886" left="463" width="196" height="12" font="26"><b>Recommendations for Outflow Tract VA</b></text>
<text top="903" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="917" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 46</b></a></text>
<text top="917" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="937" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="937" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="937" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="985" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="985" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="958" left="583" width="205" height="12" font="4">1.  In patients with symptomatic outflow tract </text>
<text top="972" left="595" width="195" height="12" font="4">VA in an otherwise normal heart for whom </text>
<text top="986" left="595" width="193" height="12" font="4">antiarrhythmic medications are ineffective, </text>
<text top="999" left="595" width="206" height="12" font="4">not tolerated, or not the patient’s preference, </text>
<text top="1013" left="595" width="118" height="12" font="4">catheter ablation is useful.</text>
<text top="1013" left="712" width="37" height="7" font="23">S8.1-1–S8.1-3</text>
<text top="1054" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="1054" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1033" left="583" width="205" height="12" font="4">2.  In patients with symptomatic outflow tract </text>
<text top="1047" left="595" width="181" height="12" font="4">VT in an otherwise normal heart, a beta </text>
<text top="1060" left="595" width="176" height="12" font="4">blocker or a calcium channel blocker is </text>
<text top="1074" left="595" width="30" height="12" font="4">useful.</text>
<text top="1074" left="624" width="37" height="7" font="23">S8.1-1–S8.1-3</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e335</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="109" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="138" left="89" width="336" height="17" font="17">1.  In 1 RCT, catheter ablation was superior to anti-</text>
<text top="157" left="111" width="324" height="17" font="17">arrhythmic medications at suppressing frequent </text>
<text top="177" left="111" width="197" height="17" font="17">PVCs arising from the RVOT.</text>
<text top="177" left="308" width="24" height="10" font="19">S8.1-4</text>
<text top="177" left="331" width="104" height="17" font="17"> Observational </text>
<text top="196" left="111" width="314" height="17" font="17">studies have shown that radiofrequency cath-</text>
<text top="215" left="111" width="314" height="17" font="17">eter ablation is effective in the treatment of idio-</text>
<text top="235" left="111" width="320" height="17" font="17">pathic VA arising from the RVOT and LV outflow  </text>
<text top="254" left="111" width="32" height="17" font="17">tract.</text>
<text top="255" left="143" width="82" height="10" font="19">S8.1-2,S8.1-5–S8.1-16</text>
<text top="254" left="225" width="203" height="17" font="17"> The site of ablation may be below </text>
<text top="274" left="111" width="260" height="17" font="17">or above the pulmonic valve in the RVOT.</text>
<text top="274" left="371" width="54" height="10" font="19">S8.1-9,S8.1-13</text>
<text top="274" left="425" width="4" height="17" font="17"> </text>
<text top="293" left="111" width="318" height="17" font="17">Although most RVOT VA can be ablated within the </text>
<text top="312" left="111" width="319" height="17" font="17">RV, 10% may require ablation within the pulmonic </text>
<text top="332" left="111" width="77" height="17" font="17">sinus cusps.</text>
<text top="333" left="188" width="24" height="10" font="19">S8.1-9</text>
<text top="332" left="211" width="214" height="17" font="17"> Serious complications are infre-</text>
<text top="351" left="111" width="319" height="17" font="17">quent. For LV outflow tract VA, the site of ablation </text>
<text top="371" left="111" width="225" height="17" font="17">may be within the aortic cusp sinuses,</text>
<text top="371" left="336" width="89" height="10" font="19">S8.1-11,S8.1-14,S8.1-16</text>
<text top="371" left="425" width="4" height="17" font="17"> </text>
<text top="390" left="111" width="143" height="17" font="17">below the aortic valve,</text>
<text top="391" left="254" width="49" height="10" font="19">S8.1-2,S8.1-6</text>
<text top="390" left="304" width="127" height="17" font="17"> at the aorto-mitral  </text>
<text top="410" left="111" width="61" height="17" font="17">continuity</text>
<text top="410" left="172" width="51" height="10" font="19">S8.1-1–S8.1-3</text>
<text top="410" left="223" width="208" height="17" font="17"> or on the epicardial surface of </text>
<text top="429" left="111" width="93" height="17" font="17">the LV summit.</text>
<text top="430" left="204" width="85" height="10" font="19">S8.1-3,S8.1-17,S8.1-18</text>
<text top="429" left="289" width="137" height="17" font="17"> The mitral and tricus-</text>
<text top="448" left="111" width="318" height="17" font="17">pid annulae are less common sites of idiopathic VA, </text>
<text top="468" left="111" width="321" height="17" font="17">but these VA can also be effectively treated with </text>
<text top="487" left="111" width="123" height="17" font="17">catheter ablation.</text>
<text top="488" left="233" width="85" height="10" font="19">S8.1-1,S8.1-19,S8.1-20</text>
<text top="487" left="318" width="125" height="17" font="17"> Approximately </text>
<text top="507" left="111" width="318" height="17" font="17">10% of idiopathic VA may arise from the summit of </text>
<text top="526" left="111" width="318" height="17" font="17">the LV. Some can be ablated from the great cardiac </text>
<text top="546" left="111" width="318" height="17" font="17">vein or the epicardial surface, but others arise from </text>
<text top="565" left="111" width="319" height="17" font="17">an inaccessible region in close proximity to the left </text>
<text top="584" left="111" width="286" height="17" font="17">coronary artery precluding effective ablation.</text>
<text top="585" left="397" width="28" height="10" font="19">S8.1-14</text>
<text top="584" left="425" width="4" height="17" font="17"> </text>
<text top="604" left="111" width="321" height="17" font="17">Intramural sites of origin are infrequent but may </text>
<text top="623" left="111" width="314" height="17" font="17">require ablation on both the endocardial and epi-</text>
<text top="643" left="111" width="200" height="17" font="17">cardial surfaces of the LV ostium.</text>
<text top="643" left="310" width="24" height="10" font="19">S8.1-3</text>
<text top="643" left="334" width="95" height="17" font="17"> Complications </text>
<text top="662" left="111" width="320" height="17" font="17">from ablation of outflow tract VA are infrequent, </text>
<text top="682" left="111" width="320" height="17" font="17">but bleeding complications related to arterial and </text>
<text top="701" left="111" width="314" height="17" font="17">venous access, pericardial tamponade, and dam-</text>
<text top="720" left="111" width="236" height="17" font="17">age to the coronary arteries can occur.</text>
<text top="740" left="89" width="336" height="17" font="17">2.  In a prospective randomized comparison of anti-</text>
<text top="759" left="111" width="320" height="17" font="17">arrhythmic medications versus catheter ablation, </text>
<text top="779" left="111" width="321" height="17" font="17">metoprolol or propafenone was shown to have </text>
<text top="798" left="111" width="317" height="17" font="17">modest effectiveness when used to suppress RVOT </text>
<text top="817" left="111" width="318" height="17" font="17">PVCs, though with a far higher rate of recurrence </text>
<text top="837" left="111" width="149" height="17" font="17">than catheter ablation.</text>
<text top="838" left="260" width="24" height="10" font="19">S8.1-4</text>
<text top="837" left="285" width="147" height="17" font="17"> Non-dihydropyradine </text>
<text top="856" left="111" width="320" height="17" font="17">calcium channel blockers suppress arrhythmia in </text>
<text top="876" left="111" width="93" height="17" font="17">some patients.</text>
<text top="876" left="204" width="24" height="10" font="19">S8.1-4</text>
<text top="920" left="74" width="201" height="21" font="18"><b>8.2. Papillary Muscle VA</b></text>
<text top="956" left="85" width="275" height="12" font="26"><b>Recommendation for Papillary Muscle VA (PVCs and VT)</b></text>
<text top="973" left="85" width="321" height="12" font="26"><b>References that support the recommendation are summarized in </b></text>
<text top="986" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 47</b></a></text>
<text top="986" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="1007" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="1007" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="1007" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="1055" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="1055" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="1028" left="205" width="192" height="12" font="4">1.  In patients with symptomatic VA arising </text>
<text top="1041" left="217" width="167" height="12" font="4">from the papillary muscles for whom </text>
<text top="1055" left="217" width="193" height="12" font="4">antiarrhythmic medications are ineffective, </text>
<text top="1068" left="217" width="206" height="12" font="4">not tolerated, or not the patient’s preference, </text>
<text top="1082" left="217" width="118" height="12" font="4">catheter ablation is useful.</text>
<text top="1082" left="334" width="37" height="7" font="23">S8.2-1–S8.2-5</text>
<text top="87" left="452" width="349" height="21" font="18"><b>Recommendation-Specific Supportive Text</b></text>
<text top="114" left="467" width="340" height="17" font="17">1.  The papillary muscles of the LV or RV can be the site </text>
<text top="132" left="485" width="319" height="17" font="17">of origin of VA in the presence or absence of struc-</text>
<text top="150" left="485" width="118" height="17" font="17">tural heart disease.</text>
<text top="151" left="602" width="52" height="10" font="19">S8.2-1–S8.2-5</text>
<text top="150" left="654" width="153" height="17" font="17"> Idiopathic left and right </text>
<text top="168" left="484" width="323" height="17" font="17">ventricular papillary muscle VA are most commonly </text>
<text top="187" left="484" width="326" height="17" font="17">PVCs and NSVT, and are usually exercise-related </text>
<text top="205" left="484" width="323" height="17" font="17">and may be induced by intravenous epinephrine or </text>
<text top="223" left="484" width="179" height="17" font="17">isoproterenol administration.</text>
<text top="223" left="663" width="24" height="10" font="19">S8.2-3</text>
<text top="223" left="687" width="120" height="17" font="17"> These arrhythmias </text>
<text top="241" left="484" width="324" height="17" font="17">have a focal, nonreentrant mechanism. Any of the </text>
<text top="259" left="484" width="323" height="17" font="17">3 RV papillary muscles may be the site of origin and </text>
<text top="277" left="484" width="227" height="17" font="17">catheter ablation is usually effective.</text>
<text top="278" left="711" width="24" height="10" font="19">S8.2-2</text>
<text top="277" left="735" width="73" height="17" font="17"> In 1 study, </text>
<text top="295" left="484" width="325" height="17" font="17">successful ablation was achieved in all 8 patients </text>
<text top="313" left="484" width="324" height="17" font="17">with a reduction in PVC burden from 17±20% to </text>
<text top="332" left="484" width="69" height="17" font="17">0.6±0.8%.</text>
<text top="332" left="553" width="24" height="10" font="19">S8.2-2</text>
<text top="332" left="577" width="230" height="17" font="17"> In the left ventricle, the site of origin </text>
<text top="350" left="485" width="319" height="17" font="17">may be either the posteromedial or the anterolat-</text>
<text top="368" left="485" width="136" height="17" font="17">eral papillary muscles.</text>
<text top="369" left="620" width="76" height="10" font="19">S8.2-1,S8.2-4,S8.2-5</text>
<text top="368" left="696" width="111" height="17" font="17"> Multiple VA QRS </text>
<text top="386" left="484" width="325" height="17" font="17">morphologies were observed in 47% of patients, </text>
<text top="404" left="484" width="322" height="17" font="17">and ablation on both sides of the papillary muscle is </text>
<text top="422" left="484" width="165" height="17" font="17">required in some patients.</text>
<text top="423" left="649" width="24" height="10" font="19">S8.2-4</text>
<text top="422" left="673" width="135" height="17" font="17"> Achieving adequate </text>
<text top="440" left="485" width="319" height="17" font="17">catheter stability can be challenging. Acute abla-</text>
<text top="459" left="485" width="319" height="17" font="17">tion success is high, but recurrences are more fre-</text>
<text top="477" left="485" width="323" height="17" font="17">quent than for idiopathic outflow tract VA. Serious </text>
<text top="495" left="485" width="323" height="17" font="17">complications, including valve injury, appear to be </text>
<text top="513" left="485" width="324" height="17" font="17">infrequent. The risks of catheter ablation include </text>
<text top="531" left="485" width="323" height="17" font="17">bleeding related to arterial and venous access and </text>
<text top="549" left="485" width="230" height="17" font="17">a low risk of pericardial tamponade.</text>
<text top="593" left="452" width="275" height="21" font="18"><b>8.3. Interfascicular Reentrant VT </b></text>
<text top="614" left="452" width="199" height="21" font="18"><b>(Belhassen Tachycardia)</b></text>
<text top="648" left="463" width="307" height="12" font="26"><b>Recommendations for Interfascicular Reentrant VT (Belhassen </b></text>
<text top="661" left="463" width="60" height="12" font="26"><b>Tachycardia)</b></text>
<text top="678" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="692" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 48</b></a></text>
<text top="692" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="712" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="712" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="712" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="767" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="767" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="733" left="583" width="174" height="12" font="4">1.  In patients with verapamil-sensitive, </text>
<text top="747" left="595" width="176" height="12" font="4">idiopathic LVT related to interfascicular </text>
<text top="760" left="595" width="206" height="12" font="4">reentry for whom antiarrhythmic medications </text>
<text top="774" left="595" width="180" height="12" font="4">are ineffective, not tolerated, or not the </text>
<text top="788" left="595" width="182" height="12" font="4">patient’s preference, catheter ablation is </text>
<text top="801" left="595" width="30" height="12" font="4">useful.</text>
<text top="801" left="624" width="37" height="7" font="23">S8.3-1–S8.3-3</text>
<text top="849" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="849" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="822" left="583" width="209" height="12" font="4">2.  In patients with sustained hemodynamically </text>
<text top="835" left="595" width="180" height="12" font="4">tolerated verapamil-sensitive, idiopathic </text>
<text top="849" left="595" width="165" height="12" font="4">LVT related to interfascicular reentry, </text>
<text top="862" left="595" width="193" height="12" font="4">intravenous verapamil is recommended for </text>
<text top="876" left="595" width="69" height="12" font="4">VT termination.</text>
<text top="876" left="664" width="37" height="7" font="23">S8.3-3–S8.3-6</text>
<text top="910" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="910" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="897" left="583" width="214" height="12" font="4">3.  In patients with recurrent verapamil-sensitive </text>
<text top="910" left="595" width="181" height="12" font="4">idiopathic LVT, chronic therapy with oral </text>
<text top="924" left="595" width="109" height="12" font="4">verapamil can be useful.</text>
<text top="924" left="703" width="40" height="7" font="23">S8.3-7–S8.3-10</text>
<text top="964" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="985" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="1012" left="467" width="342" height="17" font="17">1.  Idiopathic LVT is due to reentry involving a portion </text>
<text top="1030" left="489" width="320" height="17" font="17">of the LV Purkinje system, usually the left posterior </text>
<text top="1048" left="489" width="320" height="17" font="17">fascicle as the retrograde limb of the circuit and an </text>
<text top="1066" left="489" width="321" height="17" font="17">incompletely defined segment of LV tissue as the </text>
<text top="1085" left="489" width="321" height="17" font="17">anterograde limb, a portion of which is verapamil </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e336</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="54" height="17" font="17">sensitive.</text>
<text top="88" left="165" width="50" height="10" font="19">S8.3-1–S8.3-3</text>
<text top="88" left="215" width="217" height="17" font="17"> These VTs are typically sustained </text>
<text top="106" left="111" width="321" height="17" font="17">with a QRS that has a right bundle-branch block </text>
<text top="124" left="111" width="321" height="17" font="17">configuration with a superior axis. Less frequently </text>
<text top="142" left="111" width="322" height="17" font="17">an inferior axis VT or a relatively narrow QRS VT </text>
<text top="160" left="111" width="321" height="17" font="17">occurs as a result of alternate reentry paths, also </text>
<text top="178" left="111" width="314" height="17" font="17">involving a part of the Purkinje system. Beta block-</text>
<text top="196" left="111" width="314" height="17" font="17">ers or verapamil typically terminate these arrhyth-</text>
<text top="214" left="111" width="321" height="17" font="17">mias, but they fail to prevent recurrences in some  </text>
<text top="232" left="111" width="52" height="17" font="17">patients.</text>
<text top="232" left="163" width="50" height="10" font="19">S8.3-1–S8.3-3</text>
<text top="232" left="213" width="217" height="17" font="17"> The target of catheter ablation for </text>
<text top="250" left="111" width="318" height="17" font="17">the most common form is usually the distal insertion </text>
<text top="268" left="111" width="318" height="17" font="17">of the anterograde limb of the Purkinje system along </text>
<text top="286" left="111" width="314" height="17" font="17">the inferior portion of the LV septum near its junc-</text>
<text top="304" left="111" width="314" height="17" font="17">tion with the left posterior fascicle. Catheter abla-</text>
<text top="322" left="111" width="320" height="17" font="17">tion is acutely successful in &gt;90% of patients with </text>
<text top="340" left="111" width="320" height="17" font="17">a risk of recurrence of approximately 10%. This VT </text>
<text top="358" left="111" width="320" height="17" font="17">may resemble fascicular VA that are due to a focal </text>
<text top="376" left="111" width="314" height="17" font="17">mechanism in the left anterior or left posterior fas-</text>
<text top="394" left="111" width="319" height="17" font="17">cicles of the LV His-Purkinje system. These fascicular </text>
<text top="412" left="111" width="318" height="17" font="17">arrhythmias usually have a focal mechanism with the </text>
<text top="430" left="111" width="319" height="17" font="17">target of catheter ablation being the site of earliest </text>
<text top="448" left="111" width="314" height="17" font="17">electrical activation recorded with a presystolic fas-</text>
<text top="466" left="111" width="318" height="17" font="17">cicular potential. Catheter ablation is highly effective </text>
<text top="484" left="111" width="314" height="17" font="17">for intrafascicular and fascicular VA. Serious compli-</text>
<text top="502" left="111" width="320" height="17" font="17">cations are infrequent and include bleeding at the </text>
<text top="520" left="111" width="320" height="17" font="17">site of arterial or venous access and a small risk of </text>
<text top="538" left="111" width="274" height="17" font="17">bundle branch block or atrioventricular block.</text>
<text top="556" left="89" width="342" height="17" font="17">2.  Idiopathic LVT is based on reentrant mechanism </text>
<text top="574" left="111" width="320" height="17" font="17">involving tissue with slow conduction properties </text>
<text top="592" left="111" width="322" height="17" font="17">along the LV septum as the anterograde limb </text>
<text top="610" left="111" width="314" height="17" font="17">and the normal left posterior fascicle of the His-</text>
<text top="628" left="111" width="319" height="17" font="17">Purkinje system as the retrograde limb. The slow </text>
<text top="646" left="111" width="261" height="17" font="17">conduction zone is verapamil-sensitive.</text>
<text top="646" left="372" width="53" height="10" font="19">S8.3-3–S8.3-6</text>
<text top="646" left="425" width="8" height="17" font="17">  </text>
<text top="664" left="111" width="314" height="17" font="17">These arrhythmias typically have a right bundle-</text>
<text top="682" left="111" width="324" height="17" font="17">branch block morphology with superior axis, </text>
<text top="700" left="111" width="314" height="17" font="17">though reversal of the circuit may produce a rela-</text>
<text top="718" left="111" width="320" height="17" font="17">tively narrow QRS during VT. Verapamil typically </text>
<text top="736" left="111" width="320" height="17" font="17">terminates these arrhythmias in the anterograde </text>
<text top="754" left="111" width="144" height="17" font="17">slow conduction zone.</text>
<text top="754" left="255" width="53" height="10" font="19">S8.3-3–S8.3-6</text>
<text top="772" left="89" width="346" height="17" font="17">3. Although no RCTs have been published, the </text>
<text top="790" left="111" width="314" height="17" font="17">chronic use of oral verapamil for verapamil-sen-</text>
<text top="808" left="111" width="319" height="17" font="17">sitive idiopathic LVT has been reported to control </text>
<text top="826" left="111" width="319" height="17" font="17">this tachycardia in many patients, including both </text>
<text top="844" left="111" width="126" height="17" font="17">adults and children.</text>
<text top="844" left="237" width="85" height="10" font="19">S8.3-5,S8.3-8–S8.3-10</text>
<text top="887" left="74" width="284" height="21" font="18"><b>8.4. Idiopathic Polymorphic VT/VF</b></text>
<text top="921" left="85" width="257" height="12" font="26"><b>Recommendations for Idiopathic Polymorphic VT/VF</b></text>
<text top="938" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="951" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 49</b></a></text>
<text top="951" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="972" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="972" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="972" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="1033" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="1033" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="993" left="205" width="180" height="12" font="4">1.  In young patients (&lt;40 years of age) </text>
<text top="1006" left="217" width="189" height="12" font="4">with unexplained SCA, unexplained near </text>
<text top="1020" left="217" width="197" height="12" font="4">drowning, or recurrent exertional syncope, </text>
<text top="1034" left="217" width="163" height="12" font="4">who do not have ischemic or other </text>
<text top="1047" left="217" width="196" height="12" font="4">structural heart disease, further evaluation </text>
<text top="1061" left="217" width="166" height="12" font="4">for genetic arrhythmia syndromes is </text>
<text top="1074" left="217" width="69" height="12" font="4">recommended.</text>
<text top="1074" left="285" width="38" height="7" font="23">S8.4-1–S8.4-8</text>
<text top="157" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="157" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="136" left="583" width="196" height="12" font="4">2.  In patients resuscitated from SCA due to </text>
<text top="150" left="595" width="190" height="12" font="4">idiopathic polymorphic VT or VF, an ICD is </text>
<text top="163" left="595" width="200" height="12" font="4">recommended if meaningful survival greater </text>
<text top="177" left="595" width="106" height="12" font="4">than 1 year is expected.</text>
<text top="177" left="701" width="40" height="7" font="23">S8.4-9–S8.4-13</text>
<text top="218" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="218" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="198" left="583" width="187" height="12" font="4">3.  For patients with recurrent episodes of </text>
<text top="211" left="595" width="170" height="12" font="4">idiopathic VF initiated by PVCs with a </text>
<text top="225" left="595" width="168" height="12" font="4">consistent QRS morphology, catheter </text>
<text top="238" left="595" width="78" height="12" font="4">ablation is useful.</text>
<text top="239" left="673" width="43" height="7" font="23">S8.4-11,S8.4-14</text>
<text top="278" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="299" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="326" left="467" width="341" height="17" font="17">1.  When combined with clinical evaluation, genetic </text>
<text top="344" left="489" width="322" height="17" font="17">testing can provide a diagnosis in up to 13% </text>
<text top="362" left="489" width="320" height="17" font="17">to 60% of younger (&lt;40 years of age) survivors </text>
<text top="380" left="489" width="52" height="17" font="17">of SCA,</text>
<text top="381" left="541" width="24" height="10" font="19">S8.4-3</text>
<text top="380" left="565" width="245" height="17" font="17"> with the most common genotypes </text>
<text top="398" left="489" width="324" height="17" font="17">identified associated with long QT syndrome, </text>
<text top="416" left="489" width="314" height="17" font="17">catecholaminergic polymorphic ventricular tachy-</text>
<text top="434" left="489" width="214" height="17" font="17">cardia, and Brugada syndrome.</text>
<text top="435" left="703" width="24" height="10" font="19">S8.4-8</text>
<text top="434" left="727" width="76" height="17" font="17"> Drowning/</text>
<text top="452" left="489" width="320" height="17" font="17">near drowning events are particularly associated </text>
<text top="470" left="489" width="323" height="17" font="17">with LQT1 and catecholaminergic polymorphic </text>
<text top="488" left="489" width="318" height="17" font="17">ventricular tachycardia; genetic mutations in long </text>
<text top="506" left="489" width="318" height="17" font="17">QT syndrome and catecholaminergic polymorphic </text>
<text top="524" left="489" width="323" height="17" font="17">ventricular tachycardia have been identified in </text>
<text top="542" left="489" width="314" height="17" font="17">23% of patients with unexplained near-drown-</text>
<text top="560" left="489" width="84" height="17" font="17">ing episodes.</text>
<text top="561" left="573" width="29" height="10" font="19">S8.4-15</text>
<text top="560" left="602" width="71" height="17" font="17"> In 1 study,</text>
<text top="561" left="674" width="24" height="10" font="19">S8.4-6</text>
<text top="560" left="698" width="110" height="17" font="17"> exertion-related </text>
<text top="578" left="489" width="323" height="17" font="17">cardiac arrest, particularly in children, may be </text>
<text top="596" left="489" width="314" height="17" font="17">related to long QT syndrome, catecholaminer-</text>
<text top="614" left="489" width="324" height="17" font="17">gic polymorphic ventricular tachycardia, or to </text>
<text top="632" left="489" width="314" height="17" font="17">calmodulin/triadin-mediated long QT syndrome/</text>
<text top="650" left="489" width="314" height="17" font="17">catecholaminergic polymorphic ventricular tachy-</text>
<text top="668" left="489" width="321" height="17" font="17">cardia mutations, which may require additional </text>
<text top="686" left="489" width="171" height="17" font="17">specialized genetic testing.</text>
<text top="687" left="660" width="143" height="10" font="19">S8.4-1,S8.4-2,S8.4-4,S8.4-16–S8.4-18</text>
<text top="686" left="803" width="4" height="17" font="17"> </text>
<text top="704" left="489" width="324" height="17" font="17">Single-driver auto crashes should prompt the </text>
<text top="722" left="489" width="320" height="17" font="17">consideration of arrhythmic causes. The yield of </text>
<text top="740" left="489" width="318" height="17" font="17">genetic testing is higher if a family history of SCD </text>
<text top="758" left="489" width="319" height="17" font="17">at a young age is present. Referral to specialized </text>
<text top="776" left="489" width="314" height="17" font="17">genetic testing centers is important if local exper-</text>
<text top="794" left="489" width="115" height="17" font="17">tise is unavailable.</text>
<text top="812" left="467" width="341" height="17" font="17">2.  VF in the absence of identifiable structural heart </text>
<text top="830" left="489" width="320" height="17" font="17">disease or known genetic arrhythmia syndromes </text>
<text top="848" left="489" width="314" height="17" font="17">such as catecholaminergic polymorphic ventricu-</text>
<text top="866" left="489" width="314" height="17" font="17">lar tachycardia, long QT syndrome, short QT syn-</text>
<text top="884" left="489" width="319" height="17" font="17">drome, Brugada syndrome, or J wave syndromes </text>
<text top="902" left="489" width="319" height="17" font="17">is usually the result of short coupled PVCs arising </text>
<text top="920" left="489" width="318" height="17" font="17">from the Purkinje system in either the right or left </text>
<text top="938" left="489" width="319" height="17" font="17">ventricles or, less commonly, from the ventricular </text>
<text top="956" left="489" width="83" height="17" font="17">myocardium.</text>
<text top="957" left="572" width="58" height="10" font="19">S8.4-9–S8.4-13</text>
<text top="956" left="630" width="181" height="17" font="17"> The recurrence risk after </text>
<text top="974" left="489" width="285" height="17" font="17">resuscitation of idiopathic VF is very high.</text>
<text top="975" left="774" width="29" height="10" font="19">S8.4-12</text>
<text top="974" left="803" width="4" height="17" font="17"> </text>
<text top="992" left="489" width="319" height="17" font="17">Among 38 consecutive patients from 6 different </text>
<text top="1010" left="489" width="314" height="17" font="17">centers who underwent ablation of primary idio-</text>
<text top="1028" left="489" width="321" height="17" font="17">pathic VF initiated by short coupled PVC, 87% </text>
<text top="1046" left="489" width="319" height="17" font="17">had experienced ≥2 VF episodes in the preceding </text>
<text top="1064" left="489" width="29" height="17" font="17">year.</text>
<text top="1065" left="518" width="29" height="10" font="19">S8.4-12</text>
<text top="1064" left="548" width="259" height="17" font="17"> Because idiopathic VF is associated with </text>
<text top="95" left="463" width="318" height="12" font="26"><b>Recommendations for Idiopathic Polymorphic VT/VF (Continued)</b></text>
<text top="116" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="116" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="116" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e337</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="314" height="17" font="17">a very high risk of recurrent VF, an ICD is indi-</text>
<text top="108" left="111" width="321" height="17" font="17">cated to prevent SCD. Catheter ablation of the </text>
<text top="128" left="111" width="319" height="17" font="17">triggering focus has proved to be highly effective </text>
<text top="148" left="111" width="321" height="17" font="17">in eliminating the repetitive PVCs which induce </text>
<text top="169" left="111" width="133" height="17" font="17">VF in these patients.</text>
<text top="169" left="244" width="29" height="10" font="19">S8.4-11</text>
<text top="169" left="273" width="152" height="17" font="17"> During a median post-</text>
<text top="189" left="111" width="320" height="17" font="17">procedural follow-up of 63 months, 7 (18%) of </text>
<text top="209" left="111" width="314" height="17" font="17">38 patients undergoing catheter ablation of idio-</text>
<text top="229" left="111" width="314" height="17" font="17">pathic VF induced by short coupled PVCs experi-</text>
<text top="250" left="111" width="319" height="17" font="17">enced VF recurrence at a median follow-up of 4 </text>
<text top="270" left="111" width="317" height="17" font="17">months. Five of these 7 patients underwent repeat </text>
<text top="290" left="111" width="321" height="17" font="17">ablation without VF recurrence. Thus, although </text>
<text top="310" left="111" width="318" height="17" font="17">catheter ablation is very effective in idiopathic VF, </text>
<text top="331" left="111" width="321" height="17" font="17">the recurrence risk remains substantial after an </text>
<text top="351" left="111" width="320" height="17" font="17">apparently successful procedure and the patient </text>
<text top="371" left="111" width="314" height="17" font="17">should be protected with an ICD. The subcuta-</text>
<text top="391" left="111" width="319" height="17" font="17">neous ICD may not be a good therapy for these </text>
<text top="412" left="111" width="314" height="17" font="17">patients due to the higher risk of T-wave over-</text>
<text top="432" left="111" width="318" height="17" font="17">sensing seenin this population; however, data are </text>
<text top="452" left="111" width="47" height="17" font="17">limited.</text>
<text top="453" left="158" width="29" height="10" font="19">S8.4-10</text>
<text top="472" left="89" width="346" height="17" font="17">3. Idiopathic VF may be initiated by PVCs that </text>
<text top="493" left="111" width="320" height="17" font="17">arise from the outflow tracts or the His-Purkinje </text>
<text top="513" left="111" width="322" height="17" font="17">system within either the right ventricle or left  </text>
<text top="533" left="111" width="57" height="17" font="17">ventricle.</text>
<text top="534" left="168" width="126" height="10" font="19">S8.4-11,S8.4-14,S8.4-19–S8.4-21</text>
<text top="533" left="294" width="136" height="17" font="17"> Some patients have </text>
<text top="553" left="111" width="314" height="17" font="17">clusters of VF episodes (electrical storm) that typi-</text>
<text top="574" left="111" width="318" height="17" font="17">cally present as PVCs initiating polymorphic VT/VF. </text>
<text top="594" left="111" width="314" height="17" font="17">The PVCs usually have a consistent QRS morphol-</text>
<text top="614" left="111" width="314" height="17" font="17">ogy and a short coupling interval and can be tar-</text>
<text top="634" left="111" width="285" height="17" font="17">geted for ablation to control the arrhythmia.</text>
<text top="635" left="396" width="29" height="10" font="19">S8.4-11</text>
<text top="634" left="425" width="4" height="17" font="17"> </text>
<text top="655" left="111" width="320" height="17" font="17">For PVCs from the Purkinje system, the ablation </text>
<text top="675" left="111" width="314" height="17" font="17">target is a high-frequency Purkinje potential pre-</text>
<text top="695" left="111" width="320" height="17" font="17">ceding the PVCs. When episodes are induced by </text>
<text top="715" left="111" width="317" height="17" font="17">short-coupled PVCs arising from the outflow tracts, </text>
<text top="736" left="111" width="318" height="17" font="17">the ablation target is the site of earliest ventricular </text>
<text top="756" left="111" width="319" height="17" font="17">activation. Patients with idiopathic VF often have </text>
<text top="776" left="111" width="314" height="17" font="17">periods of frequent VT/VF interspersed with peri-</text>
<text top="796" left="111" width="170" height="17" font="17">ods of relative quiescence.</text>
<text top="797" left="281" width="60" height="10" font="19">S8.4-11,S8.4-14</text>
<text top="796" left="341" width="90" height="17" font="17"> To maximize </text>
<text top="817" left="111" width="314" height="17" font="17">the probability of successful ablation, the proce-</text>
<text top="837" left="111" width="318" height="17" font="17">dure is best performed during periods of frequent </text>
<text top="857" left="111" width="314" height="17" font="17">PVCs. Less-frequent episodes of VF may be ame-</text>
<text top="877" left="111" width="314" height="17" font="17">nable to ablation if frequent PVCs with a consis-</text>
<text top="898" left="111" width="318" height="17" font="17">tent QRS morphology are present. When the PVCs </text>
<text top="918" left="111" width="318" height="17" font="17">can be identified, ablation is highly successful, but </text>
<text top="938" left="111" width="323" height="17" font="17">late recurrences are observed in approximately </text>
<text top="958" left="111" width="318" height="17" font="17">10% of patients such that implantation of an ICD </text>
<text top="979" left="111" width="321" height="17" font="17">is prudent even if ablation is acutely successful. </text>
<text top="999" left="111" width="319" height="17" font="17">The risks of catheter ablation include bleeding at </text>
<text top="1019" left="111" width="318" height="17" font="17">the site of arterial or venous access and a small risk </text>
<text top="1039" left="111" width="319" height="17" font="17">of pericardial tamponade. Therapy with quinidine </text>
<text top="1060" left="111" width="319" height="17" font="17">acutely and chronically can suppress recurrent VF </text>
<text top="1080" left="111" width="166" height="17" font="17">episodes in some patients.</text>
<text top="1081" left="277" width="29" height="10" font="19">S8.4-22</text>
<text top="86" left="452" width="333" height="23" font="15"><b>9. PVC-INDUCED CARDIOMYOPATHY</b></text>
<text top="122" left="463" width="258" height="12" font="26"><b>Recommendations for PVC-Induced Cardiomyopathy</b></text>
<text top="139" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="153" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 50</b></a></text>
<text top="153" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="173" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="173" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="173" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="241" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="241" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="194" left="583" width="175" height="12" font="4">1.  For patients who require arrhythmia </text>
<text top="208" left="595" width="175" height="12" font="4">suppression for symptoms or declining </text>
<text top="221" left="595" width="195" height="12" font="4">ventricular function suspected to be due to </text>
<text top="235" left="595" width="183" height="12" font="4">frequent PVCs (generally &gt;15% of beats </text>
<text top="248" left="595" width="188" height="12" font="4">and predominately of 1 morphology) and </text>
<text top="262" left="595" width="188" height="12" font="4">for whom antiarrhythmic medications are </text>
<text top="275" left="595" width="204" height="12" font="4">ineffective, not tolerated, or not the patient’s </text>
<text top="289" left="595" width="171" height="12" font="4">preference, catheter ablation is useful.</text>
<text top="289" left="766" width="26" height="7" font="23">S9-1,S9-2</text>
<text top="337" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="337" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="310" left="583" width="145" height="12" font="4">2.  In patients with PVC-induced </text>
<text top="323" left="595" width="200" height="12" font="4">cardiomyopathy, pharmacological treatment </text>
<text top="337" left="595" width="200" height="12" font="4">(eg, beta blocker, amiodarone) is reasonable </text>
<text top="350" left="595" width="203" height="12" font="4">to reduce recurrent arrhythmias and improve </text>
<text top="364" left="595" width="122" height="12" font="4">symptoms and LV function.</text>
<text top="364" left="716" width="26" height="7" font="23">S9-3,S9-4</text>
<text top="404" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="425" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="453" left="467" width="336" height="17" font="17">1.  Frequent PVCs (usually &gt;15% of the total num-</text>
<text top="471" left="489" width="321" height="17" font="17">ber of beats) may produce a reversible form of </text>
<text top="490" left="489" width="99" height="17" font="17">LV dysfunction.</text>
<text top="491" left="588" width="43" height="10" font="19">S9-5–S9-18</text>
<text top="490" left="632" width="178" height="17" font="17"> However, it is sometimes </text>
<text top="508" left="489" width="319" height="17" font="17">difficult to ascertain whether the PVCs caused LV </text>
<text top="527" left="489" width="314" height="17" font="17">dysfunction or whether progressive LV dysfunc-</text>
<text top="545" left="489" width="321" height="17" font="17">tion caused frequent PVCs. LV dysfunction has </text>
<text top="564" left="489" width="319" height="17" font="17">been associated with greater PVC burden (&gt;10% </text>
<text top="582" left="489" width="321" height="17" font="17">and usually &gt;20%), NSVT, a retrograde  P-wave </text>
<text top="600" left="489" width="273" height="17" font="17">after the PVCs, and interpolated PVCs.</text>
<text top="601" left="762" width="41" height="10" font="19">S9-6,S9-15</text>
<text top="600" left="803" width="4" height="17" font="17"> </text>
<text top="619" left="489" width="322" height="17" font="17">In a prospective study of catheter ablation for </text>
<text top="637" left="489" width="314" height="17" font="17">PVC-induced cardiomyopathy, ablation was com-</text>
<text top="656" left="489" width="237" height="17" font="17">pletely successful in 80% of patients.</text>
<text top="657" left="726" width="22" height="10" font="19">S9-19</text>
<text top="656" left="747" width="56" height="17" font="17"> LV func-</text>
<text top="674" left="489" width="320" height="17" font="17">tion normalized within 6 months in 82% of the </text>
<text top="693" left="489" width="314" height="17" font="17">22 patients who had depressed ventricular dys-</text>
<text top="711" left="489" width="322" height="17" font="17">function at baseline. Thus, frequent PVCs may </text>
<text top="730" left="489" width="320" height="17" font="17">be a reversible cause of LV dysfunction that can </text>
<text top="748" left="489" width="319" height="17" font="17">be effectively treated with catheter ablation. It is </text>
<text top="766" left="489" width="314" height="17" font="17">often difficult to determine if apparent LV dys-</text>
<text top="785" left="489" width="319" height="17" font="17">function reflects impaired LV function or inability </text>
<text top="803" left="489" width="314" height="17" font="17">to accurately assess LV function due to the fre-</text>
<text top="822" left="489" width="318" height="17" font="17">quent ectopic activity. In patients who have a high </text>
<text top="840" left="489" width="319" height="17" font="17">density of PVCs with normal ventricular function, </text>
<text top="859" left="489" width="318" height="17" font="17">optimal treatment and surveillance for prevention </text>
<text top="877" left="489" width="321" height="17" font="17">and detection of decline in ventricular function </text>
<text top="895" left="489" width="171" height="17" font="17">have not been established.</text>
<text top="914" left="467" width="344" height="17" font="17">2. In a double-blind parallel study of 30 patients </text>
<text top="932" left="489" width="319" height="17" font="17">with or without ischemic heart disease with &gt;30 </text>
<text top="951" left="489" width="319" height="17" font="17">PVCs per hour comparing sotalol to propranolol, </text>
<text top="969" left="489" width="321" height="17" font="17">proarrhythmic effects were present in 1 patient </text>
<text top="988" left="489" width="322" height="17" font="17">on sotalol. There was no significant difference </text>
<text top="1006" left="489" width="314" height="17" font="17">in suppression of PVCs (sotalol 65%, proprano-</text>
<text top="1025" left="489" width="321" height="17" font="17">lol 44%), with reduction in ventricular couplets </text>
<text top="1043" left="489" width="319" height="17" font="17">being 99% for sotalol and 49% for propranolol. </text>
<text top="1061" left="489" width="318" height="17" font="17">There was a significant increase in QTc in patients </text>
<text top="1080" left="489" width="72" height="17" font="17">on sotalol.</text>
<text top="1081" left="561" width="22" height="10" font="19">S9-20</text>
<text top="1080" left="583" width="230" height="17" font="17"> In a double-blind, randomized, </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e338</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="319" height="17" font="17">placebo-controlled study of 674 patients with HF </text>
<text top="106" left="111" width="320" height="17" font="17">and LVEF  &lt;0.40 attributed to ischemic or NICM </text>
<text top="124" left="111" width="319" height="17" font="17">and ≥10 PVCs per hour, amiodarone significantly </text>
<text top="142" left="111" width="314" height="17" font="17">reduced VA, slowed heart rate, and was associ-</text>
<text top="160" left="111" width="319" height="17" font="17">ated with an increase in LVEF by 42% at 2 years </text>
<text top="178" left="111" width="320" height="17" font="17">with a nonsignificant trend toward reduction in </text>
<text top="196" left="111" width="59" height="17" font="17">mortality.</text>
<text top="197" left="170" width="17" height="10" font="19">S9-4</text>
<text top="196" left="187" width="246" height="17" font="17"> Whether the VA was contributing </text>
<text top="214" left="111" width="323" height="17" font="17">to ventricular dysfunction in these patients is </text>
<text top="232" left="111" width="65" height="17" font="17">unknown.</text>
<text top="280" left="74" width="354" height="23" font="15"><b>10. VA AND SCD RELATED TO SPECIFIC </b></text>
<text top="302" left="74" width="130" height="23" font="15"><b>POPULATIONS</b></text>
<text top="331" left="74" width="116" height="21" font="18"><b>10.1. Athletes</b></text>
<text top="358" left="74" width="351" height="17" font="17">In athletes, VAs range from isolated PVCs, cou-</text>
<text top="376" left="74" width="356" height="17" font="17">plets, and NSVT, to sustained VT and SCA leading to </text>
<text top="394" left="74" width="32" height="17" font="17">SCD.</text>
<text top="395" left="107" width="30" height="10" font="19">S10.1-1</text>
<text top="394" left="136" width="293" height="17" font="17"> Infrequent PVCs and short runs of repetitive </text>
<text top="412" left="74" width="351" height="17" font="17">NSVT, especially in the absence of structural heart dis-</text>
<text top="430" left="74" width="356" height="17" font="17">ease, are more common in nonathletes, but they are </text>
<text top="448" left="74" width="355" height="17" font="17">generally benign, requiring only a limited workup and </text>
<text top="466" left="74" width="270" height="17" font="17">rarely lead to disqualification for sports.</text>
<text top="467" left="345" width="62" height="10" font="19">S10.1-2,S10.1-3</text>
<text top="466" left="407" width="25" height="17" font="17"> In </text>
<text top="484" left="74" width="351" height="17" font="17">contrast, longer runs of NSVT, especially when exer-</text>
<text top="502" left="74" width="351" height="17" font="17">cise-induced, and sustained VT and SCA/SCD are in-</text>
<text top="520" left="74" width="355" height="17" font="17">frequent, but they have a higher incidence in athletes </text>
<text top="539" left="74" width="357" height="17" font="17">than that reported for the general population in the </text>
<text top="557" left="74" width="355" height="17" font="17">corresponding age groups. Reported estimates of SCD </text>
<text top="575" left="74" width="355" height="17" font="17">range from 1 per 53 703 athlete-years in the National </text>
<text top="593" left="74" width="273" height="17" font="17">Collegiate Athletic Association database</text>
<text top="593" left="348" width="30" height="10" font="19">S10.1-4</text>
<text top="593" left="378" width="56" height="17" font="17"> to  &lt;1 </text>
<text top="611" left="74" width="321" height="17" font="17">per 200 000 in Minnesota high school students.</text>
<text top="611" left="396" width="30" height="10" font="19">S10.1-5</text>
<text top="611" left="425" width="4" height="17" font="17"> </text>
<text top="629" left="74" width="351" height="17" font="17">Among those studies judged to have better epidemio-</text>
<text top="647" left="74" width="355" height="17" font="17">logical protocols, estimates were in the range of 1 per </text>
<text top="665" left="74" width="163" height="17" font="17">40 000 to 1 per 80 000.</text>
<text top="666" left="238" width="30" height="10" font="19">S10.1-6</text>
<text top="665" left="267" width="164" height="17" font="17"> These figures compare </text>
<text top="683" left="74" width="357" height="17" font="17">with a general population risk of 1.0 to 1.9/100 000 </text>
<text top="701" left="74" width="218" height="17" font="17">in adolescents and young adults.</text>
<text top="702" left="292" width="62" height="10" font="19">S10.1-7,S10.1-8</text>
<text top="701" left="355" width="76" height="17" font="17"> Moreover, </text>
<text top="719" left="74" width="356" height="17" font="17">there appears to be both sport and sex differences in </text>
<text top="737" left="74" width="355" height="17" font="17">the magnitude of risk, with males being at higher risk </text>
<text top="755" left="74" width="183" height="17" font="17">than females in most sports,</text>
<text top="756" left="257" width="62" height="10" font="19">S10.1-7,S10.1-9</text>
<text top="755" left="319" width="110" height="17" font="17"> blacks at higher </text>
<text top="773" left="74" width="358" height="17" font="17">risk than whites,  and male basketball players being </text>
<text top="791" left="74" width="357" height="17" font="17">the single highest risk group in the United States, 1 </text>
<text top="809" left="74" width="152" height="17" font="17">per 5200 athlete-years.</text>
<text top="810" left="226" width="30" height="10" font="19">S10.1-4</text>
<text top="827" left="92" width="333" height="17" font="17">A study that included both competitive and rec-</text>
<text top="845" left="74" width="360" height="17" font="17">reational athletes showed that both groups are at </text>
<text top="863" left="74" width="359" height="17" font="17">a higher  risk for SCD than the general population, </text>
<text top="881" left="74" width="359" height="17" font="17">with recreational athletes having greater cumulative </text>
<text top="899" left="74" width="60" height="17" font="17">numbers,</text>
<text top="900" left="134" width="29" height="10" font="19">S10.1-7</text>
<text top="899" left="163" width="269" height="17" font="17"> SCD occurring at an older age, and a </text>
<text top="917" left="74" width="356" height="17" font="17">different distribution of diseases. Postmortem data on </text>
<text top="935" left="74" width="351" height="17" font="17">SCD in athletes reveal that 25% to 40% are autopsy-</text>
<text top="954" left="74" width="351" height="17" font="17">negative, suggesting a role for genetic molecular dis-</text>
<text top="972" left="74" width="150" height="17" font="17">orders in these victims </text>
<text top="972" left="226" width="102" height="10" font="19">S10.1-4,S10.1-10,S10.1-11</text>
<text top="972" left="328" width="103" height="17" font="17"> and for family </text>
<text top="990" left="74" width="63" height="17" font="17">members.</text>
<text top="990" left="138" width="34" height="10" font="19">S10.1-12</text>
<text top="1008" left="92" width="333" height="17" font="17">Another limitation of SCD data analysis in ath-</text>
<text top="1026" left="74" width="359" height="17" font="17">letes centers on noncardiac causes, some of which </text>
<text top="1044" left="74" width="364" height="17" font="17">mimic cardiac events. Noncardiac causes include </text>
<text top="1062" left="74" width="357" height="17" font="17">acute neurological disorders, drug abuse, heat stroke, </text>
<text top="1080" left="74" width="362" height="17" font="17">rhabdomyolysis, sickle cell disorders, suicides, and </text>
<text top="1080" left="425" width="4" height="17" font="17"> </text>
<text top="88" left="452" width="63" height="17" font="17">accidents.</text>
<text top="88" left="516" width="70" height="10" font="19">S10.1-13,S10.1-14</text>
<text top="88" left="586" width="217" height="17" font="17"> Nonetheless, arrhythmias in ath-</text>
<text top="106" left="452" width="355" height="17" font="17">letes remain the most common medical cause of death </text>
<text top="124" left="452" width="266" height="17" font="17">and many occur as the first cardiac event.</text>
<text top="143" left="470" width="341" height="17" font="17">The most common structural cause of SCAs and </text>
<text top="161" left="452" width="351" height="17" font="17">SCDs in athletes in the United States is HCM, fol-</text>
<text top="180" left="452" width="362" height="17" font="17">lowed by anomalous  origins of coronary arteries, </text>
<text top="198" left="452" width="356" height="17" font="17">with myocarditis contributing a smaller but significant </text>
<text top="216" left="452" width="72" height="17" font="17">proportion.</text>
<text top="217" left="525" width="34" height="10" font="19">S10.1-15</text>
<text top="216" left="559" width="254" height="17" font="17"> Beyond these, the other inherited </text>
<text top="235" left="452" width="357" height="17" font="17">disorders contribute to the distribution of causes of a </text>
<text top="253" left="452" width="357" height="17" font="17">SCD in athletes, many of which can be suspected or </text>
<text top="272" left="452" width="351" height="17" font="17">identified by a careful family history and preparticipa-</text>
<text top="290" left="452" width="68" height="17" font="17">tion ECGs.</text>
<text top="308" left="470" width="339" height="17" font="17">In general, management of arrhythmias in athletes </text>
<text top="327" left="452" width="354" height="17" font="17">follows that in nonathletes. In regard to interventions, it </text>
<text top="345" left="452" width="356" height="17" font="17">is now generally recommended that AEDs be available </text>
<text top="363" left="452" width="317" height="17" font="17">at training and facilities for competitive athletes,</text>
<text top="364" left="769" width="34" height="10" font="19">S10.1-16</text>
<text top="363" left="803" width="4" height="17" font="17"> </text>
<text top="382" left="452" width="351" height="17" font="17">with less specific statements for AED availability at ven-</text>
<text top="400" left="452" width="355" height="17" font="17">ues (eg, tennis courts) or circumstances (eg, jogging or </text>
<text top="419" left="452" width="351" height="17" font="17">small group runs) in which recreational athletics are oc-</text>
<text top="437" left="452" width="49" height="17" font="17">curring.</text>
<text top="455" left="470" width="338" height="17" font="17">Many athletes who have had corrective procedures </text>
<text top="474" left="452" width="356" height="17" font="17">(repair of congenital or developmental defects such as </text>
<text top="492" left="452" width="255" height="17" font="17">anomalous origins of coronary arteries)</text>
<text top="493" left="707" width="70" height="10" font="19">S10.1-17,S10.1-18</text>
<text top="492" left="778" width="31" height="17" font="17"> are </text>
<text top="511" left="452" width="213" height="17" font="17">on therapy for inherited disorders</text>
<text top="511" left="666" width="34" height="10" font="19">S10.1-19</text>
<text top="511" left="700" width="104" height="17" font="17"> or have ICD im-</text>
<text top="529" left="452" width="38" height="17" font="17">plants</text>
<text top="530" left="491" width="29" height="10" font="19">S10.1-1</text>
<text top="529" left="520" width="284" height="17" font="17"> and are able to participate in athletics de-</text>
<text top="547" left="452" width="356" height="17" font="17">pending on the nature and severity of the disease and </text>
<text top="566" left="452" width="355" height="17" font="17">with appropriate precautions and counseling regarding </text>
<text top="584" left="452" width="153" height="17" font="17">potential residual risks.</text>
<text top="585" left="605" width="70" height="10" font="19">S10.1-19,S10.1-20</text>
<text top="584" left="676" width="127" height="17" font="17"> For example, ath-</text>
<text top="603" left="452" width="358" height="17" font="17">letes with acquired disorders such as myocarditis are </text>
<text top="621" left="452" width="355" height="17" font="17">advised against exercise for at least 3 to 6 months after </text>
<text top="639" left="452" width="117" height="17" font="17">disease resolution.</text>
<text top="683" left="452" width="133" height="21" font="18"><b>10.2. Pregnancy</b></text>
<text top="717" left="463" width="163" height="12" font="26"><b>Recommendations for Pregnancy</b></text>
<text top="734" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="748" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 51</b></a></text>
<text top="748" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="768" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="768" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="768" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="816" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="816" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="790" left="583" width="181" height="12" font="4">1.  In mothers with long QT syndrome, a </text>
<text top="803" left="595" width="185" height="12" font="4">beta blocker should be continued during </text>
<text top="817" left="595" width="196" height="12" font="4">pregnancy and throughout the postpartum </text>
<text top="830" left="595" width="163" height="12" font="4">period including in women who are </text>
<text top="844" left="595" width="64" height="12" font="4">breastfeeding.</text>
<text top="844" left="659" width="20" height="7" font="23">S10.2-1</text>
<text top="885" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="885" left="530" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="864" left="583" width="209" height="12" font="4">2.  In the pregnant patient with sustained VA, </text>
<text top="878" left="595" width="199" height="12" font="4">electrical cardioversion is safe and effective </text>
<text top="891" left="595" width="203" height="12" font="4">and should be used with standard electrode </text>
<text top="905" left="595" width="64" height="12" font="4">configuration.</text>
<text top="905" left="659" width="43" height="7" font="23">S10.2-2,S10.2-3</text>
<text top="946" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="946" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="926" left="583" width="204" height="12" font="4">3.  In pregnant patients needing an ICD or VT </text>
<text top="939" left="595" width="191" height="12" font="4">ablation, it is reasonable to undergo these </text>
<text top="953" left="595" width="183" height="12" font="4">procedures during pregnancy, preferably </text>
<text top="966" left="595" width="103" height="12" font="4">after the first trimester.</text>
<text top="967" left="697" width="43" height="7" font="23">S10.2-4,S10.2-5</text>
<text top="1012" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="1034" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="1061" left="467" width="336" height="17" font="17">1.  Women with long QT syndrome should be coun-</text>
<text top="1080" left="489" width="323" height="17" font="17">seled about maternal and fetal risks prior to </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="31" size="4" family="Times" color="#ffffff"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e339</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="314" height="17" font="17">pregnancy to ensure ongoing beta-blocker ther-</text>
<text top="106" left="111" width="318" height="17" font="17">apy. The risk of SCA or SCD is significantly higher </text>
<text top="124" left="111" width="319" height="17" font="17">during the 9 months after delivery, most notably </text>
<text top="143" left="111" width="172" height="17" font="17">among women with LQT2.</text>
<text top="143" left="283" width="92" height="10" font="19">S10.2-1,S10.2-6,S10.2-7</text>
<text top="143" left="375" width="54" height="17" font="17"> A large </text>
<text top="161" left="111" width="318" height="17" font="17">retrospective analysis from the long QT syndrome </text>
<text top="179" left="111" width="324" height="17" font="17">registry demonstrated an odds ratio of 40.8 </text>
<text top="198" left="111" width="321" height="17" font="17">for syncope, SCA, or SCD among women with </text>
<text top="216" left="111" width="319" height="17" font="17">long QT syndrome in the 9 months’ postpartum; </text>
<text top="235" left="111" width="321" height="17" font="17">treatment with beta blockers during pregnancy </text>
<text top="253" left="111" width="324" height="17" font="17">was independently associated with decreased </text>
<text top="271" left="111" width="26" height="17" font="17">risk.</text>
<text top="272" left="137" width="29" height="10" font="19">S10.2-7</text>
<text top="271" left="166" width="259" height="17" font="17"> Overall arrhythmic events during preg-</text>
<text top="290" left="111" width="319" height="17" font="17">nancy are not increased among women receiving </text>
<text top="308" left="111" width="141" height="17" font="17">beta-blocker therapy.</text>
<text top="309" left="252" width="92" height="10" font="19">S10.2-1,S10.2-6,S10.2-7</text>
<text top="308" left="344" width="81" height="17" font="17"> In  a case-</text>
<text top="326" left="111" width="322" height="17" font="17">control study, women with LQT1 who did not </text>
<text top="345" left="111" width="314" height="17" font="17">receive beta blockers during pregnancy, particu-</text>
<text top="363" left="111" width="317" height="17" font="17">larly those with prior syncope, were at significantly </text>
<text top="382" left="111" width="216" height="17" font="17">increased risk of SCA or syncope.</text>
<text top="382" left="327" width="29" height="10" font="19">S10.2-8</text>
<text top="382" left="356" width="74" height="17" font="17"> Frequency </text>
<text top="400" left="111" width="321" height="17" font="17">of events returned to prepregnancy levels after </text>
<text top="418" left="111" width="69" height="17" font="17">9 months.</text>
<text top="419" left="180" width="29" height="10" font="19">S10.2-1</text>
<text top="418" left="209" width="224" height="17" font="17"> Maternal use of beta blockers </text>
<text top="437" left="111" width="322" height="17" font="17">during pregnancy is associated with decreased </text>
<text top="455" left="111" width="285" height="17" font="17">newborn birth weight and hypoglycemia,</text>
<text top="456" left="396" width="29" height="10" font="19">S10.2-9</text>
<text top="455" left="425" width="4" height="17" font="17"> </text>
<text top="473" left="111" width="322" height="17" font="17">but it is not associated with increased risk of </text>
<text top="492" left="111" width="77" height="17" font="17">miscarriage.</text>
<text top="493" left="188" width="66" height="10" font="19">S10.2-8,S10.2-10</text>
<text top="492" left="253" width="172" height="17" font="17"> Fetal bradycardia is asso-</text>
<text top="510" left="111" width="321" height="17" font="17">ciated with fetal long QT syndrome and should </text>
<text top="529" left="111" width="324" height="17" font="17">not independently provoke discontinuation of </text>
<text top="547" left="111" width="140" height="17" font="17">beta-blocker therapy</text>
<text top="548" left="251" width="75" height="10" font="19">S10.2-11–S10.2-14</text>
<text top="547" left="326" width="107" height="17" font="17">; these infants </text>
<text top="565" left="111" width="314" height="17" font="17">are at increased risk of death and require care-</text>
<text top="584" left="111" width="258" height="17" font="17">ful neonatal monitoring and treatment.</text>
<text top="584" left="369" width="34" height="10" font="19">S10.2-13</text>
<text top="584" left="403" width="28" height="17" font="17"> As </text>
<text top="602" left="111" width="320" height="17" font="17">50% of offspring may be affected with long QT </text>
<text top="620" left="111" width="320" height="17" font="17">syndrome, with highest risk of adverse events in </text>
<text top="639" left="111" width="318" height="17" font="17">infancy and childhood, screening of the newborn </text>
<text top="657" left="111" width="318" height="17" font="17">at birth and during infancy for long QT syndrome </text>
<text top="676" left="111" width="81" height="17" font="17">is important.</text>
<text top="676" left="192" width="29" height="10" font="19">S10.2-8</text>
<text top="694" left="89" width="341" height="17" font="17">2.  Available data on electrical fields associated with </text>
<text top="712" left="111" width="321" height="17" font="17">properly applied AED patches suggest that the </text>
<text top="731" left="111" width="320" height="17" font="17">fetus is safe; no observational data are available </text>
<text top="749" left="111" width="323" height="17" font="17">to the contrary. Anterolateral defibrillator pad </text>
<text top="767" left="111" width="314" height="17" font="17">placement is preferred with the lateral pad/pad-</text>
<text top="786" left="111" width="321" height="17" font="17">dle placed under the breast tissue, which is an </text>
<text top="804" left="111" width="310" height="17" font="17">important consideration in the pregnant patient.</text>
<text top="823" left="89" width="349" height="17" font="17">3. The ICD in pregnant women is safe and </text>
<text top="841" left="111" width="58" height="17" font="17">effective.</text>
<text top="842" left="169" width="29" height="10" font="19">S10.2-4</text>
<text top="841" left="198" width="227" height="17" font="17"> For the rare circumstance of preg-</text>
<text top="859" left="111" width="318" height="17" font="17">nant women with an immediate indication for an </text>
<text top="878" left="111" width="320" height="17" font="17">ICD, or less common indications for VT ablation </text>
<text top="896" left="111" width="318" height="17" font="17">during pregnancy, the radiation risk to the fetus is </text>
<text top="914" left="111" width="55" height="17" font="17">minimal.</text>
<text top="915" left="166" width="66" height="10" font="19">S10.2-5,S10.2-15</text>
<text top="914" left="232" width="194" height="17" font="17"> The procedure is usually per-</text>
<text top="933" left="111" width="321" height="17" font="17">formed after the first trimester unless there are </text>
<text top="951" left="111" width="319" height="17" font="17">circumstances that demand an earlier procedure. </text>
<text top="970" left="111" width="325" height="17" font="17">Wearable cardioverter-defibrillators have been </text>
<text top="988" left="111" width="314" height="17" font="17">used in peripartum cardiomyopathy while await-</text>
<text top="1006" left="111" width="320" height="17" font="17">ing repeat assessment of recovery of ventricular </text>
<text top="1025" left="111" width="58" height="17" font="17">function.</text>
<text top="1025" left="169" width="34" height="10" font="19">S10.2-16</text>
<text top="1025" left="203" width="235" height="17" font="17"> The subcutaneous implantable </text>
<text top="1043" left="111" width="319" height="17" font="17">cardioverter-defibrillator is a potential alternative </text>
<text top="1061" left="111" width="314" height="17" font="17">to conventional ICDs, although data are unavail-</text>
<text top="1080" left="111" width="226" height="17" font="17">able to support a recommendation.</text>
<text top="87" left="452" width="334" height="21" font="18"><b>10.3. Older Patients With Comorbidities</b></text>
<text top="121" left="463" width="275" height="12" font="26"><b>Recommendation for Older Patients With Comorbidities</b></text>
<text top="138" left="463" width="152" height="12" font="26"><b>See Systematic Review Report.</b></text>
<text top="138" left="615" width="21" height="7" font="31"><b>S10.3-1</b></text>
<text top="158" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="158" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="158" left="583" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="206" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="206" left="527" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="207" left="551" width="7" height="7" font="25"><b>SR</b></text>
<text top="179" left="583" width="211" height="12" font="4">1.  For older patients and those with significant </text>
<text top="193" left="595" width="189" height="12" font="4">comorbidities, who meet indications for a </text>
<text top="206" left="595" width="203" height="12" font="4">primary prevention ICD, an ICD is reasonable </text>
<text top="220" left="595" width="199" height="12" font="4">if meaningful survival of greater than 1 year </text>
<text top="233" left="595" width="53" height="12" font="4">is expected.</text>
<text top="234" left="647" width="20" height="7" font="23">S10.3-1</text>
<text top="257" left="464" width="136" height="12" font="4">SR indicates systematic review.</text>
<text top="290" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="318" left="452" width="351" height="17" font="17">Refer to the “Systematic Review for the 2017 ACC/</text>
<text top="336" left="452" width="356" height="17" font="17">AHA/HRS Guideline for Management of Patients With </text>
<text top="354" left="452" width="356" height="17" font="17">Ventricular Arrhythmias and the Prevention of Sudden </text>
<text top="372" left="452" width="357" height="17" font="17">Cardiac Death” for the complete systematic evidence </text>
<text top="391" left="452" width="267" height="17" font="17">review for additional data and analyses.</text>
<text top="391" left="720" width="29" height="10" font="19">S10.3-1</text>
<text top="391" left="749" width="55" height="17" font="17"> The re-</text>
<text top="409" left="452" width="351" height="17" font="17">sults from the question “What is the impact of ICD im-</text>
<text top="427" left="452" width="356" height="17" font="17">plantation for primary prevention in older patients and </text>
<text top="445" left="452" width="358" height="17" font="17">patients with significant comorbidities? (Part 2)” and </text>
<text top="464" left="452" width="351" height="17" font="17">the writing committee’s review of the totality of the lit-</text>
<text top="482" left="452" width="351" height="17" font="17">erature were used to frame our decision-making. Rec-</text>
<text top="500" left="452" width="357" height="17" font="17">ommendations are based on a body of evidence that </text>
<text top="518" left="452" width="357" height="17" font="17">includes the systematic review conducted by the ERC </text>
<text top="537" left="452" width="333" height="17" font="17">and are denoted by the superscript SR (eg, LOE: B-R</text>
<text top="537" left="786" width="9" height="10" font="19">SR</text>
<text top="537" left="795" width="13" height="17" font="17">). </text>
<text top="555" left="452" width="357" height="17" font="17">Comorbidities included various combinations of renal </text>
<text top="573" left="452" width="358" height="17" font="17">disease, chronic obstructive pulmonary disease, atrial </text>
<text top="591" left="452" width="286" height="17" font="17">fibrillation, and heart disease, among others.</text>
<text top="632" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="653" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="681" left="467" width="234" height="17" font="17">1. Older age is defined as ≥75 years.</text>
<text top="699" left="470" width="333" height="17" font="17">The ERC’s analyses are helpful in clearly demonstrat-</text>
<text top="717" left="452" width="356" height="17" font="17">ing that neither age nor comorbidities alone should be </text>
<text top="735" left="452" width="357" height="17" font="17">exclusions for an ICD. However, the data included in </text>
<text top="754" left="452" width="351" height="17" font="17">the analysis are limited. Firstly, most data are from non-</text>
<text top="772" left="452" width="351" height="17" font="17">randomized studies and “both selection and uniden-</text>
<text top="790" left="452" width="357" height="17" font="17">tified confounding biases can never be fully adjusted </text>
<text top="808" left="452" width="356" height="17" font="17">for.” It is likely that the more frail patients are already </text>
<text top="826" left="452" width="351" height="17" font="17">appropriately not offered ICDs and are thus not includ-</text>
<text top="845" left="452" width="351" height="17" font="17">ed. Secondly, because most of the studies are nonran-</text>
<text top="863" left="452" width="355" height="17" font="17">domized, these findings signify only an association and </text>
<text top="881" left="452" width="83" height="17" font="17">not causality.</text>
<text top="899" left="470" width="338" height="17" font="17">Also, older adults are prone to higher complication </text>
<text top="918" left="452" width="357" height="17" font="17">rates, shorter life expectancies (and thus, fewer years </text>
<text top="936" left="452" width="357" height="17" font="17">during which they could derive benefit from an ICD), </text>
<text top="954" left="452" width="162" height="17" font="17">and varying preferences.</text>
<text top="955" left="614" width="29" height="10" font="19">S10.3-2</text>
<text top="954" left="644" width="167" height="17" font="17"> For these reasons, it is </text>
<text top="972" left="452" width="351" height="17" font="17">important to take a particularly nuanced and patient-</text>
<text top="991" left="452" width="288" height="17" font="17">centered approach to treating these patients.</text>
<text top="1034" left="452" width="242" height="21" font="18"><b>10.4. Chronic Kidney Disease</b></text>
<text top="1062" left="452" width="351" height="17" font="17">Patients with chronic kidney disease (CKD) are at an in-</text>
<text top="1080" left="452" width="351" height="17" font="17">creased risk of SCD compared with the general popula-</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e340</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="357" height="17" font="17">tion, yet the risk versus benefit of primary prevention </text>
<text top="106" left="74" width="351" height="17" font="17">ICDs has been unclear; data from observational stud-</text>
<text top="124" left="74" width="357" height="17" font="17">ies have been conflicting, and patients with moderate </text>
<text top="143" left="74" width="356" height="17" font="17">or severe CKD, especially patients with end-stage renal </text>
<text top="161" left="74" width="351" height="17" font="17">disease (ESRD) on dialysis were not included in the piv-</text>
<text top="180" left="74" width="111" height="17" font="17">otal RCTs of ICDs.</text>
<text top="180" left="185" width="62" height="10" font="19">S10.4-1–S10.4-5</text>
<text top="180" left="247" width="182" height="17" font="17"> Furthermore, prior data had </text>
<text top="198" left="74" width="357" height="17" font="17">significant limitations given that patients who received </text>
<text top="217" left="74" width="356" height="17" font="17">ICDs have been compared inconsistently with a control </text>
<text top="235" left="74" width="355" height="17" font="17">group with CKD that did not receive primary prevention </text>
<text top="253" left="74" width="351" height="17" font="17">ICDs and the degree of renal insufficiency likely influ-</text>
<text top="272" left="74" width="138" height="17" font="17">ences survival benefit.</text>
<text top="272" left="212" width="29" height="10" font="19">S10.4-6</text>
<text top="272" left="241" width="188" height="17" font="17"> Patients with CKD, especially </text>
<text top="290" left="74" width="351" height="17" font="17">ESRD on dialysis, appear to be at increased risk of ICD-</text>
<text top="309" left="74" width="357" height="17" font="17">related complications. A significant number of sudden </text>
<text top="327" left="74" width="322" height="17" font="17">deaths are unassociated with VA in this population.</text>
<text top="328" left="396" width="29" height="10" font="19">S10.4-7</text>
<text top="327" left="425" width="4" height="17" font="17"> </text>
<text top="345" left="74" width="356" height="17" font="17">Therefore, the ERC was asked to address the impact of </text>
<text top="364" left="74" width="249" height="17" font="17">ICDs on mortality in patients with CKD.</text>
<text top="382" left="92" width="339" height="17" font="17">The ERC conducted a specific analysis of 5 studies </text>
<text top="401" left="74" width="360" height="17" font="17">that explored renal dysfunction. A meta-analysis of </text>
<text top="419" left="74" width="351" height="17" font="17">these studies suggested that an association exists be-</text>
<text top="438" left="74" width="322" height="17" font="17">tween ICD implantation and improved survival.</text>
<text top="438" left="396" width="29" height="10" font="19">S10.4-8</text>
<text top="438" left="425" width="4" height="17" font="17"> </text>
<text top="456" left="74" width="351" height="17" font="17">An important limitation is that only 2 studies specifi-</text>
<text top="474" left="74" width="351" height="17" font="17">cally studied patients with ESRD and most data ana-</text>
<text top="493" left="74" width="242" height="17" font="17">lyzed were from observational studies.</text>
<text top="493" left="316" width="61" height="10" font="19">S10.4-8,S10.4-9</text>
<text top="493" left="377" width="52" height="17" font="17"> In view </text>
<text top="511" left="74" width="357" height="17" font="17">of these limitations, the writing committee concluded </text>
<text top="530" left="74" width="351" height="17" font="17">there was not enough data to inform a recommenda-</text>
<text top="548" left="74" width="351" height="17" font="17">tion on ICD implantation in patients with ESRD on di-</text>
<text top="566" left="74" width="357" height="17" font="17">alysis. Decisions regarding ICDs in patients with CKD, </text>
<text top="585" left="74" width="358" height="17" font="17">especially those with ESRD, should be individualized </text>
<text top="603" left="74" width="351" height="17" font="17">and take into consideration the patient’s functional sta-</text>
<text top="622" left="74" width="356" height="17" font="17">tus, number of comorbidities, and preferences, among </text>
<text top="640" left="74" width="86" height="17" font="17">other factors.</text>
<text top="684" left="74" width="235" height="21" font="18"><b>10.5. Valvular Heart Disease</b></text>
<text top="711" left="74" width="355" height="17" font="17">Patients with valvular heart disease should be evaluated </text>
<text top="730" left="74" width="351" height="17" font="17">and treated according to GDMT for valvular heart dis-</text>
<text top="748" left="74" width="356" height="17" font="17">ease and, when LVEF is depressed, GDMT that applies </text>
<text top="767" left="74" width="223" height="17" font="17">to NICM to reduce the risk of SCD.</text>
<text top="767" left="298" width="34" height="10" font="19">S10.6-23</text>
<text top="767" left="332" width="98" height="17" font="17"> VA in patients </text>
<text top="785" left="74" width="355" height="17" font="17">with valvular heart disease can be caused by any of the </text>
<text top="804" left="74" width="355" height="17" font="17">mechanisms responsible for VA in other cardiac disease </text>
<text top="822" left="74" width="351" height="17" font="17">including ischemic heart disease, MI, severe LV hyper-</text>
<text top="840" left="74" width="363" height="17" font="17">trophy, adrenergic-dependent rhythm disturbances, </text>
<text top="859" left="74" width="359" height="17" font="17">or an inherited molecular abnormality. Patients with </text>
<text top="877" left="74" width="357" height="17" font="17">valvular heart disease and VA are generally evaluated </text>
<text top="896" left="74" width="357" height="17" font="17">and treated using current recommendations for each </text>
<text top="914" left="74" width="54" height="17" font="17">disorder.</text>
<text top="915" left="128" width="29" height="10" font="19">S10.6-1</text>
<text top="914" left="158" width="268" height="17" font="17"> The presence of a VA alone does not con-</text>
<text top="932" left="74" width="356" height="17" font="17">stitute an indication for valve repair or replacement. In </text>
<text top="951" left="74" width="355" height="17" font="17">general, there is more knowledge on the risk for SCD in </text>
<text top="969" left="74" width="356" height="17" font="17">patients with aortic stenosis than other valvular lesions </text>
<text top="988" left="74" width="230" height="17" font="17">with a risk of 1% to 1.5% per year.</text>
<text top="988" left="304" width="29" height="10" font="19">S10.6-2</text>
<text top="988" left="333" width="97" height="17" font="17"> Most patients </text>
<text top="1006" left="74" width="357" height="17" font="17">who die suddenly have been symptomatic from their </text>
<text top="1025" left="74" width="88" height="17" font="17">valve disease.</text>
<text top="1025" left="162" width="61" height="10" font="19">S10.6-3,S10.6-4</text>
<text top="1025" left="223" width="209" height="17" font="17"> Although recurrent NSVT may </text>
<text top="1043" left="74" width="358" height="17" font="17">place a patient with severe aortic stenosis at risk for </text>
<text top="1061" left="74" width="356" height="17" font="17">syncope, the management of such a patient is guided </text>
<text top="1080" left="74" width="232" height="17" font="17">by the severity of the valvular lesion.</text>
<text top="88" left="470" width="337" height="17" font="17">Mitral valve prolapse has been implicated as a cause </text>
<text top="106" left="452" width="356" height="17" font="17">of SCD, although a study of 18 786 patients found no </text>
<text top="124" left="452" width="356" height="17" font="17">increased risk of SCA for patients with bileaflet mitral </text>
<text top="143" left="452" width="355" height="17" font="17">valve prolapse versus single leaflet mitral valve prolapse </text>
<text top="161" left="452" width="173" height="17" font="17">or no mitral valve prolapse.</text>
<text top="162" left="625" width="29" height="10" font="19">S10.6-5</text>
<text top="161" left="655" width="149" height="17" font="17"> LV fibrosis in the papil-</text>
<text top="179" left="452" width="357" height="17" font="17">lary muscles has been described in some mitral valve </text>
<text top="198" left="452" width="217" height="17" font="17">prolapse patients with VA or SCD.</text>
<text top="198" left="669" width="29" height="10" font="19">S10.6-6</text>
<text top="198" left="698" width="105" height="17" font="17"> Further, a possi-</text>
<text top="216" left="452" width="355" height="17" font="17">ble syndrome for SCD has been described that includes </text>
<text top="234" left="452" width="351" height="17" font="17">bileaflet mitral valve prolapse, female sex, T wave ab-</text>
<text top="253" left="452" width="279" height="17" font="17">normality, and complex ventricular ectopy.</text>
<text top="254" left="731" width="29" height="10" font="19">S10.6-7</text>
<text top="253" left="761" width="43" height="17" font="17"> Guid-</text>
<text top="271" left="452" width="351" height="17" font="17">ance for treatment of patients with NICM, whether val-</text>
<text top="290" left="452" width="356" height="17" font="17">vular or otherwise in origin, is provided in the current </text>
<text top="308" left="452" width="355" height="17" font="17">guideline (see Sections 7.2.1 and 7.2.2 for primary and </text>
<text top="326" left="452" width="145" height="17" font="17">secondary prevention).</text>
<text top="370" left="452" width="343" height="21" font="18"><b>10.6. Sex-Related Differences in the Risk </b></text>
<text top="391" left="452" width="57" height="21" font="18"><b>of SCD</b></text>
<text top="419" left="452" width="357" height="17" font="17">The information on associations between sex and VA </text>
<text top="437" left="452" width="357" height="17" font="17">and SCD is largely limited to epidemiological, cohort, </text>
<text top="456" left="452" width="357" height="17" font="17">and observational studies. Various population studies, </text>
<text top="474" left="452" width="354" height="17" font="17">primarily focused on SCD due to ischemic heart disease, </text>
<text top="492" left="452" width="357" height="17" font="17">have demonstrated age gradients in SCD risk among </text>
<text top="511" left="452" width="111" height="17" font="17">men and women.</text>
<text top="511" left="563" width="68" height="10" font="19">S10.6-8–S10.6-10</text>
<text top="511" left="631" width="175" height="17" font="17"> These include a 10-year lag </text>
<text top="529" left="452" width="351" height="17" font="17">in SCD incidence in women compared with men. How-</text>
<text top="547" left="452" width="357" height="17" font="17">ever, risk factor burden among women has the same </text>
<text top="566" left="452" width="357" height="17" font="17">proportional effect as in men, with a 17-fold increase </text>
<text top="584" left="452" width="274" height="17" font="17">in risk from the lowest to highest deciles.</text>
<text top="585" left="727" width="29" height="10" font="19">S10.6-9</text>
<text top="584" left="756" width="48" height="17" font="17"> Impor-</text>
<text top="602" left="452" width="357" height="17" font="17">tantly, 69% of the SCDs in women were first cardiac </text>
<text top="621" left="452" width="45" height="17" font="17">events.</text>
<text top="622" left="497" width="29" height="10" font="19">S10.6-8</text>
<text top="621" left="526" width="281" height="17" font="17"> A study of lifetime risk of SCD stratified at </text>
<text top="639" left="452" width="356" height="17" font="17">45, 55, 65, and 75 years of age identified persistently </text>
<text top="658" left="452" width="358" height="17" font="17">lower and similar proportions of lifetime risk of SCD </text>
<text top="676" left="452" width="317" height="17" font="17">among women versus men in each of the strata.</text>
<text top="677" left="769" width="34" height="10" font="19">S10.6-10</text>
<text top="676" left="803" width="4" height="17" font="17"> </text>
<text top="694" left="452" width="355" height="17" font="17">The difference between women and men is somewhat </text>
<text top="713" left="452" width="351" height="17" font="17">smaller at ages below and above 75 years, largely be-</text>
<text top="731" left="452" width="355" height="17" font="17">cause of a reduced risk in men. The overall lifetime risk </text>
<text top="749" left="452" width="357" height="17" font="17">of SCD  was 1 in 9 among men and 1 in 30 among </text>
<text top="768" left="452" width="53" height="17" font="17">women.</text>
<text top="768" left="505" width="34" height="10" font="19">S10.6-10</text>
<text top="786" left="470" width="333" height="17" font="17">In studies of outcomes after out-of-hospital car-</text>
<text top="804" left="452" width="360" height="17" font="17">diac arrest, women were older, had more SCAs in </text>
<text top="823" left="452" width="360" height="17" font="17">homes, and fewer shockable rhythms (VT/VF) than </text>
<text top="823" left="803" width="4" height="17" font="17"> </text>
<text top="841" left="452" width="32" height="17" font="17">men.</text>
<text top="842" left="484" width="70" height="10" font="19">S10.6-11,S10.6-12</text>
<text top="841" left="554" width="255" height="17" font="17"> This was associated with a somewhat </text>
<text top="860" left="452" width="358" height="17" font="17">lower probability of survival overall; however, women </text>
<text top="878" left="452" width="354" height="17" font="17">with VT/VF and those with pulseless electrical activity had </text>
<text top="896" left="452" width="175" height="17" font="17">better outcomes than men.</text>
<text top="897" left="627" width="34" height="10" font="19">S10.6-12</text>
<text top="896" left="661" width="142" height="17" font="17"> A retrospective analy-</text>
<text top="915" left="452" width="354" height="17" font="17">sis of out-of-hospital cardiac arrest reported that survival </text>
<text top="933" left="452" width="358" height="17" font="17">improved over a 10-year period, with more favorable </text>
<text top="951" left="452" width="317" height="17" font="17">outcomes in men as well as younger women.</text>
<text top="952" left="770" width="34" height="10" font="19">S10.6-13</text>
<text top="951" left="803" width="4" height="17" font="17"> </text>
<text top="970" left="452" width="351" height="17" font="17">Two studies demonstrated better outcomes in wom-</text>
<text top="988" left="452" width="359" height="17" font="17">en with VT/VF, despite adverse risk factor profiles in  </text>
<text top="1006" left="452" width="52" height="17" font="17">women.</text>
<text top="1007" left="504" width="70" height="10" font="19">S10.6-14,S10.6-15</text>
<text top="1006" left="574" width="235" height="17" font="17"> Another large study demonstrated </text>
<text top="1025" left="452" width="351" height="17" font="17">that despite similar prehospital return of spontaneous cir-</text>
<text top="1043" left="452" width="355" height="17" font="17">culation and survival to discharge, younger women had </text>
<text top="1061" left="452" width="355" height="17" font="17">lower 1-month neurologically intact survival than the 50 </text>
<text top="1080" left="452" width="111" height="17" font="17">to 60 age group.</text>
<text top="1081" left="563" width="34" height="10" font="19">S10.6-16</text>
<text top="1080" left="596" width="212" height="17" font="17"> A 17-year retrospective analysis </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e341</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="356" height="17" font="17">did not demonstrate any difference between men and </text>
<text top="106" left="74" width="279" height="17" font="17">women, although total outcomes improved.</text>
<text top="106" left="354" width="34" height="10" font="19">S10.6-17</text>
<text top="124" left="92" width="338" height="17" font="17">The proportion of ischemic heart disease-associated </text>
<text top="142" left="74" width="357" height="17" font="17">SCAs among women surviving out-of-hospital cardiac </text>
<text top="160" left="74" width="355" height="17" font="17">arrest was significantly lower than in men, but ischemic </text>
<text top="178" left="74" width="358" height="17" font="17">heart disease remained the most powerful predictor </text>
<text top="196" left="74" width="78" height="17" font="17">etiologically,</text>
<text top="196" left="152" width="34" height="10" font="19">S10.6-18</text>
<text top="196" left="186" width="246" height="17" font="17"> and women were also significantly </text>
<text top="214" left="74" width="355" height="17" font="17">less likely to have severe LV dysfunction (LVEF  ≤35%) </text>
<text top="232" left="74" width="317" height="17" font="17">or previously recognized ischemic heart disease.</text>
<text top="232" left="391" width="34" height="10" font="19">S10.6-19</text>
<text top="232" left="425" width="4" height="17" font="17"> </text>
<text top="250" left="74" width="351" height="17" font="17">Women appear to be less likely to benefit from thera-</text>
<text top="268" left="74" width="356" height="17" font="17">peutic hypothermia postcardiac arrest; however, in the </text>
<text top="286" left="74" width="355" height="17" font="17">younger age group, neurologic recovery in women was </text>
<text top="304" left="74" width="178" height="17" font="17">better than in older women.</text>
<text top="304" left="253" width="34" height="10" font="19">S10.6-20</text>
<text top="304" left="287" width="142" height="17" font="17"> Women are less likely </text>
<text top="322" left="74" width="355" height="17" font="17">to have SCA during competitive athletic events. A large </text>
<text top="340" left="74" width="351" height="17" font="17">study including both recreational and competitive ath-</text>
<text top="358" left="74" width="354" height="17" font="17">letes across a large age range noted that SCA in women </text>
<text top="376" left="74" width="316" height="17" font="17">during athletic events was 1 in 20 of that in men.</text>
<text top="376" left="390" width="34" height="10" font="19">S10.6-21</text>
<text top="394" left="92" width="333" height="17" font="17">A large literature review from 1980 to 1992 dem-</text>
<text top="412" left="74" width="351" height="17" font="17">onstrated that women accounted for 70% of re-</text>
<text top="430" left="74" width="363" height="17" font="17">corded cases  of cardiovascular medication–related </text>
<text top="448" left="74" width="79" height="17" font="17">arrhythmias.</text>
<text top="448" left="153" width="34" height="10" font="19">S10.6-22</text>
<text top="448" left="187" width="238" height="17" font="17"> This is consistent with QT interval dif-</text>
<text top="466" left="74" width="351" height="17" font="17">ferences among men and women. A retrospective anal-</text>
<text top="484" left="74" width="356" height="17" font="17">ysis of quinidine discontinuation reported a significant </text>
<text top="502" left="74" width="354" height="17" font="17">difference in discontinuation between men and women </text>
<text top="520" left="74" width="303" height="17" font="17">(66% versus 84%) largely due to prolonged QT.</text>
<text top="520" left="377" width="34" height="10" font="19">S10.6-23</text>
<text top="520" left="411" width="18" height="17" font="17"> A </text>
<text top="538" left="74" width="356" height="17" font="17">study of catheter ablation for VT reported that overall </text>
<text top="556" left="74" width="317" height="17" font="17">outcome was similar between men and women.</text>
<text top="556" left="391" width="34" height="10" font="19">S10.6-24</text>
<text top="556" left="425" width="4" height="17" font="17"> </text>
<text top="574" left="74" width="357" height="17" font="17">The only sex difference was the greater probability of </text>
<text top="592" left="74" width="357" height="17" font="17">women having RVOT VT and a greater probability of </text>
<text top="610" left="74" width="204" height="17" font="17">men having LV outflow tract VT.</text>
<text top="653" left="74" width="323" height="21" font="18"><b>10.7. Medication-Induced Arrhythmias</b></text>
<text top="687" left="85" width="274" height="12" font="26"><b>Recommendations for Medication-Induced Arrhythmias</b></text>
<text top="704" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="717" left="85" width="177" height="12" font="27"><a href=""><b>Online Data Supplements 52 and 53</b></a></text>
<text top="717" left="262" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="738" left="85" width="34" height="12" font="4">Digoxin</text>
<text top="759" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="759" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="759" left="205" width="86" height="12" font="22"><b>Recommendation</b></text>
<text top="800" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="800" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="780" left="205" width="187" height="12" font="4">1.  Administration of digoxin antibodies is </text>
<text top="793" left="217" width="180" height="12" font="4">recommended for patients who present </text>
<text top="807" left="217" width="201" height="12" font="4">with sustained VA potentially due to digoxin </text>
<text top="820" left="217" width="33" height="12" font="4">toxicity.</text>
<text top="821" left="250" width="43" height="7" font="23">S10.7-1,S10.7-2</text>
<text top="841" left="85" width="275" height="12" font="4">Medication-induced QT prolongation and torsades de pointes</text>
<text top="862" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="862" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="862" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="930" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="930" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="882" left="205" width="182" height="12" font="4">2.  In patients with recurrent torsades de </text>
<text top="896" left="217" width="164" height="12" font="4">pointes associated with acquired QT </text>
<text top="909" left="217" width="190" height="12" font="4">prolongation and bradycardia that cannot </text>
<text top="923" left="217" width="199" height="12" font="4">be suppressed with intravenous magnesium </text>
<text top="937" left="217" width="205" height="12" font="4">administration, increasing the heart rate with </text>
<text top="950" left="217" width="193" height="12" font="4">atrial or ventricular pacing or isoproterenol </text>
<text top="964" left="217" width="155" height="12" font="4">are recommended to suppress the </text>
<text top="977" left="217" width="51" height="12" font="4">arrhythmia.</text>
<text top="977" left="268" width="20" height="7" font="23">S10.7-3</text>
<text top="1032" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="1032" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="998" left="205" width="199" height="12" font="4">3.  For patients with QT prolongation due to a </text>
<text top="1011" left="216" width="196" height="12" font="4">medication, hypokalemia, hypomagnesemia, </text>
<text top="1025" left="216" width="206" height="12" font="4">or other acquired factor and recurrent torsades </text>
<text top="1038" left="216" width="180" height="12" font="4">de pointes, administration of intravenous </text>
<text top="1052" left="216" width="172" height="12" font="4">magnesium sulfate is recommended to </text>
<text top="1065" left="216" width="110" height="12" font="4">suppress the arrhythmia.</text>
<text top="1066" left="326" width="43" height="7" font="23">S10.7-4,S10.7-5</text>
<text top="164" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="164" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="136" left="583" width="180" height="12" font="4">4.  For patients with torsades de pointes </text>
<text top="150" left="595" width="186" height="12" font="4">associated with acquired QT prolongation, </text>
<text top="163" left="595" width="189" height="12" font="4">potassium repletion to 4.0 mmol/L or more </text>
<text top="177" left="595" width="191" height="12" font="4">and magnesium repletion to normal values  </text>
<text top="190" left="595" width="140" height="12" font="4">(eg, ≥2.0 mmol/L) are beneficial.</text>
<text top="191" left="734" width="41" height="7" font="23">S10.7-6,S10.7-7</text>
<text top="211" left="463" width="178" height="12" font="4">Sodium channel blocker–related toxicity</text>
<text top="232" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="232" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="232" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="286" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="286" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="252" left="583" width="205" height="12" font="4">5.  In patients taking sodium channel blockers </text>
<text top="266" left="595" width="181" height="12" font="4">who present with elevated defibrillation </text>
<text top="279" left="595" width="177" height="12" font="4">or pacing thresholds, discontinuing the </text>
<text top="293" left="595" width="165" height="12" font="4">presumed responsible medication or </text>
<text top="306" left="595" width="196" height="12" font="4">reprogramming the device can be useful to </text>
<text top="320" left="595" width="141" height="12" font="4">restore effective device therapy.</text>
<text top="320" left="735" width="43" height="7" font="23">S10.7-8,S10.7-9</text>
<text top="354" left="462" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="354" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="341" left="583" width="210" height="12" font="4">6.  In patients with congenital or acquired long </text>
<text top="354" left="595" width="205" height="12" font="4">QT syndrome, QT-prolonging medications are </text>
<text top="368" left="595" width="87" height="12" font="4">potentially harmful.</text>
<text top="368" left="682" width="24" height="7" font="23">S10.7-10</text>
<text top="408" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="430" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="457" left="467" width="346" height="17" font="17">1. Typical arrhythmias related to digoxin toxicity </text>
<text top="476" left="489" width="314" height="17" font="17">include enhanced atrial, junctional, or ventricu-</text>
<text top="494" left="489" width="314" height="17" font="17">lar automaticity (with ectopic beats or tachy-</text>
<text top="513" left="489" width="327" height="17" font="17">cardia) often combined with atrioventricular </text>
<text top="531" left="489" width="38" height="17" font="17">block.</text>
<text top="532" left="527" width="34" height="10" font="19">S10.7-11</text>
<text top="531" left="561" width="249" height="17" font="17"> VT that is fascicular or bidirectional </text>
<text top="550" left="489" width="280" height="17" font="17">in origin is suggestive of digoxin toxicity.</text>
<text top="550" left="769" width="34" height="10" font="19">S10.7-12</text>
<text top="550" left="803" width="4" height="17" font="17"> </text>
<text top="568" left="489" width="318" height="17" font="17">Severe digoxin overdose causes hyperkalemia and </text>
<text top="587" left="489" width="320" height="17" font="17">cardiac standstill. The diagnosis is established by </text>
<text top="605" left="489" width="314" height="17" font="17">the combination of characteristic rhythm distur-</text>
<text top="624" left="489" width="321" height="17" font="17">bances, ancillary symptoms (visual disturbances, </text>
<text top="642" left="489" width="324" height="17" font="17">nausea, changes in mentation), and elevated </text>
<text top="661" left="489" width="322" height="17" font="17">serum concentrations. Potentiating factors may </text>
<text top="679" left="489" width="323" height="17" font="17">include hypothyroidism, hypokalemia, or renal </text>
<text top="698" left="489" width="78" height="17" font="17">dysfunction.</text>
<text top="698" left="567" width="34" height="10" font="19">S10.7-12</text>
<text top="698" left="601" width="202" height="17" font="17"> Treatment of digoxin toxic-</text>
<text top="716" left="489" width="314" height="17" font="17">ity is based on the severity. In mild cases, dis-</text>
<text top="735" left="489" width="322" height="17" font="17">continuing the medication, monitoring rhythm, </text>
<text top="753" left="489" width="322" height="17" font="17">and maintaining normal serum potassium may </text>
<text top="772" left="489" width="89" height="17" font="17">be sufficient.</text>
<text top="773" left="578" width="34" height="10" font="19">S10.7-11</text>
<text top="772" left="612" width="202" height="17" font="17"> Intravenous magnesium is </text>
<text top="790" left="489" width="280" height="17" font="17">often administered if VAs are present.</text>
<text top="791" left="769" width="34" height="10" font="19">S10.7-12</text>
<text top="790" left="803" width="4" height="17" font="17"> </text>
<text top="809" left="489" width="321" height="17" font="17">Occasionally, temporary pacing may be needed </text>
<text top="827" left="489" width="251" height="17" font="17">for atrioventricular block or asystole.</text>
<text top="828" left="740" width="34" height="10" font="19">S10.7-13</text>
<text top="827" left="774" width="38" height="17" font="17"> For </text>
<text top="846" left="489" width="314" height="17" font="17">more severe intoxication (serum digoxin con-</text>
<text top="864" left="489" width="320" height="17" font="17">centrations exceeding 4 ng/mL and with serious </text>
<text top="883" left="489" width="319" height="17" font="17">arrhythmias such as VT), the treatment of choice </text>
<text top="901" left="489" width="209" height="17" font="17">is digoxin-specific Fab antibody.</text>
<text top="902" left="698" width="29" height="10" font="19">S10.7-1</text>
<text top="901" left="728" width="83" height="17" font="17"> In 1 series </text>
<text top="920" left="489" width="323" height="17" font="17">of 150 severely intoxicated patients, response </text>
<text top="938" left="489" width="320" height="17" font="17">was rapid (30 minutes to 4 hour), and 54% of </text>
<text top="957" left="489" width="314" height="17" font="17">patients presenting with a cardiac arrest sur-</text>
<text top="975" left="489" width="133" height="17" font="17">vived hospitalization.</text>
<text top="976" left="622" width="29" height="10" font="19">S10.7-1</text>
<text top="975" left="652" width="156" height="17" font="17"> Adverse effects include </text>
<text top="994" left="489" width="321" height="17" font="17">worsening of the underlying disease (increased </text>
<text top="1012" left="489" width="322" height="17" font="17">ventricular rate during AF, exacerbation of HF) </text>
<text top="1031" left="489" width="314" height="17" font="17">and hypokalemia. Doses lower (and less expen-</text>
<text top="1049" left="489" width="319" height="17" font="17">sive) than the full neutralizing dose are sufficient </text>
<text top="1068" left="489" width="285" height="17" font="17">as long as cardiac arrest is not imminent.</text>
<text top="1069" left="774" width="29" height="10" font="19">S10.7-2</text>
<text top="1068" left="803" width="4" height="17" font="17"> </text>
<text top="95" left="463" width="335" height="12" font="26"><b>Recommendations for Medication-Induced Arrhythmias (Continued)</b></text>
<text top="116" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="116" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="116" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e342</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="323" height="17" font="17">Digoxin concentration monitoring is unreliable </text>
<text top="106" left="111" width="265" height="17" font="17">after antidigoxin antibody administration.</text>
<text top="124" left="89" width="343" height="17" font="17">2.  Monitoring high-risk patients during initiation of </text>
<text top="142" left="111" width="326" height="17" font="17">QT-prolonging antiarrhythmic medications and </text>
<text top="160" left="111" width="318" height="17" font="17">recognition of the syndrome when it occurs are the </text>
<text top="178" left="111" width="320" height="17" font="17">first steps. Temporary pacing is highly effective in </text>
<text top="196" left="111" width="317" height="17" font="17">managing torsades de pointes that is recurrent after </text>
<text top="214" left="111" width="286" height="17" font="17">potassium and magnesium supplementation.</text>
<text top="214" left="397" width="29" height="10" font="19">S10.7-3</text>
<text top="214" left="425" width="4" height="17" font="17"> </text>
<text top="232" left="111" width="321" height="17" font="17">Isoproterenol can also be used to increase heart </text>
<text top="250" left="111" width="226" height="17" font="17">rate and abolish postectopic pauses.</text>
<text top="250" left="337" width="29" height="10" font="19">S10.7-3</text>
<text top="268" left="89" width="340" height="17" font="17">3.  Intravenous magnesium can suppress episodes of </text>
<text top="286" left="111" width="317" height="17" font="17">torsades de pointes without necessarily shortening </text>
<text top="304" left="111" width="258" height="17" font="17">QT, even when serum magnesium is normal.</text>
<text top="304" left="368" width="57" height="10" font="19">S10.7-4,S10.7-5</text>
<text top="304" left="425" width="5" height="17" font="17">  </text>
<text top="322" left="111" width="318" height="17" font="17">Repeated doses may be needed, titrated to suppress </text>
<text top="340" left="111" width="314" height="17" font="17">ectopy and nonsustained VT episodes while precipi-</text>
<text top="358" left="111" width="166" height="17" font="17">tating factors are corrected.</text>
<text top="358" left="276" width="28" height="10" font="19">S10.7-4</text>
<text top="358" left="304" width="125" height="17" font="17"> Magnesium toxicity </text>
<text top="376" left="111" width="320" height="17" font="17">(areflexia progressing to respiratory depression) can </text>
<text top="394" left="111" width="320" height="17" font="17">occur at high serum concentrations, but this risk is </text>
<text top="412" left="111" width="314" height="17" font="17">very small with the doses usually used to treat tors-</text>
<text top="430" left="111" width="236" height="17" font="17">ades de pointes, 1 to 2 g intravenously.</text>
<text top="430" left="346" width="32" height="10" font="19">S10.7-14</text>
<text top="448" left="129" width="300" height="17" font="17">Allelic variants in clinical long QT disease genes </text>
<text top="466" left="111" width="314" height="17" font="17">have been identified in patients with medication-</text>
<text top="484" left="111" width="210" height="17" font="17">induced torsades de pointes.</text>
<text top="484" left="321" width="104" height="10" font="19">S10.7-7,S10.7-15–S10.7-18</text>
<text top="484" left="425" width="4" height="17" font="17"> </text>
<text top="502" left="111" width="321" height="17" font="17">Further, whole exome sequencing implicates an </text>
<text top="520" left="111" width="314" height="17" font="17">increased burden of rare potassium channel vari-</text>
<text top="538" left="111" width="318" height="17" font="17">ants in the risk of medication-induced torsades de </text>
<text top="556" left="111" width="51" height="17" font="17">pointes.</text>
<text top="556" left="162" width="70" height="10" font="19">S10.7-17,S10.7-19</text>
<text top="556" left="232" width="193" height="17" font="17"> These findings do not yet sup-</text>
<text top="574" left="111" width="320" height="17" font="17">port general genetic screening for prediction of </text>
<text top="592" left="111" width="320" height="17" font="17">medication-induced torsades de pointes. In long </text>
<text top="610" left="111" width="319" height="17" font="17">QT syndrome, genetic testing may be performed </text>
<text top="628" left="111" width="314" height="17" font="17">in the index case who experienced medication-</text>
<text top="646" left="111" width="318" height="17" font="17">induced torsades de pointes and, if he/she did not </text>
<text top="664" left="111" width="318" height="17" font="17">survive that event, electrocardiographic screening </text>
<text top="682" left="111" width="273" height="17" font="17">of first-degree relatives may be performed.</text>
<text top="700" left="89" width="340" height="17" font="17">4.  Maintaining serum potassium between 4.5 mEq/L </text>
<text top="718" left="111" width="321" height="17" font="17">and 5 mEq/L shortens QT and may reduce the </text>
<text top="736" left="111" width="253" height="17" font="17">chance of recurrent torsades de pointes.</text>
<text top="736" left="364" width="61" height="10" font="19">S10.7-6,S10.7-7</text>
<text top="754" left="89" width="347" height="17" font="17">5. In large clinical trials, sodium channel blockers </text>
<text top="772" left="111" width="317" height="17" font="17">increased mortality among patients convalescing from </text>
<text top="790" left="111" width="20" height="17" font="17">MI,</text>
<text top="790" left="130" width="32" height="10" font="19">S10.7-20</text>
<text top="790" left="162" width="263" height="17" font="17"> but similar trends were also seen with ear-</text>
<text top="808" left="111" width="134" height="17" font="17">lier trials of mexiletine</text>
<text top="808" left="244" width="32" height="10" font="19">S10.7-21</text>
<text top="808" left="276" width="117" height="17" font="17"> and disopyramide.</text>
<text top="808" left="393" width="32" height="10" font="19">S10.7-22</text>
<text top="808" left="425" width="4" height="17" font="17"> </text>
<text top="826" left="111" width="325" height="17" font="17">Based on CAST, flecainide is contraindicated in </text>
<text top="844" left="111" width="321" height="17" font="17">patients with ischemia, prior MI, and is avoided in </text>
<text top="862" left="111" width="263" height="17" font="17">patients with other structural heart diseases.</text>
<text top="862" left="374" width="32" height="10" font="19">S10.7-20</text>
<text top="880" left="125" width="305" height="17" font="17">Sodium channel blockers increase defibrillation </text>
<text top="898" left="107" width="257" height="17" font="17">energy requirement and pacing thresholds</text>
<text top="898" left="364" width="58" height="10" font="19">S10.7-8,S10.7-9</text>
<text top="898" left="421" width="8" height="17" font="17">;  </text>
<text top="916" left="106" width="319" height="17" font="17">as a consequence, patients may require repro-</text>
<text top="934" left="106" width="323" height="17" font="17">gramming or revision of pacing or ICD systems or </text>
<text top="952" left="106" width="326" height="17" font="17">changes in their medication regimens (although </text>
<text top="970" left="106" width="327" height="17" font="17">modern pacing systems that provide automatic </text>
<text top="988" left="106" width="319" height="17" font="17">pacing threshold testing and adjustment of pac-</text>
<text top="1006" left="106" width="319" height="17" font="17">ing output have mitigated the risk of loss of cap-</text>
<text top="1024" left="106" width="324" height="17" font="17">ture). Sodium channel blockers can “convert” AF </text>
<text top="1042" left="106" width="319" height="17" font="17">to slow atrial flutter, which can show 1:1 atrioven-</text>
<text top="1060" left="106" width="323" height="17" font="17">tricular conduction with wide QRS complexes that </text>
<text top="1078" left="106" width="161" height="17" font="17">can be confused with VT.</text>
<text top="1078" left="267" width="34" height="10" font="19">S10.7-23</text>
<text top="88" left="503" width="303" height="17" font="17">Sodium channel blockers, like procainamide and </text>
<text top="106" left="485" width="325" height="17" font="17">flecainide, can occasionally precipitate the typical </text>
<text top="124" left="485" width="157" height="17" font="17">Brugada syndrome ECG.</text>
<text top="124" left="641" width="70" height="10" font="19">S10.7-24,S10.7-25</text>
<text top="124" left="711" width="97" height="17" font="17"> This has been </text>
<text top="142" left="484" width="323" height="17" font="17">reported not only with antiarrhythmic medications </text>
<text top="160" left="484" width="252" height="17" font="17">but also with tricyclic antidepressants</text>
<text top="160" left="737" width="35" height="10" font="19">S10.7-26</text>
<text top="160" left="772" width="38" height="17" font="17"> and </text>
<text top="178" left="484" width="50" height="17" font="17">cocaine</text>
<text top="178" left="534" width="35" height="10" font="19">S10.7-27</text>
<text top="178" left="569" width="34" height="17" font="17"> (</text>
<text top="178" left="604" width="156" height="17" font="20"><a href="">www.brugadadrugs.org</a></text>
<text top="178" left="760" width="8" height="17" font="17"><a href="">).</a></text>
<text top="178" left="769" width="35" height="10" font="19">S10.7-28</text>
<text top="178" left="803" width="4" height="17" font="17"> </text>
<text top="196" left="485" width="328" height="17" font="17">Whether this represents unmasking individuals </text>
<text top="214" left="485" width="325" height="17" font="17">with clinically unapparent Brugada syndrome (see </text>
<text top="232" left="485" width="324" height="17" font="17">Section 7.9.1.3) or one end of a broad spectrum of </text>
<text top="250" left="485" width="309" height="17" font="17">responses to sodium channel blockers is unknown.</text>
<text top="268" left="503" width="301" height="17" font="17">In the setting of sodium-channel blocker tox-</text>
<text top="286" left="485" width="319" height="17" font="17">icity, limited animal data suggest that adminis-</text>
<text top="304" left="485" width="325" height="17" font="17">tration of sodium, as sodium chloride or sodium </text>
<text top="322" left="485" width="329" height="17" font="17">bicarbonate, may improve conduction slowing </text>
<text top="340" left="485" width="329" height="17" font="17">or suppress frequent or cardioversion-resistant </text>
<text top="358" left="485" width="19" height="17" font="17">VT.</text>
<text top="358" left="504" width="34" height="10" font="19">S10.7-29</text>
<text top="358" left="538" width="266" height="17" font="17"> Successful treatment with beta block-</text>
<text top="376" left="485" width="18" height="17" font="17">ers</text>
<text top="376" left="503" width="34" height="10" font="19">S10.7-30</text>
<text top="376" left="537" width="277" height="17" font="17"> and intravenous fat emulsion and/or </text>
<text top="394" left="485" width="327" height="17" font="17">extracorporeal membrane oxygenation has also </text>
<text top="412" left="485" width="95" height="17" font="17">been reported.</text>
<text top="412" left="579" width="34" height="10" font="19">S10.7-31</text>
<text top="430" left="467" width="210" height="17" font="17">6. QT-prolonging medications (</text>
<text top="430" left="677" width="126" height="17" font="20"><a href="">www.crediblemeds.</a></text>
<text top="448" left="485" width="22" height="17" font="20"><a href="">org</a></text>
<text top="448" left="506" width="4" height="17" font="17">)</text>
<text top="448" left="510" width="34" height="10" font="19">S10.7-32</text>
<text top="448" left="544" width="263" height="17" font="17"> are not used in patients with congenital </text>
<text top="466" left="485" width="324" height="17" font="17">or acquired long QT syndrome unless there is no </text>
<text top="484" left="485" width="324" height="17" font="17">suitable alternative or the benefit greatly exceeds </text>
<text top="502" left="485" width="325" height="17" font="17">the risk. Episodes of torsades de pointes can be </text>
<text top="520" left="485" width="319" height="17" font="17">precipitated by exposure to a QT-prolonging medi-</text>
<text top="538" left="485" width="327" height="17" font="17">cation, and underlying prolongation of the QT </text>
<text top="556" left="485" width="326" height="17" font="17">(from genetic and clinical risk factors) increases </text>
<text top="574" left="485" width="54" height="17" font="17">this risk.</text>
<text top="574" left="538" width="34" height="10" font="19">S10.7-10</text>
<text top="574" left="572" width="236" height="17" font="17"> Medications implicated in torsades </text>
<text top="592" left="484" width="322" height="17" font="17">de pointes are found in several medication classes, </text>
<text top="610" left="484" width="319" height="17" font="17">including antiarrhythmics, antihistamines, antibi-</text>
<text top="628" left="484" width="323" height="17" font="17">otics, antifungals, antidepressants, antipsychotics, </text>
<text top="646" left="484" width="195" height="17" font="17">opiates, and anticancer agents</text>
<text top="646" left="680" width="34" height="10" font="19">S10.7-10</text>
<text top="646" left="714" width="70" height="17" font="17"> (Table 10).</text>
<text top="689" left="452" width="310" height="21" font="18"><b>10.8. Adult Congenital Heart Disease</b></text>
<text top="723" left="463" width="266" height="12" font="26"><b>Recommendations for Adult Congenital Heart Disease</b></text>
<text top="740" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="753" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 54</b></a></text>
<text top="753" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="774" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="774" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="774" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="829" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="829" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="795" left="583" width="186" height="12" font="4">1.  Adult patients with repaired complex </text>
<text top="808" left="595" width="190" height="12" font="4">congenital heart disease presenting with </text>
<text top="822" left="595" width="181" height="12" font="4">frequent, complex, or sustained VA, or </text>
<text top="836" left="595" width="175" height="12" font="4">unexplained syncope should undergo </text>
<text top="849" left="595" width="195" height="12" font="4">evaluation for potential residual anatomic </text>
<text top="863" left="595" width="121" height="12" font="4">or coronary abnormalities.</text>
<text top="863" left="716" width="45" height="7" font="23">S10.8-1–S10.8-6</text>
<text top="931" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="931" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="883" left="583" width="190" height="12" font="4">2.  In patients with adult congenital heart </text>
<text top="897" left="595" width="172" height="12" font="4">disease and complex or sustained VA </text>
<text top="910" left="595" width="171" height="12" font="4">in the presence of important residual </text>
<text top="924" left="595" width="164" height="12" font="4">hemodynamic lesions, treatment of </text>
<text top="937" left="595" width="195" height="12" font="4">hemodynamic abnormalities with catheter </text>
<text top="951" left="595" width="168" height="12" font="4">or surgical intervention as feasible is </text>
<text top="964" left="595" width="199" height="12" font="4">indicated prior to consideration of ablation </text>
<text top="978" left="595" width="46" height="12" font="4">or an ICD.</text>
<text top="978" left="641" width="71" height="7" font="23">S10.8-3,S10.8-7–S10.8-12</text>
<text top="1032" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="1032" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="999" left="583" width="186" height="12" font="4">3.  In patients with adult congenital heart </text>
<text top="1012" left="595" width="193" height="12" font="4">disease and hemodynamically unstable VT, </text>
<text top="1026" left="595" width="203" height="12" font="4">an ICD is recommended after evaluation and </text>
<text top="1039" left="595" width="187" height="12" font="4">appropriate treatment for residual lesions/</text>
<text top="1053" left="595" width="202" height="12" font="4">ventricular dysfunction if meaningful survival </text>
<text top="1066" left="595" width="153" height="12" font="4">of greater than 1 year is expected.</text>
<text top="1067" left="748" width="51" height="7" font="23">S10.8-13–S10.8-17</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e343</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="164" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="164" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="136" left="205" width="186" height="12" font="4">4.  In patients with adult congenital heart </text>
<text top="150" left="217" width="181" height="12" font="4">disease with SCA due to VT or VF in the </text>
<text top="163" left="217" width="174" height="12" font="4">absence of reversible causes, an ICD is </text>
<text top="177" left="217" width="178" height="12" font="4">recommended if meaningful survival of </text>
<text top="190" left="217" width="141" height="12" font="4">greater than 1 year is expected.</text>
<text top="191" left="358" width="51" height="7" font="23">S10.8-13–S10.8-17</text>
<text top="238" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="238" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="211" left="205" width="196" height="12" font="4">5.  In adults with repaired tetralogy of Fallot </text>
<text top="225" left="217" width="180" height="12" font="4">physiology with high-risk characteristics </text>
<text top="238" left="217" width="184" height="12" font="4">and frequent VA, an electrophysiological </text>
<text top="252" left="217" width="190" height="12" font="4">study can be useful to evaluate the risk of </text>
<text top="265" left="217" width="72" height="12" font="4">sustained VT/VF.</text>
<text top="266" left="289" width="49" height="7" font="23">S10.8-18,S10.8-19</text>
<text top="313" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="313" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="286" left="205" width="196" height="12" font="4">6.  In adults with repaired tetralogy of Fallot </text>
<text top="299" left="217" width="207" height="12" font="4">physiology and inducible VT/VF or spontaneous </text>
<text top="313" left="217" width="170" height="12" font="4">sustained VT, implantation of an ICD is </text>
<text top="326" left="217" width="200" height="12" font="4">reasonable if meaningful survival greater than </text>
<text top="340" left="217" width="80" height="12" font="4">1 year is expected.</text>
<text top="340" left="296" width="69" height="7" font="23">S10.8-1,S10.8-19,S10.8-20</text>
<text top="381" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="381" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="361" left="205" width="213" height="12" font="4">7.  In patients with adult congenital heart disease </text>
<text top="374" left="217" width="202" height="12" font="4">with recurrent sustained monomorphic VT or </text>
<text top="388" left="217" width="204" height="12" font="4">recurrent ICD shocks for VT, catheter ablation </text>
<text top="401" left="217" width="72" height="12" font="4">can be effective.</text>
<text top="402" left="289" width="50" height="7" font="23">S10.8-21–S10.8-25</text>
<text top="442" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="442" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="422" left="205" width="196" height="12" font="4">8.  In adults with repaired severe complexity </text>
<text top="435" left="217" width="198" height="12" font="4">adult congenital heart disease and frequent </text>
<text top="449" left="217" width="170" height="12" font="4">or complex VA, a beta blocker can be </text>
<text top="462" left="217" width="161" height="12" font="4">beneficial to reduce the risk of SCA.</text>
<text top="463" left="377" width="24" height="7" font="23">S10.8-26</text>
<text top="544" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="544" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="483" left="205" width="188" height="12" font="4">9.  In patients with repaired moderate or </text>
<text top="497" left="217" width="189" height="12" font="4">severe complexity adult congenital heart </text>
<text top="510" left="217" width="192" height="12" font="4">disease with unexplained syncope and at </text>
<text top="524" left="217" width="180" height="12" font="4">least moderate ventricular dysfunction </text>
<text top="537" left="217" width="161" height="12" font="4">or marked hypertrophy, either ICD </text>
<text top="551" left="217" width="182" height="12" font="4">implantation or an electrophysiological </text>
<text top="564" left="217" width="194" height="12" font="4">study with ICD implantation for inducible </text>
<text top="578" left="217" width="190" height="12" font="4">sustained VA is reasonable if meaningful </text>
<text top="591" left="217" width="151" height="12" font="4">survival of greater than 1 year is </text>
<text top="605" left="217" width="44" height="12" font="4">expected.</text>
<text top="605" left="262" width="101" height="7" font="23">S10.8-5,S10.8-16,S10.8-27–S10.8-29</text>
<text top="666" left="98" width="12" height="12" font="22"><b>IIb</b></text>
<text top="666" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="625" left="199" width="191" height="12" font="4">10.  In patients with adult congenital heart </text>
<text top="639" left="217" width="190" height="12" font="4">disease and severe ventricular dysfunction </text>
<text top="652" left="217" width="198" height="12" font="4">(LVEF &lt;35%) and symptoms of heart failure </text>
<text top="666" left="217" width="181" height="12" font="4">despite GDMT or additional risk factors, </text>
<text top="679" left="217" width="174" height="12" font="4">ICD implantation may be considered if </text>
<text top="693" left="217" width="199" height="12" font="4">meaningful survival of greater than 1 year is </text>
<text top="706" left="217" width="43" height="12" font="4">expected.</text>
<text top="707" left="260" width="76" height="7" font="23">S10.8-14–S10.8-16,S10.8-20</text>
<text top="761" left="84" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="761" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="727" left="199" width="191" height="12" font="4">11.  In patients with adult congenital heart </text>
<text top="741" left="217" width="166" height="12" font="4">disease who have asymptomatic VA, </text>
<text top="754" left="217" width="161" height="12" font="4">prophylactic antiarrhythmic therapy </text>
<text top="768" left="217" width="177" height="12" font="4">with class Ic medications (ie, flecainide, </text>
<text top="781" left="217" width="191" height="12" font="4">propafenone) or amiodarone is potentially </text>
<text top="795" left="217" width="38" height="12" font="4">harmful.</text>
<text top="795" left="255" width="51" height="7" font="23">S10.8-30–S10.8-32</text>
<text top="835" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="863" left="74" width="356" height="17" font="17">Tetralogy of Fallot (TOF) is defined as, congenital heart </text>
<text top="881" left="74" width="358" height="17" font="17">disease with RVOT obstruction and ventricular septal </text>
<text top="899" left="74" width="359" height="17" font="17">defect, often requiring right ventricle to pulmonary </text>
<text top="918" left="74" width="351" height="17" font="17">artery conduit placement or pulmonary valve replace-</text>
<text top="936" left="74" width="357" height="17" font="17">ment; includes TOF and double-outlet right ventricle. </text>
<text top="955" left="74" width="351" height="17" font="17">Moderate complexity congenital heart disease is de-</text>
<text top="973" left="74" width="356" height="17" font="17">fined as congenital heart disease requiring intracardiac </text>
<text top="992" left="74" width="355" height="17" font="17">surgical repair, other than isolated atrial and ventricular </text>
<text top="1010" left="74" width="355" height="17" font="17">septal defects; includes TOF, aortic stenosis, coarctation </text>
<text top="1028" left="74" width="357" height="17" font="17">of aorta, and Ebstein anomaly of the tricuspid valve. </text>
<text top="1047" left="74" width="357" height="17" font="17">Severe complexity congenital heart disease is defined </text>
<text top="1065" left="74" width="351" height="17" font="17">as cyanotic congenital heart disease requiring intracar-</text>
<text top="1084" left="74" width="357" height="17" font="17">diac repair in infancy, often with staging procedures; </text>
<text top="88" left="452" width="351" height="17" font="17">includes transposition of the great arteries, truncus ar-</text>
<text top="106" left="452" width="316" height="17" font="17">teriosus, and single ventricle anatomy (Figure 16).</text>
<text top="149" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="170" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="197" left="467" width="345" height="17" font="17">1. The association of VT with RV hemodynamic </text>
<text top="216" left="489" width="323" height="17" font="17">abnormalities was first established in patients </text>
<text top="234" left="489" width="125" height="17" font="17">with repaired TOF.</text>
<text top="234" left="614" width="34" height="10" font="19">S10.8-33</text>
<text top="234" left="648" width="164" height="17" font="17"> Multiple studies since </text>
<text top="252" left="489" width="321" height="17" font="17">that time have demonstrated the correlation of </text>
<text top="270" left="489" width="318" height="17" font="17">hemodynamic residue and ventricular dysfunction </text>
<text top="288" left="489" width="314" height="17" font="17">with risk of VT or SCD in patients with congeni-</text>
<text top="306" left="489" width="109" height="17" font="17">tal heart disease.</text>
<text top="307" left="598" width="206" height="10" font="19">S10.8-1,S10.8-3–S10.8-6,S10.8-18,S10.8-34–S10.8-36</text>
<text top="306" left="803" width="4" height="17" font="17"> </text>
<text top="324" left="489" width="321" height="17" font="17">Presentation with frequent or complex VA may </text>
<text top="342" left="489" width="314" height="17" font="17">indicate worsening hemodynamic function, coro-</text>
<text top="360" left="489" width="317" height="17" font="17">nary artery compromise, or decreased perfusion in </text>
<text top="378" left="489" width="319" height="17" font="17">the setting of ventricular hypertrophy. Evaluation </text>
<text top="396" left="489" width="314" height="17" font="17">may also include exercise testing to assess func-</text>
<text top="414" left="489" width="95" height="17" font="17">tional capacity.</text>
<text top="415" left="584" width="34" height="10" font="19">S10.8-35</text>
<text top="414" left="618" width="185" height="17" font="17"> Careful evaluation of hemo-</text>
<text top="433" left="489" width="320" height="17" font="17">dynamic status for optimization of management </text>
<text top="451" left="489" width="86" height="17" font="17">is important.</text>
<text top="451" left="575" width="29" height="10" font="19">S10.8-9</text>
<text top="451" left="604" width="208" height="17" font="17"> Potentially treatable residual </text>
<text top="469" left="489" width="314" height="17" font="17">hemodynamic problems may be identified dur-</text>
<text top="487" left="489" width="323" height="17" font="17">ing hemodynamic evaluation, such as outflow </text>
<text top="505" left="489" width="321" height="17" font="17">tract stenosis or significant regurgitation, which </text>
<text top="523" left="489" width="324" height="17" font="17">may benefit from either catheter or  surgical </text>
<text top="541" left="489" width="81" height="17" font="17">intervention.</text>
<text top="542" left="570" width="170" height="10" font="19">S10.8-3,S10.8-7,S10.8-10,S10.8-12,S10.8-37</text>
<text top="541" left="740" width="77" height="17" font="17"> Patients </text>
<text top="559" left="489" width="327" height="17" font="17">with markedly reduced ventricular function, </text>
<text top="577" left="489" width="323" height="17" font="17">elevated end-diastolic pressures, or pulmonary </text>
<text top="595" left="489" width="323" height="17" font="17">hypertension should be treated for underlying </text>
<text top="613" left="489" width="314" height="17" font="17">hemodynamic problems as part of their arrhyth-</text>
<text top="631" left="489" width="117" height="17" font="17">mia management.</text>
<text top="650" left="467" width="336" height="17" font="17">2.  The correlation of residual hemodynamic abnor-</text>
<text top="668" left="489" width="317" height="17" font="17">malities with VA has been most extensively studied </text>
<text top="686" left="489" width="314" height="17" font="17">in patients with repaired TOF, where RV hyperten-</text>
<text top="704" left="489" width="318" height="17" font="17">sion, residual pulmonary outflow tract obstruction </text>
<text top="722" left="489" width="320" height="17" font="17">or regurgitation, and RV dilation are risk factors </text>
<text top="740" left="489" width="83" height="17" font="17">for VT/SCD.</text>
<text top="741" left="572" width="231" height="10" font="19">S10.8-1,S10.8-2,S10.8-4,S10.8-8,S10.8-33,S10.8-34,S10.8-36</text>
<text top="740" left="803" width="4" height="17" font="17"> </text>
<text top="758" left="489" width="322" height="17" font="17">In these studies, frequent PVCs correlated with </text>
<text top="776" left="489" width="314" height="17" font="17">risk of clinical or inducible sustained VT. A com-</text>
<text top="794" left="489" width="314" height="17" font="17">bined approach of surgery for structural abnor-</text>
<text top="812" left="489" width="319" height="17" font="17">malities with map-guided arrhythmia surgery has </text>
<text top="830" left="489" width="155" height="17" font="17">been used with success,</text>
<text top="831" left="644" width="132" height="10" font="19">S10.8-3,S10.8-8,S10.8-10,S10.8-12</text>
<text top="830" left="776" width="32" height="17" font="17"> but </text>
<text top="848" left="489" width="319" height="17" font="17">elimination of VT circuits may be limited by deep </text>
<text top="867" left="489" width="320" height="17" font="17">endocardial or LV origin of VT and limitations of </text>
<text top="885" left="489" width="321" height="17" font="17">operative mapping; an empiric approach  to VT </text>
<text top="903" left="489" width="320" height="17" font="17">surgery is generally not recommended as it has </text>
<text top="921" left="489" width="314" height="17" font="17">limited effectiveness and carries risk of ventricu-</text>
<text top="939" left="489" width="116" height="17" font="17">lar proarrhythmia.</text>
<text top="940" left="605" width="34" height="10" font="19">S10.8-38</text>
<text top="939" left="639" width="165" height="17" font="17"> Pulmonary valve replace-</text>
<text top="957" left="489" width="318" height="17" font="17">ment in patients with TOF may result in improved </text>
<text top="975" left="489" width="320" height="17" font="17">hemodynamics and functional status, but it may </text>
<text top="993" left="489" width="171" height="17" font="17">not eliminate the risk of VT</text>
<text top="994" left="660" width="66" height="10" font="19">S10.8-3,S10.8-12</text>
<text top="993" left="726" width="77" height="17" font="17">; postopera-</text>
<text top="1011" left="489" width="314" height="17" font="17">tive reassessment for the need for an ICD is per-</text>
<text top="1029" left="489" width="246" height="17" font="17">formed after the early recovery period.</text>
<text top="1047" left="467" width="346" height="17" font="17">3. Correction of residual hemodynamic/structural </text>
<text top="1066" left="489" width="323" height="17" font="17">abnormalities contributing to VT may improve </text>
<text top="1084" left="489" width="321" height="17" font="17">ventricular function and reduce symptoms, but </text>
<text top="95" left="85" width="327" height="12" font="26"><b>Recommendations for Adult Congenital Heart Disease (Continued)</b></text>
<text top="116" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="116" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="116" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="32" size="5" family="Times" color="#231f20"/>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e344</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1001" left="111" width="314" height="17" font="17">it may inadequately prevent the risk of subse-</text>
<text top="1021" left="111" width="314" height="17" font="17">quent VT or SCA. The use of ICDs in adult con-</text>
<text top="1040" left="111" width="326" height="17" font="17">genital heart disease patients for secondary </text>
<text top="1060" left="111" width="322" height="17" font="17">prevention accounts for approximately 50% of </text>
<text top="1080" left="111" width="320" height="17" font="17">implantations presently, at a mean age of 36 to  </text>
<text top="1001" left="489" width="56" height="17" font="17">41 years.</text>
<text top="1002" left="545" width="72" height="10" font="19">S10.8-13–S10.8-17</text>
<text top="1001" left="617" width="188" height="17" font="17"> Patients with adult congenital </text>
<text top="1021" left="489" width="319" height="17" font="17">heart disease experience appropriate shock rates </text>
<text top="1040" left="489" width="319" height="17" font="17">of 3% to 6% per year, with equivalent or slightly </text>
<text top="1060" left="489" width="314" height="17" font="17">increased frequency of appropriate shocks for sec-</text>
<text top="1080" left="489" width="207" height="17" font="17">ondary prevention indications.</text>
<text top="1081" left="696" width="107" height="10" font="19">S10.8-14,S10.8-15,S10.8-17</text>
<text top="1080" left="803" width="9" height="17" font="17">  </text>
<text top="88" left="74" width="43" height="12" font="3"><b>Table 11.</b></text>
<text top="88" left="118" width="257" height="12" font="22"><b>  Congenital Heart Disease: Risk Factors for VA/SCD</b></text>
<text top="112" left="85" width="124" height="12" font="22"><b>Congenital Heart Disease</b></text>
<text top="112" left="383" width="76" height="12" font="22"><b>Incidence of VA</b></text>
<text top="112" left="495" width="82" height="12" font="22"><b>Incidence of SCD</b></text>
<text top="112" left="637" width="130" height="12" font="22"><b>Higher Risk Characteristics</b></text>
<text top="133" left="85" width="80" height="12" font="4">Simple complexity</text>
<text top="154" left="85" width="30" height="12" font="4"> ASD</text>
<text top="155" left="115" width="109" height="7" font="23">S10.8–44,S10.8–47,S10.8–57—S10.8–62</text>
<text top="154" left="402" width="38" height="12" font="4">2%–6%</text>
<text top="154" left="521" width="31" height="12" font="4">&lt;1.5%</text>
<text top="154" left="611" width="81" height="12" font="4">Ventricular pacing</text>
<text top="168" left="611" width="57" height="12" font="4">RV dilatation</text>
<text top="181" left="611" width="108" height="12" font="4">Pulmonary hypertension</text>
<text top="195" left="611" width="60" height="12" font="12"><i>NKX2.5</i> gene</text>
<text top="215" left="85" width="29" height="12" font="4">   VSD</text>
<text top="216" left="114" width="135" height="7" font="23">S10.8–27,S10.8–44,S10.8–47,S10.8–57—S10.8–63</text>
<text top="215" left="399" width="44" height="12" font="4">3%–18%</text>
<text top="215" left="525" width="23" height="12" font="4">&lt;3%</text>
<text top="215" left="611" width="3" height="12" font="4"> </text>
<text top="236" left="85" width="94" height="12" font="4">Moderate complexity</text>
<text top="257" left="85" width="90" height="12" font="4">   Tetralogy of Fallot</text>
<text top="257" left="175" width="186" height="7" font="23">S10.8-1,S10.8-2,S10.8-5,S10.8-6,S10.8–28,S10.8–34,S10.8–36,S10.8–</text>
<text top="271" left="95" width="175" height="7" font="23">44,S10.8–46,S10.8–47,S10.8–54—S10.8–56,S10.8–62—S10.8–65</text>
<text top="257" left="396" width="50" height="12" font="4">14%–31%</text>
<text top="257" left="509" width="55" height="12" font="4">1.4%–8.3%</text>
<text top="257" left="611" width="95" height="12" font="4">Unexplained syncope</text>
<text top="270" left="611" width="108" height="12" font="4">Frequent or complex VA</text>
<text top="284" left="611" width="58" height="12" font="4">Sustained VT</text>
<text top="297" left="611" width="102" height="12" font="4">QRS duration ≥180 ms</text>
<text top="311" left="611" width="100" height="12" font="4">Inducible sustained VT</text>
<text top="324" left="611" width="77" height="12" font="4">Atrial tachycardia</text>
<text top="338" left="611" width="69" height="12" font="4">Decreased LVEF</text>
<text top="352" left="611" width="96" height="12" font="4">Dilated right ventricle</text>
<text top="365" left="611" width="43" height="12" font="4">Severe PR</text>
<text top="379" left="611" width="42" height="12" font="4">Severe PS</text>
<text top="399" left="85" width="78" height="12" font="4">  Aortic stenosis </text>
<text top="400" left="163" width="78" height="7" font="23">S10.8–27,S10.8–44,S10.8–56</text>
<text top="399" left="396" width="50" height="12" font="4">10%–34%</text>
<text top="399" left="514" width="44" height="12" font="4">3%–20%</text>
<text top="399" left="611" width="95" height="12" font="4">Unexplained syncope</text>
<text top="413" left="611" width="99" height="12" font="4">Severe LV hypertrophy</text>
<text top="426" left="611" width="138" height="12" font="4">Aortic stenosis mean pressure  </text>
<text top="440" left="611" width="103" height="12" font="4">  gradient &gt;40 mm Hg</text>
<text top="453" left="611" width="103" height="12" font="4">Ventricular dysfunction</text>
<text top="474" left="85" width="101" height="12" font="4">   Coarctation of aorta</text>
<text top="475" left="186" width="55" height="7" font="23">S10.8–28,S10.8–29, </text>
<text top="488" left="95" width="104" height="7" font="23">S10.8–44,S10.8–46,S10.8–56,S10.8–62</text>
<text top="474" left="413" width="16" height="12" font="4">2%</text>
<text top="474" left="528" width="16" height="12" font="4">2%</text>
<text top="474" left="611" width="103" height="12" font="4">Aneurysm at repair site</text>
<text top="488" left="611" width="65" height="12" font="4">Aortic stenosis</text>
<text top="501" left="611" width="99" height="12" font="4">Systemic hypertension</text>
<text top="515" left="611" width="151" height="12" font="4">Premature coronary artery disease</text>
<text top="535" left="85" width="89" height="12" font="4">  Ebstein’s anomaly</text>
<text top="536" left="174" width="78" height="7" font="23">S10.8–45,S10.8–47,S10.8–55</text>
<text top="535" left="413" width="16" height="12" font="4">2%</text>
<text top="535" left="517" width="38" height="12" font="4">3%–6%</text>
<text top="535" left="611" width="62" height="12" font="4">Cardiomegaly</text>
<text top="549" left="611" width="72" height="12" font="4">Atrial fibrillation</text>
<text top="562" left="611" width="117" height="12" font="4">Wide complex tachycardia</text>
<text top="576" left="611" width="87" height="12" font="4">Mitral regurgitation</text>
<text top="589" left="611" width="60" height="12" font="4">Dilated RVOT</text>
<text top="610" left="85" width="80" height="12" font="4">Severe complexity</text>
<text top="631" left="85" width="160" height="12" font="4">   Transposition of the great arteries</text>
<text top="631" left="245" width="102" height="7" font="23">S10.8–27,S10.8–44—S10.8–48,S10.8–</text>
<text top="645" left="95" width="86" height="7" font="23">51,S10.8–55,S10.8–56,S10.8–62</text>
<text top="631" left="418" width="3" height="12" font="4"> </text>
<text top="631" left="533" width="3" height="12" font="4"> </text>
<text top="631" left="611" width="55" height="12" font="4">Atrial switch</text>
<text top="665" left="85" width="55" height="12" font="4">  Atrial </text>
<text top="665" left="133" width="29" height="12" font="4">switch</text>
<text top="665" left="413" width="16" height="12" font="4">2%</text>
<text top="665" left="513" width="47" height="12" font="4">3%–9.5%</text>
<text top="665" left="611" width="66" height="12" font="4">Mustard repair</text>
<text top="686" left="85" width="64" height="12" font="4">  Arterial </text>
<text top="686" left="142" width="29" height="12" font="4">switch</text>
<text top="686" left="413" width="16" height="12" font="4">2%</text>
<text top="686" left="528" width="16" height="12" font="4">1%</text>
<text top="686" left="611" width="76" height="12" font="4">Prior VSD closure</text>
<text top="707" left="85" width="54" height="12" font="4">  cc-TGA</text>
<text top="707" left="410" width="22" height="12" font="4">10%</text>
<text top="707" left="511" width="50" height="12" font="4">17%–25%</text>
<text top="707" left="611" width="95" height="12" font="4">Unexplained syncope</text>
<text top="720" left="611" width="77" height="12" font="4">Atrial tachycardia</text>
<text top="734" left="611" width="109" height="12" font="4">Coronary orifice stenosis</text>
<text top="747" left="611" width="143" height="12" font="4">Systemic ventricular dysfunction</text>
<text top="761" left="611" width="131" height="12" font="4">Severe tricuspid regurgitation</text>
<text top="781" left="85" width="91" height="12" font="4">   Truncus  arteriosus</text>
<text top="782" left="176" width="51" height="7" font="23">S10.8–66,S10.8–67</text>
<text top="781" left="410" width="22" height="12" font="4">10%</text>
<text top="781" left="528" width="16" height="12" font="4">4%</text>
<text top="781" left="611" width="106" height="12" font="4">Multiple surgical repairs</text>
<text top="795" left="611" width="89" height="12" font="4">Coronary anomalies</text>
<text top="808" left="611" width="138" height="12" font="4">Ventricular dysfunction and/or </text>
<text top="822" left="611" width="54" height="12" font="4">hypertrophy</text>
<text top="845" left="85" width="15" height="9" font="32">  </text>
<text top="843" left="92" width="195" height="12" font="4">Fontan repair for univentricular physiology*</text>
<text top="843" left="287" width="55" height="7" font="23">S10.8–27,S10.8–37, </text>
<text top="857" left="92" width="131" height="7" font="23">S10.8–44,S10.8–45,S10.8–47,S10.8–55,S10.8–68</text>
<text top="843" left="399" width="44" height="12" font="4">5%–17%</text>
<text top="843" left="509" width="55" height="12" font="4">2.8%–5.4%</text>
<text top="843" left="611" width="77" height="12" font="4">Atrial tachycardia</text>
<text top="856" left="611" width="130" height="12" font="4">Longer duration of follow-up</text>
<text top="870" left="611" width="31" height="12" font="4">Ascites</text>
<text top="883" left="611" width="118" height="12" font="4">Protein-losing enteropathy</text>
<text top="907" left="86" width="654" height="12" font="4">*Univentricular physiology includes: Tricuspid atresia, Double inlet left ventricle, Mitral atresia, Hypoplastic left heart, Unbalanced AV septal defect.</text>
<text top="920" left="86" width="701" height="12" font="4">ASD indicates atrial septal defect; cc-TGA, congenitally corrected transposition of the great arteries; LV, left ventricular; LVEF, left ventricular ejection fraction; </text>
<text top="934" left="74" width="695" height="12" font="4">PR, pulmonary regurgitation; PS, pulmonary stenosis; RV, right ventricular; RVOT, right ventricular outflow tract; SCD, sudden cardiac death; VA, ventricular </text>
<text top="947" left="74" width="331" height="12" font="4">arrhythmia; VSD, ventricular septal defect; and VT, ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e345</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="653" left="111" width="314" height="17" font="17">Patients with adult congenital heart disease expe-</text>
<text top="671" left="111" width="314" height="17" font="17">rience a higher rate of complications and inap-</text>
<text top="690" left="111" width="325" height="17" font="17">propriate shocks compared with other adult </text>
<text top="708" left="111" width="79" height="17" font="17">populations.</text>
<text top="709" left="190" width="109" height="10" font="19">S10.8-13–S10.8-17,S10.8-39</text>
<text top="727" left="89" width="342" height="17" font="17">4.  Challenges of ICD implantation in patients with </text>
<text top="746" left="111" width="314" height="17" font="17">adult congenital heart disease may include ana-</text>
<text top="764" left="111" width="318" height="17" font="17">tomic complexity, intracardiac shunts, and limited </text>
<text top="783" left="111" width="317" height="17" font="17">vascular access to the ventricle. Patients with adult </text>
<text top="801" left="111" width="318" height="17" font="17">congenital heart disease receiving an ICD have an </text>
<text top="820" left="111" width="319" height="17" font="17">increased rate of complications of 26% to 45%, </text>
<text top="838" left="111" width="318" height="17" font="17">as well as inappropriate shocks in 15% to 25% of </text>
<text top="857" left="111" width="55" height="17" font="17">patients.</text>
<text top="858" left="166" width="109" height="10" font="19">S10.8-13–S10.8-16,S10.8-40</text>
<text top="857" left="275" width="156" height="17" font="17"> Limited studies on the </text>
<text top="876" left="111" width="314" height="17" font="17">use of subcutaneous implantable cardioverter-</text>
<text top="894" left="111" width="320" height="17" font="17">defibrillator implantation, particularly in patients </text>
<text top="913" left="111" width="225" height="17" font="17">with single ventricle anatomy,</text>
<text top="913" left="336" width="34" height="10" font="19">S10.8-41</text>
<text top="913" left="370" width="71" height="17" font="17"> report </text>
<text top="931" left="111" width="318" height="17" font="17">improved success by using right in addition to left </text>
<text top="950" left="111" width="280" height="17" font="17">parasternal lead positioning for screening.</text>
<text top="951" left="391" width="34" height="10" font="19">S10.8-42</text>
<text top="950" left="425" width="4" height="17" font="17"> </text>
<text top="968" left="111" width="319" height="17" font="17">Patients with a single ventricle or a systemic right </text>
<text top="987" left="111" width="314" height="17" font="17">ventricle may not tolerate defibrillation thresh-</text>
<text top="1006" left="111" width="314" height="17" font="17">old testing, resulting in multiorgan system fail-</text>
<text top="1024" left="111" width="324" height="17" font="17">ure. Patients with complex anatomy, such as </text>
<text top="1043" left="111" width="321" height="17" font="17">older patients with univentricular physiology, or </text>
<text top="1061" left="111" width="325" height="17" font="17">patients with significantly reduced ventricular </text>
<text top="1080" left="111" width="321" height="17" font="17">function, marked hypertrophy, or multiple prior </text>
<text top="653" left="489" width="319" height="17" font="17">surgeries, may benefit from earlier consideration </text>
<text top="671" left="489" width="314" height="17" font="17">of heart transplantation before renal or liver dys-</text>
<text top="690" left="489" width="129" height="17" font="17">function progresses.</text>
<text top="708" left="467" width="339" height="17" font="17">5.  Patients with repaired TOF who are at an increased </text>
<text top="727" left="489" width="314" height="17" font="17">risk of sustained VT include those with prior pal-</text>
<text top="746" left="489" width="318" height="17" font="17">liative systemic to pulmonary shunts, unexplained </text>
<text top="764" left="489" width="321" height="17" font="17">syncope, frequent PVCs, atrial tachycardia, QRS </text>
<text top="783" left="489" width="322" height="17" font="17">duration  ≥180  ms, decreased LVEF or diastolic </text>
<text top="801" left="489" width="314" height="17" font="17">dysfunction, dilated right ventricle, severe pulmo-</text>
<text top="820" left="489" width="320" height="17" font="17">nary regurgitation or stenosis, or elevated levels </text>
<text top="838" left="489" width="314" height="17" font="17">of BNP. Patients with TOF physiology and subop-</text>
<text top="857" left="489" width="318" height="17" font="17">timal hemodynamic status are more likely to have </text>
<text top="876" left="489" width="171" height="17" font="17">inducible sustained VT,</text>
<text top="876" left="660" width="143" height="10" font="19">S10.8-18,S10.8-19,S10.8-33,S10.8-35</text>
<text top="876" left="803" width="4" height="17" font="17"> </text>
<text top="894" left="489" width="322" height="17" font="17">and inducible sustained VT correlated with an </text>
<text top="913" left="489" width="323" height="17" font="17">increased risk of SCA in a multicenter cohort </text>
<text top="931" left="489" width="37" height="17" font="17">study.</text>
<text top="932" left="526" width="34" height="10" font="19">S10.8-19</text>
<text top="931" left="560" width="256" height="17" font="17"> Evaluation of hemodynamics for </text>
<text top="950" left="489" width="319" height="17" font="17">residual abnormalities is important, with catheter </text>
<text top="968" left="489" width="318" height="17" font="17">or surgical treatment of important lesions prior to </text>
<text top="987" left="489" width="220" height="17" font="17">consideration of ICD implantation.</text>
<text top="1006" left="467" width="343" height="17" font="17">6.  In a multicenter cohort, inducible sustained VT </text>
<text top="1024" left="489" width="322" height="17" font="17">in patients with TOF was an independent risk </text>
<text top="1043" left="489" width="276" height="17" font="17">factor for subsequent clinical VT or SCD</text>
<text top="1043" left="765" width="34" height="10" font="19">S10.8-19</text>
<text top="1043" left="799" width="8" height="17" font="17">; </text>
<text top="1061" left="489" width="318" height="17" font="17">patients in that early study had cardiomegaly and  </text>
<text top="1080" left="489" width="325" height="17" font="17">prior palliative shunts. Patients with repaired </text>
<text top="528" left="74" width="51" height="12" font="3"><b>Figure 16. </b></text>
<text top="528" left="125" width="328" height="12" font="22"><b>Prevention of SCD in patients with adult congenital heart disease.</b> </text>
<text top="541" left="74" width="703" height="12" font="4">Colors correspond to Class of Recommendation in Table 1. See Section 10.8 for discussion. *High-risk features: prior palliative systemic to pulmonary shunts, </text>
<text top="555" left="74" width="716" height="12" font="4">unexplained syncope, frequent PVC, atrial tachycardia, QRS duration ≥180 ms, decreased LVEF or diastolic dysfunction, dilated right ventricle, severe pulmonary </text>
<text top="568" left="74" width="722" height="12" font="4">regurgitation or stenosis, or elevated levels of BNP. †Frequent VA refers to frequent PVCs and/or nonsustained VT. ACHD indicates adult congenital heart disease; </text>
<text top="582" left="74" width="723" height="12" font="4">BNP, B-type natriuretic peptide; EP, electrophysiological; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; PVC, premature ventricu-</text>
<text top="596" left="74" width="561" height="12" font="4">lar complexes; SCD, sudden cardiac death; TOF, tetralogy of Fallot; VA, ventricular arrhythmia; and VT, ventricular tachycardia.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e346</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="331" height="17" font="17">TOF account for approximately 50% of </text>
<text top="106" left="111" width="326" height="17" font="17">ICD implantations in adult congenital heart </text>
<text top="106" left="425" width="4" height="17" font="17"> </text>
<text top="124" left="111" width="50" height="17" font="17">disease.</text>
<text top="124" left="161" width="109" height="10" font="19">S10.8-13–S10.8-16,S10.8-40</text>
<text top="124" left="270" width="160" height="17" font="17"> Appropriate ICD shocks </text>
<text top="142" left="111" width="318" height="17" font="17">occur in up to 7.7% per year of patients with TOF </text>
<text top="160" left="111" width="319" height="17" font="17">receiving the ICD for primary prevention, compared </text>
<text top="178" left="111" width="314" height="17" font="17">with 9.8% per year in patients with a secondary pre-</text>
<text top="196" left="111" width="74" height="17" font="17">vention ICD.</text>
<text top="197" left="185" width="32" height="10" font="19">S10.8-20</text>
<text top="196" left="217" width="211" height="17" font="17"> In another study including patients </text>
<text top="214" left="111" width="318" height="17" font="17">with TOF as well as other lesions, inducible sustained </text>
<text top="232" left="111" width="321" height="17" font="17">VT did not correlate with subsequent appropriate </text>
<text top="250" left="111" width="72" height="17" font="17">ICD shocks.</text>
<text top="251" left="183" width="32" height="10" font="19">S10.8-14</text>
<text top="250" left="215" width="216" height="17" font="17"> Because of the high incidence of </text>
<text top="268" left="111" width="314" height="17" font="17">inappropriate shocks in 20% to 30% and compli-</text>
<text top="286" left="111" width="314" height="17" font="17">cations in at least 30% of patients with adult con-</text>
<text top="304" left="111" width="142" height="17" font="17">genital heart disease,</text>
<text top="305" left="253" width="172" height="10" font="19">S10.8-14–S10.8-17,S10.8-39,S10.8-40,S10.8-43</text>
<text top="304" left="425" width="4" height="17" font="17"> </text>
<text top="322" left="111" width="320" height="17" font="17">in addition to financial and psychological burdens, </text>
<text top="340" left="111" width="314" height="17" font="17">shared decision-making regarding primary preven-</text>
<text top="358" left="111" width="126" height="17" font="17">tion ICDs is essential.</text>
<text top="376" left="89" width="339" height="17" font="17">7.  In patients with recurrent sustained monomorphic VT, </text>
<text top="394" left="111" width="246" height="17" font="17">catheter ablation of VT can be effective.</text>
<text top="395" left="357" width="68" height="10" font="19">S10.8-21–S10.8-25</text>
<text top="394" left="425" width="4" height="17" font="17"> </text>
<text top="412" left="111" width="319" height="17" font="17">Hemodynamic repair, at the time that an arrhythmia </text>
<text top="430" left="111" width="319" height="17" font="17">is being ablated surgically, should be considered. For </text>
<text top="448" left="111" width="318" height="17" font="17">patients with complex adult congenital heart disease, </text>
<text top="466" left="111" width="318" height="17" font="17">care should be provided at experienced centers. After </text>
<text top="485" left="111" width="318" height="17" font="17">successful catheter ablation of VT, implantation of an </text>
<text top="503" left="111" width="314" height="17" font="17">ICD for those who do not have an ICD is an individu-</text>
<text top="521" left="111" width="314" height="17" font="17">alized decision based on overall functional and physi-</text>
<text top="539" left="111" width="320" height="17" font="17">ological status and shared decision making. Careful </text>
<text top="557" left="111" width="314" height="17" font="17">monitoring during follow-up for recurrent arrhyth-</text>
<text top="575" left="111" width="97" height="17" font="17">mias is essential.</text>
<text top="593" left="89" width="342" height="17" font="17">8.  The highest risk of SCD associated with repaired </text>
<text top="611" left="111" width="314" height="17" font="17">congenital heart disease reported from large con-</text>
<text top="629" left="111" width="314" height="17" font="17">temporaneous cohorts is in patients with transpo-</text>
<text top="647" left="111" width="319" height="17" font="17">sition of the great arteries with atrial baffle repair, </text>
<text top="665" left="111" width="314" height="17" font="17">Ebstein anomaly of the tricuspid valve, aortic ste-</text>
<text top="683" left="111" width="243" height="17" font="17">nosis, and univentricular physiology.</text>
<text top="684" left="354" width="72" height="10" font="19">S10.8-44–S10.8-47</text>
<text top="683" left="425" width="4" height="17" font="17"> </text>
<text top="701" left="111" width="323" height="17" font="17">Patients with Senning or Mustard atrial baffle </text>
<text top="719" left="111" width="318" height="17" font="17">repairs are at an increased risk for SCA, particularly </text>
<text top="737" left="111" width="101" height="17" font="17">during exertion.</text>
<text top="738" left="212" width="34" height="10" font="19">S10.8-48</text>
<text top="737" left="246" width="180" height="17" font="17"> The atrial baffle is noncom-</text>
<text top="755" left="111" width="321" height="17" font="17">pliant restricting ability to augment volume and </text>
<text top="773" left="111" width="320" height="17" font="17">may be associated with pulmonary vein stenosis </text>
<text top="791" left="111" width="318" height="17" font="17">and increased end-diastolic pressures. RV ischemia </text>
<text top="809" left="111" width="314" height="17" font="17">and infarction occur, with perfusion defects identi-</text>
<text top="827" left="111" width="320" height="17" font="17">fied by myocardial perfusion studies in &gt;40% of </text>
<text top="845" left="111" width="169" height="17" font="17">patients in this population.</text>
<text top="846" left="280" width="70" height="10" font="19">S10.8-49,S10.8-50</text>
<text top="845" left="349" width="80" height="17" font="17"> Risk factors </text>
<text top="863" left="111" width="322" height="17" font="17">for cardiac arrest in patients with transposition </text>
<text top="881" left="111" width="314" height="17" font="17">and atrial baffle repairs include prior ventricu-</text>
<text top="899" left="111" width="321" height="17" font="17">lar septal defect closure, symptoms of HF, atrial </text>
<text top="917" left="111" width="314" height="17" font="17">arrhythmia, RVEF &lt;30% to 35%, and QRS dura-</text>
<text top="936" left="111" width="89" height="17" font="17">tion ≥140 ms.</text>
<text top="936" left="200" width="70" height="10" font="19">S10.8-48,S10.8-51</text>
<text top="936" left="269" width="160" height="17" font="17"> In the single multicenter </text>
<text top="954" left="111" width="322" height="17" font="17">study assessing outcomes after implantation of </text>
<text top="972" left="111" width="319" height="17" font="17">an ICD in patients with prior atrial baffle repair of </text>
<text top="990" left="111" width="318" height="17" font="17">transposition of the great arteries, the lack of beta </text>
<text top="1008" left="111" width="314" height="17" font="17">blockers was associated with a high risk of appro-</text>
<text top="1026" left="111" width="126" height="17" font="17">priate ICD therapy.</text>
<text top="1026" left="237" width="34" height="10" font="19">S10.8-26</text>
<text top="1026" left="271" width="154" height="17" font="17"> Atrial arrhythmias fre-</text>
<text top="1044" left="111" width="319" height="17" font="17">quently precede VT in transposition patients, and </text>
<text top="1062" left="111" width="314" height="17" font="17">treatments for atrial tachycardia including cath-</text>
<text top="1080" left="111" width="321" height="17" font="17">eter ablation, antitachycardia pacing algorithms, </text>
<text top="88" left="489" width="321" height="17" font="17">and beta blockers are important to reduce ICD </text>
<text top="106" left="489" width="46" height="17" font="17">shocks.</text>
<text top="107" left="535" width="106" height="10" font="19">S10.8-26,S10.8-52,S10.8-53</text>
<text top="124" left="467" width="345" height="17" font="17">9. The risk of SCD is increased among patients </text>
<text top="143" left="489" width="323" height="17" font="17">with adult congenital heart disease compared </text>
<text top="161" left="489" width="322" height="17" font="17">with the general population, with the median </text>
<text top="179" left="489" width="322" height="17" font="17">age at death ranging from 30 to 49 years of </text>
<text top="198" left="489" width="28" height="17" font="17">age.</text>
<text top="199" left="517" width="180" height="10" font="19">S10.8-27,S10.8-44,S10.8-47,S10.8-54,S10.8-55</text>
<text top="198" left="696" width="112" height="17" font="17"> The risk of SCD </text>
<text top="216" left="489" width="324" height="17" font="17">is highest among patients with moderate or </text>
<text top="235" left="489" width="321" height="17" font="17">severe  complexity congenital heart disease, and </text>
<text top="253" left="489" width="317" height="17" font="17">accounts for approximately 25% of cardiac causes </text>
<text top="271" left="489" width="64" height="17" font="17">of death.</text>
<text top="272" left="553" width="250" height="10" font="19">S10.8-5,S10.8-27,S10.8-28,S10.8-44–S10.8-46,S10.8-55,S10.8-56</text>
<text top="271" left="803" width="9" height="17" font="17">  </text>
<text top="290" left="489" width="314" height="17" font="17">Patients with septal defects  and a positive fam-</text>
<text top="308" left="489" width="321" height="17" font="17">ily history of septal defects, cardiomyopathy, or </text>
<text top="326" left="489" width="327" height="17" font="17">bundle-branch block/conduction defects may </text>
<text top="345" left="489" width="318" height="17" font="17">have the gene mutation <i>NKX2.5</i>, which portends </text>
<text top="363" left="489" width="318" height="17" font="17">an increased risk of early SCD; genetic testing and </text>
<text top="382" left="489" width="318" height="17" font="17">early consideration of ICD implantation if positive </text>
<text top="400" left="489" width="87" height="17" font="17">is warranted.</text>
<text top="401" left="576" width="72" height="10" font="19">S10.8-57–S10.8-59</text>
<text top="400" left="649" width="163" height="17" font="17"> Patients with repaired </text>
<text top="418" left="489" width="320" height="17" font="17">complex forms of congenital heart disease have </text>
<text top="437" left="489" width="320" height="17" font="17">undergone multiple intracardiac surgeries in the </text>
<text top="455" left="489" width="314" height="17" font="17">first few decades of life with resultant hypertro-</text>
<text top="473" left="489" width="319" height="17" font="17">phy and risk for subendocardial ischemia as well </text>
<text top="492" left="489" width="314" height="17" font="17">as scar formation contributing to VT/VF. Risk fac-</text>
<text top="510" left="489" width="323" height="17" font="17">tors for SCD include increasing complexity of </text>
<text top="529" left="489" width="317" height="17" font="17">heart disease, VA, SVT, progressive increase in QRS </text>
<text top="547" left="489" width="323" height="17" font="17">duration, systemic ventricular dysfunction, and </text>
<text top="565" left="489" width="251" height="17" font="17">subpulmonary ventricular dysfunction.</text>
<text top="566" left="740" width="66" height="10" font="19">S10.8-1,S10.8-5, </text>
<text top="584" left="489" width="314" height="10" font="19">S10.8-6,S10.8-14,S10.8-28,S10.8-29,S10.8-36,S10.8-45–S10.8-47,S10.8-55</text>
<text top="584" left="803" width="4" height="17" font="17"> </text>
<text top="602" left="489" width="318" height="17" font="17">Extrapolation of data regarding specific measures </text>
<text top="620" left="489" width="318" height="17" font="17">of ventricular function warranting implantation of </text>
<text top="639" left="489" width="319" height="17" font="17">primary prevention ICDs from adult patients with </text>
<text top="657" left="489" width="314" height="17" font="17">NICM is unrealistic. The development of unex-</text>
<text top="676" left="489" width="323" height="17" font="17">plained syncope in patients with moderate or </text>
<text top="694" left="489" width="320" height="17" font="17">severe complexity adult congenital heart disease </text>
<text top="712" left="489" width="314" height="17" font="17">may be a harbinger of risk for SCD; electrophysi-</text>
<text top="731" left="489" width="321" height="17" font="17">ological study with consideration for an ICD as </text>
<text top="749" left="489" width="236" height="17" font="17">primary prevention can be beneficial.</text>
<text top="767" left="459" width="344" height="17" font="17">10. ICDs implanted in patients with adult con-</text>
<text top="786" left="489" width="325" height="17" font="17">genital heart disease, who are in their 40s </text>
<text top="804" left="489" width="326" height="17" font="17">and 50s, for primary prevention indications </text>
<text top="823" left="489" width="322" height="17" font="17">now account for &gt;40% to 67% of implanted </text>
<text top="841" left="489" width="320" height="17" font="17">devices in patients with adult congenital heart  </text>
<text top="859" left="489" width="52" height="17" font="17">disease.</text>
<text top="860" left="541" width="145" height="10" font="19">S10.8-13,S10.8-15,S10.8-16,S10.8-41</text>
<text top="859" left="686" width="122" height="17" font="17"> In these patients, </text>
<text top="878" left="489" width="325" height="17" font="17">appropriate shocks are delivered in 14% to </text>
<text top="896" left="489" width="314" height="17" font="17">22% of patients in the first 3 to 5 years of fol-</text>
<text top="914" left="489" width="49" height="17" font="17">low-up.</text>
<text top="915" left="538" width="107" height="10" font="19">S10.8-13,S10.8-15,S10.8-16</text>
<text top="914" left="645" width="158" height="17" font="17"> In patients with con-</text>
<text top="933" left="489" width="325" height="17" font="17">genital heart disease and severely depressed </text>
<text top="951" left="489" width="314" height="17" font="17">ventricular function, or single ventricle anat-</text>
<text top="970" left="489" width="323" height="17" font="17">omy, defibrillation threshold testing may pose </text>
<text top="988" left="489" width="314" height="17" font="17">excessively high risk. In patients without vas-</text>
<text top="1006" left="489" width="321" height="17" font="17">cular access or prior Fontan repairs, the risk of </text>
<text top="1025" left="489" width="322" height="17" font="17">reoperation with sternotomy for epicardial ICD </text>
<text top="1043" left="489" width="314" height="17" font="17">implantation may outweigh the potential ben-</text>
<text top="1061" left="489" width="319" height="17" font="17">efits, and consideration for transplant evaluation </text>
<text top="1080" left="489" width="324" height="17" font="17">may be preferable. Subcutaneous implantable </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e347</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="320" height="17" font="17">cardioverter-defibrillator implantation may be an </text>
<text top="106" left="111" width="240" height="17" font="17">appropriate option for some patients.</text>
<text top="106" left="351" width="70" height="10" font="19">S10.8-42,S10.8-53</text>
<text top="124" left="81" width="352" height="17" font="17">11. Adult patients with complex adult congenital </text>
<text top="142" left="111" width="324" height="17" font="17">heart disease typically have hypertrophy and </text>
<text top="160" left="111" width="328" height="17" font="17">ventricular dysfunction of varying degrees, </text>
<text top="178" left="111" width="322" height="17" font="17">increasing their risk for worsening ventricular </text>
<text top="196" left="111" width="325" height="17" font="17">function with antiarrhythmic medications. In </text>
<text top="214" left="111" width="314" height="17" font="17">the only large study of antiarrhythmic medi-</text>
<text top="232" left="111" width="323" height="17" font="17">cations for congenital heart disease, the use </text>
<text top="250" left="111" width="314" height="17" font="17">of flecainide was associated with proarrhyth-</text>
<text top="268" left="111" width="321" height="17" font="17">mia in 5.8% of patients and SCA in 3.9% of </text>
<text top="286" left="111" width="56" height="17" font="17">patients.</text>
<text top="287" left="167" width="35" height="10" font="19">S10.8-30</text>
<text top="286" left="202" width="223" height="17" font="17"> The use of amiodarone is gener-</text>
<text top="304" left="111" width="321" height="17" font="17">ally reserved for refractory symptomatic VA or </text>
<text top="322" left="111" width="314" height="17" font="17">asymptomatic VA that can aggravate ventricu-</text>
<text top="340" left="111" width="320" height="17" font="17">lar dysfunction, due to the high risk of adverse </text>
<text top="358" left="111" width="318" height="17" font="17">effects including thyroid dysfunction, particularly </text>
<text top="376" left="111" width="319" height="17" font="17">among females and patients with univentricular </text>
<text top="394" left="111" width="72" height="17" font="17">physiology.</text>
<text top="395" left="183" width="72" height="10" font="19">S10.8-31,S10.8-32</text>
<text top="442" left="74" width="315" height="23" font="15"><b>11. DEFIBRILLATORS OTHER THAN </b></text>
<text top="464" left="74" width="187" height="23" font="15"><b>TRANSVENOUS ICDS</b></text>
<text top="493" left="74" width="275" height="21" font="18"><b>11.1. Subcutaneous Implantable </b></text>
<text top="514" left="74" width="214" height="21" font="18"><b>Cardioverter-Defibrillator</b></text>
<text top="548" left="85" width="310" height="12" font="26"><b>Recommendations for Subcutaneous Implantable Cardioverter-</b></text>
<text top="561" left="85" width="60" height="12" font="26"><b>Defibrillator</b></text>
<text top="578" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="592" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 55</b></a></text>
<text top="592" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="612" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="612" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="612" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="681" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="681" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="633" left="205" width="196" height="12" font="4">1.  In patients who meet criteria for an ICD </text>
<text top="647" left="217" width="173" height="12" font="4">who have inadequate vascular access </text>
<text top="660" left="217" width="166" height="12" font="4">or are at high risk for infection, and </text>
<text top="674" left="217" width="176" height="12" font="4">in whom pacing for bradycardia or VT </text>
<text top="688" left="217" width="182" height="12" font="4">termination or as part of CRT is neither </text>
<text top="701" left="217" width="187" height="12" font="4">needed nor anticipated, a subcutaneous </text>
<text top="715" left="217" width="179" height="12" font="4">implantable cardioverter-defibrillator is </text>
<text top="728" left="217" width="69" height="12" font="4">recommended.</text>
<text top="728" left="286" width="45" height="7" font="23">S11.1-1–S11.1-5</text>
<text top="783" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="783" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="749" left="205" width="208" height="12" font="4">2.  In patients who meet indication for an ICD, </text>
<text top="762" left="217" width="200" height="12" font="4">implantation of a subcutaneous implantable </text>
<text top="776" left="217" width="179" height="12" font="4">cardioverter-defibrillator is reasonable if </text>
<text top="789" left="217" width="185" height="12" font="4">pacing for bradycardia or VT termination </text>
<text top="803" left="217" width="177" height="12" font="4">or as part of CRT is neither needed nor </text>
<text top="816" left="217" width="52" height="12" font="4">anticipated.</text>
<text top="817" left="269" width="44" height="7" font="23">S11.1-1–S11.1-4</text>
<text top="871" left="84" width="41" height="12" font="22"><b>III: Harm</b></text>
<text top="871" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="837" left="205" width="164" height="12" font="4">3.  In patients with an indication for </text>
<text top="851" left="217" width="186" height="12" font="4">bradycardia pacing or CRT, or for whom </text>
<text top="864" left="217" width="192" height="12" font="4">antitachycardia pacing for VT termination </text>
<text top="878" left="217" width="184" height="12" font="4">is required, a subcutaneous implantable </text>
<text top="891" left="217" width="179" height="12" font="4">cardioverter-defibrillator should not be </text>
<text top="905" left="217" width="49" height="12" font="4">implanted.</text>
<text top="905" left="266" width="91" height="7" font="23">S11.1-1–S11.1-4,S11.1-6–S11.1-8</text>
<text top="945" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="972" left="74" width="351" height="17" font="17">In patients being considered for a subcutaneous im-</text>
<text top="990" left="74" width="359" height="17" font="17">plantable cardioverter-defibrillator, a preimplant ECG </text>
<text top="1008" left="74" width="351" height="17" font="17">to establish QRS-T wave morphology is needed to re-</text>
<text top="1026" left="74" width="357" height="17" font="17">duce the risk of under sensing of VT/VF and the risk </text>
<text top="1044" left="74" width="159" height="17" font="17">of inappropriate shocks.</text>
<text top="1044" left="233" width="68" height="10" font="19">S11.1-9–S11.1-11</text>
<text top="1044" left="300" width="131" height="17" font="17"> The subcutaneous </text>
<text top="1062" left="74" width="355" height="17" font="17">implantable cardioverter-defibrillator is implanted using </text>
<text top="1080" left="74" width="354" height="17" font="17">primarily anatomical landmarks, thereby minimizing the </text>
<text top="88" left="452" width="359" height="17" font="17">need for fluoroscopy. The subcutaneous implantable </text>
<text top="106" left="452" width="357" height="17" font="17">cardioverter-defibrillator consists of a pulse generator </text>
<text top="124" left="452" width="356" height="17" font="17">that is placed at the midaxillary line between the fifth </text>
<text top="142" left="452" width="356" height="17" font="17">and sixth intercostal spaces and a lead with 2 sensing </text>
<text top="160" left="452" width="351" height="17" font="17">electrodes and a shocking coil, positioned subcutane-</text>
<text top="178" left="452" width="355" height="17" font="17">ously adjacent to the sternum. As with the transvenous </text>
<text top="196" left="452" width="355" height="17" font="17">ICD, the pulse generator housing serves as an electrode </text>
<text top="214" left="452" width="357" height="17" font="17">for defibrillation but, in addition, it can also serve as </text>
<text top="232" left="452" width="358" height="17" font="17">an optional electrode for sensing. The subcutaneous </text>
<text top="250" left="452" width="361" height="17" font="17">implantable cardioverter-defibrillator cannot achieve </text>
<text top="268" left="452" width="351" height="17" font="17">adequate arrhythmia sensing for all patients, and elec-</text>
<text top="286" left="452" width="355" height="17" font="17">trocardiographic screening to assess sensing is required </text>
<text top="304" left="452" width="140" height="17" font="17">prior to implantation.</text>
<text top="304" left="592" width="70" height="10" font="19">S11.1-10,S11.1-11</text>
<text top="304" left="662" width="141" height="17" font="17"> Some advocate exer-</text>
<text top="322" left="452" width="356" height="17" font="17">cise testing after device implantation to ensure proper </text>
<text top="340" left="452" width="138" height="17" font="17">sensing with exercise.</text>
<text top="358" left="470" width="343" height="17" font="17">Both transvenous and subcutaneous implantable </text>
<text top="376" left="452" width="361" height="17" font="17">cardioverter-defibrillators have SVT-VT discriminators </text>
<text top="394" left="452" width="359" height="17" font="17">that can be programmed to facilitate discrimination </text>
<text top="412" left="452" width="357" height="17" font="17">of SVT from VT; however, these discriminators do not </text>
<text top="430" left="452" width="357" height="17" font="17">always work. If sustained VT is confirmed, therapy to </text>
<text top="448" left="452" width="356" height="17" font="17">terminate the arrhythmia is delivered. All ICDs provide </text>
<text top="466" left="452" width="356" height="17" font="17">shocks to terminate VT or VF, but shocks in an awake </text>
<text top="484" left="452" width="355" height="17" font="17">patient are painful and associated with decreased QoL. </text>
<text top="502" left="452" width="356" height="17" font="17">Transvenous ICDs are capable of bradycardia pacing as </text>
<text top="520" left="452" width="355" height="17" font="17">well as antitachycardia pacing that can terminate many </text>
<text top="538" left="452" width="351" height="17" font="17">VTs painlessly. Subcutaneous implantable cardioverter-</text>
<text top="556" left="452" width="362" height="17" font="17">defibrillators provide limited postshock bradycardia </text>
<text top="574" left="452" width="351" height="17" font="17">pacing but do not provide either bradycardia or antit-</text>
<text top="592" left="452" width="118" height="17" font="17">achycardia pacing.</text>
<text top="610" left="470" width="333" height="17" font="17">The subcutaneous implantable cardioverter-defibril-</text>
<text top="628" left="452" width="355" height="17" font="17">lator recommendations supplant, but do not nullify, the </text>
<text top="646" left="452" width="355" height="17" font="17">need for waiting periods and other requirements to be </text>
<text top="664" left="452" width="358" height="17" font="17">satisfied for ICD/CRT implantation specified in other </text>
<text top="682" left="452" width="149" height="17" font="17">parts of this document.</text>
<text top="725" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="746" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="774" left="467" width="336" height="17" font="17">1. The subcutaneous implantable cardioverter-</text>
<text top="792" left="489" width="320" height="17" font="17">defibrillator was designed to avoid the need for </text>
<text top="810" left="489" width="322" height="17" font="17">venous access and some of the complications </text>
<text top="828" left="489" width="216" height="17" font="17">of inserting transvenous lead(s)</text>
<text top="828" left="705" width="63" height="10" font="19">S11.1-1–S11.1-4</text>
<text top="828" left="767" width="46" height="17" font="17"> that </text>
<text top="846" left="489" width="319" height="17" font="17">include pneumothorax, hemothorax, and cardiac </text>
<text top="864" left="489" width="78" height="17" font="17">tamponade.</text>
<text top="864" left="567" width="34" height="10" font="19">S11.1-12</text>
<text top="864" left="601" width="208" height="17" font="17"> Difficulties in achieving venous </text>
<text top="882" left="489" width="321" height="17" font="17">access can prolong the implantation procedure </text>
<text top="900" left="489" width="318" height="17" font="17">and occasionally result in failed ICD implantation. </text>
<text top="918" left="489" width="314" height="17" font="17">These difficulties are more likely to be encoun-</text>
<text top="936" left="489" width="319" height="17" font="17">tered in patients with limited venous access such </text>
<text top="954" left="489" width="320" height="17" font="17">as patients with ESRD. In a study of 27 patients </text>
<text top="972" left="489" width="314" height="17" font="17">with ESRD, the subcutaneous implantable car-</text>
<text top="990" left="489" width="324" height="17" font="17">dioverter-defibrillator was not associated with </text>
<text top="1008" left="489" width="320" height="17" font="17">an increased risk of procedural complications or </text>
<text top="1026" left="489" width="140" height="17" font="17">inappropriate shocks.</text>
<text top="1026" left="629" width="29" height="10" font="19">S11.1-5</text>
<text top="1026" left="658" width="153" height="17" font="17"> The risk of infection </text>
<text top="1044" left="489" width="314" height="17" font="17">appears to be lower with subcutaneous implant-</text>
<text top="1062" left="489" width="314" height="17" font="17">able cardioverter-defibrillators than with transve-</text>
<text top="1080" left="489" width="71" height="17" font="17">nous ICDs.</text>
<text top="1081" left="560" width="63" height="10" font="19">S11.1-1–S11.1-4</text>
<text top="1080" left="622" width="187" height="17" font="17"> Therefore,  a subcutaneous </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e348</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="314" height="17" font="17">implantable cardioverter-defibrillator may be pre-</text>
<text top="106" left="111" width="314" height="17" font="17">ferred in patients who are at high risk of infec-</text>
<text top="124" left="111" width="320" height="17" font="17">tion, such as those with a prior device infection, </text>
<text top="142" left="111" width="321" height="17" font="17">ESRD, diabetes  mellitus, or who are chronically </text>
<text top="160" left="111" width="128" height="17" font="17">immunosuppressed.</text>
<text top="178" left="89" width="336" height="17" font="17">2. Nonrandomized studies show that the subcu-</text>
<text top="196" left="111" width="330" height="17" font="17">taneous implantable cardioverter-defibrillator </text>
<text top="214" left="111" width="314" height="17" font="17">reliably detects and converts VF during defibril-</text>
<text top="232" left="111" width="314" height="17" font="17">lation threshold testing and successfully termi-</text>
<text top="250" left="111" width="325" height="17" font="17">nates spontaneous sustained VT that occurs </text>
<text top="268" left="111" width="116" height="17" font="17">during follow-up.</text>
<text top="269" left="227" width="66" height="10" font="19">S11.1-1,S11.1-13</text>
<text top="268" left="294" width="139" height="17" font="17"> In 1 study of 314 </text>
<text top="286" left="111" width="318" height="17" font="17">patients, the 180-day complication-free rate was </text>
<text top="304" left="111" width="322" height="17" font="17">99%, and the success of VF termination with </text>
<text top="322" left="111" width="146" height="17" font="17">first shock was &gt;90%.</text>
<text top="323" left="257" width="29" height="10" font="19">S11.1-2</text>
<text top="322" left="287" width="138" height="17" font="17"> All spontaneous epi-</text>
<text top="340" left="111" width="321" height="17" font="17">sodes of VT/VF recorded in 21 patients (6.7%) </text>
<text top="358" left="111" width="320" height="17" font="17">were successfully converted, and there were no </text>
<text top="376" left="111" width="314" height="17" font="17">lead failures, endocarditis or bacteremia, tam-</text>
<text top="394" left="111" width="321" height="17" font="17">ponade, cardiac perforation, pneumothorax, or </text>
<text top="412" left="111" width="322" height="17" font="17">hemothorax associated with the subcutaneous </text>
<text top="430" left="111" width="238" height="17" font="17">implantable cardioverter-defibrillator.</text>
<text top="431" left="349" width="29" height="10" font="19">S11.1-2</text>
<text top="430" left="379" width="51" height="17" font="17"> In 472 </text>
<text top="448" left="111" width="320" height="17" font="17">patients enrolled in the EFFORTLESS (Evaluation </text>
<text top="466" left="111" width="319" height="17" font="17">of Factors Impacting Clinical Outcome and Cost </text>
<text top="484" left="111" width="223" height="17" font="17">Effectiveness of the S-ICD) registry,</text>
<text top="485" left="334" width="29" height="10" font="19">S11.1-3</text>
<text top="484" left="364" width="62" height="17" font="17"> the com-</text>
<text top="503" left="111" width="321" height="17" font="17">plication-free rate was 94%, at 360 days. First </text>
<text top="521" left="111" width="320" height="17" font="17">shock conversion efficacy was 88% with 100% </text>
<text top="539" left="111" width="314" height="17" font="17">overall successful clinical conversion after a maxi-</text>
<text top="557" left="111" width="322" height="17" font="17">mum of 5 shocks. In 882 patients enrolled in </text>
<text top="575" left="111" width="322" height="17" font="17">investigational device exemption trials and the </text>
<text top="593" left="111" width="134" height="17" font="17">EFFORTLESS registry,</text>
<text top="593" left="246" width="29" height="10" font="19">S11.1-4</text>
<text top="593" left="275" width="150" height="17" font="17"> 111 spontaneous VT/</text>
<text top="611" left="111" width="321" height="17" font="17">VF events were treated in 59 patients; 90.1% </text>
<text top="629" left="111" width="319" height="17" font="17">were terminated with 1 shock, and 98.2% were </text>
<text top="647" left="111" width="322" height="17" font="17">terminated within the 5 available shocks. The </text>
<text top="665" left="111" width="321" height="17" font="17">estimated 3-year inappropriate shock rate was </text>
<text top="683" left="111" width="314" height="17" font="17">13.1% most due to oversensing of cardiac sig-</text>
<text top="701" left="111" width="323" height="17" font="17">nals, and mortality was 4.7%. Device-related </text>
<text top="719" left="111" width="318" height="17" font="17">complications occurred in 11.1% of patients. An </text>
<text top="737" left="111" width="314" height="17" font="17">ongoing trial will compare the effect of the sub-</text>
<text top="755" left="111" width="323" height="17" font="17">cutaneous implantable cardioverter-defibrillator </text>
<text top="773" left="111" width="314" height="17" font="17">with that of the transvenous ICD on the out-</text>
<text top="791" left="111" width="322" height="17" font="17">comes of inappropriate shocks, complications, </text>
<text top="809" left="111" width="186" height="17" font="17">shock efficacy, and mortality.</text>
<text top="810" left="297" width="34" height="10" font="19">S11.1-13</text>
<text top="827" left="89" width="336" height="17" font="17">3. The subcutaneous implantable cardioverter-</text>
<text top="845" left="111" width="314" height="17" font="17">defibrillator is incapable of bradycardia pac-</text>
<text top="863" left="111" width="328" height="17" font="17">ing, biventricular pacing, or antitachycardia </text>
<text top="881" left="111" width="324" height="17" font="17">pacing. Therefore, patients who need any of </text>
<text top="899" left="111" width="319" height="17" font="17">these types of pacing from an ICD should not be </text>
<text top="917" left="111" width="314" height="17" font="17">offered a subcutaneous implantable cardioverter-</text>
<text top="936" left="111" width="76" height="17" font="17">defibrillator.</text>
<text top="936" left="187" width="29" height="10" font="19">S11.1-6</text>
<text top="936" left="216" width="220" height="17" font="17"> Some clinical scenarios may </text>
<text top="954" left="111" width="320" height="17" font="17">come up in which a transvenous pacemaker for </text>
<text top="972" left="111" width="314" height="17" font="17">bradycardia pacing in a patient with a subcutane-</text>
<text top="990" left="111" width="323" height="17" font="17">ous implantable cardioverter-defibrillator which </text>
<text top="1008" left="111" width="320" height="17" font="17">is needed; this can be performed as long as the </text>
<text top="1026" left="111" width="322" height="17" font="17">pacing is not unipolar. Leadless pacing devices </text>
<text top="1044" left="111" width="320" height="17" font="17">for patients who require bradycardia pacing will </text>
<text top="1062" left="111" width="319" height="17" font="17">be evaluated with the subcutaneous implantable </text>
<text top="1080" left="111" width="274" height="17" font="17">cardioverter-defibrillator in the near future.</text>
<text top="87" left="452" width="345" height="21" font="18"><b>11.2. Wearable Cardioverter-Defibrillator</b></text>
<text top="121" left="463" width="286" height="12" font="26"><b>Recommendations for Wearable Cardioverter-Defibrillator</b></text>
<text top="138" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="151" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 56</b></a></text>
<text top="151" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="172" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="172" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="172" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="220" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="220" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="193" left="583" width="212" height="12" font="4">1.  In patients with an ICD and a history of SCA </text>
<text top="207" left="595" width="203" height="12" font="4">or sustained VA in whom removal of the ICD </text>
<text top="220" left="595" width="196" height="12" font="4">is required (as with infection), the wearable </text>
<text top="234" left="595" width="204" height="12" font="4">cardioverter-defibrillator is reasonable for the </text>
<text top="247" left="595" width="85" height="12" font="4">prevention of SCD.</text>
<text top="248" left="680" width="44" height="7" font="23">S11.2-1–S11.2-4</text>
<text top="329" left="476" width="12" height="12" font="22"><b>IIb</b></text>
<text top="329" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="268" left="583" width="184" height="12" font="4">2.  In patients at an increased risk of SCD </text>
<text top="281" left="595" width="170" height="12" font="4">but who are not ineligible for an ICD, </text>
<text top="295" left="595" width="162" height="12" font="4">such as awaiting cardiac transplant, </text>
<text top="308" left="595" width="174" height="12" font="4">having an LVEF of 35% or less and are </text>
<text top="322" left="595" width="189" height="12" font="4">within 40 days from an MI, or have newly </text>
<text top="335" left="595" width="188" height="12" font="4">diagnosed NICM, revascularization within </text>
<text top="349" left="595" width="193" height="12" font="4">the past 90 days, myocarditis or secondary </text>
<text top="362" left="595" width="198" height="12" font="4">cardiomyopathy or a systemic infection, the </text>
<text top="376" left="595" width="189" height="12" font="4">wearable cardioverter-defibrillator may be </text>
<text top="389" left="595" width="51" height="12" font="4">reasonable.</text>
<text top="390" left="646" width="44" height="7" font="23">S11.2-1–S11.2-5</text>
<text top="430" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="457" left="452" width="351" height="17" font="17">The wearable cardioverter-defibrillator is a vestlike de-</text>
<text top="475" left="452" width="351" height="17" font="17">vice worn under the clothing that continuously moni-</text>
<text top="494" left="452" width="359" height="17" font="17">tors the heart rhythm and automatically delivers an </text>
<text top="512" left="452" width="357" height="17" font="17">electric shock when VF or VT is detected. This device </text>
<text top="530" left="452" width="359" height="17" font="17">is intended to be worn continuously, 24 hours per </text>
<text top="548" left="452" width="356" height="17" font="17">day, except when the wearer is bathing or showering. </text>
<text top="567" left="452" width="351" height="17" font="17">The wearable cardioverter-defibrillator has been ap-</text>
<text top="585" left="452" width="356" height="17" font="17">proved in the United States by the US Food and Drug </text>
<text top="603" left="452" width="357" height="17" font="17">Administration for patients who are “at risk for SCA </text>
<text top="622" left="452" width="358" height="17" font="17">and are not candidates for or refuse an implantable </text>
<text top="640" left="452" width="84" height="17" font="17">defibrillator.”</text>
<text top="641" left="537" width="29" height="10" font="19">S11.2-6</text>
<text top="640" left="566" width="245" height="17" font="17"> A science advisory from the AHA </text>
<text top="658" left="452" width="355" height="17" font="17">summarizes the data and recommendations for the use </text>
<text top="676" left="452" width="259" height="17" font="17">of the wearable cardioverter-defibrillator.</text>
<text top="677" left="712" width="29" height="10" font="19">S11.2-4</text>
<text top="677" left="741" width="63" height="17" font="17"> Effective-</text>
<text top="695" left="452" width="351" height="17" font="17">ness of the wearable cardioverter-defibrillator in recog-</text>
<text top="713" left="452" width="354" height="17" font="17">nition and defibrillation of VF has been demonstrated in </text>
<text top="731" left="452" width="355" height="17" font="17">a number of studies, although no RCTs support the use </text>
<text top="750" left="452" width="355" height="17" font="17">of the wearable cardioverter-defibrillator. Among 3569 </text>
<text top="768" left="452" width="357" height="17" font="17">patients who received the device for various reasons, </text>
<text top="786" left="452" width="355" height="17" font="17">for at least 1 day in the US manufacturer registry, there </text>
<text top="805" left="452" width="356" height="17" font="17">were 80 VT/VF events in 59 patients, with a frequency </text>
<text top="823" left="452" width="355" height="17" font="17">of 1.7% per patient-year. First shock efficacy was 99%, </text>
<text top="841" left="452" width="351" height="17" font="17">with postshock survival of 90%. Overall, 2% of the pa-</text>
<text top="859" left="452" width="246" height="17" font="17">tients received an inappropriate shock.</text>
<text top="860" left="698" width="29" height="10" font="19">S11.2-1</text>
<text top="903" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="924" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="952" left="467" width="343" height="17" font="17">1.  Removal of an ICD for a period of time, most </text>
<text top="970" left="489" width="320" height="17" font="17">commonly due to infection, exposes the patient </text>
<text top="988" left="489" width="322" height="17" font="17">to risk of untreated VT/SCD unless monitoring </text>
<text top="1007" left="489" width="321" height="17" font="17">and access to emergency external defibrillation </text>
<text top="1025" left="489" width="321" height="17" font="17">is maintained. In 1 series of 354 patients who </text>
<text top="1043" left="489" width="323" height="17" font="17">received the wearable cardioverter-defibrillator, </text>
<text top="1062" left="489" width="256" height="17" font="17">the indication was infection in 10%.</text>
<text top="1062" left="745" width="29" height="10" font="19">S11.2-3</text>
<text top="1062" left="774" width="38" height="17" font="17"> For </text>
<text top="1080" left="489" width="320" height="17" font="17">patients with a history of SCA or sustained VA, </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e349</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="320" height="17" font="17">the wearable cardioverter-defibrillator may allow </text>
<text top="106" left="111" width="321" height="17" font="17">the patient to be discharged from the hospital </text>
<text top="124" left="111" width="323" height="17" font="17">with protection from VT/SCA until the clinical </text>
<text top="142" left="111" width="266" height="17" font="17">situation allows reimplantation of an ICD.</text>
<text top="160" left="89" width="343" height="17" font="17">2.  The patients listed in this recommendation are </text>
<text top="178" left="111" width="321" height="17" font="17">represented in clinical series and registries that </text>
<text top="196" left="111" width="325" height="17" font="17">demonstrate the safety and effectiveness of </text>
<text top="214" left="111" width="324" height="17" font="17">the wearable cardioverter-defibrillator. Patients </text>
<text top="232" left="111" width="321" height="17" font="17">with recent MI, newly diagnosed NICM, recent </text>
<text top="250" left="111" width="328" height="17" font="17">revascularization, myocarditis, and secondary </text>
<text top="268" left="111" width="320" height="17" font="17">cardiomyopathy are at increased risk of VT/SCA. </text>
<text top="286" left="111" width="322" height="17" font="17">However, the wearable cardioverter-defibrillator </text>
<text top="304" left="111" width="320" height="17" font="17">is of unproven benefit in these settings, in part </text>
<text top="323" left="111" width="321" height="17" font="17">because the clinical situation may improve with </text>
<text top="341" left="111" width="318" height="17" font="17">therapy and time. In patients awaiting transplant, </text>
<text top="359" left="111" width="322" height="17" font="17">even with anticipated survival  &lt;1  year without </text>
<text top="377" left="111" width="318" height="17" font="17">transplant, and depending on clinical factors such </text>
<text top="395" left="111" width="319" height="17" font="17">as use of intravenous inotropes and ambient VA, </text>
<text top="413" left="111" width="322" height="17" font="17">a wearable cardioverter-defibrillator may be an </text>
<text top="431" left="111" width="136" height="17" font="17">alternative to an ICD.</text>
<text top="474" left="74" width="324" height="21" font="18"><b>11.3. Automated External Defibrillator</b></text>
<text top="502" left="74" width="351" height="17" font="17">External defibrillation can save lives when used with-</text>
<text top="520" left="74" width="357" height="17" font="17">in minutes of the onset of VF. The AED is an efficient </text>
<text top="538" left="74" width="351" height="17" font="17">method of delivering defibrillation to persons expe-</text>
<text top="556" left="74" width="357" height="17" font="17">riencing out-of-hospital cardiac arrest, and its use by </text>
<text top="574" left="74" width="237" height="17" font="17">first responders is safe and effective.</text>
<text top="575" left="311" width="63" height="10" font="19">S11.3-1–S11.3-3</text>
<text top="574" left="374" width="56" height="17" font="17"> Federal </text>
<text top="592" left="74" width="351" height="17" font="17">efforts have been effective in placing AEDs in airports/</text>
<text top="610" left="74" width="358" height="17" font="17">airplanes and federal buildings, while varying efforts </text>
<text top="628" left="74" width="356" height="17" font="17">at the state and community levels have been effective </text>
<text top="646" left="74" width="356" height="17" font="17">in placing AEDs in many. but not all, schools, sporting </text>
<text top="664" left="74" width="359" height="17" font="17">events, high-density residential sites, and airports as </text>
<text top="682" left="74" width="288" height="17" font="17">well as in police and fire department vehicles.</text>
<text top="683" left="363" width="63" height="10" font="19">S11.3-4–S11.3-7</text>
<text top="682" left="425" width="4" height="17" font="17"> </text>
<text top="700" left="74" width="355" height="17" font="17">Resuscitation protocols with or without AED placement </text>
<text top="718" left="74" width="357" height="17" font="17">are required in most states for fitness clubs, although </text>
<text top="737" left="74" width="354" height="17" font="17">alternate indoor exercise facilities may have higher rates </text>
<text top="755" left="74" width="356" height="17" font="17">of arrest and provide for increased survival over other </text>
<text top="773" left="74" width="126" height="17" font="17">indoor public sites.</text>
<text top="773" left="200" width="29" height="10" font="19">S11.3-8</text>
<text top="773" left="230" width="203" height="17" font="17"> In a study population of 21 </text>
<text top="791" left="74" width="356" height="17" font="17">million, survival to hospital discharge was nearly twice </text>
<text top="809" left="74" width="357" height="17" font="17">as high when an AED was applied for out-of-hospital </text>
<text top="827" left="74" width="92" height="17" font="17">cardiac arrest.</text>
<text top="828" left="166" width="29" height="10" font="19">S11.3-9</text>
<text top="827" left="195" width="230" height="17" font="17"> Expanded and coordinated place-</text>
<text top="845" left="74" width="356" height="17" font="17">ment of AEDs in the community, including in high-risk </text>
<text top="863" left="74" width="359" height="17" font="17">geographic locations such as schools and organized </text>
<text top="881" left="74" width="355" height="17" font="17">sports arenas, can substantially increase the proportion </text>
<text top="899" left="74" width="357" height="17" font="17">of patients with cardiac out-of-hospital cardiac arrest </text>
<text top="917" left="74" width="165" height="17" font="17">who receive AED therapy.</text>
<text top="918" left="239" width="34" height="10" font="19">S11.3-10</text>
<text top="917" left="273" width="157" height="17" font="17"> The US Food and Drug </text>
<text top="935" left="74" width="356" height="17" font="17">Administration has approved over-the-counter sales of </text>
<text top="953" left="74" width="355" height="17" font="17">AEDs. Approximately 70% of SCAs occur in the home, </text>
<text top="971" left="74" width="355" height="17" font="17">and the rate of survival to hospital discharge after AED </text>
<text top="989" left="74" width="351" height="17" font="17">placement by emergency medical services is significant-</text>
<text top="1008" left="74" width="355" height="17" font="17">ly lower for arrest at home (12%) versus public settings </text>
<text top="1026" left="74" width="44" height="17" font="17">(34%).</text>
<text top="1026" left="118" width="34" height="10" font="19">S11.3-11</text>
<text top="1026" left="152" width="278" height="17" font="17"> However, in an RCT of AEDS, home AED </text>
<text top="1044" left="74" width="351" height="17" font="17">placement did not improve the survival of patients re-</text>
<text top="1062" left="74" width="191" height="17" font="17">covering from an anterior MI.</text>
<text top="1062" left="265" width="34" height="10" font="19">S11.3-12</text>
<text top="1062" left="299" width="131" height="17" font="17"> Appropriate device </text>
<text top="1080" left="74" width="351" height="17" font="17">location to reduce time delay after onset of SCA is criti-</text>
<text top="88" left="452" width="358" height="17" font="17">cal. In addition to prevention, critical components of </text>
<text top="106" left="452" width="357" height="17" font="17">survival from SCA include immediate recognition and </text>
<text top="124" left="452" width="360" height="17" font="17">activation of the emergency response system, early </text>
<text top="143" left="452" width="355" height="17" font="17">high-quality CPR, and rapid defibrillation for shockable </text>
<text top="161" left="452" width="56" height="17" font="17">rhythms.</text>
<text top="162" left="508" width="34" height="10" font="19">S11.3-13</text>
<text top="209" left="452" width="322" height="23" font="15"><b>12. SPECIAL CONSIDERATIONS FOR </b></text>
<text top="232" left="452" width="193" height="23" font="15"><b>CATHETER ABLATION</b></text>
<text top="268" left="463" width="200" height="12" font="26"><b>Recommendations for Catheter Ablation</b></text>
<text top="285" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="298" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 57</b></a></text>
<text top="298" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="319" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="319" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="319" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="353" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="353" left="531" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="340" left="583" width="213" height="12" font="4">1.  In patients with bundle-branch reentrant VT, </text>
<text top="354" left="595" width="193" height="12" font="4">catheter ablation is useful for reducing the </text>
<text top="367" left="595" width="160" height="12" font="4">risk of recurrent VT and ICD shocks.</text>
<text top="368" left="755" width="34" height="7" font="23">S12-1–S12-3</text>
<text top="415" left="477" width="12" height="12" font="22"><b>IIa</b></text>
<text top="415" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="388" left="583" width="213" height="12" font="4">2.  In patients with structural heart disease who </text>
<text top="401" left="595" width="188" height="12" font="4">have failed endocardial catheter ablation, </text>
<text top="415" left="595" width="202" height="12" font="4">epicardial catheter ablation can be useful for </text>
<text top="428" left="595" width="199" height="12" font="4">reducing the risk of recurrent monomorphic </text>
<text top="442" left="595" width="13" height="12" font="4">VT.</text>
<text top="442" left="608" width="34" height="7" font="23">S12-4–S12-6</text>
<text top="482" left="452" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="510" left="452" width="356" height="17" font="17">Bundle-branch reentrant VT is due to reentry involving </text>
<text top="528" left="452" width="355" height="17" font="17">the bundle branches. Catheter ablation is the preferred </text>
<text top="546" left="452" width="356" height="17" font="17">therapy for this VT, which is encountered in &lt;10% of </text>
<text top="565" left="452" width="355" height="17" font="17">patients with recurrent sustained monomorphic VT and </text>
<text top="583" left="452" width="273" height="17" font="17">structural heart disease (see Section 7.2.3).</text>
<text top="627" left="452" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="648" left="452" width="35" height="21" font="18"><b>Text</b></text>
<text top="676" left="467" width="345" height="17" font="17">1. Bundle-branch reentrant VT can occur in any </text>
<text top="694" left="489" width="314" height="17" font="17">form of heart disease associated with slow infra-</text>
<text top="712" left="489" width="314" height="17" font="17">Hisian conduction. The most common mecha-</text>
<text top="731" left="489" width="324" height="17" font="17">nism involves antegrade conduction over the </text>
<text top="749" left="489" width="321" height="17" font="17">right bundle branch and retrograde conduction </text>
<text top="768" left="489" width="314" height="17" font="17">over the left bundle branch, thereby produc-</text>
<text top="786" left="489" width="323" height="17" font="17">ing left bundle-branch block QRS morphology </text>
<text top="804" left="489" width="314" height="17" font="17">during VT, which is often rapid and poorly tol-</text>
<text top="823" left="489" width="323" height="17" font="17">erated. Catheter ablation of the right or left </text>
<text top="841" left="489" width="318" height="17" font="17">bundle branch interrupts the circuit and is usually </text>
<text top="859" left="489" width="54" height="17" font="17">curative.</text>
<text top="860" left="543" width="48" height="10" font="19">S12-1–S12-3</text>
<text top="859" left="591" width="217" height="17" font="17"> After ablation, severely impaired </text>
<text top="878" left="489" width="314" height="17" font="17">atrioventricular conduction can be present, requir-</text>
<text top="896" left="489" width="314" height="17" font="17">ing permanent pacing, which can have hemody-</text>
<text top="915" left="489" width="137" height="17" font="17">namic consequences.</text>
<text top="915" left="626" width="46" height="10" font="19">S12-4,S12-6</text>
<text top="915" left="672" width="136" height="17" font="17"> Many patients have </text>
<text top="933" left="489" width="314" height="17" font="17">other inducible scar related VTs or meet eligibil-</text>
<text top="951" left="489" width="319" height="17" font="17">ity for an ICD due to severity of associated heart </text>
<text top="970" left="489" width="50" height="17" font="17">disease.</text>
<text top="988" left="467" width="342" height="17" font="17">2.  Endocardial catheter ablation failure can be due </text>
<text top="1006" left="489" width="322" height="17" font="17">to location of the arrhythmia substrate in the </text>
<text top="1025" left="489" width="320" height="17" font="17">midmyocardium or epicardium, and this is more </text>
<text top="1043" left="489" width="322" height="17" font="17">likely in patients with nonischemic rather than </text>
<text top="1061" left="489" width="319" height="17" font="17">ischemic cardiomyopathy, and in arrhythmogenic </text>
<text top="1080" left="489" width="218" height="17" font="17">right ventricular cardiomyopathy.</text>
<text top="1081" left="707" width="48" height="10" font="19">S12-7–S12-9</text>
<text top="1080" left="755" width="56" height="17" font="17"> In the </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e350</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="86" height="17" font="17">HELP-VT trial,</text>
<text top="88" left="197" width="22" height="10" font="19">S12-4</text>
<text top="88" left="219" width="211" height="17" font="17"> epicardial ablation was required </text>
<text top="106" left="111" width="314" height="17" font="17">in 30% of patients with VT related to NICM com-</text>
<text top="124" left="111" width="314" height="17" font="17">pared with 1.2% of patients with ischemic car-</text>
<text top="143" left="111" width="320" height="17" font="17">diomyopathy. A wide QRS with marked slurring </text>
<text top="161" left="111" width="314" height="17" font="17">of the initial portion of the QRS and a QS com-</text>
<text top="179" left="111" width="314" height="17" font="17">plex in the lateral or inferior leads during VT sug-</text>
<text top="198" left="111" width="320" height="17" font="17">gests an epicardial circuit in NICM, but the ECG </text>
<text top="216" left="111" width="318" height="17" font="17">does not reliably predict epicardial VT locations in </text>
<text top="234" left="111" width="319" height="17" font="17">patients with prior MI. Preprocedural cardiac MRI </text>
<text top="253" left="111" width="326" height="17" font="17">and intraprocedural electroanatomic mapping </text>
<text top="271" left="111" width="314" height="17" font="17">are useful tools to guide the localization of epi-</text>
<text top="289" left="111" width="320" height="17" font="17">cardial scar that may be the source of reentrant  </text>
<text top="308" left="111" width="19" height="17" font="17">VT.</text>
<text top="308" left="130" width="51" height="10" font="19">S12-8,S12-10</text>
<text top="308" left="181" width="244" height="17" font="17"> Pericardial adhesions prevent percu-</text>
<text top="326" left="111" width="321" height="17" font="17">taneous access in some patients, notably many </text>
<text top="344" left="111" width="314" height="17" font="17">with prior cardiac surgery. Percutaneous pericar-</text>
<text top="363" left="111" width="318" height="17" font="17">dial access for mapping and ablation is associated </text>
<text top="381" left="111" width="318" height="17" font="17">with a serious complication rate of approximately </text>
<text top="399" left="111" width="314" height="17" font="17">5% and tamponade from RV puncture or lac-</text>
<text top="418" left="111" width="320" height="17" font="17">eration that can require emergent surgery or be </text>
<text top="436" left="111" width="322" height="17" font="17">fatal, coronary artery injury and phrenic nerve </text>
<text top="454" left="111" width="106" height="17" font="17">injury can occur.</text>
<text top="455" left="217" width="56" height="10" font="19">S12-11,S12-12</text>
<text top="454" left="273" width="158" height="17" font="17"> Reported experience is </text>
<text top="473" left="111" width="184" height="17" font="17">from tertiary referral centers.</text>
<text top="524" left="74" width="300" height="23" font="15"><b>13. POSTMORTEM EVALUATION  </b></text>
<text top="547" left="74" width="67" height="23" font="15"><b>OF SCD</b></text>
<text top="582" left="85" width="263" height="12" font="26"><b>Recommendations for Postmortem Evaluation of SCD</b></text>
<text top="599" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="613" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 58</b></a></text>
<text top="613" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="633" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="633" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="633" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="668" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="668" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="654" left="205" width="201" height="12" font="4">1.  In victims of SCD without obvious causes, </text>
<text top="668" left="217" width="186" height="12" font="4">a standardized cardiac-specific autopsy is </text>
<text top="681" left="217" width="67" height="12" font="4">recommended.</text>
<text top="682" left="284" width="32" height="7" font="23">S13-1,S13-2</text>
<text top="729" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="729" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="702" left="205" width="206" height="12" font="4">2.  In first-degree relatives of SCD victims who </text>
<text top="716" left="217" width="185" height="12" font="4">were 40 years of age or younger, cardiac </text>
<text top="729" left="217" width="187" height="12" font="4">evaluation is recommended, with genetic </text>
<text top="743" left="217" width="202" height="12" font="4">counseling and genetic testing performed as </text>
<text top="756" left="217" width="128" height="12" font="4">indicated by clinical findings.</text>
<text top="757" left="345" width="15" height="7" font="23">S13-3</text>
<text top="811" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="811" left="152" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="777" left="205" width="169" height="12" font="4">3.  In victims of SCD with an autopsy </text>
<text top="790" left="217" width="172" height="12" font="4">that implicates a potentially heritable </text>
<text top="804" left="217" width="187" height="12" font="4">cardiomyopathy or absence of structural </text>
<text top="817" left="217" width="178" height="12" font="4">disease, suggesting a potential cardiac </text>
<text top="831" left="217" width="202" height="12" font="4">channelopathy, postmortem genetic testing </text>
<text top="844" left="217" width="62" height="12" font="4">is reasonable.</text>
<text top="845" left="279" width="34" height="7" font="23">S13-4–S13-7</text>
<text top="899" left="99" width="12" height="12" font="22"><b>IIa</b></text>
<text top="899" left="153" width="23" height="12" font="22"><b>C-LD</b></text>
<text top="865" left="205" width="213" height="12" font="4">4.  In victims of SCD with a previously identified </text>
<text top="879" left="217" width="162" height="12" font="4">phenotype for a genetic arrhythmia-</text>
<text top="892" left="217" width="200" height="12" font="4">associated disorder, but without genotyping </text>
<text top="906" left="217" width="194" height="12" font="4">prior to death, postmortem genetic testing </text>
<text top="919" left="217" width="195" height="12" font="4">can be useful for the purpose of family risk </text>
<text top="933" left="217" width="40" height="12" font="4">profiling.</text>
<text top="933" left="257" width="15" height="7" font="23">S13-8</text>
<text top="976" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="997" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="1025" left="89" width="341" height="17" font="17">1.  A comprehensive postmortem protocol has been </text>
<text top="1043" left="111" width="314" height="17" font="17">recommended for the routine evaluation of sub-</text>
<text top="1062" left="111" width="314" height="17" font="17">jects (typically  &lt;40 years of age) who die sud-</text>
<text top="1080" left="111" width="318" height="17" font="17">denly without a prior diagnosis of a condition and </text>
<text top="88" left="489" width="319" height="17" font="17">circumstances of death that could be reasonably </text>
<text top="106" left="489" width="292" height="17" font="17">implicated in the cause of unexpected SCD.</text>
<text top="106" left="781" width="22" height="10" font="19">S13-1</text>
<text top="106" left="803" width="4" height="17" font="17"> </text>
<text top="124" left="489" width="314" height="17" font="17">One study documented the added value of post-</text>
<text top="142" left="489" width="325" height="17" font="17">mortem examination at a specialized cardiac </text>
<text top="160" left="489" width="116" height="17" font="17">pathology center,</text>
<text top="160" left="605" width="22" height="10" font="19">S13-2</text>
<text top="160" left="627" width="185" height="17" font="17"> with particular value for </text>
<text top="178" left="489" width="314" height="17" font="17">clarifying an apparent overdiagnosis of cardiomy-</text>
<text top="196" left="489" width="323" height="17" font="17">opathy by nonspecialized centers. Pathological </text>
<text top="214" left="489" width="314" height="17" font="17">findings limited to the specialized conduction sys-</text>
<text top="232" left="489" width="276" height="17" font="17">tem were demonstrated in 22% of cases.</text>
<text top="233" left="765" width="22" height="10" font="19">S13-9</text>
<text top="232" left="787" width="22" height="17" font="17"> A </text>
<text top="250" left="489" width="319" height="17" font="17">misdiagnosis of cardiomyopathy was reported in </text>
<text top="268" left="489" width="314" height="17" font="17">37% of referred cases that were ultimately deter-</text>
<text top="286" left="489" width="317" height="17" font="17">mined to be structurally normal. The etiologic data </text>
<text top="304" left="489" width="314" height="17" font="17">for specialized cardiac evaluation are not general-</text>
<text top="322" left="489" width="314" height="17" font="17">izable to the overall population because of skew-</text>
<text top="340" left="489" width="320" height="17" font="17">ing of age at the time of SCD. In another study </text>
<text top="358" left="489" width="319" height="17" font="17">of SCD patients at ages ranging from &lt;1 year to </text>
<text top="376" left="489" width="319" height="17" font="17">&gt;80 years (mean, 38.2 years; median, 38 years), </text>
<text top="394" left="489" width="318" height="17" font="17">the peak incidence of SCD occurred between the </text>
<text top="412" left="489" width="318" height="17" font="17">ages of 31 and 60 years, with a 5- to 7-fold excess </text>
<text top="430" left="489" width="235" height="17" font="17">of males/females in that age range.</text>
<text top="431" left="724" width="27" height="10" font="19">S13-10</text>
<text top="430" left="751" width="59" height="17" font="17"> For the </text>
<text top="448" left="489" width="319" height="17" font="17">overall group, 42% of SCD were due to ischemic </text>
<text top="466" left="489" width="322" height="17" font="17">heart disease, 12% viral myocarditis, and 5% </text>
<text top="484" left="489" width="323" height="17" font="17">cardiomyopathy, with 15% being unexplained </text>
<text top="503" left="489" width="320" height="17" font="17">by autopsy. For the subgroup &lt;35 years of age, </text>
<text top="521" left="489" width="319" height="17" font="17">13.5% were attributed to ischemic heart disease </text>
<text top="539" left="489" width="321" height="17" font="17">and 24.9% were unexplained. In the subgroup </text>
<text top="557" left="489" width="320" height="17" font="17">&gt;55 years of age, only 0.8% were unexplained. </text>
<text top="575" left="489" width="323" height="17" font="17">In patients who die suddenly despite an ICD, </text>
<text top="593" left="489" width="320" height="17" font="17">interrogation of the ICD is important to confirm </text>
<text top="611" left="489" width="314" height="17" font="17">proper device functioning and can provide infor-</text>
<text top="629" left="489" width="230" height="17" font="17">mation on the mechanism of death.</text>
<text top="647" left="467" width="353" height="17" font="17">2. Comprehensive cardiac screening including </text>
<text top="665" left="489" width="325" height="17" font="17">12-lead ECG, possible signal averaged ECG, </text>
<text top="683" left="489" width="314" height="17" font="17">echocardiogram, and ambulatory rhythm moni-</text>
<text top="701" left="489" width="320" height="17" font="17">toring or exercise testing of first-degree relatives </text>
<text top="719" left="489" width="318" height="17" font="17">of decedents with sudden unexpected death may </text>
<text top="737" left="489" width="323" height="17" font="17">identify a probable heritable cardiac cause of </text>
<text top="755" left="489" width="201" height="17" font="17">death in up to 30% of cases.</text>
<text top="756" left="690" width="58" height="10" font="19">S13-11–S13-13</text>
<text top="755" left="747" width="62" height="17" font="17"> Genetic </text>
<text top="773" left="489" width="318" height="17" font="17">testing should be targeted based on the results of </text>
<text top="791" left="489" width="111" height="17" font="17">initial evaluation.</text>
<text top="792" left="600" width="22" height="10" font="19">S13-3</text>
<text top="791" left="622" width="188" height="17" font="17"> Genetic testing in selected </text>
<text top="809" left="489" width="318" height="17" font="17">first-degree relatives may result in identification of </text>
<text top="827" left="489" width="318" height="17" font="17">inherited conditions including long QT syndrome, </text>
<text top="845" left="489" width="314" height="17" font="17">catecholaminergic polymorphic ventricular tachy-</text>
<text top="863" left="489" width="320" height="17" font="17">cardia, Brugada syndrome, arrhythmogenic right </text>
<text top="881" left="489" width="320" height="17" font="17">ventricular cardiomyopathy, and HCM in 4% to </text>
<text top="899" left="489" width="106" height="17" font="17">30% of families.</text>
<text top="900" left="595" width="85" height="10" font="19">S13-11,S13-12,S13-14</text>
<text top="917" left="467" width="345" height="17" font="17">3. For the purpose of family risk profiling, it is </text>
<text top="936" left="489" width="318" height="17" font="17">important to use the disease-specific genetic test </text>
<text top="954" left="489" width="320" height="17" font="17">panel that corresponds to the autopsy findings. </text>
<text top="972" left="489" width="318" height="17" font="17">Risk profiling of family members of an SCD victim </text>
<text top="990" left="489" width="318" height="17" font="17">suspected of having an inherited cardiomyopathy </text>
<text top="1008" left="489" width="320" height="17" font="17">at autopsy is important. Although phenotyping </text>
<text top="1026" left="489" width="314" height="17" font="17">of surviving family members is crucial, genotyp-</text>
<text top="1044" left="489" width="320" height="17" font="17">ing of the SCD proband provides a mechanism </text>
<text top="1062" left="489" width="314" height="17" font="17">for efficient follow-up evaluation of those rela-</text>
<text top="1080" left="489" width="322" height="17" font="17">tives with the disease-causing mutation found </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e351</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="111" width="322" height="17" font="17">in the proband. To be able to harvest quality </text>
<text top="106" left="111" width="314" height="17" font="17">DNA for such testing, medical examiners, hos-</text>
<text top="124" left="111" width="319" height="17" font="17">pital pathologists, and private pathologists need </text>
<text top="142" left="111" width="319" height="17" font="17">standards for harvesting and storing samples for </text>
<text top="161" left="111" width="322" height="17" font="17">later genetic testing. Family members of SCD </text>
<text top="179" left="111" width="319" height="17" font="17">probands who died suddenly (first cardiac event, </text>
<text top="197" left="111" width="317" height="17" font="17">death from natural causes, last seen alive and well </text>
<text top="215" left="111" width="319" height="17" font="17">within 12 hours), with autopsy findings showing </text>
<text top="234" left="111" width="319" height="17" font="17">structural abnormalities of uncertain significance </text>
<text top="252" left="111" width="320" height="17" font="17">(eg, ventricular hypertrophy, myocardial fibrosis, </text>
<text top="270" left="111" width="321" height="17" font="17">or minor ischemic heart disease [n=41]) had a </text>
<text top="288" left="111" width="321" height="17" font="17">51% prevalence of genetic variants associated </text>
<text top="307" left="111" width="320" height="17" font="17">with sudden arrhythmic deaths, compared with </text>
<text top="325" left="111" width="314" height="17" font="17">47% among a comparison group in which pro-</text>
<text top="343" left="111" width="271" height="17" font="17">band autopsies were completely negative.</text>
<text top="344" left="382" width="27" height="10" font="19">S13-15</text>
<text top="362" left="89" width="340" height="17" font="17">4.  Identification of the genotype can facilitate family </text>
<text top="380" left="111" width="65" height="17" font="17">screening.</text>
<text top="380" left="176" width="27" height="10" font="19">S13-16</text>
<text top="432" left="74" width="182" height="23" font="15"><b>14. TERMINAL CARE</b></text>
<text top="468" left="85" width="178" height="12" font="26"><b>Recommendations for Terminal Care</b></text>
<text top="485" left="85" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="498" left="85" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 59</b></a></text>
<text top="498" left="221" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="519" left="94" width="21" height="12" font="22"><b>COR</b></text>
<text top="519" left="155" width="19" height="12" font="22"><b>LOE</b></text>
<text top="519" left="205" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="574" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="574" left="152" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="540" left="205" width="169" height="12" font="4">1.  At the time of ICD implantation or </text>
<text top="554" left="217" width="174" height="12" font="4">replacement, and during advance care </text>
<text top="567" left="217" width="195" height="12" font="4">planning, patients should be informed that </text>
<text top="581" left="217" width="195" height="12" font="4">their ICD shock therapy can be deactivated </text>
<text top="594" left="217" width="200" height="12" font="4">at any time if it is consistent with their goals </text>
<text top="608" left="217" width="74" height="12" font="4">and preferences.</text>
<text top="656" left="103" width="3" height="12" font="22"><b>I</b></text>
<text top="656" left="152" width="24" height="12" font="22"><b>C-EO</b></text>
<text top="629" left="205" width="196" height="12" font="4">2.  In patients with refractory HF symptoms, </text>
<text top="642" left="217" width="196" height="12" font="4">refractory sustained VA, or nearing the end </text>
<text top="656" left="217" width="187" height="12" font="4">of life from other illness, clinicians should </text>
<text top="669" left="217" width="199" height="12" font="4">discuss ICD shock deactivation and consider </text>
<text top="683" left="217" width="159" height="12" font="4">the patients’ goals and preferences.</text>
<text top="723" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="750" left="74" width="351" height="17" font="17">A particularly challenging area of medicine is recogniz-</text>
<text top="768" left="74" width="351" height="17" font="17">ing when life-prolonging therapies may become bur-</text>
<text top="787" left="74" width="356" height="17" font="17">densome or even harmful. This is particularly true near </text>
<text top="805" left="74" width="351" height="17" font="17">the end of life for patients with ICDs in whom once life-</text>
<text top="823" left="74" width="351" height="17" font="17">prolonging shocks may only cause unnecessary morbid-</text>
<text top="841" left="74" width="306" height="17" font="17">ity and distress to both patients and loved ones.</text>
<text top="885" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="906" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="934" left="89" width="340" height="17" font="17">1.  Current evidence suggests that many patients are </text>
<text top="952" left="111" width="320" height="17" font="17">unaware of the possibility that their ICD can be </text>
<text top="970" left="111" width="182" height="17" font="17">deactivated without surgery.</text>
<text top="971" left="293" width="48" height="10" font="19">S14-1–S14-3</text>
<text top="970" left="341" width="84" height="17" font="17"> During deci-</text>
<text top="989" left="111" width="322" height="17" font="17">sion-making, clinicians do not routinely inform </text>
<text top="1007" left="111" width="223" height="17" font="17">patients about ICD deactivation.</text>
<text top="1007" left="334" width="22" height="10" font="19">S14-4</text>
<text top="1007" left="355" width="80" height="17" font="17"> Clinicians </text>
<text top="1025" left="111" width="314" height="17" font="17">even disagree on whether discussions of deac-</text>
<text top="1043" left="111" width="320" height="17" font="17">tivation should occur when patients are making </text>
<text top="1062" left="111" width="292" height="17" font="17">a decision about an ICD-related procedure.</text>
<text top="1062" left="403" width="22" height="10" font="19">S14-5</text>
<text top="1062" left="425" width="4" height="17" font="17"> </text>
<text top="1080" left="111" width="319" height="17" font="17">As a result, patients often do not include wishes </text>
<text top="88" left="489" width="325" height="17" font="17">about deactivation in advance care planning </text>
<text top="106" left="489" width="75" height="17" font="17">documents.</text>
<text top="107" left="564" width="22" height="10" font="19">S14-6</text>
<text top="106" left="586" width="223" height="17" font="17"> Consequently, surrogates usually </text>
<text top="124" left="489" width="321" height="17" font="17">make decisions about ICD deactivation without </text>
<text top="142" left="489" width="237" height="17" font="17">any prior discussions with the patient.</text>
<text top="143" left="726" width="22" height="10" font="19">S14-6</text>
<text top="142" left="748" width="55" height="17" font="17"> In hypo-</text>
<text top="160" left="489" width="318" height="17" font="17">thetical scenarios, patients with ICDs were able to </text>
<text top="179" left="489" width="319" height="17" font="17">identify scenarios in which they might choose to </text>
<text top="197" left="489" width="136" height="17" font="17">deactivate their ICD.</text>
<text top="198" left="625" width="46" height="10" font="19">S14-1,S14-7</text>
<text top="197" left="671" width="139" height="17" font="17"> This discussion can </text>
<text top="215" left="489" width="319" height="17" font="17">occur at any time, but it is particularly important </text>
<text top="233" left="489" width="319" height="17" font="17">to have it at the time of initial ICD implantation, </text>
<text top="252" left="489" width="314" height="17" font="17">at the time of reimplantation, and during prepa-</text>
<text top="270" left="489" width="184" height="17" font="17">ration of advance care plans.</text>
<text top="288" left="467" width="340" height="17" font="17">2.  When ICDs are not deactivated at the end of life, </text>
<text top="306" left="489" width="318" height="17" font="17">patients and families suffer unnecessarily. Families </text>
<text top="324" left="489" width="323" height="17" font="17">have had unpleasant experiences of watching </text>
<text top="343" left="489" width="314" height="17" font="17">their loved one die while getting shocked repeat-</text>
<text top="361" left="489" width="93" height="17" font="17">edly by an ICD.</text>
<text top="362" left="582" width="22" height="10" font="19">S14-8</text>
<text top="361" left="604" width="202" height="17" font="17"> In 1 survey of hospice staff, half </text>
<text top="379" left="489" width="319" height="17" font="17">of those surveyed noted that a deceased patient </text>
<text top="397" left="489" width="318" height="17" font="17">had been shocked by an ICD during the year prior </text>
<text top="416" left="489" width="90" height="17" font="17">to the survey.</text>
<text top="416" left="579" width="22" height="10" font="19">S14-9</text>
<text top="416" left="601" width="209" height="17" font="17"> This is unnecessary and easily </text>
<text top="434" left="489" width="323" height="17" font="17">preventable by having caring, patient-centered </text>
<text top="452" left="489" width="319" height="17" font="17">discussions with patients and their loved ones. In </text>
<text top="470" left="489" width="320" height="17" font="17">general, patients want their clinicians to initiate </text>
<text top="488" left="489" width="116" height="17" font="17">these discussions,</text>
<text top="489" left="605" width="51" height="10" font="19">S14-2,S14-10</text>
<text top="488" left="656" width="148" height="17" font="17"> so this recommenda-</text>
<text top="507" left="489" width="318" height="17" font="17">tion is carefully worded to put the responsibility of </text>
<text top="525" left="489" width="319" height="17" font="17">initiating the discussion on the clinician. Ethically, </text>
<text top="543" left="489" width="322" height="17" font="17">patients and surrogates are free to choose to </text>
<text top="561" left="489" width="256" height="17" font="17">deactivate antitachycardia function.</text>
<text top="562" left="745" width="58" height="10" font="19">S14-11–S14-13</text>
<text top="561" left="803" width="4" height="17" font="17"> </text>
<text top="580" left="489" width="314" height="17" font="17">Most patients only elect deactivation of the anti-</text>
<text top="598" left="489" width="322" height="17" font="17">tachycardia functions while leaving the pacing </text>
<text top="616" left="489" width="318" height="17" font="17">function on. Even at the end of life, pacing (either </text>
<text top="634" left="489" width="319" height="17" font="17">for bradycardia or for resynchronization therapy) </text>
<text top="652" left="489" width="319" height="17" font="17">may be an important aspect of the patient’s QoL </text>
<text top="671" left="489" width="323" height="17" font="17">and may facilitate more alert and meaningful </text>
<text top="689" left="489" width="319" height="17" font="17">personal interactions. These differences are easily </text>
<text top="707" left="489" width="314" height="17" font="17">misunderstood, so they need careful explanation.</text>
<text top="760" left="452" width="287" height="23" font="15"><b>15. SHARED DECISION-MAKING</b></text>
<text top="795" left="463" width="231" height="12" font="26"><b>Recommendations for Shared Decision-Making</b></text>
<text top="812" left="463" width="326" height="12" font="26"><b>References that support the recommendations are summarized in </b></text>
<text top="826" left="463" width="136" height="12" font="27"><a href=""><b>Online Data Supplement 60</b></a></text>
<text top="826" left="599" width="3" height="12" font="26"><a href=""><b>.</b></a></text>
<text top="846" left="472" width="21" height="12" font="22"><b>COR</b></text>
<text top="846" left="533" width="19" height="12" font="22"><b>LOE</b></text>
<text top="846" left="583" width="91" height="12" font="22"><b>Recommendations</b></text>
<text top="908" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="908" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="867" left="583" width="187" height="12" font="4">1.  In patients with VA or at increased risk </text>
<text top="881" left="595" width="186" height="12" font="4">for SCD, clinicians should adopt a shared </text>
<text top="894" left="595" width="161" height="12" font="4">decision-making approach in which </text>
<text top="908" left="595" width="190" height="12" font="4">treatment decisions are based not only on </text>
<text top="921" left="595" width="193" height="12" font="4">the best available evidence but also on the </text>
<text top="935" left="595" width="179" height="12" font="4">patients’ health goals, preferences, and </text>
<text top="948" left="595" width="30" height="12" font="4">values.</text>
<text top="949" left="625" width="34" height="7" font="23">S15-1–S15-5</text>
<text top="1023" left="481" width="3" height="12" font="22"><b>I</b></text>
<text top="1023" left="530" width="24" height="12" font="22"><b>B-NR</b></text>
<text top="969" left="583" width="172" height="12" font="4">2.  Patients considering implantation  </text>
<text top="983" left="595" width="167" height="12" font="4">of a new ICD or replacement of an  </text>
<text top="996" left="595" width="186" height="12" font="4">existing ICD for a low battery should be </text>
<text top="1010" left="595" width="204" height="12" font="4">informed of their individual risk of SCD and </text>
<text top="1023" left="595" width="190" height="12" font="4">nonsudden death from HF or noncardiac </text>
<text top="1037" left="595" width="187" height="12" font="4">conditions and the effectiveness, safety, </text>
<text top="1050" left="595" width="193" height="12" font="4">and potential complications of the ICD in </text>
<text top="1064" left="595" width="203" height="12" font="4">light of their health goals, preferences, and </text>
<text top="1077" left="595" width="31" height="12" font="4">values.</text>
<text top="1078" left="627" width="35" height="7" font="23">S15-1–S15-5</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e352</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="74" height="21" font="18"><b>Synopsis</b></text>
<text top="114" left="74" width="355" height="17" font="17">During most of their lives, people prefer to do everything </text>
<text top="132" left="74" width="354" height="17" font="17">possible to prevent SCD and prolong life. However, many </text>
<text top="150" left="74" width="355" height="17" font="17">people may get to a point in their lives where SCD is not </text>
<text top="169" left="74" width="356" height="17" font="17">the worst outcome. Patients may report a desire to die </text>
<text top="187" left="74" width="85" height="17" font="17">in their sleep.</text>
<text top="188" left="160" width="22" height="10" font="19">S15-6</text>
<text top="187" left="181" width="249" height="17" font="17"> Decisions related to SCD can be quite </text>
<text top="205" left="74" width="351" height="17" font="17">emotional; according to the patient’s wishes, shared de-</text>
<text top="223" left="74" width="356" height="17" font="17">cision regarding end-of-life therapy making may involve </text>
<text top="241" left="74" width="282" height="17" font="17">caregivers such as family members or friends.</text>
<text top="285" left="74" width="321" height="21" font="18"><b>Recommendation-Specific Supportive </b></text>
<text top="306" left="74" width="35" height="21" font="18"><b>Text</b></text>
<text top="334" left="89" width="336" height="17" font="17">1. Consideration of patient preferences is impor-</text>
<text top="352" left="111" width="314" height="17" font="17">tant for VA diagnosis and management deci-</text>
<text top="370" left="111" width="321" height="17" font="17">sions. Patient preferences for invasive therapies </text>
<text top="388" left="111" width="319" height="17" font="17">and acceptance of SCD risk vary and may evolve </text>
<text top="406" left="111" width="318" height="17" font="17">throughout the course of their illness. The writing </text>
<text top="425" left="111" width="323" height="17" font="17">committee endorses a shared decision-making </text>
<text top="443" left="111" width="319" height="17" font="17">approach as part of the general care for patients </text>
<text top="461" left="111" width="314" height="17" font="17">at risk for VA and SCD. A commonly accepted def-</text>
<text top="479" left="111" width="237" height="17" font="17">inition of the shared decision-making</text>
<text top="480" left="348" width="22" height="10" font="19">S15-7</text>
<text top="479" left="370" width="60" height="17" font="17"> includes </text>
<text top="497" left="111" width="314" height="17" font="17">4 components: 1) at least 2 participants, the cli-</text>
<text top="516" left="111" width="321" height="17" font="17">nician and patient, be involved; 2) both parties </text>
<text top="534" left="111" width="320" height="17" font="17">share information; 3) both parties take steps to </text>
<text top="552" left="111" width="319" height="17" font="17">build a consensus about the preferred treatment; </text>
<text top="570" left="111" width="318" height="17" font="17">and 4) an agreement is reached on the treatment </text>
<text top="588" left="111" width="319" height="17" font="17">to implement. Sharing a decision does not mean </text>
<text top="607" left="111" width="321" height="17" font="17">giving a patient a list of risks and benefits and </text>
<text top="625" left="111" width="318" height="17" font="17">telling them to make a decision—a practice some </text>
<text top="643" left="111" width="237" height="17" font="17">authors have called “abandonment.”</text>
<text top="644" left="348" width="22" height="10" font="19">S15-8</text>
<text top="643" left="370" width="59" height="17" font="17"> Notably, </text>
<text top="661" left="111" width="314" height="17" font="17">a recommendation based on evidence or guide-</text>
<text top="679" left="111" width="318" height="17" font="17">lines alone is not shared decision-making. Rather, </text>
<text top="698" left="111" width="320" height="17" font="17">a recommendation based both on the evidence </text>
<text top="716" left="111" width="323" height="17" font="17">as well as an understanding of the patients’ </text>
<text top="734" left="111" width="320" height="17" font="17">health goals, preferences, and values is essential </text>
<text top="752" left="111" width="321" height="17" font="17">to achieving true shared decision-making. Also, </text>
<text top="770" left="111" width="320" height="17" font="17">the possibility of deactivation of an existing ICD </text>
<text top="789" left="111" width="314" height="17" font="17">should be discussed with patients who have ter-</text>
<text top="807" left="111" width="94" height="17" font="17">minal illnesses.</text>
<text top="825" left="89" width="341" height="17" font="17">2.  ICDs prolong lives as highlighted in many places </text>
<text top="843" left="111" width="319" height="17" font="17">within this guideline. However, a patient with HF </text>
<text top="861" left="111" width="318" height="17" font="17">or advanced noncardiac illness may elect to forgo </text>
<text top="880" left="111" width="314" height="17" font="17">replacement of an ICD when faced with the pros-</text>
<text top="898" left="111" width="318" height="17" font="17">pect of continual decline in health and functional </text>
<text top="916" left="111" width="320" height="17" font="17">status from either progressive HF or some other </text>
<text top="934" left="111" width="136" height="17" font="17">competing morbidity.</text>
<text top="952" left="129" width="301" height="17" font="17">Unfortunately, research suggests that patients </text>
<text top="970" left="111" width="320" height="17" font="17">are ill-informed when faced with understanding </text>
<text top="989" left="111" width="321" height="17" font="17">the risks, benefits, and downstream burdens of </text>
<text top="1007" left="111" width="314" height="17" font="17">their ICDs. Patients with an ICD tend to overes-</text>
<text top="1025" left="111" width="314" height="17" font="17">timate the benefit of this therapy and underes-</text>
<text top="1043" left="111" width="104" height="17" font="17">timate its risks.</text>
<text top="1044" left="215" width="48" height="10" font="19">S15-1–S15-3</text>
<text top="1043" left="263" width="171" height="17" font="17"> Likewise, patients who </text>
<text top="1062" left="111" width="324" height="17" font="17">decline an ICD also frequently underestimate </text>
<text top="1080" left="111" width="228" height="17" font="17">their personal risk of VA and SCD.</text>
<text top="1081" left="339" width="46" height="10" font="19">S15-4,S15-5</text>
<text top="1080" left="385" width="40" height="17" font="17"> Stud-</text>
<text top="88" left="489" width="319" height="17" font="17">ies of clinician decision-making demonstrate that </text>
<text top="106" left="489" width="322" height="17" font="17">clinicians often overestimate the benefits while </text>
<text top="124" left="489" width="216" height="17" font="17">downplaying the potential harms.</text>
<text top="125" left="705" width="22" height="10" font="19">S15-3</text>
<text top="142" left="507" width="300" height="17" font="17">In kind, ICD replacement is also an important point </text>
<text top="160" left="489" width="320" height="17" font="17">in time where patients and clinicians should discuss </text>
<text top="179" left="489" width="320" height="17" font="17">whether replacing an ICD is still consistent with the </text>
<text top="197" left="489" width="319" height="17" font="17">patients’ goals. What made sense at 70 years of age </text>
<text top="215" left="489" width="318" height="17" font="17">may not make sense at 80 years of age. Patients may </text>
<text top="233" left="489" width="318" height="17" font="17">have had progressive disease or developed poor QoL. </text>
<text top="251" left="489" width="319" height="17" font="17">These factors can all change the risk/benefit ratio of </text>
<text top="270" left="489" width="226" height="17" font="17">the ICD and the patients’ preferences.</text>
<text top="318" left="452" width="200" height="23" font="15"><b>16. COST AND VALUE </b></text>
<text top="341" left="452" width="163" height="23" font="15"><b>CONSIDERATIONS</b></text>
<text top="369" left="452" width="351" height="17" font="17">The key principles of value assessment as part of clini-</text>
<text top="388" left="452" width="329" height="17" font="17">cal practice guidelines have been discussed in detail.</text>
<text top="388" left="781" width="22" height="10" font="19">S16-1</text>
<text top="388" left="803" width="4" height="17" font="17"> </text>
<text top="406" left="452" width="356" height="17" font="17">Economic outcomes of clinical management strategies </text>
<text top="424" left="452" width="351" height="17" font="17">can be documented empirically using the same re-</text>
<text top="442" left="452" width="354" height="17" font="17">search designs as used in establishing clinical outcomes, </text>
<text top="460" left="452" width="351" height="17" font="17">including RCTs and observational comparisons. In ad-</text>
<text top="479" left="452" width="356" height="17" font="17">dition, simulation models are often used to assess the </text>
<text top="497" left="452" width="355" height="17" font="17">value of management strategies, because the standard </text>
<text top="515" left="452" width="359" height="17" font="17">for cost-effectiveness studies is to compare life-time </text>
<text top="533" left="452" width="357" height="17" font="17">outcomes, and clinical studies usually have follow-up </text>
<text top="552" left="452" width="351" height="17" font="17">of a few years at most. Standards for economic model-</text>
<text top="570" left="452" width="358" height="17" font="17">ing in health care have been published by an expert </text>
<text top="588" left="452" width="42" height="17" font="17">group.</text>
<text top="589" left="495" width="22" height="10" font="19">S16-2</text>
<text top="606" left="470" width="340" height="17" font="17">Economic assessments of alternative management </text>
<text top="624" left="452" width="355" height="17" font="17">strategies for VA and prevention of SCD have primarily </text>
<text top="643" left="452" width="235" height="17" font="17">evaluated ICDs, including several RCTs</text>
<text top="643" left="687" width="48" height="10" font="19">S16-3–S16-7</text>
<text top="643" left="736" width="68" height="17" font="17"> and obser-</text>
<text top="661" left="452" width="101" height="17" font="17">vational studies,</text>
<text top="662" left="553" width="46" height="10" font="19">S16-8,S16-9</text>
<text top="661" left="599" width="147" height="17" font="17"> and simulation models.</text>
<text top="662" left="745" width="58" height="10" font="19">S16-10–S16-14</text>
<text top="661" left="803" width="4" height="17" font="17">  </text>
<text top="679" left="452" width="357" height="17" font="17">In all studies, patients who received ICDs had higher </text>
<text top="697" left="452" width="356" height="17" font="17">long-term costs. The high initial cost of the ICD device </text>
<text top="715" left="452" width="351" height="17" font="17">and the implantation procedure leads to higher long-</text>
<text top="734" left="452" width="357" height="17" font="17">term costs, because there are few, if any, subsequent </text>
<text top="752" left="452" width="360" height="17" font="17">cost-savings from implanting an ICD. ICDs without </text>
<text top="770" left="452" width="351" height="17" font="17">resynchronization capability do not reduce hospital re-</text>
<text top="788" left="452" width="357" height="17" font="17">admissions and may increase late costs due to device </text>
<text top="807" left="452" width="355" height="17" font="17">monitoring, complications, and replacement. However, </text>
<text top="825" left="452" width="356" height="17" font="17">the cost of the device and the procedure may change </text>
<text top="843" left="452" width="143" height="17" font="17">significantly over time.</text>
<text top="861" left="470" width="337" height="17" font="17">The trial based assessments of the cost-effectiveness </text>
<text top="879" left="452" width="354" height="17" font="17">of the ICD are based on 3 to 6 years of follow-up, which </text>
<text top="898" left="452" width="354" height="17" font="17">is considerably shorter than the lifetime perspective that </text>
<text top="916" left="452" width="356" height="17" font="17">is standard in cost-effectiveness models. Because most </text>
<text top="934" left="452" width="351" height="17" font="17">of the incremental cost of the ICD is incurred imme-</text>
<text top="952" left="452" width="351" height="17" font="17">diately, while most of the potential effectiveness (life-</text>
<text top="970" left="452" width="354" height="17" font="17">years of survival added by the ICD) is accrued over many </text>
<text top="989" left="452" width="351" height="17" font="17">years, estimates of ICD cost-effectiveness based on lim-</text>
<text top="1007" left="452" width="351" height="17" font="17">ited trial follow-up have a systematic bias toward show-</text>
<text top="1025" left="452" width="351" height="17" font="17">ing lower value. Trial based economic studies that pro-</text>
<text top="1043" left="452" width="354" height="17" font="17">jected long-term ICD outcomes have consistently found </text>
<text top="1061" left="452" width="355" height="17" font="17">more favorable cost-effectiveness ratios than estimates </text>
<text top="1080" left="452" width="287" height="17" font="17">restricted to the duration of trial follow-up.</text>
<text top="1081" left="739" width="48" height="10" font="19">S16-4–S16-7</text>
<text top="1080" left="787" width="22" height="17" font="17"> A </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e353</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="449" left="74" width="358" height="17" font="17">lifetime simulation model applied to each major trial </text>
<text top="467" left="74" width="357" height="17" font="17">of primary prevention ICDs also reported consistently </text>
<text top="485" left="74" width="355" height="17" font="17">more favorable estimates of cost-effectiveness than the </text>
<text top="503" left="74" width="268" height="17" font="17">estimates based on limited trial follow-up.</text>
<text top="504" left="343" width="27" height="10" font="19">S16-11</text>
<text top="503" left="369" width="60" height="17" font="17"> Because </text>
<text top="521" left="74" width="351" height="17" font="17">the framework proposed for assessing value in ACC/</text>
<text top="540" left="74" width="355" height="17" font="17">AHA clinical practice guidelines uses benchmarks based </text>
<text top="558" left="74" width="141" height="17" font="17">on lifetime estimates,</text>
<text top="558" left="215" width="22" height="10" font="19">S16-1</text>
<text top="558" left="237" width="195" height="17" font="17"> we have generally relied on </text>
<text top="576" left="74" width="359" height="17" font="17">the model-based estimates of ICD cost-effectiveness </text>
<text top="594" left="74" width="358" height="17" font="17">in applying value ratings to recommendations in this </text>
<text top="612" left="74" width="63" height="17" font="17">guideline.</text>
<text top="630" left="92" width="337" height="17" font="17">The initial cost of an ICD device is similar regardless </text>
<text top="649" left="74" width="351" height="17" font="17">of the clinical indication, so variations in ICD cost-ef-</text>
<text top="667" left="74" width="354" height="17" font="17">fectiveness are driven primarily by potential differences </text>
<text top="685" left="74" width="351" height="17" font="17">in clinical effectiveness in extending survival in differ-</text>
<text top="703" left="74" width="355" height="17" font="17">ent patient populations. The effect of the years of life </text>
<text top="721" left="74" width="356" height="17" font="17">added by an ICD on its incremental cost-effectiveness </text>
<text top="739" left="74" width="356" height="17" font="17">ratio is illustrated in Figure 17: the cost-effectiveness </text>
<text top="758" left="74" width="356" height="17" font="17">ratio becomes rapidly unfavorable as the extension in </text>
<text top="776" left="74" width="356" height="17" font="17">survival time falls below 1 year, particularly below 0.5 </text>
<text top="794" left="74" width="357" height="17" font="17">year. This inverse relation strongly suggests that the </text>
<text top="812" left="74" width="358" height="17" font="17">value provided by an ICD will be highest when the </text>
<text top="830" left="74" width="355" height="17" font="17">risk of arrhythmic death due to VT/VF is relatively high </text>
<text top="849" left="74" width="358" height="17" font="17">and the risk of nonarrhythmic death (either cardiac </text>
<text top="867" left="74" width="351" height="17" font="17">or noncardiac) is relatively low, such that a meaning-</text>
<text top="885" left="74" width="356" height="17" font="17">ful increase in survival can be expected from the ICD. </text>
<text top="903" left="74" width="356" height="17" font="17">Thus, appropriate patient selection is fundamental to </text>
<text top="921" left="74" width="357" height="17" font="17">high value care in using the ICD to prevent SCD. It </text>
<text top="939" left="74" width="358" height="17" font="17">should also be recognized that cost-effectiveness is </text>
<text top="958" left="74" width="351" height="17" font="17">also influenced by the costs for the ICD and implanta-</text>
<text top="976" left="74" width="355" height="17" font="17">tion procedure, which are likely to change significantly </text>
<text top="994" left="74" width="66" height="17" font="17">over time.</text>
<text top="1012" left="92" width="339" height="17" font="17">The empirical evidence suggests that ICDs are not </text>
<text top="1030" left="74" width="351" height="17" font="17">effective for primary prevention of SCD when im-</text>
<text top="1049" left="74" width="166" height="17" font="17">planted early after CABG</text>
<text top="1049" left="241" width="27" height="10" font="19">S16-15</text>
<text top="1048" left="268" width="163" height="17" font="17"> or an acute myocardial </text>
<text top="1067" left="74" width="65" height="17" font="17">infarction.</text>
<text top="1067" left="140" width="56" height="10" font="19">S16-16,S16-17</text>
<text top="1067" left="196" width="229" height="17" font="17"> An analysis of individual patient lev-</text>
<text top="449" left="452" width="269" height="17" font="17">el data from 3 secondary prevention trials</text>
<text top="449" left="721" width="27" height="10" font="19">S16-18</text>
<text top="449" left="748" width="59" height="17" font="17"> showed </text>
<text top="467" left="452" width="351" height="17" font="17">a significant variation (<i>P</i> =0.011) in the clinical effec-</text>
<text top="485" left="452" width="355" height="17" font="17">tiveness of ICDs between patients with an LVEF ≤35% </text>
<text top="503" left="452" width="356" height="17" font="17">(hazard ratio: 0.66) and an LVEF &gt;35% (hazard ratio: </text>
<text top="521" left="452" width="359" height="17" font="17">1.2). Some studies and simulation models suggest </text>
<text top="539" left="452" width="357" height="17" font="17">that ICDs might prolong life expectancy to a greater </text>
<text top="557" left="452" width="351" height="17" font="17">extent when used in higher-risk patients than in lower-</text>
<text top="575" left="452" width="82" height="17" font="17">risk patients.</text>
<text top="576" left="535" width="27" height="10" font="19">S16-19</text>
<text top="575" left="562" width="246" height="17" font="17"> In contrast, there is little evidence of </text>
<text top="593" left="452" width="358" height="17" font="17">variation in the effectiveness or cost-effectiveness of </text>
<text top="611" left="452" width="287" height="17" font="17">the ICD based on factors such as age or sex.</text>
<text top="612" left="739" width="27" height="10" font="19">S16-20</text>
<text top="611" left="766" width="41" height="17" font="17"> Most </text>
<text top="629" left="452" width="351" height="17" font="17">studies of ICD effectiveness and value have been per-</text>
<text top="647" left="452" width="357" height="17" font="17">formed on patients with reduced LV function due to </text>
<text top="665" left="452" width="351" height="17" font="17">prior MI or NICM. There are few data on the effec-</text>
<text top="683" left="452" width="356" height="17" font="17">tiveness or value of an ICD for other potential clinical </text>
<text top="701" left="452" width="356" height="17" font="17">indications, such as cardiac channelopathies or HCM, </text>
<text top="719" left="452" width="357" height="17" font="17">although studies have suggested that their potential </text>
<text top="737" left="452" width="355" height="17" font="17">cost effectiveness in such patients will depend on their </text>
<text top="755" left="452" width="356" height="17" font="17">underlying risk of SCD, with little evidence of value in </text>
<text top="773" left="452" width="110" height="17" font="17">low-risk patients.</text>
<text top="774" left="563" width="27" height="10" font="19">S16-14</text>
<text top="821" left="452" width="186" height="23" font="15"><b>17. QUALITY OF LIFE</b></text>
<text top="850" left="452" width="357" height="17" font="17">ICD implantation has not had a significant effect on </text>
<text top="868" left="452" width="357" height="17" font="17">QoL in  the overall population of patients enrolled in </text>
<text top="886" left="452" width="35" height="17" font="17">RCTs.</text>
<text top="887" left="487" width="49" height="10" font="19">S17-1–S17-3</text>
<text top="886" left="536" width="267" height="17" font="17"> Several studies have, however, demon-</text>
<text top="904" left="452" width="351" height="17" font="17">strated that the subset of patients who receive inap-</text>
<text top="922" left="452" width="357" height="17" font="17">propriate ICD shocks have worse QoL than patients </text>
<text top="940" left="452" width="359" height="17" font="17">who have an ICD but have not had inappropriate </text>
<text top="958" left="452" width="48" height="17" font="17">shocks.</text>
<text top="959" left="500" width="22" height="10" font="19">S17-2</text>
<text top="958" left="522" width="284" height="17" font="17"> Because an ICD is designed to prevent SCD </text>
<text top="976" left="452" width="351" height="17" font="17">rather than to reduce symptoms, it would not be ex-</text>
<text top="994" left="452" width="358" height="17" font="17">pected to improve QoL or functional status directly, </text>
<text top="1012" left="452" width="351" height="17" font="17">but may have indirect, negative effects in some pa-</text>
<text top="1031" left="452" width="355" height="17" font="17">tients due to device complications, or indirect, positive </text>
<text top="1049" left="452" width="356" height="17" font="17">effects in some patients due to reassurance of having </text>
<text top="1067" left="452" width="181" height="17" font="17">a protective device in place.</text>
<text top="381" left="74" width="51" height="12" font="3"><b>Figure 17. </b></text>
<text top="381" left="125" width="356" height="12" font="22"><b>Incremental cost-effectiveness of ICD by years of life added* (example).</b> </text>
<text top="395" left="74" width="719" height="12" font="4">*Figure based on formula: Incremental cost-effectiveness ratio = $50 000/QALYs. CE indicated cost effectiveness, ICD, implantable cardioverter-defibrillator; LYA, </text>
<text top="408" left="74" width="243" height="12" font="4">life year added; and QALYs, quality-adjusted life-years.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e354</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="86" left="74" width="309" height="23" font="15"><b>18. EVIDENCE GAPS AND FUTURE </b></text>
<text top="109" left="74" width="163" height="23" font="15"><b>RESEARCH NEEDS</b></text>
<text top="138" left="74" width="359" height="17" font="17">Despite the numerous advances in risk stratification </text>
<text top="156" left="74" width="355" height="17" font="17">for SCD and prevention and treatment of SCD and VA, </text>
<text top="174" left="74" width="341" height="17" font="17">many gaps in knowledge remain. These gaps include:</text>
<text top="192" left="90" width="346" height="17" font="17">•  Identification of patients who are most likely </text>
<text top="210" left="105" width="329" height="17" font="17">to benefit from an ICD among all ICD-eligible </text>
<text top="228" left="105" width="330" height="17" font="17">patients. The role of novel markers (including </text>
<text top="246" left="105" width="327" height="17" font="17">genetic and imaging markers) and combinations </text>
<text top="265" left="105" width="190" height="17" font="17">of markers should be studied.</text>
<text top="283" left="90" width="335" height="17" font="17">•  Characterizing the role of the ICD in patient sub-</text>
<text top="301" left="105" width="329" height="17" font="17">groups not well-represented in the pivotal ICD </text>
<text top="319" left="105" width="326" height="17" font="17">trials. Such subgroups include patients ≥80 years </text>
<text top="337" left="105" width="320" height="17" font="17">of age and those with kidney disease, espe-</text>
<text top="355" left="105" width="327" height="17" font="17">cially patients with ESRD on dialysis, or multiple </text>
<text top="373" left="105" width="90" height="17" font="17">comorbidities.</text>
<text top="391" left="90" width="335" height="17" font="17">•  Methods to identify and treat patients at high indi-</text>
<text top="409" left="105" width="320" height="17" font="17">vidual risk for SCD who are not identified by cur-</text>
<text top="428" left="105" width="324" height="17" font="17">rent ICD eligibility criteria, including those who are </text>
<text top="446" left="105" width="156" height="17" font="17">within 40 days of an MI.</text>
<text top="464" left="90" width="339" height="17" font="17">•  Defining the role of the ICD in patients with HCM, </text>
<text top="482" left="105" width="326" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy, </text>
<text top="500" left="105" width="320" height="17" font="17">cardiac sarcoidosis, and inherited cardiac chan-</text>
<text top="518" left="105" width="320" height="17" font="17">nelopathies in prospective studies (preferably RCT).</text>
<text top="536" left="90" width="341" height="17" font="17">•  Determining the best approach to patients due for </text>
<text top="554" left="105" width="327" height="17" font="17">elective ICD generator replacement due to battery </text>
<text top="573" left="105" width="325" height="17" font="17">depletion, but who may now be at low risk for SCA, </text>
<text top="591" left="105" width="320" height="17" font="17">such as if significant LVEF improvement has occurred.</text>
<text top="609" left="90" width="335" height="17" font="17">•  Obtaining more data on the efficacy and effec-</text>
<text top="627" left="105" width="320" height="17" font="17">tiveness of the subcutaneous implantable cardio-</text>
<text top="645" left="105" width="332" height="17" font="17">verter-defibrillator, compared with transvenous </text>
<text top="663" left="105" width="324" height="17" font="17">ICDs and on the extent of testing required, and its </text>
<text top="681" left="105" width="320" height="17" font="17">use with other novel technologies, including lead-</text>
<text top="699" left="105" width="107" height="17" font="17">less pacemakers.</text>
<text top="718" left="90" width="343" height="17" font="17">•  Conducting RCTs on catheter ablation of VT in </text>
<text top="736" left="105" width="333" height="17" font="17">ischemic heart disease and cardiomyopathies </text>
<text top="754" left="105" width="328" height="17" font="17">that evaluates procedural end points, mortality, </text>
<text top="772" left="105" width="255" height="17" font="17">arrhythmia suppression, QoL, and costs.</text>
<text top="790" left="90" width="335" height="17" font="17">•  Improving identification of individuals without sig-</text>
<text top="808" left="105" width="325" height="17" font="17">nificant ventricular dysfunction who are at risk of </text>
<text top="826" left="105" width="32" height="17" font="17">SCD.</text>
<text top="844" left="90" width="339" height="17" font="17">•  Identifying mechanisms and risk factors for SCD in </text>
<text top="862" left="105" width="129" height="17" font="17">patients with HF<i>p</i>EF.</text>
<text top="881" left="90" width="341" height="17" font="17">•  Improving emergency response to out-of-hospital </text>
<text top="899" left="105" width="89" height="17" font="17">cardiac arrest.</text>
<text top="917" left="90" width="344" height="17" font="17">•  Developing better methods for identifying and </text>
<text top="935" left="105" width="330" height="17" font="17">ablating  the arrhythmia substrate in structural </text>
<text top="953" left="105" width="88" height="17" font="17">heart disease.</text>
<text top="971" left="90" width="339" height="17" font="17">•  Developing better risk stratification of diseases and </text>
<text top="989" left="105" width="320" height="17" font="17">syndromes associated with sudden death, includ-</text>
<text top="1007" left="105" width="324" height="17" font="17">ing ischemic heart disease, NICM, adult congenital </text>
<text top="1026" left="105" width="244" height="17" font="17">heart disease, and Brugada syndrome.</text>
<text top="1044" left="90" width="341" height="17" font="17">•  Identifying what causes different types of long QT </text>
<text top="1062" left="105" width="320" height="17" font="17">syndrome, catecholaminergic polymorphic ven-</text>
<text top="1080" left="105" width="326" height="17" font="17">tricular tachycardia, Brugada syndrome, HCM, and </text>
<text top="88" left="483" width="331" height="17" font="17">arrhythmogenic right ventricular cardiomyopathy </text>
<text top="106" left="483" width="320" height="17" font="17">and advancing the genotype-phenotype relation-</text>
<text top="124" left="483" width="320" height="17" font="17">ships, genotype-dependent risk, and genotype-</text>
<text top="142" left="483" width="325" height="17" font="17">based tailoring of therapies for patients with inherited </text>
<text top="160" left="483" width="314" height="17" font="17">cardiomyopathies and inherited channelopathies.</text>
<text top="178" left="468" width="341" height="17" font="17">•  Defining the most appropriate and beneficial use </text>
<text top="196" left="483" width="243" height="17" font="17">of wearable cardioverter-defibrillators.</text>
<text top="214" left="468" width="340" height="17" font="17">•  Developing methods to identify and treat patients </text>
<text top="232" left="483" width="320" height="17" font="17">at high personal risk for SCD who are not identi-</text>
<text top="250" left="483" width="232" height="17" font="17">fied by current ICD eligibility criteria.</text>
<text top="268" left="468" width="335" height="17" font="17">•  Defining the role of CMR in enhancing risk strati-</text>
<text top="286" left="483" width="106" height="17" font="17">fication for SCD.</text>
<text top="304" left="470" width="333" height="17" font="17">Increasing research funding in this area, through ex-</text>
<text top="322" left="452" width="354" height="17" font="17">isting and new mechanisms is critically important. Some </text>
<text top="340" left="452" width="356" height="17" font="17">have proposed research funding strategies that would </text>
<text top="358" left="452" width="358" height="17" font="17">offer business incentives to the insurance industries, </text>
<text top="376" left="452" width="356" height="17" font="17">while providing support for unresolved research goals. </text>
<text top="394" left="452" width="222" height="17" font="17">Such approaches should be tested.</text>
<text top="442" left="452" width="304" height="23" font="15"><b>ACC/AHA TASK FORCE MEMBERS</b></text>
<text top="470" left="452" width="354" height="17" font="17">Glenn N. Levine, MD, FACC, FAHA, Chair; Patrick T. O’Gara, </text>
<text top="488" left="452" width="355" height="17" font="17">MD, MACC, FAHA, Chair-Elect; Jonathan L. Halperin, MD, </text>
<text top="506" left="452" width="356" height="17" font="17">FACC, FAHA, Immediate Past Chair*; Sana M. Al-Khatib, </text>
<text top="524" left="452" width="357" height="17" font="17">MD, MHS, FACC, FAHA; Joshua A. Beckman, MD, MS, </text>
<text top="542" left="452" width="351" height="17" font="17">FAHA; Kim K. Birtcher, MS, PharmD, AACC; Biykem Boz-</text>
<text top="560" left="452" width="354" height="17" font="17">kurt, MD, PhD, FACC, FAHA*; Ralph G. Brindis, MD, MPH, </text>
<text top="578" left="452" width="356" height="17" font="17">MACC*; Joaquin E. Cigarroa, MD, FACC; Anita Deswal, </text>
<text top="596" left="452" width="354" height="17" font="17">MD, MPH, FACC, FAHA; Lesley H. Curtis, PhD, FAHA*; Lee </text>
<text top="614" left="452" width="354" height="17" font="17">A. Fleisher, MD, FACC, FAHA; Federico Gentile, MD, FACC; </text>
<text top="632" left="452" width="359" height="17" font="17">Samuel Gidding, MD, FAHA*; Zachary D. Goldberger, </text>
<text top="650" left="452" width="355" height="17" font="17">MD, MS, FACC, FAHA; Mark A. Hlatky, MD, FACC, FAHA; </text>
<text top="668" left="452" width="358" height="17" font="17">John Ikonomidis, MD, PhD, FAHA; José A. Joglar, MD, </text>
<text top="686" left="452" width="351" height="17" font="17">FACC, FAHA; Laura Mauri, MD, MSc, FAHA; Barbara Rie-</text>
<text top="704" left="452" width="355" height="17" font="17">gel, PhD, RN, FAHA; Susan J. Pressler, PhD, RN, FAHA*;  </text>
<text top="722" left="452" width="233" height="17" font="17">Duminda N. Wijeysundera, MD, PhD</text>
<text top="770" left="452" width="217" height="23" font="15"><b>PRESIDENTS AND STAFF</b></text>
<text top="798" left="452" width="268" height="21" font="18"><b>American College of Cardiology</b></text>
<text top="826" left="452" width="264" height="17" font="17">Mary Norine Walsh, MD, FACC, President</text>
<text top="844" left="452" width="271" height="17" font="17">Shalom Jacobovitz, Chief Executive Officer</text>
<text top="862" left="452" width="360" height="17" font="17">William J. Oetgen, MD, MBA, FACC, Executive Vice  </text>
<text top="880" left="470" width="327" height="17" font="17">President, Science, Education, Quality, and Publishing</text>
<text top="898" left="452" width="359" height="17" font="17">Amelia Scholtz, PhD, Publications Manager, Science, </text>
<text top="916" left="470" width="217" height="17" font="17">Education, Quality, and Publishing</text>
<text top="959" left="452" width="275" height="21" font="18"><b>American College of Cardiology/</b></text>
<text top="980" left="452" width="234" height="21" font="18"><b>American Heart Association</b></text>
<text top="1007" left="452" width="363" height="17" font="17">Katherine A. Sheehan, PhD, Director, Guideline </text>
<text top="1007" left="803" width="4" height="17" font="17"> </text>
<text top="1025" left="470" width="155" height="17" font="17">Strategy and Operations</text>
<text top="1068" left="452" width="346" height="14" font="0">*Former Task Force member; current member during the writing </text>
<text top="1083" left="452" width="33" height="14" font="0">effort.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="33" size="13" family="Times" color="#ce171e"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e355</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="347" height="17" font="17">Abdul R. Abdullah, MD, Science and Medicine Advisor</text>
<text top="106" left="74" width="361" height="17" font="17">Sam Shahid, MBBS, MPH, Associate Science and </text>
<text top="106" left="425" width="4" height="17" font="17"> </text>
<text top="124" left="92" width="110" height="17" font="17">Medicine Advisor</text>
<text top="166" left="74" width="234" height="21" font="18"><b>American Heart Association</b></text>
<text top="193" left="74" width="191" height="17" font="17">John J. Warner, MD, President</text>
<text top="212" left="74" width="238" height="17" font="17">Nancy Brown, Chief Executive Officer</text>
<text top="230" left="74" width="357" height="17" font="17">Rose Marie Robertson, MD, FAHA, Chief Science and </text>
<text top="248" left="92" width="106" height="17" font="17">Medicine Officer</text>
<text top="266" left="74" width="356" height="17" font="17">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice </text>
<text top="284" left="92" width="248" height="17" font="17">President, Office of Science Operations</text>
<text top="303" left="74" width="361" height="17" font="17">Prashant Nedungadi, PhD, Associate Science and </text>
<text top="303" left="425" width="4" height="17" font="17"> </text>
<text top="321" left="92" width="298" height="17" font="17">Medicine Advisor, Office of Science Operations</text>
<text top="339" left="74" width="358" height="17" font="17">Jody Hundley, Production and Operations Manager,  </text>
<text top="357" left="92" width="326" height="17" font="17">Scientific Publications, Office of Science Operations</text>
<text top="408" left="74" width="164" height="18" font="33"><b>ARTICLE INFORMATION</b></text>
<text top="432" left="74" width="354" height="12" font="4">This document was approved by the American College of Cardiology Clinical </text>
<text top="446" left="74" width="351" height="12" font="4">Policy Approval Committee, the American Heart Association Science Advi-</text>
<text top="460" left="74" width="351" height="12" font="4">sory and Coordinating Committee, and the Heart Rhythm Society in Sep-</text>
<text top="473" left="74" width="355" height="12" font="4">tember 2017, and the American Heart Association Executive Committee in </text>
<text top="487" left="74" width="67" height="12" font="4">October 2017.</text>
<text top="501" left="92" width="335" height="12" font="4">The Comprehensive RWI Data Supplement table is available with this article </text>
<text top="514" left="74" width="342" height="12" font="4"><a href="">at https://www.ahajournals.org/doi/suppl/10.1161/CIR.0000000000000549.</a></text>
<text top="528" left="92" width="333" height="12" font="4">A Data Supplement is available with <a href="">this article at https://www.ahajournals.</a></text>
<text top="542" left="74" width="217" height="12" font="4"><a href="">org/doi/suppl/10.1161/CIR.0000000000000549.</a></text>
<text top="556" left="92" width="336" height="12" font="4">This article has been copublished in the <i>Journal of the American College of </i></text>
<text top="569" left="74" width="135" height="12" font="12"><i>Cardiology</i> and <b>Heart</b>Rhythm.</text>
<text top="583" left="92" width="337" height="12" font="4">Copies: This document is available on the World Wide Web sites of the </text>
<text top="597" left="74" width="351" height="12" font="4">American College of Car<a href="">diology (www.acc.org), the American Heart Associa</a>-</text>
<text top="610" left="74" width="351" height="12" font="4"><a href="">tion (professional.heart.org), and the Heart Rhythm Society (www.hrsonline.</a></text>
<text top="624" left="74" width="354" height="12" font="4"><a href="">org). </a>A copy of the document is available <a href="">at http://professional.heart.org/</a> </text>
<text top="638" left="74" width="357" height="12" font="4"><a href="">statements by using either “Sear</a>ch for Guidelines &amp; Statements” or the </text>
<text top="651" left="74" width="354" height="12" font="4">“Browse by Topic” area. To purchase additional reprints, call 843-216-2533 or </text>
<text top="665" left="74" width="181" height="12" font="4"><a href="mailto:kelle.ramsay@wolterskluwer.com">e-mail kelle.ramsay@wolterskluwer.com.</a></text>
<text top="679" left="92" width="338" height="12" font="4">The expert peer review of AHA-commissioned documents (eg, scientific </text>
<text top="693" left="74" width="354" height="12" font="4">statements, clinical practice guidelines, systematic reviews) is conducted by the </text>
<text top="706" left="74" width="351" height="12" font="4">AHA Office of Science Operations. For more on AHA statements and guide-</text>
<text top="720" left="74" width="357" height="12" font="4">lines <a href="">development, visit https://professional.heart.org/statements. </a>Select the </text>
<text top="734" left="74" width="355" height="12" font="4">“Guidelines &amp; Statements” drop-down menu near the top of the webpage, </text>
<text top="747" left="74" width="172" height="12" font="4">then click “Publication Development.”</text>
<text top="761" left="92" width="333" height="12" font="4">Permissions: Multiple copies, modification, alteration, enhancement, and/</text>
<text top="775" left="74" width="351" height="12" font="4">or distribution of this document are not permitted without the express permis-</text>
<text top="788" left="74" width="355" height="12" font="4">sion of the American Heart Association. Instructions for obtaining permission </text>
<text top="802" left="74" width="351" height="12" font="4">ar<a href="">e located at https://www.heart.org/permissions. A link to the “Copyright Per</a>-</text>
<text top="816" left="74" width="351" height="12" font="4">missions Request Form” appears in <a href="">the second paragraph (https://www.heart.</a></text>
<text top="830" left="74" width="293" height="12" font="4"><a href="">org/en/about-us/statements-and-policies/copyright-request-form).</a></text>
<text top="874" left="74" width="114" height="23" font="15"><b>REFERENCES</b></text>
<text top="932" left="74" width="99" height="23" font="15"><b>PREAMBLE</b></text>
<text top="961" left="74" width="355" height="12" font="4">  P-1.  Committee on Standards for Developing Trustworthy Clinical Practice </text>
<text top="974" left="110" width="319" height="12" font="4">Guidelines, Institute of Medicine (US) Clinical Practice Guidelines We </text>
<text top="988" left="110" width="273" height="12" font="4">Can Trust. Washington, DC: National Academies Press, 2011.</text>
<text top="1002" left="74" width="358" height="12" font="4">  P-2. Committee on Standards for Systematic Reviews of Comparative </text>
<text top="1015" left="110" width="318" height="12" font="4">Effectiveness Research, Institute of Medicine (US) Finding What Works </text>
<text top="1029" left="110" width="320" height="12" font="4">in Health Care: Standards for Systematic Reviews. Washington, DC: </text>
<text top="1043" left="110" width="146" height="12" font="4">National Academies Press, 2011.</text>
<text top="1057" left="74" width="355" height="12" font="4">  P-3.  Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement </text>
<text top="1070" left="110" width="315" height="12" font="4">on cost/value methodology in clinical practice guidelines and perfor-</text>
<text top="1084" left="110" width="315" height="12" font="4">mance measures: a report of the American College of Cardiology/</text>
<text top="88" left="488" width="320" height="12" font="4">American Heart Association Task Force on Performance Measures </text>
<text top="102" left="488" width="318" height="12" font="4">and Task Force on Practice Guidelines. Circulation. 2014;129: </text>
<text top="116" left="488" width="43" height="12" font="4">2329–45.</text>
<text top="130" left="452" width="356" height="12" font="4">  P-4.  ACCF/AHA Task Force on Practice Guidelines. Methodology Manual </text>
<text top="143" left="488" width="320" height="12" font="4">and Policies From the ACCF/AHA Task Force on Practice Guidelines. </text>
<text top="157" left="488" width="318" height="12" font="4">American College of Cardiology and American Heart Association, 2010. </text>
<text top="171" left="488" width="315" height="12" font="4">A<a href="">vailable at: http://assets.cardiosource.com/Methodology_Manual_</a></text>
<text top="185" left="488" width="315" height="12" font="4"><a href="">for_ACC_AHA_Writing_Committees.pdf and http://professional.heart.</a></text>
<text top="199" left="488" width="315" height="12" font="4"><a href="">org/idc/groups/ahamahpublic/@wcm/@sop/documents/downloadable/</a></text>
<text top="212" left="488" width="80" height="12" font="4"><a href="">ucm_319826.pdf.</a></text>
<text top="226" left="452" width="353" height="12" font="4">  P-5.  Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to </text>
<text top="240" left="488" width="315" height="12" font="4">enhance application of clinical practice guidelines in patients with car-</text>
<text top="254" left="488" width="318" height="12" font="4">diovascular disease and comorbid conditions: from the American Heart </text>
<text top="267" left="488" width="319" height="12" font="4">Association, American College of Cardiology, and US Department of </text>
<text top="281" left="488" width="266" height="12" font="4">Health and Human Services. Circulation. 2014;130:1662–7.</text>
<text top="295" left="452" width="355" height="12" font="4">  P-6.  Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the </text>
<text top="309" left="488" width="321" height="12" font="4">ACC/AHA clinical practice guideline recommendation classification </text>
<text top="323" left="488" width="315" height="12" font="4">system: a report of the American College of Cardiology Foundation/</text>
<text top="336" left="488" width="318" height="12" font="4">American Heart Association Task Force on Clinical Practice Guidelines. </text>
<text top="350" left="488" width="138" height="12" font="4">Circulation. 2016;133:1426–8.</text>
<text top="364" left="452" width="351" height="12" font="4">  P-7.  Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/</text>
<text top="378" left="488" width="320" height="12" font="4">AHA clinical practice guidelines: a 30-year journey: a report of the </text>
<text top="391" left="488" width="318" height="12" font="4">American College of Cardiology/American Heart Association Task Force </text>
<text top="405" left="488" width="248" height="12" font="4">on Practice Guidelines. Circulation. 2014;130:1208–17.</text>
<text top="419" left="452" width="351" height="12" font="4">  P-8.  Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical prac-</text>
<text top="433" left="488" width="319" height="12" font="4">tice guideline methodology summit report: a report of the American </text>
<text top="446" left="488" width="321" height="12" font="4">College of Cardiology Foundation/American Heart Association Task </text>
<text top="460" left="488" width="275" height="12" font="4">Force on Practice Guidelines. Circulation. 2013;127:268–310.</text>
<text top="504" left="452" width="165" height="23" font="15"><b>1. INTRODUCTION</b></text>
<text top="533" left="452" width="356" height="12" font="4"> S1.4-1. Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for </text>
<text top="547" left="488" width="319" height="12" font="4">the 2017 AHA/ACC/HRS guideline for management of patients with </text>
<text top="560" left="488" width="319" height="12" font="4">ventricular arrhythmias and the prevention of sudden cardiac death: </text>
<text top="574" left="488" width="322" height="12" font="4">a report of the American College of Cardiology/American Heart </text>
<text top="588" left="488" width="320" height="12" font="4">Association Task Force on Clinical Practice Guidelines and the Heart </text>
<text top="602" left="488" width="228" height="12" font="4">Rhythm Society. Circulation. 2018;138:e392–e414.</text>
<text top="616" left="452" width="353" height="12" font="4"> S1.4-2.  Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on </text>
<text top="629" left="488" width="318" height="12" font="4">cost/value methodology in clinical practice guidelines and performance </text>
<text top="643" left="488" width="319" height="12" font="4">measures: a report of the American College of Cardiology/American </text>
<text top="657" left="488" width="318" height="12" font="4">Heart Association Task Force on Performance Measures and Task Force </text>
<text top="671" left="488" width="248" height="12" font="4">on Practice Guidelines. Circulation. 2014;129:2329–45.</text>
<text top="684" left="452" width="357" height="12" font="4"> S1.4-3. World Health Organization. CHOosing Interventions that are Cost </text>
<text top="698" left="488" width="320" height="12" font="4">Effective (WHO-CHOICE): cost-effectiveness thresholds. Available at: </text>
<text top="712" left="488" width="262" height="12" font="4"><a href="">http://www.who.int/choice/en/. Accessed Mar</a>ch 26, 2013.</text>
<text top="726" left="452" width="351" height="12" font="4"> S1.4-4. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide-</text>
<text top="739" left="488" width="319" height="12" font="4">lines for management of patients with ventricular arrhythmias and </text>
<text top="753" left="488" width="320" height="12" font="4">the prevention of sudden cardiac death: a report of the American </text>
<text top="767" left="488" width="318" height="12" font="4">College of Cardiology/American Heart Association Task Force and the </text>
<text top="781" left="488" width="320" height="12" font="4">European Society of Cardiology Committee for Practice Guidelines </text>
<text top="795" left="488" width="322" height="12" font="4">(Writing Committee to Develop Guidelines for Management of </text>
<text top="808" left="488" width="318" height="12" font="4">Patients With Ventricular Arrhythmias and the Prevention of Sudden </text>
<text top="822" left="488" width="320" height="12" font="4">Cardiac Death). Developed in collaboration with the European Heart </text>
<text top="836" left="488" width="323" height="12" font="4">Rhythm Association and the Heart Rhythm Society. Circulation. </text>
<text top="850" left="488" width="97" height="12" font="4">2006;114:e385–484.</text>
<text top="863" left="452" width="356" height="12" font="4"> S1.4-5. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 </text>
<text top="877" left="488" width="315" height="12" font="4">guidelines for device-based therapy of cardiac rhythm abnormali-</text>
<text top="891" left="488" width="319" height="12" font="4">ties: a report of the American College of Cardiology/American Heart </text>
<text top="905" left="488" width="319" height="12" font="4">Association Task Force on Practice Guidelines (Writing Committee to </text>
<text top="919" left="488" width="319" height="12" font="4">Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation </text>
<text top="932" left="488" width="315" height="12" font="4">of Cardiac Pacemakers and Antiarrhythmia Devices). Developed in col-</text>
<text top="946" left="488" width="320" height="12" font="4">laboration with the American Association for Thoracic Surgery and </text>
<text top="960" left="488" width="278" height="12" font="4">Society of Thoracic Surgeons. Circulation. 2008;117:350–408.</text>
<text top="974" left="452" width="355" height="12" font="4"> S1.4-6. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for </text>
<text top="987" left="488" width="318" height="12" font="4">the diagnosis and treatment of hypertrophic cardiomyopathy: a report </text>
<text top="1001" left="488" width="320" height="12" font="4">of the American College of Cardiology Foundation/American Heart </text>
<text top="1015" left="488" width="315" height="12" font="4">Association Task Force on Practice Guidelines. Developed in collabo-</text>
<text top="1029" left="488" width="319" height="12" font="4">ration with the American Association for Thoracic Surgery, American </text>
<text top="1043" left="488" width="319" height="12" font="4">Society of Echocardiography, American Society of Nuclear Cardiology, </text>
<text top="1056" left="488" width="320" height="12" font="4">Heart Failure Society of America, Heart Rhythm Society, Society for </text>
<text top="1070" left="488" width="318" height="12" font="4">Cardiovascular Angiography and Interventions, and Society of Thoracic </text>
<text top="1084" left="488" width="191" height="12" font="4">Surgeons. Circulation. 2011;124:783–831.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e356</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="80" width="350" height="12" font="4"> S1.4-7.  Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key </text>
<text top="102" left="122" width="311" height="12" font="4">data elements and definitions for electrophysiological studies </text>
<text top="116" left="122" width="303" height="12" font="4">and procedures: a report of the American College of Cardiology/</text>
<text top="129" left="122" width="307" height="12" font="4">American Heart Association Task Force on Clinical Data Standards </text>
<text top="143" left="122" width="307" height="12" font="4">(ACC/AHA/HRS Writing Committee to Develop Data Standards on </text>
<text top="157" left="122" width="230" height="12" font="4">Electrophysiology). Circulation. 2006;114:2534–70.</text>
<text top="170" left="80" width="345" height="12" font="4"> S1.4-8.  Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/</text>
<text top="184" left="122" width="310" height="12" font="4">SOLAECE expert consensus statement on optimal implantable </text>
<text top="197" left="122" width="310" height="12" font="4">cardioverter-defibrillator programming and testing. J Arrhythm. </text>
<text top="211" left="122" width="67" height="12" font="4">2016;32:1–28.</text>
<text top="225" left="80" width="345" height="12" font="4"> S1.4-9.  Piccini JP Sr, Allen LA, Kudenchuk PJ, et al. Wearable cardioverter-</text>
<text top="238" left="122" width="307" height="12" font="4">defibrillator therapy for the prevention of sudden cardiac death: a </text>
<text top="252" left="122" width="307" height="12" font="4">science advisory from the American Heart Association. Circulation. </text>
<text top="266" left="122" width="90" height="12" font="4">2016;133:1715–27.</text>
<text top="279" left="74" width="351" height="12" font="4"> S1.4-10.  Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guide-</text>
<text top="293" left="122" width="307" height="12" font="4">line for the evaluation and management of patients with syncope: </text>
<text top="307" left="122" width="308" height="12" font="4">a report of the American College of Cardiology/American Heart </text>
<text top="320" left="122" width="306" height="12" font="4">Association Task Force on Clinical Practice Guidelines and the Heart </text>
<text top="334" left="122" width="212" height="12" font="4">Rhythm Society. Circulation. 2017;136:60–122.</text>
<text top="347" left="74" width="353" height="12" font="4"> S1.4-11.  Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused </text>
<text top="361" left="122" width="309" height="12" font="4">update of the 2013 ACCF/AHA guideline for the management </text>
<text top="375" left="122" width="303" height="12" font="4">of heart failure: a report of the American College of Cardiology/</text>
<text top="388" left="122" width="312" height="12" font="4">American Heart Association Task Force on Clinical Practice </text>
<text top="402" left="122" width="308" height="12" font="4">Guidelines and the Heart Failure Society of America. Circulation. </text>
<text top="416" left="122" width="84" height="12" font="4">2017;136:137–61.</text>
<text top="429" left="74" width="353" height="12" font="4"> S1.4-12.  Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused </text>
<text top="443" left="122" width="306" height="12" font="4">update on new pharmacological therapy for heart failure: an update </text>
<text top="457" left="122" width="303" height="12" font="4">of the 2013 ACCF/AHA guideline for the management of heart fail-</text>
<text top="470" left="122" width="306" height="12" font="4">ure: a report of the American College of Cardiology/American Heart </text>
<text top="484" left="122" width="306" height="12" font="4">Association Task Force on Clinical Practice Guidelines and the Heart </text>
<text top="497" left="122" width="259" height="12" font="4">Failure Society of America. Circulation. 2016;134:282–93.</text>
<text top="511" left="74" width="354" height="12" font="4"> S1.4-13.  Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for </text>
<text top="525" left="122" width="306" height="12" font="4">the management of heart failure: a report of the American College </text>
<text top="538" left="122" width="306" height="12" font="4">of Cardiology Foundation/American Heart Association Task Force on </text>
<text top="552" left="122" width="234" height="12" font="4">Practice Guidelines. Circulation. 2013;128:240–327.</text>
<text top="566" left="74" width="354" height="12" font="4"> S1.4-14.  Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused </text>
<text top="579" left="122" width="309" height="12" font="4">update of the 2014 AHA/ACC guideline for the management </text>
<text top="593" left="122" width="308" height="12" font="4">of patients with valvular heart disease: a report of the American </text>
<text top="607" left="122" width="308" height="12" font="4">College of Cardiology/American Heart Association Task Force on </text>
<text top="620" left="122" width="269" height="12" font="4">Clinical Practice Guidelines. Circulation. 2017;135:1159–95.</text>
<text top="634" left="74" width="354" height="12" font="4"> S1.4-15.  Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline </text>
<text top="648" left="122" width="306" height="12" font="4">for the management of patients with valvular heart disease: a report </text>
<text top="661" left="122" width="306" height="12" font="4">of the American College of Cardiology/American Heart Association </text>
<text top="675" left="122" width="297" height="12" font="4">Task Force on Practice Guidelines. Circulation. 2014;129:521–643.</text>
<text top="688" left="74" width="353" height="12" font="4"> S1.4-16.  Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline </text>
<text top="702" left="122" width="303" height="12" font="4">for the management of adult patients with supraventricular tachy-</text>
<text top="716" left="122" width="308" height="12" font="4">cardia: a report of the American College of Cardiology/American </text>
<text top="729" left="122" width="306" height="12" font="4">Heart Association Task Force on Clinical Practice Guidelines and the </text>
<text top="743" left="122" width="239" height="12" font="4">Heart Rhythm Society. Circulation. 2016;133:506–74.</text>
<text top="757" left="74" width="356" height="12" font="4"> S1.4-17.  Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC </text>
<text top="770" left="122" width="303" height="12" font="4">guidelines for the management of patients with ventricular arrhyth-</text>
<text top="784" left="122" width="307" height="12" font="4">mias and the prevention of sudden cardiac death. The Task Force </text>
<text top="798" left="122" width="307" height="12" font="4">for the Management of Patients with Ventricular Arrhythmias and </text>
<text top="811" left="122" width="306" height="12" font="4">the Prevention of Sudden Cardiac Death of the European Society of </text>
<text top="825" left="122" width="230" height="12" font="4">Cardiology. G Ital Cardiol (Rome). 2016;17:108–70.</text>
<text top="838" left="74" width="351" height="12" font="4"> S1.4-18.  Perkins GD, Jacobs IG, Nadkarni VM, et al. Cardiac arrest and car-</text>
<text top="852" left="122" width="307" height="12" font="4">diopulmonary resuscitation outcome reports: update of the Utstein </text>
<text top="866" left="122" width="306" height="12" font="4">Resuscitation Registry Templates for Out-of-Hospital Cardiac Arrest: </text>
<text top="879" left="122" width="307" height="12" font="4">a statement for healthcare professionals from a task force of the </text>
<text top="893" left="122" width="307" height="12" font="4">International Liaison Committee on Resuscitation (American Heart </text>
<text top="907" left="122" width="308" height="12" font="4">Association, European Resuscitation Council, Australian and New </text>
<text top="920" left="122" width="307" height="12" font="4">Zealand Council on Resuscitation, Heart and Stroke Foundation of </text>
<text top="934" left="122" width="307" height="12" font="4">Canada, InterAmerican Heart Foundation, Resuscitation Council of </text>
<text top="948" left="122" width="307" height="12" font="4">Southern Africa, Resuscitation Council of Asia); and the American </text>
<text top="961" left="122" width="307" height="12" font="4">Heart Association Emergency Cardiovascular Care Committee and </text>
<text top="975" left="122" width="308" height="12" font="4">the Council on Cardiopulmonary, Critical Care, Perioperative and </text>
<text top="989" left="122" width="214" height="12" font="4">Resuscitation. Circulation. 2015;132:1286–300.</text>
<text top="1002" left="74" width="351" height="12" font="4"> S1.4-19.  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide-</text>
<text top="1016" left="122" width="306" height="12" font="4">line for the management of patients with atrial fibrillation: a report </text>
<text top="1029" left="122" width="306" height="12" font="4">of the American College of Cardiology/American Heart Association </text>
<text top="1043" left="122" width="308" height="12" font="4">Task Force on Practice Guidelines and the Heart Rhythm Society. </text>
<text top="1057" left="122" width="149" height="12" font="4">Circulation. 2014;130:e199–267.</text>
<text top="1070" left="74" width="357" height="12" font="4"> S1.4-20.  Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC </text>
<text top="1084" left="122" width="308" height="12" font="4">guideline for the management of patients with non-ST-elevation </text>
<text top="88" left="500" width="308" height="12" font="4">acute coronary syndromes: a report of the American College of </text>
<text top="102" left="500" width="311" height="12" font="4">Cardiology/American Heart Association Task Force on Practice </text>
<text top="115" left="500" width="202" height="12" font="4">Guidelines. Circulation. 2014;130:e344–426.</text>
<text top="129" left="455" width="351" height="12" font="4"> S1.4-21.  Andrus B, Lacaille D, 2013 ACC/AHA guideline on the assessment of </text>
<text top="143" left="500" width="237" height="12" font="4">cardiovascular risk. J Am Coll Cardiol. 2014;63:2886.</text>
<text top="156" left="455" width="348" height="12" font="4"> S1.4-22.  O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guide-</text>
<text top="170" left="500" width="308" height="12" font="4">line for the management of ST-elevation myocardial infarction: a </text>
<text top="183" left="500" width="306" height="12" font="4">report of the American College of Cardiology Foundation/American </text>
<text top="197" left="500" width="309" height="12" font="4">Heart Association Task Force on Practice Guidelines. Circulation. </text>
<text top="210" left="500" width="95" height="12" font="4">2013;127:e362–425.</text>
<text top="224" left="455" width="348" height="12" font="4"> S1.4-23.  Steg PG, James SK, Atar D, et al. ESC guidelines for the manage-</text>
<text top="238" left="500" width="309" height="12" font="4">ment of acute myocardial infarction in patients presenting with </text>
<text top="251" left="500" width="244" height="12" font="4">ST-segment elevation. Eur Heart J. 2012;33:2569–619.</text>
<text top="265" left="455" width="351" height="12" font="4"> S1.4-24.  Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused </text>
<text top="278" left="500" width="303" height="12" font="4">update of the 2008 guidelines for device-based therapy of car-</text>
<text top="292" left="500" width="308" height="12" font="4">diac rhythm abnormalities: a report of the American College of </text>
<text top="306" left="500" width="308" height="12" font="4">Cardiology Foundation/American Heart Association Task Force on </text>
<text top="319" left="500" width="240" height="12" font="4">Practice Guidelines. Circulation. 2012;126:1784–800.</text>
<text top="333" left="455" width="352" height="12" font="4"> S1.4-25.  Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for </text>
<text top="346" left="500" width="306" height="12" font="4">coronary artery bypass graft surgery. a report of the American College of </text>
<text top="360" left="500" width="305" height="12" font="4">Cardiology Foundation/American Heart Association Task Force on Practice </text>
<text top="373" left="500" width="307" height="12" font="4">Guidelines. Developed in collaboration with the American Association </text>
<text top="387" left="500" width="308" height="12" font="4">for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and </text>
<text top="401" left="500" width="283" height="12" font="4">Society of Thoracic Surgeons. Circulation. 2011;124:e652–735.</text>
<text top="414" left="455" width="348" height="12" font="4"> S1.4-26.  Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guide-</text>
<text top="428" left="500" width="306" height="12" font="4">line for percutaneous coronary intervention: a report of the American </text>
<text top="441" left="500" width="308" height="12" font="4">College of Cardiology Foundation/American Heart Association Task </text>
<text top="455" left="500" width="309" height="12" font="4">Force on Practice Guidelines and the Society for Cardiovascular </text>
<text top="468" left="500" width="293" height="12" font="4">Angiography and Interventions. Circulation. 2011;124:e574–651.</text>
<text top="482" left="455" width="352" height="12" font="4"> S1.4-27.  Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary </text>
<text top="496" left="500" width="308" height="12" font="4">prevention and risk reduction therapy for patients with coronary </text>
<text top="509" left="500" width="303" height="12" font="4">and other atherosclerotic vascular disease: 2011 update: a guide-</text>
<text top="523" left="500" width="306" height="12" font="4">line from the American Heart Association and American College of </text>
<text top="536" left="500" width="252" height="12" font="4">Cardiology Foundation. Circulation. 2011;124:2458–73.</text>
<text top="550" left="455" width="350" height="12" font="4"> S1.4-28.  Institute of Medicine. Committee on the Treatment of Cardiac Arrest: </text>
<text top="563" left="500" width="307" height="12" font="4">Current Status and Future Directions: Strategies to improve cardiac </text>
<text top="577" left="500" width="307" height="12" font="4">arrest survival: a time to act. Washington, DC: National Academic </text>
<text top="591" left="500" width="51" height="12" font="4">Press 2015.</text>
<text top="604" left="455" width="348" height="12" font="4"> S1.4-29.  Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualifica-</text>
<text top="618" left="500" width="307" height="12" font="4">tion recommendations for competitive athletes with cardiovascular </text>
<text top="631" left="500" width="306" height="12" font="4">abnormalities: Task Force 12: emergency action plans, resuscitation, </text>
<text top="645" left="500" width="303" height="12" font="4">cardiopulmonary resuscitation, and automated external defibrilla-</text>
<text top="659" left="500" width="306" height="12" font="4">tors: a scientific statement from the American Heart Association and </text>
<text top="672" left="500" width="285" height="12" font="4">American College of Cardiology. Circulation. 2015;132:e334–8.</text>
<text top="686" left="455" width="348" height="12" font="4"> S1.4-30.  Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert con-</text>
<text top="699" left="500" width="302" height="12" font="4">sensus on ventricular arrhythmias. Heart Rhythm. 2014;11:e166–96.</text>
<text top="713" left="455" width="348" height="12" font="4"> S1.4-31.  Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consen-</text>
<text top="726" left="500" width="303" height="12" font="4">sus statement on the recognition and management of arrhyth-</text>
<text top="740" left="500" width="307" height="12" font="4">mias in adult congenital heart disease: developed in partnership </text>
<text top="754" left="500" width="307" height="12" font="4">between the Pediatric and Congenital Electrophysiology Society </text>
<text top="767" left="500" width="309" height="12" font="4">(PACES) and the Heart Rhythm Society (HRS). Heart Rhythm. </text>
<text top="781" left="500" width="86" height="12" font="4">2014;11:e102–65.</text>
<text top="794" left="455" width="352" height="12" font="4"> S1.4-32.  Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert </text>
<text top="808" left="500" width="303" height="12" font="4">consensus statement on the use of implantable cardioverter-defibril-</text>
<text top="821" left="500" width="303" height="12" font="4">lator therapy in patients who are not included or not well repre-</text>
<text top="835" left="500" width="241" height="12" font="4">sented in clinical trials. Circulation. 2014;130:94–125.</text>
<text top="849" left="455" width="348" height="12" font="4"> S1.4-33.  Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus state-</text>
<text top="862" left="500" width="306" height="12" font="4">ment on the diagnosis and management of arrhythmias associated </text>
<text top="876" left="500" width="262" height="12" font="4">with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.</text>
<text top="889" left="455" width="348" height="12" font="4"> S1.4-34.  Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con-</text>
<text top="903" left="500" width="308" height="12" font="4">sensus statement on the diagnosis and management of patients </text>
<text top="916" left="500" width="311" height="12" font="4">with inherited primary arrhythmia syndromes. Heart Rhythm. </text>
<text top="930" left="500" width="84" height="12" font="4">2013;10:1932–63.</text>
<text top="974" left="452" width="165" height="23" font="15"><b>2. EPIDEMIOLOGY</b></text>
<text top="1002" left="452" width="354" height="12" font="4"> S2.2.2-1.  Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary </text>
<text top="1016" left="500" width="208" height="12" font="4">heart disease. Circulation. 2012;125:1043–52.</text>
<text top="1030" left="452" width="355" height="12" font="4"> S2.2.2-2.  Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key </text>
<text top="1043" left="500" width="311" height="12" font="4">data elements and definitions for electrophysiological studies </text>
<text top="1057" left="500" width="303" height="12" font="4">and procedures: a report of the American College of Cardiology/</text>
<text top="1070" left="500" width="307" height="12" font="4">American Heart Association Task Force on Clinical Data Standards. </text>
<text top="1084" left="500" width="144" height="12" font="4">Circulation. 2006;114:2534–70.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e357</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="80" width="345" height="12" font="4"> S2.2.2-3. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia abla-</text>
<text top="102" left="125" width="306" height="12" font="4">tion versus escalation of antiarrhythmic drugs. N Engl J Med. </text>
<text top="116" left="125" width="84" height="12" font="4">2016;375:111–21.</text>
<text top="129" left="80" width="345" height="12" font="4"> S2.2.2-4. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con-</text>
<text top="143" left="125" width="305" height="12" font="4">sensus statement on the diagnosis and management of patients </text>
<text top="157" left="125" width="308" height="12" font="4">with inherited primary arrhythmia syndromes. Heart Rhythm. </text>
<text top="170" left="125" width="84" height="12" font="4">2013;10:1932–63.</text>
<text top="184" left="80" width="345" height="12" font="4"> S2.2.2-5.  Hiss RG, Lamb LE. Electrocardiographic findings in 122 043 individu-</text>
<text top="197" left="125" width="150" height="12" font="4">als. Circulation. 1962;25:947–61.</text>
<text top="211" left="80" width="351" height="12" font="4"> S2.2.2-6. Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by </text>
<text top="225" left="125" width="305" height="12" font="4">24 hour continuous electrocardiographic monitoring in 50 male </text>
<text top="238" left="125" width="305" height="12" font="4">medical students without apparent heart disease. Am J Cardiol. </text>
<text top="252" left="125" width="72" height="12" font="4">1977;39:390–5.</text>
<text top="266" left="80" width="350" height="12" font="4"> S2.2.2-7. Massing MW, Simpson RJ Jr, Rautaharju PM, et al. Usefulness of </text>
<text top="279" left="125" width="304" height="12" font="4">ventricular premature complexes to predict coronary heart disease </text>
<text top="293" left="125" width="303" height="12" font="4">events and mortality (from the Atherosclerosis Risk In Communities </text>
<text top="307" left="125" width="185" height="12" font="4">cohort). Am J Cardiol. 2006;98:1609–12.</text>
<text top="320" left="80" width="348" height="12" font="4"> S2.2.2-8.  Ofoma U, He F, Shaffer ML, et al. Premature cardiac contractions and </text>
<text top="334" left="125" width="300" height="12" font="4">risk of incident ischemic stroke. J Am Heart Assoc. 2012;1:e002519.</text>
<text top="347" left="80" width="349" height="12" font="4"> S2.2.2-9. Ataklte F, Erqou S, Laukkanen J, et al. Meta-analysis of ventricular </text>
<text top="361" left="125" width="300" height="12" font="4">premature complexes and their relation to cardiac mortality in gen-</text>
<text top="375" left="125" width="230" height="12" font="4">eral populations. Am J Cardiol. 2013;112:1263–70.</text>
<text top="388" left="74" width="355" height="12" font="4"> S2.2.2-10. Lin CY, Chang SL, Lin YJ, et al. Long-term outcome of multiform </text>
<text top="402" left="125" width="304" height="12" font="4">premature ventricular complexes in structurally normal heart. Int J </text>
<text top="416" left="125" width="110" height="12" font="4">Cardiol. 2015;180:80–5.</text>
<text top="429" left="74" width="351" height="12" font="4"> S2.2.2-11. Lin CY, Chang SL, Chung FP, et al. Long-term outcome of non-</text>
<text top="443" left="125" width="303" height="12" font="4">sustained ventricular tachycardia in structurally normal hearts. PloS </text>
<text top="457" left="125" width="114" height="12" font="4">One. 2016;11:e0160181.</text>
<text top="470" left="74" width="351" height="12" font="4"> S2.2.2-12. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular pre-</text>
<text top="484" left="125" width="305" height="12" font="4">mature complexes and sudden death after myocardial infarction. </text>
<text top="497" left="125" width="138" height="12" font="4">Circulation. 1981;64:297–305.</text>
<text top="511" left="74" width="351" height="12" font="4"> S2.2.2-13. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular prema-</text>
<text top="525" left="125" width="303" height="12" font="4">ture beats and mortality after myocardial infarction. N Engl J Med. </text>
<text top="538" left="125" width="78" height="12" font="4">1977;297:750–7.</text>
<text top="552" left="74" width="355" height="12" font="4"> S2.2.2-14. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of </text>
<text top="566" left="125" width="305" height="12" font="4">the antiarrhythmic agent moricizine on survival after myocardial </text>
<text top="579" left="125" width="303" height="12" font="4">infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. </text>
<text top="593" left="125" width="149" height="12" font="4">N Engl J Med. 1992;327:227–33.</text>
<text top="607" left="74" width="355" height="12" font="4"> S2.2.2-15. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in </text>
<text top="620" left="125" width="305" height="12" font="4">patients receiving encainide, flecainide, or placebo. The Cardiac </text>
<text top="634" left="125" width="276" height="12" font="4">Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.</text>
<text top="648" left="74" width="351" height="12" font="4"> S2.2.2-16. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-</text>
<text top="661" left="125" width="300" height="12" font="4">medium-term treatment of ventricular arrhythmias. A meta-analy-</text>
<text top="675" left="125" width="154" height="12" font="4">sis. Circulation. 1991;84:1977–83.</text>
<text top="688" left="74" width="351" height="12" font="4"> S2.2.2-17. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mor-</text>
<text top="702" left="125" width="304" height="12" font="4">tality in patients with left ventricular dysfunction after recent and </text>
<text top="716" left="125" width="305" height="12" font="4">remote myocardial infarction. The SWORD Investigators. Survival </text>
<text top="729" left="125" width="199" height="12" font="4">With Oral d-Sotalol. Lancet. 1996;348:7–12.</text>
<text top="743" left="74" width="351" height="12" font="4"> S2.2.2-18.  Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth-</text>
<text top="757" left="125" width="304" height="12" font="4">mic medication for treatment of ventricular premature beats from </text>
<text top="770" left="125" width="304" height="12" font="4">the right ventricular outflow tract: prospective randomized study. </text>
<text top="784" left="125" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2014;7:237–43.</text>
<text top="798" left="74" width="351" height="12" font="4"> S2.2.2-19.  Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymp-</text>
<text top="811" left="125" width="300" height="12" font="4">tomatic men with exercise-induced premature ventricular depolar-</text>
<text top="825" left="125" width="189" height="12" font="4">izations. N Engl J Med. 2000;343:826–33.</text>
<text top="838" left="74" width="351" height="12" font="4"> S2.2.2-20. Frolkis JP, Pothier CE, Blackstone EH, et al. Frequent ventricu-</text>
<text top="852" left="125" width="305" height="12" font="4">lar ectopy after exercise as a predictor of death. N Engl J Med. </text>
<text top="866" left="125" width="84" height="12" font="4">2003;348:781–90.</text>
<text top="879" left="74" width="354" height="12" font="4"> S2.2.2-21.  Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of </text>
<text top="893" left="125" width="300" height="12" font="4">frequent and complex ventricular tachyarrhythmias in trained ath-</text>
<text top="907" left="125" width="188" height="12" font="4">letes. J Am Coll Cardiol. 2002;40:446–52.</text>
<text top="920" left="74" width="356" height="12" font="4"> S2.2.2-22. Heidbüchel H, Hoogsteen J, Fagard R, et al. High prevalence of </text>
<text top="934" left="125" width="303" height="12" font="4">right ventricular involvement in endurance athletes with ventricular </text>
<text top="948" left="125" width="303" height="12" font="4">arrhythmias: role of an electrophysiologic study in risk stratification. </text>
<text top="961" left="125" width="138" height="12" font="4">Eur Heart J. 2003;24:1473–80.</text>
<text top="975" left="74" width="351" height="12" font="4"> S2.2.2-23.  Kanei Y, Friedman M, Ogawa N, et al. Frequent premature ventricu-</text>
<text top="989" left="125" width="304" height="12" font="4">lar complexes originating from the right ventricular outflow tract </text>
<text top="1002" left="125" width="305" height="12" font="4">are associated with left ventricular dysfunction. Ann Noninvasive </text>
<text top="1016" left="125" width="132" height="12" font="4">Electrocardiol. 2008;13:81–5.</text>
<text top="1029" left="74" width="351" height="12" font="4"> S2.2.2-24.  Lee GK, Klarich KW, Grogan M, et al. Premature ventricular contrac-</text>
<text top="1043" left="125" width="303" height="12" font="4">tion-induced cardiomyopathy: a treatable condition. Circ Arrhythm </text>
<text top="1057" left="125" width="139" height="12" font="4">Electrophysiol. 2012;5:229–36.</text>
<text top="1070" left="74" width="355" height="12" font="4"> S2.2.2-25. Viskin S, Rosso R, Rogowski O, et al. The “short-coupled” variant </text>
<text top="1084" left="125" width="303" height="12" font="4">of right ventricular outflow ventricular tachycardia: a not-so-benign </text>
<text top="88" left="503" width="303" height="12" font="4">form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. </text>
<text top="102" left="503" width="72" height="12" font="4">2005;16:912–6.</text>
<text top="116" left="452" width="354" height="12" font="4"> S2.2.2-26. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic </text>
<text top="129" left="503" width="300" height="12" font="4">ventricular fibrillation and polymorphic ventricular tachycardia initi-</text>
<text top="143" left="503" width="300" height="12" font="4">ated by premature extrasystoles originating from the right ventricu-</text>
<text top="157" left="503" width="245" height="12" font="4">lar outflow tract. J Am Coll Cardiol. 2005;46:1288–94.</text>
<text top="170" left="452" width="351" height="12" font="4"> S2.2.2-27. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percuta-</text>
<text top="184" left="503" width="303" height="12" font="4">neous coronary intervention is associated with better survival after </text>
<text top="197" left="503" width="304" height="12" font="4">out-of-hospital cardiac arrest: insights from the PROCAT (Parisian </text>
<text top="211" left="503" width="305" height="12" font="4">Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc </text>
<text top="225" left="503" width="97" height="12" font="4">Interv. 2010;3:200–7.</text>
<text top="238" left="452" width="354" height="12" font="4"> S2.2.2-28. Gupta S, Pressman GS, Figueredo VM. Incidence of, predictors for, </text>
<text top="252" left="503" width="304" height="12" font="4">and mortality associated with malignant ventricular arrhythmias in </text>
<text top="266" left="503" width="304" height="12" font="4">non-ST elevation myocardial infarction patients. Coron Artery Dis. </text>
<text top="279" left="503" width="72" height="12" font="4">2010;21:460–5.</text>
<text top="293" left="452" width="351" height="12" font="4"> S2.2.2-29. Terkelsen CJ, Sorensen JT, Kaltoft AK, et al. Prevalence and sig-</text>
<text top="307" left="503" width="306" height="12" font="4">nificance of accelerated idioventricular rhythm in patients with </text>
<text top="320" left="503" width="300" height="12" font="4">ST-elevation myocardial infarction treated with primary percutane-</text>
<text top="334" left="503" width="267" height="12" font="4">ous coronary intervention. Am J Cardiol. 2009;104:1641–6.</text>
<text top="348" left="452" width="356" height="12" font="4"> S2.2.2-30. Al-Khatib SM, Granger CB, Huang Y, et al. Sustained ventricular </text>
<text top="361" left="503" width="304" height="12" font="4">arrhythmias among patients with acute coronary syndromes with </text>
<text top="375" left="503" width="306" height="12" font="4">no ST-segment elevation: incidence, predictors, and outcomes. </text>
<text top="388" left="503" width="138" height="12" font="4">Circulation. 2002;106:309–12.</text>
<text top="402" left="452" width="355" height="12" font="4"> S2.2.2-31. Jabbari R, Engstrom T, Glinge C, et al. Incidence and risk factors </text>
<text top="416" left="503" width="306" height="12" font="4">of ventricular fibrillation before primary angioplasty in patients </text>
<text top="429" left="503" width="304" height="12" font="4">with first ST-elevation myocardial infarction: a nationwide study in </text>
<text top="443" left="503" width="209" height="12" font="4">Denmark. J Am Heart Assoc. 2015;4:e001399.</text>
<text top="457" left="452" width="355" height="12" font="4"> S2.2.2-32. Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes </text>
<text top="470" left="503" width="306" height="12" font="4">associated with ventricular tachycardia or fibrillation in patients </text>
<text top="484" left="503" width="306" height="12" font="4">undergoing primary percutaneous coronary intervention. JAMA. </text>
<text top="498" left="503" width="90" height="12" font="4">2009;301:1779–89.</text>
<text top="511" left="452" width="353" height="12" font="4"> S2.2.2-33.  Volpi A, Cavalli A, Franzosi MG, et al. One-year prognosis of primary </text>
<text top="525" left="503" width="303" height="12" font="4">ventricular fibrillation complicating acute myocardial infarction. The </text>
<text top="538" left="503" width="303" height="12" font="4">GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto </text>
<text top="552" left="503" width="258" height="12" font="4">miocardico) investigators. Am J Cardiol. 1989;63:1174–8.</text>
<text top="566" left="452" width="353" height="12" font="4"> S2.2.2-34.  El-Sherif N, Smith RA, Evans K. Canine ventricular arrhythmias in the </text>
<text top="579" left="503" width="303" height="12" font="4">late myocardial infarction period. 8. Epicardial mapping of reentrant </text>
<text top="593" left="503" width="156" height="12" font="4">circuits. Circ Res. 1981;49:255–65.</text>
<text top="607" left="452" width="351" height="12" font="4"> S2.2.2-35.  Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen-</text>
<text top="620" left="503" width="302" height="12" font="4">sus statement on the state of genetic testing for the channelopathies </text>
<text top="634" left="503" width="300" height="12" font="4">and cardiomyopathies: this document was developed as a partner-</text>
<text top="648" left="503" width="304" height="12" font="4">ship between the Heart Rhythm Society (HRS) and the European </text>
<text top="661" left="503" width="292" height="12" font="4">Heart Rhythm Association (EHRA). Europace. 2011;13:1077–109.</text>
<text top="675" left="452" width="351" height="12" font="4"> S2.2.2-36.  Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher-</text>
<text top="689" left="503" width="305" height="12" font="4">ited arrhythmia syndromes: insight into their natural history. Circ </text>
<text top="702" left="503" width="151" height="12" font="4">Cardiovasc Genet. 2012;5:183–9.</text>
<text top="716" left="452" width="351" height="12" font="4"> S2.2.2-37. Haïssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conduct-</text>
<text top="729" left="503" width="303" height="12" font="4">ing system in triggering of idiopathic ventricular fibrillation. Lancet. </text>
<text top="743" left="503" width="78" height="12" font="4">2002;359:677–8.</text>
<text top="757" left="452" width="355" height="12" font="4"> S2.2.2-38. Haïssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of </text>
<text top="770" left="503" width="279" height="12" font="4">idiopathic ventricular fibrillation. Circulation. 2002;106:962–7.</text>
<text top="784" left="452" width="357" height="12" font="4"> S2.2.2-39. Goldberger JJ, Buxton AE, Cain M, et al. Risk stratification for </text>
<text top="798" left="503" width="308" height="12" font="4">arrhythmic sudden cardiac death: identifying the roadblocks. </text>
<text top="811" left="503" width="144" height="12" font="4">Circulation. 2011;123:2423–30.</text>
<text top="825" left="452" width="351" height="12" font="4"> S2.2.2-40.  Fishman GI, Chugh SS, DiMarco JP, et al. Sudden cardiac death pre-</text>
<text top="839" left="503" width="305" height="12" font="4">diction and prevention: report from a National Heart, Lung, and </text>
<text top="852" left="503" width="304" height="12" font="4">Blood Institute and Heart Rhythm Society Workshop. Circulation. </text>
<text top="866" left="503" width="90" height="12" font="4">2010;122:2335–48.</text>
<text top="879" left="452" width="356" height="12" font="4"> S2.2.2-41. Myerburg RJ. Sudden cardiac death: exploring the limits of our </text>
<text top="893" left="503" width="258" height="12" font="4">knowledge. J Cardiovasc Electrophysiol. 2001;12:369–81.</text>
<text top="907" left="452" width="353" height="12" font="4"> S2.2.2-42.  Kong MH, Fonarow GC, Peterson ED, et al. Systematic review of the </text>
<text top="920" left="503" width="304" height="12" font="4">incidence of sudden cardiac death in the United States. J Am Coll </text>
<text top="934" left="503" width="122" height="12" font="4">Cardiol. 2011;57:794–801.</text>
<text top="948" left="452" width="6" height="12" font="4"> </text>
<text top="948" left="452" width="357" height="12" font="4">S2.2.2-43. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and </text>
<text top="961" left="503" width="304" height="12" font="4">stroke statistics—2016 update: a report from the American Heart </text>
<text top="975" left="503" width="200" height="12" font="4">Association. Circulation. 2016;133:e38–360.</text>
<text top="989" left="452" width="355" height="12" font="4"> S2.2.2-44. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke </text>
<text top="1002" left="503" width="308" height="12" font="4">statistics—2017 update: a report from the American Heart </text>
<text top="1016" left="503" width="206" height="12" font="4">Association. Circulation. 2017;135:e146–603.</text>
<text top="1029" left="452" width="354" height="12" font="4"> S2.2.2-45.  Merchant RM, Yang L, Becker LB, et al. Incidence of treated cardiac </text>
<text top="1043" left="503" width="304" height="12" font="4">arrest in hospitalized patients in the United States. Crit Care Med. </text>
<text top="1057" left="503" width="78" height="12" font="4">2011;39:2401–6.</text>
<text top="1070" left="452" width="355" height="12" font="4"> S2.2.2-46. Institute of Medicine. Committee on the Treatment of Cardiac Arrest: </text>
<text top="1084" left="503" width="303" height="12" font="4">Current Status and Future Directions: Strategies to improve cardiac </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e358</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="125" width="304" height="12" font="4">arrest survival: a time to act. Washington, DC: National Academic </text>
<text top="102" left="125" width="54" height="12" font="4">Press, 2015.</text>
<text top="115" left="74" width="356" height="12" font="4"> S2.2.2-47. Jollis JG, Granger CB. Improving care of out-of-hospital cardiac </text>
<text top="129" left="125" width="220" height="12" font="4">arrest: next steps. Circulation. 2016;134:2040–2.</text>
<text top="143" left="74" width="355" height="12" font="4"> S2.2.2-48. Daya MR, Schmicker R, May SH, et al. Current burden of cardiac </text>
<text top="156" left="125" width="303" height="12" font="4">arrest in the United States: report from the Resuscitation Outcomes </text>
<text top="170" left="125" width="308" height="12" font="4">Consortium. Paper commissioned by the Committee on the </text>
<text top="183" left="125" width="304" height="12" font="4">Treatment of Cardiac Arrest: Current Status and Future Directions. </text>
<text top="197" left="125" width="26" height="12" font="4">2015.</text>
<text top="211" left="74" width="354" height="12" font="4"> S2.2.2-49. Myerburg RJ, Halperin H, Egan DA, et al. Pulseless electric activity: </text>
<text top="224" left="125" width="300" height="12" font="4">definition, causes, mechanisms, management, and research priori-</text>
<text top="238" left="125" width="304" height="12" font="4">ties for the next decade: report from a National Heart, Lung, and </text>
<text top="251" left="125" width="262" height="12" font="4">Blood Institute workshop. Circulation. 2013;128:2532–41.</text>
<text top="265" left="74" width="354" height="12" font="4"> S2.2.2-50. Myerburg RJ, Goldberger JJ. Sudden cardiac arrest risk assessment: </text>
<text top="279" left="125" width="303" height="12" font="4">population science and the individual risk mandate. JAMA Cardiol. </text>
<text top="292" left="125" width="72" height="12" font="4">2017;2:689–94.</text>
<text top="306" left="74" width="353" height="12" font="4"> S2.2.2-51.  Bogle BM, Ning H, Mehrotra S, et al. Lifetime risk for sudden cardiac </text>
<text top="319" left="125" width="274" height="12" font="4">death in the community. J Am Heart Assoc. 2016;5:e002398.</text>
<text top="333" left="74" width="356" height="12" font="4"> S2.2.2-52. Junttila MJ, Hookana E, Kaikkonen KS, et al. Temporal trends in </text>
<text top="346" left="125" width="300" height="12" font="4">the clinical and pathological characteristics of victims of sudden car-</text>
<text top="360" left="125" width="303" height="12" font="4">diac death in the absence of previously identified heart disease. Circ </text>
<text top="374" left="125" width="191" height="12" font="4">Arrhythm Electrophysiol. 2016;9:e003723.</text>
<text top="387" left="74" width="351" height="12" font="4"> S2.2.2-53. Hookana E, Junttila MJ, Puurunen VP, et al. Causes of nonisch-</text>
<text top="401" left="125" width="306" height="12" font="4">emic sudden cardiac death in the current era. Heart Rhythm. </text>
<text top="414" left="125" width="72" height="12" font="4">2011;8:1570–5.</text>
<text top="428" left="74" width="354" height="12" font="4"> S2.2.2-54. Wong MK, Morrison LJ, Qiu F, et al. Trends in short- and long-term </text>
<text top="442" left="125" width="300" height="12" font="4">survival among out-of-hospital cardiac arrest patients alive at hospi-</text>
<text top="455" left="125" width="191" height="12" font="4">tal arrival. Circulation. 2014;130:1883–90.</text>
<text top="499" left="74" width="212" height="23" font="15"><b>3. MECHANISMS OF VA</b></text>
<text top="527" left="83" width="347" height="12" font="4"> S3.4-1.  Cherry EM, Fenton FH, Gilmour RF Jr. Mechanisms of ventricular </text>
<text top="541" left="125" width="304" height="12" font="4">arrhythmias: a dynamical systems-based perspective. Am J Physiol </text>
<text top="554" left="125" width="181" height="12" font="4">Heart Circ Physiol. 2012;302:H2451–63.</text>
<text top="568" left="83" width="346" height="12" font="4"> S3.4-2.  Pandit SV, Jalife J. Rotors and the dynamics of cardiac fibrillation. </text>
<text top="582" left="125" width="125" height="12" font="4">Circ Res. 2013;112:849–62.</text>
<text top="595" left="83" width="342" height="12" font="4"> S3.4-3.  Tsuji Y, Heijman J, Nattel S, et al. Electrical storm: recent pathophysi-</text>
<text top="609" left="125" width="304" height="12" font="4">ological insights and therapeutic consequences. Basic Res Cardiol. </text>
<text top="622" left="125" width="67" height="12" font="4">2013;108:336.</text>
<text top="636" left="83" width="346" height="12" font="4"> S3.4-4.  Roden DM. Predicting drug-induced QT prolongation and torsades </text>
<text top="650" left="125" width="185" height="12" font="4">de pointes. J Physiol. 2016;594:2459–68.</text>
<text top="663" left="83" width="346" height="12" font="4"> S3.4-5.  Antzelevitch C, Nesterenko V, Shryock JC, et al. The role of late I </text>
<text top="677" left="125" width="304" height="12" font="4">Na in development of cardiac arrhythmias. Handb Exp Pharmacol. </text>
<text top="690" left="125" width="84" height="12" font="4">2014;221:137–68.</text>
<text top="704" left="83" width="346" height="12" font="4"> S3.4-6.  Lerman BB. Mechanism, diagnosis, and treatment of outflow tract </text>
<text top="718" left="125" width="216" height="12" font="4">tachycardia. Nat Rev Cardiol. 2015;12:597–608.</text>
<text top="731" left="83" width="345" height="12" font="4"> S3.4-7.  Priori SG, Chen SR. Inherited dysfunction of sarcoplasmic reticulum </text>
<text top="745" left="125" width="300" height="12" font="4">Ca2+ handling and arrhythmogenesis. Circ Res. 2011;108:871–83.</text>
<text top="758" left="83" width="342" height="12" font="4"> S3.4-8.  Nogami A. Purkinje-related arrhythmias part I: monomorphic ven-</text>
<text top="772" left="125" width="292" height="12" font="4">tricular tachycardias. Pacing Clin Electrophysiol. 2011;34:624–50.</text>
<text top="785" left="83" width="342" height="12" font="4"> S3.4-9.  Haissaguerre M, Vigmond E, Stuyvers B, et al. Ventricular arrhyth-</text>
<text top="799" left="125" width="300" height="12" font="4">mias and the His-Purkinje system. Nat Rev Cardiol. 2016;13:155–66.</text>
<text top="813" left="83" width="342" height="12" font="4"> S3.4-10. Tabereaux PB, Dosdall DJ, Ideker RE. Mechanisms of VF mainte-</text>
<text top="826" left="125" width="304" height="12" font="4">nance: wandering wavelets, mother rotors, or foci. Heart Rhythm. </text>
<text top="840" left="125" width="72" height="12" font="4">2009;6:405–15.</text>
<text top="853" left="83" width="342" height="12" font="4"> S3.4-11.  Zhang J, Cooper DH, Desouza KA, et al. Electrophysiologic scar sub-</text>
<text top="867" left="125" width="302" height="12" font="4">strate in relation to VT: noninvasive high-resolution mapping and risk </text>
<text top="881" left="125" width="300" height="12" font="4">assessment with ECGI. Pacing Clin Electrophysiol. 2016;39:781–91.</text>
<text top="894" left="83" width="342" height="12" font="4"> S3.4-12. Fernandez-Armenta J, Penela D, Acosta J, et al. Substrate modi-</text>
<text top="908" left="125" width="309" height="12" font="4">fication or ventricular tachycardia induction, mapping, and </text>
<text top="921" left="125" width="306" height="12" font="4">ablation as the first step? A randomized study. Heart Rhythm. </text>
<text top="935" left="125" width="84" height="12" font="4">2016;13:1589–95.</text>
<text top="979" left="74" width="354" height="23" font="15"><b>4. GENERAL EVALUATION OF PATIENTS </b></text>
<text top="1001" left="74" width="349" height="23" font="15"><b>WITH DOCUMENTED OR SUSPECTED VA</b></text>
<text top="1030" left="74" width="316" height="21" font="18"><b>4.1. History and Physical Examination</b></text>
<text top="1057" left="89" width="341" height="12" font="4"> S4.1-1. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in </text>
<text top="1070" left="125" width="300" height="12" font="4">advanced heart failure: high risk of sudden death regardless of ori-</text>
<text top="1084" left="125" width="227" height="12" font="4">gin of syncope. J Am Coll Cardiol. 1993;21:110–6.</text>
<text top="88" left="452" width="356" height="12" font="4">  S4.1-2.  Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac </text>
<text top="102" left="503" width="305" height="12" font="4">death - Chapter 39. Mann DL, Zipes DP, Libby P, et al, editors. </text>
<text top="115" left="503" width="303" height="12" font="4">Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. </text>
<text top="129" left="503" width="198" height="12" font="4">10th ed. Oxford, UK: Elsevier, 2015:821–60.</text>
<text top="143" left="452" width="357" height="12" font="4">  S4.1-3.  Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS </text>
<text top="156" left="503" width="306" height="12" font="4">guideline for the evaluation and management of patients with </text>
<text top="170" left="503" width="303" height="12" font="4">syncope: a report of the American College of Cardiology/American </text>
<text top="183" left="503" width="303" height="12" font="4">Heart Association Task Force on Clinical Practice Guidelines and the </text>
<text top="197" left="503" width="244" height="12" font="4">Heart Rhythm Society. Circulation. 2017;136:e60–122.</text>
<text top="210" left="452" width="354" height="12" font="4">  S4.1-4.  Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis </text>
<text top="224" left="503" width="203" height="12" font="4">of syncope. N Engl J Med. 2002;347:878–85.</text>
<text top="237" left="452" width="354" height="12" font="4">  S4.1-5.  Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic </text>
<text top="251" left="503" width="300" height="12" font="4">ventricular fibrillation and polymorphic ventricular tachycardia initi-</text>
<text top="265" left="503" width="300" height="12" font="4">ated by premature extrasystoles originating from the right ventricu-</text>
<text top="278" left="503" width="245" height="12" font="4">lar outflow tract. J Am Coll Cardiol. 2005;46:1288–94.</text>
<text top="292" left="452" width="355" height="12" font="4">  S4.1-6.  Viskin S, Rosso R, Rogowski O, et al. The “short-coupled” variant </text>
<text top="305" left="503" width="303" height="12" font="4">of right ventricular outflow ventricular tachycardia: a not-so-benign </text>
<text top="319" left="503" width="303" height="12" font="4">form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. </text>
<text top="332" left="503" width="72" height="12" font="4">2005;16:912–6.</text>
<text top="346" left="452" width="351" height="12" font="4">  S4.1-7.  Zimetbaum P, Josephson ME. Evaluation of patients with palpita-</text>
<text top="359" left="503" width="182" height="12" font="4">tions. N Engl J Med. 1998;338:1369–73.</text>
<text top="373" left="452" width="355" height="12" font="4">  S4.1-8.  Credible meds. A<a href="">vailable at: http://www.crediblemeds.org. Accessed</a> </text>
<text top="387" left="503" width="92" height="12" font="4">December 26, 2016.</text>
<text top="400" left="452" width="355" height="12" font="4">  S4.1-9.  Brugada drugs. A<a href="">vailable at: http://www.brugadadrugs.org. Accessed</a> </text>
<text top="414" left="503" width="77" height="12" font="4">October 6, 2016.</text>
<text top="427" left="452" width="357" height="12" font="4"> S4.1-10.  Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada </text>
<text top="441" left="503" width="305" height="12" font="4">syndrome: clinical characteristics and risk factors. Heart Rhythm. </text>
<text top="454" left="503" width="78" height="12" font="4">2016;13:1083–7.</text>
<text top="468" left="452" width="351" height="12" font="4">  S4.1-11.  Basso C, Perazzolo MM, Rizzo S, et al. Arrhythmic mitral valve pro-</text>
<text top="481" left="503" width="285" height="12" font="4">lapse and sudden cardiac death. Circulation. 2015;132:556–66.</text>
<text top="495" left="452" width="351" height="12" font="4">  S4.1-12.  Nordhues BD, Siontis KC, Scott CG, et al. Bileaflet mitral valve pro-</text>
<text top="509" left="503" width="304" height="12" font="4">lapse and risk of ventricular dysrhythmias and death. J Cardiovasc </text>
<text top="522" left="503" width="139" height="12" font="4">Electrophysiol. 2016;27:463–8.</text>
<text top="536" left="452" width="355" height="12" font="4">  S4.1-13.  Sriram CS, Syed FF, Ferguson ME, et al. Malignant bileaflet mitral </text>
<text top="549" left="503" width="300" height="12" font="4">valve prolapse syndrome in patients with otherwise idiopathic out-</text>
<text top="563" left="503" width="277" height="12" font="4">of-hospital cardiac arrest. J Am Coll Cardiol. 2013;62:222–30.</text>
<text top="576" left="452" width="351" height="12" font="4">  S4.1-14.  Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to car-</text>
<text top="590" left="503" width="234" height="12" font="4">diac arrhythmias. N Engl J Med. 2001;345:1473–82.</text>
<text top="603" left="452" width="356" height="12" font="4"> S4.1-15.  Krahn AD, Healey JS, Simpson CS, et al. Sentinel symptoms in </text>
<text top="617" left="503" width="304" height="12" font="4">patients with unexplained cardiac arrest: from the Cardiac Arrest </text>
<text top="631" left="503" width="307" height="12" font="4">Survivors with Preserved Ejection Fraction Registry (CASPER).  </text>
<text top="644" left="503" width="191" height="12" font="4">J Cardiovasc Electrophysiol. 2012;23:60–6.</text>
<text top="658" left="452" width="355" height="12" font="4">  S4.1-16.  Ruwald MH, Hansen ML, Lamberts M, et al. The relation between </text>
<text top="671" left="503" width="300" height="12" font="4">age, sex, comorbidity, and pharmacotherapy and the risk of syn-</text>
<text top="685" left="503" width="282" height="12" font="4">cope: a Danish nationwide study. Europace. 2012;14:1506–14.</text>
<text top="724" left="452" width="234" height="21" font="18"><b>4.2. Noninvasive Evaluation</b></text>
<text top="751" left="452" width="273" height="18" font="24"><i><b>4.2.1. 12-lead ECG and Exercise Testing</b></i></text>
<text top="772" left="452" width="351" height="12" font="4"> S4.2.1-1.  Brugada P, Brugada J, Mont L, et al. A new approach to the differ-</text>
<text top="786" left="503" width="303" height="12" font="4">ential diagnosis of a regular tachycardia with a wide QRS complex. </text>
<text top="799" left="503" width="138" height="12" font="4">Circulation. 1991;83:1649–59.</text>
<text top="813" left="452" width="353" height="12" font="4"> S4.2.1-2.  Wellens HJ, Bar FW, Lie KI, The value of the electrocardiogram in the </text>
<text top="826" left="503" width="303" height="12" font="4">differential diagnosis of a tachycardia with a widened QRS complex. </text>
<text top="840" left="503" width="124" height="12" font="4">Am J Med. 1978;64:27–33.</text>
<text top="853" left="452" width="355" height="12" font="4"> S4.2.1-3.  Steinman RT, Herrera C, Schuger CD, et al. Wide QRS tachycardia </text>
<text top="867" left="503" width="303" height="12" font="4">in the conscious adult. Ventricular tachycardia is the most frequent </text>
<text top="881" left="503" width="148" height="12" font="4">cause. JAMA. 1989;261:1013–6.</text>
<text top="894" left="452" width="357" height="12" font="4"> S4.2.1-4.  Elhendy A, Chandrasekaran K, Gersh BJ, et al. Functional and </text>
<text top="908" left="503" width="304" height="12" font="4">prognostic significance of exercise-induced ventricular arrhythmias </text>
<text top="921" left="503" width="304" height="12" font="4">in patients with suspected coronary artery disease. Am J Cardiol. </text>
<text top="935" left="503" width="78" height="12" font="4">2002;90:95–100.</text>
<text top="948" left="452" width="351" height="12" font="4"> S4.2.1-5.  Grady TA, Chiu AC, Snader CE, et al. Prognostic significance of exer-</text>
<text top="962" left="503" width="285" height="12" font="4">cise-induced left bundle-branch block. JAMA. 1998;279:153–6.</text>
<text top="975" left="452" width="353" height="12" font="4"> S4.2.1-6.  Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic </text>
<text top="989" left="503" width="303" height="12" font="4">value of the electrocardiogram in patients with syncope: data from </text>
<text top="1003" left="503" width="305" height="12" font="4">the group for syncope study in the emergency room (GESINUR). </text>
<text top="1016" left="503" width="152" height="12" font="4">Heart Rhythm. 2014;11:2035–44.</text>
<text top="1030" left="452" width="357" height="12" font="4"> S4.2.1-7.  Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch </text>
<text top="1043" left="503" width="300" height="12" font="4">block is associated with increased 1-year sudden and total mortal-</text>
<text top="1057" left="503" width="304" height="12" font="4">ity rate in 5517 outpatients with congestive heart failure: a report </text>
<text top="1070" left="503" width="305" height="12" font="4">from the Italian network on congestive heart failure. Am Heart J. </text>
<text top="1084" left="503" width="88" height="12" font="4">2002;143:398–405.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e359</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="80" width="350" height="12" font="4"> S4.2.1-8. Buxton AE, Sweeney MO, Wathen MS, et al. QRS duration does </text>
<text top="102" left="125" width="304" height="12" font="4">not predict occurrence of ventricular tachyarrhythmias in patients </text>
<text top="115" left="125" width="308" height="12" font="4">with implanted cardioverter-defibrillators. J Am Coll Cardiol. </text>
<text top="129" left="125" width="72" height="12" font="4">2005;46:310–6.</text>
<text top="142" left="80" width="350" height="12" font="4"> S4.2.1-9. Desai AD, Yaw TS, Yamazaki T, et al. Prognostic significance of </text>
<text top="156" left="125" width="251" height="12" font="4">quantitative QRS duration. Am J Med. 2006;119:600–6.</text>
<text top="169" left="74" width="351" height="12" font="4"> S4.2.1-10. Dhar R, Alsheikh-Ali AA, Estes NA 3rd, et al. Association of pro-</text>
<text top="183" left="125" width="300" height="12" font="4">longed QRS duration with ventricular tachyarrhythmias and sud-</text>
<text top="196" left="125" width="308" height="12" font="4">den cardiac death in the Multicenter Automatic Defibrillator </text>
<text top="210" left="125" width="277" height="12" font="4">Implantation Trial II (MADIT-II). Heart Rhythm. 2008;5:807–13.</text>
<text top="223" left="74" width="354" height="12" font="4"> S4.2.1-11.  Freedman RA, Alderman EL, Sheffield LT, et al. Bundle branch block </text>
<text top="237" left="125" width="300" height="12" font="4">in patients with chronic coronary artery disease: angiographic corre-</text>
<text top="250" left="125" width="300" height="12" font="4">lates and prognostic significance. J Am Coll Cardiol. 1987;10:73–80.</text>
<text top="264" left="74" width="351" height="12" font="4"> S4.2.1-12. Iuliano S, Fisher SG, Karasik PE, et al. QRS duration and mor-</text>
<text top="277" left="125" width="307" height="12" font="4">tality in patients with congestive heart failure. Am Heart J. </text>
<text top="291" left="125" width="90" height="12" font="4">2002;143:1085–91.</text>
<text top="304" left="74" width="351" height="12" font="4"> S4.2.1-13.  Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan-</text>
<text top="318" left="125" width="303" height="12" font="4">tation in patients with nonischemic dilated cardiomyopathy. N Engl </text>
<text top="331" left="125" width="117" height="12" font="4">J Med. 2004;350:2151–8.</text>
<text top="345" left="74" width="355" height="12" font="4"> S4.2.1-14. Zimetbaum PJ, Buxton AE, Batsford W, et al. Electrocardiographic </text>
<text top="358" left="125" width="303" height="12" font="4">predictors of arrhythmic death and total mortality in the multicenter </text>
<text top="372" left="125" width="265" height="12" font="4">unsustained tachycardia trial. Circulation. 2004;110:766–9.</text>
<text top="385" left="74" width="355" height="12" font="4"> S4.2.1-15. Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans </text>
<text top="399" left="125" width="300" height="12" font="4">Before Cardioverter Defibrillator) Trial: strategies using T-wave alter-</text>
<text top="412" left="125" width="304" height="12" font="4">nans to improve efficiency of sudden cardiac death prevention. J </text>
<text top="426" left="125" width="149" height="12" font="4">Am Coll Cardiol. 2009;53:471–9.</text>
<text top="439" left="74" width="356" height="12" font="4"> S4.2.1-16. Monasterio V, Martinez JP, Laguna P, et al. Prognostic value of </text>
<text top="453" left="125" width="305" height="12" font="4">average T-wave alternans and QT variability for cardiac events in </text>
<text top="466" left="125" width="226" height="12" font="4">MADIT-II patients. J Electrocardiol. 2013;46:480–6.</text>
<text top="480" left="74" width="351" height="12" font="4"> S4.2.1-17. Chow T, Kereiakes DJ, Onufer J, et al. Does microvolt T-wave alter-</text>
<text top="493" left="125" width="304" height="12" font="4">nans testing predict ventricular tachyarrhythmias in patients with </text>
<text top="507" left="125" width="309" height="12" font="4">ischemic cardiomyopathy and prophylactic defibrillators? The </text>
<text top="520" left="125" width="303" height="12" font="4">MASTER (Microvolt T Wave Alternans Testing for Risk Stratification </text>
<text top="534" left="125" width="306" height="12" font="4">of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol. </text>
<text top="547" left="125" width="84" height="12" font="4">2008;52:1607–15.</text>
<text top="561" left="74" width="355" height="12" font="4"> S4.2.1-18. Gupta A, Hoang DD, Karliner L, et al. Ability of microvolt T-wave </text>
<text top="574" left="125" width="304" height="12" font="4">alternans to modify risk assessment of ventricular tachyarrhythmic </text>
<text top="588" left="125" width="248" height="12" font="4">events: a meta-analysis. Am Heart J. 2012;163:354–64.</text>
<text top="601" left="74" width="354" height="12" font="4"> S4.2.1-19.  Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave </text>
<text top="615" left="125" width="305" height="12" font="4">alternans distinguishes between patients likely and patients not </text>
<text top="628" left="125" width="300" height="12" font="4">likely to benefit from implanted cardiac defibrillator therapy: a solu-</text>
<text top="642" left="125" width="305" height="12" font="4">tion to the Multicenter Automatic Defibrillator Implantation Trial </text>
<text top="655" left="125" width="243" height="12" font="4">(MADIT) II conundrum. Circulation. 2004;110:1885–9.</text>
<text top="681" left="74" width="272" height="18" font="24"><i><b>4.2.2. Ambulatory Electrocardiography</b></i></text>
<text top="702" left="80" width="348" height="12" font="4"> S4.2.2-1.  Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour </text>
<text top="716" left="125" width="300" height="12" font="4">Holter monitoring with 14-day novel adhesive patch electrocardio-</text>
<text top="729" left="125" width="215" height="12" font="4">graphic monitoring. Am J Med. 2014;127:95–7.</text>
<text top="743" left="80" width="345" height="12" font="4"> S4.2.2-2.  de Asmundis C, Conte G, Sieira J, et al. Comparison of the patient-</text>
<text top="756" left="125" width="300" height="12" font="4">activated event recording system vs. traditional 24 h Holter elec-</text>
<text top="770" left="125" width="307" height="12" font="4">trocardiography in individuals with paroxysmal palpitations or </text>
<text top="783" left="125" width="170" height="12" font="4">dizziness. Europace. 2014;16:1231–5.</text>
<text top="797" left="80" width="350" height="12" font="4"> S4.2.2-3. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic </text>
<text top="810" left="125" width="302" height="12" font="4">yield of loop electrocardiographic recorders in unexplained syncope. </text>
<text top="824" left="125" width="135" height="12" font="4">Am J Cardiol. 1990;66:214–9.</text>
<text top="837" left="80" width="351" height="12" font="4"> S4.2.2-4. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility </text>
<text top="851" left="125" width="305" height="12" font="4">of a novel leadless arrhythmia monitoring device. Am J Cardiol. </text>
<text top="864" left="125" width="78" height="12" font="4">2013;112:520–4.</text>
<text top="890" left="74" width="238" height="18" font="24"><i><b>4.2.3. Implanted Cardiac Monitors</b></i></text>
<text top="911" left="80" width="6" height="12" font="4"> </text>
<text top="911" left="80" width="352" height="12" font="4">S4.2.3-1. Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Long-term </text>
<text top="924" left="125" width="307" height="12" font="4">recording of cardiac arrhythmias with an implantable cardiac </text>
<text top="938" left="125" width="300" height="12" font="4">monitor in patients with reduced ejection fraction after acute myo-</text>
<text top="951" left="125" width="305" height="12" font="4">cardial infarction: the Cardiac Arrhythmias and Risk Stratification </text>
<text top="965" left="125" width="306" height="12" font="4">After Acute Myocardial Infarction (CARISMA) study. Circulation. </text>
<text top="978" left="125" width="90" height="12" font="4">2010;122:1258–64.</text>
<text top="992" left="80" width="349" height="12" font="4"> S4.2.3-2. Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring </text>
<text top="1005" left="125" width="303" height="12" font="4">strategy in patients with problematic syncope. Reveal Investigators. </text>
<text top="1019" left="125" width="132" height="12" font="4">Circulation. 1999;99:406–10.</text>
<text top="1032" left="80" width="347" height="12" font="4"> S4.2.3-3.  Solbiati M, Costantino G, Casazza G, et al. Implantable loop recorder </text>
<text top="1046" left="125" width="305" height="12" font="4">versus conventional diagnostic workup for unexplained recurrent </text>
<text top="1059" left="125" width="264" height="12" font="4">syncope. Cochrane Database Syst. Rev. 2016;4:CD011637.</text>
<text top="1073" left="74" width="356" height="12" font="4"> S4.2.3-4.  Volosin K, Stadler RW, Wyszynski R, et al. Tachycardia detection </text>
<text top="1086" left="125" width="305" height="12" font="4">performance of implantable loop recorders: results from a large </text>
<text top="88" left="503" width="307" height="12" font="4">‘real-life’ patient cohort and patients with induced ventricular </text>
<text top="102" left="503" width="189" height="12" font="4">arrhythmias. Europace. 2013;15:1215–22.</text>
<text top="115" left="458" width="350" height="12" font="4"> S4.2.3-5. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic </text>
<text top="129" left="503" width="302" height="12" font="4">yield of loop electrocardiographic recorders in unexplained syncope. </text>
<text top="142" left="503" width="135" height="12" font="4">Am J Cardiol. 1990;66:214–9.</text>
<text top="156" left="458" width="351" height="12" font="4"> S4.2.3-6. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility </text>
<text top="170" left="503" width="305" height="12" font="4">of a novel leadless arrhythmia monitoring device. Am J Cardiol. </text>
<text top="183" left="503" width="78" height="12" font="4">2013;112:520–4.</text>
<text top="209" left="452" width="246" height="18" font="24"><i><b>4.2.4. Noninvasive Cardiac Imaging</b></i></text>
<text top="230" left="458" width="349" height="12" font="4"> S4.2.4-1. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in </text>
<text top="243" left="503" width="303" height="12" font="4">patients with myocardial infarction and left ventricular dysfunction, </text>
<text top="257" left="503" width="248" height="12" font="4">heart failure, or both. N Engl J Med. 2005;352:2581–8.</text>
<text top="270" left="458" width="349" height="12" font="4"> S4.2.4-2. Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment </text>
<text top="284" left="503" width="305" height="12" font="4">and survival: an analysis of the Sudden Cardiac Death in Heart </text>
<text top="297" left="503" width="260" height="12" font="4">Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196–200.</text>
<text top="311" left="458" width="345" height="12" font="4"> S4.2.4-3.  Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, pla-</text>
<text top="325" left="503" width="304" height="12" font="4">cebo-controlled trial to test the effect of highly purified omega-3 </text>
<text top="338" left="503" width="300" height="12" font="4">fatty acids on top of modern guideline-adjusted therapy after myo-</text>
<text top="352" left="503" width="218" height="12" font="4">cardial infarction. Circulation. 2010;122:2152–9.</text>
<text top="365" left="458" width="351" height="12" font="4"> S4.2.4-4. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS </text>
<text top="379" left="503" width="306" height="12" font="4">guideline for the evaluation and management of patients with </text>
<text top="392" left="503" width="303" height="12" font="4">syncope: a report of the American College of Cardiology/American </text>
<text top="406" left="503" width="303" height="12" font="4">Heart Association Task Force on Clinical Practice Guidelines and the </text>
<text top="419" left="503" width="244" height="12" font="4">Heart Rhythm Society. Circulation. 2017;136:e60–122.</text>
<text top="433" left="458" width="350" height="12" font="4"> S4.2.4-5. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of </text>
<text top="446" left="503" width="305" height="12" font="4">myocardial scarring on CMR in patients with cardiac sarcoidosis: </text>
<text top="460" left="503" width="304" height="12" font="4">a systematic review and meta-analysis. JACC Cardiovasc Imaging. </text>
<text top="474" left="503" width="78" height="12" font="4">2016;10:411–20.</text>
<text top="487" left="458" width="345" height="12" font="4"> S4.2.4-6.  Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhance-</text>
<text top="501" left="503" width="304" height="12" font="4">ment and the risk for ventricular arrhythmias or sudden death in </text>
<text top="514" left="503" width="303" height="12" font="4">dilated cardiomyopathy: systematic review and meta-analysis. JACC </text>
<text top="528" left="503" width="114" height="12" font="4">Heart Fail. 2017;5:28–38.</text>
<text top="541" left="458" width="350" height="12" font="4"> S4.2.4-7. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts </text>
<text top="555" left="503" width="305" height="12" font="4">death and other adverse events in suspected cardiac sarcoidosis. </text>
<text top="568" left="503" width="193" height="12" font="4">JACC Cardiovasc Imaging. 2013;6:501–11.</text>
<text top="582" left="458" width="350" height="12" font="4"> S4.2.4-8. Piers SR, Tao Q, van Huls van Taxis CF, et al. Contrast-enhanced </text>
<text top="595" left="503" width="303" height="12" font="4">MRI-derived scar patterns and associated ventricular tachycardias in </text>
<text top="609" left="503" width="303" height="12" font="4">nonischemic cardiomyopathy: implications for the ablation strategy. </text>
<text top="623" left="503" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2013;6:875–83.</text>
<text top="636" left="458" width="349" height="12" font="4"> S4.2.4-9.  White JA, Fine NM, Gula L, et al. Utility of cardiovascular magnetic </text>
<text top="650" left="503" width="300" height="12" font="4">resonance in identifying substrate for malignant ventricular arrhyth-</text>
<text top="663" left="503" width="206" height="12" font="4">mias. Circ Cardiovasc imaging. 2012;5:12–20.</text>
<text top="689" left="452" width="121" height="18" font="24"><i><b>4.2.5. Biomarkers</b></i></text>
<text top="710" left="458" width="349" height="12" font="4"> S4.2.5-1. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress </text>
<text top="723" left="503" width="303" height="12" font="4">and fibrosis as predictors of mode of death in patients with chronic </text>
<text top="737" left="503" width="202" height="12" font="4">heart failure. JACC Heart Fail. 2014;2:260–8.</text>
<text top="751" left="458" width="348" height="12" font="4"> S4.2.5-2.  Scott PA, Barry J, Roberts PR, et al. Brain natriuretic peptide for the </text>
<text top="764" left="503" width="304" height="12" font="4">prediction of sudden cardiac death and ventricular arrhythmias: a </text>
<text top="778" left="503" width="216" height="12" font="4">meta-analysis. Eur J Heart Fail. 2009;11:958–66.</text>
<text top="791" left="458" width="350" height="12" font="4"> S4.2.5-3. Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic </text>
<text top="805" left="503" width="304" height="12" font="4">peptide is a major predictor of ventricular tachyarrhythmias. Heart </text>
<text top="818" left="503" width="124" height="12" font="4">Rhythm. 2014;11:1109–16.</text>
<text top="832" left="458" width="345" height="12" font="4"> S4.2.5-4. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic pep-</text>
<text top="845" left="503" width="304" height="12" font="4">tide predicts sudden death in patients with chronic heart failure. </text>
<text top="859" left="503" width="138" height="12" font="4">Circulation. 2002;105:2392–7.</text>
<text top="872" left="458" width="345" height="12" font="4"> S4.2.5-5. Korngold EC, Januzzi JL Jr, Gantzer ML, et al. Amino-terminal pro-</text>
<text top="886" left="503" width="305" height="12" font="4">B-type natriuretic peptide and high-sensitivity C-reactive protein </text>
<text top="900" left="503" width="304" height="12" font="4">as predictors of sudden cardiac death among women. Circulation. </text>
<text top="913" left="503" width="90" height="12" font="4">2009;119:2868–76.</text>
<text top="927" left="458" width="348" height="12" font="4"> S4.2.5-6.  Patton KK, Sotoodehnia N, DeFilippi C, et al. N-terminal pro-B-type </text>
<text top="940" left="503" width="303" height="12" font="4">natriuretic peptide is associated with sudden cardiac death risk: the </text>
<text top="954" left="503" width="270" height="12" font="4">Cardiovascular Health Study. Heart Rhythm. 2011;8:228–33.</text>
<text top="967" left="458" width="350" height="12" font="4"> S4.2.5-7. Hussein AA, Gottdiener JS, Bartz TM, et al. Cardiomyocyte injury </text>
<text top="981" left="503" width="304" height="12" font="4">assessed by a highly sensitive troponin assay and sudden cardiac </text>
<text top="994" left="503" width="303" height="12" font="4">death in the community: the Cardiovascular Health Study. J Am Coll </text>
<text top="1008" left="503" width="122" height="12" font="4">Cardiol. 2013;62:2112–20.</text>
<text top="1034" left="452" width="311" height="18" font="24"><i><b>4.2.6. Genetic Considerations in Arrhythmia </b></i></text>
<text top="1052" left="452" width="78" height="18" font="24"><i><b>Syndromes</b></i></text>
<text top="1073" left="458" width="350" height="12" font="4"> S4.2.6-1. Andreasen C, Refsgaard L, Nielsen JB, et al. Mutations in genes </text>
<text top="1086" left="503" width="304" height="12" font="4">encoding cardiac ion channels previously associated with sudden </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e360</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="125" width="304" height="12" font="4">infant death syndrome (SIDS) are present with high frequency in </text>
<text top="102" left="125" width="224" height="12" font="4">new exome data. Can J Cardiol. 2013;29:1104–9.</text>
<text top="115" left="80" width="349" height="12" font="4"> S4.2.6-2. Jabbari J, Jabbari R, Nielsen MW, et al. New exome data question </text>
<text top="129" left="125" width="300" height="12" font="4">the pathogenicity of genetic variants previously associated with cat-</text>
<text top="142" left="125" width="303" height="12" font="4">echolaminergic polymorphic ventricular tachycardia. Circ Cardiovas </text>
<text top="156" left="125" width="102" height="12" font="4">Genetics. 2013 481–9.</text>
<text top="169" left="80" width="348" height="12" font="4"> S4.2.6-3.  Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60 000 </text>
<text top="183" left="125" width="300" height="12" font="4">exomes and ACMG guidelines question the role of catecholamin-</text>
<text top="196" left="125" width="304" height="12" font="4">ergic polymorphic ventricular tachycardia-associated variants. Clin </text>
<text top="210" left="125" width="106" height="12" font="4">Genet. 2017;91:63–72.</text>
<text top="223" left="80" width="351" height="12" font="4"> S4.2.6-4. Refsgaard L, Holst AG, Sadjadieh G, et al. High prevalence of </text>
<text top="237" left="125" width="304" height="12" font="4">genetic variants previously associated with LQT syndrome in new </text>
<text top="250" left="125" width="212" height="12" font="4">exome data. Eur J Hum Genet. 2012;20:905–8.</text>
<text top="264" left="80" width="348" height="12" font="4"> S4.2.6-5.  Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of genetic </text>
<text top="277" left="125" width="307" height="12" font="4">variants previously associated with Brugada syndrome in new </text>
<text top="291" left="125" width="190" height="12" font="4">exome data. Clin Genet. 2013;84:489–95.</text>
<text top="304" left="80" width="349" height="12" font="4"> S4.2.6-6. Costa J, Lopes CM. Barsheshet A, et al. Combined assessment of </text>
<text top="318" left="125" width="303" height="12" font="4">sex- and mutation-specific information for risk stratification in type </text>
<text top="331" left="125" width="231" height="12" font="4">1 long QT syndrome. Heart Rhythm. 2012;9:892–8.</text>
<text top="345" left="80" width="345" height="12" font="4"> S4.2.6-7. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evalua-</text>
<text top="358" left="125" width="303" height="12" font="4">tion of cardiomyopathy–a Heart Failure Society of America practice </text>
<text top="372" left="125" width="182" height="12" font="4">guideline. J Cardiac Fail. 2009;15:83–97.</text>
<text top="385" left="80" width="349" height="12" font="4"> S4.2.6-8. Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and </text>
<text top="399" left="125" width="304" height="12" font="4">response to therapy in long QT syndrome type 2. Heart Rhythm. </text>
<text top="412" left="125" width="84" height="12" font="4">2010;7:1797–805.</text>
<text top="426" left="80" width="345" height="12" font="4"> S4.2.6-9. Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender-</text>
<text top="439" left="125" width="300" height="12" font="4">specific risk in type 2 long QT syndrome: implications for risk strati-</text>
<text top="453" left="125" width="303" height="12" font="4">fication for life-threatening cardiac events in patients with long QT </text>
<text top="466" left="125" width="195" height="12" font="4">syndrome. Heart Rhythm. 2011;8:1537–43.</text>
<text top="480" left="74" width="351" height="12" font="4"> S4.2.6-10.  Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence of muta-</text>
<text top="493" left="125" width="305" height="12" font="4">tions involving BrS1- through BrS12-susceptibility genes in a cohort </text>
<text top="507" left="125" width="304" height="12" font="4">of unrelated patients referred for Brugada syndrome genetic testing: </text>
<text top="520" left="125" width="298" height="12" font="4">implications for genetic testing. J Am Coll Cardiol. 2012;60:1410–8.</text>
<text top="534" left="74" width="354" height="12" font="4"> S4.2.6-11. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of </text>
<text top="547" left="125" width="303" height="12" font="4">genetic background in the pathophysiology of Brugada syndrome. </text>
<text top="561" left="125" width="178" height="12" font="4">Circ Cardiovas Genetics. 2009;2:552–7.</text>
<text top="574" left="74" width="356" height="12" font="4"> S4.2.6-12. Dintzis RZ. Genetic variation and the meiotic process. Res Publ </text>
<text top="588" left="125" width="188" height="12" font="4">Assoc Res Nerv Ment Dis. 1991;69:39–46.</text>
<text top="601" left="74" width="354" height="12" font="4"> S4.2.6-13. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, </text>
<text top="615" left="125" width="304" height="12" font="4">long-term follow-up, and outcomes of 1001 arrhythmogenic right </text>
<text top="628" left="125" width="303" height="12" font="4">ventricular dysplasia/cardiomyopathy patients and family members. </text>
<text top="642" left="125" width="177" height="12" font="4">Circ Cardiovasc Genet. 2015;8:437–46.</text>
<text top="655" left="74" width="355" height="12" font="4"> S4.2.6-14. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right </text>
<text top="669" left="125" width="304" height="12" font="4">ventricular cardiomyopathy: a practical guide for physicians. J Am </text>
<text top="682" left="125" width="136" height="12" font="4">Coll Cardiol. 2013;61:1945–8.</text>
<text top="696" left="74" width="351" height="12" font="4"> S4.2.6-15. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhyth-</text>
<text top="709" left="125" width="304" height="12" font="4">mogenic right ventricular cardiomyopathy: impact of genetics and </text>
<text top="723" left="125" width="254" height="12" font="4">revised task force criteria. Circulation. 2011;123:2701–9.</text>
<text top="736" left="74" width="357" height="12" font="4"> S4.2.6-16. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic </text>
<text top="750" left="125" width="305" height="12" font="4">heterozygosity predicts lifetime arrhythmic outcome and sudden </text>
<text top="763" left="125" width="305" height="12" font="4">cardiac death in desmosomal gene-related arrhythmogenic right </text>
<text top="777" left="125" width="300" height="12" font="4">ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533–42.</text>
<text top="790" left="74" width="351" height="12" font="4"> S4.2.6-17.  Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen-</text>
<text top="804" left="125" width="302" height="12" font="4">sus statement on the state of genetic testing for the channelopathies </text>
<text top="817" left="125" width="300" height="12" font="4">and cardiomyopathies: this document was developed as a partner-</text>
<text top="831" left="125" width="304" height="12" font="4">ship between the Heart Rhythm Society (HRS) and the European </text>
<text top="844" left="125" width="292" height="12" font="4">Heart Rhythm Association (EHRA). Europace. 2011;13:1077–109.</text>
<text top="858" left="74" width="356" height="12" font="4"> S4.2.6-18. Gollob MH, Blier L, Brugada R, et al. Recommendations for the </text>
<text top="871" left="125" width="300" height="12" font="4">use of genetic testing in the clinical evaluation of inherited car-</text>
<text top="885" left="125" width="304" height="12" font="4">diac arrhythmias associated with sudden cardiac death: Canadian </text>
<text top="898" left="125" width="300" height="12" font="4">Cardiovascular Society/Canadian Heart Rhythm Society joint posi-</text>
<text top="912" left="125" width="194" height="12" font="4">tion paper. Can J Cardiol. 2011;27:232–45.</text>
<text top="925" left="74" width="351" height="12" font="4"> S4.2.6-19.  Kumar S, Peters S, Thompson T, et al. Familial cardiological and tar-</text>
<text top="939" left="125" width="304" height="12" font="4">geted genetic evaluation: low yield in sudden unexplained death </text>
<text top="953" left="125" width="306" height="12" font="4">and high yield in unexplained cardiac arrest syndromes. Heart </text>
<text top="966" left="125" width="124" height="12" font="4">Rhythm. 2013;10:1653–60.</text>
<text top="980" left="74" width="354" height="12" font="4"> S4.2.6-20.  Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus </text>
<text top="993" left="125" width="303" height="12" font="4">statement on the diagnosis and management of patients with inherited </text>
<text top="1007" left="125" width="293" height="12" font="4">primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932–63.</text>
<text top="1020" left="74" width="351" height="12" font="4"> S4.2.6-21.  Tester DJ, Medeiros-Domingo A, Will ML, et al. Unexplained drown-</text>
<text top="1034" left="125" width="304" height="12" font="4">ings and the cardiac channelopathies: a molecular autopsy series. </text>
<text top="1047" left="125" width="146" height="12" font="4">Mayo Clin Proc. 2011;86:941–7.</text>
<text top="1061" left="74" width="354" height="12" font="4"> S4.2.6-22.  Tzimas I, Zingraf JC, Bajanowski T, et al. The role of known variants </text>
<text top="1074" left="125" width="303" height="12" font="4">of KCNQ1, KCNH2, KCNE1, SCN5A, and NOS1AP in water-related </text>
<text top="1088" left="125" width="193" height="12" font="4">deaths. Int J Legal Med. 2016;130:1575–9.</text>
<text top="88" left="452" width="355" height="12" font="4"> S4.2.6-23. Wang D, Shah KR, Um SY, et al. Cardiac channelopathy testing in </text>
<text top="102" left="503" width="303" height="12" font="4">274 ethnically diverse sudden unexplained deaths. Forensic Sci Int. </text>
<text top="115" left="503" width="72" height="12" font="4">2014;237:90–9.</text>
<text top="129" left="452" width="356" height="12" font="4"> S4.2.6-24. Laedtke AL, O’Neill SM, Rubinstein WS, et al. Family physicians’ </text>
<text top="142" left="503" width="300" height="12" font="4">awareness and knowledge of the Genetic Information Non-</text>
<text top="156" left="503" width="270" height="12" font="4">Discrimination Act (GINA). J Genet Couns. 2012;21:345–52.</text>
<text top="169" left="452" width="351" height="12" font="4"> S4.2.6-25. Vavolizza RD, Kalia I, Erskine AK, et al. Disclosing genetic informa-</text>
<text top="183" left="503" width="300" height="12" font="4">tion to family members about inherited cardiac arrhythmias: an obli-</text>
<text top="196" left="503" width="238" height="12" font="4">gation or a choice? J Genet Couns. 2015;24:608–15.</text>
<text top="210" left="452" width="356" height="12" font="4"> S4.2.6-26. Christiaans I, van Langen IM, Birnie E, et al. Genetic counseling </text>
<text top="223" left="503" width="303" height="12" font="4">and cardiac care in predictively tested hypertrophic cardiomyopathy </text>
<text top="237" left="503" width="303" height="12" font="4">mutation carriers: the patients’ perspective. Am J Med Genet. Part A. </text>
<text top="250" left="503" width="101" height="12" font="4">2009;149a: 1444 –51.</text>
<text top="264" left="452" width="356" height="12" font="4"> S4.2.6-27. Hamang A, Eide GE, Rokne B, et al. Predictors of heart-focused </text>
<text top="277" left="503" width="303" height="12" font="4">anxiety in patients undergoing genetic investigation and counseling </text>
<text top="291" left="503" width="304" height="12" font="4">of long QT syndrome or hypertrophic cardiomyopathy: a one year </text>
<text top="304" left="503" width="200" height="12" font="4">follow-up. J Genet Counsel. 2012;21:72–84.</text>
<text top="342" left="452" width="169" height="21" font="18"><b>4.3. Invasive Testing</b></text>
<text top="369" left="452" width="281" height="18" font="24"><i><b>4.3.1. Invasive Cardiac Imaging: Cardiac </b></i></text>
<text top="387" left="452" width="247" height="18" font="24"><i><b>Catheterization or CT Angiography</b></i></text>
<text top="408" left="458" width="348" height="12" font="4"> S4.3.1-1.  Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac </text>
<text top="421" left="503" width="303" height="12" font="4">arrest patients without ST-segment elevation pattern: insights from </text>
<text top="435" left="503" width="284" height="12" font="4">the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011–8.</text>
<text top="448" left="458" width="345" height="12" font="4"> S4.3.1-2.  Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percuta-</text>
<text top="462" left="503" width="303" height="12" font="4">neous coronary intervention after out-of-hospital cardiac arrest due </text>
<text top="475" left="503" width="226" height="12" font="4">to ventricular fibrillation. Crit Care. 2011;15:R122.</text>
<text top="489" left="458" width="350" height="12" font="4"> S4.3.1-3. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary </text>
<text top="502" left="503" width="304" height="12" font="4">angiography in survivors of out-of-hospital cardiac arrest. N Engl J </text>
<text top="516" left="503" width="116" height="12" font="4">Med. 1997;336:1629–33.</text>
<text top="529" left="458" width="345" height="12" font="4"> S4.3.1-4.  Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coro-</text>
<text top="543" left="503" width="303" height="12" font="4">nary angiography on in-hospital outcome of unconscious survivors </text>
<text top="556" left="503" width="300" height="12" font="4">after out-of-hospital cardiac arrest. Am J Cardiol. 2012;110:1723–8.</text>
<text top="570" left="458" width="345" height="12" font="4"> S4.3.1-5.  O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guide-</text>
<text top="583" left="503" width="305" height="12" font="4">line for the management of ST-elevation myocardial infarction: a </text>
<text top="597" left="503" width="303" height="12" font="4">report of the American College of Cardiology Foundation/American </text>
<text top="610" left="503" width="305" height="12" font="4">Heart Association Task Force on Practice Guidelines. Circulation. </text>
<text top="624" left="503" width="95" height="12" font="4">2013;127:e362–425.</text>
<text top="648" left="452" width="277" height="18" font="24"><i><b>4.3.2. Electrophysiological Study for VA</b></i></text>
<text top="669" left="458" width="350" height="12" font="4"> S4.3.2-1. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to </text>
<text top="683" left="503" width="300" height="12" font="4">identify patients with coronary artery disease who are at risk for sud-</text>
<text top="696" left="503" width="303" height="12" font="4">den death. Multicenter Unsustained Tachycardia Trial Investigators. </text>
<text top="710" left="503" width="155" height="12" font="4">N Engl J Med. 2000;342:1937–45.</text>
<text top="723" left="458" width="348" height="12" font="4"> S4.3.2-2.  Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and </text>
<text top="737" left="503" width="304" height="12" font="4">inducible ventricular tachycardia to mode of death in patients with </text>
<text top="750" left="503" width="300" height="12" font="4">coronary artery disease: an analysis of patients enrolled in the multi-</text>
<text top="764" left="503" width="300" height="12" font="4">center unsustained tachycardia trial. Circulation. 2002;106:2466–72.</text>
<text top="777" left="458" width="349" height="12" font="4"> S4.3.2-3. Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans </text>
<text top="791" left="503" width="300" height="12" font="4">Before Cardioverter Defibrillator) Trial: strategies using T-wave alter-</text>
<text top="804" left="503" width="304" height="12" font="4">nans to improve efficiency of sudden cardiac death prevention. J </text>
<text top="818" left="503" width="149" height="12" font="4">Am Coll Cardiol. 2009;53:471–9.</text>
<text top="831" left="458" width="345" height="12" font="4"> S4.3.2-4.  Bourke JP, Richards DA, Ross DL, et al. Routine programmed electri-</text>
<text top="845" left="503" width="300" height="12" font="4">cal stimulation in survivors of acute myocardial infarction for predic-</text>
<text top="858" left="503" width="303" height="12" font="4">tion of spontaneous ventricular tachyarrhythmias during follow-up: </text>
<text top="872" left="503" width="303" height="12" font="4">results, optimal stimulation protocol and cost-effective screening. J </text>
<text top="885" left="503" width="149" height="12" font="4">Am Coll Cardiol. 1991;18:780–8.</text>
<text top="899" left="458" width="350" height="12" font="4"> S4.3.2-5. Bailey JJ, Berson AS, Handelsman H, et al. Utility of current risk </text>
<text top="912" left="503" width="300" height="12" font="4">stratification tests for predicting major arrhythmic events after myo-</text>
<text top="926" left="503" width="247" height="12" font="4">cardial infarction. J Am Coll Cardiol. 2001;38:1902–11.</text>
<text top="939" left="458" width="345" height="12" font="4"> S4.3.2-6.  Schmitt C, Barthel P, Ndrepepa G, et al. Value of programmed ven-</text>
<text top="953" left="503" width="302" height="12" font="4">tricular stimulation for prophylactic internal cardioverter-defibrillator </text>
<text top="966" left="503" width="304" height="12" font="4">implantation in postinfarction patients preselected by noninvasive </text>
<text top="980" left="503" width="226" height="12" font="4">risk stratifiers. J Am Coll Cardiol. 2001;37:1901–7.</text>
<text top="993" left="458" width="345" height="12" font="4"> S4.3.2-7. Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electro-</text>
<text top="1007" left="503" width="303" height="12" font="4">physiological studies to predict arrhythmic events. World J Cardiol. </text>
<text top="1020" left="503" width="72" height="12" font="4">2015;7:344–50.</text>
<text top="1034" left="458" width="349" height="12" font="4"> S4.3.2-8. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable </text>
<text top="1047" left="503" width="303" height="12" font="4">cardioverter-defibrillator for congestive heart failure. N Engl J Med. </text>
<text top="1061" left="503" width="84" height="12" font="4">2005;352:225–37.</text>
<text top="1074" left="458" width="345" height="12" font="4"> S4.3.2-9.  Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre-</text>
<text top="1088" left="503" width="304" height="12" font="4">vention of sudden death in patients with coronary artery disease. </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e361</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="125" width="305" height="12" font="4">Multicenter Unsustained Tachycardia Trial Investigators. N Engl J </text>
<text top="102" left="125" width="116" height="12" font="4">Med. 1999;341:1882–90.</text>
<text top="116" left="74" width="356" height="12" font="4"> S4.3.2-10. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an </text>
<text top="129" left="125" width="305" height="12" font="4">implanted defibrillator in patients with coronary disease at high </text>
<text top="143" left="125" width="304" height="12" font="4">risk for ventricular arrhythmia. Multicenter Automatic Defibrillator </text>
<text top="157" left="125" width="297" height="12" font="4">Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40.</text>
<text top="170" left="74" width="355" height="12" font="4"> S4.3.2-11. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a </text>
<text top="184" left="125" width="300" height="12" font="4">defibrillator in patients with myocardial infarction and reduced ejec-</text>
<text top="197" left="125" width="210" height="12" font="4">tion fraction. N Engl J Med. 2002;346:877–83.</text>
<text top="211" left="74" width="353" height="12" font="4"> S4.3.2-12.  Bhandari AK, Shapiro WA, Morady F, et al. Electrophysiologic testing </text>
<text top="225" left="125" width="300" height="12" font="4">in patients with the long QT syndrome. Circulation. 1985;71:63–71.</text>
<text top="238" left="74" width="351" height="12" font="4"> S4.3.2-13. Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clini-</text>
<text top="252" left="125" width="305" height="12" font="4">cal findings and diagnostic-therapeutic implications. Eur Heart J. </text>
<text top="266" left="125" width="78" height="12" font="4">2006;27:2440–7.</text>
<text top="279" left="74" width="6" height="12" font="4"> </text>
<text top="279" left="74" width="351" height="12" font="4">S4.3.2-14. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-</text>
<text top="293" left="125" width="307" height="12" font="4">up of patients with short QT syndrome. J Am Coll Cardiol. </text>
<text top="307" left="125" width="78" height="12" font="4">2011;58:587–95.</text>
<text top="320" left="74" width="351" height="12" font="4"> S4.3.2-15.  Mahida S, Derval N, Sacher F, et al. Role of electrophysiological stud-</text>
<text top="334" left="125" width="303" height="12" font="4">ies in predicting risk of ventricular arrhythmia in early repolarization </text>
<text top="347" left="125" width="205" height="12" font="4">syndrome. J Am Coll Cardiol. 2015;65:151–9.</text>
<text top="361" left="74" width="355" height="12" font="4"> S4.3.2-16. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular </text>
<text top="375" left="125" width="306" height="12" font="4">characterization of patients with catecholaminergic polymorphic </text>
<text top="388" left="125" width="238" height="12" font="4">ventricular tachycardia. Circulation. 2002;106:69–74.</text>
<text top="402" left="74" width="355" height="12" font="4"> S4.3.2-17. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of </text>
<text top="416" left="125" width="306" height="12" font="4">sudden cardiac death in a nonischemic dilated cardiomyopathy </text>
<text top="429" left="125" width="300" height="12" font="4">population: reappraisal of the role of programmed ventricular stim-</text>
<text top="443" left="125" width="242" height="12" font="4">ulation. Circ Arrhythm Electrophysiol. 2013;6:504–12.</text>
<text top="457" left="74" width="355" height="12" font="4"> S4.3.2-18. Brembilla-Perrot B, Suty-Selton C, Beurrier D, et al. Differences in </text>
<text top="470" left="125" width="305" height="12" font="4">mechanisms and outcomes of syncope in patients with coronary </text>
<text top="484" left="125" width="300" height="12" font="4">disease or idiopathic left ventricular dysfunction as assessed by elec-</text>
<text top="497" left="125" width="269" height="12" font="4">trophysiologic testing. J Am Coll Cardiol. 2004;44:594–601.</text>
<text top="511" left="74" width="355" height="12" font="4"> S4.3.2-19. Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome in </text>
<text top="525" left="125" width="307" height="12" font="4">children. An international study of 287 patients. Circulation. </text>
<text top="538" left="125" width="84" height="12" font="4">1993;87:1866–72.</text>
<text top="552" left="74" width="354" height="12" font="4"> S4.3.2-20.  Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest </text>
<text top="566" left="125" width="300" height="12" font="4">or sudden cardiac death during adolescence in the long-QT syn-</text>
<text top="579" left="125" width="157" height="12" font="4">drome. JAMA. 2006;296:1249–54.</text>
<text top="593" left="74" width="356" height="12" font="4"> S4.3.2-21. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of </text>
<text top="607" left="125" width="306" height="12" font="4">1.7 million persons: prevalence, correlates, and prognosis. Ann </text>
<text top="620" left="125" width="206" height="12" font="4">Noninvasive Electrocardiol. 2014;19:490–500.</text>
<text top="634" left="74" width="354" height="12" font="4"> S4.3.2-22. Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT </text>
<text top="648" left="125" width="292" height="12" font="4">syndrome when a sibling has died. Heart Rhythm. 2008;5:831–6.</text>
<text top="661" left="74" width="356" height="12" font="4"> S4.3.2-23. Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for </text>
<text top="675" left="125" width="303" height="12" font="4">affected parents and siblings of probands with long-QT syndrome. </text>
<text top="688" left="125" width="138" height="12" font="4">Circulation. 2001;104:557–62.</text>
<text top="702" left="74" width="356" height="12" font="4"> S4.3.2-24. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into </text>
<text top="716" left="125" width="306" height="12" font="4">the natural history of short QT syndrome. J Am Coll Cardiol. </text>
<text top="729" left="125" width="78" height="12" font="4">2014;63:1300–8.</text>
<text top="743" left="74" width="356" height="12" font="4"> S4.3.2-25. Wong JA, Gula LJ, Klein GJ, et al. Utility of treadmill testing in </text>
<text top="757" left="125" width="304" height="12" font="4">identification and genotype prediction in long-QT syndrome. Circ </text>
<text top="770" left="125" width="179" height="12" font="4">Arrhythm Electrophysiol. 2010;3:120–5.</text>
<text top="784" left="74" width="7" height="12" font="4"> </text>
<text top="784" left="74" width="358" height="12" font="4">S4.3.2-26. Walker BD, Krahn AD, Klein GJ, et al. Burst bicycle exercise </text>
<text top="798" left="125" width="306" height="12" font="4">facilitates diagnosis of latent long QT syndrome. Am Heart J. </text>
<text top="811" left="125" width="90" height="12" font="4">2005;150:1059–63.</text>
<text top="825" left="74" width="351" height="12" font="4"> S4.3.2-27. Waks JW, Sitlani CM, Soliman EZ, et al. Global electric hetero-</text>
<text top="838" left="125" width="305" height="12" font="4">geneity risk score for prediction of sudden cardiac death in the </text>
<text top="852" left="125" width="308" height="12" font="4">general population: the Atherosclerosis Risk in Communities </text>
<text top="866" left="125" width="308" height="12" font="4">(ARIC) and Cardiovascular Health (CHS) Studies. Circulation. </text>
<text top="879" left="125" width="90" height="12" font="4">2016;133:2222–34.</text>
<text top="893" left="74" width="355" height="12" font="4"> S4.3.2-28. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT </text>
<text top="907" left="125" width="300" height="12" font="4">syndrome loci and cardiac events among patients treated with beta-</text>
<text top="920" left="125" width="159" height="12" font="4">blockers. JAMA. 2004;292:1341–4.</text>
<text top="934" left="74" width="354" height="12" font="4"> S4.3.2-29. Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the </text>
<text top="948" left="125" width="243" height="12" font="4">long-QT syndrome. N Engl J Med. 2003;348:1866–74.</text>
<text top="961" left="74" width="354" height="12" font="4"> S4.3.2-30.  Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation </text>
<text top="975" left="125" width="303" height="12" font="4">and risk for cardiac events in genotyped LQTS-index children. Eur J </text>
<text top="989" left="125" width="126" height="12" font="4">Pediatr. 2009;168:1107–15.</text>
<text top="1002" left="74" width="357" height="12" font="4"> S4.3.2-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening </text>
<text top="1016" left="125" width="300" height="12" font="4">cardiac events in patients with genotype-confirmed long-QT syn-</text>
<text top="1029" left="125" width="303" height="12" font="4">drome and normal-range corrected QT intervals. J Am Coll Cardiol. </text>
<text top="1043" left="125" width="67" height="12" font="4">2011;57:51–9.</text>
<text top="1057" left="74" width="351" height="12" font="4"> S4.3.2-32.  Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher-</text>
<text top="1070" left="125" width="305" height="12" font="4">ited arrhythmia syndromes: insight into their natural history. Circ </text>
<text top="1084" left="125" width="151" height="12" font="4">Cardiovasc Genet. 2012;5:183–9.</text>
<text top="86" left="452" width="318" height="23" font="15"><b>5. THERAPIES FOR TREATMENT OR </b></text>
<text top="109" left="452" width="178" height="23" font="15"><b>PREVENTION OF VA</b></text>
<text top="137" left="452" width="204" height="21" font="18"><b>5.1. Medication Therapy</b></text>
<text top="164" left="458" width="349" height="12" font="4"> S5.1.5.2-1. Vaughan Williams EM. A classification of antiarrhythmic actions </text>
<text top="178" left="512" width="298" height="12" font="4">reassessed after a decade of new drugs. J Clin Pharmacol. </text>
<text top="191" left="512" width="78" height="12" font="4">1984;24:129–47.</text>
<text top="205" left="458" width="348" height="12" font="4"> S5.1.5.2-2.  Schleifer JW, Sorajja D, Shen WK. Advances in the pharmacologic </text>
<text top="218" left="512" width="295" height="12" font="4">treatment of ventricular arrhythmias. Expert Opin Pharmacother. </text>
<text top="232" left="512" width="84" height="12" font="4">2015;16:2637–51.</text>
<text top="245" left="458" width="349" height="12" font="4"> S5.1.5.2-3. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, </text>
<text top="259" left="512" width="294" height="12" font="4">or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; </text>
<text top="272" left="512" width="43" height="12" font="4">1711–22.</text>
<text top="286" left="458" width="350" height="12" font="4"> S5.1.5.2-4. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy </text>
<text top="299" left="512" width="295" height="12" font="4">with mexiletine reduces arrhythmic events in patients with long </text>
<text top="313" left="512" width="258" height="12" font="4">QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053–8.</text>
<text top="326" left="458" width="345" height="12" font="4"> S5.1.5.2-5. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents cat-</text>
<text top="340" left="512" width="295" height="12" font="4">echolaminergic polymorphic ventricular tachycardia in mice and </text>
<text top="353" left="512" width="159" height="12" font="4">humans. Nat Med. 2009;15:380–3.</text>
<text top="367" left="458" width="6" height="12" font="4"> </text>
<text top="367" left="458" width="352" height="12" font="4">S5.1.5.2-6. Gupta T, Khera S, Kolte D, et al. Antiarrhythmic properties </text>
<text top="381" left="512" width="296" height="12" font="4">of ranolazine: a review of the current evidence. Int J Cardiol. </text>
<text top="394" left="512" width="78" height="12" font="4">2015;187:66–74.</text>
<text top="408" left="458" width="350" height="12" font="4"> S5.1.5.2-7. Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces </text>
<text top="421" left="512" width="299" height="12" font="4">ventricular tachycardia burden and ICD shocks in patients </text>
<text top="435" left="512" width="298" height="12" font="4">with drug-refractory ICD shocks. Pacing Clin Electrophysiol. </text>
<text top="448" left="512" width="78" height="12" font="4">2011;34:1600–6.</text>
<text top="462" left="458" width="347" height="12" font="4"> S5.1.5.2-8.  Scirica BM, Braunwald E, Belardinelli L, et al. Relationship between </text>
<text top="475" left="512" width="294" height="12" font="4">nonsustained ventricular tachycardia after non-ST-elevation acute </text>
<text top="489" left="512" width="294" height="12" font="4">coronary syndrome and sudden cardiac death: observations from </text>
<text top="502" left="512" width="291" height="12" font="4">the metabolic efficiency with ranolazine for less ischemia in non-</text>
<text top="516" left="512" width="291" height="12" font="4">ST-elevation acute coronary syndrome-thrombolysis in myocar-</text>
<text top="529" left="512" width="295" height="12" font="4">dial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. </text>
<text top="543" left="512" width="138" height="12" font="4">Circulation. 2010;122:455–62.</text>
<text top="556" left="458" width="348" height="12" font="4"> S5.1.5.2-9.  Zareba W, Daubert JP, Beck CA, et al. Ranolazine in High-Risk ICD </text>
<text top="570" left="512" width="295" height="12" font="4">Patients (RAID) Trial. Presented at: Heart Rhythm Society Annual </text>
<text top="583" left="512" width="169" height="12" font="4">Scientific Sessions. 2017; LBCT02–01.</text>
<text top="597" left="452" width="354" height="12" font="4"> S5.1.5.2-10.  Reiter MJ, Reiffel JA, Importance of beta blockade in the therapy </text>
<text top="610" left="512" width="288" height="12" font="4">of serious ventricular arrhythmias. Am J Cardiol. 1998;82:9I–19I.</text>
<text top="624" left="452" width="351" height="12" font="4"> S5.1.5.2-11.  Ellison KE, Hafley GE, Hickey K, et al. Effect of beta-blocking ther-</text>
<text top="637" left="512" width="294" height="12" font="4">apy on outcome in the Multicenter UnSustained Tachycardia Trial </text>
<text top="651" left="512" width="182" height="12" font="4">(MUSTT). Circulation. 2002;106:2694–9.</text>
<text top="665" left="452" width="351" height="12" font="4"> S5.1.5.2-12. Reiken S, Wehrens XH, Vest JA, et al. Beta-blockers restore cal-</text>
<text top="678" left="512" width="291" height="12" font="4">cium release channel function and improve cardiac muscle perfor-</text>
<text top="692" left="512" width="282" height="12" font="4">mance in human heart failure. Circulation. 2003;107:2459–66.</text>
<text top="705" left="452" width="357" height="12" font="4"> S5.1.5.2-13. MERIT-HF Group Effect of metoprolol CR/XL in chronic heart </text>
<text top="719" left="512" width="299" height="12" font="4">failure: Metoprolol CR/XL Randomised Intervention Trial in </text>
<text top="732" left="512" width="284" height="12" font="4">Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.</text>
<text top="746" left="452" width="355" height="12" font="4"> S5.1.5.2-14. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol </text>
<text top="759" left="512" width="291" height="12" font="4">on morbidity and mortality in patients with chronic heart fail-</text>
<text top="773" left="512" width="296" height="12" font="4">ure. US Carvedilol Heart Failure Study Group. N Engl J Med. </text>
<text top="786" left="512" width="90" height="12" font="4">1996;334:1349–55.</text>
<text top="800" left="452" width="355" height="12" font="4"> S5.1.5.2-15. Committees of the Cardiac insufficiency Bisoprolol Study II. The </text>
<text top="813" left="512" width="296" height="12" font="4">cardiac insufficiency Bisoprolol Study II (CIBIS-II): a randomised </text>
<text top="827" left="512" width="130" height="12" font="4">trial. Lancet. 1999;353:9–13.</text>
<text top="840" left="452" width="351" height="12" font="4"> S5.1.5.2-16.  A randomized trial of propranolol in patients with acute myocar-</text>
<text top="854" left="512" width="267" height="12" font="4">dial infarction. Mortality results. JAMA. 1982;247:1707–14.</text>
<text top="867" left="452" width="355" height="12" font="4"> S5.1.5.2-17. Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes </text>
<text top="881" left="512" width="291" height="12" font="4">in patients with myocardial infarction treated with acute beta-</text>
<text top="894" left="512" width="293" height="12" font="4">blocker therapy: results from the American College of Cardiology’s </text>
<text top="908" left="512" width="184" height="12" font="4">NCDR(R). Am Heart J. 2011;161:864–70.</text>
<text top="921" left="452" width="354" height="12" font="4"> S5.1.5.2-18.  Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: </text>
<text top="935" left="512" width="291" height="12" font="4">sympathetic blockade versus advanced cardiac life support-</text>
<text top="949" left="512" width="205" height="12" font="4">guided therapy. Circulation. 2000;102:742–7.</text>
<text top="962" left="452" width="354" height="12" font="4"> S5.1.5.2-19.  Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of atenolol </text>
<text top="976" left="512" width="295" height="12" font="4">on symptomatic ventricular arrhythmia without structural heart </text>
<text top="989" left="512" width="297" height="12" font="4">disease: a randomized placebo-controlled study. Am Heart J. </text>
<text top="1003" left="512" width="67" height="12" font="4">2002;144:e10.</text>
<text top="1016" left="452" width="351" height="12" font="4"> S5.1.5.2-20. Hirsowitz G, Podrid PJ, Lampert S, et al. The role of beta block-</text>
<text top="1030" left="512" width="296" height="12" font="4">ing agents as adjunct therapy to membrane stabilizing drugs </text>
<text top="1043" left="512" width="294" height="12" font="4">in malignant ventricular arrhythmia. Am Heart J. 1986;111: </text>
<text top="1057" left="512" width="37" height="12" font="4">852–60.</text>
<text top="1070" left="452" width="356" height="12" font="4"> S5.1.5.2-21. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J </text>
<text top="1084" left="512" width="116" height="12" font="4">Cardiol. 1999;84:90R–3R.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e362</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="354" height="12" font="4"> S5.1.5.2-22.  Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug </text>
<text top="102" left="134" width="296" height="12" font="4">use in the implantable defibrillator arm of the Antiarrhythmics </text>
<text top="115" left="134" width="298" height="12" font="4">Versus Implantable Defibrillators (AVID) Study. Am Heart J. </text>
<text top="129" left="134" width="78" height="12" font="4">2001;142:520–9.</text>
<text top="142" left="74" width="355" height="12" font="4"> S5.1.5.2-23. Farre J, Romero J, Rubio JM, et al. Amiodarone and “primary” </text>
<text top="156" left="134" width="294" height="12" font="4">prevention of sudden death: critical review of a decade of clinical </text>
<text top="169" left="134" width="176" height="12" font="4">trials. Am J Cardiol. 1999;83:55D–63D.</text>
<text top="183" left="74" width="351" height="12" font="4"> S5.1.5.2-24. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implant-</text>
<text top="196" left="134" width="294" height="12" font="4">able cardioverter-defibrillator for congestive heart failure. N Engl J </text>
<text top="210" left="134" width="110" height="12" font="4">Med. 2005;352:225–37.</text>
<text top="223" left="74" width="355" height="12" font="4"> S5.1.5.2-25. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use </text>
<text top="237" left="134" width="291" height="12" font="4">after acute myocardial infarction complicated by heart failure and/</text>
<text top="250" left="134" width="291" height="12" font="4">or left ventricular dysfunction may be associated with excess mor-</text>
<text top="264" left="134" width="160" height="12" font="4">tality. Am Heart J. 2008;155:87–93.</text>
<text top="277" left="74" width="351" height="12" font="4"> S5.1.5.2-26.  Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar-</text>
<text top="291" left="134" width="294" height="12" font="4">macological interventions for prevention of sudden cardiac death. </text>
<text top="305" left="134" width="227" height="12" font="4">Cochrane Database Syst. Rev. 2015;12:CD008093.</text>
<text top="318" left="74" width="357" height="12" font="4"> S5.1.5.2-27. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for </text>
<text top="332" left="134" width="294" height="12" font="4">resuscitation after out-of-hospital cardiac arrest due to ventricular </text>
<text top="345" left="134" width="194" height="12" font="4">fibrillation. N Engl J Med. 1999;341:871–8.</text>
<text top="359" left="74" width="353" height="12" font="4"> S5.1.5.2-28.  Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with </text>
<text top="372" left="134" width="294" height="12" font="4">lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. </text>
<text top="386" left="134" width="84" height="12" font="4">2002;346:884–90.</text>
<text top="399" left="74" width="351" height="12" font="4"> S5.1.5.2-29.  Levine JH, Massumi A, Scheinman MM, et al. Intravenous amioda-</text>
<text top="413" left="134" width="291" height="12" font="4">rone for recurrent sustained hypotensive ventricular tachyarrhyth-</text>
<text top="426" left="134" width="294" height="12" font="4">mias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll </text>
<text top="440" left="134" width="110" height="12" font="4">Cardiol. 1996;27:67–75.</text>
<text top="453" left="74" width="351" height="12" font="4"> S5.1.5.2-30. Epstein AE, Olshansky B, Naccarelli GV, et al. Practical manage-</text>
<text top="467" left="134" width="293" height="12" font="4">ment guide for clinicians who treat patients with amiodarone. Am </text>
<text top="480" left="134" width="117" height="12" font="4">J Med. 2016;129:468–75.</text>
<text top="494" left="74" width="355" height="12" font="4"> S5.1.5.2-31. Kuhlkamp V, Mewis C, Mermi J, et al. Suppression of sustained </text>
<text top="507" left="134" width="294" height="12" font="4">ventricular tachyarrhythmias: a comparison of d,l-sotalol with no </text>
<text top="521" left="134" width="291" height="12" font="4">antiarrhythmic drug treatment. J Am Coll Cardiol. 1999;33:46–52.</text>
<text top="534" left="74" width="353" height="12" font="4"> S5.1.5.2-32.  Waldo AL, Camm AJ, deRuyter H, et al. Survival with oral d-sotalol </text>
<text top="548" left="134" width="297" height="12" font="4">in patients with left ventricular dysfunction after myocardial </text>
<text top="561" left="134" width="294" height="12" font="4">infarction: rationale, design, and methods (the SWORD trial). Am </text>
<text top="575" left="134" width="122" height="12" font="4">J Cardiol. 1995;75:1023–7.</text>
<text top="588" left="74" width="351" height="12" font="4"> S5.1.5.2-33.  Page RL. Effects of antiarrhythmic medication on implantable car-</text>
<text top="602" left="134" width="281" height="12" font="4">dioverter-defibrillator function. Am J Cardiol. 2000;85:1481–5.</text>
<text top="615" left="74" width="351" height="12" font="4"> S5.1.5.2-34. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intra-</text>
<text top="629" left="134" width="297" height="12" font="4">venous verapamil for sustained ventricular tachycardia. Am J </text>
<text top="642" left="134" width="122" height="12" font="4">Cardiol. 1987;59:1107–10.</text>
<text top="656" left="74" width="351" height="12" font="4"> S5.1.5.2-35. Belhassen BHorowitz LN. Use of intravenous verapamil for ven-</text>
<text top="669" left="134" width="231" height="12" font="4">tricular tachycardia. Am J Cardiol. 1984;54:1131–3.</text>
<text top="683" left="74" width="355" height="12" font="4"> S5.1.5.2-36. Griffith MJ, Garratt CJ, Rowland E, et al. Effects of intravenous </text>
<text top="696" left="134" width="291" height="12" font="4">adenosine on verapamil-sensitive “idiopathic” ventricular tachy-</text>
<text top="710" left="134" width="174" height="12" font="4">cardia. Am J Cardiol. 1994;73:759–64.</text>
<text top="723" left="74" width="354" height="12" font="4"> S5.1.5.2-37.  Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of </text>
<text top="737" left="134" width="294" height="12" font="4">idiopathic ventricular tachycardia of left bundle branch block-like </text>
<text top="750" left="134" width="204" height="12" font="4">morphology. Am Heart J. 1993;126:1126–33.</text>
<text top="764" left="74" width="356" height="12" font="4"> S5.1.5.2-38. Badhwar N, Scheinman MM. Idiopathic ventricular tachycardia: </text>
<text top="777" left="134" width="282" height="12" font="4">diagnosis and management. Curr Probl Cardiol. 2007;32:7–43.</text>
<text top="791" left="74" width="351" height="12" font="4"> S5.1.5.2-39. Gill JS, Ward DE, Camm AJ. Comparison of verapamil and dil-</text>
<text top="805" left="134" width="296" height="12" font="4">tiazem in the suppression of idiopathic ventricular tachycardia. </text>
<text top="818" left="134" width="198" height="12" font="4">Pacing Clin Electrophysiol. 1992;15:2122–6.</text>
<text top="832" left="74" width="6" height="12" font="4"> </text>
<text top="832" left="74" width="357" height="12" font="4">S5.1.5.2-40. Investigators in the Magnesium in Coronaries (MAGIC) Trial. </text>
<text top="845" left="134" width="298" height="12" font="4">Early administration of intravenous magnesium to high-risk </text>
<text top="859" left="134" width="296" height="12" font="4">patients with acute myocardial infarction in the Magnesium in </text>
<text top="872" left="134" width="295" height="12" font="4">Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet. </text>
<text top="886" left="134" width="90" height="12" font="4">2002;360:1189–96.</text>
<text top="899" left="74" width="351" height="12" font="4"> S5.1.5.2-41.  Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhyth-</text>
<text top="913" left="134" width="293" height="12" font="4">mic death in patients with left ventricular dysfunction. Circulation. </text>
<text top="926" left="134" width="84" height="12" font="4">1999;100:1311–5.</text>
<text top="940" left="74" width="357" height="12" font="4"> S5.1.5.2-42. Kafka H, Langevin L, Armstrong PW. Serum magnesium and </text>
<text top="953" left="134" width="294" height="12" font="4">potassium in acute myocardial infarction. Influence on ventricular </text>
<text top="967" left="134" width="216" height="12" font="4">arrhythmias. Arch Intern Med. 1987;147:465–9.</text>
<text top="980" left="74" width="356" height="12" font="4"> S5.1.5.2-43. Yan GX, Antzelevitch C. Cellular basis for the normal T wave </text>
<text top="994" left="134" width="291" height="12" font="4">and the electrocardiographic manifestations of the long-QT syn-</text>
<text top="1007" left="134" width="173" height="12" font="4">drome. Circulation. 1998;98:1928–36.</text>
<text top="1021" left="74" width="356" height="12" font="4"> S5.1.5.2-44. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de </text>
<text top="1034" left="134" width="275" height="12" font="4">pointes with magnesium sulfate. Circulation. 1988;77:392–7.</text>
<text top="1048" left="74" width="355" height="12" font="4"> S5.1.5.2-45. Leier CV, Dei CL, Metra M. Clinical relevance and management </text>
<text top="1061" left="134" width="294" height="12" font="4">of the major electrolyte abnormalities in congestive heart failure: </text>
<text top="1075" left="134" width="295" height="12" font="4">hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J. </text>
<text top="1088" left="134" width="84" height="12" font="4">1994;128:564–74.</text>
<text top="89" left="452" width="351" height="12" font="4"> S5.1.5.2-46.  Cohn JN, Kowey PR, Whelton PK, et al. New guidelines for potas-</text>
<text top="102" left="512" width="295" height="12" font="4">sium replacement in clinical practice: a contemporary review by </text>
<text top="116" left="512" width="294" height="12" font="4">the National Council on Potassium in Clinical Practice. Arch Intern </text>
<text top="129" left="512" width="116" height="12" font="4">Med. 2000;160:2429–36.</text>
<text top="143" left="452" width="351" height="12" font="4"> S5.1.5.2-47. Macdonald JE, Struthers AD. What is the optimal serum potas-</text>
<text top="156" left="512" width="299" height="12" font="4">sium level in cardiovascular patients? J Am Coll Cardiol. </text>
<text top="170" left="512" width="78" height="12" font="4">2004;43:155–61.</text>
<text top="183" left="452" width="354" height="12" font="4"> S5.1.5.2-48. Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and </text>
<text top="197" left="512" width="291" height="12" font="4">mortality in acute myocardial infarction. JAMA. 2012;307:157–64.</text>
<text top="210" left="452" width="356" height="12" font="4"> S5.1.5.2-49. Leaf A, Kang JX, Xiao YF, et al. Clinical prevention of sudden </text>
<text top="224" left="512" width="291" height="12" font="4">cardiac death by n-3 polyunsaturated fatty acids and mecha-</text>
<text top="237" left="512" width="296" height="12" font="4">nism of prevention of arrhythmias by n-3 fish oils. Circulation. </text>
<text top="251" left="512" width="90" height="12" font="4">2003;107:2646–52.</text>
<text top="264" left="452" width="9" height="12" font="4"> </text>
<text top="264" left="452" width="360" height="12" font="4">S5.1.5.2-50. Mozaffarian D, Rimm EB. Fish intake, contaminants, and </text>
<text top="278" left="512" width="297" height="12" font="4">human health: evaluating the risks and the benefits. JAMA. </text>
<text top="292" left="512" width="90" height="12" font="4">2006;296:1885–99.</text>
<text top="305" left="452" width="357" height="12" font="4"> S5.1.5.2-51. Marchioli R, Barzi F, Bomba E, et al. Early protection against </text>
<text top="319" left="512" width="291" height="12" font="4">sudden death by n-3 polyunsaturated fatty acids after myocar-</text>
<text top="332" left="512" width="295" height="12" font="4">dial infarction: time-course analysis of the results of the Gruppo </text>
<text top="346" left="512" width="295" height="12" font="4">Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico </text>
<text top="359" left="512" width="241" height="12" font="4">(GISSI)-Prevenzione. Circulation. 2002;105:1897–903.</text>
<text top="373" left="452" width="351" height="12" font="4"> S5.1.5.2-52. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and car-</text>
<text top="386" left="512" width="297" height="12" font="4">diovascular events after myocardial infarction. N Engl J Med. </text>
<text top="400" left="512" width="90" height="12" font="4">2010;363:2015–26.</text>
<text top="413" left="452" width="351" height="12" font="4"> S5.1.5.2-53.  Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, pla-</text>
<text top="427" left="512" width="294" height="12" font="4">cebo-controlled trial to test the effect of highly purified omega-3 </text>
<text top="440" left="512" width="296" height="12" font="4">fatty acids on top of modern guideline-adjusted therapy after </text>
<text top="454" left="512" width="237" height="12" font="4">myocardial infarction. Circulation. 2010;122:2152–9.</text>
<text top="468" left="452" width="354" height="12" font="4"> S5.1.5.2-54. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of </text>
<text top="481" left="512" width="294" height="12" font="4">dietary advice to men with angina: results of a controlled trial. Eur </text>
<text top="495" left="512" width="136" height="12" font="4">J Clin Nutr. 2003;57:193–200.</text>
<text top="508" left="452" width="354" height="12" font="4"> S5.1.5.2-55.  Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins </text>
<text top="522" left="512" width="294" height="12" font="4">and omega 3 fatty acids on cardiovascular diseases: a randomised </text>
<text top="535" left="512" width="210" height="12" font="4">placebo controlled trial. BMJ. 2010;341:c6273.</text>
<text top="549" left="452" width="351" height="12" font="4"> S5.1.5.2-56.  Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and car-</text>
<text top="562" left="512" width="294" height="12" font="4">diovascular outcomes in patients with dysglycemia. N Engl J Med. </text>
<text top="576" left="512" width="84" height="12" font="4">2012;367:309–18.</text>
<text top="589" left="452" width="354" height="12" font="4"> S5.1.5.2-57.  LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary </text>
<text top="603" left="512" width="295" height="12" font="4">disease: a meta-analysis of randomized controlled trials. JAMA. </text>
<text top="616" left="512" width="84" height="12" font="4">1999;282:2340–6.</text>
<text top="630" left="452" width="353" height="12" font="4"> S5.1.5.2-58.  Buber J, Goldenberg I, Moss AJ, et al. Reduction in life-threatening </text>
<text top="643" left="512" width="291" height="12" font="4">ventricular tachyarrhythmias in statin-treated patients with non-</text>
<text top="657" left="512" width="294" height="12" font="4">ischemic cardiomyopathy enrolled in the MADIT-CRT (Multicenter </text>
<text top="671" left="512" width="304" height="12" font="4">Automatic Defibrillator Implantation Trial with Cardiac </text>
<text top="684" left="512" width="290" height="12" font="4">Resynchronization Therapy). J Am Coll Cardiol. 2012;60:749–55.</text>
<text top="698" left="452" width="8" height="12" font="4"> </text>
<text top="698" left="452" width="351" height="12" font="4">S5.1.5.2-.  59 Investigators in TAvIDAA comparison of antiarrhythmic-</text>
<text top="711" left="512" width="291" height="12" font="4">drug therapy with implantable defibrillators in patients resus-</text>
<text top="725" left="512" width="296" height="12" font="4">citated from near-fatal ventricular arrhythmias. N Engl J Med. </text>
<text top="738" left="512" width="90" height="12" font="4">1997;337:1576–83.</text>
<text top="752" left="452" width="355" height="12" font="4"> S5.1.5.2-60. Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs </text>
<text top="765" left="512" width="296" height="12" font="4">also antiarrhythmic drugs? An analysis of the Antiarrhythmics </text>
<text top="779" left="512" width="295" height="12" font="4">versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. </text>
<text top="792" left="512" width="67" height="12" font="4">2003;42:81–7.</text>
<text top="806" left="452" width="354" height="12" font="4"> S5.1.5.2-61.  Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated </text>
<text top="819" left="512" width="291" height="12" font="4">with reduced mortality in both ischemic and nonischemic cardio-</text>
<text top="833" left="512" width="291" height="12" font="4">myopathy and in patients with implantable defibrillators: mortal-</text>
<text top="846" left="512" width="294" height="12" font="4">ity data and mechanistic insights from the Sudden Cardiac Death </text>
<text top="860" left="512" width="281" height="12" font="4">in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573–8.</text>
<text top="874" left="452" width="7" height="12" font="4"> </text>
<text top="874" left="452" width="358" height="12" font="4">S5.1.5.2-62. Goldberger JJ, Subacius H, Schaechter A, et al. Effects of </text>
<text top="887" left="512" width="297" height="12" font="4">statin therapy on arrhythmic events and survival in patients </text>
<text top="901" left="512" width="297" height="12" font="4">with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. </text>
<text top="914" left="512" width="84" height="12" font="4">2006;48:1228–33.</text>
<text top="928" left="452" width="353" height="12" font="4"> S5.1.5.2-63.  Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients </text>
<text top="941" left="512" width="272" height="12" font="4">with systolic heart failure. N Engl J Med. 2007;357:2248–61.</text>
<text top="955" left="452" width="351" height="12" font="4"> S5.1.5.2-64. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvas-</text>
<text top="968" left="512" width="296" height="12" font="4">tatin in patients with chronic heart failure (the GISSI-HF trial): </text>
<text top="982" left="512" width="298" height="12" font="4">a randomised, double-blind, placebo-controlled trial. Lancet. </text>
<text top="995" left="512" width="84" height="12" font="4">2008;372:1231–9.</text>
<text top="1034" left="452" width="347" height="21" font="18"><b>5.2. Preventing SCD With HF Medications</b></text>
<text top="1061" left="476" width="333" height="12" font="4"> S5.2-1. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA </text>
<text top="1075" left="512" width="293" height="12" font="4">focused update on new pharmacological therapy for heart failure: </text>
<text top="1088" left="512" width="294" height="12" font="4">an update of the 2013 ACCF/AHA guideline for the management </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e363</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="134" width="291" height="12" font="4">of heart failure: a report of the American College of Cardiology/</text>
<text top="102" left="134" width="299" height="12" font="4">American Heart Association Task Force on Clinical Practice </text>
<text top="116" left="134" width="294" height="12" font="4">Guidelines and the Heart Failure Society of America. Circulation. </text>
<text top="129" left="134" width="89" height="12" font="4">2016;134:e282–93.</text>
<text top="143" left="74" width="47" height="12" font="4">  S5.2-2. </text>
<text top="143" left="134" width="291" height="12" font="4">Committees for Cardiac insufficiency Bisoprolol Study II. The car-</text>
<text top="156" left="134" width="294" height="12" font="4">diac insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. </text>
<text top="170" left="134" width="107" height="12" font="4">Lancet. 1999;353:9–13.</text>
<text top="184" left="74" width="47" height="12" font="4">  S5.2-3. </text>
<text top="184" left="134" width="295" height="12" font="4">Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril </text>
<text top="197" left="134" width="295" height="12" font="4">with hydralazine-isosorbide dinitrate in the treatment of chronic </text>
<text top="211" left="134" width="259" height="12" font="4">congestive heart failure. N Engl J Med. 1991;325:303–10.</text>
<text top="224" left="74" width="355" height="12" font="4">  S5.2-4.  Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol </text>
<text top="238" left="134" width="291" height="12" font="4">on morbidity and mortality in patients with chronic heart fail-</text>
<text top="252" left="134" width="296" height="12" font="4">ure. US Carvedilol Heart Failure Study Group. N Engl J Med. </text>
<text top="265" left="134" width="90" height="12" font="4">1996;334:1349–55.</text>
<text top="279" left="74" width="46" height="12" font="4">  S5.2-5. </text>
<text top="279" left="134" width="291" height="12" font="4">Dargie HJ. Effect of carvedilol on outcome after myocardial infarc-</text>
<text top="293" left="134" width="294" height="12" font="4">tion in patients with left-ventricular dysfunction: the CAPRICORN </text>
<text top="306" left="134" width="203" height="12" font="4">randomised trial. Lancet. 2001;357:1385–90.</text>
<text top="320" left="74" width="48" height="12" font="4">  S5.2-6. </text>
<text top="320" left="134" width="291" height="12" font="4">Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldo-</text>
<text top="333" left="134" width="294" height="12" font="4">sterone blocker, in patients with left ventricular dysfunction after </text>
<text top="347" left="134" width="254" height="12" font="4">myocardial infarction. N Engl J Med. 2003;348:1309–21.</text>
<text top="361" left="74" width="46" height="12" font="4">  S5.2-7. </text>
<text top="361" left="134" width="293" height="12" font="4">Al Chekakie MO. Traditional heart failure medications and sudden </text>
<text top="374" left="134" width="294" height="12" font="4">cardiac death prevention: a review. J Cardiovasc Pharmacol Ther. </text>
<text top="388" left="134" width="78" height="12" font="4">2013;18:412–26.</text>
<text top="402" left="74" width="351" height="12" font="4">  S5.2-8.  Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, cap-</text>
<text top="415" left="134" width="297" height="12" font="4">topril, or both in myocardial infarction complicated by heart </text>
<text top="429" left="134" width="297" height="12" font="4">failure, left ventricular dysfunction, or both. N Engl J Med. </text>
<text top="442" left="134" width="96" height="12" font="4">2003;349:1893–906.</text>
<text top="456" left="74" width="358" height="12" font="4">  S5.2-9.  Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of </text>
<text top="470" left="134" width="291" height="12" font="4">controlled-release metoprolol on total mortality, hospital-</text>
<text top="483" left="134" width="297" height="12" font="4">izations, and well-being in patients with heart failure: the </text>
<text top="497" left="134" width="291" height="12" font="4">Metoprolol CR/XL Randomized Intervention Trial in conges-</text>
<text top="510" left="134" width="296" height="12" font="4">tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. </text>
<text top="524" left="134" width="98" height="12" font="4">2000;283:1295–302.</text>
<text top="538" left="74" width="47" height="12" font="4">  S5.2-10. </text>
<text top="538" left="134" width="291" height="12" font="4">McMurray J.J.V, Östergren J, Swedberg K, et al. Effects of cande-</text>
<text top="551" left="134" width="291" height="12" font="4">sartan in patients with chronic heart failure and reduced left-ven-</text>
<text top="565" left="134" width="297" height="12" font="4">tricular systolic function taking angiotensin-converting-enzyme </text>
<text top="579" left="134" width="279" height="12" font="4">inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–71.</text>
<text top="592" left="74" width="351" height="12" font="4"> S5.2-11.  Cohn JN, Tognoni G. A randomized trial of the angiotensin-</text>
<text top="606" left="134" width="294" height="12" font="4">receptor blocker valsartan in chronic heart failure. N Engl J Med. </text>
<text top="619" left="134" width="90" height="12" font="4">2001;345:1667–75.</text>
<text top="633" left="74" width="47" height="12" font="4">  S5.2-12. </text>
<text top="633" left="134" width="295" height="12" font="4">Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone </text>
<text top="647" left="134" width="295" height="12" font="4">on morbidity and mortality in patients with severe heart failure. </text>
<text top="660" left="134" width="295" height="12" font="4">Randomized Aldactone Evaluation Study Investigators. N Engl J </text>
<text top="674" left="134" width="110" height="12" font="4">Med. 1999;341:709–17.</text>
<text top="688" left="74" width="356" height="12" font="4"> S5.2-13.  Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients </text>
<text top="701" left="134" width="296" height="12" font="4">with systolic heart failure and mild symptoms. N Engl J Med. </text>
<text top="715" left="134" width="78" height="12" font="4">2011;364:11–21.</text>
<text top="728" left="74" width="47" height="12" font="4">  S5.2-14. </text>
<text top="728" left="134" width="291" height="12" font="4">Desai AS, McMurray JJ, Packer M, et al. Effect of the angioten-</text>
<text top="742" left="134" width="291" height="12" font="4">sin-receptor-neprilysin inhibitor LCZ696 compared with enala-</text>
<text top="756" left="134" width="297" height="12" font="4">pril on mode of death in heart failure patients. Eur Heart J. </text>
<text top="769" left="134" width="78" height="12" font="4">2015;36:1990–7.</text>
<text top="812" left="74" width="186" height="21" font="18"><b>5.4. Catheter Ablation</b></text>
<text top="839" left="74" width="47" height="12" font="4"> S5.4.3-1. </text>
<text top="839" left="134" width="294" height="12" font="4">Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation </text>
<text top="852" left="134" width="294" height="12" font="4">of ventricular tachycardia after repair of congenital heart disease: </text>
<text top="866" left="134" width="291" height="12" font="4">electroanatomic identification of the critical right ventricular isth-</text>
<text top="880" left="134" width="168" height="12" font="4">mus. Circulation. 2007;116:2241–52.</text>
<text top="893" left="74" width="48" height="12" font="4"> S5.4.3-2. </text>
<text top="893" left="134" width="295" height="12" font="4">Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC </text>
<text top="907" left="134" width="298" height="12" font="4">guidelines for the management of patients with ventricular </text>
<text top="920" left="134" width="296" height="12" font="4">arrhythmias and the prevention of sudden cardiac death: the </text>
<text top="934" left="134" width="297" height="12" font="4">Task Force for the Management of Patients with Ventricular </text>
<text top="948" left="134" width="299" height="12" font="4">Arrhythmias and the Prevention of Sudden Cardiac Death </text>
<text top="961" left="134" width="298" height="12" font="4">of the European Society of Cardiology (ESC). Eur Heart J. </text>
<text top="975" left="134" width="90" height="12" font="4">2015;36:2793–867.</text>
<text top="989" left="74" width="46" height="12" font="4"> S5.4.3-3. </text>
<text top="989" left="134" width="294" height="12" font="4">Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS </text>
<text top="1002" left="134" width="294" height="12" font="4">expert consensus on catheter ablation of ventricular arrhythmias: </text>
<text top="1016" left="134" width="297" height="12" font="4">developed in a partnership with the European Heart Rhythm </text>
<text top="1029" left="134" width="294" height="12" font="4">Association (EHRA), a Registered Branch of the European Society </text>
<text top="1043" left="134" width="297" height="12" font="4">of Cardiology (ESC), and the Heart Rhythm Society (HRS); in </text>
<text top="1057" left="134" width="296" height="12" font="4">collaboration with the American College of Cardiology (ACC) </text>
<text top="1070" left="134" width="298" height="12" font="4">and the American Heart Association (AHA). Heart Rhythm. </text>
<text top="1084" left="134" width="78" height="12" font="4">2009;6:886–933.</text>
<text top="87" left="452" width="296" height="21" font="18"><b>5.5. Surgery and Revascularization </b></text>
<text top="108" left="452" width="313" height="21" font="18"><b>Procedures in Patients With Ischemic </b></text>
<text top="129" left="452" width="116" height="21" font="18"><b>Heart Disease</b></text>
<text top="156" left="458" width="345" height="12" font="4">  S5.5-1.  Cook JR, Rizo-Patron C, Curtis AB, et al. Effect of surgical revascu-</text>
<text top="169" left="503" width="304" height="12" font="4">larization in patients with coronary artery disease and ventricular </text>
<text top="183" left="503" width="303" height="12" font="4">tachycardia or fibrillation in the Antiarrhythmics Versus Implantable </text>
<text top="196" left="503" width="264" height="12" font="4">Defibrillators (AVID) Registry. Am Heart J. 2002;143:821–6.</text>
<text top="210" left="458" width="351" height="12" font="4"> S5.5-2.  Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass </text>
<text top="223" left="503" width="304" height="12" font="4">surgery in patients with ischemic cardiomyopathy. N Engl J Med. </text>
<text top="237" left="503" width="90" height="12" font="4">2016;374:1511–20.</text>
<text top="251" left="458" width="345" height="12" font="4">  S5.5-3.  Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coro-</text>
<text top="264" left="503" width="300" height="12" font="4">nary bypass surgery on subsequent outcome of patients resus-</text>
<text top="278" left="503" width="306" height="12" font="4">citated from out of hospital cardiac arrest. J Am Coll Cardiol. </text>
<text top="291" left="503" width="78" height="12" font="4">1992;19:1435–9.</text>
<text top="305" left="458" width="348" height="12" font="4">  S5.5-4.  Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac </text>
<text top="318" left="503" width="303" height="12" font="4">arrest patients without ST-segment elevation pattern: insights from </text>
<text top="332" left="503" width="284" height="12" font="4">the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011–8.</text>
<text top="346" left="458" width="349" height="12" font="4">  S5.5-5.  Ngaage DL, Cale AR, Cowen ME, et al. Early and late survival after </text>
<text top="359" left="503" width="300" height="12" font="4">surgical revascularization for ischemic ventricular fibrillation/tachy-</text>
<text top="373" left="503" width="198" height="12" font="4">cardia. Ann Thorac Surg. 2008;85:1278–81.</text>
<text top="386" left="458" width="349" height="12" font="4">  S5.5-6.  Milojevic M, Head SJ, Parasca CA, et al. Causes of death following </text>
<text top="400" left="503" width="304" height="12" font="4">PCI versus CABG in complex CAD: 5-year follow-up of SYNTAX. J </text>
<text top="413" left="503" width="149" height="12" font="4">Am Coll Cardiol. 2016;67:42–55.</text>
<text top="427" left="458" width="350" height="12" font="4"> S5.5-7.  Carson P, Wertheimer J, Miller A, et al. The STICH trial (Surgical </text>
<text top="441" left="503" width="303" height="12" font="4">Treatment for Ischemic Heart Failure): mode-of-death results. JACC </text>
<text top="454" left="503" width="114" height="12" font="4">Heart Fail. 2013;1:400–8.</text>
<text top="468" left="458" width="348" height="12" font="4">  S5.5-8.  Davis JA, Cecchin F, Jones TK, et al. Major coronary artery anomalies </text>
<text top="481" left="503" width="304" height="12" font="4">in a pediatric population: incidence and clinical importance. J Am </text>
<text top="495" left="503" width="131" height="12" font="4">Coll Cardiol. 2001;37:593–7.</text>
<text top="508" left="458" width="350" height="12" font="4">  S5.5-9.  Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of </text>
<text top="522" left="503" width="304" height="12" font="4">sudden cardiac death among children and young adults. N Engl J </text>
<text top="535" left="503" width="116" height="12" font="4">Med. 2016;374:2441–52.</text>
<text top="549" left="452" width="355" height="12" font="4">  S5.5-10.  Smallman DP, Webber BJ, Mazuchowski EL, et al. Sudden cardiac </text>
<text top="563" left="503" width="300" height="12" font="4">death associated with physical exertion in the US military, 2005–</text>
<text top="576" left="503" width="177" height="12" font="4">2010. BJ Sports Med. 2016;50:118–23.</text>
<text top="590" left="452" width="351" height="12" font="4">  S5.5-11.  Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young com-</text>
<text top="603" left="503" width="306" height="12" font="4">petitive athletes: analysis of 1866 deaths in the United States, </text>
<text top="617" left="503" width="202" height="12" font="4">1980–2006. Circulation. 2009;119:1085–92.</text>
<text top="630" left="452" width="356" height="12" font="4"> S5.5-12.  Krasuski RA, Magyar D, Hart S, et al. Long-term outcome and </text>
<text top="644" left="503" width="303" height="12" font="4">impact of surgery on adults with coronary arteries originating from </text>
<text top="658" left="503" width="265" height="12" font="4">the opposite coronary cusp. Circulation. 2011;123:154–62.</text>
<text top="671" left="452" width="356" height="12" font="4"> S5.5-13.  Layser RB, Savage MP, Halpern EJ. Anomalous coronary arteries: </text>
<text top="685" left="503" width="303" height="12" font="4">analysis of clinical outcome based upon arterial course and surgical </text>
<text top="698" left="503" width="300" height="12" font="4">intervention in an adult population. Acad Radiol. 2016;23:1015–23.</text>
<text top="712" left="452" width="351" height="12" font="4"> S5.5-14.  Taylor AJ, Rogan KM, Virmani R. Sudden cardiac death associ-</text>
<text top="725" left="503" width="303" height="12" font="4">ated with isolated congenital coronary artery anomalies. J Am Coll </text>
<text top="739" left="503" width="110" height="12" font="4">Cardiol. 1992;20:640–7.</text>
<text top="764" left="452" width="305" height="18" font="24"><i><b>5.5.1. Surgery for Arrhythmia Management</b></i></text>
<text top="786" left="452" width="353" height="12" font="4"> S5.5.1-1.  Anter E, Hutchinson MD, Deo R, et al. Surgical ablation of refractory </text>
<text top="799" left="503" width="300" height="12" font="4">ventricular tachycardia in patients with nonischemic cardiomyopa-</text>
<text top="813" left="503" width="230" height="12" font="4">thy. Circ Arrhythm Electrophysiol. 2011;4:494–500.</text>
<text top="826" left="452" width="354" height="12" font="4"> S5.5.1-2.  Bhavani SS, Tchou P, Saliba W, et al. Surgical options for refractory </text>
<text top="840" left="503" width="235" height="12" font="4">ventricular tachycardia. J Card Surg. 2007;22:533–4.</text>
<text top="853" left="452" width="351" height="12" font="4"> S5.5.1-3.  Choi EK, Nagashima K, Lin KY, et al. Surgical cryoablation for ven-</text>
<text top="867" left="503" width="305" height="12" font="4">tricular tachyarrhythmia arising from the left ventricular outflow </text>
<text top="880" left="503" width="209" height="12" font="4">tract region. Heart Rhythm. 2015;12:1128–36.</text>
<text top="894" left="452" width="356" height="12" font="4"> S5.5.1-4.  Kumar S, Barbhaiya CR, Sobieszczyk P, et al. Role of alternative </text>
<text top="908" left="503" width="307" height="12" font="4">interventional procedures when endo- and epicardial catheter </text>
<text top="921" left="503" width="305" height="12" font="4">ablation attempts for ventricular arrhythmias fail. Circ Arrhythm </text>
<text top="935" left="503" width="139" height="12" font="4">Electrophysiol. 2015;8:606–15.</text>
<text top="948" left="452" width="351" height="12" font="4"> S5.5.1-5.  Mulloy DP, Bhamidipati CM, Stone ML, et al. Cryoablation dur-</text>
<text top="962" left="503" width="300" height="12" font="4">ing left ventricular assist device implantation reduces postop-</text>
<text top="975" left="503" width="306" height="12" font="4">erative ventricular tachyarrhythmias. J Thorac Cardiovasc Surg. </text>
<text top="989" left="503" width="90" height="12" font="4">2013;145:1207–13.</text>
<text top="1003" left="452" width="355" height="12" font="4"> S5.5.1-6.  Patel M, Rojas F, Shabari FR, et al. Safety and feasibility of open </text>
<text top="1016" left="503" width="305" height="12" font="4">chest epicardial mapping and ablation of ventricular tachycardia </text>
<text top="1030" left="503" width="305" height="12" font="4">during the period of left ventricular assist device implantation. J </text>
<text top="1043" left="503" width="196" height="12" font="4">Cardiovasc Electrophysiol. 2016;27:95–101.</text>
<text top="1057" left="452" width="351" height="12" font="4"> S5.5.1-7.  Sartipy U, Albage A, Straat E, et al. Surgery for ventricular tachycar-</text>
<text top="1070" left="503" width="303" height="12" font="4">dia in patients undergoing left ventricular reconstruction by the Dor </text>
<text top="1084" left="503" width="204" height="12" font="4">procedure. Ann Thorac Surg. 2006;81:65–71.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e364</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="232" height="21" font="18"><b>5.6. Autonomic Modulation</b></text>
<text top="114" left="74" width="351" height="12" font="4">  S5.6-1.  Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of ateno-</text>
<text top="127" left="125" width="304" height="12" font="4">lol on symptomatic ventricular arrhythmia without structural heart </text>
<text top="141" left="125" width="307" height="12" font="4">disease: a randomized placebo-controlled study. Am Heart J. </text>
<text top="154" left="125" width="67" height="12" font="4">2002;144:e10.</text>
<text top="168" left="74" width="351" height="12" font="4">  S5.6-2.  Vaseghi M, Barwad P, Malavassi Corrales FJ, et al. Cardiac sympa-</text>
<text top="182" left="125" width="303" height="12" font="4">thetic denervation for refractory ventricular arrhythmias. J Am Coll </text>
<text top="195" left="125" width="122" height="12" font="4">Cardiol. 2017;69:3070–80.</text>
<text top="209" left="74" width="351" height="12" font="4">  S5.6-3.  Vaseghi M, Gima J, Kanaan C, et al. Cardiac sympathetic denerva-</text>
<text top="222" left="125" width="300" height="12" font="4">tion in patients with refractory ventricular arrhythmias or electri-</text>
<text top="236" left="125" width="305" height="12" font="4">cal storm: intermediate and long-term follow-up. Heart Rhythm. </text>
<text top="250" left="125" width="72" height="12" font="4">2014;11:360–6.</text>
<text top="263" left="74" width="351" height="12" font="4">  S5.6-4.  Schwartz PJ, Motolese M, Pollavini G. Prevention of sudden car-</text>
<text top="277" left="125" width="304" height="12" font="4">diac death after a first myocardial infarction by pharmacologic or </text>
<text top="290" left="125" width="305" height="12" font="4">surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. </text>
<text top="304" left="125" width="61" height="12" font="4">1992;3:2–16.</text>
<text top="318" left="74" width="351" height="12" font="4">  S5.6-5.  Shen MJ, Zipes DP. Role of the autonomic nervous system in modu-</text>
<text top="331" left="125" width="252" height="12" font="4">lating cardiac arrhythmias. Circ Res. 2014;114:1004–21.</text>
<text top="345" left="74" width="351" height="12" font="4">  S5.6-6.  Ajijola OA, Lellouche N, Bourke T, et al. Bilateral cardiac sympa-</text>
<text top="358" left="125" width="304" height="12" font="4">thetic denervation for the management of electrical storm. J Am </text>
<text top="372" left="125" width="125" height="12" font="4">Coll Cardiol. 2012;59:91–2.</text>
<text top="421" left="74" width="270" height="23" font="15"><b>6. ACUTE MANAGEMENT OF  </b></text>
<text top="443" left="74" width="108" height="23" font="15"><b>SPECIFIC VA</b></text>
<text top="471" left="74" width="4" height="12" font="4"> </text>
<text top="471" left="94" width="335" height="12" font="4">S6-1.  Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced </text>
<text top="485" left="125" width="300" height="12" font="4">cardiovascular life support: 2015 American Heart Association guide-</text>
<text top="499" left="125" width="300" height="12" font="4">lines update for cardiopulmonary resuscitation and emergency car-</text>
<text top="512" left="125" width="256" height="12" font="4">diovascular care. Circulation. 2015;132 suppl 2:S444–64.</text>
<text top="526" left="74" width="4" height="12" font="4"> </text>
<text top="526" left="94" width="335" height="12" font="4">S6-2.  Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in </text>
<text top="540" left="125" width="283" height="12" font="4">out-of-hospital cardiac arrest. N Engl J Med. 2004;351:647–56.</text>
<text top="553" left="74" width="3" height="12" font="4"> </text>
<text top="553" left="94" width="331" height="12" font="4">S6-3.  Sasson C, Rogers MA, Dahl J, et al. Predictors of survival from out-</text>
<text top="567" left="125" width="305" height="12" font="4">of-hospital cardiac arrest: a systematic review and meta-analysis. </text>
<text top="580" left="125" width="213" height="12" font="4">Circ Cardiovasc Qual Outcomes. 2010;3:63–81.</text>
<text top="594" left="74" width="3" height="12" font="4"> </text>
<text top="594" left="94" width="334" height="12" font="4">S6-4.  Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with </text>
<text top="608" left="125" width="304" height="12" font="4">lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. </text>
<text top="621" left="125" width="84" height="12" font="4">2002;346:884–90.</text>
<text top="635" left="74" width="5" height="12" font="4"> </text>
<text top="635" left="94" width="336" height="12" font="4">S6-5.  Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, </text>
<text top="648" left="125" width="304" height="12" font="4">or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016; </text>
<text top="662" left="125" width="43" height="12" font="4">1711–22.</text>
<text top="676" left="74" width="3" height="12" font="4"> </text>
<text top="676" left="94" width="331" height="12" font="4">S6-6.  Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resusci-</text>
<text top="689" left="125" width="300" height="12" font="4">tation after out-of-hospital cardiac arrest due to ventricular fibrilla-</text>
<text top="703" left="125" width="166" height="12" font="4">tion. N Engl J Med. 1999;341:871–8.</text>
<text top="716" left="74" width="5" height="12" font="4"> </text>
<text top="716" left="94" width="335" height="12" font="4">S6-7.  Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary </text>
<text top="730" left="125" width="304" height="12" font="4">angiography in survivors of out-of-hospital cardiac arrest. N Engl J </text>
<text top="744" left="125" width="116" height="12" font="4">Med. 1997;336:1629–33.</text>
<text top="757" left="74" width="3" height="12" font="4"> </text>
<text top="757" left="94" width="331" height="12" font="4">S6-8.  Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percuta-</text>
<text top="771" left="125" width="303" height="12" font="4">neous coronary intervention after out-of-hospital cardiac arrest due </text>
<text top="784" left="125" width="226" height="12" font="4">to ventricular fibrillation. Crit Care. 2011;15:R122.</text>
<text top="798" left="74" width="2" height="12" font="4"> </text>
<text top="798" left="94" width="331" height="12" font="4">S6-9.  Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coro-</text>
<text top="812" left="125" width="303" height="12" font="4">nary angiography on in-hospital outcome of unconscious survivors </text>
<text top="825" left="125" width="300" height="12" font="4">after out-of-hospital cardiac arrest. Am J Cardiol. 2012;110:1723–8.</text>
<text top="839" left="74" width="354" height="12" font="4">  S6-10.  Dumas F, Bougouin W, Geri G, et al. Emergency PCI in post-cardiac </text>
<text top="852" left="125" width="303" height="12" font="4">arrest patients without ST-segment elevation pattern: insights from </text>
<text top="866" left="125" width="284" height="12" font="4">the PROCAT II registry. JACC Cardiovasc Interv. 2016;9:1011–8.</text>
<text top="880" left="74" width="351" height="12" font="4">  S6-11.  Gorgels AP, van den Dool A, Hofs A, et al. Comparison of procain-</text>
<text top="893" left="125" width="300" height="12" font="4">amide and lidocaine in terminating sustained monomorphic ven-</text>
<text top="907" left="125" width="220" height="12" font="4">tricular tachycardia. Am J Cardiol. 1996;78:43–6.</text>
<text top="921" left="74" width="351" height="12" font="4">  S6-12.  Markel DT, Gold LS, Allen J, et al. Procainamide and survival in ven-</text>
<text top="934" left="125" width="303" height="12" font="4">tricular fibrillation out-of-hospital cardiac arrest. Acad Emerg Med. </text>
<text top="948" left="125" width="78" height="12" font="4">2010;17:617–23.</text>
<text top="961" left="74" width="351" height="12" font="4">  S6-13.  Ortiz M, Martin A, Arribas F, et al. Randomized comparison of intra-</text>
<text top="975" left="125" width="306" height="12" font="4">venous procainamide vs. intravenous amiodarone for the acute </text>
<text top="989" left="125" width="302" height="12" font="4">treatment of tolerated wide QRS tachycardia: the PROCAMIO study. </text>
<text top="1002" left="125" width="138" height="12" font="4">Eur Heart J. 2017;38:1329–35.</text>
<text top="1016" left="74" width="351" height="12" font="4">  S6-14.  Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hos-</text>
<text top="1029" left="125" width="303" height="12" font="4">pital ventricular fibrillation. Does it improve survival? Resuscitation. </text>
<text top="1043" left="125" width="84" height="12" font="4">1997;33:199–205.</text>
<text top="1057" left="74" width="355" height="12" font="4">  S6-15.  Kudenchuk PJ, Newell C, White L, et al. Prophylactic lidocaine for </text>
<text top="1070" left="125" width="304" height="12" font="4">post resuscitation care of patients with out-of-hospital ventricular </text>
<text top="1084" left="125" width="255" height="12" font="4">fibrillation cardiac arrest. Resuscitation. 2013;84:1512–8.</text>
<text top="88" left="452" width="354" height="12" font="4">  S6-16.  Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic </text>
<text top="102" left="503" width="303" height="12" font="4">drug therapy in acute myocardial infarction. An overview of results </text>
<text top="115" left="503" width="277" height="12" font="4">from randomized controlled trials. JAMA. 1993;270:1589–95.</text>
<text top="129" left="452" width="355" height="12" font="4">  S6-17.  Nademanee K, Taylor R, Bailey WE, et al. Treating electrical storm: </text>
<text top="143" left="503" width="304" height="12" font="4">sympathetic blockade versus advanced cardiac life support-guided </text>
<text top="156" left="503" width="171" height="12" font="4">therapy. Circulation. 2000;102:742–7.</text>
<text top="170" left="452" width="353" height="12" font="4">  S6-18.  Piccini JP, Hranitzky PM, Kilaru R, et al. Relation of mortality to failure </text>
<text top="184" left="503" width="300" height="12" font="4">to prescribe beta blockers acutely in patients with sustained ventric-</text>
<text top="197" left="503" width="300" height="12" font="4">ular tachycardia and ventricular fibrillation following acute myocar-</text>
<text top="211" left="503" width="304" height="12" font="4">dial infarction (from the VALsartan In Acute myocardial iNfarcTion </text>
<text top="225" left="503" width="264" height="12" font="4">trial [VALIANT] Registry). Am J Cardiol. 2008;102:1427–32.</text>
<text top="238" left="452" width="355" height="12" font="4">  S6-19.  Callaham M, Madsen CD, Barton CW, et al. A randomized clinical </text>
<text top="252" left="503" width="303" height="12" font="4">trial of high-dose epinephrine and norepinephrine vs standard-dose </text>
<text top="266" left="503" width="300" height="12" font="4">epinephrine in prehospital cardiac arrest. JAMA. 1992;268:2667–72.</text>
<text top="279" left="452" width="351" height="12" font="4">  S6-20.  Donnino MW, Salciccioli JD, Howell MD, et al. Time to adminis-</text>
<text top="293" left="503" width="303" height="12" font="4">tration of epinephrine and outcome after in-hospital cardiac arrest </text>
<text top="306" left="503" width="300" height="12" font="4">with non-shockable rhythms: retrospective analysis of large in-hos-</text>
<text top="320" left="503" width="186" height="12" font="4">pital data registry. BMJ. 2014;348:g3028.</text>
<text top="334" left="452" width="353" height="12" font="4">  S6-21.  Gueugniaud PY, Mols P, Goldstein P, et al. A comparison of repeated </text>
<text top="347" left="503" width="303" height="12" font="4">high doses and repeated standard doses of epinephrine for cardiac </text>
<text top="361" left="503" width="304" height="12" font="4">arrest outside the hospital. European Epinephrine Study Group. N </text>
<text top="375" left="503" width="151" height="12" font="4">Engl J Med. 1998;339:1595–601.</text>
<text top="388" left="452" width="354" height="12" font="4">  S6-22.  Hagihara A, Hasegawa M, Abe T, et al. Prehospital epinephrine use </text>
<text top="402" left="503" width="305" height="12" font="4">and survival among patients with out-of-hospital cardiac arrest. </text>
<text top="416" left="503" width="117" height="12" font="4">JAMA. 2012;307:1161–8.</text>
<text top="429" left="452" width="351" height="12" font="4">  S6-23.  Jacobs IG, Finn JC, Jelinek GA, et al. Effect of adrenaline on sur-</text>
<text top="443" left="503" width="305" height="12" font="4">vival in out-of-hospital cardiac arrest: a randomised double-blind </text>
<text top="456" left="503" width="257" height="12" font="4">placebo-controlled trial. Resuscitation. 2011;82:1138–43.</text>
<text top="470" left="452" width="351" height="12" font="4">  S6-24.  Koscik C, Pinawin A, McGovern H, et al. Rapid epinephrine admin-</text>
<text top="484" left="503" width="304" height="12" font="4">istration improves early outcomes in out-of-hospital cardiac arrest. </text>
<text top="497" left="503" width="142" height="12" font="4">Resuscitation. 2013;84:915–20.</text>
<text top="511" left="452" width="351" height="12" font="4">  S6-25.  Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of ligno-</text>
<text top="525" left="503" width="303" height="12" font="4">caine versus sotalol for acute termination of spontaneous sustained </text>
<text top="538" left="503" width="219" height="12" font="4">ventricular tachycardia. Lancet. 1994;344:18–23.</text>
<text top="552" left="452" width="351" height="12" font="4">  S6-26.  Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine ver-</text>
<text top="566" left="503" width="305" height="12" font="4">sus intravenous amiodarone (in a new aqueous formulation) for </text>
<text top="579" left="503" width="285" height="12" font="4">incessant ventricular tachycardia. Am J Cardiol. 2002;90:853–9.</text>
<text top="593" left="452" width="354" height="12" font="4">  S6-27.  Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate </text>
<text top="607" left="503" width="300" height="12" font="4">the efficacy of magnesium sulphate for refractory ventricular fibril-</text>
<text top="620" left="503" width="167" height="12" font="4">lation. Emerg Med J. 2002;19:57–62.</text>
<text top="634" left="452" width="356" height="12" font="4">  S6-28.  Thel MC, Armstrong AL, McNulty SE, et al. Randomised trial of </text>
<text top="647" left="503" width="305" height="12" font="4">magnesium in in-hospital cardiac arrest. Duke Internal Medicine </text>
<text top="661" left="503" width="173" height="12" font="4">Housestaff. Lancet. 1997;350:1272–6.</text>
<text top="675" left="452" width="356" height="12" font="4">  S6-29.  Elizari MV, Martinez JM, Belziti C, et al. Morbidity and mortality </text>
<text top="688" left="503" width="304" height="12" font="4">following early administration of amiodarone in acute myocardial </text>
<text top="702" left="503" width="307" height="12" font="4">infarction. GEMICA study investigators, GEMA Group, Buenos </text>
<text top="716" left="503" width="304" height="12" font="4">Aires, Argentina. Grupo de Estudios Multicentricos en Argentina. </text>
<text top="729" left="503" width="138" height="12" font="4">Eur Heart J. 2000;21:198–205.</text>
<text top="743" left="452" width="351" height="12" font="4">  S6-30.  Belhassen B, Horowitz LN. Use of intravenous verapamil for ven-</text>
<text top="757" left="503" width="231" height="12" font="4">tricular tachycardia. Am J Cardiol. 1984;54:1131–3.</text>
<text top="770" left="452" width="351" height="12" font="4">  S6-31.  Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intrave-</text>
<text top="784" left="503" width="303" height="12" font="4">nous verapamil for sustained ventricular tachycardia. Am J Cardiol. </text>
<text top="797" left="503" width="84" height="12" font="4">1987;59:1107–10.</text>
<text top="811" left="452" width="351" height="12" font="4">  S6-32.  Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide-</text>
<text top="825" left="503" width="303" height="12" font="4">lines for management of patients with ventricular arrhythmias and </text>
<text top="838" left="503" width="304" height="12" font="4">the prevention of sudden cardiac death: a report of the American </text>
<text top="852" left="503" width="308" height="12" font="4">College of Cardiology/American Heart Association Task Force </text>
<text top="866" left="503" width="305" height="12" font="4">and the European Society of Cardiology Committee for Practice </text>
<text top="879" left="503" width="202" height="12" font="4">Guidelines. Circulation. 2006;114:e385–484.</text>
<text top="893" left="452" width="351" height="12" font="4">  S6-33.  Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopul-</text>
<text top="907" left="503" width="300" height="12" font="4">monary resuscitation prior to defibrillation in patients with out-of-</text>
<text top="920" left="503" width="255" height="12" font="4">hospital ventricular fibrillation. JAMA. 1999;281:1182–8.</text>
<text top="934" left="452" width="355" height="12" font="4">  S6-34.  Cobb LA, Weaver WD, Fahrenbruch CE, et al. Community-based </text>
<text top="947" left="503" width="305" height="12" font="4">interventions for sudden cardiac death. Impact, limitations, and </text>
<text top="961" left="503" width="206" height="12" font="4">changes. Circulation. 1992;85 suppl:I98–I102.</text>
<text top="975" left="452" width="358" height="12" font="4">  S6-35. Weisfeldt ML, Becker LB, Resuscitation after cardiac arrest: a </text>
<text top="988" left="503" width="253" height="12" font="4">3-phase time-sensitive model. JAMA. 2002;288:3035–8.</text>
<text top="1002" left="452" width="354" height="12" font="4">  S6-36.  Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic </text>
<text top="1016" left="503" width="300" height="12" font="4">cardiopulmonary resuscitation to patients with out-of-hospital ven-</text>
<text top="1029" left="503" width="294" height="12" font="4">tricular fibrillation: a randomized trial. JAMA. 2003;289:1389–95.</text>
<text top="1043" left="452" width="351" height="12" font="4">  S6-37.  Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardio-</text>
<text top="1057" left="503" width="304" height="12" font="4">vascular life support: 2010 American Heart Association guidelines </text>
<text top="1070" left="503" width="305" height="12" font="4">for cardiopulmonary resuscitation and emergency cardiovascular </text>
<text top="1084" left="503" width="203" height="12" font="4">care. Circulation. 2010;122 suppl 2:S729–67.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e365</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="355" height="12" font="4">  S6-38.  Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the </text>
<text top="102" left="125" width="300" height="12" font="4">implantable cardioverter defibrillator secondary prevention tri-</text>
<text top="115" left="125" width="300" height="12" font="4">als. AVID, CASH and CIDS studies. Antiarrhythmics vs implant-</text>
<text top="129" left="125" width="304" height="12" font="4">able defibrillator study. Cardiac Arrest Study Hamburg. Canadian </text>
<text top="142" left="125" width="273" height="12" font="4">Implantable Defibrillator Study. Eur Heart J. 2000;21:2071–8.</text>
<text top="156" left="74" width="356" height="12" font="4">  S6-39.  Kern KB. Optimal treatment of patients surviving out-of-hospital </text>
<text top="170" left="125" width="267" height="12" font="4">cardiac arrest. JACC Cardiovasc Intervent. 2012;5:597–605.</text>
<text top="183" left="74" width="351" height="12" font="4">  S6-40.  Perkins GD, Jacobs IG, Nadkarni VM, et al. Cardiac arrest and car-</text>
<text top="197" left="125" width="303" height="12" font="4">diopulmonary resuscitation outcome reports: update of the Utstein </text>
<text top="210" left="125" width="304" height="12" font="4">Resuscitation Registry Templates for out-of-hospital cardiac arrest: </text>
<text top="224" left="125" width="304" height="12" font="4">a statement for healthcare professionals from a task force of the </text>
<text top="237" left="125" width="304" height="12" font="4">International Liaison Committee on Resuscitation (American Heart </text>
<text top="251" left="125" width="304" height="12" font="4">Association, European Resuscitation Council, Australian and New </text>
<text top="264" left="125" width="304" height="12" font="4">Zealand Council on Resuscitation, Heart and Stroke Foundation of </text>
<text top="278" left="125" width="303" height="12" font="4">Canada, InterAmerican Heart Foundation, Resuscitation Council of </text>
<text top="291" left="125" width="304" height="12" font="4">Southern Africa, Resuscitation Council of Asia); and the American </text>
<text top="305" left="125" width="304" height="12" font="4">Heart Association Emergency Cardiovascular Care Committee and </text>
<text top="318" left="125" width="304" height="12" font="4">the Council on Cardiopulmonary, Critical Care, Perioperative and </text>
<text top="332" left="125" width="214" height="12" font="4">Resuscitation. Circulation. 2015;132:1286–300.</text>
<text top="345" left="74" width="351" height="12" font="4">  S6-41.  Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualifica-</text>
<text top="359" left="125" width="303" height="12" font="4">tion recommendations for competitive athletes with cardiovascular </text>
<text top="373" left="125" width="303" height="12" font="4">abnormalities: Task Force 12: emergency action plans, resuscitation, </text>
<text top="386" left="125" width="300" height="12" font="4">cardiopulmonary resuscitation, and automated external defibrilla-</text>
<text top="400" left="125" width="302" height="12" font="4">tors: a scientific statement from the American Heart Association and </text>
<text top="413" left="125" width="285" height="12" font="4">American College of Cardiology. Circulation. 2015;132:e334–8.</text>
<text top="427" left="74" width="354" height="12" font="4">  S6-42.  Joglar JA, Page RL. Out-of-hospital cardiac arrest–are drugs ever the </text>
<text top="440" left="125" width="189" height="12" font="4">answer? N Engl J Med. 2016;374:1781–2.</text>
<text top="484" left="74" width="326" height="23" font="15"><b>7. ONGOING MANAGEMENT OF VA </b></text>
<text top="507" left="74" width="337" height="23" font="15"><b>AND SCD RISK RELATED TO SPECIFIC </b></text>
<text top="529" left="74" width="148" height="23" font="15"><b>DISEASE STATES</b></text>
<text top="558" left="74" width="227" height="21" font="18"><b>7.1. Ischemic Heart Disease</b></text>
<text top="585" left="74" width="330" height="18" font="24"><i><b>7.1.1. Secondary Prevention of SCD in Patients </b></i></text>
<text top="603" left="74" width="198" height="18" font="24"><i><b>With Ischemic Heart Disease</b></i></text>
<text top="624" left="74" width="351" height="12" font="4"> S7.1.1-1.  The AVID Investigators. A comparison of antiarrhythmic-drug ther-</text>
<text top="637" left="125" width="300" height="12" font="4">apy with implantable defibrillators in patients resuscitated from near-</text>
<text top="651" left="125" width="285" height="12" font="4">fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.</text>
<text top="664" left="74" width="356" height="12" font="4"> S7.1.1-2.  Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable </text>
<text top="678" left="125" width="300" height="12" font="4">defibrillator study (CIDS): a randomized trial of the implant-</text>
<text top="691" left="125" width="306" height="12" font="4">able cardioverter defibrillator against amiodarone. Circulation. </text>
<text top="705" left="125" width="96" height="12" font="4">2000;101:1297–302.</text>
<text top="718" left="74" width="357" height="12" font="4"> S7.1.1-3.  Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of </text>
<text top="732" left="125" width="300" height="12" font="4">the implantable cardioverter defibrillator secondary preven-</text>
<text top="745" left="125" width="306" height="12" font="4">tion trials. AVID, CASH and CIDS studies. Antiarrhythmics vs </text>
<text top="759" left="125" width="305" height="12" font="4">Implantable Defibrillator study. Cardiac Arrest Study Hamburg. </text>
<text top="772" left="125" width="303" height="12" font="4">Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21: </text>
<text top="786" left="125" width="37" height="12" font="4">2071–8.</text>
<text top="800" left="74" width="355" height="12" font="4"> S7.1.1-4.  Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of </text>
<text top="813" left="125" width="307" height="12" font="4">antiarrhythmic drug therapy with implantable defibrillators in </text>
<text top="827" left="125" width="304" height="12" font="4">patients resuscitated from cardiac arrest: the Cardiac Arrest Study </text>
<text top="840" left="125" width="221" height="12" font="4">Hamburg (CASH). Circulation. 2000;102:748–54.</text>
<text top="854" left="74" width="357" height="12" font="4"> S7.1.1-5. Raitt MH, Renfroe EG, Epstein AE, et al. ”Stable” ventricular </text>
<text top="867" left="125" width="300" height="12" font="4">tachycardia is not a benign rhythm: insights from the antiarrhyth-</text>
<text top="881" left="125" width="305" height="12" font="4">mics versus implantable defibrillators (AVID) registry. Circulation. </text>
<text top="894" left="125" width="84" height="12" font="4">2001;103:244–52.</text>
<text top="908" left="74" width="351" height="12" font="4"> S7.1.1-6.  Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratifi-</text>
<text top="921" left="125" width="300" height="12" font="4">cation on cost-effectiveness of the implantable cardioverter defibril-</text>
<text top="935" left="125" width="159" height="12" font="4">lator. Am Heart J. 2002;144:440–8.</text>
<text top="948" left="74" width="354" height="12" font="4"> S7.1.1-7.  Bass EB, Elson JJ, Fogoros RN, et al. Long-term prognosis of patients </text>
<text top="962" left="125" width="300" height="12" font="4">undergoing electrophysiologic studies for syncope of unknown ori-</text>
<text top="975" left="125" width="167" height="12" font="4">gin. Am J Cardiol. 1988;62:1186–91.</text>
<text top="989" left="74" width="351" height="12" font="4"> S7.1.1-8.  Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ven-</text>
<text top="1003" left="125" width="303" height="12" font="4">tricular arrhythmias due to transient or correctable causes: high risk </text>
<text top="1016" left="125" width="272" height="12" font="4">for death in follow-up. J Am Coll Cardiol. 2001;38:1718–24.</text>
<text top="1030" left="74" width="355" height="12" font="4"> S7.1.1-9.  Maury P, Baratto F, Zeppenfeld K, et al. Radio-frequency ablation </text>
<text top="1043" left="125" width="300" height="12" font="4">as primary management of well-tolerated sustained monomor-</text>
<text top="1057" left="125" width="300" height="12" font="4">phic ventricular tachycardia in patients with structural heart dis-</text>
<text top="1070" left="125" width="304" height="12" font="4">ease and left ventricular ejection fraction over 30%. Eur Heart J. </text>
<text top="1084" left="125" width="84" height="12" font="4">2014;35:1479–85.</text>
<text top="88" left="461" width="345" height="12" font="4"> S7.1.1-10.  Pauriah M, Cismaru G, Magnin-Poull I, et al. A stepwise approach </text>
<text top="102" left="512" width="295" height="12" font="4">to the management of postinfarct ventricular tachycardia using </text>
<text top="115" left="512" width="291" height="12" font="4">catheter ablation as the first-line treatment: a single-center expe-</text>
<text top="129" left="512" width="232" height="12" font="4">rience. Circ Arrhythm Electrophysiol. 2013;6:351–6.</text>
<text top="143" left="461" width="347" height="12" font="4"> S7.1.1-11. Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness </text>
<text top="156" left="512" width="291" height="12" font="4">of the implantable cardioverter-defibrillator versus antiar-</text>
<text top="170" left="512" width="291" height="12" font="4">rhythmic drugs in survivors of serious ventricular tachyar-</text>
<text top="183" left="512" width="296" height="12" font="4">rhythmias: results of the Antiarrhythmics Versus Implantable </text>
<text top="197" left="512" width="296" height="12" font="4">Defibrillators (AVID) economic analysis substudy. Circulation. </text>
<text top="211" left="512" width="93" height="12" font="4">2002;105:2049–57.</text>
<text top="224" left="461" width="7" height="12" font="4"> </text>
<text top="224" left="461" width="349" height="12" font="4">S7.1.1-12. O’Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness </text>
<text top="238" left="512" width="298" height="12" font="4">of the implantable cardioverter-defibrillator: results from the </text>
<text top="251" left="512" width="298" height="12" font="4">Canadian Implantable Defibrillator Study (CIDS). Circulation. </text>
<text top="265" left="512" width="90" height="12" font="4">2001;103:1416–21.</text>
<text top="279" left="461" width="347" height="12" font="4"> S7.1.1-13. Buxton M, Caine N, Chase D, et al. A review of the evidence </text>
<text top="292" left="512" width="295" height="12" font="4">on the effects and costs of implantable cardioverter defibrillator </text>
<text top="306" left="512" width="291" height="12" font="4">therapy in different patient groups, and modelling of cost-effec-</text>
<text top="319" left="512" width="294" height="12" font="4">tiveness and cost-utility for these groups in a UK context. Health </text>
<text top="333" left="512" width="190" height="12" font="4">Technol Assess. 2006;10:iii–iv, ix–xi, 1–164</text>
<text top="347" left="461" width="342" height="12" font="4"> S7.1.1-14.  Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost-</text>
<text top="360" left="512" width="291" height="12" font="4">effectiveness of implantable cardioverter defibrillators in the treat-</text>
<text top="374" left="512" width="296" height="12" font="4">ment of ventricular arrhythmias among medicare beneficiaries. </text>
<text top="387" left="512" width="135" height="12" font="4">Am J Med. 2002;112:519–27.</text>
<text top="401" left="461" width="342" height="12" font="4"> S7.1.1-15. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state-</text>
<text top="414" left="512" width="296" height="12" font="4">ment on cost/value methodology in clinical practice guidelines </text>
<text top="428" left="512" width="296" height="12" font="4">and performance measures: a report of the American College </text>
<text top="442" left="512" width="301" height="12" font="4">of Cardiology/American Heart Association Task Force on </text>
<text top="455" left="512" width="296" height="12" font="4">Performance Measures and Task Force on Practice Guidelines. </text>
<text top="469" left="512" width="144" height="12" font="4">Circulation. 2014;129:2329–45.</text>
<text top="499" left="452" width="218" height="18" font="24"><i><b>7.1.1.1. Coronary Artery Spasm</b></i></text>
<text top="520" left="458" width="349" height="12" font="4"> S7.1.1.1-1.  Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest </text>
<text top="534" left="512" width="296" height="12" font="4">due to isolated coronary artery spasm: long-term outcome of </text>
<text top="548" left="512" width="281" height="12" font="4">seven resuscitated patients. J Am Coll Cardiol. 1998;31:57–61.</text>
<text top="561" left="458" width="351" height="12" font="4"> S7.1.1.1-2. Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening </text>
<text top="575" left="512" width="291" height="12" font="4">ventricular arrhythmias in patients with silent myocardial isch-</text>
<text top="588" left="512" width="294" height="12" font="4">emia due to coronary-artery spasm. N Engl J Med. 1992;326: </text>
<text top="602" left="512" width="37" height="12" font="4">1451–5.</text>
<text top="616" left="458" width="351" height="12" font="4"> S7.1.1.1-3. Ahn JM, Lee KH, Yoo SY, et al. Prognosis of variant angina </text>
<text top="629" left="512" width="294" height="12" font="4">manifesting as aborted sudden cardiac death. J Am Coll Cardiol. </text>
<text top="643" left="512" width="78" height="12" font="4">2016;68:137–45.</text>
<text top="656" left="458" width="350" height="12" font="4"> S7.1.1.1-4. Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of </text>
<text top="670" left="512" width="291" height="12" font="4">an implantable cardioverter-defibrillator in patients with vasospas-</text>
<text top="684" left="512" width="295" height="12" font="4">tic angina and lethal ventricular arrhythmia. J Am Coll Cardiol. </text>
<text top="697" left="512" width="78" height="12" font="4">2012;60:908–13.</text>
<text top="711" left="458" width="349" height="12" font="4"> S7.1.1.1-5. Takagi Y, Yasuda S, Tsunoda R, et al. Clinical characteristics and </text>
<text top="724" left="512" width="291" height="12" font="4">long-term prognosis of vasospastic angina patients who sur-</text>
<text top="738" left="512" width="297" height="12" font="4">vived out-of-hospital cardiac arrest: multicenter registry study </text>
<text top="752" left="512" width="297" height="12" font="4">of the Japanese Coronary Spasm Association. Circ Arrhythm </text>
<text top="765" left="512" width="145" height="12" font="4">Electrophysiol. 2011;4:295–302.</text>
<text top="779" left="458" width="345" height="12" font="4"> S7.1.1.1-6. Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implant-</text>
<text top="792" left="512" width="293" height="12" font="4">able cardioverter-defibrillators in refractory variant angina pectoris </text>
<text top="806" left="512" width="291" height="12" font="4">complicated by ventricular fibrillation in patients with angiograph-</text>
<text top="820" left="512" width="280" height="12" font="4">ically normal coronary arteries. Am J Cardiol. 2002;89:1114–6.</text>
<text top="833" left="458" width="348" height="12" font="4"> S7.1.1.1-7.  JCS Joint Working Group. Guidelines for diagnosis and treatment </text>
<text top="847" left="512" width="294" height="12" font="4">of patients with vasospastic angina (coronary spastic angina) (JCS </text>
<text top="860" left="512" width="146" height="12" font="4">2008). Circ J. 2010;74:1745–62.</text>
<text top="874" left="458" width="350" height="12" font="4"> S7.1.1.1-8. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC </text>
<text top="887" left="512" width="295" height="12" font="4">guideline for the management of patients with non-ST-elevation </text>
<text top="901" left="512" width="295" height="12" font="4">acute coronary syndromes: a report of the American College of </text>
<text top="915" left="512" width="297" height="12" font="4">Cardiology/American Heart Association Task Force on Practice </text>
<text top="928" left="512" width="202" height="12" font="4">Guidelines. Circulation. 2014;130:e344–426.</text>
<text top="942" left="458" width="345" height="12" font="4"> S7.1.1.1-9.  Morikawa Y, Mizuno Y, Yasue H. Letter by Morikawa et al regard-</text>
<text top="955" left="512" width="294" height="12" font="4">ing article, “coronary artery spasm: a 2009 update.” Circulation. </text>
<text top="969" left="512" width="67" height="12" font="4">2010;121:e16.</text>
<text top="983" left="452" width="354" height="12" font="4"> S7.1.1.1-10.  Sasaki S, Tomita H, Shibutani S, et al. Usefulness of the wearable </text>
<text top="996" left="512" width="293" height="12" font="4">cardioverter-defibrillator in patients at high risk for sudden cardiac </text>
<text top="1010" left="512" width="139" height="12" font="4">death. Circ J. 2014;78:2987–9.</text>
<text top="1036" left="452" width="173" height="18" font="24"><i><b>7.1.1.2. Post CABG VT/VF</b></i></text>
<text top="1057" left="458" width="345" height="12" font="4"> S7.1.1.2-1. Ascione R, Reeves BC, Santo K, et al. Predictors of new malig-</text>
<text top="1070" left="512" width="293" height="12" font="4">nant ventricular arrhythmias after coronary surgery: a case-control </text>
<text top="1084" left="512" width="190" height="12" font="4">study. J Am Coll Cardiol. 2004;43:1630–8.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e366</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="12" font="4"> S7.1.1.2-2.  Saxon LA, Wiener I, Natterson PD, et al. Monomorphic versus poly-</text>
<text top="102" left="130" width="295" height="12" font="4">morphic ventricular tachycardia after coronary artery bypass graft-</text>
<text top="115" left="130" width="155" height="12" font="4">ing. Am J Cardiol. 1995;75:403–5.</text>
<text top="129" left="74" width="351" height="12" font="4"> S7.1.1.2-3.  Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventric-</text>
<text top="142" left="130" width="295" height="12" font="4">ular tachycardia after cardiac surgery. Circulation. 1999;99:903–8.</text>
<text top="156" left="74" width="356" height="12" font="4"> S7.1.1.2-4. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators </text>
<text top="169" left="130" width="296" height="12" font="4">in patients at high risk for ventricular arrhythmias after coronary-</text>
<text top="183" left="130" width="299" height="12" font="4">artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) </text>
<text top="196" left="130" width="265" height="12" font="4">Patch Trial Investigators. N Engl J Med. 1997;337:1569–75.</text>
<text top="210" left="74" width="7" height="12" font="4"> </text>
<text top="210" left="74" width="358" height="12" font="4">S7.1.1.2-5. Vakil K, Florea V, Koene R, et al. Effect of coronary artery </text>
<text top="223" left="130" width="296" height="12" font="4">bypass grafting on left ventricular ejection fraction in men eli-</text>
<text top="237" left="130" width="303" height="12" font="4">gible for implantable cardioverter-defibrillator. Am J Cardiol. </text>
<text top="250" left="130" width="84" height="12" font="4">2016;117:957–60.</text>
<text top="264" left="74" width="354" height="12" font="4"> S7.1.1.2-6.  Mittal S, Lomnitz DJ, Mirchandani S, et al. Prognostic significance </text>
<text top="277" left="130" width="300" height="12" font="4">of nonsustained ventricular tachycardia after revascularization. J </text>
<text top="291" left="130" width="190" height="12" font="4">Cardiovasc Electrophysiol. 2002;13:342–6.</text>
<text top="305" left="74" width="354" height="12" font="4"> S7.1.1.2-7.  Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after </text>
<text top="318" left="130" width="300" height="12" font="4">coronary artery revascularization in patients with left ventricular </text>
<text top="332" left="130" width="295" height="12" font="4">dysfunction and potential role of the wearable cardioverter defi-</text>
<text top="345" left="130" width="244" height="12" font="4">brillator. Circ Arrhythm Electrophysiol. 2013;6:117–28.</text>
<text top="371" left="74" width="349" height="18" font="24"><i><b>7.1.2. Primary Prevention of SCD in Patients With </b></i></text>
<text top="389" left="74" width="160" height="18" font="24"><i><b>Ischemic Heart Disease</b></i></text>
<text top="410" left="83" width="346" height="12" font="4"> S7.1.2-1.  Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable </text>
<text top="423" left="130" width="298" height="12" font="4">cardioverter-defibrillator for congestive heart failure. N Engl J Med. </text>
<text top="437" left="130" width="84" height="12" font="4">2005;352:225–37.</text>
<text top="450" left="83" width="347" height="12" font="4"> S7.1.2-2.  Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of </text>
<text top="464" left="130" width="300" height="12" font="4">a defibrillator in patients with myocardial infarction and reduced </text>
<text top="477" left="130" width="227" height="12" font="4">ejection fraction. N Engl J Med. 2002;346:877–83.</text>
<text top="491" left="83" width="348" height="12" font="4"> S7.1.2-3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with </text>
<text top="504" left="130" width="302" height="12" font="4">an implanted defibrillator in patients with coronary disease </text>
<text top="518" left="130" width="301" height="12" font="4">at high risk for ventricular arrhythmia. Multicenter Automatic </text>
<text top="531" left="130" width="303" height="12" font="4">Defibrillator Implantation Trial Investigators. N Engl J Med. </text>
<text top="545" left="130" width="92" height="12" font="4">1996;335:1933–40.</text>
<text top="558" left="83" width="343" height="12" font="4"> S7.1.2-4.  Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk strati-</text>
<text top="572" left="130" width="296" height="12" font="4">fication on cost-effectiveness of the implantable cardioverter defi-</text>
<text top="585" left="130" width="173" height="12" font="4">brillator. Am Heart J. 2002;144:440–8.</text>
<text top="599" left="83" width="343" height="12" font="4"> S7.1.2-5.  Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre-</text>
<text top="612" left="130" width="299" height="12" font="4">vention of sudden death in patients with coronary artery disease. </text>
<text top="626" left="130" width="300" height="12" font="4">Multicenter Unsustained Tachycardia Trial Investigators. N Engl J </text>
<text top="639" left="130" width="116" height="12" font="4">Med. 1999;341:1882–90.</text>
<text top="653" left="83" width="348" height="12" font="4"> S7.1.2-6. Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, et al. </text>
<text top="666" left="130" width="302" height="12" font="4">Implantable cardioverter defibrillator for primary prevention in </text>
<text top="680" left="130" width="296" height="12" font="4">patients with severe ventricular dysfunction awaiting heart trans-</text>
<text top="693" left="130" width="209" height="12" font="4">plantation. Transplant Proc. 2013;45:3659–61.</text>
<text top="707" left="83" width="8" height="12" font="4"> </text>
<text top="707" left="83" width="351" height="12" font="4">S7.1.2-7. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic </text>
<text top="720" left="130" width="301" height="12" font="4">implantable cardioverter defibrillator treatment in patients with </text>
<text top="734" left="130" width="302" height="12" font="4">end-stage heart failure awaiting heart transplantation. Heart. </text>
<text top="747" left="130" width="84" height="12" font="4">2013;99:1158–65.</text>
<text top="761" left="83" width="343" height="12" font="4"> S7.1.2-8.  Gandjbakhch E, Rovani M, Varnous S, et al. Implantable cardio-</text>
<text top="774" left="130" width="301" height="12" font="4">verter-defibrillators in end-stage heart failure patients listed for </text>
<text top="788" left="130" width="300" height="12" font="4">heart transplantation: results from a large retrospective registry. </text>
<text top="801" left="130" width="178" height="12" font="4">Arch Cardiovasc Dis. 2016;109:476–85.</text>
<text top="815" left="83" width="343" height="12" font="4"> S7.1.2-9.  Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardio-</text>
<text top="828" left="130" width="295" height="12" font="4">verter-defibrillators on waitlist mortality among patients await-</text>
<text top="842" left="130" width="302" height="12" font="4">ing heart transplantation: an UNOS/OPTN analysis. JACC Clin </text>
<text top="856" left="130" width="133" height="12" font="4">Electrophysiol. 2017;3:33–40.</text>
<text top="869" left="77" width="353" height="12" font="4"> S7.1.2-10.  Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an </text>
<text top="883" left="130" width="296" height="12" font="4">implantable cardioverter-defibrillator after acute myocardial infarc-</text>
<text top="896" left="130" width="172" height="12" font="4">tion. N Engl J Med. 2004;351:2481–8.</text>
<text top="910" left="77" width="352" height="12" font="4"> S7.1.2-11.  Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation </text>
<text top="923" left="130" width="295" height="12" font="4">early after myocardial infarction. N Engl J Med. 2009;361:1427–36.</text>
<text top="937" left="77" width="352" height="12" font="4"> S7.1.2-12.  Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of </text>
<text top="950" left="130" width="300" height="12" font="4">automatic implantable cardiac defibrillators: results from MADIT. </text>
<text top="964" left="130" width="299" height="12" font="4">Multicenter Automatic Defibrillator Implantation Trial. Circulation. </text>
<text top="977" left="130" width="84" height="12" font="4">1998;97:2129–35.</text>
<text top="991" left="77" width="353" height="12" font="4"> S7.1.2-13.  Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of </text>
<text top="1004" left="130" width="298" height="12" font="4">implantable cardioverter-defibrillators: results from the Multicenter </text>
<text top="1018" left="130" width="301" height="12" font="4">Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll </text>
<text top="1031" left="130" width="116" height="12" font="4">Cardiol. 2006;47:2310–8.</text>
<text top="1045" left="77" width="348" height="12" font="4"> S7.1.2-14.  Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi-</text>
<text top="1058" left="130" width="301" height="12" font="4">brillator therapy or amiodarone in chronic stable heart failure: </text>
<text top="1072" left="130" width="296" height="12" font="4">results from the Sudden Cardiac Death in Heart Failure Trial (SCD-</text>
<text top="1085" left="130" width="169" height="12" font="4">HeFT). Circulation. 2006;114:135–42.</text>
<text top="88" left="455" width="348" height="12" font="4"> S7.1.2-15.  Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco-</text>
<text top="102" left="508" width="302" height="12" font="4">nomic implications of the Multicenter Automatic Defibrillator </text>
<text top="115" left="508" width="258" height="12" font="4">Implantation Trial-II. Ann Intern Med. 2005;142:593–600.</text>
<text top="129" left="455" width="352" height="12" font="4"> S7.1.2-16.  Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key </text>
<text top="142" left="508" width="302" height="12" font="4">data elements and definitions for electrophysiological studies </text>
<text top="156" left="508" width="296" height="12" font="4">and procedures: a report of the American College of Cardiology/</text>
<text top="169" left="508" width="298" height="12" font="4">American Heart Association Task Force on Clinical Data Standards. </text>
<text top="183" left="508" width="144" height="12" font="4">Circulation. 2006;114:2534–70.</text>
<text top="197" left="455" width="348" height="12" font="4"> S7.1.2-17.  Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effec-</text>
<text top="210" left="508" width="296" height="12" font="4">tiveness of prophylactic implantation of a cardioverter defibril-</text>
<text top="224" left="508" width="301" height="12" font="4">lator in patients with reduced left ventricular systolic function: </text>
<text top="237" left="508" width="299" height="12" font="4">results of Markov modelling in a European population. Europace. </text>
<text top="251" left="508" width="78" height="12" font="4">2009;11:716–26.</text>
<text top="264" left="455" width="348" height="12" font="4"> S7.1.2-18.  Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implant-</text>
<text top="278" left="508" width="293" height="12" font="4">able cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80.</text>
<text top="291" left="455" width="348" height="12" font="4"> S7.1.2-19.  Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of pri-</text>
<text top="305" left="508" width="298" height="12" font="4">mary prophylactic implantable defibrillator therapy in patients with </text>
<text top="318" left="508" width="298" height="12" font="4">ischaemic or non-ischaemic heart disease: a European analysis. Eur </text>
<text top="332" left="508" width="109" height="12" font="4">Heart J. 2013;34:211–9.</text>
<text top="345" left="455" width="348" height="12" font="4"> S7.1.2-20.  Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state-</text>
<text top="359" left="508" width="301" height="12" font="4">ment on cost/value methodology in clinical practice guidelines </text>
<text top="372" left="508" width="299" height="12" font="4">and performance measures: a report of the American College of </text>
<text top="386" left="508" width="298" height="12" font="4">Cardiology/American Heart Association Task Force on Performance </text>
<text top="399" left="508" width="302" height="12" font="4">Measures and Task Force on Practice Guidelines. Circulation. </text>
<text top="413" left="508" width="90" height="12" font="4">2014;129:2329–45.</text>
<text top="426" left="455" width="7" height="12" font="4"> </text>
<text top="426" left="455" width="348" height="12" font="4">S7.1.2-21. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic test-</text>
<text top="440" left="508" width="300" height="12" font="4">ing to identify patients with coronary artery disease who are at </text>
<text top="453" left="508" width="300" height="12" font="4">risk for sudden death. Multicenter Unsustained Tachycardia Trial </text>
<text top="467" left="508" width="217" height="12" font="4">Investigators. N Engl J Med. 2000;342:1937–45.</text>
<text top="480" left="455" width="352" height="12" font="4"> S7.1.2-22.  Zaman S, Sivagangabalan G, Narayan A, et al. Outcomes of early </text>
<text top="494" left="508" width="296" height="12" font="4">risk stratification and targeted implantable cardioverter-defibrilla-</text>
<text top="507" left="508" width="300" height="12" font="4">tor implantation after ST-elevation myocardial infarction treated </text>
<text top="521" left="508" width="302" height="12" font="4">with primary percutaneous coronary intervention. Circulation. </text>
<text top="534" left="508" width="90" height="12" font="4">2009;120:194–200.</text>
<text top="548" left="455" width="351" height="12" font="4"> S7.1.2-23.  Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization </text>
<text top="561" left="508" width="300" height="12" font="4">therapy with or without an implantable defibrillator in advanced </text>
<text top="575" left="508" width="250" height="12" font="4">chronic heart failure. N Engl J Med. 2004;350:2140–50.</text>
<text top="588" left="455" width="352" height="12" font="4"> S7.1.2-24.  Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert </text>
<text top="602" left="508" width="295" height="12" font="4">consensus statement on the use of implantable cardioverter-defi-</text>
<text top="615" left="508" width="295" height="12" font="4">brillator therapy in patients who are not included or not well rep-</text>
<text top="629" left="508" width="250" height="12" font="4">resented in clinical trials. Circulation. 2014;130:94–125.</text>
<text top="654" left="452" width="346" height="18" font="24"><i><b>7.1.3. Treatment and Prevention of Recurrent VA </b></i></text>
<text top="672" left="452" width="277" height="18" font="24"><i><b>in Patients With Ischemic Heart Disease</b></i></text>
<text top="693" left="461" width="343" height="12" font="4"> S7.1.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-</text>
<text top="707" left="508" width="299" height="12" font="4">blockers, amiodarone plus beta-blockers, or sotalol for prevention </text>
<text top="720" left="508" width="300" height="12" font="4">of shocks from implantable cardioverter defibrillators: the OPTIC </text>
<text top="734" left="508" width="235" height="12" font="4">Study: a randomized trial. JAMA. 2006;295:165–71.</text>
<text top="747" left="461" width="343" height="12" font="4"> S7.1.3-2.  Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implant-</text>
<text top="761" left="508" width="302" height="12" font="4">able-defibrillator shocks by treatment with sotalol. d,l-Sotalol </text>
<text top="774" left="508" width="299" height="12" font="4">Implantable Cardioverter-Defibrillator Study Group. N Engl J Med. </text>
<text top="788" left="508" width="90" height="12" font="4">1999;340:1855–62.</text>
<text top="801" left="461" width="346" height="12" font="4"> S7.1.3-3.  Kettering K, Mewis C, Dornberger V, et al. Efficacy of metoprolol </text>
<text top="815" left="508" width="296" height="12" font="4">and sotalol in the prevention of recurrences of sustained ventricu-</text>
<text top="828" left="508" width="300" height="12" font="4">lar tachyarrhythmias in patients with an implantable cardioverter </text>
<text top="842" left="508" width="254" height="12" font="4">defibrillator. Pacing Clin Electrophysiol. 2002;25:1571–6.</text>
<text top="855" left="461" width="343" height="12" font="4"> S7.1.3-4.  Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia abla-</text>
<text top="869" left="508" width="301" height="12" font="4">tion versus escalation of antiarrhythmic drugs. N Engl J Med. </text>
<text top="883" left="508" width="84" height="12" font="4">2016;375:111–21.</text>
<text top="896" left="461" width="346" height="12" font="4"> S7.1.3-5.  Mallidi J, Nadkarni GN, Berger RD, et al. Meta-analysis of catheter </text>
<text top="910" left="508" width="295" height="12" font="4">ablation as an adjunct to medical therapy for treatment of ven-</text>
<text top="923" left="508" width="299" height="12" font="4">tricular tachycardia in patients with structural heart disease. Heart </text>
<text top="937" left="508" width="113" height="12" font="4">Rhythm. 2011;8:503–10.</text>
<text top="950" left="461" width="346" height="12" font="4"> S7.1.3-6.  Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of </text>
<text top="964" left="508" width="296" height="12" font="4">irrigated radiofrequency catheter ablation of sustained ventricu-</text>
<text top="977" left="508" width="300" height="12" font="4">lar tachycardia: post-approval THERMOCOOL VT trial. J Am Coll </text>
<text top="991" left="508" width="116" height="12" font="4">Cardiol. 2016;67:674–83.</text>
<text top="1004" left="461" width="345" height="12" font="4"> S7.1.3-7.  Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency </text>
<text top="1018" left="508" width="298" height="12" font="4">catheter ablation guided by electroanatomic mapping for recurrent </text>
<text top="1031" left="508" width="299" height="12" font="4">ventricular tachycardia after myocardial infarction: the multicenter </text>
<text top="1045" left="508" width="303" height="12" font="4">thermocool ventricular tachycardia ablation trial. Circulation. </text>
<text top="1058" left="508" width="90" height="12" font="4">2008;118:2773–82.</text>
<text top="1072" left="461" width="343" height="12" font="4"> S7.1.3-8.  Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recur-</text>
<text top="1085" left="508" width="301" height="12" font="4">rent scar-related ventricular tachycardia using electroanatomical </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e367</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="130" width="295" height="12" font="4">mapping and irrigated ablation technology: results of the pro-</text>
<text top="102" left="130" width="302" height="12" font="4">spective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. </text>
<text top="116" left="130" width="72" height="12" font="4">2010;21:47–53.</text>
<text top="129" left="77" width="353" height="12" font="4"> S7.1.3-9.  Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent </text>
<text top="143" left="130" width="300" height="12" font="4">ventricular tachycardia after catheter ablation is associated with </text>
<text top="156" left="130" width="301" height="12" font="4">improved survival in patients with structural heart disease: an </text>
<text top="170" left="130" width="298" height="12" font="4">International VT Ablation Center Collaborative Group study. Heart </text>
<text top="184" left="130" width="136" height="12" font="4">Rhythm. 2015;12:1997–2007.</text>
<text top="197" left="77" width="351" height="12" font="4"> S7.1.3-10.  Al-Khatib SM, Daubert JP, Anstrom KJ, et al. Catheter ablation for </text>
<text top="211" left="130" width="298" height="12" font="4">ventricular tachycardia in patients with an implantable cardioverter </text>
<text top="224" left="130" width="302" height="12" font="4">defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. </text>
<text top="238" left="130" width="72" height="12" font="4">2015;26:151–7.</text>
<text top="252" left="77" width="353" height="12" font="4"> S7.1.3-11. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of </text>
<text top="265" left="130" width="300" height="12" font="4">stable ventricular tachycardia before defibrillator implantation in </text>
<text top="279" left="130" width="295" height="12" font="4">patients with coronary heart disease (VTACH): a multicentre ran-</text>
<text top="293" left="130" width="224" height="12" font="4">domised controlled trial. Lancet. 2010;375:31–40.</text>
<text top="306" left="77" width="353" height="12" font="4"> S7.1.3-12.  Sesselberg HW, Moss AJ, McNitt S, et al. Ventricular arrhythmia </text>
<text top="320" left="130" width="298" height="12" font="4">storms in postinfarction patients with implantable defibrillators for </text>
<text top="333" left="130" width="298" height="12" font="4">primary prevention indications: a MADIT-II substudy. Heart Rhythm. </text>
<text top="347" left="130" width="84" height="12" font="4">2007;4:1395–402.</text>
<text top="361" left="77" width="352" height="12" font="4"> S7.1.3-13.  Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in </text>
<text top="374" left="130" width="300" height="12" font="4">patients receiving encainide, flecainide, or placebo. The Cardiac </text>
<text top="388" left="130" width="276" height="12" font="4">Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.</text>
<text top="402" left="77" width="348" height="12" font="4"> S7.1.3-14.  Sears SF Jr, Todaro JF, Lewis TS, et al. Examining the psychoso-</text>
<text top="415" left="130" width="300" height="12" font="4">cial impact of implantable cardioverter defibrillators: a literature </text>
<text top="429" left="130" width="165" height="12" font="4">review. Clin Cardiol. 1999;22:481–9.</text>
<text top="442" left="77" width="348" height="12" font="4"> S7.1.3-15.  Steinberg JS, Gaur A, Sciacca R, et al. New-onset sustained ventric-</text>
<text top="456" left="130" width="295" height="12" font="4">ular tachycardia after cardiac surgery. Circulation. 1999;99:903–8.</text>
<text top="470" left="77" width="348" height="12" font="4"> S7.1.3-16.  Brugada J, Aguinaga L, Mont L, et al. Coronary artery revasculariza-</text>
<text top="483" left="130" width="299" height="12" font="4">tion in patients with sustained ventricular arrhythmias in the chronic </text>
<text top="497" left="130" width="300" height="12" font="4">phase of a myocardial infarction: effects on the electrophysiologic </text>
<text top="510" left="130" width="271" height="12" font="4">substrate and outcome. J Am Coll Cardiol. 2001;37:529–33.</text>
<text top="524" left="77" width="348" height="12" font="4"> S7.1.3-17.  Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar-</text>
<text top="538" left="130" width="299" height="12" font="4">macological interventions for prevention of sudden cardiac death. </text>
<text top="551" left="130" width="224" height="12" font="4">Cochrane Database Syst Rev. 2015;12:CD008093.</text>
<text top="565" left="77" width="348" height="12" font="4"> S7.1.3-18.  Bunch TJ, Mahapatra S, Murdock D, et al. Ranolazine reduces ven-</text>
<text top="579" left="130" width="295" height="12" font="4">tricular tachycardia burden and ICD shocks in patients with drug-</text>
<text top="592" left="130" width="296" height="12" font="4">refractory ICD shocks. Pacing Clin Electrophysiol. 2011;34:1600–6.</text>
<text top="606" left="77" width="352" height="12" font="4"> S7.1.3-19.  Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide </text>
<text top="619" left="130" width="300" height="12" font="4">for clinicians who treat patients with amiodarone: 2007. Heart </text>
<text top="633" left="130" width="113" height="12" font="4">Rhythm. 2007;4:1250–9.</text>
<text top="647" left="77" width="353" height="12" font="4"> S7.1.3-20.  Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients </text>
<text top="660" left="130" width="304" height="12" font="4">with congestive heart failure and asymptomatic ventricular </text>
<text top="674" left="130" width="299" height="12" font="4">arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive </text>
<text top="688" left="130" width="205" height="12" font="4">Heart Failure. N Engl J Med. 1995;333:77–82.</text>
<text top="701" left="77" width="351" height="12" font="4"> S7.1.3-21.  The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of </text>
<text top="715" left="130" width="300" height="12" font="4">the antiarrhythmic agent moricizine on survival after myocardial </text>
<text top="728" left="130" width="298" height="12" font="4">infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. </text>
<text top="742" left="130" width="149" height="12" font="4">N Engl J Med. 1992;327:227–33.</text>
<text top="756" left="77" width="353" height="12" font="4"> S7.1.3-22. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison </text>
<text top="769" left="130" width="300" height="12" font="4">of antiarrhythmic drug therapy with implantable defibrillators in </text>
<text top="783" left="130" width="299" height="12" font="4">patients resuscitated from cardiac arrest: the Cardiac Arrest Study </text>
<text top="796" left="130" width="221" height="12" font="4">Hamburg (CASH). Circulation. 2000;102:748–54.</text>
<text top="810" left="77" width="348" height="12" font="4"> S7.1.3-23.  Sears SE Jr, Conti JB, Understanding implantable cardioverter defi-</text>
<text top="824" left="130" width="296" height="12" font="4">brillator shocks and storms: medical and psychosocial consider-</text>
<text top="837" left="130" width="296" height="12" font="4">ations for research and clinical care. Clin Cardiol. 2003;26:107–11.</text>
<text top="851" left="77" width="351" height="12" font="4"> S7.1.3-24.  Sweeney MO, Sherfesee L, Degroot PJ, et al. Differences in effects </text>
<text top="865" left="130" width="299" height="12" font="4">of electrical therapy type for ventricular arrhythmias on mortality </text>
<text top="878" left="130" width="301" height="12" font="4">in implantable cardioverter-defibrillator patients. Heart Rhythm. </text>
<text top="892" left="130" width="72" height="12" font="4">2010;7:353–60.</text>
<text top="905" left="77" width="352" height="12" font="4"> S7.1.3-25.  Berntsen RF, Gunnes P, Lie M, et al. Surgical revascularization in </text>
<text top="919" left="130" width="298" height="12" font="4">the treatment of ventricular tachycardia and fibrillation exposed by </text>
<text top="933" left="130" width="271" height="12" font="4">exercise-induced ischaemia. Eur Heart J. 1993;14:1297–303.</text>
<text top="946" left="77" width="348" height="12" font="4"> S7.1.3-26.  Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/</text>
<text top="960" left="130" width="302" height="12" font="4">SOLAECE expert consensus statement on optimal implantable </text>
<text top="974" left="130" width="301" height="12" font="4">cardioverter-defibrillator programming and testing. J Arrhythm. </text>
<text top="987" left="130" width="67" height="12" font="4">2016;32:1–28.</text>
<text top="1030" left="74" width="287" height="21" font="18"><b>7.2. Nonischemic Cardiomyopathy</b></text>
<text top="1057" left="92" width="338" height="12" font="4"> S7.2-1.  Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts </text>
<text top="1070" left="130" width="300" height="12" font="4">death and other adverse events in suspected cardiac sarcoidosis. </text>
<text top="1084" left="130" width="193" height="12" font="4">JACC Cardiovasc Imaging. 2013;6:501–11.</text>
<text top="88" left="452" width="351" height="12" font="4">  S7.2-2.  Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhance-</text>
<text top="102" left="503" width="300" height="12" font="4">ment on cardiac magnetic resonance predicts adverse cardiovascu-</text>
<text top="116" left="503" width="304" height="12" font="4">lar outcomes in nonischemic cardiomyopathy: a systematic review </text>
<text top="129" left="503" width="266" height="12" font="4">and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250–8.</text>
<text top="143" left="452" width="356" height="12" font="4">  S7.2-3.  Piers SR, Tao Q, van Huls van Taxis CF, et al. Contrast-enhanced </text>
<text top="156" left="503" width="303" height="12" font="4">MRI-derived scar patterns and associated ventricular tachycardias in </text>
<text top="170" left="503" width="303" height="12" font="4">nonischemic cardiomyopathy: implications for the ablation strategy. </text>
<text top="184" left="503" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2013;6:875–83.</text>
<text top="197" left="452" width="351" height="12" font="4">  S7.2-4.  Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consen-</text>
<text top="211" left="503" width="302" height="12" font="4">sus statement on the state of genetic testing for the channelopathies </text>
<text top="224" left="503" width="300" height="12" font="4">and cardiomyopathies: this document was developed as a partner-</text>
<text top="238" left="503" width="304" height="12" font="4">ship between the Heart Rhythm Society (HRS) and the European </text>
<text top="252" left="503" width="292" height="12" font="4">Heart Rhythm Association (EHRA). Europace. 2011;13:1077–109.</text>
<text top="265" left="452" width="354" height="12" font="4">  S7.2-5.  Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues </text>
<text top="279" left="503" width="306" height="12" font="4">in dilated cardiomyopathy: a review for genetics professionals. </text>
<text top="293" left="503" width="135" height="12" font="4">Genet Med. 2010;12:655–67.</text>
<text top="306" left="452" width="355" height="12" font="4">  S7.2-6.  Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of </text>
<text top="320" left="503" width="305" height="12" font="4">myocardial scarring on CMR in patients with cardiac sarcoidosis: </text>
<text top="333" left="503" width="304" height="12" font="4">a systematic review and meta-analysis. JACC Cardiovasc Imaging. </text>
<text top="347" left="503" width="107" height="12" font="4">2016. 2017;10:411–20.</text>
<text top="361" left="452" width="351" height="12" font="4">  S7.2-7.  Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-</text>
<text top="374" left="503" width="303" height="12" font="4">defibrillators in lamin A/C mutation carriers with cardiac conduction </text>
<text top="388" left="503" width="192" height="12" font="4">disorders. Heart Rhythm. 2013;10:1492–8.</text>
<text top="402" left="452" width="354" height="12" font="4">  S7.2-8.  Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhythmic </text>
<text top="415" left="503" width="303" height="12" font="4">and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am </text>
<text top="429" left="503" width="148" height="12" font="4">Coll Cardiol. 2016;68:2299–307.</text>
<text top="442" left="452" width="351" height="12" font="4">  S7.2-9.  Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud-</text>
<text top="456" left="503" width="302" height="12" font="4">den death in patients with lamin A/C gene mutations. N Engl J Med. </text>
<text top="470" left="503" width="84" height="12" font="4">2006;354:209–10.</text>
<text top="483" left="452" width="355" height="12" font="4">  S7.2-10.  Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk </text>
<text top="497" left="503" width="306" height="12" font="4">stratification in dilated cardiolaminopathies. J Am Coll Cardiol. </text>
<text top="510" left="503" width="84" height="12" font="4">2008;52:1250–60.</text>
<text top="524" left="452" width="355" height="12" font="4">  S7.2-11.  Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis </text>
<text top="538" left="503" width="304" height="12" font="4">of clinical characteristics of 299 carriers of LMNA gene mutations: </text>
<text top="551" left="503" width="303" height="12" font="4">do lamin A/C mutations portend a high risk of sudden death? J Mol </text>
<text top="565" left="503" width="99" height="12" font="4">Med. 2005;83:79–83.</text>
<text top="579" left="452" width="357" height="12" font="4"> S7.2-12.  van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for </text>
<text top="592" left="503" width="303" height="12" font="4">malignant ventricular arrhythmias in lamin A/C mutation carriers: a </text>
<text top="606" left="503" width="274" height="12" font="4">European cohort study. J Am Coll Cardiol. 2012;59:493–500.</text>
<text top="636" left="452" width="330" height="18" font="24"><i><b>7.2.1. Secondary Prevention of SCD in Patients </b></i></text>
<text top="654" left="452" width="77" height="18" font="24"><i><b>With NICM</b></i></text>
<text top="675" left="452" width="10" height="12" font="4"> </text>
<text top="675" left="455" width="358" height="12" font="4">S7.2.1-1. The Antiarrhythmics versus Implantable Defibrillators (AVID) </text>
<text top="689" left="503" width="305" height="12" font="4">Investigators. A comparison of antiarrhythmic-drug therapy with </text>
<text top="703" left="503" width="305" height="12" font="4">implantable defibrillators in patients resuscitated from near-fatal </text>
<text top="716" left="503" width="263" height="12" font="4">ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.</text>
<text top="730" left="452" width="357" height="12" font="4"> S7.2.1-2.  Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable </text>
<text top="743" left="503" width="300" height="12" font="4">defibrillator study (CIDS): a randomized trial of the implant-</text>
<text top="757" left="503" width="308" height="12" font="4">able cardioverter defibrillator against amiodarone. Circulation. </text>
<text top="771" left="503" width="96" height="12" font="4">2000;101:1297–302.</text>
<text top="784" left="452" width="355" height="12" font="4"> S7.2.1-3.  Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for </text>
<text top="798" left="503" width="300" height="12" font="4">the prevention of mortality in patients with nonischemic cardio-</text>
<text top="811" left="503" width="304" height="12" font="4">myopathy: a meta-analysis of randomized controlled trials. JAMA. </text>
<text top="825" left="503" width="84" height="12" font="4">2004;292:2874–9.</text>
<text top="839" left="452" width="355" height="12" font="4"> S7.2.1-4.  Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of </text>
<text top="852" left="503" width="307" height="12" font="4">antiarrhythmic drug therapy with implantable defibrillators in </text>
<text top="866" left="503" width="304" height="12" font="4">patients resuscitated from cardiac arrest: the Cardiac Arrest Study </text>
<text top="880" left="503" width="221" height="12" font="4">Hamburg (CASH). Circulation. 2000;102:748–54.</text>
<text top="893" left="452" width="351" height="12" font="4"> S7.2.1-5.  Raitt MH, Renfroe EG, Epstein AE, et al. ”Stable” ventricular tachy-</text>
<text top="907" left="503" width="304" height="12" font="4">cardia is not a benign rhythm: insights from the Antiarrhythmics </text>
<text top="920" left="503" width="310" height="12" font="4">versus Implantable Defibrillators (AVID) registry. Circulation. </text>
<text top="934" left="503" width="84" height="12" font="4">2001;103:244–52.</text>
<text top="948" left="452" width="357" height="12" font="4"> S7.2.1-6.  Brilakis ES, Shen WK, Hammill SC, et al. Role of programmed </text>
<text top="961" left="503" width="305" height="12" font="4">ventricular stimulation and implantable cardioverter defibrillators </text>
<text top="975" left="503" width="305" height="12" font="4">in patients with idiopathic dilated cardiomyopathy and syncope. </text>
<text top="989" left="503" width="203" height="12" font="4">Pacing Clin Electrophysiol. 2001;24:1623–30.</text>
<text top="1002" left="452" width="356" height="12" font="4"> S7.2.1-7.  Fonarow GC, Feliciano Z, Boyle NG, et al. Improved survival in </text>
<text top="1016" left="503" width="306" height="12" font="4">patients with nonischemic advanced heart failure and syncope </text>
<text top="1029" left="503" width="303" height="12" font="4">treated with an implantable cardioverter-defibrillator. Am J Cardiol. </text>
<text top="1043" left="503" width="72" height="12" font="4">2000;85:981–5.</text>
<text top="1057" left="452" width="351" height="12" font="4"> S7.2.1-8.  Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonisch-</text>
<text top="1070" left="503" width="303" height="12" font="4">emic dilated cardiomyopathy and unexplained syncope treated with </text>
<text top="1084" left="503" width="293" height="12" font="4">an implantable defibrillator. J Am Coll Cardiol. 1999;33:1964–70.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e368</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="80" width="350" height="12" font="4"> S7.2.1-9. Middlekauff HR, Stevenson WG, Stevenson LW, et al. Syncope in </text>
<text top="102" left="125" width="300" height="12" font="4">advanced heart failure: high risk of sudden death regardless of ori-</text>
<text top="116" left="125" width="227" height="12" font="4">gin of syncope. J Am Coll Cardiol. 1993;21:110–6.</text>
<text top="129" left="74" width="351" height="12" font="4"> S7.2.1-10. Olshansky B, Poole JE, Johnson G, et al. Syncope predicts the out-</text>
<text top="143" left="125" width="303" height="12" font="4">come of cardiomyopathy patients: analysis of the SCD-HeFT study. J </text>
<text top="157" left="125" width="161" height="12" font="4">Am Coll Cardiol. 2008;51:1277–82.</text>
<text top="170" left="74" width="351" height="12" font="4"> S7.2.1-11. Ruwald MH, Okumura K, Kimura T, et al. Syncope in high-risk car-</text>
<text top="184" left="125" width="302" height="12" font="4">diomyopathy patients with implantable defibrillators: frequency, risk </text>
<text top="198" left="125" width="302" height="12" font="4">factors, mechanisms, and association with mortality: results from the </text>
<text top="211" left="125" width="300" height="12" font="4">multicenter automatic defibrillator implantation trial-reduce inap-</text>
<text top="225" left="125" width="300" height="12" font="4">propriate therapy (MADIT-RIT) study. Circulation. 2014;129:545–52.</text>
<text top="239" left="74" width="354" height="12" font="4"> S7.2.1-12. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention </text>
<text top="252" left="125" width="303" height="12" font="4">of sudden cardiac death: a meta-analysis of randomized controlled </text>
<text top="266" left="125" width="165" height="12" font="4">trials. Eur Heart J. 2009;30:1245–53.</text>
<text top="280" left="74" width="351" height="12" font="4"> S7.2.1-13. Claro JC, Candia R, Rada G, et al. Amiodarone versus other phar-</text>
<text top="294" left="125" width="304" height="12" font="4">macological interventions for prevention of sudden cardiac death. </text>
<text top="307" left="125" width="224" height="12" font="4">Cochrane Database Syst Rev. 2015;12:CD008093.</text>
<text top="321" left="74" width="351" height="12" font="4"> S7.2.1-14. Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhyth-</text>
<text top="335" left="125" width="300" height="12" font="4">mia inducibility predicts subsequent ICD activation in nonisch-</text>
<text top="348" left="125" width="305" height="12" font="4">emic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin </text>
<text top="362" left="125" width="145" height="12" font="4">Electrophysiol. 2009;32:755–61.</text>
<text top="376" left="74" width="355" height="12" font="4"> S7.2.1-15. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of </text>
<text top="389" left="125" width="306" height="12" font="4">sudden cardiac death in a nonischemic dilated cardiomyopathy </text>
<text top="403" left="125" width="300" height="12" font="4">population: reappraisal of the role of programmed ventricular stim-</text>
<text top="417" left="125" width="242" height="12" font="4">ulation. Circ Arrhythm Electrophysiol. 2013;6:504–12.</text>
<text top="430" left="74" width="351" height="12" font="4"> S7.2.1-16. Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electro-</text>
<text top="444" left="125" width="303" height="12" font="4">physiological studies to predict arrhythmic events. World J Cardiol. </text>
<text top="458" left="125" width="72" height="12" font="4">2015;7:344–50.</text>
<text top="471" left="74" width="356" height="12" font="4"> S7.2.1-17. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use </text>
<text top="485" left="125" width="300" height="12" font="4">after acute myocardial infarction complicated by heart failure and/</text>
<text top="499" left="125" width="300" height="12" font="4">or left ventricular dysfunction may be associated with excess mortal-</text>
<text top="512" left="125" width="149" height="12" font="4">ity. Am Heart J. 2008;155:87–93.</text>
<text top="538" left="74" width="315" height="18" font="24"><i><b>7.2.2. Primary Prevention of SCD in Patients  </b></i></text>
<text top="556" left="74" width="77" height="18" font="24"><i><b>With NICM</b></i></text>
<text top="578" left="80" width="349" height="12" font="4"> S7.2.2-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable </text>
<text top="591" left="125" width="303" height="12" font="4">cardioverter-defibrillator for congestive heart failure. N Engl J Med. </text>
<text top="605" left="125" width="84" height="12" font="4">2005;352:225–37.</text>
<text top="619" left="80" width="345" height="12" font="4"> S7.2.2-2.  Bänsch D, Antz M, Boczor S, et al. Primary prevention of sud-</text>
<text top="632" left="125" width="308" height="12" font="4">den cardiac death in idiopathic dilated cardiomyopathy: the </text>
<text top="646" left="125" width="266" height="12" font="4">Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453–8.</text>
<text top="660" left="80" width="349" height="12" font="4"> S7.2.2-3.  Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization </text>
<text top="673" left="125" width="305" height="12" font="4">therapy with or without an implantable defibrillator in advanced </text>
<text top="687" left="125" width="250" height="12" font="4">chronic heart failure. N Engl J Med. 2004;350:2140–50.</text>
<text top="701" left="80" width="349" height="12" font="4"> S7.2.2-4. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for </text>
<text top="714" left="125" width="300" height="12" font="4">the prevention of mortality in patients with nonischemic cardio-</text>
<text top="728" left="125" width="304" height="12" font="4">myopathy: a meta-analysis of randomized controlled trials. JAMA. </text>
<text top="742" left="125" width="84" height="12" font="4">2004;292:2874–9.</text>
<text top="755" left="80" width="345" height="12" font="4"> S7.2.2-5.  Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan-</text>
<text top="769" left="125" width="303" height="12" font="4">tation in patients with nonischemic dilated cardiomyopathy. N Engl </text>
<text top="783" left="125" width="117" height="12" font="4">J Med. 2004;350:2151–8.</text>
<text top="796" left="80" width="349" height="12" font="4"> S7.2.2-6.  Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus </text>
<text top="810" left="125" width="305" height="12" font="4">implantable cardioverter-defibrillator: randomized trial in patients </text>
<text top="824" left="125" width="300" height="12" font="4">with nonischemic dilated cardiomyopathy and asymptomatic non-</text>
<text top="838" left="125" width="306" height="12" font="4">sustained ventricular tachycardia–AMIOVIRT. J Am Coll Cardiol. </text>
<text top="851" left="125" width="84" height="12" font="4">2003;41:1707–12.</text>
<text top="865" left="80" width="345" height="12" font="4"> S7.2.2-7.  Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-</text>
<text top="879" left="125" width="303" height="12" font="4">defibrillators in lamin A/C mutation carriers with cardiac conduction </text>
<text top="892" left="125" width="192" height="12" font="4">disorders. Heart Rhythm. 2013;10:1492–8.</text>
<text top="906" left="80" width="349" height="12" font="4"> S7.2.2-8. Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk </text>
<text top="920" left="125" width="306" height="12" font="4">stratification in dilated cardiolaminopathies. J Am Coll Cardiol. </text>
<text top="933" left="125" width="84" height="12" font="4">2008;52:1250–60.</text>
<text top="947" left="80" width="349" height="12" font="4"> S7.2.2-9. Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis </text>
<text top="961" left="125" width="304" height="12" font="4">of clinical characteristics of 299 carriers of LMNA gene mutations: </text>
<text top="974" left="125" width="303" height="12" font="4">do lamin A/C mutations portend a high risk of sudden death? J Mol </text>
<text top="988" left="125" width="99" height="12" font="4">Med. 2005;83:79–83.</text>
<text top="1002" left="74" width="356" height="12" font="4"> S7.2.2-10. van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for </text>
<text top="1015" left="125" width="300" height="12" font="4">malignant ventricular arrhythmias in lamin A/C mutation car-</text>
<text top="1029" left="125" width="303" height="12" font="4">riers: a European cohort study. J Am Coll Cardiol. 2012;59: </text>
<text top="1043" left="125" width="43" height="12" font="4">493–500.</text>
<text top="1056" left="74" width="356" height="12" font="4"> S7.2.2-11.  Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in </text>
<text top="1070" left="125" width="306" height="12" font="4">patients with nonischemic systolic heart failure. N Engl J Med. </text>
<text top="1084" left="125" width="90" height="12" font="4">2016;375:1221–30.</text>
<text top="88" left="452" width="356" height="12" font="4"> S7.2.2-12. Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention </text>
<text top="102" left="503" width="304" height="12" font="4">implantable cardioverter defibillators in patients with nonischemic </text>
<text top="115" left="503" width="286" height="12" font="4">cardiomyopathy: a meta-analysis. JAMA Cardiol. 2017;2:685–8.</text>
<text top="129" left="452" width="351" height="12" font="4"> S7.2.2-13. Golwala H, Bajaj NS, Arora G, et al. Implantable cardioverter-defi-</text>
<text top="143" left="503" width="300" height="12" font="4">brillator for nonischemic cardiomyopathy: an updated meta-analy-</text>
<text top="156" left="503" width="149" height="12" font="4">sis. Circulation. 2017;135:201–3.</text>
<text top="182" left="452" width="317" height="18" font="24"><i><b>7.2.3. Treatment of Recurrent VA in Patients  </b></i></text>
<text top="200" left="452" width="77" height="18" font="24"><i><b>With NICM</b></i></text>
<text top="221" left="458" width="345" height="12" font="4"> S7.2.3-1. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-</text>
<text top="235" left="503" width="304" height="12" font="4">blockers, amiodarone plus beta-blockers, or sotalol for prevention </text>
<text top="248" left="503" width="305" height="12" font="4">of shocks from implantable cardioverter defibrillators: the OPTIC </text>
<text top="262" left="503" width="235" height="12" font="4">Study: a randomized trial. JAMA. 2006;295:165–71.</text>
<text top="276" left="458" width="345" height="12" font="4"> S7.2.3-2.  Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla-</text>
<text top="289" left="503" width="300" height="12" font="4">tion of ventricular tachycardia in dilated nonischemic cardiomy-</text>
<text top="303" left="503" width="304" height="12" font="4">opathy compared with ischemic cardiomyopathy: results from the </text>
<text top="316" left="503" width="303" height="12" font="4">Prospective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation. </text>
<text top="330" left="503" width="84" height="12" font="4">2014;129:728–36.</text>
<text top="344" left="458" width="351" height="12" font="4"> S7.2.3-3. Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent </text>
<text top="357" left="503" width="305" height="12" font="4">ventricular tachycardia after catheter ablation is associated with </text>
<text top="371" left="503" width="306" height="12" font="4">improved survival in patients with structural heart disease: an </text>
<text top="384" left="503" width="304" height="12" font="4">International VT Ablation Center Collaborative Group study. Heart </text>
<text top="398" left="503" width="136" height="12" font="4">Rhythm. 2015;12:1997–2007.</text>
<text top="412" left="458" width="350" height="12" font="4"> S7.2.3-4. Piers SR, Tao Q, Tvan Huls van Taxis CF, et al. Contrast-enhanced </text>
<text top="425" left="503" width="303" height="12" font="4">MRI-derived scar patterns and associated ventricular tachycardias in </text>
<text top="439" left="503" width="303" height="12" font="4">nonischemic cardiomyopathy: implications for the ablation strategy. </text>
<text top="452" left="503" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2013;6:875–83.</text>
<text top="466" left="458" width="345" height="12" font="4"> S7.2.3-5.  Desjardins B, Yokokawa M, Good E, et al. Characteristics of intramu-</text>
<text top="480" left="503" width="304" height="12" font="4">ral scar in patients with nonischemic cardiomyopathy and relation </text>
<text top="493" left="503" width="303" height="12" font="4">to intramural ventricular arrhythmias. Circ Arrhythm Electrophysiol. </text>
<text top="507" left="503" width="67" height="12" font="4">2013;6:891–7.</text>
<text top="521" left="458" width="6" height="12" font="4"> </text>
<text top="521" left="458" width="352" height="12" font="4">S7.2.3-6. Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment </text>
<text top="534" left="503" width="306" height="12" font="4">approach to ventricular tachycardia in cardiac sarcoidosis. Circ </text>
<text top="548" left="503" width="185" height="12" font="4">Arrhythm Electrophysiol. 2014;7:407–13.</text>
<text top="587" left="452" width="325" height="21" font="18"><b>7.3. Arrhythmogenic Right Ventricular </b></text>
<text top="608" left="452" width="141" height="21" font="18"><b>Cardiomyopathy</b></text>
<text top="635" left="467" width="340" height="12" font="4"> S7.3-1. Groeneweg JA, Bhonsale A, James CA, et al. Clinical presentation, </text>
<text top="649" left="503" width="304" height="12" font="4">long-term follow-up, and outcomes of 1001 arrhythmogenic right </text>
<text top="662" left="503" width="303" height="12" font="4">ventricular dysplasia/cardiomyopathy patients and family members. </text>
<text top="676" left="503" width="177" height="12" font="4">Circ Cardiovasc Genet. 2015;8:437–46.</text>
<text top="689" left="467" width="341" height="12" font="4"> S7.3-2. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right </text>
<text top="703" left="503" width="304" height="12" font="4">ventricular cardiomyopathy: a practical guide for physicians. J Am </text>
<text top="717" left="503" width="136" height="12" font="4">Coll Cardiol. 2013;61:1945–8.</text>
<text top="730" left="467" width="337" height="12" font="4"> S7.3-3. Quarta G, Muir A, Pantazis A, et al. Familial evaluation in arrhyth-</text>
<text top="744" left="503" width="304" height="12" font="4">mogenic right ventricular cardiomyopathy: impact of genetics and </text>
<text top="757" left="503" width="254" height="12" font="4">revised task force criteria. Circulation. 2011;123:2701–9.</text>
<text top="771" left="467" width="341" height="12" font="4"> S7.3-4. te Riele AS, James CA, Groeneweg JA, et al. Approach to family </text>
<text top="785" left="503" width="300" height="12" font="4">screening in arrhythmogenic right ventricular dysplasia/cardiomy-</text>
<text top="798" left="503" width="168" height="12" font="4">opathy. Eur Heart J. 2016;37:755–63.</text>
<text top="812" left="467" width="340" height="12" font="4"> S7.3-5. Liu T, Pursnani A, Sharma UC, et al. Effect of the 2010 task force </text>
<text top="825" left="503" width="306" height="12" font="4">criteria on reclassification of cardiovascular magnetic resonance </text>
<text top="839" left="503" width="307" height="12" font="4">criteria for arrhythmogenic right ventricular cardiomyopathy. J </text>
<text top="853" left="503" width="168" height="12" font="4">Cardiovasc Magn Reson. 2014;16:47.</text>
<text top="866" left="467" width="337" height="12" font="4"> S7.3-6. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmo-</text>
<text top="880" left="503" width="300" height="12" font="4">genic right ventricular cardiomyopathy/dysplasia: proposed modifi-</text>
<text top="894" left="503" width="287" height="12" font="4">cation of the task force criteria. Circulation. 2010;121:1533–41.</text>
<text top="907" left="467" width="342" height="12" font="4"> S7.3-7. te Riele AS, Bhonsale A, James CA, et al. Incremental value of </text>
<text top="921" left="503" width="300" height="12" font="4">cardiac magnetic resonance imaging in arrhythmic risk stratifica-</text>
<text top="934" left="503" width="300" height="12" font="4">tion of arrhythmogenic right ventricular dysplasia/cardiomyopa-</text>
<text top="948" left="503" width="305" height="12" font="4">thy-associated desmosomal mutation carriers. J Am Coll Cardiol. </text>
<text top="962" left="503" width="78" height="12" font="4">2013;62:1761–9.</text>
<text top="975" left="467" width="341" height="12" font="4"> S7.3-8. Vermes E, Strohm O, Otmani A, et al. Impact of the revision of </text>
<text top="989" left="503" width="307" height="12" font="4">arrhythmogenic right ventricular cardiomyopathy/dysplasia task </text>
<text top="1002" left="503" width="304" height="12" font="4">force criteria on its prevalence by CMR criteria. JACC Cardiovasc </text>
<text top="1016" left="503" width="95" height="12" font="4">Imag. 2011;4:282–7.</text>
<text top="1030" left="467" width="341" height="12" font="4"> S7.3-9. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors </text>
<text top="1043" left="503" width="306" height="12" font="4">of implantable cardioverter-defibrillator therapy in patients with </text>
<text top="1057" left="503" width="300" height="12" font="4">arrhythmogenic right ventricular dysplasia/cardiomyopathy under-</text>
<text top="1070" left="503" width="300" height="12" font="4">going implantable cardioverter-defibrillator implantation for pri-</text>
<text top="1084" left="503" width="246" height="12" font="4">mary prevention. J Am Coll Cardiol. 2011;58:1485–96.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e369</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="12" font="4">  S7.3-10.  Corrado D, Calkins H, Link MS, et al. Prophylactic implantable defi-</text>
<text top="102" left="125" width="300" height="12" font="4">brillator in patients with arrhythmogenic right ventricular cardiomy-</text>
<text top="116" left="125" width="305" height="12" font="4">opathy/dysplasia and no prior ventricular fibrillation or sustained </text>
<text top="129" left="125" width="250" height="12" font="4">ventricular tachycardia. Circulation. 2010;122:1144–52.</text>
<text top="143" left="74" width="354" height="12" font="4">  S7.3-11.  Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic </text>
<text top="157" left="125" width="306" height="12" font="4">right ventricular cardiomyopathy/dysplasia: an international task </text>
<text top="170" left="125" width="263" height="12" font="4">force consensus statement. Circulation. 2015;132:441–53.</text>
<text top="184" left="74" width="354" height="12" font="4">  S7.3-12.  Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the </text>
<text top="197" left="125" width="300" height="12" font="4">North American multidisciplinary study of ARVC: predictors, charac-</text>
<text top="211" left="125" width="270" height="12" font="4">teristics, and treatment. J Am Coll Cardiol. 2014;64:119–25.</text>
<text top="225" left="74" width="351" height="12" font="4">  S7.3-13.  Piccini JP, Dalal D, Roguin A, et al. Predictors of appropriate implant-</text>
<text top="238" left="125" width="305" height="12" font="4">able defibrillator therapies in patients with arrhythmogenic right </text>
<text top="252" left="125" width="241" height="12" font="4">ventricular dysplasia. Heart Rhythm. 2005;2:1188–94.</text>
<text top="266" left="74" width="351" height="12" font="4">  S7.3-14.  Marcus FI, Zareba W, Calkins H, et al. Arrhythmogenic right ventric-</text>
<text top="279" left="125" width="304" height="12" font="4">ular cardiomyopathy/dysplasia clinical presentation and diagnostic </text>
<text top="293" left="125" width="303" height="12" font="4">evaluation: results from the North American Multidisciplinary Study. </text>
<text top="307" left="125" width="140" height="12" font="4">Heart Rhythm. 2009;6:984–92.</text>
<text top="320" left="74" width="351" height="12" font="4">  S7.3-15.  Marcus GM, Glidden DV, Polonsky B, et al. Efficacy of antiarrhyth-</text>
<text top="334" left="125" width="305" height="12" font="4">mic drugs in arrhythmogenic right ventricular cardiomyopathy: a </text>
<text top="347" left="125" width="303" height="12" font="4">report from the North American ARVC Registry. J Am Coll Cardiol. </text>
<text top="361" left="125" width="78" height="12" font="4">2009;54:609–15.</text>
<text top="375" left="74" width="351" height="12" font="4">  S7.3-16.  Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopatho-</text>
<text top="388" left="125" width="300" height="12" font="4">logic manifestations of arrhythmogenic right ventricular car-</text>
<text top="402" left="125" width="305" height="12" font="4">diomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. </text>
<text top="416" left="125" width="86" height="12" font="4">1997;30:1512–20.</text>
<text top="429" left="74" width="351" height="12" font="4"> S7.3-17.  James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-</text>
<text top="443" left="125" width="300" height="12" font="4">related penetrance and arrhythmic risk in arrhythmogenic right ven-</text>
<text top="457" left="125" width="303" height="12" font="4">tricular dysplasia/cardiomyopathy-associated desmosomal mutation </text>
<text top="470" left="125" width="199" height="12" font="4">carriers. J Am Coll Cardiol. 2013;62:1290–7.</text>
<text top="484" left="74" width="355" height="12" font="4">  S7.3-18.  Ruwald AC, Marcus F, Estes NA 3rd, et al. Association of competitive </text>
<text top="497" left="125" width="304" height="12" font="4">and recreational sport participation with cardiac events in patients </text>
<text top="511" left="125" width="303" height="12" font="4">with arrhythmogenic right ventricular cardiomyopathy: results from </text>
<text top="525" left="125" width="303" height="12" font="4">the North American multidisciplinary study of arrhythmogenic right </text>
<text top="538" left="125" width="264" height="12" font="4">ventricular cardiomyopathy. Eur Heart J. 2015;36:1735–43.</text>
<text top="552" left="74" width="356" height="12" font="4"> S7.3-19.  Saberniak J, Hasselberg NE, Borgquist R, et al. Vigorous physical </text>
<text top="566" left="125" width="302" height="12" font="4">activity impairs myocardial function in patients with arrhythmogenic </text>
<text top="579" left="125" width="305" height="12" font="4">right ventricular cardiomyopathy and in mutation positive family </text>
<text top="593" left="125" width="203" height="12" font="4">members. Eur J Heart Fail. 2014;16:1337–44.</text>
<text top="607" left="74" width="351" height="12" font="4">  S7.3-20.  Sawant AC, Bhonsale A, te Riele AS, et al. Exercise has a dispropor-</text>
<text top="620" left="125" width="303" height="12" font="4">tionate role in the pathogenesis of arrhythmogenic right ventricular </text>
<text top="634" left="125" width="300" height="12" font="4">dysplasia/cardiomyopathy in patients without desmosomal muta-</text>
<text top="648" left="125" width="190" height="12" font="4">tions. J Am Heart Assoc. 2014;3:e001471.</text>
<text top="661" left="74" width="354" height="12" font="4">  S7.3-21.  Sawant AC, te Riele AS, Tichnell C, et al. Safety of American Heart </text>
<text top="675" left="125" width="309" height="12" font="4">Association-recommended minimum exercise for desmosomal </text>
<text top="688" left="125" width="233" height="12" font="4">mutation carriers. Heart Rhythm. 2016;13:199–207.</text>
<text top="702" left="74" width="351" height="12" font="4"> S7.3-22.  Bhonsale A, Groeneweg JA, James CA, et al. Impact of geno-</text>
<text top="716" left="125" width="300" height="12" font="4">type on clinical course in arrhythmogenic right ventricular dys-</text>
<text top="729" left="125" width="306" height="12" font="4">plasia/cardiomyopathy-associated mutation carriers. Eur Heart J. </text>
<text top="743" left="125" width="78" height="12" font="4">2015;36:847–55.</text>
<text top="757" left="74" width="357" height="12" font="4"> S7.3-23.  Bhonsale A, James CA, Tichnell C, et al. Risk stratification in </text>
<text top="770" left="125" width="300" height="12" font="4">arrhythmogenic right ventricular dysplasia/cardiomyopathy-associ-</text>
<text top="784" left="125" width="304" height="12" font="4">ated desmosomal mutation carriers. Circ Arrhythm Electrophysiol. </text>
<text top="798" left="125" width="72" height="12" font="4">2013;6:569–78.</text>
<text top="811" left="74" width="351" height="12" font="4"> S7.3-24.  Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evalua-</text>
<text top="825" left="125" width="303" height="12" font="4">tion of cardiomyopathy–a Heart Failure Society of America practice </text>
<text top="838" left="125" width="170" height="12" font="4">guideline. J Card Fail. 2009;15:83–97.</text>
<text top="852" left="74" width="356" height="12" font="4"> S7.3-25.  Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing </text>
<text top="866" left="125" width="300" height="12" font="4">arrhythmogenic right ventricular cardiomyopathy/dysplasia-associ-</text>
<text top="879" left="125" width="303" height="12" font="4">ated mutations from background genetic noise. J Am Coll Cardiol. </text>
<text top="893" left="125" width="84" height="12" font="4">2011;57:2317–27.</text>
<text top="907" left="74" width="357" height="12" font="4"> S7.3-26.  Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic </text>
<text top="920" left="125" width="305" height="12" font="4">heterozygosity predicts lifetime arrhythmic outcome and sudden </text>
<text top="934" left="125" width="305" height="12" font="4">cardiac death in desmosomal gene-related arrhythmogenic right </text>
<text top="948" left="125" width="300" height="12" font="4">ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533–42.</text>
<text top="961" left="74" width="355" height="12" font="4">  S7.3-27.  Philips B, te Riele AS, Sawant A, et al. Outcomes and ventricular </text>
<text top="975" left="125" width="305" height="12" font="4">tachycardia recurrence characteristics after epicardial ablation of </text>
<text top="989" left="125" width="300" height="12" font="4">ventricular tachycardia in arrhythmogenic right ventricular dyspla-</text>
<text top="1002" left="125" width="237" height="12" font="4">sia/cardiomyopathy. Heart Rhythm. 2015;12:716–25.</text>
<text top="1016" left="74" width="357" height="12" font="4"> S7.3-28.  Philips B, Madhavan S, James C, et al. Outcomes of catheter </text>
<text top="1029" left="125" width="300" height="12" font="4">ablation of ventricular tachycardia in arrhythmogenic right ven-</text>
<text top="1043" left="125" width="307" height="12" font="4">tricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol. </text>
<text top="1057" left="125" width="78" height="12" font="4">2012;5:499–505.</text>
<text top="1070" left="74" width="351" height="12" font="4">  S7.3-29.  Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter abla-</text>
<text top="1084" left="125" width="306" height="12" font="4">tion of ventricular tachycardia in patients with arrhythmogenic </text>
<text top="88" left="503" width="307" height="12" font="4">right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. </text>
<text top="102" left="503" width="78" height="12" font="4">2007;50:432–40.</text>
<text top="116" left="452" width="351" height="12" font="4"> S7.3-30.  Garcia FC, Bazan V, Zado ES, et al. Epicardial substrate and out-</text>
<text top="129" left="503" width="300" height="12" font="4">come with epicardial ablation of ventricular tachycardia in arrhyth-</text>
<text top="143" left="503" width="306" height="12" font="4">mogenic right ventricular cardiomyopathy/dysplasia. Circulation. </text>
<text top="157" left="503" width="84" height="12" font="4">2009;120:366–75.</text>
<text top="170" left="452" width="351" height="12" font="4"> S7.3-31.  Bai R, Di BL, Shivkumar K, et al. Ablation of ventricular arrhyth-</text>
<text top="184" left="503" width="300" height="12" font="4">mias in arrhythmogenic right ventricular dysplasia/cardiomyopa-</text>
<text top="197" left="503" width="304" height="12" font="4">thy: arrhythmia-free survival after endo-epicardial substrate based </text>
<text top="211" left="503" width="303" height="12" font="4">mapping and ablation. Circ Arrhythm Electrophysiol. 2011;4: </text>
<text top="225" left="503" width="37" height="12" font="4">478–85.</text>
<text top="238" left="452" width="351" height="12" font="4">  S7.3-32.  Berruezo A, Fernandez-Armenta J, Mont L, et al. Combined endo-</text>
<text top="252" left="503" width="300" height="12" font="4">cardial and epicardial catheter ablation in arrhythmogenic right ven-</text>
<text top="266" left="503" width="305" height="12" font="4">tricular dysplasia incorporating scar dechanneling technique. Circ </text>
<text top="279" left="503" width="185" height="12" font="4">Arrhythm Electrophysiol. 2012;5:111–21.</text>
<text top="293" left="452" width="358" height="12" font="4"> S7.3-33. Santangeli P, Zado ES, Supple GE, et al. Long-term outcome </text>
<text top="307" left="503" width="305" height="12" font="4">with catheter ablation of ventricular tachycardia in patients with </text>
<text top="320" left="503" width="306" height="12" font="4">arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm </text>
<text top="334" left="503" width="145" height="12" font="4">Electrophysiol. 2015;8:1413–21.</text>
<text top="348" left="452" width="355" height="12" font="4">  S7.3-34.  Choudhary N, Tompkins C, Polonsky B, et al. Clinical Presentation </text>
<text top="361" left="503" width="309" height="12" font="4">and Outcomes by Sex in Arrhythmogenic Right Ventricular </text>
<text top="375" left="503" width="303" height="12" font="4">Cardiomyopathy: findings from the North American ARVC Registry. </text>
<text top="388" left="503" width="203" height="12" font="4">J Cardiovasc Electrophysiol. 2016;27:555–62.</text>
<text top="402" left="452" width="353" height="12" font="4">  S7.3-35.  Kamath GS, Zareba W, Delaney J, et al. Value of the signal-averaged </text>
<text top="416" left="503" width="300" height="12" font="4">electrocardiogram in arrhythmogenic right ventricular cardiomyopa-</text>
<text top="429" left="503" width="202" height="12" font="4">thy/dysplasia. Heart Rhythm. 2011;8:256–62.</text>
<text top="443" left="452" width="354" height="12" font="4">  S7.3-36.  Saguner AM, Medeiros-Domingo A, Schwyzer MA, et al. Usefulness </text>
<text top="457" left="503" width="305" height="12" font="4">of inducible ventricular tachycardia to predict long-term adverse </text>
<text top="470" left="503" width="303" height="12" font="4">outcomes in arrhythmogenic right ventricular cardiomyopathy. Am </text>
<text top="484" left="503" width="122" height="12" font="4">J Cardiol. 2013;111:250–7.</text>
<text top="498" left="452" width="351" height="12" font="4">  S7.3-37.  Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhyth-</text>
<text top="511" left="503" width="303" height="12" font="4">mogenic cardiomyopathy: an under-recognized clinical entity. J Am </text>
<text top="525" left="503" width="142" height="12" font="4">Coll Cardiol. 2008;52:2175–87.</text>
<text top="538" left="452" width="351" height="12" font="4">  S7.3-38.  Te Riele AS, James CA, Philips B, et al. Mutation-positive arrhyth-</text>
<text top="552" left="503" width="306" height="12" font="4">mogenic right ventricular dysplasia/cardiomyopathy: the triangle </text>
<text top="566" left="503" width="303" height="12" font="4">of dysplasia displaced. J Cardiovasc Electrophysiol. 2013;24: </text>
<text top="579" left="503" width="43" height="12" font="4">1311–20.</text>
<text top="593" left="452" width="351" height="12" font="4">  S7.3-39.  Rastegar N, Zimmerman SL, Te Riele AS, et al. Spectrum of biven-</text>
<text top="607" left="503" width="305" height="12" font="4">tricular involvement on cmr among carriers of arvd/c-associated </text>
<text top="620" left="503" width="224" height="12" font="4">mutations. JACC Cardiovasc Imag. 2015;8:863–4.</text>
<text top="634" left="452" width="351" height="12" font="4">  S7.3-40.  Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic charac-</text>
<text top="648" left="503" width="300" height="12" font="4">terization of families with arrhythmogenic right ventricular dyspla-</text>
<text top="661" left="503" width="303" height="12" font="4">sia/cardiomyopathy provides novel insights into patterns of disease </text>
<text top="675" left="503" width="196" height="12" font="4">expression. Circulation. 2007;115:1710–20.</text>
<text top="689" left="452" width="351" height="12" font="4">  S7.3-41.  Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricu-</text>
<text top="702" left="503" width="303" height="12" font="4">lar dysplasia: a United States experience. Circulation. 2005;112: </text>
<text top="716" left="503" width="43" height="12" font="4">3823–32.</text>
<text top="729" left="452" width="354" height="12" font="4">  S7.3-42.  Brun F, Groeneweg JA, Gear K, et al. Risk stratification in arrhythmic </text>
<text top="743" left="503" width="300" height="12" font="4">right ventricular cardiomyopathy without implantable cardioverter-</text>
<text top="757" left="503" width="248" height="12" font="4">defibrillators. JACC Clin Electrophysiol. 2016;2:558–64.</text>
<text top="770" left="452" width="351" height="12" font="4"> S7.3-43. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-</text>
<text top="784" left="503" width="305" height="12" font="4">defibrillator therapy for prevention of sudden death in patients </text>
<text top="798" left="503" width="306" height="12" font="4">with arrhythmogenic right ventricular cardiomyopathy/dysplasia. </text>
<text top="811" left="503" width="144" height="12" font="4">Circulation. 2003;108:3084–91.</text>
<text top="825" left="452" width="357" height="12" font="4"> S7.3-44.  van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for </text>
<text top="839" left="503" width="303" height="12" font="4">malignant ventricular arrhythmias in lamin A/C mutation carriers: a </text>
<text top="852" left="503" width="274" height="12" font="4">European cohort study. J Am Coll Cardiol. 2012;59:493–500.</text>
<text top="866" left="452" width="354" height="12" font="4">  S7.3-45.  Cox MG, van der Zwaag PA, van der Werf C, et al. Arrhythmogenic </text>
<text top="879" left="503" width="300" height="12" font="4">right ventricular dysplasia/cardiomyopathy: pathogenic desmo-</text>
<text top="893" left="503" width="306" height="12" font="4">some mutations in index-patients predict outcome of family </text>
<text top="907" left="503" width="300" height="12" font="4">screening: Dutch arrhythmogenic right ventricular dysplasia/car-</text>
<text top="920" left="503" width="307" height="12" font="4">diomyopathy genotype-phenotype follow-up study. Circulation. </text>
<text top="934" left="503" width="96" height="12" font="4">2011;123:2690–700.</text>
<text top="948" left="452" width="351" height="12" font="4"> S7.3-46.  Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro-</text>
<text top="961" left="503" width="304" height="12" font="4">physiologic testing in risk stratification for sudden cardiac death. J </text>
<text top="975" left="503" width="153" height="12" font="4">Invasive Cardiol. 2001;13:758–62.</text>
<text top="989" left="452" width="355" height="12" font="4">  S7.3-47.  Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study </text>
<text top="1002" left="503" width="302" height="12" font="4">and prophylactic implantation of cardioverter defibrillator in patients </text>
<text top="1016" left="503" width="308" height="12" font="4">with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. </text>
<text top="1029" left="503" width="84" height="12" font="4">1998;21:299–302.</text>
<text top="1043" left="452" width="351" height="12" font="4">  S7.3-48.  Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhyth-</text>
<text top="1057" left="503" width="303" height="12" font="4">mic drugs in patients with arrhythmogenic right ventricular disease. </text>
<text top="1070" left="503" width="306" height="12" font="4">Results in patients with inducible and noninducible ventricular </text>
<text top="1084" left="503" width="183" height="12" font="4">tachycardia. Circulation. 1992;86:29–37.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e370</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="291" height="21" font="18"><b>7.4. Hypertrophic Cardiomyopathy</b></text>
<text top="114" left="80" width="349" height="12" font="4">  S7.4-1.  Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest </text>
<text top="127" left="125" width="304" height="12" font="4">or sustained ventricular tachycardia in patients with hypertrophic </text>
<text top="141" left="125" width="250" height="12" font="4">cardiomyopathy. J Am Coll Cardiol. 1999;33:1596–601.</text>
<text top="155" left="80" width="345" height="12" font="4">  S7.4-2.  Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertro-</text>
<text top="168" left="125" width="303" height="12" font="4">phic cardiomyopathy: identification of high risk patients. J Am Coll </text>
<text top="182" left="125" width="116" height="12" font="4">Cardiol. 2000;36:2212–8.</text>
<text top="196" left="80" width="349" height="12" font="4">  S7.4-3.  Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between </text>
<text top="209" left="125" width="305" height="12" font="4">severity of left-ventricular hypertrophy and prognosis in patients </text>
<text top="223" left="125" width="272" height="12" font="4">with hypertrophic cardiomyopathy. Lancet. 2001;357:420–4.</text>
<text top="237" left="80" width="348" height="12" font="4">  S7.4-4.  Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract </text>
<text top="250" left="125" width="300" height="12" font="4">obstruction and sudden death risk in patients with hypertrophic car-</text>
<text top="264" left="125" width="202" height="12" font="4">diomyopathy. Eur Heart J. 2006;27:1933–41.</text>
<text top="278" left="80" width="349" height="12" font="4">  S7.4-5.  Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death </text>
<text top="291" left="125" width="282" height="12" font="4">in hypertrophic cardiomyopathy. Am J Cardiol. 1998;82:774–8.</text>
<text top="305" left="80" width="345" height="12" font="4">  S7.4-6.  Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defi-</text>
<text top="319" left="125" width="304" height="12" font="4">brillators and prevention of sudden cardiac death in hypertrophic </text>
<text top="332" left="125" width="193" height="12" font="4">cardiomyopathy. JAMA. 2007;298:405–12.</text>
<text top="346" left="80" width="348" height="12" font="4">  S7.4-7.  O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction </text>
<text top="360" left="125" width="305" height="12" font="4">model for sudden cardiac death in hypertrophic cardiomyopathy </text>
<text top="373" left="125" width="214" height="12" font="4">(HCM risk-SCD). Eur Heart J. 2014;35:2010–20.</text>
<text top="387" left="80" width="347" height="12" font="4">  S7.4-8.  Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death </text>
<text top="401" left="125" width="291" height="12" font="4">in hypertrophic cardiomyopathy. Circulation. 2009;119:1703–10.</text>
<text top="414" left="80" width="345" height="12" font="4"> S7.4-9.  O’Mahony C, Lambiase PD, Quarta G, et al. The long-term sur-</text>
<text top="428" left="125" width="300" height="12" font="4">vival and the risks and benefits of implantable cardioverter defi-</text>
<text top="442" left="125" width="307" height="12" font="4">brillators in patients with hypertrophic cardiomyopathy. Heart. </text>
<text top="455" left="125" width="78" height="12" font="4">2012;98:116–25.</text>
<text top="469" left="74" width="351" height="12" font="4">  S7.4-10.  Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter-</text>
<text top="483" left="125" width="300" height="12" font="4">defibrillator in patients with hypertrophic cardiomyopathy: effi-</text>
<text top="496" left="125" width="305" height="12" font="4">cacy and complications of the therapy in long-term follow-up. J </text>
<text top="510" left="125" width="190" height="12" font="4">Cardiovasc Electrophysiol. 2010;21:883–9.</text>
<text top="524" left="74" width="351" height="12" font="4"> S7.4-11.  Adabag AS, Kuskowski MA, Maron BJ. Determinants for clini-</text>
<text top="537" left="125" width="308" height="12" font="4">cal diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. </text>
<text top="551" left="125" width="84" height="12" font="4">2006;98:1507–11.</text>
<text top="565" left="74" width="354" height="12" font="4">  S7.4-12.  Afonso LC, Bernal J, Bax JJ, et al. Echocardiography in hypertrophic </text>
<text top="578" left="125" width="300" height="12" font="4">cardiomyopathy: the role of conventional and emerging technolo-</text>
<text top="592" left="125" width="208" height="12" font="4">gies. JACC Cardiovasc Imag. 2008;1:787–800.</text>
<text top="606" left="74" width="354" height="12" font="4">  S7.4-13.  Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome </text>
<text top="619" left="125" width="305" height="12" font="4">of hypertrophic cardiomyopathy associated with triple sarcomere </text>
<text top="633" left="125" width="278" height="12" font="4">protein gene mutations. J Am Coll Cardiol. 2010;55:1444–53.</text>
<text top="647" left="74" width="356" height="12" font="4"> S7.4-14.  Ingles J, Sarina T, Yeates L, et al. Clinical predictors of genetic </text>
<text top="660" left="125" width="306" height="12" font="4">testing outcomes in hypertrophic cardiomyopathy. Genet Med. </text>
<text top="674" left="125" width="72" height="12" font="4">2013;15:972–7.</text>
<text top="688" left="74" width="357" height="12" font="4"> S7.4-15.  Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of </text>
<text top="701" left="125" width="303" height="12" font="4">hypertrophic cardiomyopathy in children and adolescents: a 12-year </text>
<text top="715" left="125" width="303" height="12" font="4">follow-up study of clinical screening and predictive genetic testing. </text>
<text top="729" left="125" width="132" height="12" font="4">Circulation. 2013;127:48–54.</text>
<text top="742" left="74" width="354" height="12" font="4">  S7.4-16.  Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns </text>
<text top="756" left="125" width="306" height="12" font="4">of left ventricular hypertrophy in hypertrophic cardiomyopathy: </text>
<text top="770" left="125" width="300" height="12" font="4">morphologic observations and significance as assessed by two-</text>
<text top="783" left="125" width="304" height="12" font="4">dimensional echocardiography in 600 patients. J Am Coll Cardiol. </text>
<text top="797" left="125" width="90" height="12" font="4">1995;26:1699–708.</text>
<text top="811" left="74" width="351" height="12" font="4"> S7.4-17. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic car-</text>
<text top="824" left="125" width="309" height="12" font="4">diomyopathy. Clinical spectrum and treatment. Circulation. </text>
<text top="838" left="125" width="86" height="12" font="4">1995;92:1680–92.</text>
<text top="852" left="74" width="351" height="12" font="4">  S7.4-18.  Christiaans I, Birnie E, van Langen IM, et al. The yield of risk strati-</text>
<text top="866" left="125" width="304" height="12" font="4">fication for sudden cardiac death in hypertrophic cardiomyopathy </text>
<text top="879" left="125" width="300" height="12" font="4">myosin-binding protein C gene mutation carriers: focus on predic-</text>
<text top="893" left="125" width="194" height="12" font="4">tive screening. Eur Heart J. 2010;31:842–8.</text>
<text top="907" left="74" width="353" height="12" font="4">  S7.4-19.  Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene </text>
<text top="920" left="125" width="300" height="12" font="4">mutation screening and outcome of patients with hypertrophic car-</text>
<text top="934" left="125" width="209" height="12" font="4">diomyopathy. Mayo Clin Proc. 2008;83:630–8.</text>
<text top="948" left="74" width="356" height="12" font="4"> S7.4-20.  Christiaans I, van Langen IM, Birnie E, et al. Genetic counseling </text>
<text top="961" left="125" width="303" height="12" font="4">and cardiac care in predictively tested hypertrophic cardiomyopathy </text>
<text top="975" left="125" width="303" height="12" font="4">mutation carriers: the patients’ perspective. Am J Med Genet. 2009 </text>
<text top="989" left="125" width="69" height="12" font="4">149a 1444–51.</text>
<text top="1002" left="74" width="356" height="12" font="4"> S7.4-21.  Hamang A, Eide GE, Rokne B, et al. Predictors of heart-focused </text>
<text top="1016" left="125" width="303" height="12" font="4">anxiety in patients undergoing genetic investigation and counseling </text>
<text top="1030" left="125" width="304" height="12" font="4">of long QT syndrome or hypertrophic cardiomyopathy: a one year </text>
<text top="1043" left="125" width="200" height="12" font="4">follow-up. J Genet Counsel. 2012;21:72–84.</text>
<text top="1057" left="74" width="351" height="12" font="4">  S7.4-22.  Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-</text>
<text top="1071" left="125" width="306" height="12" font="4">based genetic test prediction score for unrelated patients with </text>
<text top="1084" left="125" width="287" height="12" font="4">hypertrophic cardiomyopathy. Mayo Clin Proc. 2014;89:727–37.</text>
<text top="89" left="452" width="354" height="12" font="4">  S7.4-23.  Sorajja P, Nishimura RA, Ommen SR, et al. Use of echocardiography </text>
<text top="102" left="503" width="304" height="12" font="4">in patients with hypertrophic cardiomyopathy: clinical implications </text>
<text top="116" left="503" width="294" height="12" font="4">of massive hypertrophy. J Am Soc Echocardiogr. 2006;19:788–95.</text>
<text top="130" left="452" width="355" height="12" font="4">  S7.4-24.  Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular </text>
<text top="143" left="503" width="300" height="12" font="4">hypertrophy and risk of sudden death in hypertrophic cardiomyopa-</text>
<text top="157" left="503" width="174" height="12" font="4">thy. N Engl J Med. 2000;342:1778–85.</text>
<text top="170" left="452" width="355" height="12" font="4">  S7.4-25.  Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of </text>
<text top="184" left="503" width="303" height="12" font="4">sudden death in risk stratification and prevention of sudden death </text>
<text top="198" left="503" width="303" height="12" font="4">with implantable defibrillators in hypertrophic cardiomyopathy. Am </text>
<text top="211" left="503" width="128" height="12" font="4">J Cardiol. 2010;106:1481–6.</text>
<text top="225" left="452" width="351" height="12" font="4">  S7.4-26.  Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardio-</text>
<text top="239" left="503" width="304" height="12" font="4">verter-defibrillators for the prevention of sudden death in patients </text>
<text top="252" left="503" width="300" height="12" font="4">with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–73.</text>
<text top="266" left="452" width="351" height="12" font="4">  S7.4-27.  Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricu-</text>
<text top="280" left="503" width="305" height="12" font="4">lar tachycardia in hypertrophic cardiomyopathy: an independent </text>
<text top="293" left="503" width="304" height="12" font="4">marker of sudden death risk in young patients. J Am Coll Cardiol. </text>
<text top="307" left="503" width="72" height="12" font="4">2003;42:873–9.</text>
<text top="320" left="452" width="351" height="12" font="4">  S7.4-28.  Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of sys-</text>
<text top="334" left="503" width="300" height="12" font="4">temic blood pressure response during exercise in a community-</text>
<text top="348" left="503" width="304" height="12" font="4">based patient population with hypertrophic cardiomyopathy. J Am </text>
<text top="361" left="503" width="142" height="12" font="4">Coll Cardiol. 1999;33:2044–51.</text>
<text top="375" left="452" width="351" height="12" font="4">  S7.4-29.  Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assess-</text>
<text top="389" left="503" width="304" height="12" font="4">ment of blood pressure response during exercise in patients with </text>
<text top="402" left="503" width="274" height="12" font="4">hypertrophic cardiomyopathy. Circulation. 1997;96:2987–91.</text>
<text top="416" left="452" width="354" height="12" font="4">  S7.4-30.  McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with </text>
<text top="430" left="503" width="300" height="12" font="4">amiodarone in patients with hypertrophic cardiomyopathy and ven-</text>
<text top="443" left="503" width="212" height="12" font="4">tricular tachycardia. Br Heart J. 1985;53:412–6.</text>
<text top="457" left="452" width="354" height="12" font="4">  S7.4-31.  Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological </text>
<text top="471" left="503" width="300" height="12" font="4">strategies lack efficacy for the prevention of sudden death in hyper-</text>
<text top="484" left="503" width="219" height="12" font="4">trophic cardiomyopathy. Heart. 2007;93:708–10.</text>
<text top="498" left="452" width="351" height="12" font="4">  S7.4-32.  Kuck KH, Kunze KP, Schluter M, et al. Programmed electrical stimu-</text>
<text top="511" left="503" width="303" height="12" font="4">lation in hypertrophic cardiomyopathy. Results in patients with and </text>
<text top="525" left="503" width="281" height="12" font="4">without cardiac arrest or syncope. Eur Heart J. 1988;9:177–85.</text>
<text top="539" left="452" width="355" height="12" font="4">  S7.4-33.  Zhu DW, Sun H, Hill R, et al. The value of electrophysiology study </text>
<text top="552" left="503" width="302" height="12" font="4">and prophylactic implantation of cardioverter defibrillator in patients </text>
<text top="566" left="503" width="308" height="12" font="4">with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. </text>
<text top="580" left="503" width="84" height="12" font="4">1998;21:299–302.</text>
<text top="593" left="452" width="351" height="12" font="4">  S7.4-34.  Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and age-</text>
<text top="607" left="503" width="302" height="12" font="4">dependence of malignant mutations in the beta-myosin heavy chain </text>
<text top="621" left="503" width="300" height="12" font="4">and troponin T genes in hypertrophic cardiomyopathy: a compre-</text>
<text top="634" left="503" width="300" height="12" font="4">hensive outpatient perspective. J Am Coll Cardiol. 2002;39:2042–8.</text>
<text top="648" left="452" width="351" height="12" font="4">  S7.4-35.  Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-</text>
<text top="661" left="503" width="300" height="12" font="4">analysis of genotype-phenotype associations in patients with hyper-</text>
<text top="675" left="503" width="305" height="12" font="4">trophic cardiomyopathy caused by sarcomeric protein mutations. </text>
<text top="689" left="503" width="114" height="12" font="4">Heart. 2013;99:1800–11.</text>
<text top="702" left="452" width="354" height="12" font="4">  S7.4-36.  Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline </text>
<text top="716" left="503" width="300" height="12" font="4">for the diagnosis and treatment of hypertrophic cardiomyopa-</text>
<text top="730" left="503" width="300" height="12" font="4">thy: a report of the American College of Cardiology Foundation/</text>
<text top="743" left="503" width="305" height="12" font="4">American Heart Association Task Force on Practice Guidelines. </text>
<text top="757" left="503" width="306" height="12" font="4">Developed in collaboration with the American Association for </text>
<text top="771" left="503" width="302" height="12" font="4">Thoracic Surgery, American Society of Echocardiography, American </text>
<text top="784" left="503" width="304" height="12" font="4">Society of Nuclear Cardiology, Heart Failure Society of America, </text>
<text top="798" left="503" width="306" height="12" font="4">Heart Rhythm Society, Society for Cardiovascular Angiography </text>
<text top="812" left="503" width="304" height="12" font="4">and Interventions, and Society of Thoracic Surgeons. Circulation. </text>
<text top="825" left="503" width="92" height="12" font="4">2011;124:783–831.</text>
<text top="839" left="452" width="351" height="12" font="4">  S7.4-37.  Green JJ, Berger JS, Kramer CM, et al. Prognostic value of late gado-</text>
<text top="852" left="503" width="300" height="12" font="4">linium enhancement in clinical outcomes for hypertrophic cardio-</text>
<text top="866" left="503" width="236" height="12" font="4">myopathy. JACC Cardiovasc Imaging. 2012;5:370–7.</text>
<text top="880" left="452" width="355" height="12" font="4">  S7.4-38.  O’Hanlon R, Grasso A, Roughton M, et al. Prognostic significance </text>
<text top="893" left="503" width="305" height="12" font="4">of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll </text>
<text top="907" left="503" width="116" height="12" font="4">Cardiol. 2010;56:867–74.</text>
<text top="921" left="452" width="355" height="12" font="4">  S7.4-39.  Rubinshtein R, Glockner JF, Ommen SR, et al. Characteristics and </text>
<text top="934" left="503" width="300" height="12" font="4">clinical significance of late gadolinium enhancement by contrast-</text>
<text top="948" left="503" width="300" height="12" font="4">enhanced magnetic resonance imaging in patients with hypertro-</text>
<text top="962" left="503" width="227" height="12" font="4">phic cardiomyopathy. Circ Heart Fail. 2010;3:51–8.</text>
<text top="975" left="452" width="355" height="12" font="4">  S7.4-40.  Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic cardiomyopathy </text>
<text top="989" left="503" width="300" height="12" font="4">with left ventricular apical aneurysm: implications for risk stratifica-</text>
<text top="1002" left="503" width="267" height="12" font="4">tion and management. J Am Coll Cardiol. 2017;69:761–73.</text>
<text top="1016" left="452" width="354" height="12" font="4">  S7.4-41.  Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome </text>
<text top="1030" left="503" width="304" height="12" font="4">of patients with hypertrophic cardiomyopathy &gt;=60 years of age. </text>
<text top="1043" left="503" width="138" height="12" font="4">Circulation. 2013;127:585–93.</text>
<text top="1057" left="452" width="354" height="12" font="4">  S7.4-42.  Francia P, Adduci C, Palano F, et al. Eligibility for the subcutaneous </text>
<text top="1071" left="503" width="304" height="12" font="4">implantable cardioverter-defibrillator in patients with hypertrophic </text>
<text top="1084" left="503" width="273" height="12" font="4">cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:893–9.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e371</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="354" height="12" font="4">  S7.4-43.  Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors </text>
<text top="102" left="125" width="303" height="12" font="4">for sudden cardiac death, and cardiac events in a large nationwide </text>
<text top="115" left="125" width="303" height="12" font="4">cohort of predictively tested hypertrophic cardiomyopathy mutation </text>
<text top="129" left="125" width="304" height="12" font="4">carriers: determining the best cardiological screening strategy. Eur </text>
<text top="142" left="125" width="121" height="12" font="4">Heart J. 2011;32:1161–70.</text>
<text top="156" left="74" width="356" height="12" font="4"> S7.4-44.  Morita H, Rehm HL, Menesses A, et al. Shared genetic causes </text>
<text top="169" left="125" width="306" height="12" font="4">of cardiac hypertrophy in children and adults. N Engl J Med. </text>
<text top="183" left="125" width="96" height="12" font="4">2008;358:1899–908.</text>
<text top="196" left="74" width="355" height="12" font="4">  S7.4-45.  Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the </text>
<text top="210" left="125" width="304" height="12" font="4">gene for cardiac myosin-binding protein C and late-onset familial </text>
<text top="223" left="125" width="290" height="12" font="4">hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–57.</text>
<text top="237" left="74" width="355" height="12" font="4">  S7.4-46.  Maron BJ, Semsarian C. Emergence of gene mutation carriers and </text>
<text top="250" left="125" width="304" height="12" font="4">the expanding disease spectrum of hypertrophic cardiomyopathy. </text>
<text top="264" left="125" width="132" height="12" font="4">Eur Heart J. 2010;31:1551–3.</text>
<text top="277" left="74" width="355" height="12" font="4">  S7.4-47.  Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype </text>
<text top="291" left="125" width="303" height="12" font="4">positive (+)-phenotype negative (-) family members in hypertrophic </text>
<text top="305" left="125" width="217" height="12" font="4">cardiomyopathy. Am J Cardiol. 2011;107:604–8.</text>
<text top="318" left="74" width="351" height="12" font="4"> S7.4-48.  Ingles J, Doolan A, Chiu C, et al. Compound and double muta-</text>
<text top="332" left="125" width="303" height="12" font="4">tions in patients with hypertrophic cardiomyopathy: implications for </text>
<text top="345" left="125" width="268" height="12" font="4">genetic testing and counselling. J Med Genet. 2005;42:e59.</text>
<text top="359" left="74" width="354" height="12" font="4">  S7.4-49.  Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of </text>
<text top="372" left="125" width="304" height="12" font="4">familial hypertrophic cardiomyopathy by genetic analysis of blood </text>
<text top="386" left="125" width="216" height="12" font="4">lymphocytes. N Engl J Med. 1991;325:1753–60.</text>
<text top="399" left="74" width="354" height="12" font="4">  S7.4-50.  O’Mahony C, Jichi F, Monserrat L, et al. Inverted U-shaped relation </text>
<text top="413" left="125" width="300" height="12" font="4">between the risk of sudden cardiac death and maximal left ventricu-</text>
<text top="426" left="125" width="305" height="12" font="4">lar wall thickness in hypertrophic cardiomyopathy. Circ Arrhythm </text>
<text top="440" left="125" width="145" height="12" font="4">Electrophysiol. 2016;9:e003818.</text>
<text top="453" left="74" width="351" height="12" font="4"> S7.4-51.  Saeed M, Homoud MK, Wang PJ, et al. Role of invasive electro-</text>
<text top="467" left="125" width="304" height="12" font="4">physiologic testing in risk stratification for sudden cardiac death. J </text>
<text top="480" left="125" width="153" height="12" font="4">Invasive Cardiol. 2001;13:758–62.</text>
<text top="494" left="74" width="353" height="12" font="4">  S7.4-52.  Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: one </text>
<text top="507" left="125" width="289" height="12" font="4">gene … but many phenotypes. Am J Cardiol. 2014;113:1772–3.</text>
<text top="521" left="74" width="351" height="12" font="4"> S7.4-53.  Ho CY, Cirino AL, Lakdawala NK, et al. Evolution of hypertro-</text>
<text top="534" left="125" width="309" height="12" font="4">phic cardiomyopathy in sarcomere mutation carriers. Heart. </text>
<text top="548" left="125" width="90" height="12" font="4">2016;102:1805–12.</text>
<text top="561" left="74" width="355" height="12" font="4">  S7.4-54.  Moon JC, McKenna WJ, McCrohon JA, et al. Toward clinical risk </text>
<text top="575" left="125" width="300" height="12" font="4">assessment in hypertrophic cardiomyopathy with gadolinium cardio-</text>
<text top="588" left="125" width="295" height="12" font="4">vascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–7.</text>
<text top="602" left="74" width="354" height="12" font="4">  S7.4-55.  Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, </text>
<text top="615" left="125" width="300" height="12" font="4">and natural history of left ventricular apical aneurysms in hypertro-</text>
<text top="629" left="125" width="236" height="12" font="4">phic cardiomyopathy. Circulation. 2008;118:1541–9.</text>
<text top="642" left="74" width="351" height="12" font="4">  S7.4-56.  Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of mid-</text>
<text top="656" left="125" width="300" height="12" font="4">ventricular obstruction in patients with hypertrophic cardiomyopa-</text>
<text top="669" left="125" width="186" height="12" font="4">thy. J Am Coll Cardiol. 2011;57:2346–55.</text>
<text top="709" left="74" width="134" height="21" font="18"><b>7.5. Myocarditis</b></text>
<text top="736" left="74" width="354" height="12" font="4">  S7.5-1.  Aoyama N, Izumi T, Hiramori K, et al. National survey of fulminant </text>
<text top="749" left="125" width="300" height="12" font="4">myocarditis in Japan: therapeutic guidelines and long-term progno-</text>
<text top="763" left="125" width="304" height="12" font="4">sis of using percutaneous cardiopulmonary support for fulminant </text>
<text top="776" left="125" width="306" height="12" font="4">myocarditis (special report from a scientific committee). Circ J. </text>
<text top="790" left="125" width="78" height="12" font="4">2002;66:133–44.</text>
<text top="803" left="74" width="355" height="12" font="4">  S7.5-2.  Maleszewski JJ, Orellana VM, Hodge DO, et al. Long-term risk of </text>
<text top="817" left="125" width="304" height="12" font="4">recurrence, morbidity and mortality in giant cell myocarditis. Am J </text>
<text top="830" left="125" width="122" height="12" font="4">Cardiol. 2015;115:1733–8.</text>
<text top="844" left="74" width="351" height="12" font="4">  S7.5-3.  Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–</text>
<text top="857" left="125" width="304" height="12" font="4">natural history and treatment. Multicenter Giant Cell Myocarditis </text>
<text top="871" left="125" width="270" height="12" font="4">Study Group Investigators. N Engl J Med. 1997;336:1860–6.</text>
<text top="884" left="74" width="355" height="12" font="4">  S7.5-4.  Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, </text>
<text top="898" left="125" width="306" height="12" font="4">and outcome of giant-cell myocarditis in the era of combined </text>
<text top="911" left="125" width="230" height="12" font="4">immunosuppression. Circ Heart Fail. 2013;6:15–22.</text>
<text top="925" left="74" width="351" height="12" font="4">  S7.5-5.  Friman G, Wesslen L, Fohlman J, et al. The epidemiology of infec-</text>
<text top="938" left="125" width="300" height="12" font="4">tious myocarditis, lymphocytic myocarditis and dilated cardiomy-</text>
<text top="952" left="125" width="200" height="12" font="4">opathy. Eur Heart J. 1995:16 suppl O:36–41.</text>
<text top="965" left="74" width="356" height="12" font="4">  S7.5-6.  Hufnagel G, Pankuweit S, Richter A, et al. The European Study </text>
<text top="979" left="125" width="304" height="12" font="4">of Epidemiology and Treatment of Cardiac Inflammatory Diseases </text>
<text top="992" left="125" width="282" height="12" font="4">(ESETCID). First epidemiological results. Herz. 2000;25:279–85.</text>
<text top="1006" left="74" width="356" height="12" font="4">  S7.5-7.  Winkel E, Parrillo J. Myocarditis. Curr Treat Options. Cardiovasc </text>
<text top="1019" left="125" width="99" height="12" font="4">Med. 2002;4:455–66.</text>
<text top="1033" left="74" width="356" height="12" font="4">  S7.5-8.  Zawadowski GM, Klarich KW, Moder KG, et al. A contemporary </text>
<text top="1046" left="125" width="261" height="12" font="4">case series of lupus myocarditis. Lupus. 2012;21:1378–84.</text>
<text top="1060" left="74" width="351" height="12" font="4">  S7.5-9.  Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowl-</text>
<text top="1073" left="125" width="300" height="12" font="4">edge on aetiology, diagnosis, management, and therapy of myo-</text>
<text top="1087" left="125" width="303" height="12" font="4">carditis: a position statement of the European Society of Cardiology </text>
<text top="88" left="503" width="303" height="12" font="4">Working Group on Myocardial and Pericardial Diseases. Eur Heart J. </text>
<text top="102" left="503" width="102" height="12" font="4">2013;34:2636–2648d.</text>
<text top="115" left="452" width="354" height="12" font="4">  S7.5-10.  Elamm C, Fairweather D, Cooper LT, Pathogenesis and diagnosis of </text>
<text top="129" left="503" width="165" height="12" font="4">myocarditis. Heart. 2012;98:835–40.</text>
<text top="142" left="452" width="346" height="12" font="4">  S7.5-11.  Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738–47.</text>
<text top="156" left="452" width="351" height="12" font="4">  S7.5-12.  McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term out-</text>
<text top="169" left="503" width="300" height="12" font="4">come of fulminant myocarditis as compared with acute (nonfulmi-</text>
<text top="183" left="503" width="226" height="12" font="4">nant) myocarditis. N Engl J Med. 2000;342:690–5.</text>
<text top="196" left="452" width="357" height="12" font="4"> S7.5-13.  Kawai C. From myocarditis to cardiomyopathy: mechanisms of </text>
<text top="210" left="503" width="303" height="12" font="4">inflammation and cell death: learning from the past for the future. </text>
<text top="223" left="503" width="144" height="12" font="4">Circulation. 1999;99:1091–100.</text>
<text top="237" left="452" width="357" height="12" font="4"> S7.5-14. Kindermann I, Kindermann M, Kandolf R, et al. Predictors of </text>
<text top="250" left="503" width="308" height="12" font="4">outcome in patients with suspected myocarditis. Circulation. </text>
<text top="264" left="503" width="84" height="12" font="4">2008;118:639–48.</text>
<text top="277" left="452" width="351" height="12" font="4">  S7.5-15.  Tubman TR, Craig B, Mulholland HC. Ventricular tachycardia asso-</text>
<text top="291" left="503" width="306" height="12" font="4">ciated with Coxsackie B4 virus infection. Acta Paediatr Scand. </text>
<text top="304" left="503" width="72" height="12" font="4">1990;79:572–5.</text>
<text top="318" left="452" width="351" height="12" font="4">  S7.5-16.  Tai YT, Lau CP, Fong PC, et al. Incessant automatic ventricular tachy-</text>
<text top="331" left="503" width="307" height="12" font="4">cardia complicating acute coxsackie B myocarditis. Cardiology. </text>
<text top="345" left="503" width="78" height="12" font="4">1992;80:339–44.</text>
<text top="359" left="452" width="356" height="12" font="4"> S7.5-17.  Dhar KL, Adlakha A, Phillip PJ. Recurrent seizures and syncope, </text>
<text top="372" left="503" width="305" height="12" font="4">ventricular arrhythmias with reversible prolonged Q-Tc interval in </text>
<text top="386" left="503" width="257" height="12" font="4">typhoid myocarditis. J Indian Med Assoc. 1987;85:336–7.</text>
<text top="399" left="452" width="355" height="12" font="4">  S7.5-18.  McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for </text>
<text top="413" left="503" width="305" height="12" font="4">the diagnosis and treatment of acute and chronic heart failure </text>
<text top="426" left="503" width="303" height="12" font="4">2012: the Task Force for the Diagnosis and Treatment of Acute and </text>
<text top="440" left="503" width="303" height="12" font="4">Chronic Heart Failure 2012 of the European Society of Cardiology. </text>
<text top="453" left="503" width="303" height="12" font="4">Developed in collaboration with the Heart Failure Association (HFA) </text>
<text top="467" left="503" width="203" height="12" font="4">of the ESC. Eur J Heart Fail. 2012;14:803–69.</text>
<text top="480" left="452" width="351" height="12" font="4">  S7.5-19.  Cooper LT Jr, Elamm C, Giant cell myocarditis. Diagnosis and treat-</text>
<text top="494" left="503" width="128" height="12" font="4">ment. Herz. 2012;37:632–6.</text>
<text top="507" left="452" width="357" height="12" font="4"> S7.5-20.  Milei J, Grana D, Fernandez AG, et al. Cardiac involvement in </text>
<text top="521" left="503" width="306" height="12" font="4">acquired immunodeficiency syndrome–a review to push action. </text>
<text top="534" left="503" width="303" height="12" font="4">The Committee for the Study of Cardiac Involvement in AIDS. Clin </text>
<text top="548" left="503" width="116" height="12" font="4">Cardiol. 1998;21:465–72.</text>
<text top="561" left="452" width="353" height="12" font="4">  S7.5-21.  Yunis NA, Stone VE, Cardiac manifestations of HIV/AIDS: a review of </text>
<text top="575" left="503" width="303" height="12" font="4">disease spectrum and clinical management. J Acquir Immune Defic </text>
<text top="588" left="503" width="179" height="12" font="4">Syndr Hum Retrovirol. 1998;18:145–54.</text>
<text top="602" left="452" width="354" height="12" font="4">  S7.5-22.  Huang CN, Yu HH, Chiu SN, et al. Acute myocarditis and ventricular </text>
<text top="615" left="503" width="300" height="12" font="4">fibrillation as initial presentation of pediatric systemic lupus erythe-</text>
<text top="629" left="503" width="190" height="12" font="4">matosus. Rheumatol Int. 2013;33:1093–6.</text>
<text top="642" left="452" width="355" height="12" font="4">  S7.5-23.  Rassi A Jr, Rassi A, Little WC, Chagas’ heart disease. Clin Cardiol. </text>
<text top="656" left="503" width="72" height="12" font="4">2000;23:883–9.</text>
<text top="669" left="452" width="354" height="12" font="4">  S7.5-24.  Muratore C, Rabinovich R, Iglesias R, et al. Implantable cardioverter </text>
<text top="683" left="503" width="305" height="12" font="4">defibrillators in patients with Chagas’ disease: are they different </text>
<text top="696" left="503" width="305" height="12" font="4">from patients with coronary disease? Pacing Clin Electrophysiol. </text>
<text top="710" left="503" width="72" height="12" font="4">1997;20:194–7.</text>
<text top="723" left="452" width="351" height="12" font="4">  S7.5-25.  d’Avila A, Splinter R, Svenson RH, et al. New perspectives on cath-</text>
<text top="737" left="503" width="303" height="12" font="4">eter-based ablation of ventricular tachycardia complicating Chagas’ </text>
<text top="750" left="503" width="302" height="12" font="4">disease: experimental evidence of the efficacy of near infrared lasers </text>
<text top="764" left="503" width="305" height="12" font="4">for catheter ablation of Chagas’ VT. J Interv Card Electrophysiol. </text>
<text top="777" left="503" width="67" height="12" font="4">2002;7:23–38.</text>
<text top="791" left="452" width="355" height="12" font="4">  S7.5-26.  Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in </text>
<text top="804" left="503" width="303" height="12" font="4">heart failure (WIF): results of a prospective registry. BMC Cardiovasc </text>
<text top="818" left="503" width="96" height="12" font="4">Disord. 2012;12:123.</text>
<text top="831" left="452" width="354" height="12" font="4">  S7.5-27.  Feldman AM, Klein H, Tchou P, et al. Use of a wearable defibrillator </text>
<text top="845" left="503" width="303" height="12" font="4">in terminating tachyarrhythmias in patients at high risk for sudden </text>
<text top="859" left="503" width="305" height="12" font="4">death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol. </text>
<text top="872" left="503" width="61" height="12" font="4">2004;27:4–9.</text>
<text top="886" left="452" width="356" height="12" font="4"> S7.5-28.  Cooper LT, Okura Y. Idiopathic giant cell myocarditis. Curr Treat </text>
<text top="899" left="503" width="182" height="12" font="4">Options Cardiovasc Med. 2001;3:463–7.</text>
<text top="939" left="452" width="195" height="21" font="18"><b>7.6. Cardiac Sarcoidosis</b></text>
<text top="965" left="452" width="351" height="12" font="4">  S7.6-1.  Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epi-</text>
<text top="979" left="503" width="300" height="12" font="4">demiology, characteristics, and outcome over 25 years in a nation-</text>
<text top="992" left="503" width="191" height="12" font="4">wide study. Circulation. 2015;131:624–32.</text>
<text top="1006" left="452" width="351" height="12" font="4">  S7.6-2.  Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-</text>
<text top="1019" left="503" width="304" height="12" font="4">term survival in Japanese patients with cardiac sarcoidosis treated </text>
<text top="1033" left="503" width="225" height="12" font="4">with prednisone. Am J Cardiol. 2001;88:1006–10.</text>
<text top="1046" left="452" width="351" height="12" font="4">  S7.6-3.  Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implant-</text>
<text top="1060" left="503" width="300" height="12" font="4">able cardiac defibrillators for treatment of ventricular arrhyth-</text>
<text top="1073" left="503" width="303" height="12" font="4">mias in patients with cardiac sarcoidosis. Europace. 2013;15: </text>
<text top="1087" left="503" width="37" height="12" font="4">347–54.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e372</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="12" font="4">  S7.6-4.  Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electro-</text>
<text top="102" left="125" width="303" height="12" font="4">physiological outcomes on long-term follow-up and the role of the </text>
<text top="115" left="125" width="306" height="12" font="4">implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. </text>
<text top="129" left="125" width="72" height="12" font="4">2014;25:171–6.</text>
<text top="142" left="74" width="351" height="12" font="4">  S7.6-5.  Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defi-</text>
<text top="156" left="125" width="304" height="12" font="4">brillator therapy in patients with cardiac sarcoidosis. J Cardiovasc </text>
<text top="169" left="125" width="139" height="12" font="4">Electrophysiol. 2012;23:925–9.</text>
<text top="183" left="74" width="355" height="12" font="4">  S7.6-6.  Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of </text>
<text top="196" left="125" width="305" height="12" font="4">myocardial scarring on CMR in patients with cardiac sarcoidosis: </text>
<text top="210" left="125" width="304" height="12" font="4">a systematic review and meta-analysis. JACC Cardiovasc Imaging. </text>
<text top="223" left="125" width="78" height="12" font="4">2016;10:411–20.</text>
<text top="237" left="74" width="351" height="12" font="4">  S7.6-7.  Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial dam-</text>
<text top="250" left="125" width="304" height="12" font="4">age in sarcoidosis patients with preserved left ventricular ejection </text>
<text top="264" left="125" width="303" height="12" font="4">fraction: risk stratification using cardiovascular magnetic resonance. </text>
<text top="277" left="125" width="192" height="12" font="4">Circ Cardiovasc Imaging. 2016;9:e003738.</text>
<text top="291" left="74" width="351" height="12" font="4">  S7.6-8.  Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imag-</text>
<text top="305" left="125" width="302" height="12" font="4">ing for identifying patients with cardiac sarcoidosis and preserved or </text>
<text top="318" left="125" width="300" height="12" font="4">mildly reduced left ventricular function at risk of ventricular arrhyth-</text>
<text top="332" left="125" width="237" height="12" font="4">mias. Circ Arrhythm Electrophysiol. 2014;7:1109–15.</text>
<text top="345" left="74" width="356" height="12" font="4">  S7.6-9.  Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts </text>
<text top="359" left="125" width="305" height="12" font="4">death and other adverse events in suspected cardiac sarcoidosis. </text>
<text top="372" left="125" width="193" height="12" font="4">JACC Cardiovasc Imaging. 2013;6:501–11.</text>
<text top="386" left="74" width="354" height="12" font="4">  S7.6-10.  Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission </text>
<text top="399" left="125" width="300" height="12" font="4">tomography enhances prognostic assessments of patients with sus-</text>
<text top="413" left="125" width="282" height="12" font="4">pected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36.</text>
<text top="426" left="74" width="351" height="12" font="4">  S7.6-11.  Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ven-</text>
<text top="440" left="125" width="302" height="12" font="4">tricular stimulation in predicting future arrhythmic events in patients </text>
<text top="453" left="125" width="252" height="12" font="4">with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–82.</text>
<text top="467" left="74" width="355" height="12" font="4">  S7.6-12.  Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes </text>
<text top="480" left="125" width="306" height="12" font="4">associated with ventricular tachycardia or fibrillation in patients </text>
<text top="494" left="125" width="306" height="12" font="4">undergoing primary percutaneous coronary intervention. JAMA. </text>
<text top="507" left="125" width="90" height="12" font="4">2009;301:1779–89.</text>
<text top="521" left="74" width="354" height="12" font="4">  S7.6-13.  Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with </text>
<text top="534" left="125" width="300" height="12" font="4">high-degree atrioventricular block as the initial manifestation of car-</text>
<text top="548" left="125" width="216" height="12" font="4">diac sarcoidosis. Am J Cardiol. 2015;115:505–9.</text>
<text top="561" left="74" width="357" height="12" font="4"> S7.6-14.  Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment </text>
<text top="575" left="125" width="306" height="12" font="4">approach to ventricular tachycardia in cardiac sarcoidosis. Circ </text>
<text top="588" left="125" width="185" height="12" font="4">Arrhythm Electrophysiol. 2014;7:407–13.</text>
<text top="602" left="74" width="355" height="12" font="4">  S7.6-15.  Segawa M, Fukuda K, Nakano M, et al. Time course and factors </text>
<text top="615" left="125" width="304" height="12" font="4">correlating with ventricular tachyarrhythmias after introduction of </text>
<text top="629" left="125" width="303" height="12" font="4">steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. </text>
<text top="642" left="125" width="78" height="12" font="4">2016;9:e003353.</text>
<text top="656" left="74" width="353" height="12" font="4">  S7.6-16.  Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy </text>
<text top="669" left="125" width="303" height="12" font="4">on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann </text>
<text top="683" left="125" width="194" height="12" font="4">Noninvasive Electrocardiol. 2011;16:140–7.</text>
<text top="696" left="74" width="351" height="12" font="4">  S7.6-17.  Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus state-</text>
<text top="710" left="125" width="303" height="12" font="4">ment on the diagnosis and management of arrhythmias associated </text>
<text top="723" left="125" width="262" height="12" font="4">with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.</text>
<text top="737" left="74" width="351" height="12" font="4">  S7.6-18.  Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sud-</text>
<text top="750" left="125" width="303" height="12" font="4">den cardiac death in silent cardiac sarcoidosis: role of programmed </text>
<text top="764" left="125" width="298" height="12" font="4">ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43–8.</text>
<text top="790" left="74" width="293" height="18" font="24"><i><b>7.6.1. Other Infiltrative Cardiomyopathies</b></i></text>
<text top="811" left="74" width="351" height="12" font="4"> S7.6.1-1.  Lubitz SA, Goldbarg SH, Mehta D, Sudden cardiac death in infiltra-</text>
<text top="824" left="125" width="300" height="12" font="4">tive cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hema-</text>
<text top="838" left="125" width="225" height="12" font="4">chromatosis. Prog Cardiovasc Dis. 2008;51:58–73.</text>
<text top="851" left="74" width="351" height="12" font="4"> S7.6.1-2.  Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implanta-</text>
<text top="865" left="125" width="306" height="12" font="4">tion of cardioverter-defibrillator in patients with severe cardiac </text>
<text top="878" left="125" width="303" height="12" font="4">amyloidosis and high risk for sudden cardiac death. Heart Rhythm. </text>
<text top="892" left="125" width="72" height="12" font="4">2008;5:235–40.</text>
<text top="905" left="74" width="351" height="12" font="4"> S7.6.1-3.  Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemother-</text>
<text top="919" left="125" width="300" height="12" font="4">apy for light-chain amyloidosis in patients presenting with symp-</text>
<text top="932" left="125" width="258" height="12" font="4">tomatic heart failure. J Am Coll Cardiol. 2016;67:2941–8.</text>
<text top="946" left="74" width="351" height="12" font="4"> S7.6.1-4.  Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-</text>
<text top="959" left="125" width="304" height="12" font="4">defibrillator placement in patients with cardiac amyloidosis. Heart </text>
<text top="973" left="125" width="118" height="12" font="4">Rhythm. 2014;11:158–62.</text>
<text top="1012" left="74" width="144" height="21" font="18"><b>7.7. Heart Failure</b></text>
<text top="1039" left="74" width="283" height="18" font="24"><i><b>7.7.1. HF With Reduced Ejection Fraction</b></i></text>
<text top="1060" left="74" width="353" height="12" font="4"> S7.7.1-1.  Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable </text>
<text top="1074" left="125" width="303" height="12" font="4">cardioverter defibrillator treatment in patients with end-stage heart </text>
<text top="1087" left="125" width="286" height="12" font="4">failure awaiting heart transplantation. Heart. 2013;99:1158–65.</text>
<text top="88" left="452" width="355" height="12" font="4"> S7.7.1-2.  Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in </text>
<text top="102" left="503" width="303" height="12" font="4">heart failure (WIF): results of a prospective registry. BMC Cardiovasc </text>
<text top="115" left="503" width="96" height="12" font="4">Disord. 2012;12:123.</text>
<text top="129" left="452" width="351" height="12" font="4"> S7.7.1-3.  Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrilla-</text>
<text top="143" left="503" width="300" height="12" font="4">tor as a bridge to cardiac transplantation: a national database analy-</text>
<text top="156" left="503" width="211" height="12" font="4">sis. J Heart Lung Transplant. 2015;34:1305–49.</text>
<text top="170" left="452" width="353" height="12" font="4"> S7.7.1-4.  Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of </text>
<text top="183" left="503" width="303" height="12" font="4">the implantable cardioverter-defibrillator in patients on the waiting </text>
<text top="197" left="503" width="271" height="12" font="4">list for cardiac transplantation. Circulation. 2001;104:171–6.</text>
<text top="211" left="452" width="351" height="12" font="4"> S7.7.1-5.  Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardio-</text>
<text top="224" left="503" width="300" height="12" font="4">verter-defibrillators on waitlist mortality among patients await-</text>
<text top="238" left="503" width="306" height="12" font="4">ing heart transplantation. An UNOS/OPTN Analysis. JACC Clin </text>
<text top="251" left="503" width="133" height="12" font="4">Electrophysiol. 2017;3:33–40.</text>
<text top="265" left="452" width="355" height="12" font="4"> S7.7.1-6.  Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable </text>
<text top="279" left="503" width="303" height="12" font="4">cardioverter-defibrillator, amiodarone, and placebo on the mode of </text>
<text top="292" left="503" width="303" height="12" font="4">death in stable patients with heart failure: analysis from the sudden </text>
<text top="306" left="503" width="292" height="12" font="4">cardiac death in heart failure trial. Circulation. 2009;120:2170–6.</text>
<text top="319" left="452" width="351" height="12" font="4"> S7.7.1-7.  MERIT-HF Study Effect of metoprolol CR/XL in chronic heart fail-</text>
<text top="333" left="503" width="303" height="12" font="4">ure: Metoprolol CR/XL Randomised Intervention Trial in Congestive </text>
<text top="347" left="503" width="232" height="12" font="4">Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.</text>
<text top="360" left="452" width="355" height="12" font="4"> S7.7.1-8.  Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms </text>
<text top="374" left="503" width="303" height="12" font="4">of unexpected cardiac arrest in advanced heart failure. Circulation. </text>
<text top="387" left="503" width="84" height="12" font="4">1989;80:1675–80.</text>
<text top="401" left="452" width="355" height="12" font="4"> S7.7.1-9.  Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic </text>
<text top="415" left="503" width="300" height="12" font="4">heart failure. A request and proposition for more accurate classifica-</text>
<text top="428" left="503" width="167" height="12" font="4">tion. Eur Heart J. 1996;17:1390–403.</text>
<text top="442" left="452" width="354" height="12" font="4"> S7.7.1-10.  Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents </text>
<text top="455" left="503" width="302" height="12" font="4">in heart failure: benefits of vasodilating and non-vasodilating agents </text>
<text top="469" left="503" width="300" height="12" font="4">according to patients’ characteristics: a meta-analysis of clinical tri-</text>
<text top="483" left="503" width="175" height="12" font="4">als. Arch Intern Med. 2000;160:621–7.</text>
<text top="496" left="452" width="351" height="12" font="4"> S7.7.1-11. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldoste-</text>
<text top="510" left="503" width="300" height="12" font="4">rone blocker, in patients with left ventricular dysfunction after myo-</text>
<text top="523" left="503" width="235" height="12" font="4">cardial infarction. N Engl J Med. 2003;348:1309–21.</text>
<text top="537" left="452" width="351" height="12" font="4"> S7.7.1-12. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-</text>
<text top="551" left="503" width="305" height="12" font="4">receptor-neprilysin inhibitor LCZ696 compared with enalapril on </text>
<text top="564" left="503" width="300" height="12" font="4">mode of death in heart failure patients. Eur Heart J. 2015;36:1990–7.</text>
<text top="578" left="452" width="356" height="12" font="4"> S7.7.1-13. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac </text>
<text top="591" left="503" width="302" height="12" font="4">resynchronization on morbidity and mortality in heart failure. N Engl </text>
<text top="605" left="503" width="117" height="12" font="4">J Med. 2005;352:1539–4.</text>
<text top="619" left="452" width="354" height="12" font="4"> S7.7.1-14. Tomaselli GF, Zipes DP, What causes sudden death in heart failure? </text>
<text top="632" left="503" width="119" height="12" font="4">Circ Res. 2004;95:754–63.</text>
<text top="646" left="452" width="355" height="12" font="4"> S7.7.1-15. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a </text>
<text top="659" left="503" width="297" height="12" font="4">risk factor for primary cardiac arrest. Circulation. 1998;97:155–60.</text>
<text top="673" left="452" width="9" height="12" font="4"> </text>
<text top="673" left="452" width="360" height="12" font="4">S7.7.1-16. Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic </text>
<text top="687" left="503" width="307" height="12" font="4">and metabolic remodelling of failing human heart. J Physiol. </text>
<text top="700" left="503" width="90" height="12" font="4">2016;594:3963–80.</text>
<text top="714" left="452" width="351" height="12" font="4"> S7.7.1-17. Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter-</text>
<text top="727" left="503" width="300" height="12" font="4">defibrillator use in patients with left ventricular assist devices: a sys-</text>
<text top="741" left="503" width="296" height="12" font="4">tematic review and meta-analysis. JACC Heart Fail. 2016;4:772–9.</text>
<text top="767" left="452" width="293" height="18" font="24"><i><b>7.7.2. HF With Preserved Ejection Fraction</b></i></text>
<text top="788" left="452" width="355" height="12" font="4"> S7.7.2-1.  Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and </text>
<text top="801" left="503" width="303" height="12" font="4">outcome of heart failure with preserved ejection fraction. N Engl J </text>
<text top="815" left="503" width="104" height="12" font="4">Med. 2006;355:251–9.</text>
<text top="829" left="452" width="356" height="12" font="4"> S7.7.2-2.  Adabag S, Smith LG, Anand IS, et al. Sudden cardiac death in </text>
<text top="842" left="503" width="304" height="12" font="4">heart failure patients with preserved ejection fraction. J Card Fail. </text>
<text top="856" left="503" width="78" height="12" font="4">2012;18:749–54.</text>
<text top="869" left="452" width="355" height="12" font="4"> S7.7.2-3.  Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients </text>
<text top="883" left="503" width="304" height="12" font="4">with heart failure and preserved ejection fraction. N Engl J Med. </text>
<text top="897" left="503" width="90" height="12" font="4">2008;359:2456–67.</text>
<text top="910" left="452" width="351" height="12" font="4"> S7.7.2-4. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesar-</text>
<text top="924" left="503" width="300" height="12" font="4">tan in patients with chronic heart failure and preserved left-</text>
<text top="937" left="503" width="305" height="12" font="4">ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. </text>
<text top="951" left="503" width="84" height="12" font="4">2003;362:777–81.</text>
<text top="965" left="452" width="356" height="12" font="4"> S7.7.2-5.  Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart </text>
<text top="978" left="503" width="303" height="12" font="4">failure with preserved ejection fraction. N Engl J Med. 2014;370: </text>
<text top="992" left="503" width="43" height="12" font="4">1383–92.</text>
<text top="1005" left="452" width="354" height="12" font="4"> S7.7.2-6.  Al-Khatib SM, Shaw LK, O’Connor C, et al. Incidence and predictors </text>
<text top="1019" left="503" width="304" height="12" font="4">of sudden cardiac death in patients with diastolic heart failure. J </text>
<text top="1033" left="503" width="196" height="12" font="4">Cardiovasc Electrophysiol. 2007;18:1231–5.</text>
<text top="1046" left="452" width="351" height="12" font="4"> S7.7.2-7.  Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac-</text>
<text top="1060" left="503" width="300" height="12" font="4">tion in tetralogy of Fallot. QRS prolongation relates to right ventricu-</text>
<text top="1073" left="503" width="303" height="12" font="4">lar size and predicts malignant ventricular arrhythmias and sudden </text>
<text top="1087" left="503" width="158" height="12" font="4">death. Circulation. 1995;92:231–7.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e373</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="12" font="4"> S7.7.2-8.  Gatzoulis KA, Tsiachris D, Arsenos P, et al. Prognostic value of pro-</text>
<text top="102" left="125" width="303" height="12" font="4">grammed ventricular stimulation for sudden death in selected high </text>
<text top="115" left="125" width="305" height="12" font="4">risk patients with structural heart disease and preserved systolic </text>
<text top="129" left="125" width="192" height="12" font="4">function. Int J Cardiol. 2014;176:1449–51.</text>
<text top="154" left="74" width="246" height="18" font="24"><i><b>7.7.3. Left Ventricular Assist Device</b></i></text>
<text top="175" left="74" width="351" height="12" font="4"> S7.7.3-1.  Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter-</text>
<text top="189" left="125" width="300" height="12" font="4">defibrillator use in patients with left ventricular assist devices: a sys-</text>
<text top="202" left="125" width="296" height="12" font="4">tematic review and meta-analysis. JACC Heart Fail. 2016;4:772–9.</text>
<text top="216" left="74" width="353" height="12" font="4"> S7.7.3-2.  Cantillon DJ, Tarakji KG, Kumbhani DJ, et al. Improved survival among </text>
<text top="229" left="125" width="304" height="12" font="4">ventricular assist device recipients with a concomitant implantable </text>
<text top="243" left="125" width="252" height="12" font="4">cardioverter-defibrillator. Heart Rhythm. 2010;7:466–71.</text>
<text top="256" left="74" width="354" height="12" font="4"> S7.7.3-3.  Raasch H, Jensen BC, Chang PP, et al. Epidemiology, management, </text>
<text top="270" left="125" width="300" height="12" font="4">and outcomes of sustained ventricular arrhythmias after contin-</text>
<text top="284" left="125" width="305" height="12" font="4">uous-flow left ventricular assist device implantation. Am Heart J. </text>
<text top="297" left="125" width="78" height="12" font="4">2012;164:373–8.</text>
<text top="311" left="74" width="351" height="12" font="4"> S7.7.3-4.  Garan AR, Yuzefpolskaya M, Colombo PC, et al. Ventricular arrhyth-</text>
<text top="324" left="125" width="304" height="12" font="4">mias and implantable cardioverter-defibrillator therapy in patients </text>
<text top="338" left="125" width="302" height="12" font="4">with continuous-flow left ventricular assist devices: need for primary </text>
<text top="351" left="125" width="223" height="12" font="4">prevention? J Am Coll Cardiol. 2013;61:2542–50.</text>
<text top="365" left="74" width="351" height="12" font="4"> S7.7.3-5.  Refaat MM, Tanaka T, Kormos RL, et al. Survival benefit of implant-</text>
<text top="378" left="125" width="300" height="12" font="4">able cardioverter-defibrillators in left ventricular assist device-sup-</text>
<text top="392" left="125" width="255" height="12" font="4">ported heart failure patients. J Card Fail. 2012;18:140–5.</text>
<text top="405" left="74" width="355" height="12" font="4"> S7.7.3-6.  Enriquez AD, Calenda B, Miller MA, et al. The role of implantable </text>
<text top="419" left="125" width="300" height="12" font="4">cardioverter-defibrillators in patients with continuous flow left ven-</text>
<text top="432" left="125" width="300" height="12" font="4">tricular assist devices. Circ Arrhythm Electrophysiol. 2013;6:668–74.</text>
<text top="446" left="74" width="354" height="12" font="4"> S7.7.3-7.  Lee W, Tay A, Subbiah RN, et al. Impact of implantable cardioverter </text>
<text top="459" left="125" width="303" height="12" font="4">defibrillators on survival of patients with centrifugal left ventricular </text>
<text top="473" left="125" width="262" height="12" font="4">assist devices. Pacing Clin Electrophysiol. 2015;38:925–33.</text>
<text top="486" left="74" width="351" height="12" font="4"> S7.7.3-8.  Jorde UP, Kushwaha SS, Tatooles AJ, et al. Results of the destina-</text>
<text top="500" left="125" width="306" height="12" font="4">tion therapy post-food and drug administration approval study </text>
<text top="513" left="125" width="300" height="12" font="4">with a continuous flow left ventricular assist device: a prospec-</text>
<text top="527" left="125" width="304" height="12" font="4">tive study using the INTERMACS registry (Interagency Registry for </text>
<text top="540" left="125" width="306" height="12" font="4">Mechanically Assisted Circulatory Support). J Am Coll Cardiol. </text>
<text top="554" left="125" width="78" height="12" font="4">2014;63:1751–7.</text>
<text top="567" left="74" width="351" height="12" font="4"> S7.7.3-9.  Slaughter MS, Meyer AL, Birks EJ. Destination therapy with left ven-</text>
<text top="581" left="125" width="304" height="12" font="4">tricular assist devices: patient selection and outcomes. Curr Opin </text>
<text top="594" left="125" width="110" height="12" font="4">Cardiol. 2011;26:232–6.</text>
<text top="620" left="74" width="295" height="18" font="24"><i><b>7.7.4. ICD Use After Heart Transplantation</b></i></text>
<text top="641" left="74" width="351" height="12" font="4"> S7.7.4-1.  Tsai VW, Cooper J, Garan H, et al. The efficacy of implantable car-</text>
<text top="654" left="125" width="304" height="12" font="4">dioverter-defibrillators in heart transplant recipients: results from a </text>
<text top="668" left="125" width="237" height="12" font="4">multicenter registry. Circ Heart Fail. 2009;2:197–201.</text>
<text top="681" left="74" width="355" height="12" font="4"> S7.7.4-2.  McDowell DL, Hauptman PJ. Implantable defibrillators and cardiac </text>
<text top="695" left="125" width="303" height="12" font="4">resynchronization therapy in heart transplant recipients: results of a </text>
<text top="709" left="125" width="261" height="12" font="4">national survey. J Heart Lung Transplant. 2009;28:847–50.</text>
<text top="722" left="74" width="351" height="12" font="4"> S7.7.4-3.  Neylon A, Canniffe C, Parlon B, et al. Implantable cardioverter-defi-</text>
<text top="736" left="125" width="300" height="12" font="4">brillators in a heart transplant population: A single-center experi-</text>
<text top="749" left="125" width="210" height="12" font="4">ence. J Heart Lung Transplant. 2016;35:682–4.</text>
<text top="763" left="74" width="351" height="12" font="4"> S7.7.4-4.  Vakil K, Taimeh Z, Sharma A, et al. Incidence, predictors, and tem-</text>
<text top="776" left="125" width="304" height="12" font="4">poral trends of sudden cardiac death after heart transplantation. </text>
<text top="790" left="125" width="152" height="12" font="4">Heart Rhythm. 2014;11:1684–90.</text>
<text top="803" left="74" width="356" height="12" font="4"> S7.7.4-5.  Vaseghi M, Lellouche N, Ritter H, et al. Mode and mechanisms </text>
<text top="817" left="125" width="306" height="12" font="4">of death after orthotopic heart transplantation. Heart Rhythm. </text>
<text top="830" left="125" width="67" height="12" font="4">2009;6:503–9.</text>
<text top="869" left="74" width="247" height="21" font="18"><b>7.8. Neuromuscular Disorders</b></text>
<text top="896" left="74" width="351" height="12" font="4">  S7.8-1.  Bhakta D, Groh MR, Shen C, et al. Increased mortality with left ven-</text>
<text top="910" left="125" width="302" height="12" font="4">tricular systolic dysfunction and heart failure in adults with myotonic </text>
<text top="923" left="125" width="243" height="12" font="4">dystrophy type 1. Am Heart J. 2010;160:1137–41, 41.</text>
<text top="937" left="74" width="355" height="12" font="4">  S7.8-2.  Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of </text>
<text top="950" left="125" width="300" height="12" font="4">sustained ventricular tachycardia in myotonic dystrophy: implica-</text>
<text top="964" left="125" width="248" height="12" font="4">tions for catheter ablation. Circulation. 1998;98:541–6.</text>
<text top="977" left="74" width="351" height="12" font="4">  S7.8-3.  Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-</text>
<text top="991" left="125" width="303" height="12" font="4">defibrillators in lamin A/C mutation carriers with cardiac conduction </text>
<text top="1004" left="125" width="192" height="12" font="4">disorders. Heart Rhythm. 2013;10:1492–8.</text>
<text top="1018" left="74" width="357" height="12" font="4">  S7.8-4.  van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk factors for </text>
<text top="1031" left="125" width="303" height="12" font="4">malignant ventricular arrhythmias in lamin A/C mutation carriers: a </text>
<text top="1045" left="125" width="274" height="12" font="4">European cohort study. J Am Coll Cardiol. 2012;59:493–500.</text>
<text top="1058" left="74" width="351" height="12" font="4">  S7.8-5.  Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sud-</text>
<text top="1072" left="125" width="302" height="12" font="4">den death in patients with lamin A/C gene mutations. N Engl J Med. </text>
<text top="1085" left="125" width="84" height="12" font="4">2006;354:209–10.</text>
<text top="88" left="452" width="355" height="12" font="4">  S7.8-6.  Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk </text>
<text top="102" left="503" width="306" height="12" font="4">stratification in dilated cardiolaminopathies. J Am Coll Cardiol. </text>
<text top="116" left="503" width="84" height="12" font="4">2008;52:1250–60.</text>
<text top="129" left="452" width="355" height="12" font="4">  S7.8-7.  Van Berlo JH, de Voogt WG, van der Kooi AJ, et al. Meta-analysis </text>
<text top="143" left="503" width="304" height="12" font="4">of clinical characteristics of 299 carriers of LMNA gene mutations: </text>
<text top="157" left="503" width="303" height="12" font="4">do lamin A/C mutations portend a high risk of sudden death? J Mol </text>
<text top="170" left="503" width="99" height="12" font="4">Med. 2005;83:79–83.</text>
<text top="184" left="452" width="355" height="12" font="4">  S7.8-8.  Russo V, Nigro G. ICD role in preventing sudden cardiac death in </text>
<text top="197" left="503" width="300" height="12" font="4">Emery-Dreifuss muscular dystrophy with preserved myocardial func-</text>
<text top="211" left="503" width="300" height="12" font="4">tion: 2013 ESC guidelines on cardiac pacing and cardiac resynchro-</text>
<text top="225" left="503" width="186" height="12" font="4">nization therapy. Europace. 2015;17:337.</text>
<text top="238" left="452" width="351" height="12" font="4">  S7.8-9.  Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormali-</text>
<text top="252" left="503" width="303" height="12" font="4">ties and sudden death in myotonic dystrophy type 1. N Engl J Med. </text>
<text top="266" left="503" width="90" height="12" font="4">2008;358:2688–97.</text>
<text top="279" left="452" width="354" height="12" font="4">  S7.8-10.  Lallemand B, Clementy N, Bernard-Brunet A, et al. The evolution of </text>
<text top="293" left="503" width="303" height="12" font="4">infrahissian conduction time in myotonic dystrophy patients: clinical </text>
<text top="307" left="503" width="162" height="12" font="4">implications. Heart. 2012;98:291–6.</text>
<text top="320" left="452" width="351" height="12" font="4">  S7.8-11.  Nazarian S, Wagner KR, Caffo BS, et al. Clinical predictors of con-</text>
<text top="334" left="503" width="303" height="12" font="4">duction disease progression in type I myotonic muscular dystrophy. </text>
<text top="348" left="503" width="192" height="12" font="4">Pacing Clin Electrophysiol. 2011;34:171–6.</text>
<text top="361" left="452" width="351" height="12" font="4">  S7.8-12.  Tanawuttiwat T, Wagner KR, Tomaselli G, et al. Left ventricular dys-</text>
<text top="375" left="503" width="305" height="12" font="4">function and conduction disturbances in patients with myotonic </text>
<text top="389" left="503" width="297" height="12" font="4">muscular dystrophy type I and II. JAMA Cardiology. 2017;2:225–8.</text>
<text top="402" left="452" width="351" height="12" font="4">  S7.8-13.  Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardio-</text>
<text top="416" left="503" width="300" height="12" font="4">verter-defibrillator use in a US myotonic dystrophy type 1 popula-</text>
<text top="430" left="503" width="232" height="12" font="4">tion. J Cardiovasc Electrophysiol. 2011;22:1369–75.</text>
<text top="443" left="452" width="354" height="12" font="4">  S7.8-14.  Laurent V, Pellieux S, Corcia P, et al. Mortality in myotonic dystrophy </text>
<text top="457" left="503" width="304" height="12" font="4">patients in the area of prophylactic pacing devices. Int J Cardiol. </text>
<text top="470" left="503" width="72" height="12" font="4">2011;150:54–8.</text>
<text top="484" left="452" width="355" height="12" font="4">  S7.8-15.  Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. </text>
<text top="498" left="503" width="72" height="12" font="4">2012;9:1890–5.</text>
<text top="511" left="452" width="354" height="12" font="4">  S7.8-16.  Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 </text>
<text top="525" left="503" width="300" height="12" font="4">guidelines for device-based therapy of cardiac rhythm abnormali-</text>
<text top="539" left="503" width="302" height="12" font="4">ties: a report of the American College of Cardiology/American Heart </text>
<text top="552" left="503" width="304" height="12" font="4">Association Task Force on Practice Guidelines (Writing Committee </text>
<text top="566" left="503" width="309" height="12" font="4">to Revise the ACC/AHA/NASPE 2002 Guideline Update for </text>
<text top="580" left="503" width="305" height="12" font="4">Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) </text>
<text top="593" left="503" width="307" height="12" font="4">developed in collaboration with the American Association for </text>
<text top="607" left="503" width="305" height="12" font="4">Thoracic Surgery and Society of Thoracic Surgeons. Circulation. </text>
<text top="621" left="503" width="95" height="12" font="4">2008;117:e350–408.</text>
<text top="634" left="452" width="351" height="12" font="4">  S7.8-17.  Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhyth-</text>
<text top="648" left="503" width="304" height="12" font="4">mic and nonarrhythmic outcomes of lamin A/C mutation carriers. </text>
<text top="662" left="503" width="149" height="12" font="4">Circulation. 2008;117:e350–408.</text>
<text top="675" left="452" width="354" height="12" font="4">  S7.8-18.  Brembilla-Perrot B, Luporsi JD, Louis S, et al. Long-term follow-up of </text>
<text top="689" left="503" width="303" height="12" font="4">patients with myotonic dystrophy: an electrocardiogram every year </text>
<text top="703" left="503" width="194" height="12" font="4">is not necessary. Europace. 2011;13:251–7.</text>
<text top="716" left="452" width="351" height="12" font="4"> S7.8-19.  Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-</text>
<text top="730" left="503" width="306" height="12" font="4">ventricular conduction disease, long-term outcomes in patients </text>
<text top="743" left="503" width="304" height="12" font="4">with myotonic dystrophy types I and II Pacing. Clin Electrophysiol. </text>
<text top="757" left="503" width="78" height="12" font="4">2012;35:1262–9.</text>
<text top="799" left="452" width="244" height="21" font="18"><b>7.9. Cardiac Channelopathies</b></text>
<text top="826" left="452" width="355" height="12" font="4">  S7.9-1.  Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening in </text>
<text top="840" left="503" width="307" height="12" font="4">inherited cardiac channelopathies: how to prioritize access to </text>
<text top="854" left="503" width="265" height="12" font="4">genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6–15.</text>
<text top="867" left="452" width="357" height="12" font="4">  S7.9-2.  Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening </text>
<text top="881" left="503" width="300" height="12" font="4">cardiac events in patients with genotype-confirmed long-QT syn-</text>
<text top="894" left="503" width="303" height="12" font="4">drome and normal-range corrected QT intervals. J Am Coll Cardiol. </text>
<text top="908" left="503" width="67" height="12" font="4">2011;57:51–9.</text>
<text top="922" left="452" width="351" height="12" font="4">  S7.9-3.  Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of inher-</text>
<text top="935" left="503" width="305" height="12" font="4">ited arrhythmia syndromes: insight into their natural history. Circ </text>
<text top="949" left="503" width="151" height="12" font="4">Cardiovasc Genet. 2012;5:183–9.</text>
<text top="963" left="452" width="357" height="12" font="4">  S7.9-4.  Priori SG, Gasparini M, Napolitano C, et al. Risk stratification </text>
<text top="976" left="503" width="307" height="12" font="4">in Brugada syndrome: results of the PRELUDE (PRogrammed </text>
<text top="990" left="503" width="304" height="12" font="4">ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. </text>
<text top="1004" left="503" width="72" height="12" font="4">2012;59:37–45.</text>
<text top="1017" left="452" width="355" height="12" font="4">  S7.9-5.  Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular </text>
<text top="1031" left="503" width="306" height="12" font="4">characterization of patients with catecholaminergic polymorphic </text>
<text top="1045" left="503" width="238" height="12" font="4">ventricular tachycardia. Circulation. 2002;106:69–74.</text>
<text top="1058" left="452" width="355" height="12" font="4">  S7.9-6.  Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 </text>
<text top="1072" left="503" width="304" height="12" font="4">long-QT syndrome: an international multicenter study. Circulation. </text>
<text top="1086" left="503" width="84" height="12" font="4">2016;134:872–82.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e374</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="354" height="12" font="4">  S7.9-7.  Wedekind H, Burde D, Zumhagen S, et al. QT interval prolongation </text>
<text top="102" left="125" width="303" height="12" font="4">and risk for cardiac events in genotyped LQTS-index children. Eur J </text>
<text top="116" left="125" width="126" height="12" font="4">Pediatr. 2009;168:1107–15.</text>
<text top="129" left="74" width="355" height="12" font="4">  S7.9-8.  Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of </text>
<text top="143" left="125" width="304" height="12" font="4">beta-blocker therapy in congenital long-QT syndrome. Circulation. </text>
<text top="157" left="125" width="84" height="12" font="4">2000;101:616–23.</text>
<text top="170" left="74" width="357" height="12" font="4">  S7.9-9.  Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter </text>
<text top="184" left="125" width="304" height="12" font="4">defibrillator in high-risk long QT syndrome patients. J Cardiovasc </text>
<text top="197" left="125" width="145" height="12" font="4">Electrophysiol. 2003;14:337–41.</text>
<text top="211" left="74" width="351" height="12" font="4"> S7.9-10.  Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defi-</text>
<text top="225" left="125" width="304" height="12" font="4">brillator therapy in patients with congenital long-QT syndrome: a </text>
<text top="238" left="125" width="242" height="12" font="4">long-term follow-up. Heart Rhythm. 2005;2:497–504.</text>
<text top="252" left="74" width="354" height="12" font="4">  S7.9-11.  Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors </text>
<text top="266" left="125" width="304" height="12" font="4">of arrhythmic events in catecholaminergic polymorphic ventricular </text>
<text top="279" left="125" width="200" height="12" font="4">tachycardia. Circulation. 2009;119:2426–34.</text>
<text top="293" left="74" width="354" height="12" font="4">  S7.9-12.  Gehi AK, Duong TD, Metz LD, et al. Risk stratification of individuals </text>
<text top="307" left="125" width="304" height="12" font="4">with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc </text>
<text top="320" left="125" width="145" height="12" font="4">Electrophysiol. 2006;17:577–83.</text>
<text top="334" left="74" width="356" height="12" font="4"> S7.9-13.  Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of </text>
<text top="347" left="125" width="307" height="12" font="4">patients diagnosed with Brugada syndrome: results from the </text>
<text top="361" left="125" width="298" height="12" font="4">FINGER Brugada syndrome registry. Circulation. 2010;121:635–43.</text>
<text top="375" left="74" width="351" height="12" font="4">  S7.9-14.  Delise P, Allocca G, Marras E, et al. Risk stratification in individu-</text>
<text top="388" left="125" width="304" height="12" font="4">als with the Brugada type 1 ECG pattern without previous cardiac </text>
<text top="402" left="125" width="306" height="12" font="4">arrest: usefulness of a combined clinical and electrophysiologic </text>
<text top="416" left="125" width="180" height="12" font="4">approach. Eur Heart J. 2011;32:169–76.</text>
<text top="429" left="74" width="351" height="12" font="4">  S7.9-15.  Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk strati-</text>
<text top="443" left="125" width="304" height="12" font="4">fication of young adults with Brugada syndrome. J Electrocardiol. </text>
<text top="457" left="125" width="78" height="12" font="4">2013;46:279–83.</text>
<text top="470" left="74" width="354" height="12" font="4">  S7.9-16.  Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT </text>
<text top="484" left="125" width="292" height="12" font="4">syndrome when a sibling has died. Heart Rhythm. 2008;5:831–6.</text>
<text top="497" left="74" width="356" height="12" font="4"> S7.9-17.  Kimbrough J, Moss AJ, Zareba W, et al. Clinical implications for </text>
<text top="511" left="125" width="303" height="12" font="4">affected parents and siblings of probands with long-QT syndrome. </text>
<text top="525" left="125" width="138" height="12" font="4">Circulation. 2001;104:557–62.</text>
<text top="538" left="74" width="357" height="12" font="4"> S7.9-18.  Priori SG, Napolitano C, Gasparini M, et al. Natural history of </text>
<text top="552" left="125" width="303" height="12" font="4">Brugada syndrome: insights for risk stratification and management. </text>
<text top="566" left="125" width="138" height="12" font="4">Circulation. 2002;105:1342–7.</text>
<text top="579" left="74" width="354" height="12" font="4">  S7.9-19.  Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest </text>
<text top="593" left="125" width="300" height="12" font="4">or sudden cardiac death during adolescence in the long-QT syn-</text>
<text top="607" left="125" width="157" height="12" font="4">drome. JAMA. 2006;296:1249–54.</text>
<text top="620" left="74" width="355" height="12" font="4">  S7.9-20.  Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT </text>
<text top="634" left="125" width="300" height="12" font="4">syndrome loci and cardiac events among patients treated with beta-</text>
<text top="648" left="125" width="159" height="12" font="4">blockers. JAMA. 2004;292:1341–4.</text>
<text top="661" left="74" width="354" height="12" font="4">  S7.9-21.  Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the </text>
<text top="675" left="125" width="243" height="12" font="4">long-QT syndrome. N Engl J Med. 2003;348:1866–74.</text>
<text top="688" left="74" width="356" height="12" font="4"> S7.9-22.  Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for </text>
<text top="702" left="125" width="304" height="12" font="4">patients with long QT syndrome who experience a cardiac event </text>
<text top="716" left="125" width="225" height="12" font="4">during infancy. J Am Coll Cardiol. 2009;54:832–7.</text>
<text top="729" left="74" width="13" height="12" font="4"> </text>
<text top="729" left="80" width="358" height="12" font="4">S7.9-23. Credible meds. A<a href="">vailable at: http://www.crediblemeds.org. </a></text>
<text top="743" left="125" width="136" height="12" font="4">Accessed December 26, 2016.</text>
<text top="757" left="74" width="354" height="12" font="4">  S7.9-24.  Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of 60 000 </text>
<text top="770" left="125" width="300" height="12" font="4">exomes and ACMG guidelines question the role of catecholamin-</text>
<text top="784" left="125" width="304" height="12" font="4">ergic polymorphic ventricular tachycardia-associated variants. Clin </text>
<text top="798" left="125" width="106" height="12" font="4">Genet. 2017;91:63–72.</text>
<text top="811" left="74" width="356" height="12" font="4"> S7.9-25.  Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of </text>
<text top="825" left="125" width="300" height="12" font="4">patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587–95.</text>
<text top="838" left="74" width="351" height="12" font="4">  S7.9-26.  Mahida S, Derval N, Sacher F, et al. Role of electrophysiological stud-</text>
<text top="852" left="125" width="303" height="12" font="4">ies in predicting risk of ventricular arrhythmia in early repolarization </text>
<text top="866" left="125" width="205" height="12" font="4">syndrome. J Am Coll Cardiol. 2015;65:151–9.</text>
<text top="879" left="74" width="351" height="12" font="4">  S7.9-27.  Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natu-</text>
<text top="893" left="125" width="297" height="12" font="4">ral history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300–8.</text>
<text top="907" left="74" width="351" height="12" font="4">  S7.9-28.  Siebermair J, Sinner MF, Beckmann BM, et al. Early repolarization pat-</text>
<text top="920" left="125" width="303" height="12" font="4">tern is the strongest predictor of arrhythmia recurrence in patients </text>
<text top="934" left="125" width="304" height="12" font="4">with idiopathic ventricular fibrillation: results from a single centre </text>
<text top="948" left="125" width="284" height="12" font="4">long-term follow-up over 20 years. Europace. 2016;18:718–25.</text>
<text top="961" left="74" width="355" height="12" font="4"> S7.9-29.  Etheridge SP, Sanatani S, Cohen MI, et al. Long QT syndrome in </text>
<text top="975" left="125" width="304" height="12" font="4">children in the era of implantable defibrillators. J Am Coll Cardiol. </text>
<text top="989" left="125" width="84" height="12" font="4">2007;50:1335–40.</text>
<text top="1002" left="74" width="354" height="12" font="4">  S7.9-30.  Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter </text>
<text top="1016" left="125" width="300" height="12" font="4">defibrillator therapy for congenital long QT syndrome: a single-cen-</text>
<text top="1029" left="125" width="215" height="12" font="4">ter experience. Heart Rhythm. 2010;7:1616–22.</text>
<text top="1043" left="74" width="351" height="12" font="4">  S7.9-31.  Proclemer A, Ghidina M, Facchin D, et al. Use of implantable cardio-</text>
<text top="1057" left="125" width="304" height="12" font="4">verter-defibrillator in inherited arrhythmogenic diseases: data from </text>
<text top="1070" left="125" width="303" height="12" font="4">Italian ICD Registry for the years 2001–6. Pacing Clin Electrophysiol. </text>
<text top="1084" left="125" width="78" height="12" font="4">2009;32:434–45.</text>
<text top="88" left="470" width="334" height="12" font="4"> S7.9-32.  Adler A, Sadek MM, Chan AY, et al. Patient outcomes from a spe-</text>
<text top="102" left="512" width="295" height="12" font="4">cialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. </text>
<text top="116" left="512" width="78" height="12" font="4">2016;9:e003440.</text>
<text top="129" left="470" width="334" height="12" font="4"> S7.9-33.  Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defi-</text>
<text top="143" left="512" width="296" height="12" font="4">brillator therapy in Brugada syndrome: a 20-year single-center </text>
<text top="156" left="512" width="215" height="12" font="4">experience. J Am Coll Cardiol. 2015;65:879–88.</text>
<text top="170" left="470" width="338" height="12" font="4"> S7.9-34. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable </text>
<text top="183" left="512" width="296" height="12" font="4">cardioverter-defibrillator harm in young patients with inherited </text>
<text top="197" left="512" width="297" height="12" font="4">arrhythmia syndromes: a systematic review and meta-analysis </text>
<text top="211" left="512" width="299" height="12" font="4">of inappropriate shocks and complications. Heart Rhythm. </text>
<text top="224" left="512" width="78" height="12" font="4">2016;13:443–54.</text>
<text top="238" left="470" width="9" height="12" font="4"> </text>
<text top="238" left="470" width="343" height="12" font="4">S7.9-35. Rodriguez-Manero M, Sacher F, de Asmundis C, et al. </text>
<text top="251" left="512" width="296" height="12" font="4">Monomorphic ventricular tachycardia in patients with Brugada </text>
<text top="265" left="512" width="298" height="12" font="4">syndrome: a multicenter retrospective study. Heart Rhythm. </text>
<text top="278" left="512" width="78" height="12" font="4">2016;13:669–82.</text>
<text top="292" left="470" width="338" height="12" font="4"> S7.9-36. Rosso R, Glick A, Glikson M, et al. Outcome after implantation </text>
<text top="306" left="512" width="295" height="12" font="4">of cardioverter defibrillator [corrected] in patients with Brugada </text>
<text top="319" left="512" width="294" height="12" font="4">syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J. </text>
<text top="333" left="512" width="72" height="12" font="4">2008;10:435–9.</text>
<text top="346" left="470" width="336" height="12" font="4"> S7.9-37.  Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of </text>
<text top="360" left="512" width="295" height="12" font="4">patients with long-QT syndrome treated with beta-blockers and </text>
<text top="373" left="512" width="226" height="12" font="4">continuous pacing. Circulation. 1999;100:2431–6.</text>
<text top="387" left="470" width="334" height="12" font="4"> S7.9-38.  Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-adren-</text>
<text top="401" left="512" width="293" height="12" font="4">ergic blocking agents and long-term cardiac pacing for patients with </text>
<text top="414" left="512" width="261" height="12" font="4">the long QT syndrome. J Am Coll Cardiol. 1992;20:830–7.</text>
<text top="428" left="470" width="337" height="12" font="4"> S7.9-39.  Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in </text>
<text top="441" left="512" width="295" height="12" font="4">the management of high-risk patients with long QT syndrome. </text>
<text top="455" left="512" width="132" height="12" font="4">Circulation. 1991;84:1524–9.</text>
<text top="469" left="470" width="334" height="12" font="4"> S7.9-40. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-</text>
<text top="482" left="512" width="291" height="12" font="4">blockers in long-QT syndrome type 1: contribution of noncompli-</text>
<text top="496" left="512" width="294" height="12" font="4">ance and QT-prolonging drugs to the occurrence of beta-blocker </text>
<text top="509" left="512" width="235" height="12" font="4">treatment “failures.” Circulation. 2009;119:215–21.</text>
<text top="535" left="452" width="275" height="18" font="24"><i><b>7.9.1. Specific Cardiac Channelopathy </b></i></text>
<text top="553" left="452" width="80" height="18" font="24"><i><b>Syndromes</b></i></text>
<text top="574" left="452" width="250" height="18" font="28"><i>7.9.1.1. Congenital Long QT Syndrome</i></text>
<text top="595" left="458" width="345" height="12" font="4"> S7.9.1.1-1. Abu-Zeitone A, Peterson DR, Polonsky B, et al. Efficacy of differ-</text>
<text top="609" left="512" width="295" height="12" font="4">ent beta-blockers in the treatment of long QT syndrome. J Am </text>
<text top="622" left="512" width="136" height="12" font="4">Coll Cardiol. 2014;64:1352–8.</text>
<text top="636" left="458" width="350" height="12" font="4"> S7.9.1.1-2. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in </text>
<text top="649" left="512" width="296" height="12" font="4">high-risk patients with the congenital long-QT syndrome types </text>
<text top="663" left="512" width="297" height="12" font="4">1 and 2: implications for patient management. J Cardiovasc </text>
<text top="677" left="512" width="151" height="12" font="4">Electrophysiol. 2010;21:893–901.</text>
<text top="690" left="458" width="345" height="12" font="4"> S7.9.1.1-3. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limita-</text>
<text top="704" left="512" width="296" height="12" font="4">tions of beta-blocker therapy in congenital long-QT syndrome. </text>
<text top="717" left="512" width="138" height="12" font="4">Circulation. 2000;101:616–23.</text>
<text top="731" left="458" width="350" height="12" font="4"> S7.9.1.1-4. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults.  </text>
<text top="744" left="512" width="161" height="12" font="4">J Am Coll Cardiol. 2007;49:329–37.</text>
<text top="758" left="458" width="345" height="12" font="4"> S7.9.1.1-5. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta-</text>
<text top="772" left="512" width="291" height="12" font="4">blockers in long-QT syndrome type 1: contribution of noncompli-</text>
<text top="785" left="512" width="294" height="12" font="4">ance and QT-prolonging drugs to the occurrence of beta-blocker </text>
<text top="799" left="512" width="235" height="12" font="4">treatment “failures.” Circulation. 2009;119:215–21.</text>
<text top="812" left="458" width="345" height="12" font="4"> S7.9.1.1-6. Chorin E, Hu D, Antzelevitch C, et al. Ranolazine for congeni-</text>
<text top="826" left="512" width="294" height="12" font="4">tal long-qt syndrome type III: experimental and long-term clinical </text>
<text top="839" left="512" width="237" height="12" font="4">data. Circ Arrhythm Electrophysiol. 2016;9:e004370.</text>
<text top="853" left="458" width="348" height="12" font="4"> S7.9.1.1-7.  Chorin E, Taub R, Medina A, et al. Long-term flecainide therapy in </text>
<text top="867" left="512" width="294" height="12" font="4">type 3 long QT syndrome. Europace. 2017 euw439 [Epub ahead </text>
<text top="880" left="512" width="39" height="12" font="4">of print].</text>
<text top="894" left="458" width="350" height="12" font="4"> S7.9.1.1-8. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac </text>
<text top="907" left="512" width="294" height="12" font="4">arrest or sudden cardiac death during adolescence in the long-QT </text>
<text top="921" left="512" width="172" height="12" font="4">syndrome. JAMA. 2006;296:1249–54.</text>
<text top="934" left="458" width="350" height="12" font="4"> S7.9.1.1-9. Jons C, Moss AJ, Goldenberg I, et al. Risk of fatal arrhythmic </text>
<text top="948" left="512" width="296" height="12" font="4">events in long QT syndrome patients after syncope. J Am Coll </text>
<text top="962" left="512" width="110" height="12" font="4">Cardiol. 2010;55:783–8.</text>
<text top="975" left="452" width="355" height="12" font="4"> S7.9.1.1-10. Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy </text>
<text top="989" left="512" width="295" height="12" font="4">with mexiletine reduces arrhythmic events in patients with long </text>
<text top="1002" left="512" width="258" height="12" font="4">QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053–8.</text>
<text top="1016" left="452" width="356" height="12" font="4"> S7.9.1.1-11. Nannenberg EA, Sijbrands EJ, Dijksman LM, et al. Mortality of </text>
<text top="1030" left="512" width="294" height="12" font="4">inherited arrhythmia syndromes: insight into their natural history. </text>
<text top="1043" left="512" width="171" height="12" font="4">Circ Cardiovasc Genet. 2012;5:183–9.</text>
<text top="1057" left="452" width="351" height="12" font="4"> S7.9.1.1-12. Wedekind H, Burde D, Zumhagen S, et al. QT interval prolonga-</text>
<text top="1070" left="512" width="294" height="12" font="4">tion and risk for cardiac events in genotyped LQTS-index children. </text>
<text top="1084" left="512" width="150" height="12" font="4">Eur J Pediatr. 2009;168:1107–15.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e375</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="355" height="12" font="4"> S7.9.1.1-13. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic </text>
<text top="102" left="134" width="291" height="12" font="4">denervation for the treatment of long QT syndrome and cate-</text>
<text top="115" left="134" width="291" height="12" font="4">cholaminergic polymorphic ventricular tachycardia using video-</text>
<text top="129" left="134" width="248" height="12" font="4">assisted thoracic surgery. Heart Rhythm. 2009;6:752–9.</text>
<text top="142" left="74" width="354" height="12" font="4"> S7.9.1.1-14.  Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic </text>
<text top="156" left="134" width="291" height="12" font="4">sympathectomy for cardiac denervation in patients with life-</text>
<text top="169" left="134" width="296" height="12" font="4">threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. </text>
<text top="183" left="134" width="78" height="12" font="4">2014;147:404–9.</text>
<text top="196" left="74" width="351" height="12" font="4"> S7.9.1.1-15. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym-</text>
<text top="210" left="134" width="297" height="12" font="4">pathetic denervation for the management of life-threatening </text>
<text top="223" left="134" width="291" height="12" font="4">ventricular tachyarrhythmias in young patients with catechol-</text>
<text top="237" left="134" width="291" height="12" font="4">aminergic polymorphic ventricular tachycardia and long QT syn-</text>
<text top="250" left="134" width="189" height="12" font="4">drome. Clin Res Cardiol. 2013;102:33–42.</text>
<text top="264" left="74" width="354" height="12" font="4"> S7.9.1.1-16.  Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic </text>
<text top="277" left="134" width="294" height="12" font="4">denervation in the management of high-risk patients affected by </text>
<text top="291" left="134" width="250" height="12" font="4">the long-QT syndrome. Circulation. 2004;109:1826–33.</text>
<text top="305" left="74" width="356" height="12" font="4"> S7.9.1.1-17. Bai R, Napolitano C, Bloise R, et al. Yield of genetic screening </text>
<text top="318" left="134" width="295" height="12" font="4">in inherited cardiac channelopathies: how to prioritize access to </text>
<text top="332" left="134" width="265" height="12" font="4">genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6–15.</text>
<text top="345" left="74" width="355" height="12" font="4"> S7.9.1.1-18. Costa J, Lopes CM, Barsheshet A, et al. Combined assessment </text>
<text top="359" left="134" width="294" height="12" font="4">of sex- and mutation-specific information for risk stratification in </text>
<text top="372" left="134" width="253" height="12" font="4">type 1 long QT syndrome. Heart Rhythm. 2012;9:892–8.</text>
<text top="386" left="74" width="354" height="12" font="4"> S7.9.1.1-19.  Kim JA, Lopes CM, Moss AJ, et al. Trigger-specific risk factors and </text>
<text top="399" left="134" width="294" height="12" font="4">response to therapy in long QT syndrome type 2. Heart Rhythm. </text>
<text top="413" left="134" width="84" height="12" font="4">2010;7:1797–805.</text>
<text top="426" left="74" width="351" height="12" font="4"> S7.9.1.1-20.  Migdalovich D, Moss AJ, Lopes CM, et al. Mutation and gender-</text>
<text top="440" left="134" width="296" height="12" font="4">specific risk in type 2 long QT syndrome: implications for risk </text>
<text top="453" left="134" width="295" height="12" font="4">stratification for life-threatening cardiac events in patients with </text>
<text top="467" left="134" width="234" height="12" font="4">long QT syndrome. Heart Rhythm. 2011;8:1537–43.</text>
<text top="480" left="74" width="354" height="12" font="4"> S7.9.1.1-21.  Tester DJ, Will ML, Haglund CM, et al. Effect of clinical phenotype </text>
<text top="494" left="134" width="294" height="12" font="4">on yield of long QT syndrome genetic testing. J Am Coll Cardiol. </text>
<text top="507" left="134" width="72" height="12" font="4">2006;47:764–8.</text>
<text top="521" left="74" width="355" height="12" font="4"> S7.9.1.1-22. Adler A, van der Werf C, Postema PG, et al. The phenomenon </text>
<text top="534" left="134" width="297" height="12" font="4">of “QT stunning”: The abnormal QT prolongation provoked </text>
<text top="548" left="134" width="295" height="12" font="4">by standing persists even as the heart rate returns to normal in </text>
<text top="561" left="134" width="283" height="12" font="4">patients with long QT syndrome. Heart Rhythm. 2012;9:901–8.</text>
<text top="575" left="74" width="356" height="12" font="4"> S7.9.1.1-23. Aziz PF, Wieand TS, Ganley J, et al. Genotype- and mutation </text>
<text top="588" left="134" width="291" height="12" font="4">site-specific QT adaptation during exercise, recovery, and pos-</text>
<text top="602" left="134" width="294" height="12" font="4">tural changes in children with long-QT syndrome. Circ Arrhythm </text>
<text top="615" left="134" width="139" height="12" font="4">Electrophysiol. 2011;4:867–73.</text>
<text top="629" left="74" width="351" height="12" font="4"> S7.9.1.1-24.  Chattha IS, Sy RW, Yee R, et al. Utility of the recovery electrocar-</text>
<text top="642" left="134" width="296" height="12" font="4">diogram after exercise: a novel indicator for the diagnosis and </text>
<text top="656" left="134" width="291" height="12" font="4">genotyping of long QT syndrome? Heart Rhythm. 2010;7:906–11.</text>
<text top="669" left="74" width="351" height="12" font="4"> S7.9.1.1-25.  Laksman ZW, Hamilton RM, Chockalingam P, et al. Mutation loca-</text>
<text top="683" left="134" width="293" height="12" font="4">tion effect on severity of phenotype during exercise testing in type </text>
<text top="696" left="134" width="291" height="12" font="4">1 long-QT syndrome: impact of transmembrane and C-loop loca-</text>
<text top="710" left="134" width="232" height="12" font="4">tion. J Cardiovasc Electrophysiol. 2013;24:1015–20.</text>
<text top="723" left="74" width="354" height="12" font="4"> S7.9.1.1-26. Moltedo JM, Kim JJ, Friedman RA, et al. Use of a cardioselective </text>
<text top="737" left="134" width="294" height="12" font="4">beta-blocker for pediatric patients with prolonged QT syndrome. </text>
<text top="750" left="134" width="138" height="12" font="4">Pediatr Cardiol. 2011;32:63–6.</text>
<text top="764" left="74" width="355" height="12" font="4"> S7.9.1.1-27. Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation </text>
<text top="777" left="134" width="294" height="12" font="4">of a simple exercise-based algorithm for prediction of genetic testing  </text>
<text top="791" left="134" width="280" height="12" font="4">in relatives of LQTS probands. Circulation. 2011;124:2187–94.</text>
<text top="805" left="74" width="354" height="12" font="4"> S7.9.1.1-28.  Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac </text>
<text top="818" left="134" width="291" height="12" font="4">events with beta-blocking therapy in children with long QT syn-</text>
<text top="832" left="134" width="173" height="12" font="4">drome. Eur Heart J. 2004;25:1405–11.</text>
<text top="845" left="74" width="354" height="12" font="4"> S7.9.1.1-29. Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT </text>
<text top="859" left="134" width="291" height="12" font="4">interval to the brief tachycardia provoked by standing: a bed-</text>
<text top="872" left="134" width="296" height="12" font="4">side test for diagnosing long QT syndrome. J Am Coll Cardiol. </text>
<text top="886" left="134" width="84" height="12" font="4">2010;55:1955–61.</text>
<text top="899" left="74" width="355" height="12" font="4"> S7.9.1.1-30. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long </text>
<text top="913" left="134" width="294" height="12" font="4">QT syndrome loci and cardiac events among patients treated with </text>
<text top="926" left="134" width="183" height="12" font="4">beta-blockers. JAMA. 2004;292:1341–4.</text>
<text top="940" left="74" width="356" height="12" font="4"> S7.9.1.1-31. Goldenberg I, Horr S, Moss AJ, et al. Risk for life-threatening </text>
<text top="953" left="134" width="298" height="12" font="4">cardiac events in patients with genotype-confirmed long-QT </text>
<text top="967" left="134" width="296" height="12" font="4">syndrome and normal-range corrected QT intervals. J Am Coll </text>
<text top="980" left="134" width="104" height="12" font="4">Cardiol. 2011;57:51–9.</text>
<text top="994" left="74" width="6" height="12" font="4"> </text>
<text top="994" left="74" width="357" height="12" font="4">S7.9.1.1-32. Choy AM, Lang CC, Chomsky DM, et al. Normalization of </text>
<text top="1007" left="134" width="295" height="12" font="4">acquired QT prolongation in humans by intravenous potassium. </text>
<text top="1021" left="134" width="138" height="12" font="4">Circulation. 1997;96:2149–54.</text>
<text top="1034" left="74" width="351" height="12" font="4"> S7.9.1.1-33. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syn-</text>
<text top="1048" left="134" width="183" height="12" font="4">drome. Pharmacol Rev. 2010;62:760–81.</text>
<text top="1061" left="74" width="357" height="12" font="4"> S7.9.1.1-34. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and </text>
<text top="1075" left="134" width="296" height="12" font="4">therapy for attention deficit/hyperactivity disorder. J Cardiovasc </text>
<text top="1088" left="134" width="151" height="12" font="4">Electrophysiol. 2015;26:1039–44.</text>
<text top="88" left="452" width="353" height="12" font="4"> S7.9.1.1-35.  Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the </text>
<text top="102" left="512" width="243" height="12" font="4">long-QT syndrome. N Engl J Med. 2003;348:1866–74.</text>
<text top="115" left="452" width="354" height="12" font="4"> S7.9.1.1-36.  Wilde AA, Moss AJ, Kaufman ES, et al. Clinical aspects of type 3 </text>
<text top="129" left="512" width="293" height="12" font="4">long-QT syndrome: an international multicenter study. Circulation. </text>
<text top="142" left="512" width="84" height="12" font="4">2016;134:872–82.</text>
<text top="156" left="452" width="354" height="12" font="4"> S7.9.1.1-37.  Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: </text>
<text top="169" left="512" width="202" height="12" font="4">true or false? Heart Rhythm. 2009;6:113–20.</text>
<text top="183" left="452" width="355" height="12" font="4"> S7.9.1.1-38. Garson A Jr, Dick M, Fournier A, et al. The long QT syndrome </text>
<text top="197" left="512" width="295" height="12" font="4">in children. An international study of 287 patients. Circulation. </text>
<text top="210" left="512" width="84" height="12" font="4">1993;87:1866–72.</text>
<text top="224" left="452" width="351" height="12" font="4"> S7.9.1.1-39. Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recom-</text>
<text top="237" left="512" width="298" height="12" font="4">mendations for the use of automated external defibrillators </text>
<text top="251" left="512" width="213" height="12" font="4">(AEDs) in Europe. Eur Heart J. 2004;25:437–45.</text>
<text top="264" left="452" width="357" height="12" font="4"> S7.9.1.1-40. Steinberg C, Padfield GJ, Al-Sabeq B, et al. Experience with </text>
<text top="278" left="512" width="296" height="12" font="4">bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card </text>
<text top="291" left="512" width="145" height="12" font="4">Electrophysiol. 2016;47:163–70.</text>
<text top="305" left="452" width="351" height="12" font="4"> S7.9.1.1-41.  Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-block-</text>
<text top="318" left="512" width="295" height="12" font="4">ers are equal in the management of long QT syndrome types 1 </text>
<text top="332" left="512" width="295" height="12" font="4">and 2: higher recurrence of events under metoprolol. J Am Coll </text>
<text top="345" left="512" width="116" height="12" font="4">Cardiol. 2012;60:2092–9.</text>
<text top="359" left="452" width="351" height="12" font="4"> S7.9.1.1-42. Khositseth A, Tester DJ, Will ML, et al. Identification of a com-</text>
<text top="372" left="512" width="297" height="12" font="4">mon genetic substrate underlying postpartum cardiac events </text>
<text top="386" left="512" width="294" height="12" font="4">in congenital long QT syndrome. Heart Rhythm. 2004;1: </text>
<text top="399" left="512" width="26" height="12" font="4">60–4.</text>
<text top="413" left="452" width="355" height="12" font="4"> S7.9.1.1-43. Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on </text>
<text top="426" left="512" width="291" height="12" font="4">the risk for cardiac events in patients with hereditary long QT syn-</text>
<text top="440" left="512" width="249" height="12" font="4">drome. LQTS Investigators. Circulation. 1998;97:451–6.</text>
<text top="453" left="452" width="354" height="12" font="4"> S7.9.1.1-44.  Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow-up of </text>
<text top="467" left="512" width="295" height="12" font="4">patients with long-QT syndrome treated with beta-blockers and </text>
<text top="480" left="512" width="226" height="12" font="4">continuous pacing. Circulation. 1999;100:2431–6.</text>
<text top="494" left="452" width="351" height="12" font="4"> S7.9.1.1-45. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-</text>
<text top="507" left="512" width="300" height="12" font="4">adrenergic blocking agents and long-term cardiac pacing </text>
<text top="521" left="512" width="297" height="12" font="4">for patients with the long QT syndrome. J Am Coll Cardiol. </text>
<text top="534" left="512" width="72" height="12" font="4">1992;20:830–7.</text>
<text top="548" left="452" width="354" height="12" font="4"> S7.9.1.1-46.  Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in </text>
<text top="561" left="512" width="295" height="12" font="4">the management of high-risk patients with long QT syndrome. </text>
<text top="575" left="512" width="146" height="12" font="4">CIRCULATION. 1991;84:1524–9.</text>
<text top="588" left="452" width="351" height="12" font="4"> S7.9.1.1-47. Viskin S, Glikson M, Fish R, et al. Rate smoothing with car-</text>
<text top="602" left="512" width="296" height="12" font="4">diac pacing for preventing torsade de pointes. Am J Cardiol. </text>
<text top="615" left="512" width="83" height="12" font="4">2000;86:111k–5k.</text>
<text top="629" left="452" width="356" height="12" font="4"> S7.9.1.1-48. Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic </text>
<text top="642" left="512" width="291" height="12" font="4">denervation in long QT syndrome: analysis of therapeutic nonre-</text>
<text top="656" left="512" width="251" height="12" font="4">sponders. Circ Arrhythm Electrophysiol. 2013;6:705–11.</text>
<text top="669" left="452" width="355" height="12" font="4"> S7.9.1.1-49. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic </text>
<text top="683" left="512" width="291" height="12" font="4">denervation for catecholaminergic polymorphic ventricular tachy-</text>
<text top="697" left="512" width="181" height="12" font="4">cardia. N Engl J Med. 2008;358:2024–9.</text>
<text top="710" left="452" width="351" height="12" font="4"> S7.9.1.1-50. Li J, Liu Y, Yang F, et al. Video-assisted thoracoscopic left car-</text>
<text top="724" left="512" width="299" height="12" font="4">diac sympathetic denervation: a reliable minimally invasive </text>
<text top="737" left="512" width="296" height="12" font="4">approach for congenital long-QT syndrome. Ann Thorac Surg. </text>
<text top="751" left="512" width="78" height="12" font="4">2008;86:1955–8.</text>
<text top="764" left="452" width="351" height="12" font="4"> S7.9.1.1-51. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical manage-</text>
<text top="778" left="512" width="295" height="12" font="4">ment of catecholaminergic polymorphic ventricular tachycardia: </text>
<text top="791" left="512" width="297" height="12" font="4">the role of left cardiac sympathetic denervation. Circulation. </text>
<text top="805" left="512" width="90" height="12" font="4">2015;131:2185–93.</text>
<text top="818" left="452" width="351" height="12" font="4"> S7.9.1.1-52.  Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic dener-</text>
<text top="832" left="512" width="295" height="12" font="4">vation for long QT syndrome: effects on QT interval and heart </text>
<text top="845" left="512" width="166" height="12" font="4">rate. Heart Vessels. 2005;20:137–41.</text>
<text top="859" left="452" width="355" height="12" font="4"> S7.9.1.1-53. Burns C, Ingles J, Davis AM, et al. Clinical and genetic features </text>
<text top="872" left="512" width="295" height="12" font="4">of Australian families with long QT syndrome: a registry–based </text>
<text top="886" left="512" width="162" height="12" font="4">study. J Arrhythm. 2016;32:456–61.</text>
<text top="899" left="452" width="351" height="12" font="4"> S7.9.1.1-54. Barsheshet A, Goldenberg I, Uchi J, et al. Mutations in cyto-</text>
<text top="913" left="512" width="291" height="12" font="4">plasmic loops of the KCNQ1 channel and the risk of life-threat-</text>
<text top="926" left="512" width="298" height="12" font="4">ening events: implications for mutation-specific response to </text>
<text top="940" left="512" width="296" height="12" font="4">beta-blocker therapy in type 1 long-QT syndrome. Circulation. </text>
<text top="953" left="512" width="90" height="12" font="4">2012;125:1988–96.</text>
<text top="967" left="452" width="355" height="12" font="4"> S7.9.1.1-55. Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT </text>
<text top="980" left="512" width="291" height="12" font="4">syndrome mutation KCNQ1/A341V causes unusually severe clini-</text>
<text top="994" left="512" width="294" height="12" font="4">cal manifestations in patients with different ethnic backgrounds: </text>
<text top="1007" left="512" width="301" height="12" font="4">toward a mutation-specific risk stratification. Circulation. </text>
<text top="1021" left="512" width="90" height="12" font="4">2007;116:2366–75.</text>
<text top="1034" left="452" width="356" height="12" font="4"> S7.9.1.1-56. Zhang C, Kutyifa V, McNitt S, et al. Identification of low-risk </text>
<text top="1048" left="512" width="298" height="12" font="4">adult congenital LQTS patients. J Cardiovasc Electrophysiol. </text>
<text top="1061" left="512" width="72" height="12" font="4">2015;26:853–8.</text>
<text top="1075" left="452" width="351" height="12" font="4"> S7.9.1.1-57.  Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharma-</text>
<text top="1088" left="512" width="253" height="12" font="4">cological treatment. J Am Coll Cardiol. 2004;43:1494–9.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e376</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="355" height="12" font="4"> S7.9.1.1-58. Spazzolini C, Mullally J, Moss AJ, et al. Clinical implications for </text>
<text top="102" left="134" width="294" height="12" font="4">patients with long QT syndrome who experience a cardiac event </text>
<text top="115" left="134" width="225" height="12" font="4">during infancy. J Am Coll Cardiol. 2009;54:832–7.</text>
<text top="129" left="74" width="10" height="12" font="4"> </text>
<text top="129" left="74" width="361" height="12" font="4">S7.9.1.1-59. Credible meds. A<a href="">vailable at: http://www.crediblemeds.org. </a></text>
<text top="142" left="134" width="136" height="12" font="4">Accessed December 26, 2016.</text>
<text top="156" left="74" width="351" height="12" font="4"> S7.9.1.1-60. Rohatgi RK, Bos JM, Ackerman MJ. Stimulant therapy in chil-</text>
<text top="169" left="134" width="291" height="12" font="4">dren with attention-deficit/hyperactivity disorder and concomi-</text>
<text top="183" left="134" width="297" height="12" font="4">tant long QT syndrome: a safe combination? Heart Rhythm. </text>
<text top="196" left="134" width="84" height="12" font="4">2015;12:1807–12.</text>
<text top="210" left="74" width="351" height="12" font="4"> S7.9.1.1-61. Amin AS, Klemens CA, Verkerk AO, et al. Fever-triggered ven-</text>
<text top="223" left="134" width="296" height="12" font="4">tricular arrhythmias in Brugada syndrome and type 2 long-QT </text>
<text top="237" left="134" width="183" height="12" font="4">syndrome. Neth Heart J. 2010;18:165–9.</text>
<text top="250" left="74" width="354" height="12" font="4"> S7.9.1.1-62.  Roden DM. Drug-induced prolongation of the QT interval. N Engl </text>
<text top="264" left="134" width="123" height="12" font="4">J Med. 2004;350:1013–22.</text>
<text top="290" left="74" width="332" height="18" font="28"><i>7.9.1.2. Catecholaminergic Polymorphic Ventricular </i></text>
<text top="308" left="74" width="74" height="18" font="28"><i>Tachycardia</i></text>
<text top="328" left="80" width="348" height="12" font="4"> S7.9.1.2-1.  Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors </text>
<text top="342" left="134" width="291" height="12" font="4">of arrhythmic events in catecholaminergic polymorphic ventricu-</text>
<text top="355" left="134" width="214" height="12" font="4">lar tachycardia. Circulation. 2009;119:2426–34.</text>
<text top="369" left="80" width="350" height="12" font="4"> S7.9.1.2-2. Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic </text>
<text top="382" left="134" width="291" height="12" font="4">polymorphic ventricular tachycardia in children: analysis of thera-</text>
<text top="396" left="134" width="294" height="12" font="4">peutic strategies and outcomes from an international multicenter </text>
<text top="409" left="134" width="242" height="12" font="4">registry. Circ Arrhythm Electrophysiol. 2015;8:633–42.</text>
<text top="423" left="80" width="349" height="12" font="4"> S7.9.1.2-3. Collura CA, Johnson JN, Moir C, et al. Left cardiac sympathetic </text>
<text top="436" left="134" width="291" height="12" font="4">denervation for the treatment of long QT syndrome and cate-</text>
<text top="450" left="134" width="291" height="12" font="4">cholaminergic polymorphic ventricular tachycardia using video-</text>
<text top="463" left="134" width="248" height="12" font="4">assisted thoracic surgery. Heart Rhythm. 2009;6:752–9.</text>
<text top="477" left="80" width="348" height="12" font="4"> S7.9.1.2-4.  Hofferberth SC, Cecchin F, Loberman D, et al. Left thoracoscopic </text>
<text top="490" left="134" width="291" height="12" font="4">sympathectomy for cardiac denervation in patients with life-</text>
<text top="504" left="134" width="296" height="12" font="4">threatening ventricular arrhythmias. J Thorac Cardiovasc Surg. </text>
<text top="517" left="134" width="78" height="12" font="4">2014;147:404–9.</text>
<text top="531" left="80" width="345" height="12" font="4"> S7.9.1.2-5. Schneider HE, Steinmetz M, Krause U, et al. Left cardiac sym-</text>
<text top="544" left="134" width="297" height="12" font="4">pathetic denervation for the management of life-threatening </text>
<text top="558" left="134" width="291" height="12" font="4">ventricular tachyarrhythmias in young patients with catechol-</text>
<text top="571" left="134" width="291" height="12" font="4">aminergic polymorphic ventricular tachycardia and long QT syn-</text>
<text top="585" left="134" width="189" height="12" font="4">drome. Clin Res Cardiol. 2013;102:33–42.</text>
<text top="598" left="80" width="348" height="12" font="4"> S7.9.1.2-6.  van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy </text>
<text top="612" left="134" width="294" height="12" font="4">reduces exercise-induced ventricular arrhythmias in patients with </text>
<text top="625" left="134" width="294" height="12" font="4">catecholaminergic polymorphic ventricular tachycardia. J Am Coll </text>
<text top="639" left="134" width="116" height="12" font="4">Cardiol. 2011;57:2244–5.</text>
<text top="652" left="80" width="349" height="12" font="4"> S7.9.1.2-7. Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular </text>
<text top="666" left="134" width="295" height="12" font="4">characterization of patients with catecholaminergic polymorphic </text>
<text top="679" left="134" width="238" height="12" font="4">ventricular tachycardia. Circulation. 2002;106:69–74.</text>
<text top="693" left="80" width="345" height="12" font="4"> S7.9.1.2-8.  Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymor-</text>
<text top="706" left="134" width="294" height="12" font="4">phic ventricular tachycardia in children. A 7-year follow-up of 21 </text>
<text top="720" left="134" width="174" height="12" font="4">patients. Circulation. 1995;91:1512–9.</text>
<text top="733" left="80" width="345" height="12" font="4"> S7.9.1.2-9. Rosso R, Kalman JM, Rogowski O, et al. Calcium channel block-</text>
<text top="747" left="134" width="295" height="12" font="4">ers and beta-blockers versus beta-blockers alone for preventing </text>
<text top="760" left="134" width="296" height="12" font="4">exercise-induced arrhythmias in catecholaminergic polymorphic </text>
<text top="774" left="134" width="252" height="12" font="4">ventricular tachycardia. Heart Rhythm. 2007;4:1149–54.</text>
<text top="788" left="74" width="354" height="12" font="4"> S7.9.1.2-10.  Swan H, Laitinen P, Kontula K, et al. Calcium channel antagonism </text>
<text top="801" left="134" width="291" height="12" font="4">reduces exercise-induced ventricular arrhythmias in catechol-</text>
<text top="815" left="134" width="294" height="12" font="4">aminergic polymorphic ventricular tachycardia patients with RyR2 </text>
<text top="828" left="134" width="248" height="12" font="4">mutations. J Cardiovasc Electrophysiol. 2005;16:162–6.</text>
<text top="842" left="74" width="355" height="12" font="4"> S7.9.1.2-11. Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of </text>
<text top="855" left="134" width="291" height="12" font="4">flecainide on exercise-induced ventricular arrhythmias and recur-</text>
<text top="869" left="134" width="291" height="12" font="4">rences in genotype-negative patients with catecholaminergic poly-</text>
<text top="882" left="134" width="286" height="12" font="4">morphic ventricular tachycardia. Heart Rhythm. 2013;10:542–7.</text>
<text top="896" left="74" width="354" height="12" font="4"> S7.9.1.2-12.  Hwang HS, Hasdemir C, Laver D, et al. Inhibition of cardiac Ca2+ </text>
<text top="909" left="134" width="291" height="12" font="4">release channels (RyR2) determines efficacy of class I antiarrhyth-</text>
<text top="923" left="134" width="291" height="12" font="4">mic drugs in catecholaminergic polymorphic ventricular tachycar-</text>
<text top="936" left="134" width="224" height="12" font="4">dia. Circ Arrhythm Electrophysiol. 2011;4:128–35.</text>
<text top="950" left="74" width="351" height="12" font="4"> S7.9.1.2-13.  Adler A, Sadek MM, Chan AY, et al. Patient outcomes from a spe-</text>
<text top="963" left="134" width="295" height="12" font="4">cialized inherited arrhythmia clinic. Circ Arrhythm Electrophysiol. </text>
<text top="977" left="134" width="78" height="12" font="4">2016;9:e003440.</text>
<text top="990" left="74" width="356" height="12" font="4"> S7.9.1.2-14. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable </text>
<text top="1004" left="134" width="296" height="12" font="4">cardioverter-defibrillator harm in young patients with inherited </text>
<text top="1017" left="134" width="297" height="12" font="4">arrhythmia syndromes: a systematic review and meta-analysis </text>
<text top="1031" left="134" width="299" height="12" font="4">of inappropriate shocks and complications. Heart Rhythm. </text>
<text top="1044" left="134" width="78" height="12" font="4">2016;13:443–54.</text>
<text top="1058" left="74" width="351" height="12" font="4"> S7.9.1.2-15. Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defi-</text>
<text top="1071" left="134" width="297" height="12" font="4">brillator therapy in catecholaminergic polymorphic ventricular </text>
<text top="1085" left="134" width="196" height="12" font="4">tachycardia. Heart Rhythm. 2014;11:58–66.</text>
<text top="88" left="452" width="355" height="12" font="4"> S7.9.1.2-16. Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization </text>
<text top="102" left="512" width="291" height="12" font="4">and long-term outcomes in catecholaminergic polymorphic ven-</text>
<text top="115" left="512" width="230" height="12" font="4">tricular tachycardia. Heart Rhythm. 2011;8:864–71.</text>
<text top="129" left="452" width="351" height="12" font="4"> S7.9.1.2-17. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical manage-</text>
<text top="142" left="512" width="295" height="12" font="4">ment of catecholaminergic polymorphic ventricular tachycardia: </text>
<text top="156" left="512" width="297" height="12" font="4">the role of left cardiac sympathetic denervation. Circulation. </text>
<text top="170" left="512" width="90" height="12" font="4">2015;131:2185–93.</text>
<text top="183" left="452" width="355" height="12" font="4"> S7.9.1.2-18. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic </text>
<text top="197" left="512" width="291" height="12" font="4">denervation for catecholaminergic polymorphic ventricular tachy-</text>
<text top="210" left="512" width="181" height="12" font="4">cardia. N Engl J Med. 2008;358:2024–9.</text>
<text top="224" left="452" width="357" height="12" font="4"> S7.9.1.2-19. Zhang C, Kutyifa V, Moss AJ, et al. Long-QT syndrome and </text>
<text top="237" left="512" width="296" height="12" font="4">therapy for attention deficit/hyperactivity disorder. J Cardiovasc </text>
<text top="251" left="512" width="151" height="12" font="4">Electrophysiol. 2015;26:1039–44.</text>
<text top="265" left="452" width="351" height="12" font="4"> S7.9.1.2-20. Jabbari J, Jabbari R, Nielsen MW, et al. New exome data ques-</text>
<text top="278" left="512" width="296" height="12" font="4">tion the pathogenicity of genetic variants previously associated </text>
<text top="292" left="512" width="294" height="12" font="4">with catecholaminergic polymorphic ventricular tachycardia. Circ </text>
<text top="305" left="512" width="162" height="12" font="4">Cardiovasc Genetics. 2013;6:481–9.</text>
<text top="319" left="452" width="7" height="12" font="4"> </text>
<text top="319" left="452" width="358" height="12" font="4">S7.9.1.2-21. Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations </text>
<text top="332" left="512" width="296" height="12" font="4">associated with recurrent cardiac arrest in infants. Circulation. </text>
<text top="346" left="512" width="90" height="12" font="4">2013;127:1009–17.</text>
<text top="359" left="452" width="351" height="12" font="4"> S7.9.1.2-22. Makita N, Yagihara N, Crotti L, et al. Novel calmodulin muta-</text>
<text top="373" left="512" width="296" height="12" font="4">tions associated with congenital arrhythmia susceptibility. Circ </text>
<text top="387" left="512" width="157" height="12" font="4">Cardiovasc Genet. 2014;7:466–74.</text>
<text top="400" left="452" width="355" height="12" font="4"> S7.9.1.2-23. Marsman RF, Barc J, Beekman L, et al. A mutation in CALM1 </text>
<text top="414" left="512" width="291" height="12" font="4">encoding calmodulin in familial idiopathic ventricular fibrilla-</text>
<text top="427" left="512" width="294" height="12" font="4">tion in childhood and adolescence. J Am Coll Cardiol. 2014;63: </text>
<text top="441" left="512" width="38" height="12" font="4">259–66.</text>
<text top="454" left="452" width="355" height="12" font="4"> S7.9.1.2-24. Nyegaard M, Overgaard MT, Sondergaard MT, et al. Mutations </text>
<text top="468" left="512" width="295" height="12" font="4">in calmodulin cause ventricular tachycardia and sudden cardiac </text>
<text top="482" left="512" width="193" height="12" font="4">death. Am J Hum Genet. 2012;91:703–12.</text>
<text top="495" left="452" width="356" height="12" font="4"> S7.9.1.2-25. Paludan-Muller C, Ahlberg G, Ghouse J, et al. Integration of </text>
<text top="509" left="512" width="291" height="12" font="4">60 000 exomes and acmg guidelines question the role of cat-</text>
<text top="522" left="512" width="298" height="12" font="4">echolaminergic polymorphic ventricular tachycardia-associated </text>
<text top="536" left="512" width="166" height="12" font="4">variants. Clin Genet. 2017;91:63–72.</text>
<text top="562" left="452" width="176" height="18" font="28"><i>7.9.1.3. Brugada Syndrome</i></text>
<text top="583" left="458" width="348" height="12" font="4"> S7.9.1.3-1.  Casado-Arroyo R, Berne P, Rao JY, et al. Long-term trends in newly </text>
<text top="596" left="512" width="294" height="12" font="4">diagnosed Brugada syndrome: implications for risk stratification. J </text>
<text top="610" left="512" width="155" height="12" font="4">Am Coll Cardiol. 2016;68:614–23.</text>
<text top="623" left="458" width="345" height="12" font="4"> S7.9.1.3-2. Gehi AK, Duong TD, Metz LD, et al. Risk stratification of indi-</text>
<text top="637" left="512" width="296" height="12" font="4">viduals with the Brugada electrocardiogram: a meta-analysis. J </text>
<text top="651" left="512" width="196" height="12" font="4">Cardiovasc Electrophysiol. 2006;17:577–83.</text>
<text top="664" left="458" width="345" height="12" font="4"> S7.9.1.3-3.  Hiraoka M, Takagi M, Yokoyama Y, et al. Prognosis and risk strati-</text>
<text top="678" left="512" width="294" height="12" font="4">fication of young adults with Brugada syndrome. J Electrocardiol. </text>
<text top="691" left="512" width="78" height="12" font="4">2013;46:279–83.</text>
<text top="705" left="458" width="350" height="12" font="4"> S7.9.1.3-4. Priori SG, Gasparini M, Napolitano C, et al. Risk stratification </text>
<text top="718" left="512" width="297" height="12" font="4">in Brugada syndrome: results of the PRELUDE (PRogrammed </text>
<text top="732" left="512" width="294" height="12" font="4">ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. </text>
<text top="745" left="512" width="72" height="12" font="4">2012;59:37–45.</text>
<text top="759" left="458" width="350" height="12" font="4"> S7.9.1.3-5. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis </text>
<text top="773" left="512" width="297" height="12" font="4">of patients diagnosed with Brugada syndrome: results from </text>
<text top="786" left="512" width="294" height="12" font="4">the FINGER Brugada syndrome registry. Circulation. 2010;121: </text>
<text top="800" left="512" width="38" height="12" font="4">635–43.</text>
<text top="813" left="458" width="349" height="12" font="4"> S7.9.1.3-6. Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular </text>
<text top="827" left="512" width="297" height="12" font="4">stimulation for risk stratification in the Brugada syndrome: a </text>
<text top="840" left="512" width="212" height="12" font="4">pooled analysis. Circulation. 2016;133:622–30.</text>
<text top="854" left="458" width="351" height="12" font="4"> S7.9.1.3-7. Belhassen B, Rahkovich M, Michowitz Y, et al. Management </text>
<text top="868" left="512" width="291" height="12" font="4">of Brugada syndrome: thirty-three-year experience using elec-</text>
<text top="881" left="512" width="296" height="12" font="4">trophysiologically guided therapy with class 1A antiarrhythmic </text>
<text top="895" left="512" width="248" height="12" font="4">drugs. Circ Arrhythm Electrophysiol. 2015;8:1393–402.</text>
<text top="908" left="458" width="345" height="12" font="4"> S7.9.1.3-8.  Brugada J, Pappone C, Berruezo A, et al. Brugada syndrome phe-</text>
<text top="922" left="512" width="294" height="12" font="4">notype elimination by epicardial substrate ablation. Circ Arrhythm </text>
<text top="935" left="512" width="145" height="12" font="4">Electrophysiol. 2015;8:1373–81.</text>
<text top="949" left="458" width="349" height="12" font="4"> S7.9.1.3-9. Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention </text>
<text top="963" left="512" width="291" height="12" font="4">of ventricular fibrillation episodes in Brugada syndrome by cath-</text>
<text top="976" left="512" width="291" height="12" font="4">eter ablation over the anterior right ventricular outflow tract epi-</text>
<text top="990" left="512" width="180" height="12" font="4">cardium. Circulation. 2011;123:1270–9.</text>
<text top="1003" left="452" width="356" height="12" font="4"> S7.9.1.3-10. Sunsaneewitayakul B, Yao Y, Thamaree S, et al. Endocardial </text>
<text top="1017" left="512" width="291" height="12" font="4">mapping and catheter ablation for ventricular fibrillation preven-</text>
<text top="1030" left="512" width="294" height="12" font="4">tion in Brugada syndrome. J Cardiovasc Electrophysiol. 2012;23 </text>
<text top="1044" left="512" width="68" height="12" font="4">suppl 1:S10–6.</text>
<text top="1058" left="452" width="351" height="12" font="4"> S7.9.1.3-11. Zhang P, Tung R, Zhang Z, et al. Characterization of the epicar-</text>
<text top="1071" left="512" width="295" height="12" font="4">dial substrate for catheter ablation of Brugada syndrome. Heart </text>
<text top="1085" left="512" width="118" height="12" font="4">Rhythm. 2016;13:2151–8.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e377</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="355" height="12" font="4"> S7.9.1.3-12. Antzelevitch C, Yan GX, Ackerman MJ, et al. J-wave syndromes </text>
<text top="102" left="134" width="294" height="12" font="4">expert consensus conference report: emerging concepts and gaps </text>
<text top="116" left="134" width="192" height="12" font="4">in knowledge. Europace. 2017;19:665–94.</text>
<text top="129" left="74" width="354" height="12" font="4"> S7.9.1.3-13.  Delise P, Allocca G, Marras E, et al. Risk stratification in individuals </text>
<text top="143" left="134" width="295" height="12" font="4">with the Brugada type 1 ECG pattern without previous cardiac </text>
<text top="157" left="134" width="296" height="12" font="4">arrest: usefulness of a combined clinical and electrophysiologic </text>
<text top="170" left="134" width="180" height="12" font="4">approach. Eur Heart J. 2011;32:169–76.</text>
<text top="184" left="74" width="353" height="12" font="4"> S7.9.1.3-14.  Somani R, Krahn AD, Healey JS, et al. Procainamide infusion in the </text>
<text top="197" left="134" width="294" height="12" font="4">evaluation of unexplained cardiac arrest: from the Cardiac Arrest </text>
<text top="211" left="134" width="298" height="12" font="4">Survivors with Preserved Ejection Fraction Registry (CASPER). </text>
<text top="225" left="134" width="152" height="12" font="4">Heart Rhythm. 2014;11:1047–54.</text>
<text top="238" left="74" width="354" height="12" font="4"> S7.9.1.3-15.  Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review </text>
<text top="252" left="134" width="297" height="12" font="4">for the 2017 AHA/ACC/HRS guideline for management of </text>
<text top="266" left="134" width="297" height="12" font="4">patients with ventricular arrhythmias and the prevention of </text>
<text top="279" left="134" width="296" height="12" font="4">sudden cardiac death: a report of the American College of </text>
<text top="293" left="134" width="295" height="12" font="4">Cardiology/American Heart Association Task Force on Clinical </text>
<text top="307" left="134" width="295" height="12" font="4">Practice Guidelines and the Heart Rhythm Society. Circulation. </text>
<text top="320" left="134" width="103" height="12" font="4">2018;138:e392–e414.</text>
<text top="334" left="74" width="351" height="12" font="4"> S7.9.1.3-16. Sieira J, Ciconte G, Conte G, et al. Asymptomatic Brugada syn-</text>
<text top="347" left="134" width="297" height="12" font="4">drome: clinical characterization and long-term prognosis. Circ </text>
<text top="361" left="134" width="191" height="12" font="4">Arrhythm Electrophysiol. 2015;8:1144–50.</text>
<text top="375" left="74" width="351" height="12" font="4"> S7.9.1.3-17. Sieira J, Conte G, Ciconte G, et al. Prognostic value of pro-</text>
<text top="388" left="134" width="299" height="12" font="4">grammed electrical stimulation in Brugada syndrome: 20 </text>
<text top="402" left="134" width="294" height="12" font="4">years experience. Circ Arrhythm Electrophysiol. 2015;8: </text>
<text top="416" left="134" width="37" height="12" font="4">777–84.</text>
<text top="429" left="74" width="355" height="12" font="4"> S7.9.1.3-18. Crotti L, Marcou CA, Tester DJ, et al. Spectrum and prevalence </text>
<text top="443" left="134" width="295" height="12" font="4">of mutations involving BrS1- through BrS12-susceptibility genes </text>
<text top="457" left="134" width="295" height="12" font="4">in a cohort of unrelated patients referred for Brugada syndrome </text>
<text top="470" left="134" width="293" height="12" font="4">genetic testing: implications for genetic testing. J Am Coll Cardiol. </text>
<text top="484" left="134" width="78" height="12" font="4">2012;60:1410–8.</text>
<text top="497" left="74" width="355" height="12" font="4"> S7.9.1.3-19. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role </text>
<text top="511" left="134" width="291" height="12" font="4">of genetic background in the pathophysiology of Brugada syn-</text>
<text top="525" left="134" width="206" height="12" font="4">drome. Circ Cardiovasc Genet. 2009;2:552–7.</text>
<text top="538" left="74" width="357" height="12" font="4"> S7.9.1.3-20. Risgaard B, Jabbari R, Refsgaard L, et al. High prevalence of </text>
<text top="552" left="134" width="295" height="12" font="4">genetic variants previously associated with Brugada syndrome in </text>
<text top="566" left="134" width="238" height="12" font="4">new exome data. Clinical Genetics. 2013;84:489–95.</text>
<text top="579" left="74" width="7" height="12" font="4"> </text>
<text top="579" left="74" width="358" height="12" font="4">S7.9.1.3-21. Brugada drugs. A<a href="">vailable at: http://www.brugadadrugs.org.</a> </text>
<text top="593" left="134" width="121" height="12" font="4">Accessed October 6, 2016.</text>
<text top="607" left="74" width="351" height="12" font="4"> S7.9.1.3-22.  Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syn-</text>
<text top="620" left="134" width="295" height="12" font="4">drome patients: review of the literature, recommendations, and </text>
<text top="634" left="134" width="295" height="12" font="4"><a href="">an up-to-date website (www.brugadadrugs.org). Heart Rhythm. </a></text>
<text top="648" left="134" width="78" height="12" font="4">2009;6:1335–41.</text>
<text top="661" left="74" width="354" height="12" font="4"> S7.9.1.3-23.  Andorin A, Behr ER, Denjoy I, et al. Impact of clinical and genetic </text>
<text top="675" left="134" width="291" height="12" font="4">findings on the management of young patients with Brugada syn-</text>
<text top="688" left="134" width="187" height="12" font="4">drome. Heart Rhythm. 2016;13:1274–82.</text>
<text top="702" left="74" width="351" height="12" font="4"> S7.9.1.3-24.  Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con-</text>
<text top="716" left="134" width="295" height="12" font="4">sensus statement on the diagnosis and management of patients </text>
<text top="729" left="134" width="297" height="12" font="4">with inherited primary arrhythmia syndromes. Heart Rhythm. </text>
<text top="743" left="134" width="84" height="12" font="4">2013;10:1932–63.</text>
<text top="757" left="74" width="354" height="12" font="4"> S7.9.1.3-25. McNamara DA, Goldberger JJ, Berendsen MA, et al. Implantable </text>
<text top="770" left="134" width="294" height="12" font="4">defibrillators versus medical therapy for cardiac channelopathies. </text>
<text top="784" left="134" width="210" height="12" font="4">Cochrane Database Syst Rev. 2015;CD011168.</text>
<text top="798" left="74" width="355" height="12" font="4"> S7.9.1.3-26. Nademanee K, Veerakul G, Mower M, et al. Defibrillator versus </text>
<text top="811" left="134" width="291" height="12" font="4">beta-blockers for unexplained death in Thailand (DEBUT): a ran-</text>
<text top="825" left="134" width="235" height="12" font="4">domized clinical trial. Circulation. 2003;107:2221–6.</text>
<text top="838" left="74" width="357" height="12" font="4"> S7.9.1.3-27. Rodriguez-Manero M, Sacher F, de AC, et al. Monomorphic </text>
<text top="852" left="134" width="297" height="12" font="4">ventricular tachycardia in patients with Brugada syndrome: </text>
<text top="866" left="134" width="294" height="12" font="4">a multicenter retrospective study. Heart Rhythm. 2016;13: </text>
<text top="879" left="134" width="37" height="12" font="4">669–82.</text>
<text top="893" left="74" width="356" height="12" font="4"> S7.9.1.3-28. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel </text>
<text top="907" left="134" width="293" height="12" font="4">blockers identify risk for sudden death in patients with ST-segment </text>
<text top="920" left="134" width="295" height="12" font="4">elevation and right bundle branch block but structurally normal </text>
<text top="934" left="134" width="166" height="12" font="4">hearts. Circulation. 2000;101:510–5.</text>
<text top="948" left="74" width="354" height="12" font="4"> S7.9.1.3-29.  Shimeno K, Takagi M, Maeda K, et al. Usefulness of multichannel </text>
<text top="961" left="134" width="295" height="12" font="4">Holter ECG recording in the third intercostal space for detecting </text>
<text top="975" left="134" width="296" height="12" font="4">type 1 Brugada ECG: comparison with repeated 12-lead ECGs.  </text>
<text top="989" left="134" width="209" height="12" font="4">J Cardiovasc Electrophysiol. 2009;20:1026–31.</text>
<text top="1002" left="74" width="351" height="12" font="4"> S7.9.1.3-30.  Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defi-</text>
<text top="1016" left="134" width="296" height="12" font="4">brillator therapy in Brugada syndrome: a 20-year single-center </text>
<text top="1029" left="134" width="215" height="12" font="4">experience. J Am Coll Cardiol. 2015;65:879–88.</text>
<text top="1043" left="74" width="351" height="12" font="4"> S7.9.1.3-31. Kapplinger JD, Tester DJ, Alders M, et al. An international com-</text>
<text top="1057" left="134" width="296" height="12" font="4">pendium of mutations in the SCN5A-encoded cardiac sodium </text>
<text top="1070" left="134" width="291" height="12" font="4">channel in patients referred for Brugada syndrome genetic test-</text>
<text top="1084" left="134" width="154" height="12" font="4">ing. Heart Rhythm. 2010;7:33–46.</text>
<text top="88" left="452" width="351" height="12" font="4"> S7.9.1.3-32.  Adler A, Rosso R, Chorin E, et al. Risk stratification in Brugada syn-</text>
<text top="102" left="512" width="296" height="12" font="4">drome: clinical characteristics, electrocardiographic parameters, </text>
<text top="115" left="512" width="247" height="12" font="4">and auxiliary testing. Heart Rhythm. 2016;13:299–310.</text>
<text top="129" left="452" width="356" height="12" font="4"> S7.9.1.3-33. Priori SG, Napolitano C, Gasparini M, et al. Natural history of </text>
<text top="143" left="512" width="291" height="12" font="4">Brugada syndrome: insights for risk stratification and manage-</text>
<text top="156" left="512" width="167" height="12" font="4">ment. Circulation. 2002;105:1342–7.</text>
<text top="186" left="452" width="308" height="18" font="28"><i>7.9.1.4. Early Repolarization “J-wave” Syndrome</i></text>
<text top="207" left="458" width="345" height="12" font="4"> S7.9.1.4-1. Rosso R, Kogan E, Belhassen B, et al. J-point elevation in sur-</text>
<text top="221" left="512" width="297" height="12" font="4">vivors of primary ventricular fibrillation and matched control </text>
<text top="234" left="512" width="296" height="12" font="4">subjects: incidence and clinical significance. J Am Coll Cardiol. </text>
<text top="248" left="512" width="78" height="12" font="4">2008;52:1231–8.</text>
<text top="261" left="458" width="350" height="12" font="4"> S7.9.1.4-2. Adhikarla C, Boga M, Wood AD, et al. Natural history of the </text>
<text top="275" left="512" width="294" height="12" font="4">electrocardiographic pattern of early repolarization in ambulatory </text>
<text top="288" left="512" width="188" height="12" font="4">patients. Am J Cardiol. 2011;108:1831–5.</text>
<text top="302" left="458" width="350" height="12" font="4"> S7.9.1.4-3. Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of </text>
<text top="315" left="512" width="298" height="12" font="4">recurrent ventricular fibrillation associated with inferolateral </text>
<text top="329" left="512" width="296" height="12" font="4">early repolarization role of drug therapy. J Am Coll Cardiol. </text>
<text top="342" left="512" width="74" height="12" font="4">2009;53:612–9.</text>
<text top="356" left="458" width="345" height="12" font="4"> S7.9.1.4-4. Siebermair J, Sinner MF, Beckmann BM, et al. Early repolariza-</text>
<text top="369" left="512" width="295" height="12" font="4">tion pattern is the strongest predictor of arrhythmia recurrence </text>
<text top="383" left="512" width="297" height="12" font="4">in patients with idiopathic ventricular fibrillation: results from </text>
<text top="397" left="512" width="296" height="12" font="4">a single centre long-term follow-up over 20 years. Europace. </text>
<text top="410" left="512" width="78" height="12" font="4">2016;18:718–25.</text>
<text top="424" left="458" width="350" height="12" font="4"> S7.9.1.4-5. Sinner MF, Porthan K, Noseworthy PA, et al. A meta-analysis </text>
<text top="437" left="512" width="291" height="12" font="4">of genome-wide association studies of the electrocardio-</text>
<text top="451" left="512" width="294" height="12" font="4">graphic early repolarization pattern. Heart Rhythm. 2012;9: </text>
<text top="464" left="512" width="43" height="12" font="4">1627–34.</text>
<text top="478" left="458" width="349" height="12" font="4"> S7.9.1.4-6. Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome </text>
<text top="491" left="512" width="297" height="12" font="4">associated with early repolarization on electrocardiography. N </text>
<text top="505" left="512" width="145" height="12" font="4">Engl J Med. 2009;361:2529–37.</text>
<text top="518" left="458" width="349" height="12" font="4"> S7.9.1.4-7. Tikkanen JT, Wichmann V, Junttila MJ, et al. Association of early </text>
<text top="532" left="512" width="293" height="12" font="4">repolarization and sudden cardiac death during an acute coronary </text>
<text top="545" left="512" width="229" height="12" font="4">event. Circ Arrhythm Electrophysiol. 2012;5:714–8.</text>
<text top="559" left="458" width="350" height="12" font="4"> S7.9.1.4-8. Junttila MJ, Tikkanen JT, Kentta T, et al. Early repolarization as </text>
<text top="573" left="512" width="296" height="12" font="4">a predictor of arrhythmic and nonarrhythmic cardiac events in </text>
<text top="586" left="512" width="246" height="12" font="4">middle-aged subjects. Heart Rhythm. 2014;11:1701–6.</text>
<text top="600" left="458" width="345" height="12" font="4"> S7.9.1.4-9. Cheng YJ, Lin XX, Ji CC, et al. Role of early repolarization pat-</text>
<text top="613" left="512" width="294" height="12" font="4">tern in increasing risk of death. J Am Heart Assoc. 2016;5: </text>
<text top="627" left="512" width="43" height="12" font="4">e003375.</text>
<text top="657" left="452" width="179" height="18" font="28"><i>7.9.1.5. Short QT Syndrome</i></text>
<text top="678" left="458" width="345" height="12" font="4"> S7.9.1.5-1. Dhutia H, Malhotra A, Parpia S, et al. The prevalence and signifi-</text>
<text top="691" left="512" width="291" height="12" font="4">cance of a short QT interval in 18 825 low-risk individuals includ-</text>
<text top="705" left="512" width="206" height="12" font="4">ing athletes. Br J Sports Med. 2016;50:124–9.</text>
<text top="718" left="458" width="345" height="12" font="4"> S7.9.1.5-2. Gollob MH, Redpath CJRoberts JD, The short QT syndrome: pro-</text>
<text top="732" left="512" width="270" height="12" font="4">posed diagnostic criteria. J Am Coll Cardiol. 2011;57:802–1.</text>
<text top="745" left="458" width="345" height="12" font="4"> S7.9.1.5-3. Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-</text>
<text top="759" left="512" width="297" height="12" font="4">up of patients with short QT syndrome. J Am Coll Cardiol. </text>
<text top="773" left="512" width="78" height="12" font="4">2011;58:587–95.</text>
<text top="786" left="458" width="349" height="12" font="4"> S7.9.1.5-4. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into </text>
<text top="800" left="512" width="296" height="12" font="4">the natural history of short QT syndrome. J Am Coll Cardiol. </text>
<text top="813" left="512" width="78" height="12" font="4">2014;63:1300–8.</text>
<text top="827" left="458" width="349" height="12" font="4"> S7.9.1.5-5. Villafane J, Atallah J, Gollob MH, et al. Long-term follow-up of </text>
<text top="840" left="512" width="295" height="12" font="4">a pediatric cohort with short QT syndrome. J Am Coll Cardiol. </text>
<text top="854" left="512" width="84" height="12" font="4">2013;61:1183–91.</text>
<text top="867" left="458" width="345" height="12" font="4"> S7.9.1.5-6. Giustetto C, Di MF, Wolpert C, et al. Short QT syndrome: clini-</text>
<text top="881" left="512" width="295" height="12" font="4">cal findings and diagnostic-therapeutic implications. Eur Heart J. </text>
<text top="894" left="512" width="78" height="12" font="4">2006;27:2440–7.</text>
<text top="908" left="458" width="349" height="12" font="4"> S7.9.1.5-7. Bun SS, Maury P, Giustetto C, et al. Electrical storm in short-QT </text>
<text top="921" left="512" width="296" height="12" font="4">syndrome successfully treated with isoproterenol. J Cardiovasc </text>
<text top="935" left="512" width="151" height="12" font="4">Electrophysiol. 2012;23:1028–30.</text>
<text top="948" left="458" width="350" height="12" font="4"> S7.9.1.5-8. Guerrier K, Kwiatkowski D, Czosek RJ, et al. Short QT interval </text>
<text top="962" left="512" width="295" height="12" font="4">prevalence and clinical outcomes in a pediatric population. Circ </text>
<text top="976" left="512" width="185" height="12" font="4">Arrhythm Electrophysiol. 2015;8:1460–4.</text>
<text top="989" left="458" width="349" height="12" font="4"> S7.9.1.5-9. Iribarren C, Round AD, Peng JA, et al. Short QT in a cohort of </text>
<text top="1003" left="512" width="295" height="12" font="4">1.7 million persons: prevalence, correlates, and prognosis. Ann </text>
<text top="1016" left="512" width="206" height="12" font="4">Noninvasive Electrocardiol. 2014;19:490–500.</text>
<text top="1030" left="452" width="355" height="12" font="4"> S7.9.1.5-10. Gollob MH, Blier L, Brugada R, et al. Recommendations for the </text>
<text top="1043" left="512" width="291" height="12" font="4">use of genetic testing in the clinical evaluation of inherited car-</text>
<text top="1057" left="512" width="294" height="12" font="4">diac arrhythmias associated with sudden cardiac death: Canadian </text>
<text top="1070" left="512" width="291" height="12" font="4">Cardiovascular Society/Canadian Heart Rhythm Society joint posi-</text>
<text top="1084" left="512" width="200" height="12" font="4">tion paper. Can J Cardiol. 2011;27:232–458.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e378</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="86" left="74" width="354" height="23" font="15"><b>8. VA IN THE STRUCTURALLY NORMAL </b></text>
<text top="109" left="74" width="61" height="23" font="15"><b>HEART</b></text>
<text top="137" left="74" width="3" height="12" font="4"> </text>
<text top="137" left="94" width="334" height="12" font="4">S8-1.  Gill JS, Blaszyk K, Ward DE, et al. Verapamil for the suppression of </text>
<text top="151" left="125" width="304" height="12" font="4">idiopathic ventricular tachycardia of left bundle branch block-like </text>
<text top="165" left="125" width="204" height="12" font="4">morphology. Am Heart J. 1993;126:1126–33.</text>
<text top="178" left="74" width="3" height="12" font="4"> </text>
<text top="178" left="94" width="334" height="12" font="4">S8-2.  Gill JS, Ward DE, Camm AJ, Comparison of verapamil and diltiazem </text>
<text top="192" left="125" width="303" height="12" font="4">in the suppression of idiopathic ventricular tachycardia. Pacing Clin </text>
<text top="206" left="125" width="145" height="12" font="4">Electrophysiol. 1992;15:2122–6.</text>
<text top="219" left="74" width="5" height="12" font="4"> </text>
<text top="219" left="94" width="335" height="12" font="4">S8-3.  Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes </text>
<text top="233" left="125" width="300" height="12" font="4">in patients with myocardial infarction treated with acute beta–</text>
<text top="246" left="125" width="303" height="12" font="4">blocker therapy: results from the American College of Cardiology’s </text>
<text top="260" left="125" width="184" height="12" font="4">NCDR(R). Am Heart J. 2011;161:864–70.</text>
<text top="274" left="74" width="3" height="12" font="4"> </text>
<text top="274" left="94" width="331" height="12" font="4">S8-4.  Levine JH, Massumi A, Scheinman MM, et al. Intravenous amioda-</text>
<text top="287" left="125" width="300" height="12" font="4">rone for recurrent sustained hypotensive ventricular tachyarrhyth-</text>
<text top="301" left="125" width="304" height="12" font="4">mias. Intravenous Amiodarone Multicenter Trial Group. J Am Coll </text>
<text top="315" left="125" width="110" height="12" font="4">Cardiol. 1996;27:67–75.</text>
<text top="328" left="74" width="3" height="12" font="4"> </text>
<text top="328" left="94" width="334" height="12" font="4">S8-5.  Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic </text>
<text top="342" left="125" width="300" height="12" font="4">ventricular fibrillation and polymorphic ventricular tachycardia initi-</text>
<text top="356" left="125" width="300" height="12" font="4">ated by premature extrasystoles originating from the right ventricu-</text>
<text top="369" left="125" width="245" height="12" font="4">lar outflow tract. J Am Coll Cardiol. 2005;46:1288–94.</text>
<text top="383" left="74" width="3" height="12" font="4"> </text>
<text top="383" left="94" width="334" height="12" font="4">S8-6.  Viskin S, Idiopathic polymorphic ventricular tachycardia: a “benign </text>
<text top="396" left="125" width="303" height="12" font="4">disease” with a touch of bad luck? Korean Circ J. 2017;47: </text>
<text top="410" left="125" width="43" height="12" font="4">299–306.</text>
<text top="424" left="74" width="4" height="12" font="4"> </text>
<text top="424" left="94" width="335" height="12" font="4">S8-7.  Viskin S, Rosso R, Rogowski O, et al. The “short-coupled” variant </text>
<text top="437" left="125" width="303" height="12" font="4">of right ventricular outflow ventricular tachycardia: a not-so-benign </text>
<text top="451" left="125" width="303" height="12" font="4">form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. </text>
<text top="465" left="125" width="72" height="12" font="4">2005;16:912–6.</text>
<text top="478" left="74" width="5" height="12" font="4"> </text>
<text top="478" left="94" width="331" height="12" font="4">S8-8.  Krittayaphong R, Bhuripanyo K, Punlee K, et al. Effect of ateno-</text>
<text top="492" left="125" width="304" height="12" font="4">lol on symptomatic ventricular arrhythmia without structural heart </text>
<text top="506" left="125" width="307" height="12" font="4">disease: a randomized placebo-controlled study. Am Heart J. </text>
<text top="519" left="125" width="67" height="12" font="4">2002;144:e10.</text>
<text top="533" left="74" width="3" height="12" font="4"> </text>
<text top="533" left="94" width="331" height="12" font="4">S8-9.  Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth-</text>
<text top="547" left="125" width="304" height="12" font="4">mic medication for treatment of ventricular premature beats from </text>
<text top="560" left="125" width="304" height="12" font="4">the right ventricular outflow tract: prospective randomized study. </text>
<text top="574" left="125" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2014;7:237–43.</text>
<text top="587" left="74" width="356" height="12" font="4">  S8-10.  Hohnloser SH, Meinertz T, Stubbs P, et al. Efficacy and safety of </text>
<text top="601" left="125" width="303" height="12" font="4">d-sotalol, a pure class III antiarrhythmic compound, in patients with </text>
<text top="615" left="125" width="304" height="12" font="4">symptomatic complex ventricular ectopy. Results of a multicenter, </text>
<text top="628" left="125" width="305" height="12" font="4">randomized, double-blind, placebo-controlled dose-finding study. </text>
<text top="642" left="125" width="284" height="12" font="4">The d-Sotalol PVC Study Group. Circulation. 1995;92:1517–25.</text>
<text top="656" left="74" width="357" height="12" font="4">  S8-11.  Badhwar N, Scheinman MM, Idiopathic ventricular tachycardia: </text>
<text top="669" left="125" width="282" height="12" font="4">diagnosis and management. Curr Probl Cardiol. 2007;32:7–43.</text>
<text top="683" left="74" width="357" height="12" font="4">  S8-12.  Connolly SJ, Meta-analysis of antiarrhythmic drug trials. Am J </text>
<text top="697" left="125" width="110" height="12" font="4">Cardiol. 1999;84:90R–3.</text>
<text top="710" left="74" width="354" height="12" font="4">  S8.1-1.  Tada H, Ito S, Naito S, et al. Idiopathic ventricular arrhythmia arising </text>
<text top="724" left="125" width="300" height="12" font="4">from the mitral annulus: a distinct subgroup of idiopathic ventricu-</text>
<text top="737" left="125" width="234" height="12" font="4">lar arrhythmias. J Am Coll Cardiol. 2005;45:877–86.</text>
<text top="777" left="74" width="332" height="21" font="18"><b>8.1. Outflow Tract and Atrioventricular </b></text>
<text top="798" left="74" width="97" height="21" font="18"><b>Annular VA</b></text>
<text top="825" left="74" width="351" height="12" font="4">  S8.1-2.  Yamada T, Litovsky SH, Kay GN, The left ventricular ostium: an ana-</text>
<text top="838" left="125" width="305" height="12" font="4">tomic concept relevant to idiopathic ventricular arrhythmias. Circ </text>
<text top="852" left="125" width="191" height="12" font="4">Arrhythm Electrophysiol. 2008;1:396–404.</text>
<text top="866" left="74" width="351" height="12" font="4">  S8.1-3.  Yamada T, Maddox WR, McElderry HT, et al. Radiofrequency cath-</text>
<text top="879" left="125" width="308" height="12" font="4">eter ablation of idiopathic ventricular arrhythmias originating </text>
<text top="893" left="125" width="304" height="12" font="4">from intramural foci in the left ventricular outflow tract: efficacy </text>
<text top="907" left="125" width="304" height="12" font="4">of sequential versus simultaneous unipolar catheter ablation. Circ </text>
<text top="920" left="125" width="185" height="12" font="4">Arrhythm Electrophysiol. 2015;8:344–52.</text>
<text top="934" left="74" width="351" height="12" font="4">  S8.1-4.  Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhyth-</text>
<text top="948" left="125" width="304" height="12" font="4">mic medication for treatment of ventricular premature beats from </text>
<text top="961" left="125" width="304" height="12" font="4">the right ventricular outflow tract: prospective randomized study. </text>
<text top="975" left="125" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2014;7:237–43.</text>
<text top="988" left="74" width="351" height="12" font="4">  S8.1-5.  Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular prema-</text>
<text top="1002" left="125" width="304" height="12" font="4">ture depolarization QRS duration as a new marker of risk for the </text>
<text top="1016" left="125" width="300" height="12" font="4">development of ventricular premature depolarization-induced car-</text>
<text top="1029" left="125" width="215" height="12" font="4">diomyopathy. Heart Rhythm. 2014;11:299–306.</text>
<text top="1043" left="74" width="351" height="12" font="4">  S8.1-6.  Kamioka M, Mathew S, Lin T, et al. Electrophysiological and electro-</text>
<text top="1057" left="125" width="303" height="12" font="4">cardiographic predictors of ventricular arrhythmias originating from </text>
<text top="1070" left="125" width="305" height="12" font="4">the left ventricular outflow tract within and below the coronary </text>
<text top="1084" left="125" width="216" height="12" font="4">sinus cusps. Clin Res Cardiol. 2015;104:544–54.</text>
<text top="88" left="452" width="354" height="12" font="4">  S8.1-7.  Konstantinidou M, Koektuerk B, Wissner E, et al. Catheter ablation </text>
<text top="102" left="503" width="300" height="12" font="4">of right ventricular outflow tract tachycardia: a simplified remote-</text>
<text top="116" left="503" width="226" height="12" font="4">controlled approach. Europace. 2011;13:696–700.</text>
<text top="129" left="452" width="351" height="12" font="4">  S8.1-8.  Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter out-</text>
<text top="143" left="503" width="306" height="12" font="4">comes for catheter ablation of idiopathic premature ventricular </text>
<text top="157" left="503" width="240" height="12" font="4">complexes. JACC Clin Electrophysiol. 2015;1:116–23.</text>
<text top="170" left="452" width="351" height="12" font="4">  S8.1-9.  Liao Z, Zhan X, Wu S, et al. Idiopathic ventricular arrhythmias origi-</text>
<text top="184" left="503" width="300" height="12" font="4">nating from the pulmonary sinus cusp: prevalence, electrocardio-</text>
<text top="198" left="503" width="303" height="12" font="4">graphic/electrophysiological characteristics, and catheter ablation. J </text>
<text top="211" left="503" width="161" height="12" font="4">Am Coll Cardiol. 2015;66:2633–44.</text>
<text top="225" left="452" width="351" height="12" font="4">  S8.1-10.  Morady F, Kadish AH, DiCarlo L, et al. Long-term results of cath-</text>
<text top="239" left="503" width="303" height="12" font="4">eter ablation of idiopathic right ventricular tachycardia. Circulation. </text>
<text top="252" left="503" width="78" height="12" font="4">1990;82:2093–9.</text>
<text top="266" left="452" width="354" height="12" font="4">  S8.1-11.  Ouyang F, Fotuhi P, Ho SY, et al. Repetitive monomorphic ventricular </text>
<text top="280" left="503" width="300" height="12" font="4">tachycardia originating from the aortic sinus cusp: electrocardio-</text>
<text top="293" left="503" width="305" height="12" font="4">graphic characterization for guiding catheter ablation. J Am Coll </text>
<text top="307" left="503" width="110" height="12" font="4">Cardiol. 2002;39:500–8.</text>
<text top="321" left="452" width="356" height="12" font="4"> S8.1-12.  Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert </text>
<text top="334" left="503" width="303" height="12" font="4">consensus on ventricular arrhythmias. Heart Rhythm. 2014;11: </text>
<text top="348" left="503" width="43" height="12" font="4">e166–96.</text>
<text top="362" left="452" width="351" height="12" font="4">  S8.1-13.  Tada H, Tadokoro K, Miyaji K, et al. Idiopathic ventricular arrhyth-</text>
<text top="375" left="503" width="300" height="12" font="4">mias arising from the pulmonary artery: prevalence, character-</text>
<text top="389" left="503" width="306" height="12" font="4">istics, and topography of the arrhythmia origin. Heart Rhythm. </text>
<text top="403" left="503" width="72" height="12" font="4">2008;5:419–26.</text>
<text top="416" left="452" width="351" height="12" font="4"> S8.1-14.  Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ven-</text>
<text top="430" left="503" width="305" height="12" font="4">tricular arrhythmias originating from the aortic root prevalence, </text>
<text top="444" left="503" width="308" height="12" font="4">electrocardiographic and electrophysiologic characteristics, and </text>
<text top="457" left="503" width="306" height="12" font="4">results of radiofrequency catheter ablation. J Am Coll Cardiol. </text>
<text top="471" left="503" width="78" height="12" font="4">2008;52:139–47.</text>
<text top="485" left="452" width="351" height="12" font="4">  S8.1-15.  Yamada T, McElderry HT, Doppalapudi H, et al. Idiopathic ventricu-</text>
<text top="498" left="503" width="300" height="12" font="4">lar arrhythmias originating from the left ventricular summit: ana-</text>
<text top="512" left="503" width="304" height="12" font="4">tomic concepts relevant to ablation. Circ Arrhythm Electrophysiol. </text>
<text top="526" left="503" width="72" height="12" font="4">2010;3:616–23.</text>
<text top="539" left="452" width="355" height="12" font="4">  S8.1-16.  Yamada T, McElderry HT, Okada T, et al. Idiopathic left ventricular </text>
<text top="553" left="503" width="303" height="12" font="4">arrhythmias originating adjacent to the left aortic sinus of valsalva: </text>
<text top="567" left="503" width="305" height="12" font="4">electrophysiological rationale for the surface electrocardiogram. J </text>
<text top="581" left="503" width="190" height="12" font="4">Cardiovasc Electrophysiol. 2010;21:170–6.</text>
<text top="594" left="452" width="355" height="12" font="4">  S8.1-17.  Mountantonakis SE, Frankel DS, Tschabrunn CM, et al. Ventricular </text>
<text top="608" left="503" width="300" height="12" font="4">arrhythmias from the coronary venous system: prevalence, map-</text>
<text top="622" left="503" width="239" height="12" font="4">ping, and ablation. Heart Rhythm. 2015;12:1145–53.</text>
<text top="635" left="452" width="355" height="12" font="4">  S8.1-18.  Nagashima K, Choi EK, Lin KY, et al. Ventricular arrhythmias near </text>
<text top="649" left="503" width="304" height="12" font="4">the distal great cardiac vein: challenging arrhythmia for ablation. </text>
<text top="663" left="503" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2014;7:906–12.</text>
<text top="676" left="452" width="351" height="12" font="4"> S8.1-19.  Hai JJ, Chahal AA, Friedman PA, et al. Electrophysiologic charac-</text>
<text top="690" left="503" width="305" height="12" font="4">teristics of ventricular arrhythmias arising from the aortic mitral </text>
<text top="704" left="503" width="305" height="12" font="4">continuity-potential role of the conduction system. J Cardiovasc </text>
<text top="717" left="503" width="145" height="12" font="4">Electrophysiol. 2015;26:158–63.</text>
<text top="731" left="452" width="355" height="12" font="4">  S8.1-20.  Tada H, Tadokoro K, Ito S, et al. Idiopathic ventricular arrhythmias </text>
<text top="745" left="503" width="300" height="12" font="4">originating from the tricuspid annulus: prevalence, electrocardio-</text>
<text top="758" left="503" width="300" height="12" font="4">graphic characteristics, and results of radiofrequency catheter abla-</text>
<text top="772" left="503" width="152" height="12" font="4">tion. Heart Rhythm. 2007;4:7–16.</text>
<text top="811" left="452" width="196" height="21" font="18"><b>8.2 Papillary Muscle VA</b></text>
<text top="838" left="452" width="356" height="12" font="4">  S8.2-1.  Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics </text>
<text top="852" left="503" width="303" height="12" font="4">related to outcome after catheter ablation of idiopathic ventricular </text>
<text top="865" left="503" width="302" height="12" font="4">arrhythmia originating from the papillary muscle in the left ventricle. </text>
<text top="879" left="503" width="137" height="12" font="4">Korean Circ J. 2013;43:811–8.</text>
<text top="893" left="452" width="351" height="12" font="4">  S8.2-2.  Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias origi-</text>
<text top="906" left="503" width="304" height="12" font="4">nating from papillary muscles in the right ventricle. Heart Rhythm. </text>
<text top="920" left="503" width="72" height="12" font="4">2010;7:725–30.</text>
<text top="934" left="452" width="351" height="12" font="4">  S8.2-3.  Doppalapudi H, Yamada T, McElderry HT, et al. Ventricular tachy-</text>
<text top="947" left="503" width="305" height="12" font="4">cardia originating from the posterior papillary muscle in the left </text>
<text top="961" left="503" width="303" height="12" font="4">ventricle: a distinct clinical syndrome. Circ Arrhythm Electrophysiol. </text>
<text top="975" left="503" width="61" height="12" font="4">2008;1:23–9.</text>
<text top="988" left="452" width="354" height="12" font="4">  S8.2-4.  Yamada T, Doppalapudi H, McElderry HT, et al. Electrocardiographic </text>
<text top="1002" left="503" width="307" height="12" font="4">and electrophysiological characteristics in idiopathic ventricular </text>
<text top="1016" left="503" width="300" height="12" font="4">arrhythmias originating from the papillary muscles in the left ven-</text>
<text top="1029" left="503" width="303" height="12" font="4">tricle: relevance for catheter ablation. Circ Arrhythm Electrophysiol. </text>
<text top="1043" left="503" width="72" height="12" font="4">2010;3:324–31.</text>
<text top="1057" left="452" width="355" height="12" font="4">  S8.2-5.  Yokokawa M, Good E, Desjardins B, et al. Predictors of successful </text>
<text top="1070" left="503" width="300" height="12" font="4">catheter ablation of ventricular arrhythmias arising from the papil-</text>
<text top="1084" left="503" width="200" height="12" font="4">lary muscles. Heart Rhythm. 2010;7:1654–9.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e379</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="87" left="74" width="275" height="21" font="18"><b>8.3. Interfascicular Reentrant VT </b></text>
<text top="108" left="74" width="199" height="21" font="18"><b>(Belhassen Tachycardia)</b></text>
<text top="135" left="74" width="351" height="12" font="4">  S8.3-1.  Lin D, Hsia HH, Gerstenfeld EP, et al. Idiopathic fascicular left ven-</text>
<text top="148" left="125" width="303" height="12" font="4">tricular tachycardia: linear ablation lesion strategy for noninducible </text>
<text top="162" left="125" width="265" height="12" font="4">or nonsustained tachycardia. Heart Rhythm. 2005;2:934–9.</text>
<text top="175" left="74" width="351" height="12" font="4">  S8.3-2.  Liu Y, Fang Z, Yang B, et al. Catheter ablation of fascicular ven-</text>
<text top="189" left="125" width="304" height="12" font="4">tricular tachycardia: long-term clinical outcomes and mechanisms </text>
<text top="203" left="125" width="276" height="12" font="4">of recurrence. Circ Arrhythm Electrophysiol. 2015;8:1443–51.</text>
<text top="216" left="74" width="355" height="12" font="4">  S8.3-3.  Nogami A, Naito S, Tada H, et al. Demonstration of diastolic and </text>
<text top="230" left="125" width="303" height="12" font="4">presystolic Purkinje potentials as critical potentials in a macroreentry </text>
<text top="243" left="125" width="303" height="12" font="4">circuit of verapamil-sensitive idiopathic left ventricular tachycardia. J </text>
<text top="257" left="125" width="155" height="12" font="4">Am Coll Cardiol. 2000;36:811–23.</text>
<text top="270" left="74" width="351" height="12" font="4">  S8.3-4. Belhassen B, Rotmensch HH, Laniado S, Response of recur-</text>
<text top="284" left="125" width="306" height="12" font="4">rent sustained ventricular tachycardia to verapamil. Br Heart J. </text>
<text top="298" left="125" width="78" height="12" font="4">1981;46:679–82.</text>
<text top="311" left="74" width="356" height="12" font="4">  S8.3-5.  German LD, Packer DL, Bardy GH, et al. Ventricular tachycardia </text>
<text top="325" left="125" width="300" height="12" font="4">induced by atrial stimulation in patients without symptomatic car-</text>
<text top="338" left="125" width="200" height="12" font="4">diac disease. Am J Cardiol. 1983;52:1202–7.</text>
<text top="352" left="74" width="355" height="12" font="4">  S8.3-6.  Tsuchiya T, Okumura K, Honda T, et al. Effects of verapamil and </text>
<text top="366" left="125" width="300" height="12" font="4">lidocaine on two components of the re-entry circuit of verapamil-</text>
<text top="379" left="125" width="304" height="12" font="4">senstitive idiopathic left ventricular tachycardia. J Am Coll Cardiol. </text>
<text top="393" left="125" width="84" height="12" font="4">2001;37:1415–21.</text>
<text top="406" left="74" width="356" height="12" font="4">  S8.3-7.  Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular </text>
<text top="420" left="125" width="305" height="12" font="4">autopsy after exertion-related sudden unexplained death in the </text>
<text top="434" left="125" width="211" height="12" font="4">young. Circ Cardiovasc Genet. 2016;9:259–65.</text>
<text top="447" left="74" width="351" height="12" font="4">  S8.3-8.  Ohe T, Shimomura K, Aihara N, et al. Idiopathic sustained left ven-</text>
<text top="461" left="125" width="305" height="12" font="4">tricular tachycardia: clinical and electrophysiologic characteristics. </text>
<text top="474" left="125" width="126" height="12" font="4">Circulation. 1988;77:560–8.</text>
<text top="488" left="74" width="354" height="12" font="4">  S8.3-9.  Snyder C, Bishara J, Darling R, et al. Verapamil-sensitive ventricular </text>
<text top="501" left="125" width="268" height="12" font="4">tachycardia in an infant. Congenit Heart Dis. 2006;1:124–6.</text>
<text top="515" left="74" width="351" height="12" font="4">  S8.3-10.  Wang JD, Fu YC, Jan SL, et al. Verapamil sensitive idiopathic ven-</text>
<text top="529" left="125" width="278" height="12" font="4">tricular tachycardia in an infant. Jpn Heart J. 2003;44:667–71.</text>
<text top="568" left="74" width="284" height="21" font="18"><b>8.4. Idiopathic Polymorphic VT/VF</b></text>
<text top="595" left="74" width="356" height="12" font="4">  S8.4-1.  Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular </text>
<text top="608" left="125" width="305" height="12" font="4">autopsy after exertion-related sudden unexplained death in the </text>
<text top="622" left="125" width="211" height="12" font="4">young. Circ Cardiovasc Genet. 2016;9:259–65.</text>
<text top="636" left="74" width="354" height="12" font="4">  S8.4-2.  Dalal A, Czosek RJ, Kovach J, et al. Clinical presentation of pediatric </text>
<text top="649" left="125" width="253" height="12" font="4">patients at risk for sudden cardiac arrest. J Pediatr. 2016.</text>
<text top="663" left="74" width="351" height="12" font="4">  S8.4-3.  Kumar S, Peters S, Thompson T, et al. Familial cardiological and tar-</text>
<text top="676" left="125" width="304" height="12" font="4">geted genetic evaluation: low yield in sudden unexplained death </text>
<text top="690" left="125" width="306" height="12" font="4">and high yield in unexplained cardiac arrest syndromes. Heart </text>
<text top="704" left="125" width="124" height="12" font="4">Rhythm. 2013;10:1653–60.</text>
<text top="717" left="74" width="356" height="12" font="4">  S8.4-4.  Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic </text>
<text top="731" left="125" width="302" height="12" font="4">yield of loop electrocardiographic recorders in unexplained syncope. </text>
<text top="744" left="125" width="135" height="12" font="4">Am J Cardiol. 1990;66:214–9.</text>
<text top="758" left="74" width="355" height="12" font="4">  S8.4-5.  Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in </text>
<text top="771" left="125" width="303" height="12" font="4">patients with myocardial infarction and left ventricular dysfunction, </text>
<text top="785" left="125" width="248" height="12" font="4">heart failure, or both. N Engl J Med. 2005;352:2581–8.</text>
<text top="799" left="74" width="351" height="12" font="4">  S8.4-6.  Tester DJ, Medeiros-Domingo A, Will ML, et al. Unexplained drown-</text>
<text top="812" left="125" width="304" height="12" font="4">ings and the cardiac channelopathies: a molecular autopsy series. </text>
<text top="826" left="125" width="146" height="12" font="4">Mayo Clin Proc. 2011;86:941–7.</text>
<text top="839" left="74" width="354" height="12" font="4">  S8.4-7.  Tzimas I, Zingraf JC, Bajanowski T, et al. The role of known variants </text>
<text top="853" left="125" width="303" height="12" font="4">of KCNQ1, KCNH2, KCNE1, SCN5A, and NOS1AP in water-related </text>
<text top="867" left="125" width="173" height="12" font="4">deaths. Int J Legal Med. 2016;1575–9.</text>
<text top="880" left="74" width="355" height="12" font="4">  S8.4-8.  Wang D, Shah KR, Um SY, et al. Cardiac channelopathy testing in </text>
<text top="894" left="125" width="303" height="12" font="4">274 ethnically diverse sudden unexplained deaths. Forensic Sci Int. </text>
<text top="907" left="125" width="72" height="12" font="4">2014;237:90–9.</text>
<text top="921" left="74" width="356" height="12" font="4">  S8.4-9.  Conte G, Caputo ML, Regoli F, et al. True idiopathic ventricular </text>
<text top="934" left="125" width="305" height="12" font="4">fibrillation in out-of-hospital cardiac arrest survivors in the Swiss </text>
<text top="948" left="125" width="300" height="12" font="4">Canton Ticino: prevalence, clinical features, and long-term follow-</text>
<text top="962" left="125" width="143" height="12" font="4">up. Europace. 2017;19:259–66.</text>
<text top="975" left="74" width="351" height="12" font="4">  S8.4-10.  Frommeyer G, Dechering DG, Kochhauser S, et al. Long-time “real-</text>
<text top="989" left="125" width="300" height="12" font="4">life” performance of the subcutaneous ICD in patients with electri-</text>
<text top="1002" left="125" width="304" height="12" font="4">cal heart disease or idiopathic ventricular fibrillation. J Interv Card </text>
<text top="1016" left="125" width="139" height="12" font="4">Electrophysiol. 2016;47:185–8.</text>
<text top="1030" left="74" width="355" height="12" font="4"> S8.4-11.  Haïssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of </text>
<text top="1043" left="125" width="279" height="12" font="4">idiopathic ventricular fibrillation. Circulation. 2002;106:962–7.</text>
<text top="1057" left="74" width="351" height="12" font="4">  S8.4-12.  Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idio-</text>
<text top="1070" left="125" width="303" height="12" font="4">pathic ventricular fibrillation ablation: a multicenter study. J Am Coll </text>
<text top="1084" left="125" width="110" height="12" font="4">Cardiol. 2009;54:522–8.</text>
<text top="88" left="452" width="356" height="12" font="4"> S8.4-13.  Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant </text>
<text top="102" left="503" width="305" height="12" font="4">of torsade de pointes. A new electrocardiographic entity in the </text>
<text top="115" left="503" width="306" height="12" font="4">spectrum of idiopathic ventricular tachyarrhythmias. Circulation. </text>
<text top="129" left="503" width="78" height="12" font="4">1994;89:206–15.</text>
<text top="143" left="452" width="351" height="12" font="4"> S8.4-14.  Haïssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conduct-</text>
<text top="156" left="503" width="303" height="12" font="4">ing system in triggering of idiopathic ventricular fibrillation. Lancet. </text>
<text top="170" left="503" width="78" height="12" font="4">2002;359:677–8.</text>
<text top="183" left="452" width="355" height="12" font="4">  S8.4-15.  Albertella L, Crawford J, Skinner JR, Presentation and outcome of </text>
<text top="197" left="503" width="304" height="12" font="4">water-related events in children with long QT syndrome. Arch Dis </text>
<text top="210" left="503" width="102" height="12" font="4">Child. 2011;96:704–7.</text>
<text top="224" left="452" width="354" height="12" font="4">  S8.4-16.  Miyake CY, Motonaga KS, Fischer-Colbrie ME, et al. Risk of cardiac </text>
<text top="238" left="503" width="304" height="12" font="4">disease and observations on lack of potential predictors by clinical </text>
<text top="251" left="503" width="300" height="12" font="4">history among children presenting for cardiac evaluation of mid-</text>
<text top="265" left="503" width="242" height="12" font="4">exertional syncope. Cardiol Young. 2016;26:894–900.</text>
<text top="278" left="452" width="355" height="12" font="4">  S8.4-17.  Gula LJ, Klein GJ, Hellkamp AS, et al. Ejection fraction assessment </text>
<text top="292" left="503" width="305" height="12" font="4">and survival: an analysis of the Sudden Cardiac Death in Heart </text>
<text top="306" left="503" width="260" height="12" font="4">Failure Trial (SCD-HeFT). Am Heart J. 2008;156:1196–200.</text>
<text top="319" left="452" width="354" height="12" font="4">  S8.4-18.  Winkel BG, Yuan L, Olesen MS, et al. The role of the sodium current </text>
<text top="333" left="503" width="303" height="12" font="4">complex in a nonreferred nationwide cohort of sudden infant death </text>
<text top="346" left="503" width="195" height="12" font="4">syndrome. Heart Rhythm. 2015;12:1241–9.</text>
<text top="360" left="452" width="354" height="12" font="4">  S8.4-19.  Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic </text>
<text top="373" left="503" width="300" height="12" font="4">ventricular fibrillation and polymorphic ventricular tachycardia initi-</text>
<text top="387" left="503" width="300" height="12" font="4">ated by premature extrasystoles originating from the right ventricu-</text>
<text top="401" left="503" width="245" height="12" font="4">lar outflow tract. J Am Coll Cardiol. 2005;46:1288–94.</text>
<text top="414" left="452" width="356" height="12" font="4"> S8.4-20.  Sadek MM, Benhayon D, Sureddi R, et al. Idiopathic ventricular </text>
<text top="428" left="503" width="300" height="12" font="4">arrhythmias originating from the moderator band: electrocardio-</text>
<text top="441" left="503" width="305" height="12" font="4">graphic characteristics and treatment by catheter ablation. Heart </text>
<text top="455" left="503" width="113" height="12" font="4">Rhythm. 2015;12:67–75.</text>
<text top="468" left="452" width="354" height="12" font="4">  S8.4-21.  Van HH, Zado ES, Haqqani H, et al. Catheter ablation of ventricular </text>
<text top="482" left="503" width="303" height="12" font="4">fibrillation: importance of left ventricular outflow tract and papillary </text>
<text top="496" left="503" width="219" height="12" font="4">muscle triggers. Heart Rhythm. 2014;11:566–73.</text>
<text top="509" left="452" width="354" height="12" font="4">  S8.4-22.  Viskin S, Belhassen B, Idiopathic ventricular fibrillation. Am Heart J. </text>
<text top="523" left="503" width="78" height="12" font="4">1990;120:661–7.</text>
<text top="567" left="452" width="333" height="23" font="15"><b>9. PVC-INDUCED CARDIOMYOPATHY</b></text>
<text top="595" left="452" width="7" height="12" font="4"> </text>
<text top="595" left="472" width="331" height="12" font="4">S9-1. Haïssaguerre M, Shah DC, Jais P, et al. Role of Purkinje conduct-</text>
<text top="609" left="503" width="303" height="12" font="4">ing system in triggering of idiopathic ventricular fibrillation. Lancet. </text>
<text top="622" left="503" width="78" height="12" font="4">2002;359:677–8.</text>
<text top="636" left="452" width="7" height="12" font="4"> </text>
<text top="636" left="472" width="335" height="12" font="4">S9-2. Haïssaguerre M, Shoda M, Jais P, et al. Mapping and ablation of </text>
<text top="649" left="503" width="279" height="12" font="4">idiopathic ventricular fibrillation. Circulation. 2002;106:962–7.</text>
<text top="663" left="452" width="2" height="12" font="4"> </text>
<text top="663" left="472" width="331" height="12" font="4">S9-3.  Lee GK, Klarich KW, Grogan M, et al. Premature ventricular contrac-</text>
<text top="677" left="503" width="303" height="12" font="4">tion-induced cardiomyopathy: a treatable condition. Circ Arrhythm </text>
<text top="690" left="503" width="139" height="12" font="4">Electrophysiol. 2012;5:229–36.</text>
<text top="704" left="452" width="3" height="12" font="4"> </text>
<text top="704" left="472" width="333" height="12" font="4">S9-4.  Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with </text>
<text top="717" left="503" width="304" height="12" font="4">congestive heart failure and asymptomatic ventricular arrhythmia. </text>
<text top="731" left="503" width="303" height="12" font="4">Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. </text>
<text top="744" left="503" width="143" height="12" font="4">N Engl J Med. 1995;333:77–82.</text>
<text top="758" left="452" width="3" height="12" font="4"> </text>
<text top="758" left="472" width="334" height="12" font="4">S9-5.  Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of </text>
<text top="772" left="503" width="302" height="12" font="4">premature ventricular complexes and left ventricular function. Heart </text>
<text top="785" left="503" width="107" height="12" font="4">Rhythm. 2010;7:865–9.</text>
<text top="799" left="452" width="2" height="12" font="4"> </text>
<text top="799" left="472" width="331" height="12" font="4">S9-6.  Ban JE, Park HC, Park JS, et al. Electrocardiographic and electrophys-</text>
<text top="812" left="503" width="300" height="12" font="4">iological characteristics of premature ventricular complexes associ-</text>
<text top="826" left="503" width="303" height="12" font="4">ated with left ventricular dysfunction in patients without structural </text>
<text top="839" left="503" width="189" height="12" font="4">heart disease. Europace. 2013;15:735–41.</text>
<text top="853" left="452" width="4" height="12" font="4"> </text>
<text top="853" left="472" width="335" height="12" font="4">S9-7.  Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of </text>
<text top="867" left="503" width="300" height="12" font="4">frequent, idiopathic premature ventricular complexes: compari-</text>
<text top="880" left="503" width="305" height="12" font="4">son with a control group without intervention. Heart Rhythm. </text>
<text top="894" left="503" width="68" height="12" font="4">2007;4:863–7.</text>
<text top="907" left="452" width="4" height="12" font="4"> </text>
<text top="907" left="472" width="331" height="12" font="4">S9-8.  Carballeira Pol L, Deyell MW, Frankel DS, et al. Ventricular prema-</text>
<text top="921" left="503" width="304" height="12" font="4">ture depolarization QRS duration as a new marker of risk for the </text>
<text top="934" left="503" width="300" height="12" font="4">development of ventricular premature depolarization-induced car-</text>
<text top="948" left="503" width="215" height="12" font="4">diomyopathy. Heart Rhythm. 2014;11:299–306.</text>
<text top="962" left="452" width="4" height="12" font="4"> </text>
<text top="962" left="472" width="335" height="12" font="4">S9-9.  Del Carpio Munoz F, Syed FF, Noheria A, et al. Characteristics of </text>
<text top="975" left="503" width="300" height="12" font="4">premature ventricular complexes as correlates of reduced left ven-</text>
<text top="989" left="503" width="304" height="12" font="4">tricular systolic function: study of the burden, duration, coupling </text>
<text top="1002" left="503" width="306" height="12" font="4">interval, morphology and site of origin of PVCs. J Cardiovasc </text>
<text top="1016" left="503" width="139" height="12" font="4">Electrophysiol. 2011;22:791–8.</text>
<text top="1029" left="452" width="351" height="12" font="4">  S9-10.  Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ven-</text>
<text top="1043" left="503" width="303" height="12" font="4">tricular dysfunction after ablation of frequent ventricular premature </text>
<text top="1057" left="503" width="219" height="12" font="4">depolarizations. Heart Rhythm. 2012;9:1465–72.</text>
<text top="1070" left="452" width="356" height="12" font="4">  S9-11.  Hamon D, Blaye-Felice MS, Bradfield JS, et al. A new combined </text>
<text top="1084" left="503" width="306" height="12" font="4">parameter to predict premature ventricular complexes induced </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e380</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="125" width="306" height="12" font="4">cardiomyopathy: impact and recognition of epicardial origin. J </text>
<text top="102" left="125" width="196" height="12" font="4">Cardiovasc Electrophysiol. 2016;27:709–17.</text>
<text top="116" left="74" width="351" height="12" font="4">  S9-12.  Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced car-</text>
<text top="129" left="125" width="303" height="12" font="4">diomyopathy in patients with idiopathic ventricular arrhythmias: the </text>
<text top="143" left="125" width="305" height="12" font="4">incidence, clinical and electrophysiologic characteristics, and the </text>
<text top="157" left="125" width="247" height="12" font="4">predictors. J Cardiovasc Electrophysiol. 2011;22:663–8.</text>
<text top="170" left="74" width="351" height="12" font="4">  S9-13.  Kanei Y, Friedman M, Ogawa N, et al. Frequent premature ventricu-</text>
<text top="184" left="125" width="304" height="12" font="4">lar complexes originating from the right ventricular outflow tract </text>
<text top="198" left="125" width="305" height="12" font="4">are associated with left ventricular dysfunction. Ann Noninvasive </text>
<text top="211" left="125" width="132" height="12" font="4">Electrocardiol. 2008;13:81–5.</text>
<text top="225" left="74" width="355" height="12" font="4">  S9-14.  Kawamura M, Badhwar N, Vedantham V, et al. Coupling interval </text>
<text top="238" left="125" width="300" height="12" font="4">dispersion and body mass index are independent predictors of idio-</text>
<text top="252" left="125" width="305" height="12" font="4">pathic premature ventricular complex-induced cardiomyopathy. J </text>
<text top="266" left="125" width="190" height="12" font="4">Cardiovasc Electrophysiol. 2014;25:756–2.</text>
<text top="279" left="74" width="355" height="12" font="4">  S9-15.  Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of </text>
<text top="293" left="125" width="305" height="12" font="4">frequent premature ventricular contractions originating from the </text>
<text top="307" left="125" width="305" height="12" font="4">ventricular outflow tract in patients with normal left ventricular </text>
<text top="320" left="125" width="152" height="12" font="4">function. Heart. 2009;95:1230–7.</text>
<text top="334" left="74" width="354" height="12" font="4">  S9-16.  Olgun H, Yokokawa M, Baman T, et al. The role of interpolation in </text>
<text top="348" left="125" width="277" height="12" font="4">PVC-induced cardiomyopathy. Heart Rhythm. 2011;8:1046–9.</text>
<text top="361" left="74" width="351" height="12" font="4">  S9-17.  Yokokawa M, Good E, Crawford T, et al. Recovery from left ven-</text>
<text top="375" left="125" width="303" height="12" font="4">tricular dysfunction after ablation of frequent premature ventricular </text>
<text top="389" left="125" width="193" height="12" font="4">complexes. Heart Rhythm. 2013;10:172–5.</text>
<text top="402" left="74" width="356" height="12" font="4">  S9-18.  Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter </text>
<text top="416" left="125" width="304" height="12" font="4">ablation vs antiarrhythmic drugs in treating premature ventricular </text>
<text top="430" left="125" width="306" height="12" font="4">contractions: a single-center retrospective study. Heart Rhythm. </text>
<text top="443" left="125" width="78" height="12" font="4">2014;11:187–93.</text>
<text top="457" left="74" width="351" height="12" font="4">  S9-19.  Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ven-</text>
<text top="471" left="125" width="303" height="12" font="4">tricular dysfunction after ablation of frequent ventricular premature </text>
<text top="484" left="125" width="219" height="12" font="4">depolarizations. Heart Rhythm. 2012;9:1465–72.</text>
<text top="498" left="74" width="351" height="12" font="4">  S9-20.  Kubac G, Klinke WP, Grace M, Randomized double blind trial com-</text>
<text top="511" left="125" width="305" height="12" font="4">paring sotalol and propranolol in chronic ventricular arrhythmia. </text>
<text top="525" left="125" width="132" height="12" font="4">Can J Cardiol. 1988;4:355–9.</text>
<text top="569" left="74" width="354" height="23" font="15"><b>10. VA AND SCD RELATED TO SPECIFIC </b></text>
<text top="592" left="74" width="130" height="23" font="15"><b>POPULATIONS</b></text>
<text top="620" left="74" width="111" height="21" font="18"><b>10.1 Athletes</b></text>
<text top="647" left="74" width="351" height="12" font="4">  S10.1-1.  Zipes DP, Link MS, Ackerman MJ, et al. Eligibility and disqualifica-</text>
<text top="661" left="125" width="303" height="12" font="4">tion recommendations for competitive athletes with cardiovascular </text>
<text top="674" left="125" width="304" height="12" font="4">abnormalities: Task Force 9: arrhythmias and conduction defects: </text>
<text top="688" left="125" width="305" height="12" font="4">a scientific statement from the American Heart Association and </text>
<text top="702" left="125" width="291" height="12" font="4">American College of Cardiology. Circulation. 2015;132:e315–28.</text>
<text top="715" left="74" width="354" height="12" font="4">  S10.1-2.  Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of </text>
<text top="729" left="125" width="300" height="12" font="4">frequent and complex ventricular tachyarrhythmias in trained ath-</text>
<text top="743" left="125" width="188" height="12" font="4">letes. J Am Coll Cardiol. 2002;40:446–52.</text>
<text top="756" left="74" width="351" height="12" font="4">  S10.1-3.  Verdile L, Maron BJ, Pelliccia A, et al. Clinical significance of exer-</text>
<text top="770" left="125" width="300" height="12" font="4">cise-induced ventricular tachyarrhythmias in trained athletes with-</text>
<text top="784" left="125" width="290" height="12" font="4">out cardiovascular abnormalities. Heart Rhythm. 2015;12:78–85.</text>
<text top="797" left="74" width="355" height="12" font="4">  S10.1-4.  Harmon KG, Asif IM, Maleszewski JJ, et al. Incidence, cause, and </text>
<text top="811" left="125" width="300" height="12" font="4">comparative frequency of sudden cardiac death in national colle-</text>
<text top="825" left="125" width="304" height="12" font="4">giate athletic association athletes: a decade in review. Circulation. </text>
<text top="838" left="125" width="72" height="12" font="4">2015;132:10–9.</text>
<text top="852" left="74" width="355" height="12" font="4">  S10.1-5.  Maron BJ, Haas TS, Ahluwalia A, et al. Incidence of cardiovascular </text>
<text top="866" left="125" width="304" height="12" font="4">sudden deaths in Minnesota high school athletes. Heart Rhythm. </text>
<text top="879" left="125" width="72" height="12" font="4">2013;10:374–7.</text>
<text top="893" left="74" width="356" height="12" font="4"> S10.1-6.  Harmon KG, Drezner JA, Wilson MG, et al. Incidence of sudden </text>
<text top="907" left="125" width="303" height="12" font="4">cardiac death in athletes: a state-of-the-art review. Br J Sports Med. </text>
<text top="920" left="125" width="84" height="12" font="4">2014;48:1185–92.</text>
<text top="934" left="74" width="355" height="12" font="4"> S10.1-7.  Marijon E, Tafflet M, Celermajer DS, et al. Sports-related sudden </text>
<text top="947" left="125" width="286" height="12" font="4">death in the general population. Circulation. 2011;124:672–81.</text>
<text top="961" left="74" width="356" height="12" font="4"> S10.1-8.  Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and </text>
<text top="975" left="125" width="304" height="12" font="4">survival trends from cardiovascular-related sudden cardiac arrest in </text>
<text top="988" left="125" width="304" height="12" font="4">children and young adults 0 to 35 years of age: a 30-year review. </text>
<text top="1002" left="125" width="144" height="12" font="4">Circulation. 2012;126:1363–72.</text>
<text top="1016" left="74" width="351" height="12" font="4"> S10.1-9.  Marijon E, Bougouin W, Perier MC, et al. Incidence of sports-</text>
<text top="1029" left="125" width="304" height="12" font="4">related sudden death in France by specific sports and sex. JAMA. </text>
<text top="1043" left="125" width="78" height="12" font="4">2013;310:642–3.</text>
<text top="1057" left="74" width="356" height="12" font="4"> S10.1-10.  Anderson JH, Tester DJ, Will ML, et al. Whole-exome molecular </text>
<text top="1070" left="125" width="305" height="12" font="4">autopsy after exertion-related sudden unexplained death in the </text>
<text top="1084" left="125" width="211" height="12" font="4">young. Circ Cardiovasc Genet. 2016;9:259–65.</text>
<text top="88" left="452" width="355" height="12" font="4"> S10.1-11.  Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of </text>
<text top="102" left="503" width="304" height="12" font="4">sudden cardiac death among children and young adults. N Engl J </text>
<text top="115" left="503" width="116" height="12" font="4">Med. 2016;374:2441–52.</text>
<text top="129" left="452" width="357" height="12" font="4"> S10.1-12.  Semsarian C, Ingles J, Wilde AA, Sudden cardiac death in the </text>
<text top="142" left="503" width="303" height="12" font="4">young: the molecular autopsy and a practical approach to surviving </text>
<text top="156" left="503" width="174" height="12" font="4">relatives. Eur Heart J. 2015;36:1290–6.</text>
<text top="169" left="452" width="351" height="12" font="4"> S10.1-13.  Maron BJ, Haas TS, Ahluwalia A, et al. Demographics and epide-</text>
<text top="183" left="503" width="303" height="12" font="4">miology of sudden deaths in young competitive athletes: from the </text>
<text top="196" left="503" width="274" height="12" font="4">United States national registry. Am J Med. 2016;129:1170–7.</text>
<text top="210" left="452" width="355" height="12" font="4"> S10.1-14.  Yankelson L, Sadeh B, Gershovitz L, et al. Life-threatening events </text>
<text top="223" left="503" width="307" height="12" font="4">during endurance sports: is heat stroke more prevalent than </text>
<text top="237" left="503" width="240" height="12" font="4">arrhythmic death? J Am Coll Cardiol. 2014;64:463–9.</text>
<text top="251" left="452" width="356" height="12" font="4"> S10.1-15.  Maron BJ, Haas TS, Murphy CJ, et al. Incidence and causes of </text>
<text top="264" left="503" width="303" height="12" font="4">sudden death in US college athletes. J Am Coll Cardiol. 2014;63: </text>
<text top="278" left="503" width="43" height="12" font="4">1636–43.</text>
<text top="291" left="452" width="351" height="12" font="4"> S10.1-16.  Link MS, Myerburg RJ, Estes NA 3rd. Eligibility and disqualifica-</text>
<text top="305" left="503" width="303" height="12" font="4">tion recommendations for competitive athletes with cardiovascular </text>
<text top="318" left="503" width="303" height="12" font="4">abnormalities: Task Force 12: emergency action plans, resuscitation, </text>
<text top="332" left="503" width="300" height="12" font="4">cardiopulmonary resuscitation, and automated external defibrilla-</text>
<text top="345" left="503" width="302" height="12" font="4">tors: a scientific statement from the American Heart Association and </text>
<text top="359" left="503" width="285" height="12" font="4">American College of Cardiology. Circulation. 2015;132:e334–8.</text>
<text top="372" left="452" width="356" height="12" font="4"> S10.1-17.  Brothers JA, Frommelt MA, Jaquiss RDB, et al. Expert consensus </text>
<text top="386" left="503" width="303" height="12" font="4">guideline: anomalous aortic origin of a coronary artery – American </text>
<text top="399" left="503" width="307" height="12" font="4">Association for Thoracic Surgery Clinical Practice Guidelines.  </text>
<text top="413" left="503" width="207" height="12" font="4">J Thorac Cardiovasc Surg. 2017;153:1440–57.</text>
<text top="426" left="452" width="356" height="12" font="4"> S10.1-18.  Van Hare GF, Ackerman MJ, Evangelista JA, et al. Eligibility and </text>
<text top="440" left="503" width="300" height="12" font="4">disqualification recommendations for competitive athletes with car-</text>
<text top="453" left="503" width="304" height="12" font="4">diovascular abnormalities: Task Force 4: congenital heart disease: </text>
<text top="467" left="503" width="305" height="12" font="4">a scientific statement from the American Heart Association and </text>
<text top="480" left="503" width="285" height="12" font="4">American College of Cardiology. Circulation. 2015;132:e281–9.</text>
<text top="494" left="452" width="351" height="12" font="4"> S10.1-19.  Ackerman MJ, Zipes DP, Kovacs RJ, et al. Eligibility and disqualifica-</text>
<text top="507" left="503" width="303" height="12" font="4">tion recommendations for competitive athletes with cardiovascular </text>
<text top="521" left="503" width="300" height="12" font="4">abnormalities: Task Force 10: the cardiac channelopathies: a scien-</text>
<text top="534" left="503" width="303" height="12" font="4">tific statement from the American Heart Association and American </text>
<text top="548" left="503" width="245" height="12" font="4">College of Cardiology. Circulation. 2015;132:e326–91.</text>
<text top="561" left="452" width="351" height="12" font="4"> S10.1-20.  Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualifica-</text>
<text top="575" left="503" width="303" height="12" font="4">tion recommendations for competitive athletes with cardiovascular </text>
<text top="588" left="503" width="300" height="12" font="4">abnormalities: Task Force 3: Hypertrophic cardiomyopathy, arrhyth-</text>
<text top="602" left="503" width="300" height="12" font="4">mogenic right ventricular cardiomyopathy and other cardiomyopa-</text>
<text top="615" left="503" width="305" height="12" font="4">thies, and myocarditis: a scientific statement from the American </text>
<text top="629" left="503" width="303" height="12" font="4">Heart Association and American College of Cardiology. Circulation. </text>
<text top="642" left="503" width="89" height="12" font="4">2015;132:e273–80.</text>
<text top="679" left="452" width="133" height="21" font="18"><b>10.2. Pregnancy</b></text>
<text top="705" left="458" width="348" height="12" font="4"> S10.2-1.  Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. </text>
<text top="719" left="503" width="161" height="12" font="4">J Am Coll Cardiol. 2007;49:1092–8.</text>
<text top="733" left="458" width="345" height="12" font="4"> S10.2-2.  Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in preg-</text>
<text top="746" left="503" width="303" height="12" font="4">nancy: a scientific statement from the American Heart Association. </text>
<text top="760" left="503" width="144" height="12" font="4">Circulation. 2015;132:1747–73.</text>
<text top="773" left="458" width="350" height="12" font="4"> S10.2-3.  Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac </text>
<text top="787" left="503" width="300" height="12" font="4">arrest in special situations: 2010 American Heart Association guide-</text>
<text top="800" left="503" width="300" height="12" font="4">lines for cardiopulmonary resuscitation and emergency cardiovascu-</text>
<text top="814" left="503" width="217" height="12" font="4">lar care. Circulation. 2010;122 suppl 3:S829–61.</text>
<text top="827" left="458" width="345" height="12" font="4"> S10.2-4.  Natale A, Davidson T, Geiger MJ, et al. Implantable cardioverter-</text>
<text top="841" left="503" width="307" height="12" font="4">defibrillators and pregnancy: a safe combination? Circulation. </text>
<text top="854" left="503" width="84" height="12" font="4">1997;96:2808–12.</text>
<text top="868" left="458" width="350" height="12" font="4"> S10.2-5.  Colletti PM, Lee KH, Elkayam U, Cardiovascular imaging of the </text>
<text top="881" left="503" width="247" height="12" font="4">pregnant patient. Am J Roentgenol. 2013;200:515–21.</text>
<text top="895" left="458" width="349" height="12" font="4"> S10.2-6.  Khositseth A, Tester DJ, Will ML, et al. Identification of a common </text>
<text top="908" left="503" width="300" height="12" font="4">genetic substrate underlying postpartum cardiac events in congeni-</text>
<text top="922" left="503" width="230" height="12" font="4">tal long QT syndrome. Heart Rhythm. 2004;1:60–4.</text>
<text top="935" left="458" width="348" height="12" font="4"> S10.2-7.  Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the </text>
<text top="949" left="503" width="302" height="12" font="4">risk for cardiac events in patients with hereditary long QT syndrome. </text>
<text top="962" left="503" width="214" height="12" font="4">LQTS Investigators. Circulation. 1998;97:451–6.</text>
<text top="976" left="458" width="349" height="12" font="4"> S10.2-8.  Heradien MJ, Goosen A, Crotti L, et al. Does pregnancy increase </text>
<text top="989" left="503" width="303" height="12" font="4">cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J </text>
<text top="1003" left="503" width="155" height="12" font="4">Am Coll Cardiol. 2006;48:1410–5.</text>
<text top="1016" left="458" width="345" height="12" font="4"> S10.2-9.  Davis RL, Eastman D, McPhillips H, et al. Risks of congenital mal-</text>
<text top="1030" left="503" width="303" height="12" font="4">formations and perinatal events among infants exposed to calcium </text>
<text top="1043" left="503" width="304" height="12" font="4">channel and beta-blockers during pregnancy. Pharmacoepidemiol </text>
<text top="1057" left="503" width="123" height="12" font="4">Drug Saf. 2011;20:138–45.</text>
<text top="1070" left="452" width="354" height="12" font="4"> S10.2-10.  Ruys TP, Maggioni A, Johnson MR, et al. Cardiac medication during </text>
<text top="1084" left="503" width="291" height="12" font="4">pregnancy, data from the ROPAC. Int J Cardiol. 2014;177:124–8.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e381</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="354" height="12" font="4"> S10.2-11.  Beinder E, Grancay T, Menendez T, et al. Fetal sinus bradycardia and </text>
<text top="102" left="125" width="283" height="12" font="4">the long QT syndrome. Am J Obstet Gynecol. 2001;185:743–7.</text>
<text top="115" left="74" width="7" height="12" font="4"> </text>
<text top="115" left="74" width="358" height="12" font="4">S10.2-12. Hofbeck M, Ulmer H, Beinder E, et al. Prenatal findings in </text>
<text top="129" left="125" width="304" height="12" font="4">patients with prolonged QT interval in the neonatal period. Heart. </text>
<text top="142" left="125" width="84" height="12" font="4">1997;77:198–204.</text>
<text top="156" left="74" width="355" height="12" font="4"> S10.2-13.  Cuneo BF, Etheridge SP, Horigome H, et al. Arrhythmia phenotype </text>
<text top="169" left="125" width="300" height="12" font="4">during fetal life suggests long-QT syndrome genotype: risk stratifi-</text>
<text top="183" left="125" width="303" height="12" font="4">cation of perinatal long-QT syndrome. Circ Arrhythm Electrophysiol. </text>
<text top="196" left="125" width="72" height="12" font="4">2013;6:946–51.</text>
<text top="210" left="74" width="354" height="12" font="4"> S10.2-14.  Cuneo BF, Strasburger JF, Wakai RT, The natural history of fetal long </text>
<text top="223" left="125" width="215" height="12" font="4">QT syndrome. J Electrocardiol. 2016;49:807–13.</text>
<text top="237" left="74" width="356" height="12" font="4"> S10.2-15.  Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus </text>
<text top="250" left="125" width="304" height="12" font="4">radiation dose and risk from cardiac catheter ablation procedures. </text>
<text top="264" left="125" width="132" height="12" font="4">Circulation. 2001;104:893–7.</text>
<text top="277" left="74" width="354" height="12" font="4"> S10.2-16.  Duncker D, Haghikia A, Konig T, et al. Risk for ventricular fibrillation </text>
<text top="291" left="125" width="303" height="12" font="4">in peripartum cardiomyopathy with severely reduced left ventricular </text>
<text top="305" left="125" width="303" height="12" font="4">function-value of the wearable cardioverter/defibrillator. Eur J Heart </text>
<text top="318" left="125" width="99" height="12" font="4">Fail. 2014;16:1331–6.</text>
<text top="357" left="74" width="334" height="21" font="18"><b>10.3. Older Patients With Comorbidities</b></text>
<text top="384" left="74" width="355" height="12" font="4">  S10.3-1.  Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for </text>
<text top="398" left="125" width="305" height="12" font="4">the 2017 AHA/ACC/HRS guideline for management of patients </text>
<text top="411" left="125" width="304" height="12" font="4">with ventricular arrhythmias and the prevention of sudden cardiac </text>
<text top="425" left="125" width="304" height="12" font="4">death: a report of the American College of Cardiology/American </text>
<text top="438" left="125" width="303" height="12" font="4">Heart Association Task Force on Clinical Practice Guidelines and the </text>
<text top="452" left="125" width="256" height="12" font="4">Heart Rhythm Society. Circulation. 2018;138:e392–e414.</text>
<text top="465" left="74" width="355" height="12" font="4">  S10.3-2.  American Geriatrics Society Expert Panel on the Care of Older Adults </text>
<text top="479" left="125" width="300" height="12" font="4">with M. Guiding principles for the care of older adults with multimorbid-</text>
<text top="492" left="125" width="294" height="12" font="4">ity: an approach for clinicians. J Am Geriatr Soc. 2012;60:E1–E25.</text>
<text top="532" left="74" width="237" height="21" font="18"><b>10.4 Chronic Kidney Disease</b></text>
<text top="558" left="74" width="355" height="12" font="4">  S10.4-1.  Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable </text>
<text top="572" left="125" width="303" height="12" font="4">cardioverter-defibrillator for congestive heart failure. N Engl J Med. </text>
<text top="585" left="125" width="84" height="12" font="4">2005;352:225–37.</text>
<text top="599" left="74" width="351" height="12" font="4">  S10.4-2.  Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the pre-</text>
<text top="612" left="125" width="304" height="12" font="4">vention of sudden death in patients with coronary artery disease. </text>
<text top="626" left="125" width="305" height="12" font="4">Multicenter Unsustained Tachycardia Trial Investigators. N Engl J </text>
<text top="639" left="125" width="116" height="12" font="4">Med. 1999;341:1882–90.</text>
<text top="653" left="74" width="356" height="12" font="4"> S10.4-3.  Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an </text>
<text top="666" left="125" width="305" height="12" font="4">implanted defibrillator in patients with coronary disease at high </text>
<text top="680" left="125" width="304" height="12" font="4">risk for ventricular arrhythmia. Multicenter Automatic Defibrillator </text>
<text top="693" left="125" width="297" height="12" font="4">Implantation Trial Investigators. N Engl J Med. 1996;335:1933–40.</text>
<text top="707" left="74" width="355" height="12" font="4">  S10.4-4.  Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a </text>
<text top="720" left="125" width="300" height="12" font="4">defibrillator in patients with myocardial infarction and reduced ejec-</text>
<text top="734" left="125" width="210" height="12" font="4">tion fraction. N Engl J Med. 2002;346:877–83.</text>
<text top="748" left="74" width="351" height="12" font="4">  S10.4-5.  Pun PH, Al-Khatib SM, Han JY, et al. Implantable cardioverter-defi-</text>
<text top="761" left="125" width="303" height="12" font="4">brillators for primary prevention of sudden cardiac death in CKD: a </text>
<text top="775" left="125" width="304" height="12" font="4">meta-analysis of patient-level data from 3 randomized trials. Am J </text>
<text top="788" left="125" width="119" height="12" font="4">Kidney Dis. 2014;64:32–9.</text>
<text top="802" left="74" width="353" height="12" font="4">  S10.4-6.  Charytan DM, Patrick AR, Liu J, et al. Trends in the use and outcomes </text>
<text top="815" left="125" width="306" height="12" font="4">of implantable cardioverter-defibrillators in patients undergoing </text>
<text top="829" left="125" width="284" height="12" font="4">dialysis in the United States. Am J Kidney Dis. 2011;58:409–17.</text>
<text top="842" left="74" width="353" height="12" font="4">  S10.4-7.  Wong MC, Kalman JM, Pedagogos E, et al. Bradycardia and asystole </text>
<text top="856" left="125" width="303" height="12" font="4">is the predominant mechanism of sudden cardiac death in patients </text>
<text top="869" left="125" width="290" height="12" font="4">with chronic kidney disease. J Am Coll Cardiol. 2015;65:1263–5.</text>
<text top="883" left="74" width="355" height="12" font="4">  S10.4-8.  Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic review for </text>
<text top="896" left="125" width="305" height="12" font="4">the 2017 AHA/ACC/HRS guideline for management of patients </text>
<text top="910" left="125" width="304" height="12" font="4">with ventricular arrhythmias and the prevention of sudden cardiac </text>
<text top="923" left="125" width="304" height="12" font="4">death: a report of the American College of Cardiology/American </text>
<text top="937" left="125" width="303" height="12" font="4">Heart Association Task Force on Clinical Practice Guidelines and the </text>
<text top="950" left="125" width="256" height="12" font="4">Heart Rhythm Society. Circulation. 2018;138:e392–e414.</text>
<text top="964" left="74" width="357" height="12" font="4"> S10.4-9. Pun PH, Hellkamp AS, Sanders GD, et al. Primary prevention </text>
<text top="977" left="125" width="300" height="12" font="4">implantable cardioverter defibrillators in end-stage kidney dis-</text>
<text top="991" left="125" width="305" height="12" font="4">ease patients on dialysis: a matched cohort study. Nephrol Dial </text>
<text top="1004" left="125" width="130" height="12" font="4">Transplant. 2015;30:829–35.</text>
<text top="1044" left="74" width="235" height="21" font="18"><b>10.5. Valvular Heart Disease</b></text>
<text top="1070" left="74" width="353" height="12" font="4">  S10.6-1.  Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline </text>
<text top="1084" left="125" width="302" height="12" font="4">for the management of patients with valvular heart disease: a report </text>
<text top="88" left="503" width="303" height="12" font="4">of the American College of Cardiology/American Heart Association </text>
<text top="102" left="503" width="300" height="12" font="4">Task Force on Practice Guidelines. Circulation. 2014;129:e521–643.</text>
<text top="115" left="452" width="354" height="12" font="4">  S10.6-2.  Genereux P, Stone GW, O’Gara PT, et al. Natural history, diagnostic </text>
<text top="129" left="503" width="300" height="12" font="4">approaches, and therapeutic strategies for patients with asymptom-</text>
<text top="142" left="503" width="286" height="12" font="4">atic severe aortic stenosis. J Am Coll Cardiol. 2016;67:2263–88.</text>
<text top="156" left="452" width="357" height="12" font="4"> S10.6-3.  Avierinos JF, Gersh BJ, Melton LJ 3rd, et al. Natural history of </text>
<text top="169" left="503" width="304" height="12" font="4">asymptomatic mitral valve prolapse in the community. Circulation. </text>
<text top="183" left="503" width="90" height="12" font="4">2002;106:1355–61.</text>
<text top="196" left="452" width="358" height="12" font="4"> S10.6-4. Grigioni F, Enriquez-Sarano M, Ling LH, et al. Sudden death </text>
<text top="210" left="503" width="306" height="12" font="4">in mitral regurgitation due to flail leaflet. J Am Coll Cardiol. </text>
<text top="223" left="503" width="84" height="12" font="4">1999;34:2078–85.</text>
<text top="237" left="452" width="351" height="12" font="4">  S10.6-5.  Nordhues BD, Siontis KC, Scott CG, et al. Bileaflet mitral valve pro-</text>
<text top="250" left="503" width="304" height="12" font="4">lapse and risk of ventricular dysrhythmias and death. J Cardiovasc </text>
<text top="264" left="503" width="139" height="12" font="4">Electrophysiol. 2016;27:463–8.</text>
<text top="277" left="452" width="351" height="12" font="4">  S10.6-6.  Basso C, Perazzolo MM, Rizzo S, et al. Arrhythmic mitral valve pro-</text>
<text top="291" left="503" width="285" height="12" font="4">lapse and sudden cardiac death. Circulation. 2015;132:556–66.</text>
<text top="305" left="452" width="355" height="12" font="4">  S10.6-7.  Sriram CS, Syed FF, Ferguson ME, et al. Malignant bileaflet mitral </text>
<text top="318" left="503" width="300" height="12" font="4">valve prolapse syndrome in patients with otherwise idiopathic out-</text>
<text top="332" left="503" width="277" height="12" font="4">of-hospital cardiac arrest. J Am Coll Cardiol. 2013;62:222–30.</text>
<text top="345" left="452" width="351" height="12" font="4">  S10.6-8.  Albert CM, Chae CU, Grodstein F, et al. Prospective study of sud-</text>
<text top="359" left="503" width="303" height="12" font="4">den cardiac death among women in the United States. Circulation. </text>
<text top="372" left="503" width="96" height="12" font="4">2003;107:2096–101.</text>
<text top="386" left="452" width="356" height="12" font="4"> S10.6-9.  Kannel WB, Wilson PW, D’Agostino RB, et al. Sudden coronary </text>
<text top="399" left="503" width="219" height="12" font="4">death in women. Am Heart J. 1998;136:205–12.</text>
<text top="413" left="452" width="353" height="12" font="4"> S10.6-10.  Bogle BM, Ning H, Mehrotra S, et al. Lifetime risk for sudden cardiac </text>
<text top="426" left="503" width="274" height="12" font="4">death in the community. J Am Heart Assoc. 2016;5:e002398.</text>
<text top="440" left="452" width="356" height="12" font="4"> S10.6-11.  Kim C, Fahrenbruch CE, Cobb LA, et al. Out-of-hospital cardiac </text>
<text top="453" left="503" width="271" height="12" font="4">arrest in men and women. Circulation. 2001;104:2699–703.</text>
<text top="467" left="452" width="355" height="12" font="4"> S10.6-12.  Teodorescu C, Reinier K, Uy-Evanado A, et al. Survival advantage </text>
<text top="480" left="503" width="302" height="12" font="4">from ventricular fibrillation and pulseless electrical activity in women </text>
<text top="494" left="503" width="303" height="12" font="4">compared to men: the Oregon Sudden Unexpected Death Study. J </text>
<text top="507" left="503" width="197" height="12" font="4">Interv Card Electrophysiol. 2012;34:219–25.</text>
<text top="521" left="452" width="351" height="12" font="4"> S10.6-13.  Wissenberg M, Hansen CM, Folke F, et al. Survival after out-of-</text>
<text top="534" left="503" width="303" height="12" font="4">hospital cardiac arrest in relation to sex: a nationwide registry-based </text>
<text top="548" left="503" width="171" height="12" font="4">study. Resuscitation. 2014;85:1212–8.</text>
<text top="561" left="452" width="354" height="12" font="4"> S10.6-14.  Bray JE, Stub D, Bernard S, et al. Exploring gender differences and </text>
<text top="575" left="503" width="306" height="12" font="4">the “oestrogen effect” in an Australian out-of-hospital cardiac </text>
<text top="588" left="503" width="224" height="12" font="4">arrest population. Resuscitation. 2013;84:957–63.</text>
<text top="602" left="452" width="351" height="12" font="4"> S10.6-15.  Ng YY, Wah W, Liu N, et al. Associations between gender and car-</text>
<text top="615" left="503" width="305" height="12" font="4">diac arrest outcomes in Pan-Asian out-of-hospital cardiac arrest </text>
<text top="629" left="503" width="190" height="12" font="4">patients. Resuscitation. 2016;102:116–21.</text>
<text top="642" left="452" width="351" height="12" font="4"> S10.6-16.  Hagihara A, Onozuka D, Hasegawa M, et al. Resuscitation out-</text>
<text top="656" left="503" width="300" height="12" font="4">comes of reproductive-age females who experienced out-of-hospi-</text>
<text top="669" left="503" width="300" height="12" font="4">tal cardiac arrest. Eur Heart J Acute Cardiovasc Care. 2017;6:121–9.</text>
<text top="683" left="452" width="355" height="12" font="4"> S10.6-17.  Safdar B, Stolz U, Stiell IG, et al. Differential survival for men and </text>
<text top="696" left="503" width="305" height="12" font="4">women from out-of-hospital cardiac arrest varies by age: results </text>
<text top="710" left="503" width="270" height="12" font="4">from the OPALS study. Acad Emerg Med. 2014;21:1503–11.</text>
<text top="723" left="452" width="351" height="12" font="4"> S10.6-18.  Albert CM, McGovern BA, Newell JB, et al. Sex differences in car-</text>
<text top="737" left="503" width="225" height="12" font="4">diac arrest survivors. Circulation. 1996;93:1170–6.</text>
<text top="750" left="452" width="354" height="12" font="4"> S10.6-19.  Chugh SS, Uy-Evanado A, Teodorescu C, et al. Women have a lower </text>
<text top="764" left="503" width="305" height="12" font="4">prevalence of structural heart disease as a precursor to sudden </text>
<text top="777" left="503" width="304" height="12" font="4">cardiac arrest: The Ore-SUDS (Oregon Sudden Unexpected Death </text>
<text top="791" left="503" width="201" height="12" font="4">Study). J Am Coll Cardiol. 2009;54:2006–11.</text>
<text top="805" left="452" width="351" height="12" font="4"> S10.6-20.  Kim MJ, Shin SD, McClellan WM, et al. Neurological prognostica-</text>
<text top="818" left="503" width="304" height="12" font="4">tion by gender in out-of-hospital cardiac arrest patients receiving </text>
<text top="832" left="503" width="252" height="12" font="4">hypothermia treatment. Resuscitation. 2014;85:1732–8.</text>
<text top="845" left="452" width="351" height="12" font="4"> S10.6-21.  Marijon E, Bougouin W, Perier MC, et al. Incidence of sports-</text>
<text top="859" left="503" width="304" height="12" font="4">related sudden death in France by specific sports and sex. JAMA. </text>
<text top="872" left="503" width="78" height="12" font="4">2013;310:642–3.</text>
<text top="886" left="452" width="354" height="12" font="4"> S10.6-22.  Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk </text>
<text top="899" left="503" width="303" height="12" font="4">factor for torsades de pointes associated with cardiovascular drugs. </text>
<text top="913" left="503" width="117" height="12" font="4">JAMA. 1993;270:2590–7.</text>
<text top="926" left="452" width="356" height="12" font="4"> S10.6-23.  Higgins AY, Waks JWJosephson ME, Influence of gender on the </text>
<text top="940" left="503" width="306" height="12" font="4">tolerability, safety, and efficacy of quinidine used for treatment </text>
<text top="953" left="503" width="307" height="12" font="4">of supraventricular and ventricular arrhythmias. Am J Cardiol. </text>
<text top="967" left="503" width="90" height="12" font="4">2015;116:1845–51.</text>
<text top="980" left="452" width="351" height="12" font="4"> S10.6-24.  Tanaka Y, Tada H, Ito S, et al. Gender and age differences in candi-</text>
<text top="994" left="503" width="303" height="12" font="4">dates for radiofrequency catheter ablation of idiopathic ventricular </text>
<text top="1007" left="503" width="172" height="12" font="4">arrhythmias. Circ J. 2011;75:1585–91.</text>
<text top="1044" left="452" width="323" height="21" font="18"><b>10.7. Medication-Induced Arrhythmias</b></text>
<text top="1070" left="452" width="354" height="12" font="4"> S10.7-1.  Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases </text>
<text top="1084" left="500" width="309" height="12" font="4">of life-threatening digitalis intoxication with digoxin-specific Fab </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e382</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="122" width="306" height="12" font="4">antibody fragments. Final report of a multicenter study. Circulation. </text>
<text top="102" left="122" width="84" height="12" font="4">1990;81:1744–52.</text>
<text top="116" left="74" width="355" height="12" font="4">  S10.7-2.  Chan BS, Buckley NA, Digoxin-specific antibody fragments in the </text>
<text top="129" left="125" width="265" height="12" font="4">treatment of digoxin toxicity. Clin Toxicol. 2014;52:824–36.</text>
<text top="143" left="74" width="356" height="12" font="4"> S10.7-3.  Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and </text>
<text top="157" left="125" width="303" height="12" font="4">therapy of torsade de pointes. A study of 10 patients. Circulation. </text>
<text top="170" left="125" width="84" height="12" font="4">1981;64:1167–74.</text>
<text top="184" left="74" width="353" height="12" font="4">  S10.7-4.  Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes </text>
<text top="197" left="125" width="240" height="12" font="4">with magnesium sulfate. Circulation. 1988;77:392–7.</text>
<text top="211" left="74" width="351" height="12" font="4"> S10.7-5.  Kannankeril P, Roden DM, Darbar D, Drug-induced long QT syn-</text>
<text top="225" left="125" width="183" height="12" font="4">drome. Pharmacol Rev. 2010;62:760–81.</text>
<text top="238" left="74" width="354" height="12" font="4">  S10.7-6.  Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired </text>
<text top="252" left="125" width="303" height="12" font="4">QT prolongation in humans by intravenous potassium. Circulation. </text>
<text top="266" left="125" width="84" height="12" font="4">1997;96:2149–54.</text>
<text top="279" left="74" width="356" height="12" font="4"> S10.7-7.  Yang T, Roden DM, Extracellular potassium modulation of drug </text>
<text top="293" left="125" width="300" height="12" font="4">block of IKr. Implications for torsade de pointes and reverse use-</text>
<text top="307" left="125" width="193" height="12" font="4">dependence. Circulation. 1996;93:407–11.</text>
<text top="320" left="74" width="351" height="12" font="4">  S10.7-8.  Hellestrand KJ, Burnett PJ, Milne JR, et al. Effect of the antiarrhyth-</text>
<text top="334" left="125" width="300" height="12" font="4">mic agent flecainide acetate on acute and chronic pacing thresh-</text>
<text top="347" left="125" width="210" height="12" font="4">olds. Pacing Clin Electrophysiol. 1983;6:892–9.</text>
<text top="361" left="74" width="351" height="12" font="4"> S10.7-9.  Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhyth-</text>
<text top="375" left="125" width="305" height="12" font="4">mic drugs on defibrillation energy requirements in dogs. Sodium </text>
<text top="388" left="125" width="308" height="12" font="4">channel block and action potential prolongation. Circulation. </text>
<text top="402" left="125" width="84" height="12" font="4">1989;79:1106–17.</text>
<text top="416" left="74" width="7" height="12" font="4"> </text>
<text top="416" left="74" width="351" height="12" font="4">S10.7-10. Schwartz PJ, Woosley RL, Predicting the unpredictable: drug-</text>
<text top="429" left="125" width="306" height="12" font="4">induced QT prolongation and torsades de pointes. J Am Coll </text>
<text top="443" left="125" width="122" height="12" font="4">Cardiol. 2016;67:1639–50.</text>
<text top="457" left="74" width="337" height="12" font="4"> S10.7-11.  Hauptman PJ, Kelly RA, Digitalis. Circulation. 1999;99:1265–70.</text>
<text top="470" left="74" width="351" height="12" font="4"> S10.7-12.  Kelly RA, Smith TW, Recognition and management of digitalis toxic-</text>
<text top="484" left="125" width="172" height="12" font="4">ity. Am J Cardiol. 1992;69:108G–18G.</text>
<text top="497" left="74" width="355" height="12" font="4"> S10.7-13.  Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients </text>
<text top="511" left="125" width="303" height="12" font="4">with drug-induced atrioventricular block. Pacing Clin Electrophysiol. </text>
<text top="525" left="125" width="78" height="12" font="4">2012;35:804–10.</text>
<text top="538" left="74" width="351" height="12" font="4"> S10.7-14.  Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guide-</text>
<text top="552" left="125" width="303" height="12" font="4">lines for management of patients with ventricular arrhythmias and </text>
<text top="566" left="125" width="304" height="12" font="4">the prevention of sudden cardiac death: a report of the American </text>
<text top="579" left="125" width="308" height="12" font="4">College of Cardiology/American Heart Association Task Force </text>
<text top="593" left="125" width="305" height="12" font="4">and the European Society of Cardiology Committee for Practice </text>
<text top="607" left="125" width="202" height="12" font="4">Guidelines. Circulation. 2006;114:e385–484.</text>
<text top="620" left="74" width="351" height="12" font="4"> S10.7-15.  Behr ER, Ritchie MD, Tanaka T, et al. Genome wide analysis of drug-</text>
<text top="634" left="125" width="304" height="12" font="4">induced torsades de pointes: lack of common variants with large </text>
<text top="648" left="125" width="173" height="12" font="4">effect sizes. PloS One. 2013;8:e78511.</text>
<text top="661" left="74" width="351" height="12" font="4"> S10.7-16.  Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene sur-</text>
<text top="675" left="125" width="300" height="12" font="4">vey identifies the KCNE1 D85N polymorphism as a possible modu-</text>
<text top="688" left="125" width="304" height="12" font="4">lator of drug-induced torsades de pointes. Circ Cardiovasc Genet. </text>
<text top="702" left="125" width="61" height="12" font="4">2012;5:91–9.</text>
<text top="716" left="74" width="356" height="12" font="4"> S10.7-17.  Strauss DG, Vicente J, Johannesen L, et al. A common genetic </text>
<text top="729" left="125" width="300" height="12" font="4">variant risk score is associated with drug-induced QT prolon-</text>
<text top="743" left="125" width="306" height="12" font="4">gation and torsade de pointes risk: a pilot study. Circulation. </text>
<text top="757" left="125" width="92" height="12" font="4">2017;135:1300–10.</text>
<text top="770" left="74" width="351" height="12" font="4"> S10.7-18.  Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT dis-</text>
<text top="784" left="125" width="304" height="12" font="4">ease genes in patients with drug-associated torsades de pointes. </text>
<text top="798" left="125" width="138" height="12" font="4">Circulation. 2002;105:1943–8.</text>
<text top="811" left="74" width="355" height="12" font="4"> S10.7-19.  Weeke P, Mosley JD, Hanna D, et al. Exome sequencing implicates </text>
<text top="825" left="125" width="304" height="12" font="4">an increased burden of rare potassium channel variants in the risk </text>
<text top="838" left="125" width="305" height="12" font="4">of drug-induced long QT interval syndrome. J Am Coll Cardiol. </text>
<text top="852" left="125" width="78" height="12" font="4">2014;63:1430–7.</text>
<text top="866" left="74" width="355" height="12" font="4"> S10.7-20.  Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in </text>
<text top="879" left="125" width="305" height="12" font="4">patients receiving encainide, flecainide, or placebo. The Cardiac </text>
<text top="893" left="125" width="276" height="12" font="4">Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8.</text>
<text top="907" left="74" width="351" height="12" font="4"> S10.7-21.  Chamberlain DA, Jewitt DE, Julian DG, et al. Oral mexiletine in high-</text>
<text top="920" left="125" width="287" height="12" font="4">risk patients after myocardial infarction. Lancet. 1980;2:1324–7.</text>
<text top="934" left="74" width="355" height="12" font="4"> S10.7-22.  UK Rythmodan Multicentre Study Group Oral disopyramide after </text>
<text top="948" left="125" width="300" height="12" font="4">admission to hospital with suspected acute myocardial infarc-</text>
<text top="961" left="125" width="304" height="12" font="4">tion. U. K. Rythmodan Multicentre Study Group. Postgrad Med J. </text>
<text top="975" left="125" width="78" height="12" font="4">1984;60:98–107.</text>
<text top="989" left="74" width="351" height="12" font="4"> S10.7-23.  Crijns HJ, Van Gelder IC, Lie KI, Supraventricular tachycardia mim-</text>
<text top="1002" left="125" width="306" height="12" font="4">icking ventricular tachycardia during flecainide treatment. Am J </text>
<text top="1016" left="125" width="116" height="12" font="4">Cardiol. 1988;62:1303–6.</text>
<text top="1029" left="74" width="353" height="12" font="4"> S10.7-24.  Alings M, Wilde A, “Brugada” syndrome: clinical data and suggested </text>
<text top="1043" left="125" width="275" height="12" font="4">pathophysiological mechanism. Circulation. 1999;99:666–73.</text>
<text top="1057" left="74" width="357" height="12" font="4"> S10.7-25.  Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada </text>
<text top="1070" left="125" width="305" height="12" font="4">syndrome: clinical characteristics and risk factors. Heart Rhythm. </text>
<text top="1084" left="125" width="78" height="12" font="4">2016;13:1083–7.</text>
<text top="88" left="452" width="355" height="12" font="4"> S10.7-26.  Tada H, Sticherling C, Oral H, et al. Brugada syndrome mimicked </text>
<text top="102" left="503" width="305" height="12" font="4">by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol. </text>
<text top="116" left="503" width="61" height="12" font="4">2001;12:275.</text>
<text top="129" left="452" width="7" height="12" font="4"> </text>
<text top="129" left="452" width="351" height="12" font="4">S10.7-27. Littmann L, Monroe MH, Svenson RH, Brugada-type electro-</text>
<text top="143" left="503" width="308" height="12" font="4">cardiographic pattern induced by cocaine. Mayo Clin Proc. </text>
<text top="157" left="503" width="72" height="12" font="4">2000;75:845–9.</text>
<text top="170" left="452" width="11" height="12" font="4"> </text>
<text top="170" left="452" width="362" height="12" font="4">S10.7-28. Brugada drugs. A<a href="">vailable at: http://www.brugadadrugs.org. </a></text>
<text top="184" left="503" width="121" height="12" font="4">Accessed October 6, 2016.</text>
<text top="198" left="452" width="355" height="12" font="4"> S10.7-29.  Bajaj AK, Woosley RL, Roden DM, Acute electrophysiologic effects </text>
<text top="211" left="503" width="308" height="12" font="4">of sodium administration in dogs treated with O-desmethyl </text>
<text top="225" left="503" width="192" height="12" font="4">encainide. Circulation. 1989;80:994–1002.</text>
<text top="239" left="452" width="354" height="12" font="4"> S10.7-30.  Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic </text>
<text top="252" left="503" width="300" height="12" font="4">effects of flecainide acetate and encainide hydrochloride by pro-</text>
<text top="266" left="503" width="175" height="12" font="4">pranolol. Circulation. 1989;80:1571–9.</text>
<text top="280" left="452" width="357" height="12" font="4"> S10.7-31.  Brumfield E, Bernard KR, Kabrhel C, Life-threatening flecainide </text>
<text top="293" left="503" width="300" height="12" font="4">overdose treated with intralipid and extracorporeal membrane oxy-</text>
<text top="307" left="503" width="207" height="12" font="4">genation. Am J Emerg Med. 2015;33:1840–5.</text>
<text top="321" left="452" width="13" height="12" font="4"> </text>
<text top="321" left="452" width="364" height="12" font="4">S10.7-32. Credible meds. A<a href="">vailable at: http://www.crediblemeds.org. </a></text>
<text top="334" left="503" width="136" height="12" font="4">Accessed December 26, 2016.</text>
<text top="374" left="452" width="310" height="21" font="18"><b>10.8. Adult Congenital Heart Disease</b></text>
<text top="401" left="452" width="351" height="12" font="4"> S10.8-1.  Diller GP, Kempny A, Liodakis E, et al. Left ventricular longitu-</text>
<text top="414" left="503" width="309" height="12" font="4">dinal function predicts life-threatening ventricular arrhythmia </text>
<text top="428" left="503" width="304" height="12" font="4">and death in adults with repaired tetralogy of fallot. Circulation. </text>
<text top="442" left="503" width="84" height="12" font="4">2012;125:2440–6.</text>
<text top="455" left="452" width="351" height="12" font="4">  S10.8-2.  Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac-</text>
<text top="469" left="503" width="300" height="12" font="4">tion in tetralogy of Fallot. QRS prolongation relates to right ventricu-</text>
<text top="483" left="503" width="303" height="12" font="4">lar size and predicts malignant ventricular arrhythmias and sudden </text>
<text top="496" left="503" width="158" height="12" font="4">death. Circulation. 1995;92:231–7.</text>
<text top="510" left="452" width="353" height="12" font="4">  S10.8-3.  Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia </text>
<text top="524" left="503" width="304" height="12" font="4">in adult patients late after repair of tetralogy of Fallot. J Am Coll </text>
<text top="537" left="503" width="122" height="12" font="4">Cardiol. 1997;30:1368–73.</text>
<text top="551" left="452" width="351" height="12" font="4">  S10.8-4.  Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and func-</text>
<text top="565" left="503" width="302" height="12" font="4">tion assessed by cardiac MRI predict major adverse clinical outcomes </text>
<text top="578" left="503" width="258" height="12" font="4">late after tetralogy of Fallot repair. Heart. 2008;94:211–6.</text>
<text top="592" left="452" width="355" height="12" font="4"> S10.8-5.  Koyak Z, de Groot JR, Bouma BJ, et al. Sudden cardiac death in </text>
<text top="606" left="503" width="303" height="12" font="4">adult congenital heart disease: can the unpredictable be foreseen? </text>
<text top="619" left="503" width="119" height="12" font="4">Europace. 2017;19:401–6.</text>
<text top="633" left="452" width="354" height="12" font="4">  S10.8-6.  Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult </text>
<text top="647" left="503" width="258" height="12" font="4">congenital heart disease. Circulation. 2012;126:1944–54.</text>
<text top="660" left="452" width="354" height="12" font="4">  S10.8-7.  Adamson L, Vohra HA, Haw MP, Does pulmonary valve replacement </text>
<text top="674" left="503" width="303" height="12" font="4">post repair of tetralogy of Fallot improve right ventricular function? </text>
<text top="688" left="503" width="214" height="12" font="4">Interact Cardiovasc Thorac Surg. 2009;9:520–7.</text>
<text top="701" left="452" width="353" height="12" font="4">  S10.8-8.  Deal BJ, Scagliotti D, Miller SM, et al. Electrophysiologic drug testing </text>
<text top="715" left="503" width="304" height="12" font="4">in symptomatic ventricular arrhythmias after repair of tetralogy of </text>
<text top="729" left="503" width="171" height="12" font="4">Fallot. Am J Cardiol. 1987;59:1380–5.</text>
<text top="742" left="452" width="355" height="12" font="4">  S10.8-9.  Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert consensus </text>
<text top="756" left="503" width="304" height="12" font="4">statement on the recognition and management of arrhythmias in </text>
<text top="770" left="503" width="304" height="12" font="4">adult congenital heart disease: developed in partnership between </text>
<text top="783" left="503" width="303" height="12" font="4">the Pediatric and Congenital Electrophysiology Society (PACES) and </text>
<text top="797" left="503" width="298" height="12" font="4">the Heart Rhythm Society (HRS). Heart Rhythm. 2014;11:e102–65.</text>
<text top="811" left="452" width="351" height="12" font="4"> S10.8-10.  Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhyth-</text>
<text top="824" left="503" width="303" height="12" font="4">mia risk stratification in patients with tetralogy of Fallot at the time </text>
<text top="838" left="503" width="306" height="12" font="4">of pulmonary valve replacement. Circ Arrhythm Electrophysiol. </text>
<text top="852" left="503" width="67" height="12" font="4">2015;8:110–6.</text>
<text top="865" left="452" width="351" height="12" font="4"> S10.8-11.  Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmo-</text>
<text top="879" left="503" width="303" height="12" font="4">nary valve replacement in adults after tetralogy of Fallot repair. Am </text>
<text top="893" left="503" width="122" height="12" font="4">J Cardiol. 2005;95:779–82.</text>
<text top="906" left="452" width="351" height="12" font="4"> S10.8-12.  Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replace-</text>
<text top="920" left="503" width="305" height="12" font="4">ment on arrhythmia propensity late after repair of tetralogy of </text>
<text top="934" left="503" width="174" height="12" font="4">Fallot. Circulation. 2001;103:2489–94.</text>
<text top="947" left="452" width="7" height="12" font="4"> </text>
<text top="947" left="452" width="351" height="12" font="4">S10.8-13. Kella DK, Merchant FM, Veledar E, et al. Lesion-specific dif-</text>
<text top="961" left="503" width="307" height="12" font="4">ferences for implantable cardioverter defibrillator therapies in </text>
<text top="975" left="503" width="305" height="12" font="4">adults with congenital heart disease. Pacing Clin Electrophysiol. </text>
<text top="988" left="503" width="78" height="12" font="4">2014;37:1492–8.</text>
<text top="1002" left="452" width="354" height="12" font="4"> S10.8-14.  Koyak Z, de Groot JR, Van Gelder IC, et al. Implantable cardioverter </text>
<text top="1016" left="503" width="303" height="12" font="4">defibrillator therapy in adults with congenital heart disease: who is </text>
<text top="1029" left="503" width="285" height="12" font="4">at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5:101–10.</text>
<text top="1043" left="452" width="6" height="12" font="4"> </text>
<text top="1043" left="452" width="351" height="12" font="4">S10.8-15. Santharam S, Hudsmith L, Thorne S, et al. Long-term follow-</text>
<text top="1057" left="503" width="300" height="12" font="4">up of implantable cardioverter-defibrillators in adult congeni-</text>
<text top="1071" left="503" width="306" height="12" font="4">tal heart disease patients: indications and outcomes. Europace. </text>
<text top="1084" left="503" width="78" height="12" font="4">2017;19:407–13.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e383</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="351" height="12" font="4"> S10.8-16.  Vehmeijer JT, Brouwer TF, Limpens J, et al. Implantable cardioverter-</text>
<text top="102" left="125" width="304" height="12" font="4">defibrillators in adults with congenital heart disease: a systematic </text>
<text top="116" left="125" width="256" height="12" font="4">review and meta-analysis. Eur Heart J. 2016;37:1439–48.</text>
<text top="129" left="74" width="356" height="12" font="4"> S10.8-17.  Yap SC, Roos-Hesselink JW, Hoendermis ES, et al. Outcome of </text>
<text top="143" left="125" width="306" height="12" font="4">implantable cardioverter defibrillators in adults with congenital </text>
<text top="157" left="125" width="296" height="12" font="4">heart disease: a multi-centre study. Eur Heart J. 2007;28:1854–61.</text>
<text top="170" left="74" width="354" height="12" font="4"> S10.8-18.  Chandar JS, Wolff GS, Garson A, Jr, et al. Ventricular arrhythmias in </text>
<text top="184" left="125" width="289" height="12" font="4">postoperative tetralogy of Fallot. Am J Cardiol. 1990;65:655–61.</text>
<text top="197" left="74" width="354" height="12" font="4"> S10.8-19.  Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed </text>
<text top="211" left="125" width="303" height="12" font="4">ventricular stimulation after tetralogy of fallot repair: a multicenter </text>
<text top="225" left="125" width="184" height="12" font="4">study. Circulation. 2004;109:1994–2000.</text>
<text top="238" left="74" width="351" height="12" font="4"> S10.8-20.  Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-</text>
<text top="252" left="125" width="292" height="12" font="4">defibrillators in tetralogy of Fallot. Circulation. 2008;117:363–70.</text>
<text top="266" left="74" width="351" height="12" font="4"> S10.8-21.  Kapel GF, Reichlin T, Wijnmaalen AP, et al. Re-entry using anatomi-</text>
<text top="279" left="125" width="306" height="12" font="4">cally determined isthmuses: a curable ventricular tachycardia in </text>
<text top="293" left="125" width="306" height="12" font="4">repaired congenital heart disease. Circ Arrhythm Electrophysiol. </text>
<text top="307" left="125" width="67" height="12" font="4">2015;8:102–9.</text>
<text top="320" left="74" width="355" height="12" font="4"> S10.8-22.  Kapel GF, Reichlin T, Wijnmaalen AP, et al. Left-sided ablation of </text>
<text top="334" left="125" width="303" height="12" font="4">ventricular tachycardia in adults with repaired tetralogy of Fallot: a </text>
<text top="347" left="125" width="257" height="12" font="4">case series. Circ Arrhythm Electrophysiol. 2014;7:889–97.</text>
<text top="361" left="74" width="351" height="12" font="4"> S10.8-23.  Kapel GF, Sacher F, Dekkers OM, et al. Arrhythmogenic anatomi-</text>
<text top="375" left="125" width="300" height="12" font="4">cal isthmuses identified by electroanatomical mapping are the sub-</text>
<text top="388" left="125" width="303" height="12" font="4">strate for ventricular tachycardia in repaired tetralogy of Fallot. Eur </text>
<text top="402" left="125" width="115" height="12" font="4">Heart J. 2017;38:268–76.</text>
<text top="416" left="74" width="351" height="12" font="4"> S10.8-24.  van Zyl M, Kapa S, Padmanabhan D, et al. Mechanism and out-</text>
<text top="429" left="125" width="303" height="12" font="4">comes of catheter ablation for ventricular tachycardia in adults with </text>
<text top="443" left="125" width="300" height="12" font="4">repaired congenital heart disease. Heart Rhythm. 2016;13:1449–54.</text>
<text top="457" left="74" width="354" height="12" font="4"> S10.8-25.  Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of </text>
<text top="470" left="125" width="300" height="12" font="4">ventricular tachycardia after repair of congenital heart disease: elec-</text>
<text top="484" left="125" width="304" height="12" font="4">troanatomic identification of the critical right ventricular isthmus. </text>
<text top="497" left="125" width="144" height="12" font="4">Circulation. 2007;116:2241–52.</text>
<text top="511" left="74" width="351" height="12" font="4"> S10.8-26.  Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrilla-</text>
<text top="525" left="125" width="303" height="12" font="4">tors in transposition of the great arteries with intra-atrial baffles: a </text>
<text top="538" left="125" width="282" height="12" font="4">multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250–7.</text>
<text top="552" left="74" width="355" height="12" font="4"> S10.8-27.  Engelings CC, Helm PC, Abdul-Khaliq H, et al. Cause of death in </text>
<text top="566" left="125" width="304" height="12" font="4">adults with congenital heart disease - an analysis of the German </text>
<text top="579" left="125" width="307" height="12" font="4">National Register for Congenital Heart Defects. Int J Cardiol. </text>
<text top="593" left="125" width="72" height="12" font="4">2016;211:31–6.</text>
<text top="607" left="74" width="355" height="12" font="4"> S10.8-28.  Gallego P, Gonzalez AE, Sanchez-Recalde A, et al. Incidence and </text>
<text top="620" left="125" width="304" height="12" font="4">predictors of sudden cardiac arrest in adults with congenital heart </text>
<text top="634" left="125" width="298" height="12" font="4">defects repaired before adult life. Am J Cardiol. 2012;110:109–17.</text>
<text top="648" left="74" width="355" height="12" font="4"> S10.8-29.  Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart </text>
<text top="661" left="125" width="303" height="12" font="4">disease beyond the age of 60: emergence of a new population with </text>
<text top="675" left="125" width="305" height="12" font="4">high resource utilization, high morbidity, and high mortality. Eur </text>
<text top="688" left="125" width="115" height="12" font="4">Heart J. 2014;35:725–32.</text>
<text top="702" left="74" width="357" height="12" font="4"> S10.8-30.  Fish FA, Gillette PC, Benson DW Jr, Proarrhythmia, cardiac arrest </text>
<text top="716" left="125" width="305" height="12" font="4">and death in young patients receiving encainide and flecainide. </text>
<text top="729" left="125" width="309" height="12" font="4">The Pediatric Electrophysiology Group. J Am Coll Cardiol. </text>
<text top="743" left="125" width="78" height="12" font="4">1991;18:356–65.</text>
<text top="757" left="74" width="355" height="12" font="4"> S10.8-31.  Stan MN, Sathananthan M, Warnes C, et al. Amiodarone-induced </text>
<text top="770" left="125" width="300" height="12" font="4">thyrotoxicosis in adults with congenital heart disease-clinical pre-</text>
<text top="784" left="125" width="292" height="12" font="4">sentation and response to therapy. Endocr Pract. 2014;21:33–40.</text>
<text top="798" left="74" width="351" height="12" font="4"> S10.8-32.  Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thy-</text>
<text top="811" left="125" width="302" height="12" font="4">roid dysfunction: risk factors in adults with congenital heart disease. </text>
<text top="825" left="125" width="138" height="12" font="4">Circulation. 1999;100:149–54.</text>
<text top="838" left="74" width="355" height="12" font="4"> S10.8-33.  Garson A Jr, Porter CB, Gillette PC, et al. Induction of ventricular </text>
<text top="852" left="125" width="303" height="12" font="4">tachycardia during electrophysiologic study after repair of tetralogy </text>
<text top="866" left="125" width="209" height="12" font="4">of Fallot. J Am Coll Cardiol. 1983;1:1493–502.</text>
<text top="879" left="74" width="356" height="12" font="4"> S10.8-34.  Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in </text>
<text top="893" left="125" width="300" height="12" font="4">adults with surgically repaired tetralogy of Fallot: a multi-institu-</text>
<text top="907" left="125" width="195" height="12" font="4">tional study. Circulation. 2010;122:868–75.</text>
<text top="920" left="74" width="7" height="12" font="4"> </text>
<text top="920" left="74" width="358" height="12" font="4">S10.8-35. Tsai SF, Chan DP, Ro PS, et al. Rate of inducible ventricular </text>
<text top="934" left="125" width="304" height="12" font="4">arrhythmia in adults with congenital heart disease. Am J Cardiol. </text>
<text top="948" left="125" width="78" height="12" font="4">2010;106:730–6.</text>
<text top="961" left="74" width="351" height="12" font="4"> S10.8-36.  Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predic-</text>
<text top="975" left="125" width="303" height="12" font="4">tors of death and sustained ventricular tachycardia in patients with </text>
<text top="989" left="125" width="302" height="12" font="4">repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. </text>
<text top="1002" left="125" width="84" height="12" font="4">2014;100:247–53.</text>
<text top="1016" left="74" width="355" height="12" font="4"> S10.8-37.  Sakamoto T, Nagashima M, Hiramatsu T, et al. Fontan circulation </text>
<text top="1029" left="125" width="304" height="12" font="4">over 30 years. What should we learn from those patients? Asian </text>
<text top="1043" left="125" width="187" height="12" font="4">Cardiovasc Thorac Ann. 2016;24:765–71.</text>
<text top="1057" left="74" width="354" height="12" font="4"> S10.8-38.  Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement </text>
<text top="1070" left="125" width="303" height="12" font="4">in tetralogy of Fallot: impact on survival and ventricular tachycardia. </text>
<text top="1084" left="125" width="138" height="12" font="4">Circulation. 2009;119:445–51.</text>
<text top="88" left="452" width="355" height="12" font="4"> S10.8-39.  Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter </text>
<text top="102" left="503" width="300" height="12" font="4">retrospective implantable cardioverter-defibrillator registry of pedi-</text>
<text top="116" left="503" width="306" height="12" font="4">atric and congenital heart disease patients. J Am Coll Cardiol. </text>
<text top="129" left="503" width="84" height="12" font="4">2008;51:1685–91.</text>
<text top="143" left="452" width="354" height="12" font="4"> S10.8-40.  Khanna AD, Warnes CA, Phillips SD, et al. Single-center experience </text>
<text top="157" left="503" width="304" height="12" font="4">with implantable cardioverter-defibrillators in adults with complex </text>
<text top="170" left="503" width="261" height="12" font="4">congenital heart disease. Am J Cardiol. 2011;108:729–34.</text>
<text top="184" left="452" width="355" height="12" font="4"> S10.8-41.  Moore JP, Mondesert B, Lloyd MS, et al. Clinical experience with </text>
<text top="197" left="503" width="306" height="12" font="4">the subcutaneous implantable cardioverter-defibrillator in adults </text>
<text top="211" left="503" width="309" height="12" font="4">with congenital heart disease. Circ Arrhythm Electrophysiol. </text>
<text top="225" left="503" width="78" height="12" font="4">2016;9:e004338.</text>
<text top="238" left="452" width="354" height="12" font="4"> S10.8-42.  Okamura H, McLeod CJ, DeSimone CV, et al. Right parasternal lead </text>
<text top="252" left="503" width="300" height="12" font="4">placement increases eligibility for subcutaneous implantable cardio-</text>
<text top="266" left="503" width="304" height="12" font="4">verter defibrillator therapy in adults with congenital heart disease. </text>
<text top="279" left="503" width="114" height="12" font="4">Circ J. 2016;80:1328–35.</text>
<text top="293" left="452" width="351" height="12" font="4"> S10.8-43.  Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter-</text>
<text top="307" left="503" width="307" height="12" font="4">defibrillator therapy in adult patients with tetralogy of Fallot. </text>
<text top="320" left="503" width="125" height="12" font="4">Europace. 2008;10:926–30.</text>
<text top="334" left="452" width="354" height="12" font="4"> S10.8-44.  Raissadati A, Nieminen H, Haukka J, et al. Late causes of death after </text>
<text top="348" left="503" width="304" height="12" font="4">pediatric cardiac surgery: a 60-year population-based study. J Am </text>
<text top="361" left="503" width="136" height="12" font="4">Coll Cardiol. 2016;68:487–98.</text>
<text top="375" left="452" width="355" height="12" font="4"> S10.8-45.  Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects </text>
<text top="388" left="503" width="307" height="12" font="4">and circumstances of death in contemporary adult congenital </text>
<text top="402" left="503" width="305" height="12" font="4">heart disease patients under follow-up at a large tertiary centre. </text>
<text top="416" left="503" width="144" height="12" font="4">Circulation. 2015;132:2118–25.</text>
<text top="429" left="452" width="355" height="12" font="4"> S10.8-46.  Nieminen HP, Jokinen EV, Sairanen HI, Causes of late deaths after </text>
<text top="443" left="503" width="306" height="12" font="4">pediatric cardiac surgery: a population-based study. J Am Coll </text>
<text top="457" left="503" width="122" height="12" font="4">Cardiol. 2007;50:1263–71.</text>
<text top="470" left="452" width="354" height="12" font="4"> S10.8-47.  Zomer AC, Vaartjes I, Uiterwaal CS, et al. Circumstances of death in </text>
<text top="484" left="503" width="282" height="12" font="4">adult congenital heart disease. Int J Cardiol. 2012;154:168–72.</text>
<text top="498" left="452" width="354" height="12" font="4"> S10.8-48.  Lange R, Horer J, Kostolny M, et al. Presence of a ventricular septal </text>
<text top="511" left="503" width="303" height="12" font="4">defect and the Mustard operation are risk factors for late mortality </text>
<text top="525" left="503" width="304" height="12" font="4">after the atrial switch operation: thirty years of follow-up in 417 </text>
<text top="538" left="503" width="264" height="12" font="4">patients at a single center. Circulation. 2006;114:1905–13.</text>
<text top="552" left="452" width="354" height="12" font="4"> S10.8-49.  Lubiszewska B, Gosiewska E, Hoffman P, et al. Myocardial perfusion </text>
<text top="566" left="503" width="304" height="12" font="4">and function of the systemic right ventricle in patients after atrial </text>
<text top="579" left="503" width="302" height="12" font="4">switch procedure for complete transposition: long-term follow-up. J </text>
<text top="593" left="503" width="161" height="12" font="4">Am Coll Cardiol. 2000;36:1365–70.</text>
<text top="607" left="452" width="354" height="12" font="4"> S10.8-50.  Millane T, Bernard EJ, Jaeggi E, et al. Role of ischemia and infarction </text>
<text top="620" left="503" width="300" height="12" font="4">in late right ventricular dysfunction after atrial repair of transposi-</text>
<text top="634" left="503" width="276" height="12" font="4">tion of the great arteries. J Am Coll Cardiol. 2000;35:1661–8.</text>
<text top="648" left="452" width="354" height="12" font="4"> S10.8-51.  Schwerzmann M, Salehian O, Harris L, et al. Ventricular arrhythmias </text>
<text top="661" left="503" width="300" height="12" font="4">and sudden death in adults after a Mustard operation for transposi-</text>
<text top="675" left="503" width="247" height="12" font="4">tion of the great arteries. Eur Heart J. 2009;30:1873–9.</text>
<text top="689" left="452" width="357" height="12" font="4"> S10.8-52.  Buber J, Ackley TJ, Daniels CJ, et al. Outcomes following the </text>
<text top="702" left="503" width="304" height="12" font="4">implantation of cardioverter-defibrillator for primary prevention in </text>
<text top="716" left="503" width="304" height="12" font="4">transposition of the great arteries after intra-atrial baffle repair: a </text>
<text top="729" left="503" width="245" height="12" font="4">single-centre experience. Europace. 2016;18:1016–22.</text>
<text top="743" left="452" width="351" height="12" font="4"> S10.8-53.  Backhoff D, Kerst G, Peters A, et al. Internal cardioverter defibril-</text>
<text top="757" left="503" width="306" height="12" font="4">lator indications and therapies after atrial baffle procedure for </text>
<text top="770" left="503" width="304" height="12" font="4">d-transposition of the great arteries: a multicenter analysis. Pacing </text>
<text top="784" left="503" width="166" height="12" font="4">Clin Electrophysiol. 2016;39:1070–6.</text>
<text top="798" left="452" width="355" height="12" font="4"> S10.8-54.  Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in </text>
<text top="811" left="503" width="300" height="12" font="4">adults with congenital heart disease. Am J Cardiol. 2000;86:1111–6.</text>
<text top="825" left="452" width="353" height="12" font="4"> S10.8-55.  Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult </text>
<text top="839" left="503" width="246" height="12" font="4">congenital heart disease. Eur Heart J. 2010;31:1220–9.</text>
<text top="852" left="452" width="351" height="12" font="4"> S10.8-56.  Silka MJ, Hardy BG, Menashe VD, et al. A population-based pro-</text>
<text top="866" left="503" width="300" height="12" font="4">spective evaluation of risk of sudden cardiac death after opera-</text>
<text top="879" left="503" width="306" height="12" font="4">tion for common congenital heart defects. J Am Coll Cardiol. </text>
<text top="893" left="503" width="78" height="12" font="4">1998;32:245–51.</text>
<text top="907" left="452" width="355" height="12" font="4"> S10.8-57.  Abou Hassan OK, Fahed AC, Batrawi M, et al. NKX2-5 mutations </text>
<text top="920" left="503" width="304" height="12" font="4">in an inbred consanguineous population: genetic and phenotypic </text>
<text top="934" left="503" width="140" height="12" font="4">diversity. Sci Rep. 2015;5:8848.</text>
<text top="948" left="452" width="355" height="12" font="4"> S10.8-58.  El Malti R, Liu H, Doray B, et al. A systematic variant screening in </text>
<text top="961" left="503" width="300" height="12" font="4">familial cases of congenital heart defects demonstrates the use-</text>
<text top="975" left="503" width="305" height="12" font="4">fulness of molecular genetics in this field. Eur J Human Genet. </text>
<text top="989" left="503" width="78" height="12" font="4">2016;24:228–36.</text>
<text top="1002" left="452" width="356" height="12" font="4"> S10.8-59.  Ellesoe SG, Johansen MM, Bjerre JV, et al. Familial atrial septal </text>
<text top="1016" left="503" width="303" height="12" font="4">defect and sudden cardiac death: identification of a novel NKX2-5 </text>
<text top="1029" left="503" width="307" height="12" font="4">mutation and a review of the literature. Congenit Heart Dis. </text>
<text top="1043" left="503" width="78" height="12" font="4">2016;11:283–90.</text>
<text top="1057" left="452" width="356" height="12" font="4"> S10.8-60.  Cuypers JA, Opic P, Menting ME, et al. The unnatural history of </text>
<text top="1070" left="503" width="303" height="12" font="4">an atrial septal defect: longitudinal 35 year follow up after surgical </text>
<text top="1084" left="503" width="213" height="12" font="4">closure at young age. Heart. 2013;99:1346–52.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e384</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="355" height="12" font="4"> S10.8-61.  Kuijpers JM, van der Bom T, van Riel AC, et al. Secundum atrial </text>
<text top="102" left="125" width="304" height="12" font="4">septal defect is associated with reduced survival in adult men. Eur </text>
<text top="115" left="125" width="121" height="12" font="4">Heart J. 2015;36:2079–86.</text>
<text top="129" left="74" width="351" height="12" font="4"> S10.8-62.  Verheugt CL, Uiterwaal CS, Grobbee DE, et al. Long-term progno-</text>
<text top="142" left="125" width="304" height="12" font="4">sis of congenital heart defects: a systematic review. Int J Cardiol. </text>
<text top="156" left="125" width="78" height="12" font="4">2008;131:25–32.</text>
<text top="170" left="74" width="355" height="12" font="4"> S10.8-63.  Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult </text>
<text top="183" left="125" width="304" height="12" font="4">congenital heart disease in Europe: morbidity and mortality in a 5 </text>
<text top="197" left="125" width="304" height="12" font="4">year follow-up period. The Euro Heart Survey on adult congenital </text>
<text top="210" left="125" width="202" height="12" font="4">heart disease. Eur Heart J. 2005;26:2325–33.</text>
<text top="224" left="74" width="355" height="12" font="4"> S10.8-64.  Arya S, Kovach J, Singh H, et al. Arrhythmias and sudden death </text>
<text top="237" left="125" width="303" height="12" font="4">among older children and young adults following tetralogy of Fallot </text>
<text top="251" left="125" width="305" height="12" font="4">repair in the current era: are previously reported risk factors still </text>
<text top="264" left="125" width="216" height="12" font="4">applicable? Congenit Heart Dis. 2014;9:407–14.</text>
<text top="278" left="74" width="355" height="12" font="4"> S10.8-65.  Wu MH, Lu CW, Chen HC, et al. Arrhythmic burdens in patients </text>
<text top="291" left="125" width="304" height="12" font="4">with tetralogy of Fallot: a national database study. Heart Rhythm. </text>
<text top="305" left="125" width="72" height="12" font="4">2015;12:604–9.</text>
<text top="318" left="74" width="351" height="12" font="4"> S10.8-66.  Baraona F, Valente AM, Porayette P, et al. Coronary arteries in child-</text>
<text top="332" left="125" width="303" height="12" font="4">hood heart disease: implications for management of young adults. </text>
<text top="345" left="125" width="177" height="12" font="4">J Clin Exp Cardiolog. suppl 8 2012 006.</text>
<text top="359" left="74" width="353" height="12" font="4"> S10.8-67.  Naimo PS, Fricke TA, Yong MS, et al. Outcomes of truncus arteriosus </text>
<text top="373" left="125" width="304" height="12" font="4">repair in children: 35 years of experience from a single institution. </text>
<text top="386" left="125" width="219" height="12" font="4">Semin Thorac Cardiovasc Surg. 2016;28:500–11.</text>
<text top="400" left="74" width="355" height="12" font="4"> S10.8-68.  Pundi KN, Pundi KN, Johnson JN, et al. Sudden cardiac death and </text>
<text top="413" left="125" width="305" height="12" font="4">late arrhythmias after the Fontan operation. Congenit Heart Dis. </text>
<text top="427" left="125" width="72" height="12" font="4">2017;12:17–23.</text>
<text top="471" left="74" width="315" height="23" font="15"><b>11. DEFIBRILLATORS OTHER THAN </b></text>
<text top="493" left="74" width="187" height="23" font="15"><b>TRANSVENOUS ICDS</b></text>
<text top="522" left="74" width="275" height="21" font="18"><b>11.1. Subcutaneous Implantable </b></text>
<text top="543" left="74" width="214" height="21" font="18"><b>Cardioverter-Defibrillator</b></text>
<text top="569" left="74" width="351" height="12" font="4"> S11.1-1. Bardy GH, Smith WM, Hood MA, et al. An entirely subcuta-</text>
<text top="583" left="125" width="310" height="12" font="4">neous implantable cardioverter-defibrillator. N Engl J Med. </text>
<text top="597" left="125" width="78" height="12" font="4">2010;363:36–44.</text>
<text top="610" left="74" width="354" height="12" font="4">  S11.1-2.  Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally </text>
<text top="624" left="125" width="308" height="12" font="4">subcutaneous implantable-cardioverter defibrillator. Circulation. </text>
<text top="637" left="125" width="84" height="12" font="4">2013;128:944–53.</text>
<text top="651" left="74" width="354" height="12" font="4">  S11.1-3.  Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with </text>
<text top="664" left="125" width="304" height="12" font="4">a totally subcutaneous implantable defibrillator: early results from </text>
<text top="678" left="125" width="280" height="12" font="4">the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657–65.</text>
<text top="691" left="74" width="355" height="12" font="4"> S11.1-4.  Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the </text>
<text top="705" left="125" width="303" height="12" font="4">totally subcutaneous implantable defibrillator: 2-year results from a </text>
<text top="718" left="125" width="303" height="12" font="4">pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll </text>
<text top="732" left="125" width="122" height="12" font="4">Cardiol. 2015;65:1605–15.</text>
<text top="745" left="74" width="355" height="12" font="4">  S11.1-5.  El-Chami MF, Levy M, Kelli HM, et al. Outcome of subcutaneous </text>
<text top="759" left="125" width="304" height="12" font="4">implantable cardioverter defibrillator implantation in patients with </text>
<text top="772" left="125" width="306" height="12" font="4">end-stage renal disease on dialysis. J Cardiovasc Electrophysiol. </text>
<text top="786" left="125" width="72" height="12" font="4">2015;26:900–4.</text>
<text top="800" left="74" width="353" height="12" font="4">  S11.1-6.  de Bie MK, Thijssen J, van Rees JB, et al. Suitability for subcutaneous </text>
<text top="813" left="125" width="303" height="12" font="4">defibrillator implantation: results based on data from routine clinical </text>
<text top="827" left="125" width="155" height="12" font="4">practice. Heart. 2013;99:1018–23.</text>
<text top="840" left="74" width="351" height="12" font="4">  S11.1-7.  Olde Nordkamp LR, Dabiri AL, Boersma LV, et al. The entirely subcu-</text>
<text top="854" left="125" width="300" height="12" font="4">taneous implantable cardioverter-defibrillator: initial clinical experi-</text>
<text top="867" left="125" width="294" height="12" font="4">ence in a large Dutch cohort. J Am Coll Cardiol. 2012;60:1933–9.</text>
<text top="881" left="74" width="356" height="12" font="4"> S11.1-8.  Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of </text>
<text top="894" left="125" width="300" height="12" font="4">totally subcutaneous versus conventional implantable cardioverter-</text>
<text top="908" left="125" width="307" height="12" font="4">defibrillators: a multicenter case-control study. Heart Rhythm. </text>
<text top="921" left="125" width="72" height="12" font="4">2013;10:29–36.</text>
<text top="935" left="74" width="351" height="12" font="4"> S11.1-9.  Groh CA, Sharma S, Pelchovitz DJ, et al. Use of an electrocar-</text>
<text top="948" left="125" width="300" height="12" font="4">diographic screening tool to determine candidacy for a subcu-</text>
<text top="962" left="125" width="310" height="12" font="4">taneous implantable cardioverter-defibrillator. Heart Rhythm. </text>
<text top="976" left="125" width="78" height="12" font="4">2014;11:1361–6.</text>
<text top="989" left="74" width="6" height="12" font="4"> </text>
<text top="989" left="74" width="357" height="12" font="4">S11.1-10. Olde Nordkamp LR, Warnaars JL, Kooiman KM, et al. Which </text>
<text top="1003" left="125" width="300" height="12" font="4">patients are not suitable for a subcutaneous ICD: incidence and pre-</text>
<text top="1016" left="125" width="305" height="12" font="4">dictors of failed QRS-T-wave morphology screening. J Cardiovasc </text>
<text top="1030" left="125" width="139" height="12" font="4">Electrophysiol. 2014;25:494–9.</text>
<text top="1043" left="74" width="356" height="12" font="4"> S11.1-11.  Randles DA, Hawkins NM, Shaw M, et al. How many patients </text>
<text top="1057" left="125" width="308" height="12" font="4">fulfil the surface electrocardiogram criteria for subcutaneous </text>
<text top="1070" left="125" width="311" height="12" font="4">implantable cardioverter-defibrillator implantation? Europace. </text>
<text top="1084" left="125" width="84" height="12" font="4">2014;16:1015–21.</text>
<text top="88" left="452" width="351" height="12" font="4"> S11.1-12.  Al-Khatib SM, Greiner MA, Peterson ED, et al. Patient and implant-</text>
<text top="102" left="503" width="304" height="12" font="4">ing physician factors associated with mortality and complications </text>
<text top="115" left="503" width="300" height="12" font="4">after implantable cardioverter-defibrillator implantation, 2002–</text>
<text top="129" left="503" width="228" height="12" font="4">2005. Circ Arrhythm Electrophysiol. 2008;1:240–9.</text>
<text top="143" left="452" width="353" height="12" font="4"> S11.1-13.  Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design </text>
<text top="156" left="503" width="303" height="12" font="4">of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of </text>
<text top="170" left="503" width="300" height="12" font="4">subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrilla-</text>
<text top="184" left="503" width="194" height="12" font="4">tor therapy. Am Heart J. 2012;163:753–60.</text>
<text top="223" left="452" width="345" height="21" font="18"><b>11.2. Wearable Cardioverter-Defibrillator</b></text>
<text top="250" left="452" width="356" height="12" font="4"> S11.2-1.  Chung MK, The role of the wearable cardioverter defibrillator in </text>
<text top="264" left="503" width="210" height="12" font="4">clinical practice. Cardiol Clin. 2014;32:253–70.</text>
<text top="277" left="452" width="356" height="12" font="4"> S11.2-2.  Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national </text>
<text top="291" left="503" width="303" height="12" font="4">experience with the wearable cardioverter-defibrillator: event rates, </text>
<text top="305" left="503" width="282" height="12" font="4">compliance, and survival. J Am Coll Cardiol. 2010;56:194–203.</text>
<text top="318" left="452" width="357" height="12" font="4"> S11.2-3. Klein HU, Meltendorf U, Reek S, et al. Bridging a temporary </text>
<text top="332" left="503" width="300" height="12" font="4">high risk of sudden arrhythmic death. Experience with the wear-</text>
<text top="346" left="503" width="306" height="12" font="4">able cardioverter defibrillator (WCD). Pacing Clin Electrophysiol. </text>
<text top="359" left="503" width="78" height="12" font="4">2010;33:353–67.</text>
<text top="373" left="452" width="351" height="12" font="4">  S11.2-4.  Piccini JP Sr, Allen LA, Kudenchuk PJ, et al. Wearable cardioverter-</text>
<text top="387" left="503" width="304" height="12" font="4">defibrillator therapy for the prevention of sudden cardiac death: a </text>
<text top="400" left="503" width="303" height="12" font="4">science advisory from the American Heart Association. Circulation. </text>
<text top="414" left="503" width="90" height="12" font="4">2016;133:1715–27.</text>
<text top="428" left="452" width="351" height="12" font="4">  S11.2-5.  Ellenbogen KA, Koneru JN, Sharma PS, et al. Benefit of the wear-</text>
<text top="441" left="503" width="300" height="12" font="4">able cardioverter-defibrillator in protecting patients after implant-</text>
<text top="455" left="503" width="306" height="12" font="4">able-cardioverter defibrillator explant. Results from the National </text>
<text top="469" left="503" width="227" height="12" font="4">Registry. JACC Clin Electrophysiol. 2017;3:243–50.</text>
<text top="482" left="452" width="351" height="12" font="4"> S11.2-6.  LifeVest Wearable Cardioverter Defibrillator. Available at: <a href="">http://</a></text>
<text top="496" left="503" width="300" height="12" font="4"><a href="">www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/</a></text>
<text top="510" left="503" width="300" height="12" font="4"><a href="">DeviceApprovalsandClearances/Recently-ApprovedDevices/</a></text>
<text top="523" left="503" width="204" height="12" font="4"><a href="">ucm458494.htm. Accessed August 26, 2016.</a></text>
<text top="566" left="452" width="324" height="21" font="18"><b>11.3. Automated External Defibrillator</b></text>
<text top="592" left="452" width="351" height="12" font="4">  S11.3-1.  Marenco JP, Wang PJ, Link MS, et al. Improving survival from sud-</text>
<text top="606" left="503" width="303" height="12" font="4">den cardiac arrest: the role of the automated external defibrillator. </text>
<text top="620" left="503" width="128" height="12" font="4">JAMA. 2001;285:1193–200.</text>
<text top="633" left="452" width="351" height="12" font="4">  S11.3-2.  Priori SG, Bossaert LL, Chamberlain DA, et al. ESC-ERC recommen-</text>
<text top="647" left="503" width="304" height="12" font="4">dations for the use of automated external defibrillators (AEDs) in </text>
<text top="661" left="503" width="161" height="12" font="4">Europe. Eur Heart J. 2004;25:437–5</text>
<text top="674" left="452" width="355" height="12" font="4">  S11.3-3.  Blom MT, Beesems SG, Homma PC, et al. Improved survival after </text>
<text top="688" left="503" width="300" height="12" font="4">out-of-hospital cardiac arrest and use of automated external defi-</text>
<text top="702" left="503" width="188" height="12" font="4">brillators. Circulation. 2014;130:1868–75.</text>
<text top="715" left="452" width="354" height="12" font="4">  S11.3-4.  Koster RW, Automatic external defibrillator: key link in the chain of </text>
<text top="729" left="503" width="235" height="12" font="4">survival. J Cardiovasc Electrophysiol. 2002;13:S92–5.</text>
<text top="743" left="452" width="351" height="12" font="4">  S11.3-5.  Valenzuela TD, Roe DJ, Nichol G, et al. Outcomes of rapid defibrilla-</text>
<text top="756" left="503" width="303" height="12" font="4">tion by security officers after cardiac arrest in casinos. N Engl J Med. </text>
<text top="770" left="503" width="84" height="12" font="4">2000;343:1206–9.</text>
<text top="784" left="452" width="355" height="12" font="4">  S11.3-6.  Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated </text>
<text top="797" left="503" width="249" height="12" font="4">external defibrillators. N Engl J Med. 2002;347:1242–7.</text>
<text top="811" left="452" width="351" height="12" font="4">  S11.3-7.  Page RL, Joglar JA, Kowal RC, et al. Use of automated external defi-</text>
<text top="825" left="503" width="260" height="12" font="4">brillators by a US airline. N Engl J Med. 2000;343:1210–6.</text>
<text top="838" left="452" width="353" height="12" font="4">  S11.3-8.  Page RL, Husain S, White LY, et al. Cardiac arrest at exercise facilities: </text>
<text top="852" left="503" width="305" height="12" font="4">implications for placement of automated external defibrillators. J </text>
<text top="865" left="503" width="155" height="12" font="4">Am Coll Cardiol. 2013;62:2102–9.</text>
<text top="879" left="452" width="354" height="12" font="4">  S11.3-9.  Weisfeldt ML, Sitlani CM, Ornato JP, et al. Survival after application </text>
<text top="893" left="503" width="303" height="12" font="4">of automatic external defibrillators before arrival of the emergency </text>
<text top="906" left="503" width="300" height="12" font="4">medical system: evaluation in the resuscitation outcomes consor-</text>
<text top="920" left="503" width="300" height="12" font="4">tium population of 21 million. J Am Coll Cardiol. 2010;55:1713–20.</text>
<text top="934" left="452" width="355" height="12" font="4"> S11.3-10.  Hansen CM, Lippert FK, Wissenberg M, et al. Temporal trends in </text>
<text top="947" left="503" width="300" height="12" font="4">coverage of historical cardiac arrests using a volunteer-based net-</text>
<text top="961" left="503" width="304" height="12" font="4">work of automated external defibrillators accessible to laypersons </text>
<text top="975" left="503" width="294" height="12" font="4">and emergency dispatch centers. Circulation. 2014;130:1859–67.</text>
<text top="988" left="452" width="351" height="12" font="4"> S11.3-11.  Weisfeldt ML, Everson-Stewart S, Sitlani C, et al. Ventricular tachyar-</text>
<text top="1002" left="503" width="304" height="12" font="4">rhythmias after cardiac arrest in public versus at home. N Engl J </text>
<text top="1016" left="503" width="110" height="12" font="4">Med. 2011;364:313–21.</text>
<text top="1029" left="452" width="6" height="12" font="4"> </text>
<text top="1029" left="452" width="357" height="12" font="4">S11.3-12. Bardy GH, Lee KL, Mark DB, et al. Home use of automated </text>
<text top="1043" left="503" width="306" height="12" font="4">external defibrillators for sudden cardiac arrest. N Engl J Med. </text>
<text top="1057" left="503" width="96" height="12" font="4">2008;358:1793–804.</text>
<text top="1070" left="452" width="351" height="12" font="4"> S11.3-13.  Travers AH, Perkins GD, Berg RA, et al. Part 3: adult basic life sup-</text>
<text top="1084" left="503" width="307" height="12" font="4">port and automated external defibrillation: 2015 International </text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="114" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e385</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="125" width="308" height="12" font="4">Consensus on Cardiopulmonary Resuscitation and Emergency </text>
<text top="102" left="125" width="306" height="12" font="4">Cardiovascular Care Science With Treatment Recommendations. </text>
<text top="116" left="125" width="138" height="12" font="4">Circulation. 2015;132:S51–83.</text>
<text top="160" left="74" width="322" height="23" font="15"><b>12. SPECIAL CONSIDERATIONS FOR </b></text>
<text top="182" left="74" width="193" height="23" font="15"><b>CATHETER ABLATION</b></text>
<text top="211" left="74" width="356" height="12" font="4">  S12-1.  Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant </text>
<text top="224" left="125" width="306" height="12" font="4">ventricular tachycardia: cumulative experience in 48 patients. J </text>
<text top="238" left="125" width="190" height="12" font="4">Cardiovasc Electrophysiol. 1993;4:253–62.</text>
<text top="252" left="74" width="357" height="12" font="4">  S12-2.  Lopera G, Stevenson WG, Soejima K, et al. Identification and </text>
<text top="265" left="125" width="306" height="12" font="4">ablation of three types of ventricular tachycardia involving the </text>
<text top="279" left="125" width="306" height="12" font="4">his-purkinje system in patients with heart disease. J Cardiovasc </text>
<text top="293" left="125" width="133" height="12" font="4">Electrophysiol. 2004;15:52–8.</text>
<text top="306" left="74" width="355" height="12" font="4">  S12-3.  Mehdirad AA, Keim S, Rist K, et al. Long-term clinical outcome of </text>
<text top="320" left="125" width="303" height="12" font="4">right bundle branch radiofrequency catheter ablation for treatment </text>
<text top="334" left="125" width="306" height="12" font="4">of bundle branch reentrant ventricular tachycardia. Pacing Clin </text>
<text top="347" left="125" width="151" height="12" font="4">Electrophysiol. 1995;18:2135–43.</text>
<text top="361" left="74" width="351" height="12" font="4">  S12-4.  Dinov B, Fiedler L, Schonbauer R, et al. Outcomes in catheter abla-</text>
<text top="375" left="125" width="300" height="12" font="4">tion of ventricular tachycardia in dilated nonischemic cardiomy-</text>
<text top="388" left="125" width="304" height="12" font="4">opathy compared with ischemic cardiomyopathy: results from the </text>
<text top="402" left="125" width="303" height="12" font="4">Prospective Heart Centre of Leipzig VT (HELP-VT) study. Circulation. </text>
<text top="415" left="125" width="84" height="12" font="4">2014;129:728–36.</text>
<text top="429" left="74" width="357" height="12" font="4">  S12-5.  Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of </text>
<text top="443" left="125" width="300" height="12" font="4">recurrent scar-related ventricular tachycardia using electroana-</text>
<text top="456" left="125" width="304" height="12" font="4">tomical mapping and irrigated ablation technology: results of the </text>
<text top="470" left="125" width="304" height="12" font="4">prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. </text>
<text top="484" left="125" width="72" height="12" font="4">2010;21:47–53.</text>
<text top="497" left="74" width="355" height="12" font="4">  S12-6.  Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of </text>
<text top="511" left="125" width="300" height="12" font="4">irrigated radiofrequency catheter ablation of sustained ventricu-</text>
<text top="525" left="125" width="305" height="12" font="4">lar tachycardia: post-approval THERMOCOOL VT trial. J Am Coll </text>
<text top="538" left="125" width="116" height="12" font="4">Cardiol. 2016;67:674–83.</text>
<text top="552" left="74" width="351" height="12" font="4">  S12-7.  Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic reso-</text>
<text top="566" left="125" width="303" height="12" font="4">nance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll </text>
<text top="579" left="125" width="122" height="12" font="4">Cardiol. 2006;48:1977–85.</text>
<text top="593" left="74" width="351" height="12" font="4">  S12-8.  Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced mag-</text>
<text top="607" left="125" width="303" height="12" font="4">netic resonance imaging in nonischemic cardiomyopathy: utility for </text>
<text top="620" left="125" width="303" height="12" font="4">identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. </text>
<text top="634" left="125" width="84" height="12" font="4">2009;53:1138–45.</text>
<text top="648" left="74" width="351" height="12" font="4">  S12-9. Roberts WC, Siegel RJ, McManus BM, Idiopathic dilated car-</text>
<text top="661" left="125" width="306" height="12" font="4">diomyopathy: analysis of 152 necropsy patients. Am J Cardiol. </text>
<text top="675" left="125" width="84" height="12" font="4">1987;60:1340–55.</text>
<text top="689" left="74" width="355" height="12" font="4">  S12-10.  Piers SR, Tao Q, van Huls van Taxis C.F.B, et al. Contrast-enhanced </text>
<text top="702" left="125" width="303" height="12" font="4">MRI-derived scar patterns and associated ventricular tachycardias in </text>
<text top="716" left="125" width="303" height="12" font="4">nonischemic cardiomyopathy: implications for the ablation strategy. </text>
<text top="730" left="125" width="205" height="12" font="4">Circ Arrhythm Electrophysiol. 2013;6:875–83.</text>
<text top="743" left="74" width="355" height="12" font="4">  S12-11.  Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular </text>
<text top="757" left="125" width="304" height="12" font="4">tachycardia ablation a multicenter safety study. J Am Coll Cardiol. </text>
<text top="771" left="125" width="84" height="12" font="4">2010;55:2366–72.</text>
<text top="784" left="74" width="354" height="12" font="4">  S12-12.  Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for </text>
<text top="798" left="125" width="302" height="12" font="4">ventricular tachycardia: a European multicenter study. Circ Arrhythm </text>
<text top="812" left="125" width="133" height="12" font="4">Electrophysiol. 2011;4:653–9.</text>
<text top="855" left="74" width="300" height="23" font="15"><b>13. POSTMORTEM EVALUATION  </b></text>
<text top="878" left="74" width="67" height="23" font="15"><b>OF SCD</b></text>
<text top="906" left="74" width="351" height="12" font="4">  S13-1.  Basso C, Burke M, Fornes P, et al. Guidelines for autopsy investiga-</text>
<text top="920" left="125" width="277" height="12" font="4">tion of sudden cardiac death. Virchows Arch. 2008;452:11–8.</text>
<text top="934" left="74" width="356" height="12" font="4">  S13-2.  de Noronha SV, Behr ER, Papadakis M, et al. The importance of </text>
<text top="947" left="125" width="303" height="12" font="4">specialist cardiac histopathological examination in the investigation </text>
<text top="961" left="125" width="280" height="12" font="4">of young sudden cardiac deaths. Europace. 2014;16:899–907.</text>
<text top="975" left="74" width="355" height="12" font="4">  S13-3.  Wilde AA, Behr ER. Genetic testing for inherited cardiac disease. </text>
<text top="988" left="125" width="203" height="12" font="4">Nature reviews. Cardiology. 2013;10:571–83.</text>
<text top="1002" left="74" width="356" height="12" font="4">  S13-4.  Tester DJ, Medeiros-Domingo A, Will ML, et al. Cardiac channel </text>
<text top="1016" left="125" width="300" height="12" font="4">molecular autopsy: insights from 173 consecutive cases of autopsy-</text>
<text top="1029" left="125" width="308" height="12" font="4">negative sudden unexplained death referred for postmortem </text>
<text top="1043" left="125" width="226" height="12" font="4">genetic testing. Mayo Clin. Proc. 2012;87:524–39.</text>
<text top="1057" left="74" width="351" height="12" font="4">  S13-5.  Tang Y, Stahl-Herz J, Sampson BA. Molecular diagnostics of cardio-</text>
<text top="1070" left="125" width="304" height="12" font="4">vascular diseases in sudden unexplained death. Cardiovasc Pathol. </text>
<text top="1084" left="125" width="61" height="12" font="4">2014;23:1–4.</text>
<text top="88" left="452" width="354" height="12" font="4">  S13-6.  Bagnall RD, Das KJ, Duflou J, et al. Exome analysis-based molecular </text>
<text top="102" left="503" width="303" height="12" font="4">autopsy in cases of sudden unexplained death in the young. Heart </text>
<text top="115" left="503" width="118" height="12" font="4">Rhythm. 2014;11:655–62.</text>
<text top="129" left="452" width="355" height="12" font="4">  S13-7.  Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of </text>
<text top="143" left="503" width="304" height="12" font="4">sudden cardiac death among children and young adults. N Engl J </text>
<text top="156" left="503" width="116" height="12" font="4">Med. 2016;374:2441–52.</text>
<text top="170" left="452" width="356" height="12" font="4">  S13-8.  Semsarian C, Ingles J. Molecular autopsy in victims of inherited </text>
<text top="183" left="503" width="191" height="12" font="4">arrhythmias. J Arrhythm. 2016;32:359–65.</text>
<text top="197" left="452" width="351" height="12" font="4">  S13-9.  Vassalini M, Verzeletti A, Restori M, et al. An autopsy study of sud-</text>
<text top="210" left="503" width="304" height="12" font="4">den cardiac death in persons aged 1–40 years in Brescia (Italy). J </text>
<text top="224" left="503" width="156" height="12" font="4">Cardiovasc Med. 2016;17:446–53.</text>
<text top="238" left="452" width="357" height="12" font="4">  S13-10.  Wu Q, Zhang L, Zheng J, et al. Forensic pathological study of </text>
<text top="251" left="503" width="304" height="12" font="4">1656 cases of sudden cardiac death in southern. China Medicine. </text>
<text top="265" left="503" width="72" height="12" font="4">2016;95:e2707.</text>
<text top="278" left="452" width="356" height="12" font="4">  S13-11.  Giudici V, Spanaki A, Hendry J, et al. Sudden arrhythmic death </text>
<text top="292" left="503" width="300" height="12" font="4">syndrome: diagnostic yield of comprehensive clinical evalua-</text>
<text top="306" left="503" width="305" height="12" font="4">tion of pediatric first-degree relatives. Pacing Clin Electrophysiol. </text>
<text top="319" left="503" width="78" height="12" font="4">2014;37:1681–5.</text>
<text top="333" left="452" width="351" height="12" font="4">  S13-12.  Steinberg C, Padfield GJ, Champagne J, et al. Cardiac abnormali-</text>
<text top="346" left="503" width="305" height="12" font="4">ties in first-degree relatives of unexplained cardiac arrest victims: </text>
<text top="360" left="503" width="304" height="12" font="4">a report from the Cardiac Arrest Survivors With Preserved Ejection </text>
<text top="373" left="503" width="289" height="12" font="4">Fraction Registry. Circ Arrhythm Electrophysiol. 2016;9:e004274.</text>
<text top="387" left="452" width="351" height="12" font="4">  S13-13.  Wong LC, Roses-Noguer F, Till JA, et al. Cardiac evaluation of pedi-</text>
<text top="401" left="503" width="305" height="12" font="4">atric relatives in sudden arrhythmic death syndrome: a 2-center </text>
<text top="414" left="503" width="253" height="12" font="4">experience. Circ Arrhythm Electrophysiol. 2014;7:800–6.</text>
<text top="428" left="452" width="353" height="12" font="4">  S13-14.  van der Werf C, Stiekema L, Tan HL, et al. Low rate of cardiac events </text>
<text top="441" left="503" width="300" height="12" font="4">in first-degree relatives of diagnosis-negative young sudden unex-</text>
<text top="455" left="503" width="304" height="12" font="4">plained death syndrome victims during follow-up. Heart Rhythm. </text>
<text top="468" left="503" width="84" height="12" font="4">2014;11:1728–32.</text>
<text top="482" left="452" width="356" height="12" font="4">  S13-15.  Papadakis M, Raju H, Behr ER, et al. Sudden cardiac death with </text>
<text top="496" left="503" width="304" height="12" font="4">autopsy findings of uncertain significance: potential for erroneous </text>
<text top="509" left="503" width="272" height="12" font="4">interpretation. Circ Arrhythm Electrophysiol. 2013;6:588–96.</text>
<text top="523" left="452" width="351" height="12" font="4">  S13-16.  Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert con-</text>
<text top="536" left="503" width="305" height="12" font="4">sensus statement on the diagnosis and management of patients </text>
<text top="550" left="503" width="308" height="12" font="4">with inherited primary arrhythmia syndromes. Heart Rhythm. </text>
<text top="563" left="503" width="84" height="12" font="4">2013;10:1932–63.</text>
<text top="608" left="452" width="182" height="23" font="15"><b>14. TERMINAL CARE</b></text>
<text top="636" left="452" width="351" height="12" font="4">  S14-1.  Berger JT, Gorski M, Cohen T. Advance health planning and treat-</text>
<text top="649" left="503" width="306" height="12" font="4">ment preferences among recipients of implantable cardioverter </text>
<text top="663" left="503" width="282" height="12" font="4">defibrillators: an exploratory study. J Clin Ethics. 2006;17:72–8.</text>
<text top="677" left="452" width="351" height="12" font="4">  S14-2.  Lewis KB, Stacey D, Matlock DD. Making decisions about implant-</text>
<text top="690" left="503" width="304" height="12" font="4">able cardioverter-defibrillators from implantation to end of life: an </text>
<text top="704" left="503" width="300" height="12" font="4">integrative review of patients’ perspectives. Patient. 2014;7:243–60.</text>
<text top="717" left="452" width="351" height="12" font="4">  S14-3.  Hill L, McIlfatrick S, Taylor B, et al. Patients’ perception of implant-</text>
<text top="731" left="503" width="303" height="12" font="4">able cardioverter defibrillator deactivation at the end of life. Palliat </text>
<text top="744" left="503" width="104" height="12" font="4">Med. 2015;29:310–23.</text>
<text top="758" left="452" width="351" height="12" font="4">  S14-4.  Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physi-</text>
<text top="772" left="503" width="303" height="12" font="4">cian communication, and the implantable cardioverter-defibrillator. </text>
<text top="785" left="503" width="164" height="12" font="4">JAMA Intern Med. 2013;173:571–7.</text>
<text top="799" left="452" width="351" height="12" font="4">  S14-5.  Matlock DD, Nowels CT, Masoudi FA, et al. Patient and cardiolo-</text>
<text top="812" left="503" width="300" height="12" font="4">gist perceptions on decision making for implantable cardioverter-</text>
<text top="826" left="503" width="309" height="12" font="4">defibrillators: a qualitative study. Pacing Clin Electrophysiol. </text>
<text top="839" left="503" width="78" height="12" font="4">2011;34:1634–4.</text>
<text top="853" left="452" width="351" height="12" font="4">  S14-6.  Buchhalter LC, Ottenberg AL, Webster TL, et al. Features and out-</text>
<text top="867" left="503" width="306" height="12" font="4">comes of patients who underwent cardiac device deactivation. </text>
<text top="880" left="503" width="158" height="12" font="4">JAMA Intern Med. 2014;174:80–5.</text>
<text top="894" left="452" width="356" height="12" font="4">  S14-7.  Dodson JA, Fried TR, Van Ness PH, et al. Patient preferences for </text>
<text top="907" left="503" width="303" height="12" font="4">deactivation of implantable cardioverter-defibrillators. JAMA Intern </text>
<text top="921" left="503" width="104" height="12" font="4">Med. 2013;173:377–9.</text>
<text top="934" left="452" width="351" height="12" font="4">  S14-8.  Goldstein NE, Lampert R, Bradley E, et al. Management of implant-</text>
<text top="948" left="503" width="304" height="12" font="4">able cardioverter defibrillators in end-of-life care. Ann Intern Med. </text>
<text top="962" left="503" width="78" height="12" font="4">2004;141:835–8.</text>
<text top="975" left="452" width="351" height="12" font="4">  S14-9.  Goldstein N, Carlson M, Livote E, et al. Brief communication: man-</text>
<text top="989" left="503" width="306" height="12" font="4">agement of implantable cardioverter-defibrillators in hospice: a </text>
<text top="1002" left="503" width="241" height="12" font="4">nationwide survey. Ann Intern Med. 2010;152:296–9.</text>
<text top="1016" left="452" width="351" height="12" font="4">  S14-10.  Kirkpatrick JN, Gottlieb M, Sehgal P, et al. Deactivation of implant-</text>
<text top="1030" left="503" width="302" height="12" font="4">able cardioverter defibrillators in terminal illness and end of life care. </text>
<text top="1043" left="503" width="135" height="12" font="4">Am J Cardiol. 2012;109:91–4.</text>
<text top="1057" left="452" width="351" height="12" font="4">  S14-11.  Kelley AS, Reid MC, Miller DH, et al. Implantable cardioverter-defi-</text>
<text top="1070" left="503" width="303" height="12" font="4">brillator deactivation at the end of life: a physician survey. Am Heart </text>
<text top="1084" left="503" width="88" height="12" font="4">J. 2009;157:702–8.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="115" position="absolute" top="0" left="0" height="1174" width="877">
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e386</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="354" height="12" font="4">  S14-12.  Kramer DB, Kesselheim AS, Brock DW, et al. Ethical and legal views </text>
<text top="102" left="125" width="302" height="12" font="4">of physicians regarding deactivation of cardiac implantable electrical </text>
<text top="115" left="125" width="300" height="12" font="4">devices: a quantitative assessment. Heart Rhythm. 2010;7:1537–42.</text>
<text top="129" left="74" width="353" height="12" font="4">  S14-13.  Mueller PS, Jenkins SM, Bramstedt KA, et al. Deactivating implanted </text>
<text top="142" left="125" width="305" height="12" font="4">cardiac devices in terminally ill patients: practices and attitudes. </text>
<text top="156" left="125" width="192" height="12" font="4">Pacing Clin Electrophysiol. 2008;31:560–8.</text>
<text top="200" left="74" width="287" height="23" font="15"><b>15. SHARED DECISION-MAKING</b></text>
<text top="228" left="74" width="359" height="12" font="4">  S15-1. Lewis KB, Stacey D, Matlock DD. Making decisions about </text>
<text top="241" left="125" width="305" height="12" font="4">implantable cardioverter-defibrillators from implantation to end </text>
<text top="255" left="125" width="305" height="12" font="4">of life: an integrative review of patients’ perspectives. Patient. </text>
<text top="268" left="125" width="74" height="12" font="4">2014;7:243–60.</text>
<text top="282" left="74" width="355" height="12" font="4">  S15-2.  Stewart GC, Weintraub JR, Pratibhu PP, et al. Patient expectations </text>
<text top="295" left="125" width="304" height="12" font="4">from implantable defibrillators to prevent death in heart failure. J </text>
<text top="309" left="125" width="123" height="12" font="4">Card Fail. 2010;16:106–13.</text>
<text top="322" left="74" width="351" height="12" font="4">  S15-3.  Hauptman PJ, Chibnall JT, Guild C, et al. Patient perceptions, physi-</text>
<text top="336" left="125" width="303" height="12" font="4">cian communication, and the implantable cardioverter-defibrillator. </text>
<text top="349" left="125" width="164" height="12" font="4">JAMA Intern Med. 2013;173:571–7.</text>
<text top="363" left="74" width="354" height="12" font="4">  S15-4.  Ottenberg AL, Mueller PS, Topazian RJ, et al. ”It’s not broke, so let’s </text>
<text top="376" left="125" width="303" height="12" font="4">not try to fix it”: why patients decline a cardiovascular implantable </text>
<text top="390" left="125" width="283" height="12" font="4">electronic device. Pacing Clin Electrophysiol. 2014;37:1306–14.</text>
<text top="403" left="74" width="351" height="12" font="4">  S15-5.  Yuhas J, Mattocks K, Gravelin L, et al. Patients’ attitudes and per-</text>
<text top="417" left="125" width="300" height="12" font="4">ceptions of implantable cardioverter-defibrillators: potential barri-</text>
<text top="430" left="125" width="304" height="12" font="4">ers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. </text>
<text top="444" left="125" width="84" height="12" font="4">2012;35:1179–87.</text>
<text top="457" left="74" width="354" height="12" font="4">  S15-6.  Vig EK, Pearlman RA. Good and bad dying from the perspective of </text>
<text top="471" left="125" width="246" height="12" font="4">terminally ill men. Arch Intern Med. 2004;164:977–81.</text>
<text top="484" left="74" width="357" height="12" font="4">  S15-7.  Charles C, Gafni A, Whelan T. Shared decision-making in the </text>
<text top="498" left="125" width="303" height="12" font="4">medical encounter: what does it mean? (or it takes at least two to </text>
<text top="511" left="125" width="173" height="12" font="4">tango). Soc Sci Med. 1997;44:681–92.</text>
<text top="525" left="74" width="351" height="12" font="4">  S15-8.  Quill TE, Brody H. Physician recommendations and patient auton-</text>
<text top="538" left="125" width="306" height="12" font="4">omy: finding a balance between physician power and patient </text>
<text top="552" left="125" width="190" height="12" font="4">choice. Ann Intern Med. 1996;125:763–9.</text>
<text top="596" left="74" width="200" height="23" font="15"><b>16. COST AND VALUE </b></text>
<text top="618" left="74" width="163" height="23" font="15"><b>CONSIDERATIONS</b></text>
<text top="646" left="74" width="351" height="12" font="4">  S16-1.  Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state-</text>
<text top="660" left="125" width="306" height="12" font="4">ment on cost/value methodology in clinical practice guidelines </text>
<text top="673" left="125" width="304" height="12" font="4">and performance measures: a report of the American College of </text>
<text top="687" left="125" width="303" height="12" font="4">Cardiology/American Heart Association Task Force on Performance </text>
<text top="700" left="125" width="307" height="12" font="4">Measures and Task Force on Practice Guidelines. Circulation. </text>
<text top="714" left="125" width="90" height="12" font="4">2014;129:2329–45.</text>
<text top="727" left="74" width="356" height="12" font="4">  S16-2.  Sanders GD, Neumann PJ, Basu A, et al. Recommendations for </text>
<text top="741" left="125" width="300" height="12" font="4">conduct, methodological practices, and reporting of cost-effective-</text>
<text top="754" left="125" width="305" height="12" font="4">ness analyses: Second Panel on Cost-Effectiveness in Health and </text>
<text top="768" left="125" width="175" height="12" font="4">Medicine. JAMA. 2016;316:1093–103.</text>
<text top="781" left="74" width="356" height="12" font="4">  S16-3.  Mushlin AI, Hall J, Zwanziger J, et al. The cost-effectiveness of </text>
<text top="795" left="125" width="305" height="12" font="4">automatic implantable cardiac defibrillators. Results from MADIT. </text>
<text top="808" left="125" width="138" height="12" font="4">Circulation. 1998;97:2129–35.</text>
<text top="822" left="74" width="359" height="12" font="4">  S16-4. O’Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness </text>
<text top="835" left="125" width="308" height="12" font="4">of the implantable cardioverter-defibrillator. Results from the </text>
<text top="849" left="125" width="309" height="12" font="4">Canadian Implantable Defibrillator Study (CIDS). Circulation. </text>
<text top="862" left="125" width="90" height="12" font="4">2001;103:1416–21.</text>
<text top="876" left="74" width="354" height="12" font="4">  S16-5.  Larson G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the </text>
<text top="889" left="125" width="306" height="12" font="4">implantable cardioverter-defibrillator versus antiarrhythmic drugs </text>
<text top="903" left="125" width="304" height="12" font="4">in survivors of serious ventricular tachyarrhythmias. Results of the </text>
<text top="916" left="125" width="304" height="12" font="4">Antiarrhythmics Versus Implantable Defibrillators (AVID) Economic </text>
<text top="930" left="125" width="228" height="12" font="4">Analysis Substudy. Circulation. 2002;105:2049–57.</text>
<text top="943" left="74" width="356" height="12" font="4">  S16-6.  Zwanziger J, Hall WJ, Dick AW, et al. The cost-effectiveness of </text>
<text top="957" left="125" width="303" height="12" font="4">implantable cardioverter-defibrillators. Results from the Multicenter </text>
<text top="88" left="503" width="306" height="12" font="4">Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll </text>
<text top="102" left="503" width="116" height="12" font="4">Cardiol. 2006;47:2310–8.</text>
<text top="115" left="452" width="351" height="12" font="4">  S16-7.  Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defi-</text>
<text top="129" left="503" width="306" height="12" font="4">brillator therapy or amiodarone in chronic stable heart failure. </text>
<text top="142" left="503" width="300" height="12" font="4">Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-</text>
<text top="156" left="503" width="169" height="12" font="4">HeFT). Circulation. 2006;114:135–42.</text>
<text top="169" left="452" width="351" height="12" font="4">  S16-8.  Weiss JP, Saynina O, McDonald KM, et al. Effectiveness and cost-</text>
<text top="183" left="503" width="300" height="12" font="4">effectiveness of implantable cardioverter defibrillators in the treat-</text>
<text top="196" left="503" width="303" height="12" font="4">ment of ventricular arrhythmias among Medicare beneficiaries. Am </text>
<text top="210" left="503" width="117" height="12" font="4">J Med. 2002;112:519–27.</text>
<text top="223" left="452" width="351" height="12" font="4">  S16-9.  Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and eco-</text>
<text top="237" left="503" width="308" height="12" font="4">nomic implications of the Multicenter Automatic Defibrillator </text>
<text top="250" left="503" width="258" height="12" font="4">Implantation Trial-II. Ann Intern Med. 2005;142:593–600.</text>
<text top="264" left="452" width="355" height="12" font="4">  S16-10.  Buxton M, Caine N, Chase D, et al. A review of the evidence on the </text>
<text top="277" left="503" width="303" height="12" font="4">effects and costs of implantable cardioverter defibrillator therapy in </text>
<text top="291" left="503" width="304" height="12" font="4">different patient groups, and modelling of cost-effectiveness and </text>
<text top="304" left="503" width="303" height="12" font="4">cost-utility for these groups in a UK context. Health Technol Assess. </text>
<text top="318" left="503" width="122" height="12" font="4">2006;10:iii–iv, ix–xi, 1–164.</text>
<text top="331" left="452" width="351" height="12" font="4">  S16-11.  Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of implant-</text>
<text top="345" left="503" width="293" height="12" font="4">able cardioverter-defibrillators. N Engl J Med. 2005;353:1471–80.</text>
<text top="358" left="452" width="355" height="12" font="4">  S16-12.  Smith T, Jordaens L, Theuns D.A.M.J, et al. The cost-effectiveness </text>
<text top="372" left="503" width="303" height="12" font="4">of primary prophylactic implantable defibrillator therapy in patients </text>
<text top="385" left="503" width="302" height="12" font="4">with ischaemic or non-ischaemic heart disease: A European analysis. </text>
<text top="399" left="503" width="127" height="12" font="4">Eur Heart J. 2013;34:211–9.</text>
<text top="412" left="452" width="351" height="12" font="4">  S16-13.  Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effec-</text>
<text top="426" left="503" width="300" height="12" font="4">tiveness of prophylactic implantation of cardioverter defibril-</text>
<text top="439" left="503" width="306" height="12" font="4">lator in patients with reduced left ventricular systolic function: </text>
<text top="453" left="503" width="304" height="12" font="4">Results of Markov modelling in a European population. Europace. </text>
<text top="466" left="503" width="78" height="12" font="4">2008;11:716–26.</text>
<text top="480" left="452" width="357" height="12" font="4">  S16-14.  Goldenberg I, Moss AJ, Maron BJ, et al. Cost-effectiveness of </text>
<text top="493" left="503" width="306" height="12" font="4">implanted defibrillators in young people with inherited cardiac </text>
<text top="507" left="503" width="300" height="12" font="4">arrhythmias. Ann Noninvasive Electrocardiol. 2005;10 suppl:67–83.</text>
<text top="520" left="452" width="356" height="12" font="4">  S16-15.  Bigger JT, Prophylactic use of implanted cardiac defibrillators in </text>
<text top="534" left="503" width="302" height="12" font="4">patients at high risk for ventricular arrhythmias after coronary-artery </text>
<text top="547" left="503" width="249" height="12" font="4">bypass graft surgery. N Engl J Med. 1997;337:1569–75.</text>
<text top="561" left="452" width="356" height="12" font="4">  S16-16.  Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an </text>
<text top="574" left="503" width="300" height="12" font="4">implantable cardioverter-defibrillator after acute myocardial infarc-</text>
<text top="588" left="503" width="172" height="12" font="4">tion. N Engl J Med. 2004;351:2481–8.</text>
<text top="601" left="452" width="355" height="12" font="4">  S16-17.  Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation </text>
<text top="615" left="503" width="300" height="12" font="4">early after myocardial infarction. N Engl J Med. 2009;361:1427–36.</text>
<text top="628" left="452" width="355" height="12" font="4">  S16-18.  Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the </text>
<text top="642" left="503" width="305" height="12" font="4">implantable cardioverter defibrillator secondary prevention trials. </text>
<text top="655" left="503" width="132" height="12" font="4">Eur Heart J. 2000;21:2071–8.</text>
<text top="669" left="452" width="351" height="12" font="4">  S16-19.  Owens DK, Sanders GD, Heidenreich PA, et al. Effect of risk stratifi-</text>
<text top="682" left="503" width="300" height="12" font="4">cation on cost-effectiveness of the implantable cardioverter defibril-</text>
<text top="696" left="503" width="159" height="12" font="4">lator. Am Heart J. 2002;144:440–8.</text>
<text top="709" left="452" width="357" height="12" font="4">  S16-20.  Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: </text>
<text top="723" left="503" width="303" height="12" font="4">implantable cardioverter defibrillators for adults with left ventricular </text>
<text top="736" left="503" width="253" height="12" font="4">systolic dysfunction. Ann Intern Med. 2007;147:251–62.</text>
<text top="780" left="452" width="186" height="23" font="15"><b>17. QUALITY OF LIFE</b></text>
<text top="808" left="452" width="351" height="12" font="4">  S17-1.  Mark DB, Anstrom KJ, Sun JL, et al. Quality of life with defibril-</text>
<text top="822" left="503" width="307" height="12" font="4">lator therapy or amiodarone in heart failure. N Engl J Med. </text>
<text top="835" left="503" width="96" height="12" font="4">2008;359:999–1008.</text>
<text top="849" left="452" width="356" height="12" font="4">  S17-2.  Noyes K, Corona E, Veazie P, et al. Examination of the effect of </text>
<text top="862" left="503" width="305" height="12" font="4">implantable cardioverter-defibrillators on health-related quality of </text>
<text top="876" left="503" width="304" height="12" font="4">life: based on results from the Multicenter Automatic Defibrillator </text>
<text top="889" left="503" width="305" height="12" font="4">Trial-II. American journal of cardiovascular drugs: drugs, devices, </text>
<text top="903" left="503" width="188" height="12" font="4">and other interventions. 2009;9:393–400.</text>
<text top="916" left="452" width="351" height="12" font="4">  S17-3.  Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defi-</text>
<text top="930" left="503" width="300" height="12" font="4">brillators and quality of life: results from the defibrillators in non-</text>
<text top="943" left="503" width="305" height="12" font="4">ischemic cardiomyopathy treatment evaluation study. Archives of </text>
<text top="957" left="503" width="173" height="12" font="4">internal medicine. 2007;167:2226–32.</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="116" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="34" size="6" family="Times" color="#231f20"/>
	<fontspec id="35" size="6" family="Times" color="#231f20"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e387</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="60" height="12" font="3"><b>Appendix 1.</b></text>
<text top="88" left="134" width="661" height="12" font="22"><b>  Author Relationships With Industry and Other Entities (Relevant)—2017 AHA/ACC/HRS Guideline for Management of Patients With </b></text>
<text top="102" left="74" width="416" height="12" font="22"><b>Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (October 2017)</b></text>
<text top="148" left="85" width="45" height="10" font="34"><b>Committee </b></text>
<text top="160" left="85" width="33" height="10" font="34"><b>Member</b></text>
<text top="160" left="182" width="49" height="10" font="34"><b>Employment</b></text>
<text top="160" left="288" width="42" height="10" font="34"><b>Consultant</b></text>
<text top="148" left="370" width="37" height="10" font="34"><b>Speakers </b></text>
<text top="160" left="374" width="27" height="10" font="34"><b>Bureau</b></text>
<text top="137" left="427" width="46" height="10" font="34"><b>Ownership/</b></text>
<text top="148" left="426" width="48" height="10" font="34"><b>Partnership/</b></text>
<text top="160" left="434" width="33" height="10" font="34"><b>Principal</b></text>
<text top="160" left="488" width="70" height="10" font="34"><b>Personal Research</b></text>
<text top="126" left="579" width="52" height="10" font="34"><b>Institutional, </b></text>
<text top="137" left="574" width="62" height="10" font="34"><b>Organizational, </b></text>
<text top="148" left="569" width="72" height="10" font="34"><b>or Other Financial </b></text>
<text top="160" left="590" width="28" height="10" font="34"><b>Benefit</b></text>
<text top="148" left="658" width="28" height="10" font="34"><b>Expert </b></text>
<text top="160" left="656" width="31" height="10" font="34"><b>Witness</b></text>
<text top="148" left="714" width="75" height="10" font="34"><b>Voting Recusals by </b></text>
<text top="160" left="734" width="33" height="10" font="34"><b>Section*</b></text>
<text top="179" left="85" width="33" height="10" font="19">Sana M.  </text>
<text top="190" left="85" width="55" height="10" font="19">Al-Khatib, Chair</text>
<text top="179" left="167" width="81" height="10" font="19">Duke Clinical Research </text>
<text top="190" left="158" width="96" height="10" font="19">Institute; Duke University—</text>
<text top="201" left="168" width="76" height="10" font="19">Professor of Medicine</text>
<text top="179" left="300" width="19" height="10" font="19">None</text>
<text top="179" left="378" width="19" height="10" font="19">None</text>
<text top="179" left="441" width="19" height="10" font="19">None</text>
<text top="179" left="513" width="19" height="10" font="19">None</text>
<text top="179" left="595" width="19" height="10" font="19">None</text>
<text top="179" left="662" width="19" height="10" font="19">None</text>
<text top="179" left="741" width="19" height="10" font="19">None</text>
<text top="221" left="85" width="39" height="10" font="19">William G. </text>
<text top="232" left="85" width="57" height="10" font="19">Stevenson, Vice </text>
<text top="243" left="85" width="19" height="10" font="19">Chair</text>
<text top="221" left="155" width="104" height="10" font="19">Vanderbilt University Medical </text>
<text top="232" left="157" width="100" height="10" font="19">Center—Professor; Brigham </text>
<text top="243" left="163" width="87" height="10" font="19">and Women’s Hospital—</text>
<text top="254" left="154" width="104" height="10" font="19">Director of Clinical Cardiac EP</text>
<text top="221" left="268" width="11" height="9" font="19">•  </text>
<text top="221" left="275" width="57" height="10" font="19">St. Jude Medical</text>
<text top="221" left="360" width="11" height="9" font="19">•  </text>
<text top="221" left="367" width="27" height="10" font="19">Boston </text>
<text top="232" left="367" width="31" height="10" font="19">Scientific</text>
<text top="221" left="424" width="11" height="9" font="19">•  </text>
<text top="221" left="431" width="33" height="10" font="19">Biosense </text>
<text top="232" left="431" width="34" height="10" font="19">Webster‡</text>
<text top="221" left="513" width="19" height="10" font="19">None</text>
<text top="221" left="595" width="19" height="10" font="19">None</text>
<text top="221" left="662" width="19" height="10" font="19">None</text>
<text top="221" left="706" width="92" height="10" font="19">4.1, 4.2.2, 4.2.3, 5, 10.1, </text>
<text top="232" left="705" width="94" height="10" font="19">5.4, 5.6, 6, 7, 8, 9 (except </text>
<text top="243" left="730" width="41" height="10" font="19">9.7), 13, 15</text>
<text top="273" left="85" width="37" height="10" font="19">Michael J. </text>
<text top="285" left="85" width="36" height="10" font="19">Ackerman</text>
<text top="273" left="161" width="93" height="10" font="19">Mayo Clinic—Professor of </text>
<text top="285" left="162" width="90" height="10" font="19">Medicine, Pediatrics, and </text>
<text top="296" left="164" width="86" height="10" font="19">Pharmacology; Long QT </text>
<text top="307" left="163" width="88" height="10" font="19">Syndrome/Genetic Heart </text>
<text top="318" left="156" width="102" height="10" font="19">Rhythm Clinic and the Mayo </text>
<text top="330" left="159" width="97" height="10" font="19">Clinic Windland Smith Rice </text>
<text top="341" left="163" width="89" height="10" font="19">Sudden Death Genomics </text>
<text top="352" left="169" width="74" height="10" font="19">Laboratory—Director</text>
<text top="274" left="268" width="11" height="9" font="19">•  </text>
<text top="274" left="275" width="36" height="10" font="19">Audentes </text>
<text top="285" left="275" width="44" height="10" font="19">Therapeutics</text>
<text top="296" left="268" width="11" height="9" font="19">•  </text>
<text top="296" left="275" width="58" height="10" font="19">Boston Scientific</text>
<text top="308" left="268" width="11" height="9" font="19">•  </text>
<text top="307" left="275" width="54" height="10" font="19">Gilead Sciences</text>
<text top="319" left="268" width="11" height="9" font="19">•  </text>
<text top="319" left="275" width="23" height="10" font="19">Invitae</text>
<text top="330" left="268" width="11" height="9" font="19">•  </text>
<text top="330" left="275" width="36" height="10" font="19">Medtronic</text>
<text top="341" left="268" width="11" height="9" font="19">•  </text>
<text top="341" left="275" width="38" height="10" font="19">MyoKardia</text>
<text top="353" left="268" width="11" height="9" font="19">•  </text>
<text top="353" left="275" width="57" height="10" font="19">St. Jude Medical</text>
<text top="273" left="378" width="19" height="10" font="19">None</text>
<text top="273" left="441" width="19" height="10" font="19">None</text>
<text top="273" left="513" width="19" height="10" font="19">None</text>
<text top="274" left="569" width="11" height="9" font="19">•  </text>
<text top="274" left="576" width="51" height="10" font="19">Transgenomic </text>
<text top="285" left="576" width="39" height="10" font="19">(Familion)†</text>
<text top="296" left="569" width="11" height="9" font="19">•  </text>
<text top="296" left="576" width="55" height="10" font="19">Blue Ox Health </text>
<text top="308" left="576" width="47" height="10" font="19">Corporation‡</text>
<text top="319" left="569" width="11" height="9" font="19">•  </text>
<text top="319" left="576" width="34" height="10" font="19">AliveCor‡</text>
<text top="330" left="569" width="11" height="9" font="19">•  </text>
<text top="330" left="576" width="39" height="10" font="19">StemoniX‡</text>
<text top="274" left="662" width="19" height="10" font="19">None</text>
<text top="274" left="704" width="96" height="10" font="19">4.1, 4.2.2, 4.2.3, 5 (except </text>
<text top="285" left="704" width="96" height="10" font="19">5.1.5.2, 5.5), 6, 7, 8, 9, 10 </text>
<text top="296" left="708" width="85" height="10" font="19">(except 10.2) 11, 13, 15</text>
<text top="372" left="85" width="58" height="10" font="19">William J. Bryant</text>
<text top="372" left="167" width="78" height="10" font="19">Dominick Feld Hyde—</text>
<text top="383" left="178" width="57" height="10" font="19">Attorney at Law</text>
<text top="372" left="300" width="19" height="10" font="19">None</text>
<text top="372" left="378" width="19" height="10" font="19">None</text>
<text top="372" left="441" width="19" height="10" font="19">None</text>
<text top="372" left="513" width="19" height="10" font="19">None</text>
<text top="372" left="595" width="19" height="10" font="19">None</text>
<text top="372" left="662" width="19" height="10" font="19">None</text>
<text top="372" left="741" width="19" height="10" font="19">None</text>
<text top="402" left="85" width="55" height="10" font="19">David J. Callans</text>
<text top="402" left="161" width="93" height="10" font="19">University of Pennsylvania </text>
<text top="413" left="156" width="102" height="10" font="19">Health System—Professor of </text>
<text top="424" left="156" width="102" height="10" font="19">Medicine; Associate Director </text>
<text top="436" left="197" width="18" height="10" font="19">of EP</text>
<text top="402" left="268" width="11" height="9" font="19">•  </text>
<text top="402" left="275" width="66" height="10" font="19">Biosense Webster†</text>
<text top="414" left="268" width="11" height="9" font="19">•  </text>
<text top="413" left="275" width="31" height="10" font="19">Biotronik</text>
<text top="425" left="268" width="11" height="9" font="19">•  </text>
<text top="425" left="275" width="62" height="10" font="19">Boston Scientific†</text>
<text top="436" left="268" width="11" height="9" font="19">•  </text>
<text top="436" left="275" width="36" height="10" font="19">Medtronic</text>
<text top="447" left="268" width="11" height="9" font="19">•  </text>
<text top="447" left="275" width="57" height="10" font="19">St. Jude Medical</text>
<text top="402" left="378" width="19" height="10" font="19">None</text>
<text top="402" left="441" width="19" height="10" font="19">None</text>
<text top="402" left="485" width="11" height="9" font="19">•  </text>
<text top="402" left="492" width="64" height="10" font="19">Biosense Webster </text>
<text top="413" left="492" width="15" height="10" font="19">(PI)‡</text>
<text top="425" left="485" width="11" height="9" font="19">•  </text>
<text top="425" left="492" width="55" height="10" font="19">Endosense (PI)‡</text>
<text top="402" left="569" width="11" height="9" font="19">•  </text>
<text top="402" left="576" width="24" height="10" font="19">Acutus</text>
<text top="402" left="662" width="19" height="10" font="19">None</text>
<text top="402" left="713" width="78" height="10" font="19">4.1, 4.2.2, 4.2.3, 5.3, </text>
<text top="413" left="707" width="89" height="10" font="19">5.4, 5.5.1, 5.6, 6, 7, 8, 9 </text>
<text top="424" left="709" width="85" height="10" font="19">(expect 9.7), 10 (except </text>
<text top="436" left="728" width="46" height="10" font="19">10.3), 13, 15</text>
<text top="466" left="85" width="51" height="10" font="19">Anne B. Curtis</text>
<text top="466" left="157" width="101" height="10" font="19">University at Buffalo—SUNY </text>
<text top="478" left="164" width="86" height="10" font="19">Distinguished Professor; </text>
<text top="489" left="164" width="87" height="10" font="19">Charles and Mary Bauer </text>
<text top="500" left="172" width="69" height="10" font="19">Professor and Chair</text>
<text top="467" left="268" width="11" height="9" font="19">•  </text>
<text top="467" left="275" width="36" height="10" font="19">Medtronic</text>
<text top="478" left="268" width="11" height="9" font="19">•  </text>
<text top="478" left="275" width="57" height="10" font="19">St. Jude Medical</text>
<text top="466" left="378" width="19" height="10" font="19">None</text>
<text top="466" left="441" width="19" height="10" font="19">None</text>
<text top="466" left="513" width="19" height="10" font="19">None</text>
<text top="466" left="595" width="19" height="10" font="19">None</text>
<text top="466" left="662" width="19" height="10" font="19">None</text>
<text top="466" left="709" width="85" height="10" font="19">4.1, 4.2.2, 4.2.3, 5.1.1, </text>
<text top="478" left="709" width="85" height="10" font="19">5.1.2, 5.1.3, 5.1.4, 5.2, </text>
<text top="489" left="711" width="83" height="10" font="19">5.4, 5.6, 6, 7, 8, 9, 10, </text>
<text top="500" left="732" width="37" height="10" font="19">12, 13, 15</text>
<text top="519" left="85" width="52" height="10" font="19">Barbara J. Deal</text>
<text top="519" left="156" width="103" height="10" font="19">Getz Professor of Cardiology </text>
<text top="530" left="156" width="102" height="10" font="19">Feinberg School of Medicine </text>
<text top="542" left="164" width="84" height="10" font="19">Northwestern University</text>
<text top="519" left="300" width="19" height="10" font="19">None</text>
<text top="519" left="378" width="19" height="10" font="19">None</text>
<text top="519" left="441" width="19" height="10" font="19">None</text>
<text top="519" left="513" width="19" height="10" font="19">None</text>
<text top="519" left="595" width="19" height="10" font="19">None</text>
<text top="519" left="662" width="19" height="10" font="19">None</text>
<text top="519" left="741" width="19" height="10" font="19">None</text>
<text top="561" left="85" width="51" height="10" font="19">Timm Dickfeld</text>
<text top="561" left="163" width="87" height="10" font="19">University of Maryland—</text>
<text top="572" left="168" width="79" height="10" font="19">Associate Professor of </text>
<text top="583" left="190" width="32" height="10" font="19">Medicine</text>
<text top="561" left="268" width="11" height="9" font="19">•  </text>
<text top="561" left="275" width="30" height="10" font="19">Biosense</text>
<text top="572" left="268" width="11" height="9" font="19">•  </text>
<text top="572" left="275" width="57" height="10" font="19">St. Jude Medical</text>
<text top="584" left="268" width="11" height="9" font="19">•  </text>
<text top="584" left="275" width="29" height="10" font="19">Siemens</text>
<text top="561" left="378" width="19" height="10" font="19">None</text>
<text top="561" left="441" width="19" height="10" font="19">None</text>
<text top="561" left="485" width="11" height="9" font="19">•  </text>
<text top="561" left="492" width="35" height="10" font="19">Biosense†</text>
<text top="572" left="485" width="11" height="9" font="19">•  </text>
<text top="572" left="492" width="59" height="10" font="19">General Electric†</text>
<text top="561" left="569" width="11" height="9" font="19">•  </text>
<text top="561" left="576" width="29" height="10" font="19">Impulse </text>
<text top="572" left="576" width="38" height="10" font="19">Dynamics‡</text>
<text top="584" left="569" width="11" height="9" font="19">•  </text>
<text top="584" left="576" width="33" height="10" font="19">Siemens†</text>
<text top="561" left="662" width="19" height="10" font="19">None</text>
<text top="561" left="711" width="83" height="10" font="19">4.1, 4.2 (except 4.2.6), </text>
<text top="572" left="706" width="92" height="10" font="19">4.3, 5.3, 5.4, 5.6, 6, 7, 8, </text>
<text top="583" left="708" width="87" height="10" font="19">9 (except 9.7), 10.1, 11, </text>
<text top="595" left="739" width="23" height="10" font="19">13, 15</text>
<text top="614" left="85" width="50" height="10" font="19">Anne M. Gillis</text>
<text top="614" left="166" width="81" height="10" font="19">University of Calgary—</text>
<text top="625" left="168" width="76" height="10" font="19">Professor of Medicine</text>
<text top="614" left="300" width="19" height="10" font="19">None</text>
<text top="614" left="378" width="19" height="10" font="19">None</text>
<text top="614" left="441" width="19" height="10" font="19">None</text>
<text top="614" left="485" width="11" height="9" font="19">•  </text>
<text top="614" left="492" width="36" height="10" font="19">Medtronic</text>
<text top="614" left="594" width="19" height="10" font="19">None</text>
<text top="614" left="662" width="19" height="10" font="19">None</text>
<text top="614" left="709" width="85" height="10" font="19">4.2, 5.2.2, 5.3.2, 6.4.1, </text>
<text top="625" left="708" width="87" height="10" font="19">6.4.2, 6.4.4, 6.5, 6.7, 7, </text>
<text top="636" left="705" width="94" height="10" font="19">8, 9, 10, 11 (except 11.7), </text>
<text top="647" left="739" width="23" height="10" font="19">13, 15</text>
<text top="667" left="85" width="53" height="10" font="19">Christopher B. </text>
<text top="678" left="85" width="29" height="10" font="19">Granger</text>
<text top="667" left="167" width="81" height="10" font="19">Duke Clinical Research </text>
<text top="678" left="158" width="96" height="10" font="19">Institute; Duke University—</text>
<text top="689" left="167" width="81" height="10" font="19">Professor of Medicine; </text>
<text top="700" left="159" width="94" height="10" font="19">Director, Cardiac Care Unit</text>
<text top="667" left="268" width="11" height="9" font="19">•  </text>
<text top="667" left="275" width="48" height="10" font="19">AstraZeneca†</text>
<text top="678" left="268" width="11" height="9" font="19">•  </text>
<text top="678" left="275" width="59" height="10" font="19">Gilead Sciences†</text>
<text top="689" left="268" width="11" height="9" font="19">•  </text>
<text top="689" left="275" width="62" height="10" font="19">GlaxoSmithKline†</text>
<text top="701" left="268" width="11" height="9" font="19">•  </text>
<text top="701" left="275" width="29" height="10" font="19">Janssen </text>
<text top="712" left="275" width="61" height="10" font="19">Pharmaceuticals†</text>
<text top="723" left="268" width="11" height="9" font="19">•  </text>
<text top="723" left="275" width="41" height="10" font="19">Medtronic†</text>
<text top="734" left="268" width="11" height="9" font="19">•  </text>
<text top="734" left="275" width="24" height="10" font="19">Pfizer†</text>
<text top="746" left="268" width="11" height="9" font="19">•  </text>
<text top="746" left="275" width="54" height="10" font="19">Sanofi-aventis†</text>
<text top="667" left="378" width="19" height="10" font="19">None</text>
<text top="667" left="441" width="19" height="10" font="19">None</text>
<text top="667" left="485" width="11" height="9" font="19">•  </text>
<text top="667" left="492" width="48" height="10" font="19">AstraZeneca†</text>
<text top="678" left="485" width="11" height="9" font="19">•  </text>
<text top="678" left="492" width="58" height="10" font="19">GlaxoSmithKline</text>
<text top="689" left="485" width="11" height="9" font="19">•  </text>
<text top="689" left="492" width="29" height="10" font="19">Janssen </text>
<text top="701" left="492" width="61" height="10" font="19">Pharmaceuticals†</text>
<text top="712" left="485" width="11" height="9" font="19">•  </text>
<text top="712" left="492" width="41" height="10" font="19">Medtronic†</text>
<text top="723" left="485" width="11" height="9" font="19">•  </text>
<text top="723" left="492" width="19" height="10" font="19">Pfizer</text>
<text top="734" left="485" width="11" height="9" font="19">•  </text>
<text top="734" left="492" width="54" height="10" font="19">Sanofi-aventis†</text>
<text top="667" left="569" width="11" height="9" font="19">•  </text>
<text top="667" left="576" width="54" height="10" font="19">GE Healthcare†</text>
<text top="678" left="569" width="11" height="9" font="19">•  </text>
<text top="678" left="576" width="41" height="10" font="19">Medtronic†</text>
<text top="689" left="569" width="11" height="9" font="19">•  </text>
<text top="689" left="576" width="52" height="10" font="19">ZOLL Medical†</text>
<text top="701" left="569" width="11" height="9" font="19">•  </text>
<text top="701" left="576" width="39" height="10" font="19">Spacelabs†</text>
<text top="712" left="569" width="11" height="9" font="19">•  </text>
<text top="712" left="576" width="28" height="10" font="19">Phillips†</text>
<text top="667" left="662" width="19" height="10" font="19">None</text>
<text top="667" left="706" width="92" height="10" font="19">4, 5.1 (except 5.1.5), 5.2, </text>
<text top="678" left="709" width="85" height="10" font="19">5.3, 5.4, 5.6, 6, 7, 8, 9, </text>
<text top="689" left="732" width="37" height="10" font="19">12, 13, 15</text>
<text top="765" left="85" width="41" height="10" font="19">Stephen C. </text>
<text top="776" left="85" width="29" height="10" font="19">Hammill</text>
<text top="765" left="166" width="84" height="10" font="19">Mayo Clinic—Professor </text>
<text top="776" left="169" width="74" height="10" font="19">Emeritus of Medicine</text>
<text top="765" left="300" width="19" height="10" font="19">None</text>
<text top="765" left="378" width="19" height="10" font="19">None</text>
<text top="765" left="441" width="19" height="10" font="19">None</text>
<text top="765" left="513" width="19" height="10" font="19">None</text>
<text top="765" left="594" width="19" height="10" font="19">None</text>
<text top="765" left="662" width="19" height="10" font="19">None</text>
<text top="765" left="741" width="19" height="10" font="19">None</text>
<text top="795" left="85" width="53" height="10" font="19">Mark A. Hlatky</text>
<text top="795" left="160" width="94" height="10" font="19">Stanford University School </text>
<text top="806" left="160" width="94" height="10" font="19">of Medicine—Professor of </text>
<text top="818" left="159" width="98" height="10" font="19">Health and Research Policy, </text>
<text top="829" left="168" width="79" height="10" font="19">and of Cardiovascular </text>
<text top="840" left="190" width="32" height="10" font="19">Medicine</text>
<text top="795" left="300" width="19" height="10" font="19">None</text>
<text top="795" left="378" width="19" height="10" font="19">None</text>
<text top="795" left="441" width="19" height="10" font="19">None</text>
<text top="795" left="513" width="19" height="10" font="19">None</text>
<text top="795" left="594" width="19" height="10" font="19">None</text>
<text top="795" left="662" width="19" height="10" font="19">None</text>
<text top="795" left="741" width="19" height="10" font="19">None</text>
<text top="859" left="85" width="47" height="10" font="19">José A. Joglar</text>
<text top="859" left="161" width="93" height="10" font="19">UT Southwestern Medical </text>
<text top="870" left="155" width="105" height="10" font="19">Center—Professor of Internal </text>
<text top="882" left="161" width="93" height="10" font="19">Medicine; Clinical Cardiac </text>
<text top="893" left="164" width="87" height="10" font="19">EP—Fellowship Program </text>
<text top="904" left="192" width="28" height="10" font="19">Director</text>
<text top="859" left="300" width="19" height="10" font="19">None</text>
<text top="859" left="378" width="19" height="10" font="19">None</text>
<text top="859" left="441" width="19" height="10" font="19">None</text>
<text top="859" left="513" width="19" height="10" font="19">None</text>
<text top="859" left="594" width="19" height="10" font="19">None</text>
<text top="859" left="662" width="19" height="10" font="19">None</text>
<text top="859" left="741" width="19" height="10" font="19">None</text>
<text top="923" left="85" width="41" height="10" font="19">G. Neal Kay</text>
<text top="923" left="163" width="88" height="10" font="19">University of Alabama at </text>
<text top="934" left="165" width="85" height="10" font="19">Birmingham—Professor </text>
<text top="946" left="191" width="30" height="10" font="19">Emeritus</text>
<text top="923" left="300" width="19" height="10" font="19">None</text>
<text top="923" left="378" width="19" height="10" font="19">None</text>
<text top="923" left="441" width="19" height="10" font="19">None</text>
<text top="923" left="513" width="19" height="10" font="19">None</text>
<text top="923" left="594" width="19" height="10" font="19">None</text>
<text top="923" left="662" width="19" height="10" font="19">None</text>
<text top="923" left="741" width="19" height="10" font="19">None</text>
<text top="965" left="85" width="55" height="10" font="19">Michael E. Field</text>
<text top="965" left="166" width="84" height="10" font="19">University of Wisconsin </text>
<text top="976" left="165" width="85" height="10" font="19">School of Medicine and </text>
<text top="987" left="164" width="86" height="10" font="19">Public Health—Director, </text>
<text top="999" left="166" width="82" height="10" font="19">Clinical EP and Cardiac </text>
<text top="1010" left="154" width="106" height="10" font="19">Arrhythmia Service, Associate </text>
<text top="1021" left="168" width="76" height="10" font="19">Professor of Medicine</text>
<text top="965" left="300" width="19" height="10" font="19">None</text>
<text top="965" left="378" width="19" height="10" font="19">None</text>
<text top="965" left="441" width="19" height="10" font="19">None</text>
<text top="965" left="513" width="19" height="10" font="19">None</text>
<text top="965" left="594" width="19" height="10" font="19">None</text>
<text top="965" left="662" width="19" height="10" font="19">None</text>
<text top="965" left="741" width="19" height="10" font="19">None</text>
<text top="1039" left="761" width="42" height="10" font="19">(<i>Continued</i> )</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="117" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e388</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="162" left="85" width="34" height="10" font="19">Gregg C. </text>
<text top="173" left="85" width="31" height="10" font="19">Fonarow</text>
<text top="162" left="176" width="63" height="10" font="19">Ahmanson-UCLA </text>
<text top="173" left="160" width="92" height="10" font="19">Cardiomyopathy Center—</text>
<text top="184" left="161" width="94" height="10" font="19">Director; UCLA Division of </text>
<text top="196" left="167" width="78" height="10" font="19">Cardiology—Co-Chief</text>
<text top="162" left="268" width="11" height="9" font="19">•  </text>
<text top="162" left="275" width="26" height="10" font="19">Amgen</text>
<text top="174" left="268" width="11" height="9" font="19">•  </text>
<text top="174" left="275" width="29" height="10" font="19">Janssen </text>
<text top="185" left="275" width="56" height="10" font="19">Pharmaceuticals</text>
<text top="196" left="268" width="11" height="9" font="19">•  </text>
<text top="196" left="275" width="36" height="10" font="19">Medtronic</text>
<text top="207" left="268" width="11" height="9" font="19">•  </text>
<text top="207" left="275" width="37" height="10" font="19">ZS Pharma</text>
<text top="162" left="378" width="19" height="10" font="19">None</text>
<text top="162" left="441" width="19" height="10" font="19">None</text>
<text top="162" left="485" width="11" height="9" font="19">•  </text>
<text top="162" left="492" width="40" height="10" font="19">Medtronic–</text>
<text top="174" left="492" width="47" height="10" font="19">IMPROVE-HF </text>
<text top="185" left="492" width="33" height="10" font="19">(Steering </text>
<text top="196" left="492" width="46" height="10" font="19">Committee)‡</text>
<text top="207" left="485" width="11" height="9" font="19">•  </text>
<text top="207" left="492" width="41" height="10" font="19">Medtronic†</text>
<text top="162" left="595" width="19" height="10" font="19">None</text>
<text top="162" left="662" width="19" height="10" font="19">None</text>
<text top="162" left="714" width="76" height="10" font="19">4.1, 4.2.2, 4.2.3, 5.1 </text>
<text top="173" left="706" width="92" height="10" font="19">(except 5.1.5.1), 5.2, 5.3, </text>
<text top="185" left="711" width="83" height="10" font="19">5.4, 5.6, 6, 7, 8, 9, 10, </text>
<text top="196" left="732" width="37" height="10" font="19">12, 13, 15</text>
<text top="226" left="85" width="34" height="10" font="19">Daniel D. </text>
<text top="238" left="85" width="28" height="10" font="19">Matlock</text>
<text top="226" left="154" width="106" height="10" font="19">University of Colorado School </text>
<text top="238" left="165" width="85" height="10" font="19">of Medicine—Associate </text>
<text top="249" left="168" width="76" height="10" font="19">Professor of Medicine</text>
<text top="226" left="300" width="19" height="10" font="19">None</text>
<text top="226" left="378" width="19" height="10" font="19">None</text>
<text top="226" left="441" width="19" height="10" font="19">None</text>
<text top="226" left="513" width="19" height="10" font="19">None</text>
<text top="226" left="595" width="19" height="10" font="19">None</text>
<text top="226" left="662" width="19" height="10" font="19">None</text>
<text top="226" left="741" width="19" height="10" font="19">None</text>
<text top="268" left="85" width="33" height="10" font="19">Robert J. </text>
<text top="279" left="85" width="34" height="10" font="19">Myerburg</text>
<text top="268" left="161" width="92" height="10" font="19">University of Miami Miller </text>
<text top="279" left="168" width="76" height="10" font="19">School of Medicine—</text>
<text top="290" left="160" width="94" height="10" font="19">Professor of Medicine and </text>
<text top="302" left="188" width="37" height="10" font="19">Physiology</text>
<text top="268" left="300" width="19" height="10" font="19">None</text>
<text top="268" left="378" width="19" height="10" font="19">None</text>
<text top="268" left="441" width="19" height="10" font="19">None</text>
<text top="268" left="513" width="19" height="10" font="19">None</text>
<text top="268" left="595" width="19" height="10" font="19">None</text>
<text top="268" left="662" width="19" height="10" font="19">None</text>
<text top="268" left="741" width="19" height="10" font="19">None</text>
<text top="321" left="85" width="53" height="10" font="19">Richard L. Page</text>
<text top="321" left="166" width="84" height="10" font="19">University of Wisconsin </text>
<text top="332" left="158" width="100" height="10" font="19">Hospital and Clinics—Chair, </text>
<text top="343" left="163" width="86" height="10" font="19">Department of Medicine</text>
<text top="321" left="300" width="19" height="10" font="19">None</text>
<text top="321" left="378" width="19" height="10" font="19">None</text>
<text top="321" left="441" width="19" height="10" font="19">None</text>
<text top="321" left="513" width="19" height="10" font="19">None</text>
<text top="321" left="594" width="19" height="10" font="19">None</text>
<text top="321" left="662" width="19" height="10" font="19">None</text>
<text top="321" left="741" width="19" height="10" font="19">None</text>
<text top="365" left="86" width="702" height="10" font="19">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in </text>
<text top="376" left="74" width="711" height="10" font="19">conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of </text>
<text top="388" left="74" width="724" height="10" font="19">publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair </text>
<text top="399" left="74" width="724" height="10" font="19">market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit </text>
<text top="410" left="74" width="393" height="10" font="19">are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.</text>
<text top="421" left="86" width="714" height="10" font="19">According to the ACC/AHA, a person has a <i>relevant</i> relationship IF: a) the <i>relationship or interest</i> relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the </text>
<text top="433" left="74" width="723" height="10" font="35"><i>document</i>; or b) the <i>company/entity</i> (with whom the relationship exists) makes a drug, drug class, or device addressed in the <i>document</i>, or makes a competing drug or device addressed in the <i>document</i>; or </text>
<text top="444" left="74" width="692" height="10" font="19">c) the <i>person or a member of the person’s household</i>, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the <i>document</i>.</text>
<text top="455" left="86" width="587" height="10" font="19">*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.</text>
<text top="466" left="86" width="86" height="10" font="19">†Significant relationship.</text>
<text top="478" left="86" width="76" height="10" font="19">‡No financial benefit.</text>
<text top="489" left="86" width="688" height="10" font="19">ACC indicates American College of Cardiology; AHA, American Heart Association; EP, Electrophysiology; HRS, Heart Rhythm Society; IMPROVE-HF, Improve the Use of Evidence-Based Heart Failure </text>
<text top="500" left="74" width="440" height="10" font="19">Therapies in the Outpatient Setting; PI, principal investigator; SUNY, State University of New York; and UT, University of Texas.</text>
<text top="88" left="74" width="62" height="12" font="3"><b>Appendix 1. </b></text>
<text top="88" left="144" width="51" height="12" font="22"><b>Continued</b></text>
<text top="132" left="85" width="45" height="10" font="34"><b>Committee </b></text>
<text top="143" left="85" width="33" height="10" font="34"><b>Member</b></text>
<text top="143" left="182" width="49" height="10" font="34"><b>Employment</b></text>
<text top="143" left="288" width="42" height="10" font="34"><b>Consultant</b></text>
<text top="132" left="370" width="37" height="10" font="34"><b>Speakers </b></text>
<text top="143" left="374" width="27" height="10" font="34"><b>Bureau</b></text>
<text top="121" left="427" width="46" height="10" font="34"><b>Ownership/</b></text>
<text top="132" left="426" width="48" height="10" font="34"><b>Partnership/</b></text>
<text top="143" left="434" width="33" height="10" font="34"><b>Principal</b></text>
<text top="143" left="488" width="70" height="10" font="34"><b>Personal Research</b></text>
<text top="109" left="579" width="52" height="10" font="34"><b>Institutional, </b></text>
<text top="121" left="574" width="62" height="10" font="34"><b>Organizational, </b></text>
<text top="132" left="569" width="72" height="10" font="34"><b>or Other Financial </b></text>
<text top="143" left="590" width="28" height="10" font="34"><b>Benefit</b></text>
<text top="132" left="658" width="28" height="10" font="34"><b>Expert </b></text>
<text top="143" left="656" width="31" height="10" font="34"><b>Witness</b></text>
<text top="132" left="714" width="75" height="10" font="34"><b>Voting Recusals by </b></text>
<text top="143" left="734" width="33" height="10" font="34"><b>Section*</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="118" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="36" size="5" family="Times" color="#231f20"/>
	<fontspec id="37" size="5" family="Times" color="#231f20"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e389</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="88" left="74" width="60" height="12" font="3"><b>Appendix 2.</b></text>
<text top="88" left="134" width="636" height="12" font="22"><b>  Reviewer Relationships With Industry and Other Entities (Comprehensive)—2017 AHA/ACC/HRS Guideline for Management of </b></text>
<text top="102" left="74" width="465" height="12" font="22"><b>Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (July 2017)</b></text>
<text top="157" left="85" width="33" height="9" font="36"><b>Reviewer</b></text>
<text top="157" left="136" width="54" height="9" font="36"><b>Representation</b></text>
<text top="157" left="220" width="45" height="9" font="36"><b>Employment</b></text>
<text top="157" left="312" width="38" height="9" font="36"><b>Consultant</b></text>
<text top="157" left="379" width="59" height="9" font="36"><b>Speakers Bureau</b></text>
<text top="136" left="459" width="42" height="9" font="36"><b>Ownership/</b></text>
<text top="147" left="458" width="43" height="9" font="36"><b>Partnership/</b></text>
<text top="157" left="464" width="30" height="9" font="36"><b>Principal</b></text>
<text top="157" left="524" width="63" height="9" font="36"><b>Personal Research</b></text>
<text top="126" left="611" width="47" height="9" font="36"><b>Institutional, </b></text>
<text top="136" left="606" width="57" height="9" font="36"><b>Organizational, </b></text>
<text top="147" left="602" width="65" height="9" font="36"><b>or Other Financial </b></text>
<text top="157" left="620" width="25" height="9" font="36"><b>Benefit</b></text>
<text top="157" left="694" width="22" height="9" font="36"><b>Salary</b></text>
<text top="157" left="745" width="53" height="9" font="36"><b>Expert Witness</b></text>
<text top="176" left="85" width="29" height="9" font="32">Alfred E. </text>
<text top="187" left="85" width="23" height="9" font="32">Buxton</text>
<text top="176" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="176" left="204" width="77" height="9" font="32">Professor of Medicine—</text>
<text top="187" left="201" width="83" height="9" font="32">Harvard Medical School—</text>
<text top="197" left="208" width="71" height="9" font="32">Beth Israel Deaconess </text>
<text top="208" left="218" width="49" height="9" font="32">Medical Center</text>
<text top="176" left="322" width="17" height="9" font="32">None</text>
<text top="176" left="400" width="17" height="9" font="32">None</text>
<text top="176" left="471" width="17" height="9" font="32">None</text>
<text top="177" left="520" width="10" height="8" font="32">•  </text>
<text top="177" left="526" width="49" height="9" font="32">NHLBI (DSMB)†</text>
<text top="177" left="599" width="10" height="8" font="32">•  </text>
<text top="177" left="606" width="37" height="9" font="32">Medtronic†</text>
<text top="191" left="599" width="10" height="8" font="32">•  </text>
<text top="190" left="606" width="60" height="9" font="32">Biosense Webster†</text>
<text top="176" left="697" width="17" height="9" font="32">None</text>
<text top="176" left="762" width="17" height="9" font="32">None</text>
<text top="226" left="85" width="35" height="9" font="32">Andrew E. </text>
<text top="237" left="85" width="23" height="9" font="32">Epstein</text>
<text top="226" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="226" left="224" width="40" height="9" font="32">Professor of </text>
<text top="237" left="201" width="85" height="9" font="32">Medicine—Cardiovascular </text>
<text top="247" left="209" width="68" height="9" font="32">Division University of </text>
<text top="258" left="206" width="76" height="9" font="32">Pennsylvania—Chief of </text>
<text top="268" left="209" width="67" height="9" font="32">Cardiology Section—</text>
<text top="279" left="204" width="79" height="9" font="32">Philadelphia VA Medical </text>
<text top="289" left="232" width="22" height="9" font="32">Center</text>
<text top="227" left="293" width="10" height="8" font="32">•  </text>
<text top="227" left="300" width="15" height="9" font="32">Zoll*</text>
<text top="226" left="400" width="17" height="9" font="32">None</text>
<text top="226" left="471" width="17" height="9" font="32">None</text>
<text top="227" left="520" width="10" height="8" font="32">•  </text>
<text top="227" left="526" width="33" height="9" font="32">Biotronik*</text>
<text top="241" left="520" width="10" height="8" font="32">•  </text>
<text top="240" left="526" width="57" height="9" font="32">Boston Scientific*</text>
<text top="255" left="520" width="10" height="8" font="32">•  </text>
<text top="254" left="526" width="55" height="9" font="32">Boston Scientific </text>
<text top="265" left="526" width="28" height="9" font="32">(DSMB)*</text>
<text top="279" left="520" width="10" height="8" font="32">•  </text>
<text top="279" left="526" width="37" height="9" font="32">Medtronic*</text>
<text top="293" left="520" width="10" height="8" font="32">•  </text>
<text top="293" left="526" width="59" height="9" font="32">Medtronic (DSMB)</text>
<text top="307" left="520" width="10" height="8" font="32">•  </text>
<text top="307" left="526" width="52" height="9" font="32">St Jude Medical/</text>
<text top="317" left="526" width="27" height="9" font="32">Abbott*</text>
<text top="331" left="520" width="10" height="8" font="32">•  </text>
<text top="331" left="526" width="52" height="9" font="32">St Jude Medical/</text>
<text top="342" left="526" width="53" height="9" font="32">Abbott (DSMB)*</text>
<text top="226" left="625" width="17" height="9" font="32">None</text>
<text top="226" left="697" width="17" height="9" font="32">None</text>
<text top="227" left="743" width="10" height="8" font="32">•  </text>
<text top="227" left="750" width="38" height="9" font="32">Defendant, </text>
<text top="237" left="750" width="42" height="9" font="32">Amiodarone </text>
<text top="248" left="750" width="36" height="9" font="32">pulmonary </text>
<text top="258" left="750" width="43" height="9" font="32">toxicity, 2016</text>
<text top="272" left="743" width="10" height="8" font="32">•  </text>
<text top="272" left="749" width="36" height="9" font="32">Defendant, </text>
<text top="282" left="749" width="51" height="9" font="32">Appropriateness </text>
<text top="293" left="749" width="46" height="9" font="32">of pacemaker </text>
<text top="303" left="749" width="45" height="9" font="32">implantation, </text>
<text top="314" left="749" width="21" height="9" font="32">2016*</text>
<text top="360" left="85" width="18" height="9" font="32">Brian </text>
<text top="371" left="85" width="32" height="9" font="32">Olshansky</text>
<text top="360" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="360" left="210" width="67" height="9" font="32">Adjunct Professor of </text>
<text top="371" left="206" width="76" height="9" font="32">Medicine—Des Moines </text>
<text top="381" left="209" width="69" height="9" font="32">University—Professor </text>
<text top="392" left="210" width="68" height="9" font="32">Emeritus—University </text>
<text top="402" left="230" width="24" height="9" font="32">of Iowa</text>
<text top="361" left="293" width="10" height="8" font="32">•  </text>
<text top="361" left="300" width="68" height="9" font="32">Boehringer Ingleheim</text>
<text top="375" left="293" width="10" height="8" font="32">•  </text>
<text top="374" left="300" width="46" height="9" font="32">Lundbeck Inc*</text>
<text top="389" left="293" width="10" height="8" font="32">•  </text>
<text top="388" left="300" width="43" height="9" font="32">On-X/Cryolife</text>
<text top="361" left="377" width="10" height="8" font="32">•  </text>
<text top="361" left="384" width="46" height="9" font="32">Lundbeck Inc*</text>
<text top="375" left="377" width="10" height="8" font="32">•  </text>
<text top="374" left="384" width="43" height="9" font="32">On-X/Cryolife</text>
<text top="360" left="471" width="17" height="9" font="32">None</text>
<text top="361" left="520" width="10" height="8" font="32">•  </text>
<text top="361" left="526" width="53" height="9" font="32">Amarin (DSMB)*</text>
<text top="360" left="625" width="17" height="9" font="32">None</text>
<text top="360" left="697" width="17" height="9" font="32">None</text>
<text top="361" left="743" width="10" height="8" font="32">•  </text>
<text top="361" left="750" width="46" height="9" font="32">Plaintiff, Long </text>
<text top="371" left="750" width="37" height="9" font="32">QT sudden </text>
<text top="382" left="750" width="39" height="9" font="32">death, 2017</text>
<text top="421" left="85" width="23" height="9" font="32">Bulent </text>
<text top="431" left="85" width="27" height="9" font="32">Gorenek</text>
<text top="421" left="150" width="28" height="9" font="32">Content </text>
<text top="431" left="137" width="53" height="9" font="32">Reviewer—ACC </text>
<text top="442" left="146" width="34" height="9" font="32">EP Council</text>
<text top="421" left="234" width="17" height="9" font="32">None</text>
<text top="421" left="322" width="17" height="9" font="32">None</text>
<text top="421" left="400" width="17" height="9" font="32">None</text>
<text top="421" left="471" width="17" height="9" font="32">None</text>
<text top="421" left="547" width="17" height="9" font="32">None</text>
<text top="421" left="625" width="17" height="9" font="32">None</text>
<text top="421" left="697" width="17" height="9" font="32">None</text>
<text top="421" left="769" width="2" height="9" font="32"> </text>
<text top="460" left="85" width="32" height="9" font="32">Charles I. </text>
<text top="471" left="85" width="16" height="9" font="32">Berul</text>
<text top="460" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="460" left="202" width="84" height="9" font="32">Division Chief of Pediatric </text>
<text top="471" left="206" width="75" height="9" font="32">Cardiology—Children’s </text>
<text top="481" left="204" width="78" height="9" font="32">National Medical Center</text>
<text top="460" left="322" width="17" height="9" font="32">None</text>
<text top="460" left="400" width="17" height="9" font="32">None</text>
<text top="460" left="471" width="17" height="9" font="32">None</text>
<text top="460" left="547" width="17" height="9" font="32">None</text>
<text top="461" left="599" width="10" height="8" font="32">•  </text>
<text top="461" left="606" width="39" height="9" font="32">Circulation*</text>
<text top="460" left="697" width="17" height="9" font="32">None</text>
<text top="460" left="762" width="17" height="9" font="32">None</text>
<text top="500" left="85" width="24" height="9" font="32">Darren </text>
<text top="510" left="85" width="26" height="9" font="32">Sudman</text>
<text top="500" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="500" left="210" width="64" height="9" font="32">Executive Director—</text>
<text top="510" left="221" width="42" height="9" font="32">Simon’s Fund</text>
<text top="500" left="322" width="17" height="9" font="32">None</text>
<text top="500" left="400" width="17" height="9" font="32">None</text>
<text top="500" left="471" width="17" height="9" font="32">None</text>
<text top="500" left="547" width="17" height="9" font="32">None</text>
<text top="500" left="625" width="17" height="9" font="32">None</text>
<text top="500" left="697" width="17" height="9" font="32">None</text>
<text top="500" left="763" width="17" height="9" font="32">None</text>
<text top="529" left="85" width="33" height="9" font="32">George J. </text>
<text top="539" left="85" width="16" height="9" font="32">Klein</text>
<text top="529" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="529" left="208" width="70" height="9" font="32">Chief of Cardiology—</text>
<text top="539" left="205" width="78" height="9" font="32">London Health Sciences </text>
<text top="550" left="232" width="22" height="9" font="32">Center</text>
<text top="529" left="293" width="10" height="8" font="32">•  </text>
<text top="529" left="300" width="29" height="9" font="32">Biotronik</text>
<text top="543" left="293" width="10" height="8" font="32">•  </text>
<text top="543" left="300" width="53" height="9" font="32">Boston Scientific</text>
<text top="557" left="293" width="10" height="8" font="32">•  </text>
<text top="557" left="300" width="37" height="9" font="32">Medtronic*</text>
<text top="529" left="400" width="17" height="9" font="32">None</text>
<text top="529" left="471" width="17" height="9" font="32">None</text>
<text top="529" left="547" width="17" height="9" font="32">None</text>
<text top="529" left="625" width="17" height="9" font="32">None</text>
<text top="529" left="697" width="17" height="9" font="32">None</text>
<text top="529" left="763" width="17" height="9" font="32">None</text>
<text top="576" left="85" width="30" height="9" font="32">Glenn N. </text>
<text top="586" left="85" width="20" height="9" font="32">Levine</text>
<text top="576" left="150" width="28" height="9" font="32">Content </text>
<text top="586" left="136" width="53" height="9" font="32">Reviewer—ACC/</text>
<text top="597" left="148" width="33" height="9" font="32">AHA Task </text>
<text top="607" left="149" width="29" height="9" font="32">Force on </text>
<text top="618" left="138" width="52" height="9" font="32">Clinical Practice </text>
<text top="628" left="146" width="33" height="9" font="32">Guidelines</text>
<text top="576" left="224" width="40" height="9" font="32">Professor of </text>
<text top="586" left="214" width="58" height="9" font="32">Medicine—Baylor </text>
<text top="597" left="210" width="66" height="9" font="32">College of Medicine </text>
<text top="607" left="206" width="76" height="9" font="32">Director—Cardiac Care </text>
<text top="618" left="201" width="85" height="9" font="32">Unit—Michael E. DeBakey </text>
<text top="628" left="218" width="49" height="9" font="32">Medical Center</text>
<text top="576" left="322" width="17" height="9" font="32">None</text>
<text top="576" left="400" width="17" height="9" font="32">None</text>
<text top="576" left="471" width="17" height="9" font="32">None</text>
<text top="576" left="547" width="17" height="9" font="32">None</text>
<text top="576" left="625" width="17" height="9" font="32">None</text>
<text top="576" left="697" width="17" height="9" font="32">None</text>
<text top="576" left="743" width="10" height="8" font="32">•  </text>
<text top="576" left="749" width="36" height="9" font="32">Defendant, </text>
<text top="586" left="749" width="49" height="9" font="32">Catheterization </text>
<text top="597" left="749" width="35" height="9" font="32">Laboratory </text>
<text top="607" left="749" width="34" height="9" font="32">Procedure, </text>
<text top="618" left="749" width="16" height="9" font="32">2016</text>
<text top="632" left="743" width="10" height="8" font="32">•  </text>
<text top="632" left="749" width="36" height="9" font="32">Defendant, </text>
<text top="642" left="749" width="47" height="9" font="32">Out of hospital </text>
<text top="653" left="749" width="37" height="9" font="32">death, 2016</text>
<text top="671" left="85" width="40" height="9" font="32">Gurusher S. </text>
<text top="682" left="85" width="26" height="9" font="32">Panjrath</text>
<text top="671" left="150" width="28" height="9" font="32">Content </text>
<text top="682" left="137" width="53" height="9" font="32">Reviewer—ACC </text>
<text top="692" left="143" width="42" height="9" font="32">Heart Failure </text>
<text top="703" left="140" width="49" height="9" font="32">and Transplant </text>
<text top="713" left="151" width="24" height="9" font="32">Council</text>
<text top="671" left="209" width="70" height="9" font="32">Director Heart Failure </text>
<text top="682" left="204" width="80" height="9" font="32">and Mechanical Support </text>
<text top="692" left="213" width="60" height="9" font="32">Program—George </text>
<text top="703" left="207" width="71" height="9" font="32">Washington University</text>
<text top="672" left="293" width="10" height="8" font="32">•  </text>
<text top="671" left="300" width="41" height="9" font="32">Amgen Inc.*</text>
<text top="671" left="400" width="17" height="9" font="32">None</text>
<text top="671" left="471" width="17" height="9" font="32">None</text>
<text top="671" left="547" width="17" height="9" font="32">None</text>
<text top="672" left="599" width="10" height="8" font="32">•  </text>
<text top="671" left="606" width="30" height="9" font="32">BEAT-HF‡</text>
<text top="686" left="599" width="10" height="8" font="32">•  </text>
<text top="685" left="606" width="45" height="9" font="32">ENDEAVOUR‡</text>
<text top="671" left="697" width="17" height="9" font="32">None</text>
<text top="671" left="763" width="17" height="9" font="32">None</text>
<text top="732" left="85" width="28" height="9" font="32">James P. </text>
<text top="742" left="85" width="26" height="9" font="32">Daubert</text>
<text top="732" left="152" width="24" height="9" font="32">Official </text>
<text top="742" left="137" width="51" height="9" font="32">Reviewer—AHA</text>
<text top="732" left="204" width="79" height="9" font="32">Duke University Medical </text>
<text top="742" left="232" width="22" height="9" font="32">Center</text>
<text top="732" left="294" width="10" height="8" font="32">•  </text>
<text top="732" left="300" width="56" height="9" font="32">Biosense Webster</text>
<text top="746" left="294" width="10" height="8" font="32">•  </text>
<text top="746" left="300" width="53" height="9" font="32">Boston Scientific</text>
<text top="760" left="294" width="10" height="8" font="32">•  </text>
<text top="760" left="300" width="39" height="9" font="32">CardioFocus</text>
<text top="774" left="294" width="10" height="8" font="32">•  </text>
<text top="774" left="300" width="20" height="9" font="32">Gilead</text>
<text top="788" left="294" width="10" height="8" font="32">•  </text>
<text top="788" left="300" width="54" height="9" font="32">Heart Metabolics</text>
<text top="802" left="294" width="10" height="8" font="32">•  </text>
<text top="802" left="300" width="37" height="9" font="32">Medtronic*</text>
<text top="816" left="294" width="10" height="8" font="32">•  </text>
<text top="816" left="300" width="52" height="9" font="32">St. Jude Medical</text>
<text top="830" left="294" width="10" height="8" font="32">•  </text>
<text top="830" left="300" width="11" height="9" font="32">Zoll</text>
<text top="732" left="400" width="17" height="9" font="32">None</text>
<text top="732" left="471" width="17" height="9" font="32">None</text>
<text top="732" left="520" width="10" height="8" font="32">•  </text>
<text top="732" left="526" width="56" height="9" font="32">ARCA biopharma</text>
<text top="746" left="520" width="10" height="8" font="32">•  </text>
<text top="746" left="526" width="60" height="9" font="32">Biosense Webster*</text>
<text top="760" left="520" width="10" height="8" font="32">•  </text>
<text top="760" left="526" width="57" height="9" font="32">Boston Scientific*</text>
<text top="774" left="520" width="10" height="8" font="32">•  </text>
<text top="774" left="526" width="25" height="9" font="32">Gilead*</text>
<text top="788" left="520" width="10" height="8" font="32">•  </text>
<text top="788" left="526" width="46" height="9" font="32">Gilead (DSMB)</text>
<text top="802" left="520" width="10" height="8" font="32">•  </text>
<text top="802" left="526" width="37" height="9" font="32">Medtronic*</text>
<text top="816" left="520" width="10" height="8" font="32">•  </text>
<text top="816" left="526" width="23" height="9" font="32">NHLBI*</text>
<text top="830" left="520" width="10" height="8" font="32">•  </text>
<text top="830" left="526" width="45" height="9" font="32">NHLBI (DSMB)</text>
<text top="844" left="520" width="10" height="8" font="32">•  </text>
<text top="844" left="526" width="46" height="9" font="32">Northwestern </text>
<text top="854" left="526" width="31" height="9" font="32">University</text>
<text top="868" left="520" width="10" height="8" font="32">•  </text>
<text top="868" left="526" width="54" height="9" font="32">St. Jude Medical </text>
<text top="879" left="526" width="24" height="9" font="32">(DSMB)</text>
<text top="893" left="520" width="10" height="8" font="32">•  </text>
<text top="893" left="526" width="56" height="9" font="32">VytronUS (DSMB)</text>
<text top="732" left="600" width="10" height="8" font="32">•  </text>
<text top="732" left="606" width="32" height="9" font="32">Biosense*</text>
<text top="746" left="600" width="10" height="8" font="32">•  </text>
<text top="746" left="606" width="33" height="9" font="32">Biotronik*</text>
<text top="760" left="600" width="10" height="8" font="32">•  </text>
<text top="760" left="606" width="57" height="9" font="32">Boston Scientific*</text>
<text top="774" left="600" width="10" height="8" font="32">•  </text>
<text top="774" left="606" width="50" height="9" font="32">Gilead Scienes, </text>
<text top="784" left="606" width="15" height="9" font="32">Inc.*</text>
<text top="798" left="600" width="10" height="8" font="32">•  </text>
<text top="798" left="606" width="37" height="9" font="32">Medtronic*</text>
<text top="812" left="600" width="10" height="8" font="32">•  </text>
<text top="812" left="606" width="56" height="9" font="32">St. Jude Medical*</text>
<text top="732" left="676" width="10" height="8" font="32">•  </text>
<text top="732" left="682" width="15" height="9" font="32">ACC</text>
<text top="732" left="763" width="17" height="9" font="32">None</text>
<text top="911" left="85" width="21" height="9" font="32">James </text>
<text top="922" left="85" width="22" height="9" font="32">Tisdale</text>
<text top="911" left="150" width="28" height="9" font="32">Content </text>
<text top="922" left="137" width="53" height="9" font="32">Reviewer—ACC </text>
<text top="932" left="146" width="34" height="9" font="32">EP Council</text>
<text top="911" left="212" width="63" height="9" font="32">Professor—College </text>
<text top="922" left="211" width="66" height="9" font="32">of Pharmacy Purdue </text>
<text top="932" left="211" width="65" height="9" font="32">University—Adjunct </text>
<text top="943" left="214" width="60" height="9" font="32">Professor—School </text>
<text top="953" left="211" width="65" height="9" font="32">of Medicine Indiana </text>
<text top="964" left="227" width="31" height="9" font="32">University</text>
<text top="911" left="322" width="17" height="9" font="32">None</text>
<text top="911" left="400" width="17" height="9" font="32">None</text>
<text top="911" left="471" width="17" height="9" font="32">None</text>
<text top="911" left="520" width="10" height="8" font="32">•  </text>
<text top="911" left="526" width="19" height="9" font="32">AHA*</text>
<text top="925" left="520" width="10" height="8" font="32">•  </text>
<text top="925" left="526" width="17" height="9" font="32">HRS*</text>
<text top="939" left="520" width="10" height="8" font="32">•  </text>
<text top="939" left="526" width="50" height="9" font="32">Indiana Clinical </text>
<text top="950" left="526" width="42" height="9" font="32">Translational </text>
<text top="960" left="526" width="57" height="9" font="32">Sciences Institute/</text>
<text top="971" left="526" width="60" height="9" font="32">Strategic Research </text>
<text top="981" left="526" width="31" height="9" font="32">Initiative*</text>
<text top="911" left="600" width="10" height="8" font="32">•  </text>
<text top="911" left="606" width="19" height="9" font="32">ACC†</text>
<text top="925" left="600" width="10" height="8" font="32">•  </text>
<text top="925" left="606" width="19" height="9" font="32">AHA†</text>
<text top="939" left="600" width="10" height="8" font="32">•  </text>
<text top="939" left="606" width="27" height="9" font="32">AZCert†</text>
<text top="953" left="600" width="10" height="8" font="32">•  </text>
<text top="953" left="606" width="44" height="9" font="32">QT drugs list, </text>
<text top="964" left="606" width="46" height="9" font="32">credible meds.</text>
<text top="974" left="606" width="15" height="9" font="32">org†</text>
<text top="911" left="697" width="17" height="9" font="32">None</text>
<text top="911" left="744" width="10" height="8" font="32">•  </text>
<text top="911" left="750" width="28" height="9" font="32">Plaintiff, </text>
<text top="922" left="750" width="46" height="9" font="32">Drug-induced </text>
<text top="932" left="750" width="29" height="9" font="32">torsades </text>
<text top="943" left="750" width="38" height="9" font="32">de pointes, </text>
<text top="953" left="750" width="21" height="9" font="32">2017*</text>
<text top="1000" left="85" width="40" height="9" font="32">John L. Sapp</text>
<text top="1000" left="152" width="24" height="9" font="32">Official </text>
<text top="1010" left="138" width="49" height="9" font="32">Reviewer—HRS</text>
<text top="1000" left="206" width="75" height="9" font="32">Interim Head—Division </text>
<text top="1010" left="214" width="60" height="9" font="32">of Cardiology QEII </text>
<text top="1021" left="202" width="81" height="9" font="32">Health Sciences Centre—</text>
<text top="1031" left="204" width="77" height="9" font="32">Professor of Medicine—</text>
<text top="1042" left="210" width="64" height="9" font="32">Dalhousie University</text>
<text top="1000" left="294" width="10" height="8" font="32">•  </text>
<text top="1000" left="300" width="60" height="9" font="32">Biosense Webster*</text>
<text top="1014" left="294" width="10" height="8" font="32">•  </text>
<text top="1014" left="300" width="33" height="9" font="32">Medtronic</text>
<text top="1028" left="294" width="10" height="8" font="32">•  </text>
<text top="1028" left="300" width="25" height="9" font="32">St. Jude</text>
<text top="1000" left="400" width="17" height="9" font="32">None</text>
<text top="1000" left="471" width="17" height="9" font="32">None</text>
<text top="1000" left="520" width="10" height="8" font="32">•  </text>
<text top="1000" left="526" width="60" height="9" font="32">Biosense Webster*</text>
<text top="1014" left="520" width="10" height="8" font="32">•  </text>
<text top="1014" left="526" width="60" height="9" font="32">Canadian Institute </text>
<text top="1024" left="526" width="64" height="9" font="32">of Health Research*</text>
<text top="1038" left="520" width="10" height="8" font="32">•  </text>
<text top="1038" left="526" width="24" height="9" font="32">DSMB†</text>
<text top="1052" left="520" width="10" height="8" font="32">•  </text>
<text top="1052" left="526" width="61" height="9" font="32">Phillips healthcare*</text>
<text top="1066" left="520" width="10" height="8" font="32">•  </text>
<text top="1066" left="526" width="56" height="9" font="32">St. Jude Medical*</text>
<text top="1000" left="600" width="10" height="8" font="32">•  </text>
<text top="1000" left="606" width="31" height="9" font="32">ARTESiA‡</text>
<text top="1014" left="600" width="10" height="8" font="32">•  </text>
<text top="1014" left="606" width="37" height="9" font="32">Medtronic‡</text>
<text top="1028" left="600" width="10" height="8" font="32">•  </text>
<text top="1028" left="606" width="58" height="9" font="32">Optisure Registry‡</text>
<text top="1042" left="600" width="10" height="8" font="32">•  </text>
<text top="1042" left="606" width="29" height="9" font="32">St. Jude‡</text>
<text top="1000" left="697" width="17" height="9" font="32">None</text>
<text top="1000" left="763" width="17" height="9" font="32">None</text>
<text top="1083" left="765" width="38" height="9" font="32">(<i>Continued</i> )</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="119" position="absolute" top="0" left="0" height="1174" width="877">
<text top="1127" left="114" width="94" height="14" font="0">September 25, 2018 </text>
<text top="1127" left="476" width="327" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549</text>
<text top="1127" left="74" width="25" height="15" font="2">e390</text>
<text top="218" left="25" width="0" height="20" font="16"><b>CLINIC</b></text>
<text top="178" left="25" width="0" height="20" font="16"><b>AL ST</b></text>
<text top="145" left="25" width="0" height="20" font="16"><b>ATEMENTS</b></text>
<text top="81" left="25" width="0" height="20" font="16"><b>  </b></text>
<text top="200" left="42" width="0" height="20" font="16"><b>AND GUIDELINES</b></text>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="159" left="85" width="24" height="9" font="32">Joseph </text>
<text top="170" left="85" width="26" height="9" font="32">Edward </text>
<text top="180" left="85" width="23" height="9" font="32">Marine</text>
<text top="159" left="152" width="24" height="9" font="32">Official </text>
<text top="170" left="137" width="51" height="9" font="32">Reviewer—ACC</text>
<text top="159" left="208" width="72" height="9" font="32">Associate Professor of </text>
<text top="170" left="201" width="85" height="9" font="32">Medicine—Johns Hopkins </text>
<text top="180" left="211" width="65" height="9" font="32">University School of </text>
<text top="191" left="228" width="29" height="9" font="32">Medicine</text>
<text top="159" left="322" width="17" height="9" font="32">None</text>
<text top="159" left="400" width="17" height="9" font="32">None</text>
<text top="159" left="471" width="17" height="9" font="32">None</text>
<text top="159" left="547" width="17" height="9" font="32">None</text>
<text top="160" left="599" width="10" height="8" font="32">•  </text>
<text top="160" left="606" width="31" height="9" font="32">UpToDate</text>
<text top="159" left="697" width="17" height="9" font="32">None</text>
<text top="159" left="762" width="17" height="9" font="32">None</text>
<text top="209" left="85" width="38" height="9" font="32">Kathleen T. </text>
<text top="220" left="85" width="21" height="9" font="32">Hickey</text>
<text top="209" left="152" width="24" height="9" font="32">Official </text>
<text top="220" left="137" width="51" height="9" font="32">Reviewer—AHA</text>
<text top="209" left="206" width="72" height="9" font="32">Professor of Nursing—</text>
<text top="220" left="211" width="66" height="9" font="32">Columbia University </text>
<text top="230" left="218" width="49" height="9" font="32">Medical Center</text>
<text top="209" left="322" width="17" height="9" font="32">None</text>
<text top="209" left="400" width="17" height="9" font="32">None</text>
<text top="209" left="471" width="17" height="9" font="32">None</text>
<text top="209" left="547" width="17" height="9" font="32">None</text>
<text top="209" left="625" width="17" height="9" font="32">None</text>
<text top="209" left="697" width="17" height="9" font="32">None</text>
<text top="209" left="762" width="17" height="9" font="32">None</text>
<text top="249" left="85" width="38" height="9" font="32">Kenneth A. </text>
<text top="259" left="85" width="35" height="9" font="32">Ellenbogen</text>
<text top="249" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="249" left="208" width="70" height="9" font="32">Chief of Cardiology—</text>
<text top="259" left="203" width="80" height="9" font="32">Virginia Commonwealth </text>
<text top="270" left="202" width="82" height="9" font="32">University Medical Center</text>
<text top="249" left="293" width="10" height="8" font="32">•  </text>
<text top="249" left="300" width="15" height="9" font="32">AHA</text>
<text top="263" left="293" width="10" height="8" font="32">•  </text>
<text top="263" left="300" width="31" height="9" font="32">AtriCure*</text>
<text top="277" left="293" width="10" height="8" font="32">•  </text>
<text top="277" left="300" width="60" height="9" font="32">Biosense Webster*</text>
<text top="291" left="293" width="10" height="8" font="32">•  </text>
<text top="291" left="300" width="33" height="9" font="32">Biotronik*</text>
<text top="305" left="293" width="10" height="8" font="32">•  </text>
<text top="305" left="300" width="52" height="9" font="32">Boston Science*</text>
<text top="319" left="293" width="10" height="8" font="32">•  </text>
<text top="319" left="300" width="27" height="9" font="32">Capricor</text>
<text top="333" left="293" width="10" height="8" font="32">•  </text>
<text top="333" left="300" width="13" height="9" font="32">HRS</text>
<text top="347" left="293" width="10" height="8" font="32">•  </text>
<text top="347" left="300" width="24" height="9" font="32">Janssen</text>
<text top="361" left="293" width="10" height="8" font="32">•  </text>
<text top="361" left="300" width="37" height="9" font="32">Medtronic*</text>
<text top="375" left="293" width="10" height="8" font="32">•  </text>
<text top="375" left="300" width="22" height="9" font="32">Pfizer*</text>
<text top="389" left="293" width="10" height="8" font="32">•  </text>
<text top="389" left="300" width="39" height="9" font="32">Sentra heart</text>
<text top="403" left="293" width="10" height="8" font="32">•  </text>
<text top="403" left="300" width="56" height="9" font="32">St. Jude Medical*</text>
<text top="249" left="400" width="17" height="9" font="32">None</text>
<text top="249" left="471" width="17" height="9" font="32">None</text>
<text top="249" left="520" width="10" height="8" font="32">•  </text>
<text top="249" left="526" width="31" height="9" font="32">AtriCure*</text>
<text top="263" left="520" width="10" height="8" font="32">•  </text>
<text top="263" left="526" width="60" height="9" font="32">Biosense Webster*</text>
<text top="277" left="520" width="10" height="8" font="32">•  </text>
<text top="277" left="526" width="52" height="9" font="32">Boston Science*</text>
<text top="291" left="520" width="10" height="8" font="32">•  </text>
<text top="291" left="526" width="46" height="9" font="32">Daiichi Sankyo</text>
<text top="305" left="520" width="10" height="8" font="32">•  </text>
<text top="305" left="526" width="37" height="9" font="32">Medtronic*</text>
<text top="319" left="520" width="10" height="8" font="32">•  </text>
<text top="319" left="526" width="63" height="9" font="32">Medtronic (DSMB)*</text>
<text top="333" left="520" width="10" height="8" font="32">•  </text>
<text top="333" left="526" width="16" height="9" font="32">NIH*</text>
<text top="347" left="520" width="10" height="8" font="32">•  </text>
<text top="347" left="526" width="22" height="9" font="32">Pfizer*</text>
<text top="249" left="599" width="10" height="8" font="32">•  </text>
<text top="249" left="606" width="60" height="9" font="32">Biosense Webster*</text>
<text top="263" left="599" width="10" height="8" font="32">•  </text>
<text top="263" left="606" width="52" height="9" font="32">Boston Science*</text>
<text top="277" left="599" width="10" height="8" font="32">•  </text>
<text top="277" left="606" width="39" height="9" font="32">Circulation†</text>
<text top="291" left="599" width="10" height="8" font="32">•  </text>
<text top="291" left="606" width="48" height="9" font="32">Heart Rhythm†</text>
<text top="305" left="599" width="10" height="8" font="32">•  </text>
<text top="305" left="606" width="22" height="9" font="32">JACC†</text>
<text top="319" left="599" width="10" height="8" font="32">•  </text>
<text top="319" left="606" width="37" height="9" font="32">Medtronic*</text>
<text top="333" left="599" width="10" height="8" font="32">•  </text>
<text top="333" left="606" width="21" height="9" font="32">PACE†</text>
<text top="347" left="599" width="10" height="8" font="32">•  </text>
<text top="347" left="606" width="45" height="9" font="32">Sanofi Aventis</text>
<text top="249" left="697" width="17" height="9" font="32">None</text>
<text top="249" left="763" width="17" height="9" font="32">None</text>
<text top="421" left="85" width="23" height="9" font="32">Kim K. </text>
<text top="432" left="85" width="25" height="9" font="32">Birtcher</text>
<text top="421" left="150" width="28" height="9" font="32">Content </text>
<text top="432" left="136" width="53" height="9" font="32">Reviewer—ACC/</text>
<text top="442" left="148" width="33" height="9" font="32">AHA Task </text>
<text top="453" left="149" width="29" height="9" font="32">Force on </text>
<text top="463" left="138" width="52" height="9" font="32">Clinical Practice </text>
<text top="474" left="146" width="33" height="9" font="32">Guidelines</text>
<text top="421" left="204" width="76" height="9" font="32">University of Houston—</text>
<text top="432" left="203" width="80" height="9" font="32">College of Pharmacology</text>
<text top="421" left="294" width="10" height="8" font="32">•  </text>
<text top="421" left="300" width="59" height="9" font="32">Jones and Bartlett </text>
<text top="432" left="300" width="28" height="9" font="32">Learning</text>
<text top="421" left="400" width="17" height="9" font="32">None</text>
<text top="421" left="471" width="17" height="9" font="32">None</text>
<text top="421" left="547" width="17" height="9" font="32">None</text>
<text top="421" left="600" width="10" height="8" font="32">•  </text>
<text top="421" left="606" width="44" height="9" font="32">Accreditation </text>
<text top="432" left="606" width="63" height="9" font="32">Council for Clinical </text>
<text top="442" left="606" width="33" height="9" font="32">Lipidology</text>
<text top="421" left="676" width="10" height="8" font="32">•  </text>
<text top="421" left="682" width="33" height="9" font="32">University </text>
<text top="432" left="682" width="38" height="9" font="32">of Houston </text>
<text top="442" left="682" width="35" height="9" font="32">College of </text>
<text top="453" left="682" width="49" height="9" font="32">Pharmacology*</text>
<text top="467" left="676" width="10" height="8" font="32">•  </text>
<text top="467" left="682" width="38" height="9" font="32">Walgreens*</text>
<text top="421" left="763" width="17" height="9" font="32">None</text>
<text top="492" left="85" width="33" height="9" font="32">Kristen B. </text>
<text top="503" left="85" width="30" height="9" font="32">Campbell</text>
<text top="492" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="492" left="204" width="78" height="9" font="32">Duke University Hospital</text>
<text top="492" left="322" width="17" height="9" font="32">None</text>
<text top="492" left="400" width="17" height="9" font="32">None</text>
<text top="492" left="471" width="17" height="9" font="32">None</text>
<text top="492" left="547" width="17" height="9" font="32">None</text>
<text top="492" left="625" width="17" height="9" font="32">None</text>
<text top="492" left="697" width="17" height="9" font="32">None</text>
<text top="492" left="763" width="17" height="9" font="32">None</text>
<text top="521" left="85" width="33" height="9" font="32">Kristen K. </text>
<text top="532" left="85" width="21" height="9" font="32">Patton</text>
<text top="521" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="521" left="204" width="77" height="9" font="32">Professor of Medicine—</text>
<text top="532" left="202" width="80" height="9" font="32">University of Washington</text>
<text top="521" left="322" width="17" height="9" font="32">None</text>
<text top="521" left="400" width="17" height="9" font="32">None</text>
<text top="521" left="471" width="17" height="9" font="32">None</text>
<text top="521" left="547" width="17" height="9" font="32">None</text>
<text top="521" left="600" width="10" height="8" font="32">•  </text>
<text top="521" left="606" width="18" height="9" font="32">ABIM</text>
<text top="535" left="600" width="10" height="8" font="32">•  </text>
<text top="535" left="606" width="30" height="9" font="32">ACGME†</text>
<text top="549" left="600" width="10" height="8" font="32">•  </text>
<text top="549" left="606" width="19" height="9" font="32">AHA†</text>
<text top="563" left="600" width="10" height="8" font="32">•  </text>
<text top="563" left="606" width="13" height="9" font="32">FDA</text>
<text top="577" left="600" width="10" height="8" font="32">•  </text>
<text top="577" left="606" width="17" height="9" font="32">HRS†</text>
<text top="521" left="697" width="17" height="9" font="32">None</text>
<text top="521" left="763" width="17" height="9" font="32">None</text>
<text top="596" left="85" width="27" height="9" font="32">L. Brent </text>
<text top="606" left="85" width="25" height="9" font="32">Mitchell</text>
<text top="596" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="596" left="201" width="86" height="9" font="32">Professor—Department of </text>
<text top="606" left="205" width="77" height="9" font="32">Cardiac Sciences—Libin </text>
<text top="617" left="205" width="77" height="9" font="32">Cardiovascular Institute </text>
<text top="627" left="203" width="81" height="9" font="32">of Alberta—University of </text>
<text top="638" left="204" width="80" height="9" font="32">Calgary—Alberta Health </text>
<text top="648" left="230" width="25" height="9" font="32">Services</text>
<text top="596" left="294" width="10" height="8" font="32">•  </text>
<text top="596" left="300" width="37" height="9" font="32">Boehringer </text>
<text top="606" left="300" width="35" height="9" font="32">Ingelheim*</text>
<text top="620" left="294" width="10" height="8" font="32">•  </text>
<text top="620" left="300" width="21" height="9" font="32">Forest </text>
<text top="631" left="300" width="51" height="9" font="32">Pharmaceuticals</text>
<text top="645" left="294" width="10" height="8" font="32">•  </text>
<text top="645" left="300" width="57" height="9" font="32">Guidnat Canada*</text>
<text top="659" left="294" width="10" height="8" font="32">•  </text>
<text top="659" left="300" width="64" height="9" font="32">Medtronic Canada*</text>
<text top="673" left="294" width="10" height="8" font="32">•  </text>
<text top="673" left="300" width="48" height="9" font="32">Medtronic Inc*</text>
<text top="687" left="294" width="10" height="8" font="32">•  </text>
<text top="687" left="300" width="20" height="9" font="32">Merck</text>
<text top="701" left="294" width="10" height="8" font="32">•  </text>
<text top="701" left="300" width="22" height="9" font="32">Pfizer*</text>
<text top="715" left="294" width="10" height="8" font="32">•  </text>
<text top="715" left="300" width="52" height="9" font="32">Servier Canada*</text>
<text top="596" left="400" width="17" height="9" font="32">None</text>
<text top="596" left="471" width="17" height="9" font="32">None</text>
<text top="596" left="520" width="10" height="8" font="32">•  </text>
<text top="596" left="526" width="57" height="9" font="32">Boston Scientific*</text>
<text top="596" left="600" width="10" height="8" font="32">•  </text>
<text top="596" left="606" width="31" height="9" font="32">ARTESIA‡</text>
<text top="610" left="600" width="10" height="8" font="32">•  </text>
<text top="610" left="606" width="57" height="9" font="32">Health Protection </text>
<text top="620" left="606" width="26" height="9" font="32">Branch, </text>
<text top="631" left="606" width="51" height="9" font="32">Government of </text>
<text top="641" left="606" width="25" height="9" font="32">Canada</text>
<text top="596" left="697" width="17" height="9" font="32">None</text>
<text top="596" left="763" width="17" height="9" font="32">None</text>
<text top="733" left="85" width="23" height="9" font="32">Martin </text>
<text top="744" left="85" width="32" height="9" font="32">Borggrefe</text>
<text top="733" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="733" left="221" width="45" height="9" font="32">I Medizinische </text>
<text top="744" left="203" width="81" height="9" font="32">KlinikKlinikum Mannheim </text>
<text top="754" left="202" width="81" height="9" font="32">GmbHUniversitätsklinikum</text>
<text top="733" left="294" width="10" height="8" font="32">•  </text>
<text top="733" left="300" width="57" height="9" font="32">Bayer Health Care</text>
<text top="747" left="294" width="10" height="8" font="32">•  </text>
<text top="747" left="300" width="68" height="9" font="32">Boehringer Ingelheim</text>
<text top="761" left="294" width="10" height="8" font="32">•  </text>
<text top="761" left="300" width="57" height="9" font="32">Impulse Dynamics</text>
<text top="775" left="294" width="10" height="8" font="32">•  </text>
<text top="775" left="300" width="45" height="9" font="32">Sanofi Aventis</text>
<text top="789" left="294" width="10" height="8" font="32">•  </text>
<text top="789" left="300" width="52" height="9" font="32">St. Jude Medical</text>
<text top="733" left="400" width="17" height="9" font="32">None</text>
<text top="733" left="471" width="17" height="9" font="32">None</text>
<text top="733" left="520" width="10" height="8" font="32">•  </text>
<text top="733" left="526" width="52" height="9" font="32">German Centre </text>
<text top="744" left="526" width="60" height="9" font="32">for Cardiovascular </text>
<text top="754" left="526" width="32" height="9" font="32">Research*</text>
<text top="733" left="625" width="17" height="9" font="32">None</text>
<text top="733" left="697" width="17" height="9" font="32">None</text>
<text top="733" left="763" width="17" height="9" font="32">None</text>
<text top="808" left="85" width="38" height="9" font="32">Mathew D. </text>
<text top="818" left="85" width="36" height="9" font="32">Hutchinson</text>
<text top="808" left="152" width="24" height="9" font="32">Official </text>
<text top="818" left="138" width="49" height="9" font="32">Reviewer—HRS</text>
<text top="808" left="204" width="77" height="9" font="32">Professor of Medicine—</text>
<text top="818" left="209" width="68" height="9" font="32">University of Arizona </text>
<text top="829" left="207" width="72" height="9" font="32">College of Medicine—</text>
<text top="839" left="232" width="22" height="9" font="32">Tucson</text>
<text top="808" left="294" width="10" height="8" font="32">•  </text>
<text top="808" left="300" width="52" height="9" font="32">St. Jude Medical</text>
<text top="808" left="400" width="17" height="9" font="32">None</text>
<text top="808" left="471" width="17" height="9" font="32">None</text>
<text top="808" left="547" width="17" height="9" font="32">None</text>
<text top="808" left="625" width="17" height="9" font="32">None</text>
<text top="808" left="697" width="17" height="9" font="32">None</text>
<text top="808" left="763" width="17" height="9" font="32">None</text>
<text top="858" left="85" width="42" height="9" font="32">Matthew W. </text>
<text top="868" left="85" width="28" height="9" font="32">Martinez</text>
<text top="858" left="150" width="28" height="9" font="32">Content </text>
<text top="868" left="135" width="58" height="9" font="32">Reviewer—Sports </text>
<text top="879" left="139" width="51" height="9" font="32">and Exercise EP </text>
<text top="889" left="151" width="24" height="9" font="32">Council</text>
<text top="858" left="210" width="67" height="9" font="32">Lehigh Valley Health </text>
<text top="868" left="229" width="28" height="9" font="32">Network</text>
<text top="858" left="323" width="17" height="9" font="32">None</text>
<text top="858" left="400" width="17" height="9" font="32">None</text>
<text top="858" left="471" width="17" height="9" font="32">None</text>
<text top="858" left="547" width="17" height="9" font="32">None</text>
<text top="858" left="625" width="17" height="9" font="32">None</text>
<text top="858" left="697" width="17" height="9" font="32">None</text>
<text top="858" left="763" width="17" height="9" font="32">None</text>
<text top="908" left="85" width="34" height="9" font="32">Melissa R. </text>
<text top="918" left="85" width="30" height="9" font="32">Robinson</text>
<text top="908" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="908" left="212" width="63" height="9" font="32">Director—Complex </text>
<text top="918" left="211" width="64" height="9" font="32">Ablation Program—</text>
<text top="929" left="203" width="80" height="9" font="32">University of Washington</text>
<text top="908" left="294" width="10" height="8" font="32">•  </text>
<text top="908" left="300" width="37" height="9" font="32">Medtronic*</text>
<text top="922" left="294" width="10" height="8" font="32">•  </text>
<text top="922" left="300" width="27" height="9" font="32">Abbott*</text>
<text top="936" left="294" width="10" height="8" font="32">•  </text>
<text top="936" left="300" width="57" height="9" font="32">Boston Scientific*</text>
<text top="908" left="400" width="17" height="9" font="32">None</text>
<text top="908" left="471" width="17" height="9" font="32">None</text>
<text top="908" left="547" width="17" height="9" font="32">None</text>
<text top="908" left="625" width="17" height="9" font="32">None</text>
<text top="908" left="697" width="17" height="9" font="32">None</text>
<text top="908" left="763" width="17" height="9" font="32">None</text>
<text top="954" left="85" width="34" height="9" font="32">Michael J. </text>
<text top="965" left="85" width="15" height="9" font="32">Silka</text>
<text top="954" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="954" left="207" width="74" height="9" font="32">Children’s Hospital Los </text>
<text top="965" left="230" width="25" height="9" font="32">Angeles</text>
<text top="954" left="323" width="17" height="9" font="32">None</text>
<text top="954" left="400" width="17" height="9" font="32">None</text>
<text top="954" left="471" width="17" height="9" font="32">None</text>
<text top="954" left="547" width="17" height="9" font="32">None</text>
<text top="954" left="625" width="17" height="9" font="32">None</text>
<text top="954" left="697" width="17" height="9" font="32">None</text>
<text top="955" left="744" width="10" height="8" font="32">•  </text>
<text top="955" left="750" width="38" height="9" font="32">Defendant, </text>
<text top="965" left="750" width="14" height="9" font="32">ICD </text>
<text top="976" left="750" width="45" height="9" font="32">implantation, </text>
<text top="986" left="750" width="17" height="9" font="32">2017</text>
<text top="1005" left="85" width="33" height="9" font="32">Miguel A. </text>
<text top="1015" left="85" width="30" height="9" font="32">Quinones</text>
<text top="1005" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="1005" left="202" width="84" height="9" font="32">Methodist DeBakey Heart </text>
<text top="1015" left="211" width="64" height="9" font="32">and Vascular Center</text>
<text top="1005" left="323" width="17" height="9" font="32">None</text>
<text top="1005" left="400" width="17" height="9" font="32">None</text>
<text top="1005" left="471" width="17" height="9" font="32">None</text>
<text top="1005" left="547" width="17" height="9" font="32">None</text>
<text top="1005" left="600" width="10" height="8" font="32">•  </text>
<text top="1005" left="606" width="29" height="9" font="32">Houston </text>
<text top="1015" left="606" width="35" height="9" font="32">Methodist </text>
<text top="1026" left="606" width="30" height="9" font="32">Hospital*</text>
<text top="1005" left="697" width="17" height="9" font="32">None</text>
<text top="1005" left="763" width="17" height="9" font="32">None</text>
<text top="1044" left="85" width="35" height="9" font="32">Mitchell T. </text>
<text top="1055" left="85" width="30" height="9" font="32">Saltzberg</text>
<text top="1044" left="140" width="49" height="9" font="32">Organizational </text>
<text top="1055" left="136" width="53" height="9" font="32">Reviewer—HFSA</text>
<text top="1044" left="216" width="55" height="9" font="32">Jefferson Medical </text>
<text top="1055" left="204" width="79" height="9" font="32">College—Christiana Care </text>
<text top="1065" left="221" width="44" height="9" font="32">Health System</text>
<text top="1044" left="323" width="17" height="9" font="32">None</text>
<text top="1044" left="400" width="17" height="9" font="32">None</text>
<text top="1045" left="448" width="10" height="8" font="32">•  </text>
<text top="1045" left="454" width="55" height="9" font="32">Nephroceuticals*</text>
<text top="1059" left="448" width="10" height="8" font="32">•  </text>
<text top="1059" left="454" width="32" height="9" font="32">Stem Cell </text>
<text top="1069" left="454" width="44" height="9" font="32">Theranostics*</text>
<text top="1044" left="547" width="17" height="9" font="32">None</text>
<text top="1044" left="625" width="17" height="9" font="32">None</text>
<text top="1044" left="697" width="17" height="9" font="32">None</text>
<text top="1044" left="763" width="17" height="9" font="32">None</text>
<text top="88" left="74" width="60" height="12" font="3"><b>Appendix 2.</b></text>
<text top="88" left="134" width="62" height="12" font="22"><b> Continued</b></text>
<text top="141" left="89" width="33" height="9" font="36"><b>Reviewer</b></text>
<text top="141" left="136" width="54" height="9" font="36"><b>Representation</b></text>
<text top="141" left="220" width="45" height="9" font="36"><b>Employment</b></text>
<text top="141" left="312" width="38" height="9" font="36"><b>Consultant</b></text>
<text top="141" left="379" width="59" height="9" font="36"><b>Speakers Bureau</b></text>
<text top="120" left="459" width="42" height="9" font="36"><b>Ownership/</b></text>
<text top="130" left="458" width="43" height="9" font="36"><b>Partnership/</b></text>
<text top="141" left="464" width="30" height="9" font="36"><b>Principal</b></text>
<text top="141" left="524" width="63" height="9" font="36"><b>Personal Research</b></text>
<text top="109" left="611" width="47" height="9" font="36"><b>Institutional, </b></text>
<text top="120" left="606" width="57" height="9" font="36"><b>Organizational, </b></text>
<text top="130" left="602" width="65" height="9" font="36"><b>or Other Financial </b></text>
<text top="141" left="620" width="25" height="9" font="36"><b>Benefit</b></text>
<text top="141" left="694" width="22" height="9" font="36"><b>Salary</b></text>
<text top="141" left="745" width="53" height="9" font="36"><b>Expert Witness</b></text>
<text top="1087" left="765" width="38" height="9" font="32">(<i>Continued</i> )</text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
<page number="120" position="absolute" top="0" left="0" height="1174" width="877">
	<fontspec id="38" size="5" family="Times" color="#3c4ba7"/>
<text top="36" left="74" width="65" height="14" font="0">Al-Khatib et al </text>
<text top="36" left="700" width="103" height="14" font="0">2017 VA/SCD Guideline</text>
<text top="1127" left="74" width="330" height="14" font="1"><i>Circulation.</i> 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 </text>
<text top="1127" left="673" width="91" height="14" font="0">September 25, 2018</text>
<text top="1127" left="778" width="25" height="15" font="2">e391</text>
<text top="81" left="852" width="0" height="20" font="14"><b>CLINIC</b></text>
<text top="120" left="852" width="0" height="20" font="14"><b>AL ST</b></text>
<text top="154" left="852" width="0" height="27" font="14"><b>ATEMENTS</b></text>
<text top="218" left="852" width="0" height="23" font="14"><b>  </b></text>
<text top="99" left="836" width="0" height="20" font="14"><b>AND GUIDELINES</b></text>
<text top="159" left="85" width="35" height="9" font="32">N.A. Mark </text>
<text top="170" left="85" width="23" height="9" font="32">Estes III</text>
<text top="159" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="159" left="204" width="77" height="9" font="32">Professor of Medicine—</text>
<text top="170" left="202" width="82" height="9" font="32">Tufts University School of </text>
<text top="180" left="228" width="29" height="9" font="32">Medicine</text>
<text top="160" left="293" width="10" height="8" font="32">•  </text>
<text top="160" left="300" width="57" height="9" font="32">Boston Scientific*</text>
<text top="174" left="293" width="10" height="8" font="32">•  </text>
<text top="173" left="300" width="37" height="9" font="32">Medtronic*</text>
<text top="188" left="293" width="10" height="8" font="32">•  </text>
<text top="187" left="300" width="56" height="9" font="32">St. Jude Medical*</text>
<text top="159" left="400" width="17" height="9" font="32">None</text>
<text top="159" left="471" width="17" height="9" font="32">None</text>
<text top="160" left="520" width="10" height="8" font="32">•  </text>
<text top="160" left="526" width="57" height="9" font="32">Boston Scientific*</text>
<text top="174" left="520" width="10" height="8" font="32">•  </text>
<text top="173" left="526" width="63" height="9" font="32">International Board </text>
<text top="184" left="526" width="55" height="9" font="32">of Heart Rhythm </text>
<text top="194" left="526" width="36" height="9" font="32">Examiners†</text>
<text top="209" left="520" width="10" height="8" font="32">•  </text>
<text top="208" left="526" width="37" height="9" font="32">Medtronic*</text>
<text top="222" left="520" width="10" height="8" font="32">•  </text>
<text top="222" left="526" width="56" height="9" font="32">St. Jude Medical*</text>
<text top="159" left="625" width="17" height="9" font="32">None</text>
<text top="159" left="697" width="17" height="9" font="32">None</text>
<text top="159" left="762" width="17" height="9" font="32">None</text>
<text top="241" left="85" width="35" height="9" font="32">Norma M. </text>
<text top="251" left="85" width="18" height="9" font="32">Keller</text>
<text top="241" left="152" width="24" height="9" font="32">Official </text>
<text top="251" left="137" width="51" height="9" font="32">Reviewer—ACC</text>
<text top="241" left="211" width="66" height="9" font="32">New York University </text>
<text top="251" left="218" width="49" height="9" font="32">Medical Center</text>
<text top="241" left="322" width="17" height="9" font="32">None</text>
<text top="241" left="400" width="17" height="9" font="32">None</text>
<text top="241" left="471" width="17" height="9" font="32">None</text>
<text top="241" left="547" width="17" height="9" font="32">None</text>
<text top="241" left="625" width="17" height="9" font="32">None</text>
<text top="241" left="697" width="17" height="9" font="32">None</text>
<text top="241" left="762" width="17" height="9" font="32">None</text>
<text top="270" left="85" width="18" height="9" font="32">Peter </text>
<text top="280" left="85" width="30" height="9" font="32">Leong-Sit</text>
<text top="270" left="150" width="28" height="9" font="32">Content </text>
<text top="280" left="138" width="49" height="9" font="32">Reviewer—HRS</text>
<text top="270" left="208" width="72" height="9" font="32">Associate Professor of </text>
<text top="280" left="211" width="65" height="9" font="32">Medicine—Western </text>
<text top="291" left="211" width="65" height="9" font="32">University—London </text>
<text top="301" left="206" width="73" height="9" font="32">Health Sciences Centre</text>
<text top="270" left="293" width="10" height="8" font="32">•  </text>
<text top="270" left="300" width="59" height="9" font="32">Medtronic Canada</text>
<text top="270" left="377" width="10" height="8" font="32">•  </text>
<text top="270" left="384" width="56" height="9" font="32">Bayer Healthcare </text>
<text top="281" left="384" width="51" height="9" font="32">Pharmaceuticals</text>
<text top="295" left="377" width="10" height="8" font="32">•  </text>
<text top="295" left="384" width="30" height="9" font="32">Biosense </text>
<text top="305" left="384" width="27" height="9" font="32">Webster</text>
<text top="319" left="377" width="10" height="8" font="32">•  </text>
<text top="319" left="384" width="43" height="9" font="32">Johnson and </text>
<text top="330" left="384" width="26" height="9" font="32">Johnson</text>
<text top="270" left="471" width="17" height="9" font="32">None</text>
<text top="270" left="547" width="17" height="9" font="32">None</text>
<text top="270" left="625" width="17" height="9" font="32">None</text>
<text top="270" left="676" width="10" height="8" font="32">•  </text>
<text top="270" left="682" width="52" height="9" font="32">Bayer Healthcare </text>
<text top="281" left="682" width="52" height="9" font="32">Pharmaceuticals*</text>
<text top="270" left="762" width="17" height="9" font="32">None</text>
<text top="348" left="85" width="30" height="9" font="32">Rachel J. </text>
<text top="359" left="85" width="26" height="9" font="32">Lampert</text>
<text top="348" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="348" left="208" width="71" height="9" font="32">Yale University School </text>
<text top="359" left="204" width="80" height="9" font="32">of Medicine—Section of </text>
<text top="369" left="225" width="34" height="9" font="32">Cardiology</text>
<text top="348" left="293" width="10" height="8" font="32">•  </text>
<text top="348" left="300" width="37" height="9" font="32">Medtronic*</text>
<text top="348" left="400" width="17" height="9" font="32">None</text>
<text top="348" left="471" width="17" height="9" font="32">None</text>
<text top="348" left="520" width="10" height="8" font="32">•  </text>
<text top="348" left="526" width="57" height="9" font="32">Boston Scientific*</text>
<text top="362" left="520" width="10" height="8" font="32">•  </text>
<text top="362" left="526" width="40" height="9" font="32">GE Medical*</text>
<text top="376" left="520" width="10" height="8" font="32">•  </text>
<text top="376" left="526" width="52" height="9" font="32">Medtronic, Inc.*</text>
<text top="390" left="520" width="10" height="8" font="32">•  </text>
<text top="390" left="526" width="56" height="9" font="32">St. Jude Medical*</text>
<text top="348" left="625" width="17" height="9" font="32">None</text>
<text top="348" left="697" width="17" height="9" font="32">None</text>
<text top="348" left="763" width="17" height="9" font="32">None</text>
<text top="409" left="85" width="36" height="9" font="32">Sami Viskin</text>
<text top="409" left="134" width="57" height="9" font="32">Content Reviewer</text>
<text top="409" left="217" width="53" height="9" font="32">Tel Aviv Medical </text>
<text top="419" left="204" width="78" height="9" font="32">Center—Department of </text>
<text top="430" left="225" width="34" height="9" font="32">Cardiology</text>
<text top="409" left="293" width="10" height="8" font="32">•  </text>
<text top="409" left="300" width="55" height="9" font="32">Boston Scientific </text>
<text top="419" left="300" width="61" height="9" font="32">European Strategy </text>
<text top="430" left="300" width="48" height="9" font="32">Advisory Board</text>
<text top="409" left="400" width="17" height="9" font="32">None</text>
<text top="409" left="471" width="17" height="9" font="32">None</text>
<text top="409" left="547" width="17" height="9" font="32">None</text>
<text top="409" left="625" width="17" height="9" font="32">None</text>
<text top="409" left="697" width="17" height="9" font="32">None</text>
<text top="409" left="763" width="17" height="9" font="32">None</text>
<text top="448" left="85" width="33" height="9" font="32">Samuel S. </text>
<text top="459" left="85" width="25" height="9" font="32">Gidding</text>
<text top="448" left="150" width="28" height="9" font="32">Content </text>
<text top="459" left="136" width="53" height="9" font="32">Reviewer—ACC/</text>
<text top="469" left="148" width="33" height="9" font="32">AHA Task </text>
<text top="480" left="149" width="29" height="9" font="32">Force on </text>
<text top="490" left="138" width="52" height="9" font="32">Clinical Practice </text>
<text top="501" left="146" width="33" height="9" font="32">Guidelines</text>
<text top="448" left="211" width="65" height="9" font="32">Dupont Hospital for </text>
<text top="459" left="211" width="65" height="9" font="32">Children—Nemours </text>
<text top="469" left="219" width="48" height="9" font="32">Cardiac Center</text>
<text top="449" left="294" width="10" height="8" font="32">•  </text>
<text top="449" left="300" width="26" height="9" font="32">Familial </text>
<text top="459" left="300" width="71" height="9" font="32">Hypercholesterolemia </text>
<text top="470" left="300" width="40" height="9" font="32">Foundation†</text>
<text top="484" left="294" width="10" height="8" font="32">•  </text>
<text top="484" left="300" width="33" height="9" font="32">Regenxbio</text>
<text top="448" left="400" width="17" height="9" font="32">None</text>
<text top="448" left="471" width="17" height="9" font="32">None</text>
<text top="449" left="520" width="10" height="8" font="32">•  </text>
<text top="449" left="526" width="25" height="9" font="32">Familial </text>
<text top="459" left="526" width="64" height="9" font="32">Hypercholestrolemia </text>
<text top="470" left="526" width="39" height="9" font="32">Foundation†</text>
<text top="484" left="520" width="10" height="8" font="32">•  </text>
<text top="484" left="526" width="37" height="9" font="32">NIH Grants*</text>
<text top="449" left="600" width="10" height="8" font="32">•  </text>
<text top="449" left="606" width="63" height="9" font="32">Cardiology Division </text>
<text top="459" left="606" width="21" height="9" font="32">Head†</text>
<text top="448" left="697" width="17" height="9" font="32">None</text>
<text top="448" left="763" width="17" height="9" font="32">None</text>
<text top="520" left="85" width="27" height="9" font="32">Silvia G. </text>
<text top="530" left="85" width="16" height="9" font="32">Priori</text>
<text top="520" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="520" left="206" width="75" height="9" font="32">Professore Ordinario di </text>
<text top="530" left="205" width="77" height="9" font="32">Cardiologia—Università </text>
<text top="541" left="213" width="62" height="9" font="32">di Pavia—Direttore </text>
<text top="551" left="202" width="83" height="9" font="32">Scientifico—Istituti Clinici </text>
<text top="562" left="209" width="66" height="9" font="32">Scientifici Maugeri—</text>
<text top="572" left="225" width="35" height="9" font="32">Pavia, Italia</text>
<text top="520" left="294" width="10" height="8" font="32">•  </text>
<text top="520" left="300" width="51" height="9" font="32">Ambry Genetics</text>
<text top="534" left="294" width="10" height="8" font="32">•  </text>
<text top="534" left="300" width="53" height="9" font="32">Boston Scientific</text>
<text top="548" left="294" width="10" height="8" font="32">•  </text>
<text top="548" left="300" width="33" height="9" font="32">Medtronic</text>
<text top="562" left="294" width="10" height="8" font="32">•  </text>
<text top="562" left="300" width="48" height="9" font="32">Medtronic, Inc.</text>
<text top="520" left="400" width="17" height="9" font="32">None</text>
<text top="520" left="448" width="10" height="8" font="32">•  </text>
<text top="520" left="454" width="33" height="9" font="32">Audentes </text>
<text top="530" left="454" width="43" height="9" font="32">Therapeutics </text>
<text top="541" left="454" width="13" height="9" font="32">Inc*</text>
<text top="520" left="520" width="10" height="8" font="32">•  </text>
<text top="520" left="526" width="53" height="9" font="32">Gilead Sciences*</text>
<text top="520" left="600" width="10" height="8" font="32">•  </text>
<text top="520" left="606" width="13" height="9" font="32">HRS</text>
<text top="534" left="600" width="10" height="8" font="32">•  </text>
<text top="534" left="606" width="60" height="9" font="32">GS-US-372–1234‡</text>
<text top="520" left="697" width="17" height="9" font="32">None</text>
<text top="520" left="763" width="17" height="9" font="32">None</text>
<text top="591" left="85" width="21" height="9" font="32">Susan </text>
<text top="601" left="85" width="21" height="9" font="32">Strong</text>
<text top="591" left="152" width="24" height="9" font="32">Official </text>
<text top="601" left="137" width="51" height="9" font="32">Reviewer—AHA</text>
<text top="591" left="210" width="65" height="9" font="32">Sabin Middle School</text>
<text top="591" left="322" width="17" height="9" font="32">None</text>
<text top="591" left="400" width="17" height="9" font="32">None</text>
<text top="591" left="471" width="17" height="9" font="32">None</text>
<text top="591" left="547" width="17" height="9" font="32">None</text>
<text top="591" left="625" width="17" height="9" font="32">None</text>
<text top="591" left="697" width="17" height="9" font="32">None</text>
<text top="591" left="763" width="17" height="9" font="32">None</text>
<text top="620" left="85" width="39" height="9" font="32">Win-Kuang </text>
<text top="630" left="85" width="16" height="9" font="32">Shen</text>
<text top="620" left="135" width="57" height="9" font="32">Content Reviewer</text>
<text top="620" left="204" width="77" height="9" font="32">Professor of Medicine—</text>
<text top="630" left="203" width="82" height="9" font="32">Consultant—Mayo Clinic </text>
<text top="641" left="201" width="82" height="9" font="32">Arizona, Phoenix Campus</text>
<text top="620" left="323" width="17" height="9" font="32">None</text>
<text top="620" left="400" width="17" height="9" font="32">None</text>
<text top="620" left="471" width="17" height="9" font="32">None</text>
<text top="620" left="547" width="17" height="9" font="32">None</text>
<text top="620" left="625" width="17" height="9" font="32">None</text>
<text top="620" left="697" width="17" height="9" font="32">None</text>
<text top="620" left="763" width="17" height="9" font="32">None</text>
<text top="659" left="85" width="36" height="9" font="32">Zachary D. </text>
<text top="670" left="85" width="36" height="9" font="32">Goldberger</text>
<text top="659" left="152" width="24" height="9" font="32">Official </text>
<text top="670" left="136" width="53" height="9" font="32">Reviewer—ACC/</text>
<text top="680" left="148" width="33" height="9" font="32">AHA Task </text>
<text top="691" left="149" width="29" height="9" font="32">Force on </text>
<text top="701" left="138" width="52" height="9" font="32">Clinical Practice </text>
<text top="712" left="138" width="53" height="9" font="32">Guidelines Lead </text>
<text top="722" left="149" width="29" height="9" font="32">Reviewer</text>
<text top="659" left="208" width="70" height="9" font="32">Assistant Professor of </text>
<text top="670" left="208" width="72" height="9" font="32">Medicine—Division of </text>
<text top="680" left="203" width="81" height="9" font="32">Cardiology—Harborview </text>
<text top="691" left="214" width="56" height="9" font="32">Medical Center—</text>
<text top="701" left="202" width="82" height="9" font="32">University of Washington </text>
<text top="712" left="212" width="61" height="9" font="32">School of Medicine</text>
<text top="659" left="294" width="10" height="8" font="32">•  </text>
<text top="659" left="300" width="38" height="9" font="32">RubiconMD</text>
<text top="659" left="400" width="17" height="9" font="32">None</text>
<text top="659" left="471" width="17" height="9" font="32">None</text>
<text top="659" left="547" width="17" height="9" font="32">None</text>
<text top="659" left="625" width="17" height="9" font="32">None</text>
<text top="659" left="697" width="17" height="9" font="32">None</text>
<text top="659" left="763" width="17" height="9" font="32">None</text>
<text top="743" left="87" width="711" height="9" font="32">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was </text>
<text top="754" left="75" width="721" height="9" font="32">under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting </text>
<text top="764" left="75" width="719" height="9" font="32">stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous </text>
<text top="775" left="75" width="721" height="9" font="32">year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category </text>
<text top="785" left="75" width="81" height="9" font="32">of review. Please r<a href="">efer to </a></text>
<text top="785" left="155" width="335" height="9" font="38"><a href="">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a></text>
<text top="785" left="490" width="309" height="9" font="32"> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure </text>
<text top="796" left="75" width="98" height="9" font="32">Policy for Writing Committees.</text>
<text top="806" left="87" width="79" height="9" font="32">*Significant relationship.</text>
<text top="817" left="87" width="69" height="9" font="32">†No financial benefit.</text>
<text top="827" left="87" width="692" height="9" font="32">‡This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial </text>
<text top="838" left="75" width="249" height="9" font="32">sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.</text>
<text top="848" left="87" width="702" height="9" font="32">ABIM indicates American Board of Internal Medicine; ACC, American College of Cardiology; ACGME, Accreditation Council for Graduate Medical Education; AHA, American Heart Association; ARTESiA, Apixaban for the </text>
<text top="859" left="75" width="716" height="9" font="32">Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; BEAT-HF, Better Effectiveness After Transition–Heart Failure DSMB, data safety monitoring board; ENDEAVOUR, carfilzomib and </text>
<text top="869" left="75" width="730" height="9" font="32">dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma; EP, electrophysiology; FDA, US Food and Drug Administration; HFSA, Heart Failure Society of America; HRS, Heart </text>
<text top="880" left="75" width="718" height="9" font="32">Rhythm Society; ICD, implantable cardioverter-defibrillator; JACC, Journal of the American College of Cardiology; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; and PACE, Programs of All-</text>
<text top="890" left="75" width="92" height="9" font="32">Inclusive Care for the Elderly.</text>
<text top="88" left="74" width="60" height="12" font="3"><b>Appendix 2.</b></text>
<text top="88" left="134" width="62" height="12" font="22"><b> Continued</b></text>
<text top="141" left="89" width="33" height="9" font="36"><b>Reviewer</b></text>
<text top="141" left="136" width="54" height="9" font="36"><b>Representation</b></text>
<text top="141" left="220" width="45" height="9" font="36"><b>Employment</b></text>
<text top="141" left="312" width="38" height="9" font="36"><b>Consultant</b></text>
<text top="141" left="379" width="59" height="9" font="36"><b>Speakers Bureau</b></text>
<text top="120" left="459" width="42" height="9" font="36"><b>Ownership/</b></text>
<text top="130" left="458" width="43" height="9" font="36"><b>Partnership/</b></text>
<text top="141" left="464" width="30" height="9" font="36"><b>Principal</b></text>
<text top="141" left="524" width="63" height="9" font="36"><b>Personal Research</b></text>
<text top="109" left="611" width="47" height="9" font="36"><b>Institutional, </b></text>
<text top="120" left="606" width="57" height="9" font="36"><b>Organizational, </b></text>
<text top="130" left="602" width="65" height="9" font="36"><b>or Other Financial </b></text>
<text top="141" left="620" width="25" height="9" font="36"><b>Benefit</b></text>
<text top="141" left="694" width="22" height="9" font="36"><b>Salary</b></text>
<text top="141" left="745" width="53" height="9" font="36"><b>Expert Witness</b></text>
<text top="585" left="30" width="0" height="11" font="13">Downloaded from http://ahajournals.org by on June 13, 2019</text>
</page>
</pdf2xml>
